PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Razandi, M; Pedram, A; Jordan, VC; Fuqua, S; Levin, ER				Razandi, M.; Pedram, A.; Jordan, V. C.; Fuqua, S.; Levin, E. R.			Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer	ONCOGENE			English	Article						estrogen receptor; mitochondria; apoptosis; tamoxifen resistance	MANGANESE-SUPEROXIDE-DISMUTASE; KINASE-C-DELTA; REACTIVE OXYGEN; INDUCED APOPTOSIS; EPITHELIAL-CELLS; RESPIRATORY-CHAIN; PLASMA-MEMBRANE; CYTOCHROME-C; STRESS; ALPHA	Tamoxifen (TAM) has both cytostatic and cytotoxic properties for breast cancer. TAM engaged mitochondrial estrogen receptor beta (ER beta) as an antagonist in MCF7-BK cells, increasing reactive oxygen species (ROS) concentrations from the mitochondria that were required for cytotoxicity. In part, this derived from TAM downregulating manganese superoxide dismutase (MnSOD) activity by causing the nitrosylation of tyrosine 34, thereby increasing ROS. ROS-activated protein kinase C delta and c-jun N-terminal kinases, resulting in the mitochondrial translocation of Bax and cytochrome C release. Interestingly, TAM failed to cause high ROS levels or induce cell death in MCF7-BK-TR cells due to stimulation of MnSOD activity through agonistic effects at mitochondrial ER beta. In several mouse xenograft models, lentiviral shRNA-induced knockdown of MnSOD caused tumors that grew in the presence of TAM to undergo substantial apoptosis. Tumor MnSOD and mitochondrial ER beta are therefore targets for therapeutic intervention to reverse TAM resistance and enhance a cell death response.	[Razandi, M.; Pedram, A.; Levin, E. R.] Vet Affairs Med Ctr, Div Endocrinol, Med Serv 111 1, Long Beach, CA 90822 USA; [Razandi, M.; Pedram, A.; Levin, E. R.] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; [Razandi, M.; Pedram, A.; Levin, E. R.] Univ Calif Irvine, Dept Biochem, Irvine, CA 92717 USA; [Jordan, V. C.] Georgetown Univ, Lombardi Canc Ctr, Washington, DC USA; [Fuqua, S.] Baylor Coll Med, Houston, TX 77030 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine; Georgetown University; Baylor College of Medicine	Levin, ER (corresponding author), Vet Affairs Med Ctr, Div Endocrinol, Med Serv 111 1, 5901 E,7th St, Long Beach, CA 90822 USA.	ellis.levin@va.gov	JORDAN, V.Craig/AAX-3562-2020; Jordan, V. Craig/H-4491-2011; Levin, Ellis/J-5402-2013		Research Service of the Department of Veteran's Affairs; NIH [CA-10036]; SPORE in Breast Cancer [P50CA89018]; Department of Defense Center of Excellence Grant [W81XWH-06-1-0590]; Georgetown Lombardi Comprehensive Cancer Spore Grant [P30CA051008]; NATIONAL CANCER INSTITUTE [R01CA100366, P30CA062203, P30CA051008, R01CA072038] Funding Source: NIH RePORTER	Research Service of the Department of Veteran's Affairs(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SPORE in Breast Cancer(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense Center of Excellence Grant; Georgetown Lombardi Comprehensive Cancer Spore Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work was supported by grants from the Research Service of the Department of Veteran's Affairs, and NIH CA-10036 to ERL and SPORE in Breast Cancer (#P50CA89018), Department of Defense Center of Excellence Grant (#W81XWH-06-1-0590) (VCJ) and Georgetown Lombardi Comprehensive Cancer Spore Grant (#P30CA051008).	Arpino G, 2008, ENDOCR REV, V29, P217, DOI 10.1210/er.2006-0045; Aslan M, 2003, ANTIOXID REDOX SIGN, V5, P781, DOI 10.1089/152308603770380089; Barone I, 2011, JNCI-J NATL CANCER I, V103, P538, DOI 10.1093/jnci/djr058; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chalut KJ, 2009, CANCER RES, V69, P1199, DOI 10.1158/0008-5472.CAN-08-3079; Chapman KE, 2005, AM J PHYSIOL-LUNG C, V289, pL834, DOI 10.1152/ajplung.00069.2005; Chen JQ, 2004, AM J PHYSIOL-ENDOC M, V286, pE1011, DOI 10.1152/ajpendo.00508.2003; Chua PJ, 2009, EXP BIOL MED, V234, P1086, DOI 10.3181/0903-RM-98; Clarke M, 1998, LANCET, V351, P1451; Dejean LM, 2005, MOL BIOL CELL, V16, P2424, DOI 10.1091/mbc.e04-12-1111; Di X, 2009, BIOCHEM PHARMACOL, V77, P1139, DOI 10.1016/j.bcp.2008.12.016; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Fan P, 2007, CANCER RES, V67, P1352, DOI 10.1158/0008-5472.CAN-06-1020; Felty Q, 2005, ONCOGENE, V24, P4883, DOI 10.1038/sj.onc.1208667; Flynn JM, 2008, AM J PHYSIOL-ENDOC M, V295, pE637, DOI 10.1152/ajpendo.90407.2008; Fuqua SAW, 2004, BREAST CANCER RES TR, V87, pS3; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Halliwell B, 1999, FREE RADICAL RES, V31, P261, DOI 10.1080/10715769900300841; Han P, 2009, BIOCHEM BIOPH RES CO, V385, P251, DOI 10.1016/j.bbrc.2009.05.059; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; Hsieh YC, 2006, J MOL CELL CARDIOL, V41, P511, DOI 10.1016/j.yjmcc.2006.06.001; Huang CC, 2009, TOXICOLOGY, V255, P58, DOI 10.1016/j.tox.2008.10.001; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; James AM, 2005, J BIOL CHEM, V280, P21295, DOI 10.1074/jbc.M501527200; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Luce A, 2009, CARCINOGENESIS, V30, P432, DOI 10.1093/carcin/bgp008; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Milanesi L, 2009, STEROIDS, V74, P489, DOI 10.1016/j.steroids.2009.01.005; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Moriai R, 2009, BREAST CANCER RES TR, V117, P261, DOI 10.1007/s10549-008-0164-5; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Park WC, 2005, INT J ONCOL, V27, P1459; Pedram A, 2006, MOL BIOL CELL, V17, P2125, DOI 10.1091/mbc.E05-11-1013; Pedram A, 2006, MOL ENDOCRINOL, V20, P1996, DOI 10.1210/me.2005-0525; Pedram A, 2010, MOL ENDOCRINOL, V24, P2152, DOI 10.1210/me.2010-0154; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Poyton RO, 2009, TRENDS ENDOCRIN MET, V20, P332, DOI 10.1016/j.tem.2009.04.001; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Speirs V, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2140; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Xiao D, 2008, J BIOL CHEM, V283, P30151, DOI 10.1074/jbc.M802529200; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101	53	55	57	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2013	32	27					3274	3285		10.1038/onc.2012.335	http://dx.doi.org/10.1038/onc.2012.335			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22907432	Green Accepted, Green Submitted			2022-12-17	WOS:000321301600007
J	Chiu, CF; Ho, MY; Peng, JM; Hung, SW; Lee, WH; Liang, CM; Liang, SM				Chiu, C-F; Ho, M-Y; Peng, J-M; Hung, S-W; Lee, W-H; Liang, C-M; Liang, S-M			Raf activation by Ras and promotion of cellular metastasis require phosphorylation of prohibitin in the raft domain of the plasma membrane	ONCOGENE			English	Article						prohibitin; Akt; Raf-1; metastasis; invasion	CANCER-CELLS; ROLES; REPRESSION; TISSUE	Prohibitin (PHB) is indispensable for Ras-induced Raf-1 activation, cell migration and growth; however, the exact role of PHB in the molecular pathogenesis of cancer metastasis remains largely unexamined. Here, we found a positive correlation between plasma membrane-associated PHB and the clinical stages of cancer. The level of PHB phosphorylated at threonine 258 (T258) and tyrosine 259 (Y259) in human cancer-cell membranes correlated with the invasiveness of cancer cells. Overexpression of phosphorylated PHB (phospho-PHB) in the lipid-raft domain of the cell membrane enhanced cell migration/invasion through PI3K/Akt and Raf-1/ERK activation. It also enhanced epithelial-mesenchynnal transition, matrix metalloproteinase-2 activity and invasiveness of cancer cells in vitro. Immunoprecipitation analysis demonstrated that phospho-PHB associated with Raf-1, Akt and Ras in the membrane and was essential for the activation of Raf-1 signaling by Ras. Mice implanted with cancer cells stably overexpressing PHB in the plasma membrane showed enlarged cervical tumors, enhanced metastasis and shorter survival time compared with mice implanted with cancer cells without PHB overexpression. Dephosphorylation of PHB at T258 by site-directed mutagenesis diminished the in vitro and in vivo effects of PHB. These results suggest that increase in phospho-PHB T258 in the raft domain of the plasma membrane has a role in the Ras-driven activation of PI3K/Akt and Raf-1/ERK-signaling cascades and results in the promotion of cancer metastasis. Oncogene (2013) 32, 777-787; doi:10.1038/onc.2012.86; published online 12 March 2012	[Chiu, C-F; Liang, S-M] Natl Cheng Kung Univ, Inst Biotechnol, Coll Biosci & Biotechnol, Tainan 70101, Taiwan; [Chiu, C-F; Hung, S-W; Liang, S-M] Acad Sinica, Agr Biotechnol Res Ctr, Taipei 11529, Taiwan; [Ho, M-Y; Peng, J-M; Liang, C-M; Liang, S-M] Acad Sinica, Genom Res Ctr, Taipei 11529, Taiwan; [Lee, W-H] Taipei Med Univ, Shuang Ho Hosp, Dept Pathol, Taipei, Taiwan; [Liang, C-M] Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan	National Cheng Kung University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Taipei Medical University; Shuang Ho Hospital; Academia Sinica - Taiwan	Liang, SM (corresponding author), Acad Sinica, Agr Biotechnol Res Ctr, 128 Acad Rd,Sec 2, Taipei 11529, Taiwan.	cmliang@gate.sinica.edu.tw; smyang@gate.sinica.edu.tw		Chiu, Ching-Feng/0000-0001-5591-0288; Liang, Shu-Mei/0000-0001-8926-4747	National Science Council, Taiwan [NSC 96-2313-B-001-005-MY3, NSC 99-2313-B-001-004-MY3]; Academia Sinica	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Academia Sinica(Academia Sinica - Taiwan)	This work was supported by the National Science Council, Taiwan (grants NSC 96-2313-B-001-005-MY3 and NSC 99-2313-B-001-004-MY3 to Shu-Mei Liang), and Academia Sinica (to Shu-Mei Liang and Chi-Ming Liang). We thank Chi-Ying Huang of National Yang Ming University, Taiwan for designing phosphorylated peptides to make antibodies against phospho-PHB. We also thank Shu-Chen Shen and Tzu-Wen Tai of the Scientific Instrument Center, Academia Sinica for their assistance with confocal microscopy analyses and flow cytometric analysis.	Ande SR, 2009, BBA-MOL CELL RES, V1793, P1372, DOI 10.1016/j.bbamcr.2009.05.008; Ande SR, 2010, BIOCHEM CELL BIOL, V88, P553, DOI [10.1139/O09-177, 10.1139/o09-177]; Broustas CG, 2002, J BIOL CHEM, V277, P3053, DOI 10.1074/jbc.M106343200; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Dart DA, 2009, ENDOCR-RELAT CANCER, V16, P1157, DOI 10.1677/ERC-09-0028; DELLORCO RT, 1997, BREAST J, V3, P85; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Han EKH, 2008, ANTICANCER RES, V28, P957; Huang Q, 2006, CANCER RES, V66, P5807, DOI 10.1158/0008-5472.CAN-06-0077; Kang XD, 2008, J GASTROENTEROL, V43, P618, DOI 10.1007/s00535-008-2208-3; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; LIOTTA LA, 1991, CANCER RES, V51, pS5054; Matallanas David, 2011, Genes Cancer, V2, P232, DOI 10.1177/1947601911407323; Maurer G, 2011, ONCOGENE, V30, P3477, DOI 10.1038/onc.2011.160; Mishra S, 2006, J CELL MOL MED, V10, P353, DOI 10.1111/j.1582-4934.2006.tb00404.x; Mishra S, 2010, FEBS J, V277, P3937, DOI 10.1111/j.1742-4658.2010.07809.x; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nock NL, 2010, ENERG BALANCE CANCER, V1, P129, DOI 10.1007/978-1-4419-5515-9_5; Patel N, 2010, P NATL ACAD SCI USA, V107, P2503, DOI 10.1073/pnas.0910649107; Peng XJ, 2006, CANCER RES, V66, P7361, DOI 10.1158/0008-5472.CAN-06-1004; Rajalingam K, 2005, CELL CYCLE, V4, P1503, DOI 10.4161/cc.4.11.2142; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; SATOH T, 1992, J BIOL CHEM, V267, P24149; Sievers C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012735; Ummanni R, 2008, CANCER LETT, V266, P171, DOI 10.1016/j.canlet.2008.02.047; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wu TF, 2007, ANTICANCER RES, V27, P895; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	29	55	61	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					777	787		10.1038/onc.2012.86	http://dx.doi.org/10.1038/onc.2012.86			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22410782				2022-12-17	WOS:000315746700011
J	Ratner, ES; Keane, FK; Lindner, R; Tassi, RA; Paranjape, T; Glasgow, M; Nallur, S; Deng, Y; Lu, L; Steele, L; Sand, S; Muller, RU; Bignotti, E; Bellone, S; Boeke, M; Yao, X; Pecorelli, S; Ravaggi, A; Katsaros, D; Zelterman, D; Cristea, MC; Yu, H; Rutherford, TJ; Weitzel, JN; Neuhausen, SL; Schwartz, PE; Slack, FJ; Santin, AD; Weidhaas, JB				Ratner, E. S.; Keane, F. K.; Lindner, R.; Tassi, R. A.; Paranjape, T.; Glasgow, M.; Nallur, S.; Deng, Y.; Lu, L.; Steele, L.; Sand, S.; Muller, R-U; Bignotti, E.; Bellone, S.; Boeke, M.; Yao, X.; Pecorelli, S.; Ravaggi, A.; Katsaros, D.; Zelterman, D.; Cristea, M. C.; Yu, H.; Rutherford, T. J.; Weitzel, J. N.; Neuhausen, S. L.; Schwartz, P. E.; Slack, F. J.; Santin, A. D.; Weidhaas, J. B.			A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer	ONCOGENE			English	Article						platinum resistance; KRAS variant; ovarian cancer; outcome	LET-7 MICRORNA-BINDING; 3'-UNTRANSLATED REGION; EXPRESSION; CARBOPLATIN; PACLITAXEL; SURVIVAL; MODELS; MARKER; SITE	Germline variants in the 30 untranslated region (3'UTR) of cancer genes disrupting microRNA (miRNA) regulation have recently been associated with cancer risk. A variant in the 3'UTR of the KRAS oncogene, referred to as the KRAS variant, is associated with both cancer risk and altered tumor biology. Here, we test the hypothesis that the KRAS variant can act as a biomarker of outcome in epithelial ovarian cancer (EOC), and investigate the cause of altered outcome in KRAS variant-positive EOC patients. As this variant seems to be associated with tumor biology, we additionally test the hypothesis that this variant can be directly targeted to impact cell survival. EOC patients with complete clinical data were genotyped for the KRAS variant and analyzed for outcome (n = 536), response to neoadjuvant chemotherapy (n = 25) and platinum resistance (n = 306). Outcome was separately analyzed for women with known BRCA mutations (n = 79). Gene expression was analyzed on a subset of tumors with available tissue. Cell lines were used to confirm altered sensitivity to chemotherapy associated with the KRAS variant. Finally, the KRAS variant was directly targeted through small-interfering RNA/miRNA oligonucleotides in cell lines and survival was measured. Postmenopausal EOC patients with the KRAS variant were significantly more likely to die of ovarian cancer by multivariate analysis (hazard ratio 1.67, 95% confidence interval: 1.09-2.57, P = 0.019, n = 279). Perhaps explaining this finding, EOC patients with the KRAS variant were significantly more likely to be platinum resistant (odds ratio 3.18, confidence interval: 1.31-7.72, P = 0.0106, n = 291). In addition, direct targeting of the KRAS variant led to a significant reduction in EOC cell growth and survival in vitro. These findings confirm the importance of the KRAS variant in EOC, and indicate that the KRAS variant is a biomarker of poor outcome in EOC likely due to platinum resistance. In addition, this study supports the hypothesis that these tumors have continued dependence on such 3'UTR lesions, and that direct targeting may be a viable future treatment approach.	[Weidhaas, J. B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; [Ratner, E. S.; Bellone, S.; Rutherford, T. J.; Schwartz, P. E.; Santin, A. D.] Yale Univ, Dept Gynecol Oncol, New Haven, CT 06520 USA; [Lindner, R.] Heidelberg Univ, Inst Pharm & Mol Biotechnol, Heidelberg, Germany; [Tassi, R. A.; Bignotti, E.; Pecorelli, S.; Ravaggi, A.] Univ Brescia, Div Gynecol Oncol, Angelo Nocivelli Inst Mol Med, Brescia, Italy; [Deng, Y.; Lu, L.; Yao, X.; Zelterman, D.; Yu, H.] Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; [Steele, L.; Neuhausen, S. L.] Beckman Res Inst City Hope, Dept Populat Sci, Duarte, CA USA; [Sand, S.; Weitzel, J. N.] City Hope Natl Med Ctr, Div Clin Canc Genet, Duarte, CA USA; [Muller, R-U] Univ Cologne, Dept Med, Div Renal, D-50931 Cologne, Germany; [Muller, R-U] Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany; [Katsaros, D.] Univ Turin, Dept Gynecol Oncol, Turin, Italy; [Cristea, M. C.] City Hope Natl Med Ctr, Dept Med Oncol, Duarte, CA USA; [Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University; Ruprecht Karls University Heidelberg; University of Brescia; Yale University; City of Hope; Beckman Research Institute of City of Hope; City of Hope; University of Cologne; University of Cologne; University of Turin; City of Hope; Yale University	Weidhaas, JB (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St, New Haven, CT 06520 USA.	joanne.weidhaas@yale.edu	Müller, Roman-Ulrich/AAK-3493-2021; Ravaggi, Antonella/K-5585-2016	Müller, Roman-Ulrich/0000-0001-6910-0745; Ravaggi, Antonella/0000-0003-4661-9979; Slack, Frank/0000-0001-8263-0409; Sand, Sharon/0000-0002-9390-5583; Zelterman, Daniel/0000-0003-0711-8688; Bellone, Stefania/0000-0001-5909-5292; Weidhaas, Joanne/0000-0002-5096-3281	Women's Reproductive Health Research (WRHR) Career Development Program grant [5K12HD047018-08]; Mary Kay Foundation; NCI [CA131301-01A1, RC4CA153828]; K08 grant [CA124484]; Morris and Horowitz Families Endowed Professorship; NIH [R01CA74415]; Markel Foundation; Shannon Family Foundation; Segesta family; Office of the Director, National Institutes of Health;  [R01CA122728]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD047018] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA157749, R01CA131301, RC4CA153828, R01CA074415, R01CA122728, K08CA124484] Funding Source: NIH RePORTER	Women's Reproductive Health Research (WRHR) Career Development Program grant; Mary Kay Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); K08 grant; Morris and Horowitz Families Endowed Professorship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Markel Foundation; Shannon Family Foundation; Segesta family; Office of the Director, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank JL and his group for supplying the cell line-associated chemosensitivity data. We appreciate Greg Wilhoite for performing the TaqMan assay and Josef Herzog for processing samples for the City of Hope. We also appreciate Discovery to Cure at Yale University for samples and Jeff Boyd for supplying the BG1 cell line for targeting studies. ER was supported by a Women's Reproductive Health Research (WRHR) Career Development Program grant (5K12HD047018-08). FS and JW were supported by a Mary Kay Foundation Grant, and an R01 from the NCI (CA131301-01A1). JW also was supported by a K08 grant (CA124484). AS was supported by R01CA122728. SLN is partially supported by the Morris and Horowitz Families Endowed Professorship and NIH R01CA74415. JNW and SS are supported by RC4CA153828 from the National Cancer Institute and the Office of the Director, National Institutes of Health, and also by funding from the Markel Foundation. We also appreciate support from the Shannon Family Foundation, the Segesta family and donations made in memory of Jennifer Casey.	ACS, 2010, CANC FACTS FIG 2010, P1; Chen KX, 2008, CARCINOGENESIS, V29, P1306, DOI 10.1093/carcin/bgn116; Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129; Christensen BC, 2009, CARCINOGENESIS, V30, P1003, DOI 10.1093/carcin/bgp099; Cox D. R., 2018, ANAL BINARY DATA; COX DR, 1972, J R STAT SOC B, V34, P187; Eitan R, 2009, GYNECOL ONCOL, V114, P253, DOI 10.1016/j.ygyno.2009.04.024; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Graziano F, 2010, PHARMACOGENOMICS J, V10, P458, DOI 10.1038/tpj.2010.9; Helland A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018064; Herzog TJ, 2006, NAT CLIN PRACT ONCOL, V3, P604, DOI 10.1038/ncponc0637; Hollestelle A, 2011, BREAST CANCER RES TR, V128, P79, DOI 10.1007/s10549-010-1080-z; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34; Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544; Lu L, 2011, GYNECOL ONCOL, V122, P366, DOI 10.1016/j.ygyno.2011.04.033; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mezzanzanica D, 2010, INT J BIOCHEM CELL B, V42, P1262, DOI 10.1016/j.biocel.2009.12.017; Paranjape T, 2011, LANCET ONCOL, V12, P377, DOI 10.1016/S1470-2045(11)70044-4; Parmar MKB, 2003, LANCET, V361, P2099; Peters D, 2005, MOL CANCER THER, V4, P1605, DOI 10.1158/1535-7163.MCT-04-0311; Pfisterer J, 2006, J CLIN ONCOL, V24, P4699, DOI 10.1200/JCO.2006.06.0913; Pharoah PDP, 2011, CLIN CANCER RES, V17, P3742, DOI 10.1158/1078-0432.CCR-10-3405; Ratner E, 2010, CANCER RES, V70, P6509, DOI 10.1158/0008-5472.CAN-10-0689; Salzman DW, 2011, NAT MED, V17, P934, DOI 10.1038/nm0811-934; Sasaki H, 2011, J THORAC ONCOL, V6, P15, DOI 10.1097/JTO.0b013e31820594f0; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; van Jaarsveld MTM, 2010, INT J BIOCHEM CELL B, V42, P1282, DOI 10.1016/j.biocel.2010.01.014; Youn CK, 2004, CANCER RES, V64, P4849, DOI 10.1158/0008-5472.CAN-04-0348; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105	33	55	56	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	42					4559	4566		10.1038/onc.2011.539	http://dx.doi.org/10.1038/onc.2011.539			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22139083	Green Submitted, Green Accepted			2022-12-17	WOS:000309982100007
J	Balli, D; Ren, X; Chou, FS; Cross, E; Zhang, Y; Kalinichenko, VV; Kalin, TV				Balli, D.; Ren, X.; Chou, F-S; Cross, E.; Zhang, Y.; Kalinichenko, V. V.; Kalin, T. V.			Foxm1 transcription factor is required for macrophage migration during lung inflammation and tumor formation	ONCOGENE			English	Article						Forkhead transcription factor FoxM1; transgenic mice; macrophages; lung cancer; monocyte migration; tumor microenvironment	BUTYLATED HYDROXYTOLUENE; EPITHELIAL-CELLS; CIGARETTE-SMOKE; CANCER; MICE; FORKHEAD; EXPRESSION; PROGRESSION; ROLES; TUMORIGENESIS	Macrophages have a key role in tumor-associated pulmonary inflammation that supports the proliferation of tumor cells and promotes lung tumor growth. Although increased numbers of tumor-associated macrophages are linked to poor prognosis in lung cancer patients, little is known regarding the transcriptional mechanisms controlling recruitment of macrophages during lung tumorigenesis. Forkhead Box m1 (Foxm1) transcription factor is induced in multiple cell types within tumor lesions and its increased expression is associated with poor prognosis in patients with lung adenocarcinomas. To determine the role of Foxm1 in recruitment of tumor-associated macrophages, a mouse line with macrophage-specific Foxm1 deletion was generated (macFoxm1(-/-)). Lung tumorigenesis was induced using a 3-methylcholanthrene/butylated hydroxytoluene (BHT; 3,5-di-t-butyl-4-hydroxytoluene) tumor initiation/promotion protocol. Ablation of Foxm1 in macrophages reduced the number and size of lung tumors in macFoxm1(-/-) mice. Decreased tumorigenesis was associated with diminished proliferation of tumor cells and decreased recruitment of macrophages during the early stages of tumor formation. The expression levels of the pro-inflammatory genes iNOS, Cox-2, interleukin-1b (IL-1b) and IL-6, as well as the migration-related genes macrophage inflammatory protein-1 (MIP-1 alpha), MIP-2 and MMP-12, were decreased in macrophages isolated from macFoxm1(-/-) mice. Migration of Foxm1-deficient macrophages was reduced in vitro. The chemokine receptors responsible for monocyte recruitment to the lung, CX(3)CR1 and CXCR4, were decreased in Foxm1-deficient monocytes. In co-transfection experiments, Foxm1 directly bound to and transcriptionally activated the CX(3)CR1 promoter. Adoptive transfer of wild-type monocytes to macFoxm1(-/-) mice restored BHT-induced pulmonary inflammation to the levels observed in control mice. Expression of Foxm1 in macrophages is required for pulmonary inflammation, recruitment of macrophages into tumor sites and lung tumor growth. Oncogene (2012) 31, 3875-3888; doi:10.1038/onc.2011.549; published online 5 December 2011	[Balli, D.; Ren, X.; Cross, E.; Zhang, Y.; Kalinichenko, V. V.; Kalin, T. V.] Cincinnati Childrens Hosp Res Fdn, Div Pulm Biol, Perinatal Inst, Cincinnati, OH 45229 USA; [Chou, F-S] Cincinnati Childrens Hosp, Div Expt Hematol & Canc Biol, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cincinnati Children's Hospital Medical Center	Kalin, TV (corresponding author), Cincinnati Childrens Hosp Res Fdn, Div Pulm Biol, Perinatal Inst, 3333 Burnet Ave,MLC 7009, Cincinnati, OH 45229 USA.	Tatiana.kalin@cchmc.org	Ren, Xiaomeng/U-1751-2019	Chou, Fu-Sheng/0000-0002-5770-0580	American Cancer Society, Ohio Division; Concern Foundation [84794]; Department of Defense [PC080478]; NIH [R01 CA142724, R01 HL84151]; NATIONAL CANCER INSTITUTE [R01CA142724] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084151] Funding Source: NIH RePORTER	American Cancer Society, Ohio Division(American Cancer Society); Concern Foundation; Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We dedicate this work to the memory of Dr Robert H Costa, a pioneer in the discovery and characterization of Forkhead transcription factors. We thank Dr Jeff Whitsett, Dr Sheila Bell and Dr Craig Bolte for critical reading of the manuscript, and Shirin Akhter, Jon Snyder and Alyssa Sproles for technical assistance. This work was supported by a Research Grant from the American Cancer Society, Ohio Division (TVK); a Grant from Concern Foundation 84794 (TVK); Department of Defense Award PC080478 (TVK); and NIH Grants R01 CA142724 (TVK) and R01 HL84151 (VVK).	ADAMSON IYR, 1977, LAB INVEST, V36, P26; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Arenberg DA, 2000, CANCER IMMUNOL IMMUN, V49, P63, DOI 10.1007/s002620050603; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Balli D, 2011, CANCER RES, V71, P40, DOI 10.1158/0008-5472.CAN-10-2004; Baron JA, 2000, ANNU REV MED, V51, P511, DOI 10.1146/annurev.med.51.1.511; Bauer AK, 2001, TOXICOLOGY, V169, P1, DOI 10.1016/S0300-483X(01)00475-9; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Blaine SA, 2005, CARCINOGENESIS, V26, P209, DOI 10.1093/carcin/bgh302; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Costa RH, 2005, CURR OPIN GENET DEV, V15, P42, DOI 10.1016/j.gde.2004.12.007; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Ernst PB, 2000, ANNU REV MICROBIOL, V54, P615, DOI 10.1146/annurev.micro.54.1.615; Faux SP, 2009, BIOMARKERS, V14, P90, DOI 10.1080/13547500902965047; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Heist RS, 2006, CLIN CANCER RES, V12, P5448, DOI 10.1158/1078-0432.CCR-06-0262; Kalin TV, 2011, CELL CYCLE, V10, P396, DOI 10.4161/cc.10.3.14709; Kalin TV, 2008, P NATL ACAD SCI USA, V105, P19330, DOI 10.1073/pnas.0806748105; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kanwar JR, 2009, CURR MED CHEM, V16, P2373, DOI 10.2174/092986709788682155; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Krupczak-Hollis K, 2004, DEV BIOL, V276, P74, DOI 10.1016/j.ydbio.2004.08.022; Lala PK, 2001, LANCET ONCOL, V2, P149, DOI 10.1016/S1470-2045(00)00256-4; Malkinson AM, 1997, CANCER RES, V57, P2832; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; MARINO AA, 1972, P SOC EXP BIOL MED, V140, P122, DOI 10.3181/00379727-140-36407; Meyer AM, 2006, AM J PHYSIOL-LUNG C, V290, pL1260, DOI 10.1152/ajplung.00182.2005; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nenan S, 2005, MEM I OSWALDO CRUZ, V100, P167, DOI 10.1590/S0074-02762005000900028; Porta C, 2009, IMMUNOBIOLOGY, V214, P761, DOI 10.1016/j.imbio.2009.06.014; Ren XM, 2010, MOL CELL BIOL, V30, P5381, DOI 10.1128/MCB.00876-10; Sanchez-Martin L, 2011, BLOOD, V117, P88, DOI 10.1182/blood-2009-12-258186; Srivastava M, 2005, J IMMUNOL, V175, P1884, DOI 10.4049/jimmunol.175.3.1884; THOMPSON JA, 1987, DRUG METAB DISPOS, V15, P833; Wang IC, 2008, ONCOGENE, V27, P4137, DOI 10.1038/onc.2008.60; Wang IC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006609; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Westcott DJ, 2009, J EXP MED, V206, P3143, DOI 10.1084/jem.20091333; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zhang JL, 2010, INT J CLIN EXP MED, V3, P233; Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154	48	55	58	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	34					3875	3888		10.1038/onc.2011.549	http://dx.doi.org/10.1038/onc.2011.549			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IV	22139074	Green Accepted, Bronze			2022-12-17	WOS:000307925000005
J	Stiehl, DP; Bordoli, MR; Abreu-Rodriguez, I; Wollenick, K; Schraml, P; Gradin, K; Poellinger, L; Kristiansen, G; Wenger, RH				Stiehl, D. P.; Bordoli, M. R.; Abreu-Rodriguez, I.; Wollenick, K.; Schraml, P.; Gradin, K.; Poellinger, L.; Kristiansen, G.; Wenger, R. H.			Non-canonical HIF-2 alpha function drives autonomous breast cancer cell growth via an AREG-EGFR/ErbB4 autocrine loop	ONCOGENE			English	Article						hypoxic expression profiles; luminal breast cancer; growth factors; HIF target genes; EGF signaling	HYPOXIA-INDUCIBLE FACTOR-2-ALPHA; TRANSCRIPTIONAL REGULATION; FACTOR (HIF)-1-ALPHA; GENE-EXPRESSION; TARGET GENES; DNA-BINDING; IN-VIVO; HIF-1-ALPHA; CARCINOMA; TUMORIGENESIS	Tumor progression is intrinsically tied to the clonal selection of tumor cells with acquired phenotypes allowing to cope with a hostile microenvironment. Hypoxia-inducible factors (HIFs) master the transcriptional response to local tissue hypoxia, a hallmark of solid tumors. Here, we report significantly longer patient survival in breast cancer with high levels of HIF-2 alpha. Amphiregulin (AREG) and WNT1-inducible signaling pathway protein-2 (WISP2) expression was strongly HIF-2 alpha-dependent and their promoters were particularly responsive to HIF-2 alpha. The endogenous AREG promoter recruited HIF-2 alpha in the absence of a classical HIF-DNA interaction motif, revealing a novel mechanism of gene regulation. Loss of AREG expression in HIF-2 alpha-depleted cells was accompanied by reduced activation of epidermal growth factor (EGF) receptor family members. Apparently opposing results from patient and in vitro data point to an HIF-2 alpha-dependent auto-stimulatory tumor phenotype that, while promoting EGF signaling in cellular models, increased the survival of diagnosed and treated human patients. Our findings suggest a model where HIF-2 alpha-mediated autocrine growth signaling in breast cancer sustains a state of cellular self-sufficiency, thereby masking unfavorable microenvironmental growth conditions, limiting adverse selection and improving therapy efficacy. Importantly, HIF-2 alpha/AREG/WISP2-expressing tumors were associated with luminal tumor differentiation, indicative of a better response to classical treatments. Shifting the HIF-1/2 alpha balance toward an HIF-2-dominated phenotype could thus offer a novel approach in breast cancer therapy. Oncogene (2012) 31, 2283-2297; doi:10.1038/onc.2011.417; published online 19 September 2011	[Stiehl, D. P.; Bordoli, M. R.; Abreu-Rodriguez, I.; Wollenick, K.; Wenger, R. H.] Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; [Stiehl, D. P.; Bordoli, M. R.; Abreu-Rodriguez, I.; Wollenick, K.; Wenger, R. H.] Univ Zurich, Zurich Ctr Human Physiol ZIHP, CH-8057 Zurich, Switzerland; [Schraml, P.] Univ Zurich Hosp, Dept Surg Pathol, CH-8091 Zurich, Switzerland; [Gradin, K.; Poellinger, L.] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Poellinger, L.] Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore; [Kristiansen, G.] Univ Hosp Bonn, Inst Pathol, Bonn, Germany	University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Zurich; University Zurich Hospital; Karolinska Institutet; National University of Singapore; University of Bonn	Stiehl, DP (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	daniel.stiehl@uzh.ch	Wenger, Roland H./B-7953-2009; Stiehl, Daniel/A-3622-2008	Wenger, Roland H./0000-0001-7592-4839; Stiehl, Daniel/0000-0002-0076-4874; Bordoli, Mattia/0000-0001-6917-8753	Swiss National Science Foundation [31003A_129962/1]; Swedish Cancer Society; European Union, Metoxia; COST Action [TD0901 HypoxiaNet]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swedish Cancer Society(Swedish Cancer Society); European Union, Metoxia; COST Action(European Cooperation in Science and Technology (COST))	We thank M Sabbah, SB Lee, S Pastorekova, C Pugh and PJ Ratcliffe for providing materials and primer information. This work was supported by the Swiss National Science Foundation grant 31003A_129962/1 (to RHW and DPS), the Swedish Cancer Society and European Union, Metoxia (to LP), and the COST Action TD0901 HypoxiaNet.	Aprelikova O, 2006, CANCER RES, V66, P5641, DOI 10.1158/0008-5472.CAN-05-3345; Banerjee S, 2008, CANCER RES, V68, P7606, DOI 10.1158/0008-5472.CAN-08-1461; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Bordoli MR, 2011, ONCOGENE, V30, P548, DOI 10.1038/onc.2010.433; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Cummins EP, 2005, PFLUG ARCH EUR J PHY, V450, P363, DOI 10.1007/s00424-005-1413-7; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Franovic A, 2009, P NATL ACAD SCI USA, V106, P21306, DOI 10.1073/pnas.0906432106; Fritah A, 2008, MOL CELL BIOL, V28, P1114, DOI 10.1128/MCB.01335-07; Gatenby RA, 2007, BRIT J CANCER, V97, P646, DOI 10.1038/sj.bjc.6603922; Gatenby RA, 2009, CANCER RES, V69, P4894, DOI 10.1158/0008-5472.CAN-08-3658; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Helczynska K, 2008, CANCER RES, V68, P9212, DOI 10.1158/0008-5472.CAN-08-1135; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Hu CJ, 2007, MOL BIOL CELL, V18, P4528, DOI 10.1091/mbc.E06-05-0419; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kim HS, 2007, J BIOL CHEM, V282, P16278, DOI 10.1074/jbc.M700215200; Kim WY, 2009, J CLIN INVEST, V119, P2160, DOI 10.1172/JCI38443; Lau KW, 2007, BRIT J CANCER, V96, P1284, DOI 10.1038/sj.bjc.6603675; Le Bras A, 2007, ONCOGENE, V26, P7480, DOI 10.1038/sj.onc.1210566; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Lehmann S, 2009, P NATL ACAD SCI USA, V106, P14004, DOI 10.1073/pnas.0901194106; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Loeb DM, 2001, CANCER RES, V61, P921; Mazumdar J, 2010, P NATL ACAD SCI USA, V107, P14182, DOI 10.1073/pnas.1001296107; Minamishima YA, 2009, MOL CELL BIOL, V29, P5729, DOI 10.1128/MCB.00331-09; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959-4971.2003; Patel SA, 2008, CELL DEATH DIFFER, V15, P628, DOI 10.1038/cdd.2008.17; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Saito T, 2010, NAT MED, V16, P678, DOI 10.1038/nm.2146; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Sowter HM, 2003, CANCER RES, V63, P6130; Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200; Tomes L, 2003, BREAST CANCER RES TR, V81, P61, DOI 10.1023/A:1025476722493; Wang V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009641; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Wykoff CC, 2000, CANCER RES, V60, P7075; Yamashita T, 2008, J BIOL CHEM, V283, P18926, DOI 10.1074/jbc.M709133200; Yan Q, 2007, MOL CELL BIOL, V27, P2092, DOI 10.1128/MCB.01514-06; Yang S, 2010, NAT MED, V16, P687, DOI 10.1038/nm.2153; Yu P, 2007, J BIOL CHEM, V282, P35035, DOI 10.1074/jbc.M707557200	52	55	56	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	18					2283	2297		10.1038/onc.2011.417	http://dx.doi.org/10.1038/onc.2011.417			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21927022				2022-12-17	WOS:000303610800004
J	Hayashi, I; Takatori, S; Urano, Y; Miyake, Y; Takagi, J; Sakata-Yanagimoto, M; Iwanari, H; Osawa, S; Morohashi, Y; Li, T; Wong, PC; Chiba, S; Kodama, T; Hamakubo, T; Tomita, T; Iwatsubo, T				Hayashi, I.; Takatori, S.; Urano, Y.; Miyake, Y.; Takagi, J.; Sakata-Yanagimoto, M.; Iwanari, H.; Osawa, S.; Morohashi, Y.; Li, T.; Wong, P. C.; Chiba, S.; Kodama, T.; Hamakubo, T.; Tomita, T.; Iwatsubo, T.			Neutralization of the gamma-secretase activity by monoclonal antibody against extracellular domain of nicastrin	ONCOGENE			English	Article						Notch; gamma-secretase; functional antibody; membrane protein; intramembrane cleavage	AMYLOID PRECURSOR PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; BUDDED BACULOVIRUS; MEMBRANE-PROTEINS; BETA-APP; NOTCH; COMPLEX; PRESENILIN; CELLS; INHIBITION	Several lines of evidence suggest that aberrant Notch signaling contributes to the development of several types of cancer. Activation of Notch receptor is executed through intramembrane proteolysis by gamma-secretase, which is a multimeric membrane-embedded protease comprised of presenilin, nicastrin (NCT), anterior pharynx defective 1 and PEN-2. In this study, we report the neutralization of the gamma-secretase activity by a novel monoclonal antibody A5226A against the extracellular domain of NCT, generated by using a recombinant budded baculovirus as an immunogen. This antibody recognized fully glycosylated mature NCT in the active gamma-secretase complex on the cell surface, and inhibited the gamma-secretase activity by competing with the substrate binding in vitro. Moreover, A5226A abolished the gamma-secretase activity-dependent growth of cancer cells in a xenograft model. Our data provide compelling evidence that NCT is a molecular target for the mechanism-based inhibition of gamma-secretase, and that targeting NCT might be a novel therapeutic strategy against cancer caused by aberrant gamma-secretase activity and Notch signaling. Oncogene (2012) 31, 787-798; doi:10.1038/onc.2011.265; published online 4 July 2011	[Tomita, T.] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; [Urano, Y.; Iwanari, H.; Kodama, T.; Hamakubo, T.] Univ Tokyo, Res Ctr Adv Sci & Technol, Dept Syst Biol & Med, Tokyo 1130033, Japan; [Miyake, Y.; Sakata-Yanagimoto, M.; Chiba, S.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Clin & Expt Hematol, Tsukuba, Ibaraki, Japan; [Takagi, J.] Osaka Univ, Inst Prot Res, Lab Prot Synth & Express, Osaka, Japan; [Iwanari, H.] Perseus Prote Inc, Tokyo, Japan; [Li, T.; Wong, P. C.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Tomita, T.; Iwatsubo, T.] Japan Sci & Technol Agcy, Saitama, Japan; [Iwatsubo, T.] Univ Tokyo, Grad Sch Med, Dept Neuropathol, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; University of Tsukuba; Osaka University; Johns Hopkins University; Japan Science & Technology Agency (JST); University of Tokyo	Tomita, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	taisuke@mol.f.u-tokyo.ac.jp	Tomita, Taisuke/L-5427-2015; Mamiko, Sakata-yanagimoto/AAP-3298-2020	Tomita, Taisuke/0000-0002-0075-5943; Urano, Yasuomi/0000-0002-4901-1937	Japan Society for the Promotion of Science (JSPS); National Institute of Biomedical Innovation; Ministry of Education, Culture, Sports, Science and Technology (MEXT); MEXT; MEXT, Japan; NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [20221010, 23791068] Funding Source: KAKEN	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); National Institute of Biomedical Innovation(National Institute of Biomedical Innovation); Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Drs T Fukuyama, S Yokoshima (The University of Tokyo), C Haass (Ludwig-Maximilians-University Munchen), H Natsugari (Teikyo University), R Kopan (Washington University in St Louis), G Thinakaran (The University of Chicago), M Vooijs (University Medical Center Southwestern Medical Center) for valuable reagents and our current and previous laboratory members for helpful discussions. We also would like to thank Keiko Tamura-Kawakami and Maiko Nampo for their excellent technical support. This work is supported in part by Grants-in-Aid for Young Scientists (S) (for TT) from Japan Society for the Promotion of Science (JSPS), by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (for TT, TI), Scientific Research on Priority Areas 'Research on Pathomechanisms of Brain Disorders' from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) (for TT, TI), by Targeted Proteins Research Program grant from the MEXT (for TT, TI, JT), by Core Research for Evolutional Science and Technology grant from the MEXT (for TT, TI), Japan. IH and ST were research fellows of JSPS.	Boesze-Battaglia Kathleen, 2006, V332, P169; Chavez-Gutierrez L, 2008, J BIOL CHEM, V283, P20096, DOI 10.1074/jbc.M803040200; De Strooper B, 2010, NAT REV NEUROL, V6, P99, DOI 10.1038/nrneurol.2009.218; Dries DR, 2009, J BIOL CHEM, V284, P29714, DOI 10.1074/jbc.M109.038737; Dunn CD, 2010, P NATL ACAD SCI USA, V107, P5907, DOI 10.1073/pnas.1001647107; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Ferrando Adolfo A, 2009, Hematology Am Soc Hematol Educ Program, P353, DOI 10.1182/asheducation-2009.1.353; Filipovic A, 2011, BREAST CANCER RES TR, V125, P43, DOI 10.1007/s10549-010-0823-1; Hayashi I, 2004, J BIOL CHEM, V279, P38040, DOI 10.1074/jbc.M405597200; Hayashi I, 2009, J BIOL CHEM, V284, P27838, DOI 10.1074/jbc.M109.055061; Imamura Y, 2009, J AM CHEM SOC, V131, P7353, DOI 10.1021/ja9001458; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kimura K, 2007, CANCER SCI, V98, P155, DOI 10.1111/j.1349-7006.2006.00369.x; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; Li T, 2003, J NEUROSCI, V23, P3272; Luistro L, 2009, CANCER RES, V69, P7672, DOI 10.1158/0008-5472.CAN-09-1843; Masuda K, 2003, J BIOL CHEM, V278, P24552, DOI 10.1074/jbc.M302801200; Masuda S, 2009, CANCER SCI, V100, P2444, DOI 10.1111/j.1349-7006.2009.01328.x; Osipo C, 2008, ONCOGENE, V27, P5019, DOI 10.1038/onc.2008.149; Pannuti A, 2010, CLIN CANCER RES, V16, P3141, DOI 10.1158/1078-0432.CCR-09-2823; Saitoh R, 2006, PROTEIN EXPRES PURIF, V46, P130, DOI 10.1016/j.pep.2005.08.008; Saitoh R, 2007, J IMMUNOL METHODS, V322, P104, DOI 10.1016/j.jim.2007.02.005; Samaranayake H, 2009, ANN MED, V41, P322, DOI 10.1080/07853890802698842; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Shirotani K, 2004, J NEUROCHEM, V89, P1520, DOI 10.1111/j.1471-4159.2004.02447.x; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tarassishin L, 2004, P NATL ACAD SCI USA, V101, P17050, DOI 10.1073/pnas.0408007101; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; Tomita T, 2009, EXPERT REV NEUROTHER, V9, P661, DOI [10.1586/ern.09.24, 10.1586/ERN.09.24]; Urano Y, 2005, J LIPID RES, V46, P904, DOI 10.1194/jlr.M400333-JLR200; Urano Y, 2003, BIOCHEM BIOPH RES CO, V308, P191, DOI 10.1016/S0006-291X(03)01355-X; van Es JH, 2005, TRENDS MOL MED, V11, P496, DOI 10.1016/j.molmed.2005.09.008; van Tetering G, 2009, J BIOL CHEM, V284, P31018, DOI 10.1074/jbc.M109.006775; Vetrivel KS, 2010, BBA-MOL CELL BIOL L, V1801, P860, DOI 10.1016/j.bbalip.2010.03.007; Wakabayashi T, 2009, NAT CELL BIOL, V11, P1340, DOI 10.1038/ncb1978; Weiner LM, 2010, NAT REV IMMUNOL, V10, P317, DOI 10.1038/nri2744; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wu Y, 2010, NATURE, V464, P1052, DOI 10.1038/nature08878; Yin L, 2010, BIOCHEM PHARMACOL, V80, P690, DOI 10.1016/j.bcp.2010.03.026; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhao GJ, 2010, J NEUROSCI, V30, P1648, DOI 10.1523/JNEUROSCI.3826-09.2010	46	55	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	6					787	798		10.1038/onc.2011.265	http://dx.doi.org/10.1038/onc.2011.265			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725355	Green Accepted			2022-12-17	WOS:000300222100011
J	Rosner, M; Hengstschlager, M				Rosner, M.; Hengstschlaeger, M.			Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR	ONCOGENE			English	Article						TSC2; mTOR; S6K1; localization	MAMMALIAN TARGET; PROTEIN; MTOR; PHOSPHORYLATION; KINASE; P27(KIP1); COMPLEXES	The tuberous sclerosis complex gene 2 (TSC2)/mammalian target of rapamycin (mTOR) pathway controls many cellular functions via phosphorylation of ribosomal protein S6 kinases (S6Ks). Alternative splicing and translation generate three S6K1 proteins. Although nuclear and cytoplasmic S6K targets are known, the nucleocytoplasmic localization of the S6K1 proteins has not been comparatively elucidated so far. We show that in primary fibroblasts p85 S6K1 is cytoplasmic, p70 can be found in both compartments and p31 is exclusively nuclear. As already known for p70 and p85, our data suggest that p31 is also a target of mTOR-mediated phosphorylation. Blocking mTOR kinase activity via rapamycin and its activation in TSC2(-/-) cells and via TSC2 small interfering RNAs revealed that it regulates the localization of p70, but not of p85 and p31. The mTOR-dependent phosphorylation of p70 S6K1 at T389 is essential for its nuclear localization and exclusively hyperphosphorylated p70 S6K1 can be found in the nucleus. We further demonstrate this mTOR-controlled p70 S6K1 localization to be growth factor dependent. During the cell-cycle phosphorylation and nuclear localization of p70 S6K1 occur in mid G1 phase. We report that the different S6K1 proteins exhibit different nucleocytoplasmic localizations and that the TSC2/mTOR cascade not only regulates p70 S6K1 activity, but also its localization. These findings provide new important insights into the temporal and spatial dynamics of TSC2/mTOR/S6K regulation. Oncogene (2011) 30, 4509-4522; doi:10.1038/onc.2011.165; published online 23 May 2011	[Rosner, M.; Hengstschlaeger, M.] Med Univ Vienna, Inst Med Genet, A-1090 Vienna, Austria	Medical University of Vienna	Hengstschlager, M (corresponding author), Med Univ Vienna, Inst Med Genet, Wahringer Str 10, A-1090 Vienna, Austria.	markus.hengstschlaeger@meduniwien.ac.at			Herzfelder'sche Familienstiftung; Osterreichische Nationalbank	Herzfelder'sche Familienstiftung; Osterreichische Nationalbank	Research in our laboratory is supported via grants from the Herzfelder'sche Familienstiftung and the Osterreichische Nationalbank.	CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001; COFFER PJ, 1994, BIOCHEM BIOPH RES CO, V198, P780, DOI 10.1006/bbrc.1994.1112; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Fenton TR, 2011, INT J BIOCHEM CELL B, V43, P47, DOI 10.1016/j.biocel.2010.09.018; Hengstschlager M, 2001, PRENATAL DIAG, V21, P897, DOI 10.1002/pd.154; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kim D, 2009, GROWTH FACTORS, V27, P12, DOI 10.1080/08977190802556986; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V234, P681, DOI 10.1006/bbrc.1997.6699; Knowles MA, 2003, CANCER RES, V63, P7652; Meyuhas O, 2009, PROG MOL BIOL TRANSL, V90, P109, DOI 10.1016/S1877-1173(09)90003-5; Panasyuk G, 2006, J BIOL CHEM, V281, P31188, DOI 10.1074/jbc.M602618200; Plas DR, 2009, CURR OPIN CELL BIOL, V21, P230, DOI 10.1016/j.ceb.2008.12.013; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Rosner M, 2008, HUM MOL GENET, V17, P2934, DOI 10.1093/hmg/ddn192; Rosner M, 2007, HUM MOL GENET, V16, P1541, DOI 10.1093/hmg/ddm103; Rosner M, 2010, NAT PROTOC, V5, P1081, DOI 10.1038/nprot.2010.74; Rosner M, 2009, HUM MOL GENET, V18, P3298, DOI 10.1093/hmg/ddp271; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Shaw RJ, 2008, TRENDS BIOCHEM SCI, V33, P565, DOI 10.1016/j.tibs.2008.09.005; Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1074/jbc.M412367200; Wang X, 2009, TRENDS CELL BIOL, V19, P260, DOI 10.1016/j.tcb.2009.03.005; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64	31	55	60	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	44					4509	4522		10.1038/onc.2011.165	http://dx.doi.org/10.1038/onc.2011.165			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	844FN	21602892				2022-12-17	WOS:000296733200006
J	Seux, M; Peuget, S; Montero, MP; Siret, C; Rigot, V; Clerc, P; Gigoux, V; Pellegrino, E; Pouyet, L; N'Guessan, P; Garcia, S; Dufresne, M; Iovanna, JL; Carrier, A; Andre, F; Dusetti, NJ				Seux, M.; Peuget, S.; Montero, M. P.; Siret, C.; Rigot, V.; Clerc, P.; Gigoux, V.; Pellegrino, E.; Pouyet, L.; N'Guessan, P.; Garcia, S.; Dufresne, M.; Iovanna, J. L.; Carrier, A.; Andre, F.; Dusetti, N. J.			TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression	ONCOGENE			English	Article						TP53INP1; SPARC; migration; pancreatic cancer; PanIN	GROWTH-FACTOR-BETA; PROTEIN P53-INDUCED NUCLEAR-PROTEIN-1; CA2+-BINDING EF-HAND; GENE-EXPRESSION; NULL MICE; MATRICELLULAR PROTEIN; EXTRACELLULAR-MATRIX; MICROARRAY ANALYSIS; TUMOR-SUPPRESSOR; ENHANCED GROWTH	Tumor protein 53 induced nuclear protein 1 (TP53INP1) is a p53 target gene that induces cell growth arrest and apoptosis by modulating p53 transcriptional activity. TP53INP1 interacts physically with p53 and is a major player in the p53-driven oxidative stress response. Previously, we demonstrated that TP53INP1 is down-regulated in an early stage of pancreatic cancerogenesis and when restored is able to suppress pancreatic tumor development. TP53INP1 downregulation in pancreas is associated with an oncogenic microRNA miR-155. In the present work, we studied the effects of TP53INP1 on cell migration. We found that TP53INP1 inactivation correlates with increased cell migration both in vivo and in vitro. The impact of TP53INP1 expression on cell migration was studied in different cellular contexts: mouse embryonic fibroblast and different pancreatic cancer cell lines. Its expression decreases cell migration by the transcriptional downregulation of secreted protein acidic and rich in cysteine (SPARC). SPARC is a matrix cellular protein, which governs diverse cellular functions and has a pivotal role in regulating cell-matrix interactions, cellular proliferation and migration. SPARC was also showed to be upregulated in normal pancreas and in pancreatic intraepithelial neoplasia lesions in a pancreatic adenocarcinoma mouse model only in the TP53INP1-deficient animals. This novel TP53INP1 activity on the regulation of SPARC expression could explain in part its tumor suppressor function in pancreatic adenocarcinoma by modulating cellular spreading during the metastatic process. Oncogene (2011) 30, 3049-3061; doi: 10.1038/onc.2011.25; published online 21 February 2011	[Seux, M.; Peuget, S.; Pouyet, L.; N'Guessan, P.; Garcia, S.; Iovanna, J. L.; Carrier, A.; Dusetti, N. J.] INSERM, Stress Cellulaire U624, F-13288 Marseille, France; [Seux, M.; Peuget, S.; Pouyet, L.; N'Guessan, P.; Garcia, S.; Iovanna, J. L.; Carrier, A.; Dusetti, N. J.] Aix Marseille Univ, Marseille, France; [Montero, M. P.; Siret, C.; Rigot, V.; Pellegrino, E.; Andre, F.] Aix Marseille Univ, INSERM, CRO2, U911, Marseille, France; [Clerc, P.; Gigoux, V.; Dufresne, M.] Univ Toulouse, INSERM, IFR150, I2MR,U858, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse	Dusetti, NJ (corresponding author), INSERM, U624, Parc Sci Luminy,Case 915, F-13288 Marseille, France.	nelson.dusetti@inserm.fr	Peuget, Sylvain/AAB-4730-2022; Dusetti, Nelson/O-7919-2017; Dufresne, Marlène/M-6332-2014; Iovanna, Juan/M-9805-2017; Gigoux, Véronique/AAE-6090-2020	Dusetti, Nelson/0000-0002-6161-8483; Iovanna, Juan/0000-0003-1822-2237; Gigoux, Véronique/0000-0003-1408-5335; Montero, Marie-Pierre/0000-0003-4280-0674; Peuget, Sylvain/0000-0002-3315-1935	Institut National de la Sante et de la Recherche Medicale (INSERM); Centre National de la Recherche Scientifique; Institut National du Cancer; La Ligue Nationale Contre le Cancer; Association pour la Recherche sur le Cancer; Agence Nationale de la Recherche; Club Franicais du Pancreas; Ministeere de la Recherche et de la Technologie	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National du Cancer(Institut National du Cancer (INCA) France); La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Agence Nationale de la Recherche(French National Research Agency (ANR)); Club Franicais du Pancreas; Ministeere de la Recherche et de la Technologie	This work was supported in part by Institut National de la Sante et de la Recherche Medicale (INSERM) and Centre National de la Recherche Scientifique and grants from the Institut National du Cancer, La Ligue Nationale Contre le Cancer, Association pour la Recherche sur le Cancer and the Agence Nationale de la Recherche. M Seux was supported by Association pour la Recherche sur le Cancer and S Peuget by the Club Franicais du Pancreas and Ministeere de la Recherche et de la Technologie. Authors acknowledge Tony George JACOB and Antoine Baud for critically reading the manuscript and helpful comments respectively.	Arnold S, 2008, EXP BIOL MED, V233, P860, DOI 10.3181/0801-RM-12; Basu A, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-15; Baumgart M, 2005, CELL ONCOL, V27, P3; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; Bradshaw AD, 2003, J INVEST DERMATOL, V120, P949, DOI 10.1046/j.1523-1747.2003.12241.x; Bradshaw AD, 2002, J HISTOCHEM CYTOCHEM, V50, P1; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Brune K, 2008, CANCER EPIDEM BIOMAR, V17, P3536, DOI 10.1158/1055-9965.EPI-08-0630; Chen G, 2010, BRIT J CANCER, V102, P188, DOI 10.1038/sj.bjc.6605440; FORD R, 1993, EXP CELL RES, V206, P261, DOI 10.1006/excr.1993.1146; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Gommeaux J, 2007, MOL CELL BIOL, V27, P2215, DOI 10.1128/MCB.01454-06; Guweidhi A, 2005, ANN SURG, V242, P224, DOI 10.1097/01.sla.0000171866.45848.68; Hershko T, 2005, CELL DEATH DIFFER, V12, P377, DOI 10.1038/sj.cdd.4401575; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hunzelmann N, 1998, J INVEST DERMATOL, V110, P122, DOI 10.1046/j.1523-1747.1998.00094.x; Infante JR, 2007, J CLIN ONCOL, V25, P319, DOI 10.1200/JCO.2006.07.8824; Ito Y, 2006, ANTICANCER RES, V26, P4391; Jiang PH, 2006, WORLD J GASTROENTERO, V12, P691, DOI 10.3748/wjg.v12.i5.691; Loging WT, 2000, GENOME RES, V10, P1393, DOI 10.1101/gr.138000; Lomberk G, 2008, CURR OPIN GASTROEN, V24, P597, DOI 10.1097/MOG.0b013e32830b111d; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Massi D, 1999, HUM PATHOL, V30, P339, DOI 10.1016/S0046-8177(99)90014-X; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; Ogawa Kumiko, 2005, Medical Molecular Morphology, V38, P23, DOI 10.1007/s00795-004-0265-0; Porte H, 1998, CLIN CANCER RES, V4, P1375; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; Puolakkainen PA, 2004, MOL CANCER RES, V2, P215; REED MJ, 1994, J CELL PHYSIOL, V158, P169, DOI 10.1002/jcp.1041580121; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; Rempel SA, 1998, J NEUROPATH EXP NEUR, V57, P1112, DOI 10.1097/00005072-199812000-00002; Rempel SA, 2001, J NEURO-ONCOL, V53, P149, DOI 10.1023/A:1012201300188; Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189; Roger L, 2006, BIOL CELL, V98, P141, DOI 10.1042/BC20050058; Ryu B, 2001, CANCER RES, V61, P1833; Sage EH, 2003, J BIOL CHEM, V278, P37849, DOI 10.1074/jbc.M302946200; SAGE EH, 1995, J CELL BIOCHEM, V57, P127, DOI 10.1002/jcb.240570113; SAGE H, 1989, J HISTOCHEM CYTOCHEM, V37, P819, DOI 10.1177/37.6.2723400; Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807; Schiemann BJ, 2003, MOL BIOL CELL, V14, P3977, DOI 10.1091/mbc.E03-01-0001; Seno T, 2009, INT J ONCOL, V34, P707, DOI 10.3892/ijo_00000197; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Suzuki S, 2004, CARCINOGENESIS, V25, P439, DOI 10.1093/carcin/bgh030; Tomasin R, 2001, J BIOL CHEM, V276, P44185, DOI 10.1074/jbc.M105647200; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; Tomasini R, 2002, EUR J CELL BIOL, V81, P294, DOI 10.1078/0171-9335-00248; Vasseur S, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-25; Verrecchia F, 2007, WORLD J GASTROENTERO, V13, P3056, DOI 10.3748/wjg.v13.i22.3056; WRANA JL, 1991, EUR J BIOCHEM, V197, P519, DOI 10.1111/j.1432-1033.1991.tb15940.x; Yamanaka M, 2001, J UROLOGY, V166, P2495, DOI 10.1016/S0022-5347(05)65623-6; Yoshida K, 2006, J BIOL CHEM, V281, P5734, DOI 10.1074/jbc.M512074200	54	55	60	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	27					3049	3061		10.1038/onc.2011.25	http://dx.doi.org/10.1038/onc.2011.25			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21339733				2022-12-17	WOS:000292510100005
J	Soond, SM; Chantry, A				Soond, S. M.; Chantry, A.			Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGF beta signalling and EMT	ONCOGENE			English	Article						TGF beta; Smads; transcription; Ubiquitin ligase	E3; AUTOINHIBITION; APOPTOSIS; PATHWAY; FAMILY; SMURF2; BINDS	Ubiquitin-dependent mechanisms have emerged as essential regulatory elements controlling cellular levels of Smads and TGF beta-dependent biological outputs such as epithelial-mesenchymal transition (EMT). In this study, we identify a HECT E3 ubiquitin ligase known as WWP2 (Full-length WWP2-FL), together with two WWP2 isoforms (N-terminal, WWP2-N; C-terminal WWP2-C), as novel Smad-binding partners. We show that WWP2-FL interacts exclusively with Smad2, Smad3 and Smad7 in the TGF beta pathway. Interestingly, the WWP2-N isoform interacts with Smad2 and Smad3, whereas WWP2-C interacts only with Smad7. In addition, WWP2-FL and WWP2-C have a preference for Smad7 based on protein turnover and ubiquitination studies. Unexpectedly, we also find that WWP2-N, which lacks the HECT ubiquitin ligase domain, can also interact with WWP2-FL in a TGF beta-regulated manner and activate endogenous WWP2 ubiquitin ligase activity causing degradation of unstimulated Smad2 and Smad3. Consistent with our protein interaction data, overexpression and knockdown approaches reveal that WWP2 isoforms differentially modulate TGF beta-dependent transcription and EMT. Finally, we show that selective disruption of WWP2 interactions with inhibitory Smad7 can stabilise Smad7 protein levels and prevent TGF beta-induced EMT. Collectively, our data suggest that WWP2-N can stimulate WWP2-FL leading to increased activity against unstimulated Smad2 and Smad3, and that Smad7 is a preferred substrate for WWP2-FL and WWP2-C following prolonged TGF beta stimulation. Significantly, this is the first report of an interdependent biological role for distinct HECT E3 ubiquitin ligase isoforms, and highlights an entirely novel regulatory paradigm that selectively limits the level of inhibitory and activating Smads. Oncogene (2011) 30, 2451-2462; doi:10.1038/onc.2010.617; published online 24 January 2011	[Soond, S. M.; Chantry, A.] Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Chantry, A (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	a.chantry@uea.ac.uk			Association for International Research (AICR); BigC Charity; British Skin Foundation; Dunhill Medical Trust; The Dunhill Medical Trust [R162/0510] Funding Source: researchfish	Association for International Research (AICR); BigC Charity; British Skin Foundation; Dunhill Medical Trust(Dunhill Medical Trust); The Dunhill Medical Trust(Dunhill Medical Trust)	We thank Fiona McDonald, Caroline Hill, and Hans Clevers for generously providing cells/plasmids, and Ian Clark and Tracey Swingler for generously providing ATDC5 cDNA samples. This work was supported by the Association for International Research (AICR), with additional funding provided by the BigC Charity, the British Skin Foundation and the Dunhill Medical Trust.	ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Danckwardt S, 2008, EMBO J, V27, P482, DOI 10.1038/sj.emboj.7601932; Ellenrieder V, 2001, CANCER RES, V61, P4222; Flasza M, 2002, BIOCHEM BIOPH RES CO, V290, P431, DOI 10.1006/bbrc.2001.6206; Foot NJ, 2008, BLOOD, V112, P4268, DOI 10.1182/blood-2008-04-150953; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hong S, 2007, CANCER RES, V67, P9577, DOI 10.1158/0008-5472.CAN-07-1179; Javelaud D, 2007, CANCER RES, V67, P2317, DOI 10.1158/0008-5472.CAN-06-3950; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Li H, 2007, MOL CELL BIOL, V27, P5296, DOI 10.1128/MCB.01667-06; Li W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001487; Lonn P, 2009, CELL RES, V19, P21, DOI 10.1038/cr.2008.308; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lutz CS, 2008, ACS CHEM BIOL, V3, P609, DOI 10.1021/cb800138w; McDonald FJ, 2002, AM J PHYSIOL-RENAL, V283, pF431, DOI 10.1152/ajprenal.00080.2002; Mund T, 2009, EMBO REP, V10, P501, DOI 10.1038/embor.2009.30; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Raikwar NS, 2008, AM J PHYSIOL-RENAL, V294, pF1157, DOI 10.1152/ajprenal.00339.2007; Tazi J, 2009, BBA-MOL BASIS DIS, V1792, P14, DOI 10.1016/j.bbadis.2008.09.017; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Wicks SJ, 2005, ONCOGENE, V24, P8080, DOI 10.1038/sj.onc.1208944; Wiesner S, 2007, CELL, V130, P651, DOI 10.1016/j.cell.2007.06.050; Xu HM, 2004, J BIOL CHEM, V279, P23495, DOI 10.1074/jbc.M400516200; Xu HM, 2009, CELL RES, V19, P561, DOI 10.1038/cr.2009.31; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang ST, 2006, CELL CYCLE, V5, P2787, DOI 10.4161/cc.5.23.3523; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	34	55	58	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	21					2451	2462		10.1038/onc.2010.617	http://dx.doi.org/10.1038/onc.2010.617			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21258410	Green Accepted			2022-12-17	WOS:000291008000007
J	Kreisler, A; Strissel, PL; Strick, R; Neumann, SB; Schumacher, U; Becker, CM				Kreisler, A.; Strissel, P. L.; Strick, R.; Neumann, S. B.; Schumacher, U.; Becker, C-M			Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer	ONCOGENE			English	Article						NRSF/REST; CREB; AKT2; small-cell lung cancer; methylation	RESTRICTIVE SILENCER FACTOR; GLYCINE RECEPTOR; FIBRONECTIN GENE; CYCLIC-AMP; EXPRESSION; TRANSCRIPTION; REST; REPRESSOR; DIFFERENTIATION; CARCINOMA	The neuron-restrictive silencer factor/RE1-silencing transcription factor (NRSF/REST) is a negative regulator of gene expression restricting the expression of neuronal genes to the nervous system. NRSF/REST is highly expressed in non-neuronal tissues like the lung. In previous work, we identified small-cell lung cancer (SCLC) cell lines with no detectable NRSF/REST expression that, as a consequence, expressed neuronal markers like L1-cell adhesion molecule (L1-CAM) and neural cell adhesion molecule (NCAM). The loss of NRSF/REST expression was linked to malignant progression; however, its mechanistic role remained elusive. Here, we show that NRSF/REST itself, rather than one of its regulated genes, acts like a classic tumour suppressor, being in part regulated by methylation. In SCLCs, NRSF/REST is positively regulated by CREB, with an NRSF/REST promoter fragment showing cell type specificity. Downstream, NRSF/REST directly regulates AKT2, in which NRSF/REST loss leads to an epidermal growth factor-mediated de-regulation of AKT-Serine473 phosphorylation, important for cellular proliferation and survival. Assaying anchorage-independent growth, we observed that with reduced NRSF/REST expression, proliferation was significantly enhanced, whereas NRSF/REST rescue decreased the potential of cells to grow anchorage independently. Our observations support the fact that NRSF/REST may act as an important modulator of malignant progression in SCLC. Oncogene (2010) 29, 5828-5838; doi: 10.1038/onc.2010.321; published online 9 August 2010	[Strissel, P. L.; Strick, R.; Neumann, S. B.] Univ Klinikum Erlangen, Mol Med Lab, Frauenklin, D-91054 Erlangen, Germany; [Kreisler, A.; Becker, C-M] Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Erlangen, Germany; [Schumacher, U.] Univ Klinikum Hamburg Eppendorf, Zentrum Expt Med, Inst Anat 2, Hamburg, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Strissel, PL (corresponding author), Univ Klinikum Erlangen, Mol Med Lab, Frauenklin, Univ Str 21-23, D-91054 Erlangen, Germany.	pamela.strissel@uk-erlangen.de	Wang, Weili/D-1546-2011		Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of University of Erlangen-Nurnberg; Johannes und Frieda Marohn-Stiftung	Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of University of Erlangen-Nurnberg; Johannes und Frieda Marohn-Stiftung	We thank Barbara Orlicz-Welcz, Rosa Weber, Florentine Koppitz, Sonja Oeser and Eli Stiegler for dedicated technical assistance and the group of Michael Wegner for their help with the luciferase assays. We thank Magnus von Knebel-Doeberitz from the University of Heidelberg for the NRSF/REST expression vector pcNRSFwt. This project was supported by a grant from the Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of University of Erlangen-Nurnberg to CM Becker and PL Strissel and a grant from the Johannes und Frieda Marohn-Stiftung.	Anbazhagan R, 1999, CANCER RES, V59, P5119; Arboleda MJ, 2003, CANCER RES, V63, P196; BARCO A, 2006, ROLE CREB CBP BRAIN; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; CARNEY DN, 1985, CANCER RES, V45, P2913; Chong S, 2006, RADIOGRAPHICS, V26, P41, DOI 10.1148/rg.261055057; Ciombor Kristen Keon, 2006, Curr Treat Options Oncol, V7, P59, DOI 10.1007/s11864-006-0032-7; Coulson JM, 2005, CURR BIOL, V15, pR665, DOI 10.1016/j.cub.2005.08.032; Coulson JM, 2000, CANCER RES, V60, P1840; Ekici M, 2008, J BIOL CHEM, V283, P9257, DOI 10.1074/jbc.M709388200; FERGUSON AT, 1995, CANCER RES, V55, P2279; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; Fuller GN, 2005, MOL CANCER THER, V4, P343; GAZDAR AF, 1980, CANCER RES, V40, P3502; GRIFFIN CA, 1985, CANCER RES, V45, P272; Guardavaccaro D, 2008, NATURE, V452, P365, DOI 10.1038/nature06641; Gurrola-Diaz C, 2003, ONCOGENE, V22, P5636, DOI 10.1038/sj.onc.1206790; Kitamura H, 2009, ENDOCR PATHOL, V20, P101, DOI 10.1007/s12022-009-9072-4; Koenigsberger C, 2000, P NATL ACAD SCI USA, V97, P2291, DOI 10.1073/pnas.050578797; Kojima T, 2001, MOL BRAIN RES, V90, P174, DOI 10.1016/S0169-328X(01)00107-3; Laufs TL, 2004, NEUROSCI LETT, V362, P83, DOI 10.1016/j.neulet.2004.02.072; Lee BH, 1998, EXP MOL MED, V30, P240, DOI 10.1038/emm.1998.35; Lenz B, 2006, EXP CELL RES, V312, P4049, DOI 10.1016/j.yexcr.2006.09.004; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; MABRY M, 1988, P NATL ACAD SCI USA, V85, P6523, DOI 10.1073/pnas.85.17.6523; Magin A, 2002, NEUROCHEM INT, V40, P195, DOI 10.1016/S0197-0186(01)00091-2; Moss AC, 2009, CLIN CANCER RES, V15, P274, DOI 10.1158/1078-0432.CCR-08-1163; Neumann SB, 2004, MOL BRAIN RES, V120, P173, DOI 10.1016/j.molbrainres.2003.10.021; Ng RK, 2008, CELL CYCLE, V7, P1173, DOI 10.4161/cc.7.9.5791; Onganer PU, 2005, BRIT J CANCER, V93, P1197, DOI 10.1038/sj.bjc.6602857; Ooi L, 2007, NAT REV GENET, V8, P544, DOI 10.1038/nrg2100; Otto SJ, 2007, J NEUROSCI, V27, P6729, DOI 10.1523/JNEUROSCI.0091-07.2007; Palm K, 1999, MOL BRAIN RES, V72, P30, DOI 10.1016/S0169-328X(99)00196-5; Palm K, 1998, J NEUROSCI, V18, P1280; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Pio R, 2009, J THORAC ONCOL, V4, P674, DOI 10.1097/JTO.0b013e3181a520dc; Rasband W., 2022, IMAGEJ; Reddy BY, 2009, P NATL ACAD SCI USA, V106, P4408, DOI 10.1073/pnas.0809130106; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schug J, 2003, CURRENT PROTOCOLS BI; Shimojo M, 1999, MOL CELL BIOL, V19, P6788; Smith B, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-S1-S15; Strick R, 2007, J MOL MED, V85, P23, DOI 10.1007/s00109-006-0104-y; Strissel PL, 2008, INT J CANCER, V123, P2871, DOI 10.1002/ijc.23900; Strissel PL, 2000, HUM MOL GENET, V9, P1671, DOI 10.1093/hmg/9.11.1671; Su XH, 2006, MOL CELL BIOL, V26, P1666, DOI 10.1128/MCB.26.5.1666-1678.2006; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; TRAVIS WD, 1995, CANCER-AM CANCER SOC, V75, P191, DOI 10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y; VANHAASTERT PJM, 1984, J BIOL CHEM, V259, P20; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Westbrook TF, 2008, NATURE, V452, P370, DOI 10.1038/nature06780; Wu J, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r85; Zimmermann S, 1997, CANCER IMMUNOL IMMUN, V44, P1, DOI 10.1007/s002620050348	54	55	57	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	43					5828	5838		10.1038/onc.2010.321	http://dx.doi.org/10.1038/onc.2010.321			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20697351				2022-12-17	WOS:000283586200008
J	Redmond, KL; Crawford, NT; Farmer, H; D'Costa, ZC; O'Brien, GJ; Buckley, NE; Kennedy, RD; Johnston, PG; Harkin, DP; Mullan, PB				Redmond, K. L.; Crawford, N. T.; Farmer, H.; D'Costa, Z. C.; O'Brien, G. J.; Buckley, N. E.; Kennedy, R. D.; Johnston, P. G.; Harkin, D. P.; Mullan, P. B.			T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells	ONCOGENE			English	Article						TBX2; NDRG1; EGR1; breast cancer	P53-DEPENDENT APOPTOSIS; TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; GENE; TBX2; P53; SENESCENCE; EXPRESSION; GROWTH; BRCA1	T-box 2 (TBX2) is a transcription factor involved in mammary development and is known to be overexpressed in a subset of aggressive breast cancers. TBX2 has previously been shown to repress growth control genes such as p14(ARF) and p21(WAF1/cip1). In this study we show that TBX2 drives proliferation in breast cancer cells and this is abrogated after TBX2 small interfering RNA (siRNA) knockdown or after the expression of a dominant-negative TBX2 protein. Using microarray analysis we identified a large cohort of novel TBX2-repressed target genes including the breast tumour suppressor NDRG1 (N-myc downregulated gene 1). We show that TBX2 targets NDRG1 through a previously undescribed mechanism involving the recruitment of early growth response 1 (EGR1). We show EGR1 is required for the ability of TBX2 to repress NDRG1 and drive cell proliferation. We show that TBX2 interacts with EGR1 and that TBX2 requires EGR1 to target the NDRG1 proximal promoter. Abrogation of either TBX2 or EGR1 expression is accompanied by the upregulation of cell senescence and apoptotic markers. NDRG1 can recapitulate these effects when transfected into TBX2-expressing cells. Together, these data identify a novel mechanism for TBX2-driven oncogenesis and highlight the importance of NDRG1 as a growth control gene in breast tissue. Oncogene (2010) 29, 3252-3262; doi: 10.1038/onc.2010.84; published online 29 March 2010	[Redmond, K. L.; Crawford, N. T.; Farmer, H.; D'Costa, Z. C.; Buckley, N. E.; Johnston, P. G.; Harkin, D. P.; Mullan, P. B.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; [O'Brien, G. J.; Kennedy, R. D.; Harkin, D. P.] Almac Diagnost, Craigavon, North Ireland	Queens University Belfast	Mullan, PB (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, CCRCB Bldg,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	p.mullan@qub.ac.uk	Kennedy, Richard/J-3489-2012	Kennedy, Richard/0000-0003-4737-6163; Buckley, Niamh/0000-0001-9326-8513	Department of Employment and Learning Northern Ireland; Breast Cancer Campaign; Action Cancer; OSF; Cancer Research UK; Research and Development Northern Ireland	Department of Employment and Learning Northern Ireland; Breast Cancer Campaign; Action Cancer; OSF; Cancer Research UK(Cancer Research UK); Research and Development Northern Ireland	Special thanks to Dr James Murray (CCRCB, QUB) for gift of sheep anti-human NDRG1 antibody, Professor Carlos Caldas (University of Cambridge) for TBX2-expressing breast cancer cell lines and Professor Max Costa (University of New York) for NDRG1 promoter luciferase constructs. We also thank Professor Neil Perkins (University of Bristol) for reading this manuscript. This study was supported by the Department of Employment and Learning Northern Ireland (KLR), Breast Cancer Campaign (NTC, PBM), Action Cancer (HF, PBM), OSF (ZCD'C), Cancer Research UK (GJO'B, PGJ, DPH) and Research and Development Northern Ireland (NEB).	Boogerd KJ, 2008, CARDIOVASC RES, V78, P485, DOI 10.1093/cvr/cvn049; Buckley NE, 2007, MOL CANCER RES, V5, P261, DOI 10.1158/1541-7786.MCR-06-0250; Carlson H, 2002, ONCOGENE, V21, P3827, DOI 10.1038/sj.onc.1205476; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; de Belle I, 1999, ONCOGENE, V18, P3633, DOI 10.1038/sj.onc.1202696; Habets PEMH, 2002, GENE DEV, V16, P1234, DOI 10.1101/gad.222902; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Ismail A, 2009, CANCER LETT, V278, P230, DOI 10.1016/j.canlet.2009.01.006; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841; Krones-Herzig A, 2003, P NATL ACAD SCI USA, V100, P3233, DOI 10.1073/pnas.2628034100; Le NTV, 2004, BLOOD, V104, P2967, DOI 10.1182/blood-2004-05-1866; Lingbeek ME, 2002, J BIOL CHEM, V277, P26120, DOI 10.1074/jbc.M200403200; Lu Shaolei, 2008, Endocrinology, V149, P4809, DOI 10.1210/en.2008-0035; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Prince S, 2004, CANCER RES, V64, P1669, DOI 10.1158/0008-5472.CAN-03-3286; Qian YJ, 2008, J BIOL CHEM, V283, P2896, DOI 10.1074/jbc.M708624200; Ronski K, 2005, CANCER-AM CANCER SOC, V104, P925, DOI 10.1002/cncr.21262; Roylance R, 1999, CANCER RES, V59, P1433; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sinclair CS, 2002, CANCER RES, V62, P3587; Stein S, 2004, J BIOL CHEM, V279, P48930, DOI 10.1074/jbc.M400386200; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Yu J, 2007, CELL DEATH DIFFER, V14, P436, DOI 10.1038/sj.cdd.4402029; Zagurovskaya M, 2009, ONCOGENE, V28, P1121, DOI 10.1038/onc.2008.461; Zhang J, 2008, GENE, V417, P5, DOI 10.1016/j.gene.2008.03.002; Zhang P, 2007, CANCER RES, V67, P9125, DOI 10.1158/0008-5472.CAN-07-1525	30	55	56	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	2010	29	22					3252	3262		10.1038/onc.2010.84	http://dx.doi.org/10.1038/onc.2010.84			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20348948				2022-12-17	WOS:000278321100008
J	Bocanegra, M; Bergamaschi, A; Kim, YH; Miller, MA; Rajput, AB; Kao, J; Langerod, A; Han, W; Noh, DY; Jeffrey, SS; Huntsman, DG; Borresen-Dale, AL; Pollack, JR				Bocanegra, M.; Bergamaschi, A.; Kim, Y. H.; Miller, M. A.; Rajput, A. B.; Kao, J.; Langerod, A.; Han, W.; Noh, D-Y; Jeffrey, S. S.; Huntsman, D. G.; Borresen-Dale, A-L; Pollack, J. R.			Focal amplification and oncogene dependency of GAB2 in breast cancer	ONCOGENE			English	Article						GAB2; DNA amplification; genomic profiling; array-based comparative genomic hybridization; breast cancer; oncogene dependency	DOCKING PROTEIN; TRANSFORMATION; PATTERNS	DNA amplifications in breast cancer are frequent on chromosome 11q, in which multiple driver oncogenes likely reside in addition to cyclin D1 (CCND1). One such candidate, the scaffolding adapter protein, GRB2-associated binding protein 2 (GAB2), functions in ErbB signaling and was recently shown to enhance mammary epithelial cell proliferation, and metastasis of ERBB2 (HER2/neu)-driven murine breast cancer. However, the amplification status and function of GAB2 in the context of amplification remain undefined. In this study, by genomic profiling of 172 breast tumors, and fluorescence in situ hybridization validation in an independent set of 210 scorable cases, we observed focal amplification spanning GAB2 (11q14.1) independent of CCND1 (11q13.2) amplification, consistent with a driver role. Further, small interfering RNA (siRNA)-mediated knockdown of GAB2 in breast cancer lines (SUM52, SUM44PE and MDA468) with GAB2 amplification revealed a dependency on GAB2 for cell proliferation, cell-cycle progression, survival and invasion, likely mediated through altered phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling. GAB2 knockdown also reduced proliferation and survival in a cell line (BT474) with ERBB2 amplification, consistent with the possibility that GAB2 can function downstream of ERBB2. Our studies implicate focal amplification of GAB2 in breast carcinogenesis, and underscore an oncogenic role of scaffolding adapter proteins, and a potential new point of therapeutic intervention. Oncogene (2010) 29, 774-779; doi: 10.1038/onc.2009.364; published online 2 November 2009	[Pollack, J. R.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Bergamaschi, A.; Langerod, A.; Borresen-Dale, A-L] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Genet, Oslo, Norway; [Miller, M. A.; Rajput, A. B.; Huntsman, D. G.] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada; [Miller, M. A.; Rajput, A. B.; Huntsman, D. G.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; [Han, W.; Noh, D-Y] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Han, W.; Noh, D-Y] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea; [Jeffrey, S. S.] Stanford Univ, Dept Surg, Stanford, CA 94305 USA; [Borresen-Dale, A-L] Univ Oslo, Fac Div, Norwegian Radium Hosp, Fac Med, Oslo, Norway	Stanford University; University of Oslo; University of British Columbia; British Columbia Cancer Agency; Seoul National University (SNU); Seoul National University (SNU); Stanford University; University of Oslo	Pollack, JR (corresponding author), Stanford Univ, Dept Pathol, Sch Med, CCSR-3245A,269 Campus Dr, Stanford, CA 94305 USA.	pollack1@stanford.edu	Noh, Dong-Young/G-5531-2011; Huntsman, David/ABE-6082-2020; Bergamaschi, Anna/D-2022-2009; Han, Wonshik/B-3699-2008	Bergamaschi, Anna/0000-0001-8709-1766; Han, Wonshik/0000-0001-7310-0764; Jeffrey, Stefanie/0000-0003-4478-2764	National Institutes of Health [CA97139, CA09302, CA130172]; Department of Defense Breast Cancer Research Program [BC073467]; California Breast Cancer Research Program [8KB-0135, 11IB-0175]; Norwegian Research Council, NFR [155218/300]; Korea Health 21 R&D Project, Ministry of Health Welfare ROK [01-PJ3-PG601GN07-0004]; Sanofi-aventis, Canada; NATIONAL CANCER INSTITUTE [T32CA009302, R01CA097139, F31CA130172] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program(United States Department of Defense); California Breast Cancer Research Program; Norwegian Research Council, NFR(Research Council of Norway); Korea Health 21 R&D Project, Ministry of Health Welfare ROK; Sanofi-aventis, Canada; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Stanford Functional Genomics Facility for microarray manufacture, the Stanford Microarray Database for database support and members of the Pollack lab for helpful discussion. This work was supported in part by grants from the National Institutes of Health, CA97139 (JRP), CA09302 and CA130172 (MB); the Department of Defense Breast Cancer Research Program, BC073467 (MB); the California Breast Cancer Research Program, 8KB-0135 (JRP) and 11IB-0175 (SSJ); the Norwegian Research Council, NFR, 155218/300 (ALBD); and the Korea Health 21 R&D Project, Ministry of Health & Welfare ROK, 01-PJ3-PG601GN07-0004 (WH and D-YN). AB was during this work a fellow of The Norwegian Cancer Society. DGH is a Michael Smith Foundation for Health Research Scholar. Funding for the thermomechanical analysis was provided in part by an unrestricted educational grant from Sanofi-aventis, Canada.	Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bergamaschi A, 2008, MOL ONCOL, V2, P327, DOI 10.1016/j.molonc.2008.09.004; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Ischenko I, 2003, ONCOGENE, V22, P6311, DOI 10.1038/sj.onc.1206742; Jemal A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1672; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Pegram M D, 2000, Cancer Treat Res, V103, P57; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Sarmay G, 2006, IMMUNOL LETT, V104, P76, DOI 10.1016/j.imlet.2005.11.017; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tibshirani R, 2008, BIOSTATISTICS, V9, P18, DOI 10.1093/biostatistics/kxm013	19	55	61	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					774	779		10.1038/onc.2009.364	http://dx.doi.org/10.1038/onc.2009.364			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19881546				2022-12-17	WOS:000274223700013
J	Hoover, AC; Strand, GL; Nowicki, PN; Anderson, ME; Vermeer, PD; Klingelhutz, AJ; Bossler, AD; Pottala, JV; Hendriks, WJAJ; Lee, JH				Hoover, A. C.; Strand, G. L.; Nowicki, P. N.; Anderson, M. E.; Vermeer, P. D.; Klingelhutz, A. J.; Bossler, A. D.; Pottala, J. V.; Hendriks, W. J. A. J.; Lee, J. H.			Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway	ONCOGENE			English	Article						human papilloma virus; HPV E6 oncogene; PTPN13; MAP Kinase; ErbB2	TUMOR-SUPPRESSOR GENE; ANCHORAGE-INDEPENDENT GROWTH; ORAL MEK INHIBITOR; HEPATOCELLULAR-CARCINOMA; HUMAN-PAPILLOMAVIRUS; PROGNOSTIC IMPACT; EPITHELIAL-CELLS; INVASIVE GROWTH; CERVICAL-CANCER; FACTOR RECEPTOR	Human papillomaviruses (HPVs) are a causative factor in over 90% of cervical and 25% of head and neck squamous cell carcinomas (HNSCCs). The C terminus of the high-risk HPV 16 E6 oncoprotein physically associates with and degrades a non-receptor protein tyrosine phosphatase (PTPN13), and PTPN13 loss synergizes with H-Ras(V12) or ErbB2 for invasive growth in vivo. Oral keratinocytes that have lost PTPN13 and express H-Ras(V12) or ErbB2 show enhanced Ras/RAF/MEK/Erk signaling. In co-transfection studies, wild-type PTPN13 inhibited Ras/RAF/MEK/Erk signaling in HEK 293 cells that overexpress ErbB2, EGFR or H-Ras(V12), whereas an enzymatically inactive PTPN13 did not. Twenty percent of HPV-negative HNSCCs had PTPN13 phosphatase mutations that did not inhibit Ras/RAF/MEK/Erk signaling. Inhibition of Ras/RAF/MEK/Erk signaling using MEK inhibitor U0126 blocked anchorage-independent growth in cells lacking PTPN13. These findings show that PTPN13 phosphatase activity has a physiologically significant role in regulating MAP kinase signaling. Oncogene (2009) 28, 3960-3970; doi:10.1038/onc.2009.251; published online 7 September 2009	[Hoover, A. C.; Anderson, M. E.] Univ Iowa, Dept Otolaryngol Head & Neck Surg, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Strand, G. L.; Bossler, A. D.] Univ Iowa, Dept Pathol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Vermeer, P. D.; Pottala, J. V.; Lee, J. H.] Sanford Res USD, Canc Biol Res Ctr, Sioux Falls, SD USA; [Klingelhutz, A. J.] Univ Iowa, Dept Microbiol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Hendriks, W. J. A. J.] Radboud Univ Nijmegen, Med Ctr, Dept Cell Biol, NL-6525 ED Nijmegen, Netherlands; [Lee, J. H.] Sanford Hlth, Sanford ENT Head & Neck Surg, Sioux Falls, SD USA	University of Iowa; University of Iowa; Sanford Health; University of Iowa; Radboud University Nijmegen; Sanford Health	Lee, JH (corresponding author), Sanford HPV Res Inst, Dept Otolaryngol, 1310 22nd St, Sioux Falls, SD 57105 USA.	leej@sanfordhealth.org	Vermeer, Paola D/O-2572-2013; Klingelhutz, Aloysius/L-9081-2018; Hendriks, Wiljan/Q-4325-2019; Hendriks, Wiljan J.A.J./A-5214-2013	Klingelhutz, Aloysius/0000-0003-4258-5046; Hendriks, Wiljan/0000-0001-9481-8281; Hendriks, Wiljan J.A.J./0000-0001-9481-8281; Bossler, Aaron/0000-0002-8748-2510	NIDCR [1R01DE018386-01A1]; HHMI; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE018386] Funding Source: NIH RePORTER	NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); HHMI(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	JHL was supported by an NIDCR 1R01DE018386-01A1 and ACH was supported by an HHMI medical student fellowship. We acknowledge Jan Schepens' technical expertise for completing the phosphatase assays and Catherine Christopherson for manuscript preparation.	Abaan OD, 2008, CANCER METAST REV, V27, P205, DOI 10.1007/s10555-008-9114-2; Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Al Moustafa AE, 2004, ONCOGENE, V23, P350, DOI 10.1038/sj.onc.1207148; Avila MA, 2006, ONCOGENE, V25, P3866, DOI 10.1038/sj.onc.1209550; Barault L, 2008, INT J CANCER, V122, P2255, DOI 10.1002/ijc.23388; Cavalot A, 2007, HEAD NECK-J SCI SPEC, V29, P655, DOI 10.1002/hed.20574; Dromard M, 2007, CANCER RES, V67, P6806, DOI 10.1158/0008-5472.CAN-07-0513; Erdmann KS, 2003, EUR J BIOCHEM, V270, P4789, DOI 10.1046/j.1432-1033.2003.03895.x; Landro ME, 2008, J MED VIROL, V80, P694, DOI 10.1002/jmv.21076; Ford AC, 2003, HEAD NECK-J SCI SPEC, V25, P67, DOI 10.1002/hed.10224; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hardisson D, 2003, EUR ARCH OTO-RHINO-L, V260, P502, DOI 10.1007/s00405-003-0581-3; Hopfner M, 2008, WORLD J GASTROENTERO, V14, P1, DOI 10.3748/wjg.14.1; Hoover AC, 2007, ARCH OTOLARYNGOL, V133, P495, DOI 10.1001/archotol.133.5.495; Hsu J. C, 1992, J COMPUTATIONAL STAT, V1, P151, DOI DOI 10.2307/1390839; Jelen F, 2003, ACTA BIOCHIM POL, V50, P985; Lee JH, 1996, GYNECOL ONCOL, V62, P49, DOI 10.1006/gyno.1996.0188; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Nakahira M, 2007, IMMUNITY, V26, P163, DOI 10.1016/j.immuni.2007.01.010; Perez-Regadera J, 2009, ONCOLOGY-BASEL, V76, P133, DOI 10.1159/000195539; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Revillion F, 2009, INT J CANCER, V124, P638, DOI 10.1002/ijc.23989; Rinehart J, 2004, J CLIN ONCOL, V22, P4456, DOI 10.1200/JCO.2004.01.185; Schreiber K, 2004, ONCOGENE, V23, P3972, DOI 10.1038/sj.onc.1207507; Spanos WC, 2008, J VIROL, V82, P2493, DOI 10.1128/JVI.02188-07; Spanos WC, 2008, HEAD NECK-J SCI SPEC, V30, P139, DOI 10.1002/hed.20673; Villa F, 2005, J BIOL CHEM, V280, P8180, DOI 10.1074/jbc.M412211200; Wang D, 2007, BBA-MOL CELL RES, V1773, P1248, DOI 10.1016/j.bbamcr.2006.11.009; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Wansink DG, 2004, PHYSIOL GENOMICS, V19, P50, DOI 10.1152/physiolgenomics.00079.2004; YARBROUGH WG, 1994, LARYNGOSCOPE, V104, P1337; Yeh SH, 2006, CLIN CANCER RES, V12, P1097, DOI 10.1158/1078-0432.CCR-05-1383; Ying J, 2006, LEUKEMIA, V20, P1173, DOI 10.1038/sj.leu.2404193; Zhan M, 2004, HISTOL HISTOPATHOL, V19, P973, DOI 10.14670/HH-19.973; Zhu JH, 2008, ONCOGENE, V27, P2525, DOI 10.1038/sj.onc.1210922	39	55	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					3960	3970		10.1038/onc.2009.251	http://dx.doi.org/10.1038/onc.2009.251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19734941	Green Accepted			2022-12-17	WOS:000272560300002
J	Narita, N; Tanemura, A; Murali, R; Scolyer, RA; Huang, S; Arigami, T; Yanagita, S; Chong, KK; Thompson, JF; Morton, DL; Hoon, DS				Narita, N.; Tanemura, A.; Murali, R.; Scolyer, R. A.; Huang, S.; Arigami, T.; Yanagita, S.; Chong, K. K.; Thompson, J. F.; Morton, D. L.; Hoon, D. S.			Functional RET G691S polymorphism in cutaneous malignant melanoma	ONCOGENE			English	Article						RET; polymorphism; mutation; melanoma; desmoplastic; BRAF	DESMOPLASTIC MELANOMA; NEUROTROPHIC FACTOR; TYROSINE KINASE; BRAF MUTATIONS; THYROID-CARCINOMA; CANCER; INHIBITION; CELLS; GENE; PROTOONCOGENE	RET proto-oncogene encodes a receptor tyrosine kinase whose ligand is glial cell line-derived neurotrophic factor (GDNF), and its polymorphism at G691S juxtamembrane region (RETp) is a germline polymorphism. Cutaneous melanomas, particularly the desmoplastic subtype, are highly neurotropic; thus we sought to determine the frequency of RETp in cutaneous melanoma and its functional responsiveness to GDNF. RETp was assessed in 71 non-desmoplastic cutaneous melanomas (non-DMs) and 70 desmoplastic melanomas (DMs). Melanoma cell lines with RETp, RET wild type (RETwt), BRAF V600E mutation (BRAFmt) or BRAF wild type (BRAFwt) were assessed for functional activity. RETp frequency was significantly higher in DMs (61%) than in non-DMs (31%, P<0.001). BRAFmt was detected in only 11% of DMs. GDNF stimulation significantly amplified cell proliferation, migration and invasion in RETp, but not in RETwt melanoma cells. GDNF stimulation of RETp cell lines enhanced phosphorylation of extracellular signal-regulated kinase (ERK) and Akt of the RET-RAS-RAF-ERK and RET-phosphatidylinositol 3-kinase (PI3K)-Akt pathways, respectively. GDNF response of RETp cells in signal transduction and other functional studies were not affected by BRAFmt. The study demonstrates that RETp is frequently found in cutaneous melanoma, particularly desmoplastic subtypes, and responds to GDNF inducing events favorable for tumor progression. Oncogene (2009) 28, 3058-3068; doi:10.1038/onc.2009.164; published online 29 June 2009	[Narita, N.; Tanemura, A.; Huang, S.; Arigami, T.; Yanagita, S.; Chong, K. K.; Hoon, D. S.] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA; [Murali, R.; Scolyer, R. A.] Royal Prince Alfred Hosp, Sydney Canc Ctr, Dept Anat Pathol, Camperdown, NSW 2050, Australia; [Murali, R.; Scolyer, R. A.; Thompson, J. F.] Royal Prince Alfred Hosp, Sydney Canc Ctr, Sydney Melanoma Unit, Camperdown, NSW 2050, Australia; [Morton, D. L.] St Johns Hlth Ctr, John Wayne Canc Inst, Div Surg Oncol, Santa Monica, CA 90404 USA	John Wayne Cancer Institute; University of Sydney; Melanoma Institute Australia; University of Sydney; John Wayne Cancer Institute	Hoon, DS (corresponding author), St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	hoon@jwci.org	Thompson, John/F-9075-2013; Narita, Norihiko/AAA-4801-2022; Scolyer, Richard/AAE-8511-2019; MURALI, RAJMOHAN/A-7960-2008; Hoon, Dave SB/C-7146-2018	Thompson, John/0000-0002-2816-2496; Narita, Norihiko/0000-0001-9765-9669; Scolyer, Richard/0000-0002-8991-0013; MURALI, RAJMOHAN/0000-0001-6988-4295; Hoon, Dave SB/0000-0003-1915-3683	National Institutes of Health; National Cancer Institute [P0 CA029605, CA012582]; Ruth and Martin H Weil Foundation; Leslie and Susan Gonda Foundation; Melanoma Foundation of the University of Sydney, Australia; NATIONAL CANCER INSTITUTE [P01CA029605, P01CA012582] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ruth and Martin H Weil Foundation; Leslie and Susan Gonda Foundation; Melanoma Foundation of the University of Sydney, Australia(University of Sydney); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Sandy L Nguyen and Linhda Nguyen for expert editorial assistance and Emily H Liang for technical assistance. This work was supported by the National Institutes of Health, National Cancer Institute (Project II P0 CA029605 and CA012582 grants to DH); Ruth and Martin H Weil Foundation (to DH); the Leslie and Susan Gonda Foundation (to DH) and the Melanoma Foundation of the University of Sydney, Australia (to JT, RS, RM).	Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Bounacer A, 2002, BRIT J CANCER, V86, P1929, DOI 10.1038/sj.bjc.6600371; Busam KJ, 2005, ADV ANAT PATHOL, V12, P92, DOI 10.1097/01.pap.0000155071.86944.a6; Busam KJ, 2005, J INVEST DERMATOL, V124, P412, DOI 10.1111/j.0022-202X.2004.23600.x; Carlomagno F, 2006, JNCI-J NATL CANCER I, V98, P326, DOI 10.1093/jnci/djj069; CECCHERINI I, 1994, ONCOGENE, V9, P3025; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davison JM, 2005, CANCER-AM CANCER SOC, V103, P788, DOI 10.1002/cncr.20861; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Elisei R, 2004, J CLIN ENDOCR METAB, V89, P3579, DOI 10.1210/jc.2003-031898; Fujiwara Y, 1999, CANCER RES, V59, P1567; Goto Y, 2006, CANCER RES, V66, P4443, DOI 10.1158/0008-5472.CAN-05-2505; Goto Y, 2008, MOL CANCER THER, V7, P3642, DOI 10.1158/1535-7163.MCT-08-0582; Govindarajan B, 2007, J CLIN INVEST, V117, P719, DOI 10.1172/JCI30102; Gumireddy K, 2007, P NATL ACAD SCI USA, V104, P6696, DOI 10.1073/pnas.0701145104; Hoon DSB, 2001, J INVEST DERMATOL, V117, P375, DOI 10.1046/j.0022-202x.2001.01417.x; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Jaroszewski DE, 2001, AM J SURG, V182, P590, DOI 10.1016/S0002-9610(01)00819-4; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Koyanagi K, 2005, J CLIN ONCOL, V23, P8057, DOI 10.1200/JCO.2005.02.0958; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Livestro DP, 2005, J CLIN ONCOL, V23, P6739, DOI 10.1200/JCO.2005.04.515; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Mologni L, 2006, J MOL ENDOCRINOL, V37, P199, DOI 10.1677/jme.1.01999; Plaza-Menacho I, 2007, J BIOL CHEM, V282, P29230, DOI 10.1074/jbc.M703461200; Quinn MJ, 1998, CANCER-AM CANCER SOC, V83, P1128, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1128::AID-CNCR11>3.3.CO;2-Y; Runeberg-Roos P, 2007, ANN MED, V39, P572, DOI 10.1080/07853890701646256; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sawai H, 2005, CANCER RES, V65, P11536, DOI 10.1158/0008-5472.CAN-05-2843; Selek U, 2004, INT J RADIAT ONCOL, V59, P1097, DOI 10.1016/j.ijrobp.2003.12.037; Shinozaki M, 2004, CLIN CANCER RES, V10, P1753, DOI 10.1158/1078-0432.CCR-1169-3; Shinozaki M, 2007, CLIN CANCER RES, V13, P2068, DOI 10.1158/1078-0432.CCR-06-2120; Stephens LA, 2005, THYROID, V15, P100, DOI 10.1089/thy.2005.15.100; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538; Weber F, 2008, J CLIN ENDOCR METAB, V93, P1097, DOI 10.1210/jc.2008-0212; Zbuk KM, 2007, NAT REV CANCER, V7, P35, DOI 10.1038/nrc2037	42	55	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2009	28	34					3058	3068		10.1038/onc.2009.164	http://dx.doi.org/10.1038/onc.2009.164			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487ZU	19561646	Green Accepted			2022-12-17	WOS:000269319000005
J	Sun, Q; Ming, L; Thomas, SM; Wang, Y; Chen, ZG; Ferris, RL; Grandis, JR; Zhang, L; Yu, J				Sun, Q.; Ming, L.; Thomas, S. M.; Wang, Y.; Chen, Z. G.; Ferris, R. L.; Grandis, J. R.; Zhang, L.; Yu, J.			PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells	ONCOGENE			English	Article						PUMA; EGFR-TKI; p73; apoptosis; PI3K/AKT; head and neck cancer	BH3-ONLY PROTEINS; CARCINOMA; GROWTH; EXPRESSION; P53; INDUCTION; P63; (-)-GOSSYPOL; GEFITINIB; DISCOVERY	Overexpression of epidermal growth factor receptor (EGFR) is found in over 80% of head and neck squamous cell carcinomas (HNSCC) and associated with poor clinical outcomes. EFGR selective tyrosine kinase inhibitors (TKIs) or antibodies have recently emerged as promising treatments for solid tumors, including HNSCC, though the response rate to these agents is low. p53 upregulated modulator of apoptosis (PUMA), a BH3-only Bcl-2 family protein, is required for apoptosis induced by p53 and various chemotherapeutic agents. In this study, we show that PUMA induction is correlated with EGFR-TKI sensitivity, and is mediated through the p53 family protein p73 beta and inhibition of the PI3K/AKT pathway. In some HNSCC cells, the gefitinib-induced degradation of oncogenic Delta Np63 seems to facilitate p73-mediated PUMA transcription. Inhibiting PUMA expression by small hairpin RNA (shRNA) impairs gefitinib-induced apoptosis. Furthermore, PUMA or BH3 mimetics sensitize HNSCC cells to gefitinib-induced apoptosis. Our results suggest that PUMA induction through p73 represents a new mechanism of EGFR inhibitor-induced apoptosis, and provide potential ways for enhancing and predicting the sensitivity to EGFR-targeted therapies in HNSCC. Oncogene (2009) 28, 2348-2357; doi:10.1038/onc.2009.108; published online 4 May 2009	[Sun, Q.; Ming, L.; Yu, J.] Univ Pittsburgh, Dept Pathol, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA 15213 USA; [Thomas, S. M.; Ferris, R. L.; Grandis, J. R.] Univ Pittsburgh, Dept Otolaryngol, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA 15213 USA; [Wang, Y.] Univ Pittsburgh, Dept Biostat, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA 15213 USA; [Chen, Z. G.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Grandis, J. R.; Zhang, L.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yu, J (corresponding author), Univ Pittsburgh, Dept Pathol, Hillman Canc Ctr, Inst Canc, Suite 2-26H,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	yuj2@upmc.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009; Thomas, Sufi Mary/AFR-1642-2022; Thomas, Sufi/O-1487-2018	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Thomas, Sufi Mary/0000-0001-5370-0842; Thomas, Sufi/0000-0001-5370-0842	NIH [CA129829, P50CA097190, CA106348, CA121105]; American Cancer Society [RSG-07-156-01-CNE]; NATIONAL CANCER INSTITUTE [R01CA121105, R01CA129829, P50CA097190, R01CA106348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085570] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank other members of our laboratories for helpful discussion and advice. We also thank Drs Cary Wu, Susanne M Gollin (University of Pittsburgh), Bert Vogelstein (HHMI and Sidney Kimmel Cancer Center at Johns Hopkins), David Sidransky (Sidney Kimmel Cancer Center at Johns Hopkins), and Carol Prives (Columbia University) for reagents. This work is supported in part by NIH grant CA129829, P50CA097190 (Head and Neck SPORE career development award) and those from ACGT and FAMRI (J Yu), and by NIH grants CA106348, CA121105, and American Cancer Society grant RSG-07-156-01-CNE (L Zhang).	Barbieri CE, 2006, EXP CELL RES, V312, P695, DOI 10.1016/j.yexcr.2005.11.028; Barbieri CE, 2003, J BIOL CHEM, V278, P51408, DOI 10.1074/jbc.M309943200; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Choong NW, 2006, CRIT REV ONCOL HEMAT, V57, P25, DOI 10.1016/j.critrevonc.2005.06.002; Chun PY, 2006, CANCER RES, V66, P981, DOI 10.1158/0008-5472.CAN-05-2665; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; Karst AM, 2005, ONCOGENE, V24, P1111, DOI 10.1038/sj.onc.1208374; Kitada S, 2003, J MED CHEM, V46, P4259, DOI 10.1021/jm030190z; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Liu B, 2000, BRIT J CANCER, V82, P1991; Matheny KE, 2003, LARYNGOSCOPE, V113, P936, DOI 10.1097/00005537-200306000-00004; Ming LH, 2008, CARCINOGENESIS, V29, P1878, DOI 10.1093/carcin/bgn150; Muller S, 2008, CANCER-AM CANCER SOC, V113, P97, DOI 10.1002/cncr.23557; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oliver CL, 2004, CLIN CANCER RES, V10, P7757, DOI 10.1158/1078-0432.CCR-04-0551; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Qiu W, 2008, CELL STEM CELL, V2, P576, DOI 10.1016/j.stem.2008.03.009; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Sun Q, 2007, MOL CANCER THER, V6, P3180, DOI 10.1158/1535-7163.MCT-07-0265; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang GP, 2006, J MED CHEM, V49, P6139, DOI 10.1021/jm060460o; Wang HJ, 2006, CANCER BIOL THER, V5, P380, DOI 10.4161/cbt.5.4.2477; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104; Wolter KG, 2006, NEOPLASIA, V8, P163, DOI 10.1593/neo.05691; Wu B, 2007, GUT, V56, P645, DOI 10.1136/gut.2006.101683; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Yu J, 2007, ONCOGENE, V26, P4189, DOI 10.1038/sj.onc.1210196; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2006, CLIN CANCER RES, V12, P2928, DOI 10.1158/1078-0432.CCR-05-2429; Yu J, 2004, CURR OPIN ONCOL, V16, P19, DOI 10.1097/00001622-200401000-00005; Yu J, 2003, CANCER CELL, V4, P248, DOI 10.1016/S1535-6108(03)00249-6; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2007, DRUG RESIST UPDATE, V10, P207, DOI 10.1016/j.drup.2007.08.002	45	55	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	24					2348	2357		10.1038/onc.2009.108	http://dx.doi.org/10.1038/onc.2009.108			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459GJ	19421143	Green Accepted			2022-12-17	WOS:000267089100005
J	Shiue, CN; Berkson, RG; Wright, APH				Shiue, C-N; Berkson, R. G.; Wright, A. P. H.			c-Myc induces changes in higher order rDNA structure on stimulation of quiescent cells	ONCOGENE			English	Article						c-Myc; nucleolus; transcription; ribosome biogenesis; RNA polymerase I	RNA-POLYMERASE-I; RIBOSOMAL DNA; SPATIAL-ORGANIZATION; NUCLEAR-MATRIX; TRANSCRIPTION; GENES; VIVO; NUCLEOLAR; UBF; TUMORIGENESIS	c-Myc is an oncogenic transcription factor capable of activating transcription by all three nuclear RNA polymerases, thus acting as a high-level coordinator of protein synthesis capacity and cell growth rate. c-Myc recruits RNA polymerase I-related transcription factors to the rDNA when quiescent cells are stimulated to re-enter the cell cycle. Using a model system of cell lines with variable c-Myc status, we show that on stimulation c-Myc rapidly induces gene loop structures in rDNA chromatin that juxtapose upstream and downstream rDNA sequences. c-Myc activation is both necessary and sufficient for this change in rDNA chromatin conformation. c-Myc activation induces association of TTF-1 with the rDNA, and c-Myc is physically associated with induced rDNA gene loops. The origins of two or more rDNA gene loops are closely juxtaposed, suggesting the possibility that c-Myc induces nucleolar chromatin hubs. Induction of rDNA gene loops may be an early step in the reprogramming of quiescent cells as they re-enter the growth cycle.	[Shiue, C-N; Berkson, R. G.; Wright, A. P. H.] Karolinska Inst, Sch Life Sci, Sodertorns Hogskola & Dept Biosci & Nutr, SE-14189 Huddinge, Sweden	Karolinska Institutet	Wright, APH (corresponding author), Karolinska Inst, Sch Life Sci, Sodertorns Hogskola & Dept Biosci & Nutr, Alfred Nobels Alle 7, SE-14189 Huddinge, Sweden.	anthony.wright@sh.se	Berkson, Rachel/D-3438-2009; Wright, Anthony/J-8187-2015	Wright, Anthony/0000-0003-1029-9969	Taiwan Root Medical Peace Corps; Swedish Cancer Society; Karolinska Institute	Taiwan Root Medical Peace Corps; Swedish Cancer Society(Swedish Cancer Society); Karolinska Institute(Karolinska Institutet)	We thank Lars-Gunnar Larsson for the provision of rat fibroblasts HO15.15, TGR1 and Rat1MycER and Professor Dirk Eick for the generous gift of Smoxi4 cells. This work was supported by a Taiwan Fellowship from the Taiwan Root Medical Peace Corps, the Swedish Cancer Society and the research foundations of the Karolinska Institute.	Ansari A, 2005, GENE DEV, V19, P2969, DOI 10.1101/gad.1362305; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Bukhari MH, 2007, INT J EXP PATHOL, V88, P47, DOI 10.1111/j.1365-2613.2006.00522.x; CASSIDY BG, 1987, MOL CELL BIOL, V7, P2388, DOI 10.1128/MCB.7.7.2388; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; de Laat W, 2003, CHROMOSOME RES, V11, P447, DOI 10.1023/A:1024922626726; DEAN M, 1986, J BIOL CHEM, V261, P9161; Fischer AH, 2004, J CELL BIOCHEM, V91, P170, DOI 10.1002/jcb.10735; Friedrich JK, 2005, J BIOL CHEM, V280, P29551, DOI 10.1074/jbc.M501595200; Gomez-Roman N, 2006, BIOCHEM SOC SYMP, V73, P141, DOI 10.1042/bss0730141; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Holzel M, 2001, EMBO REP, V2, P1125, DOI 10.1093/embo-reports/kve251; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; KEPPEL F, 1986, J MOL BIOL, V187, P15, DOI 10.1016/0022-2836(86)90402-X; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; Kumar P, 2007, NAT CELL BIOL, V9, P45, DOI 10.1038/ncb1516; Lawlor ER, 2006, CANCER RES, V66, P4591, DOI 10.1158/0008-5472.CAN-05-3826; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Mais C, 2005, GENE DEV, V19, P50, DOI 10.1101/gad.310705; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Nemeth A, 2008, EMBO J, V27, P1255, DOI 10.1038/emboj.2008.57; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; O'Sullivan JM, 2004, NAT GENET, V36, P1014, DOI 10.1038/ng1411; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Seo J, 2005, J BIOL CHEM, V280, P24600, DOI 10.1074/jbc.M414076200; Shav-Tal Y, 2005, MOL BIOL CELL, V16, P2395, DOI 10.1091/mbc.E04-11-0992; Splinter E, 2004, METHOD ENZYMOL, V375, P493; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641	36	55	55	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2009	28	16					1833	1842		10.1038/onc.2009.21	http://dx.doi.org/10.1038/onc.2009.21			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PW	19270725				2022-12-17	WOS:000265640500002
J	Cole, MD; Cowling, VH				Cole, M. D.; Cowling, V. H.			Specific regulation of mRNA cap methylation by the c-Myc and E2F1 transcription factors	ONCOGENE			English	Article						E2F1; gene expression; mRNA cap methylation; Myc; translation	CONDITIONAL MUTANTS; POLYMERASE-II; GENES; EXPRESSION; TRANSLATION; BINDING; IDENTIFICATION; ONCOPROTEINS; RECRUITMENT; ACTIVATION	Methylation of the mRNA 50 guanosine cap is essential for efficient gene expression. The 50 methyl cap binds to eIF4E, which is the first step in the recruitment of mRNA to the 40S ribosomal subunit. To investigate whether mRNA cap methylation is regulated in a gene-specific manner, we established a method to detect the relative level of cap methylation on specific mRNAs. We found that two transcription factors, c-Myc and E2F1, induce cap methylation of their transcriptional target genes, and therefore, c-Myc and E2F1 upregulate gene expression by simultaneously inducing transcription and promoting translation. c-Myc-induced cap methylation is greater than transcriptional induction for the majority of its target genes, indicating that this is a major mechanism by which Myc regulates gene expression.	[Cowling, V. H.] Univ Dundee, Coll Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland; [Cole, M. D.] Dartmouth Med Sch, Dept Pharmacol, Lebanon, NH USA; [Cole, M. D.] Dartmouth Med Sch, Dept Genet, Lebanon, NH USA	University of Dundee; Dartmouth College; Dartmouth College	Cowling, VH (corresponding author), Univ Dundee, Coll Life Sci, Div Cell Biol & Immunol, Dow St,MSI WTB Complex, Dundee DD1 5EH, Scotland.	v.h.cowling@dundee.ac.uk		Cowling, Victoria/0000-0001-7638-4870	NIH; MRC; NATIONAL CANCER INSTITUTE [P30CA023108, R01CA055248] Funding Source: NIH RePORTER; Medical Research Council [G0700240] Funding Source: researchfish; MRC [G0700240] Funding Source: UKRI	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Klara Acs for much helpful advice. We thank Kristian Helin for the E2F1-ER construct. This study was funded by NIH grants to MDC and an MRC grant to VHC.	Bentley DL, 2005, CURR OPIN CELL BIOL, V17, P251, DOI 10.1016/j.ceb.2005.04.006; Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cowling VH, 2007, MOL CELL BIOL, V27, P2059, DOI 10.1128/MCB.01828-06; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Cowling VH, 2006, MOL CELL BIOL, V26, P4226, DOI 10.1128/MCB.01959-05; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gomez-Roman N, 2006, BIOCHEM SOC SYMP, V73, P141, DOI 10.1042/bss0730141; Gu MG, 2005, CURR OPIN STRUC BIOL, V15, P99, DOI 10.1016/j.sbi.2005.01.009; Guo QM, 2000, CANCER RES, V60, P5922; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Moteki S, 2002, MOL CELL, V10, P599, DOI 10.1016/S1097-2765(02)00660-3; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Schwer B, 1998, NUCLEIC ACIDS RES, V26, P2050, DOI 10.1093/nar/26.9.2050; Schwer B, 2000, GENETICS, V155, P1561; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; Sims RJ, 2004, CURR OPIN CELL BIOL, V16, P263, DOI 10.1016/j.ceb.2004.04.004; von der Haar T, 2004, NAT STRUCT MOL BIOL, V11, P503, DOI 10.1038/nsmb779; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	29	55	56	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1169	1175		10.1038/onc.2008.463	http://dx.doi.org/10.1038/onc.2008.463			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19137018	Green Accepted			2022-12-17	WOS:000263906200001
J	de Muga, SV; Timpson, P; Cubells, L; Evans, R; Hayes, TE; Rentero, C; Hegemann, A; Reverter, M; Leschner, J; Pol, A; Tebar, F; Daly, RJ; Enrich, C; Grewal, T				Vila de Muga, S.; Timpson, P.; Cubells, L.; Evans, R.; Hayes, T. E.; Rentero, C.; Hegemann, A.; Reverter, M.; Leschner, J.; Pol, A.; Tebar, F.; Daly, R. J.; Enrich, C.; Grewal, T.			Annexin A6 inhibits Ras signalling in breast cancer cells	ONCOGENE			English	Article						Annexin A6; p120GAP; Ras; EGF receptor; breast cancer	GTPASE-ACTIVATING PROTEIN; GROWTH-FACTOR RECEPTOR; COMPARATIVE GENOMIC HYBRIDIZATION; CARCINOMA-CELLS; H-RAS; INTERACTION NETWORK; MEMBRANE-BINDING; RAF-1 ACTIVATION; PLASMA-MEMBRANE; GENETIC SCREEN	Overexpression of epidermal growth factor receptor (EGFR) is associated with enhanced activation of wild-type (hyperactive) Ras in breast cancer. Little is known about the regulation of Ras inactivation and GTPase-activating proteins (GAPs), such as p120GAP, in cells with hyperactive Ras. Recently, we showed that in EGFR-over-expressing A431 cells, which lack endogenous Annexin A6 (AnxA6), ectopic expression of AnxA6 stimulates membrane recruitment of p120GAP to modulate Ras signalling. We now demonstrate that, AnxA6 is downregulated in a number of EGFR-overexpressing and estrogen receptor (ER)-negative breast cancer cells. In these cells, AnxA6 overexpression promotes Ca2+ - and EGF-inducible membrane targeting of p120GAP. In ER-negative MDA-MB-436 cells, overexpression of p120GAP, but not CAPRI or a p120GAP mutant lacking the AnxA6-binding domain inhibits Ras/MAPK activity. AnxA6 knockdown in MDA-MB-436 increases Ras activity and cell proliferation in anchorage-independent growth assays. Furthermore, AnxA6 co-immunoprecipitates with H-Ras in a Ca2+ - and EGF-inducible manner and fluorescence resonance energy transfer (FRET) microscopy confirmed that AnxA6 is in close proximity of active (G12V), but not inactive (S17N) H-Ras. Thus, association of AnxA6 with H-Ras-containing protein complexes may contribute to regulate p120GAP/Ras assembly in EGFR-overexpressing and ER-negative breast cancer cells.	[Evans, R.; Hayes, T. E.; Hegemann, A.; Leschner, J.; Grewal, T.] Univ Sydney, Fac Pharm A15, Sydney, NSW 2006, Australia; [Vila de Muga, S.; Cubells, L.; Rentero, C.; Reverter, M.; Tebar, F.; Enrich, C.] Univ Barcelona, Fac Med, Dept Cellular Biol, Barcelona 7, Spain; [Timpson, P.; Daly, R. J.] Garvan Inst Med Res, Sydney, NSW, Australia; [Pol, A.; Enrich, C.] Univ Barcelona, Fac Med, IDIBAPS, Barcelona 7, Spain	University of Sydney; University of Barcelona; Garvan Institute of Medical Research; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Grewal, T (corresponding author), Univ Sydney, Fac Pharm A15, Sydney, NSW 2006, Australia.	enrich@ub.edu; tgrewal@pharm.usyd.edu.au	Pol, Albert/M-1865-2014; Timpson, Paul/A-9429-2016; Daly, Roger J/C-8179-2009; timpson, paul/E-1618-2011; Rentero Alfonso, Carles/L-4430-2017; Tebar, Francesc/H-1498-2015	Pol, Albert/0000-0002-1750-1085; Rentero Alfonso, Carles/0000-0003-4684-0278; Tebar, Francesc/0000-0002-9522-9726; Enrich, Carlos/0000-0003-0382-2993; Timpson, Paul/0000-0002-5514-7080; Grewal, Thomas/0000-0002-7937-8887; Daly, Roger/0000-0002-5739-8027	Ministerio de Educacion y Ciencia, Spain [BFU2006-01151, V-2006-RET2008-0, PR-2006-0142]; National Health and Medical Research Council of Australia [510293, 510294]; National Heart Foundation of Australia [G06S2559]	Ministerio de Educacion y Ciencia, Spain(Spanish Government); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Heart Foundation of Australia(National Heart Foundation of Australia)	We thank Dr Maria Calvo (SCT-UB) for her excellent assistance in confocal microscopy. This study was supported by grants to CE (BFU2006-01151, V-2006-RET2008-0 and fellowship PR-2006-0142 from Ministerio de Educacion y Ciencia, Spain) and TG (510293 and 510294 from the National Health and Medical Research Council of Australia and G06S2559 from the National Heart Foundation of Australia). SV is thankful to Ministerio de Educacion y Ciencia, Spain, (FPI mobility Program) for a short-term fellowship at the laboratory of TG (Sydney, Australia).	Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Bernards A, 2005, GROWTH FACTORS, V23, P143, DOI 10.1080/08977190500130480; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Boon LM, 2005, CURR OPIN GENET DEV, V15, P265, DOI 10.1016/j.gde.2005.03.004; Chetcuti A, 2001, CANCER RES, V61, P6331; Chow A, 1999, FEBS LETT, V460, P166, DOI 10.1016/S0014-5793(99)01336-8; Cook SJ, 2006, CELL CALCIUM, V39, P101, DOI 10.1016/j.ceca.2005.10.014; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; Cubells L, 2008, J BIOL CHEM, V283, P10174, DOI 10.1074/jbc.M706618200; Cubells L, 2007, TRAFFIC, V8, P1568, DOI 10.1111/j.1600-0854.2007.00640.x; Cullen PJ, 2006, CURR OPIN CELL BIOL, V18, P157, DOI 10.1016/j.ceb.2006.02.012; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; DAVIES AA, 1989, HUM GENET, V82, P234, DOI 10.1007/BF00291161; Davis AJ, 1996, J BIOL CHEM, V271, P24333, DOI 10.1074/jbc.271.40.24333; de Diego I, 2002, J BIOL CHEM, V277, P32187, DOI 10.1074/jbc.M205499200; deFazio A, 2000, INT J CANCER, V87, P487, DOI 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; EDWARDS HC, 1995, MOL CELL BIOCHEM, V149, P293, DOI 10.1007/BF01076591; Fleet A, 1999, BIOCHEM BIOPH RES CO, V260, P540, DOI 10.1006/bbrc.1999.0915; Fridman M, 2000, J BIOL CHEM, V275, P30363, DOI 10.1074/jbc.M003193200; GAWLER DJ, 1995, ONCOGENE, V10, P817; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; Grewal T, 2000, J BIOL CHEM, V275, P33806, DOI 10.1074/jbc.M002662200; Grewal T, 2005, ONCOGENE, V24, P5809, DOI 10.1038/sj.onc.1208743; Grewal T, 2006, CURR SIGNAL TRANSD T, V1, P147, DOI 10.2174/157436206777012066; Grewal T, 2006, BIOESSAYS, V28, P1211, DOI 10.1002/bies.20503; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104; Johannsdottir HK, 2006, INT J CANCER, V119, P1052, DOI 10.1002/ijc.21934; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Karpova TS, 2003, J MICROSC-OXFORD, V209, P56, DOI 10.1046/j.1365-2818.2003.01100.x; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; Kupzig S, 2006, J BIOL CHEM, V281, P9891, DOI 10.1074/jbc.M512802200; Leighton X, 2004, CANCER LETT, V210, P239, DOI 10.1016/j.canlet.2004.01.018; Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5; Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992; Malaney S, 2001, J MAMMARY GLAND BIOL, V6, P101, DOI 10.1023/A:1009572700317; Moreto J, 2008, CELL SIGNAL, V20, P1092, DOI 10.1016/j.cellsig.2008.01.022; MOSS SE, 1990, FEBS LETT, V261, P299, DOI 10.1016/0014-5793(90)80576-5; Murakoshi H, 2004, P NATL ACAD SCI USA, V101, P7317, DOI 10.1073/pnas.0401354101; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; Pena V, 2008, EMBO REP, V9, P350, DOI 10.1038/embor.2008.20; Pierga JY, 2007, BRIT J CANCER, V96, P341, DOI 10.1038/sj.bjc.6603483; Plowman SJ, 2005, BBA-MOL CELL RES, V1746, P274, DOI 10.1016/j.bbamcr.2005.06.004; Pons M, 2001, FEBS LETT, V501, P69, DOI 10.1016/S0014-5793(01)02635-7; Pons M, 2001, EXP CELL RES, V269, P13, DOI 10.1006/excr.2001.5268; Rentero C, 2006, CELL SIGNAL, V18, P1006, DOI 10.1016/j.cellsig.2005.08.008; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Sacks DB, 2006, BIOCHEM SOC T, V34, P833, DOI 10.1042/BST0340833; SMYTHE E, 1994, J CELL BIOL, V124, P301, DOI 10.1083/jcb.124.3.301; Strzelecka-Kiliszek A, 2008, J CELL BIOCHEM, V104, P418, DOI 10.1002/jcb.21632; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; THEOBALD J, 1994, BBA-MOL CELL RES, V1223, P383, DOI 10.1016/0167-4889(94)90099-X; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; Timpson P, 2007, CANCER RES, V67, P9304, DOI 10.1158/0008-5472.CAN-07-0798; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; Vishwanatha JK, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-8; Walker SA, 2004, EMBO J, V23, P1749, DOI 10.1038/sj.emboj.7600197; Walker SA, 2003, FEBS LETT, V546, P6, DOI 10.1016/S0014-5793(03)00412-5; Wang Z, 2002, J BIOL CHEM, V277, P24022, DOI 10.1074/jbc.M201949200; Wang ZX, 1996, CELL GROWTH DIFFER, V7, P123; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033	67	55	56	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					363	377		10.1038/onc.2008.386	http://dx.doi.org/10.1038/onc.2008.386			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18850003				2022-12-17	WOS:000262550300005
J	Wickenden, JA; Jin, H; Johnson, M; Gillings, AS; Newson, C; Austin, M; Chell, SD; Balmanno, K; Pritchard, CA; Cook, SJ				Wickenden, J. A.; Jin, H.; Johnson, M.; Gillings, A. S.; Newson, C.; Austin, M.; Chell, S. D.; Balmanno, K.; Pritchard, C. A.; Cook, S. J.			Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM	ONCOGENE			English	Article						apoptosis; BIM; BRAF; colorectal cancer; ERK1/2	B-RAF; BH3-ONLY PROTEIN; BCL-2 PROTEINS; PHOSPHORYLATION; EXPRESSION; APOPTOSIS; GENE; PROMOTES; PROLIFERATION; DEGRADATION	The RAF-mitogen-activated protein kinase kinase 1/2 extracellular signal-regulated kinase 1/2 (RAF-MEK1/2-ERK1/2) pathway is activated in many human tumours and can protect cells against growth factor deprivation; however, most such studies have relied upon overexpression of RAF or MEK constructs that are not found in tumours. Here we show that expression of the endogenous BRAF(V600E) allele in mouse embryonic fibroblasts from conditional knock-in transgenic mice activates ERK1/2, represses the BH3-only protein BIM and protects cells from growth factor withdrawal. Human colorectal cancer (CRC) cell lines harbouring BRAF(V600E) are growth factor independent for the activation of ERK1/2 and survival. However, treatment with the MEK1/2 inhibitors U0126, PD184352 or the novel clinical candidate AZD6244 (ARRY-142886) overcomes growth factor independence, causing CRC cell death. BIM is de-phosphorylated and upregulated following MEK1/2 inhibition in all CRC cell lines studied and knockdown of BIM reduces cell death, indicating that repression of BIM is a major part of the ability of BRAF(V600E) to confer growth factor-independent survival. We conclude that a single endogenous BRAF(V600E) allele is sufficient to repress BIM and prevent death arising from growth factor withdrawal, and CRC cells with BRAF(V600E) mutations are addicted to the ERK1/2 pathway for repression of BIM and growth factor-independent survival.	[Jin, H.; Pritchard, C. A.] Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; [Wickenden, J. A.; Johnson, M.; Gillings, A. S.; Newson, C.; Austin, M.; Chell, S. D.; Balmanno, K.; Cook, S. J.] Babraham Inst, Mol Signalling Lab, Cambridge, England	University of Leicester; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Pritchard, CA (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.	cap8@le.ac.uk; simon.cook@bbsrc.ac.uk		Balmanno, Kathryn/0000-0002-6417-3889; Chell, Simon/0000-0001-5321-9119; Pritchard, Catrin/0000-0003-1859-4487; Austin, Mark/0000-0003-4943-7265	CRUK [C1362/A6969]; Association for International Cancer Research (AICR); AstraZeneca, BBSRC [BB/E02162X/1]; Babraham Institute; BBSRC [BB/E02162X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E02162X/1, BBS/E/B/0000C199, BBS/E/B/0000H151] Funding Source: researchfish	CRUK(Cancer Research UK); Association for International Cancer Research (AICR); AstraZeneca, BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)AstraZeneca); Babraham Institute(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We thank members of the SJC and CAPlabs for discussions and Richard Marais for his advice and encouragement. We particularly thank the Division of Biomedical Services at Leicester for help with breeding and Susan Giblett for isolation of MEFs. We are grateful to the Trono lab for provision of lentiviral expression systems, Paul Smith (AstraZeneca) for provision of AZD6244 and discussions and Richard Hamelin for provision of CO115 cells. Work in the CAPlab was funded by a CRUK programme grant number C1362/A6969. Work in the SJC lab was supported by the Association for International Cancer Research (AICR), AstraZeneca, BBSRC (BB/E02162X/1) and the Babraham Institute.	Boisvert-Adamo K, 2008, ONCOGENE, V27, P3301, DOI 10.1038/sj.onc.1211003; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eisenmann KM, 2003, CANCER RES, V63, P8330; Ewings KE, 2007, CELL CYCLE, V6, P2236, DOI 10.4161/cc.6.18.4728; Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723; Frese KK, 2007, NAT REV CANCER, V7, P645, DOI 10.1038/nrc2192; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; Mercer K, 2005, CANCER RES, V65, P11493, DOI 10.1158/0008-5472.CAN-05-2211; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Todd DE, 2004, ONCOGENE, V23, P3284, DOI 10.1038/sj.onc.1207467; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wallace EM, 2006, J MED CHEM, V49, P441, DOI 10.1021/jm050834y; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yuen ST, 2002, CANCER RES, V62, P6451; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510	45	55	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7150	7161		10.1038/onc.2008.335	http://dx.doi.org/10.1038/onc.2008.335			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18806830	Green Accepted			2022-12-17	WOS:000261384100002
J	Caffarel, MM; Moreno-Bueno, G; Cerutti, C; Palacios, J; Guzman, M; Mechta-Grigoriou, F; Sanchez, C				Caffarel, M. M.; Moreno-Bueno, G.; Cerutti, C.; Palacios, J.; Guzman, M.; Mechta-Grigoriou, F.; Sanchez, C.			JunD is involved in the antiproliferative effect of Delta(9)-tetrahydrocannabinol on human breast cancer cells	ONCOGENE			English	Article						cannabinoids; breast cancer; JunD; AP-1; p27; testin	NEUROPROTECTIVE ANTIOXIDANTS; INDUCED APOPTOSIS; TUMOR-CELLS; PROTEIN; TRANSFORMATION; CANNABINOIDS; CANNABIDIOL; STRESS; AP-1; PROLIFERATION	It has been recently shown that cannabinoids, the active components of marijuana and their derivatives, inhibit cell cycle progression of human breast cancer cells. Here we studied the mechanism of Delta(9)-tetrahydrocannabinol (THC) antiproliferative action in these cells, and show that it involves the modulation of JunD, a member of the AP-1 transcription factor family. THC activates JunD both by upregulating gene expression and by translocating the protein to the nuclear compartment, and these events are accompanied by a decrease in cell proliferation. Of interest, neither JunD activation nor proliferation inhibition was observed in human non-tumour mammary epithelial cells exposed to THC. We confirmed the importance of JunD in THC action by RNA interference and genetic ablation. Thus, in both JunD-silenced human breast cancer cells and JunD knockout mice-derived immortalized. broblasts, the antiproliferative effect exerted by THC was significantly diminished. Gene array and siRNA experiments support that the cyclin-dependent kinase inhibitor p27 and the tumour suppressor gene testin are candidate JunD targets in cannabinoid action. In addition, our data suggest that the stress-regulated protein p8 participates in THC antiproliferative action in a JunD-independent manner. In summary, this is the first report showing not only that cannabinoids regulate JunD but, more generally, that JunD activation reduces the proliferation of cancer cells, which points to a new target to inhibit breast cancer progression.	[Caffarel, M. M.; Cerutti, C.; Palacios, J.; Sanchez, C.] Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; [Moreno-Bueno, G.] Univ Autonoma Madrid, Dept Biochem, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Palacios, J.] Hosp Univ Virgen Rocio, Dept Pathol, Seville, Spain; [Mechta-Grigoriou, F.] Inst Curie, INSERM, U830, Paris, France	Complutense University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Virgen del Rocio University Hospital; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite	Sanchez, C (corresponding author), Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, C Jose Antonio Novais 2, E-28040 Madrid, Spain.	cristina.sanchez@quim.ucm.es	Sanchez, Cristina/H-4980-2017; Cerutti, Camilla/ABC-4159-2021; Moreno-Bueno, Gema/K-9354-2016; MECHTA-GRIGORIOU, Fatima/C-5253-2017; Sanchez, Cristina/AFQ-4745-2022; Cerutti, Camilla/U-8890-2019; Palacios, Jose/AAV-3765-2020	Sanchez, Cristina/0000-0002-1428-3078; Cerutti, Camilla/0000-0001-9426-686X; Moreno-Bueno, Gema/0000-0002-5030-6687; MECHTA-GRIGORIOU, Fatima/0000-0002-3751-6989; Caffarel, Maria/0000-0002-7442-6827; Guzman, Manuel/0000-0001-7475-118X	Fondo de Investigaciones Sanitarias; Fundacion Mutua Madrilena; Spanish Ministry of Education and Science; ISCIII-RETIC; Comunidad de Madrid; Inserm Avenir; Institut Curie; Fondation de France	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fundacion Mutua Madrilena(Instituto de Salud Carlos III); Spanish Ministry of Education and Science(Spanish Government); ISCIII-RETIC(Instituto de Salud Carlos III); Comunidad de Madrid(Comunidad de Madrid); Inserm Avenir(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut Curie; Fondation de France(Fondation de France)	We are indebted to the personnel of the Genomics Unit ( Complutense University) for expert advice on RT-qPCR experiments, and to the members of our laboratories for technical support and critical discussions on this work, especially to M Salazar. C Sanchez and G Moreno-Bueno are researchers of the 'Ramon y Cajal Program' of the Spanish Ministry of Education and Science. MM Caffarel is the recipient of a fellowship from the Spanish Ministry of Education and Science. This work was supported by grants from Fondo de Investigaciones Sanitarias (C Sanchez and J Palacios), Fundacion Mutua Madrilena (C Sanchez), Spanish Ministry of Education and Science (J Palacios and M Guzman), ISCIII-RETIC (J Palacios), Comunidad de Madrid (M Guzman) and Inserm Avenir, Institut Curie and Fondation de France (F Mechta-Grigoriou).	Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Berdyshev EV, 2001, BIOCHEM J, V360, P67, DOI 10.1042/0264-6021:3600067; Blazquez C, 2006, FASEB J, V20, P2633, DOI 10.1096/fj.06-6638fje; Caffarel MM, 2006, CANCER RES, V66, P6615, DOI 10.1158/0008-5472.CAN-05-4566; Carracedo A, 2006, CANCER CELL, V9, P301, DOI 10.1016/j.ccr.2006.03.005; Carracedo A, 2006, CANCER RES, V66, P6748, DOI 10.1158/0008-5472.CAN-06-0169; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; Drusco A, 2005, P NATL ACAD SCI USA, V102, P10947, DOI 10.1073/pnas.0504934102; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Giuliano M, 2006, INT J MOL MED, V17, P811; Guzman M, 2006, BRIT J CANCER, V95, P197, DOI 10.1038/sj.bjc.6603236; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hampson AJ, 2000, ANN NY ACAD SCI, V899, P274, DOI 10.1111/j.1749-6632.2000.tb06193.x; Iuvone T, 2004, J NEUROCHEM, V89, P134, DOI 10.1111/j.1471-4159.2003.02327.x; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Ligresti A, 2006, J PHARMACOL EXP THER, V318, P1375, DOI 10.1124/jpet.106.105247; Maccarrone M, 2003, J BIOL CHEM, V278, P33896, DOI 10.1074/jbc.M303994200; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Sarnataro D, 2006, MOL PHARMACOL, V70, P1298, DOI 10.1124/mol.106.025601; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Zhao Q, 2005, J BIOL CHEM, V280, P26735, DOI 10.1074/jbc.M412828200	29	55	58	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5033	5044		10.1038/onc.2008.145	http://dx.doi.org/10.1038/onc.2008.145			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18454173				2022-12-17	WOS:000258914800006
J	Lin, J; Arlinghaus, R				Lin, J.; Arlinghaus, R.			Activated c-Abl tyrosine kinase in malignant solid tumors	ONCOGENE			English	Review						c-Abl; FUS1; NSCLC; lung cancer; imatinib; breast cancer	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER CELLS; HOMOZYGOUS DELETION REGION; SRC-FAMILY KINASES; LUNG-CANCER; ONCOGENIC ACTIVATION; GENE-PRODUCT; FUS1 PROTEIN; IN-VITRO; EXPRESSION	Mutant forms of the c-ABL gene are well known to be involved in hematopoietic malignancies such as chronic myeloid leukemia (CML). CML patients possess a fused BCR-ABL gene that activates the Abl tyrosine kinase domain within Bcr-Abl. In general fusion proteins that cause oligomerization of Abl lead to activation of its tyrosine kinase activity. In this review, we highlight recent discoveries indicating that the activated c-Abl tyrosine kinase, not as a fusion protein, plays an important role in malignant solid tumors of lung and breast.	[Lin, J.; Arlinghaus, R.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77054 USA	University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Arlinghaus, R (corresponding author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcomb Blvd, Houston, TX 77054 USA.	rarlingh@mdanderson.org						Buchdunger E, 1996, CANCER RES, V56, P100; Bunn PA, 2002, SEMIN ONCOL, V29, P38, DOI 10.1053/sonc.2002.35646; Dowell JE, 2005, NEW ENGL J MED, V352, P830, DOI 10.1056/NEJMe058033; Girard L, 2000, CANCER RES, V60, P4894; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Ito T, 2004, OPT REV, V11, P7, DOI 10.1007/s10043-004-0007-5; Ji L, 2002, CANCER RES, V62, P2715; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lin J, 2007, ONCOGENE, V26, P6989, DOI 10.1038/sj.onc.1210500; LIN J, 2005, 96 ANN AM ASS CANC R; Ling XY, 2003, CANCER RES, V63, P298; Liu JX, 1996, CANCER RES, V56, P5120; Ma ZY, 2007, CELL MOL BIOL LETT, V12, P556, DOI 10.2478/s11658-007-0022-1; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Negri T, 2007, BRIT J CANCER, V96, P180, DOI 10.1038/sj.bjc.6603542; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, CELL CYCLE, V2, P273, DOI 10.4161/cc.2.4.409; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Prudkin L, 2008, CLIN CANCER RES, V14, P41, DOI 10.1158/1078-0432.CCR-07-1252; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Sirvent A, 2007, ONCOGENE, V26, P7313, DOI 10.1038/sj.onc.1210543; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; Uno F, 2004, CANCER RES, V64, P2969, DOI 10.1158/0008-5472.CAN-03-3702; *US CANC STAT WORK, 2004, US CANC STAT 2001 IN; Vlahovic G, 2006, BRIT J CANCER, V95, P1013, DOI 10.1038/sj.bjc.6603366; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zhang Peilin, 2003, Mol Cancer, V2, P1	36	55	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4385	4391		10.1038/onc.2008.86	http://dx.doi.org/10.1038/onc.2008.86			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18391983				2022-12-17	WOS:000257881700001
J	Langenau, DM; Keefe, MD; Storer, NY; Jette, CA; Smith, ACH; Ceol, CJ; Bourque, C; Look, AT; Zon, LI				Langenau, D. M.; Keefe, M. D.; Storer, N. Y.; Jette, C. A.; Smith, A. C. H.; Ceol, C. J.; Bourque, C.; Look, A. T.; Zon, L. I.			Co-injection strategies to modify radiation sensitivity and tumor initiation in transgenic Zebrafish	ONCOGENE			English	Article						Myc; ras; heat-shock; T-cell acute lymphoblastic leukemia; rhabdomyosarcoma	ACUTE LYMPHOBLASTIC-LEUKEMIA; CELLS; TRANSPLANTATION; EXPRESSION; APOPTOSIS; GENESIS; MODEL	The zebrafish has emerged as a powerful genetic model of cancer, but has been limited by the use of stable transgenic approaches to induce disease. Here, a co-injection strategy is described that capitalizes on both the numbers of embryos that can be microinjected and the ability of transgenes to segregate together and exert synergistic effects in forming tumors. Using this mosaic transgenic approach, gene pathways involved in tumor initiation and radiation sensitivity have been identified.	[Langenau, D. M.; Keefe, M. D.; Storer, N. Y.; Smith, A. C. H.; Ceol, C. J.; Bourque, C.; Zon, L. I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA; [Langenau, D. M.; Keefe, M. D.; Storer, N. Y.; Smith, A. C. H.; Ceol, C. J.; Bourque, C.; Zon, L. I.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; [Langenau, D. M.; Keefe, M. D.; Storer, N. Y.; Smith, A. C. H.; Ceol, C. J.; Bourque, C.; Zon, L. I.] Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute	Langenau, DM (corresponding author), Childrens Hosp, Stem Cell Program, 1 Blackfan Circle,Karp 7, Boston, MA 02115 USA.	dlangenau@enders.tch.harvard.edu	Langenau, David/GXI-0197-2022	Langenau, David/0000-0001-6664-8318	NATIONAL CANCER INSTITUTE [R01CA093152, P01CA068484, R01CA104605, R01CA103846, R01CA119066] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK074555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [5R01 CA103846-02, P01 CA068484, R01 CA104605, CA93152-05, 1R01 CA119066-01, R01 CA119066, CA104605-03, R01 CA093152, CA68484-11, R01 CA103846] Funding Source: Medline; NHLBI NIH HHS [HL-088664, R01 HL088664] Funding Source: Medline; NIDDK NIH HHS [K01 DK074555, 1KO1 DK074555-01] Funding Source: Medline; NIGMS NIH HHS [T32 GM007753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Burns CE, 2005, GENE DEV, V19, P2331, DOI 10.1101/gad.1337005; Halloran MC, 2000, DEVELOPMENT, V127, P1953; Haramis APG, 2006, EMBO REP, V7, P444, DOI 10.1038/sj.embor.7400638; Hong WY, 2004, CANCER RES, V64, P7256, DOI 10.1158/0008-5472.CAN-04-0931; Jessen JR, 2001, GENESIS, V29, P156, DOI 10.1002/gene.1019; Kratz E, 2006, CELL DEATH DIFFER, V13, P1631, DOI 10.1038/sj.cdd.4402016; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Langenau DM, 2005, BLOOD, V105, P3278, DOI 10.1182/blood-2004-08-3073; Langenau DM, 2005, P NATL ACAD SCI USA, V102, P6068, DOI 10.1073/pnas.0408708102; Langenau DM, 2003, SCIENCE, V299, P887, DOI 10.1126/science.1080280; Le XN, 2007, P NATL ACAD SCI USA, V104, P9410, DOI 10.1073/pnas.0611302104; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Pyati UJ, 2005, DEVELOPMENT, V132, P2333, DOI 10.1242/dev.01806; Sabaawy HE, 2006, P NATL ACAD SCI USA, V103, P15166, DOI 10.1073/pnas.0603349103; Traver D, 2004, BLOOD, V104, P1298, DOI 10.1182/blood-2004-01-0100; Traver D, 2003, NAT IMMUNOL, V4, P1238, DOI 10.1038/ni1007; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; Xiao T, 2003, J NEUROSCI, V23, P4190	20	55	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4242	4248		10.1038/onc.2008.56	http://dx.doi.org/10.1038/onc.2008.56			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345029	Green Accepted			2022-12-17	WOS:000257496800011
J	Eliseev, RA; Dong, YF; Sampson, E; Zuscik, MJ; Schwarz, EM; O'Keefe, RJ; Rosier, RN; Drissi, MH				Eliseev, R. A.; Dong, Y-F; Sampson, E.; Zuscik, M. J.; Schwarz, E. M.; O'Keefe, R. J.; Rosier, R. N.; Drissi, M. H.			Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis	ONCOGENE			English	Article						Runx2; Bax; osteosarcoma; apoptosis	TUMOR-SUPPRESSOR; OSTEOBLAST DIFFERENTIATION; GASTRIC-CANCER; TRANSCRIPTIONAL ACTIVATOR; INDUCE APOPTOSIS; RUNX3; GROWTH; DEATH; EXPRESSION; PROTEINS	The Runx family of transcription factors regulate cell growth and differentiation, and control the expression of target genes involved in cell fate decisions. We examined the role of the bone-related member of this family, Runx2, in regulating apoptosis via modulation of the Bcl2 family of genes in the osteosarcoma cell line Saos2. Our data demonstrate that Runx2 directly binds to two Runx-specific regulatory elements on the human bax promoter thereby inducing Bax expression. Furthermore, bone morphogenetic protein-induced or vector-mediated expression of Runx2 resulted in upregulation of Bax expression, and subsequent increased sensitivity of Saos2 cells to apoptosis. Finally, the observed upregulation of Bax expression and increased apoptosis were Runx2 dependent as Runx2 loss of function abrogated these effects. Our study provides the first evidence for Bax as a direct target of Runx2, suggesting that Runx2 may act as a proapoptotic factor in osteosarcoma cells.	[Drissi, M. H.] Univ Connecticut, Ctr Hlth, Dept Orthopaed, New England Musculoskeletal Inst,MARB, Farmington, CT 06034 USA; [Eliseev, R. A.; Dong, Y-F; Sampson, E.; Zuscik, M. J.; Schwarz, E. M.; O'Keefe, R. J.; Rosier, R. N.] Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Dept Orthopaed, Rochester, NY 14642 USA	University of Connecticut; University of Rochester	Drissi, MH (corresponding author), Univ Connecticut, Ctr Hlth, Dept Orthopaed, New England Musculoskeletal Inst,MARB, Suite 4048,263 Farmington Ave, Farmington, CT 06034 USA.	Drissi@UCHC.edu		drissi, hicham/0000-0002-3322-281X; Zuscik, Michael/0000-0003-0461-8708	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052674] Funding Source: NIH RePORTER; NIAMS NIH HHS [R0-1 AR-052674-01, R01 AR052674] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antignani A, 2006, CURR OPIN CELL BIOL, V18, P685, DOI 10.1016/j.ceb.2006.10.004; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Barnes GL, 2003, CANCER RES, V63, P2631; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Brubaker KD, 2003, PROSTATE, V56, P13, DOI 10.1002/pros.10233; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Coffman JA, 2003, CELL BIOL INT, V27, P315, DOI 10.1016/S1065-6995(03)00018-0; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Drissi H, 2002, J CELL BIOCHEM, V86, P403, DOI 10.1002/jcb.10238; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fukuda N, 2006, ONCOGENE, V25, P3509, DOI 10.1038/sj.onc.1209393; Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Komori T, 2003, J BONE MINER METAB, V21, P193, DOI 10.1007/s00774-002-0408-0; Lee JS, 2006, J BONE MINER RES, V21, P921, DOI 10.1359/JBMR.060303; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MIYASHITA T, 1995, CELL, V80, P293; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Noda M, 2006, J PHARMACOL SCI, V100, P211, DOI 10.1254/jphs.FMJ05004X6; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pratap J, 2003, CANCER RES, V63, P5357; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Torquati A, 2004, SURGERY, V136, P310, DOI 10.1016/j.surg.2004.05.005; van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1; van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758; Vogiatzi P, 2006, CANCER BIOL THER, V5, P371, DOI 10.4161/cbt.5.4.2748; Wang LL, 2005, CANCER J, V11, P294, DOI 10.1097/00130404-200507000-00005; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05	43	55	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3605	3614		10.1038/sj.onc.1211020	http://dx.doi.org/10.1038/sj.onc.1211020			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223689	Green Accepted			2022-12-17	WOS:000256468500012
J	Binda, O; Nassif, C; Branton, PE				Binda, O.; Nassif, C.; Branton, P. E.			SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins	ONCOGENE			English	Article						transcription; RBP1; BCAA; SIRT1; HDAC1; mSIN3A	CANDIDATE TUMOR-SUPPRESSOR; HISTONE DEACETYLASE COMPLEX; N-COR; COREPRESSOR COMPLEX; DNA-BINDING; LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; GROWTH ARREST; CANCER-CELLS	Both RBP1 and the highly related protein BCAA play a role in the induction of growth arrest and cellular senescence via mechanisms involving transcriptional repression. While investigating the transcriptional repression activities of RBP1, we observed a genetic link between RBP1 and SIR2. Further work uncovered an interaction between RBP1 family proteins and the mammalian homologue of SIR2, SIRT1. Interestingly, the HDAC-dependent transcriptional repression domain of RBP1 proteins, termed R2, is necessary and sufficient for the interaction with SIRT1. In vitro and in vivo binding studies indicated that the p33(ING1b) and p33(ING2) subunits of the mSIN3A/HDAC1 complex are responsible for the recruitment of SIRT1 to the R2 domain. To investigate the biological relevance of this interaction, we used the sirtuin activator resveratrol and the sirtuin inhibitor sirtinol in transcriptional repression assays and demonstrated that SIRT1 activity negatively regulates R2-mediated transcriptional repression activity. We therefore propose a novel mechanism of class I HDAC regulation by a class III HDAC. Explicitly, SIRT1 is recruited by ING proteins and inhibits R2-associated mSIN3A/HDAC1 transcriptional repression activity.	[Binda, O.; Nassif, C.; Branton, P. E.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Branton, P. E.] McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; [Branton, P. E.] McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Bldg,Room 702,3655 Promenader Sir Wi, Montreal, PQ H3G 1Y6, Canada.	philip.branton@mcgill.ca	Binda, Olivier/A-5941-2009	Binda, Olivier/0000-0002-1539-0828				Bae NS, 2004, J BIOCHEM, V135, P695, DOI 10.1093/jb/mvh084; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Binda O, 2006, MOL CELL BIOL, V26, P1917, DOI 10.1128/MCB.26.5.1917-1931.2006; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fleischer TC, 2003, MOL CELL BIOL, V23, P3456, DOI 10.1128/MCB.23.10.3456-3467.2003; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guarente L, 2005, MECH AGEING DEV, V126, P923, DOI 10.1016/j.mad.2005.03.013; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Huang EY, 2000, GENE DEV, V14, P45; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kataoka H, 2003, CANCER RES, V63, P5785; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim S, 1999, MOL BIOL CELL, V10, P3125, DOI 10.1091/mbc.10.10.3125; Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Lai A, 1999, ONCOGENE, V18, P2091, DOI 10.1038/sj.onc.1202520; Laj A, 1999, MOL CELL BIOL, V19, P6632; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Longo VD, 2006, CELL, V126, P257, DOI 10.1016/j.cell.2006.07.002; Lu RQ, 1999, J CELL PHYSIOL, V179, P297, DOI 10.1002/(SICI)1097-4652(199906)179:3<297::AID-JCP7>3.0.CO;2-P; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Meehan WJ, 2004, J BIOL CHEM, V279, P1562, DOI 10.1074/jbc.M307969200; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nikolaev AY, 2004, BIOCHEM BIOPH RES CO, V323, P1216, DOI 10.1016/j.bbrc.2004.08.227; North BJ, 2005, METHODS, V36, P338, DOI 10.1016/j.ymeth.2005.03.004; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Ota H, 2007, J MOL CELL CARDIOL, V43, P571, DOI 10.1016/j.yjmcc.2007.08.008; Parsons XH, 2003, P NATL ACAD SCI USA, V100, P1609, DOI 10.1073/pnas.0434064100; Patsialou A, 2005, NUCLEIC ACIDS RES, V33, P66, DOI 10.1093/nar/gki145; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Qiu Y, 2006, MOL CELL, V22, P669, DOI 10.1016/j.molcel.2006.04.019; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Rogina B, 2002, SCIENCE, V298, P1745, DOI 10.1126/science.1078986; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Sasaki T, 2006, AGING CELL, V5, P413, DOI 10.1111/j.1474-9726.2006.00235.x; Sgambato A, 2001, MUTAT RES-GEN TOX EN, V496, P171, DOI 10.1016/S1383-5718(01)00232-7; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Takata T, 2003, BIOCHEM BIOPH RES CO, V301, P250, DOI 10.1016/S0006-291X(02)03020-6; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Wilsker D, 2005, GENOMICS, V86, P242, DOI 10.1016/j.ygeno.2005.03.013; Wilson JM, 2006, EMBO REP, V7, P1247, DOI 10.1038/sj.embor.7400829; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	73	55	55	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3384	3392		10.1038/sj.onc.1211014	http://dx.doi.org/10.1038/sj.onc.1211014			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193082				2022-12-17	WOS:000256309900003
J	Zhu, JH; Chen, R; Yi, W; Cantin, GT; Fearns, C; Yang, Y; Yates, JR; Lee, JD				Zhu, J-H; Chen, R.; Yi, W.; Cantin, G. T.; Fearns, C.; Yang, Y.; Yates, J. R., III; Lee, J-D			Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling	ONCOGENE			English	Article						PTPN13; Her2; dephosphorylation; invasion and negative feedback	HUMAN-BREAST-CANCER; TUMOR-SUPPRESSOR; GROWTH; CELLS; NEU; METASTASIS; MUTATIONS; CARCINOMA; DISEASE; GENE	Deregulated Her2/ErbB2 receptor tyrosine kinase drives tumorigenesis and tumor progression in a variety of human tissues. Her2 transmits oncogenic signals through phosphorylation of its cytosolic domain. To study innate cellular mechanisms for containing Her2 oncogenic phosphorylation, a siRNA phosphatase library was screened for cellular phosphatase(s) that enhance phosphorylation in the signaling motif of Her2 after knockdown. We found that silencing protein tyrosine phosphatase PTPN13 significantly augmented growth factor-induced phosphorylation of the Her2 signaling domain and promoted the invasiveness of Her2-deregulated cancer cells. In addition, we discovered that growth factor-induced phosphorylation of PTPN13 was essential for the dephosphorylation of Her2 suggesting a negative feedback mechanism induced by growth factor to inhibit cellular Her2 activity through PTPN13. Importantly, we showed that PTPN13 mutations previously reported in human tumors significantly reduced the phosphatase activity of PTPN13, and consequently elevated the oncogenic potential of Her2 and the invasiveness of Her2-overexpressing human cancer cells. Taken together, these results suggest that cellular PTPN13 inhibits Her2 activity by dephosphorylating the signal domain of Her2 and plays a role in attenuating invasiveness and metastasis of Her2 overactive tumors.	[Zhu, J-H; Chen, R.; Yi, W.; Fearns, C.; Lee, J-D] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; [Cantin, G. T.; Yates, J. R., III] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Yang, Y.] Johnson & Johnson Pharmaceut Res & Dev, San Diego, CA USA	Scripps Research Institute; Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA	Lee, JD (corresponding author), Scripps Res Inst, Dept Immunol, IMM-12,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jdlee@scripps.edu	Zhu, Jian-Hong/E-3927-2010	Zhu, Jian-Hong/0000-0001-9412-8264	NATIONAL CANCER INSTITUTE [R01CA079871, R01CA114059] Funding Source: NIH RePORTER; NCI NIH HHS [CA079871, CA114059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Bentires-Alj M, 2007, CANCER RES, V67, P2420, DOI 10.1158/0008-5472.CAN-06-4610; Bompard G, 2002, J BIOL CHEM, V277, P47861, DOI 10.1074/jbc.M208950200; Cantin GT, 2006, J PROTEOME RES, V5, P127, DOI 10.1021/pr050270m; Engelman JA, 2006, CLIN CANCER RES, V12, p4372S, DOI 10.1158/1078-0432.CCR-06-0795; Erdmann KS, 2003, EUR J BIOCHEM, V270, P4789, DOI 10.1046/j.1432-1033.2003.03895.x; Gensler M, 2004, J BIOL CHEM, V279, P12110, DOI 10.1074/jbc.M309527200; Gil-Henn H, 2003, J BIOL CHEM, V278, P15579, DOI 10.1074/jbc.M210273200; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hayes DF, 2002, SEMIN ONCOL, V29, P231, DOI 10.1053/sonc.2002.32899; Inazawa J, 1996, GENOMICS, V31, P240, DOI 10.1006/geno.1996.0039; Julien SG, 2007, NAT GENET, V39, P338, DOI 10.1038/ng1963; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; Menard S, 2004, CELL MOL LIFE SCI, V61, P2965, DOI 10.1007/s00018-004-4277-7; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tartaglia M, 2005, EUR J MED GENET, V48, P81, DOI 10.1016/j.ejmg.2005.03.001; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Xu YR, 2005, J BIOL CHEM, V280, P42694, DOI 10.1074/jbc.M507722200; Yeh SH, 2006, CLIN CANCER RES, V12, P1097, DOI 10.1158/1078-0432.CCR-05-1383	27	55	55	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2008	27	18					2525	2531		10.1038/sj.onc.1210922	http://dx.doi.org/10.1038/sj.onc.1210922			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17982484				2022-12-17	WOS:000255057000002
J	Bae, SI; Cheriyath, V; Jacobs, BS; Reu, FJ; Borden, EC				Bae, S. I.; Cheriyath, V.; Jacobs, B. S.; Reu, F. J.; Borden, E. C.			Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL	ONCOGENE			English	Article						apoptosis; 5-AZAdC; IFNs; DR4; melanoma	TUMOR-SUPPRESSOR; EPIGENETIC INACTIVATION; CUTANEOUS MELANOMA; STIMULATED GENES; APOPTOSIS; HYPERMETHYLATION; IDENTIFICATION; XIAP; INHIBITOR; CARCINOMA	Human melanoma cell lines, SK-MEL-3 and SK-MEL-28, despite induction of the proapoptotic cytokine, Apo2L/TRAIL, did not undergo apoptosis in response to interferons ( IFN-alpha 2b or IFN-beta). Postulating that genes important for apoptosis induction by IFNs might be silenced by methylation, the DNA demethylating agent 5-aza-2'-deoxycytidine ( 5-AZAdC) was assessed. DR4 ( TRAIL-R1) was identified as one of the genes reactivated by 5-AZAdC with a > 3-fold increase in 8 of 10 melanoma cell lines. Pretreatment with 5-AZAdC sensitized SK-MEL-3 and SK-MEL-28 cells to apoptosis induced by IFN-a2b and IFN-b; methylation-specific PCR and bisulfite sequencing confirmed demethylation of 5'CpG islands of DR4 and flow cytometry showed an increase in DR4 protein on the cell surface. In cells with reactivated DR4, neutralizing mAB to TRAIL reduced apoptosis in response to IFN-b or Apo2L/TRAIL. To further confirm the role of DR4, it was expressed by retroviral vector in SK-MEL-3 and SK-MEL-28 cells with reversal of resistance to IFN-b and Apo2L/TRAIL. Thus, reexpressing DR4 by 5-AZAdC or retroviral transfection in melanoma cell in which promoter methylation had suppressed its expression, potentiated apoptosis by IFN-alpha 2b, IFN-beta and Apo2L/TRAIL. Reactivation of silenced proapoptotic genes by inhibitors of DNA methylation may enhance clinical response to IFNs or Apo2L/TRAIL.	[Bae, S. I.; Cheriyath, V.; Jacobs, B. S.; Reu, F. J.; Borden, E. C.] Cleveland Clin Fdn, Taussig Canc Ctr, Ctr Hematol & Oncol Mol Therapeut, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Borden, EC (corresponding author), Cleveland Clin Fdn, Taussig Canc Ctr, Ctr Hematol & Oncol Mol Therapeut, 9500 Euclid Ave,R 40, Cleveland, OH 44195 USA.	bordene@ccf.org		Reu, Frederic/0000-0003-1160-8030	NATIONAL CANCER INSTITUTE [R01CA090914] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 90914] Funding Source: Medline; NCRR NIH HHS [M01 RR-018390] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BORDEN EC, 2003, CANC MED, P830; Byun DS, 2003, CANCER RES, V63, P7068; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Esteller M, 2001, CANCER RES, V61, P3225; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Leaman DW, 2003, J INTERF CYTOK RES, V23, P745, DOI 10.1089/107999003772084860; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Pfeffer LM, 1998, CANCER RES, V58, P2489; Reu FJ, 2006, CANCER RES, V66, P2785, DOI 10.1158/0008-5472.CAN-05-2303; Reu FJ, 2006, J CLIN ONCOL, V24, P3771, DOI 10.1200/JCO.2005.03.4074; Spugnardi M, 2003, CANCER RES, V63, P1639; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227	23	55	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					490	498		10.1038/sj.onc.1210655	http://dx.doi.org/10.1038/sj.onc.1210655			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653094				2022-12-17	WOS:000252426100009
J	Kawasaki, Y; Sagara, M; Shibata, Y; Shirouzu, M; Yokoyama, S; Akiyama, T				Kawasaki, Y.; Sagara, M.; Shibata, Y.; Shirouzu, M.; Yokoyama, S.; Akiyama, T.			Identification and characterization of Asef2, a guanine-nucleotide exchange factor specific for Rac1 and Cdc42	ONCOGENE			English	Article						tumor suppressor; APC; Asef; GEF; Rac1; Cdc42	TUMOR-SUPPRESSOR APC; COLORECTAL-CANCER; ACTIN CYTOSKELETON; MIGRATION; PROTEIN; LINK	The tumor suppressor adenomatous polyposis coli (APC) is mutated in sporadic and familial colorectal tumors. APC interacts with the Rac1-specific guanine-nucleotide exchange factor (GEF) Asef, which contains an APC-binding region (ABR) in addition to Dbl homology (DH), Pleckstrin (PH) and Src homology 3 (SH3) domains. APC stimulates the GEF activity of Asef, and thereby regulates cell adhesion and migration. Here, we have identified a second Asef, termed Asef2, that shows significant structural and functional similarities to Asef. We found that both the N-terminal ABR and SH3 domains of Asef2 are responsible for its interaction with APC. When expressed in HeLa cells, a mutant Asef2 lacking the ABR and SH3 domains, Asef2-Delta ABR/SH3, induced increases in the levels of the active forms of Rac1 and Cdc42. Full-length Asef2 also showed this activity when co-transfected with truncated mutant APC expressed in colorectal tumor cells. Consistent with this, either Asef2-Delta ABR/SH3 or Asef2 plus truncated mutant APC stimulated lamellipodia formation in MDCK cells and filopodia formation in HeLa cells. Furthermore, RNA interference experiments showed that Asef2 is required for migration of colorectal tumor cells expressing truncated APC. These results suggest that similar to Asef, Asef2 plays an important role in cell migration, and that Asef2 activated by truncated mutant APC is required for aberrant migration of colorectal tumor cells.	[Kawasaki, Y.; Sagara, M.; Shibata, Y.; Akiyama, T.] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; [Shirouzu, M.; Yokoyama, S.] RIKEN Genom Sci Ctr, Yokohama Inst, Bunkyo Ku, Tokyo, Japan; [Yokoyama, S.] Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 113, Japan	University of Tokyo; RIKEN; University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@imcbns.iam.u-tokyo.ac.jp	Shirouzu, Mikako/A-6521-2016; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Feng QY, 2004, EMBO J, V23, P3492, DOI 10.1038/sj.emboj.7600331; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Gotthardt K, 2007, BIOL CHEM, V388, P67, DOI 10.1515/BC.2007.008; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamann MJ, 2007, MOL CELL BIOL, V27, P1380, DOI 10.1128/MCB.01608-06; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Murayama K, 2007, J BIOL CHEM, V282, P4238, DOI 10.1074/jbc.C600234200; Oshima H, 1997, CANCER RES, V57, P1644; Polakis P, 2000, GENE DEV, V14, P1837; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; VAN AL, 1997, GENE DEV, V11, P2295; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588	20	55	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7620	7627		10.1038/sj.onc.1210574	http://dx.doi.org/10.1038/sj.onc.1210574			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17599059				2022-12-17	WOS:000251537800003
J	Li, XL; Arai, Y; Harada, H; Shima, Y; Yoshida, H; Rokudai, S; Aikawa, Y; Kimura, A; Kitabayashi, I				Li, X-L; Arai, Y.; Harada, H.; Shima, Y.; Yoshida, H.; Rokudai, S.; Aikawa, Y.; Kimura, A.; Kitabayashi, I.			Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1-and p53-mediated transcription	ONCOGENE			English	Article						leukemia; HIPK2; mutation; AML1	INTERACTING PROTEIN KINASE-2; NUCLEAR-PORE COMPLEX; ACUTE LYMPHOBLASTIC-LEUKEMIA; GTPASE-ACTIVATING PROTEIN; FETAL LIVER HEMATOPOIESIS; ACUTE MONOCYTIC LEUKEMIA; SUMO-1 MODIFICATION; HOMEODOMAIN-INTERACTING-PROTEIN-KINASE-2 HIPK2; CHROMOSOME-TRANSLOCATION; AML1/PEBP2-ALPHA-B GENE	The AML1 transcription factor complex is the most frequent target of leukemia-associated chromosomal translocations. Homeodomain-interacting protein kinase 2 (HIPK2) is a part of the AML1 complex and activates AML1-mediated transcription. However, chromosomal translocations and mutations of HIPK2 have not been reported. In the current study, we screened mutations of the HIPK2 gene in 50 cases of acute myeloid leukemia (AML) and in 80 cases of myelodysplastic syndrome (MDS). Results indicated there were two missense mutations ( R868W and N958I) in the speckle-retention signal (SRS) domain of HIPK2. Subcellular localization analyses indicated that the two mutants were largely localized to nuclear regions with conical or ring shapes, and were somewhat diffused in the nucleus, in contrast to the wild type, which were mainly localized in nuclear speckles. The mutations impaired the overlapping localization of AML1 and HIPK2. The mutants showed decreased activities and a dominant-negative function over wild-type protein in AML1- and p53-dependent transcription. These findings suggest that dysfunction of HIPK2 may play a role in the pathogenesis of leukemia.	Natl Canc Ctr, Res Inst, Div Mol Oncol, Chuo Ku, Tokyo 104, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima, Japan	National Cancer Center - Japan; Hiroshima University	Kitabayashi, I (corresponding author), Natl Canc Ctr, Res Inst, Div Mol Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 104, Japan.	ikitabay@gan2.ncc.go.jp	Rokudai, Susumu/O-6771-2018; Kitabayashi, Issay/G-2204-2017	Rokudai, Susumu/0000-0003-0300-0391; Kitabayashi, Issay/0000-0002-8409-0407				Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Carapeti M, 1999, CANCER GENET CYTOGEN, V113, P70, DOI 10.1016/S0165-4608(99)00007-2; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Duprez E, 1999, J CELL SCI, V112, P381; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; Hofmann TG, 2005, J BIOL CHEM, V280, P29224, DOI 10.1074/jbc.M503921200; Hofmann TG, 2003, CANCER RES, V63, P8271; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hofmann TG, 2000, BIOCHIMIE, V82, P1123, DOI 10.1016/S0300-9084(00)01196-2; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kim YH, 2005, FEBS LETT, V579, P6272, DOI 10.1016/j.febslet.2005.10.010; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Moller A, 2003, ONCOGENE, V22, P8731, DOI 10.1038/sj.onc.1207079; Moller A, 2003, CANCER RES, V63, P4310; Nguyen LA, 2005, BLOOD, V105, P292, DOI 10.1182/blood-2004-03-1185; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Sung KS, 2005, FEBS LETT, V579, P3001, DOI 10.1016/j.febslet.2005.04.053; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang Y, 2001, BBA-GENE STRUCT EXPR, V1518, P168, DOI 10.1016/S0167-4781(00)00308-0; Wiggins AK, 2004, J CELL BIOL, V167, P257, DOI 10.1083/jcb.200406131; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2005, P NATL ACAD SCI USA, V102, P2802, DOI 10.1073/pnas.0409373102	62	55	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7231	7239		10.1038/sj.onc.1210523	http://dx.doi.org/10.1038/sj.onc.1210523			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17533375				2022-12-17	WOS:000250955600007
J	Giagkousiklidis, S; Vellanki, SH; Debatin, KM; Fulda, S				Giagkousiklidis, S.; Vellanki, S. H.; Debatin, K-M; Fulda, S.			Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition	ONCOGENE			English	Article						apoptosis; radiotherapy; IAPs; pancreatic cancer	RADIATION-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; X-LINKED INHIBITOR; PROTEIN XIAP; SURVIVIN; CANCER; MITOCHONDRIA; ACTIVATOR	Resistance of pancreatic cancer to current treatments including radiotherapy remains a major challenge in oncology and may be caused by defects in apoptosis programs. Since 'inhibitor of apoptosis proteins' (IAPs) block apoptosis at the core of the apoptotic machinery by inhibiting caspases, therapeutic modulation of IAPs could tackle a key resistance mechanism. Here, we report that targeting X-linked inhibitor of apoptosis (XIAP) by RNA-interference-mediated knockdown or overexpression of second mitochondria-derived activator of caspase significantly enhanced apoptosis and markedly reduced clonogenic growth of pancreatic carcinoma cells upon gamma-irradiation. Analysis of signaling pathways revealed that antagonizing XIAP increased activation of caspase-2, -3, -8 and -9 and loss of mitochondrial membrane potential upon gamma-irradiation. Interestingly, inhibition of caspases also reduced the cooperative effect of XIAP targeting and gamma-irradiation to trigger mitochondrial perturbations, suggesting that XIAP controls a feedback mitochondrial amplification loop by regulating caspase activity. Importantly, our data demonstrate for the first time that small molecule XIAP inhibitors sensitized pancreatic carcinoma cells for gamma-irradiation-induced apoptosis, whereas they had no effect on gamma-irradiation-mediated apoptosis of non-malignant fibroblasts indicating some tumor specification. In conclusion, targeting XIAP, for example by small molecules, is a promising novel approach to enhance radiosensitivity of pancreatic cancer that warrants further investigation.	Univ Childrens Hosp, D-89075 Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fulda, S (corresponding author), Univ Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Cao C, 2004, ONCOGENE, V23, P7047, DOI 10.1038/sj.onc.1207929; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 1997, CANCER RES, V57, P3823; FULDA S, 2006, APOPTOSIS CANC THERA, P849; Fulda S, 2006, RECENT PAT ANTI-CANC, V1, P81, DOI 10.2174/157489206775246539; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; JENDROSSEK V, 2006, APOPTOSIS CANC THERA, P1049; Lu B, 2004, CANCER RES, V64, P2840, DOI 10.1158/0008-5472.CAN-03-3547; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k; Rodel C, 2003, INT J RADIAT ONCOL, V55, P1341, DOI 10.1016/S0360-3016(02)04618-7; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Turk B, 2002, CURR PHARM DESIGN, V8, P1623, DOI 10.2174/1381612023394124; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Vogler M, 2007, ONCOGENE, V26, P248, DOI 10.1038/sj.onc.1209776; Vogler M, 2005, ONCOGENE, V24, P7190, DOI 10.1038/sj.onc.1208876; Westphal Sabine, 2003, Mol Cancer, V2, P6, DOI 10.1186/1476-4598-2-6; Wilkinson JC, 2004, MOL CELL BIOL, V24, P7003, DOI 10.1128/MCB.24.16.7003-7014.2004	28	55	58	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					7006	7016		10.1038/sj.onc.1210502	http://dx.doi.org/10.1038/sj.onc.1210502			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17471230				2022-12-17	WOS:000250412200006
J	Irmer, D; Funk, JO; Blaukat, A				Irmer, D.; Funk, J. O.; Blaukat, A.			EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy	ONCOGENE			English	Review						EGFR; mutation; NSCLC; gefitinib; erlotimb; cetuximab	GROWTH-FACTOR-RECEPTOR; ACQUIRED-RESISTANCE; GENE-MUTATIONS; GEFITINIB SENSITIVITY; ACTIVATING MUTATIONS; PROLONGED SURVIVAL; SOMATIC MUTATIONS; MOLECULAR-BIOLOGY; DOWN-REGULATION; ERBB RECEPTORS	In 2004 remarkable clinical responses in non-small-cell lung cancer (NSCLC) patients treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib were reported to correlate with the presence of certain somatic EGFR kinase domain mutations in tumors. Since then, a surge of enthusiasm has been encountered in the field of molecular and clinical oncology. Beyond the promise of a tailored medicine, questions about the molecular mechanisms underlying the observed effects have arisen. In vitro analysis of NSCLC cells with endogenous EGFR mutations, recombinant expression of EGFR variants by transfection of several cell lines and the generation of transgenic mice expressing mutant EGFR were applied to study the impact of these genetic alterations on cellular signaling and cell fate. This review outlines the current mechanistic knowledge derived from such studies and discusses the relevance of EGFR kinase domain mutations for EGFR-directed therapies, including monoclonal antibodies.	Merck KGaA, Oncol Res Darmstadt, D-64293 Darmstadt, Germany	Merck KGaA	Blaukat, A (corresponding author), Merck KGaA, Oncol Res Darmstadt, Frankfurter Str 250,A25-501, D-64293 Darmstadt, Germany.	andree.blaukat@merck.de						Amann J, 2005, CANCER RES, V65, P226; Ando K, 2005, CLIN CANCER RES, V11, P8872, DOI 10.1158/1078-0432.CCR-05-0811; Arao T, 2004, CANCER RES, V64, P9101, DOI 10.1158/0008-5472.CAN-04-2360; Asahina H, 2006, BRIT J CANCER, V95, P998, DOI 10.1038/sj.bjc.6603393; Barber TD, 2004, NEW ENGL J MED, V351, P2883, DOI 10.1056/NEJM200412303512724; Bell DW, 2005, NAT GENET, V37, P1315, DOI 10.1038/ng1671; Bell DW, 2005, J CLIN ONCOL, V23, P8081, DOI 10.1200/JCO.2005.02.7078; Blencke S, 2003, J BIOL CHEM, V278, P15435, DOI 10.1074/jbc.M211158200; Calvo E, 2006, J CLIN ONCOL, V24, P2158, DOI 10.1200/JCO.2006.06.5961; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Cappuzzo F, 2004, JNCI-J NATL CANCER I, V96, P1133, DOI 10.1093/jnci/djh217; Carey KD, 2006, CANCER RES, V66, P8163, DOI 10.1158/0008-5472.CAN-06-0453; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; Choong NW, 2006, NAT CLIN PRACT ONCOL, V3, P50, DOI 10.1038/ncponc0400; Coldren CD, 2006, MOL CANCER RES, V4, P521, DOI 10.1158/1541-7786.MCR-06-0095; Damstrup L, 2002, INT J CANCER, V97, P7, DOI 10.1002/ijc.1572; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2006, J CLIN INVEST, V116, P2695, DOI 10.1172/JCI28656; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Fong KM, 2003, THORAX, V58, P892, DOI 10.1136/thorax.58.10.892; Fujimoto N, 2005, CANCER RES, V65, P11478, DOI 10.1158/0008-5472.CAN-05-1977; Gazdar AF, 2004, TRENDS MOL MED, V10, P481, DOI 10.1016/j.molmed.2004.08.008; Giaccone G, 2006, CLIN CANCER RES, V12, P6049, DOI 10.1158/1078-0432.CCR-06-0260; Gow CH, 2005, PLOS MED, V2, P924, DOI 10.1371/journal.pmed.0020269; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Harari PM, 2004, ENDOCR-RELAT CANCER, V11, P689, DOI 10.1677/erc.1.00600; Heymach JV, 2006, CLIN CANCER RES, V12, p4441S, DOI 10.1158/1078-0432.CCR-06-0286; Hirsch FR, 2006, J CLIN ONCOL, V24, P5034, DOI 10.1200/JCO.2006.06.3958; Inukai M, 2006, CANCER RES, V66, P7854, DOI 10.1158/0008-5472.CAN-06-1951; Jackman DM, 2006, CLIN CANCER RES, V12, P3908, DOI 10.1158/1078-0432.CCR-06-0462; Janmaat ML, 2006, INT J CANCER, V118, P209, DOI 10.1002/ijc.21290; Janne PA, 2005, J CLIN ONCOL, V23, P3227, DOI 10.1200/JCO.2005.09.985; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; Johnson BE, 2005, J CLIN ONCOL, V23, P6813, DOI 10.1200/JCO.2005.97.008; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kobayashi S, 2005, CANCER RES, V65, P7096, DOI 10.1158/0008-5472.CAN-05-1346; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kokubo Y, 2005, BRIT J CANCER, V92, P1711, DOI 10.1038/sj.bjc.6602559; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lee JW, 2005, CLIN CANCER RES, V11, P2879, DOI 10.1158/1078-0432.CCR-04-2029; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; LYNCH TJ, 2004, 40 ANN M AM SOC CLIN; Marchetti A, 2006, NEW ENGL J MED, V354, P526; Mellstedt H, 2003, DRUG TODAY, V39, P1; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331; Niho S, 2006, J CLIN ONCOL, V24, P64, DOI 10.1200/JCO.2005.02.5825; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Normanno N, 2005, CURR DRUG TARGETS, V6, P243, DOI 10.2174/1389450053765879; Okamoto I, 2003, CANCER SCI, V94, P50, DOI 10.1111/j.1349-7006.2003.tb01351.x; Oliveira S, 2006, EXPERT OPIN BIOL TH, V6, P605, DOI 10.1517/14712598.6.6.605; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; PAZARES L, 2006, 42 ANN M AM SOC CLIN; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Perez-Torres M, 2006, J BIOL CHEM, V281, P40183, DOI 10.1074/jbc.M607958200; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Reis JS, 2006, J PATHOL, V209, P445, DOI 10.1002/path.2004; Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846; ROBERSTON J, 2003, 39 ANN M AM SOC CLIN; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; Sato J D, 1983, Mol Biol Med, V1, P511; Shepherd FA, 2006, J CLIN ONCOL, V24, P1219, DOI 10.1200/JCO.2005.04.4420; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; Sihto H, 2005, J MOL MED, V83, P976, DOI 10.1007/s00109-005-0699-4; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; Toyooka S, 2005, NEW ENGL J MED, V352, P2136; Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Tsuchihashi Z, 2005, NEW ENGL J MED, V353, P208, DOI 10.1056/NEJM200507143530218; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yarden Y, 2001, EUR J CANCER, V37, pS3	83	55	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5693	5701		10.1038/sj.onc.1210383	http://dx.doi.org/10.1038/sj.onc.1210383			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353898				2022-12-17	WOS:000248885100001
J	Camus, S; Menendez, S; Cheok, CF; Stevenson, LF; Lain, S; Lane, DP				Camus, S.; Menendez, S.; Cheok, C. F.; Stevenson, L. F.; Lain, S.; Lane, D. P.			Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6	ONCOGENE			English	Article						ubiquitination; p53; human papillomavirus; E6; degradation; proteasome	MDM2 PROMOTES; ORNITHINE-DECARBOXYLASE; PROTEASOMAL DEGRADATION; GROWTH SUPPRESSION; CONJUGATING ENZYME; DNA-BINDING; CELL-LINES; C-TERMINUS; ONCOPROTEIN; E6-AP	In vitro, high-risk human papillomavirus E6 proteins have been shown, in conjunction with E6-associated protein (E6AP), to mediate ubiquitination of p53 and its degradation by the 26S proteasome by a pathway that is thought to be analogous to Mdm2-mediated p53 degradation. However, differences in the requirements of E6/E6AP and Mdm2 to promote the degradation of p53, both in vivo and in vitro, suggest that these two E3 ligases may promote p53 degradation by distinct pathways. Using tools that disrupt ubiquitination and degradation, clear differences between E6-and Mdm2-mediated p53 degradation are presented. The consistent failure to fully protect p53 protein from E6-mediated degradation by disrupting the ubiquitin-degradation pathway provides the first evidence of an E6-dependent, ubiquitin-independent, p53 degradation pathway in vivo.	Inst Mol & Cell Biol, Dept Cell Cycle Control, Proteos 138673, Singapore; Univ Dundee, Dept Surg & Mol Oncol, Dundee DD1 4HN, Scotland; Ninewells Hosp & Med Sch, Dundee, Scotland	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); University of Dundee; University of Dundee	Camus, S (corresponding author), Inst Mol & Cell Biol, Dept Cell Cycle Control, 61 Biopolis Dr, Proteos 138673, Singapore.	scamus@imcb.a-star.edu.sg	Lane, David P/C-4920-2008; Lain, Sonia/B-6980-2014	Lain, Sonia/0000-0001-9693-5246; Menendez, Sergio/0000-0002-7929-8641; Lane, David/0000-0003-0551-3545	Cancer Research UK [A6613] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Benaroudj N, 2001, BIOCHIMIE, V83, P311, DOI 10.1016/S0300-9084(01)01244-5; BERCOVICH Z, 1993, EUR J BIOCHEM, V213, P205, DOI 10.1111/j.1432-1033.1993.tb17749.x; Camus S, 2003, FEBS LETT, V536, P220, DOI 10.1016/S0014-5793(03)00054-1; Chen Z, 2004, SHOCK, V21, P1; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Coffino P, 2001, BIOCHIMIE, V83, P319, DOI 10.1016/S0300-9084(01)01252-4; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hengstermann A, 2005, J VIROL, V79, P9296, DOI 10.1128/JVI.79.14.9296-9300.2005; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hoyt MA, 2005, METHOD ENZYMOL, V398, P399, DOI 10.1016/S0076-6879(05)98033-6; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hwang SG, 2005, J BIOL CHEM, V280, P12758, DOI 10.1074/jbc.M413367200; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Ju DH, 2004, J BIOL CHEM, V279, P23851, DOI 10.1074/jbc.C400111200; Kahana Chaim, 2005, V301, P83; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kretz-Remy C, 2003, BIOL CHEM, V384, P589, DOI 10.1515/BC.2003.066; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Lagrange M, 2005, J GEN VIROL, V86, P1001, DOI 10.1099/vir.0.80607-0; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Li XQ, 1996, J BIOL CHEM, V271, P4447; Li XT, 2006, CELL, V124, P381, DOI 10.1016/j.cell.2005.11.037; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Nakamura S, 2002, ONCOGENE, V21, P2605, DOI 10.1038/sj.onc.1205343; Ness GC, 2005, FEBS LETT, V579, P3126, DOI 10.1016/j.febslet.2005.05.001; Nomine Y, 2006, MOL CELL, V21, P665, DOI 10.1016/j.molcel.2006.01.024; PENA MM, 2005, BIOCHEM J, V394, P355; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; Saeki Y, 2004, GENES GENET SYST, V79, P77, DOI 10.1266/ggs.79.77; Salvat C, 2000, EUR J BIOCHEM, V267, P3712, DOI 10.1046/j.1432-1327.2000.01404.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scheffner M, 1998, PHARMACOL THERAPEUT, V78, P129, DOI 10.1016/S0163-7258(98)00003-5; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Stewart D, 2005, J VIROL, V79, P8773, DOI 10.1128/JVI.79.14.8773-8783.2005; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	53	55	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4059	4070		10.1038/sj.onc.1210188	http://dx.doi.org/10.1038/sj.onc.1210188			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17224909	Green Accepted			2022-12-17	WOS:000247252700002
J	Liu, SL; D Miller, A				Liu, S-L; D Miller, A.			Oncogenic transformation by the jaagsiekte sheep retrovirus envelope protein	ONCOGENE			English	Review						Jaagsiekte sheep retrovirus; envelope protein; transformation; lung cancer; signaling pathways; mouse model	OVINE PULMONARY ADENOCARCINOMA; MACROPHAGE-STIMULATING PROTEIN; LONG TERMINAL REPEAT; HUMAN BRONCHIOLOALVEOLAR CARCINOMA; BETARETROVIRUS ENV PROTEINS; RECEPTOR TYROSINE KINASE; LUNG EPITHELIAL-CELLS; ENZOOTIC NASAL TUMOR; RODENT FIBROBLASTS; PHOSPHATIDYLINOSITOL 3-KINASE	Retroviruses have played profound roles in our understanding of the genetic and molecular basis of cancer. Jaagsiekte sheep retrovirus (JSRV) is a simple retrovirus that causes contagious lung tumors in sheep, known as ovine pulmonary adenocarcinoma (OPA). Intriguingly, OPA resembles pulmonary adenocarcinoma in humans, and may provide a model for this frequent human cancer. Distinct from the classical mechanisms of retroviral oncogenesis by insertional activation of or virus capture of host oncogenes, the native envelope (Env) structural protein of JSRV is itself the active oncogene. A major pathway for Env transformation involves interaction of the Env cytoplasmic tail with as yet unidentified cellular adaptor(s), leading to the activation of PI3K/Akt and MAPK signaling cascades. Another potential mechanism involves the cell-entry receptor for JSRV, Hyaluronidase 2 (Hyal2), and the RON receptor tyrosine kinase, but the exact roles of these proteins in JSRV Env transformation remain to be better understood. Recently, a mouse model of lung cancer induced by JSRV Env has been developed, and the tumors in mice resemble those seen in sheep infected with JSRV and in humans. In this review, we summarize recent progress in our understanding the molecular mechanisms of oncogenic transformation by JSRV Env protein, and discuss the relevance to human lung cancer.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA	McGill University; Fred Hutchinson Cancer Center	Liu, SL (corresponding author), McGill Univ, Dept Microbiol & Immunol, 3775 Univ St,Lyman Duff Bldg,Room 608, Montreal, PQ H3A 2B4, Canada.	shan-lu.liu@mcgill.ca	Liu, Shan-Lu/L-5923-2016	Liu, Shan-Lu/0000-0003-1620-3817; Miller, Dusty/0000-0002-3736-3660				Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Alberti A, 2002, J VIROL, V76, P5387, DOI 10.1128/JVI.76.11.5387-5394.2002; Alian A, 2000, VIROLOGY, V276, P161, DOI 10.1006/viro.2000.0550; Allen TE, 2002, J GEN VIROL, V83, P2733, DOI 10.1099/0022-1317-83-11-2733; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Bai JR, 1999, VIROLOGY, V258, P333, DOI 10.1006/viro.1999.9728; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; BARSKY SH, 1994, CANCER-AM CANCER SOC, V73, P1163, DOI 10.1002/1097-0142(19940215)73:4<1163::AID-CNCR2820730407>3.0.CO;2-J; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BONNE C., 1939, AMER JOUR CANCER, V35, P491; Cavanaugh JE, 2004, EUR J BIOCHEM, V271, P2056, DOI 10.1111/j.1432-1033.2004.04131.x; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chow YHJ, 2003, J VIROL, V77, P6341, DOI 10.1128/JVI.77.11.6341-6350.2003; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; Cousens C, 2004, J VIROL, V78, P8506, DOI 10.1128/JVI.78.16.8506-8512.2004; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Danilkovitch-Miagkova A, 2003, P NATL ACAD SCI USA, V100, P4580, DOI 10.1073/pnas.0837136100; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De las Heras M, 2000, EUR RESPIR J, V16, P330, DOI 10.1034/j.1399-3003.2000.16b23.x; De Las Heras M, 2003, CURR TOP MICROBIOL, V275, P201; DeMartini JC, 2003, CURR TOP MICROBIOL, V275, P117; DeMartini JC, 2001, J VIROL, V75, P4239, DOI 10.1128/JVI.75.9.4239-4246.2001; Dirks C, 2002, J VIROL, V76, P2141, DOI 10.1128/JVI.76.5.2141-2149.2002; Duh FM, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-59; Fan H, 2003, CURR TOP MICROBIOL, V275, P139; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Halbert CL, 2001, J VIROL, V75, P6615, DOI 10.1128/JVI.75.14.6615-6624.2001; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hecht SJ, 1996, P NATL ACAD SCI USA, V93, P3297, DOI 10.1073/pnas.93.8.3297; Hiatt KM, 2002, HUM PATHOL, V33, P680, DOI 10.1053/hupa.2002.125776; Hofacre A, 2004, J VIROL, V78, P10479, DOI 10.1128/JVI.78.19.10479-10489.2004; Ji L, 2002, CANCER RES, V62, P2715; Klymiuk N, 2003, J VIROL, V77, P11268, DOI 10.1128/JVI.77.20.11268-11273.2003; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Liu SL, 2005, J VIROL, V79, P927, DOI 10.1128/JVI.79.2.927-933.2005; Liu SL, 2003, J VIROL, V77, P7924, DOI 10.1128/JVI.77.14.7924-7935.2003; Liu SL, 2003, J VIROL, V77, P2850, DOI 10.1128/JVI.77.5.2850-2858.2003; Maeda N, 2005, J VIROL, V79, P4440, DOI 10.1128/JVI.79.7.4440-4450.2005; Maeda N, 2003, J VIROL, V77, P9951, DOI 10.1128/JVI.77.18.9951-9959.2003; Maeda N, 2001, P NATL ACAD SCI USA, V98, P4449, DOI 10.1073/pnas.071547598; McGee-Estrada K, 2006, J VIROL, V80, P332, DOI 10.1128/JVI.80.1.332-341.2006; Mcgee-Estrada K, 2005, VIRUS GENES, V31, P257, DOI 10.1007/s11262-005-3239-y; McGee-Estrada K, 2002, VIROLOGY, V292, P87, DOI 10.1006/viro.2001.1247; Menzel EJ, 1998, CANCER LETT, V131, P3, DOI 10.1016/S0304-3835(98)00195-5; Miller Walter J, 2004, J Transl Med, V2, P4, DOI 10.1186/1479-5876-2-4; Mornex JF, 2003, CURR TOP MICROBIOL, V275, P225; Morozov VA, 2004, VIROLOGY, V327, P162, DOI 10.1016/j.virol.2004.05.028; Ortin A, 1998, VET IMMUNOL IMMUNOP, V61, P229, DOI 10.1016/S0165-2427(97)00149-9; Overbaugh J, 2001, MICROBIOL MOL BIOL R, V65, P371, DOI 10.1128/MMBR.65.3.371-389.2001; Palmarini M, 2000, J VIROL, V74, P5776, DOI 10.1128/JVI.74.13.5776-5787.2000; Palmarini M, 2000, J VIROL, V74, P8065, DOI 10.1128/JVI.74.17.8065-8076.2000; Palmarini M, 1999, J VIROL, V73, P6964, DOI 10.1128/JVI.73.8.6964-6972.1999; PALMARINI M, 1995, J GEN VIROL, V76, P2731, DOI 10.1099/0022-1317-76-11-2731; Palmarini M, 1996, J GEN VIROL, V77, P2991, DOI 10.1099/0022-1317-77-12-2991; Palmarini M, 2001, JNCI-J NATL CANCER I, V93, P1603, DOI 10.1093/jnci/93.21.1603; Palmarini M, 2001, J VIROL, V75, P11002, DOI 10.1128/JVI.75.22.11002-11009.2001; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Philbey AW, 2006, VIRUS RES, V117, P254, DOI 10.1016/j.virusres.2005.10.020; Rai SK, 2000, J VIROL, V74, P4698, DOI 10.1128/JVI.74.10.4698-4704.2000; Rai SK, 2001, P NATL ACAD SCI USA, V98, P4443, DOI 10.1073/pnas.071572898; Raz DJ, 2006, CLIN CANCER RES, V12, P3698, DOI 10.1158/1078-0432.CCR-06-0457; REDDEL RR, 1988, CANCER RES, V48, P1904; Rosenberg N., 1997, P475; Ruscetti SK, 1999, INT J BIOCHEM CELL B, V31, P1089, DOI 10.1016/S1357-2725(99)00074-6; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sanna E, 2002, EUR J HISTOCHEM, V46, P273; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sharp J. M., 1990, Maedi-visna and related diseases., P177; Sharp JM, 2003, CURR TOP MICROBIOL, V275, P55; SHARP JM, 1983, J GEN VIROL, V64, P2323, DOI 10.1099/0022-1317-64-10-2323; Spencer TE, 2003, J VIROL, V77, P749, DOI 10.1128/JVI.77.1.749-753.2003; Summers C, 2002, J GEN VIROL, V83, P1753, DOI 10.1099/0022-1317-83-7-1753; Tam BYY, 2003, J BIOL CHEM, V278, P49610, DOI 10.1074/jbc.M308492200; Travis WD, 1999, INT HISTOLOGICAL CLA; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; Varela M, 2006, VIROLOGY, V350, P347, DOI 10.1016/j.virol.2006.01.040; VERWOERD DW, 1980, ONDERSTEPOORT J VET, V47, P13; Vigdorovich V, 2005, J VIROL, V79, P79, DOI 10.1128/JVI.79.1.79-86.2005; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Wootton SK, 2005, NATURE, V434, P904, DOI 10.1038/nature03492; YORK DF, 1992, J VIROL, V66, P4930, DOI 10.1128/JVI.66.8.4930-4939.1992; Yousem SA, 2001, HUM PATHOL, V32, P1039, DOI 10.1053/hupa.2001.28249; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zavala G, 2003, VIROLOGY, V312, P95, DOI 10.1016/S0042-6822(03)00205-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	90	55	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					789	801		10.1038/sj.onc.1209850	http://dx.doi.org/10.1038/sj.onc.1209850			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16909114				2022-12-17	WOS:000244063800001
J	Dunne, J; Cullmann, C; Ritter, M; Soria, NM; Drescher, B; Debernardi, S; Skoulakis, S; Hartmann, O; Krause, M; Krauter, J; Neubauer, A; Young, BD; Heidenreich, O				Dunne, J.; Cullmann, C.; Ritter, M.; Soria, N. Martinez; Drescher, B.; Debernardi, S.; Skoulakis, S.; Hartmann, O.; Krause, M.; Krauter, J.; Neubauer, A.; Young, B. D.; Heidenreich, O.			siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8 ; 21)-positive cell lines and primary AML blasts	ONCOGENE			English	Article						RNA interference; siRNA; gene expression profiling; acute myeloid leukaemia; AML1/MTG8	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; T(8/21) FUSION PROTEIN; EPITHELIAL-CELLS; MESSENGER-RNA; GROWTH ARREST; TARGET GENE; C/EBP-ALPHA; AML1-ETO; BINDING	The chromosomal translocation t(8; 21) is associated with 10 - 15% of all cases of acute myeloid leukaemia (AML). The resultant fusion protein AML1/MTG8 interferes with haematopoietic gene expression and is an important regulator of leukaemogenesis. We studied the effects of small interfering RNA (siRNA)-mediated AML1/MTG8 depletion on global gene expression in t(8; 21)- positive leukaemic cell lines and in primary AML blasts using cDNA arrays, oligonucleotide arrays and real-time reverse transcription-polymerase chain reaction (RT-PCR). Suppression of AML1/MTG8 results in the increased expression of genes associated with myeloid differentiation, such as AZU1, BPI, CTSG, LYZ and RNASE2 as well as of antiproliferative genes such as IGFBP7, MS4A3 and SLA both in blasts and in cell lines. Furthermore, expression levels of several genes affiliated with drug resistance or indicative of poor prognosis AML (BAALC, CD34, PRG2, TSPAN7) are affected by AML1/MTG8 depletion. In conclusion, siRNA-mediated suppression of AML1/MTG8 cause very similar changes in gene expression pattern in t(8; 21)- positive cell lines and in primary AML blasts. Furthermore, the results suggest that the specific targeting of AML1/MTG8 function may be a promising approach for complementing existing treatment strategies.	Univ Tubingen, Dept Mol Biol, Interfac Inst Cell Biol, Fac Biol, D-72076 Tubingen, Germany; Barts & London Queen Marys Sch Med & Dent, Canc Res UK Med Oncol Lab, London, England; Univ Hosp Marburg, Dept Haematol Oncol & Immunol, Marburg, Germany; Hannover Med Sch, Dept Haematol Haemostaseol & Oncol, D-3000 Hannover, Germany; Univ Marburg, Inst Med Biometry & Epidemiol, Marburg, Germany; Univ Marburg, Inst Mol Biol & Tumour Res, Marburg, Germany	Eberhard Karls University of Tubingen; Cancer Research UK; University of London; Queen Mary University London; University Hospital of Giessen & Marburg; Hannover Medical School; Philipps University Marburg; Philipps University Marburg	Heidenreich, O (corresponding author), Univ Tubingen, Dept Mol Biol, Interfac Inst Cell Biol, Fac Biol, Morgenstelle 15, D-72076 Tubingen, Germany.	olaf.heidenreich@uni-tuebingen.de	Heidenreich, Olaf/AAP-5045-2021	Heidenreich, Olaf/0000-0001-5404-6483	Cancer Research UK [A6438, A6789] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; ASOU H, 1991, BLOOD, V77, P2031; Baldus CD, 2003, EXP HEMATOL, V31, P1051, DOI 10.1016/j.exphem.2003.08.004; Baldus CD, 2003, BLOOD, V102, P1613, DOI 10.1182/blood-2003-02-0359; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562; Basecke J, 2005, LEUKEMIA LYMPHOMA, V46, P265, DOI 10.1080/10428190400010767; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Debernardi S, 2003, GENE CHROMOSOME CANC, V37, P149, DOI 10.1002/gcc.10198; Donato JL, 2002, J CLIN INVEST, V109, P51, DOI 10.1172/JCI14025; ERICKSON P, 1992, BLOOD, V80, P1825; Fliegauf M, 2004, ONCOGENE, V23, P9070, DOI 10.1038/sj.onc.1208042; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; Frank R, 1995, ONCOGENE, V11, P2667; Garwicz D, 2005, HAEMATOLOGICA, V90, P38; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Heuser M, 2005, HAEMATOLOGICA, V90, P1484; Hiebert SW, 1996, CURR TOP MICROBIOL, V211, P253; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; KUSEC R, 1994, LEUKEMIA, V8, P735; Landberg G, 2001, ONCOGENE, V20, P3497, DOI 10.1038/sj.onc.1204471; LAUSENJ, 2006, ONCOGENE, V25, P1349; Lebigot I, 2003, BLOOD, V102, P4555, DOI 10.1182/blood-2003-06-2077; Lennartsson A, 2003, BIOCHEM BIOPH RES CO, V311, P853, DOI 10.1016/j.bbrc.2003.10.067; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Martinez N, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-44; MATOZAKI S, 1995, BRIT J HAEMATOL, V89, P805; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Morohoshi F, 2000, GENE, V241, P287, DOI 10.1016/S0378-1119(99)00481-3; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Mutaguchi K, 2003, CANCER RES, V63, P7717; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Philippar U, 2004, MOL CELL, V16, P867, DOI 10.1016/j.molcel.2004.11.039; Puccetti E, 2002, CANCER RES, V62, P7050; Rhoades KL, 2000, BLOOD, V96, P2108; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Ross ME, 2004, BLOOD, V104, P3679, DOI 10.1182/blood-2004-03-1154; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Tonks A, 2003, BLOOD, V101, P624, DOI 10.1182/blood-2002-06-1732; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WEISS J, 1987, BLOOD, V69, P652; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yagi T, 2003, BLOOD, V102, P1849, DOI 10.1182/blood-2003-02-0578; Yamanaka Y, 1997, J BIOL CHEM, V272, P30729, DOI 10.1074/jbc.272.49.30729; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937; ZIMMER M, 1992, P NATL ACAD SCI USA, V89, P8215, DOI 10.1073/pnas.89.17.8215	68	55	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6067	6078		10.1038/sj.onc.1209638	http://dx.doi.org/10.1038/sj.onc.1209638			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652140				2022-12-17	WOS:000241101200004
J	Keren-Paz, A; Bercovich, Z; Porat, Z; Erez, O; Brener, O; Kahana, C				Keren-Paz, A.; Bercovich, Z.; Porat, Z.; Erez, O.; Brener, O.; Kahana, C.			Overexpression of antizyme-inhibitor in NIH3T3 fibroblasts provides growth advantage through neutralization of antizyme functions	ONCOGENE			English	Article						antizyme inhibitor; antizyme; ornithine decarboxylase; polyamines; cell growth; cellular transformation	ORNITHINE-DECARBOXYLASE ACTIVITY; TISSUE-CULTURE CELLS; POLYAMINE TRANSPORT; GENE-EXPRESSION; TRANSGENIC MICE; REQUIRES INTERACTION; RETICULOCYTE LYSATE; NEGATIVE REGULATION; HOMOLOGOUS PROTEIN; PROSTATE-CANCER	Antizyme inhibitor (AzI) is a homolog of ornithine decarboxylase (ODC), a key enzyme of polyamine synthesis. Antizyme inhibitor retains no enzymatic activity, but exhibits high affinity to antizyme (Az), a negative regulator of polyamine homeostasis. As polyamines are involved in maintaining cellular proliferation, and since AzI may negate Az functions, we have investigated the role of AzI in regulating cell growth. We show here that overexpression of AzI in NIH3T3 cells increased growth rate, enabled growth in low serum, and permitted anchorage-independent growth in soft agar, while reduction of AzI levels by AzI siRNA reduced cellular proliferation. Moreover, AzI overproducing cells gave rise to tumors when injected into nude mice. AzI overexpression resulted in elevation of ODC activity and of polyamine uptake. These effects of AzI are a result of its ability to neutralize Az, as overexpression of an AzI mutant with reduced Az binding failed to alter cellular polyamine metabolism and growth properties. We also demonstrate upregulation of AzI in Ras transformed cells, suggesting its relevance to some naturally occurring transformations. Finally, increased uptake activity rendered AzI overproducing and Ras-transformed cells more sensitive to toxic polyamine analogs. Our results therefore imply that AzI has a central and meaningful role in modulation of polyamine homeostasis, and in regulating cellular proliferation and transformation properties.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Vet Resources, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Kahana, C (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	chaim.kahana@weizmann.ac.il	Porat, Ziv/K-1672-2012	Porat, Ziv/0000-0003-3059-181X				AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bercovich Z, 2004, J BIOL CHEM, V279, P54097, DOI 10.1074/jbc.M410234200; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BEY P, 1978, J MED CHEM, V21, P50, DOI 10.1021/jm00199a009; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BRUMMELKAMP TR, 2002, SCIENCE, V21, P21; Choi KS, 2005, BIOCHEM BIOPH RES CO, V328, P206, DOI 10.1016/j.bbrc.2004.11.172; CLIFFORD A, 1995, CANCER RES, V55, P1680; DON S, 1975, CANCER RES, V35, P3618; Feith DJ, 2001, CANCER RES, V61, P6073; Fong LYY, 2003, CANCER RES, V63, P3945; FUJITA K, 1982, BIOCHEM J, V204, P647, DOI 10.1042/bj2040647; Gandre S, 2002, EUR J BIOCHEM, V269, P1316, DOI 10.1046/j.1432-1033.2002.02774.x; GAZDAR AF, 1976, NATURE, V262, P696, DOI 10.1038/262696a0; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; GILMOUR SK, 1985, J BIOL CHEM, V260, P6439; HADDOX MK, 1980, CANCER RES, V40, P604; HE Y, 1994, BIOCHEM BIOPH RES CO, V203, P608, DOI 10.1006/bbrc.1994.2226; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; Janne J, 1983, Spec Top Endocrinol Metab, V5, P227; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATZ A, 1989, EMBO J, V8, P1163, DOI 10.1002/j.1460-2075.1989.tb03487.x; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KITANI T, 1989, BIOCHIM BIOPHYS ACTA, V991, P44, DOI 10.1016/0304-4165(89)90026-3; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; LUK GD, 1984, NEW ENGL J MED, V311, P80, DOI 10.1056/NEJM198407123110202; MAMROUDKIDRON E, 1994, EUR J BIOCHEM, V226, P547, DOI 10.1111/j.1432-1033.1994.tb20079.x; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MEGOSH L, 1995, CANCER RES, V55, P4205; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; Mitchell JLA, 2002, BIOCHEM J, V366, P663, DOI 10.1042/BJ20011612; Moinard C, 2005, CLIN NUTR, V24, P184, DOI 10.1016/j.clnu.2004.11.001; MOSHIER JA, 1993, CANCER RES, V53, P2618; MURAKAMI Y, 1989, BIOCHEM J, V259, P839, DOI 10.1042/bj2590839; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; Nilsson J, 2000, BIOCHEM J, V346, P699, DOI 10.1042/0264-6021:3460699; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1995, J CELL BIOCHEM, P132; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; Sakata K, 2000, BIOCHEM J, V347, P297, DOI 10.1042/0264-6021:3470297; Sakata K, 1997, BIOCHEM BIOPH RES CO, V238, P415, DOI 10.1006/bbrc.1997.7266; Schaner ME, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-26; Seiler N, 1970, Methods Biochem Anal, V18, P259, DOI 10.1002/9780470110362.ch5; SHANTZ LM, 1994, CANCER RES, V54, P2313; Shantz LM, 1998, CANCER RES, V58, P2748; Shantz LM, 2004, BIOCHEM J, V377, P257, DOI 10.1042/BJ20030778; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TOBIAS KE, 1993, BIOCHEMISTRY-US, V32, P5842, DOI 10.1021/bi00073a017; TONIN PN, 1989, ONCOGENE, V4, P1117; Valasinas A, 2003, BIOORGAN MED CHEM, V11, P4121, DOI 10.1016/S0968-0896(03)00453-X; van Duin M, 2005, GENE CHROMOSOME CANC, V44, P438, DOI 10.1002/gcc.20259; YUSPA SH, 1976, NATURE, V262, P402, DOI 10.1038/262402a0	61	55	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5163	5172		10.1038/sj.onc.1209521	http://dx.doi.org/10.1038/sj.onc.1209521			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16568078				2022-12-17	WOS:000240063700009
J	Wang, TH; Chan, YH; Chen, CW; Kung, WH; Lee, YS; Wang, ST; Chang, TC; Wang, HS				Wang, T-H; Chan, Y-H; Chen, C-W; Kung, W-H; Lee, Y-S; Wang, S-T; Chang, T-C; Wang, H-S			Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways	ONCOGENE			English	Article						paclitaxel; Taxol; JNK; interleukin 6 (IL-6)	NF-KAPPA-B; GENE-EXPRESSION; PROTEIN-KINASE; NUCLEAR-FACTOR; APOPTOSIS; ACTIVATION; RESISTANCE; INHIBITION; IL-6; LIPOPOLYSACCHARIDE	Paclitaxel (Taxol) is an antineoplastic agent that specifically targets microtubules and arrests cells at the G2/M phase of the cell cycle. In addition to mitotic arrest, the activation of c-Jun N-terminal kinase (JNK) signaling pathway has been demonstrated to be involved in the process leading to apoptosis. In an attempt to explore what genes are transcriptionally regulated by the activated JNK signaling pathway upon paclitaxel treatment, we used cDNA microarrays to analyse the changes of gene expression in human ovarian cancer cells that were treated with paclitaxel and/or the JNK inhibitor SP600125. Among 20 genes that were specifically regulated by the paclitaxel-activated JNK pathway, interleukin (IL)-6 was shown to elicit function through the JAK-STAT signaling pathway in an autocrine and/or paracrine fashion. Subsequently, we identified that 87.5% of eight tested ovarian cancer lines secreted detectable levels of IL-6, which could be further upregulated 2-3.2 fold by 1 mu M paclitaxel. Dissection on regulatory pathways for IL-6 indicated that (i) when ovarian cancer cells were treated with paclitaxel at low but clinically achievable concentrations (exemplified by 1 mu M in this study), the JNK signaling pathway was the major stimulator of IL-6 gene regulation and (ii) at suprapharmacologically high concentrations (exemplified by 50 mu M), paclitaxel exerted lipopolysaccharide-like effects, most likely through the Toll-like receptor 4 signaling pathway. Collectively, these results suggest that paclitaxel upregulates functional IL-6 expression in human ovarian cancer cells through multiple signaling pathways.	Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Tao Yuan 333, Taiwan; Chang Gung Mem Hosp, Dept Obstet & Gynecol, Lin Kou Med Ctr, Tao Yuan, Taiwan; Chang Gung Mem Hosp, GMRCL, Tao Yuan, Taiwan; Min Chuan Univ, Dept Biotechnol, Tao Yuan, Taiwan; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Northwestern University; Feinberg School of Medicine	Wang, HS (corresponding author), Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, 5 Fuhsing St, Tao Yuan 333, Taiwan.	hswang@cgmh.org.tw						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAFFET G, 1991, MOL BIOL MED, V8, P141; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Brichory FM, 2001, P NATL ACAD SCI USA, V98, P9824, DOI 10.1073/pnas.171320598; Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; Cui XQ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-210; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Dey S, 2003, CLIN CANCER RES, V9, P1557; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Duan ZF, 1999, CLIN CANCER RES, V5, P3445; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Flynn V, 2003, INT J ONCOL, V23, P317; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Hefler LA, 2003, CANCER RES, V63, P3066; Huang Y, 2002, MOL PHARMACOL, V61, P105, DOI 10.1124/mol.61.1.105; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kawasaki K, 2003, J IMMUNOL, V170, P413, DOI 10.4049/jimmunol.170.1.413; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074-5521(01)00049-7; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; Lee LF, 1996, CANCER RES, V56, P1303; Lee YS, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-132; LI BY, 1992, CANCER RES, V52, P2248; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Nakshatri H, 2004, ONCOGENE, V23, P7330, DOI 10.1038/sj.onc.1207995; Penson RT, 2000, INT J GYNECOL CANCER, V10, P33, DOI 10.1046/j.1525-1438.2000.00003.x; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; Pusztai L, 2004, CYTOKINE, V25, P94, DOI 10.1016/j.cyto.2003.10.004; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; Sriuranpong V, 2003, CANCER RES, V63, P2948; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Taxman DJ, 2003, CANCER RES, V63, P5095; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Uzzo RG, 2002, CLIN CANCER RES, V8, P3579; Villunger A, 1996, INT J CANCER, V65, P498, DOI 10.1002/(SICI)1097-0215(19960208)65:4<498::AID-IJC18>3.0.CO;2-6; Vivat-Hannah V, 2001, CANCER RES, V61, P8703; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wang XX, 2004, DRUG CHEM TOXICOL, V27, P243, DOI 10.1081/DCT-120037505; WATSON JM, 1990, CANCER RES, V50, P6959; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Yusuf RZ, 2003, CURR CANCER DRUG TAR, V3, P1, DOI 10.2174/1568009033333754	56	55	63	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4857	4866		10.1038/sj.onc.1209498	http://dx.doi.org/10.1038/sj.onc.1209498			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547493				2022-12-17	WOS:000239687100004
J	Vitagliano, D; Portella, G; Troncone, G; Francione, A; Rossi, C; Bruno, A; Giorgini, A; Coluzzi, S; Nappi, TC; Rothstein, JL; Pasquinelli, R; Chiappetta, G; Terracciano, D; Macchia, V; Melillo, RM; Fusco, A; Santoro, M				Vitagliano, D.; Portella, G.; Troncone, G.; Francione, A.; Rossi, C.; Bruno, A.; Giorgini, A.; Coluzzi, S.; Nappi, T. C.; Rothstein, J. L.; Pasquinelli, R.; Chiappetta, G.; Terracciano, D.; Macchia, V.; Melillo, R. M.; Fusco, A.; Santoro, M.			Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas	ONCOGENE			English	Article						kinase; carcinoma; thyroid; ras; progression; differentiation	TISSUE-SPECIFIC EXPRESSION; PAPILLARY CARCINOMAS; RAS ONCOGENE; THYROGLOBULIN PROMOTER; RET/PTC1 ONCOGENE; PCCL3 CELLS; MUTATIONS; CANCER; INSTABILITY; DEDIFFERENTIATION	Ras oncogenes are frequently mutated in thyroid carcinomas. To verify the role played by N-ras in thyroid carcinogenesis, we generated transgenic mice in which a human N-ras(Gln61Lys) oncogene (Tg-N-ras) was expressed in the thyroid follicular cells.Tg-N-ras mice developed thyroid follicular neoplasms; 11% developed follicular adenomas and similar to 40% developed invasive follicular carcinomas, in some cases with a mixed papillary/follicular morphology. About 25% of the Tg-N-ras carcinomas displayed large, poorly differentiated areas, featuring vascular invasion and forming lung, bone or liver distant metastases. N-ras(Gln61Lys) express ion in cultured PC Cl 3 thyrocytes induced thyroid-stimulating hormone-independent proliferation and genomic instability with micronuclei formation and centrosome amplification. These findings support the notion that mutated ras oncogenes could be able to drive the formation of thyroid tumors that can progress to poorly differentiated, metastatic carcinomas.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med, CNR,Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Sci Biomorfol & Funzionali, I-80131 Naples, Italy; Consorzio Mario Negri Sud, Chieti, Italy; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19107 USA; Fdn Pascale, Ist Nazl Tumori, Funt Genom Unit, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; Consorzio Mario Negri Sud; Jefferson University; Jefferson University; IRCCS Fondazione Pascale	Santoro, M (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med, CNR,Ist Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.	masantor@unina.it	vitagliano, donata/B-8976-2012; melillo, rosa marina/O-5255-2015; Terracciano, Daniela/AAB-9521-2022; Portella, Giuseppe/AFU-6826-2022	Terracciano, Daniela/0000-0003-4296-429X; MELILLO, Rosa Marina/0000-0002-9233-5275; PORTELLA, Giuseppe/0000-0001-8276-9769; Coluzzi, Sabrina/0000-0003-4483-6232; Fusco, Alfredo/0000-0003-3332-5197				CARCANGIU ML, 1984, AM J SURG PATHOL, V8, P655, DOI 10.1097/00000478-198409000-00005; DELELLIS RA, 2004, TUMOURS ENDOCRINE OR, P51; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; Fagin JA, 2004, J ENDOCRINOL, V183, P249, DOI 10.1677/joe.1.05895; Fagin JA, 2002, MOL ENDOCRINOL, V16, P903, DOI 10.1210/me.16.5.903; Garcia-Rostan G, 2003, J CLIN ONCOL, V21, P3226, DOI 10.1200/JCO.2003.10.130; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; GRECO A, 1992, ONCOGENE, V7, P237; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; JOKINEN MP, 1994, PATHOLOGY TUMOURS LA, V2, P565; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; Knauf JA, 2006, J BIOL CHEM, V281, P3800, DOI 10.1074/jbc.M511690200; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; Ledent C, 1996, EXP CLIN ENDOCR DIAB, V104, P43, DOI 10.1055/s-0029-1211683; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Mitsutake N, 2005, CANCER RES, V65, P2465, DOI 10.1158/0008-5472.CAN-04-3314; Motoi O, 2000, PATHOL RES PRACT, V196, P1; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P2318, DOI 10.1210/jc.2002-021907; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Postiglione MP, 2002, P NATL ACAD SCI USA, V99, P15462, DOI 10.1073/pnas.242328999; Powell DJ, 1998, CANCER RES, V58, P5523; Rochefort P, 1996, ONCOGENE, V12, P111; Russell JP, 2000, ONCOGENE, V19, P5729, DOI 10.1038/sj.onc.1203922; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; SANTELLI G, 1993, CANCER RES, V53, P5523; Santoro M, 1996, ONCOGENE, V12, P1821; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Tallini G, 2002, ENDOCR PATHOL, V13, P271, DOI 10.1385/EP:13:4:271; Vasko V, 2003, J CLIN ENDOCR METAB, V88, P2745, DOI 10.1210/jc.2002-021186; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978; Zhu ZW, 2003, AM J CLIN PATHOL, V120, P71, DOI 10.1309/ND8D9LAJTRCTG6QD	35	55	56	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5467	5474		10.1038/sj.onc.1209527	http://dx.doi.org/10.1038/sj.onc.1209527			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16785999				2022-12-17	WOS:000240144900011
J	Niikura, Y; Ohta, S; Vandenbeldt, KJ; Abdulle, R; McEwen, BF; Kitagawa, K				Niikura, Y.; Ohta, S.; Vandenbeldt, K. J.; Abdulle, R.; McEwen, B. F.; Kitagawa, K.			17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation	ONCOGENE			English	Article						kinetochore; centromere; HSP90; SGT1 (SUGT1); 17-AAG	SACCHAROMYCES-CEREVISIAE KINETOCHORE; BUDDING YEAST KINETOCHORE; BREAST-CANCER CELLS; SPINDLE CHECKPOINT; ATP BINDING; IN-VIVO; CHROMOSOME CONGRESSION; MOLECULAR CHAPERONE; ANAPHASE TRANSITION; CENTROMERE PROTEIN	The Hsp90 inhibitor 17-allylaminogeldanamycin (17-AAG), which is currently in clinical trials, is thought to exert antitumor activity by simultaneously targeting several oncogenic signaling pathways. Here we report a novel mechanism by which 17-AAG inhibits cell proliferation, and we provide the first evidence that HSP90 is required for the assembly of kinetochore protein complexes in humans. 17-AAG caused delocalization of several kinetochore proteins including CENP-I and CENP-H but excluding CENP-B and CENP-C. Consistently, 17-AAG induced a mitotic arrest that depends on the spindle checkpoint and induced misalignment of chromosomes and aneuploidy. We found that HSP90 associates with SGT1 (suppressor of G2 allele of skp1; SUGT1) in human cells and that depletion of SGT1 sensitizes HeLa cells to 17-AAG. Overexpression of SGT1 restored the localization of specific kinetochore proteins and chromosome alignment in cells treated with 17-AAG. Biochemical and genetic results suggest that HSP90, through its interaction with SGT1 (SUGT1), is required for kinetochore assembly. Furthermore, time-course experiments revealed that transient treatment with 17-AAG between late S andG2/M phases causes substantial delocalization of CENP-H and CENP-I, a finding that strongly suggests that HSP90 participates in kinetochore assembly in a cell cycle-dependent manner.	St Jude Childrens Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Div Mol Med, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY USA	St Jude Children's Research Hospital; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Kitagawa, K (corresponding author), St Jude Childrens Hosp, Dept Mol Pharmacol, 332 N Lauderdale St,Mail Stop 230,Rm D3007C, Memphis, TN 38105 USA.	katsumi.kitagawa@stjude.org			NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066270, R01GM068418] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM68418, GM066270] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreassen Paul R, 2004, Methods Mol Biol, V281, P213; Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; Bansal PK, 2004, MOL CELL BIOL, V24, P8069, DOI 10.1128/MCB.24.18.8069-8079.2004; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Beliakoff J, 2004, ANTI-CANCER DRUG, V15, P651, DOI 10.1097/01.cad.0000136876.11928.be; Biggins S, 2003, CURR BIOL, V13, pR449, DOI 10.1016/S0960-9822(03)00369-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; de Carcer G, 2004, CANCER RES, V64, P5106, DOI 10.1158/0008-5472.CAN-03-2214; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; DROUIN R, 1988, CYTOBIOS, V56, P107; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Fukagawa T, 2001, EMBO J, V20, P4603, DOI 10.1093/emboj/20.16.4603; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Goetz MP, 2005, J CLIN ONCOL, V23, P1078, DOI 10.1200/JCO.2005.09.119; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hostein I, 2001, CANCER RES, V61, P4003; JIANG WD, 1993, J CELL BIOL, V121, P513, DOI 10.1083/jcb.121.3.513; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; Kelland LR, 1999, J NATL CANCER I, V91, P1940, DOI 10.1093/jnci/91.22.1940; Kitagawa K, 2002, BIOTECHNIQUES, V33, P288, DOI 10.2144/02332bm07; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Kitagawa K, 2001, NAT REV MOL CELL BIO, V2, P678, DOI 10.1038/35089568; Kranc KR, 2003, MOL CELL BIOL, V23, P7658, DOI 10.1128/MCB.23.21.7658-7666.2003; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LECHNER J, 1994, EMBO J, V13, P5203, DOI 10.1002/j.1460-2075.1994.tb06851.x; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Lingelbach LB, 2004, MOL CELL BIOL, V24, P8938, DOI 10.1128/MCB.24.20.8938-8950.2004; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; McEwen BF, 1997, J CELL BIOL, V137, P1567, DOI 10.1083/jcb.137.7.1567; McEwen BF, 2001, MOL BIOL CELL, V12, P2776, DOI 10.1091/mbc.12.9.2776; Meraldi P, 2005, EMBO J, V24, P1621, DOI 10.1038/sj.emboj.7600641; Munster PN, 2001, CANCER RES, V61, P2945; Neckers L, 2002, CLIN CANCER RES, V8, P962; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; Nimmanapalli R, 2001, CANCER RES, V61, P1799; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Piper PW, 2003, GENE, V302, P165, DOI 10.1016/S0378-1119(02)01102-2; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Reilly PT, 2002, MOL CELL BIOL, V22, P6767, DOI 10.1128/MCB.22.19.6767-6778.2002; Solit DB, 2002, CLIN CANCER RES, V8, P986; Srethapakdi M, 2000, CANCER RES, V60, P3940; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Steensgaard P, 2004, EMBO REP, V5, P626, DOI 10.1038/sj.embor.7400154; Stemmann O, 1996, EMBO J, V15, P3611, DOI 10.1002/j.1460-2075.1996.tb00730.x; Stemmann O, 2002, P NATL ACAD SCI USA, V99, P8585, DOI 10.1073/pnas.082223899; STRUNNIKOV AV, 1995, J CELL BIOL, V128, P749, DOI 10.1083/jcb.128.5.749; Tatsumi Y, 2003, J BIOL CHEM, V278, P41528, DOI 10.1074/jbc.M307534200; Taylor SS, 2001, J CELL SCI, V114, P4385; TENHAGEN KG, 1990, MOL CELL BIOL, V10, P6348, DOI 10.1128/MCB.10.12.6348; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Workman P, 2003, CURR CANCER DRUG TAR, V3, P297, DOI 10.2174/1568009033481868; Yang ZY, 2005, MOL CELL BIOL, V25, P4062, DOI 10.1128/MCB.25.10.4062-4074.2005; Yoda K, 1996, MOL CELL BIOL, V16, P5169	62	55	58	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4133	4146		10.1038/sj.onc.1209461	http://dx.doi.org/10.1038/sj.onc.1209461			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501598				2022-12-17	WOS:000239004800001
J	Gandhi, M; Medvedovic, M; Stringer, JR; Nikiforov, YE				Gandhi, M; Medvedovic, M; Stringer, JR; Nikiforov, YE			Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements	ONCOGENE			English	Article						chromosomal rearrangements; thyroid cancer; RET/ PTC; nuclear architecture	PAPILLARY THYROID CARCINOMAS; NUCLEAR ARCHITECTURE; RET PROTOONCOGENE; HUMAN-CELLS; CANCER; RADIATION; MODEL; ACTIVATION; FUSION; LOOPS	Recurrent chromosomal rearrangements are common in cancer cells and may be influenced by nonrandom positioning of recombination-prone genetic loci in the nucleus. However, the mechanism responsible for spatial proximity of specific loci is unknown. In this study, we use an 18Mb region on 10q11.2-21 containing the RET gene and its recombination partners, the H4 and NCOA4 (ELE1) genes, as a model chromosomal region frequently involved in RET/PTC rearrangements in thyroid cancer. RET/PTC is particularly common in tumors from children exposed to ionizing radiation. Using fluorescence in situ hybridization and three-dimensional microscopy, the locations of. five different loci in this region were mapped in interphase nuclei of normal human thyroid cells. We show that RET and NCOA4 are much closer to each other than expected based on their genomic separation. Modeling of chromosome folding in this region suggests the presence of chromosome coiling with coils of similar to 8Mb in length, which positions the RET gene close to both, the NCOA4 and H4, loci. There was no significant variation in gene proximity between adult and pediatric thyroid cells. This study provides evidence for large-scale chromosome folding of the 10q11.2-21 region that offers a structural basis for nonrandom positioning and spatial proximity of potentially recombinogenic intrachromosomal loci.	Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Ctr Biostat Serv, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Childrens Hosp Res Fdn, Div Biomed Informat, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Nikiforov, YE (corresponding author), Univ Cincinnati, Dept Pathol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	Yuri.Nikiforov@uc.edu			NCI NIH HHS [CA88041] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088041] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; BONGARZONE I, 1994, CANCER RES, V54, P2979; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Cornforth MN, 2002, J CELL BIOL, V159, P237, DOI 10.1083/jcb.200206009; Cremer C, 1996, MUTAT RES-REV GENET, V366, P97, DOI 10.1016/S0165-1110(96)90031-7; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Kozubek S, 1997, BLOOD, V89, P4537, DOI 10.1182/blood.V89.12.4537; MANTON I, 1950, BIOL REV, V25, P486, DOI 10.1111/j.1469-185X.1950.tb00770.x; MANUELIDIS L, 1990, CYTOMETRY, V11, P8, DOI 10.1002/cyto.990110104; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Munkel C, 1999, J MOL BIOL, V285, P1053, DOI 10.1006/jmbi.1998.2361; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; ONHUKI Y, 1965, NATURE, V208, P916; Parada LA, 2002, CURR BIOL, V12, P1692, DOI 10.1016/S0960-9822(02)01166-1; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; RATTNER JB, 1985, CELL, V42, P291, DOI 10.1016/S0092-8674(85)80124-0; Roccato E, 2005, CANCER RES, V65, P2572, DOI 10.1158/0008-5472.CAN-04-4294; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; SACHS RK, 1995, P NATL ACAD SCI USA, V92, P2710, DOI 10.1073/pnas.92.7.2710; SANTORO M, 1994, ONCOGENE, V9, P509; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; YOKOTA H, 1995, J CELL BIOL, V130, P1239, DOI 10.1083/jcb.130.6.1239	27	55	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2360	2366		10.1038/sj.onc.1209268	http://dx.doi.org/10.1038/sj.onc.1209268			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331264				2022-12-17	WOS:000236764300008
J	Borzacchiello, G; Russo, V; Gentile, F; Roperto, F; Venuti, A; Nitsch, L; Campo, MS; Roperto, S				Borzacchiello, G; Russo, V; Gentile, F; Roperto, F; Venuti, A; Nitsch, L; Campo, MS; Roperto, S			Bovine papillomavirus E5 oncoprotein binds to the activated form of the platelet-derived growth factor beta receptor in naturally occurring bovine urinary bladder tumours	ONCOGENE			English	Article						bovine papillomavirus type 2; E5; PDGF beta receptor; urinary bladder tumours	MHC CLASS-I; DOWN-REGULATION; INTERCELLULAR COMMUNICATION; TUMORIGENIC TRANSFORMATION; CELL-TRANSFORMATION; UROPLAKIN-III; BRACKEN-FERN; TYPE-4 E8; PROTEIN; EXPRESSION	Studies regarding the functions of the bovine papillomavirus (BPV) E5 oncoprotein in vivo are lacking and no E5-mediated mechanism underlying epithelial carcinogenesis is known. We have shown that BPV-2 DNA is present in the majority of naturally occurring urinary bladder tumours of cattle and that E5 is expressed in the cancer cells. Here we show that the interaction between the platelet-derived growth factor (PDGF) beta receptor and BPV E5, described in vitro in cultured cells, takes place in vivo in bovine urinary bladder cancers. In these cancers, E5 and PDGF beta receptor colocalize, as shown by confocal microscopy, and physically interact, as shown by coimmunoprecipitation. Furthermore, the PDGF b receptor associated with E5 is highly phosphorylated, suggesting the functional activation of the receptor upon E5 interaction. Our results demonstrate, for the first time, that E5-PDGF beta receptor interaction occurs during the natural history of bovine urinary bladder tumours, suggesting an important role for E5 in carcinogenesis. Finally, the system provides a suitable animal model of papillomavirus-associated cancer to test therapeutic vaccination against E5. Successful bladder tumour regression would provide a valuable model for therapeutic vaccination against papillomavirus-associated tumours.	Univ Naples Federico II, Fac Med Vet, Dept Pathol & Anim Hlth, I-80137 Naples, Italy; IEOS, CNR, Dept Cellular & Mol Biol & Pathol L Califano, Naples, Italy; Regina Elena Inst Canc Res, Virol Lab, Rome, Italy; Univ Glasgow, Div Pathol Sci, Inst Comparat Med, Glasgow, Lanark, Scotland	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Glasgow	Borzacchiello, G (corresponding author), Univ Naples Federico II, Fac Med Vet, Dept Pathol & Anim Hlth, Via F Delpino 1, I-80137 Naples, Italy.	borzacch@unina.it	Venuti, Aldo/K-9637-2016	Venuti, Aldo/0000-0003-2322-6857; Borzacchiello, Giuseppe/0000-0003-3943-2604; roperto, sante/0000-0001-6210-5519				Ambrosio V, 2001, VET PATHOL, V38, P657, DOI 10.1354/vp.38-6-657; Anderson RA, 1997, VET J, V154, P69, DOI 10.1016/S1090-0233(05)80010-3; ANGLIANO AM, 1994, UROL INT, V52, P125; Araibi EH, 2004, J GEN VIROL, V85, P2809, DOI 10.1099/vir.0.80128-0; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; Ashrafi GH, 2002, ONCOGENE, V21, P248; Borzacchiello G, 2003, VET PATHOL, V40, P455, DOI 10.1354/vp.40-4-455; Borzacchiello G, 2003, J COMP PATHOL, V128, P203, DOI 10.1053/jcpa.2002.0626; Borzacchiello G, 2003, J GEN VIROL, V84, P2921, DOI 10.1099/vir.0.19412-0; Borzacchiello G, 2001, VET PATHOL, V38, P113, DOI 10.1354/vp.38-1-113; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BURNETT S, 1992, P NATL ACAD SCI USA, V89, P5665, DOI 10.1073/pnas.89.12.5665; Campo MS, 1997, VET J, V154, P175, DOI 10.1016/S1090-0233(97)80019-6; CAMPO MS, 1992, CANCER RES, V52, P6898; CAMPO MS, 1994, RES VET SCI, V56, P151, DOI 10.1016/0034-5288(94)90097-3; Campo MS, 2002, VIRUS RES, V89, P249, DOI 10.1016/S0168-1702(02)00193-4; Chen YF, 2004, J VIROL, V78, P1333, DOI 10.1128/JVI.78.3.1333-1343.2004; COLTRERA MD, 1995, CANCER RES, V55, P2703; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; De Gaetani C, 1999, J CLIN PATHOL, V52, P103, DOI 10.1136/jcp.52.2.103; DiMaio D, 2000, CYTOKINE GROWTH F R, V11, P283, DOI 10.1016/S1359-6101(00)00012-5; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; dos Santos RCS, 1998, J GEN VIROL, V79, P2127, DOI 10.1099/0022-1317-79-9-2127; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FINBOW ME, 1991, MOL CARCINOGEN, V4, P441, DOI 10.1002/mc.2940040605; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Kaufmann O, 2000, AM J CLIN PATHOL, V113, P683, DOI 10.1309/PYQC-17CB-063T-Q07J; Lai CC, 2000, J BIOL CHEM, V275, P9832, DOI 10.1074/jbc.275.13.9832; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; Liu DW, 2000, J VIROL, V74, P9083, DOI 10.1128/JVI.74.19.9083-9089.2000; Marchetti B, 2002, ONCOGENE, V21, P7808, DOI 10.1038/sj.onc.1205885; Mayer TJ, 2000, IN VITRO CELL DEV-AN, V36, P667; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; Oliver RTD, 1998, CANCER SURV, V31, P29; OLSON C, 1965, CANCER RES, V25, P840; PAMUKCU AM, 1976, VET PATHOL, V13, P110, DOI 10.1177/030098587601300205; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Ramos-Vara JA, 2003, VET PATHOL, V40, P55, DOI 10.1354/vp.40-1-55; Roperto S, 2005, VET PATHOL, V42, P812, DOI 10.1354/vp.42-6-812; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Schmandt RE, 2003, CANCER-AM CANCER SOC, V98, P758, DOI 10.1002/cncr.11561; SHIBUTANI YF, 1992, UROLOGY, V40, P15, DOI 10.1016/0090-4295(92)90429-Z; SMITH BL, 1997, HDB PLANT FUNGAL TOX; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Sun TT, 1999, ADV EXP MED BIOL, V462, P7; VENUTI A, 2002, PERSP MED V, V8, P143	53	55	56	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1251	1260		10.1038/sj.onc.1209152	http://dx.doi.org/10.1038/sj.onc.1209152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205631				2022-12-17	WOS:000235537500012
J	Knauth, K; Bex, C; Jemth, P; Buchberger, A				Knauth, K; Bex, C; Jemth, P; Buchberger, A			Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1 alpha interactions	ONCOGENE			English	Article						VHL; RCC; HIF-1 alpha	TUMOR-SUPPRESSOR PROTEIN; PROLYL HYDROXYLATION/; LIGASE ACTIVITY; REGULATE HIF; VHL DISEASE; IN-VIVO; MUTATIONS; BINDING; COMPLEX; GENE	The von Hippel-Lindau (VHL) tumor suppressor protein is the substrate binding subunit of the CBCVHL E3 ubiquitin ligase complex. Mutations in the VHL gene cause a variety of tumors with complex genotype/ phenotype correlations. Type 2A and type 2B VHL disease are characterized by a low or high risk of renal cell carcinoma, respectively. To investigate the molecular basis underlying the difference between disease types 2A and 2B, we performed a detailed biochemical analysis of the two most frequent type 2A mutations, Y98H and Y112 H, in comparison to type 2B mutations in the same residues, Y98N and Y112N. While none of these mutations affected the assembly of CBCVHL complexes, the type 2A mutant proteins exhibited higher stabilities at physiological temperature. Moreover, the type 2A mutant proteins possessed higher binding affinities for the key cellular substrate, hypoxia-inducible transcription factor 1 (HIF-1 alpha). Consistent with these results, type 2A but not type 2B mutant VHL proteins retained significant ubiquitin ligase activity towards HIF-1 alpha in vitro. We propose that this residual ubiquitin ligase activity is sufficient to suppress renal cell carcinogenesis in vivo.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany; MRC, Ctr Prot Engn, Cambridge, England	Max Planck Society; University of Cambridge	Buchberger, A (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	buchberg@biochem.mpg.de	Buchberger, Alexander/AAF-4728-2019; Buchberger, Alexander/J-4070-2019	Buchberger, Alexander/0000-0002-2836-0820; Buchberger, Alexander/0000-0002-2836-0820; Pfander, Claudia/0000-0002-9574-9553				Allen DL, 1998, PROTEIN SCI, V7, P1262, DOI 10.1002/pro.5560070524; Bradley JF, 1999, AM J MED GENET, V87, P163, DOI 10.1002/(SICI)1096-8628(19991119)87:2<163::AID-AJMG7>3.0.CO;2-A; BRAUCH H, 1995, HUM GENET, V95, P551, DOI 10.1007/BF00223868; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Buchberger A, 1999, J BIOL CHEM, V274, P38017, DOI 10.1074/jbc.274.53.38017; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Chen F, 1996, J MED GENET, V33, P716, DOI 10.1136/jmg.33.8.716; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feldman DE, 2003, MOL CELL, V12, P1213, DOI 10.1016/S1097-2765(03)00423-4; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Hansen WJ, 2002, MOL CELL BIOL, V22, P1947, DOI 10.1128/MCB.22.6.1947-1960.2002; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Killenberg-Jabs M, 2002, BIOPHYS CHEM, V96, P259, DOI 10.1016/S0301-4622(02)00017-0; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Li ZB, 2003, EMBO J, V22, P1857, DOI 10.1093/emboj/cdg173; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Rathmell WK, 2004, CANCER RES, V64, P8595, DOI 10.1158/0008-5472.CAN-04-1430; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657	41	55	57	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					370	377		10.1038/sj.onc.1209062	http://dx.doi.org/10.1038/sj.onc.1209062			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16261165				2022-12-17	WOS:000234714100005
J	Taylor, JR; Brownlow, N; Domin, J; Dibb, NJ				Taylor, JR; Brownlow, N; Domin, J; Dibb, NJ			FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance	ONCOGENE			English	Article						imatinib; FMS; CSF-1; M-CSF; D802V; v-fms	PROTO-ONCOGENE PRODUCT; CELL-LINE FDC-P1; C-FMS; TYROSINE KINASE; GROWTH-FACTOR; ACTIVATING MUTATIONS; LUNG-CANCER; WILD-TYPE; IN-VITRO; STI-571 INHIBITION	The kinase inhibitor imatinib is used in the treatment of chronic myeloid leukaemia, where it targets the intracellular Bcr-Abl tyrosine kinase, and gastrointestinal stromal tumours, where it targets either the KIT or PDGF tyrosine kinase receptors. Here, we report that imatinib is also an effective inhibitor of the closely related FMS receptor for macrophage colony stimulating factor and that mutation of Asp 802 of FMS to Val confers imatinib resistance. Imatinib readily reverted the transformed phenotype of haemopoietic and fibroblast cell lines that express the oncogene v-fms and also inhibited the growth of the Bacl. 2F5 macrophage cell line. The cellular IC50 value of imatinib for FMS was similar to those for Bcr-Abl and KIT. Consequently, imatinib may also prove effective for the treatment of diseases whose progression is dependent upon macrophage-colony stimulating factor, this includes certain aspects of cancer and inflammation.	Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Div Med, London W12 0NN, England	Imperial College London; Imperial College London	Dibb, NJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	n.dibb@imperial.ac.uk	Taylor, James R/F-7960-2014; brownlow, nicola/H-6826-2015	brownlow, nicola/0000-0003-4733-9960				Aldskogius H., 2001, EXPER OPIN THER TAR, V5, P655; BAKER DA, 1994, LEUKEMIA, V8, P141; Bohmer FD, 2003, J BIOL CHEM, V278, P5148, DOI 10.1074/jbc.M209861200; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; CARUANA G, 1993, EXP HEMATOL, V21, P761; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Corbin AS, 2003, BLOOD, V101, P4611, DOI 10.1182/blood-2002-12-3659; Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood-2004-10-3967; Dewar AL, 2003, LEUKEMIA, V17, P1713, DOI 10.1038/sj.leu.2403071; Dibb NJ, 1990, GROWTH FACTORS, V2, P301, DOI 10.3109/08977199009078018; Dibb NJ, 2004, NAT REV CANCER, V4, P718, DOI 10.1038/nrc1434; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Frost MJ, 2002, MOL CANCER THER, V1, P1115; GLOVER HR, 1995, ONCOGENE, V11, P1347; Joensuu H, 2002, LANCET ONCOL, V3, P655, DOI 10.1016/S1470-2045(02)00899-9; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; Morley GM, 1999, ONCOGENE, V18, P3076, DOI 10.1038/sj.onc.1202646; Mundy GR, 2002, ANNU REV MED, V53, P337, DOI 10.1146/annurev.med.53.082901.104047; Murray LJ, 2003, CLIN EXP METASTAS, V20, P757, DOI 10.1023/B:CLIN.0000006873.65590.68; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Perry VH, 2004, BRAIN BEHAV IMMUN, V18, P407, DOI 10.1016/j.bbi.2004.01.004; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Pollard JW, 1997, MOL REPROD DEV, V46, P54, DOI 10.1002/(SICI)1098-2795(199701)46:1&lt;54::AID-MRD9&gt;3.0.CO;2-Q; Pollard JW, 1997, MOL REPROD DEV, V46, P60; Reilly JT, 2002, BRIT J HAEMATOL, V116, P744, DOI 10.1046/j.0007-1048.2001.03294.x; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Sweet MJ, 2003, ARCH IMMUNOL THER EX, V51, P169; Uden M, 1999, ONCOGENE, V18, P3846, DOI 10.1038/sj.onc.1202743; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120	44	55	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					147	151		10.1038/sj.onc.1209007	http://dx.doi.org/10.1038/sj.onc.1209007			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170366				2022-12-17	WOS:000234406400016
J	Sansom, OJ; Griffiths, DFR; Reed, KR; Winton, DJ; Clarke, AR				Sansom, OJ; Griffiths, DFR; Reed, KR; Winton, DJ; Clarke, AR			Apc deficiency predisposes to renal carcinoma in the mouse	ONCOGENE			English	Article						Apc; kidney; Wnt; Cre; renal cancer	BETA-CATENIN GENE; WILMS-TUMORS; EMBRYONIC LETHALITY; CELL CARCINOMAS; TSC2 MUTATION; P53 GENE; EXPRESSION; MICE; CARCINOGENESIS; INACTIVATION	Deregulation of Wnt signalling has recently been implicated in human renal cancer. Here, we directly test this association by using a Cre-LoxP strategy to inactivate the Adenomatous Polyposis Coli (Apc) gene in the murine renal epithelium. Mice homozygous for a conditional Apc allele were intercrossed with mice transgenic for Cre recombinase under control of the Cyp1A promoter, which delivers constitutive recombination within a proportion of cells in the renal epithelium. Inactivation of Apc leads to the accumulation of nuclear beta-catenin and the rapid development of multiple dysplastic foci. Renal carcinoma was observed with an earliest onset of 4 months. This predisposition was accelerated by p53 deficiency, reducing the earliest onset to 2 months. Compared to other murine models of kidney neoplasia, this represents particularly rapid onset of disease, and so implicates an important role for Apc in suppressing renal carcinoma.	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, Wales; Univ Wales Coll Cardiff, Coll Med, Dept Pathol, Cardiff CF10 3US, Wales; Cambridge Inst Med Res, Canc Res UK, Dept Oncol, Cambridge CB2 2XY, England	Cardiff University; Cardiff University; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Clarke, AR (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, Wales.	clarkear@cf.ac.uk	Reed, Karen/B-8813-2011; clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Reed, Karen/0000-0002-7467-1718; Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X				BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bilim V, 2000, CLIN CANCER RES, V6, P460; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9; Gallagher RCJ, 2002, ONCOGENE, V21, P6446, DOI 10.1038/sj.onc.1205892; Guo LM, 2001, ONCOL REP, V8, P521; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kleymenova E, 2004, CARCINOGENESIS, V25, P309, DOI 10.1093/carcin/bgh017; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Koesters R, 1999, CANCER RES, V59, P3880; Koesters R, 2003, J PATHOL, V199, P68, DOI 10.1002/path.1248; Kusafuka T, 2002, INT J MOL MED, V10, P395; Menke AL, 2002, CANCER RES, V62, P6615; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Pecina-Slaus N, 1999, J MOL MED-JMM, V77, P446, DOI 10.1007/s001090050375; Qian CN, 2005, J BIOL CHEM, V280, P3938, DOI 10.1074/jbc.M410697200; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Wirths O, 2003, LAB INVEST, V83, P429, DOI 10.1097/01.LAB.0000059926.66359.BD; Zang T, 2001, CHINESE MED J-PEKING, V114, P152; Zhu XD, 2000, PATHOL INT, V50, P945, DOI 10.1046/j.1440-1827.2000.01139.x	26	55	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8205	8210		10.1038/sj.onc.1208956	http://dx.doi.org/10.1038/sj.onc.1208956			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16116480				2022-12-17	WOS:000233809400012
J	Gyorffy, B; Serra, V; Jurchott, K; Abdul-Ghani, R; Garber, M; Stein, U; Petersen, I; Lage, H; Dietel, M; Schafer, R				Gyorffy, B; Serra, V; Jurchott, K; Abdul-Ghani, R; Garber, M; Stein, U; Petersen, I; Lage, H; Dietel, M; Schafer, R			Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival	ONCOGENE			English	Article						cancer chemoresistance; gene expression; microarray; breast cancer	COMPLETE PATHOLOGICAL RESPONSE; PANCREATIC-CARCINOMA CELLS; MULTIDRUG-RESISTANCE; CDNA MICROARRAY; CANCER-CELLS; NEOADJUVANT CHEMOTHERAPY; ANTICANCER DRUGS; CHEMORESISTANCE; TRANSPORTERS	Up to date clinical tests for predicting cancer chemotherapy response are not available and individual markers have shown little predictive value. We hypothesized that gene expression patterns attributable to chemotherapy-resistant cells can predict response and cancer prognosis. We contrasted the expression profiles of 13 different human tumor cell lines of gastric (EPG85-257), pancreatic (EPP85-181), colon (HT29) and breast (MCF7 and MDA-MB-231) origin and their counterparts resistant to the topoisomerase inhibitors daunorubicin, doxorubicin or mitoxantrone. We interrogated cDNA arrays with 43 000 cDNA clones (similar to 30 000 unique genes) to study the expression pattern of these cell lines. We divided gene expression profiles into two sets: we compared the expression patterns of the daunorubicin/doxorubicin- resistant cell lines and the mitoxantrone-resistant cell lines independently to the parental cell lines. For identifying predictive genes, the Prediction Analysis for Mircorarrays algorithm was used. The analysis revealed 79 genes best correlated with doxorubicin resistance and 70 genes with mitoxantrone resistance. In an independent classification experiment, we applied our model of resistance for predicting the sensitivity of 44 previously characterized breast cancer samples. The patient group characterized by the gene expression pro. le similar to those of doxorubicin-sensitive cell lines exhibited longer survival (49.7 +/- 26.1 months, n = 21, P = 0.034) than the resistant group (32.9 +/- 18.7 months, n = 23). The application of gene expression signatures derived from doxorubicin-resistant and -sensitive cell lines allowed to predict effectively clinical survival after doxorubicin monotherapy. Our approach demonstrates the significance of in vitro experiments in the development of new strategies for cancer response prediction.	Humboldt Univ, Inst Pathol, Charite, D-10117 Berlin, Germany; Semmelweis Univ, Dept Internal Med 2, H-1088 Budapest, Hungary; Ctr Nacl Invest Oncol, E-28029 Madrid, Spain; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Semmelweis University; Stanford University; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Gyorffy, B (corresponding author), Humboldt Univ, Inst Pathol, Charite, Schumannstr 20-21, D-10117 Berlin, Germany.	zsalab2@yahoo.com	Schäfer, Reinhold/AAB-5110-2021; Gyorffy, Balazs/AAA-9135-2021; Serra, Violeta/AAG-8328-2019	Gyorffy, Balazs/0000-0002-5772-3766; Serra, Violeta/0000-0001-6620-1065; Stein, Ulrike/0000-0001-7006-282X; Jurchott, Karsten/0000-0003-1589-0037				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alonso O, 2002, NUCL MED COMMUN, V23, P765, DOI 10.1097/00006231-200208000-00010; Ayers M, 2004, J CLIN ONCOL, V22, P2284, DOI 10.1200/JCO.2004.05.166; Bodo A, 2003, TOXICOL LETT, V140, P133, DOI 10.1016/S0378-4274(02)00497-6; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6; Chollet P, 2002, BRIT J CANCER, V86, P1041, DOI 10.1038/sj/bjc/6600210; DIETEL M, 1990, CANCER RES, V50, P6100; Ein-Dor L, 2005, BIOINFORMATICS, V21, P171, DOI 10.1093/bioinformatics/bth469; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FISHER TC, 1993, CANCER RES, V53, P3321; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Kudoh K, 2000, CANCER RES, V60, P4161; Kuerer HM, 1999, J CLIN ONCOL, V17, P460, DOI 10.1200/JCO.1999.17.2.460; Lage H, 2002, J CANCER RES CLIN, V128, P349, DOI 10.1007/s00432-002-0349-y; Lage H, 2000, INT J HYPERTHER, V16, P291, DOI 10.1080/02656730050074069; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Nooter K, 1995, CLIN CANCER RES, V1, P1301; Robert J, 2003, J MED CHEM, V46, P4805, DOI 10.1021/jm030183a; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; Ross DD, 1999, J NATL CANCER I, V91, P429, DOI 10.1093/jnci/91.5.429; Sciuto R, 2002, J NUCL MED, V43, P745; Sinha P, 1999, ELECTROPHORESIS, V20, P2961, DOI 10.1002/(SICI)1522-2683(19991001)20:14<2961::AID-ELPS2961>3.0.CO;2-L; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Suganuma K, 2003, CANCER SCI, V94, P355, DOI 10.1111/j.1349-7006.2003.tb01446.x; Tan PK, 2003, NUCLEIC ACIDS RES, V31, P5676, DOI 10.1093/nar/gkg763; Thomas Hilary, 2003, Cancer Control, V10, P159; Troester MA, 2004, CANCER RES, V64, P4218, DOI 10.1158/0008-5472.CAN-04-0107; Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van 't Veer LJ, 2003, BREAST CANCER RES, V5, P57, DOI 10.1186/bcr562; Zembutsu H, 2002, CANCER RES, V62, P518	39	55	58	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7542	7551		10.1038/sj.onc.1208908	http://dx.doi.org/10.1038/sj.onc.1208908			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16044152				2022-12-17	WOS:000233333800004
J	Kim, H; Chan, R; Dankort, DL; Zuo, DM; Najoukas, M; Park, M; Muller, WJ				Kim, H; Chan, R; Dankort, DL; Zuo, DM; Najoukas, M; Park, M; Muller, WJ			The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation	ONCOGENE			English	Article						receptor; activation; kinase; transformation; tumorigenesis	EPIDERMAL-GROWTH-FACTOR; HUMAN BREAST-CANCER; FACTOR RECEPTOR; MAMMARY-TUMORS; TRANSGENIC MICE; NEU ONCOGENE; FAMILY KINASES; POINT MUTATION; ACTIVATION; PHOSPHORYLATION	c-Src associates with and is activated by the ErbB-2 receptor tyrosine kinase, but is unable to bind the EGFR. Although c-Src has been found to interact directly and specifically with the ErbB-2 receptor, the significance of this interaction is unclear. Using both chimeric receptor and site-directed mutagenesis approaches, the region of interaction of c-Src on ErbB-2 was identified. Significantly, EGFR could be converted into a receptor capable of binding c-Src by replacement of a catalytic domain of ErbB-2. We further demonstrated that MDCK cells that express mutant EGFR that are competent in c-Src recruitment lose epithelial polarity in organoid cultures, whereas cells overexpressing the wild-type EGFR retain a polarized phenotype. ErbB-2-dependent activation of c-Src results in disruption of epithelial cell-cell contacts leading to cell dispersal that correlates with the re-localization of phospho-MAPK to focal adhesions. Taken together, these observations suggest that recruitment of c-Src to these closely related EGFR family members plays a critical role in modulating cell polarity.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McMaster Univ, Dept Med Sci, Hamilton, ON L8S 4L8, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; McMaster Univ, Dept Biol, Hamilton, ON L8S 4L8, Canada; McGill Univ, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; Univ Calif San Francisco, Inst Canc Res, Ctr Comprehens Canc, San Francisco, CA 94115 USA; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4L8, Canada	McGill University; McMaster University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; McMaster University; McGill University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; McMaster University	Muller, WJ (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, Rm H5-21,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	william.muller@mcgill.ca		Dankort, David/0000-0002-5862-6829				Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; Khoury H, 2001, ONCOGENE, V20, P788, DOI 10.1038/sj.onc.1204166; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Latta EK, 2002, MODERN PATHOL, V15, P1318, DOI 10.1097/01.MP.0000038462.62634.B1; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Tapon N, 2003, CANCER CELL, V4, P333, DOI 10.1016/S1535-6108(03)00279-4; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wrobel CN, 2004, J CELL BIOL, V165, P263, DOI 10.1083/jcb.200309102; Zhang HT, 1998, ONCOGENE, V16, P2835, DOI 10.1038/sj.onc.1201820	37	55	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7599	7607		10.1038/sj.onc.1208898	http://dx.doi.org/10.1038/sj.onc.1208898			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16170374				2022-12-17	WOS:000233333800009
J	Kamrava, M; Simpkins, F; Alejandro, E; Michener, C; Meltzer, E; Kohn, EC				Kamrava, M; Simpkins, F; Alejandro, E; Michener, C; Meltzer, E; Kohn, EC			Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer	ONCOGENE			English	Article						ovarian cancer; progranulin; apoptosis; EPAC; signaling	DEPENDENT PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; CARCINOMA CELLS; COUPLED RECEPTORS; CYCLIC-AMP; SIGNALING PATHWAYS; ALPHA SUBUNIT; FACTOR PCDGF; ACTIVATION; EPAC	Granulin-epithelin precursor (GEP/progranulin) is an autocrine growth factor for ovarian cancer. We examined the production and function of GEP and report that: (1) GEP production is regulated by endothelin (ET-1), lysophosphatidic acid (LPA), and cAMP; (2) cAMP signals GEP production through exchange protein activated by cAMP (EPAC); (3) ET-1 and cAMP/EPAC induce GEP through ERK1/2; and (4) neutralization of GEP results in apoptosis. Exposure of HEY-A8 and OVCAR3 ovarian cancer cells to LPA and ET-1 yielded GEP production and secretion in a dose- and time-dependent fashion; neither stimulated significant concentrations of cAMP directly. Stimulation of cAMP production with pertussis and cholera toxin, or forskolin induced GEP in a PKA-independent fashion. EPAC, an intracellular cAMP receptor, is activated specifically by the cAMP analog, 8-CPT-2'-O-Me-cAMP (8-CPT); 8-CPT treatment stimulated GEP production and secretion. The MEK inhibitor, U0126, abrogated GEP production in response to ET-1 and 8-CPT, confirming involvement of MAPK. A partial inhibition of basal and stimulated GEP production was observed when cells were treated with a internal calcium chelator, BAPTA. Neutralizing anti-GEP antibody reversed basal as well as LPA, ET-1 and 8CPT-induced ovarian cancer cell growth and induced apoptosis as demonstrated by caspase-3 and PARP cleavage, DNA fragmentation, and nuclear condensation. These results indicate that GEP is a growth and survival factor for ovarian cancer, induced by LPA and ET-1 and cAMP/EPAC through ERK1/2.	NCI, Pathol Lab, Mol Signaling Sect, Canc Res Ctr, Bethesda, MD 20892 USA; NIH, Howard Hughes Med Inst, Res Scholars Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA	Kohn, EC (corresponding author), NCI, Pathol Lab, Mol Signaling Sect, Canc Res Ctr, 10 Ctr Dr MSC 1500, Bethesda, MD 20892 USA.	ek1b@nih.gov		Alejandro, Emilyn/0000-0002-7941-8439	NATIONAL CANCER INSTITUTE [Z01SC009163, ZIASC009163] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alper O, 1999, ONCOGENE, V18, P4999, DOI 10.1038/sj.onc.1202830; Amsterdam A, 1999, TRENDS ENDOCRIN MET, V10, P255, DOI 10.1016/S1043-2760(99)00164-2; Bagnato A, 1999, CANCER RES, V59, P720; Bagnato A, 1995, CLIN CANCER RES, V1, P1059; Bagnato A, 1997, CANCER RES, V57, P1306; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; Bateman A, 1998, J ENDOCRINOL, V158, P145, DOI 10.1677/joe.0.1580145; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Cho YS, 2001, P NATL ACAD SCI USA, V98, P9819, DOI 10.1073/pnas.171314398; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Davidson B, 2004, CANCER-AM CANCER SOC, V100, P2139, DOI 10.1002/cncr.20219; Del Bufalo D, 2002, CLIN SCI, V103, p302S, DOI 10.1042/CS103S302S; Del Bufalo D, 2002, MOL PHARMACOL, V61, P524, DOI 10.1124/mol.61.3.524; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Goetzl EJ, 1999, CANCER RES, V59, P4732; Guirland C, 2003, J NEUROSCI, V23, P2274; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jones MB, 2003, CLIN CANCER RES, V9, P44; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Keiper M, 2004, J BIOL CHEM, V279, P46497, DOI 10.1074/jbc.M403604200; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Kopperud R, 2003, FEBS LETT, V546, P121, DOI 10.1016/S0014-5793(03)00563-5; Liotta LA, 2003, CANCER CELL, V3, P317, DOI 10.1016/S1535-6108(03)00086-2; Lu RQ, 1999, BIOCHEM BIOPH RES CO, V256, P204, DOI 10.1006/bbrc.1999.0253; Lu RQ, 2000, P NATL ACAD SCI USA, V97, P3993, DOI 10.1073/pnas.97.8.3993; Lu RQ, 2001, P NATL ACAD SCI USA, V98, P142, DOI 10.1073/pnas.011525198; McDaid HM, 1999, BRIT J CANCER, V79, P933, DOI 10.1038/sj.bjc.6690149; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Nicosia SV, 2003, HEMATOL ONCOL CLIN N, V17, P927, DOI 10.1016/S0889-8588(03)00056-X; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Rosano L, 2003, CANCER RES, V63, P2447; Rosano L, 2001, CANCER RES, V61, P8340; Salani D, 2000, AM J PATHOL, V157, P1537, DOI 10.1016/S0002-9440(10)64791-8; Salani D, 2002, CLIN SCI, V103, p318S, DOI 10.1042/CS103S318S; SHABB JB, 1990, J BIOL CHEM, V265, P5267; Vacca F, 2000, CANCER RES, V60, P5310; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Zanassi P, 2001, J BIOL CHEM, V276, P11487, DOI 10.1074/jbc.M007631200; Zanocco-Marani T, 1999, CANCER RES, V59, P5331; Zhang HD, 1998, P NATL ACAD SCI USA, V95, P14202, DOI 10.1073/pnas.95.24.14202; ZHOU J, 1993, J BIOL CHEM, V268, P10863; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	47	55	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7084	7093		10.1038/sj.onc.1208857	http://dx.doi.org/10.1038/sj.onc.1208857			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16044162				2022-12-17	WOS:000232833200010
J	Lairmore, MD; Silverman, L; Ratner, L				Lairmore, MD; Silverman, L; Ratner, L			Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation	ONCOGENE			English	Review						HTLV-1; animal models; leukemia; lymphoma	CELL LEUKEMIA-VIRUS; MONKEYS SAIMIRI-SCIUREUS; I-ASSOCIATED MYELOPATHY; COMBINED IMMUNODEFICIENT MICE; TROPICAL SPASTIC PARAPARESIS; TAX-TRANSGENIC MICE; NF-KAPPA-B; CHRONIC PROGRESSIVE MYELONEUROPATHY; RESEMBLING RHEUMATOID-ARTHRITIS; PROTEASOME INHIBITOR PS-341	Over the past 25 years, animal models of human T-lymphotropic virus type 1 (HTLV-1) infection and transformation have provided critical knowledge about viral and host factors in adult T-cell leukemia/ lymphoma (ATL). The virus consistently infects rabbits, some non-human primates, and to a lesser extent rats. In addition to providing fundamental concepts in viral transmission and immune responses against HTLV- 1 infection, these models have provided new information about the role of viral proteins in carcinogenesis. Mice and rats, in particular immuno-deficient strains, are useful models to assess immunologic parameters mediating tumor outgrowth and therapeutic invention strategies against lymphoma. Genetically altered mice including both transgenic and knockout mice offer important models to test the role of specific viral and host genes in the development of HTLV-1-associated lymphoma. Novel approaches in genetic manipulation of both HTLV-1 and animal models are available to address the complex questions that remain about viral-mediated mechanisms of cell transformation and disease. Current progress in the understanding of the molecular events of HTLV-1 infection and transformation suggests that answers to these questions are approachable using animal models of HTLV-1-associated lymphoma.	Ohio State Univ, Ctr Retrovirus Res, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Comprehens Canc Ctr, Arthur G James Canc Hosp, Columbus, OH 43210 USA; Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA; Washington Univ, Sch Med, Dept Med Pathl & Mol Microbiol, Div Biol & Biol Sci, St Louis, MO 63110 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Washington University (WUSTL)	Lairmore, MD (corresponding author), Ohio State Univ, Ctr Retrovirus Res, 1925 Coffey Rd, Columbus, OH 43210 USA.	lairmore.1@osu.edu		Ratner, Lee/0000-0003-2744-7294	NCI NIH HHS [P01 CA100730-02, P01 CA100730-069003, P01 CA100730-03, CA-100730, T32 CA009338, CA-70529, P01 CA100730, CA-09338] Funding Source: Medline; NCRR NIH HHS [R01 RR014324, RR-14324, T32 RR007073-07, R01 RR014324-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009338, P01CA100730] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR014324, T32RR007073] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKAGI T, 1985, JPN J CANCER RES, V76, P86; Akari H, 1997, VACCINE, V15, P1391, DOI 10.1016/S0264-410X(97)00055-8; Albrecht B, 2002, J VIROL, V76, P3493, DOI 10.1128/JVI.76.7.3493-3501.2002; Albrecht B, 2000, J VIROL, V74, P9828, DOI 10.1128/JVI.74.21.9828-9835.2000; Apte RN, 2002, SEMIN CANCER BIOL, V12, P277, DOI 10.1016/S1044-579X(02)00014-7; Asquith B, 2000, PHILOS T ROY SOC B, V355, P1013, DOI 10.1098/rstb.2000.0638; Bangham CRM, 2003, INT J HEMATOL, V78, P297, DOI 10.1007/BF02983553; Bangham CRM, 2000, J CLIN PATHOL, V53, P581, DOI 10.1136/jcp.53.8.581; Bangham CRM, 2003, J GEN VIROL, V84, P3177, DOI 10.1099/vir.0.19334-0; Bartoe JT, 2000, J VIROL, V74, P1094, DOI 10.1128/JVI.74.3.1094-1100.2000; Beilke MA, 1996, ARTHRITIS RHEUM, V39, P610, DOI 10.1002/art.1780390410; BENVENISTY N, 1992, ONCOGENE, V7, P2399; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; Carvalho EM, 2001, J ACQ IMMUN DEF SYND, V27, P1, DOI 10.1097/00126334-200105010-00001; Cavrois M, 1996, BLOOD, V88, P4646, DOI 10.1182/blood.V88.12.4646.bloodjournal88124646; CHEN YMA, 1991, J IMMUNOL, V147, P2368; Ciminale V, 1999, ONCOGENE, V18, P4505, DOI 10.1038/sj.onc.1203047; CIMINALE V, 1995, VIROLOGY, V209, P445, DOI 10.1006/viro.1995.1277; CLEGHORN FR, 1995, JNCI-J NATL CANCER I, V87, P1009, DOI 10.1093/jnci/87.13.1009; COCKERELL GL, 1990, INT J CANCER, V45, P127, DOI 10.1002/ijc.2910450123; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; Collins ND, 1996, J VIROL, V70, P7241, DOI 10.1128/JVI.70.10.7241-7246.1996; Conrad S F, 1995, Biomed Pept Proteins Nucleic Acids, V1, P83; D'Agostino DM, 2000, AIDS RES HUM RETROV, V16, P1765, DOI 10.1089/08892220050193281; de la Fuente C, 2003, MOL CELL BIOCHEM, V245, P99, DOI 10.1023/A:1022866027585; Delebecque F, 2002, J VIROL, V76, P7883, DOI 10.1128/JVI.76.15.7883-7889.2002; DERSE D, 1995, J VIROL, V69, P1907, DOI 10.1128/JVI.69.3.1907-1912.1995; Dewan MZ, 2003, J VIROL, V77, P5286, DOI 10.1128/JVI.77.9.5286-5294.2003; Ding W, 2002, J VIROL, V76, P10374, DOI 10.1128/JVI.76.20.10374-10382.2002; Etoh K, 1997, CANCER RES, V57, P4862; Fang JH, 1998, J VIROL, V72, P3952, DOI 10.1128/JVI.72.5.3952-3957.1998; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; Feng RQ, 1999, JPN J CANCER RES, V90, P48, DOI 10.1111/j.1349-7006.1999.tb00664.x; Feng RQ, 2001, JPN J CANCER RES, V92, P410, DOI 10.1111/j.1349-7006.2001.tb01110.x; FEUER G, 1993, BLOOD, V82, P722; FEUER G, 1995, J VIROL, V69, P1328, DOI 10.1128/JVI.69.2.1328-1333.1995; Franchini G, 2003, ADV CANCER RES, V89, P69, DOI 10.1016/S0065-230X(03)01003-0; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Frangione-Beebe M, 2000, VACCINE, V19, P1068, DOI 10.1016/S0264-410X(00)00340-6; Fujisawa K, 1996, J CLIN INVEST, V98, P271, DOI 10.1172/JCI118789; Furuta RA, 2002, J VIROL, V76, P2703, DOI 10.1128/JVI.76.6.2703-2713.2002; Furuya T, 1999, J NEUROIMMUNOL, V95, P185, DOI 10.1016/S0165-5728(98)00263-X; Gabet AS, 2003, INT J CANCER, V107, P74, DOI 10.1002/ijc.11329; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; Gessain A, 1996, ADV VIRUS RES, V47, P377, DOI 10.1016/S0065-3527(08)60740-X; Grant C, 2002, J CELL PHYSIOL, V190, P133, DOI 10.1002/JCP.10053; Grossman WJ, 1997, BLOOD, V90, P783, DOI 10.1182/blood.V90.2.783.783_783_794; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hakata Y, 2001, J VIROL, V75, P11515, DOI 10.1128/JVI.75.23.11515-11525.2001; Hall AP, 1998, J PATHOL, V186, P209; Hanabuchi S, 2001, J NATL CANCER I, V93, P1775, DOI 10.1093/jnci/93.23.1775; Hasegawa A, 2003, J VIROL, V77, P2956, DOI 10.1128/JVI.77.5.2956-2963.2003; HIROSE S, 1988, VIROLOGY, V162, P487, DOI 10.1016/0042-6822(88)90492-8; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; HOMMA T, 1984, SCIENCE, V225, P716, DOI 10.1126/science.6087453; Horn F, 2000, IMMUNOBIOLOGY, V202, P151, DOI 10.1016/S0171-2985(00)80061-3; IBRAHIM F, 1994, INT J CANCER, V58, P446, DOI 10.1002/ijc.2910580324; Ibuki K, 1997, J GEN VIROL, V78, P147, DOI 10.1099/0022-1317-78-1-147; Imada K, 1996, JPN J CANCER RES, V87, P887, DOI 10.1111/j.1349-7006.1996.tb02116.x; IMADA K, 1995, BLOOD, V86, P2350, DOI 10.1182/blood.V86.6.2350.bloodjournal8662350; ISHIGURO N, 1992, J EXP MED, V176, P981, DOI 10.1084/jem.176.4.981; ISHIHARA S, 1992, JPN J CANCER RES, V83, P320, DOI 10.1111/j.1349-7006.1992.tb00108.x; IWAHARA Y, 1990, INT J CANCER, V45, P980, DOI 10.1002/ijc.2910450534; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; IWAKURA Y, 1995, J IMMUNOL, V155, P1588; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Kanki P J, 1985, Haematol Blood Transfus, V29, P345; Kannagi M, 2000, AIDS RES HUM RETROV, V16, P1737, DOI 10.1089/08892220050193236; Kasai T, 1999, ACTA NEUROPATHOL, V97, P107, DOI 10.1007/s004010050962; KATAOKA R, 1990, BLOOD, V76, P1657; Kato H, 1998, J VIROL, V72, P7289, DOI 10.1128/JVI.72.9.7289-7293.1998; Kazanji M, 1997, VIROLOGY, V231, P258, DOI 10.1006/viro.1997.8528; Kazanji M, 2001, J VIROL, V75, P5939, DOI 10.1128/JVI.75.13.5939-5948.2001; Kazanji M, 2000, AIDS RES HUM RETROV, V16, P1741, DOI 10.1089/08892220050193245; Kazanji M, 2000, J VIROL, V74, P4860, DOI 10.1128/JVI.74.10.4860-4867.2000; Kehn K, 2004, FRONT BIOSCI-LANDMRK, V9, P2347, DOI 10.2741/1401; Kim SJ, 2003, J BIOL CHEM, V278, P15550, DOI 10.1074/jbc.M210210200; KIMATA JT, 1994, VIROLOGY, V204, P656, DOI 10.1006/viro.1994.1581; Kimzey AL, 1999, J BIOL CHEM, V274, P34226, DOI 10.1074/jbc.274.48.34226; Kindt TJ, 2000, MICROBES INFECT, V2, P1139, DOI 10.1016/S1286-4579(00)01268-5; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KONDO A, 1993, BLOOD, V82, P2501; KONDO T, 1989, INT J CANCER, V43, P1061, DOI 10.1002/ijc.2910430618; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; KOTANI S, 1986, INT J CANCER, V37, P843, DOI 10.1002/ijc.2910370608; KUSHIDA S, 1993, JPN J CANCER RES, V84, P831, DOI 10.1111/j.1349-7006.1993.tb02052.x; Kushida Shigeki, 1997, Leukemia (Basingstoke), V11, P260; LAIRMORE MD, 1992, INT J CANCER, V50, P124, DOI 10.1002/ijc.2910500125; LAL RB, 1991, J GEN VIROL, V72, P2321, DOI 10.1099/0022-1317-72-9-2321; Lenzmeier BA, 1999, J MOL BIOL, V291, P731, DOI 10.1006/jmbi.1999.2969; Liu YX, 2002, LEUKEMIA RES, V26, P561, DOI 10.1016/S0145-2126(01)00169-2; Mahieux R, 2000, AIDS RES HUM RETROV, V16, P1677, DOI 10.1089/08892220050193137; McGinn TM, 2002, VIROLOGY, V304, P364, DOI 10.1006/viro.2002.1705; Michael Bindhu, 2004, Retrovirology, V1, P39, DOI 10.1186/1742-4690-1-39; Mitra-Kaushik S, 2004, BLOOD, V104, P3305, DOI 10.1182/blood-2004-01-0266; Mitra-Kaushik S, 2004, BLOOD, V104, P802, DOI 10.1182/blood-2003-11-3967; Miyoshi I, 1984, Princess Takamatsu Symp, V15, P121; MIYOSHI I, 1985, INT J CANCER, V35, P81, DOI 10.1002/ijc.2910350113; MIYOSHI I, 1992, LEUKEMIA, V6, P24; Mortreux F, 2003, LEUKEMIA, V17, P26, DOI 10.1038/sj.leu.2402777; Mortreux F, 2001, J NATL CANCER I, V93, P367, DOI 10.1093/jnci/93.5.367; Mortreux F, 2001, J VIROL, V75, P1083, DOI 10.1128/JVI.75.2.1083-1089.2001; Murata N, 1996, LEUKEMIA, V10, P1971; NAKAMURA H, 1987, INT J CANCER, V40, P403, DOI 10.1002/ijc.2910400320; NAKAMURA H, 1986, INT J CANCER, V38, P867, DOI 10.1002/ijc.2910380614; NERENBERG MI, 1990, CURR TOP MICROBIOL, V160, P121; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; Nitta T, 2003, BIOCHEM BIOPH RES CO, V309, P161, DOI 10.1016/S0006-291X(03)01543-2; Nomura M, 2004, J VIROL, V78, P3827, DOI 10.1128/JVI.78.8.3827-3836.2004; OGAWA K, 1989, LEUKEMIA RES, V13, P399, DOI 10.1016/0145-2126(89)90080-5; Ohashi T, 1999, J VIROL, V73, P6031, DOI 10.1128/JVI.73.7.6031-6040.1999; OHSUGI T, 1994, J VET MED SCI, V56, P601, DOI 10.1292/jvms.56.601; Ohsugi T, 2004, LAB INVEST, V84, P263, DOI 10.1038/labinvest.3700034; Ohya O, 2000, APMIS, V108, P459, DOI 10.1034/j.1600-0463.2000.d01-83.x; Ohya Osamu, 1997, Leukemia (Basingstoke), V11, P255; OSAME M, 1990, ANN NEUROL, V28, P50, DOI 10.1002/ana.410280110; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; Portis T, 2001, BLOOD, V98, P1200, DOI 10.1182/blood.V98.4.1200; Portis T, 2001, J VIROL, V75, P2185, DOI 10.1128/JVI.75.5.2185-2193.2001; Ressler S, 1997, J VIROL, V71, P1181, DOI 10.1128/JVI.71.2.1181-1190.1997; Richard V, 2001, AM J PATHOL, V158, P2219, DOI 10.1016/S0002-9440(10)64694-9; Robek MD, 1998, J VIROL, V72, P4458, DOI 10.1128/JVI.72.5.4458-4462.1998; Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400; SAWADA T, 1991, J INFECT DIS, V164, P1193, DOI 10.1093/infdis/164.6.1193; Scholz C, 1996, J NEUROSCI RES, V45, P786; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SETO A, 1988, JPN J CANCER RES, V79, P335, DOI 10.1111/j.1349-7006.1988.tb01596.x; Silverman LR, 2004, J VIROL, V78, P3837, DOI 10.1128/JVI.78.8.3837-3845.2004; Simpson RM, 1996, J INFECT DIS, V173, P722, DOI 10.1093/infdis/173.3.722; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; Stewart SA, 1996, VIROLOGY, V226, P167, DOI 10.1006/viro.1996.0643; SUGA T, 1991, INT J CANCER, V49, P764, DOI 10.1002/ijc.2910490522; Sun B, 1999, J NEUROL SCI, V167, P16, DOI 10.1016/S0022-510X(99)00128-8; Sundaram R, 2004, J BIOL CHEM, V279, P24141, DOI 10.1074/jbc.M313210200; TAGUCHI H, 1993, LAB INVEST, V69, P336; TAKEHARA N, 1989, INT J CANCER, V44, P332, DOI 10.1002/ijc.2910440224; Takemura T, 2002, J VIROL, V76, P1642, DOI 10.1128/JVI.76.4.1642-1648.2002; Tan C, 2002, CANCER RES, V62, P1083; Tanaka M, 2001, J VIROL, V75, P4420, DOI 10.1128/JVI.75.9.4420-4423.2001; TANAKA Y, 1991, J IMMUNOL, V147, P354; TANAKA Y, 1994, J VIROL, V68, P6323, DOI 10.1128/JVI.68.10.6323-6331.1994; Tomaru U, 2003, J NEUROVIROL, V9, P530, DOI 10.1080/13550280390241160; Trovato R, 1999, J VIROL, V73, P6460, DOI 10.1128/JVI.73.8.6460-6467.1999; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Tsuruma T, 1996, ARTIF ORGANS, V20, P895, DOI 10.1111/j.1525-1594.1996.tb04565.x; Uchiyama T, 1996, J CLIN IMMUNOL, V16, P305, DOI 10.1007/BF01541665; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; UEMURA Y, 1986, JPN J CANCER RES, V77, P970; UEMURA Y, 1987, BLOOD, V69, P1255; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; Wilks R, 1996, INT J CANCER, V65, P272, DOI 10.1002/(SICI)1097-0215(19960117)65:2<272::AID-IJC23>3.0.CO;2-E; Willems L, 2000, AIDS RES HUM RETROV, V16, P1787, DOI 10.1089/08892220050193326; YAMAGUCHI K, 1993, CLIN HAEMATOL, V6, P899; YAMAMOTO H, 1993, ARTHRITIS RHEUM-US, V36, P1612, DOI 10.1002/art.1780361117; YAMAMOTO N, 1984, MED MICROBIOL IMMUN, V173, P57, DOI 10.1007/BF02123570; Ye JX, 2003, BLOOD, V102, P3963, DOI 10.1182/blood-2003-05-1490; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yoshiki T, 1995, INTERVIROLOGY, V38, P229, DOI 10.1159/000150437; Yoshiki Takahashi, 1997, Leukemia (Basingstoke), V11, P245; Younis I, 2004, J VIROL, V78, P11077, DOI 10.1128/JVI.78.20.11077-11083.2004; Zhang ML, 2005, BLOOD, V105, P1231, DOI 10.1182/blood-2004-05-1709; Zhang ML, 2002, BLOOD, V100, P208, DOI 10.1182/blood-2002-01-0107; Zhang WQ, 2001, J VIROL, V75, P9885, DOI 10.1128/JVI.75.20.9885-9895.2001; Zhang WQ, 2000, J VIROL, V74, P11270, DOI 10.1128/JVI.74.23.11270-11277.2000; Zhang Z, 2003, CANCER RES, V63, P6453; Zhang Z, 2003, BLOOD, V102, P284, DOI 10.1182/blood-2002-11-3601; ZHAO TM, 1995, J VIROL, V69, P2024, DOI 10.1128/JVI.69.4.2024-2030.1995; ZHAO TM, 1993, VIROLOGY, V195, P271, DOI 10.1006/viro.1993.1373; Zhao TM, 2002, AIDS RES HUM RETROV, V18, P253, DOI 10.1089/088922202753472829	177	55	58	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					6005	6015		10.1038/sj.onc.1208974	http://dx.doi.org/10.1038/sj.onc.1208974			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155607	Bronze, Green Accepted			2022-12-17	WOS:000231623400010
J	Landis, MD; Seachrist, DD; Montanez-Wiscovich, ME; Danielpour, D; Keri, RA				Landis, MD; Seachrist, DD; Montanez-Wiscovich, ME; Danielpour, D; Keri, RA			Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice	ONCOGENE			English	Article						mammary cancer progression; gene expression pro. ling; ErbB2/Neu/HER2; transgenic mice; transforming growth factor-beta	MAMMARY-GLAND DEVELOPMENT; BREAST-CANCER; TGF-BETA; NEU PROTOONCOGENE; EPITHELIAL-CELLS; FACTOR RECEPTOR; ERBB RECEPTORS; ACTIVATED NEU; CYCLIN D1; PATTERNS	Upregulation of HER2/ErbB2/Neu occurs in 15-30% of human breast cancers and correlates with poor prognosis. Identification of ErbB2/Neu transcriptional targets should facilitate development of novel therapeutic approaches. Development of breast cancer is a multistep process; thus, to identify the transcriptomes associated with different stages of progression of tumorigenesis, we compared expression profiles of mammary tumors and preneoplastic mammary tissue from MMTV-Neu transgenic mice to expression profiles of wild-type mammary glands using Affymetrix microarrays. We identified 324 candidate genes that were unique to ErbB2/Neu-induced tumors relative to normal mammary gland tissue from wild-type controls. Expression of a subset of these genes (82) was also changed in the preneoplastic mammary glands compared to wild-type controls, indicating that they may play a pivotal role during early events of ErbB2/Neu-initiated mammary tumorigenesis. Further analysis of the microarray data revealed that expression of several known transforming growth factor (TGF)-beta target genes was altered, suggesting that the TGF-beta signaling cascade is downregulated in ErbB2/Neu-induced tumors. Western blot analysis for TGF-beta-Receptor-I/ALK5 and immunohistochemistry for TGF-beta-Receptor-I/ALK5 and phosphorylated/activated Smad2 confirmed that the Smad-dependent TGF-beta signaling cascade was inactive in these tumors. Although absent in most of the tumor, phosphorylated Smad2 was present in the periphery of tumors. Interestingly, presence of phosphorylated/ activated Smad2 correlated with expression of Activin-Receptor-IB/ALK4, suggesting that although Smad-dependent TGF-beta signaling is absent in ErbB2/Neu-induced tumors, Activin signaling may be active at the leading edge of these tumors. Cumulatively, these data indicate that the TGF-beta pathway is intrinsically suppressed in ErbB2/Neu tumors via a mechanism involving loss of TGF-beta-Receptor-I/ALK5.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Div Gen Med Sci, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Keri, RA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd RT300, Cleveland, OH 44106 USA.	ruth.keri@case.edu	Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088	NCI NIH HHS [R01-CA90398, P30CA43703, R01 CA090398, P30 CA043703] Funding Source: Medline; NIGMS NIH HHS [T32 GM008803, GM08803A1, T32 GM007250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA090398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008803, T32GM007250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Andrechek ER, 2003, CANCER RES, V63, P4920; Barcellos-Hoff MH, 2000, BREAST CANCER RES, V2, P92, DOI 10.1186/bcr40; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Boggio K, 1998, J EXP MED, V188, P589, DOI 10.1084/jem.188.3.589; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Chambers RC, 2003, AM J PATHOL, V162, P533, DOI 10.1016/S0002-9440(10)63847-3; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Dowdy SC, 2003, J BIOL CHEM, V278, P44377, DOI 10.1074/jbc.M307202200; Dressman MA, 2003, CANCER RES, V63, P2194; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jacquemier J, 2005, CANCER RES, V65, P767; Kauraniemi P, 2004, ONCOGENE, V23, P1010, DOI 10.1038/sj.onc.1207200; Kauraniemi P, 2001, CANCER RES, V61, P8235; Krishnamurthy S, 2002, ADV ANAT PATHOL, V9, P185, DOI 10.1097/00125480-200205000-00002; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Milliken EL, 2002, ENDOCRINOLOGY, V143, P3671, DOI 10.1210/en.2002-220228; MORRISON BW, 1994, ONCOGENE, V9, P3417; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pimentel RC, 2002, CIRC RES, V90, P671, DOI 10.1161/01.RES.0000014823.75393.4D; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; SALMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wakefield LM, 2000, BREAST CANCER RES, V2, P100, DOI 10.1186/bcr41; Wang N, 2004, ONCOGENE, V23, P1507, DOI 10.1038/sj.onc.1207288; WELLINGS SR, 1973, J NATL CANCER I, V50, P1111, DOI 10.1093/jnci/50.5.1111; Wilson KS, 2002, AM J PATHOL, V161, P1171, DOI 10.1016/S0002-9440(10)64394-5; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7	56	55	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5173	5190		10.1038/sj.onc.1208712	http://dx.doi.org/10.1038/sj.onc.1208712			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897883	Green Accepted			2022-12-17	WOS:000230964600004
J	Mirkin, BL; Clark, S; Zheng, X; Chu, F; White, BD; Greene, M; Rebbaa, A				Mirkin, BL; Clark, S; Zheng, X; Chu, F; White, BD; Greene, M; Rebbaa, A			Identification of midkine as a mediator for intercellular transfer of drug resistance	ONCOGENE			English	Article						midkine; drug resistance; apoptosis; senescence; Akt; p21/WAF1	ACID-RESPONSIVE GENE; CLINICAL RESISTANCE; INDUCED APOPTOSIS; CONSTANT LIGHT; CANCER-THERAPY; TUMOR-CELLS; SURVIVAL; DEATH; NEURONS; GROWTH	Resistance to cytotoxic agents is a major limitation for their clinical use to treat human cancers. Tumors become resistant to chemotherapy when a subset of cells undergoes molecular changes leading to overexpression of drug transport proteins, alterations in drug-target interactions or reduced ability to commit apoptosis. However, such changes may not be sufficient to explain why both resistant and nonresistant cells survive drug's action in tumors that ultimately become drug resistant. We hypothesized that, in such tumors, a cytoprotective relationship may exist between drug-resistant and neighboring drug-sensitive cells. The present study addresses the possibility that drug-resistant cells secrete in their culture medium factors able to protect sensitive cells from drug toxicity. A survival molecule, midkine, was identified by cDNA array to be expressed only in drug-resistant cells. Midkine-enriched fractions obtained by affinity chromatography exert a significant cytoprotective effect against doxorubicin in the wild-type drug-sensitive cells. Moreover, transfection of these cells with the midkine gene caused a decreased response to doxorubicin. The underlying mechanism of this cytoprotection appeared to imply activation of the Akt pathway and inhibition of drug-induced proliferation arrest as well as apoptotic cell death. These findings provide evidence for the existence of intercellular cytoprotective signals such as the one mediated by midkine, originating from cells with acquired drug resistance to protect neighboring drug-sensitive cells and thus contribute to development of resistance to chemotherapy.	Childrens Mem Res Ctr, Canc Biol Program, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60614 USA; Univ Washington, Program Neurobiol & Behav, Seattle, WA 98195 USA; Univ Chicago, Ben May Inst, Chicago, IL 60637 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Washington; University of Washington Seattle; University of Chicago	Rebbaa, A (corresponding author), Childrens Mem Res Ctr, Canc Biol Program, 2430 N Halsted,Box 224, Chicago, IL 60614 USA.	arebbaa@childrensmemorial.org			NATIONAL CANCER INSTITUTE [R01CA096616] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA096616-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Dalton WS, 1999, SEMIN ONCOL, V26, P23; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Emran MA, 2002, CANCER LETT, V182, P53, DOI 10.1016/S0304-3835(02)00062-9; Fulda S, 2003, CANCER LETT, V197, P131, DOI 10.1016/S0304-3835(03)00091-0; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Hartmann A, 2001, J NEUROSCI, V21, P2247, DOI 10.1523/JNEUROSCI.21-07-02247.2001; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Ikematsu S, 2003, BRIT J CANCER, V88, P1522, DOI 10.1038/sj.bjc.6600938; JOHNSON DE, 1998, FRONT BIOSCI, V3, P313; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Klein B, 2003, INT J HEMATOL, V78, P106, DOI 10.1007/BF02983377; Li QF, 2004, CANCER RES, V64, P7078, DOI 10.1158/0008-5472.CAN-04-1152; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Martinsson P, 2001, ANTI-CANCER DRUG, V12, P699, DOI 10.1097/00001813-200109000-00009; MASUDA K, 1995, INVEST OPHTH VIS SCI, V36, P2142; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; MURAMATSU T, 1993, INT J DEV BIOL, V37, P183; Owada K, 1999, J NEUROCHEM, V73, P2084; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Qi MS, 2000, J BIOCHEM, V127, P269, DOI 10.1093/oxfordjournals.jbchem.a022604; Ratovitski EA, 1998, J BIOL CHEM, V273, P3654, DOI 10.1074/jbc.273.6.3654; Rebbaa A, 2003, ONCOGENE, V22, P2805, DOI 10.1038/sj.onc.1206366; Rebbaa A, 2001, MOL MED, V7, P393, DOI 10.1007/BF03402185; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; Sakaguchi N, 2003, NEUROSCI RES, V45, P219, DOI 10.1016/S0168-0102(02)00226-2; SATOH J, 1993, DEV BRAIN RES, V75, P201, DOI 10.1016/0165-3806(93)90024-5; Schmitt E, 1997, BIOCHEM CELL BIOL, V75, P301, DOI 10.1139/bcb-75-4-301; Shannon KM, 2002, CANCER CELL, V2, P99, DOI 10.1016/S1535-6108(02)00101-0; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; UNOKI K, 1994, INVEST OPHTH VIS SCI, V35, P4063; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Yaginuma H, 2001, MOL CELL NEUROSCI, V18, P168, DOI 10.1006/mcne.2001.1009	36	55	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4965	4974		10.1038/sj.onc.1208671	http://dx.doi.org/10.1038/sj.onc.1208671			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897897				2022-12-17	WOS:000230646500009
J	Cho, YG; Kim, CJ; Park, CH; Yang, YM; Kim, SY; Nam, SW; Lee, SH; Yoo, NJ; Lee, JY; Park, WS				Cho, YG; Kim, CJ; Park, CH; Yang, YM; Kim, SY; Nam, SW; Lee, SH; Yoo, NJ; Lee, JY; Park, WS			Genetic alterations of the KLF6 gene in gastric cancer	ONCOGENE			English	Article						mutation; tumor suppressor gene; loss of heterozygosity	TUMOR-SUPPRESSOR GENE; KRUPPEL-LIKE FACTOR-6; DIFFERENTIATED ADENOCARCINOMA; CHROMOSOME 10P15; HETEROZYGOSITY; ALLELOTYPE; MUTATION; PROTEIN	The KLF6 is a zinc-finger tumor suppressor that is frequently mutated in several human cancers and broadly involved in differentiation and development, growth-related signal transduction, cell proliferation, apoptosis, and angiogenesis. To determine whether genetic alterations of KLF6 gene are involved in the development and/or progression of gastric cancer, we have screened a set of 80 sporadic gastric cancers for mutations and allele loss of the KLF6 gene. Four missense mutations, S155R, P172 T, S180L, and R198 K, were detected in transactivation domain of the KLF6 gene and one of them had biallelic mutations with somatic mutation of one allele and loss of the remaining allele. All of the cases with mutation were of advanced intestinal-type gastric cancer with lymph node metastasis. In addition, 16 (43.2%) of 37 informative cases showed allelic loss at KLF6 locus. Interestingly, allelic loss was also frequent in intestinal-type gastric cancer. Therefore, our data suggest that genetic alterations of KLF6 gene might play an important role in the development or progression of sporadic gastric cancers.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Surg Pathol, Seoul 137701, South Korea; Konkuk Univ Coll Med, Genet Lab Premed Course, Chungju 380701, South Korea	Catholic University of Korea; Catholic University of Korea; Konkuk University	Park, WS (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea.	wonsang@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Clements WM, 2002, CANCER RES, V62, P3503; Fodde R, 2002, SCIENCE, V298, P761, DOI 10.1126/science.1077707; Hiyama T, 2003, ONCOL REP, V10, P1297; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Nishizuka S, 1998, J PATHOL, V185, P38, DOI 10.1002/(SICI)1096-9896(199805)185:1<38::AID-PATH58>3.0.CO;2-T; Onyango P, 1998, GENOMICS, V48, P143, DOI 10.1006/geno.1997.5124; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SUH CI, 2000, J KOREAN CANC ASS, V32, P827; Tamura G, 1996, J PATHOL, V180, P371, DOI 10.1002/(SICI)1096-9896(199612)180:4<371::AID-PATH704>3.0.CO;2-2; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yustein AS, 1999, CANCER RES, V59, P1437	21	55	58	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4588	4590		10.1038/sj.onc.1208670	http://dx.doi.org/10.1038/sj.onc.1208670			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15824733				2022-12-17	WOS:000230157100012
J	Iuliano, R; Le Pera, I; Cristofaro, C; Baudi, F; Arturi, F; Pallante, P; Martelli, ML; Trapasso, F; Chiariotti, L; Fusco, A				Iuliano, R; Le Pera, I; Cristofaro, C; Baudi, F; Arturi, F; Pallante, P; Martelli, ML; Trapasso, F; Chiariotti, L; Fusco, A			The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis	ONCOGENE			English	Article						polymorphisms; tyrosine phosphatase; thyroid; carcinoma; loss of heterozygosity	CARCINOMA CELL-LINES; ETA SUPPRESSES; CANCER CELLS; PROTEIN; EXPRESSION; GROWTH; INHIBITION; TUMORS; PROLIFERATION; DIMERIZATION	We recently isolated the r-PTPeta gene, which encodes a receptor-type tyrosine phosphatase protein that suppresses the neoplastic phenotype of retrovirally transformed rat thyroid cells. The human homologue gene PTPRJ/DEP-1 is deleted in various tumors. Moreover, the Gln276Pro polymorphism, located in the extracellular region of the gene, seems to play a critical role in susceptibility to some human neoplasias. Here we report the loss of heterozygosity ( LOH) of PTPRJ in 11/76 (14.5%) informative thyroid tumors ( including adenomas and carcinomas). We also looked for the Gln276Pro, Arg326Gln and Asp872Glu polymorphisms in exons 5, 6 and 13 of PTPRJ in 88 patients with thyroid tumors and in 54 healthy individuals. We found that the PTPRJ genotypes homozygous for the Gln276Pro and Arg326Gln polymorphisms, and the Asp872 allele were more frequent in thyroid carcinoma patients than in healthy individuals ( P = 0.032). In addition, PTPRJ LOH was more frequent in thyroid carcinomas of heterozygotes for Gln276Pro and Arg326Gln compared with homozygotes ( P = 0.006). This suggests that the presence of hemizygosity for these polymorphisms in the tumor facilitates tumor progression. These results indicate that the genotypic pro. le of PTPRJ affects susceptibility to thyroid carcinomas, and that allelic loss of this gene is involved in thyroid carcinogenesis.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulaire & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Catanzaro Magna Graecia, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulaire & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Pallante, Pierlorenzo/AAX-8758-2020; Chiariotti, Lorenzo/AAC-5262-2022	Fusco, Alfredo/0000-0003-3332-5197; CHIARIOTTI, Lorenzo/0000-0001-6097-4171; ARTURI, Franco/0000-0002-1660-1228				Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Chiappetta G, 1998, CANCER RES, V58, P4193; DIRENZO MF, 1992, ONCOGENE, V7, P2549; Dumont JE, 2002, AM J PHYSIOL-CELL PH, V283, pC2, DOI 10.1152/ajpcell.00581.2001; Fiore L, 1997, J CLIN ENDOCR METAB, V82, P4094, DOI 10.1210/jc.82.12.4094; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; Florio T, 2001, MOL ENDOCRINOL, V15, P1838, DOI 10.1210/me.15.10.1838; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; Iuliano R, 2003, CANCER RES, V63, P882; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; Keane MM, 1996, CANCER RES, V56, P4236; Kitamura Y, 2001, J CLIN ENDOCR METAB, V86, P4268, DOI 10.1210/jc.86.9.4268; Kovalerchuk B, 2000, IEEE ENG MED BIOL, V19, P26, DOI 10.1109/51.853479; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Martelli ML, 2000, EUR J ENDOCRINOL, V143, P515, DOI 10.1530/eje.0.1430515; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Sorby M, 2001, ONCOGENE, V20, P5219, DOI 10.1038/sj.onc.1204581; Takahashi T, 2003, MOL CELL BIOL, V23, P1817, DOI 10.1128/MCB.23.5.1817-1831.2003; Tallini G, 2002, ENDOCR PATHOL, V13, P271, DOI 10.1385/EP:13:4:271; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659	31	55	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8432	8438		10.1038/sj.onc.1207766	http://dx.doi.org/10.1038/sj.onc.1207766			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378013				2022-12-17	WOS:000224870700003
J	Cheng, PL; Chang, MH; Chao, CH; Lee, YHW				Cheng, PL; Chang, MH; Chao, CH; Lee, YHW			Hepatitis C viral proteins interact with Smad3 and differentially regulate TGF-beta/Smad3-mediated transcriptional activation	ONCOGENE			English	Article						HCV; core protein; NS3 protein; TGF-beta; Smad3; hepatocarcinogenesis	GROWTH-FACTOR-BETA; VIRUS CORE PROTEIN; INDUCED APOPTOSIS; GENE-EXPRESSION; PROMOTER; RECEPTOR; BINDING; REPLICATION; SUPPRESSION; CELLS	Transforming growth factor-beta (TGF-beta) is a pleiotropic cytokine implicated as a pathogenic mediator in various liver diseases. Enhanced TGF-beta production and lack of TGF-beta responses are often observed during hepatitis C virus (HCV) infection. In this study, we demonstrate that TGF-beta-mediated transactivation is decreased in cells exogenously expressing the intact HCV polyprotein. Among 16 viral products of HCV, only core and nonstructural protein 3 (NS3) physically interact with the MH1 (Mad homology 1) region of the Smad3 and block TGF-beta/Smad3-mediated transcriptional activation through interference with the DNA-binding ability of Smad3, not the nuclear translocation. However, the interactive domain of NS3 extends to the MH2 (Mad homology 2) region of Smad3 and a distinction is found between effects mediated, respectively, by these two viral proteins. HCV core, in the presence or absence of TGF-beta, has a stronger suppressive effect on the DNA-binding and transactivation ability of Smad3 than NS3. Although HCV core, NS3, and the HCV subgenomic replicon all attenuate TGF-beta/Smad3-mediated apoptosis, only HCV core represses TGF-beta-induced G1 phase arrest through downregulation of the TGF-beta-induced p21 promoter activation. Along with this, HCV core, rather than NS3, exhibits a significant inhibitory effect on the binding of Smad3/Sp1 complex to the proximal p21 promoter in response to TGF-beta. In conclusion, HCV viral proteins interact with the TGF-beta signaling mediator Smad3 and differentially impair TGF-beta/Smad3-mediated transactivation and growth inhibition. This functional counteraction of TGF-beta responses provides insights into possible mechanisms, whereby the HCV oncogenic proteins antagonize the host defenses during hepatocarcinogenesis.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.	yhwulee@ym.edu.tw	Cheng, Pei-Lin/ABB-2255-2021	Cheng, Pei-Lin/0000-0002-0090-8153; Lee Wu, Yan-Hwa/0000-0001-7299-7354; Chao, Chi-Hong/0000-0001-9890-4902				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; Chen SY, 2003, J BIOL CHEM, V278, P591, DOI 10.1074/jbc.M204241200; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; De Francesco R, 2000, CURR TOP MICROBIOL, V242, P149; DeBleser PJ, 1997, J HEPATOL, V26, P886, DOI 10.1016/S0168-8278(97)80257-7; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dey A, 1997, VIROLOGY, V228, P190, DOI 10.1006/viro.1996.8363; Dubourdeau M, 2002, J HEPATOL, V37, P486, DOI 10.1016/S0168-8278(02)00241-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fujita T, 1996, BIOCHEM BIOPH RES CO, V229, P825, DOI 10.1006/bbrc.1996.1887; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; ITO N, 1991, CANCER RES, V51, P4080; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kim DH, 1997, J BIOL CHEM, V272, P688; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kwong AD, 2000, CURR TOP MICROBIOL, V242, P171; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Lee MN, 2002, J GEN VIROL, V83, P2145, DOI 10.1099/0022-1317-83-9-2145; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Matsuzaki K, 2000, CANCER RES, V60, P1394; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Prokova V, 2002, J BIOL CHEM, V277, P9342, DOI 10.1074/jbc.M109099200; Ray RB, 1998, GENE, V208, P331, DOI 10.1016/S0378-1119(98)00030-4; Ray S, 2003, J GASTROEN HEPATOL, V18, P393, DOI 10.1046/j.1440-1746.2003.02985.x; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; SAKAMURO D, 1995, J VIROL, V69, P3893, DOI 10.1128/JVI.69.6.3893-3896.1995; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zemel R, 2001, J VIRAL HEPATITIS, V8, P96, DOI 10.1046/j.1365-2893.2001.00283.x; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	48	55	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7821	7838		10.1038/sj.onc.1208066	http://dx.doi.org/10.1038/sj.onc.1208066			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334054				2022-12-17	WOS:000224331600008
J	Xin, H; Pereira-Smith, OM; Choubey, D				Xin, H; Pereira-Smith, OM; Choubey, D			Role of IFI 16 in cellular senescence of human fibroblasts	ONCOGENE			English	Article						interferon-inducible IFI 16; fibroblasts; senescence; immortalization; DNA methylation	HUMAN TELOMERASE; NEGATIVE REGULATOR; ID PROTEINS; INTERFERON; EXPRESSION; GENE; FAMILY; CELLS; P202; P53	Defects in interferon (IFN) signaling that result in loss of expression of IFN-inducible proteins are associated with cellular immortalization, an important early event in the development of human cancer. Here we report that loss of IFN-inducible IFI 16 expression in human fibroblasts allows bypass of cellular senescence. We found that levels of IFI 16 mRNA and protein were higher in human old versus young fibroblasts and immortalization of fibroblasts with telomerase resulted in decreased expression of IFI 16. Moreover, overexpression of IFI 16 in immortalized fibroblasts strongly inhibited cell proliferation. Interestingly, knockdown of IFI 16 expression in fibroblasts inhibited p53-mediated transcription, downregulated p21(WAF1) expression, and extended the proliferation potential. Importantly, treatment of immortal cell lines with 5-aza-2'-deoxycytidine, an inhibitor of DNA methyltransferase, resulted in upregulation of IFI 16. Our observations support the idea that increased levels of IFI 16 in older populations of human fibroblasts contribute to cellular senescence.	Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL 60153 USA; Univ Texas, Hlth Sci Ctr, Sam & Ann Barshop Ctr Longet & Aging Studies, San Antonio, TX USA	Loyola University Chicago; University of Texas System; University of Texas Health San Antonio	Choubey, D (corresponding author), Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, 2160 S 1st Ave,Mail Code 114B, Maywood, IL 60153 USA.	dchoube@lumc.edu	Choubey, Divaker/A-4771-2008		NATIONAL INSTITUTE ON AGING [P01AG020752, R03AG022124] Funding Source: NIH RePORTER; NIA NIH HHS [AG022124, P01 AG20752] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aglipay JA, 2003, ONCOGENE, V22, P8931, DOI 10.1038/sj.onc.1207057; Akca H, 2003, SCAND J CLIN LAB INV, V63, P505, DOI 10.1080/00365510310003382; Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Asefa B, 2004, BLOOD CELL MOL DIS, V32, P155, DOI 10.1016/j.bcmd.2003.10.002; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Choubey D, 2002, FRONT BIOSCI-LANDMRK, V7, pE252, DOI 10.2741/choubey; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; DAWSON MJ, 1995, BIOCHEM BIOPH RES CO, V214, P152, DOI 10.1006/bbrc.1995.2269; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FUJIUCHI N, 2004, J BIOL CHEM     0227; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Johnstone RW, 2000, ONCOGENE, V19, P6033, DOI 10.1038/sj.onc.1204005; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Karlsson C, 1996, CANCER RES, V56, P241; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KINGSMORE SF, 1989, EMBO J, V8, P4073, DOI 10.1002/j.1460-2075.1989.tb08591.x; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Kwak JC, 2003, J BIOL CHEM, V278, P40899, DOI 10.1074/jbc.M308012200; Lee SH, 2003, ONCOGENE, V22, P381, DOI 10.1038/sj.onc.1206133; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Raffaella R, 2004, EXP CELL RES, V293, P331, DOI 10.1016/j.yexcr.2003.10.014; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; SEN GC, 1992, J BIOL CHEM, V267, P5017; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Untergasser G, 2002, CANCER RES, V62, P6255; Wang H, 1999, GENOMICS, V60, P281, DOI 10.1006/geno.1999.5923; Xin H, 2003, ONCOGENE, V22, P4831, DOI 10.1038/sj.onc.1206754; Young JI, 2003, J BIOL CHEM, V278, P19904, DOI 10.1074/jbc.M301685200	44	55	59	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6209	6217		10.1038/sj.onc.1207836	http://dx.doi.org/10.1038/sj.onc.1207836			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208661				2022-12-17	WOS:000223399000005
J	Fernandez, P; Carretero, J; Medina, PP; Jimenez, AI; Rodriguez-Perales, S; Paz, MF; Cigudosa, JC; Esteller, M; Lombardia, L; Morente, M; Sanchez-Verde, L; Sotelo, T; Sanchez-Cespedes, M				Fernandez, P; Carretero, J; Medina, PP; Jimenez, AI; Rodriguez-Perales, S; Paz, MF; Cigudosa, JC; Esteller, M; Lombardia, L; Morente, M; Sanchez-Verde, L; Sotelo, T; Sanchez-Cespedes, M			Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations	ONCOGENE			English	Article						LKB1/STK11; Peutz-Jeghers syndrome; lung adenocarcinomas; cDNA microarrays	PEUTZ-JEGHERS-SYNDROME; SERINE/THREONINE PROTEIN-KINASE; SERINE-THREONINE KINASE; TUMOR-SUPPRESSOR; SOMATIC MUTATIONS; GROWTH ARREST; KNOCKOUT MICE; IN-VIVO; CANCER; LKB1/STK11	LKB1, a tumor-suppressor gene that codifies for a serine/threonine kinase, is mutated in the germ-line of patients affected with the Peutz-Jeghers syndrome (PJS), which have an increased incidence of several cancers including gastrointestinal, pancreatic and lung carcinomas. Regarding tumors arising in non-PJS patients, we recently observed that at least one-third of lung adenocarcinomas (LADs) harbor somatic LKB1 gene mutations, supporting a role for LKB1 in the origin of some sporadic tumors. To characterize the pattern of LKB1 mutations in LADs further, we first screened for LKB1 gene alterations ( gene mutations, promoter hypermethylation and homozygous deletions) in 19 LADs and, in agreement with our previous data, five of them (26%) were shown to harbor mutations, all of which gave rise to a truncated protein. Recent reports demonstrate that LKB1 is able to suppress cell growth, but little is known about the specific mechanism by which it functions. To further our understanding of LKB1 function, we analysed global expression in lung primary tumors using cDNA microarrays to identify LKB1-specific variations in gene expression. In all, 34 transcripts, 24 of which corresponded to known genes, differed significantly between tumors with and without LKB1 gene alterations. Among the most remarkable findings was deregulation of transcripts involved in signal transduction (e.g. FRAP1/mTOR, ARAF1 and ROCK2), cytoskeleton (e.g. MPP1), transcription factors (e.g. MEIS2, ATF5), metabolism of AMP (AMPD3 and APRT) and ubiquitinization (e.g. USP16 and UBE2L3). Real-time quantitative RT-PCR on 15 tumors confirmed the upregulation of the homeobox MEIS2 and of the AMP-metabolism AMPD3 transcripts in LKB1-mutant tumors. In addition, immunohistochemistry in 10 of the lung tumors showed the absence of phosphorylated FRAP1/mTOR protein in LKB1-mutant tumors, indicating that LKB1 mutations do not lead to FRAP1/mTOR protein kinase activation. In conclusion, our results reveal that several important factors contribute to LKB1-mediated carcinogenesis in LADs, confirming previous observations and identifying new putative pathways that should help to elucidate the biological role of LKB1.	Spanish Natl Canc Ctr, Lymphomas & Lung Canc Lab, Madrid, Spain; Spanish Natl Canc Ctr, Cytogenet Unit, Madrid, Spain; Spanish Natl Canc Ctr, Canc Epigenet Lab, Madrid, Spain; Spanish Natl Canc Ctr, Tumor Bank, Madrid, Spain; Spanish Natl Canc Ctr, Immunohistochem Unit, Madrid, Spain; Spanish Natl Canc Ctr, Histol Unit, Madrid, Spain; Hosp Univ 12 Octubre, Dept Pathol, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario 12 de Octubre	Sanchez-Cespedes, M (corresponding author), Spanish Natl Canc Ctr, Lymphomas & Lung Canc Lab, Madrid, Spain.	msanchez@cnio.es	Rodriguez-Perales, Sandra/T-7667-2017; Vico, Pedro Pablo Medina/D-1688-2013; Carretero, Julian/N-5214-2014; Esteller, Manel/L-5956-2014; Cigudosa, Juan C/E-4105-2016; Sanchez-Cespedes, Montse/H-8485-2012	Rodriguez-Perales, Sandra/0000-0001-7221-3636; Vico, Pedro Pablo Medina/0000-0002-7834-7093; Carretero, Julian/0000-0001-7269-8506; Esteller, Manel/0000-0003-4490-6093; Sanchez-Cespedes, Montse/0000-0002-6045-5627; Fernandez, Paloma/0000-0001-5941-8442; Morente, Manuel M/0000-0001-6004-330X				Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; CARRETERO J, 2004, ONCOGENE        0315; Choe G, 2003, CANCER RES, V63, P2742; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Geerts D, 2003, CANCER LETT, V197, P87, DOI 10.1016/S0304-3835(03)00087-9; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; HANSSEN AMN, 1995, J MED GENET, V32, P117, DOI 10.1136/jmg.32.2.117; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Herrero J, 2001, BIOINFORMATICS, V17, P126, DOI 10.1093/bioinformatics/17.2.126; JEGHERS H, 1949, NEW ENGL J MED, V241, P1031, DOI 10.1056/NEJM194912292412601; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jimenez AI, 2003, CANCER RES, V63, P1382; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Miyoshi H, 2002, CANCER RES, V62, P2261; Nakau M, 2002, CANCER RES, V62, P4549; Nezu J, 1999, BIOCHEM BIOPH RES CO, V261, P750, DOI 10.1006/bbrc.1999.1047; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sapkota GP, 2002, BIOCHEM J, V368, P507, DOI 10.1042/BJ20021284; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Schimanski CC, 1999, CANCER RES, V59, P5169; Smith DP, 1999, HUM MOL GENET, V8, P1479, DOI 10.1093/hmg/8.8.1479; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Tracey L, 2002, AM J PATHOL, V161, P1825, DOI 10.1016/S0002-9440(10)64459-8; Watts JL, 2000, DEVELOPMENT, V127, P1467; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Zhang X, 2002, GENE DEV, V16, P2097, DOI 10.1101/gad.1007602	39	55	63	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5084	5091		10.1038/sj.onc.1207665	http://dx.doi.org/10.1038/sj.onc.1207665			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15077168				2022-12-17	WOS:000222237300015
J	Wang, JW; Gamsby, JJ; Highfill, SL; Mora, LB; Bloom, GC; Yeatman, TJ; Pan, TC; Ramne, AL; Chodosh, LA; Cress, WD; Chen, JD; Kerr, WG				Wang, JW; Gamsby, JJ; Highfill, SL; Mora, LB; Bloom, GC; Yeatman, TJ; Pan, TC; Ramne, AL; Chodosh, LA; Cress, WD; Chen, JD; Kerr, WG			Deregulated expression of LRBA facilitates cancer cell growth	ONCOGENE			English	Article						LRBA; gene expression profiling; RNA interference; p53; E2F	CHEDIAK-HIGASHI-SYNDROME; KINASE ANCHOR PROTEIN; MAMMALIAN-CELLS; IDENTIFICATION; GENE; P53; CLASSIFICATION; INVOLVEMENT; PATHWAYS; RECEPTOR	LRBA expression is induced by mitogens in lymphoid and myeloid cells. The Drosophila LRBA orthologue rugose/ DAKAP550 is involved in Notch, Ras and EGFR pathways. These findings suggest that LRBA could play a role in cell types that have increased proliferative and survival capacity. Here, we show by microarray and real-time PCR analyses that LRBA is overexpressed in several different cancers relative to their normal tissue controls. We also show that LRBA promoter activity and endogenous LRBA mRNA levels are reduced by p53 and increased by E2F1, indicating that mutations in the tumor suppressors p53 and Rb could contribute to the deregulation of LRBA. Furthermore, inhibition of LRBA expression by RNA interference, or inhibition of its function by a dominant-negative mutant, leads to significant growth inhibition of cancer cells, demonstrating that deregulated expression of LRBA contributes to the altered growth properties of a cancer cell. Finally, we show that the phosphorylation of EGFR is affected by the dominant-negative mutant, suggesting LRBA plays a role in the mammalian EGFR pathway. These findings demonstrate that LRBA facilitates cancer cell growth and thus LRBA may represent a novel molecular target for cancer therapy.	Immunol Programs, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Comprehens Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem, Tampa, FL 33612 USA; Mol Oncol Programs, Tampa, FL 33612 USA; Gastrointestinal Programs, Tampa, FL 33612 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Kerr, WG (corresponding author), 12902 Magnolia Dr,SRB-2, Tampa, FL 33612 USA.	kerrw@moffitt.usf.edu	Gamsby, Joshua J/H-9606-2014; Wang, Jia-Wang/I-4966-2012; Kerr, William G/B-8616-2015	Kerr, William G/0000-0002-4720-7135	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS027405] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL72523] Funding Source: Medline; NIDDK NIH HHS [R01 DK54767] Funding Source: Medline; NINDS NIH HHS [P01 NS27405] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Bloom G, 2004, AM J PATHOL, V164, P9, DOI 10.1016/S0002-9440(10)63090-8; Dyomin VG, 2002, GENOMICS, V80, P158, DOI 10.1006/geno.2002.6822; Han JD, 1997, J BIOL CHEM, V272, P26611, DOI 10.1074/jbc.272.42.26611; Harborth J, 2001, J CELL SCI, V114, P4557; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jogl G, 2002, EMBO J, V21, P4785, DOI 10.1093/emboj/cdf502; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kerr WG, 1996, P NATL ACAD SCI USA, V93, P3947, DOI 10.1073/pnas.93.9.3947; Kwak E, 1999, MOL BIOL CELL, V10, P4429, DOI 10.1091/mbc.10.12.4429; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; Miller WR, 2002, ANN NY ACAD SCI, V968, P37, DOI 10.1111/j.1749-6632.2002.tb04325.x; MORRIS C, 2002, BREAST CANC RES TREA, V75; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; Ohtani Kiyoshi, 1999, Frontiers in Bioscience, V4, pd793, DOI 10.2741/Ohtani; Segui B, 2001, J CLIN INVEST, V108, P143, DOI 10.1172/JCI200111498; Shamloula HK, 2002, GENETICS, V161, P693; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Spritz RA, 1998, J CLIN IMMUNOL, V18, P97, DOI 10.1023/A:1023247215374; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang JW, 2001, J IMMUNOL, V166, P4586, DOI 10.4049/jimmunol.166.7.4586; Wang XL, 2000, J NEUROSCI, V20, P8551; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8	29	55	60	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4089	4097		10.1038/sj.onc.1207567	http://dx.doi.org/10.1038/sj.onc.1207567			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064745				2022-12-17	WOS:000221520200007
J	Hanissian, SH; Akbar, U; Teng, B; Janjetovic, Z; Hoffmann, A; Hitzler, JK; Iscove, N; Hamre, K; Du, XP; Tong, Y; Mukatira, S; Robertson, JH; Morris, SW				Hanissian, SH; Akbar, U; Teng, B; Janjetovic, Z; Hoffmann, A; Hitzler, JK; Iscove, N; Hamre, K; Du, XP; Tong, Y; Mukatira, S; Robertson, JH; Morris, SW			CDNA cloning and characterization of a novel gene encoding the MLF1-interacting protein MLF1IP	ONCOGENE			English	Article						MLF1; NPM-MLF1; MLF1IP; acute myeloid leukemia	CHROMOSOMAL LOCALIZATION; MYELOID-LEUKEMIA; BINDING; PHOSPHORYLATION; NUCLEOPHOSMIN; TRANSPORT; RECEPTOR; ADAPTER; DOMAIN; SITE	Myelodysplasia/acute myeloid leukemia (MDS/AML) is characterized by a t(3;5)(q25.1;q34) chromosomal translocation that forms a fusion gene between nucleophosmin (NPM) and MDS/myeloid leukemia factor 1 (MLF1). We identified a novel protein, MLF1-interacting protein (MLF1IP), that specifically associates with MLF1 by yeast two-hybrid analysis and in pulldown assays, and colocalizes with it in both the nuclei and cytoplasm of cells. The MLF1IP gene locus is at chromosome 4q35.1 and is composed of 14 exons spanning 75.8 kb of genomic DNA. The MLF1IP cDNA encodes a 46-kDa protein that contains two bipartite and two classical nuclear localization signals, two nuclear receptor-binding motifs (LXXLL), two leucine zippers, two PEST residues and several potential phosphorylation sites. MLF1IP transcripts are expressed in a variety of tissues (e.g. fetal liver, bone marrow, thymus and testis). MLF1IP appears to be a lineage-specific gene whose expression is confined exclusively to the CFU-E erythroid precursor cells, but not in mature erythrocytes. These observations, together with previous data demonstrating a role for MLF1 in suppressing red cell maturation, suggest a possible role for MLF1IP and MLF1 deregulation in the genesis of erythroleukemias.	Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA; Univ Kiel, Ctr Biochem & Mol Biol, D-24118 Kiel, Germany; Univ Toronto, Hosp Sick Children, Dept Pediat, Div Hematol Oncol Canc & Blood, Toronto, ON, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Kiel; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Hanissian, SH (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, 847 Monroe,Room 427, Memphis, TN 38163 USA.	shanissi@utmem.edu		Akbar, Umair/0000-0001-5423-0002	NATIONAL CANCER INSTITUTE [R01CA076301] Funding Source: NIH RePORTER; NCI NIH HHS [CA76301, CA27165] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1992, IN SITU HYBRIDIZATIO; Billia F, 2001, BLOOD, V97, P2257, DOI 10.1182/blood.V97.8.2257; Bornberg-Bauer E, 1998, NUCLEIC ACIDS RES, V26, P2740, DOI 10.1093/nar/26.11.2740; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Gregson HC, 2002, CHROMOSOME RES, V10, P267, DOI 10.1023/A:1016563523208; Gregson HC, 2001, J BIOL CHEM, V276, P47575, DOI 10.1074/jbc.M103364200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hitzler JK, 1999, AM J PATHOL, V155, P53, DOI 10.1016/S0002-9440(10)65098-5; ISCOVE NN, 1977, CELL TISSUE KINET, V10, P323, DOI 10.1111/j.1365-2184.1977.tb00300.x; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kozak M, 2000, GENOMICS, V70, P396, DOI 10.1006/geno.2000.6412; Kuefer MU, 1996, GENOMICS, V35, P392, DOI 10.1006/geno.1996.0376; Lim R, 2002, J BIOL CHEM, V277, P40997, DOI 10.1074/jbc.M206041200; Matsumoto N, 2000, LEUKEMIA, V14, P1757, DOI 10.1038/sj.leu.2401897; OLSON MOJ, 1986, BIOCHEMISTRY-US, V25, P484, DOI 10.1021/bi00350a031; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Schmiesing JA, 1998, P NATL ACAD SCI USA, V95, P12906, DOI 10.1073/pnas.95.22.12906; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	30	55	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3700	3707		10.1038/sj.onc.1207448	http://dx.doi.org/10.1038/sj.onc.1207448			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116101				2022-12-17	WOS:000221101700022
J	Miyaoka, Y; Kadowaki, Y; Ishihara, S; Ose, T; Fukuhara, H; Kazumori, H; Takasawa, S; Okamoto, H; Chiba, T; Kinoshita, Y				Miyaoka, Y; Kadowaki, Y; Ishihara, S; Ose, T; Fukuhara, H; Kazumori, H; Takasawa, S; Okamoto, H; Chiba, T; Kinoshita, Y			Transgenic overexpression of Reg protein caused gastric cell proliferation and differentiation along parietal cell and chief cell lineages	ONCOGENE			English	Article						Reg; gastric cells; transgenic mice; growth factor	GROWTH-FACTOR-ALPHA; REGENERATING GENE PROTEIN; PANCREATIC THREAD PROTEIN; MUCOUS EPITHELIAL-CELLS; MENETRIERS DISEASE; PRIMARY CULTURES; MOUSE STOMACH; EXPRESSION; INSULIN; MICE	Reg (regenerating gene product) was originally identified as a growth factor involved in pancreatic regeneration. During the healing course of gastric erosion, Reg expression is highly increased in the enterochromaffin-like (ECL) cells surrounding the ulcer crater, suggesting its role as a regulator of gastric mucosal regeneration. However, there has been no direct in vivo evidence of a growth-promoting role of Reg for the gastric mucosal cells. In the current study, Reg-transgenic mice were created and gastric mucosa were analysed for histological changes. Transgenic mice showed a marked increase in the thickness of the fundic mucosa. Anti-proliferating cell nuclear antigen ( PCNA) staining of the fundic mucosa demonstrated the enlargement of the proliferating neck zone and the lower PCNA-negative zone. Histological analysis employing antibodies against cell-type markers revealed expansion of the chief cell and parietal cell populations and no change in the number of surface mucus-producing cells, ECL cells, or G cells. In conclusion, Reg has a growth-promoting effect on gastric progenitor cells and an activity to direct the differentiation of the cells into chief cell and parietal cell lineages. This was in contrast to other factors, all of which had been shown to drive differentiation towards mucus producing cells in vivo. In the injured gastric mucosa, Reg may play a unique and important part in the reconstruction of the properly organized mucosal architecture.	Tohoku Univ, Grad Sch Med, Dept Biochem, Sendai, Miyagi 980, Japan; Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto, Japan	Tohoku University; Kyoto University	Kadowaki, Y (corresponding author), Shimane Med Univ, Dept Internal Med 2, Izumo, Shimane 6938501, Japan.	y-kado@momo.so-net.ne.jp						Asahara M, 1996, GASTROENTEROLOGY, V111, P45, DOI 10.1053/gast.1996.v111.pm8698224; BEAUCHAMP RD, 1989, J CLIN INVEST, V84, P1017, DOI 10.1172/JCI114223; BORDI C, 1995, ENDOCR PATHOL, V6, P103, DOI 10.1007/BF02739873; CHEN MC, 1991, J CLIN INVEST, V87, P1716, DOI 10.1172/JCI115189; DEMPSEY PJ, 1992, GASTROENTEROLOGY, V103, P1950, DOI 10.1016/0016-5085(92)91455-D; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fukui H, 1998, GASTROENTEROLOGY, V115, P1483, DOI 10.1016/S0016-5085(98)70027-7; HATTORI T, 1976, CELL TISSUE RES, V172, P171; Higham AD, 1999, GASTROENTEROLOGY, V116, P1310, DOI 10.1016/S0016-5085(99)70495-6; Kadowaki Y, 2002, FEBS LETT, V530, P59, DOI 10.1016/S0014-5793(02)03398-7; KARAM SM, 1993, ANAT REC, V236, P333, DOI 10.1002/ar.1092360206; KARAM SM, 1992, ANAT RECORD, V232, P231, DOI 10.1002/ar.1092320208; Kazumori H, 2000, GASTROENTEROLOGY, V119, P1610, DOI 10.1053/gast.2000.20262; Kobayashi S, 2000, J BIOL CHEM, V275, P10723, DOI 10.1074/jbc.275.15.10723; POLK WH, 1992, GASTROENTEROLOGY, V102, P1467, DOI 10.1016/0016-5085(92)91703-7; RUTTEN MJ, 1993, AM J PHYSIOL, V265, pG361, DOI 10.1152/ajpgi.1993.265.2.G361; RUTTEN MJ, 1991, SCAND J GASTROENTERO, V26, P965, DOI 10.3109/00365529108996250; SHARP R, 1995, DEVELOPMENT, V121, P149; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TAKAHASHI M, 1995, J CLIN INVEST, V95, P1994, DOI 10.1172/JCI117884; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; TERAZONO K, 1990, DIABETOLOGIA, V33, P250, DOI 10.1007/BF00404804; UNNO M, 1993, J BIOL CHEM, V268, P15974; WATANABE T, 1990, J BIOL CHEM, V265, P7432; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; YOSHIURA K, 1994, DIGEST DIS SCI, V39, P1454, DOI 10.1007/BF02088048; Zenilman ME, 1996, GASTROENTEROLOGY, V110, P1208, DOI 10.1053/gast.1996.v110.pm8613011	27	55	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3572	3579		10.1038/sj.onc.1207333	http://dx.doi.org/10.1038/sj.onc.1207333			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116092				2022-12-17	WOS:000221101700008
J	Alphonse, G; Bionda, C; Aloy, MT; Ardail, D; Rousson, R; Rodriguez-Lafrasse, C				Alphonse, G; Bionda, C; Aloy, MT; Ardail, D; Rousson, R; Rodriguez-Lafrasse, C			Overcoming resistance to gamma-rays in squamous carcinoma cells by poly-drug elevation of ceramide levels	ONCOGENE			English	Article						SQ20B cells; SCC61 cells; gamma-irradiation; apoptosis; inhibitors of sphingolipid metabolism	RADIATION-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; NIEMANN-PICK DISEASE; CANCER-CELLS; GLUCOSYLCERAMIDE SYNTHASE; IONIZING-RADIATION; LEUKEMIA-CELLS; DNA-DAMAGE; TUMOR-CELL; SPHINGOMYELINASE	Recent strategies to sensitize radioresistant tumours are based on combining gamma-irradiation with inducers of apoptosis. We report that the combination of three inhibitors of sphingolipid metabolism, DL-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol. HCl(DL-PDMP) +imipramine+/-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol (D-MAPP), with 10-Gy irradiation triggers both mitotic and apoptotic killing in radioresistant SQ20B squamous carcinoma cells. In these cells, apoptosis is defective due to a lack of ceramide generation upstream, which cannot be explained by sphingomyelinase (neutral and acidic) deficiency or rapid derivation to the sphingolipid pathway. We present evidence of a functional transduction death pathway when ceramide generation is restored, which involves the mitochondrial-mediated pathway coupled to alterations in redox status and to executive caspases activation. The poly-drug treatment restored apoptosis to levels similar to those observed in radiosensitive SCC61 squamous carcinoma cells. Simultaneous exposure to gamma-irradiation and poly-drug treatment acted synergistically in SQ20B cells to produce a marked increase in both mitochondrial dysfunction and caspase cleavage, which led to a 7.8-fold increase in apoptosis within 48 h, relative to irradiated cells. Moreover, the results suggest that the ceramide released by irradiation or poly-drug treatment converges upon common cellular targets. Modulation of endogenous ceramide levels by inhibitors of sphingolipid metabolism may represent a new cellular target for the sensitization of radioresistant tumours to gamma-ray therapy.	Lyon Sud Med Sch, Dept Biochem, INSERM, U189, F-69921 Oullins, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Rodriguez-Lafrasse, C (corresponding author), Lyon Sud Med Sch, Dept Biochem, INSERM, U189, BP12, F-69921 Oullins, France.	rodriguez@lyon-sud.univ-lyon1.fr	Alphonse, Gersende/G-7721-2018; Rodriguez-Lafrasse, Claire/G-7741-2018					Alphonse G, 2002, INT J RADIAT BIOL, V78, P821, DOI 10.1080/09553000210153943; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Birbes H, 2002, ADV ENZYME REGUL, V42, P113, DOI 10.1016/S0065-2571(01)00026-7; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Chmura SJ, 1997, CANCER RES, V57, P4340; Chmura SJ, 1997, CANCER RES, V57, P1270; Choi MS, 2003, GENE, V315, P113, DOI 10.1016/S0378-1119(03)00721-2; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Decaudin D, 1998, INT J ONCOL, V12, P141; di Bartolomeo S, 2001, BIOCHEM BIOPH RES CO, V288, P269, DOI 10.1006/bbrc.2001.5748; El-Assaad W, 2003, BIOCHEM J, V376, P725, DOI 10.1042/BJ20030888; Fiske CH, 1925, J BIOL CHEM, V66, P375; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gewirtz DA, 2000, BREAST CANCER RES TR, V62, P223, DOI 10.1023/A:1006414422919; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Grazide S, 2002, FASEB J, V16, P1685, DOI 10.1096/fj.01-0794fje; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Ito A, 1999, BBA-MOL CELL RES, V1452, P263, DOI 10.1016/S0167-4889(99)00131-7; Itoh M, 2003, CLIN CANCER RES, V9, P415; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Jafrezou JP, 2001, FASEB J, V15, P123, DOI 10.1096/fj.00-0305com; Kimura K, 2003, CELL DEATH DIFFER, V10, P240, DOI 10.1038/sj.cdd.4401145; Kokunai T, 2001, J NEURO-ONCOL, V51, P111, DOI 10.1023/A:1010645205169; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Lavrentiadou SN, 2001, AM J RESP CELL MOL, V25, P676, DOI 10.1165/ajrcmb.25.6.4321; Lee JU, 1999, EUR J CANCER, V35, P1374, DOI 10.1016/S0959-8049(99)00134-3; Li W, 2000, FEBS LETT, V470, P35, DOI 10.1016/S0014-5793(00)01286-2; Lin JY, 2001, ANTICANCER RES, V21, P831; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Liu YY, 2000, J BIOL CHEM, V275, P7138, DOI 10.1074/jbc.275.10.7138; Liu YY, 1999, EXP CELL RES, V252, P464, DOI 10.1006/excr.1999.4649; Lozano J, 2001, J BIOL CHEM, V276, P442, DOI 10.1074/jbc.M006353200; Lucci A, 1998, ANTICANCER RES, V18, P475; MATSUO N, 1992, BIOCHIM BIOPHYS ACTA, V1116, P97, DOI 10.1016/0304-4165(92)90105-4; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Michael JM, 1997, CANCER RES, V57, P3600; NEUSCHWANDERTETRI BA, 1989, ANAL BIOCHEM, V179, P236, DOI 10.1016/0003-2697(89)90121-8; Pena LA, 2000, CANCER RES, V60, P321; Perry DK, 1999, BIOCHEM SOC T, V27, P399, DOI 10.1042/bst0270399; Petit PX, 1997, MOL CELL BIOCHEM, V174, P185, DOI 10.1023/A:1006848205880; Radin NS, 2003, BIOCHEM J, V371, P243, DOI 10.1042/BJ20021878; Raisova M, 2002, FEBS LETT, V516, P47, DOI 10.1016/S0014-5793(02)02472-9; Ramstedt B, 2002, FEBS LETT, V531, P33, DOI 10.1016/S0014-5793(02)03406-3; Riboni L, 2002, GLIA, V39, P105, DOI 10.1002/glia.10087; Rodriguez-Lafrasse C, 2002, INT J CANCER, V101, P589, DOI 10.1002/ijc.10652; Rodriguez-Lafrasse C, 2001, BIOCHEM J, V357, P407, DOI 10.1042/0264-6021:3570407; RODRIGUEZLAFRASSE C, 1994, BBA-MOL BASIS DIS, V1226, P138, DOI 10.1016/0925-4439(94)90021-3; ROSENWALD AG, 1994, J LIPID RES, V35, P1232; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sautin Y, 2000, THYROID, V10, P733, DOI 10.1089/thy.2000.10.733; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Selzner M, 2001, CANCER RES, V61, P1233; Shi YQ, 2001, RADIAT ENVIRON BIOPH, V40, P301, DOI 10.1007/s00411-001-0124-5; Shinoura N, 2001, INT J CANCER, V93, P252, DOI 10.1002/ijc.1327; Sietsma H, 2000, CLIN CANCER RES, V6, P942; Solary E, 2001, THERAPIE, V56, P511; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Sugiki H, 2000, BRIT J DERMATOL, V143, P1154, DOI 10.1046/j.1365-2133.2000.03882.x; Tepper AD, 2000, J BIOL CHEM, V275, P34810, DOI 10.1074/jbc.M005142200; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; VANIER MT, 1980, CLIN CHIM ACTA, V106, P257, DOI 10.1016/0009-8981(80)90309-5; Veldman RJ, 2003, FASEB J, V17, P1144, DOI 10.1096/fj.02-1053fje; Yokogawa K, 2002, METHOD FIND EXP CLIN, V24, P81, DOI 10.1358/mf.2002.24.2.677131	70	55	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2703	2715		10.1038/sj.onc.1207357	http://dx.doi.org/10.1038/sj.onc.1207357			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048093				2022-12-17	WOS:000220714900012
J	Weeraratna, AT; Becker, D; Carr, KM; Duray, PH; Rosenblatt, KP; Yang, S; Chen, YD; Bittner, M; Strausberg, RL; Riggins, GJ; Wagner, U; Kallioniemi, OP; Trent, JM; Morin, PJ; Meltzer, PS				Weeraratna, AT; Becker, D; Carr, KM; Duray, PH; Rosenblatt, KP; Yang, S; Chen, YD; Bittner, M; Strausberg, RL; Riggins, GJ; Wagner, U; Kallioniemi, OP; Trent, JM; Morin, PJ; Meltzer, PS			Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome	ONCOGENE			English	Article						SAGE; melanoma; tissue microarray; CD74; calpain; Wnt5a	GENE-EXPRESSION; SERIAL ANALYSIS; MALIGNANT-MELANOMA; GASTRIC-CANCER; CELL-LINES; PROTEINS; TUMOR; MUTATIONS; BINDING; FAMILY	In this study, we generated three SAGE libraries from melanoma tissues. Using bioinformatics tools usually applied to microarray data, we identified several genes, including novel transcripts, which are preferentially expressed in melanoma. SAGE results converged with previous microarray analysis on the importance of intracellular calcium and G- protein signaling, and the Wnt/ Frizzled family. We also examined the expression of CD74, which was specifically, albeit not abundantly, expressed in the melanoma libraries using a melanoma progression tissue microarray, and demonstrate that this protein is expressed by melanoma cells but not by benign melanocytes. Many genes involved in intracellular calcium and G- protein signaling were highly expressed in melanoma, results we had observed earlier from microarray studies ( Bittner et al., 2000). One of the genes most highly expressed in our melanoma SAGE libraries was a calcium-regulated gene, calpain 3 ( p94). Immunohistochemical analysis demonstrated that calpain 3 moves from the nuclei of non- neoplastic cells to the cytoplasm of malignant cells, suggesting activation of this intracellular proteinase. Our SAGE results and the clinical validation data demonstrate how SAGE profiles can highlight specific links between signaling pathways as well as associations with tumor progression. This may provide insights into new genes that may be useful for the diagnosis and therapy of melanoma.	NIA, Immunol Lab, NIH, Gerontol Res Ctr, Baltimore, MD 21224 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA; NCI, Bethesda, MD 20892 USA; NHGRI, Bethesda, MD 20892 USA; Translat Genom Res Inst, Phoenix, AZ USA; Inst Genom Res, Rockville, MD USA; Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD USA; Univ Basel, Inst Pathol, Basel, Switzerland; Univ Turku, Turku, Finland; Tech Res Ctr Finland, Med Biotechnol Grp, Turku, Finland	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Translational Genomics Research Institute; J. Craig Venter Institute; Johns Hopkins University; University of Basel; University of Turku; VTT Technical Research Center Finland	Weeraratna, AT (corresponding author), NIA, Immunol Lab, NIH, Gerontol Res Ctr, 5600 Nathan Shock Dr,Box 21, Baltimore, MD 21224 USA.	weerarat@grc.nia.nih.gov; pmeltzer@nhgri.nih.gov	Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000442, Z01AG000512, ZIAAG000442] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Datson NA, 1999, NUCLEIC ACIDS RES, V27, P1300, DOI 10.1093/nar/27.5.1300; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dejmek J, 2003, INT J CANCER, V103, P344, DOI 10.1002/ijc.10752; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; DEMETRICK DJ, 1992, J NATL CANCER I, V84, P422, DOI 10.1093/jnci/84.6.422; Desmond RA, 2003, SURG CLIN N AM, V83, P1, DOI 10.1016/S0039-6109(02)00092-0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Eisenberg CA, 1997, DEVELOPMENT, V124, P525; El-Rifai W, 2002, CANCER RES, V62, P6823; Hodgkinson JL, 2000, J MUSCLE RES CELL M, V21, P115, DOI 10.1023/A:1005697301043; Hough CD, 2000, CANCER RES, V60, P6281; Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x; Ishigami S, 2001, CANCER LETT, V168, P87, DOI 10.1016/S0304-3835(01)00503-1; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5; MARTI GE, 1992, LEUKEMIA LYMPHOMA, V7, P497, DOI 10.3109/10428199209049807; O'Rourke FA, 2003, BIOCHEM J, V373, P133, DOI 10.1042/BJ20030013; OHNO S, 1990, CYTOGENET CELL GENET, V53, P225, DOI 10.1159/000132937; Ong GL, 1999, IMMUNOLOGY, V98, P296; PFAFFSMITH, 2004, IN PRESS CANC BIOL T; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Polsky D, 2003, ONCOGENE, V22, P3087, DOI 10.1038/sj.onc.1206449; Porter DA, 2001, CANCER RES, V61, P5697; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; Ribe A, 2003, MODERN PATHOL, V16, P505, DOI 10.1097/01.MP.0000071128.67149.FD; Richard I, 1999, AM J HUM GENET, V64, P1524, DOI 10.1086/302426; ROSS AH, 1983, ARCH BIOCHEM BIOPHYS, V225, P370, DOI 10.1016/0003-9861(83)90042-5; Saitoh T, 2002, INT J MOL MED, V9, P515; Sakai C, 1997, MELANOMA RES, V7, P83, DOI 10.1097/00008390-199704000-00001; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Smedley D, 2000, GENE CHROMOSOME CANC, V28, P121, DOI 10.1002/(SICI)1098-2264(200005)28:1<121::AID-GCC14>3.0.CO;2-O; Taniguchi S, 2001, CANCER RES, V61, P7627; VANRUISSEN F, 1995, GENOMICS, V79, P671; Velculescu VE, 2000, TRENDS GENET, V16, P423, DOI 10.1016/S0168-9525(00)02114-4; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wang CY, 2001, NEURON, V32, P99, DOI 10.1016/S0896-6273(01)00434-2; Weeraratna AT, 2003, PIGM CELL RES, V16, P183, DOI 10.1034/j.1600-0749.2003.00042.x; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Weisz OA, 2000, J BIOL CHEM, V275, P24341, DOI 10.1074/jbc.M000671200; Young AN, 2001, AM J PATHOL, V158, P1639, DOI 10.1016/S0002-9440(10)64120-X	45	55	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2264	2274		10.1038/sj.onc.1207337	http://dx.doi.org/10.1038/sj.onc.1207337			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14755246				2022-12-17	WOS:000220280900017
J	Pak, BJ; Lee, J; Thai, BL; Fuchs, SY; Shaked, Y; Ronai, Z; Kerbel, RS; Ben-David, Y				Pak, BJ; Lee, J; Thai, BL; Fuchs, SY; Shaked, Y; Ronai, Z; Kerbel, RS; Ben-David, Y			Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase	ONCOGENE			English	Article						radiation resistance; malignant melanoma; DOPAchrome tautomerase; mitogen-activated protein kinase	TYROSINASE-RELATED PROTEIN-2; CISPLATIN-INDUCED APOPTOSIS; JUN NH2-TERMINAL KINASE; DNA MISMATCH REPAIR; DRUG-RESISTANCE; CANCER CELLS; FRIEND-VIRUS; ACTIVATION; EXPRESSION; CIS-DIAMMINEDICHLOROPLATINUM(II)	While melanomas are resistant to the cytotoxic effects of radiotherapy, little is known about the molecular mechanisms underlying this intrinsic resistance. Here, we describe the utilization of retroviral insertional mutagenesis to facilitate the analysis of genetic changes that are associated with radioresistance in human melanoma. A radial growth phase human melanoma cell line, WM35, was infected with a replication-defective amphotropic murine retrovirus and subsequently selected for X-ray radiation-resistant variants. Several radiation-resistant clones were independently isolated and characterized. Interestingly, these clones also displayed resistance to ultraviolet radiation and to the chemotherapeutic drug cis-diamminedichloroplatinum(II) (CDDP). By Northern and Western analyses, we showed that the expression of DOPAchrome tautomerase (DCT), also known as tyrosinase-related protein 2 (TYRP2), an enzyme that functions in eumelanin synthesis, was significantly elevated in the radiation-resistant clones relative to the parental WM35 cells. Moreover, the levels of DCT in a variety of human melanoma cell lines correlated with their relative levels of radioresistance and the enforced expression of DCT conferred increased resistance to UV(B) treatment. An analysis of stress signaling induced by radiation as well other cytotoxic stressors showed that resistance associated with DCT overexpression applied specifically to treatments that activate the ERK/MAPK pathway. Indeed, DCT overexpression in a melanoma cell line resulted in increased ERK activity. Moreover, ectopic expression of dominant-active MEK in this melanoma cell line conferred UV(B) resistance suggesting that the ERK/MAPK pathway downstream of DCT may play a critical role in radiation and drug resistance. Overall, given that each gamma- and UV(B)-resistant cell line also exhibited resistance to CDDP and that CDDP-resistant clones showed increased resistance to UV(B) irradiation, these results suggest a common mechanism underlying radio- and chemoresistance, which is mediated by DCT expression.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada; Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY USA; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Icahn School of Medicine at Mount Sinai; University of Toronto	Ben-David, Y (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto Sunnybrook Reg Canc Ctr, Res Bldg,S Wing Rm S-218,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	bendavid@srcl.sunnybrook.utoronto.ca		RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bani MR, 1996, CANCER RES, V56, P3075; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHEN F, 1995, BIOCHEM J, V312, P341, DOI 10.1042/bj3120341; Chu W, 2000, ONCOGENE, V19, P395, DOI 10.1038/sj.onc.1203315; Cooksey CJ, 1997, J BIOL CHEM, V272, P26226, DOI 10.1074/jbc.272.42.26226; DACQUISTO F, 1995, LIFE SCI, V57, pPL401, DOI 10.1016/0024-3205(95)02244-2; DAVID YB, 1988, ONCOGENE, V3, P179; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; Fang D, 2001, PIGM CELL RES, V14, P132, DOI 10.1034/j.1600-0749.2001.140209.x; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; Hayakawa J, 2003, J BIOL CHEM, V278, P20582, DOI 10.1074/jbc.M210992200; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; JARA JR, 1990, BIOCHIM BIOPHYS ACTA, V1035, P276, DOI 10.1016/0304-4165(90)90089-F; KUBODA H, 1991, INT J CANCER, V47, P732; Lin XJ, 1999, MOL PHARMACOL, V56, P390, DOI 10.1124/mol.56.2.390; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; LU SJ, 1995, CANCER RES, V55, P1139; Mandic A, 2001, MELANOMA RES, V11, P11, DOI 10.1097/00008390-200102000-00002; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MAZZONI A, 1990, ONCOLOGY, V47, P488; Memoli S, 1997, BBA-LIPID LIPID MET, V1346, P61, DOI 10.1016/S0005-2760(97)00018-0; Merienne K, 2000, ONCOGENE, V19, P4221, DOI 10.1038/sj.onc.1203712; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Nehme A, 1997, CANCER RES, V57, P3253; Nishioka E, 1999, MELANOMA RES, V9, P433, DOI 10.1097/00008390-199910000-00002; Olivares C, 2001, BIOCHEM J, V354, P131, DOI 10.1042/bj3540131; Pak BJ, 2000, MELANOMA RES, V10, P499, DOI 10.1097/00008390-200010000-00013; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; Rosengren E, 1998, MELANOMA RES, V8, P469, DOI 10.1097/00008390-199810000-00013; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; WOLF CR, 1987, INT J CANCER, V39, P695, DOI 10.1002/ijc.2910390607; YAN MH, 1994, J BIOL CHEM, V269, P19067	36	55	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					30	38		10.1038/sj.onc.1207007	http://dx.doi.org/10.1038/sj.onc.1207007			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712208				2022-12-17	WOS:000187895300004
J	Eberle, J; Fecker, LF; Hossini, AM; Wieder, T; Daniel, PT; Orfanos, CE; Geilen, CC				Eberle, J; Fecker, LF; Hossini, AM; Wieder, T; Daniel, PT; Orfanos, CE; Geilen, CC			CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants	ONCOGENE			English	Article						CD95L/FasL; melanoma; transfection; apoptosis	CERAMIDE-MEDIATED APOPTOSIS; DRUG-INDUCED APOPTOSIS; FAS-LIGAND; SURFACE-ANTIGENS; TUMOR-REGRESSION; MONOCLONAL-ANTIBODY; DEATH RECEPTORS; GENE-EXPRESSION; CANCER CELLS; IN-VIVO	The significance of CD95/Fas ligand expression by melanoma cells has remained a controversial matter in recent years. On the other hand, CD95 activation may represent a powerful tool for eliminating tumor cells. Here, we demonstrate expression of CD95 in 15/17 human melanoma cell lines analysed, but complete lack of CD95 ligand (CD95L). Overexpression of CD95 in a tetracycline-inducible expression system enhanced melanoma cell sensitivity to CD95 ligation but was unable to trigger apoptosis by itself. In clear contrast, all melanoma cells tested responded with increased apoptosis to conditional expression of CD95L (2-10-fold), both after transient and after stable transfection. Activation of caspase-8, Bid cleavage, cytochrome c release and caspase-3 activation followed after CD95L induction indicating a functional CD95-signaling cascade. CD95L was also able to enhance the proapoptotic effect of chemotherapeutics applied in parallel. Nude mouse experiments revealed that tumorigenicity was lost when melanoma xenografts were triggered to express CD95L. In addition, further progression of pre-existing melanomas was inhibited and even regression was seen after induction of CD95L expression. Due to these data, transfection of CD95L proofs as a highly efficient tool against melanoma cells in vitro and in vivo, and targeted expression of CD95L may thus represent a suitable strategy for melanoma therapy.	Charite Univ Med Berlin, Dept Dermatol, D-14195 Berlin, Germany; Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Eberle, J (corresponding author), Charite Univ Med Berlin, Dept Dermatol, Campus Benjamin Franklin,Fabeckstr 60-62, D-14195 Berlin, Germany.			Eberle, Jurgen/0000-0001-8533-1519				Ambar BB, 1999, HUM GENE THER, V10, P1641, DOI 10.1089/10430349950017644; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Aragane Y, 2000, J INVEST DERMATOL, V115, P1008, DOI 10.1046/j.1523-1747.2000.00164.x; Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; BEAN MA, 1975, CANCER RES, V35, P2902; Behrens CK, 2001, J IMMUNOL, V166, P3240, DOI 10.4049/jimmunol.166.5.3240; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BRUGGEN J, 1981, CANCER IMMUNOL IMMUN, V10, P121; Bullani RR, 2002, MELANOMA RES, V12, P263, DOI 10.1097/00008390-200206000-00010; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; Chappell DB, 1999, CANCER RES, V59, P59; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CONEY LR, 1994, INT J CANCER, V58, P562, DOI 10.1002/ijc.2910580419; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; DHEIN J, 1992, J IMMUNOL, V149, P3166; EBERLE J, 1995, ARCH DERMATOL RES, V287, P421, DOI 10.1007/BF00373422; Eberle J, 2002, BRIT J CANCER, V86, P1957, DOI 10.1038/sj.bjc.6600351; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gross A, 2001, IUBMB LIFE, V52, P231, DOI 10.1080/15216540152846046; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hedlund TE, 1999, CELL DEATH DIFFER, V6, P175, DOI 10.1038/sj.cdd.4400477; Helmbach H, 2001, INT J CANCER, V93, P617, DOI 10.1002/ijc.1378; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; LOCKSHIN A, 1985, CANCER RES, V45, P345; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; Muschen M, 2000, J MOL MED-JMM, V78, P312, DOI 10.1007/s001090000112; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Okamoto S, 1999, J SURG RES, V84, P77, DOI 10.1006/jsre.1999.5613; Park BJ, 1999, HUM GENE THER, V10, P889, DOI 10.1089/10430349950018292; Pruschy M, 2001, INT J RADIAT ONCOL, V49, P561, DOI 10.1016/S0360-3016(00)01480-2; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Redondo P, 2002, BRIT J DERMATOL, V147, P80, DOI 10.1046/j.1365-2133.2002.04745.x; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Shinoura N, 2000, CANCER GENE THER, V7, P732, DOI 10.1038/sj.cgt.7700160; Sieg S, 1999, CELL IMMUNOL, V195, P89, DOI 10.1006/cimm.1999.1530; Strater J, 2001, CELL DEATH DIFFER, V8, P273, DOI 10.1038/sj.cdd.4400813; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Timmer T, 2002, J PATHOL, V196, P125, DOI 10.1002/path.1028; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	54	55	58	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9131	9141		10.1038/sj.onc.1207228	http://dx.doi.org/10.1038/sj.onc.1207228			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668794				2022-12-17	WOS:000187149100003
J	Zhang, XQ; Kondrikov, D; Yuan, TC; Lin, FF; Hansen, J; Lin, MF				Zhang, XQ; Kondrikov, D; Yuan, TC; Lin, FF; Hansen, J; Lin, MF			Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen ablation; neuroendocrine differentiation; receptor protein tyrosine phosphatase alpha; ERK/MAPK	MAP KINASE CASCADES; NERVE GROWTH-FACTOR; ACID-PHOSPHATASE; NEURONAL DIFFERENTIATION; REGULATED KINASE; TUMOR-CELLS; PC12 CELLS; MEGAKARYOCYTIC DIFFERENTIATION; SUSTAINED ACTIVATION; STIMULATES GROWTH	The neuroendocrine (NE) cells represent the third cell population in the normal prostate. Results of several clinical studies strongly indicate that the NE cell population is greatly increased in prostate carcinomas during androgen ablation therapy that correlates with hormone-refractory growth and poor prognosis. However, the mechanism of NE cell enrichment in prostate carcinoma remains an enigma. We investigated the molecular mechanism by which androgen-sensitive C-33 LNCaP human prostate cancer cells become NE-like cells in an androgen-reduced environment, mimicking clinical phenomenon. In the androgen-depleted condition, androgen-sensitive C-33 LNCaP cells gradually acquired the NE-like morphology and expressed an increased level of neuron-specific enolase (NSE), a classical marker of neuronal cells. Several NE-like subclone cells were established. Biochemical characterizations of these subclone cells showed that receptor-type protein-tyrosine phosphatase alpha (RPTPalpha) is elevated and ERK is constitutively activated, several folds higher than that in parental cells. In androgen-depleted condition, PD98059, an MEK inhibitor, could efficiently block not only the activation of ERK, but also the acquisition of the NE-like morphology and the elevation of NSE in C-33 LNCaP cells. In RPTPa cDNA-transfected C-33 LNCaP cells, ERK was activated and NSE was elevated. In those cells in the presence of PD98059, the ERK activation and NSE elevation were abolished, following a dose-response fashion. Additionally, in constitutively active MEK mutant cDNA-transfected C-33 LNCaP cells, ERK was activated and NSE level was elevated, and cells obtained the NE-like phenotype. Our data collectively indicated that RPTPa signaling via ERK is involved in the NE transdifferentiation of androgen-sensitive C-33 LNCaP human prostate cancer cells in the androgen-depleted condition.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Coll Med, Dept Surg, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Inst, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 984525 Nebraska Med Ctr, Omaha, NE 68198 USA.	mlin@unmc.edu			NCI NIH HHS [CA88184, CA72274] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088184, R01CA072274] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; ABRAHAMSSON PA, 1989, PROSTATE, V14, P71, DOI 10.1002/pros.2990140109; Abrahamsson PA, 1999, ENDOCR-RELAT CANCER, V6, P503, DOI 10.1677/erc.0.0060503; ALMAGRO UA, 1986, ARCH PATHOL LAB MED, V110, P916; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BOLOGNA M, 1989, CANCER, V63, P1714; Bonkhoff H, 1998, PROSTATE, P18; Bonkhoff H, 1996, PROSTATE, V28, P98; BONKHOFF H, 1991, PROSTATE, V19, P91, DOI 10.1002/pros.2990190202; Burchardt T, 1999, J UROLOGY, V162, P1800, DOI 10.1016/S0022-5347(05)68241-9; Chen TS, 1999, CANCER RES, V59, P213; COCKETT ATK, 1993, UROLOGY, V42, P512, DOI 10.1016/0090-4295(93)90260-H; COHEN RJ, 1991, BRIT J UROL, V68, P258, DOI 10.1111/j.1464-410X.1991.tb15318.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cox ME, 1999, CANCER RES, V59, P3821; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; di Sant'Agnese PA, 1998, PROSTATE, P74; Di Sant'Agnese PA, 1998, UROLOGY, V51, P121, DOI 10.1016/S0090-4295(98)00064-8; Diaz M, 1998, PROSTATE, P32; diSantAgnese PA, 1996, CANCER, V78, P357, DOI 10.1002/(SICI)1097-0142(19960715)78:2<357::AID-CNCR27>3.0.CO;2-U; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Fronsdal K, 2000, PROSTATE, V43, P111, DOI 10.1002/(SICI)1097-0045(20000501)43:2<111::AID-PROS5>3.0.CO;2-4; FUKUDA M, 1995, ONCOGENE, V11, P239; Gioeli D, 1999, CANCER RES, V59, P279; GKONOS PJ, 1995, UROL RES, V23, P81, DOI 10.1007/BF00307937; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hu XT, 2000, CELL GROWTH DIFFER, V11, P191; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; IWAMURA M, 1994, UROLOGY, V43, P675, DOI 10.1016/0090-4295(94)90183-X; Iwasaki S, 1996, J BIOL CHEM, V271, P17360, DOI 10.1074/jbc.271.29.17360; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Jongsma J, 2000, CANCER RES, V60, P741; Kim J, 2002, CANCER RES, V62, P1549; Lammers R, 1997, FEBS LETT, V404, P37, DOI 10.1016/S0014-5793(97)00080-X; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lee MS, 2003, ONCOGENE, V22, P781, DOI 10.1038/sj.onc.1206066; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIN MF, 1986, BIOCHEM J, V235, P351, DOI 10.1042/bj2350351; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIN MF, 1992, CANCER RES, V52, P4600; Lin MF, 2001, J UROLOGY, V166, P1943, DOI 10.1016/S0022-5347(05)65725-4; Lin MF, 2000, CELL BIOL INT, V24, P681, DOI 10.1006/cbir.2000.0433; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meng TC, 2000, ONCOGENE, V19, P2664, DOI 10.1038/sj.onc.1203576; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; Mori S, 1999, BIOCHEM BIOPH RES CO, V257, P609, DOI 10.1006/bbrc.1999.0515; Noordzij MA, 1996, AM J PATHOL, V149, P859; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Ruokonen M, 1996, BIOCHEM BIOPH RES CO, V218, P794, DOI 10.1006/bbrc.1996.0141; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Seethalakshmi L, 1997, PROSTATE, V31, P183, DOI 10.1002/(SICI)1097-0045(19970515)31:3<183::AID-PROS7>3.0.CO;2-M; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEUWEN K, 1990, BIOCHEM PHARMACOL, V39, P985, DOI 10.1016/0006-2952(90)90276-Q; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; Shen R, 1997, Urol Oncol, V3, P67, DOI 10.1016/S1078-1439(97)00039-2; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Sundaram M, 1996, BIOESSAYS, V18, P473, DOI 10.1002/bies.950180609; TARLE M, 1994, PROSTATE, V24, P143, DOI 10.1002/pros.2990240308; TETU B, 1987, CANCER, V59, P1803, DOI 10.1002/1097-0142(19870515)59:10<1803::AID-CNCR2820591019>3.0.CO;2-X; Theodorescu D, 1997, CANCER, V80, P2109, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2109::AID-CNCR10>3.0.CO;2-2; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tsai W, 1999, EMBO J, V18, P109, DOI 10.1093/emboj/18.1.109; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; vanInzen WG, 1996, DEV BRAIN RES, V91, P304, DOI 10.1016/0165-3806(95)00186-7; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; Zelivianski S, 2000, MOL CELL BIOCHEM, V208, P11, DOI 10.1023/A:1007010304194; Zelivianski S, 1998, BIOCHEM BIOPH RES CO, V245, P108, DOI 10.1006/bbrc.1998.8386; Zelivianski S, 2001, BBA-MOL CELL RES, V1539, P28, DOI 10.1016/S0167-4889(01)00087-8; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zhang XQ, 2001, J BIOL CHEM, V276, P2544, DOI 10.1074/jbc.M006661200; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1994, J BIOL CHEM, V269, P23302; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	86	55	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6704	6716		10.1038/sj.onc.1206764	http://dx.doi.org/10.1038/sj.onc.1206764			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555984				2022-12-17	WOS:000185799300006
J	Maio, M; Coral, S; Fratta, E; Altomonte, M; Sigalotti, L				Maio, M; Coral, S; Fratta, E; Altomonte, M; Sigalotti, L			Epigenetic targets for immune intervention in human malignancies	ONCOGENE			English	Review						DNA methylation; histone acetylation; cancer; immunotherapy; HLA antigens; tumor antigens	CANCER-TESTIS ANTIGENS; CLASS-I ANTIGENS; 5-AZA-2'-DEOXYCYTIDINE DECITABINE TREATMENT; CYTOLYTIC T-LYMPHOCYTES; SQUAMOUS-CELL CARCINOMA; HUMAN GENE MAGE-1; DNA METHYLATION; MYELODYSPLASTIC SYNDROME; MELANOMA-CELLS; HETEROGENEOUS EXPRESSION	Emerging evidences suggest that epigenetic events associated with tumor development and progression, such as deregulated methylation of CpG dinucleotides and aberrant histone acetylation, may impair the immunogenic potential of cancer cells. In fact, DNA hypermethylation and/or histone deacetylation contribute to the absent or downregulated expression of different components of the 'tumor recognition complex' (i.e., HLA class I antigens, cancer/testis antigens and accessory/costimulatory molecules) in solid and hemopoietic human malignancies. However, pharmacologic agents that induce DNA hypomethylation or inhibit histone deacetylation can modify these epigenetic phenomena, restoring the defective expression of selected components of the 'tumor recognition complex' in cancer cells. These antigenic modi. cations positively modulate the immunogenicity and the immune recognition of cancer cells, making epigenetic drugs attractive agents to design new combined chemoimmunotherapeutic strategies for the treatment of cancer patients.	IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, I-33081 Aviano, Italy	IRCCS Aviano (CRO)	Maio, M (corresponding author), IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, Via Pedemontana Occle 12, I-33081 Aviano, Italy.	mmaio@cro.it	Fratta, Elisabetta/J-8707-2016; Sigalotti, Luca/A-5893-2013; altomonte, maresa/G-7734-2011; Sigalotti, Luca/AAC-2926-2020; Coral, Sandra/AAB-9552-2022	Fratta, Elisabetta/0000-0002-7472-8841; Sigalotti, Luca/0000-0003-3362-5026; Sigalotti, Luca/0000-0002-1436-2358; Maio, Michele/0000-0002-0323-6321; Altomonte, Maresa/0000-0001-8021-1921; coral, sandra/0000-0002-1308-3082				ALTOMONTE M, 1993, CANCER RES, V53, P3343; Arnold JM, 2001, BRIT J CANCER, V85, P1351, DOI 10.1054/bjoc.2001.2075; Boussiotis VA, 1996, IMMUNOL REV, V153, P5, DOI 10.1111/j.1600-065X.1996.tb00918.x; BRASSEUR F, 1992, INT J CANCER, V52, P839, DOI 10.1002/ijc.2910520528; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chambost H, 2001, LEUKEMIA, V15, P1769, DOI 10.1038/sj.leu.2402278; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; Coral S, 1999, J IMMUNOTHER, V22, P16, DOI 10.1097/00002371-199901000-00003; Coral S, 2002, CLIN CANCER RES, V8, P2690; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; De Smet C, 1999, MOL CELL BIOL, V19, P7327; DESMET C, 1995, IMMUNOGENETICS, V42, P282, DOI 10.1007/BF00176446; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; dos Santos NR, 2000, CANCER RES, V60, P1654; EURA M, 1995, INT J CANCER, V64, P304, DOI 10.1002/ijc.2910640504; Fonsatti E, 2003, INT J CANCER, V105, P430, DOI 10.1002/ijc.11077; Fujie T, 1997, ANN ONCOL, V8, P369, DOI 10.1023/A:1008255630202; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Jager E, 2000, P NATL ACAD SCI USA, V97, P4760, DOI 10.1073/pnas.97.9.4760; Jungbluth AA, 2000, BRIT J CANCER, V83, P493, DOI 10.1054/bjoc.2000.1291; Jungbluth AA, 2001, INT J CANCER, V92, P856, DOI 10.1002/ijc.1282; Kienstra MA, 2003, HEAD NECK-J SCI SPEC, V25, P457, DOI 10.1002/hed.10223; Kim JJ, 1999, J CLIN INVEST, V103, P869, DOI 10.1172/JCI6024; Li J, 1996, CLIN CANCER RES, V2, P1619; Luo Guorong, 2002, Cancer Immun, V2, P11; Maeda T, 2000, BLOOD, V96, P3847, DOI 10.1182/blood.V96.12.3847.h8003847_3847_3856; Maio M, 2003, J CLIN ENDOCR METAB, V88, P748, DOI 10.1210/jc.2002-020830; Mashino K, 2001, BRIT J CANCER, V85, P713, DOI 10.1054/bjoc.2001.1974; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Mori M, 1996, ANN SURG, V224, P183, DOI 10.1097/00000658-199608000-00011; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Nie Y, 2001, CARCINOGENESIS, V22, P1615, DOI 10.1093/carcin/22.10.1615; Quillien V, 1997, ANTICANCER RES, V17, P387; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Sandor V, 2002, CLIN CANCER RES, V8, P718; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Scanlan MJ, 2000, CANCER LETT, V150, P155, DOI 10.1016/S0304-3835(99)00385-7; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Seliger B, 2002, SEMIN CANCER BIOL, V12, P3, DOI 10.1006/scbi.2001.0404; Serrano A, 2001, INT J CANCER, V94, P243, DOI 10.1002/ijc.1452; Sigalotti L, 2003, BLOOD, V101, P4644, DOI 10.1182/blood-2002-11-3458; Sigalotti L, 2002, BRIT J CANCER, V86, P979, DOI 10.1038/sj.bjc.6600174; Sigalotti L, 2002, J IMMUNOTHER, V25, P16, DOI 10.1097/00002371-200201000-00002; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Soling A, 1999, ANTICANCER RES, V19, P2205; Traversari C, 1999, MINERVA BIOTECNOL, V11, P243; Tureci O, 1998, INT J CANCER, V77, P19, DOI 10.1002/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2; WEBER J, 1994, CANCER RES, V54, P1766; Weiser TS, 2001, ANN THORAC SURG, V71, P295, DOI 10.1016/S0003-4975(00)02421-8; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Worm J, 2002, J ORAL PATHOL MED, V31, P443, DOI 10.1034/j.1600-0714.2002.00034.x; Zendman AJW, 2003, J CELL PHYSIOL, V194, P272, DOI 10.1002/jcp.10215; Zuckerman LA, 1998, J IMMUNOL, V160, P3259	54	55	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6484	6488		10.1038/sj.onc.1206956	http://dx.doi.org/10.1038/sj.onc.1206956			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528272				2022-12-17	WOS:000185700700004
J	Stampfer, MR; Garbe, J; Nijjar, T; Wigington, D; Swisshelm, K; Yaswen, P				Stampfer, MR; Garbe, J; Nijjar, T; Wigington, D; Swisshelm, K; Yaswen, P			Loss of p53 function accelerates acquisition of telomerase activity in indefinite lifespan human mammary epithelial cell lines	ONCOGENE			English	Article						immortal transformation; telomerase; telomeres; TGF beta; genomic instability; conversion; p53	HUMAN BREAST-CANCER; MUTANT P53-INDUCED IMMORTALIZATION; HUMAN-PAPILLOMAVIRUS TYPE-16; CARCINOMA IN-SITU; HUMAN FIBROBLASTS; TUMOR-CELLS; EXPRESSION; GENE; TRANSFORMATION; PROTEIN	We describe novel effects of p53 loss on immortal transformation, based upon comparison of immortally transformed human mammary epithelial cell (HMEC) lines lacking functional p53 with closely related p53(+) lines. Our previous studies of p53(+) immortal HMEC lines indicated that overcoming the stringent replicative senescence step associated with critically short telomeres (agonescence), produced indefinite lifespan lines that maintained growth without immediately expressing telomerase activity. These telomerase(-) 'conditionally immortal' HMEC underwent an additional step, termed conversion, to become fully immortal telomerase( +) lines with uniform good growth. The very gradual conversion process was associated with slow heterogeneous growth and high expression of the cyclin-dependent kinase inhibitor p57(Kip2). We now show that p53 suppresses telomerase activity and is necessary for the p57 expression in early passage p53(+) conditionally immortal HMEC lines, and that p53(-/-) lines exhibit telomerase reactivation and attain full immortality much more rapidly. A p53-inhibiting genetic suppressor element introduced into early passages of a conditionally immortal telomerase(-) p53(+) HMEC line led to rapid induction of hTERT mRNA, expression of telomerase activity, loss of p57 expression, and quick attainment of uniform good growth. These studies indicate that derangements in p53 function may impact malignant progression through direct effects on the conversion process, a potentially rate-limiting step in HMEC acquisition of uniform unlimited growth potential. These studies also provide evidence that the function of p53 in suppression of telomerase activity is separable from its cell cycle checkpoint function.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Washington; University of Washington Seattle	Stampfer, MR (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Bldg 70A1118, Berkeley, CA 94720 USA.				NCI NIH HHS [CA24844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA024844, R01CA024844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Allred DC, 2000, J MAMMARY GLAND BIOL, V5, P351, DOI 10.1023/A:1009573710675; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bacchetti S, 1996, CANCER SURV, V28, P197; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bednarek AK, 1997, CLIN CANCER RES, V3, P11; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Bunz F, 2002, CANCER RES, V62, P1129; Cao YA, 1997, CANCER RES, V57, P5584; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Chang S, 2001, SEMIN CANCER BIOL, V11, P227, DOI 10.1006/scbi.2000.0374; CLARK R, 1988, CANCER RES, V48, P4689; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Done SJ, 1998, CANCER RES, V58, P785; FINER MH, 1994, BLOOD, V83, P43; Gao QS, 1996, CANCER RES, V56, P3129; Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523; Gollahon LS, 1996, ONCOGENE, V12, P715; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HERMAN JG, 1995, CANCER RES, V55, P4525; Iacopetta B, 1998, CLIN CANCER RES, V4, P1597; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Nijjar T, 1999, CANCER RES, V59, P5112; Nonet GH, 2001, CANCER RES, V61, P1250; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Poremba C, 1999, J CLIN ONCOL, V17, P2020, DOI 10.1200/JCO.1999.17.7.2020; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1993, ONCOGENE, V8, P1407; Shpitz B, 1999, BREAST CANCER RES TR, V58, P65, DOI 10.1023/A:1006394209922; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STAMPFER MR, 2001, ADV CELL AGING GERON, V8, P103; STAMPFER MR, 1988, BREAST CANCER CELLUL, P1; Sugino T, 1996, INT J CANCER, V69, P301, DOI 10.1002/(SICI)1097-0215(19960822)69:4<301::AID-IJC11>3.0.CO;2-8; Tlsty TD, 2001, J MAMMARY GLAND BIOL, V6, P235, DOI 10.1023/A:1011369026168; WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890	57	55	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5238	5251		10.1038/sj.onc.1206667	http://dx.doi.org/10.1038/sj.onc.1206667			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917625				2022-12-17	WOS:000184734900003
J	Kunapuli, P; Chitta, KS; Cowell, JK				Kunapuli, P; Chitta, KS; Cowell, JK			Suppression of the cell proliferation and invasion phenotypes in glioma cells by the LGI1 gene	ONCOGENE			English	Article						LGI1; tumor suppressor gene; brain tumors; leucine-rich repeat; tumor invasion	MALIGNANT BRAIN-TUMORS; GLIOBLASTOMA-MULTIFORME; CHROMOSOME-10; HETEROZYGOSITY; PTEN; IDENTIFICATION; PROGRESSION; ASTROCYTOMA; MUTATIONS; REGIONS	The leucine-rich, glioma-inactivated (LGI1) gene, located in 10q24, was originally identified because it was interrupted and inactivated by a reciprocal chromosome translocation in the T98G glioma cell line. Loss of LGI1 expression in high-grade brain tumors is correlated with the frequent loss of chromosome 10 during progression of gliomas. To investigate whether this gene can suppress the malignant phenotype in glioma cells, we introduced the LGI1 gene into cells that do (U87) and do not (T98G and A172) express LGI1 endogenously. A172 and T98G cells showed a significant reduction in cell proliferation potential as a result of re-expression of LGI1, whereas U87 cells did not. Using BD matrigel matrix chamber assays we were also able to show that the migration ability of the reconstituted A172 and T98G cells was also reduced considerably. Finally, these reconstituted T98G and A172 cells showed a significant reduction in the ability to form colonies in soft agar compared with the parental cells. This analysis clearly demonstrates that re-expression of the LGI1 gene in glioma cells that were null for its activity can greatly reduce their malignant potential. These observations provide the opportunity to investigate the role of LGI1 in gliomagenesis and, since LGI1 is predicted to be a membrane-bound protein, potentially provides the opportunity to develop novel treatment strategies for malignant gliomas.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.			Cowell, John/0000-0002-2079-5950				Albarosa R, 1996, AM J HUM GENET, V58, P1260; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; Chernova OB, 2001, ONCOGENE, V20, P5378, DOI 10.1038/sj.onc.1204694; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Jacobs JR, 2000, PROG NEUROBIOL, V62, P475, DOI 10.1016/S0301-0082(00)00016-2; JAMES CD, 1988, CANCER RES, V48, P5546; KARLBOM AE, 1993, HUM GENET, V92, P169; Kleihues P, 2000, PATHOLOGY GENETICS T; Krex D, 2002, ACTA NEUROPATHOL, V103, P255, DOI 10.1007/s004010100463; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MYERS PM, 1997, P NATL ACAD SCI USA, V94, P9502; Papazisis KT, 1997, J IMMUNOL METHODS, V208, P151, DOI 10.1016/S0022-1759(97)00137-3; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; PONTEN J, 1968, ACTA PATHOL MIC SC, V74, P465; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Rasheed BKA, 1997, CANCER RES, V57, P4187; Sasaki H, 2002, CANCER RES, V62, P1790; Somerville RPT, 2000, MAMM GENOME, V11, P622, DOI 10.1007/s0033500101280; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Wang SI, 1997, CANCER RES, V57, P4183	31	55	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					3985	3991		10.1038/sj.onc.1206584	http://dx.doi.org/10.1038/sj.onc.1206584			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821932				2022-12-17	WOS:000183707600001
J	Kyng, KJ; May, A; Brosh, RM; Cheng, WH; Chen, C; Becker, KG; Bohr, VA				Kyng, KJ; May, A; Brosh, RM; Cheng, WH; Chen, C; Becker, KG; Bohr, VA			The transcriptional response after oxidative stress is defective in Cockayne syndrome group B cells	ONCOGENE			English	Article						microarray; Cockayne syndrome; transcription; DNA repair; DNA damage; aging	RNA-POLYMERASE-II; ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION PROFILE; BASE EXCISION-REPAIR; HEAT-SHOCK PROTEINS; CALORIC RESTRICTION; HYDROGEN-PEROXIDE; GENOME-WIDE; DNA-REPAIR; SKIN FIBROBLASTS	Cockayne syndrome (CS) is a human hereditary disease belonging to the group of segmental progerias, and the clinical phenotype is characterized by postnatal growth failure, neurological dysfunction, cachetic dwarfism, photosensitivity, sensorineural hearing loss, and retinal degradation. CS-B cells are defective in transcription-coupled DNA repair, base excision repair, transcription, and chromatin structural organization. Using array analysis, we have examined the expression profile in CS complementation group B (CS-B) fibroblasts after exposure to oxidative stress (H2O2) before and after complete complementation with the CSB gene. The following isogenic cell lines were compared: CS-B cells (CS-B null), CS-B cells complemented with wild-type CSB (CS-B wt), and a stably transformed cell fine with a point mutation in the ATPase domain of CSB (CS-B ATPase mutant). In the wt rescued cells, we detected significant induction ( > two-fold) of 112 genes out of the 6912 analysed. The patterns suggested an induction or upregulation of genes involved in several DNA metabolic processes including DNA repair, transcription, and signal transduction. In both CS-B mutant cell lines, we found a general deficiency in transcription after oxidative stress, suggesting that the CSB protein influenced the regulation of transcription of certain genes. Of the 6912 genes, 122 were differentially regulated by more than two-fold. Evidently, the ATPase function of CSB is biologically important as the deficiencies seen in the ATPase mutant cells are very similar to those observed in the CS-B-null cells. Some major defects are in the transcription of genes involved in DNA repair, signal transduction, and ribosomal functions.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; NIA, DNA Array Unit, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bohr, VA (corresponding author), Aarhus Univ, Danish Ctr Mol Gerontol, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark.		Bohr, Vilhelm/AAP-5931-2020; Kyng, Kasper/AAA-5339-2019	Kyng, Kasper/0000-0001-7940-1656; Becker, Kevin/0000-0002-6794-6656	NATIONAL INSTITUTE ON AGING [Z01AG000731] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; Balajee AS, 2000, GENE, V250, P15, DOI 10.1016/S0378-1119(00)00172-4; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; De Wit R, 2001, FASEB J, V15, P306; Dhar V, 1996, CELL GROWTH DIFFER, V7, P841; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Friedberg EC, 1996, BIOESSAYS, V18, P731, DOI 10.1002/bies.950180908; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Hollenbach S, 1999, CARCINOGENESIS, V20, P1863, DOI 10.1093/carcin/20.9.1863; Huang CS, 2001, J BIOL CHEM, V276, P40234, DOI 10.1074/jbc.M103684200; Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KEYSE SM, 1987, J BIOL CHEM, V262, P14821; Kim SW, 2001, J BIOL CHEM, V276, P10199, DOI 10.1074/jbc.M010640200; Krokan HE, 1997, BIOCHEM J, V325, P1; Krokan HE, 2001, PROG NUCLEIC ACID RE, V68, P365; KUO ML, 1995, BBA-MOL CELL RES, V1268, P229, DOI 10.1016/0167-4889(95)00076-5; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lee HM, 2002, J NEUROCHEM, V80, P928, DOI 10.1046/j.0022-3042.2002.00774.x; Lee SK, 2001, MOL CELL BIOL, V21, P8651, DOI 10.1128/MCB.21.24.8651-8656.2001; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Miller RA, 2001, J GERONTOL A-BIOL, V56, pB52, DOI 10.1093/gerona/56.2.B52; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; PARSONS R, 1995, CANCER RES, V55, P5548; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selzer RR, 2002, NUCLEIC ACIDS RES, V30, P782, DOI 10.1093/nar/30.3.782; Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Tuo J, 2001, J BIOL CHEM, V276, P45772, DOI 10.1074/jbc.M107888200; TYRRELL RM, 1994, METHOD ENZYMOL, V234, P224; Wang YX, 2000, INT J ONCOL, V16, P757; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weindruch R, 2002, MECH AGEING DEV, V123, P177, DOI 10.1016/S0047-6374(01)00344-X; Wheaton K, 1996, BIOCHEM CELL BIOL, V74, P523, DOI 10.1139/o96-056; Yu AD, 2000, MOL CELL, V5, P801, DOI 10.1016/S1097-2765(00)80320-2; Zhao RB, 2000, GENE DEV, V14, P981; Zou S, 2000, P NATL ACAD SCI USA, V97, P13726, DOI 10.1073/pnas.260496697	55	55	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1135	1149		10.1038/sj.onc.1206187	http://dx.doi.org/10.1038/sj.onc.1206187			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606941				2022-12-17	WOS:000181249700003
J	Plymate, SR; Haugk, KH; Sprenger, CC; Nelson, PS; Tennant, MK; Zhang, YP; Oberley, LW; Zhong, WX; Drivdahl, R; Oberley, TD				Plymate, SR; Haugk, KH; Sprenger, CC; Nelson, PS; Tennant, MK; Zhang, YP; Oberley, LW; Zhong, WX; Drivdahl, R; Oberley, TD			Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1	ONCOGENE			English	Article						SOD-2; Mac25; prostate; cancer; IGFBP-rP1	EPITHELIAL-CELLS; EXPRESSION; APOPTOSIS; P53; OVEREXPRESSION; FIBROBLASTS; INHIBITION; SENESCENCE; IGFBP-RP1; SUBLINES	Increased expression of mac25/insulin-like growth factor binding-protein related protein-1 (IGFBP-rP1) in human breast and prostate epithelial cell lines results in the suppression of tumor growth. CDNA expression array analysis revealed increased manganese superoxide dismutase (SOD-2) expression in the mac25/IGFBP-rP1-transfected M12 human prostate cancer cell line compared to M12 control cells. SOD-2 has been postulated to be a tumor suppressor. SOD-2 was also increased in LNCaP cells stably transfected with mac25/IGFBP-rP1, but not in mac25/IGFBP-rP1-transfected PC-3 cells. Mac25 LNCaP cells had a marked decrease in tumor growth in nude mice compared to controls, but there was no difference in tumor growth in mac25 PC-3 cells compared to control. Phosphorylated Erk and Akt were increased in the M12 and LNCaP transfected mac25/ IGFBP-rP1 cells but not PC-3 mac25. Inhibition of PI-3 kinase results in a marked decrease in viability of the M12-mac25 cells compared to M12 controls. Cells treated with H2O2 result, in an increase in phospho-ERK. Transfection of SOD-2 in M12 cells markedly decreased tumor growth, apoptosis, G1 delay in the cell cycle, and expression of senescence associated beta-galactosidase. These results suggest that one of the downstream mediators of the senescence-associated tumor suppression effect of mac25/IGFBP-rP1 is SOD-2.	Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Mol, Seattle, WA 98105 USA; Univ Washington, Sch Med, Cell Biol Program, Seattle, WA 98105 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98107 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53705 USA; William S Middleton Mem Vet Adm Med Ctr, Pathol Serv, Madison, WI 53705 USA	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Iowa; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	Plymate, SR (corresponding author), Univ Washington, Harborview Med Ctr, 325 9Th Ave,Box 359755, Seattle, WA 98104 USA.	splymate@u.washington.edu			NATIONAL CANCER INSTITUTE [P01CA085859] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052683] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA 85859] Funding Source: Medline; NIDDK NIH HHS [DK52683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAE V, 1995, P AM ASS CANC RES CA, V642, P55; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Baker AM, 1997, PROSTATE, V32, P229, DOI 10.1002/(SICI)1097-0045(19970901)32:4<229::AID-PROS1>3.0.CO;2-E; Birkenkamp KU, 1999, LEUKEMIA, V13, P1037, DOI 10.1038/sj.leu.2401447; BIRNBAUM RS, 1994, J ENDOCRINOL, V141, P535, DOI 10.1677/joe.0.1410535; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Bostwick DG, 2000, CANCER, V89, P123, DOI 10.1002/1097-0142(20000701)89:1<123::AID-CNCR17>3.0.CO;2-9; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; deHaan JB, 1996, HUM MOL GENET, V5, P283, DOI 10.1093/hmg/5.2.283; Hawkins V, 1999, NUCLEIC ACIDS RES, V27, P204, DOI 10.1093/nar/27.1.204; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Hwa V, 1998, J CLIN ENDOCR METAB, V83, P4355, DOI 10.1210/jc.83.12.4355; HWA V, 1998, ACTA PAEDIATR SCAND, V428, P37; JacksonCook C, 1996, CANCER GENET CYTOGEN, V87, P14, DOI 10.1016/0165-4608(95)00232-4; Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455; Kim KH, 2001, ANTIOXID REDOX SIGN, V3, P361, DOI 10.1089/15230860152409013; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; Oberley TD, 1997, HISTOL HISTOPATHOL, V12, P525; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Plymate SR, 1996, J CLIN ENDOCR METAB, V81, P3709, DOI 10.1210/jc.81.10.3709; Pritchard CC, 2001, P NATL ACAD SCI USA, V98, P13266, DOI 10.1073/pnas.221465998; RHEE SG, 2000, SCI STKE, P1; Sachdeva RM, 2001, AM J HUM GENET, V69, P261; Sprenger CC, 1999, CANCER RES, V59, P2370; Sprenger CC, 2002, ONCOGENE, V21, P140, DOI 10.1038/sj.onc.1205021; Wartenberg M, 1999, J BIOL CHEM, V274, P27759, DOI 10.1074/jbc.274.39.27759; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Wilson EM, 2001, J CLIN ENDOCR METAB, V86, P4504, DOI 10.1210/jc.86.9.4504; Zhong WX, 2001, CANCER RES, V61, P7071	34	55	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					1024	1034		10.1038/sj.onc.1206210	http://dx.doi.org/10.1038/sj.onc.1206210			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592389				2022-12-17	WOS:000180926100008
J	Lu, WC; Liu, YN; Kang, BB; Chen, JH				Lu, WC; Liu, YN; Kang, BB; Chen, JH			Trans-activation of heparanase promoter by ETS transcription factors	ONCOGENE			English	Article						ETS; heparanase promoter; tumor metastasis	MAMMALIAN HEPARANASE; PROTEIN; CLONING; CANCER; INVASION	The remodeling of extracellular matrix (ECM) is an important process required for cancer cells to turn into invasive and metastatic cancer cells. To dissolve the protein components of ECM, matrix metalloproteinases are some of the essential enzymes. Another ECM remodeling enzyme is the heparanase (Hpa) that digests the heparin sulfate component of the matrix. In metastatic cancer cells the Hpa gene is upregulated. To investigate the mechanism of why Hpa was upregulated in metastatic cancer cells, the regulatory sequence of heparanase gene was isolated and its function analysed in metastatic breast cancer cells. We found there are four ETS transcription factor binding sites. Two of them flanking the transcription initiation of the Hpa gene are nonfunctional, whereas two others are highly functional and responded to exogenously added ETS transcription factors. Mutation of these two ETS binding sites abolished the transcriptional activation of Hpa promoter by ETS transcription factors. Among four transcription factors tested (ETS1, ETS2, PEA3, and ER81), ETS1 and ETS2 are more potent in transactivating the human Hpa gene. Furthermore, dominant-negative ETS transcription factors failed to transactivate Hpa promoter and could abrogate the function of wild-type transcription factor in transactivation activity of ETS transcription factors on the Hpa promoter. These results suggest that ETS transcription factors play an important role in tumor invasion and metastasis by modulating the remodeling of ECM.	Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien, Taiwan; Tzu Chi Univ, Grad Inst Human Genet, Hualien, Taiwan; Tzu Chi Univ, Coll Med, Dept Med Technol, Hualien, Taiwan	Tzu Chi University; Tzu Chi University; Tzu Chi University	Chen, JH (corresponding author), Tzu Chi Univ, Grad Inst Mol & Cell Biol, 701 Chung Yang Rd,Sec 3, Hualien, Taiwan.	jhc@mail.tcu.edu.tw	LU, Wei-Cheng/O-5577-2017					Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen JH, 1996, ONCOGENE, V13, P1667; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Dong J, 2000, GENE, V253, P171, DOI 10.1016/S0378-1119(00)00251-1; Eccles SA, 1999, NAT MED, V5, P735, DOI 10.1038/10455; FOLKMAN J, 1997, CANC MED, P181; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Hiroumi H, 2001, INT J CANCER, V93, P786, DOI 10.1002/ijc.1410; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; KOHN EC, 1995, CANCER RES, V55, P1856; NICOLSON GL, 1993, CANCER METAST REV, V12, P325, DOI 10.1007/BF00665961; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8	19	55	57	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					919	923		10.1038/sj.onc.1206201	http://dx.doi.org/10.1038/sj.onc.1206201			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584571				2022-12-17	WOS:000180864300014
J	Knockaert, M; Lenormand, P; Gray, N; Schultz, P; Pouyssegur, J; Meijer, L				Knockaert, M; Lenormand, P; Gray, N; Schultz, P; Pouyssegur, J; Meijer, L			p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol	ONCOGENE			English	Article						kinases; inhibitors; CDKs; MAPK; erk; purvalanol	CYCLIN-DEPENDENT KINASE; ACTIVATED PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE-3-BETA; P70 S6 KINASE; CELL-CYCLE; NUCLEAR TRANSLOCATION; CHEMICAL INHIBITORS; SELECTIVE INHIBITOR; ALZHEIMERS-DISEASE; CRYSTAL-STRUCTURE	Chemical inhibitors of cyclin-dependent kinases (CDKs) have a great therapeutic potential against various proliferative and neurodegenerative disorders. Intensive screening of a combinatorial chemistry library of 2,6,9-trisubstituted purines has led to the identification of purvalanol, one of the most potent and selective CDK inhibitors to date. In preliminary studies, this compound demonstrates definite anti-mitotic properties, consistent with its nanomolar range efficiency towards purified CDK1 and CDK2. However, the actual intracellular targets of purvalanol remain to be identified, and a method for the determination of its in vivo selectivity was developed. In this technique, cell extracts were screened for purvalanol-interacting proteins by affinity chromatography on immobilized inhibitor. In addition to CDK1, p42/p44 MAPK were found to be two major purvalanol-interacting proteins in five different mammalian cell lines (CCL39, PC12, HBL100, MCF-7 and Jurkat cells), suggesting the generality of the purvalanol/p42/p44 MAPK interaction. The Chinese hamster lung fibroblast cell line CCL39 was used as a model to investigate the anti-proliferative properties of purvalanol. The compound inhibited cell growth with a GI(50) value of 2.5 muM and induced a G2/M block when added to exponentially growing cells. It did not appear to trigger massive activation of caspase. We next tested whether CDKs and p42/p44 MAPK were actually targeted by the compound in vivo. p42/p44 MAPK activity was visuatized using an Elk-Gal4 luciferase reporter system and CDK1 activity was detected by the phosphonucleolin level. When cells were treated with purvalanol, p42/p44 MAPK and CDK1 activities were inhibited in a dose-dependent manner. Furthermore, purvalanol inhibited the nuclear accumulation of p42/p44 MAPK, an event dependent on the catalytic activity of these kinases. We conclude that the anti-proliferative properties of purvalanol are mediated by inhibition of both p42/p44 MAPK and CDKs. These observations highlight the potency of moderate selectivity compounds and encourage the search for new therapeutics which simultaneously target distinct but relevant pathways of cell proliferation.	CNRS, Stn Biol Roscoff, F-29682 Roscoff, France; Ctr Antoine Lacassagne, UNSA, CNRS, UMR 6453, F-06189 Nice, France; Novartis Inst Funct Genom, San Diego, CA 92121 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; Novartis	Meijer, L (corresponding author), CNRS, Stn Biol Roscoff, BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr	Lenormand, Philippe/N-5996-2018	, laurent/0000-0003-3511-4916				Arris CE, 2000, J MED CHEM, V43, P2797, DOI 10.1021/jm990628o; Barvian M, 2000, J MED CHEM, V43, P4606, DOI 10.1021/jm000271k; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Brooks EE, 1997, J BIOL CHEM, V272, P29207, DOI 10.1074/jbc.272.46.29207; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Carini DJ, 2001, BIOORG MED CHEM LETT, V11, P2209, DOI 10.1016/S0960-894X(01)00416-4; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Clare PM, 2001, J BIOL CHEM, V276, P48292, DOI 10.1074/jbc.M102034200; Damiens E, 2000, PATHOL BIOL, V48, P340; Davis ST, 2001, SCIENCE, V291, P134, DOI 10.1126/science.291.5501.134; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Dranovsky A, 2001, NEUROBIOL AGING, V22, P517, DOI 10.1016/S0197-4580(00)00248-7; Dreyer MK, 2001, J MED CHEM, V44, P524, DOI 10.1021/jm001043t; DUNPHY WG, 1997, METHOD ENZYMOL, V283, P1; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Fischer PM, 2000, CURR MED CHEM, V7, P1213, DOI 10.2174/0929867003374048; Fry DW, 2001, J BIOL CHEM, V276, P16617, DOI 10.1074/jbc.M008867200; Garrett MD, 1999, CURR OPIN GENET DEV, V9, P104, DOI 10.1016/S0959-437X(99)80015-X; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gray N, 1999, CURR MED CHEM, V6, P859; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Hardcastle IR, 2002, ANNU REV PHARMACOL, V42, P325, DOI 10.1146/annurev.pharmtox.42.090601.125940; Herrera R, 2002, TRENDS MOL MED, V8, pS27, DOI 10.1016/S1471-4914(02)02307-9; HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jeong HW, 2000, BIOORG MED CHEM LETT, V10, P1819, DOI 10.1016/S0960-894X(00)00357-7; Kaiser A, 2001, ARCH BIOCHEM BIOPHYS, V386, P179, DOI 10.1006/abbi.2000.2220; Kaubisch A, 2000, CANCER J, V6, P192; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; Kent LL, 1999, BIOCHEM BIOPH RES CO, V260, P768, DOI 10.1006/bbrc.1999.0891; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; Knockaert M, 2002, J BIOL CHEM, V277, P25493, DOI 10.1074/jbc.M202651200; KNOCKAERT M, 2002, IN PRESS TRENDS PHAR; Lane ME, 2001, CANCER RES, V61, P6170; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Legraverend M, 2000, J MED CHEM, V43, P1282, DOI 10.1021/jm9911130; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Leost M, 2000, EUR J BIOCHEM, V267, P5983, DOI 10.1046/j.1432-1327.2000.01673.x; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Malumbres M, 2000, BIOL CHEM, V381, P827, DOI 10.1515/BC.2000.105; Mani S, 2000, EXPERT OPIN INV DRUG, V9, P1849, DOI 10.1517/13543784.9.8.1849; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Meijer L, 2000, DRUG RESIST UPDATE, V3, P83, DOI 10.1054/drup.2000.0129; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NEANT I, 1988, EXP CELL RES, V176, P68, DOI 10.1016/0014-4827(88)90121-8; Nugiel DA, 2001, J MED CHEM, V44, P1334, DOI 10.1021/jm0100032; Oikonomakos NG, 2000, J BIOL CHEM, V275, P34566, DOI 10.1074/jbc.M004485200; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Park SG, 1996, MOL CELLS, V6, P679; PARKER CW, 1986, PHYTOCHEMISTRY, V25, P303, DOI 10.1016/S0031-9422(00)85471-0; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; RIALET V, 1991, ANTICANCER RES, V11, P1581; Rosania GR, 1999, P NATL ACAD SCI USA, V96, P4797, DOI 10.1073/pnas.96.9.4797; ROSANIA GR, 2000, EXPERT OPIN THER PAT, V10, P1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schang LM, 2002, J VIROL, V76, P7874, DOI 10.1128/JVI.76.15.7874-7882.2002; Schnier JB, 1999, FEBS LETT, V454, P100, DOI 10.1016/S0014-5793(99)00773-5; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; Shewchuk L, 2000, J MED CHEM, V43, P133, DOI 10.1021/jm990401t; Shum PW, 2001, NUCLEOS NUCLEOT NUCL, V20, P1067, DOI 10.1081/NCN-100002493; Sielecki TM, 2001, BIOORG MED CHEM LETT, V11, P1157, DOI 10.1016/S0960-894X(01)00185-8; Sielecki TM, 2000, J MED CHEM, V43, P1, DOI 10.1021/jm990256j; Soni R, 2000, BIOCHEM BIOPH RES CO, V275, P877, DOI 10.1006/bbrc.2000.3349; Soni R, 2001, JNCI-J NATL CANCER I, V93, P436, DOI 10.1093/jnci/93.6.436; Toogood PL, 2001, MED RES REV, V21, P487, DOI 10.1002/med.1021; URBANI L, 1995, EXP CELL RES, V219, P159, DOI 10.1006/excr.1995.1216; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Villerbu N, 2002, INT J CANCER, V97, P761, DOI 10.1002/ijc.10125; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143; Zaharevitz DW, 1999, CANCER RES, V59, P2566; ZIMMERMANN J, 1995, Patent No. 9509853	89	55	60	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6413	6424		10.1038/sj.onc.1205908	http://dx.doi.org/10.1038/sj.onc.1205908			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226745	Bronze			2022-12-17	WOS:000177925300002
J	Forbes, LV; Gale, RE; Pizzey, A; Pouwels, K; Nathwani, A; Linch, DC				Forbes, LV; Gale, RE; Pizzey, A; Pouwels, K; Nathwani, A; Linch, DC			An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia	ONCOGENE			English	Article						point mutation; constitutive activation; helix-helix interaction; asparagine	CELL-SURFACE RECEPTORS; RAS GENE-MUTATIONS; ERYTHROPOIETIN RECEPTOR; HEMATOPOIETIC-CELLS; POINT MUTATIONS; BETA-SUBUNIT; IN-VIVO; N-RAS; G-CSF; DIFFERENTIATION	To date, constitutively activating point mutations reported in hematopoietic growth factor receptors in patients with acute myeloid leukemia (AML) have been restricted to receptors with intrinsic tyrosine kinase activity such as c-kit and FLT3. We describe here a Thr617Asn mutation in the transmembrane domain of the non-tyrosine kinase receptor for granulocyte colony-stimulating factor (G-CSF) in the blast cells of two out of 555 AML patients examined. The mutant receptor conferred growth factor independence on factor-dependent Ba/F3 cells. In the absence of ligand, immunoblotting showed weak phosphorylation of JAK2, STAT3, ERKs 1 and 2 and the receptor itself, and there was approximately 70% of maximal growth in a proliferation assay. All signals were significantly enhanced in the presence of G-CSF. Retroviral transduction of mutant receptor into primary hematopoietic CD34+ cells induced G-CSF independent myeloid differentiation as assessed by the development of neutrophils and surface expression of CD11b and CD14. These results confirm the importance of the transmembrane domain for receptor function and suggest that introduction of an asparagine residue can cause sufficient stabilization of helix-helix interactions in the absence of ligand to activate downstream signaling pathways involved in directing proliferation and differentiation.	UCL, Dept Haematol, London WC1E 6HX, England	University of London; University College London	Gale, RE (corresponding author), UCL, Dept Haematol, 98 Chenies Mews, London WC1E 6HX, England.	rosemary.gale@ucl.ac.uk	Ashby, Louisa/GRN-9388-2022; SHAKOORI, ABDUL RAUF/Q-9373-2019; Pizzey, Arnold/E-6301-2015	Ashby, Louisa/0000-0001-8247-096X; Pizzey, Arnold/0000-0003-1850-1121				Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P983, DOI 10.1046/j.1365-2141.2001.02850.x; Alexander WS, 1998, LEUKEMIA RES, V22, P1097, DOI 10.1016/S0145-2126(98)00110-6; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Bernard T, 1996, BRIT J HAEMATOL, V93, P527, DOI 10.1046/j.1365-2141.1996.d01-1696.x; BERNSTEIN ID, 1991, BLOOD, V77, P2316; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Byrne JL, 1998, BRIT J HAEMATOL, V100, P256; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Dong F, 1998, J IMMUNOL, V161, P6503; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; Gonda TJ, 1997, BLOOD, V89, P355, DOI 10.1182/blood.V89.2.355; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Ihle JN, 1996, ADV CANCER RES, V68, P23, DOI 10.1016/S0065-230X(08)60351-6; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Jenkins BJ, 1998, BLOOD, V92, P1989, DOI 10.1182/blood.V92.6.1989; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; Kelly PF, 2000, BLOOD, V96, P1206, DOI 10.1182/blood.V96.4.1206.h8001206_1206_1214; Kitamura T, 1998, BLOOD, V92, P2596, DOI 10.1182/blood.V92.7.2596; Kiyoi H, 1999, BLOOD, V93, P3074; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; KOTTARIDIS PD, 2002, IN PRESS BLOOD; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; McKinstry WJ, 1997, BLOOD, V89, P65, DOI 10.1182/blood.V89.1.65.65_65_71; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; MOLINEUX G, 1991, BLOOD, V78, P961; Nakano Y, 1999, BRIT J HAEMATOL, V104, P659, DOI 10.1046/j.1365-2141.1999.01256.x; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Persons DA, 1998, BLOOD CELL MOL DIS, V24, P167, DOI 10.1006/bcmd.1998.0184; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; SHINJO K, 1995, BRIT J HAEMATOL, V91, P783, DOI 10.1111/j.1365-2141.1995.tb05390.x; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Zaliauskiene L, 2000, MOL BIOL CELL, V11, P2643, DOI 10.1091/mbc.11.8.2643; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	41	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					5981	5989		10.1038/sj.onc.1205767	http://dx.doi.org/10.1038/sj.onc.1205767			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203110				2022-12-17	WOS:000177671300001
J	Mason, SL; Loughran, O; La Thangue, NB				Mason, SL; Loughran, O; La Thangue, NB			p14(ARF) regulates E2F activity	ONCOGENE			English	Article						E2F; p14(ARF); MDM2; p53	TUMOR-SUPPRESSOR; TRANSCRIPTION FACTOR; NUCLEOLAR LOCALIZATION; GENE-PRODUCT; P53; MDM2; P19(ARF); DEGRADATION; INHIBITION; PATHWAY	The ARF protein product of the ink4a/arf locus is induced by a variety of oncogenic signals. ARF facilitates growth arrest through the p53 pathway by hindering the down-regulation of p53 activity mediated by MDM2, through the formation of a protein complex with MDM2. Here we have explored the possibility that human p14(LambdaRF) activity is integrated with growth regulating pathways other than p53, and report our results that p14(LambdaRF) can control the activity of the E217 transcription factor. p14(LambdaRF) regulates E2F activity in different cell-types, including p53(-/-)/mdm(-/-) MEFs, thus excluding that the effects of p14(LambdaRF) are indirectly caused through MDM2 modulation. p14(LambdaRF) down-regulates E2F-dependent transcription, and in cells undergoing E2F-dependent apoptosis prompts cell cycle arrest. p14(LambdaRF) possesses multiple binding domains for E2F-1, one of which resides within the N-terminal region and coincides with the regulation of E2F activity. A mutational analysis of p14(LambdaRF) indicates that the E2F-1 and MDM2 binding domains can be distinguished. These results highlight the potential interplay between p14(LambdaRF) and E2F, and establish p14(LambdaRF) as a pleiotrophic regulator of cell growth that acts by targetting at least two key pathways in the control of proliferation, namely E2F and p53.	Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	N.LaThangue@bio.gla.ac.uk			Cancer Research UK [13058] Funding Source: Medline; Medical Research Council [G9400953] Funding Source: Medline; MRC [G9400953] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Botz J, 1996, MOL CELL BIOL, V16, P3401; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Lomax M, 2001, ONCOGENE, V20, P4951, DOI 10.1038/sj.onc.1204717; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	46	55	61	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4220	4230		10.1038/sj.onc.1205524	http://dx.doi.org/10.1038/sj.onc.1205524			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082609				2022-12-17	WOS:000176174200004
J	Rozenfeld-Granot, G; Krishnamurthy, J; Kannan, K; Toren, A; Amariglio, N; Givol, D; Rechavi, G				Rozenfeld-Granot, G; Krishnamurthy, J; Kannan, K; Toren, A; Amariglio, N; Givol, D; Rechavi, G			A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1	ONCOGENE			English	Article						apoptosis; Apaf-1; p53 target; Zac-1 coactivation; promoter luciferase assay	TUMOR-SUPPRESSOR P53; BCL-2 FAMILY; APOPTOSIS; GENE; TARGET; CASPASE-9; PROTEINS; BINDING; DOMAIN; PUMA	p53 exerts its tumor suppressor effects by activating genes involved in cell growth arrest and programmed cell death. The p53 target genes inducing growth arrest are well defined whereas those inducing apoptosis are not fully characterized. Proapoptotic activity of p53 was shown to involve several genes like Bax, Noxa and Puma, which may function in the release of cytochrome c from the mitochondria. Cytochrome c associates with Apaf-1 and caspase 9 to form the apoptosome. Genetic and cellular data indicate that Apaf-1 deficiency abrogates the apoptotic effect of p53 and substitutes for p53 loss in promoting tumor formation. Here we show that Apaf-1, the mammalian homologue of C. elegans CED4, is a direct target of p53 as demonstrated by gel shift analysis of the target site sequence in the presence of p53 and by Apaf-1 promoter-luciferase assays. We also show that the p53 activation of the Apaf-1 luciferase construct can be enhanced by the putative tumor suppressor gene product, Zac-1, a transcription factor that has previously been shown to inhibit cell proliferation. Furthermore, we demonstrate that Zac-1 is a possible direct target of p53 since the sequence upstream to the first coding exon of Zac-1 contains a p53 recognition site and the luciferase construct containing this region is activated by p53. These results suggests the existence of a tightly controlled self amplifying mechanism of transcriptional activation leading to apoptosis by p53.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Pediat Hematooncol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	david.givol@weizmann.ac.il						Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Arima T, 2000, GENOMICS, V67, P248, DOI 10.1006/geno.2000.6266; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Huang SM, 2001, ONCOGENE, V20, P2134, DOI 10.1038/sj.onc.1204298; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Robles AI, 2001, CANCER RES, V61, P6660; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Varrault A, 2001, J BIOL CHEM, V276, P18653, DOI 10.1074/jbc.C100095200; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	35	55	56	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1469	1476		10.1038/sj.onc.1205218	http://dx.doi.org/10.1038/sj.onc.1205218			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896574				2022-12-17	WOS:000173956800001
J	She, QB; Ma, WY; Dong, ZG				She, QB; Ma, WY; Dong, ZG			Role of MAP kinases in UVB-induced phosphorylation of p53 at serine 20	ONCOGENE			English	Article						JNKs; MAPKAPK-2; p53; phosphorylation; UV radiation	ACTIVATED PROTEIN-KINASE; RADIATION-INDUCED APOPTOSIS; N-TERMINAL KINASE; DNA-DAMAGE; AP-1 TRANSACTIVATION; ULTRAVIOLET-RADIATION; GAMMA-RADIATION; JNK ACTIVATION; IN-VITRO; T-CELLS	Phosphorylation of the p53 tumor suppressor protein is one of the key regulatory steps in its activation process. Serine 20 phosphorylation of p53 has been shown to be required for the activation of p53 following UV radiation, but the signaling pathway mediating UV-induced phosphorylation is unknown. Here, we determined the role of MAP kinases in UVB-induced phosphorylation and found that JNKs are directly involved in the phosphorylation of p53 at serine 20. In a mouse JB6 epidermal cell line, dominant negative JNK1 abrogated UVB-induced phosphorylation of p53 at serine 20, whereas dominant negative p38 kinase or its inhibitor, SB202190, partially attenuated the phosphorylation. In contrast, dominant negative ERK2 or the MEK1 inhibitor, PD98059, had no effect on p53 phosphorylation at serine 20. Importantly, UVB-activated or active recombinant JNK1/2, or the p38 kinase downstream target, MAPKAPK-2, but not ERKs or p38 kinase, phosphorylated p53 at serine 20 in vitro. Furthermore, phosphorylation of p53 at serine 20 by UVB-activated JNKs and UVB-induced p53-dependent transcriptional activity were suppressed in Jnk1 or Jnk2 knockout (Jnk1(-/-) or Jnk2(-/-)) cells. Additionally, Jnk1(-/-), Jnk2(-/-), and p53-deficient (p53(-/-)) cells, as well as re-introduction of a p53 mutant with substitution of serine 20 to alanine into p53(-/-) cells, were defective for UVB-induced apoptosis. These findings strongly suggest that JNKs are the major direct signaling mediators of UVB-induced p53 phosphorylation at serine 20.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu		She, Qing-Bai/0000-0002-7207-0599	NCI NIH HHS [CA 77646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRITSCHE M, 1993, ONCOGENE, V8, P307; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1991, CANCER RES, V51, P4279; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOO D, 1994, CELL BIOL LAB HDB, P45; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MERRITT AJ, 1994, CANCER RES, V54, P614; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Prives C, 1999, J PATHOL, V187, P112; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SOUSSI T, 1990, ONCOGENE, V5, P945; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200	58	55	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1580	1589		10.1038/sj.onc.1205239	http://dx.doi.org/10.1038/sj.onc.1205239			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896587	Bronze			2022-12-17	WOS:000173956800014
J	Ala-Aho, R; Grenman, R; Seth, P; Kahari, VM				Ala-Aho, R; Grenman, R; Seth, P; Kahari, VM			Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells	ONCOGENE			English	Article						p53; collagenase; matrix metalloproteinase; squamous cell carcinoma	WILD-TYPE; MATRIX METALLOPROTEINASES; MESSENGER-RNA; HUMAN HEAD; GROWTH; CANCER; KERATINOCYTES; ACTIVATION; APOPTOSIS; PROMOTER	Squamous cell carcinomas (SCCs) of the head and neck are characterized by high tendency to invade locally and metastasize to lymph nodes. SCC cells express several matrix metalloproteinases (MMPs) and they often harbor mutations in p53 tumor suppressor gene. Collagenase-3 (MMP-13) is specifically expressed by tumor cells of SCCs and it apparently plays an important role in their invasion and metastasis. We used adenoviral gene delivery to examine the effect of wild-type p53 on MMP-13 expression in four head and neck SCC cell lines with mutated p53. Adenoviral delivery of p53 resulted in potent inhibition in production of proMMP-13 (by 71 to 92%) and collagenase-1 (MMP-1) (by 27 to 93%) by all cell lines in 24 h, whereas production of gelatinase-A (MMP-2) and gelatinase-B (MMP-9) was not altered. Adenoviral expression of p53 also suppressed invasion of SCC cells through Matrigel by 35%. Expression of cyclin-dependent kinase inhibitor p21(Waf1/Cip1) was induced 24 h after p53 gene delivery in all SCC cell lines, except one, which lacked detectable p21(Waf1/Cip1) expression. Number of viable cells was not altered and no apoptotic cells were seen 24 h after p53 delivery. These results show, that wild-type p53 potently inhibits expression of MMP-13 and MMP-1 by SCC cells independently of its pro-apoptotic effect. Together there results indicate, that p53 exerts a bi-phasic tumor suppressor effect on SCC cells: inhibition of cell invasion followed by induction of programmed cell death.	Univ Turku, Dept Med Biochem, Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, FIN-20520 Turku, Finland; Des Moines Univ, Univ Res, Des Moines, IA 50312 USA; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University; University of Turku; University of Turku	Kahari, VM (corresponding author), Univ Turku, Dept Med Biochem, Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Kahari, Veli-Matti/E-5144-2011	Kahari, Veli-Matti/0000-0003-2421-9368				Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Ala-Aho R, 2002, INT J CANCER, V97, P283, DOI 10.1002/ijc.1619; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bostrom PJ, 2000, INT J CANCER, V88, P417, DOI 10.1002/1097-0215(20001101)88:3<417::AID-IJC14>3.3.CO;2-7; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clayman GL, 1999, CLIN CANCER RES, V5, P1715; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; Eicheler W, 2002, J HISTOCHEM CYTOCHEM, V50, P197, DOI 10.1177/002215540205000207; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Etoh T, 2000, GUT, V47, P50, DOI 10.1136/gut.47.1.50; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Heppner KJ, 1996, AM J PATHOL, V149, P273; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Johansson N, 2000, J CELL SCI, V113, P227; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; LANSFORD CD, 1999, HUMAN CELL CULTURE, V2, P185; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Nikkola J, 2001, MELANOMA RES, V11, P157, DOI 10.1097/00008390-200104000-00011; OGRADY RL, 1984, ANAL BIOCHEM, V140, P490, DOI 10.1016/0003-2697(84)90199-4; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PYKE C, 1992, CANCER RES, V52, P1336; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; Servomaa K, 1996, CELL PROLIFERAT, V29, P219, DOI 10.1046/j.1365-2184.1996.01009.x; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	58	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1187	1195		10.1038/sj.onc.1205198	http://dx.doi.org/10.1038/sj.onc.1205198			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850838				2022-12-17	WOS:000173729400006
J	Harrington, L; Robinson, MO				Harrington, L; Robinson, MO			Telomere dysfunction: multiple paths to the same end	ONCOGENE			English	Article						telomere; telomerase; genome stability; DNA damage; apoptosis; p53	HUMAN-CELLS LEADS; HUMAN TUMOR-CELLS; LIFE-SPAN; HUMAN FIBROBLASTS; MOUSE TELOMERASE; HUMAN CANCER; LENGTH; TRF2; RNA; RECONSTITUTION	The molecular cloning of telomerase and telomere components has enabled the analysis and precise manipulation of processes that regulate telomere length maintenance. In mammalian cells and in other organisms, we now recognize that disruption of telomere integrity via any one of a number of perturbations induces chromosome instability and the activation of DNA damage responses. Thus, telomere dysfunction may represent a physiological trigger of the DNA damage or apoptotic response in an analogous fashion to other genotoxic insults that introduce chromosome breaks. Initial studies in mice lacking the murine telomerase RNA and in cells expressing a dominant negative version of the telomere binding protein TRF2 revealed a strong p53-dependent response to telomere dysfunction. Yet, telomere dysfunction exhibits p53-independent effects as well, an observation supported by p53-independent responses to telomere dysfunction in p53 mutant human tumor cell lines and mouse cells. As most tumors are compromised for p53 function, examination of this p53-independent response warrants closer attention. A better understanding of this p53-independent response may prove critical for determining the ultimate utility of telomerase inhibitors in the clinic. This review will summarize our current understanding of the molecular responses to telomere dysfunction in mammalian cells.	Amgen Inc, Thousand Oaks, CA 91320 USA; Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Amgen Res Inst, Toronto, ON M5G 2C1, Canada	Amgen; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Robinson, MO (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.			Robinson, Murray/0000-0003-4462-0685				Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Engelhardt M, 1998, LEUKEMIA, V12, P13, DOI 10.1038/sj.leu.2400889; Engelhardt M, 1997, CLIN CANCER RES, V3, P1931; GREIDER CW, 1996, ANNU REV BIOCHEM, V65, P377; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Guo CH, 2001, J UROLOGY, V166, P694, DOI 10.1016/S0022-5347(05)66045-4; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1996, TELOMERES, P247; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Ludwig A, 2001, CANCER RES, V61, P3053; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	49	55	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					592	597		10.1038/sj.onc.1205084	http://dx.doi.org/10.1038/sj.onc.1205084			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850784				2022-12-17	WOS:000173390500011
J	Okorokov, AL; Rubbi, CP; Metcalfe, S; Milner, J				Okorokov, AL; Rubbi, CP; Metcalfe, S; Milner, J			The interaction of p53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage	ONCOGENE			English	Article						p53; nuclear F-actin; FRET; DNA damage	NORMAL HUMAN-FIBROBLASTS; C-TERMINAL DOMAIN; WILD-TYPE P53; ULTRAVIOLET-LIGHT; NONACTIVATED P53; TRANSCRIPTION; PROTEIN; COMPLEX; BINDING; CELLS	The tumour suppressor protein p53 is localized in the cell nucleus where it serves to initiate cellular responses to a variety of stresses, particularly DNA damage and has the capacity to transactivate stress response genes. An emerging body of evidence indicates that its action is also exerted through direct protein-protein interactions. An approach to understanding p53 function has been to analyse its positioning in relation to nuclear structures and we have shown that p53 can associate with the nuclear matrix. A potential nuclear matrix component for this association is actin. Here we show that p53 interacts with nuclear F-actin and we map the domains involved in this interaction. Using fluorescence resonance energy transfer, we demonstrate that the partition of p53 between F-actin bound and unbound forms is not constant, but is modulated by the presence of DNA damage, which increases binding. Our results indicate that the dynamic interaction of p53 with the nuclear matrix has to be considered for a full understanding of the mechanisms of the p53-mediated cellular response to DNA damage.	Univ York, Dept Biol, Res Grp, York YO10 5DD, N Yorkshire, England; Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England	University of York - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Milner, J (corresponding author), Univ York, Dept Biol, Res Grp, YCR P53, York YO10 5DD, N Yorkshire, England.			Okorokov, Andrei/0000-0003-2477-3254				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Haugland R.P, 1996, HDB FLUORESCENT PROB, V6th; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Iborra FJ, 1996, J CELL SCI, V109, P1427; JaresErijman EA, 1996, J MOL BIOL, V257, P597, DOI 10.1006/jmbi.1996.0188; Jiang M, 2001, ONCOGENE, V20, P5449, DOI 10.1038/sj.onc.1204705; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MCCREADY SJ, 1984, J CELL SCI, V70, P189; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Metcalfe S, 1999, ONCOGENE, V18, P2351, DOI 10.1038/sj.onc.1202559; MULLENDERS LHF, 1988, NUCLEIC ACIDS RES, V16, P10607, DOI 10.1093/nar/16.22.10607; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NAKAYASU H, 1985, EXP CELL RES, V160, P319, DOI 10.1016/0014-4827(85)90179-X; Nguyen E, 1998, MOL REPROD DEV, V50, P263, DOI 10.1002/(SICI)1098-2795(199807)50:3&lt;263::AID-MRD2&gt;3.0.CO;2-H; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Okorokov AL, 1999, MOL CELL BIOL, V19, P7501; Pederson T, 1998, J MOL BIOL, V277, P147, DOI 10.1006/jmbi.1997.1618; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Szak ST, 1999, J BIOL CHEM, V274, P3904, DOI 10.1074/jbc.274.6.3904; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188	40	55	60	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					356	367		10.1038/sj.onc.1205112	http://dx.doi.org/10.1038/sj.onc.1205112			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821948				2022-12-17	WOS:000173311200004
J	Aguilar-Lemarroy, A; Gariglio, P; Whitaker, NJ; Eichhorst, ST; zur Hausen, H; Krammer, PH; Rosl, F				Aguilar-Lemarroy, A; Gariglio, P; Whitaker, NJ; Eichhorst, ST; zur Hausen, H; Krammer, PH; Rosl, F			Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis	ONCOGENE			English	Article						CD95; cervical cancer; myc; p53; HPV; proteasome inhibitor	PROGRAMMED CELL-DEATH; RETINOBLASTOMA GENE-PRODUCT; FAS-MEDIATED APOPTOSIS; IN-VIVO; EPITHELIAL-CELLS; CANCER-CELLS; PROTEASOME INHIBITORS; MONOCLONAL-ANTIBODY; SIGNALING COMPLEX; MOLECULAR-CLONING	To understand the function of the individual oncogenes of HPV16 in modulating the cellular response to apoptogenic signals, we used human keratinocytes immortalized with either E6, E7 or E6/E7 oncoproteins as model system. Applying CD95 antibodies or recombinant CD95 ligand, only the E7-immortalized cells underwent extensive apoptosis. In contrast, E6- and E6/E7-expressing keratinocytes were resistant. Dominance of E6 correlated with significant down-regulation of p53, c-Myc, p21 and Bcl-2. CD95 was found to be reduced in resistant HPV-positive cells, while there were no quantitative differences in expression levels of FADD, FLICE/caspase-8 or caspase-3. Notably, in contrast to primary human keratinocytes, all immortalized cells showed a general reduction of c-FLIP, an inhibitory protein which normally prevents unscheduled CD95-induced apoptosis. E6- and E6/E7-positive keratinocytes, however, can be sensitized to CD95 apoptosis by blocking proteasome-mediated proteolysis. CD95-resistant HPV-positive cells underwent apoptosis within 3-5 h upon co-incubation with MG132 and agonistic antibodies or CD95 ligand, which was preceded by a strong re-expression of p53 and c-Myc, but not of other half-life controlled proteins such as Bax or I kappaB alpha. Blockage of proteasomal activity alone did not result in apoptosis, although the same set of pro-apoptotic proteins was up-regulated. Performing similar experiments with cervical carcinoma cells expressing mutated p53 (C33a) or with P53-'null' lung carcinoma cells (H1299), no CD95 cell killing occurred eventhough c-Myc was strong induced. These data indicate that the reduced bioavailability of p53 is a key-regulatory event in perturbation of CD95 signaling in HPV16 immortalized keratinocytes.	Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, Abt Tumorvirus Immunol, D-69120 Heidelberg, Germany; Inst Politecn Nacl, CINVESTAV, Dept Mol Biol & Genet, Mexico City, DF, Mexico; Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia; Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Tumorimmunol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; University of New South Wales Sydney; Helmholtz Association; German Cancer Research Center (DKFZ)	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, Abt Tumorvirus Immunol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	F.Roesl@DKFZ.de	Aguilar-Lemarroy, Adriana/Y-7001-2018	Aguilar-Lemarroy, Adriana/0000-0001-9288-4824				BARBOSA MS, 1989, ONCOGENE, V4, P1529; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Boyer SN, 1996, CANCER RES, V56, P4620; BRISTOW RG, 1994, ONCOGENE, V9, P1527; Brown J, 1997, J CELL BIOCHEM, V66, P245, DOI 10.1002/(SICI)1097-4644(19970801)66:2<245::AID-JCB11>3.0.CO;2-G; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DHEIN J, 1992, J IMMUNOL, V149, P3166; DOORBAR J, 1990, VIROLOGY, V178, P254, DOI 10.1016/0042-6822(90)90401-C; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Duerksen-Hughes PJ, 1999, VIROLOGY, V264, P55, DOI 10.1006/viro.1999.9977; EL DW, 1993, CELL, V75, P817; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Gehring S, 2000, J BIOL CHEM, V275, P10413, DOI 10.1074/jbc.275.14.10413; Griffiths DJ, 1997, J VIROL, V71, P2866, DOI 10.1128/JVI.71.4.2866-2872.1997; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hengstermann A, 1998, ONCOGENE, V17, P2933, DOI 10.1038/sj.onc.1202282; IFTNER T, 1992, J VIROL, V66, P4639, DOI 10.1128/JVI.66.8.4639-4646.1992; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KHANDJIAN EW, 1986, ANAL BIOCHEM, V159, P227, DOI 10.1016/0003-2697(86)90332-5; Kim CY, 1997, CANCER RES, V57, P4200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kobayashi T, 1998, CELL DEATH DIFFER, V5, P584, DOI 10.1038/sj.cdd.4400382; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; LANGONE JJ, 1982, J IMMUNOL METHODS, V51, P3, DOI 10.1016/0022-1759(82)90376-3; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Leverkus M, 2000, CANCER RES, V60, P553; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIANG XH, 1993, ONCOGENE, V8, P2645; Maki CG, 1996, CANCER RES, V56, P2649; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nair P, 1999, Pathol Oncol Res, V5, P95, DOI 10.1053/paor.1999.0161; NATOLI G, 1995, ONCOGENE, V11, P1157; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OEHM A, 1992, J BIOL CHEM, V267, P10709; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pim D, 1999, ONCOGENE, V18, P7403, DOI 10.1038/sj.onc.1203134; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schmitz I, 1999, CELL DEATH DIFFER, V6, P821, DOI 10.1038/sj.cdd.4400569; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; Seewaldt VL, 2001, CANCER RES, V61, P616; Sheets EE, 1996, GYNECOL ONCOL, V63, P94, DOI 10.1006/gyno.1996.0285; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; von Reyher U, 1998, CANCER RES, V58, P526; Winoto A, 1997, CURR OPIN IMMUNOL, V9, P365, DOI 10.1016/S0952-7915(97)80083-0; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; YEE C, 1985, AM J PATHOL, V119, P361; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	85	55	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					165	175		10.1038/sj.onc.1204979	http://dx.doi.org/10.1038/sj.onc.1204979			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803460				2022-12-17	WOS:000173026200001
J	Bowe, DB; Kenney, NJ; Adereth, Y; Maroulakou, IG				Bowe, DB; Kenney, NJ; Adereth, Y; Maroulakou, IG			Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E	ONCOGENE			English	Article						Neu; mice; mammary gland; cyclin E; cyclin D1	NEGATIVE BREAST-CANCER; TRANSGENIC MICE; POINT MUTATION; ONCOGENIC ACTIVATION; GLAND HYPERPLASIA; SIGNALING PATHWAY; INDUCTION; RAS; EXPRESSION; OVEREXPRESSION	Amplification and/or overexpression of the receptor tyrosine kinase HER2/Neu and the cell cycle regulatory gene cyclin D1 are frequently associated with human breast cancer. We studied the functional significance of cyclin D1 in Neu-induced mammary oncogenesis by developing mice overexpressing either wild-type or mutant Neu in a cyclin D1 deficient background. The absence of cyclin D1 suppresses mammary tumor formation induced by the wild-type or activated mutant form of Neu, which promote multi- and single-step progression of tumorigenesis, respectively. These data indicate that cyclin D1 is preferentially required for Neu-mediated signal transduction pathways in mammary oncogenesis. Significantly, 35% of mutant Neu/cyclin D1(-/-) mice regained mammary tumor potential due to compensation by cyclin E. Thus, shared targets of cyclins D1 and E are important in modulating Neu function in mammary tumorigenesis. Our results imply that the combinatorial inhibition of cyclins D1 and E might be useful in the treatment of malignancies induced by Neu.	Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Dept Med, Charleston, SC 29425 USA; Hampton Univ, Dept Biol Sci, Hampton, VA 23668 USA	Medical University of South Carolina; Medical University of South Carolina; Hampton University	Maroulakou, IG (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Room 337,86 Jonathan Lucas St, Charleston, SC 29425 USA.							ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BRISCOE WT, 1993, BREAST CANCER RES TR, V28, P45, DOI 10.1007/BF00666355; Evron E, 2001, CANCER RES, V61, P2782; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FILMUS J, 1994, ONCOGENE, V9, P3627; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; JANES PW, 1994, ONCOGENE, V9, P3601; KEYOMARSI K, 1994, CANCER RES, V54, P380; Kurebayashi  J, 2001, Breast Cancer, V8, P45, DOI 10.1007/BF02967477; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRESS MF, 1993, CANCER RES, V53, P4960; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	35	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					291	298		10.1038/sj/onc/1205025	http://dx.doi.org/10.1038/sj/onc/1205025			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803472				2022-12-17	WOS:000173026200013
J	Hermanto, U; Zong, CS; Wang, LH				Hermanto, U; Zong, CS; Wang, LH			ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth	ONCOGENE			English	Article						ErbB2; PI3 kinase; breast cancer; cell growth	NF-KAPPA-B; PROTEIN-KINASE; INDUCED APOPTOSIS; BREAST-CANCER; UP-REGULATION; S6 KINASE; ONCOGENE; AKT; OVEREXPRESSION; AMPLIFICATION	The proto-oncogene ErbB2 is known to be amplified and to play an important role in the development of about one-third of human breast cancers. Phosphatidylinositol 3-kinase (PI3K), which is often activated in ErbB2-overexpressing breast cancer cells, is known to regulate cell proliferation and cell survival. Selective inhibitors of the PI3K pathway were used to assess the relevance of PI3K signaling in the anchorage-independent growth of a series of human mammary carcinoma cell lines. Wortmannin, LY294002, and rapamycin at concentrations that did not affect MAPK phosphorylation but substantially inhibited PI3K, Akt, and p70(S6K) significantly suppressed the soft agar growth of tumor cell lines that overexpress ErbB2 but not the growth of tumor lines with low ErbB2 expression. A similar growth inhibition of ErbB2-overexpressing carcinoma lines was observed when a dominant negative p85(PI3K) mutant was introduced into these cells. Forced expression of ErbB2 in breast cancer lines originally expressing low ErbB2 levels augmented receptor expression and sensitized those lines to LY294002- and rapamycin-mediated inhibition of colony formation. Furthermore, treatment with LY294002 resulted in the selective increase of cyclin-dependent kinase inhibitors p21(CIP1) or p27(Kipt) and suppression of cyclin E-associated Cdk2 kinase activity in ErbB2-overexpressing lines, which may account for their hypersensitivity toward inhibitors of the PI3K pathway in anchorage-independent growth. Our results indicate that the PI3K/Akt/p70(S6K) pathway plays an enhanced role in the anchorage-independent growth of ErbB2-overexpressing breast cancer cells, therefore providing a molecular basis for the selective targeting of this signaling pathway in the treatment of ErbB2-related human breast malignancies.	Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), Mt Sinai Sch Med, Dept Microbiol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	1u-hai.wang@mssm.edu			NCI NIH HHS [CA 29339, CA 55054] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07280] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029339, R01CA055054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007280] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Ozes ON, 1999, NATURE, V401, P82; PIERCE JH, 1991, ONCOGENE, V6, P1189; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Roh H, 2000, ONCOGENE, V19, P6138, DOI 10.1038/sj.onc.1204001; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; YANO H, 1993, J BIOL CHEM, V268, P25846; YOKOTA J, 1986, LANCET, V1, P765; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	42	55	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7551	7562		10.1038/sj.onc.1204964	http://dx.doi.org/10.1038/sj.onc.1204964			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709727				2022-12-17	WOS:000171976900012
J	Fima, E; Shtutman, M; Libros, P; Missel, A; Shahaf, G; Kahana, G; Livneh, E				Fima, E; Shtutman, M; Libros, P; Missel, A; Shahaf, G; Kahana, G; Livneh, E			PKC eta enhances cell cycle progression, the expression of G1 cyclins and p21 in MCF-7 cells	ONCOGENE			English	Article						PKC eta; cell cycle; cyclin E; cyclin D; p21; MCF-7	PROTEIN-KINASE-C; CAPILLARY ENDOTHELIAL-CELLS; METASTATIC MELANOMA-CELLS; BREAST-CANCER CELLS; CDK INHIBITORS; PHORBOL ESTER; RETINOBLASTOMA PROTEIN; ALTERED EXPRESSION; GROWTH-INHIBITION; PHASE-TRANSITION	Protein kinase C encodes a family of enzymes implicated in cellular differentiation, growth control and tumor promotion. However, not much is known with respect to the molecular mechanisms that link protein kinase C to cell cycle control. Here we report that the expression of PKC eta in MCF-7 cells, under the control of a tetracycline-responsive inducible promoter, enhanced cell growth and affected the cell cycle at several points. The induced expression of another PKC isoform, PKC delta, in MCF-7 cells had opposite effects and inhibited their growth. PKC eta expression activated cellular pathways in these cells that resulted in the increased expression of the G1 phase cyclins, cyclin D and cyclin E. Expression of the cyclin-dependent kinase inhibitor p21(WAF1) was also specifically elevated in PKC eta expressing cells, but its overall effects were not inhibitory. Although, the protein levels of the cyclin-dependent kinase inhibitor p27(KIP1) were not altered by the induced expression of PK eta the cyclin E associated Cdk2 kinase activity was in correlation with the p27(KIP1) bound to the cyclin E complex and not by p21(WAF1) binding. PK eta expression enhanced the removal of p27(KIP1) from this complex, and its re-association with the cyclin D/Cdk4 complex. Reduced binding of p27(KIP1) to the cyclin D/Cdk4 complex at early time points of the cell cycle also enhanced the activity of this complex, while at later time points the decrease in bound p21WAF1 correlated with its increased activity in PKC eta -expressing cells. Thus, PKC eta induces altered expression of several cell cycle functions, which may contribute to its ability to affect cell growth.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel	Ben Gurion University	Livneh, E (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel.							AGRAWAL D, 1995, CELL GROWTH DIFFER, V6, P1199; Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Arita Y, 1998, EXP CELL RES, V242, P381, DOI 10.1006/excr.1997.3911; Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COPPOCK DL, 1992, CELL GROWTH DIFFER, V3, P485; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; Downward J, 1997, CURR BIOL, V7, P258; ELDAR H, 1990, J BIOL CHEM, V265, P13290; Fishman DD, 1998, INT J ONCOL, V12, P181; Frey MR, 1997, J BIOL CHEM, V272, P9424; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; Hamada K, 1996, BBA-MOL CELL RES, V1310, P149, DOI 10.1016/0167-4889(95)00148-4; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; HASS R, 1993, CELL GROWTH DIFFER, V4, P159; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Hussaini IM, 2000, J BIOL CHEM, V275, P22348, DOI 10.1074/jbc.M003203200; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Livneh E, 1996, ONCOGENE, V12, P1545; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MICHIELI P, 1994, CANCER RES, V54, P3391; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Nakaigawa N, 1996, BIOCHEM BIOPH RES CO, V222, P95, DOI 10.1006/bbrc.1996.0703; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Slosberg ED, 1999, ONCOGENE, V18, P6658, DOI 10.1038/sj.onc.1203083; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston JT, 1996, ONCOGENE, V12, P127; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; Zeng YX, 1996, ONCOGENE, V12, P1557; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHOU W, 1993, J BIOL CHEM, V268, P23041	63	55	56	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6794	6804		10.1038/sj.onc.1204885	http://dx.doi.org/10.1038/sj.onc.1204885			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709714	Bronze			2022-12-17	WOS:000171551600016
J	Baisden, JM; Qian, Y; Zot, HM; Flynn, DC				Baisden, JM; Qian, Y; Zot, HM; Flynn, DC			The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity	ONCOGENE			English	Article						adaptor protein; Src; actin; AFAP-110	PLECKSTRIN HOMOLOGY DOMAIN; TYROSINE KINASE; CROSS-LINKING; FOCAL ADHESIONS; SH2 DOMAIN; PH DOMAIN; V-SRC; MONOCLONAL-ANTIBODIES; MECHANICAL-PROPERTIES; INOSITOL PHOSPHATES	The actin filament-associated protein of 110 kDa (AFAP-110) was first identified as an SH3/SH2 binding partner for the nonreceptor tyrosine kinase, Src. Subsequent data have demonstrated that AFAP-110 can interact with other Src family members. AFAP-110 contains additional protein binding modules including two pleckstrin homology domains, a leucine zipper motif and a target sequence for serine/threonine phosphorylation. AFAP-110 interacts with actin filaments directly via a carboxy terminal actin-binding domain. Thus AFAP-110 may function as an adaptor protein by linking Src family members and/or other signaling proteins to actin filaments. AFAP-110 also has an intrinsic capability to alter actin filament integrity that can be revealed upon conformational changes associated with phosphorylation or mutagenesis. Recent data has indicated that AFAP-110 may also serve to activate cSrc in response to this conformational change as well. Thus, AFAP-110 may function in several ways by (1) acting as an adaptor protein that links signaling molecules to actin filaments, (2) serving as a platform for the construction of larger signaling complexes, (3) serving as an activator of Src family kinases in response to cellular signals that alter its conformation and (4) directly effecting actin filament organization as an actin filament cross-linking protein. Here, we will review the structure and function of AFAP-110 as well as potential binding partners and effectors of AFAP-110's ability to alter actin filament integrity.	W Virginia Univ, Mary Babb Randolph Canc Ctr, Dept Microbiol & Immunol, Morgantown, WV 26506 USA; Eastern Michigan Univ, Dept Biol, Ypsilanti, MI 48197 USA	West Virginia University; Eastern Michigan University	Flynn, DC (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, Dept Microbiol & Immunol, Morgantown, WV 26506 USA.	dflynn@hsc.wvu.edu	Baisden, Joseph/AAN-7747-2021	Baisden, Joseph/0000-0002-8986-407X	NCI NIH HHS [CA60731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060731, R01CA060731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Bubb MR, 1999, J BIOL CHEM, V274, P36472, DOI 10.1074/jbc.274.51.36472; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Cramer Louise P., 1997, Frontiers in Bioscience (online), V2, pD260; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DwyerNield LD, 1996, AM J PHYSIOL-LUNG C, V270, pL526, DOI 10.1152/ajplung.1996.270.4.L526; FECHHEIMER M, 1993, J CELL BIOL, V123, P1, DOI 10.1083/jcb.123.1.1; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Fincham VJ, 1999, J CELL SCI, V112, P947; FLYNN DC, 1995, J BIOL CHEM, V270, P3894, DOI 10.1074/jbc.270.8.3894; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FLYNN DC, 1992, ONCOGENE, V7, P579; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Ishikawa R, 1998, J BIOL CHEM, V273, P26991, DOI 10.1074/jbc.273.41.26991; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Keshavjee S, 2000, TRANSPLANTATION, V70, P525, DOI 10.1097/00007890-200008150-00022; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; LIU XQ, 1993, ONCOGENE, V8, P1119; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Morris GE, 1998, BIOCHEMISTRY-US, V37, P11117, DOI 10.1021/bi9805137; Murray RC, 1999, SEMIN CELL DEV BIOL, V10, P421, DOI 10.1006/scdb.1999.0329; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Oldenbourg R, 2000, BIOPHYS J, V78, P1176, DOI 10.1016/S0006-3495(00)76675-6; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Qian Y, 1999, HYBRIDOMA, V18, P167, DOI 10.1089/hyb.1999.18.167; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Scholler JK, 1997, DNA CELL BIOL, V16, P515, DOI 10.1089/dna.1997.16.515; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Shiraishi Y, 1999, J NEUROSCI, V19, P8389; Small J. Victor, 1994, Seminars in Cell Biology, V5, P157, DOI 10.1006/scel.1994.1020; Summy JM, 2000, ONCOGENE, V19, P155, DOI 10.1038/sj.onc.1203265; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Verkhusha VV, 1999, FEBS LETT, V445, P395, DOI 10.1016/S0014-5793(99)00124-6; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; Yamakita Y, 1996, J BIOL CHEM, V271, P12632, DOI 10.1074/jbc.271.21.12632; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	76	55	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6435	6447		10.1038/sj.onc.1204784	http://dx.doi.org/10.1038/sj.onc.1204784			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607843				2022-12-17	WOS:000171640600016
J	Lu, AP; Gupta, A; Li, C; Ahlborn, TE; Ma, YS; Shi, EY; Liu, JW				Lu, AP; Gupta, A; Li, C; Ahlborn, TE; Ma, YS; Shi, EY; Liu, JW			Molecular mechanisms for aberrant expression of the human breast cancer specific gene 1 in breast cancer cells: control of transcription by DNA methylation and intronic sequences	ONCOGENE			English	Article						breast cancer specific gene 1; DNA demethylation; transcriptional repression	ONCOSTATIN-M; SYNUCLEIN-GAMMA; IDENTIFICATION; DISEASE; POLYMORPHISM; PROMOTER; RECEPTOR; CLONING; GROWTH	Breast cancer specific gene I (BCSG1), also referred as synuclein gamma, is the third member of a neuronal protein family synuclein. BCSG1 is not expressed in normal breast tissues but highly expressed in advanced infiltrating breast carcinomas. When over expressed, BCSG1 significantly stimulates breast cancer metastasis. To elucidate the molecular mechanisms underlying the abnormal transcription of BCSG1 in breast cancer cells, in this study, we isolated a 2195 base pair fragment of human BCSG1 gene. This fragment includes I kb 5'-flanking region, exon 1, and intron 1. By analysing the promoter activity and the methylation status of the exon I region, we show that (1) Intron I plays critical roles in the control of BCSG1 gene transcription through cis-regulatory sequences that affect BCSG1 transcription in cell type-specific and cell type-nonspecific manners. (2) The activator protein-1 (AP-1) is functionally involved in BCSG1 transcription in breast cancer cells through its binding to an AP-I motif located in the intron 1. (3) The exon I region of BCSG1 gene contains a CpG island that is unmethylated in BCSG1-positive SKBR-3 and T47D cells but densely methylated in BCSG1-negative MCF-7 cells. (4) Treating MCF-7 cells with a demethylating agent 5-Aza-2'-deoxycytidine specifically activated BCSG1 transcription. Thus, our results suggest that while the cellular content of transcription activators and repressors that interact with the cis-regulatory sequences present in the intron I contribute prominently to the tissue-specific expression of BCSG1, demethylation of exon 1 is an important factor responsible for the aberrant expression of BCSG1 in breast carcinomas.	VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; VA Med Ctr, Idaho Falls, ID 83702 USA; Long Isl Jewish Med Ctr, New Hyde Pk, NY 11042 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Northwell Health	Liu, JW (corresponding author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.				NCI NIH HHS [1RO1CA83648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Esteller M, 2000, CANCER RES, V60, P4366; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Griswold MD, 2001, BIOL REPROD, V64, P602, DOI 10.1095/biolreprod64.2.602; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Ji HJ, 1997, CANCER RES, V57, P759; Jia TL, 1999, CANCER RES, V59, P742; KUDO S, 1995, J BIOL CHEM, V270, P13298, DOI 10.1074/jbc.270.22.13298; Lavedan C, 1998, HUM GENET, V103, P106, DOI 10.1007/s004390050792; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; Liu JW, 1997, J LIPID RES, V38, P2035; Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012; Ma YS, 1999, NUCLEIC ACIDS RES, V27, P4649, DOI 10.1093/nar/27.23.4649; Ninkina NN, 1998, HUM MOL GENET, V7, P1417, DOI 10.1093/hmg/7.9.1417; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; SHARRARD R, 1992, ONCOGENE, V1, P670; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Xia Y, 1996, ANN NEUROL, V40, P207, DOI 10.1002/ana.410400212	20	55	62	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5173	5185		10.1038/sj.onc.1204668	http://dx.doi.org/10.1038/sj.onc.1204668			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526506				2022-12-17	WOS:000170464000011
J	Schuldiner, O; Benvenisty, N				Schuldiner, O; Benvenisty, N			A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors	ONCOGENE			English	Article						MYC; oncogenesis; DNA microarray; target genes	BLASTOMA CELL-LINES; EMBRYONIC LETHALITY; MURINE DEVELOPMENT; BREAST CARCINOMAS; TRANSGENIC MICE; TARGET GENES; GROWTH; EXPRESSION; PROTEIN; DIFFERENTIATION	MYC proto-oncogenes play a major role in various types of human tumors. The products of these genes are transcription factors that bind to specific sequences and activate the expression of target genes. Identifying these target genes and their downstream effectors is a crucial step in understanding and preventing MYC induced oncogenesis. Until now, most of the efforts to identify such genes were performed by analysing in vitro systems whose relevance to the malignant process in vivo remains unclear. We aimed at identifying genes that play a major role in the malignant process of MYC induced carcinogenesis. Thus, we analysed the expression profiles of human MYC induced tumors and compared them to similar, non-MYC tumors. Moreover, we looked for the common characteristics of different types of MYC induced tumors. We identified several genes, most of them involved in cell cycle regulation, that are over expressed in MYC induced lymphomas as well as MYC induced neuronal-like tumors. In order to determine whether MYC induced oncogenesis is similar in human and in the mouse model system, we analysed the expression of the identified genes in cells derived from transgenic mice tumors. We also present the distribution of MYC putative binding sites in the regulatory sequences of the genes identified in our analysis. This analysis pointed to two genes (E2F1 and TSC2) as candidates to be targets of Myc activity. We thus further analysed the expression of these genes in the tumor cell lines, and examined the plausibility that elements in their promoter bind the Myc protein. Our data points to several genes that may be involved in c-MYC and N-MYC induced tumors and to two genes that may be targets for MYC activity.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Benvenisty, N (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel.		Schuldiner, Oren/K-1353-2012	Schuldiner, Oren/0000-0002-7350-9380				Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Ben-Porath I, 1999, MOL CELL BIOL, V19, P3529; Ben-Yosef T, 1998, ONCOGENE, V17, P165, DOI 10.1038/sj.onc.1201939; BENBASSAT H, 1992, LEUKEMIA LYMPHOMA, V6, P513, DOI 10.3109/10428199209053591; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DAVIS LJ, 1993, ONCOGENE, V8, P125; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GUERIN M, 1988, ONCOGENE RES, V3, P21; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Malynn BA, 2000, GENE DEV, V14, P1390; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; OSWALD F, 1994, ONCOGENE, V9, P2029; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; SADEE W, 1987, CANCER RES, V47, P5207; Sambrook J, 1989, MOL CLONING LAB MANU; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STEINITZ M, 1975, P NATL ACAD SCI USA, V72, P3518, DOI 10.1073/pnas.72.9.3518; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEGER H, 1988, DIFFERENTIATION, V39, P216, DOI 10.1111/j.1432-0436.1988.tb00095.x; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	55	55	58	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					4984	4994		10.1038/sj.onc.1204459	http://dx.doi.org/10.1038/sj.onc.1204459			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526483				2022-12-17	WOS:000170439800008
J	Frasca, F; Vigneri, P; Vella, V; Vigneri, R; Wang, JYJ				Frasca, F; Vigneri, P; Vella, V; Vigneri, R; Wang, JYJ			Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor	ONCOGENE			English	Article						Akt; branching morphogenesis; c-Abl; cell motility; ERK; Met; PDGF receptor	C-KIT RECEPTOR; CARCINOMA CELLS; SCATTER FACTOR; RHO-GTPASES; IN-VITRO; ABL; MET; EXPRESSION; STI-571; PROTOONCOGENE	Met are physiological regulators of cell migration, HGF and Met have also been implicated in tumor progression and metastasis. We show here that the tyrosine kinase inhibitor STI571 has a stimulatory effect on HGF-induced migration and branching morphogenesis in thyroid cancer but not in primary or immortalized thyroid epithelial cells. These stimulatory effects of STI571 are observed at a concentration that is clinically relevant. The STI571-enhanced motile response can be correlated with an increase in the Met receptor tyrosine phosphorylation as well as ERK and Akt activation by HGF, Interestingly, one of the targets of STI571, namely the c-Abl tyrosine kinase, is activated by HGF and is recruited at the migrating edge of thyroid cancer cells, These data suggests that c-Abl and/or STI571-inhibited tyrosine kinases can negatively regulate the Met receptor to restrain the motile response in thyroid cancer cells.	Univ Catania, Ist Med Interna Malattie Endocrine & Metab, Osped Garibaldi, I-95123 Catania, Italy; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Catania; University of California System; University of California San Diego; University of California System; University of California San Diego; Magna Graecia University of Catanzaro	Frasca, F (corresponding author), Univ Catania, Ist Med Interna Malattie Endocrine & Metab, Osped Garibaldi, Piazza S Maria di Gesu, I-95123 Catania, Italy.		Vigneri, Paolo G/K-8504-2016; Frasca, Francesco/J-1332-2018; Vella, Veronica/AAX-5690-2020; Vella, Veronica/N-7977-2018; Vigneri, Riccardo/M-3968-2017	Vigneri, Paolo G/0000-0002-5943-6066; Frasca, Francesco/0000-0002-5556-3201; Vella, Veronica/0000-0002-4968-8550; Vigneri, Riccardo/0000-0002-4401-3140	NCI NIH HHS [R37 CA043054, R01 CA043054] Funding Source: Medline; NHLBI NIH HHS [HL57900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belfiore A, 1997, J CLIN ENDOCR METAB, V82, P2322, DOI 10.1210/jc.82.7.2322; Bergstrom JD, 2000, EXP CELL RES, V259, P293, DOI 10.1006/excr.2000.4967; Bergstrom JD, 1999, BRIT J CANCER, V80, P650, DOI 10.1038/sj.bjc.6690406; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; DIRENZO MF, 1995, J ENDOCRINOL INVEST, V18, P134, DOI 10.1007/BF03349722; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; HELDIN NE, 1991, ENDOCRINOLOGY, V129, P2187, DOI 10.1210/endo-129-4-2187; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; Kilic T, 2000, CANCER RES, V60, P5143; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; NATALI PG, 1995, CANCER RES, V55, P1787; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Stuart KA, 2000, INT J EXP PATHOL, V81, P17, DOI 10.1046/j.1365-2613.2000.00138.x; TANAKA T, 1995, ENDOCR J, V42, P723, DOI 10.1507/endocrj.42.723; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698	32	55	56	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3845	3856		10.1038/sj.onc.1204531	http://dx.doi.org/10.1038/sj.onc.1204531			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439348				2022-12-17	WOS:000169494700010
J	Mattila, MMT; Ruohola, JK; Valve, EM; Tasanen, MJ; Seppanen, JA; Harkonen, PL				Mattila, MMT; Ruohola, JK; Valve, EM; Tasanen, MJ; Seppanen, JA; Harkonen, PL			FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells	ONCOGENE			English	Article						FGF-8 isoforms; angiogenesis; breast cancer; tumorigenesis; androgen; hormone-independence	IN-VIVO; PROGNOSTIC INDICATOR; MOLECULAR-CLONING; STEROID-HORMONES; PROSTATE-CANCER; AUTOCRINE LOOP; STEP METHOD; EXPRESSION; MAMMARY; FGF8	Fibroblast growth factor 8 (FGF-8) is a secreted heparin-binding protein, which has transforming potential. Alternative splicing of the mouse Fgf-8 gene potentially codes for eight protein isoforms (a-h) which differ in their transforming capacity in transfected cells. S115 mouse mammary tumor cells express a transformed phenotype and secrete FGF-8 in an androgen-dependent manner. In order to study the role of FGF-8 isoforms in the induction of transformed phenotype of breast cancer cells, we over-expressed FGF-8 isoforms a, b and e in S115 cells. Over-expression of FGF-8b, but not FGF-8a or FGF-8e, induced androgen and anchorage independent growth of S115 cells. FGF-8b-transfected S115 eels formed rapidly growing tumors with increased vascularization when injected s.c, into nude mice. FGF-8a also slightly increased tumor growth and probably tumor vascularization but FGF-8e was not found to have any effects. The angiogenic activity of FGF-8b and heparin-binding growth factor fraction (HBGF) of S115 cell conditioned media was tested in in vitro and in vivo models for angiogenesis using immortomouse brain capillary endothelial cells (IBEC) and chorion allantoic membrane (CAM) assays. Recombinant FGF-8b protein was able to stimulate proliferation, migration, and vessellike tube formation of IBECs, In addition, stimulatory effect of S115-HBGF on IBE cell proliferation was evident. A positive angiogenic response to FGF-8b was also seen in CAM assay. The results demonstrate that the expression of Fgf-8b is able to promote vessel formation. Angiogenic capacity probably markedly contributes to the ability of FGF-8b to increase tumor growth of androgen-regulated S115 mouse breast cancer cells.	Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland; Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland	University of Turku; University of Turku	Harkonen, PL (corresponding author), Univ Turku, Inst Biomed, Dept Anat, Kiinamyllnkatu 10, FIN-20520 Turku, Finland.							AUERBACH R, 1974, DEV BIOL, V41, P391, DOI 10.1016/0012-1606(74)90316-9; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; DARBRE PD, 1987, CANCER RES, V47, P2937; DARBRE PD, 1988, BREAST CANCER CELLUL, P307; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gasparini G, 1997, J NATL CANCER I, V89, P139, DOI 10.1093/jnci/89.2.139; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Gerwins P, 2000, CRIT REV ONCOL HEMAT, V34, P185, DOI 10.1016/S1040-8428(00)00062-7; Ghosh AK, 1996, CELL GROWTH DIFFER, V7, P1425; GOTO F, 1993, LAB INVEST, V69, P508; Guidi AJ, 1997, CANCER, V80, P1945, DOI 10.1002/(SICI)1097-0142(19971115)80:10<1945::AID-CNCR11>3.0.CO;2-Y; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hansen S, 2000, CLIN CANCER RES, V6, P139; HARKONEN PL, 1990, EXP CELL RES, V186, P288, DOI 10.1016/0014-4827(90)90308-W; HARLEY CB, 1987, GENE ANAL TECH, V4, P17, DOI 10.1016/0735-0651(87)90013-6; HARTMANN KKP, 1990, ENDOCRINOLOGY, V127, P2038, DOI 10.1210/endo-127-4-2038; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; JOUANNEAU J, 1995, GROWTH FACTORS, V12, P37, DOI 10.3109/08977199509003212; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KOUHARA H, 1994, ONCOGENE, V9, P455; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; LORENZI MV, 1995, ONCOGENE, V10, P2051; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; Nicholson RI, 2000, BRIT J CANCER, V82, P501; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Relf M, 1997, CANCER RES, V57, P963; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rudra-Ganguly N, 1998, ONCOGENE, V16, P1487, DOI 10.1038/sj.onc.1201652; Ruohola JK, 1999, MOL CELL ENDOCRINOL, V149, P29, DOI 10.1016/S0303-7207(99)00003-9; RUOHOLA JK, 1995, ENDOCRINOLOGY, V136, P2179, DOI 10.1210/en.136.5.2179; SATO B, 1993, J STEROID BIOCHEM, V47, P91, DOI 10.1016/0960-0760(93)90061-Z; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Szebenyi G, 1999, INT REV CYTOL, V185, P45; TAKATSUKA D, 1992, ANTICANCER RES, V12, P2001; Tanaka A, 1998, CANCER RES, V58, P2053; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TOI M, 1995, BREAST CANCER RES TR, V36, P193, DOI 10.1007/BF00666040; TOI M, 1994, JAPANESE J CANC RES, V885, P1045; Valve E, 2000, INT J CANCER, V88, P718, DOI 10.1002/1097-0215(20001201)88:5<718::AID-IJC6>3.0.CO;2-F; Valve E, 1997, BIOCHEM BIOPH RES CO, V232, P173, DOI 10.1006/bbrc.1997.6256; Valve EM, 1998, BIOCHEM BIOPH RES CO, V250, P805, DOI 10.1006/bbrc.1998.9397; Wang Q, 1999, J CLIN PATHOL, V52, P29, DOI 10.1136/jcp.52.1.29; WARRI AM, 1993, JNCI-J NATL CANCER I, V85, P1412, DOI 10.1093/jnci/85.17.1412; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; YAMANISHI H, 1995, J STEROID BIOCHEM, V52, P49, DOI 10.1016/0960-0760(94)00148-F; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; YAN GC, 1991, IN VITRO CELL DEV B, V27, P437; YATES J, 1981, CANCER RES, V41, P258	67	55	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2001	20	22					2791	2804		10.1038/sj.onc.1204430	http://dx.doi.org/10.1038/sj.onc.1204430			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420691				2022-12-17	WOS:000168712000007
J	Hsu, T; Schulz, RA				Hsu, T; Schulz, RA			Sequence and functional properties of Ets genes in the model organism Drosophila	ONCOGENE			English	Article						Drosophila; ets; pointed; yan; D-elg; E74	DOMAIN TRANSCRIPTION FACTOR; GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; VENTRAL NEUROBLASTS; MAP KINASE; FACTOR CF2; D-ELG; OOGENESIS; PATHWAY; ACTIVATION	Detailed molecular and genetic studies, coupled with the recent sequencing of the fly genome, have identified eight Ets-related genes in the model organism Drosophila. All show homology to genes in vertebrate species. Functional analyses of some of the Drosophila ets genes have revealed their essential roles in developmental processes such as metamorphosis, oogenesis, neurogenesis, myogenesis, and eye development. Such studies have yielded important insights into our understanding of the genetic control of hormonally-regulated gene expression, programmed cell death, and signal transduction during cell fate determination and differentiation. The developmental roles of E74 (ELF1), pointed (Ets 1), yan (TEL), and D-elg (GABP alpha) will be reviewed in this article, The context of their participation in signal transduction and gene regulation will also be discussed. The information should be of significant value to the study of related processes in higher organisms due to the growing evidence for the cross species conservation of developmental mechanisms.	Med Univ S Carolina, Ctr Mol & Struct Biol, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev, Houston, TX 77030 USA	Medical University of South Carolina; Medical University of South Carolina; University of Texas System; UTMD Anderson Cancer Center	Hsu, T (corresponding author), Med Univ S Carolina, Ctr Mol & Struct Biol, Hollings Canc Ctr, 86 Jonathan Lucas St, Charleston, SC 29425 USA.			Hsu, Tien/0000-0003-2308-4297				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Adryan B, 2000, ONCOGENE, V19, P2803, DOI 10.1038/sj.onc.1203611; Andrew DJ, 2000, MECH DEVELOP, V92, P5, DOI 10.1016/S0925-4773(99)00321-4; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Buff E, 1998, DEVELOPMENT, V125, P2075; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; Chinenov Y, 2000, J BIOL CHEM, V275, P7749, DOI 10.1074/jbc.275.11.7749; Chu H, 1998, GENE DEV, V12, P3613, DOI 10.1101/gad.12.22.3613; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FLETCHER JC, 1995, DEVELOPMENT, V121, P1455; Fletcher JC, 1997, P NATL ACAD SCI USA, V94, P4582, DOI 10.1073/pnas.94.9.4582; Gabay L, 1996, DEVELOPMENT, V122, P3355; GAJEWSKI KM, 1995, ONCOGENE, V11, P1033; Golembo M, 1996, DEVELOPMENT, V122, P3363; Golembo M, 1996, DEVELOPMENT, V122, P223; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Hsu T, 1996, GENE DEV, V10, P1411, DOI 10.1101/gad.10.11.1411; JANKNECHT R, 1989, NUCLEIC ACIDS RES, V17, P4455, DOI 10.1093/nar/17.12.4455; Jiang CA, 2000, MOL CELL, V5, P445, DOI 10.1016/S1097-2765(00)80439-6; Jiang CG, 1997, DEVELOPMENT, V124, P4673; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; Mantrova EY, 1998, GENE DEV, V12, P1166; Mantrova EY, 1999, P NATL ACAD SCI USA, V96, P11889, DOI 10.1073/pnas.96.21.11889; McDonald JA, 1998, GENE DEV, V12, P3603, DOI 10.1101/gad.12.22.3603; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; Michelson AM, 1998, DEV GENET, V22, P212, DOI 10.1002/(SICI)1520-6408(1998)22:3<212::AID-DVG4>3.0.CO;2-9; Morimoto AM, 1996, DEVELOPMENT, V122, P3745; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Rebay I, 2000, GENETICS, V154, P695; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Riddiford Lynn M., 1993, P899; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; Rubin GM, 1997, COLD SPRING HARB SYM, V62, P347; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; SCHULZ RA, 1993, P NATL ACAD SCI USA, V90, P10076, DOI 10.1073/pnas.90.21.10076; Schulz RA, 1999, ONCOGENE, V18, P6818, DOI 10.1038/sj.onc.1203081; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; Spradling AC, 1999, GENETICS, V153, P135; Spradling Allan C., 1993, P1; Thummel CS, 1996, TRENDS GENET, V12, P306, DOI 10.1016/0168-9525(96)10032-9; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Twombly V, 1996, DEVELOPMENT, V122, P1555; Urness LD, 1995, EMBO J, V14, P6239, DOI 10.1002/j.1460-2075.1995.tb00314.x; Van Buskirk C, 1999, TRENDS CELL BIOL, V9, P1, DOI 10.1016/S0962-8924(98)01413-5; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5	56	55	57	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6409	6416		10.1038/sj.onc.1204033	http://dx.doi.org/10.1038/sj.onc.1204033			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175357				2022-12-17	WOS:000166595000003
J	Perez-Losada, J; Sanchez-Martin, M; Rodriguez-Garcia, MA; Perez-Mancera, PA; Pintado, B; Flores, T; Battaner, E; Sanchez-Garcia, I				Perez-Losada, J; Sanchez-Martin, M; Rodriguez-Garcia, MA; Perez-Mancera, PA; Pintado, B; Flores, T; Battaner, E; Sanchez-Garcia, I			Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical Pole in the pathogenesis of liposarcoma	ONCOGENE			English	Article						chromosomal abnormality; malignant solid tumors; adipose tissue; cancer development	HUMAN MYELOID-LEUKEMIA; RNA-BINDING PROTEIN; CHROMOSOMAL TRANSLOCATION; MYXOID LIPOSARCOMA; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; CHIMERIC PROTEIN; TLS-CHOP; GENE; FUSION	The most common chromosomal translocation in liposarcomas, t(12;16)(q13;p11), creates the FUS/TLS-CHOP fusion gene. We previously developed a mouse model of liposarcoma by expressing PUS-CHOP in murine mesenchymal stem cells. In order to understand how PUS-CHOP can initiate liposarcoma, we have now generated transgenic mice expressing altered forms of the PUS-CHOP protein. Transgenic mice expressing high levels of CHOP, which lacks the FUS domain, do not develop any tumor despite its tumorigenicity in vitro and widespread activity of the EF1 alpha promoter, These animals consistently show the accumulation of a glycoprotein material within the terminally differentiated adipocytes, a characteristic figure of liposarcomas associated with PUS-CHOP. On the contrary, transgenic mice expressing the altered form of PUS-CHOP created by the in frame fusion of the PUS domain to the carboxy end of CHOP (CHOP-FUS) developed liposarcomas. No tumors of other tissues were found in these transgenic mice despite widespread activity of the EF1 alpha promoter. The characteristics of the liposarcomas arising in the CHOP-PUS mice were very similar to those previously observed in our PUS-CHOP transgenic mice indicating that the FUS domain is required not only for transformation but also influences the phenotype of the tumor cells. These results provide evidence that the FUS domain of PUS-CHOP plays a specific and critical role in the pathogenesis of liposarcoma.	Univ Salamanca, CSIC, Ctr Invest Canc, Inst Bilogia Mol & Celular Canc, E-37008 Salamanca, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid 28040, Spain; Univ Salamanca, Serv Anat Patol, Salamanca 37007, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Inst Bilogia Mol & Celular Canc, E-37008 Salamanca, Spain.		Sanchez-Martin, Manuel/N-5327-2016; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Pérez-Losada, Jesús/A-5883-2019; Pintado, Belen/N-3233-2014	Sanchez-Martin, Manuel/0000-0001-8370-1336; Pérez-Losada, Jesús/0000-0003-2400-624X; Pintado, Belen/0000-0002-8485-2520; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905	NCI NIH HHS [1 R01 CA79955-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelmant G, 1998, J BIOL CHEM, V273, P15574, DOI 10.1074/jbc.273.25.15574; Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHANG HR, 1989, CANCER, V64, P1514, DOI 10.1002/1097-0142(19891001)64:7<1514::AID-CNCR2820640726>3.0.CO;2-2; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Cui KY, 2000, J BIOL CHEM, V275, P7591, DOI 10.1074/jbc.275.11.7591; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KNIGHT JC, 1995, CANCER RES, V55, P24; Kuroda M, 1997, AM J PATHOL, V151, P735; MACK TM, 1995, CANCER-AM CANCER SOC, V75, P211, DOI 10.1002/1097-0142(19950101)75:1+<211::AID-CNCR2820751309>3.0.CO;2-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; PRASAD DDK, 1994, ONCOGENE, V9, P3717; PRICE BD, 1992, CANCER RES, V52, P3814; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	28	55	59	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6015	6022		10.1038/sj.onc.1204018	http://dx.doi.org/10.1038/sj.onc.1204018			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146553				2022-12-17	WOS:000165827900008
J	Schoenfeld, AR; Parris, T; Eisenberger, A; Davidowitz, EJ; De Leon, M; Talasazan, F; Devarajan, P; Burk, RD				Schoenfeld, AR; Parris, T; Eisenberger, A; Davidowitz, EJ; De Leon, M; Talasazan, F; Devarajan, P; Burk, RD			The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis	ONCOGENE			English	Article						VHL; von Hippel-Lindau; renal cell carcinoma; apoptosis; UV	BIOLOGICALLY-ACTIVE PRODUCT; CARCINOMA-CELLS; VHL GENE; P53; PHOSPHORYLATION; IDENTIFICATION; INITIATION; INHIBITION; COMPLEX; PATHWAY	The familial cancer syndrome, von Hlippel-Lindau (VHL) disease, characterized by a predisposition to renal cell carcinoma and certain other tumor types, is caused by mutational inactivation of the VHL tumor suppressor gene. Loss of VHL gene function is detected also in the vast majority of sporadic renal cell carcinomas. Previous reports have determined a protective role for VHL in response to serum withdrawal and glucose deprivation, In this study, the effect of UV irradiation on VHL-negative and VHL-positive renal carcinoma cells was examined, VHL-negative 786-O renal carcinoma cells underwent apoptosis following UV irradiation, In contrast, reintroduction of wild-type VHL expression protected 786-O cells from UV-mediated cell death, p53 and Bax levels were equivalent in VHL-negative and VHL-positive 786-O cells. Strikingly, cyclin-dependent kinase? inhibitors p21 and p27 underwent proteasome-dependent degradation in VHL-negative 786-O cells following UV treatment. However, p21 and p27 protein levels were stable in VHL-positive cells. Also, levels of the anti-apoptotic proteins, Bcl-2 and Bcl-xL were elevated in VH L-positive cells, consistent with the protection from apoptotic stimuli, UV treatment led to increased S phase in VHL-negative, but not VHL-positive cells, Thus, following UV irradiation, diminution of p21 and p27 levels resulted in a hyperproliferative state in VHL-negative cells, leading to apoptosis, These results suggest that loss of VHL function promotes apoptosis and may provide selective pressure toward cells that are able to escape apoptosis, leading to tumorigenesis.	Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Pediat, Bronx, NY 10461 USA; Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Epidemiol & Social Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Burk, RD (corresponding author), Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Microbiol & Immunol, Ullmann Bldg,Rm 515,1300 Morris Pk Ave, Bronx, NY 10461 USA.			Schoenfeld, Alan R./0000-0002-6778-1548	NIDDK NIH HHS [DK 07218] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007218] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Lu X, 1996, ONCOGENE, V13, P413; Lubensky IA, 1996, AM J PATHOL, V149, P2089; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471	28	55	55	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5851	5857		10.1038/sj.onc.1203985	http://dx.doi.org/10.1038/sj.onc.1203985			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127815				2022-12-17	WOS:000165563100003
J	Worm, J; Bartkova, J; Kirkin, AF; Straten, PT; Zeuthen, J; Bartek, J; Guldberg, P				Worm, J; Bartkova, J; Kirkin, AF; Straten, PT; Zeuthen, J; Bartek, J; Guldberg, P			Aberrant p27(Kip1) promoter methylation in malignant melanoma	ONCOGENE			English	Article						p27; Kip1; tumor suppressor; malignant melanoma; cell cycle; haploinsufficiency; methylation; cyclin-dependent kinase inhibitor	KINASE INHIBITOR P27; CELL LUNG-CANCER; CDK INHIBITORS; BREAST-CANCER; FREQUENT LOSS; GENE; CYCLE; HETEROZYGOSITY; EXPRESSION; MUTATION	p27(Kip1) is a regulator of the mammalian cell cycle and a putative tumor suppressor. Distinct altered patterns of p27(Kip1) protein expression are found in a variety of human carcinomas, and p27(Kip1) expression levels usually correlate directly with disease-free survival. The mechanism(s) by which p27(Kip1) expression is reduced or lost during tumorigenesis remains unclear, Specific alterations of the p27(Kip1) gene, including mutations and homozygous deletions, are exceedingly rare in human cancers. We have used methylation-specific PCR and bisulfite genomic sequencing to examine the methylation status of p27(Kip1) in 61 primary and metastatic tumors and 35 cell lines from patients with malignant melanoma, Dense methylation of a CpG island in the promoter region of p27(Kip1) was detected in four of 45 metastatic tumors (9%) and three of the cell lines (9%), including two cell lines established from two different metastases from the same patient. Examination of a naturally occurring, allele-specific sequence variant demonstrated that p27(Kip1) methylation is associated with transcriptional silencing in situ, Cell lines with p27(Kip1) methylation showed retention of the wild-type allele and detectable p27(Kip1) protein whose abundance was reduced compared with normal melanocytes, Collectively, our data suggest that DNA methylation may be a cause of monoallelic p27(Kip1) silencing in malignant melanoma, which would support a role for p27(Kip1) haploinsuffciency in human cancer.	Danish Canc Soc, Inst Canc Biol, Dept Tumor Cell Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Guldberg, P (corresponding author), Danish Canc Soc, Inst Canc Biol, Dept Tumor Cell Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.		Bartek, Jiri/G-5870-2014	thor Straten, Per/0000-0002-4731-4969				Bartkova J, 1996, INT J CANCER, V66, P732, DOI 10.1002/(SICI)1097-0215(19960611)66:6<732::AID-IJC4>3.0.CO;2-0; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DECKER HJH, 1990, CANCER GENET CYTOGEN, V46, P135, DOI 10.1016/0165-4608(90)90021-2; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Florenes VA, 1998, AM J PATHOL, V153, P305, DOI 10.1016/S0002-9440(10)65572-1; Guldberg P, 1997, CANCER RES, V57, P3660; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAMATA N, 1995, CANCER RES, V55, P2266; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Spirin KS, 1996, CANCER RES, V56, P2400; Takeuchi S, 1996, CANCER RES, V56, P738	26	55	64	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5111	5115		10.1038/sj.onc.1203891	http://dx.doi.org/10.1038/sj.onc.1203891			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042700				2022-12-17	WOS:000089930100009
J	Klausen, P; Pedersen, L; Jurlander, J; Baumann, H				Klausen, P; Pedersen, L; Jurlander, J; Baumann, H			Oncostatin M and Interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells	ONCOGENE			English	Article						HepG3 cells; IL-6 type cytokines; IL-10; p27kip1; growth arrest	CYTOKINE RECEPTOR SUPERFAMILY; HEPATIC CELLS; RESPONSE ELEMENTS; DEPENDENT PHOSPHORYLATION; HEMATOPOIETIN RECEPTORS; GROWTH-INHIBITION; MELANOMA-CELLS; P27(KIP1); EXPRESSION; CANCER	We analysed the regulation of G1-phase progression in relation to cytokine receptor signalling in HepG2 hepatoma cells, stably transduced with the IL-10 receptor after stimulation with Oncostatin M (OSM), IL-6. Leukaemia Inhibitory Factor (LIF) and IL-10. All cytokines induced STAT3 phosphorylation to approximately the same level, but only OSM, and to a lesser extent IL-6, induced STAT5 phosphorylation. The cytokines also stimulated phosphorylation of ERK in the order of decreasing effectiveness: OSM>IL-6>LIF>IL-10. The same order of activity of the cytokines was observed on inhibition of DNA synthesis and accumulation of cells in the G1-phase of the cell cycle. These processes were accompanied by a decrease in cyclin A expression and CDK2 activity, and enhanced accumulation of p27kip1. The level of p27kip1 mRNA expression was unaffected by the cytokines, and maintenance of the elevated level of p27kip1 occurred independently of de novo protein synthesis. Furthermore, inhibition of proteasomal activity increased the level of p27kip1 in the unstimulated cells to the same level as in OSM-treated cells. Inhibition of MEK activation completely abrogated OSM and IL-6 induced p27kip1 accumulation, while expression of dominant negative STAT5 decreased the OSM and IL-6 mediated inhibition of DNA-synthesis and partially inhibited p27kip1 accumulation.	Rigshosp, Finsen Ctr, Leukemia & Lymphoma Marker Lab L4041, DK-2100 Copenhagen, Denmark; Roswell Pk Canc Inst, Dept Mol & Cell Biol, Buffalo, NY 14263 USA	Rigshospitalet; University of Copenhagen; Roswell Park Cancer Institute	Klausen, P (corresponding author), Rigshosp, Finsen Ctr, Leukemia & Lymphoma Marker Lab L4041, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.			Klausen, Pia/0000-0001-9386-9167	NCI NIH HHS [CA 26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Cariou S, 1998, BREAST CANCER RES TR, V52, P29, DOI 10.1023/A:1006154900130; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Lai CF, 1996, J BIOL CHEM, V271, P13968, DOI 10.1074/jbc.271.24.13968; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Lai CF, 1999, J BIOL CHEM, V274, P7793, DOI 10.1074/jbc.274.12.7793; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TAKIZAWA H, 1993, CANCER RES, V53, P4175; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsihlias J, 1999, ANNU REV MED, V50, P401; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; Wiznerowicz M, 1998, ADV EXP MED BIOL, V451, P441	33	55	56	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3675	3683		10.1038/sj.onc.1203707	http://dx.doi.org/10.1038/sj.onc.1203707			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951574				2022-12-17	WOS:000088568300014
J	Chami, M; Gozuacik, D; Saigo, K; Capiod, T; Falson, P; Lecoeur, H; Urashima, T; Beckmann, J; Gougeon, ML; Claret, M; le Maire, M; Brechot, C; Paterlini-Brechot, P				Chami, M; Gozuacik, D; Saigo, K; Capiod, T; Falson, P; Lecoeur, H; Urashima, T; Beckmann, J; Gougeon, ML; Claret, M; le Maire, M; Brechot, C; Paterlini-Brechot, P			Hepatitis B virus-related insertional mutagenesis implicates SERCA1 gene in the control of apoptosis	ONCOGENE			English	Article						SERCA1; Hepatitis B Virus; calcium; apoptosis; cancer	NF-KAPPA-B; X-PROTEIN; HEPATOCELLULAR-CARCINOMA; HBX PROTEIN; SARCOPLASMIC-RETICULUM; TRANSGENIC MICE; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEINS; DNA-BINDING; IN-VITRO	We have used the Hepatitis B Virus DIVA genome as a probe to identify genes clonally mutated in vivo, in human liver cancers. In a tumor, HBV-DNA mas found to be integrated into the gene encoding Sarco/Endoplasmic Reticulum Calcium ATPase (SERCA), which pumps calcium, an important intracellular messenger for cell viability and growth, from the cytosol to the endoplasmic reticulum. The HBV X gene promoter cis-activates chimeric HBV X/SERCA1 transcripts, with splicing of SERCA1 exon II, encoding C-terminally truncated SERCA1 proteins. Two chimeric HBV X/SERCA1 proteins accumulate in the tumor and form dimers. III vitro analyses have demonstrated that these proteins localize to the ER, determine its calcium depletion and induce cell death. We have also shown that these biological effects are related to expression of the SERCA, rather than of the viral moiety. This report involves for the first time the expression of mutated SERCA proteins in vivo in a tumor cell proliferation and in vitro in the control of cell viability.	Necker Inst, U370 INSERM, F-75015 Paris, France; Chiba Univ, Dept Surg 2, Chiba 2638852, Japan; Univ Paris Sud, U442 INSERM, F-91405 Orsay, France; CEA, URA CNRS 2096, F-91191 Gif Sur Yvette, France; Inst Pasteur, F-75015 Paris, France; Ctr Natl Genotypage, F-91057 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Chiba University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CEA; UDICE-French Research Universities; Universite Paris Saclay	Paterlini-Brechot, P (corresponding author), Necker Inst, U370 INSERM, 156 Rue Vaugirard, F-75015 Paris, France.		CAPIOD, Thierry/K-4234-2017; Chami, Mounia/S-6471-2019; Beckmann, Jacques S/A-9772-2008; Devrim, Gozuacik/C-3330-2008	CAPIOD, Thierry/0000-0002-8448-7041; Chami, Mounia/0000-0003-1498-7187; Beckmann, Jacques S/0000-0002-9741-1900; Devrim, Gozuacik/0000-0001-7739-2346; Paterlini- Brechot, Patrizia/0000-0001-7981-6325; Falson, Pierre/0000-0002-9760-4577				Bayle D, 1997, J RECEPT SIGNAL TR R, V17, P29, DOI 10.3109/10799899709036593; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; Chung DC, 1998, CANCER RES, V58, P3706; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dorjsuren D, 1998, MOL CELL BIOL, V18, P7546, DOI 10.1128/MCB.18.12.7546; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; GRAEF E, 1994, ONCOGENE, V9, P81; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guerini D, 1998, ACTA PHYSIOL SCAND, V163, P265; HEILMANN C, 1985, J BIOL CHEM, V260, P788; Hildt E, 1996, SEMIN VIROL, V7, P333, DOI 10.1006/smvy.1996.0041; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KEKULE AS, 1994, PRIMARY LIVER CANC E, V13; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOHN EC, 1995, CANCER RES, V55, P1856; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; Koike K, 1998, HEPATITIS B VIRUS, P133; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; LIN MH, 1989, BIOCHEM BIOPH RES CO, V164, P14, DOI 10.1016/0006-291X(89)91676-8; Ma TS, 1999, CELL CALCIUM, V26, P25, DOI 10.1054/ceca.1999.0049; MacLennan DH, 1998, ACTA PHYSIOL SCAND, V163, P55; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Martonosi AN, 1996, BBA-BIOENERGETICS, V1275, P111, DOI 10.1016/0005-2728(96)00059-X; MINAMI M, 1995, GENOMICS, V29, P403, DOI 10.1006/geno.1995.9004; Morgan AJ, 1998, J PHYSIOL-LONDON, V513, P83, DOI 10.1111/j.1469-7793.1998.083by.x; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; PATERLINI P, 1994, PRIMARY LIVER CANC E, V12, P167; PATERLINI P, 1990, VIRAL HEPATITIS LIVE, P556; Peacocke M, 1999, NAT GENET, V21, P252, DOI 10.1038/6758; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Pineau P, 1996, J VIROL, V70, P7280, DOI 10.1128/JVI.70.10.7280-7284.1996; PircDanoewinata H, 1996, WIEN KLIN WOCHENSCHR, V108, P752; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Raney AK, 1991, MOL BIOL HEPATITIS B, P1; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; Sun BS, 1998, HEPATOLOGY, V27, P228, DOI 10.1002/hep.510270135; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Weil R, 1999, MOL CELL BIOL, V19, P6345; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Zhang YL, 1995, GENOMICS, V30, P415, DOI 10.1006/geno.1995.1259	70	55	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2000	19	25					2877	2886		10.1038/sj.onc.1203605	http://dx.doi.org/10.1038/sj.onc.1203605			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871838				2022-12-17	WOS:000087544500001
J	Hotti, A; Jarvinen, K; Siivola, P; Holtta, E				Hotti, A; Jarvinen, K; Siivola, P; Holtta, E			Caspases and mitochondria in c-Myc-induced apoptosis: identification of ATM as a new target of caspases	ONCOGENE			English	Article						apoptosis; ATM (ataxia telangiectasia mutated); caspases; c-Myc; mitochondria; p53	CYCLE CHECKPOINT PATHWAY; ATAXIA-TELANGIECTASIA; CELL-CYCLE; DNA-DAMAGE; IONIZING-RADIATION; CYTOCHROME-C; P53-DEPENDENT APOPTOSIS; MEDIATED APOPTOSIS; PROTEIN-KINASE; WILD-TYPE	The mechanism(s) of c-Myc transcription factor-induced apoptosis is still obscure. The activation of c-Myc has been found to lead into the processing/activation of caspases (caspase-3), but the significance of this for the cell demise is debatable, Here we report that several targets of caspases (PKC delta, MDM2, PARP, replication factor C, 70 kDa UlsnRNP, fodrin and lamins) are cleaved during c-Myc-induced apoptosis in Rat-1 MycER(TM) cells, indicating an important role for caspases in the apoptotic process. We further found that the ATM (ataxia telangiectasia mutated) - protein is a novel key substrate of caspases, In in vitro assays, purified recombinant ATM protein was found to be cleaved by the effector caspases 3 and 7, The functional significance of the ATM cleavage is supported by the finding that ectopic expression of ATM protected in part against apoptosis, We also show that c-Myc-induced apoptosis involves loss of mitochondrial transmembrane potential, release of cytochrome c from mitochondria into the cytosol and subsequent processing of caspase-9, The cleavage of caspase-9 is, hone, er, minimal and a much later event than the processing/activation of caspase-3, suggesting that it is not the apical caspase, Evidence is provided that there is, nevertheless, an upstream caspase(s) regulating the functions of caspase-3 and mitochondria, Additionally, it mas found that p53 becomes upregulated, together,vith its transcriptional targets MDM2 and p21, upon c-Myc induction, but this occurs also at a later time than the activation of caspase-3.	Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland	University of Helsinki	Holtta, E (corresponding author), Univ Helsinki, Haartman Inst, Dept Pathol, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.							Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; LUCKOW B, 1994, MOL CELL BIOL, V14, P1626, DOI 10.1128/MCB.14.3.1626; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MEYN MS, 1995, CANCER RES, V55, P5991; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NARVANEN O, 1987, FEBS LETT, V224, P156, DOI 10.1016/0014-5793(87)80440-4; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Tsunoda H, 1999, BIOCHEM BIOPH RES CO, V255, P722, DOI 10.1006/bbrc.1999.0143; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhang N, 1998, ONCOGENE, V17, P811, DOI 10.1038/sj.onc.1202007; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	52	55	55	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2354	2362		10.1038/sj.onc.1203567	http://dx.doi.org/10.1038/sj.onc.1203567			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822387				2022-12-17	WOS:000086974300011
J	Ng, SW; Yiu, GK; Liu, Y; Huang, LW; Palnati, M; Jun, SH; Berkowitz, RS; Mok, SC				Ng, SW; Yiu, GK; Liu, Y; Huang, LW; Palnati, M; Jun, SH; Berkowitz, RS; Mok, SC			Analysis of p73 in human borderline and invasive ovarian tumor	ONCOGENE			English	Article						p53-related gene; tumor suppressor; gene expression; ovarian carcinoma; loss of heterozygosity	P53 HOMOLOG; EPITHELIAL TUMORS; CELL-LINES; GENE; MUTATION; EXPRESSION; PROTEIN; CARCINOMA; CANCER; NEUROBLASTOMA	p73 is a novel gene that has high sequence homology and similar gene structure to the tumor suppressor gene p53, We analysed p73 in seven ovarian carcinoma cell Lines and a total of 63 human borderline and invasive ovarian tumor samples. Loss of heterozygosity at this locus was observed in 50% of invasive tumors but in none of the borderline tumors. Biallelic expression of the gene was observed in the heterozygous tumor tissues. Direct sequencing and single-strand conformation polymorphism analyses of the p73 cDNA sequence homologous to the highly mutatable region of p53 did not reveal any mutations. When compared to the primary cultures of normal human ovarian surface epithelial cells and immortalized cell lines, four of the seven ovarian carcinoma cell lines, 71% of the invasive tumors, and 92% of the borderline tumor tissues express elevated levels of p73 transcript. Except for the OVCA3 cell line, Western blot analysis of the nuclear extracts prepared from the cell lines showed concordant levels of p73 protein. Our analysis also demonstrated the expression of a spliced variant of p73 transcript with the omission of exon 2 solely in the cancer cell lines and invasive tumor tissues. This exon 2-spliced transcript would give rise to a truncated p73 protein without the N-terminal transactivation domain. In reminiscence of the dominant negative phenotype of the N-terminal truncated variants of another p53-related gene, p63, the expression of the truncated p73 variant form in ovarian tumors may play an important role in the pathogenesis of ovarian cancer.	Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Ng, SW (corresponding author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, 221 Longwood Ave, Boston, MA 02115 USA.		Yiu, Glenn/AAF-2858-2020		NCI NIH HHS [CA70216, R01CA69453, R01CA69291] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA070216, R01CA069291, R01CA069453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; FAJAC A, 1995, INT J CANCER, V64, P146, DOI 10.1002/ijc.2910640213; FRANKEL RH, 1992, CANCER RES, V52, P1427; GOLENBERG EM, 1993, MOL PHYLOGENET EVOL, V2, P52, DOI 10.1006/mpev.1993.1006; Hagiwara K, 1999, CANCER RES, V59, P4165; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MOK SC, 1995, GYNECOL ONCOL, V57, P299, DOI 10.1006/gyno.1995.1146; MOK SCH, 1993, CANCER RES, V53, P1489; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PEJOVIC T, 1995, ANN MED, V27, P73, DOI 10.3109/07853899509031940; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Shimada A, 1999, CANCER RES, V59, P2781; Takahashi H, 1998, CANCER RES, V58, P2076; Thompson FH, 1997, CANCER GENET CYTOGEN, V96, P106, DOI 10.1016/S0165-4608(96)00307-X; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	30	55	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1885	1890		10.1038/sj.onc.1203512	http://dx.doi.org/10.1038/sj.onc.1203512			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773878				2022-12-17	WOS:000086424300004
J	Tsihlias, J; Zhang, W; Bhattacharya, N; Flanagan, M; Klotz, L; Slingerland, J				Tsihlias, J; Zhang, W; Bhattacharya, N; Flanagan, M; Klotz, L; Slingerland, J			Involvement of p27(Kip1) in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells	ONCOGENE			English	Article						p27; cell cycle; prostate cancer; androgen; cyclin E/cdk2	DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; CYCLE ARREST; TGF-BETA; TRANSCRIPTION FACTOR; ANDROGEN-RECEPTOR; EPITHELIAL-CELLS; MAMMALIAN-CELLS; PROTEIN-KINASE; CDK INHIBITORS	The cell cycle is governed by cyclin dependent kinases (cdks), which are activated by binding of cyclins, inhibited by cdk inhibitors and regulated by phosphorylation and dephosphorylation. Exposure to high dose dihydrotestosterone (DHT) inhibits population growth of the human prostate carcinoma cell line, LNCaP, To determine the mechanism of growth arrest by high dose DHT, we assayed the changes in cell cycle profile and the cell cycle regulators that mediate these effects. Treatment of asynchronously growing LNCaP cells with 100 nM DHT caused a G1 arrest, The proportion of cells in S phase fell from 22 to 2%, while the G1 fraction rose from 74 to 92% by 24 h, Loss of phosphorylation of the retinoblastoma protein was noted and cdk4 and cyclin E/cdk2 activities fell. Inhibition of these G1 cyclin dependent kinases was not due to loss of either cyclin or cdk proteins nor to increases in the cdk inhibitors p16(INK4A) and p21(Cip1). p21(Cip1) protein levels remained constant, and cyclin E-associated p21(Cip1) fell, suggesting that p21(Cip1) is not relevant to this form of cyclin E/cdk2 inhibition, Of note, total p27(Kip1) levels and cyclin E-associated p27(Kip1) increased as cells arrested and the amount of the CAK activated cdk2 bound to cyclin E decreased, p27(Kip1) immunodepletion experiments demonstrated that the DHT-mediated increase in p27(Kip1) was sufficient to fully saturate and inhibit target cyclin E/cdk2, The inhibition of cyclin E/cdk2 by p27(Kip1) contributes to G1 arrest of LNCaP following high dose DHT. p27(Kip1) may be a key effector of androgen dependent growth modulation in prostate cancer cells.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Res, Toronto, ON M4N 3M5, Canada; Gilead Sci Inc, Foster City, CA 94404 USA; Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Urol, Toronto, ON M4N 3M5, Canada; Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Gilead Sciences; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Slingerland, J (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Res, S-218,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; BERNS EMJJ, 1986, PROSTATE, V9, P247, DOI 10.1002/pros.2990090305; Cariou S, 1998, BREAST CANCER RES TR, V52, P29, DOI 10.1023/A:1006154900130; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen Y, 1996, CELL GROWTH DIFFER, V7, P1571; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Cote RJ, 1998, J NATL CANCER I, V90, P916, DOI 10.1093/jnci/90.12.916; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Enders GH, 1996, ONCOGENE, V12, P1239; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Guo YP, 1997, CLIN CANCER RES, V3, P2269; Hakimi JM, 1996, WORLD J UROL, V14, P329; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KAIGHN ME, 1979, INVEST UROL, V17, P16; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kim S H, 1996, Prog Cell Cycle Res, V2, P137; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Kokontis JM, 1998, MOL ENDOCRINOL, V12, P941, DOI 10.1210/me.12.7.941; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Menjo M, 1998, ONCOGENE, V17, P2619, DOI 10.1038/sj.onc.1202193; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pagano M, 1996, PEZ FDN SYM, V7, P241; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PEEHL DM, 1994, ATLAS HUMAN TUMOUR C; PEELING WB, 1989, UROLOGY, V33, P45, DOI 10.1016/0090-4295(89)90106-4; Peng D, 1996, CANCER RES, V56, P3666; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REED SI, 1994, J CELL SCI, P69; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; StCroix B, 1996, NAT MED, V2, P1204; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Tan P, 1997, CANCER RES, V57, P1259; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsihlias J, 1998, CANCER RES, V58, P542; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang QM, 1996, CANCER RES, V56, P264; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5; Zi XL, 1998, CANCER RES, V58, P1920	76	55	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2000	19	5					670	679		10.1038/sj.onc.1203369	http://dx.doi.org/10.1038/sj.onc.1203369			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698512				2022-12-17	WOS:000085192000009
J	Duval, A; Iacopetta, B; Ranzani, GN; Lothe, RA; Thomas, G; Hamelin, R				Duval, A; Iacopetta, B; Ranzani, GN; Lothe, RA; Thomas, G; Hamelin, R			Variable mutation frequencies in coding repeats of TCF-4 and other target genes in colon, gastric and endometrial carcinoma showing microsatellite instability	ONCOGENE			English	Article						TCF-4; coding repeat; stomach; endometrium; colon; microsatellite instability	REPLICATION ERROR PHENOTYPE; II RECEPTOR GENE; BETA-CATENIN; COLORECTAL-CANCER; SOMATIC MUTATIONS; HOMOLOG; APC; ACTIVATION; TUMORS; DNA	Frameshift mutations in genes containing mononucleotide repeats are often observed in cancers exhibiting a high frequency of microsatellite instability (MSI-H). Several tumor types, including colorectal, gastric, and endometrial carcinomas, display this phenotype in a significant proportion of cases. We recently showed in a large series of MSI-H colorectal tumors that approximately 40% of them exhibited frameshift mutations in an (A)9 tract within the coding region of the TCF-4 gene, a crucial member of the APC/beta-catenin/TCF pathway. In the present study, we have examined MSI-H cancers from other primary tumor sites for mutations in this new target gene. Two of 22 (9%) MSI-H primary gastric cancers and none of 23 MSI-H endometrial primary tumors and cell lines were found to have a 1 bp deletion in the TCF-4 repeat. In the same series of tumors we also looked for frameshift mutations in other coding repeats localized within the TGF beta-RII, BAX, IGFIIR, hMSH3 and hMSH6 genes. Our results suggest that the TCF-4 gene, in a similar manner to some of these latter genes, is differentially altered in MSI-H tumors from different primary sites.	INSERM, U434, CEPH, F-75010 Paris, France; Univ Western Australia, Dept Surg, Nedlands, WA 6009, Australia; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; Norwegian Radium Hosp, Inst Canc Res, Dept Genet, Oslo, Norway	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Western Australia; University of Pavia; University of Oslo	Hamelin, R (corresponding author), INSERM, U434, CEPH, 27 Rue Juliette Dodu, F-75010 Paris, France.			Lothe, Ragnhild A./0000-0002-1693-1032; Ranzani, Guglielmina/0000-0002-3080-6473				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Candidus S, 1996, CANCER RES, V56, P49; Duval A, 1999, CANCER RES, V59, P4213; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fukuchi T, 1998, CANCER RES, V58, P3526; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoang JM, 1997, CANCER RES, V57, P300; HORII A, 1992, CANCER RES, V52, P5231; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MYEROFF LL, 1995, CANCER RES, V55, P5545; OGASAWARA S, 1994, VIRCHOWS ARCH, V424, P607, DOI 10.1007/BF01069740; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, CANCER RES, V55, P5548; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; TAMURA G, 1994, CANCER RES, V54, P1149; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Wu MS, 1998, CANCER RES, V58, P1494; Yamamoto H, 1997, CANCER RES, V57, P4420; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	26	55	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6806	6809		10.1038/sj.onc.1203287	http://dx.doi.org/10.1038/sj.onc.1203287			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597289				2022-12-17	WOS:000083792000023
J	Vooijs, M; Berns, A				Vooijs, M; Berns, A			Developmental defects and tumor predisposition in Rb mutant mice	ONCOGENE			English	Review						tumor suppressor; knockout mice; tissue specific; cancer models	LARGE-T-ANTIGEN; RETINOID-BINDING PROTEIN; CYCLIN-DEPENDENT KINASES; SKELETAL-MUSCLE CELLS; EMBRYONIC STEM-CELLS; 4 DIFFERENT LINES; TRANSGENIC MICE; RETINOBLASTOMA-PROTEIN; SUPPRESSOR GENE; P53-DEPENDENT APOPTOSIS	Targeted gene disruption in the mouse germline permits the introduction of gene mutations similar to those found in inherited human diseases, New advances in gene targeting that enable cell type specific gene disruption in mice further increases the utility of mouse models to study genetic defects as found in cancer. Here we review the phenotypes observed in mice carrying germline mutated copies of the retinoblastoma tumor suppressor gene. We will illustrate holy methods that permit tissue-specific Rb inactivation in mice provide new and more versatile tools to gain insight into the etiology of sporadic cancer.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Vooijs, Marc/K-3522-2019					Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; AlUbaidi MR, 1997, EXP EYE RES, V64, P573, DOI 10.1006/exer.1996.0240; ALUBAIDI MR, 1992, P NATL ACAD SCI USA, V89, P1194, DOI 10.1073/pnas.89.4.1194; ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681; BADER JL, 1980, LANCET, V2, P582; Balmain A, 1998, TRENDS GENET, V14, P139, DOI 10.1016/S0168-9525(98)01422-X; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BERNARDS R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P33; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; BOOKSTEIN R, 1994, J CELL BIOCHEM, P217; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Bremner R, 1997, AM J HUM GENET, V61, P556, DOI 10.1086/515499; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; CHEN JZ, 1993, CURR BIOL, V3, P405, DOI 10.1016/0960-9822(93)90347-Q; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Coxon AB, 1998, ONCOGENE, V17, P1625, DOI 10.1038/sj.onc.1202381; CRYNS VL, 1994, NEW ENGL J MED, V330, P757, DOI 10.1056/NEJM199403173301105; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FUNG KM, 1994, LAB INVEST, V70, P114; Gallie BL, 1999, CANCER RES, V59, p1731S; Ghebranious N, 1998, ONCOGENE, V17, P3385, DOI 10.1038/sj.onc.1202573; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Griep AE, 1998, INVEST OPHTH VIS SCI, V39, P2723; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HAMMANG JP, 1993, NEURON, V10, P1197, DOI 10.1016/0896-6273(93)90067-2; HANSPAL M, 1994, BLOOD, V84, P3494; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARVEY M, 1993, ONCOGENE, V8, P2457; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HARVEY M, 1995, CANCER RES, V55, P1146; Hooper ML, 1999, BRIT J CANCER, V79, P1273, DOI 10.1038/sj.bjc.6690204; Hooper ML, 1998, EMBO J, V17, P6783, DOI 10.1093/emboj/17.23.6783; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWES KA, 1994, INVEST OPHTH VIS SCI, V35, P342; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hu NP, 1997, CANCER RES, V57, P4123; HU NP, 1994, ONCOGENE, V9, P1021; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; ITO M, 1994, INT J ONCOL, V4, P1329; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; JAKOBIEC FA, 1977, CANCER-AM CANCER SOC, V39, P2048, DOI 10.1002/1097-0142(197705)39:5<2048::AID-CNCR2820390522>3.0.CO;2-9; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kanoe H, 1998, ANTICANCER RES, V18, P2317; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lahoz EG, 1999, MOL CELL BIOL, V19, P353; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LIOU GI, 1990, J BIOL CHEM, V265, P8373; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Marcus DM, 1996, INVEST OPHTH VIS SCI, V37, P392; Marcus DM, 1998, SURV OPHTHALMOL, V43, P59, DOI 10.1016/S0039-6257(98)00019-8; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; MIYAMOTO H, 1995, BRIT J CANCER, V71, P831, DOI 10.1038/bjc.1995.160; Moll AC, 1997, OPHTHALMIC GENET, V18, P27, DOI 10.3109/13816819709057880; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Nork TM, 1997, ARCH OPHTHALMOL-CHIC, V115, P213, DOI 10.1001/archopht.1997.01100150215011; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Parry D, 1999, MOL CELL BIOL, V19, P1775; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Porter A, 1998, TRENDS GENET, V14, P73, DOI 10.1016/S0168-9525(97)01326-7; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Rampalli AM, 1998, ONCOGENE, V16, P399, DOI 10.1038/sj.onc.1201546; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; ROBANUSMAANDAG EC, 1994, EMBO J, V13, P4260; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Ueki K, 1996, CANCER RES, V56, P150; VARLEY JM, 1989, ONCOGENE, V4, P725; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Vooijs M, 1998, ONCOGENE, V17, P1, DOI 10.1038/sj.onc.1202169; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yamasaki L., 1999, BIOCHIM BIOPHYS ACTA, V1423, P9; YOKOYAMA T, 1992, EXP EYE RES, V55, P225, DOI 10.1016/0014-4835(92)90186-V; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zou MJ, 1998, ENDOCRINE, V8, P61, DOI 10.1385/ENDO:8:1:61	137	55	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	1999	18	38					5293	5303		10.1038/sj.onc.1202999	http://dx.doi.org/10.1038/sj.onc.1202999			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498881				2022-12-17	WOS:000082808400007
J	Albagli, O; Lantoine, D; Quief, S; Quignon, F; Englert, C; Kerckaert, JP; Montarras, D; Pinset, C; Lindon, C				Albagli, O; Lantoine, D; Quief, S; Quignon, F; Englert, C; Kerckaert, JP; Montarras, D; Pinset, C; Lindon, C			Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci	ONCOGENE			English	Article						BCL6(LAZ3) protooncogene; tetracycline regulated expression; cell cycle; DNA replication; growth suppression; apoptosis	ACUTE PROMYELOCYTIC LEUKEMIA; GERMINAL-CENTER FORMATION; ZINC-FINGER PROTEIN; B-CELL LYMPHOMA; PLZF-RAR-ALPHA; NON-HODGKINS-LYMPHOMA; AFFECTING BAND 3Q27; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; SOMATIC HYPERMUTATION	One of the most frequent genetic abnormalities associated with non Hodgkin lymphoma is the structural alteration of the 5' non coding/regulatory region of the BCL6 (LAZ3) protooncogene. BCL6 encodes a POZ/Zn finger protein, a structure similar to that of many Drosophila developmental regulators and to another protein involved in a human hematopoietic malignancy, PLZF, BCL6 is a sequence specific transcriptional repressor controlling germinal center formation and T cell dependent immune response. Although the expression of BCL6 negatively correlates with cellular proliferation in different cell types, the influence of BCL6 on cell growth and survival is currently unknown so that the way its deregulation may contribute to cancer remains elusive. To directly address this issue, we used a tetracycline-regulated system in human U2OS osteosarcoma cells and thus found that BCL6 mediates growth suppression associated with impaired S phase progression and apoptosis, Interestingly, overexpressed BCL6 can colocalize with sites of ongoing DNA synthesis, suggesting that it may directly interfere with S phase initiation and/or progression, In contrast, the isolated Zn finger region of BCL6, which binds BCL6 target sequence but lacks transcriptional repression activity, slows, but does not suppress, U2OS cell growth, is less efficient at delaying S phase progression, and does not trigger apoptosis, Thus, for a large part, the effects of BCL6 overexpression on cell growth and survival depend on its ability to engage protein/protein interactions with itself and/or its transcriptional corepressors. That BCL6 restricts cell growth suggests that its deregulation upon structural alterations may alleviate negative controls on the cell cycle and cell survival.	IRCL, INSERM, U524, F-59045 Lille, France; Inst Pasteur, Dept Biol Mol, CNRS, URA 1947, F-72015 Paris, France; Hop St Louis, Ctr Georges Hayem, CNRS, UPR 9051, F-75475 Paris 10, France; Res Ctr Karlsruhe, Inst Genet, D-76344 Eggenstein Leopoldshafen, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); Helmholtz Association; Karlsruhe Institute of Technology	Albagli, O (corresponding author), IRCL, INSERM, U524, Pl Verdun, F-59045 Lille, France.		Quignon, Frédérique/P-4249-2017	Lindon, Catherine/0000-0003-3554-2574; Englert, Christoph/0000-0002-5931-3189				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Albagli-Curiel O, 1998, DIFFERENTIATION, V64, P33, DOI 10.1046/j.1432-0436.1998.6410033.x; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P323, DOI 10.1002/(SICI)1098-2264(199812)23:4<323::AID-GCC7>3.3.CO;2-V; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen WY, 1998, ONCOGENE, V17, P1717, DOI 10.1038/sj.onc.1202098; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; FUKUDA T, 1995, ONCOGENE, V11, P1657; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LIMADEFARIA A, 1968, NATURE, V217, P138, DOI 10.1038/217138a0; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MAKOSWALES M, 1995, NAT MED, V1, P570; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Moriyama M, 1997, ONCOGENE, V14, P2465, DOI 10.1038/sj.onc.1201084; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; NUMOTO M, 1995, JPN J CANCER RES, V86, P277, DOI 10.1111/j.1349-7006.1995.tb03051.x; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; Okabe S, 1998, MOL CELL BIOL, V18, P4235, DOI 10.1128/MCB.18.7.4235; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yamochi T, 1997, LEUKEMIA, V11, P694, DOI 10.1038/sj.leu.2400631; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V228, P216, DOI 10.1006/bbrc.1996.1642	66	55	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	1999	18	36					5063	5075		10.1038/sj.onc.1202892	http://dx.doi.org/10.1038/sj.onc.1202892			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490843				2022-12-17	WOS:000082497100006
J	Lee, ST; Hoeflich, KP; Wasfy, GW; Woodgett, JR; Leber, B; Andrews, DW; Hedley, DW; Penn, LZ				Lee, ST; Hoeflich, KP; Wasfy, GW; Woodgett, JR; Leber, B; Andrews, DW; Hedley, DW; Penn, LZ			Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts	ONCOGENE			English	Article						Myc; Bcl-2; apoptosis; etoposide; mitochondrial; membrane potential	PROGRAMMED CELL-DEATH; MITOCHONDRIAL PERMEABILITY TRANSITION; C-MYC; INTRACELLULAR CALCIUM; OUTER-MEMBRANE; PROTEIN; LOCALIZATION; ONCOPROTEIN; HOMEOSTASIS; GENERATION	Bcl-2 is a key inhibitor of a broad range of apoptotic pathways, yet neither the mechanism of action nor the role of Bcl-2 subcellular localization are well understood. The subcellular localization of Bcl-2 includes the mitochondrial membrane as well as the contiguous membrane of the endoplasmic reticulum and nuclear envelope. Most studies suggest that the ability of Bcl-2 to confer cell survival is dependent upon its localization to the mitochondria, In this manuscript, we show that Bcl-2 targeted to the endoplasmic reticulum can inhibit Myc-, but not etoposide-induced apoptosis in the Rat-1 fibroblast cell line. By contrast, wild type Bcl-2 can inhibit apoptosis triggered by either death agonist, We further show both Myc and etoposide trigger disruption of mitochondrial membrane potential (MMP) and induce poly-ADP ribose polymerase (PARP) cleavage, but release of calcium was not evident. Bcl-2 abrogates apoptosis at or upstream of MMP depletion showing that Bcl-2 does not have to reside at the mitochondria to prevent apoptosis, These results further elucidate the biochemical events associated with Myc- and etoposide-induced apoptosis and significantly advance our understanding of Bcl-2 function.	Princess Margaret Hosp, Ontario Canc Inst, Div Cellular Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Princess Margaret Hosp, Ontario Canc Inst, Div Mol Biol, Toronto, ON M5G 2M9, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; McMaster University; McMaster University	Penn, LZ (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Div Cellular Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Penn, Linda/0000-0001-8133-5459; Andrews, David/0000-0002-9266-7157; Hedley, David/0000-0003-1323-2655; Leber, Brian/0000-0001-5502-1480				AKAO Y, 1994, CANCER RES, V54, P2468; Backway KL, 1997, CANCER RES, V57, P2446; BAFFY G, 1993, J BIOL CHEM, V268, P6511; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GREEN DR, 1995, CURR OPIN IMMUNOL, V7, P694, DOI 10.1016/0952-7915(95)80079-4; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RIPARBELLI MG, 1995, EXP CELL RES, V221, P363, DOI 10.1006/excr.1995.1386; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	46	55	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3520	3528		10.1038/sj.onc.1202716	http://dx.doi.org/10.1038/sj.onc.1202716			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376530				2022-12-17	WOS:000080850600010
J	Rhee, CH; Hess, K; Jabbur, J; Ruiz, M; Yang, Y; Chen, S; Chenchik, A; Fuller, GN; Zhang, W				Rhee, CH; Hess, K; Jabbur, J; Ruiz, M; Yang, Y; Chen, S; Chenchik, A; Fuller, GN; Zhang, W			cDNA expression array reveals heterogeneous gene expression profiles in three glioblastoma cell lines	ONCOGENE			English	Article						gene expression; glioblastoma; cDNA array	TUMOR-SUPPRESSOR GENE; P53; GROWTH; INHIBITION; INDUCTION; CANDIDATE; DPC4	Tumor cell lines are an indispensable tool for cancer research. However, among cell lines of the same pathological group, heterogeneity has been detected in gene expression, gene mutation, and cellular response to various treatments. In this study, we systematically investigated the extent of heterogeneity of gene expression in three glioblastoma cell lines using cDNA array technology in which the expression of 588 cellular genes is studied simultaneously. Comparison of the expression profiles revealed substantial qualitative and quantitative heterogeneity, Among the 588 genes, 197 genes were expressed in all three lines and 56 genes were not expressed in any of the three lines; total of 222 genes were expressed in only two of the three cell lines, acid 113 genes were expressed in only one of the three cell lines. These results provide molecular evidence that cell lines of the same pathological origin can be highly heterogeneous.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Clontech Labs Inc, Palo Alto, CA 94303 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Zhang, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA.		Hess, Kenneth/K-6546-2019	Hess, Kenneth/0000-0003-1377-6070; Fuller, Gregory/0000-0001-9447-2647	NATIONAL CANCER INSTITUTE [R29CA067987, P01CA055164] Funding Source: NIH RePORTER; NCI NIH HHS [CA67987, CA55164] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DIMERY IW, 1983, EXP HEMATOL, V11, P601; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Grau AM, 1997, CANCER RES, V57, P3929; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JUNG JM, 1995, CELL GROWTH DIFFER, V6, P909; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KASTAN MB, 1991, CANCER RES, V51, P6304; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; NOWELL PC, 1986, CANCER RES, V46, P2203; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; VAN MEIR EG, 1994, CANCER RES, V54, P649; WEINBERG RA, 1989, CANCER RES, V49, P3713; ZHANG W, 1995, CANCER RES, V55, P668	16	55	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2711	2717		10.1038/sj.onc.1202623	http://dx.doi.org/10.1038/sj.onc.1202623			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348345				2022-12-17	WOS:000080124900006
J	Fujimoto, A; Morita, R; Hatta, N; Takehara, K; Takata, M				Fujimoto, A; Morita, R; Hatta, N; Takehara, K; Takata, M			p16(INK4a) inactivation is not frequent in uncultured sporadic primary cutaneous melanoma	ONCOGENE			English	Article						loss of heterozygosity; microsatellites; gene mutation; tumour suppressor gene; immunohistochemistry	TUMOR-SUPPRESSOR GENE; CELL LUNG-CANCER; ACRAL LENTIGINOUS MELANOMA; CHROMOSOME 9P DELETIONS; KINASE-4 INHIBITOR GENE; HOMOZYGOUS DELETIONS; GERMLINE MUTATIONS; DELETED REGION; OVARIAN-TUMORS; METHYLATION	In an attempt to examine whether the inactivation of p16(INK4a) is an important early event in the development of sporadic melanoma in vivo, we have systematically analysed 46 uncultured primary cutaneous melanomas, Loss of heterozygosity (LOH) of chromosome region 9p21-22 (where the p16(INK4a) resides) was detected in II tumours (24%) by PCR-based LOH analyses. Direct sequencing of all three exons of the p16(INK4a) gene in these 11 tumours revealed no somatic mutation although germline mutations which have not been reported previously as common polymorphisms were detected in two patients. Further sequencing analyses of the p16(INK4a) gene exon 2 in 19 additional tumours with no evidence of LOH on 9p21-22 identified only one heterozygous C->T mutation at codon 81 altering a proline to a leucine. A sensitive methylation-specific PCR assay did not reveal ne novo methylation of the 5'CpG island in exon 1 of the p16(INK4a) gene in any of the tumours showing 9p21-22 allelic loss or a heterozygous p16(INK4a) mutation. Complete loss of p16(INK4a) protein, most likely due to homozygous deletion of the p16(INK4a) gene, was observed in 6 (15%) out of 39 evaluable cases by immunohistochemical analyses on frozen sections using two different anti-p16(INK4a) antibodies. The results show that inactivation of p16(INK4a) is not as frequent in primary melanoma as has been reported in cell lines, and warrant further search for another tumour suppressor on 9p21-22. This study also emphasizes the importance of examining uncultured primary tumours rather than cell lines to define early events in tumorigenesis.	Kanazawa Univ, Sch Med, Dept Dermatol, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University	Takata, M (corresponding author), Kanazawa Univ, Sch Med, Dept Dermatol, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.			HATTA, NAOHITO/0000-0003-1590-8348				Biden K, 1997, HEPATOLOGY, V25, P593, DOI 10.1002/hep.510250317; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Castellano M, 1997, CANCER RES, V57, P4868; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; Farrell WE, 1997, CANCER RES, V57, P2703; Flores JF, 1996, CANCER RES, V56, P5023; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; Gonzalgo ML, 1997, CANCER RES, V57, P5336; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Healy E, 1996, J INVEST DERMATOL, V107, P318, DOI 10.1111/1523-1747.ep12363118; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; Healy E, 1996, CANCER RES, V56, P589; HERMAN JG, 1995, CANCER RES, V55, P4525; Hermann RC, 1996, HARVARD REV PSYCHIAT, V4, P98, DOI 10.3109/10673229609030529; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISSHIKI K, 1994, ONCOGENE, V9, P1649; KAGESHITA T, 1991, CANCER RES, V51, P1726; Kamb A, 1994, Nat Genet, V8, P23; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kim SK, 1997, CANCER RES, V57, P400; Kinoshita I, 1996, CANCER RES, V56, P5557; KREMENTZ ET, 1982, ANN SURG, V195, P632, DOI 10.1097/00000658-198205000-00013; LIU Q, 1995, ONCOGENE, V10, P1061; Marchini S, 1997, BRIT J CANCER, V76, P146, DOI 10.1038/bjc.1997.355; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Morita R, 1998, J INVEST DERMATOL, V111, P919, DOI 10.1046/j.1523-1747.1998.00458.x; Myohanen SK, 1998, CANCER RES, V58, P591; NAKAGAWA K, 1995, ONCOGENE, V11, P1843; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; Ohta M, 1996, INT J CANCER, V65, P762, DOI 10.1002/(SICI)1097-0215(19960315)65:6<762::AID-IJC9>3.0.CO;2-X; POLLOCK PM, 1995, ONCOGENE, V11, P663; PUIG S, 1995, AM J HUM GENET, V57, P395; REED JA, 1995, CANCER RES, V55, P2713; Schmidt EE, 1997, BRIT J CANCER, V75, P2, DOI 10.1038/bjc.1997.2; SEIJI M, 1979, PIGMENT CELL, V5, P95; Shih YC, 1997, INT J CANCER, V70, P508, DOI 10.1002/(SICI)1097-0215(19970304)70:5<508::AID-IJC3>3.3.CO;2-6; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; Wiest JS, 1997, CANCER RES, V57, P1	47	55	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2527	2532		10.1038/sj.onc.1202803	http://dx.doi.org/10.1038/sj.onc.1202803			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229204				2022-12-17	WOS:000079703300013
J	Lian, ZR; Pan, JB; Liu, J; Zhang, SM; Zhu, MH; Arbuthnot, P; Kew, M; Feitelson, MA				Lian, ZR; Pan, JB; Liu, J; Zhang, SM; Zhu, MH; Arbuthnot, P; Kew, M; Feitelson, MA			The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis	ONCOGENE			English	Article						translation initiation; hepatitis B X antigen; Sui1; hepatocellular carcinoma	VIRUS HBX PROTEIN; HEPATOCELLULAR-CARCINOMA; LIVER-CANCER; DNA-BINDING; TRANSACTIVATION FUNCTION; REPLICATIVE SENESCENCE; CELLULAR SENESCENCE; INTEGRATED STATE; CARRIER PATIENTS; GENE PRODUCT(S)	The role of hepatitis B virus X antigen in the development of hepatocellular carcinoma was explored by stably transfecting HepG2 cells with an X antigen expression vector, and identifying the differences in gene expression that distinguish X positive from X negative cells by subtractive PCR, One differentially expressed gene, the human homolog of sdl (hu-sui1), encodes a translation initiation factor whose expression was suppressed by X antigen in HepG2 cells. Hu-Sui1 was also expressed in nontumor liver but not in tumor cells from patients with hepatocellular carcinoma. Introduction of hu-sui1 into HepG2 cells inhibited cell growth in culture, in soft agar, and partially inhibited tumor formation in nude mice. Hence, the suppression of hu-sui1 by X antigen may result in the abrogation of negative growth regulation and contribute to the development of hepatocellular carcinoma.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Witwatersrand, Dept Med, Mol Hepatol Res Unit, Johannesburg, South Africa; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Fourth Mil Med Coll, Dept Pathol, Xian, Shanxi, Peoples R China	Jefferson University; University of Witwatersrand; Jefferson University; Air Force Military Medical University	Feitelson, MA (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 222 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.		Arbuthnot, Patrick Brian/B-8163-2009; Lian, Zhaorui/AAW-2379-2020		NCI NIH HHS [CA48656, CA66971] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048656, R29CA048656, R01CA066971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; AUTUNOVIC J, 1993, CELL MOL BIOL RES, V39, P463; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benson DA, 1997, NUCLEIC ACIDS RES, V25, P1, DOI 10.1093/nar/25.1.1; Bond J, 1996, ONCOGENE, V13, P2097; CEPKO CL, 1992, TRANSDUCTION GENES U; CHEN JY, 1988, HEPATOLOGY, V8, P518, DOI 10.1002/hep.1840080315; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Cui Y, 1998, MOL CELL BIOL, V18, P1506, DOI 10.1128/MCB.18.3.1506; DANOS O, 1991, METHOD MOL BIOL, V8, P17; DUAN LX, 1995, HUM GENE THER, V6, P561; FEITELSON MA, 1988, J MED VIROL, V24, P121, DOI 10.1002/jmv.1890240202; FEITELSON MA, 1990, GASTROENTEROLOGY, V98, P1071, DOI 10.1016/0016-5085(90)90035-Y; FEITELSON MA, 1990, VIROLOGY, V177, P357, DOI 10.1016/0042-6822(90)90491-9; FEITELSON MA, 1986, HEPATOLOGY, V6, P191, DOI 10.1002/hep.1840060207; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FEITELSON MA, 1990, VIROLOGY, V177, P367, DOI 10.1016/0042-6822(90)90492-A; FIELDS C, 1994, BIOCHEM BIOPH RES CO, V198, P288, DOI 10.1006/bbrc.1994.1040; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; HENSLER PJ, 1995, AM J PATHOL, V147, P1; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HORIIKE N, 1991, J INFECT DIS, V164, P1104, DOI 10.1093/infdis/164.6.1104; KASTAN MB, 1991, CANCER RES, V51, P6304; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; KWEE L, 1992, J VIROL, V66, P4382, DOI 10.1128/JVI.66.7.4382-4389.1992; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P224, DOI 10.1073/pnas.95.1.224; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Luber B, 1996, ONCOGENE, V12, P1597; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MARAKAMI S, 1994, J BIOL CHEM, V269, P15118; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; Ozer A, 1996, GASTROENTEROLOGY, V110, P1519, DOI 10.1053/gast.1996.v110.pm8613059; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; ROBINSON WS, 1982, VIRAL HEPATITIS, P57; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; SEEGER C, 1991, J VIROL, V65, P1673, DOI 10.1128/JVI.65.4.1673-1679.1991; SEIFER M, 1991, J HEPATOL, V13, P61, DOI DOI 10.1016/0168-8278(91)90026-8; SHAFRITZ DA, 1981, NEW ENGL J MED, V305, P1067, DOI 10.1056/NEJM198110293051807; Shantz LM, 1996, CANCER RES, V56, P5136; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Sun BS, 1998, HEPATOLOGY, V27, P228, DOI 10.1002/hep.510270135; Szmuness W, 1978, Prog Med Virol, V24, P40; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TAKADA S, 1995, J CANCER RES CLIN, V121, P593, DOI 10.1007/BF01197776; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; TWU JS, 1989, J VIROL, V63, P2857, DOI 10.1128/JVI.63.6.2857-2860.1989; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; VALENZUELA P, 1980, ANIMAL VIRUS GENETIC, P57; VILE R, 1991, VIRAL VECTORS GENE E, V8, P1; WANG WL, 1991, CANCER RES, V51, P4971; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU YZ, 1987, J NATL CANCER I, V79, P223; ZHU MH, 1993, INT J CANCER, V55, P571, DOI 10.1002/ijc.2910550409	81	55	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1677	1687		10.1038/sj.onc.1202470	http://dx.doi.org/10.1038/sj.onc.1202470			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208429				2022-12-17	WOS:000079025000003
J	Adnane, J; Shao, ZH; Robbins, PD				Adnane, J; Shao, ZH; Robbins, PD			Cyclin D1 associates with the TBP-associated factor TAF(II)250 to regulate Sp1-mediated transcription	ONCOGENE			English	Article						cyclin D1; Sp1; Rb; TAF(II)250	CDK-ACTIVATING KINASE; RETINOBLASTOMA PROTEIN; G1 CYCLINS; DIFFERENTIAL REGULATION; GROWTH SUPPRESSION; ESTROGEN-RECEPTOR; CELL-LINE; GENE; BINDING; E2F	We have previously shown that Sp1-mediated transcription is stimulated by Rb and repressed by cyclin D1. The stimulation of Sp1 transcriptional activity by Rb iis conferred, in part, through a direct interaction with the TBP-associated factor TAF(II)250. Here we investigated the mechanism(s) through which cyclin D1 represses Sp1. We examined the ability of cyclin D1 to regulate transcription mediated by Gal4-Sp1 fusion proteins, which contain the Gal4 DNA-binding domain and Spl trans-activation domain(s). The domain of Spl sufficient to confer repression by cyclin D1 was mapped to a region important for interaction with TAF(II)110. We further demonstrate that TAF(II)250-cyclin D1 complexes can be immunoprecipitated from mammalian and baculovirus-infected insect cells and that recombinant GST-TAF(II)250 (amino acids 1-434) associates with cyclin D1 in vitro. Moreover, the overexpression of Rb or CDK4 reduced the level of TAF(II)250-cyclin D1 complex. The amino terminus of cyclin D1 (amino acids 1-100) was sufficient for association with TAF(II)250 and for repressing Spl-mediated transcription. Taken together, the results suggest that cyclin D1 may regulate transcription by interacting directly or indirectly with TAF(II)250.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Robbins, PD (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA.				NCI NIH HHS [CA55227] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; CROSS F, 1995, TRENDS GENET, V11, P209, DOI 10.1016/S0168-9525(00)89047-2; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAYASHIDA T, 1994, GENE, V141, P267; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; KATO J, 1993, GENE DEV, V7, P331; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; Rushton JJ, 1997, CELL GROWTH DIFFER, V8, P1099; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; SHAO ZH, 1995, ONCOGENE, V10, P221; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SIEGERT J, 1998, UNPUB MOL CELL BIOL; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	49	55	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					239	247		10.1038/sj.onc.1202297	http://dx.doi.org/10.1038/sj.onc.1202297			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926939	Bronze			2022-12-17	WOS:000078166000026
J	Chaffanet, M; Popovici, C; Leroux, D; Jacrot, M; Adelaide, J; Dastugue, N; Gregoire, MJ; Hagemeijer, A; Lafage-Pochitaloff, M; Birnbaum, D; Pebusque, MJ				Chaffanet, M; Popovici, C; Leroux, D; Jacrot, M; Adelaide, J; Dastugue, N; Gregoire, MJ; Hagemeijer, A; Lafage-Pochitaloff, M; Birnbaum, D; Pebusque, MJ			t(6;8), t(8;9) and t(8;13) translocations associated with stem cell myeloproliferative disorders have close or identical breakpoints in chromosome region 8p11-12	ONCOGENE			English	Article						FGFR1 gene; leukemia; lymphoma; human chromosome pairs 6, 8, 9, 13; translocation; fluorescence in situ hybridization; stem cell; hematopoiesis	ACUTE MONOCYTIC LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE MONOBLASTIC LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; T-CELL; CLINICOPATHOLOGICAL ENTITY; RECIPROCAL TRANSLOCATION; MYELOMONOCYTIC LEUKEMIA; RECEPTOR GENES; SHORT ARM	A stem-cell myeloproliferative disorder involving T- and B-cell, and myeloid lineages, is associated with three different translocations with a breakpoint in region p11-12 of chromosome 8: t(6;8)(q27;p11), t(8;9)(p11;q33), and t(8;13)(p12;q12), respectively. Using fluorescence in situ hybridization (FISH), we have analysed blood cells from a series of five patients carrying these different translocations. We have identified cosmids from chromosome region 8p11-12 that span the breakpoint in all the cases. They are specific for the FGFR1 gene that encodes a receptor for members of the FGF family. The breakpoint was further detected by Southern and pulsed-field gel electrophoresis analyses with probes from the FGFR1 locus.	Inst Cancerol & Immunol Marseille, INSERM, U119, Oncol Mol Lab, F-13009 Marseille, France; Inst J Paoli I Calmettes, Lab Biol Tumeurs, F-13009 Marseille, France; Univ Grenoble 1, Inst Albert Bonniot, Grp Rech Lymphomes, Grenoble, France; Hop Purpan, Lab Hematol Genet Hemopathies, Toulouse, France; Ctr Hosp Univ, Genet Lab, Nancy, France; Univ Leuven, Ctr Human Genet, Louvain, Belgium; IPC, Dept Hematol, Lab Cytogenet, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU de Toulouse; CHU de Nancy; KU Leuven; UNICANCER; Institut Paoli-Calmette (IPC)	Pebusque, MJ (corresponding author), Inst Cancerol & Immunol Marseille, INSERM, U119, Oncol Mol Lab, 27 Bd Roure, F-13009 Marseille, France.		CHAFFANET, Max/AAU-5743-2020; POPOVICI, Cornel/A-2027-2009; Leroux, Dominique/G-7309-2014; ADELAIDE, José JA/O-4390-2017	POPOVICI, Cornel/0000-0001-8226-3127; ADELAIDE, José JA/0000-0003-4364-9857; CHAFFANET, Max/0000-0002-2344-1488				AGUIAR RCT, 1995, BLOOD, V86, P834, DOI 10.1182/blood.V86.2.834.bloodjournal862834; BEHRINGER D, 1995, LEUKEMIA, V9, P988; BELLOMO MJ, 1992, BRIT J HAEMATOL, V81, P307, DOI 10.1111/j.1365-2141.1992.tb08225.x; BERNSTEIN R, 1987, CANCER GENET CYTOGEN, V24, P213, DOI 10.1016/0165-4608(87)90101-4; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chaffanet M, 1996, CYTOGENET CELL GENET, V72, P63, DOI 10.1159/000134164; DIB A, 1995, ONCOGENE, V10, P995; DREXLER HG, 1995, LEUKEMIA, V9, P480; Elsner S., 1994, British Journal of Haematology, V87, P124; FAGAN K, 1993, CANCER GENET CYTOGEN, V65, P71, DOI 10.1016/0165-4608(93)90062-Q; FRIEDHOFF F, 1983, CANCER GENET CYTOGEN, V9, P391, DOI 10.1016/0165-4608(83)90088-2; HEIM S, 1987, BRIT J HAEMATOL, V66, P323, DOI 10.1111/j.1365-2141.1987.tb06917.x; INHORN RC, 1995, BLOOD, V85, P1881, DOI 10.1182/blood.V85.7.1881.bloodjournal8571881; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEMPSKI H, 1995, GENE CHROMOSOME CANC, V12, P283, DOI 10.1002/gcc.2870120408; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LAI JL, 1992, CANCER GENET CYTOGEN, V60, P180, DOI 10.1016/0165-4608(92)90013-X; LAI JL, 1987, CANCER GENET CYTOGEN, V27, P101, DOI 10.1016/0165-4608(87)90265-2; LESLIE J, 1994, BRIT J HAEMATOL, V86, P876, DOI 10.1111/j.1365-2141.1994.tb04847.x; LEWIS JP, 1983, AM J PEDIAT HEMATOL, V5, P265; MACDONALD D, 1995, LEUKEMIA, V9, P1628; MACDONALD D, 1994, BRIT J HAEMATOL, V86, P879, DOI 10.1111/j.1365-2141.1994.tb04848.x; Michaux L, 1996, BLOOD, V87, P1658, DOI 10.1182/blood.V87.4.1658.bloodjournal8741658; MITELMAN F, 1992, GENE CHROMOSOME CANC, V5, P57, DOI 10.1002/gcc.2870050109; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; NAEEM R, 1995, GENE CHROMOSOME CANC, V12, P148, DOI 10.1002/gcc.2870120210; Nakayama H, 1996, BRIT J HAEMATOL, V92, P692, DOI 10.1046/j.1365-2141.1996.00386.x; OSCIER DG, 1985, J MED GENET, V22, P398, DOI 10.1136/jmg.22.5.398; PEBUSQUE MJ, 1993, GENE CHROMOSOME CANC, V8, P119, DOI 10.1002/gcc.2870080209; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RUTA M, 1988, ONCOGENE, V3, P9; Sainati L, 1996, PEDIATR HEMAT ONCOL, V13, P151, DOI 10.3109/08880019609030805; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SLOVAK ML, 1991, CANCER GENET CYTOGEN, V56, P237, DOI 10.1016/0165-4608(91)90176-U; Soenen V, 1996, GENE CHROMOSOME CANC, V15, P191, DOI 10.1002/(SICI)1098-2264(199603)15:3<191::AID-GCC9>3.0.CO;2-Y; STARK B, 1995, LEUKEMIA RES, V19, P367, DOI 10.1016/0145-2126(94)00150-9; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; vandenBerg H, 1996, LEUKEMIA, V10, P1252; VANNIER JP, 1984, LEUKEMIA RES, V8, P647, DOI 10.1016/0145-2126(84)90013-4; Velloso ERP, 1996, LEUKEMIA LYMPHOMA, V21, P137, DOI 10.3109/10428199609067591; ZELEZNIKLE NJ, 1995, SEMIN HEMATOL, V32, P201	42	55	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					945	949		10.1038/sj.onc.1201601	http://dx.doi.org/10.1038/sj.onc.1201601			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484786				2022-12-17	WOS:000072053200014
J	Nozaki, C; Asai, N; Murakami, H; Iwashita, T; Iwata, Y; Horibe, K; Klein, RD; Rosenthal, A; Takahashi, M				Nozaki, C; Asai, N; Murakami, H; Iwashita, T; Iwata, Y; Horibe, K; Klein, RD; Rosenthal, A; Takahashi, M			Calcium-dependent ret activation by GDNF and neurturin	ONCOGENE			English	Article						Ret; GDNF; neurturin; Ca2+ ion; neuroblastoma	MICE LACKING GDNF; NEUROBLASTOMA CELL-LINES; TYROSINE KINASE; PROTOONCOGENE PRODUCTS; TRANSMITTER SECRETION; HIRSCHSPRUNGS-DISEASE; DOPAMINERGIC-NEURONS; SEQUENCE SIMILARITY; NEUROTROPHIC FACTOR; MOTOR-NEURONS	Glial cell line-derived neurotrophic factor (GDNF) and neurturin (NTN) define a new family of neurotrophic factors that play crucial roles in survival and differentiation of various neurons. Recent studies demonstrated that GDNF and NTN use a multicomponent receptor system in which glycosyl-phosphatidylinositol (GPI)-linked cell surface proteins and Ret receptor tyrosine kinase function as the ligand-binding and signalling components, respectively. In the present study, we investigated the role of Ca2+ ions for biochemical and biological activities of Ret because Ret has a unique structure of the extracellular domain with the cadherin-like motif. The results demonstrated that Ca2+ ions might be required for the complex formation of Ret and GDNF or NTN that induces Ret oligomerization and autophosphorylation. Full morphological differentiation of neuroblastoma cells by these neurotrophic factors was also Ca2+-dependent. These findings thus suggested that, in addition to GPI-linked cell surface proteins, Ca2+ ions are components of the signal transducing complex formed by Ret and GDNF protein family.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 466, Japan; Nagoya Univ, Sch Med, Dept Pediat, Showa Ku, Nagoya, Aichi 466, Japan; Genentech Inc, Dept Neurosci, San Francisco, CA 94080 USA	Nagoya University; Nagoya University; Roche Holding; Genentech	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 466, Japan.		Takahashi, Masahide/AAN-4770-2020; ASAI, Naoya/I-7377-2014; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; 				ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Chakravarti A, 1996, HUM MOL GENET, V5, P303; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Ghosh A, 1996, CURR BIOL, V6, P130, DOI 10.1016/S0960-9822(02)00442-6; IKEDA I, 1990, ONCOGENE, V5, P1291; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Iwashita T, 1996, HUM MOL GENET, V5, P1577, DOI 10.1093/hmg/5.10.1577; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; KUMA K, 1993, MOL BIOL EVOL, V10, P539; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MORIMOTO T, 1995, NEURON, V15, P689, DOI 10.1016/0896-6273(95)90156-6; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1995, CRIT REV ONCOGENESIS, V6, P35, DOI 10.1615/CritRevOncog.v6.i1.30; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0	44	55	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					293	299		10.1038/sj.onc.1201548	http://dx.doi.org/10.1038/sj.onc.1201548			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467954				2022-12-17	WOS:000071582100001
J	Kon, H; Sonoda, Y; Kumabe, T; Yoshimoto, T; Sekiya, T; Murakami, Y				Kon, H; Sonoda, Y; Kumabe, T; Yoshimoto, T; Sekiya, T; Murakami, Y			Structural and functional evidence for the presence of tumor suppressor genes on the short arm of chromosome 10 in human gliomas	ONCOGENE			English	Article						glioma; tumor suppressor gene; chromosome 10p; loss of heterozygosity; chromosome transfer	CANCER CELL-LINE; GLIOBLASTOMA-MULTIFORME; MALIGNANT PHENOTYPE; BRAIN-TUMORS; HETEROZYGOSITY; DELETION; AMPLIFICATION; ASTROCYTOMA; PROGRESSION; REGION	Loss of heterozygosity (LOH) observed at polymorphic loci on both arms of chromosome 10 in many human gliomas suggests the presence of multiple tumor suppressor genes on this chromosome. Recently, the PTEN/MMAC1 gene on 10q23 was isolated as one of these putative glioma suppressors. To determine the subchromosomal localization of others, we analysed 79 gliomas for LOH using 30 polymorphic microsatellite markers on the short arm and 10 markers on the long arm of chromosome 10. Twenty tumors showed LOH at all the loci examined, while 17 others showed LOH at loci on a portion of chromosome 10. Deletion mapping of the latters demonstrated that two distinct regions, encompassing genetic distances of 5.6 cM on 10p15 and 5.5 cM on 10p14, were lost frequently. Introduction of chromosomal fragments 10p14-p15, which included the entire region on 10p15 and a portion of that on 10p14 assigned by deletion mapping, into the human glioblastoma cell line T98G through microcell-mediated chromosome transfer markedly suppressed colony forming ability in soft agar compared with parental T98G cells. The combined results of structural and functional analyses strongly suggest that aberrations of the tumor suppressor gene(s) within chromosomal region 10p14-p15 are involved in development of human gliomas.	Natl Canc Ctr, Res Inst, Div Oncogene, Chuo Ku, Tokyo 104, Japan; Tohoku Univ, Sch Med, Dept Neurosurg, Aoba Ku, Sendai, Miyagi 980, Japan	National Cancer Center - Japan; Tohoku University	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Div Oncogene, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 104, Japan.			Sonoda, Yukihiko/0000-0001-7651-1374				Albarosa R, 1996, AM J HUM GENET, V58, P1260; BERGERHEIM U, 1989, CANCER RES, V49, P1390; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; DOWDY SF, 1987, SCIENCE, V236, P175; FOURNIER REK, 1981, P NATL ACAD SCI-BIOL, V78, P6349, DOI 10.1073/pnas.78.10.6349; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRANT R, 1995, NEUROLOGY, V45, P929, DOI 10.1212/WNL.45.5.929; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HE J, 1994, GENE CHROMOSOME CANC, V11, P91, DOI 10.1002/gcc.2870110205; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; HUNTER SB, 1995, J NEUROPATH EXP NEUR, V54, P57, DOI 10.1097/00005072-199501000-00007; IITTMANN M, 1996, CANCER RES, V56, P2143; IZUMOTO S, 1995, CANCER LETT, V97, P241, DOI 10.1016/0304-3835(95)03981-2; JAMES CD, 1988, CANCER RES, V48, P5546; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARLBOM AE, 1993, HUM GENET, V92, P169; Kimmelman AC, 1996, GENOMICS, V34, P250, DOI 10.1006/geno.1996.0277; Kleihues P., 1993, WHO INT HISTOLOGICAL, V2nd ed.; Konig JJ, 1996, HUM PATHOL, V27, P720, DOI 10.1016/S0046-8177(96)90404-9; KUMABE T, 1992, ONCOGENE, V7, P627; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; Murakami YS, 1996, CANCER RES, V56, P2157; MURAKAMI YS, 1995, CANCER RES, V55, P3389; PERHOUSE MA, 1993, CANCER RES, V53, P5043; RASHEED BKA, 1995, ONCOGENE, V10, P2243; REMPEL SA, 1993, CANCER RES, V53, P2386; SONODA Y, 1995, CANCER RES, V55, P2166; Sonoda Y, 1996, JPN J CANCER RES, V87, P363, DOI 10.1111/j.1349-7006.1996.tb00231.x; SONODA Y, 1995, ONCOGENE, V11, P2145; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816	43	55	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					257	263		10.1038/sj.onc.1201488	http://dx.doi.org/10.1038/sj.onc.1201488			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464544				2022-12-17	WOS:000071427100013
J	Veldhoen, N; Stewart, J; Brown, R; Milner, J				Veldhoen, N; Stewart, J; Brown, R; Milner, J			Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog	ONCOGENE			English	Article						therapy-induced p53 mutation; canine p53 germ line mutation; canine lymphoma	CHRONIC MYELOCYTIC-LEUKEMIA; P-GLYCOPROTEIN EXPRESSION; BREAST-CANCER; DNA DAMAGE; CLONAL EVOLUTION; FREE-RADICALS; MUTANT-CELLS; THERAPY; DOXORUBICIN; RESISTANCE	Mutations of the p53 gene are associated with a number of non-lymphoid cancers of the dog. The present study investigates the p53 gene status within canine patients treated for primary and secondary lymphoma. Three out of eight patients exhibited p53 gene mutations, These included one patient with a germ line mutation and two patients with de novo p53 mutations associated with the secondary lymphoma. Allelic loss of the p53 gene was also observed within primary and secondary tumours of the three canine patients. The results indicate that germ line p53 mutations exist in dogs and may be involved in the known predisposition of some breeds to cancer, The presence of therapy-related p53 point mutations was found to be associated with chemoresistant secondary lymphomas. A causative role for DNA-damaging chemotherapy in de novo mutation of the p53 gene is discussed, Characterization of p53 inactivation in canine tumorigenesis may provide a valuable clinical model for assessing the efficacy and optimal therapeutic regimens of anti-cancer agents.	Univ York, Dept Biol, YCRC Res Grp P53, York YO1 5DD, N Yorkshire, England; Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland	University of York - UK; Beatson Institute; University of Glasgow	Veldhoen, N (corresponding author), Univ York, Dept Biol, YCRC Res Grp P53, York YO1 5DD, N Yorkshire, England.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AKMAN SA, 1992, BIOCHEMISTRY-US, V31, P3500, DOI 10.1021/bi00128a026; BARTKOWIAK D, 1992, CANCER CHEMOTH PHARM, V30, P189, DOI 10.1007/BF00686310; CARTER RF, 1986, CAN J VET RES, V50, P154; CERVANTES A, 1988, CANCER LETT, V41, P169, DOI 10.1016/0304-3835(88)90113-9; CHANG H, 1994, BLOOD, V83, P452; DEVILEE P, 1994, ANTICANCER RES, V14, P2039; Doroshaw J., 1996, CANC CHEMOTHERAPY BI, P409; ELROUBY S, 1993, BLOOD, V82, P3452; Felix CA, 1996, BLOOD, V87, P4376, DOI 10.1182/blood.V87.10.4376.bloodjournal87104376; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; FULTON R, 1987, NATURE, V326, P190, DOI 10.1038/326190a0; GREENLEE PG, 1990, CANCER-AM CANCER SOC, V66, P480, DOI 10.1002/1097-0142(19900801)66:3&lt;480::AID-CNCR2820660314&gt;3.0.CO;2-X; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hoffmann L, 1995, ANN ONCOL, V6, P781, DOI 10.1093/oxfordjournals.annonc.a059316; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; KAPPUS H, 1986, BIOCHEM PHARMACOL, V35, P1, DOI 10.1016/0006-2952(86)90544-7; KATZ JP, 1990, J VIROL, V64, P4288, DOI 10.1128/JVI.64.9.4288-4295.1990; KEIZER HG, 1990, PHARMACOL THERAPEUT, V47, P219, DOI 10.1016/0163-7258(90)90088-J; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAEGEL SA, 1995, CANCER LETT, V92, P181, DOI 10.1016/0304-3835(95)03779-V; KUROSAWA M, 1994, BLOOD, V83, P2750; Lee JJ, 1996, CANCER, V77, P1892, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1892::AID-CNCR20>3.0.CO;2-U; Liu PK, 1996, ONCOGENE, V12, P2267; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MACVEAN DW, 1978, VET PATHOL, V15, P700, DOI 10.1177/030098587801500602; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MAYR B, 1994, BRIT VET J, V150, P81, DOI 10.1016/S0007-1935(05)80099-5; MCBRIDE TJ, 1991, BIOCHEMISTRY-US, V30, P207, DOI 10.1021/bi00215a030; MUINDI J, 1985, MOL PHARMACOL, V27, P356; ONIONS DE, 1984, JNCI-J NATL CANCER I, V72, P909; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; PEDERSENBJERGAARD J, 1992, J CLIN ONCOL, V10, P1444, DOI 10.1200/JCO.1992.10.9.1444; PREUDHOMME C, 1993, LEUKEMIA, V7, P1888; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SQUIRE RA, 1973, JNCI-J NATL CANCER I, V51, P565; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; TURNER MJ, 1990, FREE RADICAL BIO MED, V9, P415, DOI 10.1016/0891-5849(90)90018-E; vanLeeuwen IS, 1997, CANCER LETT, V111, P173, DOI 10.1016/S0304-3835(96)04529-6; vanLeeuwen IS, 1996, ANTICANCER RES, V16, P3737; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041; WADA H, 1994, LEUKEMIA, V8, P53; WISHART GC, 1990, BRIT J CANCER, V62, P758, DOI 10.1038/bjc.1990.373	49	55	56	1	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					249	255		10.1038/sj.onc.1201489	http://dx.doi.org/10.1038/sj.onc.1201489			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464543				2022-12-17	WOS:000071427100012
J	Thien, CBF; Langdon, WY				Thien, CBF; Langdon, WY			Tyrosine kinase activity of the EGF receptor is enhanced by the expression of oncogenic 70Z-Cbl	ONCOGENE			English	Article						growth factor; oncogene; receptor; signal transduction; tyrosine kinase	EPIDERMAL GROWTH-FACTOR; C-CBL PROTOONCOGENE; CELL ANTIGEN RECEPTOR; PC12 CELLS; ADAPTER PROTEINS; SH3 DOMAIN; V-CBL; PHOSPHOTYROSINE PHOSPHATASE; NEURONAL DIFFERENTIATION; PHOSPHORYLATED CBL	The 120kD product of the c-Cbl oncogene is a prominent substrate of protein tyrosine kinases that lacks a known catalytic activity but possesses an array of binding sites for cytoplasmic signalling proteins, An oncogenic form of Cbl was recently identified in the 70Z/3 pre-B cell lymphoma which has a small deletion at the N-terminus of the Ring finger domain. This form of Cbl, termed 70Z-Cbl, exhibits an enhanced level of tyrosine phosphorylation compared with c-Cbl, Here we demonstrate that the expression of 70Z-Cbl induces a tenfold enhancement in the kinase activity of the EGF receptor in serum-starved and EGF-stimulated cells, In serum-starved cells this results in EGF receptor autophosphorylation and the recruitment of Grb2, Shc and Sos1 but does not induce a corresponding increase in MAP kinase activity, Furthermore the expression of 70Z-Cbl greatly enhances EGF-induced tyrosine phosphorylation of the protein tyrosine phosphatase SHP-2, We also show that the Cbl/EGF receptor complex is predominantly associated with CrkII and is distinct to the Grb2/Shc/Sos1 complex that associates with the EGF receptor. These findings therefore demonstrate a biochemical effect of an oncogenic Cbl protein and support predictions from C, elegans that Cbl functions as regulator of receptor tyrosine kinases.	UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT PATHOL,NEDLANDS,WA 6907,AUSTRALIA	University of Western Australia			Thien, Christine/GQP-0424-2022	Thien, Christine/0000-0003-3884-5546				Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASE RD, 1994, J BIOL CHEM, V269, P10467; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20241; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; JONGEWARD GD, 1995, GENETICS, V139, P1553; Khwaja A, 1996, ONCOGENE, V12, P2491; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; Kontani K, 1996, J BIOL CHEM, V271, P1534; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PANCHAMOORTHY G, 1996, J BIOL CHEM, V271, P387; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Ribon V, 1996, MOL CELL BIOL, V16, P45; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sabe H, 1995, J BIOL CHEM, V270, P31219, DOI 10.1074/jbc.270.52.31219; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; Sattler M, 1996, ONCOGENE, V12, P839; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; SCHAEFER E, 1996, PROMEGA NOTES, V59, P2; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSYGANKOV AY, 1996, J BIOL CHEM, V271; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	64	55	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2909	2919		10.1038/sj.onc.1201468	http://dx.doi.org/10.1038/sj.onc.1201468			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416834				2022-12-17	WOS:A1997YK37700003
J	Pusch, O; Bernaschek, G; Eilers, M; Hengstschlager, M				Pusch, O; Bernaschek, G; Eilers, M; Hengstschlager, M			Activation of c-myc uncouples DNA replication from activation of G1-cyclin-dependent kinases	ONCOGENE			English	Article						c-Myc; G1-cyclins; cell cycle; initiation of replication	CYCLIN-DEPENDENT KINASES; S-PHASE ENTRY; CELL-CYCLE; TRANSCRIPTION FACTOR; THYMIDINE KINASE; PROTEIN-KINASE; RESTRICTION POINT; GROWTH-REGULATION; EXPRESSION; BINDING	Proto-oncogenes like c-myc are thought to control exit from the cell cycle rather than progression through the cell cycle itself, We now present a different view of Myc function, Exponentially growing Rat1-MycER(TM) fibroblasts were size-fractionated by centrifugal elutriation, In these cells, activation of cyclin E- and cyclin A- dependent kinases, degradation of p27, hyperphosphorylation of retinoblastoma protein and activation of E2F occur sequentially at specific cell sizes, Upon activation of Myc, however, these transitions all occur simultaneously in small cells immediately after exit from mitosis. In contrast, Myc has no discernible effect on the cell size at which DNA replication is initiated, These data show first that Myc centrals the activity of G1 cyclin-dependent kinases independently from the transition between quiescence and proliferation and from any effect on cell growth in size, These data also provide evidence of at least one dominant mechanism besides activation of E2F and of cyclin E/cdk2 kinase, which prevents DNA replication unless a critical cell size has been reached.	UNIV VIENNA,DEPT PRENATAL DIAG & THERAPY,A-1090 VIENNA,AUSTRIA; ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY	University of Vienna; Ruprecht Karls University Heidelberg				Pusch, Oliver/0000-0001-7166-2800; Eilers, Martin/0000-0002-0376-6533				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DOU QP, 1994, J BIOL CHEM, V269, P1306; DOU QP, 1993, CANCER RES, V53, P1493; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GIUNTA M, 1995, CELL CYCLE, P46; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; HENGSTSCHLAGER M, 1994, CELL GROWTH DIFFER, V5, P1389; Hengstschlager M, 1996, ONCOGENE, V12, P1635; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JANSENDURR P, 1995, CELL CYCLE, P243; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KILLANDER D, 1965, EXP CELL RES, V40, P12, DOI 10.1016/0014-4827(65)90285-5; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELHAM MJ, 1990, ONCOGENE, V5, P161; Winston JT, 1996, ONCOGENE, V12, P127; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	62	55	55	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					649	656		10.1038/sj.onc.1201236	http://dx.doi.org/10.1038/sj.onc.1201236			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264405	Bronze			2022-12-17	WOS:A1997XP68300004
J	Hime, GR; Dhungat, MP; Ng, A; Bowtell, DDL				Hime, GR; Dhungat, MP; Ng, A; Bowtell, DDL			D-Cbl, the Drosophila homologue of the c-Cbl proto-oncogene, interacts with the Drosophila EGF receptor in vivo, despite lacking C-terminal adaptor binding sites	ONCOGENE			English	Article						cbl; EGF receptor; Drosophila; signal transduction	TYROSINE KINASE; SH3 DOMAIN; V-CBL; PROTOONCOGENE PRODUCT; JURKAT CELLS; STIMULATION; PHOSPHORYLATION; ASSOCIATION; COMPLEXES; ELEGANS	The c-Cbl proto-oncogene encodes a multidomain phosphoprotein that has been demonstrated to interact with a wide range of signalling proteins. The biochemical function of c-Cbl in these complexes is, however, unclear. Recent studies with the C. elegans Cbl homologue, sli-1, have suggested that Cbl proteins may act as negative regulators of EGF receptor (EGFR) signalling. As the EGFR and other protein tyrosine kinase receptor signalling pathways are highly conserved between insects and vertebrates, we sought a Drosophila homologue of c-Cbl for a detailed genetic analysis. We report here that Drosophila melanogaster has a single gene, D-cbl, that is homologous to c-cbl. We find that D-cbl encodes a 52 kDa protein that has a high degree of similarity to c-Cbl and SLI-1 across novel phosphotyrosine-binding (PTB) and RING finger domains. Surprisingly, however, D-Cbl is C-terminally truncated relative to c-Cbl and SLI-1 and consequently is unable to bind SH3-domain containing adaptor proteins, including the Drosophila Grb2 homologue, Drk. Although the D-Cbl protein lacks Drk binding sites it can nevertheless associate with a tyrosine phosphorylated protein, or is itself tyrosine phosphorylated in an DER dependent manner and associates,vith activated Drosophila EGF receptors (DER) in vivo. Consistent with a role for D-Cbl in DER dependent patterning in the embryo and adult, D-Cbl is expressed at a high level in early embryos and throughout the imaginal discs in third instar larvae. This study forms the basis for future genetic analysis of D-Chl, aimed at gaining insights into the role of Cbl proteins in signal transduction.	PETER MACCALLUM CANC INST,TRESCOWTHICK RES LABS,MELBOURNE,VIC 3000,AUSTRALIA	Peter Maccallum Cancer Center			Ng, Ashley/D-3842-2011; Bowtell, David/H-1007-2016; Hime, Gary/B-7162-2015	Ng, Ashley/0000-0001-9690-0879; Bowtell, David/0000-0001-9089-7525; Hime, Gary/0000-0003-4732-3184				Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BAUMANN P, 1993, DEVELOPMENT, P65; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BLAKE TJ, 1991, ONCOGENE, V6, P653; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BOWTELL DDL, 1996, GENETICS RAS SIGNALL; Bridges CB, 1935, J HERED, V26, P60, DOI 10.1093/oxfordjournals.jhered.a104022; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HIME G, 1992, DEVELOPMENT, V114, P165; Johnson RL, 1995, DEVELOPMENT, V121, P4161; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; JONGEWARD GD, 1995, GENETICS, V139, P1553; KEANE MM, 1995, ONCOGENE, V10, P2367; Khwaja A, 1996, ONCOGENE, V12, P2491; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LAROCHELLE S, 1995, GENE, V164, P209; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LINDBLOM A, 1994, AM J HUM GENET, V54, P871; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Matsuo T, 1996, FEBS LETT, V397, P113, DOI 10.1016/S0014-5793(96)01151-9; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PARDUE M, 1994, DROSOPHILA MELANOGAS, V44; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REGNIER DC, 1989, J VIROL, V63, P3678, DOI 10.1128/JVI.63.9.3678-3682.1989; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; Ribon V, 1996, MOL CELL BIOL, V16, P45; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sambrook J, 1989, MOL CLONING LAB MANU; Sattler M, 1996, ONCOGENE, V12, P839; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Wisniewski D, 1996, LEUKEMIA, V10, P1436; XU T, 1993, DEVELOPMENT, V117, P1223; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZAK NB, 1990, DEVELOPMENT, V109, P865	64	55	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2709	2719		10.1038/sj.onc.1201223	http://dx.doi.org/10.1038/sj.onc.1201223			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178769				2022-12-17	WOS:A1997XB97800010
J	Kurtz, A; Wang, HL; Darwiche, N; Harris, V; Wellstein, A				Kurtz, A; Wang, HL; Darwiche, N; Harris, V; Wellstein, A			Expression of a binding protein for FGF is associated with epithelial development and skin carcinogenesis	ONCOGENE			English	Article						FGF-binding protein; gene; skin; carcinogenesis; development; expression	FIBROBLAST GROWTH-FACTOR; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; CELL-GROWTH; MALIGNANT CONVERSION; TARGETED EXPRESSION; WOUND REPAIR; TUMOR-GROWTH; ONCOGENE; DIFFERENTIATION; ANGIOGENESIS	Fibroblast growth factors (FGF)-1 and -2 are found in most embryonic and adult normal and tumor tissues, where they are immobilized in the extracellular matrix (EM), Mobilization of these FGFs is part of a tightly controlled process resulting in the activation of high-affinity receptors, Recently, we have shown that a novel human FGF-binding protein (FGF-BP) mediates the release of immobilized FGF-2 from the EM. Here we isolated genomic and cDNA clones of the mouse FGF-BP homologue and studied its expression during embryonic development and skin carcinogenesis, The murine gene contains two exons that generate a 1.2 kb mRNA and predicts an 18 kDa secreted protein that is 63% identical to its human homologue, FGF-BP mRNA expression during embryogenesis is restricted to skin, intestine and lung. In the developing skin, FGF-BP expression starts at embryonic day 9, reaches peak levels perinatally and is downregulated during postnatal development. Develepment regulation in the intestine is similar, but in lungs and ovaries high expression was also observed in the adult, FGF-BP mRNA expression in the adult skin is dramatically increased during early stages of carcinogen-induced transformation in vivo and by rasactivation in vitro, Finally, mouse FGF-BP binds to FGF-2 and can function as a modulator of FGF in FGF-responsive cells, Our results suggest a potential function of FGF-BP during development and tumorigenesis.	GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT NEUROSURG,WASHINGTON,DC 20007; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,NIH,BETHESDA,MD 20892	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kurtz, A (corresponding author), GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,3970 RESERVOIR RD,WASHINGTON,DC 20007, USA.			Kurtz, Andreas/0000-0003-3301-6546; Darwiche, Nadine/0000-0002-1862-5426; Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [CA-58185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; Brem H., 1993, ONCOGENES TUMOR SUPP, P211; BROADLEY KN, 1989, LAB INVEST, V61, P571; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; DANDEKAR T, 1995, TRENDS GENET, V11, P45, DOI 10.1016/S0168-9525(00)88996-9; DAVIDSON JM, 1985, J CELL BIOL, V100, P1219, DOI 10.1083/jcb.100.4.1219; DIGNASS AU, 1994, GASTROENTEROLOGY, V106, P1254, DOI 10.1016/0016-5085(94)90017-5; DUCROS DL, 1993, J INVEST DERMATOL, V101, pS106, DOI 10.1111/1523-1747.ep12363020; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; GREENHALGH DA, 1988, MOL CARCINOGEN, V1, P134, DOI 10.1002/mc.2940010209; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HENNINGS H, 1983, NATURE, V304, P67, DOI 10.1038/304067a0; HENNINGS H, 1988, TUMOR PROMOTERS BIOL, P31; HORI A, 1991, CANCER RES, V51, P6180; HUANG YQ, 1993, J CLIN INVEST, V91, P1191, DOI 10.1172/JCI116279; JANOT F, 1995, INT J CANCER, V64, P117, DOI 10.1002/ijc.2910640208; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MOSCATELLI D, 1991, ANN NY ACAD SCI, V638, P177, DOI 10.1111/j.1749-6632.1991.tb49028.x; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sambrook J, 1989, MOL CLONING LAB MANU; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHULTZHECTOR S, 1993, CANCER RES, V53, P1444; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; STRICKLAND JE, 1988, CANCER RES, V48, P165; VELLUCCI VF, 1995, GENE, V9, P213; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1991, ANN NY ACAD SCI, V638, P207; Vlodavsky I, 1988, Adv Exp Med Biol, V233, P201; WANAKA A, 1991, DEVELOPMENT, V111, P455; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WU DQ, 1991, J BIOL CHEM, V266, P16778	41	55	61	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2671	2681		10.1038/sj.onc.1201117	http://dx.doi.org/10.1038/sj.onc.1201117			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178765				2022-12-17	WOS:A1997XB97800006
J	Lacy, S; Whyte, P				Lacy, S; Whyte, P			Identification of a p130 domain mediating interactions with cyclin A cdk2 and cyclin E cdk2 complexes	ONCOGENE			English	Review						cell cycle; p130; cyclins; cdk	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT KINASE INHIBITOR; TRANSCRIPTION FACTOR E2F; LARGE T-ANTIGENS; CELL-CYCLE; SUSCEPTIBILITY GENE; PROTEIN-KINASE; POTENTIAL MEDIATOR; GROWTH SUPPRESSION; TUMOR SUPPRESSION	P130 shares structural and functional homology with pRb and p107. One property common to p107 and p130, but not to pRb, is the ability to stably interact with cyclin A/cdk2 and cyclin E/cdk2 complexes in vitro and in vivo. Using GST-p130 fusion proteins representing various regions of p130, baculovirus-produced cyclin A/ cdk2 and cyclin E/cdk2 complexes were found to interact with residues within a part of p130 known as the spacer region. Cyclin E was able to bind the p130 spacer region in the presence or absence of cdk2 whereas cyclin A binding was dependent upon the presence of cdk2. The smallest p130 fusion protein sufficient to interact with cyclin A/cdk2 or cyclin E/cdk2 complexes contained p130 amino acids 652-698 and deletion of p130 amino acids 680-682 abolished binding to both of the cyclin/cdk2 complexes. When overexpressed in C33A cells, a p130 mutant containing a deletion of amino acids 620-697 was unable to form complexes with either cyclin A or cyclin E. This p130 mutant was at least as active as wild type p130 in suppressing the growth of G418 resistant colonies when overexpressed in C33A or SAOS-2 cells.	MCMASTER UNIV, INST MOL BIOL & BIOTECHNOL, HAMILTON, ON L8S 4K1, CANADA	McMaster University								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUCK V, 1995, ONCOGENE, V11, P31; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOUBIN F, 1995, ONCOGENE, V10, P2281; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KITAGAWA M, 1995, ONCOGENE, V10, P229; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lin JY, 1996, MOL CELL BIOL, V16, P1786; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MAYOL X, 1995, ONCOGENE, V11, P801; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; WOLF DA, 1995, ONCOGENE, V10, P2067; WU CL, 1995, MOL CELL BIOL, V15, P2536; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; ZAKUT R, 1995, ONCOGENE, V11, P393; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	105	55	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2395	2406		10.1038/sj.onc.1201085	http://dx.doi.org/10.1038/sj.onc.1201085			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188854				2022-12-17	WOS:A1997WZ68000003
J	Bernardin, F; CollyndHooghe, M; Quief, S; Bastard, C; Leprince, D; Kerckaert, JP				Bernardin, F; CollyndHooghe, M; Quief, S; Bastard, C; Leprince, D; Kerckaert, JP			Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation	ONCOGENE			English	Article						LAZ3/BCL6; lymphoma; major translocation cluster	PROTEIN INTERACTION MOTIF; FINGER ENCODING GENE; CENTER B-CELLS; PROMOTER REGION; DNA-BINDING; BCL-6 GENE; CHROMOSOMAL TRANSLOCATIONS; BTB/POZ DOMAIN; SEQUENCE; MOUSE	The LAZ3/BCL6 gene encoding a Zinc-finger nuclear protein is altered in Non-Hodgkin's Lymphomas (NHLs) by translocations, mutations and/or deletions clustered in its 5' non coding region, in a 3.3 Kbp EcoRI fragment which thus defines the Major Translocation Cluster (MTC). In the present study, we describe at the molecular level the deletions found in the MTC of two (NHL) cases using, (i) DNA obtained from a patient (GUI) with a monosomy 3 and three microdeletions of 101, 22, 25 bp in its unique untranslocated 3q27 allele; (ii) a cell line derived from a patient (VAL) carrying a t(3;4) (q27;pll) translocation and a 2.4 Kbp deletion in the untranslocated allele. As the MTC is recurrently subject to alterations, me have cloned and sequenced the murine equivalent of the human MTC and promoter region in an attempt to identify sequences well conserved in mammals that may be thus important for the LAZ3/BCL6 gene regulation. We show that the human and mouse 5' upstream regions of the LAZ3/BCL6 gene although mainly intronic share a particularly high homology of 79% on the overall sequence. Strikingly, the small sequences which are deleted in patient (GUI) are highly conserved (81%, 100% and 92% respectively). Furthermore, they may play a role in the pathogenesis since proteins prepared from B cell lines and HeLa nuclear extracts bind to these sequences in gel retardation assays. Although a large part of this region is intronic, the high conservation of its sequence and the frequency of alterations in NHLs suggest that they are likely to be significant for the regulation of the LAZ3/BCL6 gene.	INST RECH CANC LILLE,U124 INSERM,F-59045 LILLE,FRANCE; CTR TRANSFUS SANGUINE,DEPT CYTOGENET,F-76232 BOIS GUILLAUME,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)				Leprince, Dominique/0000-0002-1999-0775				Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; BASTARD C, 1994, BLOOD, V83, P2423; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; DALLERY E, 1995, ONCOGENE, V10, P2171; DEWEINDT C, 1993, GENE CHROMOSOME CANC, V8, P149, DOI 10.1002/gcc.2870080303; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1995, ONCOGENE, V11, P2689; FLENGHI L, 1995, AM J PATHOL, V147, P405; FOLEY J, 1994, GENOMICS, V22, P456, DOI 10.1006/geno.1994.1410; FUKUDA T, 1995, ONCOGENE, V11, P1657; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; GALSON DL, 1993, BLOOD, V82, P3321; GWYNN B, 1990, MOL CELL BIOL, V10, P5244, DOI 10.1128/MCB.10.10.5244; HAJRA A, 1994, GENOMICS, V21, P649, DOI 10.1006/geno.1994.1328; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; LIN BY, 1995, GENOMICS, V25, P707, DOI 10.1016/0888-7543(95)80014-D; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Nakamura Y, 1996, LEUKEMIA, V10, P658; NAKAMURA Y, 1995, BRIT J HAEMATOL, V90, P404, DOI 10.1111/j.1365-2141.1995.tb05166.x; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YE BHH, 1993, CANCER RES, V53, P2732; YU BW, 1993, J BIOL CHEM, V268, P19586; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	39	55	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					849	855		10.1038/sj.onc.1200903	http://dx.doi.org/10.1038/sj.onc.1200903			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047392				2022-12-17	WOS:A1997WJ11200011
J	Zarkowska, T; U, S; Harlow, E; Mittnacht, S				Zarkowska, T; U, S; Harlow, E; Mittnacht, S			Monoclonal antibodies specific for underphosphorylated retinoblastoma protein identify a cell cycle regulated phosphorylation site targeted by CDKs	ONCOGENE			English	Article						pRB; epitope mapping; cyclin D1-CDK4 kinase; phosphorylation site; cell cycle	SUSCEPTIBILITY GENE-PRODUCT; MAP KINASE; PROGRESSION; PHOSPHATASE; FAMILY	The growth suppressive activity of the retinoblastoma tumour suppressor protein is controlled by cell cycle dependent phosphorylation, However, while many in vivo phosphorylation sites have been mapped, the identities of those residues whose phosphorylation is regulated remain elusive, We have mapped the epitopes of three independent monoclonal antibodies that recognise a distinction between differentially phosphorylated pRB sub-populations. All three antibodies recognise an identical epitope which encompasses an essential serine positioned within a consensus site for proline directed kinase phosphorylation, We provide evidence that this residue, serine 608 of pRB, is an authentic phosphorylation site that can be phosphorylated in vitro by cyclin A-CDK2 and cyclin D1-CDK4 kinases but not by cyclin E-CDK2 kinase or the mitogen activated kinase ERK2. Phosphorylation at this residue seems to be cell cycle regulated, occurring prior to entry into the S phase.	INST CANC RES,DEPT CELL & MOL BIOL,LONDON SW3 6JB,ENGLAND; MASSACHUSETTS GEN HOSP,ONCOL MOL LAB,CHARLESTOWN,MA 02129	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Harvard University; Massachusetts General Hospital								BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Belbrahem A, 1996, EXP CELL RES, V225, P286, DOI 10.1006/excr.1996.0178; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; HAMEL PA, 1992, ONCOGENE, V7, P693; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Possee RD., 1992, BACULOVIRUS EXPRESSI; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	22	55	59	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					249	254		10.1038/sj.onc.1200824	http://dx.doi.org/10.1038/sj.onc.1200824			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010227				2022-12-17	WOS:A1997WC81800013
J	Sood, AK; Buller, RE				Sood, AK; Buller, RE			Genomic instability in ovarian cancer: A reassessment using an arbitrarily primed polymerase chain reaction	ONCOGENE			English	Article						ovarian cancer; genomic instability; replication error	COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; GENETIC INSTABILITY; REPEATED SEQUENCES; MISMATCH REPAIR; ALU REPEATS; CELL-LINES; DNA; MUTATIONS; TUMORS	Traditional polymerase chain reaction (PCR) amplification of multiple microsatellite markers to detect microsatellite instability (MI) is labor intensive and may be marker dependent, An arbitrarily primed polymerase chain reaction (AP-PCR) is a modification of PCR that generates a genomic DNA fingerprint using a single, arbitrarily chosen primer which is useful in the detection of somatic genetic alterations, We hypothesize that AP-PCR of an AluI DNA restriction digest, which we term Alu/AP-PCR, identifies genomic instability as well, In order to test this hypothesis, we correlated Alu/AP-PCR fingerprints with analyses of traditional PCR amplified microsatellite markers using paired germline and tumor DNA samples obtained from 68 patients with ovarian cancer, The microsatellite markers tested included dinucleotide, trinucleotide, and tetranucleotide repeats. We found that MI is more common in ovarian cancer than previously thought, We estimate a minimum incidence of MI at 37% based on the 10 traditional markers we tested, to an incidence of 53% based upon our Alu/AP-PCR analysis, All cases of MI were associated with an abnormal Alu/AP-PCR banding pattern, Both MI, detected by polymorphic markers (P=0.03), and an abnormal Alu/MAP-PCR pattern (P=0.01) were significantly associated with the occurrence of a second primary malignancy in the same patient. In addition, abnormal Alu/AP-PCR patterns were associated with higher grade lesions (P=0.02), and family history of cancer (P=0.009), These findings suggest: (1) MI may play an important role in ovarian carcinogenesis, and (2) Alu/AP-PCR is a novel technique for identification of genomic instability.	UNIV IOWA HOSP & CLIN, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, IOWA CITY, IA 52242 USA; UNIV IOWA HOSP & CLIN, DEPT PHARMACOL, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ARCOT SS, 1995, GENOMICS, V29, P136, DOI 10.1006/geno.1995.1224; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BOYER JC, 1995, CANCER RES, V55, P6063; BULLER RE, 1995, GYNECOL ONCOL, V58, P368, DOI 10.1006/gyno.1995.1244; Cass I., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P544; CHARLIEU JP, 1992, NUCLEIC ACIDS RES, V20, P1333, DOI 10.1093/nar/20.6.1333; DESOUZA AP, 1994, GENOMICS, V19, P391, DOI 10.1006/geno.1994.1079; HAN HJ, 1993, CANCER RES, V53, P5087; HOUCK CM, 1979, J MOL BIOL, V132, P289, DOI 10.1016/0022-2836(79)90261-4; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACOBS IJ, 1993, CANCER RES, V53, P1218; KOLODNER RD, 1995, CANCER RES, V55, P242; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LOEB LA, 1991, CANCER RES, V51, P3075; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MUTA H, 1990, CANCER, V77, P265; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PEROLAT P, 1994, J CLIN MICROBIOL, V32, P1949, DOI 10.1128/JCM.32.8.1949-1957.1994; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Skilling JS, 1996, ONCOGENE, V13, P117; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WEBER JL, 1989, AM J HUM GENET, V44, P388; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YANGFENG TL, 1992, INT J CANCER, V52, P575, DOI 10.1002/ijc.2910520414; YULUG IG, 1995, GENOMICS, V27, P544, DOI 10.1006/geno.1995.1090	35	55	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2499	2504						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957095				2022-12-17	WOS:A1996VX10800026
J	Gruda, MC; vanAmsterdam, J; Rizzo, CA; Durham, SK; Lira, S; Bravo, R				Gruda, MC; vanAmsterdam, J; Rizzo, CA; Durham, SK; Lira, S; Bravo, R			Expression of FosB during mouse development: Normal development of FosB knockout mice	ONCOGENE			English	Article						FosB expression knockout mice; development; AP-1 activity	EMBRYONIC STEM-CELLS; IMMEDIATE-EARLY GENES; C-FOS; TRANSGENIC MICE; NERVOUS-SYSTEM; JUN PROTEINS; MESSENGER-RNAS; RAT-1A CELLS; SHORT FORM; INDUCTION	FosB, one of the members of the Fos family, is rapidly induced in many cell types upon stimulation and has a stimulatory effect on the proliferation of cultured cells, To understand the tissue distribution of FosB, we have studied its expression pattern my immunohistochemistry in newborn and late embryonic stage mice, These results show that FosB is widely expressed with the highest levels of expression observed in both bony and cartilagenous regions of developing bone, FosB is also detected within whisker follicles, liver, and epidermal tissue, To study the role of FosB in mammalian development we generated embryonic stem mice (ES) cells, mice and mouse embryo fibroblasts (MEFs) that are deficient for FosB, FosB (-/-) mice are born at a normal frequency, are fertile and present no obvious phenotypic or histologic abnormalities, FosB-deficient ES cells and MEFs proliferate and enter the S phase normally and we do not find upregulation of other fos family genes to compensate for the lack of FosB, However, we do find that the induction of two AP-1 containing genes is reduced after stimulation of FosB-deficient cells, demonstrating that FosB does indeed play a functional role in transcriptional regulation.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT ONCOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ANGEL P, 1994, FOS JUN FAMILIES TRA, P3; BELE S, 1994, MOL BRAIN RES, V22, P9, DOI 10.1016/0169-328X(94)90027-2; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; BURKERT U, 1991, NEW BIOL, V3, P698; CARRASCO D, 1995, ONCOGENE, V10, P1069; CAUBET JF, 1989, MOL CELL BIOL, V9, P2269, DOI 10.1128/MCB.9.5.2269; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; DRAGUNOW M, 1994, MOL BRAIN RES, V25, P19, DOI 10.1016/0169-328X(94)90274-7; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; GASS P, 1993, EUR J NEUROSCI, V5, P933, DOI 10.1111/j.1460-9568.1993.tb00944.x; GASS P, 1992, NEUROSCIENCE, V48, P315, DOI 10.1016/0306-4522(92)90493-L; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HERDEGEN T, 1991, J COMP NEUROL, V313, P178, DOI 10.1002/cne.903130113; HERDEGEN T, 1992, MOL BRAIN RES, V14, P155, DOI 10.1016/0169-328X(92)90170-G; HERDEGEN T, 1995, J COMP NEUROL, V354, P39, DOI 10.1002/cne.903540105; HOPE BT, 1994, J NEUROSCI, V14, P4318; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; HUO L, 1995, J IMMUNOL, V154, P3300; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN JN, 1994, MOL CELL BIOL, V14, P1566, DOI 10.1128/MCB.14.3.1566; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KIMURA E, 1993, MOL ENDOCRINOL, V7, P1463, DOI 10.1210/me.7.11.1463; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, NEW BIOL, V3, P870; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAZO PS, 1992, NUCLEIC ACIDS RES, V20, P343, DOI 10.1093/nar/20.2.343; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LUCIBELLO FC, 1993, ONCOGENE, V8, P1667; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MINET ML, 1993, J COMP NEUROL, V333, P223; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; REDEMANNFIBI B, 1991, DIFFERENTIATION, V46, P43, DOI 10.1111/j.1432-0436.1991.tb00864.x; Robertson E. J., 1987, TERATOCARCINOMAS EMB; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; RYSECK RP, 1991, ONCOGENE, V6, P533; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANDBERG M, 1988, DEVELOPMENT, V102, P461; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WILES MV, 1991, DEVELOPMENT, V111, P259; WILES MV, 1993, METHOD ENZYMOL, V225, P900; WISDOM R, 1993, MOL CELL BIOL, V13, P2635, DOI 10.1128/MCB.13.5.2635; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; Wurst W., 1993, Gene targeting: a practical approach., P33; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	75	55	55	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	1996	12	10					2177	2185						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668344				2022-12-17	WOS:A1996UP28300017
J	Santos, J; Perez de Castro, I; Herranz, M; Pellicer, A; FernandezPiqueras, J				Santos, J; Perez de Castro, I; Herranz, M; Pellicer, A; FernandezPiqueras, J			Allelic losses on chromosome 4 suggest the existence of a candidate tumor suppressor gene region of about 0.6 cM in gamma-radiation-induced mouse primary thymic lymphomas	ONCOGENE			English	Article						mouse thymic lymphomas; gamma-radiation; microsatellites; loss of heterozygosity; chromosome 4; tumour suppressor genes	HOMOZYGOUS DELETIONS; N-METHYLNITROSOUREA; GENOME; ONCOGENES; RAS; MICROSATELLITES; HETEROZYGOSITY; CARCINOGENESIS; ABNORMALITIES; IRRADIATION	Mouse chromosome 4 was investigated to assess the involvement of tumor suppressor genes in primary thymic lymphomas induced by gamma-irradiation. PCR analysis using microsatellite DNA polymorphic markers was performed in F1 animals generated from a cross between the strains C57BL/6J and RF/J. Microsatellite markers were selected with focus on chromosome 4 around the region containing the interferon alpha gene cluster (D4Mit17, D4Wsm1, D4Mit9, and D4Mit205 and a more distal region (D4Mit12, D4Mit54, and D4Mit13). Allelic losses were detected in 21/47 (44.7%) gamma-radiation-induced thymic lymphomas, Analysis of markers located on six other chromosomes as well as on the proximal region of chromosome 4 illustrates the specificity of the occurrences of LOH appearing on the former markers. This analysis clearly suggests the existence of a candidate tumor suppressor gene region on mouse chromosome 4 of about 0.6 cM between the markers D4Wsm1 and D4Mit9 (TLSR1, Thymic Lymphoma Suppressor Region 1). In addition, another more distal region centered at the marker D4Mit58 could be also exist (TLSR2), In most tumors, allelic losses on these chromosome regions involved the paternal RF/J allele (19 of 20).	UNIV AUTONOMA MADRID, FAC CIENCIAS, DEPT BIOL, LAB GENET MOLEC HUMANA, E-28049 MADRID, SPAIN; NYU, MED CTR, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU, MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	Autonomous University of Madrid; New York University; New York University			Santos, Javier/ABF-5755-2021; MARTINEZ, ANTONIO PELLICER/C-4832-2015; de Castro, Ignacio Pérez/A-6260-2012	Santos, Javier/0000-0002-4168-6251; de Castro, Ignacio Pérez/0000-0002-8822-8274				ABBOTT CM, 1994, MAMM GENOME, V5, pS51; ABBOTT CM, 1992, MAMM GENOME, V3, pS55, DOI 10.1007/BF00648422; AITMAN TJ, 1991, MAMM GENOME, V1, P206, DOI 10.1007/BF00352326; ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BARDI G, 1993, CANCER RES, V53, P1895; BIECHE I, 1994, CANCER RES, V54, P4274; BRATHWAITE O, 1992, CANCER RES, V52, P3791; CAIRNS P, 1994, CANCER RES, V54, P1422; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHENG JQ, 1994, CANCER RES, V54, P5547; CHENG JQ, 1993, CANCER RES, V53, P4761; CHENG NC, 1995, ONCOGENE, V10, P291; CORNALL RJ, 1991, GENOMICS, V10, P874, DOI 10.1016/0888-7543(91)90175-E; DIAMOND LE, 1988, MOL CELL BIOL, V8, P2233, DOI 10.1128/MCB.8.5.2233; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; FONG CT, 1992, CANCER RES, V52, P1780; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HARRIS LJ, 1982, P NATL ACAD SCI-BIOL, V79, P4175, DOI 10.1073/pnas.79.13.4175; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HEGI ME, 1994, CANCER RES, V54, P6257; HERZOG CR, 1994, CANCER RES, V54, P4007; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEEN AJ, 1994, ONCOGENE, V9, P2083; KEMP CJ, 1993, CANCER RES, V53, P6022; KLINGER HP, 1982, CYTOGENET CELL GENET, V32, P68, DOI 10.1159/000131688; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LO KW, 1995, CANCER RES, V55, P2039; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MCMORROW LE, 1988, LEUKEMIA, V2, P115; MIYASAKA K, 1995, MOL CARCINOGEN, V13, P37, DOI 10.1002/mc.2940130107; MORI T, 1994, CANCER RES, V54, P3396; NEWCOMB EW, 1988, CANCER RES, V48, P5514; NEWCOMB EW, 1989, ANTICANCER RES, V9, P1407; NISHIMORI H, 1994, INT J CANCER, V59, P108, DOI 10.1002/ijc.2910590120; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; OKAMOTO A, 1995, CANCER RES, V55, P1448; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; OTSUKI T, 1995, CANCER RES, V55, P1436; QUELLE DE, 1995, ONCOGENE, V11, P635; SAEZ GT, 1994, MOL CARCINOGEN, V9, P40, DOI 10.1002/mc.2940090108; SANTOS J, 1995, CYTOGENET CELL GENET, V71, P223, DOI 10.1159/000134114; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIMON D, 1991, ONCOGENE, V6, P765; SOKOVA OI, 1992, CANCER GENET CYTOGEN, V58, P24, DOI 10.1016/0165-4608(92)90128-U; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SREEKANTAIAH C, 1993, AM J PATHOL, V142, P293; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; VANDERRIET P, 1994, CANCER RES, V54, P1156; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759	65	55	55	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					669	676						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637724				2022-12-17	WOS:A1996TV59700024
J	Bies, J; Hoffman, B; Amanullah, A; Giese, T; Wolff, L				Bies, J; Hoffman, B; Amanullah, A; Giese, T; Wolff, L			B-Myb prevents growth arrest associated with terminal differentiation of monocytic cells	ONCOGENE			English	Article						B-myb; differentiation; monocytic cells; growth arrest; apoptosis	MYELOID-LEUKEMIA CELLS; C-MYB; V-MYB; TRANSCRIPTIONAL ACTIVATION; REGULATED EXPRESSION; HEMATOPOIETIC-CELLS; MESSENGER-RNA; MIM-1 GENE; A-MYB; PROLIFERATION	B-Myb is a transcriptional regulator of gene expression and is highly homologous to c-Myb in its N-terminal DNA binding domain. However, unlike c-myb, whose expression is restricted largely to immature hematopoietic cells, B-myb mRNA has been found to be expressed in all proliferating mammalian cell lines and is clearly regulated in a cell cycle dependent manner. That c-Myb and B-Myb proteins perform different roles in proliferation and/or differentiation is suggested by the redundancy of their expression. It was previously shown that deregulated c-Myb expression can inhibit IL-6 induced terminal differentiation of the leukemia cell line M1. We found that, unlike the downregulation of c-Myb protein which is an early response of progenitor M1 cells to IL-6 treatment, the downregulation of B-Myb occurs late, just prior to terminal differentiation and growth arrest. It was, therefore, of interest to examine the role of the murine B-Myb protein in the proliferation and differentiation of the M1 cells and to compare these effects to those of c-Myb in the same system. Clones ectopically producing B-Myb, like those ectopically expressing c-Myb, proliferated in the presence of the differentiation-inducing agent and did not undergo the programmed cell death which normally follows terminal macrophage differentiation. In addition, the cell-cycle distribution of M1/B-Myb cells was comparable to untreated cells. Although M1/B-Myb and M1/c-Myb clones treated with IL-6 appeared quite immature, differentiation markers were demonstrated to be maintained at near normal levels (e.g. MyD88, Mac-2), or be partially reduced in expression (C3, Fc and Mac-1 receptors) suggesting that the cells had undergone commitment to maturation, but were unable to terminally differentiate.	NCI,GENET LAB,BETHESDA,MD 20892; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NCI NIH HHS [1RO1CA51162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIES J, 1995, CANCER RES, V55, P501; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOLAY J, 1992, J IMMUNOL, V149, P300; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1991, SEMINARS VIROLOGY, V2, P351; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KU DH, 1993, J BIOL CHEM, V268, P2255; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LORD KA, 1990, ONCOGENE, V5, P1095; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sambrook J., 1989, MOL CLONING LAB MANU; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TASHIRO S, 1995, ONCOGENE, V10, P1699; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267	48	55	55	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					355	363						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570212				2022-12-17	WOS:A1996TR53800014
J	Franklin, CC; Kraft, AS				Franklin, CC; Kraft, AS			Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells	ONCOGENE			English	Article						SAPK(JNK); MAPK(ERK); MEK; MPK-1; c-Jun	SERUM RESPONSE ELEMENT; PROTEIN-KINASE; ACTIVATION DOMAIN; SIGNAL-TRANSDUCTION; TERNARY COMPLEX; GENE-PRODUCT; FOS PROMOTER; PHOSPHORYLATION; DIFFERENTIATION; PROLIFERATION	Treatment of U937 human leukemic cells with the phorbol ester PMA, activates both mitogen-activated kinase (MAPK) and stress-activated protein kinase (SAPK), stimulates c-Jun phosphorylation and transcriptional activity, and induces a macrophage-like differentiation of U937 cells, The involvement of the MAPK pathway in mediating both the early phosphorylation and transcriptional activation events and the chronic differentiation of U937 cells was examined utilizing constitutively active MAPK kinase (MEK1) mutants, Transient expression of an activated MEK1 construct in U937 cells was found to stimulate MAPK and SAPK activity, as well as enhancing AP1-, SRE- and c-Jun-mediated transcriptional activity, Transient transfection of MAPK phosphatase-l (MKP-1), a protein phosphatase which preferentially dephosphorylates and inactivates MAPK, inhibited the functional effects of both PMA and the constitutively active MEK1 mutants, To determine whether specific activation of the MEK/MAPK pathway was sufficient to induce hematopoietic differentiation, U937 cell lines were established that conditionally expressed the activataed MEK1 mutant under the control of the human IIa metallothionein promoter, The induction of constitutively active MEK1 protein expression resulted in an increase in MEK1 activity, c-Jun and AP-1 transcriptional activity and an inhibition of U937 cell growth, However, this growth inhibition was not accompanied by U937 cell differentiation, These results suggest that a cross-talk mechanism exists between the MAPK and SAPK signal transduction pathways in U937 cells and that PMA-mediated SAPK activation may involve the MAPK pathway, Furthermore, selective activation of the MEK/MAPK pathway utilizing a constitutively active MEK1 mutant, while growth inhibitory, was not sufficient to induce the macrophage-like differentiation of U937 cells.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NCI NIH HHS [CA42533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADUNYAH SE, 1992, J CELL PHYSIOL, V151, P415, DOI 10.1002/jcp.1041510223; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUNET A, 1994, ONCOGENE, V9, P3379; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRANKLIN CC, 1993, CELL GROWTH DIFFER, V4, P377; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU A, 1995, J BIOL CHEM, V270, P8377; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; WAYS DK, 1994, CELL GROWTH DIFFER, V5, P1195; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; YAN MH, 1994, NATURE, V372, P798; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	55	55	56	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2365	2374						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570188				2022-12-17	WOS:A1995TK70200021
J	Stoesz, SP; Gould, MN				Stoesz, SP; Gould, MN			Overexpression of neu-related lipocalin (NRL) in neu-initiated but not ras or chemically initiated rat mammary carcinomas	ONCOGENE			English	Article						lipocalin; neu; ras; mammary cancer	HUMAN-BREAST-CANCER; EPITHELIAL-CELLS; CLASS-I; GENE-EXPRESSION; PROTEIN FAMILY; ONCOGENE; SEQUENCE; GELATINASE; ANTIGENS; AMPLIFICATION	The activated neu (HER2/c-erbB-2) oncogene is extremely potent in inducing mammary cancer, For example, neu induces greater than 200 times as many tumors as the activated ras oncogene when directly introduced into in situ rat mammary epithelial cells using replication-defective retroviral vectors. In order to characterize mechanisms underlying this potency, we sought to identify uniquely overexpressed genes in neu-initiated tumors that were not overexpressed in tumors induced by weaker initiating agents, including activated ras and the chemical carcinogens dimethylbenz[a]anthracene and N-nitroso-N-methylurea. Several genes, including those encoding keratin K7 and the u haplotype of MHC class I RT1-A, were found to be overexpressed in neu-initiated carcinomas as well as in mammary carcinomas induced by other agents, when compared to their expression in normal mammary tissue, One gene, however, encoding a member of the lipocalin and calycin protein families, was 12-fold overexpressed in neu mammary tumors and was not overexpressed in ras or chemically induced carcinomas, This uniquely overexpressed gene was termed neu-related lipocalin (NRL). NRL protein was produced in a baculovirus system, purified and used to generate polyclonal antibodies, Western blot analysis indicated that neu-initiated mammary carcinomas express abundant NRL protein when compared to other mammary tumors.	UNIV WISCONSIN, DEPT HUMAN ONCOL, MADISON, WI 53792 USA; UNIV WISCONSIN, CELLULAR & MOLEC BIOL PROGRAM, MADISON, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Gould, Michael N/C-7414-2014		NCI NIH HHS [CA58328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; ANDERSSON LM, 1994, EXP CELL RES, V212, P389, DOI 10.1006/excr.1994.1159; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BERGER MS, 1988, CANCER RES, V48, P1238; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BIFLOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BUNDGAARD JR, 1994, BIOCHEM BIOPH RES CO, V202, P1468, DOI 10.1006/bbrc.1994.2096; CANCEDDA FD, 1988, J CELL BIOL, V107, P2455, DOI 10.1083/jcb.107.6.2455; CHAN YL, 1988, NUCLEIC ACIDS RES, V16, P11368, DOI 10.1093/nar/16.23.11368; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DICKSON SR, 1992, J HISTOCHEM CYTOCHEM, V40, P697, DOI 10.1177/40.5.1315355; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; GLASS C, 1985, J CELL BIOL, V101, P2366, DOI 10.1083/jcb.101.6.2366; GLASS C, 1988, J CELL BIOL, V107, P1337, DOI 10.1083/jcb.107.4.1337; GOULD MN, 1993, J CELL BIOCHEM, P66; GRAND RJA, 1987, INT J CANCER, V40, P213, DOI 10.1002/ijc.2910400215; HAAG JD, 1992, CANCER RES, V52, P4021; HRABARENEVEY S, 1989, ONCOGENE, V4, P601; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; MAUXION F, 1989, IMMUNOGENETICS, V29, P397, DOI 10.1007/BF00375868; MCCANN AH, 1991, CANCER RES, V51, P3296; MERUELO D, 1978, J EXP MED, V147, P470, DOI 10.1084/jem.147.2.470; MORRISON BW, 1994, ONCOGENE, V9, P3417; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161; STRANGE R, 1992, DEVELOPMENT, V115, P49; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TETU B, 1994, CANCER, V73, P2359, DOI 10.1002/1097-0142(19940501)73:9<2359::AID-CNCR2820730919>3.0.CO;2-9; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; WANG BC, 1991, CANCER RES, V51, P2642; WANG BC, 1991, CANCER RES, V51, P5649; YANG YM, 1994, J CELL BIOL, V127, P1097, DOI 10.1083/jcb.127.4.1097	43	55	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2233	2241						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570173				2022-12-17	WOS:A1995TK70200006
J	TOBIAS, KE; SHOR, J; KAHANA, C				TOBIAS, KE; SHOR, J; KAHANA, C			C-MYC AND MAX TRANSREGULATE THE MOUSE ORNITHINE DECARBOXYLASE PROMOTER THROUGH INTERACTION WITH 2 DOWNSTREAM CACGTG MOTIFS	ONCOGENE			English	Article						TRANSCRIPTION; ORNITHINE DECARBOXYLASE; C-MYC; MAX; USF	HAMSTER OVARY CELLS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; LEUCINE ZIPPER; GENE; PROTEIN; SEQUENCE; EXPRESSION; DOMAINS; DIMERIZATION	Ornithine decarboxylase (ODC), the first enzyme in the biosynthesis of polyamines, is essential for the process of cellular proliferation. ODC is a typical delayed early gene, as its mitogenic activation requires ongoing protein synthesis in the stimulated cells. This study provides evidence that the immediate early c-Myc protein is a potential transactivator of the ODC gene. We demonstrate that overexpression of c-Myc results in efficient activation of the ODC promoter, whereas overexpression of Max exerts a repressive effect. Both effects depend on the presence of two evolutionary conserved CACGTG motifs found in the first intron of the ODC gene. Transactivation of the ODC promoter also requires the dimerization of c-Myc with Max. Interestingly, overexpression of USF, a member of the same family of proteins which efficiently binds these two CACGTG motifs, fails to transregulate the ODC promoter. Our data suggest that c-Myc and Max are potential transcriptional regulators of the ODC promoter.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FITZGERALD MC, 1989, DNA-J MOLEC CELL BIO, V8, P623, DOI 10.1089/dna.1.1989.8.623; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KATZ A, 1988, J BIOL CHEM, V263, P7604; KATZ A, 1989, EMBO J, V8, P7604; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENA A, 1993, J BIOL CHEM, V268, P27277; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; POHJANPELTO P, 1985, MOL CELL BIOL, V5, P1385, DOI 10.1128/MCB.5.6.1385; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REDDY CD, 1992, ONCOGENE, V7, P2085; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STEGLICH C, 1982, J BIOL CHEM, V257, P4603; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WEN L, 1989, J BIOL CHEM, V264, P9016; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	56	55	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1721	1727						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478599				2022-12-17	WOS:A1995TD09400006
J	BARLAT, I; HENGLEIN, B; PLET, A; LAMB, N; FERNANDEZ, A; MCKENZIE, F; POUYSSEGUR, J				BARLAT, I; HENGLEIN, B; PLET, A; LAMB, N; FERNANDEZ, A; MCKENZIE, F; POUYSSEGUR, J			TGF-BETA-1 AND CAMP ATTENUATE CYCLIN-A GENE-TRANSCRIPTION VIA A CAMP-RESPONSIVE ELEMENT THROUGH INDEPENDENT PATHWAYS	ONCOGENE			English	Article						TGF-BETA; CYCLIN-A; CAMP; INHIBITION OF PROLIFERATION	GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; TGF-BETA; SIGNAL TRANSDUCTION; NEGATIVE REGULATION; CATALYTIC SUBUNIT; DNA-REPLICATION; A EXPRESSION; CROSS-TALK; PHOSPHORYLATION	Transforming growth factor beta (TGF-beta) is a potent inhibitor of the proliferation of many cell lines. The expression of Cyclin A is down-regulated by TGF-beta 1 in Chinese hamster lung fibroblasts and most of this effect is mediated at the transcriptional level through a cAMP-reponsive element (CRE), but does not require a functional cAMP-dependent protein kinase. However, activation of the cAMP pathway in these cells gives rise to a strong inhibition of proliferation, paralleled by a down-regulation of Cyclin A promoter activity. This effect requires the integrity of the CRE, suggesting a role for CRE-binding proteins in late G1/S controls.	CNRS,CTR GENET MOLEC,UPR 2420,F-91198 GIF SUR YVETTE,FRANCE; CNRS,INSERM,CRBM,CELL BIOL UNIT,F-34033 MONTPELLIER 1,FRANCE; UNIV NICE,CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	BARLAT, I (corresponding author), INST GENET MOLEC MONTPELLIER,CNRS,UMR 9942,BP 5051,1919 ROUTE MENDE,F-34033 MONTPELLIER 1,FRANCE.							ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHAMBARD JC, 1988, J CELL PHYSIOL, V135, P101, DOI 10.1002/jcp.1041350114; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DARBON JM, 1994, ONCOGENE, V9, P3127; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FERNANDEZPOL JA, 1987, BIOCHEM BIOPH RES CO, V144, P1197, DOI 10.1016/0006-291X(87)91438-0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P2355, DOI 10.1073/pnas.79.7.2355; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MCCORMICK F, 1993, CURRENT OP GENET DEV, V4, P71; MECHTA F, 1989, New Biologist, V1, P297; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PINES J, 1993, BIOCHEM SOC T, V18, P921; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROGERS KV, 1990, P NATL ACAD SCI USA, V87, P8975, DOI 10.1073/pnas.87.22.8975; ROSKOSKI R, 1993, METHOD ENZYMOL, V99, P3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCOTTO L, 1990, J BIOL CHEM, V265, P2203; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	79	55	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1309	1318						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478551				2022-12-17	WOS:A1995RY96700011
J	JIANG, HP; LIN, J; YOUNG, SM; GOLDSTEIN, NI; WAXMAN, S; DAVILA, V; CHELLAPPAN, SP; FISHER, PB				JIANG, HP; LIN, J; YOUNG, SM; GOLDSTEIN, NI; WAXMAN, S; DAVILA, V; CHELLAPPAN, SP; FISHER, PB			CELL-CYCLE GENE-EXPRESSION AND E2F TRANSCRIPTION FACTOR COMPLEXES IN HUMAN-MELANOMA CELLS INDUCED TO TERMINALLY DIFFERENTIATE	ONCOGENE			English	Review						TERMINAL CELL DIFFERENTIATION; REVERSIBLE DIFFERENTIATION; HUMAN MELANOMA; E2F GROWTH ARREST COMPLEX; E2F TERMINAL DIFFERENTIATION COMPLEX	DNA POLYMERASE-DELTA; WILD-TYPE P53; PROTEIN-KINASE-C; MESSENGER-RNA; AUXILIARY PROTEIN; NUCLEAR ANTIGEN; S-PHASE; RETINOBLASTOMA PROTEIN; DOWN-REGULATION; F9 CELLS	Defects in cellular differentiation are a common occurrence in human cancers, The combination of recombinant human fibroblast interferon (IFN-beta) and the antileukemic compound mezerein (MEZ) results in an irreversible loss of proliferative capacity and terminal cell differentiation in H0-1 human melanoma cells, In contrast, either agent alone induces reversible growth arrest and/or specific components of the differentiation process without inducing terminal differentiation, The current study investigates changes in cell cycle, cell cycle gene expression and E2F transcription factor complex formation during the processes of reversible and irreversible (terminal) differentiation, Induction of both terminal differentiation and reversible differentiation (MEZ treatment) results in a temporal decrease in DNA synthesis and the percentage of cells in S phase and a decrease in the expression of cell cycle and growth regulated genes, including cdc2, cyclin A, cyclin B, histone H1, histone H4, nm23-H1, p53 and c-myc, Persistent gene expression changes occur in terminally differentiated cells, but not in reversibly differentiated cells, H0-1 cells contain several E2F binding activities, including uncomplexed E2F, an E2F-p107-cyclin A-cdk2 kinase complex and an Rb-E2F complex, Induction of growth arrest by MEZ results in a slow migrating gel-shift band that contains E2F associated with the pRb2/p130 protein. There is also a loss of the Rb-E2F complex. Induction of terminal differentiation after treatment with IFN-beta+MEZ generates a second pRb2/p130-E2F complex that migrates considerably faster than the pRb2/p130-E2F complex resulting from growth arrest, The slower migrating complex may contribute to growth arrest, whereas the faster migrating complex may play a role in terminal differentiation. Our results demonstrate that terminal cell differentiation involves a co-ordinate and continuous suppression of a number of cell cycle and growth related genes and results in the development of a novel E2F transcription factor complex not apparent in growth arrested and reversibly differentiated human melanoma cells.	COLUMBIA UNIV, COLL PHYS & SURG,CTR COMPREHENS CANC, INST CANC RES,DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG,CTR COMPREHENS CANC, INST CANC RES,DEPT UROL, NEW YORK, NY 10032 USA; IMCLONE SYST INC, DEPT IMMUNOL MONOCLONAL ANTIBODIES, NEW YORK, NY 10014 USA; MT SINAI MED CTR, DEPT MED, DIV MED ONCOL, NEW YORK, NY 10029 USA	Columbia University; Columbia University; Eli Lilly; Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R01CA063136, R01CA035675] Funding Source: NIH RePORTER; NCI NIH HHS [CA63136, CA35675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKHURST RJ, 1989, DIFFERENTIATION, V40, P36, DOI 10.1111/j.1432-0436.1989.tb00811.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BRAVO R, 1980, J CELL BIOL, V84, P795, DOI 10.1083/jcb.84.3.795; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CAROZZI N, 1984, SCIENCE, V224, P1115, DOI 10.1126/science.6719136; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHELLAPPAN SP, 1994, MOL CELL DIFFER, V22, P201; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COLLART DG, 1988, J BIOL CHEM, V263, P15860; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; FISHER PB, 1991, SERONO SYM, V82, P201; FISHER PB, 1988, PHARM EFFECTS LIPIDS, V3, P69; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAETANO C, 1991, CELL GROWTH DIFFER, V2, P487; GIOVANELLA BC, 1976, J NATL CANCER I, V56, P1131, DOI 10.1093/jnci/56.6.1131; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAHAM GM, 1991, CANCER IMMUNOL IMMUN, V32, P382, DOI 10.1007/BF01741333; GUARINI L, 1992, PIGM CELL RES, P123; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARPER JW, 1993, CELL, V75, P805; HASS R, 1993, CELL GROWTH DIFFER, V4, P159; HAYES TE, 1991, NEW BIOL, V3, P259; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; JIANG HP, 1992, INT J ONCOL, V1, P227; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KEIM DR, 1993, CLIN EXP METASTAS, V11, P83, DOI 10.1007/BF00880069; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KIYOKAWA H, 1992, CELL GROWTH DIFFER, V3, P377; KIYOKAWA H, 1993, P NATL ACAD SCI USA, V90, P6746, DOI 10.1073/pnas.90.14.6746; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAYOL X, 1993, ONCOGENE, V8, P2561; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; RICHON VM, 1989, ONCOGENE, V4, P165; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHEN DW, 1993, P NATL ACAD SCI USA, V80, P5919; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEIN G S, 1992, Current Opinion in Cell Biology, V4, P166, DOI 10.1016/0955-0674(92)90028-B; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SU ZZ, 1991, MOL CARCINOGEN, V4, P231, DOI 10.1002/mc.2940040310; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; WHITMAN MM, 1990, CANCER RES, V50, P3193; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMASHIRO S, 1994, ONCOGENE, V9, P2461; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	102	55	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1179	1189						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566979				2022-12-17	WOS:A1995RX18000022
J	SHOU, CC; WURMSER, A; LING, K; BARBACID, M; FEIG, LA				SHOU, CC; WURMSER, A; LING, K; BARBACID, M; FEIG, LA			DIFFERENTIAL RESPONSE OF THE RAS EXCHANGE FACTOR, RAS-GRF TO TYROSINE KINASE AND G-PROTEIN MEDIATED SIGNALS	ONCOGENE			English	Article						RAS; EXCHANGE FACTORS; GRF	EPIDERMAL GROWTH-FACTOR; SACCHAROMYCES-CEREVISIAE CDC25; GRB2 ADAPTER PROTEIN; T-CELL ACTIVATION; MOLECULAR-CLONING; GUANINE-NUCLEOTIDES; HEMATOPOIETIC-CELLS; MAP KINASE; RECEPTOR; PHOSPHORYLATION	Ras-GRF, a guanine-nucleotide exchange factor that activates Ras p21, was tested for its ability to couple to either tyrosine kinase or heterotrimeric G protein signal transduction pathways. Ras-GRF failed to bind the SH2 and SH3 containing adaptor protein Grb2, either in vitro or in vivo. Furthermore, Ras-GRF did not form a stable complex with activated EGF receptor. However, as has been shown previously (Cen et al., 1994), the presence of Ras-GRF in NIH3T3 cells enhanced the activation of Ras induced by serum stimulation. A similar effect was not observed with PDGF stimulation. Moreover, serum stimulation lead to the hyperphosphorylation of Ras-GRF. Both the serum induced super-activation of Ras, and the hyperphosphorylation of Ras-GRF were blocked by pretreatment of cells with the G(i,o) inhibitor pertussis toxin, but not by pretreatment with the tyrosine kinase inhibitor genistein. These results suggest that Ras-GRF has the capacity to mediate Ras activation initiated by signals using heterotrimeric G proteins.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; BRISTOL MYERS SQUIBB CO,DEPT MOLEC BIOL,PRINCETON,NJ	Tufts University; Bristol-Myers Squibb								ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BUSTELLO, 1994, ONCOGENE, V9, P2405; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1994, MOL CELL BIOL, V13, P7718; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LAMORTE VJ, 1993, J BIOL CHEM, V26, P19411; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SWANSON ME, 1986, J CELL BIOL, V103, P485, DOI 10.1083/jcb.103.2.485; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEI W, 1993, MOL BRAIN RES, V19, P124; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	45	55	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1887	1893						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761090				2022-12-17	WOS:A1995QZ92600002
J	COLOMBEL, M; RADVANYI, F; BLANCHE, M; ABBOU, C; BUTTYAN, R; DONEHOWER, LA; CHOPIN, D; THIERY, JP				COLOMBEL, M; RADVANYI, F; BLANCHE, M; ABBOU, C; BUTTYAN, R; DONEHOWER, LA; CHOPIN, D; THIERY, JP			ANDROGEN SUPPRESSED APOPTOSIS IS MODIFIED IN P53 DEFICIENT MICE	ONCOGENE			English	Article						APOPTOSIS; GENE, P53; PROSTATE, GLAND; CELL CYCLE; CASTRATION EFFECT; DNA FRAGMENTATION	WILD-TYPE P53; RAT PROSTATE; CELL-CYCLE; DNA; DEATH; INVOLUTION; INDUCTION; GLAND; GENE	Several in vitro studies have provided evidence that the tumor suppressor protein, p53, is involved in the cell death process referred to as apoptosis, The recent development of p53 knock-out mice has enabled further investigation into the function of p53 for apoptosis, in vivo. Radiation-induced apoptosis is suppressed in such mice, yet other forms of apoptosis do not seem to be significantly affected, In this report, we present evidence that such male p53 nullizygous mice have less apoptosis in the prostate glands associated,vith the first 4 days following castration, Ventral prostate glands were obtained from normal, heterozygous p53-null and p53 nullizygous mice at daily intervals after castration, These tissues were stained for apoptosis with the use of the irt situ end labeling method and apoptotic bodies were quantified by microscopy, Although labeled apoptotic bodies were observed in post-castrated tissues from all of these genetic variant mice, the onset of apoptosis was delayed and the occurrence of apoptosis was significantly reduced in the p53 nullizygous mice when compared to normal controls, Heterozygous p53-null mice were intermediate for these criteria, Examination of the internucleosomal DNA fragmentation pattern at 2 days of castration supports a significant diminution of prostate cell apoptosis in nullizygous p53 mice, Additionally, large nucleated and multinucleated cells were detected in the prostate epithelium of noncastrated p53 nullizygous mice and these abnormal cells were increased after castration, Flow cytometric analysis of these tissues confirmed a high number of 4C and 8C DNA content cells in the p53 nullizygous prostates and their frequency was increased by castration, In concordance with an earlier study, we conclude that functional p53 protein is not essential for prostate epithelial cells to undergo catration-induced apoptosis, However, wild-type p53 does appear to enhance this process, especially in the early period following castration, and this protein may regulate an aberrant prostate cell cycling activity that follows castration.	CNRS, URA 1337, PARIS, FRANCE; ECOLE NORMALE SUPER, F-75230 PARIS 05, FRANCE; COLUMBIA UNIV, PRESBYTERIAN HOSP, DEPT UROL, NEW YORK, NY 10032 USA; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Columbia University; NewYork-Presbyterian Hospital; Baylor College of Medicine	COLOMBEL, M (corresponding author), CHU HENRI MONDOR, SERV UROL, ETUD TUMEURS UROL GRP, F-94010 CRETEIL, FRANCE.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; colombel, marc/0000-0002-0152-8021; Radvanyi, Francois/0000-0002-5696-6424				BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CASEY G, 1991, ONCOGENE, V6, P1791; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; KATZ AE, 1989, CANCER RES, V49, P5889; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; KIPRIANOU N, 1990, CANCER RES, V50, P3748; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARIE D, 1993, BIOL CELL, V78, P41, DOI 10.1016/0248-4900(93)90113-S; MERRITT AJ, 1994, CANCER RES, V54, P614; RAMVQVIST T, 1993, ONCOGENE, V8, P1495; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STRANGE R, 1992, DEVELOPMENT, V115, P49; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG XJ, 1994, BIOCHEM BIOPH RES CO, V198, P1189, DOI 10.1006/bbrc.1994.1168	21	55	55	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1269	1274						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731676				2022-12-17	WOS:A1995QR65100002
J	KRANENBURG, O; DEGROOT, RP; VANDEREB, AJ; ZANTEMA, A				KRANENBURG, O; DEGROOT, RP; VANDEREB, AJ; ZANTEMA, A			DIFFERENTIATION OF P19 EC CELLS LEADS TO DIFFERENTIAL MODULATION OF CYCLIN-DEPENDENT KINASE-ACTIVITIES AND TO CHANGES IN THE CELL-CYCLE PROFILE	ONCOGENE			English	Article						CYCLIN-DEPENDENT KINASES; PIG CELLS; DIFFERENTIATION; CELL CYCLE CONTROL; RETINOBLASTOMA GENE PRODUCT	EMBRYONAL CARCINOMA-CELLS; SUSCEPTIBILITY GENE-PRODUCT; SV40 LARGE-T; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; DNA-REPLICATION; EXPRESSION; FAMILY; E2F; PHASE	The retinoblastoma gene product (pRb) is essential for normal embryonic development, Phosphorylation of pRb by cyclin dependent kinases (cdk's) is believed to be crucial for the regulation of its function, In this report we have studied the regulation of pRb and cdk's during in vitro differentiation of P19 embryonal carcinoma (EC) cells, as a model for early developmental processes, During EC cell differentiation, the synthesis of pRb is strongly induced, In addition, the phosphorylation state of induced pRb is modulated, yielding mainly underphosphorylated pRb, Concomitantly, the pRb kinases cdk2 and cdk4 are differentially regulated: cdk2 kinase activity is impaired, whereas cdk4 kinase activity is stimulated, due to an induction of cyclins D1 and D2. Furthermore, the DNA binding activity of E2F transcription factors is strongly impaired during differentiation and the number of cells in G1 is increased. Thus, P19 EC cell differentiation is accompanied by changes in cdk-activities, pRb regulation and E2F DNA-binding, resulting in the generation of cell types with an altered cell cycle profile.	UNIV UTRECHT HOSP,DEPT PULM DIS,3508 GA UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center	KRANENBURG, O (corresponding author), LEIDEN UNIV,DEPT MOLEC CARCINOGENESIS,SYLVIUS LAB,POB 9503,2300 RA LEIDEN,NETHERLANDS.		Kranenburg, Onno/K-4115-2015	Kranenburg, Onno/0000-0002-2112-4390				AJCHENBAUM F, 1993, J BIOL CHEM, V25, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KATA JY, 1993, GENE DEV, V7, P331; KITAGAWA M, 1992, ONCOGENE, V7, P1067; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUMMERY CL, 1986, EXP CELL RES, V165, P229, DOI 10.1016/0014-4827(86)90547-1; MUMMERY CL, 1985, DEV BIOL, V109, P402, DOI 10.1016/0012-1606(85)90466-X; MUMMERY CL, 1987, CELL DIFFER DEV, V20, P153, DOI 10.1016/0045-6039(87)90429-5; MURRAY EJ, 1991, MOL CELL BIOL, V11, P5534, DOI 10.1128/MCB.11.11.5534; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PALERMO L, 1993, ONCOGENES, V8, P1049; PINES J, 1993, BIOCHEM SOC T, V21, P921, DOI 10.1042/bst0210921; ROSSANT J, 1982, J EMBRYOL EXP MORPH, V70, P99; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SLACK RS, 1993, ONCOGENE, V8, P1585; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSAI LH, 1993, ONCOGENE, V8, P1593; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	51	55	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					87	95						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824282				2022-12-17	WOS:A1995QA98000011
J	GOLAY, J; LOFFARELLI, L; LUPPI, M; CASTELLANO, M; INTRONA, M				GOLAY, J; LOFFARELLI, L; LUPPI, M; CASTELLANO, M; INTRONA, M			THE HUMAN A-MYB PROTEIN IS A STRONG ACTIVATOR OF TRANSCRIPTION	ONCOGENE			English	Article							DNA-BINDING DOMAIN; GENE V-MYB; HUMAN HEMATOPOIETIC-CELLS; C-MYB; B-MYB; REGULATED EXPRESSION; CELLULAR PROGENITOR; ONCOGENE PRODUCT; LEUKEMIA-VIRUS; LEUCINE-ZIPPER	The A-myb gene belongs to the family of the c-myb proto-oncogene. We report here the cloning from a B lymphocyte cDNA library of the previously missing 3' half of the human A-myb cDNA, thus closing the previously still incomplete open reading frame. Analysis of the homologies between the different myb proteins reveals four domains of high conservation. We show, using a polyclonal rabbit antibody, that the 90 kd human A-myb protein is nuclear and that it activates transcription from the KHK-CAT reporter 6-10 times more strongly than c-myb in NIH3T3 cells. The transactivating function of A-myb depends on the presence of the myb binding site in the reporter, and on both the DNA binding and acidic domains of the A-myb protein. The bacterially expressed protein protects the myb binding sites of the reporter in footprint experiments. Binding of the A-myb protein is shown in gel retardation assays to be specific for the classical c-myb recognition sequence PyAAC(G)/(T)G. In addition, like c-myb, A-myb binds more strongly to the MIM-A synthetic oligonucleotide that carries the TAACGG sequence than to the MBS-I oligonucleotide containing TAAGTG. Finally, DNA binding activity is demonstrated to require the N-terminal portion of the protein containing the three tandem repeats of amino acids conserved in all myb proteins. We have thus shown that the A-myb protein is a strong activator of transcription and that this activity depends on both the DNA-binding and acidic domains.			GOLAY, J (corresponding author), IST RIC FARMACOL MARIO NEGRI, VIA ERITREA 62, I-20157 MILAN, ITALY.		Luppi, Mario/J-3668-2016; Golay, Josee/AAA-4085-2022; Introna, Martino/AAA-5823-2019	Luppi, Mario/0000-0002-0373-1154; Golay, Josee/0000-0002-7932-909X; Introna, Martino/0000-0001-6216-0892				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; ARSURA M, 1992, BLOOD, V79, P2708; ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOHMANN D, 1987, NATURE, V325, P268, DOI 10.1038/325268a0; BORTNER DM, 1991, NUCLEIC ACIDS RES, V19, P1533, DOI 10.1093/nar/19.7.1533; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DASGUPTA P, 1992, J VIROL, V66, P270, DOI 10.1128/JVI.66.1.270-276.1992; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1992, J IMMUNOL, V149, P300; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, IN PRESS J IMMUNOL; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRASSER FA, 1992, ONCOGENE, V7, P1005; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KASTAN MB, 1989, BLOOD, V74, P1517; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LAM EWF, 1992, ONCOGENE, V7, P1885; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Maxam A M, 1980, Methods Enzymol, V65, P499; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NOMURA T, 1993, J BIOL CHEM, V268, P21914; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WATSON RJ, 1992, ONCOGENE, V7, P1885; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; ZOBEL A, 1991, ONCOGENE, V6, P1397	64	55	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2469	2479						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058310				2022-12-17	WOS:A1994PC05400006
J	GRIECO, M; CERRATO, A; SANTORO, M; FUSCO, A; MELILLO, RM; VECCHIO, G				GRIECO, M; CERRATO, A; SANTORO, M; FUSCO, A; MELILLO, RM; VECCHIO, G			CLONING AND CHARACTERIZATION OF H4 (D10S170), A GENE INVOLVED IN RET REARRANGEMENTS IN-VIVO	ONCOGENE			English	Article							PAPILLARY THYROID CARCINOMAS; TYROSINE KINASE; INSITU HYBRIDIZATION; ONCOGENE ACTIVATION; TRANSFORMING GENE; PROTO-ONCOGENE; MESSENGER-RNA; COILED-COIL; PROTOONCOGENE; EXPRESSION	H4(D10S170) is a gene which we isolated because of its frequent rearrangement with the RET proto-oncogene in vivo. Its fusion to RET generates the RET/PTC1 oncogene, which has been detected in about 20% of human thyroid papillary carcinomas. We have cloned and sequenced the cDNA corresponding to the H4(D10S170) gene from a human normal thyroid cDNA library. The nucleotide sequence of the H4(D10S170) 3kb transcript shows no significant homology to known genes and contains an open reading frame (ORF) of 585 amino acids. H4(D10S170) predicted protein has no transmembrane domain and shows extensive regions in the alpha helical conformation, which are 30%.homologous to the alpha-helical domains of several proteins including tropomyosin, vimentin, keratin and the tail region of myosin heavy chain. A putative SH3 binding site is present at the carboxy terminus, which suggests that H4(D10S170) might be a cytoskeletal protein.	UNIV REGGIO CALABRIA,FAC MED & CHIRURG,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Universita Mediterranea di Reggio Calabria	GRIECO, M (corresponding author), FAC MED & CHIRURG NAPOLI,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CAL,CNR,I-80131 NAPLES,ITALY.		Cerrato, Aniello/AAY-1484-2020; melillo, rosa marina/O-5255-2015	MELILLO, Rosa Marina/0000-0002-9233-5275; Fusco, Alfredo/0000-0003-3332-5197; Grieco, Michele/0000-0002-4212-7814				BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRECO A, 1992, ONCOGENE, V7, P237; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; ITO T, 1993, CANCER RES, V53, P2940; JHIANG SM, 1992, ONCOGENE, V7, P1331; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; KUNIEDA T, 1991, GENE, V107, P323, DOI 10.1016/0378-1119(91)90334-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANZI C, 1992, ONCOGENE, V7, P2189; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MITCHELL PJ, 1992, ONCOGENE, V7, P383; MITCHELL PJ, 1992, ONCOGENE, V7, P2329; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1994, ONCOGENE, V9, P509; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; WAJJWALKU W, 1992, JPN J CANCER RES, V83, P671, DOI 10.1111/j.1349-7006.1992.tb01963.x; WATSON CJ, 1985, DNA CLONING	39	55	57	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2531	2535						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058316				2022-12-17	WOS:A1994PC05400012
J	VALENTINIS, B; PORCU, P; QUINN, K; BASERGA, R				VALENTINIS, B; PORCU, P; QUINN, K; BASERGA, R			THE ROLE OF THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR IN THE TRANSFORMATION BY SIMIAN-VIRUS-40 T-ANTIGEN	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; CELLULAR DNA-SYNTHESIS; MESSENGER-RNA LEVELS; SV40-TRANSFORMED CELLS; PERMISSIVE CELLS; SOMATOMEDIN-C; A REGULATION; PROTEIN; BINDING; PHOSPHORYLATION	Balb/c 3T3 cells transformed by the tsA58 temperature-sensitive (ts) mutant of SV40 large T antigen, BalbA58 cells, grow in 1% serum at the permissive temperature of 34 degrees C but fail to grow at the restrictive temperature of 39.6 degrees C. Although incapable of growing, BalbA58 cells, in low serum at 39.6 degrees C, stilt synthesize DNA and tend to accumulate in the G(2) phase of the cell cycle. Growth in 1% serum at 39.6 degrees C resumes if BalbA58 cells are treated with insulin-like growth factor I (IGF-I). By using cells overexpressing the IGF-I receptor, and cells with a targeted disruption of the IGF-I receptor genes, we show that: 1) the activation of the IGP-I receptor by its ligand(s) plays a major role in the ability of the SV40 large T antigen to promote growth in low serum; and 2) the IGF-I receptor plays a role in the progression of cells not only through G(1), but also through the S and G(2) phases of the cell cycle. These findings, together with other recent findings from the literature, suggest that one of the mechanisms by which oncogenes and tumor suppresser genes regulate cell growth is through the modulation of growth factors and their receptors.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,PHILADELPHIA,PA 19107; NCI,DCPC,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER; NCI NIH HHS [CA56309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; CAMPISI J, 1984, MOL CELL BIOL, V4, P1807, DOI 10.1128/MCB.4.9.1807; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CRISTOFALO VJ, 1989, J GERONTOL, V44, P55, DOI 10.1093/geronj/44.6.55; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1991, ONCOGENE, V6, P1931; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FERBER A, 1993, J BIOL CHEM, V268, P17883; FOYT HL, 1991, INSULIN LIKE GROWTH, P1; Gai X X, 1988, Oncogene Res, V3, P377; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HISCOTT JB, 1979, J VIROL, V30, P590, DOI 10.1128/JVI.30.2.590-599.1979; HISCOTT JB, 1981, J VIROL, V37, P802, DOI 10.1128/JVI.37.2.802-812.1981; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEOF EB, 1982, EXP CELL RES, V141, P107, DOI 10.1016/0014-4827(82)90073-8; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MERCER W E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P251; NIELSEN FC, 1993, MOL CELL ENDOCRINOL, V93, P87, DOI 10.1016/0303-7207(93)90143-8; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; OTTAVIO L, 1990, MOL CELL BIOL, V10, P303, DOI 10.1128/MCB.10.1.303; PERDUE JF, 1991, ENDOCRINOLOGY, V129, P3101, DOI 10.1210/endo-129-6-3101; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RUSSELL WE, 1984, P NATL ACAD SCI-BIOL, V81, P2389, DOI 10.1073/pnas.81.8.2389; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SELL C, IN PRESS P NATL ACAD; SIEGFRIED JM, 1992, P NATL ACAD SCI USA, V89, P8107, DOI 10.1073/pnas.89.17.8107; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TRAVALI S, 1991, ONCOGENE, V6, P887; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WERNER H, 1991, INSULIN LIKE GROWTH, P17; YAMORI T, 1991, CANCER RES, V51, P5859; YOSHINOUCHI M, 1993, CELL PROLIFERAT, V26, P139, DOI 10.1111/j.1365-2184.1993.tb00014.x	49	55	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					825	831						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108125				2022-12-17	WOS:A1994MW55100018
J	LOGANZO, F; DOSIK, JS; ZHAO, Y; VIDAL, MJ; NANUS, DM; SUDOL, M; ALBINO, AP				LOGANZO, F; DOSIK, JS; ZHAO, Y; VIDAL, MJ; NANUS, DM; SUDOL, M; ALBINO, AP			ELEVATED EXPRESSION OF PROTEIN-TYROSINE KINASE C-YES, BUT NOT C-SRC, IN HUMAN-MALIGNANT MELANOMA	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; HUMAN MELANOCYTES; POINT MUTATIONS; GENE-PRODUCT; MONOCLONAL-ANTIBODIES; CUTANEOUS MELANOMA; SURFACE-ANTIGENS; CELLULAR-YES; HUMAN DNA; DIFFERENTIATION	The c-yes proto-oncogene encodes a protein tyrosine kinase, p62c-yes (c-Yes) that belongs to the Src family of non-receptor type protein tyrosine kinases. We compared the levels of c-Yes kinase activity and protein by immune complex kinase assays and immune blot analysis in 20 human melanoma and 10 human melanocyte cell tines. Results show that the average kinase activity of c-Yes in most melanoma cell lines is 5-10-fold higher than that in melanocyte cell lines. The protein level of c-Yes in these melanoma cell lines is correspondingly higher than that in melanocytes. The increase in c-Yes kinase activity is most likely attributable to the elevated protein level because single-strand conformational polymorphism of all structural and functional domains detected no mutations in any of the c-yes coding regions. Subcellular fractionation analysis indicated that c-Yes localizes to the plasma membrane, perinuclear and cytosolic compartments while c-Src predominantly associates with plasma membranes. In melanoma cells in which an elevated level of c-Yes is observed, a protein of 39 kD is heavily phosphorylated on tyrosine. This protein is only observed in melanoma cells and not in melanocytes, suggesting a perturbed signaling pathway in melanoma cells that results in abnormal tyrosine phosphorylation of cellular proteins. These data suggest that derangement of expression of the c-Yes tyrosine kinase may have a role in the malignant progression of the human melanocyte.	MEM SLOAN KETTERING CANC CTR,MAMMALIAN CELL TRANSFORMAT LAB,1275 YORK AVE,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Rockefeller University					NCI NIH HHS [CA-37907, CA-01605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1989, ONCOGENE, V4, P1363; ALBINO AP, 1991, CANCER RES, V51, P4815; ALBINO AP, 1993, IN PRESS CANCER TREA; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DANENBERG PV, 1992, NUCLEIC ACIDS RES, V20, P573, DOI 10.1093/nar/20.3.573; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P5847, DOI 10.1073/pnas.78.9.5847; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GOLDEN A, 1988, ONCOGENE HDB, P149; GRANDORI C, 1991, ONCOGENE, V6, P1063; HALABAN R, 1991, Critical Reviews in Oncogenesis, V2, P247; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; Houghton A N, 1988, Prog Clin Biol Res, V256, P333; HOUGHTON AN, 1988, J EXP MED, V167, P197, DOI 10.1084/jem.167.1.197; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; KOPF AW, 1984, J AM ACAD DERMATOL, V11, P674, DOI 10.1016/S0190-9622(84)70225-8; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KRUEGER J, 1991, ONCOGENE, V6, P933; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LASSAM N, 1992, ONCOGENE, V7, P51; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LONGSTRETH J, 1988, CANCER METAST REV, V7, P321, DOI 10.1007/BF00051373; MATSUZAWA Y, 1991, ONCOGENE, V6, P1561; MCCLAY EF, 1991, CRIT REV ONCOL HEMAT, V11, P299, DOI 10.1016/1040-8428(91)90030-G; OCONNOR TJ, 1992, CELL GROWTH DIFFER, V3, P435; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PESCE A, 1964, J BIOL CHEM, V239, P1753; REDMOND T, 1992, CELL GROWTH DIFFER, V3, P567; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; ROWLEY JD, 1990, CANCER RES, V50, P3816; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LAB MANU; SEKI T, 1985, JPN J CANCER RES, V76, P907; SEMBA K, 1992, GENES CANCER, P74; SOBER AJ, 1991, DERMATOL CLIN, V9, P617; SUDOL M, 1988, BRAIN RES REV, V13, P391, DOI 10.1016/0165-0173(88)90014-8; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUDOL M, 1992, MOL BASIS HUMAN CANC; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; VEILLETTE A, 1989, ONCOGENES, P121; VOLKENANDT M, 1991, PIGM CELL RES, V4, P35, DOI 10.1111/j.1600-0749.1991.tb00311.x; ZHAO YH, 1991, ONCOGENE, V6, P1725; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZHENG XF, 1989, ONCOGENE, V4, P99	65	55	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2637	2644						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	7690926				2022-12-17	WOS:A1993LX34300004
J	CARBONAROHALL, D; WILLIAMS, R; WU, LT; WARBURTON, D; ZEICHNERDAVID, M; MACDOUGALL, M; TOLO, V; HALL, F				CARBONAROHALL, D; WILLIAMS, R; WU, LT; WARBURTON, D; ZEICHNERDAVID, M; MACDOUGALL, M; TOLO, V; HALL, F			G1 EXPRESSION AND MULTISTAGE DYNAMICS OF CYCLIN-A IN HUMAN OSTEOSARCOMA CELLS	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; P34CDC2 PROTEIN-KINASE; MATURATION-PROMOTING FACTOR; DNA-BINDING PROTEIN; CDC2 PROTEIN; TRANSCRIPTION FACTOR; HISTONE-H1 KINASE; RB PROTEIN; M-PHASE; PHOSPHORYLATION	Cyclin A was initially characterized as a 'mitotic cyclin', believed to function exclusively at the G2-to-M phase transition; however, recent studies have provided compelling evidence that cyclin A additionally functions earlier in the mammalian somatic cell cycle as a putative 'S-phase-promoting factor'. Moreover, numerous inconsistencies have arisen concerning the temporal induction, subcellular localization, subunit configuration, covalent modification and proteolytic destruction of cyclin A, as well as the physiological function of the cyclin A-associated protein kinase complexes. Utilizing precisely synchronized human MG-63 osteosarcoma cells, the present study demonstrates that cyclin A mRNA and protein are clearly expressed in late G1 prior to S-phase entry, as is cyclin A-associated kinase activity and concomitant phosphorylation of the Rb protein. A series of monospecific cyclin A antibodies were generated and utilized to confirm that multiple covalent modifications of cyclin A occur during the course of the cell cycle, and to characterize the subcellular dynamics in additional detail. Pharmacological blockade with mimosine was utilized to further delineate cyclin A expression and to distinguish the temporal induction from the mechanisms of enzyme activation. Subcellular fractionation and immunocytochemical staining localized nascent cyclin A to the cytoplasm, and revealed a distinct translocation to the nucleus during the G1-to-S phase transition. The results of these studies support a multistage model of cyclin A metabolism and enzyme activation.	CHILDRENS HOSP, DIV ORTHOPAED SURG, 4650 SUNSET BLVD, LOS ANGELES, CA 90054 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90033 USA; CHILDRENS HOSP, DIV NEONATAL & PEDIAT PULM, LOS ANGELES, CA 90054 USA; UNIV SO CALIF, SCH DENT, LOS ANGELES, CA 90089 USA; UNIV SO CALIF, CTR CRANIOFACIAL MOLEC BIOL, LOS ANGELES, CA 90089 USA; UNIV SO CALIF, SCH PHARM, LOS ANGELES, CA 90089 USA; UNIV SO CALIF, DEPT MOLEC PHARMACOL & TOXICOL, LOS ANGELES, CA 90089 USA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California; University of Southern California			Zeichner-David, Margarita/A-6567-2008					BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLANQUET V, 1990, GENOMICS, V8, P595, DOI 10.1016/0888-7543(90)90052-V; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; Braun R K, 1989, Proc West Pharmacol Soc, V32, P15; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Cooper JA, 1990, CURR OPIN CELL BIOL, V2, P285, DOI 10.1016/0955-0674(90)90021-6; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ERIKSON E, 1989, J BIOL CHEM, V264, P19577; FOX MH, 1987, CYTOMETRY, V8, P315, DOI 10.1002/cyto.990080312; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOSCIN LP, 1982, BIOCHEMISTRY-US, V21, P2513, DOI 10.1021/bi00539a034; HALL FL, 1990, J BIOL CHEM, V265, P6944; HALL FL, 1991, J BIOL CHEM, V266, P17430; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNT T, 1991, NATURE, V350, P462, DOI 10.1038/350462a0; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Kulp K S, 1990, Proc West Pharmacol Soc, V33, P219; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LALANDE M, 1990, EXP CELL RES, V188, P117, DOI 10.1016/0014-4827(90)90285-I; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LU XP, 1992, J BIOL CHEM, V267, P2841; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; Maniatis T., 1982, MOL CLONING; MARIA T, ONCOGENE, V43, P477; MARX J, 1991, SCIENCE, V252, P1490, DOI 10.1126/science.1828620; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MURRAY AW, 1991, NATURE, V349, P367, DOI 10.1038/349367a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TAMURA T, 1990, ONCOGENE, V5, P1259; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; Vulliet P R, 1988, Proc West Pharmacol Soc, V31, P255; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WILLIAMS RT, 1992, ONCOGENE, V7, P423; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	77	55	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1649	1659						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502485				2022-12-17	WOS:A1993LE06400029
J	CHARLES, CH; YOON, JK; SIMSKE, JS; LAU, LF				CHARLES, CH; YOON, JK; SIMSKE, JS; LAU, LF			GENOMIC STRUCTURE, CDNA-SEQUENCE, AND EXPRESSION OF GLY96, A GROWTH FACTOR-INDUCIBLE IMMEDIATE-EARLY GENE ENCODING A SHORT-LIVED GLYCOSYLATED PROTEIN	ONCOGENE			English	Note							NF-KAPPA-B; C-FOS; CELLS; FIBROBLASTS; TRANSITION; MYC; SET	We report the cDNA sequence and genomic structure of gly96, an immediate early gene inducible by serum growth factors in mouse fibroblasts. It encodes a 153-amino acid protein that does not share significant sequence similarity with any known protein. In the adult mouse, gly96 is expressed predominantly in the lung, testes and the uterus. We have identified the Gly96 protein in Balb/c 3T3 cells using affinity-purified antibodies recognizing the Gly96 polypeptide. We show that Gly96 is glycosylated and has a short half-life in serum stimulated fibroblasts.	UNIV ILLINOIS,COLL MED,DEPT GENET,808 S WOOD ST,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Lau, Lester/0000-0002-4364-2914	NATIONAL CANCER INSTITUTE [R01CA046565, R01CA052220] Funding Source: NIH RePORTER; NCI NIH HHS [CA52220, CA46565] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CROZE E, 1989, J CELL BIOL, V108, P1597, DOI 10.1083/jcb.108.5.1597; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; HARLOW E, 1988, ANTIBODIES LABORATOR; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WILLIAMS GT, 1992, MOL CELLULAR APPROAC, P1151	22	55	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					797	801						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437864				2022-12-17	WOS:A1993KN00800034
J	ZHAO, YH; BAKER, H; WALAAS, SI; SUDOL, M				ZHAO, YH; BAKER, H; WALAAS, SI; SUDOL, M			LOCALIZATION OF P62C-YES PROTEIN IN MAMMALIAN NEURAL TISSUES	ONCOGENE			English	Article							AVIAN-SARCOMA VIRUS; CEREBELLAR MUTANT MOUSE; SRC GENE-PRODUCT; VIRAL YES GENE; C-SRC; RETINAL DEGENERATION; TRANSFORMING GENE; MESSENGER-RNA; CELLULAR-YES; RAT-BRAIN	Expression of the c-yes proto-oncogene in mammalian brain, retina and adrenal gland was studied by immunohistochemistry and immune assays with affinity-purified anti-yes IgG. Immunohistochemical staining with anti-yes IgG showed that in the central nervous system p62c-yes is highly expressed in mitral cells of the olfactory bulb, Purkinje cells of the cerebellum, hippocampal neurons and granule neurons of the dentate gyrus and ependymal cells lining central nervous system ventricles. Less intense labeling by anti-yes IgG was observed in most neuronal cell bodies in the brain. In addition, we observed intense c-yes immunoreactivity in the ganglion cells of the retina, the inner segment layer of rods and cones and medullary cells of the adrenal gland. Mapping p62c-yes expression to specific areas of mammalian neural tissues points to attractive experimental systems which could be used to investigate the function of the proto-oncogene product in neural processes.	ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021; UNIV OSLO,NEUROCHEM LAB,N-0317 OSLO 3,NORWAY; CORNELL UNIV,COLL MED,BURKE MED INST,MOLEC NEUROBIOL LAB,WHITE PLAINS,NY 10605	Rockefeller University; University of Oslo; Cornell University					NCI NIH HHS [CA 45757] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1987, FUNCTIONAL HISTOLOGY; BAKER H, 1986, J COMP NEUROL, V252, P206, DOI 10.1002/cne.902520206; BLANKS JC, 1982, J COMP NEUROL, V212, P231, DOI 10.1002/cne.902120303; BLOOM W, 1975, TEXT BOOK HISTOLOGY; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; GESSLER M, 1984, BIOSCIENCE REP, V4, P757, DOI 10.1007/BF01128817; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P2611, DOI 10.1073/pnas.78.4.2611; GREEN MC, 1981, GENETIC VARIANTS STR, P276; Ham A.W., 1979, HISTOLOGY, P866; HANLEY MR, 1988, NEURON, V1, P175, DOI 10.1016/0896-6273(88)90137-7; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAVAIL MM, 1982, J COMP NEUROL, V212, P217, DOI 10.1002/cne.902120302; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Mitro A., 1981, MORPHOLOGY RAT BRAIN; MULLEN RJ, 1977, NATURE, V270, P245, DOI 10.1038/270245a0; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PYPER JM, 1989, J NEUROSCI RES, V24, P89, DOI 10.1002/jnr.490240113; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; Steward O, 1989, PRINCIPLES CELLULAR; SUDOL M, 1989, J NEUROSCI RES, V24, P1, DOI 10.1002/jnr.490240103; SUDOL M, 1988, BRAIN RES REV, V13, P391, DOI 10.1016/0165-0173(88)90014-8; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUDOL M, 1989, MOL CELL BIOL, V9, P4545, DOI 10.1128/MCB.9.10.4545; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SUKEGAWA J, 1990, ONCOGENE, V5, P611; YOSHIDA MC, 1985, JPN J CANCER RES, V76, P556; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZHENG XF, 1989, ONCOGENE, V4, P99	46	55	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1725	1733						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923498				2022-12-17	WOS:A1991GX11800002
J	ANDERSON, SM; CARROLL, PM; LEE, FD				ANDERSON, SM; CARROLL, PM; LEE, FD			ABROGATION OF IL-3 DEPENDENT GROWTH REQUIRES A FUNCTIONAL V-SRC GENE-PRODUCT - EVIDENCE FOR AN AUTOCRINE GROWTH-CYCLE	ONCOGENE			English	Article									SUNY STONY BROOK,PROGRAM CELLULAR & DEV BIOL,STONY BROOK,NY 11794; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	ANDERSON, SM (corresponding author), SUNY STONY BROOK,DEPT PATHOL,BHS-9,ROOM 153,STONY BROOK,NY 11794, USA.				NCI NIH HHS [CA45241] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045241, R29CA045241] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ANDERSON SM, 1987, VIROLOGY, V160, P263, DOI 10.1016/0042-6822(87)90070-5; ANDERSON SM, 1985, MOL CELL BIOL, V5, P3369, DOI 10.1128/MCB.5.12.3369; ANDERSON SM, 1983, J VIROL, V46, P594, DOI 10.1128/JVI.46.2.594-605.1983; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BOETTIGER D, 1984, CELL, V36, P763, DOI 10.1016/0092-8674(84)90356-8; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CHATTOPADHYAY SK, 1981, VIROLOGY, V113, P465, DOI 10.1016/0042-6822(81)90175-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU CP, 1988, P NATL ACAD SCI USA, V85, P7099, DOI 10.1073/pnas.85.19.7099; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; GREENBERGER JS, 1984, METHODS HEMATOLOGY, V11, P203; KINASHI T, 1986, NATURE, V324, P70, DOI 10.1038/324070a0; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LI CL, 1985, NATURE, V316, P633, DOI 10.1038/316633a0; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATSUDA H, 1988, P NATL ACAD SCI USA, V85, P6508, DOI 10.1073/pnas.85.17.6508; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; METCALF D, 1987, EMBO J, V6, P3703, DOI 10.1002/j.1460-2075.1987.tb02704.x; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METCALF D, 1985, BLOOD, V65, P357; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OLIFF A, 1985, P NATL ACAD SCI USA, V82, P3306, DOI 10.1073/pnas.82.10.3306; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PALACIOS R, 1984, NATURE, V309, P126, DOI 10.1038/309126a0; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1984, P NATL ACAD SCI-BIOL, V81, P2374, DOI 10.1073/pnas.81.8.2374; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RENNICK DM, 1985, J IMMUNOL, V134, P910; ROVERA G, 1987, ONCOGENE, V1, P29; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; TSUCHIYA M, 1986, P NATL ACAD SCI USA, V83, P7633, DOI 10.1073/pnas.83.20.7633; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; WATSON JD, 1987, J IMMUNOL, V139, P123; YOKOTA T, 1984, P NATL ACAD SCI-BIOL, V81, P1070, DOI 10.1073/pnas.81.4.1070; ZIPORI D, 1985, EXP HEMATOL, V13, P603	47	55	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					317	325						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2107491				2022-12-17	WOS:A1990CW41500009
J	SYMONDS, G; HARTSHORN, A; KENNEWELL, A; OMARA, MA; BRUSKIN, A; BISHOP, JM				SYMONDS, G; HARTSHORN, A; KENNEWELL, A; OMARA, MA; BRUSKIN, A; BISHOP, JM			TRANSFORMATION OF MURINE MYELOMONOCYTIC CELLS BY MYC - POINT MUTATIONS IN V-MYC CONTRIBUTE SYNERGISTICALLY TO TRANSFORMING POTENTIAL	ONCOGENE			English	Article									UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	SYMONDS, G (corresponding author), CHILDRENS MED RES FDN,POB 61,CAMPERDOWN,NSW 2050,AUSTRALIA.							ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; Beug H., 1982, CANCER SURV, V1, P205; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1985, MOL BIOL TUMOR VIRUS, P249; BISTER K, 1987, ONCOGENE, V1, P97; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BRAUN MJ, 1985, J VIROL, V55, P177, DOI 10.1128/JVI.55.1.177-183.1985; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; BROWN AMC, 1987, DNA CLONING, V3, P189; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; ENRIETTO PJ, 1983, VIROLOGY, V124, P164, DOI 10.1016/0042-6822(83)90300-8; ENRIETTO PJ, 1982, J VIROL, V44, P711, DOI 10.1128/JVI.44.2.711-715.1982; FRYKBERG L, 1987, ONCOGENE, V1, P415; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HAYMAN MJ, 1983, CURR TOP MICROBIOL, V103, P109; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HUME DA, 1983, J EXP MED, V158, P1522, DOI 10.1084/jem.158.5.1522; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; METCALF D, 1984, CLOINAL CULTURE HEMO, P109; Moscovici C., 1973, Methods Cell Biol, V7, P313; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PALMIERI S, 1986, J VIROL, V58, P134, DOI 10.1128/JVI.58.1.134-141.1986; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PATSCHINSKY T, 1986, J VIROL, V59, P341, DOI 10.1128/JVI.59.2.341-353.1986; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RAMSAY G, 1980, NATURE, V288, P170, DOI 10.1038/288170a0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RAMSAY GM, 1982, J VIROL, V41, P745, DOI 10.1128/JVI.41.3.745-753.1982; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SHAW J, 1985, J VIROL, V56, P943, DOI 10.1128/JVI.56.3.943-950.1985; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SYMONDS G, 1982, EMBO J, V1, P1343, DOI 10.1002/j.1460-2075.1982.tb01320.x; SYMONDS G, 1986, MOL CELL BIOL, V6, P1796, DOI 10.1128/MCB.6.5.1796; VARMUS HE, 1984, ANNU REV GENET, V18, P553; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WESTAWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P843, DOI 10.1073/pnas.81.3.843; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WILLIAMS WJ, 1977, HEMATOLOGY; WYKE JA, 1980, VIROLOGY, V106, P217, DOI 10.1016/0042-6822(80)90246-9	62	55	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					285	294						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2649846				2022-12-17	WOS:A1989U567600003
J	HANCOCK, JF; MARSHALL, CJ; MCKAY, IA; GARDNER, S; HOUSLAY, MD; HALL, A; WAKELAM, MJO				HANCOCK, JF; MARSHALL, CJ; MCKAY, IA; GARDNER, S; HOUSLAY, MD; HALL, A; WAKELAM, MJO			MUTANT BUT NOT NORMAL P21-RAS ELEVATES INOSITOL PHOSPHOLIPID BREAKDOWN IN 2 DIFFERENT CELL SYSTEMS	ONCOGENE			English	Article									UNIV GLASGOW,DEPT BIOCHEM,MOLEC PHARMACOL GRP,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow	HANCOCK, JF (corresponding author), ROYAL CANC HOSP,INST CANC RES,CHESTER BEATTY LABS,CELL & MOLEC BIOL SECT,FULHAM RD,LONDON SW3 6JB,ENGLAND.		Houslay, Miles/AAM-5281-2020; Houslay, Miles D/A-6825-2011	Hancock, John/0000-0003-0542-4710; Houslay, Miles/0000-0002-3826-8091; Wakelam, Michael/0000-0003-4059-9276				BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GARRETT JS, 1984, P NATL ACAD SCI-BIOL, V81, P7466, DOI 10.1073/pnas.81.23.7466; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HALL A, 1986, J BIOL CHEM, V261, P963; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; MARSHALL CJ, 1982, NATURE, V299, P171, DOI 10.1038/299171a0; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; TABIN C, 1982, NATURE, V300, P762; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WILLINGHAM MC, 1983, EXP CELL RES, V149, P141, DOI 10.1016/0014-4827(83)90387-7; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1985, EMBO J, V4, P2893, DOI 10.1002/j.1460-2075.1985.tb04019.x	29	55	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					187	193						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2842715				2022-12-17	WOS:A1988Q053400009
J	BARKA, T; VANDERNOEN, H; SHAW, PA				BARKA, T; VANDERNOEN, H; SHAW, PA			PROTO-ONCOGENE-FOS (C-FOS) EXPRESSION IN THE HEART	ONCOGENE			English	Article									CUNY MT SINAI SCH MED, DEPT ANAT & PATHOL, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	BARKA, T (corresponding author), CUNY MT SINAI SCH MED, DEPT ANAT, BOX 1007, NEW YORK, NY 10029 USA.				NIDCR NIH HHS [DE08174, DE07637] Funding Source: Medline; NIDDK NIH HHS [DK19753] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007637, R01DE008174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019753] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALAZS T, 1982, CARDIOVASCULAR TOXIC, P199; BARKA T, 1986, MOL CELL BIOL, V6, P2984, DOI 10.1128/MCB.6.8.2984; BAUMANN G, 1982, J CARDIOVASC PHARM, V4, P542, DOI 10.1097/00005344-198207000-00004; BAUMANN G, 1981, RES EXP MED, V179, P81, DOI 10.1007/BF01852128; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1981, CURRENT REV BIOMEDIC, V1, P122; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BROWN J H, 1986, P245; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; BRUNTON LL, 1979, NATURE, V280, P78, DOI 10.1038/280078a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; CURRAN T, 1987, IN PRESS ONCOGENE HD; DESCHAMPS J, 1985, COLD SPRING HARB SYM, V50, P733, DOI 10.1101/SQB.1985.050.01.091; ENGLAND PJ, 1984, ADV CYCLIC NUCL PROT, V17, P383; FISHER RA, 1984, J CYCLIC NUCL PROT, V9, P449; Graham R.M., 1986, HEART CARDIOVASCULAR, P1059; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GUBITS RM, 1984, J BIOL CHEM, V259, P2803; GUBITS RM, 1986, J CELL BIOL, V103, pA166; HAYES JS, 1982, J CYCLIC NUCL PROT, V8, P1; HICKS MJ, 1979, CIRC RES, V44, P384, DOI 10.1161/01.RES.44.3.384; HOESCHEN RJ, 1977, CAN J PHYSIOL PHARM, V55, P1098, DOI 10.1139/y77-150; JOHNSON CL, 1977, J PHARMACOL EXP THER, V200, P174; KANGASAHO M, 1978, EUR J PHARMACOL, V52, P93, DOI 10.1016/0014-2999(78)90025-0; KARMAZYN M, 1983, CAN J PHYSIOL PHARM, V61, P1207, DOI 10.1139/y83-180; KEELY SL, 1979, MOL PHARMACOL, V15, P235; KLEIN I, 1971, J CLIN INVEST, V50, P1012, DOI 10.1172/JCI106571; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LEVI R, 1982, PHARM HISTAMINE RECE, P236; LONGABAUGH JP, 1986, HEART CARDIOVASCULAR, P1097; MCNEILL JH, 1984, CAN J PHYSIOL PHARM, V62, P720, DOI 10.1139/y84-119; METSAKETELA T, 1981, ACTA PHYSIOL SCAND, V112, P481, DOI 10.1111/j.1748-1716.1981.tb06847.x; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MITCHELL RH, 1981, CURRENT REV BIOMEDIC, V1, P132; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MOVSESIAN MA, 1985, FEBS LETT, V185, P328, DOI 10.1016/0014-5793(85)80932-7; MULLER R, 1985, BIOCHIM BIOPHYS ACTA, V823, P207; NAYLER WG, 1981, BASIC RES CARDIOL, V76, P1, DOI 10.1007/BF01908159; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OTANI H, 1986, BIOCHEM BIOPH RES CO, V136, P863, DOI 10.1016/0006-291X(86)90412-2; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; RONA G, 1985, J MOL CELL CARDIOL, V17, P291, DOI 10.1016/S0022-2828(85)80130-9; RONA G, 1977, MIKROZIRKULATION HDB, P701; SAKUMA I, 1987, FASEB J, V46, P962; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; STARKSEN NF, 1986, P NATL ACAD SCI USA, V83, P8348, DOI 10.1073/pnas.83.21.8348; STILES GL, 1984, ANNU REV MED, V35, P149, DOI 10.1146/annurev.me.35.020184.001053; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; TSIEN RW, 1983, ANNU REV PHYSIOL, V45, P341, DOI 10.1146/annurev.ph.45.030183.002013; TSUDA T, 1986, FEBS LETT, V208, P39, DOI 10.1016/0014-5793(86)81527-7; VANVLEET JF, 1986, AM J PATHOL, V124, P95; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; WATANABE AM, 1974, J PHARMACOL EXP THER, V191, P241	57	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene		1987	1	4					439	443						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	3330786				2022-12-17	WOS:A1987K748300014
J	DERY, CV; HERRMANN, CH; MATHEWS, MB				DERY, CV; HERRMANN, CH; MATHEWS, MB			RESPONSE OF INDIVIDUAL ADENOVIRUS PROMOTERS TO THE PRODUCTS OF THE E1A GENE	ONCOGENE			English	Article									COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory					NCI NIH HHS [CA13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALWINE JC, 1985, MOL CELL BIOL, V5, P1034, DOI 10.1128/MCB.5.5.1034; ARRIGO S, 1987, MOL CELL BIOL, V7, P388, DOI 10.1128/MCB.7.1.388; BERGER SL, 1985, NUCLEIC ACIDS RES, V13, P1413, DOI 10.1093/nar/13.4.1413; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOS JL, 1983, EMBO J, V2, P73, DOI 10.1002/j.1460-2075.1983.tb01383.x; BRADY J, 1984, P NATL ACAD SCI-BIOL, V81, P2040, DOI 10.1073/pnas.81.7.2040; CHOW LT, 1979, J MOL BIOL, V134, P265, DOI 10.1016/0022-2836(79)90036-6; COURTOIS G, 1984, EMBO J, V3, P1145; DERY CV, 1985, J GEN VIROL, V66, P2671, DOI 10.1099/0022-1317-66-12-2671; DURNAM DM, 1980, P NATL ACAD SCI-BIOL, V77, P6511, DOI 10.1073/pnas.77.11.6511; EVERETT RD, 1984, NUCLEIC ACIDS RES, V12, P5969, DOI 10.1093/nar/12.15.5969; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; GALLIMORE PH, 1985, CANCER RES, V45, P2670; GAYNOR RB, 1985, SCIENCE, V230, P447, DOI 10.1126/science.2996135; GAYNOR RB, 1984, P NATL ACAD SCI-BIOL, V81, P1193, DOI 10.1073/pnas.81.4.1193; GILARDI P, 1984, NUCLEIC ACIDS RES, V12, P7877, DOI 10.1093/nar/12.20.7877; GLUZMAN Y, 1980, P NATL ACAD SCI-BIOL, V77, P3898, DOI 10.1073/pnas.77.7.3898; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GUILFOYLE RA, 1985, EMBO J, V4, P707, DOI 10.1002/j.1460-2075.1985.tb03687.x; HEARING P, 1985, MOL CELL BIOL, V5, P3214, DOI 10.1128/MCB.5.11.3214; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HERRMANN CH, 1987, ONCOGENE, V2, P25; HOEFFLER WK, 1985, CELL, V41, P955, DOI 10.1016/S0092-8674(85)80076-3; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; IMPERIALE MJ, 1983, CELL, V35, P127, DOI 10.1016/0092-8674(83)90215-5; IMPERIALE MJ, 1985, P NATL ACAD SCI USA, V82, P381, DOI 10.1073/pnas.82.2.381; JAMEEL S, 1986, MOL CELL BIOL, V6, P710, DOI 10.1128/MCB.6.2.710; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KAO HT, 1983, MOL CELL BIOL, V4, P1970; KAUFMAN RJ, 1985, P NATL ACAD SCI USA, V82, P689, DOI 10.1073/pnas.82.3.689; KELLER JM, 1984, CELL, V36, P381, DOI 10.1016/0092-8674(84)90231-9; KINGSTON RE, 1984, MOL CELL BIOL, V4, P1970, DOI 10.1128/MCB.4.10.1970; KRIPPL B, 1984, P NATL ACAD SCI-BIOL, V81, P6988, DOI 10.1073/pnas.81.22.6988; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEFF T, 1986, MOL CELL BIOL, V6, P201, DOI 10.1128/MCB.6.1.201; LEFF T, 1985, NUCLEIC ACIDS RES, V13, P1209, DOI 10.1093/nar/13.4.1209; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LEWIS ED, 1985, MOL CELL BIOL, V5, P2433, DOI 10.1128/MCB.5.9.2433; LEWIS JB, 1980, CELL, V21, P303, DOI 10.1016/0092-8674(80)90138-5; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MANIATIS T, 1982, MOL CLONING LABORATO; MANSOUR SL, 1986, MOL CELL BIOL, V6, P2684, DOI 10.1128/MCB.6.7.2684; MATSUI T, 1986, MOL CELL BIOL, V6, P4149, DOI 10.1128/MCB.6.12.4149; MONTELL C, 1982, NATURE, V295, P380, DOI 10.1038/295380a0; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; NATARAJAN V, 1986, NUCLEIC ACIDS RES, V14, P9445, DOI 10.1093/nar/14.23.9445; NATARAJAN V, 1985, NUCLEIC ACIDS RES, V13, P4067, DOI 10.1093/nar/13.11.4067; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PRESTON CM, 1979, J VIROL, V29, P275, DOI 10.1128/JVI.29.1.275-284.1979; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RICCIARDI RP, 1981, P NATL ACAD SCI-BIOL, V78, P6121, DOI 10.1073/pnas.78.10.6121; ROSSINI M, 1983, VIROLOGY, V131, P49, DOI 10.1016/0042-6822(83)90532-9; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SHAW AR, 1980, CELL, V22, P905, DOI 10.1016/0092-8674(80)90568-1; SHENK T, 1979, COLD SPRING HARB SYM, V44, P367, DOI 10.1101/SQB.1980.044.01.041; SMITH DH, 1985, MOL CELL BIOL, V5, P2684, DOI 10.1128/MCB.5.10.2684; SPECTOR DJ, 1978, J MOL BIOL, V126, P395, DOI 10.1016/0022-2836(78)90048-7; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SVENSSON C, 1984, EMBO J, V3, P789, DOI 10.1002/j.1460-2075.1984.tb01886.x; TAMANOI F, 1983, P NATL ACAD SCI-BIOL, V80, P6446, DOI 10.1073/pnas.80.21.6446; THOMAS GP, 1980, CELL, V22, P523; TIBBETTS C, 1986, J VIROL, V57, P1055, DOI 10.1128/JVI.57.3.1055-1064.1986; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; VANDENELSEN P, 1982, GENE, V18, P175, DOI 10.1016/0378-1119(82)90115-9; VASUDEVACHARI MB, 1987, MOL CELL BIOL, V7, P1063, DOI 10.1128/MCB.7.3.1063; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VIRTANEN A, 1983, J MOL BIOL, V165, P496, DOI 10.1016/S0022-2836(83)80215-0; WATSON RJ, 1980, NATURE, V285, P329, DOI 10.1038/285329a0; WEEKS DL, 1983, MOL CELL BIOL, V3, P1222, DOI 10.1128/MCB.3.7.1222; WEIL PA, 1979, CELL, V18, P469; WEST BL, 1987, MOL CELL BIOL, V7, P1193, DOI 10.1128/MCB.7.3.1193; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; YOSHINAGA S, 1986, EMBO J, V5, P343, DOI 10.1002/j.1460-2075.1986.tb04218.x; ZAJCHOWSKI DA, 1985, EMBO J, V4, P1293, DOI 10.1002/j.1460-2075.1985.tb03775.x; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	82	55	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	2	1					15	23						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	L4813	2963989				2022-12-17	WOS:A1987L481300003
J	Ge, XL; Li, GY; Jiang, L; Jia, LQ; Zhang, ZZ; Li, XL; Wang, RR; Zhou, M; Zhou, YH; Zeng, ZY; Xiang, JJ; Li, Z				Ge, Xiaolu; Li, Gui-yuan; Jiang, Lin; Jia, Liqing; Zhang, Zhezhe; Li, Xiaoling; Wang, Ranran; Zhou, Ming; Zhou, Yanhong; Zeng, Zhaoyang; Xiang, Juanjuan; Li, Zheng			Long noncoding RNA CAR10 promotes lung adenocarcinoma metastasis via miR-203/30/SNAI axis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STATISTICS; DOWN-REGULATION; IDENTIFICATION; MALAT1; ANRIL; GENE	Long noncoding RNAs (lncRNAs) play an important role in lung adenocarcinoma (LUAD) metastasis. Here, we found that lncRNA chromatin-associated RNA 10 (CAR10) was upregulated in the tumor tissue of patients with LUAD and enhanced tumor metastasis in vitro and in vivo. Mechanistically, CAR10 induced epithelial-to-mesenchymal transition (EMT) by directly binding with miR-30 and miR-203 and then regulating the expression of SNAH and SNAI2. CAR10 overexpression was positively correlated with a poor prognosis in LUAD patients, whereas overexpression of both CAR10 and SNAI was correlated with even worse clinical outcomes. In conclusion, the CAR10/miR-30/203/SNAI axis is a novel and potential therapeutic target for LUAD.	[Ge, Xiaolu; Li, Gui-yuan; Jiang, Lin; Jia, Liqing; Zhang, Zhezhe; Li, Xiaoling; Zhou, Ming; Zhou, Yanhong; Zeng, Zhaoyang; Xiang, Juanjuan; Li, Zheng] Cent South Univ, Hunan Canc Hosp, Key Lab Carcinogenesis, Chinese Minist Hlth, Changsha, Hunan, Peoples R China; [Ge, Xiaolu; Li, Gui-yuan; Jiang, Lin; Jia, Liqing; Zhang, Zhezhe; Li, Xiaoling; Zhou, Ming; Zhou, Yanhong; Zeng, Zhaoyang; Xiang, Juanjuan; Li, Zheng] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China; [Ge, Xiaolu; Li, Gui-yuan; Jiang, Lin; Jia, Liqing; Zhang, Zhezhe; Li, Xiaoling; Zhou, Ming; Zhou, Yanhong; Zeng, Zhaoyang; Xiang, Juanjuan; Li, Zheng] Cent South Univ, Sch Basic Med Sci, Canc Res Inst, Changsha, Hunan, Peoples R China; [Ge, Xiaolu; Li, Zheng] Cent South Univ, Canc Res Inst, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, Changsha, Hunan, Peoples R China; [Wang, Ranran] Cent South Univ, Xiangya Hosp 2, Dept Thorac & Cardiovasc Surg, Changsha 410011, Hunan, Peoples R China; [Li, Zheng] Cent South Univ, High Resolut Mass Spectrometry Lab, Adv Res Ctr, Changsha, Hunan, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University	Li, Z (corresponding author), Cent South Univ, Hunan Canc Hosp, Key Lab Carcinogenesis, Chinese Minist Hlth, Changsha, Hunan, Peoples R China.; Li, Z (corresponding author), Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China.; Li, Z (corresponding author), Cent South Univ, Sch Basic Med Sci, Canc Res Inst, Changsha, Hunan, Peoples R China.; Li, Z (corresponding author), Cent South Univ, Canc Res Inst, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, Changsha, Hunan, Peoples R China.; Li, Z (corresponding author), Cent South Univ, High Resolut Mass Spectrometry Lab, Adv Res Ctr, Changsha, Hunan, Peoples R China.	lizheng@csu.edu.cn	li, xiaofeng/GXF-9442-2022; li, xiao/GSN-6181-2022	LI, ZHENG/0000-0002-3758-8165; Jia, Liqing/0000-0003-1734-6043; Xiaolu, Ge/0000-0002-5533-7749	Overseas Expertise Introduction Project for Discipline Innovation (111 Project) [111-2-12]; National Natural Science Foundation of China [81602030]; National Undergraduate Free Exploration Program of Central South University [201810533372]; Open-End Fund for the Valuable and Precision Instruments of Central South University [CSUZC2014044]	Overseas Expertise Introduction Project for Discipline Innovation (111 Project); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Undergraduate Free Exploration Program of Central South University; Open-End Fund for the Valuable and Precision Instruments of Central South University	This study was supported by grants from the Overseas Expertise Introduction Project for Discipline Innovation (111 Project, No. 111-2-12), the National Natural Science Foundation of China (81602030), the National Undergraduate Free Exploration Program of Central South University (201810533372), and the Open-End Fund for the Valuable and Precision Instruments of Central South University (No. CSUZC2014044).	Alves CP, 2013, STEM CELLS, V31, P2827, DOI 10.1002/stem.1547; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Guo HY, 2014, ONCOTARGET, V5, P8625, DOI 10.18632/oncotarget.2349; Ho TT, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1198; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Huang JW, 2013, CANCER SCI, V104, P1609, DOI 10.1111/cas.12291; Jen JY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0674-z; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Jiang SM, 2016, MOL MED REP, V13, P4101, DOI 10.3892/mmr.2016.5010; Kao CJ, 2014, ONCOGENE, V33, P2495, DOI 10.1038/onc.2013.200; Klingenberg M, 2018, HEPATOLOGY, V68, P1817, DOI 10.1002/hep.30102; Li CH, 2013, INT J BIOCHEM CELL B, V45, P1895, DOI 10.1016/j.biocel.2013.05.030; Lin L, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0247-7; Liu H, 2017, ONCOTARGET, V8, P101899, DOI 10.18632/oncotarget.22058; Liu MJ, 2016, ONCOL REP, V36, P1679, DOI 10.3892/or.2016.4909; Mondal T, 2010, GENOME RES, V20, P899, DOI 10.1101/gr.103473.109; Nie FQ, 2015, MOL CANCER THER, V14, P268, DOI 10.1158/1535-7163.MCT-14-0492; Otsuki Y, 2018, DEV DYNAM, V247, P462, DOI 10.1002/dvdy.24596; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pasmant E, 2007, CANCER RES, V67, P3963, DOI 10.1158/0008-5472.CAN-06-2004; Pillai R, 2011, J MOL DIAGN, V13, P48, DOI 10.1016/j.jmoldx.2010.11.001; Roberts L, 2009, GENOMICS, V94, P341, DOI 10.1016/j.ygeno.2009.07.007; Rodriguez Luis G, 2005, Methods Mol Biol, V294, P23; Rousseaux S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005723; Savagner P, 2010, ANN ONCOL, V21, P89, DOI 10.1093/annonc/mdq292; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shen LQ, 2015, J NEURO-ONCOL, V121, P101, DOI 10.1007/s11060-014-1613-0; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Travis WD, 2014, PATHOLOGE, V35, P188, DOI 10.1007/s00292-014-1974-3; Van Grembergen O, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600220; Wang D, 2017, EUR REV MED PHARMACO, V21, P4584; Wang Q, 2017, ONCOTARGET, V8, P2558, DOI 10.18632/oncotarget.13708; Wei MM, 2016, ONCOTARGET, V7, P59556, DOI 10.18632/oncotarget.10006; Wei YZ, 2017, ONCOTARGET, V8, P71430, DOI 10.18632/oncotarget.19864; Wen X, 2018, J CELL BIOCHEM, V119, P1827, DOI 10.1002/jcb.26344; Xiang Y, 2017, CELL PHYSIOL BIOCHEM, V42, P357, DOI 10.1159/000477479; Xu S, 2018, ONCOL REP, V39, P2376, DOI 10.3892/or.2018.6316; Yuan S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0472-6; Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743; Zhou M, 2016, ONCOTARGET, V7, P29720, DOI 10.18632/oncotarget.8825	41	54	56	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3061	3076		10.1038/s41388-018-0645-x	http://dx.doi.org/10.1038/s41388-018-0645-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30617305	Green Published, hybrid			2022-12-17	WOS:000465167600014
J	Cai, L; Lin, SY; Girard, L; Zhou, YY; Yang, L; Ci, B; Zhou, QB; Luo, DN; Yao, B; Tang, H; Allen, J; Huffman, K; Gazdar, A; Heymach, J; Wistuba, I; Xiao, GH; Minna, J; Xie, Y				Cai, Ling; Lin, ShinYi; Girard, Luc; Zhou, Yunyun; Yang, Lin; Ci, Bo; Zhou, Qinbo; Luo, Danni; Yao, Bo; Tang, Hao; Allen, Jeffrey; Huffman, Kenneth; Gazdar, Adi; Heymach, John; Wistuba, Ignacio; Xiao, Guanghua; Minna, John; Xie, Yang			LCE: an open web portal to explore gene expression and clinical associations in lung cancer	ONCOGENE			English	Article							PUBLIC REPOSITORY; KLOTHO; CLASSIFICATION; ARRAYEXPRESS; BLOCKADE; MICE	We constructed a lung cancer-specific database housing expression data and clinical data from over 6700 patients in 56 studies. Expression data from 23 genome-wide platforms were carefully processed and quality controlled, whereas clinical data were standardized and rigorously curated. Empowered by this lung cancer database, we created an open access web resource-the Lung Cancer Explorer (LCE), which enables researchers and clinicians to explore these data and perform analyses. Users can perform meta-analyses on LCE to gain a quick overview of the results on tumor vs non-malignant tissue (normal) differential gene expression and expression-survival association. Individual dataset-based survival analysis, comparative analysis, and correlation analysis are also provided with flexible options to allow for customized analyses from the user.	[Cai, Ling; Zhou, Yunyun; Yang, Lin; Ci, Bo; Yao, Bo; Tang, Hao; Allen, Jeffrey; Xiao, Guanghua; Xie, Yang] UT Southwestern Med Ctr, Quantitat Biomed Res Ctr, Dept Clin Sci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Cai, Ling] UT Southwestern Med Ctr, Childrens Med Ctr, Res Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Lin, ShinYi; Zhou, Qinbo; Luo, Danni; Yao, Bo; Xiao, Guanghua; Xie, Yang] UT Southwestern Med Ctr, Bioinformat Core Facil, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Girard, Luc; Huffman, Kenneth; Gazdar, Adi; Minna, John] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Zhou, Yunyun] Univ Mississippi, Med Ctr, Dept Data Sci, 2500N State St, Jackson, MS 39216 USA; [Yang, Lin] Chinese Acad Med Sci, Dept Pathol, Natl Canc Ctr, Canc Hosp, Beijing 100021, Peoples R China; [Yang, Lin] Peking Union Med Coll, Beijing 100021, Peoples R China; [Gazdar, Adi] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Heymach, John] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77005 USA; [Wistuba, Ignacio] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Xiao, Guanghua; Minna, John; Xie, Yang] Univ Texas Southwestern Med Ctr Dallas, Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Minna, John] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Minna, John] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Mississippi; University of Mississippi Medical Center; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Xiao, GH; Xie, Y (corresponding author), UT Southwestern Med Ctr, Quantitat Biomed Res Ctr, Dept Clin Sci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Xiao, GH; Xie, Y (corresponding author), UT Southwestern Med Ctr, Bioinformat Core Facil, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Minna, J (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Xiao, GH; Minna, J; Xie, Y (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Minna, J (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Minna, J (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Guanghua.Xiao@UTSouthwestern.edu; John.Minna@UTSouthwestern.edu; Yang.Xie@UTSouthwestern.edu	Heymach, John/AAG-2361-2019; Yang, Lin/J-6807-2019	Heymach, John/0000-0001-9068-8942; Yang, Lin/0000-0002-7594-3770	National Institutes of Health [5R01CA152301, P50CA70907, 5P30CA142543, 1R01GM115473, 1R01CA172211]; Cancer Prevention and Research Institute of Texas [RP120732, RP180805, RP150596]; NATIONAL CANCER INSTITUTE [P30CA142543, R01CA172211, P50CA070907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM115473] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was partially supported by grants from the National Institutes of Health [5R01CA152301, P50CA70907, 5P30CA142543, 1R01GM115473, and 1R01CA172211], and the Cancer Prevention and Research Institute of Texas [RP120732, RP180805, and RP150596]. We thank Jessie Norris for proofreading the manuscript.	Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Bai J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059772; Brazma A, 2003, NUCLEIC ACIDS RES, V31, P68, DOI 10.1093/nar/gkg091; Broad Institute TCGA Genome Data Analysis Center, 2016, AN READ STAND TCGA B, DOI [10.7908/C11G0KM9, DOI 10.7908/C11G0KM9]; Cheng WC, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-421; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Feichtinger J, 2012, DATABASE-OXFORD, DOI 10.1093/database/bas055; Fraley C, 2002, J AM STAT ASSOC, V97, P611, DOI 10.1198/016214502760047131; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Girard L, 2016, CLIN CANCER RES, V22, P4880, DOI 10.1158/1078-0432.CCR-15-2900; Goswami Chirayu Pankaj, 2013, J Clin Bioinforma, V3, P22, DOI 10.1186/2043-9113-3-22; Gray KA, 2015, NUCLEIC ACIDS RES, V43, pD1079, DOI 10.1093/nar/gku1071; Greene CS, 2015, NAT GENET, V47, P569, DOI 10.1038/ng.3259; Hellmann Matthew D, 2018, N Engl J Med, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2018, CANCER CELL, V33, P853, DOI 10.1016/j.ccell.2018.04.001; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Kang DD, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gkr1071; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Morishita K, 2001, J NUTR, V131, P3182, DOI 10.1093/jn/131.12.3182; Nicholson Andrew G, 2018, G048 DATASET HISTOPA; Niehrs C, 1999, NATURE, V402, P483, DOI 10.1038/990025; NORDENBERG D, 1990, JAMA-J AM MED ASSOC, V264, P1556, DOI 10.1001/jama.264.12.1556; Omberg L, 2013, NAT GENET, V45, P1121, DOI 10.1038/ng.2761; Orvis T, 2014, CANCER RES, V74, P6486, DOI 10.1158/0008-5472.CAN-14-0061; Parkinson H, 2005, NUCLEIC ACIDS RES, V33, pD553; Parmigiani G, 2004, CLIN CANCER RES, V10, P2922, DOI 10.1158/1078-0432.CCR-03-0490; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rizvi H, 2018, J CLIN ONCOL, V36, P633, DOI 10.1200/JCO.2017.75.3384; Schabath MB, 2016, ONCOGENE, V35, P3209, DOI 10.1038/onc.2015.375; Schwarzer G., 2007, R NEWS, V7, P40, DOI DOI 10.1007/978-3-319-21416-0; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Therneau T.M., 2000, STAT BIOL HEALTH; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Torres PU, 2007, KIDNEY INT, V71, P730, DOI 10.1038/sj.ki.5002163; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Xie B, 2013, PATHOL ONCOL RES, V19, P611, DOI 10.1007/s12253-013-9663-8; Zappasodi R, 2018, CANCER CELL, V33, P581, DOI 10.1016/j.ccell.2018.03.005; Zhang A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110052; Zhu YL, 2008, BIOINFORMATICS, V24, P2798, DOI 10.1093/bioinformatics/btn520; Zoubarev A, 2012, BIOINFORMATICS, V28, P2272, DOI 10.1093/bioinformatics/bts430	50	54	55	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2551	2564		10.1038/s41388-018-0588-2	http://dx.doi.org/10.1038/s41388-018-0588-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30532070	Green Published, hybrid			2022-12-17	WOS:000463335200008
J	Jung, SH; Hwang, HJ; Kang, D; Park, HA; Lee, HC; Jeong, D; Lee, K; Park, HJ; Ko, YG; Lee, JS				Jung, Seung Hee; Hwang, Hyun Jung; Kang, Donghee; Park, Hyun A.; Lee, Hyung Chul; Jeong, Daecheol; Lee, Keunwook; Park, Heon Joo; Ko, Young-Gyu; Lee, Jae-Seon			mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; BINDING PARTNER; AKT; GROWTH; CELLS; ACTIVATION; RICTOR; RAPTOR; TOR	Loss of PTEN, the major negative regulator of the PI3K/AKT pathway induces a cellular senescence as a failsafe mechanism to defend against tumorigenesis, which is called PTEN-loss-induced cellular senescence (PICS). Although many studies have indicated that the mTOR pathway plays a critical role in cellular senescence, the exact functions of mTORC1 and mTORC2 in PICS are not well understood. In this study, we show that mTOR acts as a critical relay molecule downstream of PI3K/AKT and upstream of p53 in PICS. We found that PTEN depletion induces cellular senescence via p53-p21 signaling without triggering DNA damage response. mTOR kinase, a major component of mTORC1 and mTORC2, directly binds p53 and phosphorylates it at serine 15. mTORC1 and mTORC2 compete with MDM2 and increase the stability of p53 to induce cellular senescence via accumulation of the cell cycle inhibitor, p21. In embryonic fibroblasts of PTEN-knockout mice, PTEN deficiency also induces mTORC1 and mTORC2 to bind to p53 instead of MDM2, leading to cellular senescence. These results collectively demonstrate for the first time that mTOR plays a critical role in switching cells from proliferation signaling to senescence signaling via a direct link between the growth-promoting activity of AKT and the growth-suppressing activity of p53.	[Jung, Seung Hee; Hwang, Hyun Jung; Kang, Donghee; Park, Hyun A.; Lee, Hyung Chul; Lee, Jae-Seon] Inha Univ, Dept Mol Med, Coll Med, Incheon 22212, South Korea; [Jung, Seung Hee; Hwang, Hyun Jung; Kang, Donghee; Park, Hyun A.; Lee, Hyung Chul; Park, Heon Joo; Lee, Jae-Seon] Inha Univ, Coll Med, Hypoxia Related Dis Res Ctr, Incheon 22212, South Korea; [Jeong, Daecheol; Lee, Keunwook] Hallym Univ, Dept Biomed Sci, Chunchon 24252, Gangwon Do, South Korea; [Park, Heon Joo] Inha Univ, Dept Microbiol, Coll Med, Incheon 22212, South Korea; [Ko, Young-Gyu] Korea Univ, Div Life Sci, Seoul 02841, South Korea	Inha University; Inha University; Hallym University; Inha University; Korea University	Lee, JS (corresponding author), Inha Univ, Dept Mol Med, Coll Med, Incheon 22212, South Korea.; Lee, JS (corresponding author), Inha Univ, Coll Med, Hypoxia Related Dis Res Ctr, Incheon 22212, South Korea.	jaeslee@inha.ac.kr			National Research Foundation (NRF) - Korean government (MSIT) [MRC 2014R1A5A2009392, 2017R1A2B2007542, 2017M2A2A7A01070591]	National Research Foundation (NRF) - Korean government (MSIT)	The pcDNA3-Flag mTOR WT and mTOR KD constructs were generously gifted by Jie Chen (University of Illinois, Illinois, USA). We acknowledge Korea Mouse Phenotyping Center (KMPC) for providing mouse embryonic fibroblasts. This work was supported by grants to JSL (MRC 2014R1A5A2009392, 2017R1A2B2007542, and 2017M2A2A7A01070591) through the National Research Foundation (NRF) funded by the Korean government (MSIT).	Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Astle MV, 2012, ONCOGENE, V31, P1949, DOI 10.1038/onc.2011.394; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Mitri D, 2016, TRENDS CELL BIOL, V26, P215, DOI 10.1016/j.tcb.2015.10.005; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Gorgoulis VG, 2010, CURR OPIN CELL BIOL, V22, P816, DOI 10.1016/j.ceb.2010.07.013; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Humphrey SJ, 2013, CELL METAB, V17, P1009, DOI 10.1016/j.cmet.2013.04.010; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jung SH, 2016, CELL DEATH DIFFER, V23, P417, DOI 10.1038/cdd.2015.107; Kolesnichenko M, 2012, CELL CYCLE, V11, P2391, DOI 10.4161/cc.20683; Korotchkina LG, 2010, AGING-US, V2, P344, DOI 10.18632/aging.100160; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee GH, 2016, J CELL BIOL, V215, P705, DOI 10.1083/jcb.201605121; Lee JJ, 2011, CELL DEATH DIFFER, V18, P666, DOI 10.1038/cdd.2010.139; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; Moral M, 2009, CANCER RES, V69, P1099, DOI 10.1158/0008-5472.CAN-08-3240; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Perez-Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; Xie JL, 2013, NAT CELL BIOL, V15, P1263, DOI 10.1038/ncb2877; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	37	54	55	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1639	1650		10.1038/s41388-018-0521-8	http://dx.doi.org/10.1038/s41388-018-0521-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30337688	hybrid, Green Published			2022-12-17	WOS:000460423800005
J	Maurizi, G; Verma, N; Gadi, A; Mansukhani, A; Basilico, C				Maurizi, Giulia; Verma, Narendra; Gadi, Abhilash; Mansukhani, Alka; Basilico, Claudio			Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma	ONCOGENE			English	Article							HIPPO PATHWAY; SELF-RENEWAL; MAINTAIN STEMNESS; ADULT; YAP; P53; RB	The stem cell transcription factor Sox2 is highly expressed in many cancers where it is thought to mark cancer stem cells (CSCs). In osteosarcomas, the most common bone malignancy, high Sox2 expression marks and maintains a fraction of tumor-initiating cells that show all the properties of CSC. Knockdown of Sox2 expression abolishes tumorigenicity and suppresses the CSC phenotype. Here we show that, in a mouse model of osteosarcoma, osteoblast-specific Sox2 conditional knockout (CKO) causes a drastic reduction in the frequency and onset of tumors. The rare tumors detected in the Sox2 CKO animals were all Sox2 positive, indicating that they arose from cells that had escaped Sox2 deletion. Furthermore, Sox2 inactivation in cultured osteosarcoma cells by CRISPR/CAS technology leads to a loss of viability and proliferation of the entire cell population. Inactivation of the YAP gene, a major Hippo pathway effector which is a direct Sox2 target, causes similar results and YAP overexpression rescues cells from the lethality caused by Sox2 inactivation. These effects were osteosarcoma-specific, suggesting a mechanism of cell "addiction" to Sox2-initiated pathways. The requirement of Sox2 for osteosarcoma formation as well as for the survival of the tumor cells suggests that disruption of Sox2-initiated pathways could be an effective strategy for the treatment of osteosarcoma.	[Maurizi, Giulia; Verma, Narendra; Gadi, Abhilash; Mansukhani, Alka; Basilico, Claudio] NYU Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University	Mansukhani, A; Basilico, C (corresponding author), NYU Sch Med, Dept Microbiol, New York, NY 10016 USA.	Alka.Mansukhani@med.nyu.edu; Claudio.Basilico@med.nyu.edu		Mansukhani, Alka/0000-0003-1020-3242; Maurizi, Giulia/0000-0003-0373-1370	NYSTEM [CO29560];  [NIH/NCI-R21CA186031]; NATIONAL CANCER INSTITUTE [R21CA186031] Funding Source: NIH RePORTER	NYSTEM; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This investigation was supported by NYSTEM contract CO29560 and NIH/NCI-R21CA186031. We thank Dr. Stuart Orkin for providing us with the Tp53, Rb mutant mice; Matthew Murtha for his contribution to some of the initial experiments; and Upal BasuRoy for helpful discussions. We also wish to acknowledge the Histopathology core services at NYU Langone Medical Center.	Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; BASILICO C, 1969, J VIROL, V3, P140, DOI 10.1128/JVI.3.2.140-145.1969; Basu-Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405; Basu-Roy U, 2010, CELL DEATH DIFFER, V17, P1345, DOI 10.1038/cdd.2010.57; Basu-Roy U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7411; Basu-Roy U, 2013, CANCER LETT, V338, P158, DOI 10.1016/j.canlet.2012.05.028; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936; Driessens G, 2011, CELL STEM CELL, V9, P283, DOI 10.1016/j.stem.2011.09.007; Ferone G, 2016, CANCER CELL, V30, P519, DOI 10.1016/j.ccell.2016.09.001; Guernet A, 2017, METHODS, V121, P130, DOI 10.1016/j.ymeth.2017.03.007; Lian I, 2010, GENE DEV, V24, P1106, DOI 10.1101/gad.1903310; Liao SR, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv675; Mansouri Sheila, 2016, CNS Oncol, V5, P159, DOI 10.2217/cns-2016-0001; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787; Palumbo P, 2017, ONCOTARGET, V8, P25582, DOI 10.18632/oncotarget.16106; Rainusso N, 2013, CURR ONCOL REP, V15, P296, DOI 10.1007/s11912-013-0321-9; Santini R, 2014, ONCOGENE, V33, P4697, DOI 10.1038/onc.2014.71; Seo E, 2013, CELL REP, V3, P2075, DOI 10.1016/j.celrep.2013.05.029; Shahriyari L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076195; Siegle JM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5511; Song WS, 2016, J CHIN MED ASSOC, V79, P538, DOI 10.1016/j.jcma.2016.03.010; Tafani M, 2014, CURR MED CHEM, V21, P1146, DOI 10.2174/0929867321666131129125624; Tan YH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5619; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Weina K, 2016, PIGM CELL MELANOMA R, V29, P453, DOI 10.1111/pcmr.12483; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112	31	54	56	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4626	4632		10.1038/s41388-018-0292-2	http://dx.doi.org/10.1038/s41388-018-0292-2			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29743593	Green Accepted			2022-12-17	WOS:000441736700010
J	Miskolczi, Z; Smith, MP; Rowling, EJ; Ferguson, J; Barriuso, J; Wellbrock, C				Miskolczi, Zsofia; Smith, Michael P.; Rowling, Emily J.; Ferguson, Jennifer; Barriuso, Jorge; Wellbrock, Claudia			Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; HIPPO PATHWAY; TRANSCRIPTIONAL REGULATORS; TARGETED THERAPY; IN-VIVO; YAP; CANCER; RESISTANCE; EXPRESSION; CELLS	Despite the general focus on an invasive and de-differentiated phenotype as main driver of cancer metastasis, in melanoma patients many metastatic lesions display a high degree of pigmentation, indicative for a differentiated phenotype. Indeed, studies in mice and fish show that melanoma cells switch to a differentiated phenotype at secondary sites, possibly because in melanoma differentiation is closely linked to proliferation through the lineage-specific transcriptional master regulator MITF. Importantly, while a lot of effort has gone into identifying factors that induce the de-differentiated/invasive phenotype, it is not well understood how the switch to the differentiated/proliferative phenotype is controlled. We identify collagen as a contributor to this switch. We demonstrate that collagen stiffness induces melanoma differentiation through a YAP/PAX3/MITF axis and show that in melanoma patients increased collagen abundance correlates with nuclear YAP localization. However, the interrogation of large patient datasets revealed that in the context of the tumour microenvironment, YAP function is more complex. In the absence of fibroblasts, YAP/PAX3-mediated transcription prevails, but in the presence of fibroblasts tumour growth factor-beta suppresses YAP/PAX3-mediated MITF expression and induces YAP/TEAD/SMAD-driven transcription and a de-differentiated phenotype. Intriguingly, while high collagen expression is correlated with poorer patient survival, the worst prognosis is seen in patients with high collagen expression, who also express MITF target genes such as the differentiation markers TRPM1, TYR and TYRP1, as well as CDK4. In summary, we reveal a distinct lineage-specific route of YAP signalling that contributes to the regulation of melanoma pigmentation and uncovers a set of potential biomarkers predictive for poor survival.	[Miskolczi, Zsofia; Smith, Michael P.; Rowling, Emily J.; Ferguson, Jennifer; Barriuso, Jorge; Wellbrock, Claudia] Univ Manchester, Fac Biol Med & Hlth, Manchester Canc Res Ctr, Sch Med Sci,Div Canc Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England	University of Manchester	Wellbrock, C (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Manchester Canc Res Ctr, Sch Med Sci,Div Canc Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	Claudia.Wellbrock@manchester.ac.uk		Barriuso, Jorge/0000-0002-5641-9105; Smith, Michael/0000-0002-5980-7840; Wellbrock, Claudia/0000-0002-3825-6381	Cancer Research UK [C11591/A16416]; BBSRC; Wellcome; UoM Strategic Fund; MRC [MR/L011840/1] Funding Source: UKRI; Cancer Research UK [16416] Funding Source: researchfish; Medical Research Council [MR/L011840/1] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome; UoM Strategic Fund; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Guillaume Jacquement University of Manchester (UoM) for the fibroblasts, and David Gomez Matallanas (UCD Dublin, Ireland) for advice with YAP signalling and providing reagents. C.W. acknowledges the support by Cancer Research UK (grant number C11591/A16416). We thank Peter Walker (UoM) for help with the histology, Peter March, Roger Meadows and Steven Marsden (UoM) for help with microscopy. The Bioimaging Facility microscopes were purchased with grants from BBSRC, Wellcome and the UoM Strategic Fund that also funded the Histology Facility equipment.	Ahn A, 2017, MOL CANCER THER, V16, P1002, DOI 10.1158/1535-7163.MCT-16-0535; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Akhmanova M, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/167025; Arozarena I, 2017, FEBS J, V284, P2148, DOI 10.1111/febs.14040; Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419; Brozyna AA, 2016, ONCOTARGET, V7, P17844, DOI 10.18632/oncotarget.7528; Chadwick S, 2012, INDIAN J PLAST SURG, V45, P403, DOI 10.4103/0970-0358.101328; Chapman A, 2014, CELL REP, V8, P688, DOI 10.1016/j.celrep.2014.06.045; Cirenajwis H, 2015, ONCOTARGET, V6, P12297, DOI 10.18632/oncotarget.3655; Dimitrijevic N, 1998, ONCOGENE, V16, P1681, DOI 10.1038/sj.onc.1201693; Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Elbediwy A, 2016, DEVELOPMENT, V143, P1674, DOI 10.1242/dev.133728; Flach EH, 2011, MOL PHARMACEUT, V8, P2039, DOI 10.1021/mp200421k; Frey K, 2011, EXP DERMATOL, V20, P685, DOI 10.1111/j.1600-0625.2011.01314.x; Fujii M, 2012, J EXP MED, V209, P479, DOI 10.1084/jem.20111653; Hiemer SE, 2014, J BIOL CHEM, V289, P13461, DOI 10.1074/jbc.M113.529115; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Jonsson G, 2010, CLIN CANCER RES, V16, P3356, DOI 10.1158/1078-0432.CCR-09-2509; Kim IS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14343; Kim MH, 2017, CELL MOL LIFE SCI, V74, P1457, DOI 10.1007/s00018-016-2412-x; Kirkpatrick SJ, 2006, OPT EXPRESS, V14, P9770, DOI 10.1364/OE.14.009770; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lee CI, 2017, MED CLIN N AM, V101, P725, DOI 10.1016/j.mcna.2017.03.005; Lee JT, 2007, J CELL BIOCHEM, V101, P862, DOI 10.1002/jcb.21204; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Mahoney JE, 2014, DEV CELL, V30, P137, DOI 10.1016/j.devcel.2014.06.003; Manderfield LJ, 2015, DEVELOPMENT, V142, P2962, DOI 10.1242/dev.125807; Marsol IB, 2013, ACTAS DERMO-SIFILOGR, V104, P654, DOI [10.1016/j.adengl.2012.10.012, 10.1016/j.ad.2012.10.003]; Nagelkerke A, 2015, SEMIN CANCER BIOL, V35, P62, DOI 10.1016/j.semcancer.2015.09.001; Nallet-Staub F, 2014, J INVEST DERMATOL, V134, P123, DOI 10.1038/jid.2013.319; Nishimura EK, 2010, CELL STEM CELL, V6, P130, DOI 10.1016/j.stem.2009.12.010; Nsengimana J, 2015, ONCOTARGET, V6, P11683, DOI 10.18632/oncotarget.3549; Paul NR, 2015, J CELL BIOL, V210, P1013, DOI 10.1083/jcb.201502040; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Simmons JL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11366-y; Smith MP, 2017, EMBO MOL MED, V9, P1011, DOI 10.15252/emmm.201607156; Smith MP, 2016, CANCER CELL, V29, P270, DOI 10.1016/j.ccell.2016.02.003; Smith MP, 2014, CANCER DISCOV, V4, P1214, DOI 10.1158/2159-8290.CD-13-1007; Smith MP, 2013, JNCI-J NATL CANCER I, V105, P33, DOI 10.1093/jnci/djs471; Taylor KL, 2011, DEVELOPMENT, V138, P3579, DOI 10.1242/dev.064014; Vandamme N, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00352; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Wellbrock C, 1999, EUR J BIOCHEM, V260, P275, DOI 10.1046/j.1432-1327.1999.00180.x; Wellbrock C, 2000, EUR J BIOCHEM, V267, P3513, DOI 10.1046/j.1432-1327.2000.01378.x; Wellbrock C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002734; Wellbrock C, 2015, PIGM CELL MELANOMA R, V28, P390, DOI 10.1111/pcmr.12370; Yang G, 2008, MOL CELL, V32, P554, DOI 10.1016/j.molcel.2008.11.002; Young HL, 2017, J EXP MED, V214, P1691, DOI 10.1084/jem.20160855; Yu HM, 2011, TRENDS CELL BIOL, V21, P47, DOI 10.1016/j.tcb.2010.08.015; Zhang K, 2015, BIOCHEMISTRY-US, V54, P6555, DOI 10.1021/acs.biochem.5b01014; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhou LL, 2015, J CANCER, V6, P717, DOI 10.7150/jca.10865	55	54	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3166	3182		10.1038/s41388-018-0209-0	http://dx.doi.org/10.1038/s41388-018-0209-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29545604	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000434641400009
J	Takayama, K; Suzuki, T; Tanaka, T; Fujimura, T; Takahashi, S; Urano, T; Ikeda, K; Inoue, S				Takayama, Ken-ichi; Suzuki, Takashi; Tanaka, Tomoaki; Fujimura, Tetsuya; Takahashi, Satoru; Urano, Tomohiko; Ikeda, Kazuhiro; Inoue, Satoshi			TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer	ONCOGENE			English	Article							RESPONSIVE FINGER PROTEIN; ANDROGEN RECEPTOR GENE; E3 UBIQUITIN LIGASE; BREAST-CANCER; MUTANT P53; NUCLEAR EXPORT; NONCODING RNA; TUMOR-GROWTH; EFP; 14-3-3-SIGMA	Prostate cancer growth is promoted by the gene regulatory action of androgen receptor (AR) and its downstream signals. The aberrant dysfunction of tumor suppressor p53 has an important role in the prognosis of cancer. We previously found that androgen treatments translocate p53 to the cytoplasm. The mechanism of this translocation depends on sumoylation of p53 by complex of SUMO E3 ligase RanBP2 with androgen-induced GTPase-activating protein-binding protein 2 (G3BP2). Here, we identified tripartite motif-containing protein 25 (TRIM25)/estrogen-responsive finger protein (Efp) as a novel interacting partner of G3BP2 protein complex. Then, we demonstrated that TRIM25 knockdown resulted in p53 downstream activation for cell cycle inhibition and apoptosis induction in LNCaP and 22Rv1 cells. In contrast, overexpression of TRIM25 promoted prostate cancer cell proliferation and inhibited apoptosis by docetaxel treatment in LNCaP cells. We observed that p53 activity was reduced by mechanism of G3BP2-mediated nuclear export in TRIM25-overexpressing prostate cancer cells. We also found TRIM25 is important for G3BP2/RanBP2-mediated p53 modification. Clinically, we newly demonstrated that TRIM25 is a prognostic factor for prostate cancer patients. Expression of TRIM25 is significantly associated with cytoplasmic p53 expression and G3BP2. Moreover, TRIM25 knockdown results in reduced tumor growth and increased p53 activity in the mouse xenograft model of prostate cancer. Thus, our findings show that overexpression of TRIM25 promoted prostate cancer cell proliferation and cell survival by modulating p53 nuclear export mechanism with G3BP2 interaction.	[Takayama, Ken-ichi; Inoue, Satoshi] Tokyo Metropolitan Inst, Dept Funct Biogerontol, Itabashi Ku, 35-2 Sakae Cho, Tokyo, Japan; [Suzuki, Takashi] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi, Japan; [Tanaka, Tomoaki] Chiba Univ, Grad Sch Med, Dept Clin Cell Biol, Chuo Ku, Chiba, Japan; [Tanaka, Tomoaki] Chiba Univ, Grad Sch Med, Div Endocrinol & Metab, Chuo Ku, Chiba, Japan; [Fujimura, Tetsuya] Univ Tokyo, Grad Sch Med, Dept Urol, Bunkyo Ku, Tokyo, Japan; [Takahashi, Satoru] Nihon Univ, Sch Med, Dept Urol, Itabashi Ku, Tokyo, Japan; [Urano, Tomohiko] Int Univ Hlth & Welf, Dept Geriatr Med, Chiba, Japan; [Ikeda, Kazuhiro; Inoue, Satoshi] Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan	Tohoku University; Chiba University; Chiba University; University of Tokyo; Nihon University; International University of Health & Welfare; Saitama Medical University	Inoue, S (corresponding author), Tokyo Metropolitan Inst, Dept Funct Biogerontol, Itabashi Ku, 35-2 Sakae Cho, Tokyo, Japan.; Inoue, S (corresponding author), Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan.	sinoue@tmig.or.jp	Takayama, Kenichi/AAK-9238-2020; Urano, Tomohiko/AFS-9574-2022	Tanaka, Tomoaki/0000-0002-9761-1750; Urano, Tomohiko/0000-0002-1771-024X	P-DIRECT from the Ministry of Education, Culture, Sports, Science and Technology, Japan; P-CREATE from the Ministry of Education, Culture, Sports, Science and Technology, Japan; Japan Society for the Promotion of Science, Japan [15K15581, 15K15353]; Program for Promotion of Fundamental Studies in Health Sciences from the National Institute of Biomedical Innovation, Japan; Ministry of Health, Labor and Welfare, Japan; Takeda Science Foundation; Terumo foundation for Life Sciences and Arts; NOVARTIS Foundation for the Promotion of Science, Japan	P-DIRECT from the Ministry of Education, Culture, Sports, Science and Technology, Japan; P-CREATE from the Ministry of Education, Culture, Sports, Science and Technology, Japan; Japan Society for the Promotion of Science, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Program for Promotion of Fundamental Studies in Health Sciences from the National Institute of Biomedical Innovation, Japan; Ministry of Health, Labor and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Takeda Science Foundation(Takeda Science Foundation (TSF)); Terumo foundation for Life Sciences and Arts; NOVARTIS Foundation for the Promotion of Science, Japan	This work was supported by grants of the P-DIRECT and the P-CREATE from the Ministry of Education, Culture, Sports, Science and Technology, Japan (to SI); grants from the Japan Society for the Promotion of Science, Japan (to KT, grant 15K15581; to SI, grant 15K15353); a grant of the Program for Promotion of Fundamental Studies in Health Sciences from the National Institute of Biomedical Innovation, Japan (to SI); Grants-in-Aid (to SI) from the Ministry of Health, Labor and Welfare, Japan, and grants from the Takeda Science Foundation (to SI and KT), the Terumo foundation for Life Sciences and Arts (to KT) and the NOVARTIS Foundation for the Promotion of Science (to KT), Japan.	Agell L, 2008, MODERN PATHOL, V21, P1470, DOI 10.1038/modpathol.2008.145; Ashikari D, 2017, ONCOGENE, V36, P6272, DOI 10.1038/onc.2017.225; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Cai CM, 2013, TRANSL ANDROL UROL, V2, P148, DOI 10.3978/j.issn.2223-4683.2013.09.02; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Cheng L, 2004, CLIN CANCER RES, V10, P3064, DOI 10.1158/1078-0432.CCR-03-0652; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gack MU, 2007, NATURE, V446, P916, DOI 10.1038/nature05732; Henrique R, 2005, DNA CELL BIOL, V24, P264, DOI 10.1089/dna.2005.24.264; Horie-Inoue K, 2006, SEMIN CANCER BIOL, V16, P235, DOI 10.1016/j.semcancer.2006.03.006; Ikeda K, 1998, GENE, V216, P155, DOI 10.1016/S0378-1119(98)00307-2; Ikeda K, 2000, FEBS LETT, V472, P9, DOI 10.1016/S0014-5793(00)01421-6; INOUE S, 1995, GENOMICS, V25, P581, DOI 10.1016/0888-7543(95)80064-S; Jain S, 2016, CELL, V164, P487, DOI 10.1016/j.cell.2015.12.038; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Lee NR, 2015, MOL CELLS, V38, P759, DOI 10.14348/molcells.2015.0047; Linja MJ, 2001, CANCER RES, V61, P3550; Liu CF, 2013, PROSTATE, V73, P418, DOI 10.1002/pros.22583; Melchior F, 2002, CELL CYCLE, V1, P243, DOI 10.4161/cc.1.4.131; Moreira JMA, 2005, MOL CELL PROTEOMICS, V4, P555, DOI 10.1074/mcp.M400205-MCP200; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Nakasato N, 2006, BIOCHEM BIOPH RES CO, V351, P540, DOI 10.1016/j.bbrc.2006.10.061; Orimo A, 1999, P NATL ACAD SCI USA, V96, P12027, DOI 10.1073/pnas.96.21.12027; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Sakuma M, 2005, GYNECOL ONCOL, V99, P664, DOI 10.1016/j.ygyno.2005.07.103; Shimada N, 2004, MOL CELL ENDOCRINOL, V218, P147, DOI 10.1016/j.mce.2003.12.008; Simooka H, 2004, PATHOL INT, V54, P595, DOI 10.1111/j.1440-1827.2004.01668.x; Suzuki T, 2005, CLIN CANCER RES, V11, P6148, DOI 10.1158/1078-0432.CCR-05-0040; Takayama K, 2011, ONCOGENE, V30, P619, DOI 10.1038/onc.2010.436; Takayama K, 2016, BRIEF FUNCT GENOMICS, V15, P257, DOI 10.1093/bfgp/elv057; Takayama K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9219; Takayama K, 2014, CANCER RES, V74, P6542, DOI 10.1158/0008-5472.CAN-14-1030; Takayama K, 2013, INT J UROL, V20, P756, DOI 10.1111/iju.12146; Takayama K, 2013, EMBO J, V32, P1665, DOI 10.1038/emboj.2013.99; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Ueyama K, 2010, CANCER GENE THER, V17, P624, DOI 10.1038/cgt.2010.19; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Urano T, 2004, BIOCHEM BIOPH RES CO, V319, P795, DOI 10.1016/j.bbrc.2004.05.056; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Valentino E, 2017, P NATL ACAD SCI USA, V114, P7623, DOI 10.1073/pnas.1700996114; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wang S, 2016, ONCOTARGET, V7, P64921, DOI 10.18632/oncotarget.11915; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Yue XT, 2017, J MOL BIOL, V429, P1595, DOI 10.1016/j.jmb.2017.03.030; Zhang P, 2015, ONCOGENE, V34, P5729, DOI 10.1038/onc.2015.21; Zhao KW, 2011, BIOCHEM J, V437, P323, DOI 10.1042/BJ20101388; Zurita M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-217	52	54	55	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2165	2180		10.1038/s41388-017-0095-x	http://dx.doi.org/10.1038/s41388-017-0095-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29379164				2022-12-17	WOS:000430589000007
J	Olsen, RR; Otero, JH; Garcia-Lopez, J; Wallace, K; Finkelstein, D; Rehg, JE; Yin, Z; Wang, D; Freeman, KW				Olsen, R. R.; Otero, J. H.; Garcia-Lopez, J.; Wallace, K.; Finkelstein, D.; Rehg, J. E.; Yin, Z.; Wang, D.; Freeman, K. W.			MYCN induces neuroblastoma in primary neural crest cells	ONCOGENE			English	Article							STEM-CELLS; NEURONAL DIFFERENTIATION; MOUSE MODEL; IN-VITRO; N-MYC; B-MYB; TUMORS; THERAPY; SENSITIVITY; EXPRESSION	Neuroblastoma (NBL) is an embryonal cancer of the sympathetic nervous system (SNS), which causes 15% of pediatric cancer deaths. High-risk NBL is characterized by N-Myc amplification and segmental chromosomal gains and losses. Owing to limited disease models, the etiology of NBL is largely unknown, including both the cell of origin and the majority of oncogenic drivers. We have established a novel system for studying NBL based on the transformation of neural crest cells (NCCs), the progenitor cells of the SNS, isolated from mouse embryonic day 9.5 trunk neural tube explants. Based on pathology and gene expression analysis, we report the first successful transformation of wild-type NCCs into NBL by enforced expression of N-Myc, to generate phenotypically and molecularly accurate tumors that closely model human MYCN-amplified NBL. Using comparative genomic hybridization, we found that NCC-derived NBL tumors acquired copy number gains and losses that are syntenic to those observed in human MYCN-amplified NBL including 17q gain, 2p gain and loss of 1p36. When p53-compromised NCCs were transformed with N-Myc, we generated primitive neuroectodermal tumors with divergent differentiation including osteosarcoma. These subcutaneous tumors were metastatic to regional lymph nodes, liver and lung. Our novel experimental approach accurately models human NBL and establishes a new system with potential to study early stages of NBL oncogenesis, to functionally assess NBL oncogenic drivers and to characterize NBL metastasis.	[Olsen, R. R.; Otero, J. H.; Garcia-Lopez, J.; Wallace, K.; Yin, Z.; Freeman, K. W.] St Jude Childrens Res Hosp, Dept Oncol, 262 Danny Thomas Pl,MS 354,Room D5048C, Memphis, TN 38105 USA; [Finkelstein, D.; Wang, D.] St Jude Childrens Res Hosp, Computat Biol Dept, 262 Danny Thomas Pl,MS 354,Room D5048C, Memphis, TN 38105 USA; [Rehg, J. E.] St Jude Childrens Res Hosp, Pathol Dept, 262 Danny Thomas Pl,MS 354,Room D5048C, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Freeman, KW (corresponding author), St Jude Childrens Res Hosp, Dept Oncol, 262 Danny Thomas Pl,MS 354,Room D5048C, Memphis, TN 38105 USA.	kevin.freeman@stjude.org	Rehg, Jerold E/N-8111-2018; Lopez, Jesus Garcia/N-7952-2019	Lopez, Jesus Garcia/0000-0002-1877-3402	Department of Defense [W81XWH-14-1-0090]; ALSAC	Department of Defense(United States Department of Defense); ALSAC(American Lebanese Syrian Associated Charities (ALSAC))	We thank the following for their contributions: Yasmine A Valentin-Vega for assistance with microscopy and secondary antibodies, Jamy Peng for antibodies to MAP2 and GFAP, Martine Roussel for N-Myc overexpression plasmids, Joe Opferman for providing TH-MycN tumor lysate, Manon Fortier and Michelle Mary-Sinclair for technical assistance, and the services provided by St. Jude core facilities including the Veterinary Pathology Core, the Microscopy Core, the Flow Cytometry Shared Resource and the Hartwell Center. This work was supported by research funds from the Department of Defense award number W81XWH-14-1-0090 and ALSAC.	Althoff K, 2015, ONCOGENE, V34, P3357, DOI 10.1038/onc.2014.269; Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bielle F, 2012, AM J SURG PATHOL, V36, P1141, DOI 10.1097/PAS.0b013e31825a6895; Carr-Wilkinson J, 2010, CLIN CANCER RES, V16, P1108, DOI 10.1158/1078-0432.CCR-09-1865; Fukuta M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112291; Gualdrini F, 2010, ONCOTARGET, V1, P278; Hata JL, 2015, ARCH PATHOL LAB MED, V139, P543, DOI 10.5858/arpa.2014-0255-OA; Huber K, 2015, CELL TISSUE RES, V359, P333, DOI 10.1007/s00441-014-1947-0; Ikegaki N, 2013, P NATL ACAD SCI USA, V110, P6097, DOI 10.1073/pnas.1118262110; Joel M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0398-x; Karunasena E, 2015, ONCOTARGET, V6, P22038, DOI 10.18632/oncotarget.4194; Kawauchi D, 2012, CANCER CELL, V21, P168, DOI 10.1016/j.ccr.2011.12.023; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Louis CU, 2015, ANNU REV MED, V66, P49, DOI 10.1146/annurev-med-011514-023121; Mahomed F, 2015, J ORAL MAXIL SURG, V73, P1314, DOI 10.1016/j.joms.2015.01.007; Meany HJ, 2014, PEDIATR BLOOD CANCER, V61, P1932, DOI 10.1002/pbc.25134; Montavon G, 2014, ONCOTARGET, V5, P4452, DOI 10.18632/oncotarget.2036; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Olsen RR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116998; Rao MS, 1997, J NEUROBIOL, V32, P722, DOI 10.1002/(SICI)1097-4695(19970620)32:7<722::AID-NEU7>3.0.CO;2-6; Russell MR, 2013, CANCER RES, V73, P776, DOI 10.1158/0008-5472.CAN-12-2669; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Schulte JH, 2013, ONCOGENE, V32, P1059, DOI 10.1038/onc.2012.106; Schwermer M, 2015, ONCOTARGET, V6, P15425, DOI 10.18632/oncotarget.3908; Simoes-Costa M, 2015, DEVELOPMENT, V142, P242, DOI 10.1242/dev.105445; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; Tornoczky T, 2004, CANCER-AM CANCER SOC, V100, P390, DOI 10.1002/cncr.20005; Tornoczky T, 2007, PATHOL ONCOL RES, V13, P269, DOI 10.1007/BF02940304; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Wang ZB, 2011, CANCER RES, V71, P4292, DOI 10.1158/0008-5472.CAN-10-4087; Watt F, 2007, CANCER GENE THER, V14, P287, DOI 10.1038/sj.cgt.7701012; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wolter J, 2010, FUTURE ONCOL, V6, P429, DOI [10.2217/fon.09.176, 10.2217/FON.09.176]; Wylie LA, 2015, DIS MODEL MECH, V8, P429, DOI 10.1242/dmm.018630	36	54	54	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5075	5082		10.1038/onc.2017.128	http://dx.doi.org/10.1038/onc.2017.128			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459463	hybrid, Green Published			2022-12-17	WOS:000408768800012
J	Whelan, KA; Chandramouleeswaran, PM; Tanaka, K; Natsuizaka, M; Guha, M; Srinivasan, S; Darling, DS; Kita, Y; Natsugoe, S; Winkler, JD; Klein-Szanto, AJ; Amaravadi, RK; Avadhani, NG; Rustgi, AK; Nakagawa, H				Whelan, K. A.; Chandramouleeswaran, P. M.; Tanaka, K.; Natsuizaka, M.; Guha, M.; Srinivasan, S.; Darling, D. S.; Kita, Y.; Natsugoe, S.; Winkler, J. D.; Klein-Szanto, A. J.; Amaravadi, R. K.; Avadhani, N. G.; Rustgi, A. K.; Nakagawa, H.			Autophagy supports generation of cells with high CD44 expression via modulation of oxidative stress and Parkin-mediated mitochondrial clearance	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ESOPHAGEAL CANCER; PROMOTES; GROWTH; TUMORIGENESIS; CARCINOMA; PROGNOSIS; SUBPOPULATION; SUPPRESSION; INHIBITION	High CD44 expression is associated with enhanced malignant potential in esophageal squamous cell carcinoma (ESCC), among the deadliest of all human carcinomas. Although alterations in autophagy and CD44 expression are associated with poor patient outcomes in various cancer types, the relationship between autophagy and cells with high CD44 expression remains incompletely understood. In transformed oesophageal keratinocytes, CD44(Low)-CD24(High) (CD44L) cells give rise to CD44(High)-CD24(-/Low) (CD44H) cells via epithelial-mesenchymal transition (EMT) in response to transforming growth factor (TGF)-beta. We couple patient samples and xenotransplantation studies with this tractable in vitro system of CD44L to CD44H cell conversion to investigate the functional role of autophagy in generation of cells with high CD44 expression. We report that high expression of the autophagy marker cleaved LC3 expression correlates with poor clinical outcome in ESCC. In ESCC xenograft tumours, pharmacological autophagy inhibition with chloroquine derivatives depletes cells with high CD44 expression while promoting oxidative stress. Autophagic flux impairment during EMT-mediated CD44L to CD44H cell conversion in vitro induces mitochondrial dysfunction, oxidative stress and cell death. During CD44H cell generation, transformed keratinocytes display evidence of mitophagy, including mitochondrial fragmentation, decreased mitochondrial content and mitochondrial translocation of Parkin, essential in mitophagy. RNA interference-mediated Parkin depletion attenuates CD44H cell generation. These data suggest that autophagy facilitates EMT-mediated CD44H generation via modulation of redox homeostasis and Parkin-dependent mitochondrial clearance. This is the first report to implicate mitophagy in regulation of tumour cells with high CD44 expression, representing a potential novel therapeutic avenue in cancers where EMT and CD44H cells have been implicated, including ESCC.	[Whelan, K. A.; Chandramouleeswaran, P. M.; Tanaka, K.; Natsuizaka, M.; Rustgi, A. K.; Nakagawa, H.] Univ Penn, Div Gastroenterol, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Whelan, K. A.; Chandramouleeswaran, P. M.; Tanaka, K.; Natsuizaka, M.; Winkler, J. D.; Amaravadi, R. K.; Rustgi, A. K.; Nakagawa, H.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Guha, M.; Srinivasan, S.; Avadhani, N. G.] Univ Penn, Dept Anim Biol, Mari Lowe Ctr Comparat Oncol, Sch Vet Med, Philadelphia, PA 19104 USA; [Darling, D. S.] Univ Louisville, Dept Oral Immunol & Infect Dis, Louisville, KY 40292 USA; [Darling, D. S.] Univ Louisville, Ctr Genet & Mol Med, Louisville, KY 40292 USA; [Kita, Y.; Natsugoe, S.] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Digest Surg Breast & Thyroid Surg, Kagoshima, Japan; [Winkler, J. D.] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; [Klein-Szanto, A. J.] Fox Chase Canc Ctr, Histopathol Facil, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Klein-Szanto, A. J.] Fox Chase Canc Ctr, Canc Biol Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Amaravadi, R. K.] Univ Penn, Div Hematol Oncol, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Louisville; University of Louisville; Kagoshima University; University of Pennsylvania; Fox Chase Cancer Center; Fox Chase Cancer Center; University of Pennsylvania; Pennsylvania Medicine	Nakagawa, H (corresponding author), Univ Penn, Div Gastroenterol, 421 Curie Blvd,956 Biomed Res Bldg 2-3, Philadelphia, PA 19104 USA.	nakagawh@mail.med.upenn.edu	Darling, Douglas S/D-4573-2009	Natsuizaka, Mitsuteru/0000-0002-1819-1955; Darling, Douglas/0000-0002-9039-1169	NIH [P01CA098101, K26RR032714]; American Cancer Society [RP-10-033-01-CCE]; NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases [P30DK050306]; Molecular Pathology and Imaging, Molecular Biology/Gene Expression, Cell Culture and Mouse Core Facilities; Pennsylvania Department of Health, Pennsylvania CURE Program Grant; Ministry of Education, Culture, Sports, Science and Technology of Japan [15K15501, 26293306, 15K10108]; University of Pennsylvania Center of Excellence in Environmental Toxicology [P30ES013508, K01DK103953, F32CA174176, T32DK007066]; Japan Society for the Promotion of Science; NATIONAL CANCER INSTITUTE [F31CA174176, P01CA114046, P01CA098101, P30CA016520, P30CA006927, F32CA174146] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K26RR032714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306, T32DK007066, K01DK103953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases; Molecular Pathology and Imaging, Molecular Biology/Gene Expression, Cell Culture and Mouse Core Facilities; Pennsylvania Department of Health, Pennsylvania CURE Program Grant; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); University of Pennsylvania Center of Excellence in Environmental Toxicology; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We appreciate the support the support of members the Nakagawa and Rustgi laboratories for thoughtful discussions and support. We thank Ben Rhodes, Sanders Chang, Andy Guo, Amanda B. Muir, MD and Ashley Lento, PhD for technical support. We acknowledge the Flow Cytometry and Cell Sorting Resource Laboratory, the Electron Microscopy Resource Laboratory, and the Cell and Developmental Biology Microscopy Core at the University of Pennsylvania. This study was supported by the following NIH Grants: P01CA098101 (KAW, KT, PMC, AJK-S, HN, AKR), K26RR032714 (HN), P30ES013508 University of Pennsylvania Center of Excellence in Environmental Toxicology (HN), K01DK103953 (KAW), F32CA174176 (KAW), T32DK007066 (KAW), the American Cancer Society RP-10-033-01-CCE (AKR), NIH/NIDDK P30DK050306 Center of Molecular Studies in Digestive and Liver Diseases, The Molecular Pathology and Imaging, Molecular Biology/Gene Expression, Cell Culture and Mouse Core Facilities. Additional support was provided by the Pennsylvania Department of Health, Pennsylvania CURE Program Grant (HN). KT is a recipient of the Japan Society for the Promotion of Science Postdoctoral Fellowship. His study was supported by the Grant-in-Aid for challenging Exploratory Research, Grant in Aid for Scientific Research B and Grant in Aid for Scientific Research C from the Ministry of Education, Culture, Sports, Science and Technology of Japan (15K15501 and 26293306 to SN; and 15K10108 to YK).	Amaravadi RK, 2012, AUTOPHAGY, V8, P1383, DOI 10.4161/auto.20958; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Biddle A, 2016, EBIOMEDICINE, V4, P138, DOI 10.1016/j.ebiom.2016.01.007; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Chen YS, 2015, MOL MED REP, V12, P1645, DOI 10.3892/mmr.2015.3623; Cufi S, 2011, CELL CYCLE, V10, P3871, DOI 10.4161/cc.10.22.17976; Darling DS, 2003, GENE EXPR PATTERNS, V3, P709, DOI 10.1016/S1567-133X(03)00147-9; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Garcia-Prat L, 2016, ONCOTARGET, V7, P12286, DOI 10.18632/oncotarget.7766; Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187; Grassi G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.249; Guha M, 2014, ONCOGENE, V33, P5238, DOI 10.1038/onc.2013.467; Hao CL, 2014, INT J CLIN EXP PATHO, V7, P4213; Hoshino A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3308; Kagawa S, 2015, ONCOGENE, V34, P2347, DOI 10.1038/onc.2014.169; Kalabis J, 2012, NAT PROTOC, V7, P235, DOI 10.1038/nprot.2011.437; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001; Kinugasa H, 2015, ONCOGENE, V34, P5229, DOI 10.1038/onc.2014.449; Kishimoto T., 1998, P 6 INT WORKSH C 10; Kleinberg L, 2007, NAT CLIN PRACT ONCOL, V4, P282, DOI 10.1038/ncponc0796; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kong JP, 2016, MOL CARCINOGEN, V55, P1526, DOI 10.1002/mc.22406; Li J, 2013, CARCINOGENESIS, V34, P1343, DOI 10.1093/carcin/bgt063; Long A, 2015, CARCINOGENESIS, V36, P598, DOI 10.1093/carcin/bgv025; Lv Q, 2012, CANCER RES, V72, P3238, DOI 10.1158/0008-5472.CAN-11-3832; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200; Martegani MP, 1999, AM J PATHOL, V154, P291, DOI 10.1016/S0002-9440(10)65275-3; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Natsuizaka M, 2014, AM J CANCER RES, V4, P29; Nozoe T, 2004, J CANCER RES CLIN, V130, P334, DOI 10.1007/s00432-004-0542-2; Ohashi S, 2011, CANCER RES, V71, P6836, DOI 10.1158/0008-5472.CAN-11-0846; Ohashi S, 2010, CANCER RES, V70, P4174, DOI 10.1158/0008-5472.CAN-09-4614; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Reznik E, 2016, ELIFE, V5, DOI 10.7554/eLife.10769; Rubio N, 2012, AUTOPHAGY, V8, P1312, DOI 10.4161/auto.20763; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Schlossman SF, 1995, P 5 INT WORKSH C 3 7; Shiozaki M, 2011, ONCOL LETT, V2, P429, DOI 10.3892/ol.2011.264; Takahashi Y, 2013, BLOOD, V121, P1622, DOI 10.1182/blood-2012-10-459826; Tanaka K, 2016, AM J CANCER RES, V6, P781; Tseng LM, 2006, GENE CHROMOSOME CANC, V45, P629, DOI 10.1002/gcc.20326; Uchikado Y, 2005, CLIN CANCER RES, V11, P1174; Usami Y, 2008, J PATHOL, V215, P330, DOI 10.1002/path.2365; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Whelan KA, 2017, GUT, V66, P1197, DOI 10.1136/gutjnl-2015-310341; Yang H, 2014, J THORAC DIS, V6, P91, DOI 10.3978/j.issn.2072-1439.2013.11.16; Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028; Yu L, 2014, CANCER LETT, V355, P34, DOI 10.1016/j.canlet.2014.09.020; Yu M, 2011, LIFE SCI, V89, P65, DOI 10.1016/j.lfs.2011.05.010; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Yuen HF, 2007, J CLIN PATHOL, V60, P510, DOI 10.1136/jcp.2006.039099; Zhao JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021419; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	64	54	56	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4843	4858		10.1038/onc.2017.102	http://dx.doi.org/10.1038/onc.2017.102			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28414310	Green Accepted			2022-12-17	WOS:000408234400003
J	Miller, A; McLeod, L; Alhayyani, S; Szczepny, A; Watkins, DN; Chen, W; Enriori, P; Ferlin, W; Ruwanpura, S; Jenkins, BJ				Miller, A.; McLeod, L.; Alhayyani, S.; Szczepny, A.; Watkins, D. N.; Chen, W.; Enriori, P.; Ferlin, W.; Ruwanpura, S.; Jenkins, B. J.			Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma	ONCOGENE			English	Article							WEIGHT-LOSS; RECEPTOR ANTIBODY; CANCER; INTERLEUKIN-6; PROGRESSION; SURVIVAL; STAT3	Lung cancer is the leading cause of cancer death worldwide, and is frequently associated with the devastating paraneoplastic syndrome of cachexia. The potent immunomodulatory cytokine interleukin (IL)-6 has been linked with the development of lung cancer as well as cachexia; however, the mechanisms by which IL-6 promotes muscle wasting in lung cancer cachexia are ill-defined. In this study, we report that the gp130(F/F) knock-in mouse model displaying hyperactivation of the latent transcription factor STAT3 via the common IL-6 cytokine family signalling receptor, gp130, develops cachexia during Kras-driven lung carcinogenesis. Specifically, exacerbated weight loss, early mortality and reduced muscle and adipose tissue mass were features of the gp130(F/F): Kras(G12D) model, but not parental Kras(G12D) mice in which STAT3 was not hyperactivated. Gene expression profiling of muscle tissue in cachectic gp130(F/F): Kras(G12D) mice revealed the upregulation of IL-6 and STAT3-target genes compared with Kras(G12D) muscle tissue. These cachectic features of gp130(F/F): Kras(G12D) mice were abrogated upon the genetic normalization of STAT3 activation or ablation of IL-6 in gp130(F/F): Kras(G12D): Stat3(-/+) or gp130(F/F): Kras(G12D): Il6(-/-)mice, respectively. Furthermore, protein levels of the soluble IL-6 receptor (sIL-6R), which is the central facilitator of IL-6 trans-signalling, were elevated in cachectic muscle from gp130(F/F): Kras(G12D) mice, and the specific blockade of IL-6 trans-signalling, but not classical signalling, with an anti-IL-6R antibody ameliorated cachexia-related characteristics in gp130(F/F): Kras(G12D) mice. Collectively, these preclinical findings identify transsignalling via STAT3 as the signalling modality by which IL-6 promotes muscle wasting in lung cancer cachexia, and therefore support the clinical evaluation of the IL-6 trans-signalling/STAT3 axis as a therapeutic target in advanced lung cancer patients presenting with cachexia.	[Miller, A.; McLeod, L.; Alhayyani, S.; Szczepny, A.; Watkins, D. N.; Ruwanpura, S.; Jenkins, B. J.] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic, Australia; [Miller, A.] Monash Hlth, Monash Med Ctr, Gen & Resp Med, Clayton, Vic, Australia; [McLeod, L.; Alhayyani, S.; Szczepny, A.; Ruwanpura, S.; Jenkins, B. J.] Monash Univ, Dept Mol Translat Sci, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Alhayyani, S.] King Abdulaziz Univ, Dept Biol Sci, Rabigh Coll Sci & Art, Jeddah, Saudi Arabia; [Watkins, D. N.] Kinghorn Canc Ctr, Garvan Inst Med Res, Darlinghurst, NSW, Australia; [Chen, W.; Enriori, P.] Monash Univ, Dept Physiol, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Ferlin, W.] NovImmune SA, Geneva, Switzerland	Hudson Institute of Medical Research; Monash University; Monash University; King Abdulaziz University; Garvan Institute of Medical Research; Monash University; NovImmune SA	Jenkins, BJ (corresponding author), Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, 27-31 Wright St, Clayton, Vic 3168, Australia.	brendan.jenkins@hudson.org.au	Miller, Alistair/AAE-8766-2022; Alhayyani/AAR-7025-2020	Miller, Alistair/0000-0002-0439-9747; Ruwanpura, saleela/0000-0002-4074-2012; Jenkins, Brendan/0000-0002-7552-4656	National Health and Medical Research Council (NHMRC) of Australia; Lung Cancer Research Foundation; NHMRC; Victorian Government of Australia	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Lung Cancer Research Foundation; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government of Australia	This work was supported by grants awarded by the National Health and Medical Research Council (NHMRC) of Australia and the Lung Cancer Research Foundation, as well as the Operational Infrastructure Support Program by the Victorian Government of Australia. SMR is supported by a NHMRC Post-doctoral Training Fellowship. BJJ is supported by a NHMRC Senior Medical Research Fellowship.	Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Ando K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102436; Ando K, 2013, J CLIN ONCOL, V31, pE69, DOI 10.1200/JCO.2012.44.2020; Angevin E, 2014, CLIN CANCER RES, V20, P2192, DOI 10.1158/1078-0432.CCR-13-2200; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Baltgalvis KA, 2008, AM J PHYSIOL-REG I, V294, pR393, DOI 10.1152/ajpregu.00716.2007; Bayliss TJ, 2011, EXPERT OPIN BIOL TH, V11, P1663, DOI 10.1517/14712598.2011.627850; Bonetto A, 2012, AM J PHYSIOL-ENDOC M, V303, pE410, DOI 10.1152/ajpendo.00039.2012; Bonetto A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022538; Brooks GD, 2016, CANCER RES, V76, P866, DOI 10.1158/0008-5472.CAN-15-2388; Del Ferraro C, 2012, J HOSP PALLIAT NURS, V14, P397, DOI 10.1097/NJH.0b013e31825f3470; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Garbers C, 2012, CYTOKINE GROWTH F R, V23, P85, DOI 10.1016/j.cytogfr.2012.04.001; Gilabert M, 2014, J CELL PHYSIOL, V229, P1437, DOI 10.1002/jcp.24580; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Kennedy CL, 2014, ONCOGENE, V33, P2540, DOI 10.1038/onc.2013.205; Lacroix M, 2015, J BIOL CHEM, V290, P26943, DOI 10.1074/jbc.M115.682138; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Lissilaa R, 2010, J IMMUNOL, V185, P5512, DOI 10.4049/jimmunol.1002015; OHE Y, 1993, BRIT J CANCER, V67, P939, DOI 10.1038/bjc.1993.174; Puppa MJ, 2014, FASEB J, V28, P998, DOI 10.1096/fj.13-240580; Rose-John S, 2006, J LEUKOCYTE BIOL, V80, P227, DOI 10.1189/jlb.1105674; Ross PJ, 2004, BRIT J CANCER, V90, P1905, DOI 10.1038/sj.bjc.6601781; Ruwanpura SM, 2012, AM J PHYSIOL-LUNG C, V302, P1627, DOI 10.1152/ajplung.00285.2011; Ruwanpura SM, 2011, AM J RESP CELL MOL, V45, P720, DOI 10.1165/rcmb.2010-0462OC; Scott HR, 1996, BRIT J CANCER, V73, P1560, DOI 10.1038/bjc.1996.294; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Songur N, 2004, TUMORI J, V90, P196, DOI 10.1177/030089160409000207; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; Tan BHL, 2011, J GENET, V90, P165, DOI 10.1007/s12041-011-0027-4; Tsujinaka T, 1996, J CLIN INVEST, V97, P244, DOI 10.1172/JCI118398; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; VANDENBREKEL AJS, 1995, J CLIN ONCOL, V13, P2600, DOI 10.1200/JCO.1995.13.10.2600; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818	36	54	55	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					3059	3066		10.1038/onc.2016.437	http://dx.doi.org/10.1038/onc.2016.437			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27893707				2022-12-17	WOS:000402000400013
J	Zhang, D; Jin, N; Sun, W; Li, X; Liu, B; Xie, Z; Qu, J; Xu, J; Yang, X; Su, Y; Tang, S; Han, H; Chen, D; Ding, J; Tan, M; Huang, M; Geng, M				Zhang, D.; Jin, N.; Sun, W.; Li, X.; Liu, B.; Xie, Z.; Qu, J.; Xu, J.; Yang, X.; Su, Y.; Tang, S.; Han, H.; Chen, D.; Ding, J.; Tan, M.; Huang, M.; Geng, M.			Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity	ONCOGENE			English	Article							PYRUVATE-KINASE M2; GENE-TRANSCRIPTION; CREATINE-KINASE; ACTIN ACTA2; GLYCOLYSIS; TARGET; IDENTIFICATION; PHOSPHATASE; ISOENZYMES; APOPTOSIS	Phosphoglycerate mutase 1 (PGAM1) is a glycolytic enzyme that coordinates glycolysis and biosynthesis to promote cancer growth via its metabolic activity. Here, we report the discovery of a non-metabolic function of PGAM1 in promoting cancer metastasis. A proteomic study identified a-smooth muscle actin (ACTA2) as a PGAM1-associated protein. PGAM1 modulated actin filaments assembly, cell motility and cancer cell migration via directly interacting with ACTA2, which was independent of its metabolic activity. The enzymatically inactive H186R mutant retained its association with ACTA2, whereas 201-210 amino acids deleted PGAM1 mutant lost the interaction with ACTA2 regardless of intact metabolic activity. Importantly, PGAM1 knockdown decreased metastatic potential of breast cancer cells in vivo and PGAM1 and ACTA2 were jointly associated with the prognosis of breast cancer patients. Together, this study provided the first evidence revealing a non-metabolic function of PGAM1 in promoting cell migration, and gained new insights into the role of PGAM1 in cancer progression.	[Zhang, D.; Jin, N.; Sun, W.; Li, X.; Xie, Z.; Qu, J.; Xu, J.; Yang, X.; Su, Y.; Tang, S.; Ding, J.; Huang, M.; Geng, M.] Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Room 2431,555 Zuchongzhi Rd,Room 1320, Shanghai 201203, Peoples R China; [Liu, B.; Tan, M.] Chinese Acad Sci, Shanghai Inst Mat Med, Chem Prote Ctr, State Key Lab Drug Res, Shanghai, Peoples R China; [Han, H.; Chen, D.] Chinese Acad Sci, Shanghai Inst Mat Med, Lab Pharmaceut Anal, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	Huang, M; Geng, M (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Room 2431,555 Zuchongzhi Rd,Room 1320, Shanghai 201203, Peoples R China.	mhuang@simm.ac.cn; mygeng@simm.ac.cn	Tan, Minjia/C-4491-2014; huang, min/AAC-6965-2022	Tan, Minjia/0000-0002-6784-9653; 	China International Science and Technology Cooperation Program [2015DFM30040]; National Science and Technology Major Project [2015ZX09101009]; National Natural Science Foundation of China [81573464, 81321092]; NSFC-Shandong Joint Fund for Marine Science Research Centers [U1406402]	China International Science and Technology Cooperation Program; National Science and Technology Major Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NSFC-Shandong Joint Fund for Marine Science Research Centers	This work was supported by the China International Science and Technology Cooperation Program (No. 2015DFM30040 to MH), the National Science and Technology Major Project (No. 2015ZX09101009 to MH), grants from the National Natural Science Foundation of China (No. 81573464 to MH, No. 81321092 to JD) and NSFC-Shandong Joint Fund for Marine Science Research Centers (No. U1406402 to JD)	Chen GA, 2003, P NATL ACAD SCI USA, V100, P13537, DOI 10.1073/pnas.2233850100; Croise Pauline, 2014, Small GTPases, V5, pe29469, DOI 10.4161/sgtp.29469; Durany N, 1997, BRIT J CANCER, V76, P1139, DOI 10.1038/bjc.1997.525; Durany N, 2000, BRIT J CANCER, V82, P20; Engel M, 2004, J BIOL CHEM, V279, P35803, DOI 10.1074/jbc.M402768200; Evans MJ, 2005, NAT BIOTECHNOL, V23, P1303, DOI 10.1038/nbt1149; Fothergill-Gilmore L. A., 1989, ADV ENZYMOLOGY RELAT, V62, P227; Fritz G, 2006, CURR CANCER DRUG TAR, V6, P1, DOI 10.2174/156800906775471752; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Guo DC, 2007, NAT GENET, V39, P1488, DOI 10.1038/ng.2007.6; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hallows WC, 2012, J BIOL CHEM, V287, P3850, DOI 10.1074/jbc.M111.317404; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hinz B, 2002, J CELL BIOL, V157, P657, DOI 10.1083/jcb.200201049; Hitosugi T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2759; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hu H, 2016, CELL, V164, P433, DOI 10.1016/j.cell.2015.12.042; Kondoh H, 2005, CANCER RES, V65, P177; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lambrechts A, 2004, INT J BIOCHEM CELL B, V36, P1890, DOI 10.1016/j.biocel.2004.01.024; Lee HW, 2013, CLIN CANCER RES, V19, P5879, DOI 10.1158/1078-0432.CCR-13-1181; Lee HW, 2012, INT J ONCOL, V41, P2013, DOI 10.3892/ijo.2012.1663; Li C, 2006, PROTEOMICS, V6, P547, DOI 10.1002/pmic.200500256; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Mathupala SP, 2009, SEMIN CANCER BIOL, V19, P17, DOI 10.1016/j.semcancer.2008.11.006; Morisaki H, 2009, HUM MUTAT, V30, P1406, DOI 10.1002/humu.21081; Narayanan NK, 2004, CANCER DETECT PREV, V28, P443, DOI 10.1016/j.cdp.2004.08.009; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Ren FL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-81; Rockey DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077166; Thomasson MS, 2013, ANAL BIOCHEM, V443, P156, DOI 10.1016/j.ab.2013.09.008; Turhani D, 2006, ELECTROPHORESIS, V27, P1417, DOI 10.1002/elps.200500510; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yeh CS, 2008, ONCOL REP, V19, P81	38	54	57	3	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2900	2909		10.1038/onc.2016.446	http://dx.doi.org/10.1038/onc.2016.446			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27991922				2022-12-17	WOS:000401697800012
J	Xie, X; Kaoud, TS; Edupuganti, R; Zhang, T; Kogawa, T; Zhao, Y; Chauhan, GB; Giannoukos, DN; Qi, Y; Tripathy, D; Wang, J; Gray, NS; Dalby, KN; Bartholomeusz, C; Ueno, NT				Xie, X.; Kaoud, T. S.; Edupuganti, R.; Zhang, T.; Kogawa, T.; Zhao, Y.; Chauhan, G. B.; Giannoukos, D. N.; Qi, Y.; Tripathy, D.; Wang, J.; Gray, N. S.; Dalby, K. N.; Bartholomeusz, C.; Ueno, N. T.			c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun	ONCOGENE			English	Article							NH2-TERMINAL KINASE; JNK; EXPRESSION; APOPTOSIS; SURVIVAL; PROLIFERATION; MODELS; MOUSE	c-Jun N-terminal kinase (JNK) plays a vital role in malignant transformation of different cancers, and JNK is highly activated in basallike triple-negative breast cancer (TNBC). However, the roles of JNK in regulating cancer stem-like cell (CSC) phenotype and tumorigenesis in TNBC are not well defined. JNK is known to mediate many cellular events via activating c-Jun. Here, we found that JNK regulated c-Jun activation in TNBC cells and that JNK activation correlated with c-Jun activation in TNBC tumors. Furthermore, the expression level of c-Jun was significantly higher in TNBC tumors than in non-TNBC tumors, and high c-Jun mRNA level was associated with shorter disease-free survival of patients with TNBC. Thus, we hypothesized that the JNK/c-Jun signaling pathway contributes to TNBC tumorigenesis. We found that knockdown of JNK1 or JNK2 or treatment with JNK-IN-8, an adenosine triphosphate-competitive irreversible pan-JNK inhibitor, significantly reduced cell proliferation, the ALDH1(+) and CD44(+)/CD24 -CSC subpopulations, and mammosphere formation, indicating that JNK promotes CSC self-renewal and maintenance in TNBC. We further demonstrated that both JNK1 and JNK2 regulated Notch1 transcription via activation of c-Jun and that the JNK/c-Jun signaling pathway promoted CSC phenotype through Notch1 signaling in TNBC. In a TNBC xenograft mouse model, JNK-IN-8 significantly suppressed tumor growth in a dose-dependent manner by inhibiting acquisition of the CSC phenotype. Taken together, our data demonstrate that JNK regulates TNBC tumorigenesis by promoting CSC phenotype through Notch1 signaling via activation of c-Jun and indicate that JNK/c-Jun/Notch1 signaling is a potential therapeutic target for TNBC.	[Xie, X.; Kogawa, T.; Chauhan, G. B.; Giannoukos, D. N.; Tripathy, D.; Bartholomeusz, C.; Ueno, N. T.] Univ Texas MD Anderson Canc Ctr, Sect Translat Breast Canc Res, Houston, TX 77030 USA; [Xie, X.; Kogawa, T.; Chauhan, G. B.; Giannoukos, D. N.; Tripathy, D.; Bartholomeusz, C.; Ueno, N. T.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Kaoud, T. S.; Edupuganti, R.; Dalby, K. N.] Univ Texas Austin, Coll Pharm, Div Med Chem, 107 West Dean Keeton,Biomed Engn Bldg, Austin, TX 78712 USA; [Zhang, T.; Gray, N. S.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA; [Kogawa, T.] Natl Canc Ctr Hosp East, Dept Expt Therapeut, Kashiwa, Chiba, Japan; [Zhao, Y.; Qi, Y.; Wang, J.] Univ Texas MD Anderson Canc Ctr, Div Quantitat Sci, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin; Harvard University; Harvard Medical School; National Cancer Center - Japan; University of Texas System; UTMD Anderson Cancer Center	Dalby, KN (corresponding author), Univ Texas Austin, Coll Pharm, Div Med Chem, 107 West Dean Keeton,Biomed Engn Bldg, Austin, TX 78712 USA.; Bartholomeusz, C; Ueno, NT (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Sect Translat Breast Canc Res, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dalby@austin.utexas.edu; chbartho@mdanderson.org; nueno@mdanderson.org	Dalby, Kevin N/A-1905-2013; Kaoud, Tamer S/C-3618-2019	Dalby, Kevin N/0000-0001-9272-5129; Kaoud, Tamer S/0000-0003-1298-8725	MD Anderson Cancer Center Inflammatory Breast Cancer funds [105655]; Nylene Eckles funds [101478]; MD Anderson Cancer Center [111411]; Cancer Prevention and Research Institute of Texas [RP140648, RP140649]; Susan G Komen for the Cure Postdoctoral Fellowship [KG111170]; National Institutes of Health Cancer Center Support Grant [CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	MD Anderson Cancer Center Inflammatory Breast Cancer funds; Nylene Eckles funds; MD Anderson Cancer Center; Cancer Prevention and Research Institute of Texas; Susan G Komen for the Cure Postdoctoral Fellowship(Susan G. Komen Breast Cancer Foundation); National Institutes of Health Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The MIGR1 vectors were generous gifts from Dr Khaled A. Hassan (University of Michigan, Ann Arbor, MI). We thank Naoko Matsuda of the Department of Breast Medical Oncology at MD Anderson for assistance with the RPPA data analysis. We acknowledge Stephanie P Deming of the Department of Scientific Publications at MD Anderson for editorial assistance and Wendy Schober, Nalini Patel and Duncan Mak of the Flow Cytometry and Cellular Imaging Facility at MD Anderson for assistance with cell cycle distribution and stem cell subpopulation analyses. This work was supported by MD Anderson Cancer Center Inflammatory Breast Cancer funds (105655) and Nylene Eckles funds (101478) to Naoto T Ueno; startup funds from MD Anderson Cancer Center (111411) to Chandra Bartholomeusz; Cancer Prevention and Research Institute of Texas (RP140648 and RP140649) to Kevin N Dalby; a Susan G Komen for the Cure Postdoctoral Fellowship to Xuemei Xie (KG111170); and National Institutes of Health Cancer Center Support Grant to MD Anderson Cancer Center (CA016672).	Bartholomeusz C, 2012, ONCOLOGIST, V17, P766, DOI 10.1634/theoncologist.2011-0377; Bogoyevitch MA, 2006, MICROBIOL MOL BIOL R, V70, P1061, DOI 10.1128/MMBR.00025-06; Cantrell MA, 2015, ONCOTARGET, V6, P11863, DOI 10.18632/oncotarget.3787; Capaccione KM, 2013, CARCINOGENESIS, V34, P1420, DOI 10.1093/carcin/bgt127; Chang QS, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-64; Chaterjee M, 2011, BONE MARROW RES, DOI 10.1155/2011/362938; Chen F, 2012, CANCER RES, V72, P379, DOI 10.1158/0008-5472.CAN-11-1982; Cheng L, 2010, TOXICOL PATHOL, V38, P62, DOI 10.1177/0192623309354109; Cubero Francisco Javier, 2011, Hepatology, V54, P1470, DOI 10.1002/hep.24532; D'Amato NC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045684; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Economopoulou P, 2012, ONCOLOGIST, V17, P1394, DOI 10.1634/theoncologist.2012-0163; Fujishita T, 2011, GASTROENTEROLOGY, V140, P1556, DOI 10.1053/j.gastro.2011.02.007; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; Gozdecka M, 2014, CELL REP, V9, P1361, DOI 10.1016/j.celrep.2014.10.043; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Harrison H, 2010, CANCER RES, V70, P709, DOI 10.1158/0008-5472.CAN-09-1681; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Kappelmann M, 2014, EUR J CELL BIOL, V93, P76, DOI 10.1016/j.ejcb.2013.10.003; Kong Dejuan, 2011, Cancers (Basel), V3, P716, DOI 10.3390/cancers30100716; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Leong KG, 2006, BLOOD, V107, P2223, DOI 10.1182/blood-2005-08-3329; Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118; Li JY, 2008, J NEURO-ONCOL, V88, P11, DOI 10.1007/s11060-008-9529-1; Liu H, 2006, EMBO J, V25, P1058, DOI 10.1038/sj.emboj.7601020; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Malhotra Gautam K, 2011, J Carcinog, V10, P38, DOI 10.4103/1477-3163.91413; McDermott SP, 2010, MOL ONCOL, V4, P404, DOI 10.1016/j.molonc.2010.06.005; Park CY, 2009, MOL THER, V17, P219, DOI 10.1038/mt.2008.254; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; She QB, 2002, CANCER RES, V62, P1343; Song WQ, 2014, CANCER RES, V74, P2444, DOI 10.1158/0008-5472.CAN-13-2136; Trosko JE, 2009, VET PATHOL, V46, P176, DOI 10.1354/vp.46-2-176; Tsuiki H, 2003, CANCER RES, V63, P250; Wang JL, 2012, ADV EXP MED BIOL, V727, P174, DOI 10.1007/978-1-4614-0899-4_13; Wang JH, 2010, MOL CANCER RES, V8, P266, DOI 10.1158/1541-7786.MCR-09-0221; Wang X, 2010, HUM PATHOL, V41, P401, DOI 10.1016/j.humpath.2009.08.018; Wang Yue J, 2013, Methods Mol Biol, V980, P281, DOI 10.1007/978-1-62703-287-2_15; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wojtaszek PA, 1998, J BIOL CHEM, V273, P800, DOI 10.1074/jbc.273.2.800; Xia Y, 2013, J BIOL CHEM, V288, P19321, DOI 10.1074/jbc.M113.475442; Yeh YT, 2006, INT J CANCER, V118, P2678, DOI 10.1002/ijc.21707; Yoon CH, 2012, ONCOGENE, V31, P4655, DOI 10.1038/onc.2011.634; Zhang T, 2012, CHEM BIOL, V19, P140, DOI 10.1016/j.chembiol.2011.11.010	46	54	56	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2599	2608		10.1038/onc.2016.417	http://dx.doi.org/10.1038/onc.2016.417			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27941886	Green Accepted			2022-12-17	WOS:000400597300010
J	Shi, L; Wang, Y; Lu, Z; Zhang, H; Zhuang, N; Wang, B; Song, Z; Chen, G; Huang, C; Xu, D; Zhang, Y; Zhang, W; Gao, Y				Shi, L.; Wang, Y.; Lu, Z.; Zhang, H.; Zhuang, N.; Wang, B.; Song, Z.; Chen, G.; Huang, C.; Xu, D.; Zhang, Y.; Zhang, W.; Gao, Y.			miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop	ONCOGENE			English	Article							NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; MOUSE MODEL; ACTIVATION; EXPRESSION; A20; RESISTANCE; GENE; HETEROGENEITY; MICRORNA-127	The coordination between cellular differentiation and the mesenchymal/stem transition is essential for both embryo development and neoplasia, suggesting a mechanistic link between these two major processes. In this work we show that miR-127, an embryoexpressing lung miRNA, was prominently induced in lung adenocarcinoma and correlated with poor prognosis. Elevated miR-127 level drove a pronounced shift from the epithelial to the mesenchymal phenotype in cancer cells, and this shift was associated with their acquisition of stem-like traits, increased resistance to the epidermal growth factor receptor inhibitor and tumor-propagating potential. In contrast, antagonizing miR-127 markedly reversed this malignant transition, compromised the stem-like properties and the in vivo tumorigenic capability of cancer cells. Importantly, a regulatory loop involving the inflammatory signals NF-.B, miR-127 and tumor necrosis factor alpha-induced protein 3 was uncovered as a self-reinforcing circuitry that ensured an aggressive transition in lung cancer. Thus, this work identifies a novel molecular mechanism linking stemness, malignancy and inflammation, opening a new avenue for cancer treatment.	[Shi, L.; Zhang, W.; Gao, Y.] Nanjing Univ Chinese Med, Sch Basic Med Sci, Dept Immunol, Nanjing, Jiangsu, Peoples R China; [Shi, L.; Wang, Y.; Lu, Z.; Zhang, H.; Zhuang, N.; Wang, B.; Xu, D.] Hangzhou Normal Univ, Sch Med, Dept Basic Med Sci, Hangzhou, Zhejiang, Peoples R China; [Song, Z.; Zhang, Y.] Zhejiang Canc Hosp, Key Lab Diag & Treatment Technol Thorac Oncol, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China; [Chen, G.; Huang, C.] Hangzhou Normal Univ, Affiliated Hosp, Dept Oncol, Hangzhou, Zhejiang, Peoples R China; [Xu, D.] Monash Univ, Dept Mol & Translat Sci, Melbourne, Vic, Australia	Nanjing University of Chinese Medicine; Hangzhou Normal University; Zhejiang Cancer Hospital; Hangzhou Normal University; Monash University	Shi, L (corresponding author), Nanjing Univ Chinese Med, Sch Basic Med Sci, 138 Xianlin Rd, Nanjing 210046, Jiangsu, Peoples R China.	shi_liyun@msn.com		Shi, Liyun/0000-0003-1767-0126; Shi, Liyun/0000-0003-3538-1571	National Key Scientific Research Project [2012CB911200]; National Natural Scientific Funds of Science [81270066, 31200581, 81470210]	National Key Scientific Research Project; National Natural Scientific Funds of Science	We are grateful to Dr Weifeng Ni (the Animal Facility, Hangzhou Normal University) for his assistance in tumor xenograft experiments. This work was supported by the National Key Scientific Research Project (2012CB911200) and the National Natural Scientific Funds of Science (81270066, 31200581 and 81470210).	Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bhaskaran M, 2009, PHYSIOL GENOMICS, V37, P268, DOI 10.1152/physiolgenomics.90268.2008; Bivona TG, 2011, NATURE, V471, P523, DOI 10.1038/nature09870; Calbo J, 2011, CANCER CELL, V19, P244, DOI 10.1016/j.ccr.2010.12.021; Chao CH, 2014, J CLIN INVEST, V124, P3093, DOI 10.1172/JCI73351; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; De S, 2014, P NATL ACAD SCI USA, V111, P11721, DOI 10.1073/pnas.1412390111; Edwards CA, 2008, PLOS BIOL, V6, P1292, DOI 10.1371/journal.pbio.0060135; Espin-Palazon R, 2014, CELL, V159, P1070, DOI 10.1016/j.cell.2014.10.031; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Gazdar AF, 2009, NEW ENGL J MED, V361, P1018, DOI 10.1056/NEJMe0905763; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Goswami RS, 2013, J CLIN ONCOL, V31, P2903, DOI 10.1200/JCO.2012.45.3050; Han XK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4261; Hymowitz SG, 2010, NAT REV CANCER, V10, P332, DOI 10.1038/nrc2775; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Ito M, 2015, DEVELOPMENT, V142, P2425, DOI 10.1242/dev.121996; Jeon YJ, 2015, P NATL ACAD SCI USA, V112, pE3355, DOI 10.1073/pnas.1504630112; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; Li L, 2014, CLIN CANCER RES, V20, P2714, DOI 10.1158/1078-0432.CCR-13-2613; Li QQ, 2011, CELL DEATH DIFFER, V18, P16, DOI 10.1038/cdd.2010.103; Lim PK, 2011, CANCER RES, V71, P1550, DOI 10.1158/0008-5472.CAN-10-2372; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Nakagawa MM, 2015, J EXP MED, V212, P203, DOI 10.1084/jem.20132544; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Potu H, 2010, CANCER RES, V70, P655, DOI 10.1158/0008-5472.CAN-09-1942; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Schmitz R, 2009, J EXP MED, V206, P981, DOI 10.1084/jem.20090528; Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953; Shien K, 2013, CANCER RES, V73, P3051, DOI 10.1158/0008-5472.CAN-12-4136; Song LB, 2012, J CLIN INVEST, V122, P3563, DOI 10.1172/JCI62339; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7; Vande Walle L, 2014, NATURE, V512, P69, DOI 10.1038/nature13322; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Yang ZH, 2013, J BIOL CHEM, V288, P28893, DOI 10.1074/jbc.M113.502682; Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642; Yin C, 2013, HEPATOLOGY, V58, P1964, DOI 10.1002/hep.26573; Ying HJ, 2015, J IMMUNOL, V194, P1239, DOI 10.4049/jimmunol.1402088; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930	50	54	60	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1631	1643		10.1038/onc.2016.332	http://dx.doi.org/10.1038/onc.2016.332			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27869168				2022-12-17	WOS:000397460600003
J	Lin, LY; Du, LM; Cao, K; Huang, Y; Yu, PF; Zhang, LY; Li, FY; Wang, Y; Shi, YF				Lin, L. Y.; Du, L. M.; Cao, K.; Huang, Y.; Yu, P. F.; Zhang, L. Y.; Li, F. Y.; Wang, Y.; Shi, Y. F.			Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities	ONCOGENE			English	Article							STEM-CELLS; ANGIOGENESIS; PROGRESSION; BIOGENESIS; MICRORNAS	Mesenchymal stromal cells (MSCs) are a major component of the tumour microenvironment. A plethora of elegant studies focusing on tumour-derived MSCs have shown that they, unlike normal MSCs in other tissue, exhibit a strong ability to promote tumour progression. However, the mechanisms underlying the conversion of normal MSCs into tumour-associated MSCs are unknown. We report here a critical role of tumour cell-derived exosomes in endowing bone marrow-derived MSCs (BM-MSCs) with a tumour-favourable phenotype. Tumour cell-derived exosomes affected neither the growth factor production nor the immunosuppressive property of MSCs; rather, they endowed MSCs with a strong ability to promote macrophage infiltration into B16-F0 melanoma or EL-4 lymphoma. Ablation of macrophages by clodronate liposome administration reversed the tumour-promoting effect of MSCs educated by tumour cell-derived exosomes (TE-MSCs) on the tumour growth. By comparing the chemokine profile of BM-MSCs with that of TE-MSCs, we found that TE-MSCs produced a large amount of CCR2 ligands, CCL2 and CCL7, which are responsible for macrophage recruitment. CCR2-specific inhibitor was found to block the tumour-promoting effect of TE-MSCs. Thus, our investigations demonstrated that tumour cell-derived exosomes confer BM-MSCs the ability to enhance tumour growth. Therefore, we uncovered a novel mechanism underlying the conversion of normal MSCs to tumour-associated MSCs.	[Lin, L. Y.; Du, L. M.; Cao, K.; Huang, Y.; Yu, P. F.; Li, F. Y.; Wang, Y.; Shi, Y. F.] Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol,Inst Hlth Sci, 320 Yueyang Rd, Shanghai 200030, Peoples R China; [Lin, L. Y.; Du, L. M.; Cao, K.; Huang, Y.; Yu, P. F.; Li, F. Y.; Wang, Y.; Shi, Y. F.] Shanghai Jiao Tong Univ Med, 320 Yueyang Rd, Shanghai 200030, Peoples R China; [Zhang, L. Y.; Shi, Y. F.] Soochow Univ, Inst Translat Med, Affiliated Hosp 1, 199 Renai Rd, Suzhou, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Shanghai Jiao Tong University; Soochow University - China	Wang, Y; Shi, YF (corresponding author), Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol,Inst Hlth Sci, 320 Yueyang Rd, Shanghai 200030, Peoples R China.; Wang, Y; Shi, YF (corresponding author), Shanghai Jiao Tong Univ Med, 320 Yueyang Rd, Shanghai 200030, Peoples R China.	yingwang@sibs.ac.cn; yfshi@suda.edu.cn	Du, Liming/M-8227-2019; cao, kai/AAG-6833-2021; HUANG, YIN/AAH-6871-2020; Shi, Yufang/AAE-4431-2020; Yu, Pengfei/AHC-3497-2022	HUANG, YIN/0000-0001-5602-9871; Shi, Yufang/0000-0001-8964-319X; Yu, Pengfei/0000-0002-3894-5697; cao, kai/0000-0002-7939-7279; Du, Liming/0000-0002-0527-3556; wang, ying/0000-0002-2571-9367	Scientific Innovation Project of the Chinese Academy of Science [XDA 01040107]; Ministry of Science and Technology of China [2015CB964400]; Programs of National Natural Science of China [81330046, 81273316, 81530043, 81571612]; External Cooperation Program of BIC, Chinese Academy of Sciences [GJHZ201307]; Shanghai Municipal Key Projects of Basic Research [12JC1409200]; Shanghai Rising-Star Program [14QA1404200]	Scientific Innovation Project of the Chinese Academy of Science; Ministry of Science and Technology of China(Ministry of Science and Technology, China); Programs of National Natural Science of China(National Natural Science Foundation of China (NSFC)); External Cooperation Program of BIC, Chinese Academy of Sciences; Shanghai Municipal Key Projects of Basic Research; Shanghai Rising-Star Program	This study was supported by grants from the Scientific Innovation Project of the Chinese Academy of Science (XDA 01040107), the Ministry of Science and Technology of China (2015CB964400), the Programs of National Natural Science of China (81330046, 81273316, 81530043 and 81571612), the External Cooperation Program of BIC, Chinese Academy of Sciences (GJHZ201307), Shanghai Municipal Key Projects of Basic Research (12JC1409200) and Shanghai Rising-Star Program (14QA1404200).	Arendt LM, 2013, CANCER RES, V73, P6080, DOI 10.1158/0008-5472.CAN-13-0926; Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Beckermann BM, 2008, BRIT J CANCER, V99, P622, DOI 10.1038/sj.bjc.6604508; Christianson HC, 2013, P NATL ACAD SCI USA, V110, P17380, DOI 10.1073/pnas.1304266110; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Cuiffo BG, 2014, CELL STEM CELL, V15, P762, DOI 10.1016/j.stem.2014.10.001; De Boeck A, 2013, GUT, V62, P550, DOI 10.1136/gutjnl-2011-301393; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang WH, 2013, ONCOGENE, V32, P4343, DOI 10.1038/onc.2012.458; Huang Y, 2014, ONCOGENE, V33, P3830, DOI 10.1038/onc.2013.355; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Lin R, 2013, STEM CELLS DEV, V22, P2836, DOI 10.1089/scd.2013.0166; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; McLean K, 2011, J CLIN INVEST, V121, P3206, DOI 10.1172/JCI45273; Ono M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005231; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ren G, 2014, ONCOGENE, V33, P4016, DOI 10.1038/onc.2013.387; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002; Webber JP, 2015, ONCOGENE, V34, P319, DOI 10.1038/onc.2013.560	27	54	61	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					6038	6042		10.1038/onc.2016.131	http://dx.doi.org/10.1038/onc.2016.131			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27132512	Green Published, hybrid			2022-12-17	WOS:000388509400010
J	Zhao, X; Li, D; Pu, J; Mei, H; Yang, D; Xiang, X; Qu, H; Huang, K; Zheng, L; Tong, Q				Zhao, X.; Li, D.; Pu, J.; Mei, H.; Yang, D.; Xiang, X.; Qu, H.; Huang, K.; Zheng, L.; Tong, Q.			CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression	ONCOGENE			English	Article							MATRIX-METALLOPROTEINASE 14; GASTRIC-CANCER CELLS; HUMAN P53 GENE; N-MYC; TUMOR-SUPPRESSOR; NEURONAL DIFFERENTIATION; AMPLIFIED NEUROBLASTOMA; CONDITIONAL EXPRESSION; EPIGENETIC REGULATION; TRANSCRIPTION FACTOR	Previous studies have indicated the important roles of MYCN in tumorigenesis and progression of neuroblastoma (NB), the most common extracranial solid tumor derived from neural crest in childhood. However, the regulatory mechanisms of MYCN expression in NB still remain largely unknown. In this study, through mining public microarray databases and analyzing the cis-regulatory elements and chromatin immunoprecipitation data sets, we identified CCCTC-binding factor (CTCF) as a crucial transcription factor facilitating the MYCN expression in NB. RNA immunoprecipitation, RNA electrophoretic mobility shift assay, RNA pull down and in vitro binding assay indicated the physical interaction between CTCF and MYCN opposite strand (MYCNOS), a natural noncoding RNA surrounding the MYNC promoter. Gain- and loss-of-function studies revealed that MYCNOS facilitated the recruitment of CTCF to its binding sites within the MYCN promoter to induce chromatin remodeling, resulting in enhanced MYCN levels and altered downstream gene expression, in cultured NB cell lines. CTCF cooperated with MYCNOS to suppress the differentiation and promote the growth, invasion and metastasis of NB cells in vitro and in vivo. In clinical NB tissues and cell lines, CTCF and MYCNOS were upregulated and positively correlated with MYCN expression. CTCF was an independent prognostic factor for unfavorable outcome of NB, and patients with high MYCNOS expression had lower survival probability. Taken together, these results demonstrate that CTCF cooperates with noncoding RNA MYCNOS to exhibit oncogenic activity that affects the aggressiveness and progression of NB through transcriptional upregulation of MYCN.	[Zhao, X.; Li, D.; Pu, J.; Mei, H.; Yang, D.; Xiang, X.; Qu, H.; Tong, Q.] Huazhong Univ Sci & Technol, Union Hosp, Dept Pediat Surg, Tongji Med Coll, Wuhan 430022, Hubei Province, Peoples R China; [Huang, K.; Zheng, L.; Tong, Q.] Huazhong Univ Sci & Technol, Union Hosp, Clin Ctr Human Genom Res, Tongji Med Coll, Wuhan, Peoples R China; [Huang, K.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiol, Wuhan, Peoples R China; [Zheng, L.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pathol, Wuhan 430022, Hubei Province, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Tong, Q (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Pediat Surg, Tongji Med Coll, Wuhan 430022, Hubei Province, Peoples R China.; Zheng, L (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pathol, Wuhan 430022, Hubei Province, Peoples R China.	ld_zheng@hotmail.com; qs_tong@hotmail.com	Tong, Qiangsong/B-4500-2014; Zhao, Xiang/AAL-6578-2020	Tong, Qiangsong/0000-0002-2615-6404; Zhao, Xiang/0000-0002-5332-4602	National Natural Science Foundation of China [81272779, 81372667, 81372401, 81472363, 81402301, 81402408, 81572423]; Fundamental Research Funds for the Central Universities [2012QN224, 2013ZHYX003, 01-18-530112, 01-18-530115]; Natural Science Foundation of Hubei Province [2014CFA012]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Natural Science Foundation of Hubei Province(Natural Science Foundation of Hubei Province)	We are grateful to Drs William L Carroll and Danny Reinberg for providing vectors. This work was supported by the National Natural Science Foundation of China (81272779, 81372667, 81372401, 81472363, 81402301, 81402408, 81572423), Fundamental Research Funds for the Central Universities (2012QN224, 2013ZHYX003, 01-18-530112, 01-18-530115) and Natural Science Foundation of Hubei Province (2014CFA012).	ARMSTRONG BC, 1992, CELL GROWTH DIFFER, V3, P385; Bell E, 2010, CANCER LETT, V293, P144, DOI 10.1016/j.canlet.2010.01.015; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chernukhin IV, 2000, J BIOL CHEM, V275, P29915, DOI 10.1074/jbc.M001538200; Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024; De la Rosa-Velazquez IA, 2007, CANCER RES, V67, P2577, DOI 10.1158/0008-5472.CAN-06-2024; Docquier F, 2005, CANCER RES, V65, P5112, DOI 10.1158/0008-5472.CAN-03-3498; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Hasan MK, 2013, SCI REP-UK, V3, DOI 10.1038/srep03450; Henriksen JR, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-1; Huang KM, 2013, J BIOL CHEM, V288, P26067, DOI 10.1074/jbc.M113.486175; Inge TH, 2002, SURGERY, V132, P232, DOI 10.1067/msy.2002.125387; Jacobs JFM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-239; Jiang GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031379; Kaneko Y, 2015, CANCER SCI, V106, P840, DOI 10.1111/cas.12677; Kramps C, 2004, J BIOL CHEM, V279, P5110, DOI 10.1074/jbc.M304758200; Li D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0320-6; Li D, 2013, ONCOTARGET, V4, P2021, DOI 10.18632/oncotarget.1579; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Liu PY, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju113; Loven J, 2010, P NATL ACAD SCI USA, V107, P1553, DOI 10.1073/pnas.0913517107; Lutz W, 1996, ONCOGENE, V13, P803; Michel AM, 2014, NUCLEIC ACIDS RES, V42, pD859, DOI 10.1093/nar/gkt1035; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Pandey GK, 2014, CANCER CELL, V26, P722, DOI 10.1016/j.ccell.2014.09.014; Pession A, 2005, CURR CANCER DRUG TAR, V5, P273, DOI 10.2174/1568009054064606; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Qu HX, 2015, HUM MOL GENET, V24, P2539, DOI 10.1093/hmg/ddv018; Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021; Saldana-Meyer R, 2014, GENE DEV, V28, P723, DOI 10.1101/gad.236869.113; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Shoji W, 2015, BIOCHEM BIOPH RES CO, V461, P501, DOI 10.1016/j.bbrc.2015.04.050; Sivak LE, 1997, ONCOGENE, V15, P1937, DOI 10.1038/sj.onc.1201363; Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509; Suenaga Y, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1003996; Suenaga Y, 2009, BIOCHEM BIOPH RES CO, V390, P21, DOI 10.1016/j.bbrc.2009.09.044; Sun S, 2013, CELL, V153, P1537, DOI 10.1016/j.cell.2013.05.028; Tanaka N, 2008, INT J ONCOL, V33, P815, DOI 10.3892/ijo_00000069; Tee AE, 2014, ONCOTARGET, V5, P1793, DOI 10.18632/oncotarget.1785; Thomas WD, 2004, INT J BIOCHEM CELL B, V36, P771, DOI 10.1016/S1357-2725(03)00254-1; Vance KW, 2014, EMBO J, V33, P296, DOI 10.1002/embj.201386225; Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Xiang X, 2015, CANCER LETT, V359, P187, DOI 10.1016/j.canlet.2015.01.008; Yang JH, 2013, NUCLEIC ACIDS RES, V41, pD177, DOI 10.1093/nar/gks1060; Yu M, 2009, INT J ONCOL, V34, P931, DOI 10.3892/ijo_00000219; Zhang H, 2014, ONCOGENE, V33, P387, DOI 10.1038/onc.2012.574; Zhang HY, 2012, MOL CANCER THER, V11, P1454, DOI 10.1158/1535-7163.MCT-12-0001; Zhang XH, 1999, ANTICANCER RES, V19, P1641; Zheng LD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055719; Zheng LD, 2013, MOL CANCER RES, V11, P182, DOI 10.1158/1541-7786.MCR-12-0534; Zheng LD, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-74; Zheng LD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-33	56	54	55	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3565	3576		10.1038/onc.2015.422	http://dx.doi.org/10.1038/onc.2015.422			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26549029				2022-12-17	WOS:000379621500009
J	Coarfa, C; Fiskus, W; Eedunuri, VK; Rajapakshe, K; Foley, C; Chew, SA; Shah, SS; Geng, C; Shou, J; Mohamed, JS; O'Malley, BW; Mitsiades, N				Coarfa, C.; Fiskus, W.; Eedunuri, V. K.; Rajapakshe, K.; Foley, C.; Chew, S. A.; Shah, S. S.; Geng, C.; Shou, J.; Mohamed, J. S.; O'Malley, B. W.; Mitsiades, N.			Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; DOWN-REGULATION; FOCAL ADHESION; EXPRESSION; TRANSCRIPTION; RECURRENCE; GENE; PROLIFERATION; AMPLIFICATION; COACTIVATOR	MicroRNAs are important epigenetic regulators of protein expression by triggering degradation of target mRNAs and/or inhibiting their translation. Dysregulation of microRNA expression has been reported in several cancers, including prostate cancer (PC). We comprehensively characterized the proteomic footprint of a panel of 12 microRNAs that are potently suppressed in metastatic PC (SiM-miRNAs: miR-1, miR-133a, miR-133b, miR-135a, miR-143-3p, miR-145-3p, miR-205, miR-221-3p, miR-221-5p, miR-222-3p, miR-24-1-5p, and miR-31) using reverse-phase proteomic arrays. Re-expression of these SiM-miRNAs in PC cells suppressed cell proliferation and targeted key oncogenic pathways, including cell cycle, apoptosis, Akt/mammalian target of rapamycin signaling, metastasis and the androgen receptor (AR) axis. However, only 12%, at most, of these observed protein expression changes could be explained by predicted direct binding of miRNAs to corresponding mRNAs, suggesting that the majority of these proteomic effects result indirectly. AR and its steroid receptor coactivators (SRCs; SRC-1, -2 and -3) were recurrently affected by these SiMmiRNAs. In agreement, we identified inverse correlations between expression of these SiM-miRNAs and early clinical recurrence, as well as with AR transcriptional activity in human PC tissues. We also identified robust induction of miR-135a by androgen and strong direct binding of AR to the miR-135a locus. As miR-135a potently suppresses AR expression, this results in a negative feedback loop that suppresses AR protein expression in an androgen-dependent manner, while de-repressing AR expression upon androgen deprivation. Our results demonstrate that epigenetic silencing of these SiM-miRNAs can result in increased AR axis activity and cell proliferation, thus contributing to disease progression. We further demonstrate that a negative feedback loop involving miR-135a can restore AR expression under androgen-deprivation conditions, thus contributing to the upregulation of AR protein expression in castration-resistant PC. Finally, our unbiased proteomic profiling demonstrates that the majority of actual protein expression changes induced by SiM-miRNAs cannot be explained based on predicted direct interactions.	[Coarfa, C.; Fiskus, W.; Rajapakshe, K.; Foley, C.; Chew, S. A.; Shah, S. S.; Geng, C.; O'Malley, B. W.; Mitsiades, N.] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza,Suite R407,MS BCM187, Houston, TX 77030 USA; [Coarfa, C.; Mitsiades, N.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Fiskus, W.; Foley, C.; Chew, S. A.; Shah, S. S.; Geng, C.; Shou, J.; Mohamed, J. S.; Mitsiades, N.] Baylor Coll Med, Dept Med, One Baylor Plaza,Suite R407,MS BCM187, Houston, TX 77030 USA; [Eedunuri, V. K.] Adrienne Helis Malvin Med Res Fdn, New Orleans, LA USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Mitsiades, N (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza,Suite R407,MS BCM187, Houston, TX 77030 USA.; Mitsiades, N (corresponding author), Baylor Coll Med, Dept Med, One Baylor Plaza,Suite R407,MS BCM187, Houston, TX 77030 USA.	mitsiade@bcm.edu	Eedunuri, VIJAY KUMAR/L-2213-2015; Mohamed, Junaith/AAC-4050-2020		American Cancer Society [RSG-14-218-01-TBG]; Prostate Cancer Foundation; Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator and Career Development Awards; NICHD [8818]; Department of Defense Breast Cancer Research Program Innovator Award; Pilot/Feasibility Program of the Diabetes and Endocrinology Research Center at Baylor College of Medicine [P30-DK079638]; Alkek Foundation for Molecular Discovery Pilot grant; NCI Cancer Center Support [P30CA125123]; Center for Drug Discovery at Baylor College of Medicine; Functional Proteomics RPPA Core Facility (The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD008188] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA125123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079638] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Prostate Cancer Foundation; Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator and Career Development Awards; NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Department of Defense Breast Cancer Research Program Innovator Award; Pilot/Feasibility Program of the Diabetes and Endocrinology Research Center at Baylor College of Medicine; Alkek Foundation for Molecular Discovery Pilot grant; NCI Cancer Center Support(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Drug Discovery at Baylor College of Medicine; Functional Proteomics RPPA Core Facility (The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We acknowledge the joint participation by Adrienne Helis Malvin Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with Baylor College of Medicine. This work was also supported by the American Cancer Society RSG-14-218-01-TBG (to NM), the Prostate Cancer Foundation (to BWO and NM), the Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator and Career Development Awards (both to NM), NICHD 8818 and Department of Defense Breast Cancer Research Program Innovator Award (to BWO), the Pilot/Feasibility Program of the Diabetes and Endocrinology Research Center (P30-DK079638) at Baylor College of Medicine (to NM), and an Alkek Foundation for Molecular Discovery Pilot grant (to CC). NM is a Dan L. Duncan Scholar, a Caroline Wiess Law Scholar and a member of the Dan L. Duncan Cancer Center (supported by the NCI Cancer Center Support grant P30CA125123) and the Center for Drug Discovery at Baylor College of Medicine. We thank the assistance of the Shared Resources of the Dan L. Duncan Cancer Center (supported by the NCI Cancer Center Support grant P30CA125123) and the Functional Proteomics RPPA Core Facility (The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA).	Agoulnik IU, 2006, CANCER RES, V66, P10594, DOI 10.1158/0008-5472.CAN-06-1023; Agoulnik IU, 2005, CANCER RES, V65, P7959, DOI 10.1158/0008-5472.CAN-04-3541; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Aryee MJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005211; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Casanova-Salas I, 2014, J UROLOGY, V192, P252, DOI 10.1016/j.juro.2014.01.107; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Demichelis F, 2009, GENE CHROMOSOME CANC, V48, P366, DOI 10.1002/gcc.20647; Erhard F, 2014, GENOME RES, V24, P906, DOI 10.1101/gr.166702.113; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Fang YX, 2014, ONCOGENE, V33, P135, DOI 10.1038/onc.2013.54; Formosa A, 2014, ONCOGENE, V33, P5173, DOI 10.1038/onc.2013.451; Formosa A, 2013, ONCOGENE, V32, P127, DOI 10.1038/onc.2012.14; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Geng C, 2014, CANCER RES, V74, P5631, DOI 10.1158/0008-5472.CAN-14-0476; Gottwein E, 2011, CELL HOST MICROBE, V10, P515, DOI 10.1016/j.chom.2011.09.012; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gregory CW, 2001, CANCER RES, V61, P2892; Gregory CW, 2001, CANCER RES, V61, P4315; Haecker I, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002884; Hart M, 2014, MOL CANCER RES, V12, P250, DOI 10.1158/1541-7786.MCR-13-0230; He B, 2014, P NATL ACAD SCI USA, V111, P18261, DOI 10.1073/pnas.1421415111; Hudson RS, 2013, ONCOGENE, V32, P4139, DOI 10.1038/onc.2012.424; Hudson RS, 2012, NUCLEIC ACIDS RES, V40, P3689, DOI 10.1093/nar/gkr1222; Hulf T, 2013, ONCOGENE, V32, P2891, DOI 10.1038/onc.2012.300; Kishore S, 2011, NAT METHODS, V8, P559, DOI [10.1038/nmeth.1608, 10.1038/NMETH.1608]; Koivisto P, 1997, CANCER RES, V57, P314; Kroiss A, 2015, ONCOGENE, V34, P2846, DOI 10.1038/onc.2014.222; Lin PC, 2013, CANCER RES, V73, P1232, DOI 10.1158/0008-5472.CAN-12-2968; Linja MJ, 2001, CANCER RES, V61, P3550; Liu C, 2012, CANCER RES, V72, P3393, DOI 10.1158/0008-5472.CAN-11-3864; Liu C, 2011, CANCER RES, V71, P5950, DOI 10.1158/0008-5472.CAN-11-1035; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Mitsiades N, 2013, CANCER RES, V73, P4599, DOI 10.1158/0008-5472.CAN-12-4414; Mitsiades N, 2012, CANCER RES, V72, P6142, DOI 10.1158/0008-5472.CAN-12-1335; Nelson PS, 2012, J CLIN ONCOL, V30, P644, DOI 10.1200/JCO.2011.39.1300; Ostling P, 2011, CANCER RES, V71, P1956, DOI 10.1158/0008-5472.CAN-10-2421; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Reyes-Herrera Paula H., 2012, Genomics Proteomics & Bioinformatics, V10, P254, DOI 10.1016/j.gpb.2012.10.001; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Saini S, 2012, CANCER RES, V72, P3618, DOI 10.1158/0008-5472.CAN-12-0540; Skalsky RL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002484; Sun T, 2014, ONCOGENE, V33, P2790, DOI 10.1038/onc.2013.230; Sun T, 2012, PROSTATE, V72, P1093, DOI 10.1002/pros.22456; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Taipaleenmaki H, 2015, CANCER RES, V75, P1433, DOI 10.1158/0008-5472.CAN-14-1026; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Therneau T.M., 2000, STAT BIOL HEALTH; Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77; Vidigal JA, 2015, TRENDS CELL BIOL, V25, P137, DOI 10.1016/j.tcb.2014.11.004; Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Witkos TM, 2011, CURR MOL MED, V11, P93; Yan J, 2008, CANCER RES, V68, P5460, DOI 10.1158/0008-5472.CAN-08-0955; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Yue D, 2009, CURR GENOMICS, V10, P478, DOI 10.2174/138920209789208219; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076	59	54	54	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2345	2356		10.1038/onc.2015.295	http://dx.doi.org/10.1038/onc.2015.295			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26364608	Green Accepted			2022-12-17	WOS:000376165000007
J	Hua, G; Lv, X; He, C; Remmenga, SW; Rodabough, KJ; Dong, J; Yang, L; Lele, SM; Yang, P; Zhou, J; Karst, A; Drapkin, RI; Davis, JS; Wang, C				Hua, G.; Lv, X.; He, C.; Remmenga, S. W.; Rodabough, K. J.; Dong, J.; Yang, L.; Lele, S. M.; Yang, P.; Zhou, J.; Karst, A.; Drapkin, R. I.; Davis, J. S.; Wang, C.			YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells	ONCOGENE			English	Article							FIBROBLAST-GROWTH-FACTOR; HIPPO SIGNALING PATHWAY; OVARIAN-CANCER CELLS; TRANSCRIPTIONAL COACTIVATOR; EXPRESSION; PROLIFERATION; TRANSFORMATION; DROSOPHILA; PATHOGENESIS; SUPPRESSES	Accumulating evidence indicates that ovarian high-grade serous carcinoma (HGSC) originates from fallopian tube secretory epithelial cells (FTSECs). However, the molecular mechanisms underlying the initiation and progression of HGSC derived from FTSECs remains unclear. In this study, we found that the Hippo/Yes-associated protein (YAP) signaling pathway has a critical role in the initiation and progression of fallopian tube and ovarian HGSC. Importantly, YAP was overexpressed in inflammatory and cancerous fallopian tube tissues. Further, overexpression of wild-type YAP, or constitutively active YAP in immortalized FTSECs, induced cell proliferation, migration, colony formation and tumorigenesis. Moreover, the Hippo/YAP and the fibroblast growth factor (FGF) signaling pathways formed an autocrine/paracrine-positive feedback loop to drive the progression of the FTSEC-derived HGSC. Evidence in this study strongly suggests that combined therapy with inhibitors of YAP (such as verteporfin) and FGF receptors (such as BGJ398) can provide a novel therapeutic strategy to treat fallopian tube and ovarian HGSC.	[Hua, G.; Lv, X.; He, C.; Remmenga, S. W.; Rodabough, K. J.; Davis, J. S.; Wang, C.] Univ Nebraska Med Ctr, Dept Obstet Gynecol, Olson Ctr Womens Hlth, Omaha, NE USA; [Hua, G.; He, C.; Yang, L.] Huazhong Agr Univ, Coll Anim Sci & Technol, Key Lab Agr Anim Genet Breeding & Reprod, Minist Educ, Wuhan, Peoples R China; [Dong, J.; Davis, J. S.; Wang, C.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA; [Lele, S. M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Yang, P.] Univ Maryland, Sch Med, Dept Obstet Gynecol & Reprod Sci, Baltimore, MD 21201 USA; [Zhou, J.] Urumuqi Gen Hosp Lanzhou Mil Reg, Dept Obstet & Gynecol, Urumqi, Peoples R China; [Karst, A.; Drapkin, R. I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA; [Davis, J. S.] Omaha Vet Affairs Med Ctr, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; Huazhong Agricultural University; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University System of Maryland; University of Maryland Baltimore; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System	Wang, C (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Dept Obstet Gynecol, Olson Ctr Womens Hlth, 985860 Nebraska Med Ctr, Omaha, NE 68198 USA.	chengwang@unmc.edu	Lv, Xiangmin/I-7106-2019; Davis, John S/C-3234-2014; Drapkin, Ronny/E-9944-2016	Lv, Xiangmin/0000-0001-8338-6014; Drapkin, Ronny/0000-0002-6912-6977; Davis, John/0000-0003-3468-4079	Eunice Kennedy Shriver National Institute of Child Health and Human Development [5R00HD059985, 5P01AG029531]; Olson Center for Women's Health; Fred and Pamela Buffett Cancer Center [LB595]; Colleen's Dream Foundation; Omaha Veterans Administration Medical Center [5I01BX000512]; National Institute of Food and Agriculture [2011-67015-20076]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R00HD059985] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K99HD059985] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA197976] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG029531] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000512] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Olson Center for Women's Health; Fred and Pamela Buffett Cancer Center; Colleen's Dream Foundation; Omaha Veterans Administration Medical Center; National Institute of Food and Agriculture(United States Department of Agriculture (USDA)National Institute of Food and Agriculture); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Veterans Affairs(US Department of Veterans Affairs)	We thank Dr Adam Karpf (The Pamela and Fred Cancer Center, University of Nebraska Medical Center) for providing ovarian HGSC cell lines. We acknowledge the cBioPortal for Cancer Genomics (http://cbioportal.org) for providing data sets and online analyzing tools. We also acknowledge the TCGA research Network (http://cancergenome.nih.gov) for providing data sets. This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (5R00HD059985, 5P01AG029531); the Olson Center for Women's Health (no number); the Fred and Pamela Buffett Cancer Center (LB595), the Colleen's Dream Foundation (no number), the Omaha Veterans Administration Medical Center (5I01BX000512) and the National Institute of Food and Agriculture (2011-67015-20076). We thank Melody Montgomery at the University of Nebraska Medical Center (UNMC) Research Editorial Office for the professional editing of the manuscript.	Al-Hussaini M, 2004, HISTOPATHOLOGY, V44, P109, DOI 10.1111/j.1365-2559.2004.01787.x; Ando H, 2000, HUM REPROD, V15, P1597, DOI 10.1093/humrep/15.7.1597; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Barakat RR, 2000, CANCER, V89, P383, DOI 10.1002/1097-0142(20000715)89:2<383::AID-CNCR25>3.0.CO;2-T; Beaufort CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103988; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Berek JS, 2012, INT J GYNECOL OBSTET, V119, pS118, DOI 10.1016/S0020-7292(12)60025-3; Bowen NJ, 2007, GYNECOL ONCOL, V104, P331, DOI 10.1016/j.ygyno.2006.08.052; Cai H, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-31; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Casey MJ, 2000, GYNECOL ONCOL, V78, P278, DOI 10.1006/gyno.2000.5861; Cathro HP, 2002, AM J CLIN PATHOL, V117, P944, DOI 10.1309/2T1Y-7BB7-DAPE-PQ6L; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; Crum CP, 2007, CURR OPIN OBSTET GYN, V19, P3, DOI 10.1097/GCO.0b013e328011a21f; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; De Cecco L, 2004, ONCOGENE, V23, P8171, DOI 10.1038/sj.onc.1207979; DIBLASIO AM, 1993, AM J OBSTET GYNECOL, V169, P1517, DOI 10.1016/0002-9378(93)90428-L; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dubeau L, 2013, ANN ONCOL, V24, P28, DOI 10.1093/annonc/mdt308; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fearon AE, 2013, INT J BIOCHEM CELL B, V45, P2832, DOI 10.1016/j.biocel.2013.09.017; Friedrich J, 2009, NAT PROTOC, V4, P309, DOI 10.1038/nprot.2008.226; Fu D, 2014, ENDOCR-RELAT CANCER, V21, P297, DOI 10.1530/ERC-13-0339; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Goodman MT, 2009, CANCER EPIDEM BIOMAR, V18, P132, DOI 10.1158/1055-9965.EPI-08-0771; Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222; Hall CA, 2010, CANCER RES, V70, P8517, DOI 10.1158/0008-5472.CAN-10-1242; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; He C, 2015, ONCOGENE, V34, P6040, DOI 10.1038/onc.2015.52; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Hwang H, 2004, APPL IMMUNOHISTO M M, V12, P122; Jazaeri AA, 2011, NEOPLASIA, V13, P899, DOI 10.1593/neo.11138; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Karst AM, 2012, NAT PROTOC, V7, P1755, DOI 10.1038/nprot.2012.097; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Katabuchi Hidetaka, 2003, Medical Electron Microscopy, V36, P74; Kendall SD, 2005, CANCER RES, V65, P9824, DOI 10.1158/0008-5472.CAN-05-1543; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krejci P, 2007, PEDIATR RES, V61, P267, DOI 10.1203/pdr.0b013e318030d157; Kuhn E, 2010, AM J SURG PATHOL, V34, P829, DOI 10.1097/PAS.0b013e3181dcede7; Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003; Laury AR, 2010, AM J SURG PATHOL, V34, P627, DOI 10.1097/PAS.0b013e3181da7687; Lee KP, 2010, P NATL ACAD SCI USA, V107, P8248, DOI 10.1073/pnas.0912203107; Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107; Li T, 2010, PHARM BIOL, V48, P161, DOI 10.3109/13880200903062630; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Madore J, 2010, J PATHOL, V220, P392, DOI 10.1002/path.2659; MEYER GE, 1995, CANCER, V76, P2304, DOI 10.1002/1097-0142(19951201)76:11<2304::AID-CNCR2820761119>3.0.CO;2-N; Ono I, 2002, J DERMATOL SCI, V29, P104, DOI 10.1016/S0923-1811(02)00019-1; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Seidman JD, 2004, INT J GYNECOL PATHOL, V23, P41, DOI 10.1097/01.pgp.0000101080.35393.16; Selvaggi, 2000, Arch Pathol Lab Med, V124, P477; Shan WW, 2012, CELL CYCLE, V11, P2107, DOI 10.4161/cc.20544; Sherman-Baust CA, 2014, J PATHOL, V233, P228, DOI 10.1002/path.4353; Siffroi-Fernandez S, 2005, ARCH OPHTHALMOL-CHIC, V123, P368, DOI 10.1001/archopht.123.3.368; Smith JA, 2001, BIOCHEM PHARMACOL, V62, P469, DOI 10.1016/S0006-2952(01)00690-6; Stewart SL, 2007, GYNECOL ONCOL, V107, P392, DOI 10.1016/j.ygyno.2007.09.018; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Tung CS, 2009, MODERN PATHOL, V22, P1243, DOI 10.1038/modpathol.2009.92; Wang C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.397; Wang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048299; Wang C, 2010, ENDOCRINOLOGY, V151, P2319, DOI 10.1210/en.2009-1489; Yang SP, 2013, CANCER RES, V73, P6722, DOI 10.1158/0008-5472.CAN-13-2049; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8	75	54	55	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2247	2265		10.1038/onc.2015.288	http://dx.doi.org/10.1038/onc.2015.288			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26364602	Green Submitted, Green Accepted			2022-12-17	WOS:000374986000010
J	Srinivasan, S; Guha, M; Dong, DW; Whelan, KA; Ruthel, G; Uchikado, Y; Natsugoe, S; Nakagawa, H; Avadhani, NG				Srinivasan, S.; Guha, M.; Dong, D. W.; Whelan, K. A.; Ruthel, G.; Uchikado, Y.; Natsugoe, S.; Nakagawa, H.; Avadhani, N. G.			Disruption of cytochrome c oxidase function induces the Warburg effect and metabolic reprogramming	ONCOGENE			English	Article							MITOCHONDRIAL RESPIRATORY STRESS; KAPPA-B-BETA; CANCER-CELLS; DNA MUTATIONS; ALTERED METABOLISM; COMPLEX-III; SUBUNIT-VB; FACTOR-I; ACTIVATION; HYPOXIA	Defects in mitochondrial oxidative phosphorylation complexes, altered bioenergetics and metabolic shift are often seen in cancers. Here we show a role for the dysfunction of the electron transport chain component cytochrome c oxidase (CcO) in cancer progression. We show that genetic silencing of the CcO complex by shRNA expression and loss of CcO activity in multiple cell types from the mouse and human sources resulted in metabolic shift to glycolysis, loss of anchorage-dependent growth and acquired invasive phenotypes. Disruption of the CcO complex caused loss of transmembrane potential and induction of Ca2+/Calcineurin-mediated retrograde signaling. Propagation of this signaling includes activation of PI3-kinase, IGF1R and Akt, Ca2(+)-sensitive transcription factors and also TGF beta 1, MMP16 and periostin, which are involved in oncogenic progression. Whole-genome expression analysis showed the upregulation of genes involved in cell signaling, extracellular matrix interactions, cell morphogenesis, cell motility and migration. The transcription profiles reveal extensive similarity to retrograde signaling initiated by partial mitochondrial DNA depletion, although distinct differences are observed in signaling induced by CcO dysfunction. The possible CcO dysfunction as a biomarker for cancer progression was supported by data showing that esophageal tumors from human patients show reduced CcO subunits IVi1 and Vb in regions that were previously shown to be the hypoxic core of the tumors. Our results show that mitochondrial electron transport chain defect initiates a retrograde signaling. These results suggest that a defect in the CcO complex can potentially induce tumor progression.	[Srinivasan, S.; Guha, M.; Dong, D. W.; Ruthel, G.; Avadhani, N. G.] Mari Lowe Ctr Comparat Oncol, Dept Biomed Sci, Sch Vet Med, Philadelphia, PA USA; [Whelan, K. A.; Nakagawa, H.] Univ Penn, Dept Med, Div Gastroenterol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Uchikado, Y.; Natsugoe, S.] Kagoshima Univ, Dept Digest Surg Breast & Thyroid Surg, Grad Sch Med, Kagoshima 890, Japan	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Kagoshima University	Avadhani, NG (corresponding author), Univ Penn, Dept Biomed Sci, Sch Vet Med, 3800 Spruce St,Room 189E Vet, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu	Ruthel, Gordon/GYU-9133-2022		NIH [CA-22762, GM-34883]; Mitochondria research affinity group, Children's hospital of Philadelphia; Harriet Ellison Woodward Trust; NATIONAL CANCER INSTITUTE [R01CA022762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR067066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034883] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mitochondria research affinity group, Children's hospital of Philadelphia; Harriet Ellison Woodward Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grants CA-22762 and GM-34883, and an endowment from the Harriet Ellison Woodward Trust to NGA and a grant to SS from Mitochondria research affinity group, Children's hospital of Philadelphia. We also acknowledge the help of the Imaging Core facility at the School of Veterinary Medicine and the NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases (P30DK050306) and its Molecular Pathology and Imaging Core facilities at the Perelman School of Medicine.	Acin-Perez R, 2008, MOL CELL, V32, P529, DOI 10.1016/j.molcel.2008.10.021; Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; Bansal S, 2012, J BIOL CHEM, V287, P15284, DOI 10.1074/jbc.M111.314062; Bardella C, 2011, BBA-BIOENERGETICS, V1807, P1432, DOI 10.1016/j.bbabio.2011.07.003; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104; Biswas G, 2005, GENE, V354, P132, DOI 10.1016/j.gene.2005.03.028; Biswas G, 2008, J BIOL CHEM, V283, P12586, DOI 10.1074/jbc.M710481200; Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Chen ZX, 2010, CELL DEATH DIFFER, V17, P408, DOI 10.1038/cdd.2009.132; Dakubo GD, 2006, J CLIN PATHOL, V59, P10, DOI 10.1136/jcp.2005.027664; Dasgupta S, 2008, CANCER RES, V68, P700, DOI 10.1158/0008-5472.CAN-07-5532; Devin A, 2001, EUR J BIOCHEM, V268, P3943, DOI 10.1046/j.1432-1327.2001.02306.x; Fang HZ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-421; Fang JK, 2007, FEBS LETT, V581, P1302, DOI 10.1016/j.febslet.2007.02.042; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Frezza C, 2014, INT J BIOCHEM CELL B, V48, P11, DOI 10.1016/j.biocel.2013.12.013; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Galati D, 2009, BIOCHEM J, V420, P439, DOI 10.1042/BJ20090214; Gallardo ME, 2006, HUM MUTAT, V27, P575, DOI 10.1002/humu.20338; Guha M, 2014, ONCOGENE, V33, P5238, DOI 10.1038/onc.2013.467; Guha M, 2007, J BIOL CHEM, V282, P14536, DOI 10.1074/jbc.M611693200; Guha M, 2013, MITOCHONDRION, V13, P577, DOI 10.1016/j.mito.2013.08.007; Guha M, 2010, MOL BIOL CELL, V21, P3578, DOI 10.1091/mbc.E10-03-0192; Guha M, 2009, MOL BIOL CELL, V20, P4107, DOI 10.1091/mbc.E09-04-0296; Guzy RD, 2006, EXP PHYSIOL, V91, P807, DOI 10.1113/expphysiol.2006.033506; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Krell D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019868; Li YF, 2006, J BIOENERG BIOMEMBR, V38, P283, DOI 10.1007/s10863-006-9052-z; Liu X, 2011, CELL DEATH DIFFER, V18, P1561, DOI 10.1038/cdd.2011.13; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miccoli L, 1996, BIOCHEM J, V313, P957, DOI 10.1042/bj3130957; Moro L, 2009, CELL DEATH DIFFER, V16, P571, DOI 10.1038/cdd.2008.178; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; Natsuizaka M, 2012, FASEB J, V26, P2620, DOI 10.1096/fj.11-198598; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Picaud S, 2011, J INHERIT METAB DIS, V34, P671, DOI 10.1007/s10545-011-9294-8; Prabu SK, 2006, J BIOL CHEM, V281, P2061, DOI 10.1074/jbc.M507741200; Rainbolt TK, 2014, TRENDS ENDOCRIN MET, V25, P528, DOI 10.1016/j.tem.2014.06.007; Sayen MR, 2003, AM J PHYSIOL-CELL PH, V284, pC562, DOI 10.1152/ajpcell.00336.2002; Schafer E, 2006, J BIOL CHEM, V281, P15370, DOI 10.1074/jbc.M513525200; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Sharma LK, 2011, HUM MOL GENET, V20, P4605, DOI 10.1093/hmg/ddr395; Srinivasan S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077129; Srinivasan S, 2012, FREE RADICAL BIO MED, V53, P1252, DOI 10.1016/j.freeradbiomed.2012.07.021; Vannuvel K, 2013, J CELL PHYSIOL, V228, P1802, DOI 10.1002/jcp.24360; Vonck J, 2009, BBA-MOL CELL RES, V1793, P117, DOI 10.1016/j.bbamcr.2008.05.019; WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; WARBURG O, 1956, SCIENCE, V124, P269; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064	59	54	54	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1585	1595		10.1038/onc.2015.227	http://dx.doi.org/10.1038/onc.2015.227			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26148236	Green Accepted			2022-12-17	WOS:000373063600011
J	Lee, KM; Nam, K; Oh, S; Lim, J; Kim, RK; Shim, D; Choi, JH; Lee, SJ; Yu, JH; Lee, JW; Ahn, SH; Shin, I				Lee, K-m; Nam, K.; Oh, S.; Lim, J.; Kim, R. K.; Shim, D.; Choi, J-h; Lee, S-J; Yu, J-H; Lee, J. W.; Ahn, S. H.; Shin, I.			ECM1 regulates tumor metastasis and CSC-like property through stabilization of beta-catenin	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX PROTEIN-1; NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; LYMPHATIC METASTASIS; SELF-RENEWAL; CANCER; EXPRESSION; IDENTIFICATION; ACTIVATION	Extracellular Matrix Protein 1 (ECM1) is a marker for tumorigenesis and is correlated with invasiveness and poor prognosis in various types of cancer. However, the functional role of ECM1 in cancer metastasis is unclear. Here, we detected high ECM1 level in breast cancer patient sera that was associated with recurrence of tumor. The modulation of ECM1 expression affected not only cell migration and invasion, but also sphere-forming ability and drug resistance in breast cancer cell lines. In addition, ECM1 regulated the gene expression associated with the epithelial to mesenchymal transition (EMT) progression and cancer stem cell (CSC) maintenance. Interestingly, ECM1 increased beta-catenin expression at the post-translational level through induction of MUC1, which was physically associated with beta-catenin. Indeed, the association between beta-catenin and the MUC1 cytoplasmic tail was increased by ECM1. Furthermore, forced expression of beta-catenin altered the gene expression that potentiated EMT progression and CSC phenotype maintenance in the cells. These data provide evidence that ECM1 has an important role in cancer metastasis through beta-catenin stabilization.	[Lee, K-m; Nam, K.; Oh, S.; Lim, J.; Kim, R. K.; Shim, D.; Choi, J-h; Lee, S-J; Shin, I.] Hanyang Univ, Dept Life Sci, Seoul 133791, South Korea; [Yu, J-H; Lee, J. W.; Ahn, S. H.] Univ Ulsan, Coll Med, Dept Surg, Seoul, South Korea; [Yu, J-H; Lee, J. W.; Ahn, S. H.] Asan Med Ctr, Seoul, South Korea; [Shin, I.] Hanyang Univ, Nat Sci Inst, Seoul 133791, South Korea	Hanyang University; University of Ulsan; Hanyang University	Shin, I (corresponding author), Hanyang Univ, Dept Life Sci, Haengdang 1 Dong, Seoul 133791, South Korea.	incheol@hanyang.ac.kr	Lee, kyung-min/ABH-7692-2020; Choi, Jae-Hoon/R-6224-2016	Lee, kyung-min/0000-0001-8381-2423; Choi, Jae-Hoon/0000-0002-5265-3463	NRF grant from the Korea Research Foundation [2013-059143]; Converging Research Center Program [2014048814]	NRF grant from the Korea Research Foundation; Converging Research Center Program	This work was supported by an NRF grant (2013-059143) from the Korea Research Foundation and Converging Research Center Program (2014048814).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; Gu MZ, 2013, INT J CLIN EXP PATHO, V6, P1132; Han ZQ, 2001, FASEB J, V15, P988, DOI 10.1096/fj.99-0934com; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Horvay K, 2011, STEM CELLS DEV, V20, P737, DOI 10.1089/scd.2010.0188; Howe LR, 2003, CANCER RES, V63, P1906; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kebebew E, 2005, ANN SURG, V242, P353, DOI 10.1097/sla.0000179623.87329.6b; Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381; Lal G, 2009, ANN SURG ONCOL, V16, P2280, DOI 10.1245/s10434-009-0533-2; Lee KM, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0479-6; Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005; Liu W, 2012, J INVEST DERMATOL, V132, P2828, DOI 10.1038/jid.2012.211; Maier HJ, 2010, CANCER LETT, V295, P214, DOI 10.1016/j.canlet.2010.03.003; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MATHIEU E, 1994, J BONE MINER RES, V9, P903; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Neth P, 2007, STEM CELL REV, V3, P18, DOI 10.1007/s12015-007-0001-y; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Raina D, 2014, ONCOGENE, V33, P3422, DOI 10.1038/onc.2013.308; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Sakai D, 2005, DEV GROWTH DIFFER, V47, P471, DOI 10.1111/j.1440-169X.2005.00821.x; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Takao Y, 2007, BIOCHEM BIOPH RES CO, V353, P699, DOI 10.1016/j.bbrc.2006.12.072; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Tanida S, 2014, BBA-GEN SUBJECTS, V1840, P1790, DOI 10.1016/j.bbagen.2014.02.008; Wang LP, 2003, CANCER LETT, V200, P57, DOI 10.1016/S0304-3835(03)00350-1; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Wu QW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-47; Wu QW, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-132; Xiong GP, 2012, NEOPLASMA, V59, P409, DOI 10.4149/neo_2012_053; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Zhao QC, 2009, CANCER RES, V69, P6799, DOI 10.1158/0008-5472.CAN-09-1096	46	54	57	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2015	34	50					6055	6065		10.1038/onc.2015.54	http://dx.doi.org/10.1038/onc.2015.54			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RQ	25746001				2022-12-17	WOS:000366113800003
J	Zhang, P; Elabd, S; Hammer, S; Solozobova, V; Yan, H; Bartel, F; Inoue, S; Henrich, T; Wittbrodt, J; Loosli, F; Davidson, G; Blattner, C				Zhang, P.; Elabd, S.; Hammer, S.; Solozobova, V.; Yan, H.; Bartel, F.; Inoue, S.; Henrich, T.; Wittbrodt, J.; Loosli, F.; Davidson, G.; Blattner, C.			TRIM25 has a dual function in the p53/Mdm2 circuit	ONCOGENE			English	Article							ESTROGEN-RESPONSIVE GENE; FINGER PROTEIN; BREAST-CANCER; RECEPTOR-ALPHA; P53 PATHWAY; ACETYLATION; EFP; ACTIVATION; 14-3-3-SIGMA; DEGRADATION	P53 is an important tumor suppressor that, upon activation, induces growth arrest and cell death. Control of p53 is thus of prime importance for proliferating cells, but also for cancer therapy, where p53 activity contributes to the eradication of tumors. Mdm2 functionally inhibits p53 and targets the tumor suppressor protein for degradation. In a genetic screen, we identified TRIM25 as a novel regulator of p53 and Mdm2. TRIM25 increased p53 and Mdm2 abundance by inhibiting their ubiquitination and degradation in 26 S proteasomes. TRIM25 co-precipitated with p53 and Mdm2 and interfered with the association of p300 and Mdm2, a critical step for p53 polyubiquitination. Despite the increase in p53 levels, p53 activity was inhibited in the presence of TRIM25. Downregulation of TRIM25 resulted in an increased acetylation of p53 and p53-dependent cell death in HCT116 cells. Upon genotoxic insults, TRIM25 dampened the p53-dependent DNA damage response. The downregulation of TRIM25 furthermore resulted in massive apoptosis during early embryogenesis of medaka, which was rescued by the concomitant downregulation of p53, demonstrating the functional relevance of the regulation of p53 by TRIM25 in an organismal context.	[Zhang, P.; Elabd, S.; Solozobova, V.; Yan, H.; Loosli, F.; Davidson, G.; Blattner, C.] Karlsruhe Inst Technol, Inst Toxicol & Genet, D-76021 Karlsruhe, Baden Wurttembe, Germany; [Zhang, P.; Yan, H.] Heidelberg Univ, Fac Biosci, Heidelberg, Germany; [Hammer, S.; Bartel, F.] Univ Halle Wittenberg, Fac Med, Inst Pathol, D-06108 Halle, Germany; [Inoue, S.] Univ Tokyo, Dept Antiaging Med, Tokyo, Japan; [Henrich, T.] Osaka Univ, Int Coll, Chem Biol Combined Major Program, Osaka, Japan; [Wittbrodt, J.] Heidelberg Univ, Ctr Organismal Studies Dev Biol & Physiol, Heidelberg, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Ruprecht Karls University Heidelberg; Martin Luther University Halle Wittenberg; University of Tokyo; Osaka University; Ruprecht Karls University Heidelberg	Blattner, C (corresponding author), Karlsruhe Inst Technol, Inst Toxicol & Genet, POB 3640, D-76021 Karlsruhe, Baden Wurttembe, Germany.	gary.davidson@kit.edu; christine.blattner@kit.edu	Davidson, Gary/J-6059-2013; Blattner, Christine/ABI-2152-2020; Davidson, Gary/AAA-7321-2021; Wittbrodt, Joachim/D-4735-2014; Loosli, Felix/H-7415-2013; Blattner, Christine/H-2105-2013	Blattner, Christine/0000-0002-7250-5273; Davidson, Gary/0000-0002-2264-5518; Wittbrodt, Joachim/0000-0001-8550-7377; Blattner, Christine/0000-0002-7250-5273; Zhang, Ping/0000-0001-7063-7769	DFG [FOR 1036]; COST Action [BM1307]	DFG(German Research Foundation (DFG)); COST Action(European Cooperation in Science and Technology (COST))	We thank Germana Meroni (CBM S.c.r.l., Trieste) for the TRIM25 plasmid, Yi Su for help with the screening and Christina Bauer, Tanja Kuhn, Beate Heydel and Cathrin Herder for technical assistance. PZ was a CSC fellow. GD acknowledges the funding from the DFG (FOR 1036) for the screening experiments. This work is supported by COST Action BM1307.	Amsterdam A, 2004, P NATL ACAD SCI USA, V101, P12792, DOI 10.1073/pnas.0403929101; Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200; Bartel F, 2008, CLIN CANCER RES, V14, P89, DOI 10.1158/1078-0432.CCR-07-1192; Boehme KA, 2009, CRIT REV BIOCHEM MOL, V44, P367, DOI 10.3109/10409230903401507; Brooks CL, 2011, PROTEIN CELL, V2, P456, DOI 10.1007/s13238-011-1063-9; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Hurd C, 1999, ONCOGENE, V18, P1067, DOI 10.1038/sj.onc.1202398; Ikeda K, 2000, FEBS LETT, V472, P9, DOI 10.1016/S0014-5793(00)01421-6; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kulikov R, 2010, P NATL ACAD SCI USA, V107, P10038, DOI 10.1073/pnas.0911716107; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Loosli F, 1998, MECH DEVELOP, V74, P159, DOI 10.1016/S0925-4773(98)00055-0; Nakayama H, 2005, PATHOL INT, V55, P707, DOI 10.1111/j.1440-1827.2005.01900.x; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Okumura N, 2002, JPN J CANCER RES, V93, P867, DOI 10.1111/j.1349-7006.2002.tb01331.x; Orimo A, 1999, P NATL ACAD SCI USA, V96, P12027, DOI 10.1073/pnas.96.21.12027; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shimada N, 2004, MOL CELL ENDOCRINOL, V218, P147, DOI 10.1016/j.mce.2003.12.008; Solozobova V, 2010, EXP CELL RES, V316, P2434, DOI 10.1016/j.yexcr.2010.06.006; Souren M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r92; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Watanabe T, 2001, GYNECOL ONCOL, V81, P172, DOI 10.1006/gyno.2001.6132; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zou WG, 2006, J BIOL CHEM, V281, P3989, DOI 10.1074/jbc.M510787200	28	54	56	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5729	5738		10.1038/onc.2015.21	http://dx.doi.org/10.1038/onc.2015.21			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	25728675				2022-12-17	WOS:000364594600005
J	Han, F; Liu, W; Jiang, X; Shi, X; Yin, L; Ao, L; Cui, Z; Li, Y; Huang, C; Cao, J; Liu, J				Han, F.; Liu, W.; Jiang, X.; Shi, X.; Yin, L.; Ao, L.; Cui, Z.; Li, Y.; Huang, C.; Cao, J.; Liu, J.			SOX30, a novel epigenetic silenced tumor suppressor, promotes tumor cell apoptosis by transcriptional activating p53 in lung cancer	ONCOGENE			English	Article							COLORECTAL-CANCER; DNA METHYLATION; BH3-ONLY MEMBER; GENE; EXPRESSION; DEATH; BCL-2; NOXA; INHIBITION; MEDIATOR	Although members of SOX family have been well documented for their essential roles in embryonic development, cell proliferation and disease, the functional role and molecular mechanism of SOX30 in cancer are largely unexplored. Here, we first identified SRY-box containing gene 30 (SOX30) as a novel preferentially methylated gene using genome-wide methylation screening. SOX30 hypermethylation was detected in 100% of lung cancer cell lines (9/9) and 70.83% (85/120) of primary lung tumor tissues compared with none (0/20) of normal and 8.0% (2/25) of peri-tumoral lung tissues (P<0.01). SOX30 was expressed in normal and peri-tumoral lung tissues in which SOX30 was unmethylated, but was silenced or downregulated in lung cancer cell lines and primary lung tumor tissues harboring a hypermethylated SOX30. De-methylation experiments further confirmed that silence of SOX30 was regulated by its hypermethylation. Ectopic expression of SOX30 induces cancer cell apoptosis with inhibiting proliferation in vitro and represses tumor formation in vivo, whereas knockdown of SOX30 demonstrates a reversed effect both in vitro and in vivo. At the molecular level, the antitumorigenic effect of SOX30 is mediated by directly binding to CACTTTG (+115 to +121) of p53 promoter region and activating p53 transcription, suggesting that SOX30 is a novel transcriptional activating factor of p53. Indeed, blockade of p53 attenuates the tumor inhibition of SOX30. Overall, these findings demonstrate that SOX30 is a novel epigenetic silenced tumor suppressor acting through direct regulation of p53 transcription and expression. This study provides novel insights on the mechanism of tumorigenesis in lung cancer.	[Han, F.; Liu, W.; Jiang, X.; Shi, X.; Yin, L.; Ao, L.; Cui, Z.; Li, Y.; Cao, J.; Liu, J.] Third Mil Med Univ, Coll Prevent Med, Inst Toxicol, Chongqing 400038, Peoples R China; [Han, F.; Liu, W.; Jiang, X.; Shi, X.; Yin, L.; Ao, L.; Cui, Z.; Li, Y.; Cao, J.; Liu, J.] Minist Educ China, Key Lab Med Protect Electromagnet Radiat, Chongqing, Peoples R China; [Huang, C.] NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY USA	Army Medical University; Ministry of Education, China; New York University	Cao, J (corresponding author), Third Mil Med Univ, Coll Prevent Med, Inst Toxicol, 30 Gaotanyan St, Chongqing 400038, Peoples R China.	caojia1962@126.com; jinyiliutmmu@163.com	Han, Fei/AAH-2028-2020; Han, Fei/AAG-9260-2020	Han, Fei/0000-0002-0265-5487; Cui, Zhihong/0000-0001-9729-5375; Jiang, Xiao/0000-0001-8881-4890; Huang, Chuanshu/0000-0003-4133-5096	National Natural Science Foundation of China [81172714, 81071695]; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Natural Science Foundation of China (nos. 81172714 and 81071695).	Ballow D, 2006, DEV BIOL, V294, P161, DOI 10.1016/j.ydbio.2006.02.027; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chew LJ, 2009, J NEUROSCI RES, V87, P3277, DOI 10.1002/jnr.22128; Cronauer MV, 2004, ONCOGENE, V23, P3541, DOI 10.1038/sj.onc.1207346; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.t01-1-00220.x; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Gorgoulis VG, 2003, EMBO J, V22, P1567, DOI 10.1093/emboj/cdg157; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Gudkov AV, 2005, BIOCHEM BIOPH RES CO, V331, P726, DOI 10.1016/j.bbrc.2005.03.153; HALDAR S, 1994, CANCER RES, V54, P2095; Han F, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-98; HARPER JW, 1993, CELL, V75, P805; Hassan M, 2008, ONCOGENE, V27, P4557, DOI 10.1038/onc.2008.90; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Khare Sharad, 2012, Methods Mol Biol, V863, P177, DOI 10.1007/978-1-61779-612-8_10; Kim HR, 2013, J TOXICOL SCI, V38, P337, DOI 10.2131/jts.38.337; Liu WB, 2012, BIOCHEM BIOPH RES CO, V429, P180, DOI 10.1016/j.bbrc.2012.10.116; Liu WB, 2010, MOL CARCINOGEN, V49, P556, DOI 10.1002/mc.20621; Minguez B, 2011, DIS MARKERS, V31, P181, DOI [10.1155/2011/310675, 10.3233/DMA-2011-0841]; MIYASHITA T, 1995, CELL, V80, P293; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Osaki E, 1999, NUCLEIC ACIDS RES, V27, P2503, DOI 10.1093/nar/27.12.2503; Patai AV, 2012, DIGEST DIS, V30, P310, DOI 10.1159/000337004; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Suzuki S, 2009, CANCER SCI, V100, P759, DOI 10.1111/j.1349-7006.2009.01096.x; Tsao CM, 2012, HEPATOLOGY, V56, P2277, DOI 10.1002/hep.25933; Yang IV, 2011, AM J RESP CRIT CARE, V183, P1295, DOI 10.1164/rccm.201010-1579PP; Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103; Zitt M, 2007, DIS MARKERS, V23, P51, DOI 10.1155/2007/891967	41	54	57	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4391	4402		10.1038/onc.2014.370	http://dx.doi.org/10.1038/onc.2014.370			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25435374	hybrid, Green Published			2022-12-17	WOS:000359494400010
J	Zhao, S; Sedwick, D; Wang, Z				Zhao, S.; Sedwick, D.; Wang, Z.			Genetic alterations of protein tyrosine phosphatases in human cancers	ONCOGENE			English	Review							TUMOR-SUPPRESSOR GENE; CELL-CELL ADHESION; BLOOD-VESSEL DEVELOPMENT; BCR-ABL ONCOGENE; COLON-CANCER; PTP-MU; VE-PTP; BREAST-CANCER; FUNCTIONAL-CHARACTERIZATION; HOMOPHILIC BINDING	Protein tyrosine phosphatases (PTPs) are enzymes that remove phosphate from tyrosine residues in proteins. Recent whole- exome sequencing of human cancer genomes reveals that many PTPs are frequently mutated in a variety of cancers. Among these mutated PTPs, PTP receptor T (PTPRT) appears to be the most frequently mutated PTP in human cancers. Beside PTPN11, which functions as an oncogene in leukemia, genetic and functional studies indicate that most of mutant PTPs are tumor suppressor genes. Identification of the substrates and corresponding kinases of the mutant PTPs may provide novel therapeutic targets for cancers harboring these mutant PTPs.	[Zhao, S.] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Gastroenterol & Hepatol, Shanghai 200030, Peoples R China; [Zhao, S.] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Inst Digest Dis, Shanghai 200030, Peoples R China; [Zhao, S.; Wang, Z.] Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA; [Zhao, S.; Sedwick, D.; Wang, Z.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Sedwick, D.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Wang, Z (corresponding author), Case Western Reserve Univ, Genet & Genome Sci, 2103 Cornell Rd,WRB 3120, Cleveland, OH 44106 USA.	zxw22@case.edu			NIH [R01CA127590, P50CA150964, P30 CA043703]; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA127590, P50CA150964] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Susann Brady-Kalnay for critical reading of the manuscript. This work is supported by NIH grants R01CA127590, P50CA150964 and P30 CA043703.	Abaan OD, 2013, EXP CELL RES, V319, P1, DOI 10.1016/j.yexcr.2012.09.003; Agarwal S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062852; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Arora D, 2011, J BIOL CHEM, V286, P10918, DOI 10.1074/jbc.M110.205021; Au AC, 2010, AM J HUM GENET, V87, P436, DOI 10.1016/j.ajhg.2010.08.008; Aya-Bonilla C, 2013, GENE CHROMOSOME CANC, V52, P467, DOI 10.1002/gcc.22044; Baumer S, 2006, BLOOD, V107, P4754, DOI 10.1182/blood-2006-01-0141; Balavenkatraman KK, 2006, ONCOGENE, V25, P6319, DOI 10.1038/sj.onc.1209647; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Barr AJ, 2009, CELL, V136, P352, DOI 10.1016/j.cell.2008.11.038; Becka S, 2010, CELL COMMUN ADHES, V17, P34, DOI 10.3109/15419061.2010.487957; Behjati S, 2014, NAT GENET, V46, P376, DOI 10.1038/ng.2921; Bentires-Alj M, 2007, CANCER RES, V67, P2420, DOI 10.1158/0008-5472.CAN-06-4610; Besco JA, 2006, BRAIN RES, V1116, P50, DOI 10.1016/j.brainres.2006.07.122; Bowen ME, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002050; Brady-Kalnay SM, CELL ADHESION FRONTI, V39, P217; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; Broermann A, 2011, J EXP MED, V208, P2393, DOI 10.1084/jem.20110525; Brognard J, 2011, CURR OPIN GENET DEV, V21, P4, DOI 10.1016/j.gde.2010.10.012; Burden-Gulley SM, 2010, NEOPLASIA, V12, P305, DOI 10.1593/neo.91940; Burgoyne AM, 2009, CANCER RES, V69, P6960, DOI 10.1158/0008-5472.CAN-09-0863; Casagrande S, 2013, J PATHOL, V229, P525, DOI 10.1002/path.4107; Cox C, 2005, P NATL ACAD SCI USA, V102, P4542, DOI 10.1073/pnas.0408593102; Craig SEL, 2011, CANCER RES, V71, P303, DOI 10.1158/0008-5472.CAN-10-2301; Darnell JE, 2005, NAT MED, V11, P595, DOI 10.1038/nm0605-595; Dominguez MG, 2007, P NATL ACAD SCI USA, V104, P3243, DOI 10.1073/pnas.0611510104; Feng XJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100783; Flavell JR, 2008, BLOOD, V111, P292, DOI 10.1182/blood-2006-11-059881; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Freiss G, 2011, ANTI-CANCER AGENT ME, V11, P78, DOI 10.2174/187152011794941262; Funato K, 2011, EXP THER MED, V2, P457, DOI 10.3892/etm.2011.231; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; Giefing M, 2011, GENE CHROMOSOME CANC, V50, P154, DOI 10.1002/gcc.20840; Goel S, 2013, JNCI-J NATL CANCER I, V105, P1188, DOI 10.1093/jnci/djt164; Gunawardana J, 2014, NAT GENET, V46, P329, DOI 10.1038/ng.2900; Hagemann N, 2013, ONCOGENE, V32, P4602, DOI 10.1038/onc.2012.485; Hayashi M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2683; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; Hoover AC, 2009, ONCOGENE, V28, P3960, DOI 10.1038/onc.2009.251; Huang JM, 2013, ONCOGENE, V32, P2220, DOI 10.1038/onc.2012.231; Huang WQ, 2013, J BIOL CHEM, V288, P12766, DOI 10.1074/jbc.M112.429696; Huang WQ, 2013, LEUKEMIA LYMPHOMA, V54, P619, DOI 10.3109/10428194.2012.720979; Iervolino A, 2006, CANCER RES, V66, P6280, DOI 10.1158/0008-5472.CAN-06-0228; Iuliano R, 2004, ONCOGENE, V23, P8432, DOI 10.1038/sj.onc.1207766; Jiang YY, 2013, ONCOTARGET, V4, P884, DOI 10.18632/oncotarget.1021; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Kim YS, 2011, BIOCHEM BIOPH RES CO, V404, P96, DOI 10.1016/j.bbrc.2010.11.071; Kohno T, 2010, GENE CHROMOSOME CANC, V49, P342, DOI 10.1002/gcc.20746; Kuchay S, 2013, NAT CELL BIOL, V15, P472, DOI 10.1038/ncb2731; Laczmanska I, 2013, J HUM GENET, V58, P11, DOI 10.1038/jhg.2012.119; Lauriol J, 2011, TRENDS CARDIOVAS MED, V21, P97, DOI 10.1016/j.tcm.2012.03.006; Legius E, 2002, J MED GENET, V39, P571, DOI 10.1136/jmg.39.8.571; Lesueur F, 2005, HUM MOL GENET, V14, P2349, DOI 10.1093/hmg/ddi237; Lim SH, 2013, BIOCHEM BIOPH RES CO, V439, P40, DOI 10.1016/j.bbrc.2013.08.033; Liu Dong-Sheng, 2011, SENSORS, V11, P6494, DOI DOI 10.1109/W; Liu X, 2013, ONCOGENE, V32, P1266, DOI 10.1038/onc.2012.147; Liu X, 2012, CANCER RES, V72, P5296, DOI 10.1158/0008-5472.CAN-12-1495; Liu ZJ, 2014, CLIN CANCER RES, V20, P4598, DOI 10.1158/1078-0432.CCR-13-3380; Lucci MA, 2010, CELL ONCOL, V32, P361, DOI 10.3233/CLO-2010-0520; Lui VWY, 2014, P NATL ACAD SCI USA, V111, P1114, DOI 10.1073/pnas.1319551111; Luo L, 2006, CARCINOGENESIS, V27, P1153, DOI 10.1093/carcin/bgi354; Meehan M, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-6; Mellberg S, 2009, FASEB J, V23, P1490, DOI 10.1096/fj.08-123810; Michaloglou C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061916; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Nakamura M, 2003, CANCER RES, V63, P737; Nariai Y, 2011, INT J ORAL MAX SURG, V40, P419, DOI 10.1016/j.ijom.2010.10.020; Novellino L, 2008, CELL SIGNAL, V20, P872, DOI 10.1016/j.cellsig.2007.12.024; Omerovic J, 2010, BIOCHEM J, V426, P65, DOI 10.1042/BJ20091413; Ortiz B, 2014, P NATL ACAD SCI USA, V111, P8149, DOI 10.1073/pnas.1401952111; Paduano F, 2013, FEBS J, V280, P401, DOI 10.1111/j.1742-4658.2012.08624.x; Paduano F, 2012, ACS CHEM BIOL, V7, P1666, DOI 10.1021/cb300281t; Park AR, 2012, J CELL SCI, V125, P4518, DOI 10.1242/jcs.105502; Petermann A, 2011, BRAIN PATHOL, V21, P405, DOI 10.1111/j.1750-3639.2010.00464.x; Phillips-Mason PJ, 2014, J CELL BIOCHEM, V115, P1609, DOI 10.1002/jcb.24824; Phillips-Mason PJ, 2011, CELL ADHES MIGR, V5, P298, DOI 10.4161/cam.5.4.16970; Phillips-Mason PJ, 2011, J CELL BIOCHEM, V112, P39, DOI 10.1002/jcb.22710; Phillips-Mason PJ, 2008, J CELL BIOCHEM, V105, P1059, DOI 10.1002/jcb.21907; Purdie KJ, 2007, GENE CHROMOSOME CANC, V46, P661, DOI 10.1002/gcc.20447; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; SAP J, 1994, MOL CELL BIOL, V14, P1; Schickel R, 2010, MOL CELL, V38, P908, DOI 10.1016/j.molcel.2010.05.018; Scrima M, 2012, AM J PATHOL, V180, P1202, DOI 10.1016/j.ajpath.2011.11.038; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Solomon DA, 2008, CANCER RES, V68, P10300, DOI 10.1158/0008-5472.CAN-08-3272; Spanos WC, 2008, J VIROL, V82, P2493, DOI 10.1128/JVI.02188-07; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Trapasso F, 2004, CARCINOGENESIS, V25, P2107, DOI 10.1093/carcin/bgh224; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Trapasso F, 2006, DNA CELL BIOL, V25, P376, DOI 10.1089/dna.2006.25.376; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Venkatachalam R, 2010, GASTROENTEROLOGY, V139, P2221, DOI 10.1053/j.gastro.2010.08.063; Vermeer PD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030447; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577; Wang SE, 2005, MOL CELL BIOL, V25, P4703, DOI 10.1128/MCB.25.11.4703-4715.2005; Wang WQ, 2012, GENE DEV, V26, P1959, DOI 10.1101/gad.192955.112; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Wieckowski E, 2007, J CELL BIOCHEM, V100, P16, DOI 10.1002/jcb.20922; Winderlich M, 2009, J CELL BIOL, V185, P657, DOI 10.1083/jcb.200811159; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; Wyatt L, 2008, CELL CYCLE, V7, P2290, DOI 10.4161/cc.6443; Xiao ZY, 2010, WORLD J GASTROENTERO, V16, P112, DOI 10.3748/wjg.v16.i1.112; Xu YR, 2005, J BIOL CHEM, V280, P42694, DOI 10.1074/jbc.M507722200; Yang WT, 2013, NATURE, V499, P491, DOI 10.1038/nature12396; Ying J, 2006, LEUKEMIA, V20, P1173, DOI 10.1038/sj.leu.2404193; Yip SC, 2010, TRENDS BIOCHEM SCI, V35, P442, DOI 10.1016/j.tibs.2010.03.004; Yu JS, 2008, MOL CANCER RES, V6, P1106, DOI 10.1158/1541-7786.MCR-07-2123; Zhang P, 2013, ONCOGENE, V32, P2087, DOI 10.1038/onc.2012.220; Zhang P, 2011, MOL CANCER RES, V9, P1418, DOI 10.1158/1541-7786.MCR-11-0147; Zhang P, 2009, CELL COMMUN ADHES, V16, P146, DOI 10.3109/15419061003653771; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104; Zhao YQ, 2010, P NATL ACAD SCI USA, V107, P2592, DOI 10.1073/pnas.0914884107; Zheng H, 2013, J BIOL CHEM, V288, P25727, DOI 10.1074/jbc.M113.462291; Zhu JH, 2008, ONCOGENE, V27, P2525, DOI 10.1038/sj.onc.1210922	125	54	54	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3885	3894		10.1038/onc.2014.326	http://dx.doi.org/10.1038/onc.2014.326			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25263441	Green Accepted			2022-12-17	WOS:000358544200001
J	Liu, XD; Yao, J; Tripathi, DN; Ding, Z; Xu, Y; Sun, M; Zhang, J; Bai, S; German, P; Hoang, A; Zhou, L; Jonasch, D; Zhang, X; Conti, CJ; Efstathiou, E; Tannir, NM; Eissa, NT; Mills, GB; Walker, CL; Jonasch, E				Liu, X-D; Yao, J.; Tripathi, D. N.; Ding, Z.; Xu, Y.; Sun, M.; Zhang, J.; Bai, S.; German, P.; Hoang, A.; Zhou, L.; Jonasch, D.; Zhang, X.; Conti, C. J.; Efstathiou, E.; Tannir, N. M.; Eissa, N. T.; Mills, G. B.; Walker, C. L.; Jonasch, E.			Autophagy mediates HIF2 alpha degradation and suppresses renal tumorigenesis	ONCOGENE			English	Article							REGULATE AUTOPHAGY; CELL CARCINOMA; DIRECT BINDING; INHIBITION; UBIQUITIN; PROTEIN; P62; PHOSPHORYLATION; MECHANISMS; BECLIN-1	Autophagy is a conserved process involved in lysosomal degradation of protein aggregates and damaged organelles. The role of autophagy in cancer is a topic of intense debate, and the underlying mechanism is still not clear. The hypoxia-inducible factor 2 alpha (HIF2 alpha), an oncogenic transcription factor implicated in renal tumorigenesis, is known to be degraded by the ubiquitin-proteasome system (UPS). Here, we report that HIF2 alpha is in part constitutively degraded by autophagy. HIF2 alpha interacts with autophagy-lysosome system components. Inhibition of autophagy increases HIF2 alpha, whereas induction of autophagy decreases HIF2 alpha. The E3 ligase von Hippel-Lindau and autophagy receptor protein p62 are required for autophagic degradation of HIF2 alpha. There is a compensatory interaction between the UPS and autophagy in HIF2 alpha degradation. Autophagy inactivation redirects HIF2 alpha to proteasomal degradation, whereas proteasome inhibition induces autophagy and increases the HIF2 alpha-p62 interaction. Importantly, clear-cell renal cell carcinoma (ccRCC) is frequently associated with monoallelic loss and/or mutation of autophagy-related gene ATG7, and the low expression level of autophagy genes correlates with ccRCC progression. The protein levels of ATG7 and beclin 1 are also reduced in ccRCC tumors. This study indicates that autophagy has an anticancer role in ccRCC tumorigenesis, and suggests that constitutive autophagic degradation of HIF2 alpha is a novel tumor suppression mechanism.	[Liu, X-D; Sun, M.; Bai, S.; German, P.; Hoang, A.; Zhou, L.; Zhang, X.; Efstathiou, E.; Tannir, N. M.; Jonasch, E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, Houston, TX 77030 USA; [Yao, J.] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Tripathi, D. N.; Zhang, J.; Jonasch, D.; Walker, C. L.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA; [Ding, Z.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Xu, Y.; Eissa, N. T.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Conti, C. J.] Texas A&M Hlth Sci Ctr, Dept Mol & Cellular Med, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Jonasch, E (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, 1515 Holcombe Blvd, Houston, TX 77030 USA.	xliu10@mdanderson.org; ejonasch@mdanderson.org	Tripathi, Durga Nand/H-3247-2019	Tripathi, Durga Nand/0000-0001-8736-4808; Liu, xiande/0000-0002-9639-0458	Nanomedicine Roadmap Initiative Grant; Renee Kaye Cure Fur Cancer Grant; MD Anderson Cancer Center Kidney Cancer Research Program; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA143811] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [PN2EY016525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES023512] Funding Source: NIH RePORTER	Nanomedicine Roadmap Initiative Grant; Renee Kaye Cure Fur Cancer Grant; MD Anderson Cancer Center Kidney Cancer Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We acknowledge the TCGA Research network. This work was supported by the Nanomedicine Roadmap Initiative Grant, the Renee Kaye Cure Fur Cancer Grant and the MD Anderson Cancer Center Kidney Cancer Research Program.	Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188; Ding ZY, 2012, J BIOMOL SCREEN, V17, P572, DOI 10.1177/1087057112436557; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Guo GW, 2012, NAT GENET, V44, P17, DOI 10.1038/ng.1014; Hacker KE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003801; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hubbi ME, 2013, J BIOL CHEM, V288, P10703, DOI 10.1074/jbc.M112.414771; Jonasch E, 2012, MOL CANCER RES, V10, P859, DOI 10.1158/1541-7786.MCR-12-0117; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim J, 2009, CLIN CANCER RES, V15, P81, DOI 10.1158/1078-0432.CCR-08-0170; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu XD, 2012, J BIOL CHEM, V287, P19687, DOI 10.1074/jbc.M112.350934; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853; Prasad SR, 2006, RADIOGRAPHICS, V26, P1795, DOI 10.1148/rg.266065010; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Shen C, 2011, CANCER DISCOV, V1, P222, DOI 10.1158/2159-8290.CD-11-0098; Shinojima T, 2007, CARCINOGENESIS, V28, P529, DOI 10.1093/carcin/bgl143; Tripathi DN, 2013, P NATL ACAD SCI USA, V110, pE2950, DOI 10.1073/pnas.1307736110; Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	45	54	57	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2450	2460		10.1038/onc.2014.199	http://dx.doi.org/10.1038/onc.2014.199			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998849	Green Accepted			2022-12-17	WOS:000354190400004
J	Wan, C; Hou, S; Ni, R; Lv, L; Ding, Z; Huang, X; Hang, Q; He, S; Wang, Y; Cheng, C; Gu, XX; Xu, G; Shen, A				Wan, C.; Hou, S.; Ni, R.; Lv, L.; Ding, Z.; Huang, X.; Hang, Q.; He, S.; Wang, Y.; Cheng, C.; Gu, X. X.; Xu, G.; Shen, A.			MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability	ONCOGENE			English	Article						p27; hepatocellular carcinoma; cell cycle regulation; MIF4GD	DEPENDENT KINASE INHIBITOR; HISTONE MESSENGER-RNA; HEPATOCELLULAR-CARCINOMA; EXPRESSION; P27(KIP1); BINDING; PHOSPHORYLATION; CANCER; PROLIFERATION; TRANSLATION	The CDK inhibitor p27(kip1) plays crucial roles in cell cycle regulation and cancer progression. Through yeast two-hybrid screening, we identified MIF4G domain containing protein (MIF4GD) as a novel binding partner for p27. The association of MIF4GD and p27 was verified using immunoprecipitation and glutathione S-transferase (GST) pull-down assays. Interaction with MIF4GD led to the stabilization of p27 both in the nucleus and in the cytoplasm in hepatocellular carcinoma (HCC) cells as a result of suppressed phosphorylation of p27 by CDK2 at threonine187. Serum stimulation decreased the levels of MIF4GD and p27 simultaneously. In addition, MIF4GD overexpression resulted in increased p27 levels and reduced cell proliferation, while knockdown of MIF4GD promoted cell cycle progression with decreased p27 levels in cells. Furthermore, overexpression of MIF4GD reduced colony formation and inhibited xenograft tumor growth in nude mice. Finally, we found that both MIF4GD and p27 were expressed at low levels in HCC tissues compared to non-cancerous tissues, and that low expression levels of MIF4GD and p27 were associated with significantly worse prognosis in HCC patients. Our results suggest that MIF4GD is a potential regulator of p27-dependent cell proliferation in HCC. These findings provide a rational framework for the development of potential HCC therapy by targeting the MIF4GD-p27 interaction.	[Wan, C.; Xu, G.] Nantong Univ, Sch Publ Hlth, Nantong 226001, Peoples R China; [Hou, S.; Ni, R.; Lv, L.; Huang, X.] Nantong Univ, Dept Gastroenterol, Nantong 226001, Peoples R China; [Ding, Z.; Hang, Q.; He, S.; Wang, Y.; Cheng, C.; Gu, X. X.; Shen, A.] Nantong Univ, Dept Immunol, Nantong 226001, Peoples R China	Nantong University; Nantong University; Nantong University	Shen, A (corresponding author), Nantong Univ, Dept Immun, 19 Qixiu Rd, Nantong 226001, Peoples R China.	Shen_aiguo@yahoo.com	Hang, Qinglei/GOP-0218-2022	Hang, Qinglei/0000-0003-0419-6621; ni, runzhou/0000-0001-8187-185X	National Basic Research Program of China (973 Program) [2012CB822104, 2011CB910604]; National Natural Science Foundation of China [31070723, 31270802, 81272708, 81300720]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	We thank Professor Joel Belasco of New York University School of Medicine for the generous gift of pCL-6E1 and pCL-6E1. HSL constructs. This work was supported by Grants from National Basic Research Program of China (973 Program, No. 2012CB822104, and No. 2011CB910604), the National Natural Science Foundation of China (No. 31070723, No. 31270802, No. 81272708 and No. 81300720), and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Andrisani OM, 2011, SEMIN CANCER BIOL, V21, P4, DOI 10.1016/j.semcancer.2010.09.002; Bansal N, 2013, BIOCHEMISTRY-US, V52, P520, DOI 10.1021/bi301074r; Cakmakci NG, 2008, MOL CELL BIOL, V28, P1182, DOI 10.1128/MCB.01500-07; Chen L, 2010, J KOREAN MED SCI, V25, P1438, DOI 10.3346/jkms.2010.25.10.1438; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Coleman WB, 2003, CURR MOL MED, V3, P573, DOI 10.2174/1566524033479546; De Vita F, 2012, CELL CYCLE, V11, P1583, DOI 10.4161/cc.20003; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Finn RS, 2010, CLIN CANCER RES, V16, P390, DOI 10.1158/1078-0432.CCR-09-2084; Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178; Gorgoni B, 2005, RNA, V11, P1030, DOI 10.1261/rna.7281305; Greenbaum LE, 2004, CANCER BIOL THER, V3, P1200, DOI 10.4161/cbt.3.12.1392; He G, 2006, BRIT J CANCER, V95, P1514, DOI 10.1038/sj.bjc.6603448; Huang XD, 2011, HUM PATHOL, V42, P507, DOI 10.1016/j.humpath.2010.04.021; Ke Q, 2009, EXP MOL PATHOL, V87, P167, DOI 10.1016/j.yexmp.2009.07.011; Lee J, 2009, EXP MOL MED, V41, P765, DOI 10.3858/emm.2009.41.11.102; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Matsuda Y, 2008, WORLD J GASTROENTERO, V14, P1734, DOI 10.3748/wjg.14.1734; Motti ML, 2004, CELL CYCLE, V3, P1074; Naka T, 1998, ANTICANCER RES, V18, P555; Nakamura S, 2008, LEUKEMIA RES, V32, P1358, DOI 10.1016/j.leukres.2008.02.012; Nan KJ, 2004, WORLD J GASTROENTERO, V10, P1425; Narita T, 2007, MOL CELL, V26, P349, DOI 10.1016/j.molcel.2007.04.011; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Perez-Luna M, 2012, NUCLEIC ACIDS RES, V40, P6520, DOI 10.1093/nar/gks343; Pietras EM, 2011, J CELL BIOL, V195, P709, DOI 10.1083/jcb.201102131; Pippa R, 2012, ONCOGENE, V31, P4207, DOI 10.1038/onc.2011.582; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Qin J, 2010, HEPATO-GASTROENTEROL, V57, P547; Qin LF, 2001, CANCER LETT, V172, P7, DOI 10.1016/S0304-3835(01)00701-7; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sullivan E, 2001, GENE DEV, V15, P173, DOI 10.1101/gad.862801; Tannapfel A, 2000, INT J CANCER, V89, P350, DOI 10.1002/1097-0215(20000720)89:4<350::AID-IJC6>3.0.CO;2-3; Thun MJ, 2010, CARCINOGENESIS, V31, P100, DOI 10.1093/carcin/bgp263; Vervoorts J, 2008, CELL MOL LIFE SCI, V65, P3255, DOI 10.1007/s00018-008-8296-7; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Zhao XJ, 2004, J CELL SCI, V117, P6043, DOI 10.1242/jcs.01523; Zhao YH, 2013, HUM PATHOL, V44, P365, DOI 10.1016/j.humpath.2012.03.030; Zhou Q, 2003, WORLD J GASTROENTERO, V9, P2450	40	54	54	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					237	245		10.1038/onc.2013.536	http://dx.doi.org/10.1038/onc.2013.536			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24336329				2022-12-17	WOS:000347790500011
J	Wang, IC; Ustiyan, V; Zhang, Y; Cai, Y; Kalin, TV; Kalinichenko, VV				Wang, I-C; Ustiyan, V.; Zhang, Y.; Cai, Y.; Kalin, T. V.; Kalinichenko, V. V.			Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D)	ONCOGENE			English	Article						FOXM1; K-Ras; non-small-cell lung cancer; transgenic mice	K-RAS; RESPIRATORY EPITHELIUM; TUMOR-SUPPRESSOR; EXPRESSION; FORKHEAD; CANCER; GENE; ADENOCARCINOMAS; ACTIVATION; SIGNATURE	Lung cancer is the leading cause of deaths in cancer patients in the United States. Identification of new molecular targets is clearly needed to improve therapeutic outcomes of this devastating human disease. Activating mutations in K-Ras oncogene and increased expression of FOXM1 protein are associated with poor prognosis in patients with non-small-cell lung cancer. Transgenic expression of activated Kras(G12D) in mouse respiratory epithelium is sufficient to induce lung adenocarcinomas; however, transcriptional mechanisms regulated by K-Ras during the initiation of lung cancer remain poorly understood. Foxm1 transcription factor, a downstream target of K-Ras, stimulates cellular proliferation during embryogenesis, organ repair and tumor growth, but its role in tumor initiation is unknown. In the present study, we used transgenic mice expressing KrasG12D under control of Sftpc promoter to demonstrate that Foxm1 was induced in type II epithelial cells before the formation of lung tumors. Conditional deletion of Foxm1 from Kras(G12D)-expressing respiratory epithelium prevented the initiation of lung tumors in vivo. The loss of Foxm1 inhibited expression of K-Ras target genes critical for the nuclear factor-kappa B (NF-kappa B) and c-Jun N-terminal kinase (JNK) pathways, including Ikbkb, Nfkb1, Nfkb2, Rela, Jnk1, N-Myc, Pttg1 and Cdkn2a. Transgenic overexpression of activated FOXM1 mutant was sufficient to induce expression of these genes in alveolar type II cells. FOXM1 directly bound to promoter regions of Ikbkb, Nfkb2, N-Myc, Pttg1 and Cdkn2a, indicating that these genes are direct FOXM1 targets. FOXM1 is required for K-Ras-mediated lung tumorigenesis by activating genes critical for the NF-kB and JNK pathways.	[Wang, I-C; Ustiyan, V.; Zhang, Y.; Cai, Y.; Kalin, T. V.; Kalinichenko, V. V.] Cincinnati Childrens Hosp Res Fdn, Perinatal Inst, Div Pulm Biol, Cincinnati, OH 45229 USA; [Wang, I-C] Natl Tsing Hua Univ, Dept Life Sci, Hsinchu, Taiwan; [Wang, I-C] Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu, Taiwan	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; National Tsing Hua University; National Tsing Hua University	Kalinichenko, VV (corresponding author), Cincinnati Childrens Hosp Res Fdn, Perinatal Inst, Div Pulm Biol, 3333 Burnet Ave,MLC 7009, Cincinnati, OH 45229 USA.	Vladimir.Kalinichenko@cchmc.org		Wang, I-Ching/0000-0003-4398-2975	NIH [HL84151, CA142724]; Career Development Award from National Lung Cancer Partnership; National Science Council of Taiwan [102B0023V8]; Toward World-Class University Project of National Tsing Hua University [102N2052E1]; NATIONAL CANCER INSTITUTE [R01CA142724] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084151] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Career Development Award from National Lung Cancer Partnership; National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Toward World-Class University Project of National Tsing Hua University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Ron Pratt for technical support with microCT imaging and Craig Bolte for helpful comments. This work was supported by NIH grants HL84151 (VVK) and CA142724 (TVK), the Career Development Award from National Lung Cancer Partnership (I-CW), research grants from National Science Council of Taiwan 102B0023V8 (I-CW) and Toward World-Class University Project of National Tsing Hua University 102N2052E1 (I-CW).	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Ahn YH, 2011, MOL CELL BIOL, V31, P4270, DOI 10.1128/MCB.05562-11; Alberg AJ, 2003, CHEST, V123, p21S, DOI 10.1378/chest.123.1_suppl.21S; Behren A, 2010, ONCOGENE, V29, P1519, DOI 10.1038/onc.2009.436; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Cellurale C, 2011, MOL CELL BIOL, V31, P1565, DOI 10.1128/MCB.01122-10; Costa RH, 2005, CURR OPIN GENET DEV, V15, P42, DOI 10.1016/j.gde.2004.12.007; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Ihara Y, 2010, P NATL ACAD SCI USA, V107, P17309, DOI 10.1073/pnas.1001165107; Iwao K, 2001, INT J CANCER, V91, P433, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1059>3.0.CO;2-B; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kalin TV, 2011, CELL CYCLE, V10, P396, DOI 10.4161/cc.10.3.14709; Kalin TV, 2008, P NATL ACAD SCI USA, V105, P19330, DOI 10.1073/pnas.0806748105; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Magudia K, 2012, J CELL BIOL, V198, P185, DOI 10.1083/jcb.201202108; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Wang IC, 2008, ONCOGENE, V27, P4137, DOI 10.1038/onc.2008.60; Wang IC, 2008, J BIOL CHEM, V283, P20770, DOI 10.1074/jbc.M709892200; Wang IC, 2012, MOL CELL BIOL, V32, P3838, DOI 10.1128/MCB.00355-12; Wang IC, 2010, DEV BIOL, V347, P301, DOI 10.1016/j.ydbio.2010.08.027; Wang IC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006609; Watters JW, 2006, MOL CANCER THER, V5, P2444, DOI 10.1158/1535-7163.MCT-06-0340; Whitsett JA, 1998, BIOCHIM BIOPHYS ACTA, V19, P2; Whitsett JA, 2010, ANNU REV MED, V61, P105, DOI 10.1146/annurev.med.60.041807.123500; Zhou YH, 2010, NAT BIOTECHNOL, V28, P71, DOI 10.1038/nbt.1595	33	54	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5391	5396		10.1038/onc.2013.475	http://dx.doi.org/10.1038/onc.2013.475			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24213573				2022-12-17	WOS:000345120600009
J	Takwi, AA; Wang, YM; Wu, J; Michaelis, M; Cinatl, J; Chen, T				Takwi, A. A.; Wang, Y-M; Wu, J.; Michaelis, M.; Cinatl, J.; Chen, T.			miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells	ONCOGENE			English	Article						microRNA; constitutive androstane receptor; miR-137; MDR1; doxorubicin	MULTIDRUG-RESISTANCE; GENE-EXPRESSION; MICRORNA EXPRESSION; DRUG-RESISTANCE; PROMOTER METHYLATION; NUCLEAR RECEPTORS; LIVER-INJURY; IN-VIVO; AMPLIFICATION; INDUCTION	Chemotherapy is the most common treatment for cancer. However, multidrug resistance (MDR) remains a major obstacle to effective chemotherapy, limiting the efficacy of both conventional chemotherapeutic and novel biologic agents. The constitutive androstane receptor (CAR), a xenosensor, is a key regulator of MDR. It functions in xenobiotic detoxification by regulating the expression of phase I drug-metabolizing enzymes and ATP-binding cassette (ABC) transporters, whose overexpression in cancers and whose role in drug resistance make them potential therapeutic targets for reducing MDR. MicroRNAs (miRNAs) are endogenous negative regulators of gene expression and have been implicated in most cellular processes, including drug resistance. Here, we report the inversely related expression of miR-137 and CAR in parental and doxorubicin-resistant neuroblastoma cells, wherein miR-137 is downregulated in resistant cells. miR-137 overexpression resulted in downregulation of CAR protein and mRNA (via mRNA degradation); it sensitized doxorubicin-resistant cells to doxorubicin (as shown by reduced proliferation, increased apoptosis and increased G2-phase cell cycle arrest) and reduced the in vivo growth rate of neuroblastoma xenografts. We observed similar results in cellular models of hepatocellular and colon cancers, indicating that the doxorubicin-sensitizing effect of miR-137 is not tumor type-specific. Finally, we show for the first time a negative feedback loop whereby miR-137 downregulates CAR expression and CAR downregulates miR-137 expression. Hypermethylation of the miR-137 promoter and negative regulation of miR-137 by CAR contribute in part to reduced miR-137 expression and increased CAR and MDR1 expression in doxorubicin-resistant neuroblastoma cells. These findings demonstrate that miR-137 is a crucial regulator of cancer response to doxorubicin treatment, and they identify miR-137 as a highly promising target to reduce CAR-driven doxorubicin resistance.	[Takwi, A. A.; Wang, Y-M; Wu, J.; Chen, T.] St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA; [Michaelis, M.] Univ Kent, Sch Biosci, Canterbury, Kent, England; [Cinatl, J.] Clin Goethe Univ, Inst Med Virol, Frankfurt, Germany	St Jude Children's Research Hospital; University of Kent; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Chen, T (corresponding author), St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, 262 Danny Thomas Pl, Memphis, TN 38105 USA.	taosheng.chen@stjude.org	Chen, Taosheng/I-6351-2013; Wang, Yueming/B-4658-2015	Chen, Taosheng/0000-0001-6420-3809; Michaelis, Martin/0000-0002-5710-5888	American Lebanese Syrian Associated Charities (ALSAC); St Jude Children's Research Hospital (SJCRH); National Cancer Institute [P30CA027165]; National Institute of General Medical Sciences [GM086415]; Hilfe fur krebskranke Kinder Frankfurt eV; Frankfurter Stiftung fur krebskranke Kinder; Kent Cancer Trust; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086415] Funding Source: NIH RePORTER	American Lebanese Syrian Associated Charities (ALSAC)(American Lebanese Syrian Associated Charities (ALSAC)); St Jude Children's Research Hospital (SJCRH); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Hilfe fur krebskranke Kinder Frankfurt eV; Frankfurter Stiftung fur krebskranke Kinder; Kent Cancer Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs David Moore and Hongbing Wang for plasmids; the Flow Cytometry and Cell Sorting Shared Resource, the St Jude Animal Resources Center and Veterinary Pathology Core for technical assistance; other members of the Chen group and Drs Yong Li, John Schuetz, and Kip Guy for valuable discussions; and Sharon Naron for editing the manuscript. This work was supported by the American Lebanese Syrian Associated Charities (ALSAC), St Jude Children's Research Hospital (SJCRH), National Cancer Institute grant P30CA027165, National Institute of General Medical Sciences Grant GM086415, the Hilfe fur krebskranke Kinder Frankfurt eV, the Frankfurter Stiftung fur krebskranke Kinder, and the Kent Cancer Trust.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622; Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Baskin-Bey ES, 2006, HEPATOLOGY, V44, P252, DOI 10.1002/hep.21236; Beilke LD, 2009, TOXICOL LETT, V188, P38, DOI 10.1016/j.toxlet.2009.03.005; Bemis LT, 2008, CANCER RES, V68, P1362, DOI 10.1158/0008-5472.CAN-07-2912; Benbow U, 1999, CLIN CANCER RES, V5, P203; Blower PE, 2008, MOL CANCER THER, V7, P1, DOI 10.1158/1535-7163.MCT-07-0573; Boyer DS, 2002, AM J OPHTHALMOL, V133, P484; Bray I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007850; Brennecke J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-228; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Buckley PG, 2010, CLIN CANCER RES, V16, P2971, DOI 10.1158/1078-0432.CCR-09-3215; Charlet J, 2012, BIOCHEM PHARMACOL, V83, P858, DOI 10.1016/j.bcp.2012.01.009; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen QJ, 2011, DIGEST DIS SCI, V56, P2009, DOI 10.1007/s10620-010-1536-3; Chen T, 2010, J PHARMACOL EXP THER, V332, P106, DOI 10.1124/jpet.109.159210; Chen YK, 2012, BIOCHEM PHARMACOL, V83, P1112, DOI 10.1016/j.bcp.2012.01.030; Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667; Cherian MT, 2012, J BIOL CHEM, V287, P23368, DOI 10.1074/jbc.M112.344671; Cinatl J, 1996, INT J CANCER, V65, P90, DOI 10.1002/(SICI)1097-0215(19960103)65:1<90::AID-IJC16>3.0.CO;2-M; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Fabbri M, 2011, CURR OPIN HEMATOL, V18, P266, DOI 10.1097/MOH.0b013e3283476012; Faucette SR, 2006, J PHARMACOL EXP THER, V317, P1200, DOI 10.1124/jpet.105.098160; Fiebig AA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-213; Fojo T, 2007, DRUG RESIST UPDATE, V10, P59, DOI 10.1016/j.drup.2007.02.002; Haenisch S, 2012, EPIGENOMICS-UK, V4, P369, DOI [10.2217/EPI.12.39, 10.2217/epi.12.39]; Haldar Subrata, 2011, Mol Cell Pharmacol, V3, P135; HE L, 2004, NAT REV GENET, V5, P522; Hodzic J, 2011, NUCLEOS NUCLEOT NUCL, V30, P1214, DOI 10.1080/15257770.2011.629271; Ji M, 2009, BRIT J HAEMATOL, V145, P648, DOI 10.1111/j.1365-2141.2009.07678.x; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kotchetkov R, 2005, INT J ONCOL, V27, P1029; Kotchetkov R, 2003, INT J CANCER, V104, P36, DOI 10.1002/ijc.10917; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; KRISHAN A, 1980, CANCER RES, V40, P3895; KRISHAN A, 1985, CANCER RES, V45, P1046; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lahoti TS, 2012, CURR NEUROVASC RES, V9, P282; Langevin SM, 2011, CANCER-AM CANCER SOC, V117, P1454, DOI 10.1002/cncr.25689; Langevin SM, 2010, CARCINOGENESIS, V31, P864, DOI 10.1093/carcin/bgq051; Li Y, 2010, EUR J PHARMACOL, V640, P46, DOI 10.1016/j.ejphar.2010.05.017; Lin WW, 2008, J BIOL CHEM, V283, P30650, DOI 10.1074/jbc.M806132200; Liu JH, 2008, AM J PHYSIOL-HEART C, V295, pH1956, DOI 10.1152/ajpheart.00407.2008; Liu M, 2011, INT J CANCER, V128, P1269, DOI 10.1002/ijc.25452; Lu ZX, 2011, EMBO J, V30, P57, DOI 10.1038/emboj.2010.296; Lujambio A, 2007, CELL CYCLE, V6, P1455; Manohar CF, 2004, ONCOGENE, V23, P753, DOI 10.1038/sj.onc.1207151; Michaelis M, 2007, CANCER LETT, V250, P107, DOI 10.1016/j.canlet.2006.09.018; Michaelis M, 2009, CANCER RES, V69, P416, DOI 10.1158/0008-5472.CAN-08-1856; Moitra K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045268; Passetti F, 2009, PHARMACOGENOMICS J, V9, P1, DOI 10.1038/tpj.2008.14; Porro A, 2010, J BIOL CHEM, V285, P19532, DOI 10.1074/jbc.M109.078584; Porro A, 2010, CURR PHARM DESIGN, V16, P431, DOI 10.2174/138161210790232112; Schulte JH, 2010, INT J CANCER, V127, P2374, DOI 10.1002/ijc.25436; Shen F, 2008, J PHARMACOL EXP THER, V324, P95, DOI 10.1124/jpet.107.127704; St Clair S, 2004, MOL CELL, V16, P725; Tabe Y, 2006, BLOOD, V107, P1546, DOI 10.1182/blood-2004-10-4126; Takwi AAL, 2012, EMBO MOL MED, V4, P896, DOI 10.1002/emmm.201101045; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tojima H, 2012, TOXICOL LETT, V212, P288, DOI 10.1016/j.toxlet.2012.06.001; van Jaarsveld MTM, 2013, ONCOGENE, V32, P4284, DOI 10.1038/onc.2012.433; Venne A, 1996, CANCER RES, V56, P3626; Wang HB, 2003, J BIOL CHEM, V278, P14146, DOI 10.1074/jbc.M212482200; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Zhang J, 2002, SCIENCE, V298, P422, DOI 10.1126/science.1073502; Zhao YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039102	71	54	59	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3717	3729		10.1038/onc.2013.330	http://dx.doi.org/10.1038/onc.2013.330			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23934188	Green Accepted			2022-12-17	WOS:000338942900011
J	Tallet, A; Nault, JC; Renier, A; Hysi, I; Galateau-Salle, F; Cazes, A; Copin, MC; Hofman, P; Andujar, P; Le Pimpec-Barthes, F; Zucman-Rossi, J; Jaurand, MC; Jean, D				Tallet, A.; Nault, J-C; Renier, A.; Hysi, I.; Galateau-Salle, F.; Cazes, A.; Copin, M-C; Hofman, P.; Andujar, P.; Le Pimpec-Barthes, F.; Zucman-Rossi, J.; Jaurand, M-C; Jean, D.			Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma	ONCOGENE			English	Article						thoracic neoplasm; mesothelioma; asbestos; telomere; telomerase reverse transcriptase; mutation	INDUCED MURINE; TELOMERASE; SUPPRESSION; MECHANISMS; EXPRESSION; PROFILES; SUBUNIT; CELLS; BAP1	Malignant pleural mesothelioma (MPM) is a very aggressive tumor with no known curative treatment. Better knowledge of the molecular mechanisms of mesothelial carcinogenesis is required to develop new therapeutic strategies. MPM, like all cancer cells, needs to maintain telomere length to prevent senescence. Previous studies suggested that the telomere lengthening mechanism in MPM is based mainly on telomerase activity. For this reason, we focused on the key catalytic enzyme, TERT (telomerase reverse transcriptase), by analyzing its gene expression in MPM and by studying the mechanism underlying its upregulation. We used our large collection of MPM composed of 61 MPM in culture and 71 frozen MPM tumor samples. Evaluation of TERT mRNA expression by quantitative RT-PCR showed overexpression in MPM in culture compared with normal mesothelial cells, and in MPM tumor samples compared with normal pleura. We identified a 'hot spot' of mutations in the TERT gene core promoter in both MPM in culture and in MPM tumor samples with an overall frequency of 15%. Furthermore, data clearly identified mutation in the TERT promoter as a mechanism of TERT mRNA upregulation in MPM. In contrast, gene copy number amplification was not associated with TERT overexpression. Then, we analyzed the clinicopathological, etiological and genetic characteristics of MPM with mutations in the TERT promoter. TERT promoter mutations were more frequent in MPM with sarcomatoid histologic subtype (P<0.01), and they were frequently associated with CDKN2A gene inactivation (P = 0.03). In conclusion, a subgroup of MPM presents TERT promoter mutations, which lead to TERT mRNA upregulation. This is the first recurrent gain-of-function oncogenic mutations identified in MPM.	[Tallet, A.; Nault, J-C; Renier, A.; Le Pimpec-Barthes, F.; Zucman-Rossi, J.; Jaurand, M-C; Jean, D.] INSERM, UMR 674, IUH, F-75010 Paris, France; [Tallet, A.; Nault, J-C; Renier, A.; Le Pimpec-Barthes, F.; Zucman-Rossi, J.; Jaurand, M-C; Jean, D.] Univ Paris 05, Labex Immunooncol, Sorbonne Paris Cite, Fac Med, Paris, France; [Hysi, I.] CHRU Lille, Serv Chirurg Card, F-59037 Lille, France; [Galateau-Salle, F.] CHU Caen, Serv Anatomopathol, F-14000 Caen, France; [Galateau-Salle, F.] INSERM, U1086, Caen, France; [Cazes, A.] Hop Europeen Georges Pompidou, AP HP, GHU Ouest, Anat Pathol Lab, Paris, France; [Copin, M-C] Univ Lille 2, CHRU Lille, Inst Pathol, Ctr Biol Pathol, Lille, France; [Hofman, P.] CHU Nice, Hop Louis Pasteur, Lab Pathol Clin & LPCE & Biobanque Humaine, F-06202 Nice, France; [Andujar, P.] Ctr Hosp Intercommunal Creteil, Serv Pneumol & Pathol Profess, Creteil, France; [Andujar, P.] Hop Henri Mondor, INSERM, U955, Equipe 4, F-94010 Creteil, France; [Le Pimpec-Barthes, F.] Hop Europe Georges Pompidou, AP HP, GHU Ouest, Serv Chirurg Thorac, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; CHU de Caen NORMANDIE; Universite de Caen Normandie; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; Universite de Lille; CHU Nice; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Jean, D (corresponding author), INSERM, UMR S 674, 27 Rue Juliette Dodu, F-75010 Paris, France.	didier.jean@inserm.fr	Hofman, Paul/P-7654-2018; Jean, Didier/A-1615-2009; j, zucman-rossi/AAV-3594-2021; Salle, Francoise BJ Galateau/J-1530-2015; JAURAND, MARIE-CLAUDE/S-3538-2017; Le+Pimpec-Barthes, Francoise/ABD-1300-2021; zucman-rossi, Jessica/B-5098-2009; Andujar, Pascal/A-2395-2013	Hofman, Paul/0000-0003-0431-9353; Jean, Didier/0000-0001-5823-7404; j, zucman-rossi/0000-0002-5687-0334; Salle, Francoise BJ Galateau/0000-0003-3642-0165; JAURAND, MARIE-CLAUDE/0000-0002-0915-6728; zucman-rossi, Jessica/0000-0002-5687-0334; Le Pimpec-Barthes, Francoise/0000-0001-6364-4813; nault, jean charles/0000-0002-4875-9353; Andujar, Pascal/0000-0002-9408-7033	INSERM; University of Paris-Descartes; French League against Cancer (Ligue Nationale Contre le Cancer); 'Carte d'Identite des Tumeurs' CIT1 program; 'Carte d'Identite des Tumeurs' CIT2 program; Chancellerie des Universite ' s de Paris (Legs POIX); Comite de l'Oise	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University of Paris-Descartes; French League against Cancer (Ligue Nationale Contre le Cancer); 'Carte d'Identite des Tumeurs' CIT1 program; 'Carte d'Identite des Tumeurs' CIT2 program; Chancellerie des Universite ' s de Paris (Legs POIX); Comite de l'Oise	This work was supported by funds and grants from INSERM, the University of Paris-Descartes, the French League against Cancer (Ligue Nationale Contre le Cancer, 'Carte d'Identite des Tumeurs' CIT1 and CIT2 programs and the Comite ' de l'Oise) and the Chancellerie des Universite ' s de Paris (Legs POIX).	Andujar P, 2013, MUTAGENESIS, V28, P323, DOI 10.1093/mutage/get008; Andujar P, 2010, LUNG CANCER, V67, P23, DOI 10.1016/j.lungcan.2009.03.018; Au AYM, 2011, LUNG CANCER, V73, P283, DOI 10.1016/j.lungcan.2010.12.023; Bazarov AV, 2010, AGING CELL, V9, P736, DOI 10.1111/j.1474-9726.2010.00599.x; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; Cao Y, 2008, CANCER SCI, V99, P1092, DOI 10.1111/j.1349-7006.2008.00815.x; Cesare AJ, 2010, NAT REV GENET, V11, P319, DOI 10.1038/nrg2763; Chretien JB J, 1985, PLEURA HLTH DIS, P23; Daniel M, 2012, GENE, V498, P135, DOI 10.1016/j.gene.2012.01.095; Dhaene K, 1998, THORAX, V53, P915, DOI 10.1136/thx.53.11.915; Ganem NJ, 2012, J CELL BIOL, V199, P871, DOI 10.1083/jcb.201210040; Gladych M, 2011, BIOCHEM CELL BIOL, V89, P359, DOI 10.1139/O11-037; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Huang SXL, 2011, J TOXICOL ENV HEAL B, V14, P179, DOI 10.1080/10937404.2011.556051; Husain AN, 2009, ARCH PATHOL LAB MED, V133, P1317, DOI 10.1043/1543-2165-133.8.1317; Jasani B, 2012, ARCH PATHOL LAB MED, V136, P262, DOI 10.5858/arpa.2011-0039-RA; Jean D, 2012, ARCH PATHOL LAB MED, V136, P277, DOI 10.5858/arpa.2011-0215-RA; Jean D, 2011, AM J PATHOL, V178, P881, DOI 10.1016/j.ajpath.2010.10.039; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Kumaki F, 2002, AM J SURG PATHOL, V26, P365, DOI 10.1097/00000478-200203000-00011; Larsson LG, 2011, SEMIN CANCER BIOL, V21, P367, DOI 10.1016/j.semcancer.2011.10.005; Lecomte C, 2005, CELL CYCLE, V4, P1862, DOI 10.4161/cc.4.12.2300; Mutsaers SE, 2002, RESPIROLOGY, V7, P171, DOI 10.1046/j.1440-1843.2002.00404.x; RAMAEL M, 1995, HISTOL HISTOPATHOL, V10, P639; Shen XH, 2013, INT IMMUNOPHARMACOL, V16, P261, DOI 10.1016/j.intimp.2013.04.003; Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912; Villa R, 2008, CLIN CANCER RES, V14, P4134, DOI 10.1158/1078-0432.CCR-08-0099; ZENG L, 1993, INT J CANCER, V55, P515, DOI 10.1002/ijc.2910550331	30	54	54	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3748	3752		10.1038/onc.2013.351	http://dx.doi.org/10.1038/onc.2013.351			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23975423	Green Submitted			2022-12-17	WOS:000338942900014
J	Feng, H; Hu, B; Vuori, K; Sarkaria, JN; Furnari, FB; Cavenee, WK; Cheng, SY				Feng, H.; Hu, B.; Vuori, K.; Sarkaria, J. N.; Furnari, F. B.; Cavenee, W. K.; Cheng, S-Y			EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180	ONCOGENE			English	Article						glioblastomas; EGFRvIII; Dock180; phosphorylation; PKA	PROTEIN-KINASE-A; CELL-MIGRATION; LIVING CELLS; RAC; GLIOBLASTOMA; ACTIVATION; GEF; TUMORIGENESIS; PATHWAY; COMPLEX	Glioblastomas (GBMs), the most common and malignant brain tumors, are highly resistant to current therapies. The failure of targeted therapies against aberrantly activated oncogenic signaling, such as that of the EGFR-PI3K/Akt pathway, underscores the urgent need to understand alternative downstream pathways and to identify new molecular targets for the development of more effective treatments for gliomas. Here, we report that EGFRvIII (Delta EGFR/de2-7EGFR), a constitutively active EGFR mutant that is frequently co-overexpressed with EGFR in clinical GBM tumors, promotes glioma growth and invasion through protein kinase A (PKA)-dependent phosphorylation of Dock180, a bipartite guanine nucleotide exchange factor (GEF) for Rac1. We demonstrate that EGFRvIII induces serine phosphorylation of Dock180, stimulates Rac1 activation and glioma cell migration. Treatments of glioma cells using the PKA inhibitors H-89 and KT5720, overexpression of a PKA inhibitor (PKI), and in vitro PKA kinase assays show that EGFRvIII induction of serine phosphorylation of Dock180 is PKA-dependent. Significantly, PKA induces phosphorylation of Dock180 at amino acid residue S1250 that resides within its Rac1-activating DHR-2 domain. Expression of the Dock180(S1250L) mutant, but not wild type Dock180(WT), protein in EGFRvIII-expressing glioma cells inhibited receptor-stimulated cell proliferation, survival, migration in vitro and glioma tumor growth and invasion in vivo. Together, our findings describe a novel mechanism by which EGFRvIII drives glioma tumorigenesis and invasion through PKA-dependent phosphorylation of Dock180, thereby suggesting that targeting EGFRvIII-PKA-Dock180-Rac1 signaling axis could provide a novel pathway to develop potential therapeutic strategies for malignant gliomas.	[Feng, H.; Hu, B.; Cheng, S-Y] Northwestern Univ, Feinberg Sch Med, Northwestern Brain Tumor Inst, Dept Neurol, Chicago, IL 60611 USA; [Feng, H.; Hu, B.; Cheng, S-Y] Northwestern Univ, Ctr Genet Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Feng, H.; Hu, B.; Cheng, S-Y] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA; [Feng, H.] Shanghai Jiao Tong Univ, Renji Hosp, Stem Cell Res Ctr, Sch Med, Shanghai 200030, Peoples R China; [Vuori, K.] Sanford Burnham Med Res Inst, La Jolla, CA USA; [Sarkaria, J. N.; Cavenee, W. K.] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA; [Furnari, F. B.] Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, La Jolla, CA 92093 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Shanghai Jiao Tong University; Sanford Burnham Prebys Medical Discovery Institute; Mayo Clinic; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Hu, B (corresponding author), Northwestern Univ, Feinberg Sch Med, Northwestern Brain Tumor Inst, Dept Neurol, Chicago, IL 60611 USA.	bo.hu@northwestern.edu; shiyuan.cheng@northwestern.edu	Feng, Haizhong/E-5795-2017	Feng, Haizhong/0000-0003-3552-6865; Furnari, Frank/0000-0003-1909-4361	University of Pittsburgh Cancer Institute; NIH [CA130966, CA158911]; Northwestern Brain Tumor Institute; Department of Neurology at Northwestern University Feinberg School of Medicine; Zell Scholar Award from the Zell Family Foundation; Brain Cancer Research; Pennsylvania Department of Health; Innovative Research Scholar Awards of the Hillman Foundation; NATIONAL CANCER INSTITUTE [P30CA030199, R01CA159811, R01CA130966] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS080939] Funding Source: NIH RePORTER	University of Pittsburgh Cancer Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Northwestern Brain Tumor Institute; Department of Neurology at Northwestern University Feinberg School of Medicine; Zell Scholar Award from the Zell Family Foundation; Brain Cancer Research; Pennsylvania Department of Health; Innovative Research Scholar Awards of the Hillman Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Most of the studies (and all the animal studies) were performed at the University of Pittsburgh in accordance with a protocol approved by the IACUC of the University of Pittsburgh. We acknowledge the support of University of Pittsburgh Cancer Institute and various core facilities. We also thank M Matsuda, R Tsien, E van Meir and Y Zhou for providing reagents, and Angel Alvarez for proofreading of this manuscript. WK Cavenee is a Fellow of the National Foundation for Cancer Research. This work was supported in part by a NIH grant CA130966, CA158911 to S-Y Cheng, a Zell Scholar Award from the Zell Family Foundation and funds from Northwestern Brain Tumor Institute and Department of Neurology at Northwestern University Feinberg School of Medicine to S-Y Cheng; Brain Cancer Research Awards from the James S McDonnell Foundation to B Hu and F Furnari; a grant with the Pennsylvania Department of Health, and Innovative Research Scholar Awards of the Hillman Foundation to S-Y Cheng and B Hu.	Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Cai XM, 2005, INT J CANCER, V117, P905, DOI 10.1002/ijc.21251; Chahdi A, 2005, J BIOL CHEM, V280, P578, DOI 10.1074/jbc.M411130200; Chahdi A, 2008, MOL CELL BIOL, V28, P1679, DOI 10.1128/MCB.00898-07; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cote JF, 2007, TRENDS CELL BIOL, V17, P383, DOI 10.1016/j.tcb.2007.05.001; de Farias CB, 2008, ONCOLOGY-BASEL, V75, P27, DOI 10.1159/000151616; Duchek P, 2001, SCIENCE, V291, P131, DOI 10.1126/science.291.5501.131; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Feng HZ, 2012, P NATL ACAD SCI USA, V109, P3018, DOI 10.1073/pnas.1121457109; Feng HZ, 2011, J CLIN INVEST, V121, P4670, DOI 10.1172/JCI58559; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Grimsley CM, 2004, J BIOL CHEM, V279, P6087, DOI 10.1074/jbc.M307087200; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jarzynka NJ, 2007, CANCER RES, V67, P7203, DOI 10.1158/0008-5472.CAN-07-0473; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Ku BM, 2011, MOL CELLS, V31, P275, DOI 10.1007/s10059-011-0027-5; Liu KW, 2011, J CLIN INVEST, V121, P905, DOI 10.1172/JCI43690; Martin BR, 2007, CHEM BIOL, V14, P1031, DOI 10.1016/j.chembiol.2007.07.017; Meiri D, 2009, MOL CELL BIOL, V29, P5963, DOI 10.1128/MCB.01268-08; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; Paulucci-Holthauzen AA, 2009, J BIOL CHEM, V284, P5956, DOI 10.1074/jbc.M805606200; Payner T, 2006, MOL CANCER THER, V5, P1817, DOI 10.1158/1535-7163.MCT-05-0548; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Raymond E, 2000, DRUGS, V60, P15, DOI 10.2165/00003495-200060001-00002; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wykosky Jill, 2011, Chin J Cancer, V30, P5; Yang BC, 2003, J IMMUNOL, V171, P3947, DOI 10.4049/jimmunol.171.8.3947; Yiin JJ, 2010, MOL CANCER THER, V9, P929, DOI 10.1158/1535-7163.MCT-09-0953	33	54	56	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2504	2512		10.1038/onc.2013.198	http://dx.doi.org/10.1038/onc.2013.198			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23728337	Green Accepted			2022-12-17	WOS:000336033600010
J	Mora-Blanco, EL; Mishina, Y; Tillman, EJ; Cho, YJ; Thom, CS; Pomeroy, SL; Shao, W; Roberts, CWM				Mora-Blanco, E. L.; Mishina, Y.; Tillman, E. J.; Cho, Y-J; Thom, C. S.; Pomeroy, S. L.; Shao, W.; Roberts, C. W. M.			Activation of beta-catenin/TCF targets following loss of the tumor suppressor SNF5	ONCOGENE			English	Article						chromatin remodeling; tumor suppressor; Swi/Snf; beta-catenin; epigenetics	CHROMATIN REMODELING COMPLEXES; GENOMIC INSTABILITY; BINDING REGIONS; RHABDOID TUMORS; MULTIPLE ROLES; CANCER; DIFFERENTIATION; TUMORIGENESIS; MUTATIONS; CELLS	The SWI/SNF chromatin remodeling complex is a master regulator of developmental cell-fate decisions, although the key target pathways are poorly characterized. Here, we interrogated the contribution of the SWI/SNF subunit and tumor suppressor SNF5 to the regulation of developmental pathways using conditional mouse and cell culture models. We find that loss of SNF5 phenocopies beta-catenin hyperactivation and that SNF5 is essential for regulating Wnt/beta-catenin pathway target expression. These data provide insight into chromatin-based mechanisms that underlie developmental regulation and elucidate the emerging theme that mutation of this tumor suppressor complex can activate developmental pathways by uncoupling them from upstream control.	[Mora-Blanco, E. L.; Tillman, E. J.; Thom, C. S.; Roberts, C. W. M.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Mora-Blanco, E. L.; Tillman, E. J.; Thom, C. S.; Roberts, C. W. M.] Harvard Univ, Sch Med, Dept Pediat, Div Hematol Oncol,Childrens Hosp Boston, Boston, MA 02115 USA; [Mishina, Y.; Shao, W.] Novartis Inst Biomed Res, Cambridge, MA USA; [Cho, Y-J; Pomeroy, S. L.] Childrens Hosp Boston, Dept Neurol, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Novartis; Harvard University; Boston Children's Hospital	Roberts, CWM (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave, Boston, MA 02115 USA.	Charles_Roberts@dfci.harvard.edu	Roberts, Charles/N-2541-2018	Roberts, Charles/0000-0003-1135-1896; Tillman, Erik/0000-0003-3599-0297	National Cancer Institute, National Institutes of Health [1F31CA130553, R01CA113794, U01-1156106]; Stand Up 2 Cancer Innovative Research Grant; The Garrett B Smith Foundation; Cure AT/RT; Miles for Mary; NATIONAL CANCER INSTITUTE [R01CA109467, R01CA113794, F31CA130553] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Stand Up 2 Cancer Innovative Research Grant; The Garrett B Smith Foundation; Cure AT/RT; Miles for Mary; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank ES McKenna for critical reading of the manuscript and A Lassar for helpful discussions. The in situ probe constructs were generously provided by C Tabin (Harvard Medical School). This work was supported in part by National Cancer Institute, National Institutes of Health Pre-Doctoral NRSA award 1F31CA130553 (ELMB), R01CA113794 (CWMR) and U01-1156106 (Stuart H Orkin). CWM R is a recipient of a Stand Up 2 Cancer Innovative Research Grant. Miles for Mary, The Garrett B Smith Foundation and Cure AT/RT Now provided additional support.	Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Biegel JA, 1999, CANCER RES, V59, P74; Bottomly D, 2010, NUCLEIC ACIDS RES, V38, P5735, DOI 10.1093/nar/gkq363; Chi TH, 2003, IMMUNITY, V19, P169, DOI 10.1016/S1074-7613(03)00199-7; Chien AJ, 2009, J INVEST DERMATOL, V129, P1614, DOI 10.1038/jid.2008.445; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Collins RT, 2000, GENE DEV, V14, P3140, DOI 10.1101/gad.854300; Curtis CD, 2012, MOL CELL BIOL, V32, P1312, DOI 10.1128/MCB.06222-11; DasGupta R, 1999, DEVELOPMENT, V126, P4557; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; Ettenberg SA, 2010, P NATL ACAD SCI USA, V107, P15473, DOI 10.1073/pnas.1007428107; Gresh L, 2005, EMBO J, V24, P3313, DOI 10.1038/sj.emboj.7600802; Griffin CT, 2011, P NATL ACAD SCI USA, V108, P2282, DOI 10.1073/pnas.1013751108; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Hill TP, 2006, DEVELOPMENT, V133, P1219, DOI 10.1242/dev.02298; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Ho L, 2010, NATURE, V463, P474, DOI 10.1038/nature08911; Hu MC, 2005, DEVELOPMENT, V132, P215, DOI 10.1242/dev.01573; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Jagani Z, 2010, NAT MED, V16, P1429, DOI 10.1038/nm.2251; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Lee RS, 2012, J CLIN INVEST, V122, P2983, DOI 10.1172/JCI64400; Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092; Mahmoudi T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000539; McKenna ES, 2008, MOL CELL BIOL, V28, P6223, DOI 10.1128/MCB.00658-08; McKenna ES, 2009, CELL CYCLE, V8, P23, DOI 10.4161/cc.8.1.7290; Miller KA, 2007, DEV BIOL, V311, P665, DOI 10.1016/j.ydbio.2007.07.022; Ngo-Muller V, 2000, DEV BIOL, V219, P224, DOI 10.1006/dbio.2000.9612; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wilson BG, 2010, CANCER CELL, V18, P316, DOI 10.1016/j.ccr.2010.09.006	38	54	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					933	938		10.1038/onc.2013.37	http://dx.doi.org/10.1038/onc.2013.37			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23435428	Green Accepted			2022-12-17	WOS:000331626900015
J	Gujral, TS; Karp, RL; Finski, A; Chan, M; Schwartz, PE; MacBeath, G; Sorger, P				Gujral, T. S.; Karp, R. L.; Finski, A.; Chan, M.; Schwartz, P. E.; MacBeath, G.; Sorger, P.			Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays	ONCOGENE			English	Article						reverse-phase protein arrays; breast cancer; tumor lysate; cell signaling; MET; AXL	C-MET; HGF TRANSCRIPTION; AXL; RECEPTOR; PATHWAYS; METASTASIS; RESISTANCE; DISCOVERY; SURVIVAL; KINASE	Measuring the states of cell signaling pathways in tumor samples promises to advance the understanding of oncogenesis and identify response biomarkers. Here, we describe the use of Reverse Phase Protein Arrays (RPPAs or RPLAs) to profile signaling proteins in 56 breast cancers and matched normal tissue. In RPPAs, hundreds to thousands of lysates are arrayed in dense regular grids and each grid is probed with a different antibody (100 in the current work, of which 71 yielded strong signals with breast tissue). Although RPPA technology is quite widely used, measuring changes in phosphorylation reflective of protein activation remains challenging. Using repeat deposition and well-validated antibodies, we show that diverse patterns of phosphorylation can be monitored in tumor samples and changes mapped onto signaling networks in a coherent fashion. The patterns are consistent with biomarker-based classification of breast cancers and known mechanisms of oncogenesis. We explore in detail one tumor-associated pattern that involves changes in the abundance of the Axl receptor tyrosine kinase (RTK) and phosphorylation of the cMet RTK. Both cMet and Axl have been implicated in breast cancer, or in resistance to anticancer drugs, but the two RTKs are not known to be linked functionally. Protein depletion and overexpression studies in a 'triple-negative' breast cell line reveal cross talk between Axl and cMet involving Axl-mediated modification of cMet, a requirement for cMet in efficient and timely signal transduction by the Axl ligand Gas6 and the potential for the two receptors to interact physically. These findings have potential therapeutic implications, as they imply that bi-specific receptor inhibitors (for example, ATP-competitive small-kinase inhibitors such as GSK1363089, BMS-777607 or MP470) may be more efficacious than the mono-specific therapeutic antibodies currently in development (for example, Onartuzumab).	[Gujral, T. S.; Karp, R. L.; Finski, A.; Chan, M.; MacBeath, G.; Sorger, P.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; [Gujral, T. S.; MacBeath, G.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; [Finski, A.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; [Schwartz, P. E.] Prot Biotechnol Inc, Ramona, CA USA	Harvard University; Harvard Medical School; Harvard University; Harvard University	MacBeath, G (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, WAB 438,200 Longwood Ave, Boston, MA 02115 USA.	gavin_macbeath@hms.harvard.edu; peter_sorger@hms.harvard.edu		Sorger, Peter/0000-0002-3364-1838; Gujral, Taran/0000-0002-4453-3031	National Institutes of Health [R33 CA128726, R21 CA126720, 5RC1-HG005354]; Stand Up to Cancer Project [AACR-SU2C-DT0409]; NSF [0856285]; NATIONAL CANCER INSTITUTE [R21CA126720, R33CA128726] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [RC1HG005354] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stand Up to Cancer Project; NSF(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This study was supported by grants from the National Institutes of Health (R33 CA128726, R21 CA126720, and 5RC1-HG005354) and from the Stand Up to Cancer Project (AACR-SU2C-DT0409). TSG is a Human Frontier Science Program Fellow. RLK is partially supported by NSF 0856285. Supplementary Information accompanies the paper on the Oncogene website.	Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bowers PM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r35; Burstein HJ, 2003, J CLIN ONCOL, V21, P2889, DOI 10.1200/JCO.2003.02.018; Carey MS, 2010, CLIN CANCER RES, V16, P2852, DOI 10.1158/1078-0432.CCR-09-2502; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Goentoro L, 2009, MOL CELL, V36, P872, DOI 10.1016/j.molcel.2009.11.017; Gonzalez-Angulo Ana M, 2011, Clin Proteomics, V8, P11, DOI 10.1186/1559-0275-8-11; Grubb RL, 2003, PROTEOMICS, V3, P2142, DOI 10.1002/pmic.200300598; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hennessy Bryan T, 2010, Clin Proteomics, V6, P129, DOI 10.1007/s12014-010-9055-y; Herrero J, 2001, BIOINFORMATICS, V17, P126, DOI 10.1093/bioinformatics/17.2.126; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; ISOLA JJ, 1993, J PATHOL, V170, P31, DOI 10.1002/path.1711700106; Janes KA, 2008, CELL, V135, P343, DOI 10.1016/j.cell.2008.08.034; Jiang RC, 2006, PROTEOMICS, V6, P2964, DOI 10.1002/pmic.200500555; Kataoka Y, 2012, INVEST NEW DRUG, V30, P1352, DOI 10.1007/s10637-011-9699-0; Kolch W, 2010, NAT REV CANCER, V10, P618, DOI 10.1038/nrc2900; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; Lim CT, 2007, BIOSENS BIOELECTRON, V22, P1197, DOI 10.1016/j.bios.2006.06.005; Lin Y, 2003, CLIN CHEM LAB MED, V41, P139, DOI 10.1515/CCLM.2003.023; Liu GG, 2010, ADV EXP MED BIOL, V680, P253, DOI 10.1007/978-1-4419-5913-3_29; Luckert K, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002372; Mackiewicz M, 2011, BREAST CANCER RES TR, V130, P663, DOI 10.1007/s10549-011-1690-0; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Makretsov NA, 2004, CLIN CANCER RES, V10, P6143, DOI 10.1158/1078-0432.CCR-04-0429; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Menashe I, 2010, CANCER RES, V70, P4453, DOI 10.1158/0008-5472.CAN-09-4502; Mood K, 2006, MOL BIOL CELL, V17, P3717, DOI 10.1091/mbc.e06-03-0244; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Nanjundan M, 2010, J THORAC ONCOL, V5, P1894, DOI 10.1097/JTO.0b013e3181f2a266; Nishizuka S, 2003, P NATL ACAD SCI USA, V100, P14229, DOI 10.1073/pnas.2331323100; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Pe'er D, 2011, CELL, V144, P864, DOI 10.1016/j.cell.2011.03.001; Previdi S, 2012, MOL CANCER THER, V11, P214, DOI 10.1158/1535-7163.MCT-11-0277; Sam MR, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-69; Sevecka M, 2006, NAT METHODS, V3, P825, DOI 10.1038/nmeth931; Sevecka M, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.005363; Shankavaram UT, 2007, MOL CANCER THER, V6, P820, DOI 10.1158/1535-7163.MCT-06-0650; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spruessel A, 2004, BIOTECHNIQUES, V36, P1030, DOI 10.2144/04366RR04; Storey John D, 2003, Methods Mol Biol, V224, P149; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Underiner TL, 2010, ANTI-CANCER AGENT ME, V10, P7, DOI 10.2174/1871520611009010007; VanMeter A, 2007, EXPERT REV MOL DIAGN, V7, P625, DOI 10.1586/14737159.7.5.625; Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wojcik EJ, 2006, ONCOGENE, V25, P2773, DOI 10.1038/sj.onc.1209306; Yeh CY, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-139; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661	54	54	56	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2013	32	29					3470	3476		10.1038/onc.2012.378	http://dx.doi.org/10.1038/onc.2012.378			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22945653	Green Accepted			2022-12-17	WOS:000322014900008
J	Hong, SW; Lee, SH; Moon, JH; Hwang, JJ; Kim, DE; Ko, E; Kim, HS; Cho, IJ; Kang, JS; Kim, DJ; Kim, JE; Shin, JS; Jung, DJ; Jeong, YJ; Cho, BJ; Kim, TW; Lee, JS; Kang, JS; Hwang, YI; Noh, DY; Jin, DH; Lee, WJ				Hong, S-W; Lee, S-H; Moon, J-H; Hwang, J. J.; Kim, D. E.; Ko, E.; Kim, H-S; Cho, I. J.; Kang, J. S.; Kim, D. J.; Kim, J-E; Shin, J-S; Jung, D-J; Jeong, Y-J; Cho, B-J; Kim, T-W; Lee, J. S.; Kang, J-S; Hwang, Y-I; Noh, D-Y; Jin, D-H; Lee, W. J.			SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment	ONCOGENE			English	Article						L-ascorbate; autophagy; SVCT-2; ROS; Beclin-1; LC3	VITAMIN-C TRANSPORTER; TERMINAL HUMAN CANCER; SUPPLEMENTAL ASCORBATE; SUPPORTIVE TREATMENT; HYDROGEN-PEROXIDE; SURVIVAL TIMES; ACID; CELLS; AUTOPHAGY; GROWTH	L-ascorbate (L-ascorbic acid, vitamin C) clearly has an inhibitory effect on cancer cells. However, the mechanism underlying differential sensitivity of cancer cells from same tissue to L-ascorbate is yet to be clarified. Here, we demonstrate that L-ascorbate has a selective killing effect, which is influenced by sodium-dependent vitamin C transporter 2 (SVCT-2) in human breast cancer cells. Treatment of human breast cancer cells with L-ascorbate differentially induced cell death, dependent on the SVCT-2 protein level. Moreover, knockdown of endogenous SVCT-2 via RNA interference in breast cancer cells expressing high levels of the protein induced resistance to L-ascorbate treatment, whereas transfection with SVCT-2 expression plasmids led to enhanced L-ascorbate chemosensitivity. Surprisingly, tumor regression by L-ascorbate administration in mice bearing tumor cell xenograft also corresponded to the SVCT-2 protein level. Interestingly, SVCT-2 expression was absent or weak in normal tissues, but strongly detected in tumor samples obtained from breast cancer patients. In addition, enhanced chemosensitivity to L-ascorbate occurred as a result of caspase-independent autophagy, which was mediated by beclin-1 and LC3 II. In addition, treatment with N-acetyl-L-cysteine, a reactive oxygen species (ROS) scavenger, suppressed the induction of beclin-1 and LC3 II, implying that the differential SVCT-2 protein-dependent L-ascorbate uptake was attributable to intracellular ROS induced by L-ascorbate, subsequently leading to autophagy. These results suggest that functional SVCT-2 sensitizes breast cancer cells to autophagic damage by increasing the L-ascorbate concentration and intracellular ROS production and furthermore, SVCT-2 in breast cancer may act as an indicator for commencing L-ascorbate treatment. Oncogene (2013) 32, 1508-1517; doi:10.1038/onc.2012.176; published online 4 June 2012	[Hong, S-W; Lee, S-H; Kim, J-E; Shin, J-S; Jung, D-J; Jeong, Y-J; Kang, J-S; Hwang, Y-I; Jin, D-H; Lee, W. J.] Seoul Natl Univ, Coll Med, Dept Anat, Seoul, South Korea; [Hong, S-W; Lee, S-H; Kim, J-E; Shin, J-S; Jung, D-J; Jeong, Y-J; Kang, J-S; Hwang, Y-I; Jin, D-H; Lee, W. J.] Seoul Natl Univ, Coll Med, Tumor Immun Res Ctr, Seoul, South Korea; [Hong, S-W; Moon, J-H; Hwang, J. J.; Kim, D. E.; Shin, J-S; Kim, T-W; Lee, J. S.; Jin, D-H] Univ Ulsan, Coll Med, Asan Med Ctr, Inst Innovat Canc Res, Seoul 138736, South Korea; [Lee, S-H] Inje Univ, Paik Hosp, Dept Plast & Reconstruct Surg, Gyeonggi Do, South Korea; [Ko, E.; Kim, H-S; Noh, D-Y] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea; [Ko, E.; Kim, H-S; Noh, D-Y] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Cho, I. J.; Kang, J. S.] Korea Res Insit Biosci & Biotechnol, Bioevaluat Ctr, Chungbuk, South Korea; [Kim, D. J.] Chung Ang Univ, Coll Med, Dept Anat, Seoul 156756, South Korea; [Cho, B-J] Konkuk Univ, Konkuk Univ Hosp, Sch Med, Dept Ophthalmol, Seoul, South Korea; [Cho, B-J; Kim, T-W; Lee, J. S.] Asan Med Ctr, Dept Oncol, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); University of Ulsan; Asan Medical Center; Inje University; Seoul National University (SNU); Seoul National University (SNU); Chung Ang University; Chung Ang University Hospital; Konkuk University; Konkuk University Medical Center; University of Ulsan; Asan Medical Center	Jin, DH (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Inst Innovat Canc Res, Seoul 138736, South Korea.	inno183@amc.seoul.kr; kinglee@snu.ac.kr	Kang, Jae Seung/J-5363-2012; Hwang, Jung Jin/F-3424-2014; Noh, Dong-Young/G-5531-2011	Kang, Jong Soon/0000-0001-7698-0162	Korean Science and Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University College of Medicine [R13-2002-025-02001-0]; Ministry of Health and Welfare and Family Affairs, Republic of Korea [A062254]	Korean Science and Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University College of Medicine(Korea Science and Engineering Foundation); Ministry of Health and Welfare and Family Affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This work was supported by Korean Science and Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University College of Medicine (R13-2002-025-02001-0) and by grants from the Korea Health 21 R&D Project, Ministry of Health and Welfare and Family Affairs, Republic of Korea (A062254). We would like to thank Dr Norio Itoh, Osaka University, for providing SVCT-2 antibody; and Dr Tobias P Dick, German Cancer Research Center, for providing redox-probe cDNAs.	Baader SL, 1996, FEBS LETT, V381, P131, DOI 10.1016/0014-5793(96)00098-1; CAMERON E, 1976, P NATL ACAD SCI USA, V73, P3685, DOI 10.1073/pnas.73.10.3685; CAMERON E, 1978, P NATL ACAD SCI USA, V75, P4538, DOI 10.1073/pnas.75.9.4538; CAMERON E, 1974, CHEM-BIOL INTERACT, V9, P285, DOI 10.1016/0009-2797(74)90019-2; Chen AA, 2009, CARCINOGENESIS, V30, P977, DOI 10.1093/carcin/bgp076; Chen Q, 2005, P NATL ACAD SCI USA, V102, P13604, DOI 10.1073/pnas.0506390102; Chen Q, 2008, P NATL ACAD SCI USA, V105, P11105, DOI 10.1073/pnas.0804226105; CREAGAN ET, 1979, NEW ENGL J MED, V301, P687, DOI 10.1056/NEJM197909273011303; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; Halliwell B, 1996, FREE RADICAL RES, V25, P439, DOI 10.3109/10715769609149066; Head K A, 1998, Altern Med Rev, V3, P174; Jung MS, 2004, J BIOL CHEM, V279, P17765, DOI 10.1074/jbc.M305015200; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kang JS, 2005, J CELL PHYSIOL, V204, P192, DOI 10.1002/jcp.20286; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kuo SM, 2004, J NUTR, V134, P2216; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Maramag C, 1997, PROSTATE, V32, P188, DOI 10.1002/(SICI)1097-0045(19970801)32:3<188::AID-PROS5>3.0.CO;2-H; Martin A, 2002, J NEUROCHEM, V82, P538, DOI 10.1046/j.1471-4159.2002.00978.x; MENNITI FS, 1986, J BIOL CHEM, V261, P6901; MOERTEL CG, 1985, NEW ENGL J MED, V312, P137, DOI 10.1056/NEJM198501173120301; MURAD S, 1981, P NATL ACAD SCI-BIOL, V78, P2879, DOI 10.1073/pnas.78.5.2879; Ohtani S, 2007, CANCER RES, V67, P6293, DOI 10.1158/0008-5472.CAN-06-3884; Ouyang YB, 2002, FREE RADICAL BIO MED, V33, P544, DOI 10.1016/S0891-5849(02)00912-7; Padayatty SJ, 2000, J AM COLL NUTR, V19, P423, DOI 10.1080/07315724.2000.10718941; Patak P, 2004, ENDOCR RES, V30, P871, DOI 10.1081/ERC-200044126; PETERKOFSKY B, 1977, J CELL PHYSIOL, V90, P61, DOI 10.1002/jcp.1040900109; Reidling JC, 2008, AM J PHYSIOL-GASTR L, V295, pG1217, DOI 10.1152/ajpgi.90399.2008; SCHAUS EE, 1986, BIOCHEM MED METAB B, V36, P369, DOI 10.1016/0885-4505(86)90149-0; Takanaga H, 2004, PFLUG ARCH EUR J PHY, V447, P677, DOI 10.1007/s00424-003-1104-1; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; Wang HP, 1999, BBA-BIOMEMBRANES, V1461, P1, DOI 10.1016/S0005-2736(99)00182-0	32	54	56	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 21	2013	32	12					1508	1517		10.1038/onc.2012.176	http://dx.doi.org/10.1038/onc.2012.176			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22665050				2022-12-17	WOS:000316456000004
J	Taccioli, C; Chen, H; Jiang, Y; Liu, XP; Huang, K; Smalley, KJ; Farber, JL; Croce, CM; Fong, LY				Taccioli, C.; Chen, H.; Jiang, Y.; Liu, X. P.; Huang, K.; Smalley, K. J.; Farber, J. L.; Croce, C. M.; Fong, L. Y.			Dietary zinc deficiency fuels esophageal cancer development by inducing a distinct inflammatory signature	ONCOGENE			English	Article						inflammation; esophageal squamous cell carcinoma; zinc deficiency; transcriptome profiling	NF-KAPPA-B; SQUAMOUS-CELL CARCINOMA; EXPRESSION; PROGRESSION; S100A8; GENES; NITROSOMETHYLBENZYLAMINE; SUPPLEMENTATION; OVEREXPRESSION; CARCINOGENESIS	Chronic inflammation is implicated in the pathogenesis of esophageal squamous cell carcinoma (ESCC). The causes of inflammation in ESCC, however, are undefined. Dietary zinc (Zn)-deficiency (ZD) increases the risk of ESCC. We have previously shown that short-term ZD (6 weeks) in rats induces overexpression of the proinflammatory mediators S100a8 and S100a9 in the esophageal mucosa with accompanying esophageal epithelial hyperplasia. Here we report that prolonged ZD (21 weeks) in rats amplified this inflammation that when combined with non-carcinogenic low doses of the environmental carcinogen, N-nitrosomethylbenzylamine (NMBA) elicited a 66.7% (16/24) incidence of ESCC. With Zn-sufficiency, NMBA produced no cancers (0/21) (P<0.001). At tumor endpoint, the neoplastic ZD esophagus, as compared with Zn-sufficient esophagus, had an inflammatory gene signature with upregulation of numerous cancer-related inflammation genes (CXC and CC chemokines, chemokine receptors, cytokines and Cox-2) in addition to S100a8 and S100a9. This signature was already activated in the earlier dysplastic stage. Additionally, time-course bioinformatics analysis of expression profiles at tumor endpoint and before NMBA exposure revealed that this sustained inflammation was due to ZD rather than carcinogen exposure. Importantly, Zn replenishment reversed this inflammatory signature at both the dysplastic and neoplastic stages of ESCC development, and prevented cancer formation. Thus, the molecular definition of ZD-induced inflammation as a critical factor in ESCC development has important clinical implications with regard to development and prevention of this deadly disease.	[Chen, H.; Jiang, Y.; Fong, L. Y.] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA; [Taccioli, C.; Liu, X. P.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Smalley, K. J.; Fong, L. Y.] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Farber, J. L.] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Jefferson University; Jefferson University	Fong, LY (corresponding author), Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Room 420,Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	louise.fong@jefferson.edu	Taccioli, Cristian/ABC-3379-2020; Smalley, Karl/AGF-1390-2022; Young, Richard A/F-6495-2012; Huang, Kun/E-3272-2011; Taccioli, Cristian/F-8801-2010	Taccioli, Cristian/0000-0003-2995-5612; Young, Richard A/0000-0001-8855-8647; Taccioli, Cristian/0000-0003-2995-5612; Chen, Hongping/0000-0002-1670-5449; Smalley, Karl J./0000-0003-1502-6759; Fong, Louise/0000-0001-7654-7035	NIH [R01CA118560, R01CA115965]; NATIONAL CANCER INSTITUTE [R01CA118560, R01CA115965] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Kay Huebner (The Ohio State University) for reading and critical discussion of the manuscript. We thank Shao-gui Wan's assistance with animal care and validation of the array data. The microarray data were submitted to ArrayExpress (Accession number: E-MTAB-428). This work was supported by NIH grants R01CA118560 (LYYF) and R01CA115965 (CMC).	Abnet CC, 2005, JNCI-J NATL CANCER I, V97, P301, DOI 10.1093/jnci/dji042; Allavena P, 2011, EXP CELL RES, V317, P664, DOI 10.1016/j.yexcr.2010.11.013; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Cintorino M, 2001, ANTICANCER RES, V21, P4195; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fong LYY, 2011, CARCINOGENESIS, V32, P554, DOI 10.1093/carcin/bgr004; Fong LYY, 2005, J NATL CANCER I, V97, P40, DOI 10.1093/jnci/dji006; Fong LYY, 2001, JNCI-J NATL CANCER I, V93, P1525, DOI 10.1093/jnci/93.20.1525; Gebhardt C, 2006, BIOCHEM PHARMACOL, V72, P1622, DOI 10.1016/j.bcp.2006.05.017; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Ho E, 2002, P NATL ACAD SCI USA, V99, P16770, DOI 10.1073/pnas.222679399; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kaifi JT, 2005, J NATL CANCER I, V97, P1840, DOI 10.1093/jnci/dji431; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; KMET J, 1972, SCIENCE, V175, P846, DOI 10.1126/science.175.4024.846; Kumar A, 2007, INT J CANCER, V120, P230, DOI 10.1002/ijc.22246; LOZANO JC, 1994, MOL CARCINOGEN, V9, P33, DOI 10.1002/mc.2940090107; MAGEE PN, 1989, CANCER SURV, V8, P207; Mandard AM, 2000, MUTAT RES-REV MUTAT, V462, P335, DOI 10.1016/S1383-5742(00)00019-3; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Miyazaki H, 2006, CANCER RES, V66, P4279, DOI 10.1158/0008-5472.CAN-05-4398; Nemeth J, 2009, HEPATOLOGY, V50, P1251, DOI 10.1002/hep.23099; PEGG AE, 1984, CANCER INVEST, V2, P223, DOI 10.3109/07357908409104376; Poschl G, 2004, ALCOHOL ALCOHOLISM, V39, P155, DOI 10.1093/alcalc/agh057; Prasad AS, 2002, CANCER METAST REV, V21, P291, DOI 10.1023/A:1021215111729; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Rink L, 2007, TRENDS IMMUNOL, V28, P1, DOI 10.1016/j.it.2006.11.005; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; STINSON SF, 1978, JNCI-J NATL CANCER I, V61, P1471; Stoner GD, 2001, CARCINOGENESIS, V22, P1737, DOI 10.1093/carcin/22.11.1737; Sun J, 2011, CARCINOGENESIS, V32, P351, DOI 10.1093/carcin/bgq251; Taccioli C, 2009, GASTROENTEROLOGY, V136, P953, DOI 10.1053/j.gastro.2008.11.039; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wang B, 2006, CANCER RES, V66, P3071, DOI 10.1158/0008-5472.CAN-05-2871; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yamamoto K, 2004, EXP TOXICOL PATHOL, V56, P145, DOI 10.1016/j.etp.2004.07.001; YANG CS, 1980, CANCER RES, V40, P2633; Zimmermann KC, 1999, CANCER RES, V59, P198	47	54	58	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	42					4550	4558		10.1038/onc.2011.592	http://dx.doi.org/10.1038/onc.2011.592			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22179833	Green Submitted, Green Accepted			2022-12-17	WOS:000309982100006
J	Pippa, R; Espinosa, L; Gundem, G; Garcia-Escudero, R; Dominguez, A; Orlando, S; Gallastegui, E; Saiz, C; Besson, A; Pujol, MJ; Lopez-Bigas, N; Paramio, JM; Bigas, A; Bachs, O				Pippa, R.; Espinosa, L.; Gundem, G.; Garcia-Escudero, R.; Dominguez, A.; Orlando, S.; Gallastegui, E.; Saiz, C.; Besson, A.; Pujol, M. J.; Lopez-Bigas, N.; Paramio, J. M.; Bigas, A.; Bachs, O.			p27(Kip1) represses transcription by direct interaction with p130/E2F4 at the promoters of target genes	ONCOGENE			English	Article						p27; p130; E2F4; transcription	CELL-CYCLE KINASES; CDK INHIBITOR P27; MICE LACKING; EXPRESSION; CANCER; MIGRATION; PROTEINS; DIFFERENTIATION; LEUKEMIA; PHOSPHORYLATION	The cyclin-cdk (cyclin-dependent kinase) inhibitor p27(Kip1) (p27) has a crucial negative role on cell cycle progression. In addition to its classical role as a cyclin-cdk inhibitor, it also performs cyclin-cdk-independent functions as the regulation of cytoskeleton rearrangements and cell motility. p27 deficiency has been associated with tumor aggressiveness and poor clinical outcome, although the mechanisms underlying this participation still remain elusive. We report here a new cellular function of p27 as a transcriptional regulator in association with p130/E2F4 complexes that could be relevant for tumorigenesis. We observed that p27 associates with specific promoters of genes involved in important cellular functions as processing and splicing of RNA, mitochondrial organization and respiration, translation and cell cycle. On these promoters p27 co-localizes with p130, E2F4 and co-repressors as histone deacetylases (HDACs) and mSIN3A. p27 co-immunoprecipitates with these proteins and by affinity chromatography, we demonstrated a direct interaction of p27 with p130 and E2F4 through its carboxyl-half. We have also shown that p130 recruits p27 on the promoters, and there p27 is needed for the subsequent recruitment of HDACs and mSIN3A. Expression microarrays and luciferase assays revealed that p27 behaves as transcriptional repressor of these p27-target genes (p27-TGs). Finally, in human tumors, we established a correlation with overexpression of p27-TGs and poor survival. Thus, this new function of p27 as a transcriptional repressor could have a role in the major aggressiveness of tumors with low levels of p27. Oncogene (2012) 31, 4207-4220; doi:10.1038/onc.2011.582; published online 19 December 2011	[Espinosa, L.; Bigas, A.] Hosp Mar, Inst Municipal Invest Med, Barcelona, Spain; [Gundem, G.; Lopez-Bigas, N.] Univ Pompeu Fabra, Catalan Inst Res & Adv Studies ICREA, Dept Expt & Hlth Sci, Res Unit Biomed Informat, Barcelona, Spain; [Garcia-Escudero, R.; Saiz, C.] CIEMAT, Div Biomed, Mol Oncol Unit, E-28040 Madrid, Spain; [Besson, A.] Canc Res Ctr Toulouse, INSERM, UMR1037, Toulouse, France; [Pippa, R.; Dominguez, A.; Orlando, S.; Gallastegui, E.; Pujol, M. J.; Bachs, O.] Univ Barcelona, IDIBAPS, Dept Cell Biol Immunol & Neurosci, E-08036 Barcelona, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; ICREA; Pompeu Fabra University; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bachs, O (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Fac Med, Dept Cell Biol Immunol & Neurosci, Casanova 143, E-08036 Barcelona, Spain.	obachs@ub.edu	Paramio, Jesus M/M-8482-2014; Lopez-Bigas, Nuria/F-6193-2011; Gasull, Martina/J-4076-2019; Bigas, Anna/A-7457-2014; Pippa, Raffaella/J-4566-2012; Espinosa, Lluis/ABA-4564-2020; Garcia-Escudero, Ramon/A-2735-2012; Besson, Arnaud/J-6254-2014; Orlando, Serena/AAA-7963-2019	Paramio, Jesus M/0000-0001-7520-3177; Lopez-Bigas, Nuria/0000-0003-4925-8988; Pippa, Raffaella/0000-0002-1028-6511; Espinosa, Lluis/0000-0002-2897-4099; Garcia-Escudero, Ramon/0000-0001-5640-6542; Besson, Arnaud/0000-0002-9599-3943; Saiz Ladera, Cristina/0000-0001-8094-5992; Bigas, Anna/0000-0003-4801-6899	Ministerio de Ciencia y Tecnologia of Spain [SAF2006-05212, SAF2009-07769, SAF2009-06954]; Fondo de Investigacion Sanitaria [PI070778]; Instituto de Salud Carlos III (RETICS) [RD06/0020/0010, RD06/0020/0029, RD06/0020/0098]; Comunidad Autonoma de Madrid (Oncocycle Program) [S2006/BIO-0232]; Generalitat de Catalunya [SGR 09-1382]; AGAUR of the Catalonian Government; Association pour la recherche sur le Cancer; Ligue Nationale Contre le Cancer; Institue National du Cancer; ICREA Funding Source: Custom	Ministerio de Ciencia y Tecnologia of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Fondo de Investigacion Sanitaria(Instituto de Salud Carlos III); Instituto de Salud Carlos III (RETICS)(Instituto de Salud Carlos III); Comunidad Autonoma de Madrid (Oncocycle Program); Generalitat de Catalunya(Generalitat de Catalunya); AGAUR of the Catalonian Government(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Association pour la recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Institue National du Cancer; ICREA(ICREA)	We thank Dr Anxo Vidal for p27<SUP>Delta 51</SUP>- MEF cells; Dr Antonio Giordano for p130 pGEX plasmids; Dr Xavier Mayol for GST-E2F4 vector; and Dr Alan Cassady for the pGL2b plasmid. This work was supported by the Ministerio de Ciencia y Tecnologia of Spain (grants SAF2006-05212 and SAF2009-07769 to OB and SAF2009-06954 to NL-B; the Fondo de Investigacion Sanitaria (grant PI070778 to LE), the Instituto de Salud Carlos III (RETICS RD06/0020/0010 to OB, RD06/0020/0029 to JP and RD06/0020/0098 to A. Bigas), the Comunidad Autonoma de Madrid (Oncocycle Program grant S2006/BIO-0232 to JP) and the Generalitat de Catalunya (grant SGR 09-1382 to OB). GG is supported by a fellowship from AGAUR of the Catalonian Government. AB is supported by grants from the Association pour la recherche sur le Cancer, Ligue Nationale Contre le Cancer and Institue National du Cancer.	Acosta JC, 2008, MOL CELL BIOL, V28, P7286, DOI 10.1128/MCB.00752-08; Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Blain SW, 2008, CELL CYCLE, V7, P892, DOI 10.4161/cc.7.7.5637; Blanco E, 2006, PLOS COMPUT BIOL, V2, P403, DOI 10.1371/journal.pcbi.0020049; Brune V, 2008, J EXP MED, V205, P2251, DOI 10.1084/jem.20080809; Carter BZ, 2006, CELL CYCLE, V5, P2223, DOI 10.4161/cc.5.19.3255; Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Flicek P, 2008, NUCLEIC ACIDS RES, V36, pD707, DOI 10.1093/nar/gkm988; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Gundem G, 2010, NAT METHODS, V7, P92, DOI 10.1038/nmeth0210-92; Gutierrez NC, 2007, LEUKEMIA, V21, P541, DOI 10.1038/sj.leu.2404520; Hollenhorst PC, 2007, GENE DEV, V21, P1882, DOI 10.1101/gad.1561707; Huszar D, 2009, CANCER METAST REV, V28, P197, DOI 10.1007/s10555-009-9185-8; James MK, 2008, MOL CELL BIOL, V28, P498, DOI 10.1128/MCB.02171-06; Jones MH, 2004, LANCET, V363, P775, DOI 10.1016/S0140-6736(04)15693-6; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Lopez-Bigas N, 2008, MOL CELL, V31, P520, DOI 10.1016/j.molcel.2008.08.004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macaluso M, 2006, ONCOGENE, V25, P5263, DOI 10.1038/sj.onc.1209680; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2007, CURR OPIN GENET DEV, V17, P60, DOI 10.1016/j.gde.2006.12.008; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Munoz-Alonso MJ, 2005, J BIOL CHEM, V280, P18120, DOI 10.1074/jbc.M500758200; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nguyen L, 2006, GENE DEV, V20, P1511, DOI 10.1101/gad.377106; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Perez-Llamas C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019541; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Piccaluga PP, 2007, J CLIN INVEST, V117, P823, DOI 10.1172/JCI26833; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Saijo T, 2006, LUNG CANCER, V54, P217, DOI 10.1016/j.lungcan.2006.06.018; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Sicinski P, 2007, GENE DEV, V21, P1703, DOI 10.1101/gad.1583207; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Soeiro I, 2006, MOL CELL BIOL, V26, P6170, DOI 10.1128/MCB.02182-05; Vera J, 2007, PROTEOMICS, V7, P578, DOI 10.1002/pmic.200600458; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Yeh N, 2007, MOL CELL BIOL, V27, P5161, DOI 10.1128/MCB.02431-06	58	54	54	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	38					4207	4220		10.1038/onc.2011.582	http://dx.doi.org/10.1038/onc.2011.582			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22179826				2022-12-17	WOS:000308975800004
J	Rzymski, T; Petry, A; Kracun, D; Riess, F; Pike, L; Harris, AL; Gorlach, A				Rzymski, T.; Petry, A.; Kracun, D.; Riess, F.; Pike, L.; Harris, A. L.; Goerlach, A.			The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress	ONCOGENE			English	Article						ADAM17/TACE; hypoxia; ER stress; unfolded protein response; TNF alpha receptor; cancer	TUMOR-NECROSIS-FACTOR; ENDOPLASMIC-RETICULUM STRESS; ALPHA-CONVERTING-ENZYME; NF-KAPPA-B; UP-REGULATED EXPRESSION; ISOLATED LIMB PERFUSION; SOLUBLE RECEPTORS; TNF-ALPHA; SIGNALING PATHWAYS; PROGNOSTIC-FACTORS	The family of ADAM (a disintegrin and metalloproteinase) proteins has been implicated in tumor initiation and progression. ADAM17/tumor necrosis factor-alpha (TNF alpha)-converting enzyme (TACE) has been initially recognized to release TNF alpha as well as its receptors (TNFRs) from the membrane. ADAM17, TNF alpha and TNFR have been found upregulated in cancer patients, although the underlying mechanisms remain largely unknown. As hypoxia is a hallmark of cancer that can lead to severe stress conditions accumulating in endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), we investigated the role of these stress conditions in the regulation of ADAM17 and release of TNFR1. We found that severe hypoxia induced ADAM17 expression and activity. Although hypoxia-inducible factor 1 alpha (HIF1 alpha) was important to maintain basal ADAM17 mRNA levels during moderate hypoxia, it was not sufficient to induce ADAM17 levels under severe hypoxia. Instead, we found that ADAM17 induction by severe hypoxia can be mimicked by ER stressors such as Thapsigargin and occurs as a consequence of the activation of the PERK/eIF2 alpha/ATF4 and activating transcription factor 6 (ATF6) arms of UPR in several tumor cell lines. ADAM17 expression was also increased in xenografts displaying ER stress because of treatment with the vascular endothelial growth factor (VEGF) inhibitory antibody Bevacizumab. Additionally, severe hypoxia and ER stress activated ADAM17 and ectodomain shedding of TNFR1 involving mitogen-activated protein (MAP) kinases and reactive oxygen species (ROS). Collectively, these results show that ADAM17 is a novel UPR-regulated gene in response to severe hypoxia and ER stress, which is actively involved in the release of TNFR1 under these conditions. These data provide a novel link between severe hypoxic stress conditions and inflammation in the tumor environment. Oncogene (2012) 31, 3621-3634; doi:10.1038/onc.2011.522; published online 21 November 2011	[Rzymski, T.; Petry, A.; Kracun, D.; Riess, F.; Goerlach, A.] Tech Univ Munich, German Heart Ctr Munich, D-80636 Munich, Bavaria, Germany; [Pike, L.; Harris, A. L.] John Radcliffe Hosp, Weatherall Inst Mol Med, Univ Dept Med Oncol, Mol Oncol Labs, Oxford OX3 9DU, England	German Heart Centre Munich; Technical University of Munich; University of Oxford	Gorlach, A (corresponding author), Tech Univ Munich, German Heart Ctr Munich, Lazarettstr 36, D-80636 Munich, Bavaria, Germany.	goerlach@dhm.mhn.de	Harris, Adrian L/ABA-3343-2020; Gorlach, Agnes/B-3494-2013	Harris, Adrian L/0000-0003-1376-8409; 	EU 7th FP Metoxia [222471]; Fondation Leducq; DFG [GO709/4-4]	EU 7th FP Metoxia; Fondation Leducq(Leducq Foundation); DFG(German Research Foundation (DFG))	We thank Merel Gijsen, Francesca Buffa and Ji-Liang Li for help with tumor sample preparation, bioinformatics and xenograft work. This work was supported by EU 7th FP 222471 Metoxia, DFG GO709/4-4 and Fondation Leducq.	ADERKA D, 1991, CANCER RES, V51, P5602; AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Arsenault D, 2012, J CELL PHYSIOL, V227, P789, DOI 10.1002/jcp.22792; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Blanchot-Jossic F, 2005, J PATHOL, V207, P156, DOI 10.1002/path.1814; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Burton Elizabeth R, 2009, J Biol, V8, P85, DOI 10.1186/jbiol189; Charbonneau M, 2007, J BIOL CHEM, V282, P33714, DOI 10.1074/jbc.M704041200; Chen YJ, 2005, MOL CANCER RES, V3, P669, DOI 10.1158/1541-7786.MCR-05-0181; Coleman ML, 2007, ESSAYS BIOCHEM, V43, P1; Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200; Dai RY, 2009, INT J ONCOL, V34, P1749, DOI 10.3892/ijo_00000306; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; Diebold I, 2010, MOL BIOL CELL, V21, P2087, DOI 10.1091/mbc.E09-12-1003; DIEZRUIZ A, 1995, EUR J HAEMATOL, V54, P1, DOI 10.1111/j.1600-0609.1995.tb01618.x; Eggermont AMM, 2003, LANCET ONCOL, V4, P429, DOI 10.1016/S1470-2045(03)01141-0; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; FEINBERG B, 1988, J CLIN ONCOL, V6, P1328, DOI 10.1200/JCO.1988.6.8.1328; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Fraker DL, 1996, J CLIN ONCOL, V14, P479, DOI 10.1200/JCO.1996.14.2.479; Gargalovic PS, 2006, ARTERIOSCL THROM VAS, V26, P2490, DOI 10.1161/01.ATV.0000242903.41158.a1; Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006; Hu P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200; Hung JH, 2004, J BIOL CHEM, V279, P46384, DOI 10.1074/jbc.M403568200; Jiang CC, 2007, CANCER RES, V67, P9750, DOI 10.1158/0008-5472.CAN-07-2047; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kenny PA, 2007, J CLIN INVEST, V117, P337, DOI 10.1172/JCI29518; Kornfeld JW, 2011, BRIT J CANCER, V104, P138, DOI 10.1038/sj.bjc.6606017; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Koumenis C, 2006, MOL CANCER RES, V4, P423, DOI 10.1158/1541-7786.MCR-06-0150; LANGKOPF F, 1994, LANCET, V344, P57, DOI 10.1016/S0140-6736(94)91078-2; Li JM, 2009, FEBS LETT, V583, P1521, DOI 10.1016/j.febslet.2009.04.007; Liu LP, 2008, J BIOL CHEM, V283, P31153, DOI 10.1074/jbc.M805056200; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; McCulloch DR, 2000, MOL CELL ENDOCRINOL, V167, P11, DOI 10.1016/S0303-7207(00)00305-1; McGowan PM, 2007, CLIN CANCER RES, V13, P2335, DOI 10.1158/1078-0432.CCR-06-2092; McMahon S, 2005, J BIOL CHEM, V280, P6561, DOI 10.1074/jbc.M413248200; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Mochizuki S, 2007, CANCER SCI, V98, P621, DOI 10.1111/j.1349-7006.2007.00434.x; Mujcic H, 2009, RADIOTHER ONCOL, V92, P450, DOI 10.1016/j.radonc.2009.08.017; Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459; Myers TJ, 2009, MOL BIOL CELL, V20, P5236, DOI 10.1091/mbc.E08-12-1256; Nakagawa M, 2009, CANCER SCI, V100, P654, DOI 10.1111/j.1349-7006.2009.01089.x; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Peters LR, 2011, J IMMUNOL, V187, P919, DOI 10.4049/jimmunol.1100690; REIBNEGGER G, 1994, LANCET, V344, P681, DOI 10.1016/S0140-6736(94)92115-6; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rzymski T, 2008, ONCOGENE, V27, P4532, DOI 10.1038/onc.2008.100; Rzymski T, 2010, ONCOGENE, V29, P4424, DOI 10.1038/onc.2010.191; Rzymski T, 2007, CLIN CANCER RES, V13, P2537, DOI 10.1158/1078-0432.CCR-06-2126; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Srour N, 2003, FEBS LETT, V554, P275, DOI 10.1016/S0014-5793(03)01159-1; Szalad A, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-129; Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3; Tanaka Y, 2005, CLIN CANCER RES, V11, P4783, DOI 10.1158/1078-0432.CCR-04-1426; Vahdat AM, 2010, LEUKEMIA, V24, P51, DOI 10.1038/leu.2009.230; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; Viac J, 1996, EUR J CANCER, V32A, P447, DOI 10.1016/0959-8049(95)00541-2; Waetzig GH, 2004, FASEB J, V18, P91, DOI 10.1096/fj.04-2073fje; Willems SH, 2010, BIOCHEM J, V428, P439, DOI 10.1042/BJ20100179; Xu PL, 2010, MOL CELL, V37, P551, DOI 10.1016/j.molcel.2010.01.034; Xue X, 2005, J BIOL CHEM, V280, P33917, DOI 10.1074/jbc.M505818200; Yoshimura T, 2002, J INFECT DIS, V185, P332, DOI 10.1086/338191; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhang ZL, 2001, FASEB J, V15, P303; Zheng X, 2009, CANCER BIOL THER, V8, P1045, DOI 10.4161/cbt.8.11.8539	83	54	56	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	31					3621	3634		10.1038/onc.2011.522	http://dx.doi.org/10.1038/onc.2011.522			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985EG	22105359				2022-12-17	WOS:000307245600005
J	Kelly, KR; Espitia, CM; Mahalingam, D; Oyajobi, BO; Coffey, M; Giles, FJ; Carew, JS; Nawrocki, ST				Kelly, K. R.; Espitia, C. M.; Mahalingam, D.; Oyajobi, B. O.; Coffey, M.; Giles, F. J.; Carew, J. S.; Nawrocki, S. T.			Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma	ONCOGENE			English	Article						bortezomib; NOXA; ER stress; Reolysin; reovirus	PROTEASOME INHIBITOR BORTEZOMIB; PANCREATIC-CANCER CELLS; ONCOLYTIC VIRUS THERAPY; ER STRESS; MELANOMA-CELLS; VIRAL THERAPY; IFN-BETA; IN-VITRO; KAPPA-B; PHASE-I	Oncolytic virotherapy with reovirus has demonstrated anti-cancer activity and minimal toxicity in clinical trials, but the mechanisms underlying these effects have not been fully elucidated. Reolysin, a proprietary formulation of reovirus for cancer therapy, stimulated selective viral replication and apoptosis in multiple myeloma (MM) cells. Reolysin-mediated apoptosis was associated with an induction of endoplasmic reticular (ER) stress-related gene expression, swelling of the endoplasmic reticulum, increases in intracellular calcium levels and a strong induction of the Bcl-2 homology 3 (BH3)-only pro-apoptotic protein NOXA. Knockdown of NOXA expression by short hairpin RNA significantly reduced the pro-apoptotic effects of Reolysin. We next showed that co-administration of Reolysin and bortezomib resulted in the dual accumulation of viral and ubiquitinated proteins, which led to enhanced ER stress, NOXA induction and apoptosis. Importantly, the combination of reovirus infection and proteasomal inhibition significantly decreased tumor burden in a xenograft and syngeneic bone disease model of MM without exhibiting adverse side effects. Our study establishes ER stress stimulation and NOXA induction as novel mediators of reovirus-induced apoptosis. Furthermore, reovirus infection can be used as a promising approach to augment the anti-myeloma activity of bortezomib by promoting additional stress to the endoplasmic reticulum of MM cells. Oncogene (2012) 31, 3023-3038; doi: 10.1038/onc.2011.478; published online 17 October 2011	[Kelly, K. R.; Espitia, C. M.; Mahalingam, D.; Giles, F. J.; Carew, J. S.; Nawrocki, S. T.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, Dept Med, San Antonio, TX 78229 USA; [Oyajobi, B. O.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA; [Coffey, M.] Oncolyt Biotech Inc, Calgary, AB, Canada	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Oncolytics Biotech	Nawrocki, ST (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, Dept Med, 7979 Wurzbach Rd, San Antonio, TX 78229 USA.	Nawrocki@uthscsa.edu		Oyajobi, Babatunde/0000-0002-1064-3072	Leukemia and Lymphoma Society of America [6319-11]; International Myeloma Foundation; William and Ella Owens Foundation; National Cancer Institute P30 Cancer Center Support Grant [CA054174]; NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society of America(Leukemia and Lymphoma Society); International Myeloma Foundation; William and Ella Owens Foundation; National Cancer Institute P30 Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by The Leukemia and Lymphoma Society of America (6319-11), The International Myeloma Foundation, The William and Ella Owens Foundation and the National Cancer Institute P30 Cancer Center Support Grant # CA054174.	Alain T, 2007, MOL THER, V15, P1512, DOI 10.1038/sj.mt.6300207; Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x; Carew JS, 2006, BLOOD, V107, P222, DOI 10.1182/blood-2005-05-1923; Clarke P, 2004, J VIROL, V78, P13132, DOI 10.1128/JVI.78.23.13132-13138.2004; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Dallas SL, 1999, BLOOD, V93, P1697, DOI 10.1182/blood.V93.5.1697.405a17_1697_1706; Etoh T, 2003, CLIN CANCER RES, V9, P1218; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Forsyth P, 2008, MOL THER, V16, P627, DOI 10.1038/sj.mt.6300403; Fribley AM, 2006, J BIOL CHEM, V281, P31440, DOI 10.1074/jbc.M604356200; Gomez-Bougie P, 2007, CANCER RES, V67, P5418, DOI 10.1158/0008-5472.CAN-06-4322; Hamamdzic D, 2001, AM J PHYSIOL-LUNG C, V280, pL18, DOI 10.1152/ajplung.2001.280.1.L18; Harrington KJ, 2010, CYTOKINE GROWTH F R, V21, P91, DOI 10.1016/j.cytogfr.2010.02.006; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Holm GH, 2007, J BIOL CHEM, V282, P21953, DOI 10.1074/jbc.M702112200; Homicsko K, 2005, CANCER RES, V65, P6882, DOI 10.1158/0008-5472.CAN-05-0309; Jordan R, 2002, J VIROL, V76, P9588, DOI 10.1128/JVI.76.19.9588-9599.2002; Kelly K, 2009, EXPERT OPIN BIOL TH, V9, P817, DOI 10.1517/14712590903002039; Kottke T, 2010, J CLIN INVEST, V120, P1551, DOI 10.1172/JCI41431; Kumar SK, 2004, MAYO CLIN PROC, V79, P867, DOI 10.4065/79.7.867; Kurozumi K, 2007, JNCI-J NATL CANCER I, V99, P1768, DOI 10.1093/jnci/djm229; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Libertini S, 2008, CLIN CANCER RES, V14, P6505, DOI 10.1158/1078-0432.CCR-08-0200; Marcato P, 2007, MOL THER, V15, P1522, DOI 10.1038/sj.mt.6300179; Meister S, 2007, CANCER RES, V67, P1783, DOI 10.1158/0008-5472.CAN-06-2258; Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008-5472.CAN-05-2961; Nawrocki ST, 2002, MOL CANCER THER, V1, P1243; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; Nawrocki ST, 2008, BLOOD, V112, P2917, DOI 10.1182/blood-2007-12-130823; Nencioni A, 2006, BLOOD, V108, P551, DOI 10.1182/blood-2005-08-3494; Neubert K, 2008, NAT MED, V14, P748, DOI 10.1038/nm1763; Oyajobi BO, 2007, MOL CANCER THER, V6, P1701, DOI 10.1158/1535-7163.MCT-07-0121; Pandha HS, 2009, CLIN CANCER RES, V15, P6158, DOI 10.1158/1078-0432.CCR-09-0796; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Qiao J, 2008, CLIN CANCER RES, V14, P259, DOI 10.1158/1078-0432.CCR-07-1510; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Rhim JH, 2007, J NATL CANCER I, V99, P1739, DOI 10.1093/jnci/djm234; Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008-5472.CAN-05-1195; Rudd P, 2005, J GEN VIROL, V86, P1489, DOI 10.1099/vir.0.80628-0; Sei S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-47; Shmulevitz M, 2010, CANCER RES, V70, P4912, DOI 10.1158/0008-5472.CAN-09-4676; SIDKY YA, 1987, CANCER RES, V47, P5155; Smakman N, 2006, CANCER GENE THER, V13, P815, DOI 10.1038/sj.cgt.7700949; Steele L, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-20; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002; Sun K, 2004, P NATL ACAD SCI USA, V101, P8120, DOI 10.1073/pnas.0401563101; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Taylor KL, 2008, J INTERF CYTOK RES, V28, P733, DOI 10.1089/jir.2008.0030; Thirukkumaran Chandini, 2009, V542, P607, DOI 10.1007/978-1-59745-561-9_31; Thirukkumaran CM, 2003, BLOOD, V102, P377, DOI 10.1182/blood-2002-08-2508; Twigger K, 2008, CLIN CANCER RES, V14, P912, DOI 10.1158/1078-0432.CCR-07-1400; van Houdt WJ, 2008, CANCER GENE THER, V15, P284, DOI 10.1038/cgt.2008.2; Vidal L, 2008, CLIN CANCER RES, V14, P7127, DOI 10.1158/1078-0432.CCR-08-0524; Wang Q, 2009, P NATL ACAD SCI USA, V106, P2200, DOI 10.1073/pnas.0807611106; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	59	54	54	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	25					3023	3038		10.1038/onc.2011.478	http://dx.doi.org/10.1038/onc.2011.478			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22002308				2022-12-17	WOS:000305705900002
J	Lorenzon, E; Colladel, R; Andreuzzi, E; Marastoni, S; Todaro, F; Schiappacassi, M; Ligresti, G; Colombatti, A; Mongiat, M				Lorenzon, E.; Colladel, R.; Andreuzzi, E.; Marastoni, S.; Todaro, F.; Schiappacassi, M.; Ligresti, G.; Colombatti, A.; Mongiat, M.			MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway	ONCOGENE			English	Article						angiogenesis; extracellular matrix; VEGF	AORTIC RING MODEL; ENDOTHELIAL-CELLS; MICROENVIRONMENTAL REGULATION; THERAPEUTIC IMPLICATIONS; TYROSINE KINASE; RECEPTOR; VEGF; THROMBOSPONDIN-1; IDENTIFICATION; GLYCOPROTEIN	MULTIMERIN2 (MMRN2), also known as Endoglyx-1, is an extracellular matrix glycoprotein whose function has so far remained elusive. Given its specific localization in tight association with the endothelium we hypothesized that this protein could modulate neo-angiogenesis. By multiple assays we showed that MMRN2 significantly impaired endothelial cell (EC) migration and organization of a functional vessel network. The interaction of ECs with MMRN2 induced a striking impairment of VEGFR1 and VEGFR2 activation. We focused our attention on VEGFR2, a chief regulator of angiogenesis, and clarified that MMRN2 interfered with the VEGF/VEGFR2 axis through a direct binding with VEGF-A. This novel interaction was assessed in several assays and the affinity was estimated (Kd similar to 50 nM). We next questioned whether the anti-angiogenic properties of MMRN2 could impair tumor growth. Although overexpression of MMRN2 by HT1080 cells did not affect their growth and apoptotic rate in vitro, it remarkably affected their growth in vivo. In fact, MMRN2-positive cells failed to efficiently grow and form well-vascularized tumors; a similar outcome was observed following treatment of established tumors with a MMRN2 adenoviral construct. Tumor-section immunostaining revealed a strong co-localization of VEGF-A with the ectopically expressed MMRN2. These novel findings suggest that VEGF may be sequestered by MMRN2 and be less available for the engagement to the receptors. Taken together these results highlight MMRN2 as a crucial player in the regulation of EC function, neo-angiogenesis and hence tumor growth. We hypothesize that secreted and deposited MMRN2 may function as a homeostatic barrier halting the sprouting of novel vessels, and suggest that these studies may embody the potential for the development of novel tools for cancer treatment. Oncogene (2012) 31, 3136-3147; doi:10.1038/onc.2011.487; published online 24 October 2011	[Colombatti, A.; Mongiat, M.] CRO IRCCS, Dept Mol Oncol & Translat Res, Expt Oncol Div 2, Aviano, PN, Italy; [Andreuzzi, E.; Colombatti, A.] Univ Udine, MATI Ctr Excellence, I-33100 Udine, Italy; [Ligresti, G.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA	IRCCS Aviano (CRO); University of Udine; University of Washington; University of Washington Seattle	Mongiat, M (corresponding author), CRO IRCCS, Dept Mol Oncol & Translat Res, Expt Oncol Div 2, Via Franco Gallini 2, Aviano, PN, Italy.	acolombatti@cro.it; mmongiat@cro.it	Andreuzzi, Eva/AAX-5692-2020; Mongiat, Maurizio/H-8297-2018; Ligresti, Giovanni/AAB-9881-2019; Schiappacassi, Monica/AAX-5505-2020	Andreuzzi, Eva/0000-0002-5925-5230; Mongiat, Maurizio/0000-0001-6509-0068; Schiappacassi, Monica/0000-0003-4804-4291; colombatti, alfonso/0000-0002-3676-2379	ISS-ACC; AIRC; MIUR [RBRN07BMCT]	ISS-ACC; AIRC(Fondazione AIRC per la ricerca sul cancro); MIUR(Ministry of Education, Universities and Research (MIUR))	We thank Dr Philip Thorpe and Dr Rolf Brekken for the generous gift of the Gv39M antibody. We thank the ISS-ACC Program 2, AIRC and MIUR (grant no.RBRN07BMCT) for supporting this work.	Anghelina M, 2006, AM J PATHOL, V168, P529, DOI 10.2353/ajpath.2006.050255; Aplin AC, 2008, METHOD ENZYMOL, V443, P119, DOI 10.1016/S0076-6879(08)02007-7; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Braghetta P, 2004, MATRIX BIOL, V22, P549, DOI 10.1016/j.matbio.2003.10.005; Brekken RA, 1998, CANCER RES, V58, P1952; Campbell NE, 2010, J ONCOL, V2010, DOI 10.1155/2010/586905; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chen TT, 2010, J CELL BIOL, V188, P595, DOI 10.1083/jcb.200906044; Cheresh DA, 2008, ONCOGENE, V27, P6285, DOI 10.1038/onc.2008.304; Christian S, 2001, J BIOL CHEM, V276, P48588, DOI 10.1074/jbc.M106152200; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Greenaway J, 2007, J CELL PHYSIOL, V210, P807, DOI 10.1002/jcp.20904; Hirama M, 2003, CANCER LETT, V198, P107, DOI 10.1016/S0304-3835(03)00286-6; Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200; Hotz B, 2010, NEOPLASIA, V12, P797, DOI 10.1593/neo.10418; Hu M, 2008, CURR OPIN GENET DEV, V18, P27, DOI 10.1016/j.gde.2007.12.006; Huber MA, 2006, J CUTAN PATHOL, V33, P145, DOI 10.1111/j.0303-6987.2006.00446.x; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Koperek O, 2007, INT J ONCOL, V31, P59; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x; Ligresti G, 2011, ARTERIOSCL THROM VAS, V31, P1151, DOI 10.1161/ATVBAHA.111.223917; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mongiat M, 2010, NEOPLASIA, V12, P294, DOI 10.1593/neo.91930; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Nicosia RF, 2009, J CELL MOL MED, V13, P4113, DOI 10.1111/j.1582-4934.2009.00891.x; Nyberg P, 2008, FRONT BIOSCI, V13, P6537, DOI 10.2741/3173; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008-5472.CAN-05-1195; Sahni A, 2000, BLOOD, V96, P3772, DOI 10.1182/blood.V96.12.3772.h8003772_3772_3778; SANZMONCASI MP, 1994, LAB INVEST, V71, P366; Spessotto P, 2000, METH MOL B, V139, P321; Sun JF, 2009, AM J PHYSIOL-HEART C, V296, pH1344, DOI 10.1152/ajpheart.01246.2008; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Ventura E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009145; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; Zoeller JJ, 2009, MATRIX BIOL, V28, P284, DOI 10.1016/j.matbio.2009.04.010	43	54	57	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	26					3136	3147		10.1038/onc.2011.487	http://dx.doi.org/10.1038/onc.2011.487			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22020326	Bronze			2022-12-17	WOS:000305934400003
J	Wang, J; Anderson, PD; Luo, W; Gius, D; Roh, M; Abdulkadir, SA				Wang, J.; Anderson, P. D.; Luo, W.; Gius, D.; Roh, M.; Abdulkadir, S. A.			Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells	ONCOGENE			English	Article						Pim1 kinase; MYC; gene expression; Erk; tumorigenicity	C-MYC; TUMOR-GROWTH; MICE; PHOSPHORYLATION; INHIBITION; CARCINOMA; APOPTOSIS; PROTEIN	PIM1 kinase and MYC are commonly co-expressed in human prostate cancer and synergize to induce rapidly progressing prostate cancer in mouse models. Deficiency of the Pim kinase genes is well tolerated in vivo, suggesting that PIM1 inhibition might offer an attractive therapeutic modality for prostate cancer, particularly for MYC-expressing tumors. Here we examine the molecular consequences of Pim1 and MYC overexpression in the prostate as well as the effects of depleting Pim1 in prostate carcinoma cells with high levels of MYC. Overexpression of Pim1 in the mouse prostate induces several pro-tumorigenic genetic programs including cell cycle genes and Myc regulated genes before the induction of any discernible pathology. Pim1 depletion by RNA interference in mouse and human prostate cancer cells decreased cellular proliferation, survival, Erk signaling and tumorigenicity even when MYC levels were not significantly altered. These results indicate that PIM1 may be necessary to maintain tumorigenicity, and further support efforts aimed at developing PIM1 inhibitors for prostate cancer therapy. Oncogene (2012) 31, 1794-1803; doi: 10.1038/onc.2011.371; published online 22 August 2011	[Anderson, P. D.; Roh, M.; Abdulkadir, S. A.] Vanderbilt Univ, Dept Pathol, Med Ctr, Nashville, TN 37232 USA; [Wang, J.; Gius, D.; Abdulkadir, S. A.] Vanderbilt Univ, Dept Canc Biol, Med Ctr, Nashville, TN 37232 USA; [Luo, W.] Vanderbilt Univ, Dept Cell & Dev Biol, Med Ctr, Nashville, TN 37232 USA; [Gius, D.] Vanderbilt Univ, Dept Pediat, Med Ctr, Nashville, TN 37232 USA; [Gius, D.] Vanderbilt Univ, Dept Radiat Oncol, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Abdulkadir, SA (corresponding author), Vanderbilt Univ, Dept Pathol, Med Ctr, B33321A MCN, Nashville, TN 37232 USA.	sarki.abdulkadir@vanderbilt.edu			NCI [RO1CA123484, R01CA152601]; DOD [BC093803]; NATIONAL CANCER INSTITUTE [R01CA123484, R01CA152601] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Robert Matusik, Simon Hayward, Vito Quaranta, Xiuping Yu and Fritz Parl for helpful discussions. Micrographs were taken from Cell Imaging Core at Vanderbilt University Medical Center. This work was supported by Grant RO1CA123484 from the NCI to SAA. while DG is supported by R01CA152601 from the NCI and BC093803 from the DOD.	Abdulkadir SA, 2000, HUM PATHOL, V31, P443, DOI 10.1053/hp.2000.6547; Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Berns A, 1999, CANCER RES, V59, p1773S; Burton GR, 2004, GENE, V329, P167, DOI 10.1016/j.gene.2003.12.012; Chen J, 2009, AM J PATHOL, V175, P400, DOI 10.2353/ajpath.2009.080972; Chen LS, 2009, BLOOD, V114, P4150, DOI 10.1182/blood-2009-03-212852; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Grundler R, 2009, J EXP MED, V206, P1957, DOI 10.1084/jem.20082074; Gu JJ, 2009, ONCOGENE, V28, P4261, DOI 10.1038/onc.2009.276; Hu XF, 2009, J CLIN INVEST, V119, P362, DOI 10.1172/JCI33216; Jager J, 2010, DIABETES, V59, P61, DOI 10.2337/db09-0470; Kim J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-248; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Leiblich A, 2007, PROSTATE, V67, P1761, DOI 10.1002/pros.20654; Magnuson NS, 2010, FUTURE ONCOL, V6, P1461, DOI 10.2217/FON.10.106; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Mumenthaler SM, 2009, MOL CANCER THER, V8, P2882, DOI 10.1158/1535-7163.MCT-09-0293; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; Roh M, 2003, CANCER RES, V63, P8079; Shah N, 2008, EUR J CANCER, V44, P2144, DOI 10.1016/j.ejca.2008.06.044; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wang J, 2010, ONCOGENE, V29, P2477, DOI 10.1038/onc.2010.10; Zhang Y, 2008, ONCOGENE, V27, P4809, DOI 10.1038/onc.2008.123; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	31	54	58	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	14					1794	1803		10.1038/onc.2011.371	http://dx.doi.org/10.1038/onc.2011.371			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21860423	Green Accepted			2022-12-17	WOS:000302785200005
J	Coombs, GS; Schmitt, AA; Canning, CA; Alok, A; Low, ICC; Banerjee, N; Kaur, S; Utomo, V; Jones, CM; Pervaiz, S; Toone, EJ; Virshup, DM				Coombs, G. S.; Schmitt, A. A.; Canning, C. A.; Alok, A.; Low, I. C. C.; Banerjee, N.; Kaur, S.; Utomo, V.; Jones, C. M.; Pervaiz, S.; Toone, E. J.; Virshup, D. M.			Modulation of Wnt/beta-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer	ONCOGENE			English	Article						Wnt/beta-catenin; iron; iron chelator; drug therapy; mouse models of cancer	CONNECTIVITY MAP; BINDING; WNT; EXPRESSION; DISEASE; INHIBITION; ANALOGS; PROTEIN; TUMORS; CELLS	Using a screen for Wnt/beta-catenin inhibitors, a family of 8-hydroxyquinolone derivatives with in vivo anti-cancer properties was identified. Analysis of microarray data for the lead compound N-((8-hydroxy-7-quinolinyl) (4-methylphenyl)methyl)benzamide (HQBA) using the Connectivity Map database suggested that it is an iron chelator that mimics the hypoxic response. HQBA chelates Fe(2+) with a dissociation constant of similar to 10(-19) M, with much weaker binding to Fe(3+) and other transition metals. HQBA inhibited proliferation of multiple cell lines in culture, and blocked the progression of established spontaneous cancers in two distinct genetically engineered mouse models of mammary cancer, MMTV-Wnt1 and MMTV-PyMT mice, without overt toxicity. HQBA may inhibit an iron-dependent factor that regulates cell-type-specific beta-catenin-driven transcription. It inhibits cancer cell proliferation independently of its effect on beta-catenin signaling, as it works equally well in MMTV-PyMT tumors and diverse beta-catenin-independent cell lines. HQBA is a promising specific intracellular Fe(2+) chelator with activity against spontaneous mouse mammary cancers. Oncogene (2012) 31, 213-225; doi:10.1038/onc.2011.228; published online 13 June 2011	[Coombs, G. S.; Alok, A.; Kaur, S.; Utomo, V.; Virshup, D. M.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore, Singapore; [Canning, C. A.; Jones, C. M.] ASTAR, Inst Med Biol, Singapore, Singapore; [Schmitt, A. A.; Toone, E. J.] Duke Univ, Dept Chem, Durham, NC 27706 USA; [Low, I. C. C.; Pervaiz, S.; Virshup, D. M.] Natl Univ Singapore, Dept Physiol, Singapore 117548, Singapore; [Banerjee, N.] Univ Utah, Sch Med, Salt Lake City, UT USA; [Virshup, D. M.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; [Virshup, D. M.] Duke Univ, Dept Pediat, Sch Med, Durham, NC 27706 USA	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Duke University; National University of Singapore; Utah System of Higher Education; University of Utah; National University of Singapore; Duke University	Virshup, DM (corresponding author), Duke NUS Grad Med Sch Singapore, Program Canc & Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore.	david.virshup@duke-nus.edu.sg	Virshup, David M/C-1449-2009; Low, Ivan Cherh Chiet/O-1649-2013; Pervaiz, Shazib/C-4188-2015	Virshup, David M/0000-0001-6976-850X; Kaur, Simran/0000-0003-1510-928X; Low, Ivan Cherh Chiet/0000-0003-2735-395X; Coombs, Gary/0000-0002-0711-185X	Duke-NUS; Singapore Translational Research (STaR); Agency for Science, Technology and Research, Singapore; Ministry of Health, Singapore; NIH [T32-GM007105-37]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007105] Funding Source: NIH RePORTER	Duke-NUS; Singapore Translational Research (STaR); Agency for Science, Technology and Research, Singapore(Agency for Science Technology & Research (A*STAR)); Ministry of Health, Singapore(Ministry of Health-Singapore); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Chuck Perou and Philipp Kaldis for assistance with the MMTV-Wnt1 and MMTV-PyMT mice, and Elizabeth Leibold for helpful discussions. The compound library was provided by the Huntsman Cancer Institute Drug Screening Resource at the University of Utah. This research was supported by the Duke-NUS Signature Research Program and the Singapore Translational Research (STaR) Investigator Award (to DMV) funded by the Agency for Science, Technology and Research, Singapore, and the Ministry of Health, Singapore. CAC and CMJ were funded by A*STAR, Singapore. AAS acknowledges support from the Duke Pharmacological Sciences Training Program, NIH T32-GM007105-37.	BERGERON RJ, 1993, BLOOD, V81, P2166; Bergeron RJ, 1999, J MED CHEM, V42, P95, DOI 10.1021/jm980340j; Brookes MJ, 2008, ONCOGENE, V27, P966, DOI 10.1038/sj.onc.1210711; Canning CA, 2007, DEV BIOL, V305, P276, DOI 10.1016/j.ydbio.2007.02.009; Coombs GS, 2008, CURR DRUG TARGETS, V9, P513, DOI 10.2174/138945008784911796; Coombs GS, 2010, J CELL SCI, V123, P3357, DOI 10.1242/jcs.072132; DiTusa CA, 2001, BIOCHEMISTRY-US, V40, P5338, DOI 10.1021/bi001731e; Eberhard Y, 2009, BLOOD, V114, P3064, DOI 10.1182/blood-2009-03-209965; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Henderson WR, 2010, P NATL ACAD SCI USA, V107, P14309, DOI 10.1073/pnas.1001520107; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hodges YK, 2004, BIOCHEM BIOPH RES CO, V315, P595, DOI 10.1016/j.bbrc.2004.01.101; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jansson PJ, 2010, J INORG BIOCHEM, V104, P1224, DOI 10.1016/j.jinorgbio.2010.07.012; KEBERLE H, 1964, ANN NY ACAD SCI, V119, P758; Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lucero OM, 2010, CURR ONCOL REP, V12, P314, DOI 10.1007/s11912-010-0114-3; McCulloch MWB, 2009, J NAT PROD, V72, P1651, DOI 10.1021/np900336f; McCulloch MWB, 2009, BIOORGAN MED CHEM, V17, P2189, DOI 10.1016/j.bmc.2008.10.077; Mosimann C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654; Pang H, 2004, J BIOL CHEM, V279, P1491, DOI 10.1074/jbc.M310022200; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Rai K, 2010, CELL, V142, P930, DOI 10.1016/j.cell.2010.08.030; Richardson DR, 2009, BBA-GEN SUBJECTS, V1790, P702, DOI 10.1016/j.bbagen.2008.04.003; Rutherford JC, 2004, EUKARYOT CELL, V3, P1, DOI 10.1128/EC.3.1.1-13.2004; Sheftel A, 2010, TRENDS ENDOCRIN MET, V21, P302, DOI 10.1016/j.tem.2009.12.006; Sigurskjold BW, 2000, ANAL BIOCHEM, V277, P260, DOI 10.1006/abio.1999.4402; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Teo JL, 2010, ADV DRUG DELIVER REV, V62, P1149, DOI 10.1016/j.addr.2010.09.012; Tian JQ, 2010, CANCER LETT, V298, P231, DOI 10.1016/j.canlet.2010.07.010; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Zhou HY, 2010, INT J CANCER, V127, P2467, DOI 10.1002/ijc.25255	33	54	62	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	2					213	225		10.1038/onc.2011.228	http://dx.doi.org/10.1038/onc.2011.228			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21666721	Green Published, hybrid			2022-12-17	WOS:000299307400007
J	HuangFu, WC; Qian, J; Liu, C; Liu, J; Lokshin, AE; Baker, DP; Rui, H; Fuchs, SY				HuangFu, W-C; Qian, J.; Liu, C.; Liu, J.; Lokshin, A. E.; Baker, D. P.; Rui, H.; Fuchs, S. Y.			Inflammatory signaling compromises cell responses to interferon alpha	ONCOGENE			English	Article						inflammation; cancer; interferon; receptor; ubiquitin; melanoma	HUMAN-MELANOMA CELLS; CANCER-RELATED INFLAMMATION; HUMAN-MALIGNANT MELANOMA; TUMOR-NECROSIS-FACTOR; I-INTERFERON; ADJUVANT THERAPY; MULTIPLEX ANALYSIS; INNATE IMMUNITY; RECEPTOR; EXPRESSION	Interferon alpha (IFN alpha) is widely used for treatment of melanoma and certain other malignancies. This cytokine as well as the related IFN beta exerts potent anti-tumorigenic effects; however, their efficacy in patients is often suboptimal. Here, we report that inflammatory signaling impedes the effects of IFN alpha/beta. Melanoma cells can secrete pro-inflammatory cytokines that inhibit cellular responses to IFN alpha/beta via activating the ligand-independent pathway for the phosphorylation and subsequent ubiquitination and accelerated degradation of the IFNAR1 chain of type I IFN receptor. Catalytic activity of the p38 protein kinase was required for IFNAR1 downregulation and inhibition of IFN alpha/beta signaling induced by proinflammatory cytokines such as interleukin 1 (IL-1). Activation of p38 kinase inversely correlated with protein levels of IFNAR1 in clinical melanoma specimens. Inhibition of p38 kinase augmented the inhibitory effects of IFN alpha/beta on cell viability and growth in vitro and in vivo. The roles of inflammation and p38 protein kinase in regulating cellular responses to IFN alpha/beta in normal and tumor cells are discussed. Oncogene (2012) 31, 161-172; doi:10.1038/onc.2011.221; published online 13 June 2011	[HuangFu, W-C; Qian, J.; Liu, J.; Fuchs, S. Y.] Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; [HuangFu, W-C; Qian, J.; Liu, J.; Fuchs, S. Y.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; [Liu, C.; Rui, H.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; [Lokshin, A. E.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; [Lokshin, A. E.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA; [Lokshin, A. E.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Lokshin, A. E.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA; [Baker, D. P.] Biogen Idec Inc, Cambridge, MA USA	University of Pennsylvania; University of Pennsylvania; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Biogen	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 380 S Univ Ave,Hill 316, Philadelphia, PA 19104 USA.	syfuchs@vet.upenn.edu		Liu, Jianghuai/0000-0002-2382-9140	NIH [CA092900, CA142425]; NATIONAL CANCER INSTITUTE [R01CA142425, R01CA092900] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs M Gaestel, LM Duncan, RJ Davis, M Herlyn, M May, E Meggers, A Nebreda, J Ninomiya-Tsuji and Z Ronai for reagents. This work was supported by NIH grants CA092900 and CA142425 (to SYF).	Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Alonso-Curbelo D, 2010, AUTOPHAGY, V6, P148, DOI 10.4161/auto.6.1.10464; Ascierto PA, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-62; Balkwill F, 2010, CLIN PHARMACOL THER, V87, P401, DOI 10.1038/clpt.2009.312; BENNICELLI JL, 1989, CANCER RES, V49, P930; Bhattacharya S, 2010, J BIOL CHEM, V285, P2318, DOI 10.1074/jbc.M109.071498; Bracarda S, 2010, EUR J CANCER, V46, P284, DOI 10.1016/j.ejca.2009.10.013; Bregman H, 2006, J AM CHEM SOC, V128, P877, DOI 10.1021/ja055523r; Coccia EM, 2006, CELL MOL BIOL, V52, P77, DOI 10.1170/T701; Fecher LA, 2009, J NATL COMPR CANC NE, V7, P295, DOI 10.6004/jnccn.2009.0022; Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014; Goldman LA, 1999, J INTERF CYTOK RES, V19, P15, DOI 10.1089/107999099314379; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gu Y, 2009, CYTOKINE, V45, P44, DOI 10.1016/j.cyto.2008.10.014; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HuangFu WC, 2010, PIGM CELL MELANOMA R, V23, P838, DOI 10.1111/j.1755-148X.2010.00770.x; Hui LJ, 2007, CELL CYCLE, V6, P2429, DOI 10.4161/cc.6.20.4774; Kaehler KC, 2010, EUR J CANCER, V46, P41, DOI 10.1016/j.ejca.2009.10.004; KOCK A, 1989, J NATL CANCER I, V81, P36, DOI 10.1093/jnci/81.1.36; Kumar KGS, 2007, CANCER BIOL THER, V6, P1437; Kumar KGS, 2007, J CELL BIOL, V179, P935, DOI 10.1083/jcb.200706034; Kumar KGS, 2004, J BIOL CHEM, V279, P46614, DOI 10.1074/jbc.M407082200; Kumar KGS, 2003, EMBO J, V22, P5480; Leiter U, 2008, ADV EXP MED BIOL, V624, P89, DOI 10.1007/978-0-387-77574-6_8; Li JL, 2007, J BIOMED SCI, V14, P303, DOI 10.1007/s11373-007-9148-4; Li Y, 2006, ONCOGENE, V25, P1896, DOI 10.1038/sj.onc.1209214; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Linkov F, 2008, PROTEOM CLIN APPL, V2, P1575, DOI 10.1002/prca.200780095; Liu J, 2007, ONCOGENE, V26, P1954, DOI 10.1038/sj.onc.1209994; Liu J, 2008, BIOCHEM BIOPH RES CO, V367, P388, DOI 10.1016/j.bbrc.2007.12.137; Liu JH, 2009, MOL CELL BIOL, V29, P6401, DOI 10.1128/MCB.00478-09; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marijanovic Z, 2006, BIOCHEM J, V397, P31, DOI 10.1042/BJ20060272; Megason SG, 2002, DEVELOPMENT, V129, P2087; Melnikova VO, 2009, PIGM CELL MELANOMA R, V22, P257, DOI 10.1111/j.1755-148X.2009.00570.x; Messina Jane L, 2008, Cancer Control, V15, P196; Mocellin S, 2010, JNCI-J NATL CANCER I, V102, P493, DOI 10.1093/jnci/djq009; Moretti S, 1999, INT J CANCER, V84, P160, DOI 10.1002/(SICI)1097-0215(19990420)84:2<160::AID-IJC12>3.3.CO;2-I; Nazarian RM, 2010, J CUTAN PATHOL, V37, P41, DOI 10.1111/j.1600-0560.2010.01505.x; Okamoto M, 2010, J BIOL CHEM, V285, P6477, DOI 10.1074/jbc.M109.064907; OXHOLM A, 1988, BRIT J DERMATOL, V118, P369, DOI 10.1111/j.1365-2133.1988.tb02430.x; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Rigualt NR, 2008, EXPERT REV ANTICANC, V8, P403, DOI 10.1586/14737140.8.3.403; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sander B, 1996, INT J CANCER, V66, P42, DOI 10.1002/(SICI)1097-0215(19960328)66:1<42::AID-IJC8>3.0.CO;2-Z; Smalley KSM, 2009, CANCER RES, V69, P3241, DOI 10.1158/0008-5472.CAN-08-4305; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Spiegelman V, 2002, ONCOGENE, V21, P856, DOI 10.1038/sj.onc.1205132; Torisu H, 2000, INT J CANCER, V85, P182, DOI 10.1002/(SICI)1097-0215(20000115)85:2<182::AID-IJC6>3.0.CO;2-M; Uze G, 2007, CURR TOP MICROBIOL, V316, P71; Weber A., 2010, SCI SIGNAL, V3; Yao K, 2009, SURG CLIN N AM, V89, P267, DOI 10.1016/j.suc.2008.11.002; Yurkovetsky ZR, 2007, CLIN CANCER RES, V13, P2422, DOI 10.1158/1078-0432.CCR-06-1805; Zheng H, 2011, MOL CELL BIOL, V31, P710, DOI 10.1128/MCB.01154-10; Zwang Y, 2006, EMBO J, V25, P4195, DOI 10.1038/sj.emboj.7601297	55	54	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					161	172		10.1038/onc.2011.221	http://dx.doi.org/10.1038/onc.2011.221			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21666722	Green Published, Green Accepted			2022-12-17	WOS:000299307400003
J	Shenoy, SK; Han, S; Zhao, YL; Hara, MR; Oliver, T; Cao, Y; Dewhirst, MW				Shenoy, S. K.; Han, S.; Zhao, Y. L.; Hara, M. R.; Oliver, T.; Cao, Y.; Dewhirst, M. W.			beta-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression	ONCOGENE			English	Article						arrestin; HIF-1; VEGF; hypoxia	NUCLEAR EXPORT SIGNAL; INDUCIBLE FACTOR-I; BETA-ARRESTIN; ENDOTHELIAL-CELLS; IMATINIB MESYLATE; PROSTATE-CANCER; GENE-EXPRESSION; RECEPTOR; HYPOXIA; ANGIOGENESIS	beta-Arrestins 1 and 2 are multifunctional adaptor proteins originally discovered for their role in desensitizing seven-transmembrane receptor signaling via the heterotrimeric guanine nucleotide-binding proteins. Recently identified roles of beta-arrestins include regulation of cancer cell chemotaxis and proliferation. Herein, we report that beta-arrestin1 expression regulates breast tumor colonization in nude mice and cancer cell viability during hypoxia. beta-Arrestin1 robustly interacts with nuclear hypoxia-induced factor-1 alpha (HIF-1 alpha) that is stabilized during hypoxia and potentiates HIF-1-dependent transcription of the angiogenic factor vascular endothelial growth factor-A (VEGF-A). Increased expression of beta-arrestin1 in human breast cancer (infiltrating ductal carcinoma or IDC and metastatic IDC) correlates with increased levels of VEGF-A. While the anti-angiogenic drug thalidomide inhibits HIF-1-dependent VEGF transcription in breast carcinoma cells, it does not prevent HIF-1 alpha stabilization, but leads to aberrant localization of HIF-1 alpha to the perinuclear compartments and surprisingly stimulates nuclear export of beta-arrestin1. Additionally, imatinib mesylate that inhibits release of VEGF induces nuclear export of beta-arrestin1-HIF-1 alpha complexes. Our findings suggest that beta-arrestin1 regulates nuclear signaling during hypoxia to promote survival of breast cancer cells via VEGF signaling and that drugs that induce its translocation from the nucleus to the cytoplasm could be useful in anti-angiogenic and breast cancer therapies. Oncogene (2012) 31, 282-292; doi:10.1038/onc.2011.238; published online 20 June 2011	[Shenoy, S. K.; Han, S.; Hara, M. R.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Shenoy, S. K.; Oliver, T.] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; [Zhao, Y. L.; Cao, Y.; Dewhirst, M. W.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Shenoy, SK (corresponding author), Duke Univ, Med Ctr, Dept Med, Room 412,SANDS Bldg,POB 103204, Durham, NC 27710 USA.	sudha@receptor-biol.duke.edu	Dewhirst, Mark/Q-1302-2019; Shenoy, Sudha/AAN-4075-2021	Dewhirst, Mark/0000-0003-3459-6546; Shenoy, Sudha/0000-0002-2565-4663	NIH [HL080525, CA40355]; NATIONAL CANCER INSTITUTE [R01CA040355] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080525] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We are grateful to Dr Lefkowitz for his insightful comments. We thank Ms Vidya Venkat for technical support. We acknowledge grant support from the NIH (HL080525 to SKS and CA40355 to MWD).	Alvarez CJP, 2009, ENDOCR-RELAT CANCER, V16, P599, DOI 10.1677/ERC-08-0192; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Beppu K, 2004, JNCI-J NATL CANCER I, V96, P46, DOI 10.1093/jnci/djh004; Buchanan FG, 2006, P NATL ACAD SCI USA, V103, P1492, DOI 10.1073/pnas.0510562103; Chuaqui RF, 1997, AM J PATHOL, V150, P297; DAAKA Y, 2004, SCI STKE, pRE2; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Dasgupta P, 2006, J CLIN INVEST, V116, P3083, DOI 10.1172/JCI28164C1; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Dredge K, 2002, BRIT J CANCER, V87, P1166, DOI 10.1038/sj.bjc.6600607; Ebos JML, 2002, MOL CANCER RES, V1, P89; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Figg WD, 2006, CLIN PHARMACOL THER, V79, P1, DOI 10.1016/j.clpt.2005.09.006; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Ge L, 2004, J BIOL CHEM, V279, P55419, DOI 10.1074/jbc.M410312200; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; Holaday JW, 2009, MOL INTERV, V9, P157, DOI 10.1124/mi.9.4.2; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Lakshmikanthan V, 2009, P NATL ACAD SCI USA, V106, P9379, DOI 10.1073/pnas.0900258106; Lal A, 2005, MOL CELL PROBE, V19, P385, DOI 10.1016/j.mcp.2005.06.007; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li TT, 2009, MOL CANCER RES, V7, P1064, DOI 10.1158/1541-7786.MCR-08-0578; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Niida A, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-71; Raghuwanshi SK, 2008, J IMMUNOL, V180, P5699, DOI 10.4049/jimmunol.180.8.5699; Rosano L, 2009, P NATL ACAD SCI USA, V106, P2806, DOI 10.1073/pnas.0807158106; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; SEMENZA GL, 2007, SCI STKE, pCM8, DOI DOI 10.1126/STKE.4072007CM8; Shenoy SK, 2008, J BIOL CHEM, V283, P22166, DOI 10.1074/jbc.M709668200; Vacca A, 2005, J CLIN ONCOL, V23, P5334, DOI 10.1200/JCO.2005.03.723; Vlahovic G, 2006, BRIT J CANCER, V95, P1013, DOI 10.1038/sj.bjc.6603366; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Zou L, 2008, FASEB J, V22, P355, DOI 10.1096/fj.07-9046com	48	54	54	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					282	292		10.1038/onc.2011.238	http://dx.doi.org/10.1038/onc.2011.238			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21685944	Green Accepted			2022-12-17	WOS:000299542100002
J	Udayakumar, D; Zhang, G; Ji, Z; Njauw, CN; Mroz, P; Tsao, H				Udayakumar, D.; Zhang, G.; Ji, Z.; Njauw, C-N; Mroz, P.; Tsao, H.			Epha2 is a critical oncogene in melanoma	ONCOGENE			English	Article						melanoma; EphA2; survival	RECEPTOR TYROSINE KINASE; VASCULOGENIC MIMICRY; PROSTATE-CANCER; CELL-MIGRATION; OVARIAN-CANCER; TUMOR-CELLS; OVEREXPRESSION; EXPRESSION; INVASION; GROWTH	EphA2 is a member of the Eph family of receptor tyrosine kinases and is highly expressed in many aggressive cancer types, including melanoma. We recently showed that EphA2 is also upregulated by ultraviolet radiation and is able to induce apoptosis. These findings suggest that EphA2 may have different, even paradoxical, effects on viability depending on the cellular context and that EphA2 mediates a delicate balance between life and death of the cell. To functionally clarify EphA2's role in melanoma, we analyzed a panel of melanoma cell lines and found that EphA2 levels are elevated in a significant fraction of the samples. Specific depletion of EphA2 in high-expressing melanoma cells using short hairpin RNA led to profound reductions in cellular viability, colony formation and migration in vitro and a dramatic loss of tumorigenic potential in vivo. Stable introduction of EphA2 into low-expressing cell lines enhanced proliferation, colony formation and migration, further supporting its pro-malignant phenotype. Interestingly, transient expression of EphA2 and/or Braf(V600E) in non-transformed melanocytes led to significant and additive apoptosis. These results verify that EphA2 is an important oncogene and potentially a common source of 'addiction' for many melanoma cells. Moreover, acute induction of EphA2 may purge genetically susceptible cells, thereby uncovering a more aggressive population that is in fact dependent on the oncogene. Oncogene (2011) 30, 4921-4929; doi:10.1038/onc.2011.210; published online 13 June 2011	[Udayakumar, D.; Ji, Z.; Mroz, P.; Tsao, H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA 02114 USA; [Udayakumar, D.; Ji, Z.; Njauw, C-N; Mroz, P.; Tsao, H.] Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed, Boston, MA 02114 USA; [Zhang, G.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg,Ctr Vasc Biol Res, Boston, MA 02114 USA; [Tsao, H.] Massachusetts Gen Hosp, Melanoma & Pigmented Les Ctr, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Massachusetts General Hospital	Tsao, H (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Bartlett 622,48 Blossom St, Boston, MA 02114 USA.	htsao@partners.org	Mroz, Pawel/P-1258-2019	Mroz, Pawel/0000-0003-3838-4743	National Institutes of Health [1R21ES013964]; Dermatology Foundation; American Skin Association; Melanoma Research Alliance; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES013964] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dermatology Foundation; American Skin Association; Melanoma Research Alliance; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the National Institutes of Health (1R21ES013964; HT), the Dermatology Foundation (DU), the American Skin Association (HT and DU), the Melanoma Research Alliance (to HT) and the generous philanthropic donors at MGH. We thank Dr Jie Zhao and other members of the Wellman Center Pathology core facility for their help with the tissue sections and confocal analysis. We also thank Dr Michael Hamblin for his support in mice tumor studies.	ALBINI A, 1987, CANCER RES, V47, P3239; ANDRES AC, 1994, ONCOGENE, V9, P1461; Bogan C, 2009, INT J CANCER, V124, P1366, DOI 10.1002/ijc.24083; Chen L, 2010, NATURE, V465, P492, DOI 10.1038/nature09075; Connor RJ, 1998, DEV BIOL, V193, P21, DOI 10.1006/dbio.1997.8786; Cui XD, 2010, INT J CANCER, V126, P940, DOI 10.1002/ijc.24798; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; GANJU P, 1994, ONCOGENE, V9, P1613; Han LQ, 2005, GYNECOL ONCOL, V99, P278, DOI 10.1016/j.ygyno.2005.06.036; Hendrix MJC, 2003, ONCOGENE, V22, P3070, DOI 10.1038/sj.onc.1206447; Herath NI, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-144; Hess AR, 2006, CANCER BIOL THER, V5, P228, DOI 10.4161/cbt.5.2.2510; Hingorani SR, 2003, CANCER RES, V63, P5198; Kamat AA, 2009, CANCER-AM CANCER SOC, V115, P2684, DOI 10.1002/cncr.24335; Kataoka H, 2004, CANCER SCI, V95, P136, DOI 10.1111/j.1349-7006.2004.tb03194.x; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liu Y, 2011, J CANCER RES CLIN, V137, P761, DOI 10.1007/s00432-010-0936-2; Lu C, 2008, CANCER BIOL THER, V7, P1098, DOI 10.4161/cbt.7.7.6168; Margaryan NV, 2009, CANCER BIOL THER, V8, P275, DOI 10.4161/cbt.8.3.7485; Menges CW, 2008, ONCOGENE, V27, P2934, DOI 10.1038/sj.onc.1210957; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Miyazaki T, 2003, INT J CANCER, V103, P657, DOI 10.1002/ijc.10860; Moore-Scott BA, 2007, DEV DYNAM, V236, P1997, DOI 10.1002/dvdy.21204; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; Parri M, 2009, CANCER RES, V69, P2072, DOI 10.1158/0008-5472.CAN-08-1845; RUIZ JC, 1994, MECH DEVELOP, V46, P87; Seftor EA, 2002, CRIT REV ONCOL HEMAT, V44, P17, DOI 10.1016/S1040-8428(01)00199-8; Straume O, 2002, AM J PATHOL, V160, P1009, DOI 10.1016/S0002-9440(10)64922-X; Sulman EP, 1997, GENOMICS, V40, P371, DOI 10.1006/geno.1996.4569; Taddei ML, 2009, AM J PATHOL, V174, P1492, DOI 10.2353/ajpath.2009.080473; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Vaught D, 2009, MOL BIOL CELL, V20, P2572, DOI 10.1091/mbc.E08-04-0378; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Yang G, 2006, J INVEST DERMATOL, V126, P2490, DOI 10.1038/sj.jid.5700470; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhang GQ, 2008, CANCER RES, V68, P1691, DOI 10.1158/0008-5472.CAN-07-2372	41	54	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	50					4921	4929		10.1038/onc.2011.210	http://dx.doi.org/10.1038/onc.2011.210			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YJ	21666714	Green Accepted			2022-12-17	WOS:000298346500001
J	Zhang, S; Wang, X; Osunkoya, AO; Iqbal, S; Wang, Y; Chen, Z; Muller, S; Chen, Z; Josson, S; Coleman, IM; Nelson, PS; Wang, YA; Wang, R; Shin, DM; Marshall, FF; Kucuk, O; Chung, LWK; Zhau, HE; Wu, D				Zhang, S.; Wang, X.; Osunkoya, A. O.; Iqbal, S.; Wang, Y.; Chen, Z.; Mueller, S.; Chen, Z.; Josson, S.; Coleman, I. M.; Nelson, P. S.; Wang, Y. A.; Wang, R.; Shin, D. M.; Marshall, F. F.; Kucuk, O.; Chung, L. W. K.; Zhau, H. E.; Wu, D.			EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis	ONCOGENE			English	Article						EPLIN; epithelial-mesenchymal transition; prostate cancer; lymph node metastasis; cytoskeleton	GENE-EXPRESSION; PROTEIN LOST; PROTEOMIC IDENTIFICATION; ACTIN-CYTOSKELETON; GROWTH; INVASION; BONE; PROGRESSION; NEOPLASM; REVEALS	Epithelial-mesenchymal transition (EMT) is a crucial mechanism for the acquisition of migratory and invasive capabilities by epithelial cancer cells. By conducting quantitative proteomics in experimental models of human prostate cancer (PCa) metastasis, we observed strikingly decreased expression of EPLIN (epithelial protein lost in neoplasm; or LIM domain and actin binding 1, LIMA-1) upon EMT. Biochemical and functional analyses demonstrated that EPLIN is a negative regulator of EMT and invasiveness in PCa cells. EPLIN depletion resulted in the disassembly of adherens junctions, structurally distinct actin remodeling and activation of beta-catenin signaling. Microarray expression analysis identified a subset of putative EPLIN target genes associated with EMT, invasion and metastasis. By immunohistochemistry, EPLIN downregulation was also demonstrated in lymph node metastases of human solid tumors including PCa, breast cancer, colorectal cancer and squamous cell carcinoma of the head and neck. This study reveals a novel molecular mechanism for converting cancer cells into a highly invasive and malignant form, and has important implications in prognosis and treating metastasis at early stages. Oncogene (2011) 30, 4941-4952; doi:10.1038/onc.2011.199; published online 30 May 2011	[Zhang, S.; Osunkoya, A. O.; Iqbal, S.; Wang, Y.; Kucuk, O.; Wu, D.] Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA; [Zhang, S.; Osunkoya, A. O.; Iqbal, S.; Wang, Y.; Marshall, F. F.; Wu, D.] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; [Wang, X.; Chen, Z.; Shin, D. M.; Kucuk, O.] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Osunkoya, A. O.; Mueller, S.] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; [Osunkoya, A. O.; Mueller, S.] Emory Univ, Sch Med, Lab Med, Atlanta, GA 30322 USA; [Chen, Z.] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA; [Josson, S.; Wang, R.; Chung, L. W. K.; Zhau, H. E.] Cedars Sinai Med Ctr, Dept Med, Uro Oncol Res Program, Los Angeles, CA 90048 USA; [Coleman, I. M.; Nelson, P. S.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98195 USA; [Wang, Y. A.] Ocean NanoTech LLC, Springdale, AR USA	Emory University; Emory University; Emory University; Emory University; Emory University; Emory University; Rollins School Public Health; Cedars Sinai Medical Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Wu, D (corresponding author), Emory Univ, Sch Med, Dept Urol, 1365 Clifton Rd,NE,Bldg B,B4108, Atlanta, GA 30322 USA.	Haiyen.Zhau@cshs.org; dwu2@emory.edu	Shin, Dong Moon/G-9649-2013; Ray, Dana M/C-3470-2013	Shin, Dong Moon/0000-0002-8245-4174; , Shareen/0000-0002-9489-7781	Department of Defense [PC060566, PC060866]; American Cancer Society [RSG-10-140-01]; Georgia Cancer Coalition Cancer Research Award; Kennedy Seed Grant; Emory University Research Committee; Winship MPB Seed Grant; National Cancer Institute [P01 CA98912, R01 CA122602, 1R43CA141870]; Georgia Cancer Coalition Distinguished Scholar Grant; NATIONAL CANCER INSTITUTE [R01CA122602, P01CA098912, R43CA141870] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); American Cancer Society(American Cancer Society); Georgia Cancer Coalition Cancer Research Award; Kennedy Seed Grant; Emory University Research Committee; Winship MPB Seed Grant; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Georgia Cancer Coalition Distinguished Scholar Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Jin-Tang Dong for critical reading of the manuscript, and Dr Anthea Hammond for editorial assistance. This work was supported by the Department of Defense PC060566, American Cancer Society RSG-10-140-01, Georgia Cancer Coalition Cancer Research Award, Kennedy Seed Grant, Emory University Research Committee Award, Winship MPB Seed Grant (DW), National Cancer Institute grants P01 CA98912, R01 CA122602 and Department of Defense PC060866 (LWKC), Georgia Cancer Coalition Distinguished Scholar Grant (OK) and National Cancer Institute grant 1R43CA141870 (YAW).	Abe K, 2008, P NATL ACAD SCI USA, V105, P13, DOI 10.1073/pnas.0710504105; Arnold RS, 2009, PROSTATE, V69, P1, DOI 10.1002/pros.20854; Baygi ME, 2010, CELL BIOL TOXICOL, V26, P553, DOI 10.1007/s10565-010-9163-5; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chen SX, 2000, GENE, V248, P69, DOI 10.1016/S0378-1119(00)00144-X; Chircop M, 2009, CELL CYCLE, V8, P757, DOI 10.4161/cc.8.5.7878; Dong JT, 2009, CELL MOL LIFE SCI, V66, P2691, DOI 10.1007/s00018-009-0045-z; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559; Larriba MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010221; Jiang WG, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-71; Katiyar Santosh K., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P17; Keshamouni VG, 2009, J PROTEOME RES, V8, P35, DOI 10.1021/pr8006478; Keshamouni VG, 2006, J PROTEOME RES, V5, P1143, DOI 10.1021/pr050455t; Khwaja FW, 2006, ONCOGENE, V25, P7650, DOI 10.1038/sj.onc.1209969; Khwaja FW, 2007, J PROTEOME RES, V6, P559, DOI 10.1021/pr060240z; Klarmann GJ, 2009, CLIN EXP METASTAS, V26, P433, DOI 10.1007/s10585-009-9242-2; Koreckij TD, 2009, NEOPLASIA, V11, P1216, DOI 10.1593/neo.09960; Kwon MJ, 2005, FRONT BIOSCI-LANDMRK, V10, P300, DOI 10.2741/1529; Lang SH, 2009, J PATHOL, V217, P299, DOI 10.1002/path.2478; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Liu J, 2010, PROSTATE, V70, P1768, DOI 10.1002/pros.21213; Machesky LM, 2009, CANCER CELL, V16, P5, DOI 10.1016/j.ccr.2009.06.009; Mathias RA, 2009, BBA-PROTEINS PROTEOM, V1794, P1325, DOI 10.1016/j.bbapap.2009.05.001; Maul RS, 2003, J CELL BIOL, V160, P399, DOI 10.1083/jcb.200212057; Maul RS, 1999, ONCOGENE, V18, P7838, DOI 10.1038/sj.onc.1203206; McKeithen D, 2010, PROSTATE, V70, P982, DOI 10.1002/pros.21132; O'Connell PA, 2010, BLOOD, V116, P1136, DOI 10.1182/blood-2010-01-264754; Percipalle P, 2009, RNA BIOL, V6, P171, DOI 10.4161/rna.6.2.8195; Pokutta S, 2007, ANNU REV CELL DEV BI, V23, P237, DOI 10.1146/annurev.cellbio.22.010305.104241; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Sakko AJ, 2003, CANCER RES, V63, P4786; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Schneider R, 2007, GENE DEV, V21, P3027, DOI 10.1101/gad.1604607; Smith SC, 2009, NAT REV CANCER, V9, P253, DOI 10.1038/nrc2594; Song YH, 2002, MOL BIOL CELL, V13, P1408, DOI 10.1091/mbc.01-08-0414; Sung SY, 2008, CANCER RES, V68, P9996, DOI 10.1158/0008-5472.CAN-08-2492; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiolloy S, 2011, SEMIN CANCER BIOL, V21, P89, DOI 10.1016/j.semcancer.2010.12.008; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Wei JC, 2008, ANTICANCER RES, V28, P327; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Willipinski-Stapelfeldt B, 2005, CLIN CANCER RES, V11, P8006, DOI 10.1158/1078-0432.CCR-05-0632; Wong SY, 2007, P NATL ACAD SCI USA, V104, P12784, DOI 10.1073/pnas.0705499104; Wu D, 2007, ONCOGENE, V26, P5070, DOI 10.1038/sj.onc.1210316; Xu JC, 2006, PROSTATE, V66, P1664, DOI 10.1002/pros.20488; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhang SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-9; Zhau HE, 2008, CLIN EXP METASTAS, V25, P601, DOI 10.1007/s10585-008-9183-1	53	54	56	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	50					4941	4952		10.1038/onc.2011.199	http://dx.doi.org/10.1038/onc.2011.199			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YJ	21625216	Green Accepted			2022-12-17	WOS:000298346500003
J	Fu, G; Peng, C				Fu, G.; Peng, C.			Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells	ONCOGENE			English	Article						Nodal; ALK7; cyclin G2; FoxO3a; Smad; ovarian cancer	VERTEBRATE DEVELOPMENT; PHOSPHOINOSITIDE 3-KINASE; PROMOTES TUMORIGENESIS; DEPENDENT REGULATION; TUMOR SUPPRESSION; UP-REGULATION; FORKHEAD; APOPTOSIS; EXPRESSION; GROWTH	Nodal, a member of the transforming growth factor-beta superfamily, has been recently shown to suppress cell proliferation and to stimulate the expression of cyclin G2 (CCNG2) in human epithelial ovarian cancer cells. However, the precise mechanisms underlying these events are not fully understood. In this study, we investigated the transcriptional regulation of CCNG2 by the Nodal signaling pathway. In ovarian cancer cells, overexpression of Nodal or its receptors, activin receptor-like kinase 7 (ALK7) or ALK4, resulted in an increase in the CCNG2 promoter activity. Several putative Forkhead box class O (FoxO)3a-binding sites are present in the human CCNG2 promoter and overexpression of FoxO3a enhanced the CCNG2 promoter activity. The functional FoxO3a-binding element (FBE) was mapped to a proximal region located between -398 and -380 bp (FBE1) through deletion and mutation analyses, as well as chromatin immunoprecipitation (IP) assay. Interestingly, mutation of the FBE1 not only abolished the effect of FoxO3a, but also blocked Nodal-induced CCNG2 transcription. Nodal stimulated FoxO3a mRNA and protein expression through the canonical Smad pathway and suppressed FoxO3a inactivation by inhibiting AKT activity. Silencing of FoxO3a using small interfering RNA significantly reduced the effect of Nodal on the CCNG2 promoter activity. On the other hand, overexpression of Smad2 and Smad3 enhanced the FoxO3a-induced CCNG2 promoter activity whereas knockdown of Smad4 blocked the activity of FoxO3a. Furthermore, IP assays revealed that FoxO3a formed complexes with Smad proteins and that Nodal enhanced the binding of FoxO3a to the CCNG2 promoter. Finally, silencing of FoxO3a reversed the inhibitory effect of Nodal on cell proliferation. Taken together, these findings demonstrated that Nodal signaling promotes CCNG2 transcription by upregulating FoxO3a expression, inhibiting FoxO3a phosphorylation and enhancing its synergistic interaction with Smads. These results also suggest that FoxO3a is an important mediator of Nodal signaling in ovarian cancer cells. Oncogene (2011) 30, 3953-3966; doi:10.1038/onc.2011.127; published online 2 May 2011	[Fu, G.; Peng, C.] York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada	York University - Canada	Peng, C (corresponding author), York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	cpeng@yorku.ca	Fu, Guodong/AGF-1991-2022		CIHR [MOP-89931]; CIHR/OWHC	CIHR(Canadian Institutes of Health Research (CIHR)); CIHR/OWHC(Canadian Institutes of Health Research (CIHR))	This work was supported by a CIHR grant (MOP-89931) and a CIHR/OWHC Mid-Career Award to CP.	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Baker K, 2008, P NATL ACAD SCI USA, V105, P13924, DOI 10.1073/pnas.0802159105; Bates S, 1996, ONCOGENE, V13, P1103; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chen J, 2006, J IMMUNOL, V176, P2711, DOI 10.4049/jimmunol.176.5.2711; Cornforth AN, 2008, ONCOGENE, V27, P4422, DOI 10.1038/onc.2008.80; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Fei M, 2009, CANCER INVEST, V27, P52, DOI 10.1080/07357900802146204; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Hauck L, 2007, CIRC RES, V100, P50, DOI 10.1161/01.RES.0000254704.92532.b9; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Katayama K, 2008, ONCOGENE, V27, P1677, DOI 10.1038/sj.onc.1210813; Kenney NJ, 2004, J MAMMARY GLAND BIOL, V9, P133, DOI 10.1023/B:JOMG.0000037158.91940.1c; Kim Y, 2004, CANCER RES, V64, P8980, DOI 10.1158/0008-5472.CAN-04-1926; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kumar A, 2001, J BIOL CHEM, V276, P656, DOI 10.1074/jbc.M004649200; Le XF, 2007, MOL CANCER THER, V6, P2843, DOI 10.1158/1535-7163.MCT-07-0109; Li YW, 2007, J BIOL CHEM, V282, P21542, DOI 10.1074/jbc.M701978200; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Marshall GM, 2010, ONCOGENE, V29, P5957, DOI 10.1038/onc.2010.332; Martinez-Gac L, 2004, MOL CELL BIOL, V24, P2181, DOI 10.1128/MCB.24.5.2181-2189.2004; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Matsuyama S, 2003, CANCER RES, V63, P7791; Munir S, 2004, J BIOL CHEM, V279, P31277, DOI 10.1074/jbc.M400641200; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Ogawa K, 2007, J CELL SCI, V120, P55, DOI 10.1242/jcs.03296; Papageorgiou I, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-122; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shen MM, 2007, DEVELOPMENT, V134, P1023, DOI 10.1242/dev.000166; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; Strizzi Luigi, 2008, Breast Dis, V29, P91; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tian J, 2008, DEVELOPMENT, V135, P2649, DOI 10.1242/dev.019794; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Tsai KL, 2007, NUCLEIC ACIDS RES, V35, P6984, DOI 10.1093/nar/gkm703; Wang H, 2006, MOL ENDOCRINOL, V20, P2469, DOI 10.1210/me.2005-0446; Weidinger C, 2008, ENDOCR-RELAT CANCER, V15, P917, DOI 10.1677/ERC-08-0153; Xu GX, 2008, MOL BIOL CELL, V19, P4968, DOI 10.1091/mbc.E08-03-0259; Xu GX, 2006, MOL CANCER RES, V4, P235, DOI 10.1158/1541-7786.MCR-05-0174; Xu GX, 2004, J CLIN ENDOCR METAB, V89, P5523, DOI 10.1210/jc.2004-0893; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2010, CANCER RES, V70, P4709, DOI 10.1158/0008-5472.CAN-09-4524; Ye G, 2011, J CELL SCI, V124, P359, DOI 10.1242/jcs.072223; You H, 2006, P NATL ACAD SCI USA, V103, P9051, DOI 10.1073/pnas.0600889103; Zhang N, 2006, DIABETOLOGIA, V49, P506, DOI 10.1007/s00125-005-0095-1; Zhang YQ, 2008, DEV DYNAM, V237, P1255, DOI 10.1002/dvdy.21527	62	54	57	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	37					3953	3966		10.1038/onc.2011.127	http://dx.doi.org/10.1038/onc.2011.127			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820FG	21532621				2022-12-17	WOS:000294890400005
J	Clem, BF; Clem, AL; Yalcin, A; Goswami, U; Arumugam, S; Telang, S; Trent, JO; Chesney, J				Clem, B. F.; Clem, A. L.; Yalcin, A.; Goswami, U.; Arumugam, S.; Telang, S.; Trent, J. O.; Chesney, J.			A novel small molecule antagonist of choline kinase-alpha that simultaneously suppresses MAPK and PI3K/AKT signaling	ONCOGENE			English	Article						chemotherapy; choline kinase; metabolism; in silico; phosphocholine	BREAST-CANCER-CELLS; PHOSPHATIDIC-ACID; PHOSPHOLIPASE-D; PROSTATE-CANCER; RAS ACTIVATION; GROWTH-FACTORS; PHOSPHATIDYLCHOLINE; INHIBITORS; RAF-1; P-31	Choline kinase-alpha expression and activity are increased in multiple human neoplasms as a result of growth factor stimulation and activation of cancer-related signaling pathways. The product of choline kinase-alpha, phosphocholine, serves as an essential metabolic reservoir for the production of phosphatidylcholine, the major phospholipid constituent of membranes and substrate for the production of lipid second messengers. Using in silico screening for small molecules that may interact with the choline kinase-alpha substrate binding domain, we identified a novel competitive inhibitor, N-(3,5-dimethylphenyl)-2-[[5-(4-ethylphenyl)-1H-1,2,4-triazol-3-yl] sulfanyl] acetamide (termed CK37) that inhibited purified recombinant human choline kinase-alpha activity, reduced the steady-state concentration of phosphocholine in transformed cells, and selectively suppressed the growth of neoplastic cells relative to normal epithelial cells. Choline kinase-alpha activity is required for the downstream production of phosphatidic acid, a promoter of several Ras signaling pathways. CK37 suppressed mitogen-activated protein kinase and phosphatidylinositol 3-kinase/AKT signaling, disrupted actin cytoskeletal organization, and reduced plasma membrane ruffling. Finally, administration of CK37 significantly decreased tumor growth in a lung tumor xenograft mouse model, suppressed tumor phosphocholine, and diminished activating phosphorylations of extracellular signal-regulated kinase and AKT in vivo. Together, these results further validate choline kinase-alpha as a molecular target for the development of agents that interrupt Ras signaling pathways, and indicate that receptor-based computational screening should facilitate the identification of new classes of choline kinase-alpha inhibitors. Oncogene (2011) 30, 3370-3380; doi:10.1038/onc.2011.51; published online 21 March 2011	[Clem, B. F.; Clem, A. L.; Yalcin, A.; Goswami, U.; Arumugam, S.; Telang, S.; Trent, J. O.; Chesney, J.] Univ Louisville, Dept Med, Louisville, KY 40202 USA; [Clem, B. F.; Yalcin, A.; Telang, S.; Trent, J. O.; Chesney, J.] Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; [Clem, B. F.; Clem, A. L.; Yalcin, A.; Goswami, U.; Telang, S.; Trent, J. O.; Chesney, J.] Univ Louisville, Mol Targets Grp, Louisville, KY 40202 USA; [Arumugam, S.; Trent, J. O.] Univ Louisville, Struct Biol Program, James Graham Brown Canc Ctr, Louisville, KY 40202 USA; [Yalcin, A.] Uludag Univ, Dept Biochem, Sch Vet Med, Bursa, Turkey	University of Louisville; University of Louisville; University of Louisville; University of Louisville; Uludag University	Chesney, J (corresponding author), Univ Louisville, Dept Med, 505 S Hancock St,CTRB,Room 424, Louisville, KY 40202 USA.	jotrent01@louisville.edu; jason.chesney@louisville.edu	Yalcin, Abdullah/ABI-4164-2020; Yalcin, Abdullah/AAA-6938-2022	Yalcin, Abdullah/0000-0001-8519-8375; trent, John/0000-0002-7346-4231	Brown Foundation; NCCRR [1P20 RR18733]; James Graham Brown Cancer Center; Ky Lung Cancer Research Program; National Cancer Institute [2R56CA116428-0509]; NATIONAL CANCER INSTITUTE [R01CA116428, R56CA116428] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018733] Funding Source: NIH RePORTER	Brown Foundation; NCCRR; James Graham Brown Cancer Center; Ky Lung Cancer Research Program; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We acknowledge Deanna Siow and Binks Wattenburg for assistance with the thin layer chromatography protocol, Erin Brock for assisting with the confocal microscopy experiments, Bennet Jenson for histopathology assistance, and Andrew Lane for NMR interpretation. We also thank Dr Arnon Lavie for providing the Delta 49N-hCK alpha 2 plasmid for the expression of recombinant choline kinase. NMR experiments were carried out at the James Graham Brown Cancer Center NMR facility, supported in part by the Brown Foundation and NCCRR Grant 1P20 RR18733. This work was supported by institutional funds from the James Graham Brown Cancer Center and by grants from the Ky Lung Cancer Research Program (JC & BFC) and the National Cancer Institute (JC: 2R56CA116428-0509).	Ackerstaff E, 2003, J CELL BIOCHEM, V90, P525, DOI 10.1002/jcb.10659; Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; Buchanan FG, 2005, P NATL ACAD SCI USA, V102, P1638, DOI 10.1073/pnas.0406698102; Chua BT, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-131; Chung TW, 2000, CELL SIGNAL, V12, P279, DOI 10.1016/S0898-6568(00)00065-6; de Molina AR, 2002, ONCOGENE, V21, P4317, DOI 10.1038/sj.onc.1205556; de Molina AR, 2004, CANCER LETT, V206, P137, DOI 10.1016/j.canlet.2003.08.031; DEGANI H, 1986, RADIOLOGY, V161, P53, DOI 10.1148/radiology.161.1.3020609; Eliyahu G, 2007, INT J CANCER, V120, P1721, DOI 10.1002/ijc.22293; EXTON JH, 1990, J BIOL CHEM, V265, P1; Fan TWM, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-79; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Foster DA, 2003, MOL CANCER RES, V1, P789; Glunde K, 2005, CANCER RES, V65, P11034, DOI 10.1158/0008-5472.CAN-05-1807; Glunde K, 2008, CANCER RES, V68, P172, DOI 10.1158/0008-5472.CAN-07-2678; Glunde K, 2007, LANCET ONCOL, V8, P855, DOI 10.1016/S1470-2045(07)70289-9; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Hancock JF, 2007, NAT CELL BIOL, V9, P615, DOI 10.1038/ncb0607-615; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; Iero M, 2008, CELL DEATH DIFFER, V15, P80, DOI 10.1038/sj.cdd.4402237; Iorio E, 2005, CANCER RES, V65, P9369, DOI 10.1158/0008-5472.CAN-05-1146; Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+; Jain AN, 2007, J COMPUT AID MOL DES, V21, P281, DOI 10.1007/s10822-007-9114-2; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; KO KWS, 1986, J BIOL CHEM, V261, P7846; Li GP, 1997, J BIOL CHEM, V272, P10337; Malito E, 2006, J MOL BIOL, V364, P136, DOI 10.1016/j.jmb.2006.08.084; McCubrey JA, 2007, ADV ENZYME REGUL, V47, P64, DOI 10.1016/j.advenzreg.2006.12.013; NEEMAN M, 1989, P NATL ACAD SCI USA, V86, P5585, DOI 10.1073/pnas.86.14.5585; ONODERA K, 1986, JPN J CANCER RES, V77, P1201; Ramirez de Molina A, 2005, CANCER RES, V65, P5647, DOI 10.1158/0008-5472.CAN-04-4416; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Ramirez de Molina A, 2004, CANCER RES, V64, P6732, DOI 10.1158/0008-5472.CAN-04-0489; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 2002, PHARMACOL THERAPEUT, V94, P35, DOI 10.1016/S0163-7258(02)00170-5; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rodriguez-Gonzalez A, 2003, ONCOGENE, V22, P8803, DOI 10.1038/sj.onc.1207062; Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Scales SJ, 1999, NATURE, V401, P123, DOI 10.1038/43582; TAETLE R, 1987, CANCER TREAT REP, V71, P297; Telang S, 2006, ONCOGENE, V25, P7225, DOI 10.1038/sj.onc.1209709; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Uchida T, 1996, BBA-LIPID LIPID MET, V1304, P89, DOI 10.1016/S0005-2760(96)00109-9; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; Wu GS, 2008, J BIOL CHEM, V283, P1456, DOI 10.1074/jbc.M708766200; Yalcin A, 2010, ONCOGENE, V29, P139, DOI 10.1038/onc.2009.317; Zhao C, 2007, NAT CELL BIOL, V9, P706, DOI 10.1038/ncb1594	54	54	60	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	30					3370	3380		10.1038/onc.2011.51	http://dx.doi.org/10.1038/onc.2011.51			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21423211	Green Accepted			2022-12-17	WOS:000293215700007
J	Malapeira, J; Esselens, C; Bech-Serra, JJ; Canals, F; Arribas, J				Malapeira, J.; Esselens, C.; Bech-Serra, J. J.; Canals, F.; Arribas, J.			ADAM17 (TACE) regulates TGF beta signaling through the cleavage of vasorin	ONCOGENE			English	Article						vasorin; ADAM17; TACE; ectodomain shedding; TGF beta	EPITHELIAL-MESENCHYMAL TRANSITIONS; ALPHA-CONVERTING ENZYME; GROWTH-FACTOR-BETA; MATRIX METALLOPROTEINASES; BREAST-CANCER; ACTIVATION; PROTEINS; EGFR; METASTASIS; PROTEASES	The activity of a variety of extracellular signaling factors is tightly regulated by proteins containing A Disintegrin And a Metalloprotease domain ( ADAM) metalloproteases through limited proteolysis. Thus, the identification of ADAM substrates may unveil novel components and mechanisms of cell signaling pathways. We report the identification of the transmembrane protein vasorin (VASN), a transforming growth factor-beta (TGF beta) trap, as a substrate of ADAM17. The metalloprotease efficiently generates a soluble fragment encompassing the extracellular domain of VASN. Despite the importance of TGF beta in normal development and tumor progression, the regulation of VASN is completely unknown. Here, we show that only the soluble form of VASN inhibits TGFb and that the secretion of VASN is tightly controlled by ADAM17. Hence, inhibition of ADAM17 leads to the upregulation of TGFb signaling. Adding a new level of complexity to the function of ADAM17, we finally show that, through the cleavage of VASN, the metalloprotease controls TGFb-mediated epithelial-to-mesenchymal transition. Oncogene (2011) 30, 1912-1922; doi: 10.1038/onc.2010.565; published online 20 December 2010	[Malapeira, J.; Esselens, C.; Arribas, J.] Vall Hebron Univ Hosp, VHIO, Med Oncol Res Program, Barcelona 08035, Spain; [Bech-Serra, J. J.; Canals, F.] Vall Hebron Univ Hosp, Res Inst Fdn, Prote Lab, Barcelona 08035, Spain; [Arribas, J.] Autonomous Univ Barcelona, Dept Biochem & Mol Biol, Bellaterra, Spain; [Arribas, J.] ICREA, Barcelona, Spain	Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; ICREA	Arribas, J (corresponding author), Vall Hebron Univ Hosp, VHIO, Med Oncol Res Program, Psg Vall Hebron 119-129, Barcelona 08035, Spain.	jarribas@vhio.net	Bech-Serra, Joan Josep/AAA-2330-2020; Arribas, Joaquin/M-4482-2014; Malapeira, Jordi/I-7956-2014	Bech-Serra, Joan Josep/0000-0003-3486-781X; Arribas, Joaquin/0000-0002-0504-0664; Esselens, Cary/0000-0001-8876-634X; Malapeira, Jordi/0000-0003-3503-1272	Instituto de Salud Carlos III [PI081154, RD06/0020/0022, PI071058]; ICREA Funding Source: Custom	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); ICREA(ICREA)	We thank Dr Fernando Lopez-Casillas for critical reading of the manuscript. The Proteomics Laboratory is a member of the National Spanish Institute for Proteomics (PROTEORED) and it is funded in part by Fundacio Cellex. CW Esselens is a postdoctoral fellow from the Juan de la Cierva program (Spanish Ministry of Education). This research was supported by Grants from the Instituto de Salud Carlos III (Intrasalud PI081154 and the network of cooperative cancer research (RTICC-RD06/0020/0022) to JA and PI071058	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Arribas J, 2003, CURR TOP DEV BIOL, V54, P125, DOI 10.1016/S0070-2153(03)54007-8; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Arribas J, 2009, CURR PHARM DESIGN, V15, P2319, DOI 10.2174/138161209788682398; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Borroto A, 2003, J BIOL CHEM, V278, P25933, DOI 10.1074/jbc.M301673200; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; de la Torre TV, 2004, BIOCHEM BIOPH RES CO, V314, P1028, DOI 10.1016/j.bbrc.2003.12.186; Esselens CW, 2008, BIOL CHEM, V389, P1075, DOI 10.1515/BC.2008.121; Friedman S, 2009, CANCER RES, V69, p783S; Guo L, 2002, MOL CELL PROTEOMICS, V1, P30, DOI 10.1074/mcp.M100020-MCP200; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hyytiainen M, 2004, CRIT REV CL LAB SCI, V41, P233, DOI 10.1080/10408360490460933; Ikeda Y, 2004, P NATL ACAD SCI USA, V101, P10732, DOI 10.1073/pnas.0404117101; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Kenny PA, 2007, J CLIN INVEST, V117, P337, DOI 10.1172/JCI29518; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Liu C, 2009, MOL CELL, V35, P26, DOI 10.1016/j.molcel.2009.06.018; Lopez-Otin C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Overall CM, 2007, NAT REV MOL CELL BIO, V8, P245, DOI 10.1038/nrm2120; Pedersen K, 2009, MOL CELL BIOL, V29, P3319, DOI 10.1128/MCB.01803-08; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	29	54	54	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	16					1912	1922		10.1038/onc.2010.565	http://dx.doi.org/10.1038/onc.2010.565			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21170088				2022-12-17	WOS:000289777700007
J	Zhou, J; Yang, Z; Tsuji, T; Gong, J; Xie, J; Chen, C; Li, W; Amar, S; Luo, Z				Zhou, J.; Yang, Z.; Tsuji, T.; Gong, J.; Xie, J.; Chen, C.; Li, W.; Amar, S.; Luo, Z.			LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth	ONCOGENE			English	Article						AMPK; LITAF; TNFSF15; p53; tumor suppressor; tumorigenesis	TNF-ALPHA FACTOR; ACTIVATED PROTEIN-KINASE; PROSTATE-CANCER CELLS; MARIE-TOOTH-DISEASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; SIMPLE MUTATION; CYTOKINE	Lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF) a factor (LITAF) is a multiple functional molecule whose sequence is identical to the small integral membrane protein of the lysosome/ late endosome. LITAF was initially identified as a transcription factor that activates transcription of proinflammatory cytokine in macrophages in response to LPS. Mutations of the LITAF gene are associated with a genetic disease, called Charcot-Marie-Tooth syndrome. Recently, we have reported that mRNA levels of LITAF and TNF superfamily member 15 (TNFSF15) are upregulated by 50 adenosine monophosphate (AMP)-activated protein kinase (AMPK). The present study further assesses their biological functions. Thus, we show that 5-aminoimidazole4- carboxamide ribonucleoside (AICAR), a pharmacological activator of AMPK, increases the abundance of LITAF and TNFSF15 in LNCaP and C4-2 prostate cancer cells, which is abrogated by small hairpin RNA (shRNA) or the dominant-negative mutant of AMPK a1 subunit. Our data further demonstrate that AMPK activation upregulates the transcription of LITAF. Intriguingly, silencing LITAF by shRNA enhances proliferation, anchorageindependent growth of these cancer cells and tumor growth in the xenograft model. In addition, our study reveals that LITAF mediates the effect of AMPK by binding to a specific sequence in the promoter region. Furthermore, we show that TNFSF15 remarkably inhibits the growth of prostate cancer cells and bovine aortic endothelial cells in vitro, with a more potent effect toward the latter. In conjuncture, intratumoral injection of TNFSF15 significantly reduces the size of tumors and number of blood vessels and induces changes that are characteristic of tumor cell differentiation. Therefore, our studies for the first time establish the regulatory axis of AMPK-LITAF-TNFSF15 and also suggest that LITAF may function as a tumor suppressor. Oncogene (2011) 30, 1892-1900; doi: 10.1038/onc.2010.575; published online 10 January 2011	[Zhou, J.; Gong, J.; Xie, J.; Li, W.; Luo, Z.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Yang, Z.] Shaanxi Normal Univ, Coll Life Sci, Dept Biochem & Mol Biol, Xian, Peoples R China; [Tsuji, T.; Chen, C.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Radiat Oncol, Boston, MA 02215 USA; [Amar, S.] Boston Univ, Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02118 USA	Boston University; Shaanxi Normal University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University	Luo, Z (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St,Evans 645, Boston, MA 02118 USA.	zluo@bu.edu	Luo, Zhijun/AAE-9302-2019	Luo, Zhijun/0000-0001-8105-5289; Amar, Salomon/0000-0002-0017-5930	NIH [R01 CA118918, R01 DE014079, CA124490]; NATIONAL CANCER INSTITUTE [R01CA124490, R01CA118918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011340] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work is supported by NIH grants (R01 CA118918 to ZL, R01 DE014079 to SA and CA124490 to CC). We thank Dr Zhixiong Xiao (BUMC) for providing p53 shRNA pSuperRetro construct as a generous gift. We are also thankful to Miss Siu Wong for her assistance in animal dissection, to Dr Wen Guo for helping us with confirmatory qPCR analysis and to Dr Mengwei Zang for her advice on statistical analysis.	Bayry J, 2010, NAT REV RHEUMATOL, V6, P67, DOI 10.1038/nrrheum.2009.263; Beauvais K, 2006, NEUROMUSCULAR DISORD, V16, P14, DOI 10.1016/j.nmd.2005.09.008; Bennett CL, 2004, ANN NEUROL, V55, P713, DOI 10.1002/ana.20094; Chang JY, 2010, EXP BIOL MED, V235, P796, DOI 10.1258/ebm.2010.009351; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Haridas V, 1999, ONCOGENE, V18, P6496, DOI 10.1038/sj.onc.1203059; Hong YH, 2006, DEV COMP IMMUNOL, V30, P919, DOI 10.1016/j.dci.2005.12.007; Hou W, 2005, CLIN CANCER RES, V11, P5595, DOI 10.1158/1078-0432.CCR-05-0384; Latour P, 2006, J PERIPHER NERV SYST, V11, P148, DOI 10.1111/j.1085-9489.2006.00080.x; Ludes-Meyers JH, 2004, ONCOGENE, V23, P5049, DOI 10.1038/sj.onc.1207680; Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI [10.2217/fon.09.174, 10.2217/FON.09.174]; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; Myokai F, 1999, P NATL ACAD SCI USA, V96, P4518, DOI 10.1073/pnas.96.8.4518; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Niemann A, 2006, NEUROMOL MED, V8, P217, DOI 10.1385/NMM:8:1:217; Pan X, 2004, WORLD J GASTROENTERO, V10, P1409; Parr Christian, 2006, Angiogenesis, V9, P73, DOI 10.1007/s10456-006-9033-1; Picornell Y, 2007, INFLAMM BOWEL DIS, V13, P1333, DOI 10.1002/ibd.20223; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sethi G, 2009, ADV EXP MED BIOL, V647, P207, DOI 10.1007/978-0-387-89520-8_15; Stucchi A, 2006, INFLAMM BOWEL DIS, V12, P581, DOI 10.1097/01.MIB.0000225338.14356.d5; Tang XR, 2007, CANCER RES, V67, P1308, DOI 10.1158/0008-5472.CAN-06-1600; Tang XR, 2006, P NATL ACAD SCI USA, V103, P13777, DOI 10.1073/pnas.0605988103; Tang XR, 2005, P NATL ACAD SCI USA, V102, P5132, DOI 10.1073/pnas.0501159102; Tang XR, 2003, P NATL ACAD SCI USA, V100, P4096, DOI 10.1073/pnas.0630562100; Xiang XQ, 2004, BIOCHEM BIOPH RES CO, V321, P161, DOI 10.1016/j.bbrc.2004.06.133; Xiang XQ, 2002, J BIOL CHEM, V277, P44996, DOI 10.1074/jbc.M203953200; Young HA, 2006, P NATL ACAD SCI USA, V103, P8303, DOI 10.1073/pnas.0602655103; Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479; Zhai YF, 1999, INT J CANCER, V82, P131, DOI 10.1002/(SICI)1097-0215(19990702)82:1<131::AID-IJC22>3.3.CO;2-F; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181; Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012; Zhou J, 2009, ONCOGENE, V28, P1993, DOI 10.1038/onc.2009.63	33	54	59	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	16					1892	1900		10.1038/onc.2010.575	http://dx.doi.org/10.1038/onc.2010.575			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21217782	Green Accepted			2022-12-17	WOS:000289777700005
J	Wiebusch, L; Hagemeier, C				Wiebusch, L.; Hagemeier, C.			p53-and p21-dependent premature APC/C-Cdh1 activation in G2 is part of the long-term response to genotoxic stress	ONCOGENE			English	Article						APC/C; p53; p21; Emi1; senescence; apoptosis	ANAPHASE-PROMOTING COMPLEX; NORMAL HUMAN FIBROBLASTS; DNA-DAMAGE-RESPONSE; HUMAN CANCER-CELLS; S-PHASE; TRANSCRIPTIONAL REPRESSION; ANTICANCER AGENTS; TUMOR-SUPPRESSION; UBIQUITIN LIGASE; DOWN-REGULATION	The long-term cellular response to DNA damage is controlled by the tumor suppressor p53. It results in cell-cycle arrest followed by DNA repair and, depending on the degree of damage inflicted, premature senescence or apoptotic cell death. Here we show that in normal diploid fibroblasts the ubiquitin ligase anaphase-promoting complex or cyclosome (APC/C)-Cdh1 becomes prematurely activated in G2 as part of the sustained long-term but not the rapid short-term response to genotoxic stress and results in the degradation of numerous APC/C substrates. Using HCT116 somatic knockout cells we show that mechanistically premature APC/C activation depends on p53 and its transcriptional target p21 that mediates the signal through downregulation of the APC/C inhibitor Emi1. Cdc14B is dispensable in this setting but might function redundantly. Our data suggest an unexpected role for the APC/C in executing a part of the p53-dependent DNA damage response that leads to premature senescence. Oncogene (2010) 29, 3477-3489; doi:10.1038/onc.2010.99; published online 12 April 2010	[Wiebusch, L.; Hagemeier, C.] Charite, Childrens Hosp, Mol Biol Lab, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Wiebusch, L (corresponding author), Charite, Childrens Hosp, Mol Biol Lab, Ziegelstr 5-9, D-10117 Berlin, Germany.	lueder.wiebusch@charite.de; christian.hagemeier@charite.de	Wiebusch, Lüder/AAR-6668-2021	Wiebusch, Lüder/0000-0002-7210-6731	Deutsche Forschungsgemeinschaft (DFG) [HA1575/2-1, WI2043/2-2]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	We thank Eli Berdougo, Philipp Haemmati, Christoph Hanski, Hans-Jurgen Heidebrecht, Prasad Jallepalli, Bert Vogelstein and Ralph Wasch for the generous supply of reagents. We acknowledge Matthias Truss for help with lentivirus production and Ralf Uecker for excellent technical assistance. This work was supported by Grants HA1575/2-1 and WI2043/2-2 from the Deutsche Forschungsgemeinschaft (DFG).	Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931; Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Andreassen PR, 2001, CANCER RES, V61, P7660; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Banerjee T, 2009, NUCLEIC ACIDS RES, V37, P2688, DOI 10.1093/nar/gkp110; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Berdougo E, 2008, CELL CYCLE, V7, P1184, DOI 10.4161/cc.7.9.5792; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang BD, 1999, CANCER RES, V59, P3761; Demidenko ZN, 2008, CELL CYCLE, V7, P3355, DOI 10.4161/cc.7.21.6919; Di Fiore B, 2007, J CELL BIOL, V177, P425, DOI 10.1083/jcb.200611166; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Duursma A, 2005, MOL CELL BIOL, V25, P6937, DOI 10.1128/MCB.25.16.6937-6947.2005; Gillis LD, 2009, CELL CYCLE, V8, P253, DOI 10.4161/cc.8.2.7550; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hansen DV, 2004, MOL BIOL CELL, V15, P5623, DOI 10.1091/mbc.E04-07-0598; HARPER JW, 1993, CELL, V75, P805; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Janicke RU, 2007, CELL CYCLE, V6, P407; Kan QM, 2008, P NATL ACAD SCI USA, V105, P4757, DOI 10.1073/pnas.0706392105; Kidokoro T, 2008, ONCOGENE, V27, P1562, DOI 10.1038/sj.onc.1210799; Kob R, 2009, CELL CYCLE, V8, P2041, DOI 10.4161/cc.8.13.8850; Kurose A, 2006, CELL PROLIFERAT, V39, P231, DOI 10.1111/j.1365-2184.2006.00380.x; Lee J, 2009, MOL BIOL CELL, V20, P1891, DOI 10.1091/mbc.E08-08-0818; Liu WJ, 2007, MOL CELL BIOL, V27, P2967, DOI 10.1128/MCB.01830-06; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Machida YJ, 2007, GENE DEV, V21, P184, DOI 10.1101/gad.1495007; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Matthew EM, 2007, CELL CYCLE, V6, P2571, DOI 10.4161/cc.6.20.5079; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Pfleger CM, 2000, GENE DEV, V14, P655; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rodier G, 2008, EMBO J, V27, P679, DOI 10.1038/emboj.2008.6; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Spurgers KB, 2006, J BIOL CHEM, V281, P25134, DOI 10.1074/jbc.M513901200; St Clair S, 2004, MOL CELL, V16, P725; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Summers MK, 2008, MOL CELL, V31, P544, DOI 10.1016/j.molcel.2008.07.014; Wasch R, 2010, ONCOGENE, V29, P1, DOI 10.1038/onc.2009.325; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang W, 2005, BIOCHEMISTRY-US, V44, P14553, DOI 10.1021/bi051071j; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039	60	54	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3477	3489		10.1038/onc.2010.99	http://dx.doi.org/10.1038/onc.2010.99			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20383190				2022-12-17	WOS:000278835400003
J	Richard, C; Lanner, C; Naryzhny, SN; Sherman, L; Lee, H; Lambert, PF; Zehbe, I				Richard, C.; Lanner, C.; Naryzhny, S. N.; Sherman, L.; Lee, H.; Lambert, P. F.; Zehbe, I.			The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer	ONCOGENE			English	Article						human papillomavirus; human primary foreskin keratinocytes; immortalization; transformation; cervical cancer	MAMMARY EPITHELIAL-CELLS; TYPE-16 E6; HUMAN-PAPILLOMAVIRUS-16 E6; INTRAEPITHELIAL NEOPLASIA; TELOMERASE ACTIVATION; HUMAN KERATINOCYTES; NATURAL VARIANTS; P53 DEGRADATION; E7 ONCOGENES; IN-VIVO	Persistent infection with high-risk human papillomaviruses (HPVs), especially type 16 has been undeniably linked to cervical cancer. The Asian-American (AA) variant of HPV16 is more common in the Americas than the prototype in cervical cancer. The different prevalence is based on three amino acid changes within the E6 protein denoted Q14H/H78Y/L83V. To investigate the mechanism(s) behind this observation, both E6 proteins, in the presence of E7, were evaluated for their ability to extend the life span of and transform primary human foreskin keratinocytes (PHFKs). Longterm cell culture studies resulted in death at passage 9 of vector-transduced PHFKs (negative control), but survival of both E6 PHFKs to passage 65 (and beyond). Compared with E6/E7 PHFKs, AA/E7 PHFKs were significantly faster dividing, developed larger cells in monolayer cultures, showed double the epithelial thickness and expressed cytokeratin 10 when grown as organotypic raft cultures. Telomerase activation and p53 inactivation, two hallmarks of immortalization, were not significantly different between the two populations. Both were resistant to anoikis at later passages, but only AA/E7 PHFKs acquired the capacity for in vitro transformation. Proteomic analysis revealed markedly different protein patterns between E6/E7 and AA/E7, particularly with respect to key cellular metabolic enzymes. Our results provide new insights into the reasons underlying the greater prevalence of the AA variant in cervical cancer as evidenced by characteristics associated with higher oncogenic potential. Oncogene (2010) 29, 3435-3445; doi:10.1038/onc.2010.93; published online 12 April 2010	[Zehbe, I.] Thunder Bay Reg Res Inst, Thunder Bay, ON P7B 6V4, Canada; [Richard, C.] Thunder Bay Reg Hlth Sci Ctr, Res Lab, Thunder Bay, ON, Canada; [Lanner, C.; Lee, H.] Laurentian Univ, No Ontario Sch Med, Sudbury, ON P3E 2C6, Canada; [Naryzhny, S. N.] Laurentian Univ, Dept Chem & Biochem, Sudbury, ON P3E 2C6, Canada; [Naryzhny, S. N.; Lee, H.] Sudbury Reg Hosp, NE Ontario Reg Canc Program, Sudbury, ON, Canada; [Sherman, L.] Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, IL-69978 Tel Aviv, Israel; [Lambert, P. F.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	Northern Ontario School of Medicine; Northern Ontario School of Medicine; Laurentian University; Northern Ontario School of Medicine; Laurentian University; Health Sciences North; Tel Aviv University; Sackler Faculty of Medicine; University of Wisconsin System; University of Wisconsin Madison	Zehbe, I (corresponding author), Thunder Bay Reg Res Inst, 980 Oliver Rd, Thunder Bay, ON P7B 6V4, Canada.	zehbei@tbh.net	Lambert, Paul F/F-3747-2012; Naryzhny, Stanislav/D-1683-2012	Naryzhny, Stanislav/0000-0002-4102-3423	Natural Sciences and Engineering Research Council of Canada (NSERC)	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC))	We are grateful to the staff from the Central Laboratory of the Thunder Bay Regional Health Sciences Centre for technical assistance and Bruce Weaver from the Northern School of Medicine, West-Campus, Thunder Bay for help with statistical analysis. This work was funded by a Discovery Grant to IZ from the Natural Sciences and Engineering Research Council of Canada (NSERC).	Allen-Hoffmann BL, 2000, J INVEST DERMATOL, V114, P444, DOI 10.1046/j.1523-1747.2000.00869.x; ANDROPHY EJ, 1985, SCIENCE, V230, P442, DOI 10.1126/science.2996134; Asadurian Y, 2007, J MED VIROL, V79, P1751, DOI 10.1002/jmv.20978; Bernard HU, 2006, INT J CANCER, V118, P1071, DOI 10.1002/ijc.21655; Bernard HU, 2005, J CLIN VIROL, V32, pS1, DOI 10.1016/j.jcv.2004.10.021; Berumen J, 2001, JNCI-J NATL CANCER I, V93, P1325, DOI 10.1093/jnci/93.17.1325; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Camus S, 2007, ONCOGENE, V26, P4059, DOI 10.1038/sj.onc.1210188; Carujo S, 2006, ONCOGENE, V25, P4033, DOI 10.1038/sj.onc.1209433; Castellsague X, 2008, GYNECOL ONCOL, V110, pS4, DOI 10.1016/j.ygyno.2008.07.045; Chakrabarti O, 2004, J VIROL, V78, P5934, DOI 10.1128/JVI.78.11.5934-5945.2004; Chen ZG, 2005, J VIROL, V79, P7014, DOI 10.1128/JVI.79.11.7014-7023.2005; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; Souza PSD, 2009, FUTURE ONCOL, V5, P359, DOI [10.2217/fon.09.8, 10.2217/FON.09.8]; DeCarlo CA, 2008, ANAL BIOCHEM, V381, P59, DOI 10.1016/j.ab.2008.06.009; Fu BJ, 2003, CANCER RES, V63, P7815; Grodzki M, 2006, CANCER EPIDEM BIOMAR, V15, P820, DOI 10.1158/1055-9965.EPI-05-0864; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; James MA, 2006, INT J CANCER, V119, P1878, DOI 10.1002/ijc.22064; Ji Q, 2004, CANCER RES, V64, P7610, DOI 10.1158/0008-5472.CAN-04-1608; Kammer C, 2002, BRIT J CANCER, V86, P269, DOI 10.1038/sj.bjc.6600024; KAUR P, 1989, VIROLOGY, V173, P302, DOI 10.1016/0042-6822(89)90247-X; Kirkpatrick Katharine L, 2004, J Carcinog, V3, P1, DOI 10.1186/1477-3163-3-1; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kondoh H, 2008, EXP CELL RES, V314, P1923, DOI 10.1016/j.yexcr.2008.03.007; Kyo S, 1999, INT J CANCER, V80, P60, DOI 10.1002/(SICI)1097-0215(19990105)80:1<60::AID-IJC12>3.3.CO;2-5; Lee K, 2008, VIRUS RES, V131, P106, DOI 10.1016/j.virusres.2007.08.003; Lichtig H, 2006, VIROLOGY, V350, P216, DOI 10.1016/j.virol.2006.01.038; Maddox P, 1999, J CLIN PATHOL, V52, P41, DOI 10.1136/jcp.52.1.41; Marconi A, 2004, J CELL SCI, V117, P5815, DOI 10.1242/jcs.01490; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; McMurray HR, 2004, J VIROL, V78, P5698, DOI 10.1128/JVI.78.11.5698-5706.2004; Naryzhny SN, 2007, FEBS LETT, V581, P4917, DOI 10.1016/j.febslet.2007.09.022; Nomine Y, 2006, MOL CELL, V21, P665, DOI 10.1016/j.molcel.2006.01.024; Penning TM, 2009, ANN NY ACAD SCI, V1155, P33, DOI 10.1111/j.1749-6632.2009.03700.x; Pollard PJ, 2009, SCIENCE, V324, P192, DOI 10.1126/science.1173362; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHONK DM, 1989, HUM GENET, V83, P297, DOI 10.1007/BF00285178; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; Sekaric P, 2008, J VIROL, V82, P71, DOI 10.1128/JVI.01776-07; Shamanin VA, 2008, J VIROL, V82, P3912, DOI 10.1128/JVI.02466-07; Shen ZY, 2004, ONCOL REP, V11, P647; SMEDTS F, 1992, AM J PATHOL, V141, P497; SMEDTS F, 1993, OBSTET GYNECOL, V82, P465; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Sprague DL, 2002, VIROLOGY, V301, P247, DOI 10.1006/viro.2002.1542; Stoppler MC, 1996, J VIROL, V70, P6987; Sumida T, 1999, INT J CANCER, V80, P1, DOI 10.1002/(SICI)1097-0215(19990105)80:1<1::AID-IJC1>3.0.CO;2-U; TIDY JA, 1989, LANCET, V1, P1225; WOODWORTH CD, 1988, CANCER RES, V48, P4620; Xi LF, 1998, CANCER RES, V58, P3839; Xi LF, 1997, JNCI-J NATL CANCER I, V89, P796, DOI 10.1093/jnci/89.11.796; Xi LF, 2007, CANCER EPIDEM BIOMAR, V16, P4, DOI 10.1158/1055-9965.EPI-06-0670; Xi LF, 2006, J NATL CANCER I, V98, P1045, DOI 10.1093/jnci/djj297; Zehbe I, 1999, ONCOGENE, V18, P2201, DOI 10.1038/sj.onc.1202549; Zehbe I, 2003, HUM IMMUNOL, V64, P538, DOI 10.1016/S0198-8859(03)00033-8; Zehbe I, 1998, LANCET, V352, P1441, DOI 10.1016/S0140-6736(05)61263-9; Zehbe I, 2001, INT J CANCER, V94, P711, DOI 10.1002/ijc.1520; Zehbe I, 1998, CANCER RES, V58, P829; Zehbe I, 2009, VIROLOGY, V383, P69, DOI 10.1016/j.virol.2008.09.036; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944; Zwerschke W, 2000, J BIOL CHEM, V275, P9534, DOI 10.1074/jbc.275.13.9534	65	54	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3435	3445		10.1038/onc.2010.93	http://dx.doi.org/10.1038/onc.2010.93			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20383192				2022-12-17	WOS:000278622700011
J	Asnaghi, L; Vass, WC; Quadri, R; Day, PM; Qian, X; Braverman, R; Papageorge, AG; Lowy, DR				Asnaghi, L.; Vass, W. C.; Quadri, R.; Day, P. M.; Qian, X.; Braverman, R.; Papageorge, A. G.; Lowy, D. R.			E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases	ONCOGENE			English	Article						E-cadherin; NSCLC; tumorigenesis; cell migration; Rho-family GTPases	BETA-CATENIN; FACTOR RECEPTOR; FAMILY GTPASES; BREAST-CANCER; ACTIVATING PROTEIN; REDUCED EXPRESSION; TISSUE MICROARRAY; TUMOR PROGRESSION; TYROSINE KINASES; ALPHA-CATENIN	Non-small cell lung cancers (NSCLC) that express the cell surface adhesion protein E-cadherin may carry a better prognosis than E-cadherin-negative tumors. Here, we found substantial inhibition of anchorage-independent growth in soft agar and cell migration in each of four NSCLC lines stably transfected with E-cadherin. The inhibitory effects were independent of the EGFR and beta-catenin/Wnt-signaling pathways. However, E-cadherin expression was associated with an adhesion-dependent reduction in the activity of Rho family proteins, RhoA in two lines and Cdc42 in the other two. The reduction of RhoA activity was dependent on DLC-1 Rho-GAP and p190 Rho-GAP and associated with an increase in a membrane-associated p190 Rho-GAP/p120 Ras-GAP complex. In parental cells with high levels of RhoAGTP, siRNA-mediated knock-down of RhoA reduced cell migration and agar growth in a manner analogous to E-cadherin. In parental cells with high levels of Cdc42-GTP, transfection of a Cdc42 dominant-negative mutant reduced cell growth and migration similarly to cells expressing E-cadherin. Thus, E-cadherin can negatively regulate cell proliferation and migration in NSCLC by reducing the level of the predominant active form of Rho family protein, RhoA or Cdc42. These proteins can be considered downstream effectors of E-cadherin and might represent therapeutic targets in some NSCLC. Oncogene (2010) 29, 2760-2771; doi: 10.1038/onc. 2010.39; published online 15 March 2010	[Asnaghi, L.; Vass, W. C.; Quadri, R.; Day, P. M.; Qian, X.; Braverman, R.; Papageorge, A. G.; Lowy, D. R.] NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lowy, DR (corresponding author), NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, 37 Convent Dr MSC 4264,Bldg 37,Rm 4106,37 Convent, Bethesda, MD 20892 USA.	lowyd@mail.nih.gov			National Institutes of Health; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC008905] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Margaret Wheelock, Wen Jin Wu, Dianne Hirsch and Silvio Gutkind for providing plasmids, Drs Curt Harris and Terry Moody for providing NSCLC cell lines, Dr Cynthia Masison and Mike Radanovich for technical assistance and Dr Giovanna Tosato for helpful discussions. This research has been supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.	Aktories K, 2005, REV PHYSIOL BIOCH P, V152, P1, DOI 10.1007/s10254-004-0034-4; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boerner JL, 2005, MOL CARCINOGEN, V44, P262, DOI 10.1002/mc.20138; BOHM M, 1994, CLIN EXP METASTAS, V12, P55, DOI 10.1007/BF01784334; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Bremm A, 2008, CANCER RES, V68, P707, DOI 10.1158/0008-5472.CAN-07-1588; Bremnes RM, 2002, J CLIN ONCOL, V20, P2417, DOI 10.1200/JCO.2002.08.159; Bremnes RM, 2002, LUNG CANCER, V36, P115, DOI 10.1016/S0169-5002(01)00471-8; CAPUZZO F, 2005, J NATL CANCER I, V97, P743; Chong IW, 2007, ONCOL REP, V18, P17; Deeb G, 2004, MODERN PATHOL, V17, P430, DOI 10.1038/modpathol.3800041; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Fei QY, 2002, LUNG CANCER, V37, P147, DOI 10.1016/S0169-5002(02)00077-6; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukata M, 1999, J CELL SCI, V112, P4491; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Grewal T, 2006, BIOESSAYS, V28, P1211, DOI 10.1002/bies.20503; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hajra KM, 2002, CANCER RES, V62, P1613; Heijink IH, 2007, J IMMUNOL, V178, P7678, DOI 10.4049/jimmunol.178.12.7678; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hlubek F, 2007, FRONT BIOSCI, V12, P458, DOI 10.2741/2075; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Huang CL, 2008, EUR J CANCER, V44, P2680, DOI 10.1016/j.ejca.2008.08.004; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kris MG, 2005, ONCOLOGIST, V10, P23, DOI 10.1634/theoncologist.10-90002-23; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HC, 2006, FRONT BIOSCI-LANDMRK, V11, P1901, DOI 10.2741/1933; Lock JG, 2005, TRAFFIC, V6, P1142, DOI 10.1111/j.1600-0854.2005.00349.x; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Molina-Ortiz I, 2009, J BIOL CHEM, V284, P15147, DOI 10.1074/jbc.M807834200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Pirinen RT, 2001, J CLIN PATHOL, V54, P391, DOI 10.1136/jcp.54.5.391; Qian XL, 2007, P NATL ACAD SCI USA, V104, P9012, DOI 10.1073/pnas.0703033104; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Riely GJ, 2008, CLIN CANCER RES, V14, P5731, DOI 10.1158/1078-0432.CCR-08-0646; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Shen Y, 2008, J BIOL CHEM, V283, P5127, DOI 10.1074/jbc.M703300200; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tang Y, 2008, FRONT BIOSCI-LANDMRK, V13, P759, DOI 10.2741/2718; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Toyoyama H, 1999, ONCOL REP, V6, P81; Tu SS, 2002, BIOCHEMISTRY-US, V41, P12350, DOI 10.1021/bi026167h; Uchikado Y, 2005, CLIN CANCER RES, V11, P1174; van de Wetering M, 2001, CANCER RES, V61, P278; Vincan E, 2008, CLIN EXP METASTAS, V25, P657, DOI 10.1007/s10585-008-9156-4; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	66	54	56	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2760	2771		10.1038/onc.2010.39	http://dx.doi.org/10.1038/onc.2010.39			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20228844	Green Accepted, Green Submitted			2022-12-17	WOS:000277591900002
J	Hofstetter, G; Berger, A; Fiegl, H; Slade, N; Zoric, A; Holzer, B; Schuster, E; Mobus, VJ; Reimer, D; Daxenbichler, G; Marth, C; Zeimet, AG; Concin, N; Zeillinger, R				Hofstetter, G.; Berger, A.; Fiegl, H.; Slade, N.; Zoric, A.; Holzer, B.; Schuster, E.; Mobus, V. J.; Reimer, D.; Daxenbichler, G.; Marth, C.; Zeimet, A. G.; Concin, N.; Zeillinger, R.			Alternative splicing of p53 and p73: the novel p53 splice variant p53 delta is an independent prognostic marker in ovarian cancer	ONCOGENE			English	Article						ovarian cancer; p53; p73; splice variants	SITE MUTATION; EXPRESSION; ISOFORMS; CARCINOMA; DELTA-NP73; GENE	Similar to p73, the tumor suppressor gene p53 is subject to alternative splicing. Besides p53 Delta E6 and p53 beta, we identified p53 zeta, p53 delta and p53 epsilon, arising from alternative splicing of exon 6 and intron 9, respectively. p53 splice variants were present in 18 of 34 ovarian cancer cell lines (52.9%) and 134 of 245 primary ovarian cancers (54.7%). p53 delta expression was associated with impaired response to primary platinum-based chemotherapy (P = 0.032). Also, p53 delta expression constituted an independent prognostic marker for recurrence-free and overall survival (hazard ratio 1.854, 95% confidence interval 1.121-3.065, P = 0.016; and hazard ratio 1.937, 95% confidence interval 1.177-3.186, P = 0.009, respectively). p53 beta expression was associated with adverse clinicopathologic markers, that is, serous and poorly differentiated cancers (P = 0.002 and P = 0.008, respectively), and correlated with worse recurrence-free survival in patients exhibiting functionally active p53 (P = 0.049). Delta N'p73 constituted the main N-terminally truncated p73 isoform and was preferentially found in ovarian cancer cell lines showing functionally active p53, supporting our hypothesis that N-terminally truncated p73 isoforms can alleviate the selection pressure for p53 mutations by the inhibition of p53 protein function. Oncogene (2010) 29, 1997-2004; doi:10.1038/onc.2009.482; published online 18 January 2010	[Holzer, B.; Schuster, E.; Zeillinger, R.] Med Univ Vienna, Dept Obstet & Gynecol, Mol Oncol Grp, A-1090 Vienna, Austria; [Hofstetter, G.; Berger, A.; Fiegl, H.; Reimer, D.; Daxenbichler, G.; Marth, C.; Zeimet, A. G.; Concin, N.] Innsbruck Med Univ, Dept Gynecol & Obstet, Innsbruck, Austria; [Slade, N.; Zoric, A.] Rudjer Boskovic Inst, Dept Mol Med, Mol Oncol Lab, Zagreb, Croatia; [Mobus, V. J.] Staedt Kliniken, Dept Obstet & Gynecol, Frankfurt, Germany; [Zeillinger, R.] Ludwig Boltzmann Gesell, Cluster Translat Oncol, Vienna, Austria	Medical University of Vienna; Medical University of Innsbruck; Rudjer Boskovic Institute; Ludwig Boltzmann Institute	Zeillinger, R (corresponding author), Med Univ Vienna, Dept Obstet & Gynecol, Mol Oncol Grp, Waehringer Guertel 18-20,5Q, A-1090 Vienna, Austria.	robert.zeillinger@meduniwien.ac.at	Zeillinger, Robert/AAI-6164-2020; Fiegl, Heidi/K-4445-2017	Zeillinger, Robert/0000-0001-6771-4591; Concin, Nicole/0000-0002-9795-2643; Hofstetter, Gerda/0000-0001-8912-3725; Fiegl, Heidi/0000-0002-1236-6806				Anczukow O, 2008, HUM MUTAT, V29, P65, DOI 10.1002/humu.20590; Avery-Kiejda KA, 2008, CLIN CANCER RES, V14, P1659, DOI 10.1158/1078-0432.CCR-07-1422; Boldrup L, 2007, EUR J CANCER, V43, P617, DOI 10.1016/j.ejca.2006.10.019; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Casciano I, 2002, CELL DEATH DIFFER, V9, P343, DOI 10.1038/sj.cdd.4400992; Chan WM, 2004, MOL CELL BIOL, V24, P3536, DOI 10.1128/MCB.24.8.3536-3551.2004; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; Concin N, 2004, CANCER RES, V64, P2449, DOI 10.1158/0008-5472.CAN-03-1060; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; Concin N, 2003, INT J ONCOL, V22, P51; Cui Rutao, 2005, Biochem Biophys Res Commun, V336, P339; Duddy PM, 2000, J MOL DIAGN, V2, P139, DOI 10.1016/S1525-1578(10)60629-0; Ebrahimi M, 2008, ORAL ONCOL, V44, P156, DOI 10.1016/j.oraloncology.2007.01.014; Fischer DC, 2004, ONCOL REP, V11, P1085; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Graupner V, 2009, CELL CYCLE, V8, P1238, DOI 10.4161/cc.8.8.8251; Guan M, 2005, J CLIN PATHOL, V58, P1175, DOI 10.1136/jcp.2005.026955; Holmila R, 2003, Hum Mutat, V21, P101, DOI 10.1002/humu.9104; Janicke RU, 2009, BIOL CHEM, V390, P951, DOI 10.1515/BC.2009.093; JOLLY KW, 1994, ONCOGENE, V9, P97; Levy S, 2007, PLOS BIOL, V5, P2113, DOI 10.1371/journal.pbio.0050254; Magnusson KP, 2000, GENE, V246, P247, DOI 10.1016/S0378-1119(00)00068-8; Marabese M, 2008, EUR J CANCER, V44, P131, DOI 10.1016/j.ejca.2007.10.011; MOBUS V, 1992, INT J CANCER, V52, P76, DOI 10.1002/ijc.2910520115; Oswald C, 2008, CELL CYCLE, V7, P1726, DOI 10.4161/cc.7.12.6148; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Slade N, 2004, CELL DEATH DIFFER, V11, P357, DOI 10.1038/sj.cdd.4401335; Stiewe T, 2004, CLIN CANCER RES, V10, P626, DOI 10.1158/1078-0432.CCR-0153-03; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Yu J, 2007, CELL DEATH DIFFER, V14, P436, DOI 10.1038/sj.cdd.4402029	31	54	56	4	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	13					1997	2004		10.1038/onc.2009.482	http://dx.doi.org/10.1038/onc.2009.482			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20101229				2022-12-17	WOS:000276199600012
J	Cheung, AF; Carter, AM; Kostova, KK; Woodruff, JF; Crowley, D; Bronson, RT; Haigis, KM; Jacks, T				Cheung, A. F.; Carter, A. M.; Kostova, K. K.; Woodruff, J. F.; Crowley, D.; Bronson, R. T.; Haigis, K. M.; Jacks, T.			Complete deletion of Apc results in severe polyposis in mice	ONCOGENE			English	Article						Apc truncation; Apc null; colon cancer; mouse model	FAMILIAL ADENOMATOUS POLYPOSIS; BETA-CATENIN; MOUSE MODEL; MUTATION; ACTIVATION; REGULATOR; PHENOTYPE; PROTEIN; SITE; RAS	The adenomatous polyposis coli (APC) gene product is mutated in the vast majority of human colorectal cancers. APC negatively regulates the WNT pathway by aiding in the degradation of beta-catenin, which is the transcription factor activated downstream of WNT signaling. APC mutations result in beta-catenin stabilization and constitutive WNT pathway activation, leading to aberrant cellular proliferation. APC mutations associated with colorectal cancer commonly fall in a region of the gene termed the mutation cluster region and result in expression of an N-terminal fragment of the APC protein. Biochemical and molecular studies have revealed localization of APC/Apc to different sub-cellular compartments and various proteins outside of the WNT pathway that associate with truncated APC/Apc. These observations and genotype-phenotype correlations have led to the suggestion that truncated APC bears neomorphic and/or dominant-negative function that support tumor development. To analyze this possibility, we have generated a novel allele of Apc in the mouse that yields complete loss of Apc protein. Our studies reveal that whole-gene deletion of Apc results in more rapid tumor development than the APC multiple intestinal neoplasia (Apc(Min)) truncation. Furthermore, we found that adenomas bearing truncated Apc had increased beta-catenin activity when compared with tumors lacking Apc protein, which could lead to context-dependent inhibition of tumorigenesis. Oncogene (2010) 29, 1857-1864; doi:10.1038/onc.2009.457; published online 14 December 2009	[Cheung, A. F.; Carter, A. M.; Kostova, K. K.; Woodruff, J. F.; Crowley, D.; Jacks, T.] MIT, Robert Koch Inst, Cambridge, MA 02139 USA; [Cheung, A. F.; Carter, A. M.; Kostova, K. K.; Woodruff, J. F.; Crowley, D.; Jacks, T.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Crowley, D.; Jacks, T.] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; [Bronson, R. T.] Tufts Univ, Sch Med & Vet Med, Dept Pathol, Boston, MA 02111 USA; [Haigis, K. M.] Harvard Univ, Sch Med, Dept Pathol, Masschusetts Gen Hosp,Canc Ctr, Charlestown, MA USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Tufts University; Harvard University	Jacks, T (corresponding author), MIT, Robert Koch Inst, 77 Massachusetts Ave,E17-517, Cambridge, MA 02139 USA.	tjacks@mit.edu	Kostova, Kamena/AAK-9431-2020	Kostova, Kamena/0000-0001-9973-401X	Howard Hughes Medical Institute; National Cancer Institute [P30-CA14051]; NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Jacks labs, Keara Lane in particular, for experimental advice and assistance. This work was supported by the Howard Hughes Medical Institute and partially by the Cancer Center Support (core) Grant P30-CA14051 from the National Cancer Institute. TJ is a Howard Hughes Investigator and a Daniel K Ludwig Scholar.	Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Colnot S, 2004, LAB INVEST, V84, P1619, DOI 10.1038/labinvest.3700180; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Fodde R, 2001, TRENDS MOL MED, V7, P369, DOI 10.1016/S1471-4914(01)02050-0; Gaspar C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000547; Gherzi R, 2007, PLOS BIOL, V5, P82, DOI 10.1371/journal.pbio.0050005; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Haigis KM, 2004, P NATL ACAD SCI USA, V101, P9769, DOI 10.1073/pnas.0403338101; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; McCartney BM, 2008, CURR OPIN CELL BIOL, V20, P186, DOI 10.1016/j.ceb.2008.02.001; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nathke I, 2004, J CELL SCI, V117, P4873, DOI 10.1242/jcs.01313; Nieuwenhuis MH, 2007, CRIT REV ONCOL HEMAT, V61, P153, DOI 10.1016/j.critrevonc.2006.07.004; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Pollard P, 2009, GASTROENTEROLOGY, V136, P2204, DOI 10.1053/j.gastro.2009.02.058; Sieber OM, 2002, P NATL ACAD SCI USA, V99, P2954, DOI 10.1073/pnas.042699199; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Soravia C, 1998, AM J HUM GENET, V62, P1290, DOI 10.1086/301883; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Takacs CM, 2008, SCIENCE, V319, P333, DOI 10.1126/science.1151232; Tallquist MD, 2000, GENESIS, V26, P113, DOI 10.1002/(SICI)1526-968X(200002)26:2<113::AID-GENE3>3.0.CO;2-2	32	54	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1857	1864		10.1038/onc.2009.457	http://dx.doi.org/10.1038/onc.2009.457			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20010873	Green Accepted, Green Submitted			2022-12-17	WOS:000276022800014
J	Kim, YH; Kwei, KA; Girard, L; Salari, K; Kao, J; Pacyna-Gengelbach, M; Wang, P; Hernandez-Boussard, T; Gazdar, AF; Petersen, I; Minna, JD; Pollack, JR				Kim, Y. H.; Kwei, K. A.; Girard, L.; Salari, K.; Kao, J.; Pacyna-Gengelbach, M.; Wang, P.; Hernandez-Boussard, T.; Gazdar, A. F.; Petersen, I.; Minna, J. D.; Pollack, J. R.			Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer	ONCOGENE			English	Article						CRKL; lung cancer; DNA amplification; genomic profiling; adapter protein	BRONCHIAL EPITHELIAL-CELLS; HUMAN BREAST-CANCER; ADAPTER PROTEIN; HOMOZYGOUS DELETIONS; TYROSINE KINASE; GENE; MUTATIONS; LINES; MET; AMPLIFICATIONS	DNA amplifications, leading to the overexpression of oncogenes, are a cardinal feature of lung cancer and directly contribute to its pathogenesis. To uncover such novel alterations, we performed an array-based comparative genomic hybridization survey of 128 non-small-cell lung cancer cell lines and tumors. Prominent among our findings, we identified recurrent high-level amplification at cytoband 22q11.21 in 3% of lung cancer specimens, with another 11% of specimens exhibiting low-level gain spanning that locus. The 22q11.21 amplicon core contained eight named genes, only four of which were overexpressed (by transcript pro. ling) when amplified. Among these, CRKL encodes an adapter protein functioning in signal transduction, best known as a substrate of the BCR-ABL kinase in chronic myelogenous leukemia. RNA-interference-mediated knockdown of CRKL in lung cancer cell lines with (but not without) amplification led to significantly decreased cell proliferation, cell-cycle progression, cell survival, and cell motility and invasion. In addition, overexpression of CRKL in immortalized human bronchial epithelial cells led to enhanced growth factor-independent cell growth. Our findings indicate that amplification and resultant overexpression of CRKL contribute to diverse oncogenic phenotypes in lung cancer, with implications for targeted therapy, and highlight a role of adapter proteins as primary genetic drivers of tumorigenesis. Oncogene (2010) 29, 1421-1430; doi:10.1038/onc.2009.437; published online 7 December 2009	[Kim, Y. H.; Kwei, K. A.; Salari, K.; Kao, J.; Pollack, J. R.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Girard, L.; Gazdar, A. F.; Minna, J. D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [Salari, K.; Hernandez-Boussard, T.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Pacyna-Gengelbach, M.] Univ Hosp Charite, Inst Pathol, Berlin, Germany; [Wang, P.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA; [Petersen, I.] Univ Klinikum Jena, Inst Pathol, Jena, Germany	Stanford University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Stanford University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Fred Hutchinson Cancer Center; Friedrich Schiller University of Jena	Pollack, JR (corresponding author), Stanford Univ, Dept Pathol, CCSR Bldg,Room 3245A,269 Campus Dr, Stanford, CA 94305 USA.	pollack1@stanford.edu			NIH [R01 CA97139, SPORE P50CA70907, EDRN U01CA084971]; DOD VITAL; Longenbaugh Foundations; TRDRP [17FT-0062]; Deutsche Krebshilfe [108003]; Medical Scientist Training Program; NATIONAL CANCER INSTITUTE [T32CA009151, U01CA084971, R01CA097139, P50CA070907] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD VITAL; Longenbaugh Foundations; TRDRP; Deutsche Krebshilfe(Deutsche Krebshilfe); Medical Scientist Training Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the SFGF for fabrication of microarrays and the SMD for database support. We thank Eon Rios for assistance with flow cytometry analysis. We also thank the members of the Pollack lab for helpful discussion. This work was supported in part by grants from the NIH: R01 CA97139 (JRP), SPORE P50CA70907 (JDM), EDRN U01CA084971 (AFG); DOD VITAL (JDM); Longenbaugh Foundations (JDM); TRDRP (17FT-0062; KAK) and the Deutsche Krebshilfe: 108003 (IP). KS was supported by the Medical Scientist Training Program and is a Paul & Daisy Soros fellow.	Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366; DALY RJ, 1994, ONCOGENE, V9, P2723; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Garnis C, 2006, INT J CANCER, V118, P1556, DOI 10.1002/ijc.21491; Gay B, 1999, INT J CANCER, V83, P235, DOI 10.1002/(SICI)1097-0215(19991008)83:2<235::AID-IJC15>3.0.CO;2-B; Hemmeryckx B, 2001, CANCER RES, V61, P1398; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma PC, 2003, CANCER RES, V63, P6272; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Singer CF, 2006, ONCOL REP, V15, P353; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Tibshirani R, 2008, BIOSTATISTICS, V9, P18, DOI 10.1093/biostatistics/kxm013; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	33	54	54	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1421	1430		10.1038/onc.2009.437	http://dx.doi.org/10.1038/onc.2009.437			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19966867	Green Accepted			2022-12-17	WOS:000275392400002
J	Bui-Nguyen, TM; Pakala, SB; Sirigiri, RD; Xia, W; Hung, MC; Sarin, SK; Kumar, V; Slagle, BL; Kumar, R				Bui-Nguyen, T. M.; Pakala, S. B.; Sirigiri, R. D.; Xia, W.; Hung, M-C; Sarin, S. K.; Kumar, V.; Slagle, B. L.; Kumar, R.			NF-kappa B signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx	ONCOGENE			English	Article						MTA1; hepatitis B virus; HBx; signaling; MTA coregulator; liver cancer	X-PROTEIN; HEPATOCELLULAR-CARCINOMA; UP-REGULATION; CELL-LINES; EXPRESSION; TRANSCRIPTION; GENE; CANCER; COREGULATORS; COREPRESSOR	Metastasis-associated protein 1 (MTA1), a master chromatin modi. er, has been shown to regulate cancer progression and is widely upregulated in human cancer, including hepatitis B virus-associated hepatocellular carcinomas (HCCs). Here we provide evidence that hepatitis B virus transactivator protein HBx stimulates the expression of MTA1 but not of MTA2 or MTA3. The underlying mechanism of HBx stimulation of MTA1 involves HBx targeting of transcription factor nuclear factor (NF)-kappa B and the recruitment of HBx/p65 complex to the NF-kappa B consensus motif on the relaxed MTA1 gene chromatin. We also discovered that MTA1 depletion in HBx-expressing cells severely impairs the ability of HBx to stimulate NF-kappa B signaling and the expression of target proinflammatory molecules. Furthermore, the presence of HBx in HBx-infected HCCs correlated well with increased MTA1 and NF-kappa B-p65. Collectively, these findings revealed a previously unrecognized integral role of MTA1 in HBx stimulation of NF-kappa B signaling and consequently, the expression of NF-kappa B targets gene products with functions in inflammation and tumorigenesis. Oncogene (2010) 29, 1179-1189; doi: 10.1038/onc.2009.404; published online 14 December 2009	[Bui-Nguyen, T. M.; Pakala, S. B.; Sirigiri, R. D.; Kumar, R.] George Washington Univ, Dept Biochem & Mol Biol, Inst Coregulator Biol, Washington, DC 20037 USA; [Xia, W.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Hung, M-C] China Med Univ & Hosp, Grad Inst Canc Biol, Ctr Mol Med, Taichung, Taiwan; [Sarin, S. K.] GB Pant Hosp, Dept Gastroenterol, Inst Liver & Biliary Sci, New Delhi, India; [Sarin, S. K.] Inst Liver & Biliary Sci, Dept Hepatol, New Delhi, India; [Kumar, V.] Int Ctr Genet Engn & Biotechnol, Virol Lab, New Delhi, India; [Slagle, B. L.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	George Washington University; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; Govind Ballabh Pant Institute of Postgraduate Medical Education & Research; Institute of Liver & Biliary Sciences (ILBS); Institute of Liver & Biliary Sciences (ILBS); Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; Baylor College of Medicine	Kumar, R (corresponding author), George Washington Univ, Dept Biochem & Mol Biol, Inst Coregulator Biol, 2300 1 St, Washington, DC 20037 USA.	bcmrxk@gwumc.edu	sirigiri, divijendranathareddy/A-9857-2010; Kumar, Rakesh/ABD-1065-2020; Hung, Mien-Chie/ABD-5911-2021	Kumar, Rakesh/0000-0001-7664-0803; Hung, Mien-Chie/0000-0003-4317-4740; Pakala, Suresh Babu/0000-0002-5679-4837	NIH [CA98823, 95388]; NATIONAL CANCER INSTITUTE [R01CA098823] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Aleem Siddiqui for pCMVXF and pCMV-Core constructs, Ranjit Banerjee for the HVC core plasmid, Amanda J Hodgson for technical assistance and Xuemei Wang for statistical analysis. The work was supported by NIH Grant CA98823 (RK). Work in Dr Betty L Slagle laboratory is supported by the NIH Grant 95388.	Anderson P, 2007, MOL CELL, V25, P796, DOI 10.1016/j.molcel.2007.03.005; Bagheri-Yarmand R, 2004, DEVELOPMENT, V131, P3469, DOI 10.1242/dev.01213; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Bouchard MJ, 2004, J VIROL, V78, P12725, DOI 10.1128/JVI.78.23.12725-12734.2004; Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Cheng ASL, 2004, MODERN PATHOL, V17, P1169, DOI 10.1038/modpathol.3800196; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Dvorchik I, 2007, CURR PHARM DESIGN, V13, P1527, DOI 10.2174/138161207780765846; Giannini R, 2005, ANTICANCER RES, V25, P4287; Gururaj AE, 2006, P NATL ACAD SCI USA, V103, P6670, DOI 10.1073/pnas.0601989103; Hamatsu T, 2003, ONCOL REP, V10, P599; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Jang KS, 2006, CANCER SCI, V97, P374, DOI 10.1111/j.1349-7006.2006.00186.x; Keasler VV, 2007, J VIROL, V81, P2656, DOI 10.1128/JVI.02020-06; Kidd M, 2006, ANN SURG ONCOL, V13, P253, DOI 10.1245/ASO.2006.12.011; Kim SY, 2008, BMB REP, V41, P158, DOI 10.5483/BMBRep.2008.41.2.158; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Li DQ, 2009, P NATL ACAD SCI USA, V106, P17493, DOI 10.1073/pnas.0908027106; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; Lupberger J, 2007, WORLD J GASTROENTERO, V13, P74, DOI 10.3748/wjg.v13.i1.74; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Manavathi Bramanandam, 2007, Nucl Recept Signal, V5, pe010, DOI 10.1621/nrs.05010; Manavathi B, 2007, P NATL ACAD SCI USA, V104, P13128, DOI 10.1073/pnas.0705878104; Manavathi B, 2007, J BIOL CHEM, V282, P1529, DOI 10.1074/jbc.R600029200; Moon EJ, 2003, FASEB J, V17, P382, DOI 10.1096/fj.03-0153fje; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Ryu SH, 2008, HEPATOLOGY, V47, P929, DOI 10.1002/hep.22124; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SLAGLE BL, 1991, CANCER RES, V51, P49; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; TOH Y, 1995, GENE, V159, P97, DOI 10.1016/0378-1119(94)00410-T; Weil R, 1999, MOL CELL BIOL, V19, P6345; Yoo YG, 2008, ONCOGENE, V27, P3405, DOI 10.1038/sj.onc.1211000; Yun C, 2002, CANCER LETT, V184, P97, DOI 10.1016/S0304-3835(02)00187-8; Zhang XD, 2006, J LAB CLIN MED, V147, P58, DOI 10.1016/j.lab.2005.10.003	38	54	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1179	1189		10.1038/onc.2009.404	http://dx.doi.org/10.1038/onc.2009.404			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	20010875	Green Accepted			2022-12-17	WOS:000274912100009
J	Wan, X; Kim, SY; Guenther, LM; Mendoza, A; Briggs, J; Yeung, C; Currier, D; Zhang, H; Mackall, C; Li, WJ; Tuan, RS; Deyrup, AT; Khanna, C; Helman, L				Wan, X.; Kim, S. Y.; Guenther, L. M.; Mendoza, A.; Briggs, J.; Yeung, C.; Currier, D.; Zhang, H.; Mackall, C.; Li, W-J; Tuan, R. S.; Deyrup, A. T.; Khanna, C.; Helman, L.			Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin	ONCOGENE			English	Article						beta 4 integrin; osteosarcoma; metastases; ezrin; interaction	ALPHA-6-BETA-4 INTEGRIN; DOMAIN INTERACTIONS; BINDING; KINASE; EXPRESSION; TRANSDUCTION; INVASION; PATHWAY	The development of pulmonary metastasis is the major cause of death in osteosarcoma, and its molecular basis is poorly understood. In this study, we show that beta 4 integrin is highly expressed in human osteosarcoma cell lines and tumor samples. Furthermore, highly metastatic MNNG-HOS cells have increased levels of beta 4 integrin. Suppression of beta 4 integrin expression by shRNA and disruption of beta 4 integrin function by transfection of dominant-negative beta 4 integrin was sufficient to revert this highly metastatic phenotype in the MNNG-HOS model without significantly affecting primary tumor growth. These findings suggest a role for beta 4 integrin expression in the metastatic phenotype in human osteosarcoma cells. In addition, we identified a previously uncharacterized interaction between beta 4 integrin and ezrin, a membrane-cytoskeletal linker protein that is implicated in the metastatic behavior of osteosarcoma. The beta 4 integrin-ezrin interaction appears to be critical for maintenance of beta 4 integrin expression. These data begin to integrate ezrin and beta 4 integrin expression into a model of action for the mechanism of osteosarcoma metastases. Oncogene (2009) 28, 3401-3411; doi: 10.1038/onc.2009.206; published online 13 July 2009	[Wan, X.] NCI, Mol Oncol Sect, Pediat Oncol Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; [Li, W-J; Tuan, R. S.] NIAMSD, Cartilage Biol & Orthopaed Branch, NIH, Bethesda, MD 20892 USA; [Deyrup, A. T.] Emory Univ, Dept Pathol, Atlanta, GA USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Emory University	Wan, X (corresponding author), NCI, Mol Oncol Sect, Pediat Oncol Branch, Ctr Canc Res,NIH, Bldg 10,Rm CRC-1W-3750, Bethesda, MD 20892 USA.	xiaolinw@mail.nih.gov			NIH; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC011074, ZIABC011024, ZIASC006892, ZIABC010566, ZIASC006891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041131] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Dr AM Mercurio for providing empty vector and beta 4 mutant (Y1494F), Dr L Trusolino for providing control-shRNA and beta 4-shRNA, Dr M Arpin for providing GST and GST-ezrin-CT, Dr R Nguyen for providing BSA and ezrinNT. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	ANDREOLI C, 1994, J CELL SCI, V107, P2509; Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Bertotti A, 2005, CANCER RES, V65, P10674, DOI 10.1158/0008-5472.CAN-05-2827; Bertotti A, 2006, J CELL BIOL, V175, P993, DOI 10.1083/jcb.200605114; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; GAFFNEY R, 2006, HUM PATHOL, V244, P799; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grossman HB, 2000, ONCOL REP, V7, P13; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Harris MB, 1998, J CLIN ONCOL, V16, P3641, DOI 10.1200/JCO.1998.16.11.3641; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kim SY, 2008, CLIN EXP METASTAS, V25, P201, DOI 10.1007/s10585-007-9133-3; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LIU S, 2002, J CELL SCI, V113, P3563; Liu XF, 2000, CANCER RES, V60, P4752; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu S, 2008, CLIN CANCER RES, V14, P1050, DOI 10.1158/1078-0432.CCR-07-4116; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; MEYERS PA, 1993, J CLIN ONCOL, V11, P449, DOI 10.1200/JCO.1993.11.3.449; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Tagliabue E, 1998, CLIN CANCER RES, V4, P407; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Wan XL, 2003, ONCOGENE, V22, P8205, DOI 10.1038/sj.onc.1206878	39	54	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3401	3411		10.1038/onc.2009.206	http://dx.doi.org/10.1038/onc.2009.206			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19597468	Green Accepted			2022-12-17	WOS:000270103300007
J	Fox, BP; Kandpal, RP				Fox, B. P.; Kandpal, R. P.			EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells	ONCOGENE			English	Article						breast cancer; EphB6; Eph receptors; ephrin ligands; invasiveness; growth rate	GENE-EXPRESSION; MATRIX METALLOPROTEINASES; CANCER METASTASIS; ESTROGEN-RECEPTOR; TYROSINE KINASES; TISSUE INHIBITOR; ASSOCIATION; APOPTOSIS; TUMORIGENICITY; IDENTIFICATION	Breast cancer mortality in women is largely attributed to the metastasis of primary breast tumors. We have analysed the function of EphB6, a kinase-deficient receptor, in the invasive phenotype of breast cancer cell lines. We have demonstrated the loss of EphB6 protein in invasive breast carcinoma cell lines and absence of EphB6 transcript in a metastatic breast tumor specimen. The function of EphB6 in invasiveness was confirmed by the ability of EphB6 protein to decrease the in vitro invasiveness of MDA-MB-231, MDA-MB-435 and BT549 cells transfected with an EphB6 expression construct. In MDA-MB-231 cells, the decreased invasiveness appeared to be mediated by decreased transcript levels of matrix metalloproteinase (MMP)7 and MMP19, and increased transcript levels of tissue inhibitors of metalloproteinase 2. In addition to affecting invasiveness phenotype, EphB6 overexpression was also responsible for altering the growth rate and colony-forming efficiency of MCF-7 and MDA-MB-231 cells in a cell-line-specific manner. We suggest that the significant decrease in the invasiveness of MDA-MB-231 and other cell lines transfected with EphB6 is likely occurring by the ability of EphB6 to transduce signals to the nucleus and altering relevant gene expression.	[Fox, B. P.; Kandpal, R. P.] Western Univ Hlth Sci, Dept Basic Med Sci, Pomona, CA 91766 USA	Western University of Health Sciences	Kandpal, RP (corresponding author), Western Univ Hlth Sci, Dept Basic Med Sci, 309 E 2nd St, Pomona, CA 91766 USA.	rkandpal@westernu.edu						Adams RH, 2002, SEMIN CELL DEV BIOL, V13, P55, DOI 10.1006/scdb.2001.0289; Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Bashyam MD, 2002, CANCER, V94, P1821, DOI 10.1002/cncr.10362; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Bong YS, 2007, P NATL ACAD SCI USA, V104, P17305, DOI 10.1073/pnas.0702337104; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Campbell TN, 2008, CURR ISSUES MOL BIOL, V10, P61; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Drescher U, 1997, CURR BIOL, V7, pR799, DOI 10.1016/S0960-9822(06)00409-X; Duxbury MS, 2004, BIOCHEM BIOPH RES CO, V320, P1096, DOI 10.1016/j.bbrc.2004.06.054; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI200113171; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Freywald A, 2002, J BIOL CHEM, V277, P3823, DOI 10.1074/jbc.M108011200; Freywald A, 2003, J BIOL CHEM, V278, P10150, DOI 10.1074/jbc.M208179200; Hafner C, 2003, INT J ONCOL, V23, P1553; Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237; Himanen JP, 2003, INT J BIOCHEM CELL B, V35, P130, DOI 10.1016/S1357-2725(02)00096-1; Hojilla CV, 2003, BRIT J CANCER, V89, P1817, DOI 10.1038/sj.bjc.6601327; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kagara N, 2007, CANCER SCI, V98, P692, DOI 10.1111/j.1349-7006.2007.00446.x; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lai KO, 2004, J BIOL CHEM, V279, P13383, DOI 10.1074/jbc.M313356200; Luo HY, 2001, J IMMUNOL, V167, P1362, DOI 10.4049/jimmunol.167.3.1362; MADSEN MW, 1990, EUR J CANCER, V26, P793, DOI 10.1016/0277-5379(90)90154-L; Malemud CJ, 2006, FRONT BIOSCI-LANDMRK, V11, P1696, DOI 10.2741/1915; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Matsuoka H, 1997, BIOCHEM BIOPH RES CO, V235, P487, DOI 10.1006/bbrc.1997.6812; Matsuoka H, 2005, J BIOL CHEM, V280, P29355, DOI 10.1074/jbc.M500010200; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Muller-Tidow C, 2005, CANCER RES, V65, P1778, DOI 10.1158/0008-5472.CAN-04-3388; Munthe E, 2000, FEBS LETT, V466, P169, DOI 10.1016/S0014-5793(99)01793-7; Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265; Nagaraja GM, 2004, BIOCHEM BIOPH RES CO, V313, P654, DOI 10.1016/j.bbrc.2003.12.001; Nakamoto M, 2000, INT J BIOCHEM CELL B, V32, P7, DOI 10.1016/S1357-2725(99)00096-5; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Pratt RL, 2003, MOL CANCER RES, V1, P1070; Schagdarsurengin U, 2007, ONCOGENE, V26, P3089, DOI 10.1038/sj.onc.1210107; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Tanaka M, 2007, J CELL SCI, V120, P2179, DOI 10.1242/jcs.008607; Tang XX, 2004, CLIN CANCER RES, V10, P5837, DOI 10.1158/1078-0432.CCR-04-0395; Tang XX, 2001, MED PEDIATR ONCOL, V36, P80, DOI 10.1002/1096-911X(20010101)36:1<80::AID-MPO1019>3.0.CO;2-N; Tang XX, 2000, MED PEDIATR ONCOL, V35, P656, DOI 10.1002/1096-911X(20001201)35:6<656::AID-MPO37>3.0.CO;2-A; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tong D, 1999, BREAST CANCER RES TR, V56, P91, DOI 10.1023/A:1006262501062; Xu QL, 1997, J MOL MED-JMM, V75, P576, DOI 10.1007/s001090050142; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	53	54	60	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2009	28	14					1706	1713		10.1038/onc.2009.18	http://dx.doi.org/10.1038/onc.2009.18			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430WQ	19234485				2022-12-17	WOS:000265022000005
J	Grosjean-Raillard, J; Tailler, M; Ades, L; Perfettini, JL; Fabre, C; Braun, T; De Botton, S; Fenaux, P; Kroemer, G				Grosjean-Raillard, J.; Tailler, M.; Ades, L.; Perfettini, J-L; Fabre, C.; Braun, T.; De Botton, S.; Fenaux, P.; Kroemer, G.			ATM mediates constitutive NF-kappa B activation in high-risk myelodysplastic syndrome and acute myeloid leukemia	ONCOGENE			English	Article						myelodysplastic syndrome; acute myeloid leukemia; ATM; NF-kappa B; IKK	INTERNAL TANDEM DUPLICATION; WORLD-HEALTH-ORGANIZATION; DNA-DAMAGE RESPONSE; THERAPEUTIC TARGET; INHIBITION; APOPTOSIS; CLASSIFICATION; MITOCHONDRIAL; SYSTEM; MUTATIONS	The anti-apoptotic transcription factor nuclear factor-kappa B (NF-kappa B) is constitutively activated in CD34(+) myeloblasts from high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients. Inhibition of NF-kappa B by suppressing the canonical NF-kappa B activation pathway, for instance by knockdown of the three subunits of the inhibitor of NF-kappa B (I kappa B) kinase (IKK) complex (IKK1, IKK2 and NEMO) triggers apoptosis in such cells. Here, we show that an MDS/AML model cell line exhibits a constitutive interaction, within the nucleus, of activated, S1981-phosphorylated ataxia telangiectasia mutated (ATM) with NEMO. Inhibition of ATM with two distinct pharmacological inhibitors suppressed the activating autophosphorylation of ATM, blocked the interaction of ATM and NEMO, delocalized NEMO as well as another putative NF-kappa B activator, PIDD, from the nucleus, abolished the activating phosphorylation of the catalytic proteins of the IKK complex (IKK1/2 on serines 176/180), enhanced the expression of I kappa B alpha and caused the relocalization of NF-kappa B from the nucleus to the cytoplasm, followed by apoptosis. Knockdown of ATM with small-interfering RNAs had a similar effect that could not be enhanced by knockdown of NEMO, PIDD and the p65 NF-kappa B subunit, suggesting that an ATM inhibition/depletion truly induced apoptosis through inhibition of the NF-kappa B system. Pharmacological inhibition of ATM also induced the nucleocytoplasmic relocalization of p65 in malignant myeloblasts purified from patients with high-risk MDS or AML, correlating with the induction of apoptosis. Altogether, these results support the contention that constitutively active ATM accounts for the activation of NF-kappa B in high-risk MDS and AML.	[Grosjean-Raillard, J.; Tailler, M.; Ades, L.; Perfettini, J-L; Fabre, C.; Fenaux, P.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Grosjean-Raillard, J.; Tailler, M.; Ades, L.; Perfettini, J-L; Fabre, C.; Fenaux, P.; Kroemer, G.] Univ Paris 11, Villejuif, France; [Ades, L.; Braun, T.; Fenaux, P.] Univ Paris 13, AP HP, Hop Avicenne, Serv Hematol Clin, Bobigny, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Braun, Thorsten/GRJ-8918-2022; PERFETTINI, Jean-Luc/N-4699-2017; Ades, lionel/T-6882-2019; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	PERFETTINI, Jean-Luc/0000-0002-2427-2604; KROEMER, Guido/0000-0002-9334-4405				Bakkenist CJ, 2004, TRENDS CELL BIOL, V14, P339, DOI 10.1016/j.tcb.2004.05.001; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Barzilai A, 2004, DNA REPAIR, V3, P1109, DOI 10.1016/j.dnarep.2004.03.002; Bennett JM, 2000, INT J HEMATOL, V72, P131; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Birkenkamp KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874; Braun T, 2006, BLOOD, V107, P1156; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Carvalho G, 2007, ONCOGENE, V26, P2299, DOI 10.1038/sj.onc.1210043; Castedo M, 2002, J EXP MED, V196, P1121, DOI 10.1084/jem.20021758; Castedo M, 1996, J IMMUNOL, V157, P512; Fabre C, 2007, ONCOGENE, V26, P4071, DOI 10.1038/sj.onc.1210187; Gale RE, 2008, BLOOD, V111, P2776, DOI 10.1182/blood-2007-08-109090; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Grosjean-Raillard J, 2008, APOPTOSIS, V13, P1148, DOI 10.1007/s10495-008-0243-4; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Habraken Y, 2006, BIOCHEM PHARMACOL, V72, P1132, DOI 10.1016/j.bcp.2006.07.015; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hassan Z, 1999, EXP HEMATOL, V27, P1322, DOI 10.1016/S0301-472X(99)00066-1; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Knapper S, 2007, BRIT J HAEMATOL, V138, P687, DOI 10.1111/j.1365-2141.2007.06700.x; Leone G, 2007, HAEMATOLOGICA, V92, P1389, DOI 10.3324/haematol.11034; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Lin XJ, 2000, MOL PHARMACOL, V58, P1222, DOI 10.1124/mol.58.6.1222; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Mufti Ghulam, 2003, Hematology Am Soc Hematol Educ Program, P176; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yanada M, 2005, LEUKEMIA, V19, P1345, DOI 10.1038/sj.leu.2403838; ZAMZAMI N, 2003, METH MOL B, V282, P103	41	54	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1099	1109		10.1038/onc.2008.457	http://dx.doi.org/10.1038/onc.2008.457			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19079347				2022-12-17	WOS:000263722900005
J	Sankar, N; Baluchamy, S; Kadeppagari, RK; Singhal, G; Weitzman, S; Thimmapaya, B				Sankar, N.; Baluchamy, S.; Kadeppagari, R-K; Singhal, G.; Weitzman, S.; Thimmapaya, B.			p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc	ONCOGENE			English	Article						c-Myc; p300; gene expression; cell cycle; YY1; HDAC3	TRANSCRIPTIONAL REPRESSION; BINDING PROTEIN; CELL-GROWTH; G(1) EXIT; PROMOTER; ACETYLATION; CBP; ASSOCIATION; ACTIVATION; DEPLETION	We showed earlier that p300/CBP plays an important role in G1 progression by negatively regulating c-Myc and thereby preventing premature G1 exit. Here, we have studied the mechanism by which p300 represses c-Myc and show that in quiescent cells p300 cooperates with histone deacetylase 3 (HDAC3) to repress transcription. p300 and HDAC3 are recruited to the upstream YY1-binding site of the c-Myc promoter resulting in chromatin deacetylation and repression of c-Myc transcription. Consistent with this, ablation of p300, YY1 or HDAC3 expression results in chromatin acetylation and induction of c-Myc. These three proteins exist as a complex in vivo and form a multiprotein complex with the YY1-binding site in vitro. The C-terminal region of p300 is both necessary and sufficient for the repression of c-Myc. These and other results suggest that in quiescent cells the C-terminal region of p300 provides corepressor function and facilitates the recruitment of p300 and HDAC3 to the YY1-binding site and represses the c-Myc promoter. This corepressor function of p300 prevents the inappropriate induction of c-Myc and S phase.	[Sankar, N.; Baluchamy, S.; Kadeppagari, R-K; Singhal, G.; Thimmapaya, B.] Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA; [Weitzman, S.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Thimmapaya, B (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol & Immunol, 303 E Chicago Ave,Olson 8452, Chicago, IL 60611 USA.	b-thimmapaya@northwestern.edu	Natesan, Sankar/C-9866-2015; KADEPPAGARI, RAVI KUMAR/C-1682-2015	KADEPPAGARI, RAVI KUMAR/0000-0003-0576-9508	NIH [CA73303]; NATIONAL CANCER INSTITUTE [R43CA073303] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are very grateful to Drs E Seto (Moffits Cancer Center), Dr Wu (University of Oregon), Yang Shi (Harvard University), N Perkins and R Hayward (University of Dundee, UK), and G Chinnadurai (St Louis University) for providing various plasmids and viruses. We also thank Dr Kathy Rundell for helpful discussion and editing this article. This work was supported by the NIH Grant CA73303.	Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Albert T, 2001, J BIOL CHEM, V276, P20482, DOI 10.1074/jbc.M100265200; Baluchamy S, 2007, ONCOGENE, V26, P781, DOI 10.1038/sj.onc.1209825; Baluchamy S, 2003, P NATL ACAD SCI USA, V100, P9524, DOI 10.1073/pnas.1633700100; Black JC, 2006, MOL CELL, V23, P809, DOI 10.1016/j.molcel.2006.07.018; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; Dang CV, 1999, MOL CELL BIOL, V19, P1; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goodman RH, 2000, GENE DEV, V14, P1553; Guermah M, 2006, CELL, V125, P275, DOI 10.1016/j.cell.2006.01.055; Guidez F, 2005, MOL CELL BIOL, V25, P5552, DOI 10.1128/MCB.25.13.5552-5566.2005; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hong R, 2003, J BIOL CHEM, V278, P44505, DOI 10.1074/jbc.M303138200; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Iyer NG, 2007, ONCOGENE, V26, P21, DOI 10.1038/sj.onc.1209771; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Izzo MW, 1999, J BIOL CHEM, V274, P19498, DOI 10.1074/jbc.274.27.19498; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Kung AL, 2000, GENE DEV, V14, P272; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Poizat C, 2000, MOL CELL BIOL, V20, P8643, DOI 10.1128/MCB.20.23.8643-8654.2000; Rajabi HN, 2005, J BIOL CHEM, V280, P361, DOI 10.1074/jbc.M408633200; Santoso BY, 2006, NAT STRUCT MOL BIOL, V13, P131, DOI 10.1038/nsmb1048; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; SOULE HD, 1990, CANCER RES, V50, P6075; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zou X, 1997, CURR TOP MICROBIOL, V224, P57	39	54	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5717	5728		10.1038/onc.2008.181	http://dx.doi.org/10.1038/onc.2008.181			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18542060				2022-12-17	WOS:000259487100007
J	Logunov, DY; Scheblyakov, DV; Zubkova, OV; Shmarov, MM; Rakovskaya, IV; Gurova, KV; Tararova, ND; Burdelya, LG; Naroditsky, BS; Ginzburg, AL; Gudkov, AV				Logunov, D. Y.; Scheblyakov, D. V.; Zubkova, O. V.; Shmarov, M. M.; Rakovskaya, I. V.; Gurova, K. V.; Tararova, N. D.; Burdelya, L. G.; Naroditsky, B. S.; Ginzburg, A. L.; Gudkov, A. V.			Mycoplasma infection suppresses p53, activates NF-kappa B and cooperates with oncogenic Ras in rodent fibroblast transformation	ONCOGENE			English	Article						oncogene; tumor suppressor; p21; senescence; transactivation	INSTABILITY; CHECKPOINT; PATHWAY; MICE	Prokaryotes of the genus Mycoplasma are the smallest cellular organisms that persist as obligate extracellular parasites. Although mycoplasma infection is known to be associated with chromosomal instability and can promote malignant transformation, the mechanisms underlying these phenomena remain unknown. Since persistence of many cellular parasites requires suppression of apoptosis in host cells, we tested the effect of mycoplasma infection on the activity of the p53 and nuclear factor (NF)-kappa B pathways, major mechanisms controlling programmed cell death. To monitor the activity of p53 and NF-kappa B in mycoplasma-infected cells, we used a panel of reporter cell lines expressing the bacterial beta-galactosidase gene under the control of p53- or NF-kappa B-responsive promoters. Cells incubated with media conditioned with different species of mycoplasma showed constitutive activation of NF-kappa B and reduced activation of p53, common characteristics of the majority of human tumor cells, with M. arginini having the strongest effect among the species tested. Moreover, mycoplasma infection reduced the expression level and inducibility of an endogenous p53- responsive gene, p21(waf1), and inhibited apoptosis induced by genotoxic stress. Infection with M. arginini made rat and mouse embryo fibroblasts susceptible to transformation with oncogenic H-Ras, whereas mycoplasma-free cells underwent irreversible p53- dependent growth arrest. Mycoplasma infection was as effective as shRNA-mediated knockdown of p53 expression in making rodent fibroblasts permissive to Ras-induced transformation. These observations indicate that mycoplasma infection plays the role of a p53- suppressing oncogene that cooperates with Ras in cell transformation and suggest that the carcinogenic and mutagenic effects of mycoplasma might be due to inhibition of p53 tumor suppressor function by this common human parasite.	[Burdelya, L. G.; Gudkov, A. V.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Logunov, D. Y.; Scheblyakov, D. V.; Zubkova, O. V.; Shmarov, M. M.; Rakovskaya, I. V.; Naroditsky, B. S.; Ginzburg, A. L.] NF Gamalei Inst Epidemiol & Microbiol, Moscow, Russia; [Gurova, K. V.; Tararova, N. D.; Burdelya, L. G.; Gudkov, A. V.] Cleveland BioLabs Inc, Buffalo, NY USA	Roswell Park Cancer Institute; Russian Academy of Medical Sciences; Gamaleya National Research Center for Epidemiology & Microbiology, RAMS	Gudkov, AV (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, MRC N 212,Elm & Carlton St, Buffalo, NY 14263 USA.	bsnar1941@yahoo.com; andrei.gudkov@roswellpark.org	Shmarov, Maxim M/D-8662-2014; Naroditsky, Boris S/F-9135-2012	Gudkov, Andrei/0000-0003-2548-0154; Shmarov, Maxim/0000-0002-5268-1296; Naroditsky, Boris/0000-0001-5522-8238; Gintsburg, Alexander/0000-0003-1769-5059	NCI NIH HHS [R01 CA098374, CA098374, CA60730, R01 CA075179, CA75179, R01 CA060730] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075179, R01CA098374, R01CA060730] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baek KH, 2003, J LEUKOCYTE BIOL, V73, P850, DOI 10.1189/jlb.1202607; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Bubici C, 2006, HISTOL HISTOPATHOL, V21, P69, DOI 10.14670/HH-21.69; Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273; Chu HW, 2005, J IMMUNOL, V174, P5713, DOI 10.4049/jimmunol.174.9.5713; Cimolai N, 2001, CAN J MICROBIOL, V47, P691, DOI 10.1139/cjm-47-8-691; Correa P, 2007, GASTROENTEROLOGY, V133, P659, DOI 10.1053/j.gastro.2007.06.026; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Donehower LA, 1996, PROG CLIN BIOL RES, V395, P1; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Feng SH, 1999, MOL CELL BIOL, V19, P7995; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gurova KV, 2004, CANCER RES, V64, P1951, DOI 10.1158/0008-5472.CAN-03-1541; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; JIANG S, 2007, J CELL BIOCH; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lee CH, 2007, BIOFACTORS, V29, P19, DOI 10.1002/biof.5520290103; Lisowska K, 2003, ARCH IMMUNOL THER EX, V51, P367; Lu T, 2004, ONCOGENE, V23, P2138, DOI 10.1038/sj.onc.1207332; Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; McCormick F, 2000, SEMIN CANCER BIOL, V10, P453, DOI 10.1006/scbi.2000.0336; Nelyudova AM, 2004, CELL CYCLE, V3, P1427, DOI 10.4161/cc.3.11.1204; ORIEL JD, 1983, SEX TRANSM DIS, V10, P263; Poyurovsky MV, 2006, GENE DEV, V20, P125, DOI 10.1101/gad.1397506; PROZOROVSKIY SV, 1995, MED MYCOPLASMOLOGY, P187; Razin S, 1998, MICROBIOL MOL BIOL R, V62, P1094, DOI 10.1128/MMBR.62.4.1094-1156.1998; Rottem S, 2003, PHYSIOL REV, V83, P417, DOI 10.1152/physrev.00030.2002; Sablina AA, 1999, CELL BIOL INT, V23, P323, DOI 10.1006/cbir.1999.0362; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Takeda K, 2002, J ENDOTOXIN RES, V8, P459, DOI 10.1179/096805102125001073; TSAI S, 1995, P NATL ACAD SCI USA, V92, P10197, DOI 10.1073/pnas.92.22.10197; Yaswen P, 2007, CELL, V128, P233, DOI 10.1016/j.cell.2007.01.005; Zhang BX, 1997, P SOC EXP BIOL MED, V214, P359	37	54	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4521	4531		10.1038/onc.2008.103	http://dx.doi.org/10.1038/onc.2008.103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408766	Green Accepted			2022-12-17	WOS:000258077300002
J	Katayama, K; Nakamura, A; Sugimoto, Y; Tsuruo, T; Fujita, N				Katayama, K.; Nakamura, A.; Sugimoto, Y.; Tsuruo, T.; Fujita, N.			FOXO transcription factor-dependent p15(INK4b) and p19(INK4d) expression	ONCOGENE			English	Article						Akt; FOXO; INK4	CYTOPLASMIC LOCALIZATION; GENE-EXPRESSION; CELL-LINES; PHOSPHORYLATION; AKT; INHIBITORS; P27(KIP1); BINDING; FKHR; INVOLVEMENT	FOXO (Forkhead box O) transcription factors are involved in cell-cycle arrest or apoptosis induction by transcripting cell-cycle inhibitor p27(KIP1) or apoptosis-related genes, respectively. Akt/protein kinase B promotes cell proliferation and suppresses apoptosis, in part, by phosphorylating FOXOs. Phosphorylated FOXOs could not exhibit transcriptional activity because of their nuclear export. Here we show that p15(INK4b) and p19(INK4d) transcription is associated with FOXO-mediated G(1) cell-cycle arrest. Inhibition of Akt signaling by PI3K inhibitors, a PDK1 inhibitor, or dominant-negative Akt transfection increased expression of p15(INK4b) and p19(INK4d) but not p16(INK4a) and p18(INK4c). Ectopic expression of wild type or active FOXO but not inactive form also increased p15(INK4b) and p19(INK4d) levels. FOXOs bound to promoter regions and induced transcription of these genes. No increase in the G1-arrested cell population, mediated by PI3K inhibitor LY294002, was observed in INK4b(-/-) or INK4d(-/-) murine embryonic fibroblasts. In summary, FOXOs are involved in G1 arrest caused by Akt inactivation via p15(INK4b) and p19(INK4d) transcription.	[Katayama, K.; Nakamura, A.; Sugimoto, Y.; Tsuruo, T.; Fujita, N.] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Expt Chemotherapy, Tokyo 1358550, Japan; [Katayama, K.; Sugimoto, Y.] Kyoritsu Univ Pharm, Dept Chemotherapy, Tokyo, Japan; [Nakamura, A.] Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo, Japan	Japanese Foundation for Cancer Research; Keio University; University of Tokyo	Fujita, N (corresponding author), Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Expt Chemotherapy, Tokyo 1358550, Japan.	naoya.fujita@jfcr.or.jp	Katayama, Kazuhiro/AAH-2914-2019; Fujita, Naoya/A-7349-2010	Katayama, Kazuhiro/0000-0003-4232-7661; Fujita, Naoya/0000-0002-9631-9264				Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Katayama K, 2005, MOL CELL BIOL, V25, P5725, DOI 10.1128/MCB.25.13.5725-5737.2005; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Ogasawara T, 2004, MOL CELL BIOL, V24, P6560, DOI 10.1128/mcb.24.15.6560-6568.2004; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Rokudai S, 2002, MOL CELL BIOL, V22, P8695, DOI 10.1128/MCB.22.24.8695-8708.2002; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tsuruo T, 2003, CANCER SCI, V94, P15, DOI 10.1111/j.1349-7006.2003.tb01345.x; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Woods YL, 2002, BIOCHEM SOC T, V30, P391, DOI 10.1042/bst0300391; Zariwala M, 1996, ONCOGENE, V12, P451; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	29	54	56	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1677	1686		10.1038/sj.onc.1210813	http://dx.doi.org/10.1038/sj.onc.1210813			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17873901				2022-12-17	WOS:000253962100003
J	Xiao, W; Zhang, Q; Habermacher, G; Yang, X; Zhang, AY; Cai, X; Hahn, J; Liu, J; Pins, M; Doglio, L; Dhir, R; Gingrich, J; Wang, Z				Xiao, W.; Zhang, Q.; Habermacher, G.; Yang, X.; Zhang, A-y; Cai, X.; Hahn, J.; Liu, J.; Pins, M.; Doglio, L.; Dhir, R.; Gingrich, J.; Wang, Z.			U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia	ONCOGENE			English	Article						U19/Eaf2; lung adenocarcinoma; B-cell lymphoma; hepatocellular carcinoma; prostate cancer; tumor suppressor	ELONGATION-FACTOR ELL; TUMOR-SUPPRESSOR; VASCULAR TUMORS; FACTOR-2 EAF2; CAJAL BODY; GENE; POLYMERASE; MLL; INACTIVATION; EXPRESSION	Upregulated gene 19 (U19)/ELL-associated factor 2 (Eaf2) is a potential human tumor suppressor that exhibits frequent allelic loss and downregulation in high-grade prostate cancer. U19/Eaf2, along with its homolog Eaf1, has been reported to regulate transcriptional elongation via interaction with the eleven-nineteen lysine-rich leukemia (ELL) family of proteins. To further explore the tumor-suppressive effects of U19/Eaf2, we constructed and characterized a murine U19/Eaf2-knockout model. Homozygous or heterozygous deletion of U19/Eaf2 resulted in high rates of lung adenocarcinoma, B-cell lymphoma, hepato cellular carcinoma and prostate intraepithelial neoplasia. Within the mouse prostate, U19/Eaf2 defficiency enhanced cell proliferation and increased epithelial cell size. The knockout mice also exhibited cardiac cell hypertrophy. These data indicate a role for U19/Eaf2 in growth suppression and cell size control as well as argue for U19/Eaf2 as a novel tumor suppressor in multiple mouse tissues. The U19/Eaf2 knockout mouse also provides a unique animal model for three important cancers: lung adenocarcinoma, B-cell lymphoma and hepatocellular carcinoma.	[Zhang, A-y; Liu, J.; Gingrich, J.; Wang, Z.] Univ Pittsburgh, Dept Urol, Shadyside Med Ctr, Inst Canc,Sch Med, Pittsburgh, PA 15232 USA; [Xiao, W.; Zhang, Q.; Habermacher, G.; Zhang, A-y; Cai, X.; Hahn, J.; Wang, Z.] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA; [Xiao, W.] Chinese Acad Sci, Inst Hydrobiol, Wuhan, Peoples R China; [Yang, X.; Pins, M.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Yang, X.; Pins, M.; Wang, Z.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Doglio, L.; Wang, Z.] Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Chicago, IL 60611 USA; [Dhir, R.] Univ Pittsburgh, Sch Med, Dept Pathol, Inst Canc, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University; Feinberg School of Medicine; Chinese Academy of Sciences; Institute of Hydrobiology, CAS; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, Z (corresponding author), Univ Pittsburgh, Dept Urol, Shadyside Med Ctr, Inst Canc,Sch Med, Suite G40,5200 Ctr Ave, Pittsburgh, PA 15232 USA.	wangz2@upmc.edu	Xiao, Wuhan/GLU-7352-2022	Gingrich, Jeffrey/0000-0002-4516-2893	NATIONAL CANCER INSTITUTE [R01CA120386, P50CA090386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051193, R37DK051193] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA90386, R01 CA120386, P50 CA090386-06A25083, P50 CA090386, R01 CA120386-03] Funding Source: Medline; NIDDK NIH HHS [R01 DK51193, R01 DK051193, R37 DK051193-14, R37 DK051193] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cioce M, 2005, ANNU REV CELL DEV BI, V21, P105, DOI 10.1146/annurev.cellbio.20.010403.103738; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Gall JG, 2003, NAT REV MOL CELL BIO, V4, P975, DOI 10.1038/nrm1262; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kong SE, 2005, P NATL ACAD SCI USA, V102, P10094, DOI 10.1073/pnas.0503017102; Li M, 2003, DEV DYNAM, V228, P273, DOI 10.1002/dvdy.10367; Luo RT, 2001, MOL CELL BIOL, V21, P5678, DOI 10.1128/MCB.21.16.5678-5687.2001; Ma WB, 2003, CANCER RES, V63, P5320; Maurus D, 2005, EMBO J, V24, P1181, DOI 10.1038/sj.emboj.7600603; Mitani K, 2000, BIOCHEM BIOPH RES CO, V279, P563, DOI 10.1006/bbrc.2000.3970; Polak PE, 2003, MOL BIOL CELL, V14, P1517, DOI 10.1091/mbc.E02-07-0394; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; Simone F, 2003, BLOOD, V101, P2355, DOI 10.1182/blood-2002-06-1664; Simone F, 2001, BLOOD, V98, P201, DOI 10.1182/blood.V98.1.201; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wang Z, 1997, P NATL ACAD SCI USA, V94, P12999, DOI 10.1073/pnas.94.24.12999; Xiao WH, 2003, CANCER RES, V63, P4698; Zhu N, 1999, CANCER RES, V59, P1896	26	54	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1536	1544		10.1038/sj.onc.1210786	http://dx.doi.org/10.1038/sj.onc.1210786			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873910	Green Accepted			2022-12-17	WOS:000253815800005
J	Rashmi, R; Pillai, SG; Vijayalingam, S; Ryerse, J; Chinnadurai, G				Rashmi, R.; Pillai, S. G.; Vijayalingam, S.; Ryerse, J.; Chinnadurai, G.			BH3-only protein BIK induces caspase-independent cell death with autophagic features in Bcl-2 null cells	ONCOGENE			English	Article						BIK; Bcl-2; autophagy; Beclin-1; LC3	MALIGNANT GLIOMA-CELLS; FAMILY PROTEINS; DOWN-REGULATION; CANCER-CELLS; APOPTOSIS; BAX; EXPRESSION; SURVIVAL; REQUIREMENT; INDUCTION	The BH3-only protein BIK normally induces apoptotic cell death. Here, we have investigated the role of BCL-2 in BIK-induced cell death using Bcl-2(+/+) and Bcl-2(-/-) mouse embryo fibroblasts. Ectopic expression of BIK in Bcl-2(-/-) cells resulted in enhanced cell death compared to Bcl-2(-/-) cells. In these cells, while caspase-8 was activated, there was no significant activation of caspase-9 and 3. There was no detectable mitochondrial to cytosolic release of cytochrome-c. However, there was significant redistribution of AIF from mitochondria to the nucleus. The extent of BIK-induced cell death was augmented by treatment with the pancaspase inhibitor, zVAD-fmk. The Bcl- 2 null cells expressingB IK exhibited autophagic features such as cytosolic vacuoles, punctate distribution of LC3 and enhanced expression of Beclin-1. The survival of BIK-expressing Bcl-2(-/-) cells was enhanced in the presence of PI3 kinase inhibitors 3-methyladenine and Wortmannin and also by depletion of Atg5 and Beclin-1. Death of BIK-expressing Bcl-2(-/-) cells treated with zVAD-fmk was increased under caspase-8 depletion. Our results suggest enhanced expression of BIK in the Bcl- 2 deficient cells leads to cell death with autophagic features and the extent of such cell death could be increased by inhibition of caspases.	[Rashmi, R.; Pillai, S. G.; Vijayalingam, S.; Chinnadurai, G.] St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA; [Ryerse, J.] St Louis Univ, Hlth Sci Ctr, Dept Pathol, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.	chinnag@slu.edu	Pillai, Sreeraj G/M-2369-2013; Pillai, Rashmi Ramachandran/B-8130-2012	Pillai, Sreeraj G/0000-0002-0285-0813; Pillai, Rashmi Ramachandran/0000-0002-1619-7763	NATIONAL CANCER INSTITUTE [R01CA033616, R01CA073803, R21CA116262] Funding Source: NIH RePORTER; NCI NIH HHS [CA-73803, CA-116262, R01 CA033616-27, R21 CA116262-01, R21 CA116262, R01 CA033616, R01 CA073803, R01 CA073803-08, CA-33616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; BOYD JM, 1995, ONCOGENE, V11, P1921; Dai ZY, 2006, BIOCHEM BIOPH RES CO, V351, P455, DOI 10.1016/j.bbrc.2006.10.055; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Garcia N, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-93; Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001; Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200; Naumann U, 2003, HUM GENE THER, V14, P1235, DOI 10.1089/104303403767740777; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Oppermann M, 2005, ONCOGENE, V24, P7369, DOI 10.1038/sj.onc.1208890; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Rashmi R, 2005, CARCINOGENESIS, V26, P713, DOI 10.1093/carcin/bgi025; Saeki K, 2000, CELL DEATH DIFFER, V7, P1263, DOI 10.1038/sj.cdd.4400759; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782; Theodorakis P, 2002, CANCER RES, V62, P3373; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xu Y, 2006, J BIOL CHEM, V281, P19179, DOI 10.1074/jbc.M513377200; Yanagisawa H, 2003, CELL DEATH DIFFER, V10, P798, DOI 10.1038/sj.cdd.4401246; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	31	54	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1366	1375		10.1038/sj.onc.1210783	http://dx.doi.org/10.1038/sj.onc.1210783			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17873911	Green Accepted			2022-12-17	WOS:000253548200003
J	Demuth, I; Digweed, M				Demuth, I.; Digweed, M.			The clinical manifestation of a defective response to DNA double-strand breaks as exemplified by Nijmegen breakage syndrome	ONCOGENE			English	Review						immunodeficiency; lymphoma; haploinsufficient tumor suppressor	CLASS-SWITCH RECOMBINATION; GERMLINE 657DEL5 MUTATION; SYNDROME GENE NBS1; CHROMOSOMAL INSTABILITY; DEPENDENT PHOSPHORYLATION; TARGETED DISRUPTION; ATM ACTIVATION; INCREASED RISK; MRE11 COMPLEX; CANCER	The autosomal recessive genetic disorder Nijmegen breakage syndrome (NBS) was first described in 1981 in patients living in Nijmegen, Holland. NBS patients display a characteristic facial appearance, microcephaly and a range of symptoms including immunodeficiency, increased cancer risk and growth retardation. In addition, NBS patient cells were found to have elevated levels of chromosomal damage and to be sensitive to ionizing irradiation (IR). This radiosensitivity had fatal consequences in some undiagnosed patients. The most dangerous DNA lesion caused by IR is considered to be the double-strand break (DSB) and indeed, NBS patient cells are sensitive to all mutagens that produce DSBs directly or indirectly. We discuss here our current understanding of how a deficiency in DSB repair manifests as the particular symptom complex of NBS.	Charite Univ Med Berlin, Inst Humangenet, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Digweed, M (corresponding author), Charite Univ Med Berlin, Inst Humangenet, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	martin.digweed@charite.de	Demuth, Ilja/ABD-5352-2021	Demuth, Ilja/0000-0002-4340-2523				Buslov KG, 2005, INT J CANCER, V114, P585, DOI 10.1002/ijc.20765; Carlomagno F, 1999, GENE CHROMOSOME CANC, V25, P393, DOI 10.1002/(SICI)1098-2264(199908)25:4<393::AID-GCC12>3.0.CO;2-8; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen WE, 2005, WIREL NETW MOB COMP, V1, P3; Cherry SM, 2007, CURR BIOL, V17, P373, DOI 10.1016/j.cub.2006.12.048; Chrzanowska KH, 2006, INT J CANCER, V118, P1269, DOI 10.1002/ijc.21439; Cybulski C, 2004, CANCER RES, V64, P1215, DOI 10.1158/0008-5472.CAN-03-2502; Debniak T, 2003, MELANOMA RES, V13, P365, DOI 10.1097/00008390-200308000-00005; Demuth I, 2004, HUM MOL GENET, V13, P2385, DOI 10.1093/hmg/ddh278; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Difilippantonio S, 2007, J EXP MED, V204, P1003, DOI 10.1084/jem.20070319; Dumon-Jones V, 2003, CANCER RES, V63, P7263; Frappart PO, 2005, NAT MED, V11, P538, DOI 10.1038/nm1228; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gorski B, 2003, INT J CANCER, V106, P379, DOI 10.1002/ijc.11231; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Kracker S, 2005, P NATL ACAD SCI USA, V102, P1584, DOI 10.1073/pnas.0409191102; Kruger L, 2007, CARCINOGENESIS, V28, P107, DOI 10.1093/carcin/bgl126; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lian GW, 2006, CURR OPIN PEDIATR, V18, P614, DOI 10.1097/MOP.0b013e328010542d; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Meyer P, 2007, MELANOMA RES, V17, P109, DOI 10.1097/CMR.0b013e3280dec638; O'Driscoll M, 2007, AM J HUM GENET, V81, P77, DOI 10.1086/518696; Orii KE, 2006, P NATL ACAD SCI USA, V103, P10017, DOI 10.1073/pnas.0602436103; Payne SR, 2005, CARCINOGENESIS, V26, P2031, DOI 10.1093/carcin/bgi223; Porcedda P, 2006, DNA REPAIR, V5, P904, DOI 10.1016/j.dnarep.2006.05.002; Powers JT, 2004, MOL CANCER RES, V2, P203; Reina-San-Martin B, 2005, P NATL ACAD SCI USA, V102, P1590, DOI 10.1073/pnas.0406289102; Resnick IB, 2003, AM J MED GENET A, V120A, P174, DOI 10.1002/ajmg.a.20188; Rhee JG, 2007, INT J RADIAT ONCOL, V67, P273, DOI 10.1016/j.ijrobp.2006.09.019; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Seemanova E, 2006, Cas Lek Cesk, V145, P201; Seemanova E, 2006, Cas Lek Cesk, V145, P138; SEEMANOVA E, 1990, MUTAT RES, V238, P321, DOI 10.1016/0165-1110(90)90024-6; Seemanova E, 2006, J MED GENET, V43, P218, DOI 10.1136/jmg.2005.035287; SEEMANOVA E, 2004, CSL PEDIAT, V59, P242; Stanulla M, 2000, BRIT J HAEMATOL, V109, P117, DOI 10.1046/j.1365-2141.2000.01973.x; Steffen J, 2004, INT J CANCER, V111, P67, DOI 10.1002/ijc.20239; Steffen J, 2006, INT J CANCER, V119, P472, DOI 10.1002/ijc.21853; Steffen J, 2006, INT J CANCER, V119, P2970, DOI 10.1002/ijc.22280; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stracker TH, 2007, NATURE, V447, P218, DOI 10.1038/nature05740; TAYLOR GM, 2001, CANCER RES, V61, P3570; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 2001, CANCER RES, V61, P3570; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; WEEMAES CMR, 1981, ACTA PAEDIATR SCAND, V70, P557, DOI 10.1111/j.1651-2227.1981.tb05740.x; Yeo TC, 2000, MOL IMMUNOL, V37, P1131, DOI 10.1016/S0161-5890(01)00026-8; Yuan LX., 2001, ACTA AGRON SINICA, V27, P149, DOI 10.3321/j.issn:0496-3490.2001.02.003; Zhang Y, 2007, TOXICOL LETT, V171, P50, DOI 10.1016/j.toxlet.2007.04.006; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	54	54	55	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	2007	26	56					7792	7798		10.1038/sj.onc.1210876	http://dx.doi.org/10.1038/sj.onc.1210876			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066092				2022-12-17	WOS:000251537900010
J	Garcia-Morales, P; Carrasco-Garcia, E; Ruiz-Rico, P; Martinez-Mira, R; Menendez-Gutierrez, MP; Ferragut, JA; Saceda, M; Martinez-Lacaci, I				Garcia-Morales, P.; Carrasco-Garcia, E.; Ruiz-Rico, P.; Martinez-Mira, R.; Menendez-Gutierrez, M. P.; Ferragut, J. A.; Saceda, M.; Martinez-Lacaci, I.			Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines	ONCOGENE			English	Article						ansamycins; G(2)/M arrest; cdc2; cdc25c; glioblastoma	CYCLE-ARREST; GELDANAMYCIN; APOPTOSIS; CHAPERONE; COMPLEX; AKT; DEGRADATION; PROTEINS; KINASE	Ansamycins exert their effects by binding heat shock protein 90 (Hsp90) and targeting important signalling molecules for degradation via the proteasome pathway. We wanted to study the effect of geldanamycin (GA) and its derivative 17-allylamino-17-demethoxygeldanamycin (17-AAG) on glioblastoma cell lines. We show that these cells are growth inhibited by ansamycins by being arrested in G(2)/M and, subsequently, cells undergo apoptosis. The protein levels of cell division cycle 2 (cdc2) kinase and cell division cycle 25c (cdc25c) were downregulated upon GA and 17-AAG treatment and cdc2 kinase activity was inhibited. However, other proteins involved in the G(2)/M checkpoint were not affected. The cdc2 and cdc25c mRNA levels did not show significant differences upon ansamycin treatment, but the stability of cdc2 protein was reduced. The association of cdc2 and cdc25c with p50(cdc37), an Hsp90 cochaperone, decreased, but the interaction of cdc2 and cdc25c with the Hsp70 co-chaperone increased after ansamycin treatment. Proteasome inhibitors were able to rescue the cdc2 downregulation, but not the cdc25c reduction. However, calpain inhibitors were able to rescue the cdc25c downregulation, suggesting that cdc25c is proteolysed by calpains in the presence of ansamycins, and not by the proteasome. We conclude that ansamycins downregulate cdc2 and cdc25c by two different mechanisms.	Univ Miguel Hernandez, Inst Mol & Cellular Biol, E-03202 Alicante, Spain; Hosp Gen Univ Elche, Unidad Invest, Alicante, Spain	Universidad Miguel Hernandez de Elche	Martinez-Lacaci, I (corresponding author), Univ Miguel Hernandez, Inst Mol & Cellular Biol, Edificio Torregaitan, E-03202 Alicante, Spain.	imlacaci@umh.es	Garcia Morales, Pilar/ABD-4362-2021; Saceda, Miguel/A-1581-2008	Saceda, Miguel/0000-0002-1564-3602				An WG, 2000, CELL GROWTH DIFFER, V11, P355; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bellocq A, 1999, J BIOL CHEM, V274, P36891, DOI 10.1074/jbc.274.52.36891; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; de Carcer G, 2004, CANCER RES, V64, P5106, DOI 10.1158/0008-5472.CAN-03-2214; Demidenko ZN, 2006, CELL DEATH DIFFER, V13, P1434, DOI 10.1038/sj.cdd.4401812; Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632; Drysdale MJ, 2006, CURR OPIN DRUG DISC, V9, P483; Georgakis GV, 2006, BRIT J HAEMATOL, V135, P68, DOI 10.1111/j.1365-2141.2006.06247.x; Georgakis GV, 2006, CLIN CANCER RES, V12, P584, DOI 10.1158/1078-0432.CCR-05-1194; Grbovic OM, 2006, P NATL ACAD SCI USA, V103, P57, DOI 10.1073/pnas.0609973103; Hostein I, 2001, CANCER RES, V61, P4003; Kamal A, 2004, TRENDS MOL MED, V10, P283, DOI 10.1016/j.molmed.2004.04.006; Kim HR, 1999, IUBMB LIFE, V48, P425, DOI 10.1080/152165499306810; McIlwrath AJ, 1996, CANCER CHEMOTH PHARM, V37, P423, DOI 10.1007/s002800050407; MILLER P, 1994, CANCER RES, V54, P2724; Munster PN, 2002, CANCER RES, V62, P3132; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nomura M, 2004, J CELL PHYSIOL, V201, P374, DOI 10.1002/jcp.20090; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Senju M, 2006, J CANCER RES CLIN, V132, P150, DOI 10.1007/s00432-005-0047-7; Sharp S, 2006, ADV CANCER RES, V95, P323, DOI 10.1016/S0065-230X(06)95009-X; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Srethapakdi M, 2000, CANCER RES, V60, P3940; Stupp R, 2006, ONCOLOGIST, V11, P165, DOI 10.1634/theoncologist.11-2-165; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xiao L, 2006, MINI-REV MED CHEM, V6, P1137, DOI 10.2174/138955706778560166	28	54	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7185	7193		10.1038/sj.onc.1210534	http://dx.doi.org/10.1038/sj.onc.1210534			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525741				2022-12-17	WOS:000250955600002
J	Adiga, SK; Toyoshima, M; Shiraishi, K; Shimura, T; Takeda, J; Taga, M; Nagai, H; Kumar, P; Niwa, O				Adiga, S. K.; Toyoshima, M.; Shiraishi, K.; Shimura, T.; Takeda, J.; Taga, M.; Nagai, H.; Kumar, P.; Niwa, O.			p21 provides stage specific DNA damage control to preimplantation embryos	ONCOGENE			English	Article						radiation; p21 activation; preimplantation stage embryos	CELL-CYCLE; MOUSE DEVELOPMENT; GENE-EXPRESSION; CARCINOMA-CELLS; IN-VITRO; X-RAY; APOPTOSIS; P21(WAF1/CIP1); ACTIVATION; SPERM	The early stage embryogenesis of higher eukaryotes lacks some of the damage response pathways such as G1/S checkpoint, G2/M checkpoint and apoptosis. We examined here the damage response of preimplantation stage embryos after fertilization with 6 Gy irradiated sperm. Sperm-irradiated embryos developed normally for the first 2.5 days, but started to exhibit a developmental delay at day 3.5. p21 was activated in the delayed embryos, which carried numerous micronuclei owing to delayed chromosome instability. Apoptosis was observed predominantly in the inner cell mass of the day 4.0 embryos. Sperm-irradiated p21 -/- embryos lacked the delay, but chromosome instability and apoptosis were more pronounced than the corresponding p21 wild-type embryos. We conclude from the result that damage responses come in a stagespeci. c manner during preimplantation stage development; p53-dependent S checkpoint at the zygote stage, p21-mediated cell cycle arrest at the morula/blastocyst stages and apoptosis after the blastocyst stage in the inner cell mass.	Kasturba Med Coll & Hosp, Manipal, India; Kyoto Univ, Radiat Biol Ctr, Kyoto, Japan; Osaka Prefecture Univ, Adv Sci & Technol Inst, Osaka, Japan; RIKEN, Genome Damage Respone Res Unit, Wako, Saitama, Japan	Manipal Academy of Higher Education (MAHE); Kasturba Medical College, Manipal; Kyoto University; Osaka Metropolitan University; RIKEN	Niwa, O (corresponding author), Kyoto Univ, Studies Rdiat Biol Ctr, Yoshida konoe Sakyo-ku, Kyoto 606850, Japan.	oniwa@house.rbc.kyoto-u.ac.jp	Adiga, Satish Kumar/AAU-4386-2020	Adiga, Satish Kumar/0000-0002-2897-4697; , pratap kumar/0000-0002-7245-1746				Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Clute P, 1997, DEV BIOL, V185, P1, DOI 10.1006/dbio.1997.8540; FENECH M, 1993, ENVIRON HEALTH PERSP, V101, P101, DOI 10.2307/3431708; FLEMING TP, 2001, FRONT BIOSCI, V6, P2566; FRIESNER JD, 2005, MOL BIOL CELL, V16, pD1000; Gartel AL, 2002, MOL CANCER THER, V1, P639; GOLDSTEIN LS, 1975, RADIAT RES, V62, P276, DOI 10.2307/3574220; Gottifredi V, 2004, J BIOL CHEM, V279, P5802, DOI 10.1074/jbc.M310373200; Hamatani T, 2004, P NATL ACAD SCI USA, V101, P10326, DOI 10.1073/pnas.0402597101; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Heyer BS, 2000, GENE DEV, V14, P2072; Ikegami R, 1997, ZYGOTE, V5, P153, DOI 10.1017/S0967199400003828; Iliakis G, 2004, CYTOGENET GENOME RES, V104, P14, DOI 10.1159/000077461; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Jeong YJ, 2005, MOL REPROD DEV, V71, P284, DOI 10.1002/mrd.20269; Jurisicova A, 1998, MOL HUM REPROD, V4, P139, DOI 10.1093/molehr/4.2.139; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Kamjoo M, 2002, MOL REPROD DEV, V61, P67, DOI 10.1002/mrd.1132; Liu SX, 2003, DRUG RESIST UPDATE, V6, P183, DOI 10.1016/S1368-7646(03)00044-X; Malashicheva AB, 2000, ONCOGENE, V19, P3858, DOI 10.1038/sj.onc.1203736; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; MUKHERJEE AB, 1976, P NATL ACAD SCI USA, V73, P1608, DOI 10.1073/pnas.73.5.1608; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Shimura T, 2002, RADIAT RES, V158, P735, DOI 10.1667/0033-7587(2002)158[0735:TNSMOT]2.0.CO;2; Taga M, 2000, J RADIAT RES, V41, P227, DOI 10.1269/jrr.41.227; TAYLOR SL, 2001, FOOD ALLERGY INTOLER, V2, P53; Toyoshima M, 2005, ONCOGENE, V24, P3229, DOI 10.1038/sj.onc.1208514; Wright SJ, 1999, CURR TOP DEV BIOL, V46, P133, DOI 10.1016/S0070-2153(08)60328-2; Zeng FY, 2004, DEV BIOL, V272, P483, DOI 10.1016/j.ydbio.2004.05.018; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; ZIOMEK CA, 1980, CELL, V21, P935, DOI 10.1016/0092-8674(80)90457-2	33	54	55	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6141	6149		10.1038/sj.onc.1210444	http://dx.doi.org/10.1038/sj.onc.1210444			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17420724				2022-12-17	WOS:000249401300004
J	Zhu, Q; Wani, G; Yao, J; Patnaik, S; Wang, QE; El-Mahdy, MA; Praetorius-Ibba, M; Wani, AA				Zhu, Q.; Wani, G.; Yao, J.; Patnaik, S.; Wang, Q-E; El-Mahdy, M. A.; Praetorius-Ibba, M.; Wani, A. A.			The ubiquitin-proteasome system regulates p53-mediated transcription at p21(waf1) promoter	ONCOGENE			English	Article						ubiquitin; proteasome; degradationtranscription; p53	RNA-POLYMERASE-II; HORMONE-RECEPTOR; HUMAN HOMOLOG; DNA-REPAIR; P53; ACTIVATION; PROTEIN; COACTIVATOR; DEGRADATION; RECRUITMENT	The ubiquitin (Ub)-proteasome system (UPS) promotes the proteasomal degradation of target proteins by decorating them with Ub labels. Emerging evidence indicates a role of UPS in regulating gene transcription. In this study, we provided evidence for the involvement of UPS in the transcriptional activation function of tumor suppressor p53. We showed that both ubiquitylation and proteasomal functions are required for efficient transcription mediated by p53. Disruption of transcription by actinomycin D, 5,6-dichloro-1-beta-D-ribofuranosyl-benzimadazole or alpha-amanitin leads to accumulation of cellular p53 protein. Proteasome inhibition by MG132 increases the occupancy of p53 protein at p53-responsive p21(waf1) promoter. In addition, the Sug-1 component of 19S proteasome physically interacts with p53 in vitro and in vivo. Moreover, in response to ultraviolet-induced DNA damage, both the 19S proteasomal components, Sug1 and S1, are recruited to p21(waf1) promoter region in a kinetic pattern similar to that of p53. These results suggested that UPS positively regulates p53-mediated transcription at p21(waf1) promoter.	Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Wani, AA (corresponding author), Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA.	wani.2@osu.edu	Zhu, Qianzheng/A-4902-2013		NCI NIH HHS [CA93413] Funding Source: Medline; NIEHS NIH HHS [ES12991, R01 ES012991, ES02388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002388, R01ES012991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Dvir A, 2001, CURR OPIN GENET DEV, V11, P209, DOI 10.1016/S0959-437X(00)00181-7; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; Ferdous A, 2002, BIOCHEMISTRY-US, V41, P12798, DOI 10.1021/bi020425t; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Gillette TG, 2004, P NATL ACAD SCI USA, V101, P5904, DOI 10.1073/pnas.0305411101; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim J, 2005, MOL CELL, V20, P759, DOI 10.1016/j.molcel.2005.11.012; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin L, 2005, ONCOGENE, V24, P3385, DOI 10.1038/sj.onc.1208554; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; O'Hagan HM, 2004, ONCOGENE, V23, P5505, DOI 10.1038/sj.onc.1207709; Rajendra R, 2004, J BIOL CHEM, V279, P36440, DOI 10.1074/jbc.C400300200; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Saleh A, 1998, J MOL BIOL, V282, P933, DOI 10.1006/jmbi.1998.2036; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VENKATACHALAM S, 1995, CARCINOGENESIS, V16, P2029, DOI 10.1093/carcin/16.9.2029; VOM BE, 1996, EMBO J, V15, P110; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhu QZ, 2004, FEBS LETT, V556, P19, DOI 10.1016/S0014-5793(03)01347-4	50	54	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4199	4208		10.1038/sj.onc.1210191	http://dx.doi.org/10.1038/sj.onc.1210191			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17224908				2022-12-17	WOS:000247619900002
J	Karagiannis, TC; Kn, H; El-Osta, A				Karagiannis, T. C.; Kn, H.; El-Osta, A.			Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments	ONCOGENE			English	Article						histone acetylation; HDAC inhibitor; trichostatin A; radiation sensitivity; gamma H2AX; ChIP	NUCLEOTIDE EXCISION-REPAIR; ACTIVE CHROMATIN; IN-VIVO; SACCHAROMYCES-CEREVISIAE; TUMOR RADIOSENSITIVITY; HUMAN-CELLS; ENHANCEMENT; METHYLATION; PHOTOLYASE; CANCER	Epigenetic regulation of chromatin structure is central to the process of DNA repair. A well-characterized epigenetic feature is the dynamic phosphorylation of the histone H2AX ( gamma H2AX) and mobilization of double strand break ( DSB) recognition and repair factors to the site. How chromatin structure is altered in response to DNA damage and how such alterations influence DSB repair mechanisms are currently relevant issues. Despite the clear link between histone deacetylases ( HDACs) and radiosensitivity, how histone hyperacetylation influence DSB repair remains poorly understood. We have determined the structure of chromatin is a major factor determining radiosensitivity and repair in human cells. Trichostatin A ( TSA) enhances radiosensitivity with dose modi. cation factors of 1.2 and 1.9 at 0.2 and 1 mu M, respectively. Cells treated with TSA causing hyperacetylation and remodelling on euchromatic alleles coexist with gamma H2AX accumulation in radiosensitized cells. Formation of gamma H2AX on heterochromatin was significantly reduced even when cells were treated with TSA, suggesting that chromatin structure and histone hyperacetylation are pronounced features of radiation sensitivity and repair in euchromatic regions.	Baker Med Res Inst, Epigenet Human Hlth & Dis Lab, Alfred Med Res & Educ Precinct, Melbourne, Vic 3004, Australia; Peter MacCallum Canc Ctr, Trescowthick Res Labs, Dept Mol Radiat Biol, Melbourne, Vic, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia	Baker Heart and Diabetes Institute; Peter Maccallum Cancer Center; University of Melbourne	El-Osta, A (corresponding author), Baker Med Res Inst, Epigenet Human Hlth & Dis Lab, Alfred Med Res & Educ Precinct, 2nd Floor,Commercial Rd, Melbourne, Vic 3004, Australia.	assam.el-osta@baker.edu.au		Kaipananickal, Harikrishnan/0000-0002-4662-659X; El-Osta, Assam/0000-0003-2969-9137; El-Osta, Assam/0000-0001-7968-7375; Karagiannis, Tom/0000-0002-9967-1546				Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Camphausen K, 2005, INT J CANCER, V114, P380, DOI 10.1002/ijc.20774; Camphausen K, 2004, CLIN CANCER RES, V10, P6066, DOI 10.1158/1078-0432.CCR-04-0537; Camphausen K, 2004, CANCER RES, V64, P316, DOI 10.1158/0008-5472.CAN-03-2630; Chinnaiyan P, 2005, INT J RADIAT ONCOL, V62, P223, DOI 10.1016/j.ijrobp.2004.12.088; CHIU SM, 1982, BIOCHIM BIOPHYS ACTA, V699, P15, DOI 10.1016/0167-4781(82)90166-X; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; El-Osta A, 2000, GENE EXPRESSION, V9, P63; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Harikrishnan KN, 2005, NAT GENET, V37, P254, DOI 10.1038/ng1516; Jiang GC, 2004, J CELL BIOCHEM, V93, P286, DOI 10.1002/jcb.20146; Jung M, 2005, RADIAT RES, V163, P488, DOI 10.1667/RR3345; Karagiannis TC, 2005, CANCER BIOL THER, V4, P787, DOI 10.4161/cbt.4.7.1922; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kelly WK, 2005, NAT CLIN PRACT ONCOL, V2, P150, DOI 10.1038/ncponc0106; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kladde MP, 1996, EMBO J, V15, P6290, DOI 10.1002/j.1460-2075.1996.tb01019.x; Livingstone-Zatchej M, 2003, J BIOL CHEM, V278, P37471, DOI 10.1074/jbc.M306335200; Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311; Marks PA, 2005, EXPERT OPIN INV DRUG, V14, P1497, DOI 10.1517/13543784.14.12.1497; Marks Paul A, 2004, Novartis Found Symp, V259, P269; Meier A, 2002, J BIOL CHEM, V277, P11845, DOI 10.1074/jbc.M110941200; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; Munshi A, 2005, CLIN CANCER RES, V11, P4912, DOI 10.1158/1078-0432.CCR-04-2088; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Piekarz RL, 2004, BLOOD, V103, P4636, DOI 10.1182/blood-2003-09-3068; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Suter B, 1997, EMBO J, V16, P2150, DOI 10.1093/emboj/16.8.2150; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; TERLETH C, 1990, MOL CELL BIOL, V10, P4678, DOI 10.1128/MCB.10.9.4678; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Vidanes GM, 2005, CELL, V121, P973, DOI 10.1016/j.cell.2005.06.013; Xu M, 1998, MOL CELL BIOL, V18, P1201, DOI 10.1128/MCB.18.3.1201; Zhang Y, 2004, RADIAT RES, V161, P667, DOI 10.1667/RR3192; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452	38	54	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3963	3971		10.1038/sj.onc.1210174	http://dx.doi.org/10.1038/sj.onc.1210174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213813				2022-12-17	WOS:000247144500006
J	Kang, Y; Hong, JA; Chen, GA; Nguyen, DM; Schrump, DS				Kang, Y.; Hong, J. A.; Chen, G. A.; Nguyen, D. M.; Schrump, D. S.			Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells	ONCOGENE			English	Article						lung cancer; epigenetics; NY-ESO-1; BORIS; CTCF; Sp1	GC-RICH DNA; GENE-TRANSCRIPTION; BINDING; FAMILY; IDENTIFICATION; DEREPRESSION; EPIGENETICS; ANTIGEN; DOMAIN; P300	Previously, we reported that the paralogous zinc-finger proteins-CTCF and brother of the regulator of imprinted sites (BORIS), directly contribute to transcriptional regulation of NY-ESO-1 in lung cancer cells. To further examine mechanisms that mediate expression of this cancer-testis gene, we performed software-guided analysis of the NY-ESO-1 promoter region, which revealed several potential Sp1- binding motifs. Sequential 5-aza-2 ' deoxycytidine/ depsipeptide FK228 treatment markedly induced BORIS expression and enhanced nuclear translocation of Sp1 in lung cancer cells. Transient transfection assays using promoter-reporter constructs, as well as gel-shift and chromatin immunoprecipitation experiments revealed that NY-ESO-1 promoter activity coincided with occupancy of the proximal Spi-binding site in lung cancer cells. Mutations within the Sp1 recognition sequence specifi. cally eliminated binding of Sp1 to this motif in vitro, and markedly diminished NY-ESO-1 promoter activity in vivo. siRNA-mediated inhibition of Sp1 expression decreased NY-ESO-1 promoter activity, whereas knock down of CTCF expression augmented NY-ESO-1 transcription in lung cancer cells. Co-immunoprecipitation experiments indicated that Sp1 physically interacts with BORIS but not with CTCF in vivo. Collectively, these. findings suggest that BORIS recruits Sp1 to mediate de-repression of NY-ESO-1 during pulmonary carcinogenesis.	NCI, Ctr Canc Res, Surg Branch, Thorac Oncol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schrump, DS (corresponding author), NCI, Ctr Canc Res, Surg Branch, Thorac Oncol Sect, Bldg 10,Rm 4-3942,10 Ctr Dr, Bethesda, MD 20892 USA.	David_Schrump@nih.gov			NATIONAL CANCER INSTITUTE [Z01BC010519, ZIASC010093, Z01SC010093] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertini V, 2006, NUCLEIC ACIDS RES, V34, P1721, DOI 10.1093/nar/gkl063; DePlaen E, 1997, GENOMICS, V40, P305, DOI 10.1006/geno.1996.4566; Gnjatic S, 2006, ADV CANCER RES, V95, P1, DOI 10.1016/S0065-230X(06)95001-5; Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823; Hosoi Y, 2004, INT J ONCOL, V25, P461; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; Hung JJ, 2006, MOL CELL BIOL, V26, P1770, DOI 10.1128/MCB.26.5.1770-1785.2006; Husmann M, 2000, BIOCHEM J, V352, P763, DOI 10.1042/0264-6021:3520763; James SR, 2006, ONCOGENE, V25, P6975, DOI 10.1038/sj.onc.1209678; Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3; Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699; Nguyen DM, 2004, CLIN CANCER RES, V10, P1813, DOI 10.1158/1078-0432.CCR-0901-3; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Persengiev SP, 1996, ENDOCRINOLOGY, V137, P638, DOI 10.1210/en.137.2.638; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Schrump DS, 2005, SEMIN ONCOL, V32, P488, DOI 10.1053/j.seminoncol.2005.07.007; Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Thomas K, 2005, BIOL REPROD, V72, P898, DOI 10.1095/biolreprod.104.030528; Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858; Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628; Zendman AJW, 2003, J CELL PHYSIOL, V194, P272, DOI 10.1002/jcp.10215; Zhang Y, 2005, MOL CELL BIOL, V25, P7929, DOI 10.1128/MCB.25.18.7929-7939.2005	27	54	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2007	26	30					4394	4403		10.1038/sj.onc.1210218	http://dx.doi.org/10.1038/sj.onc.1210218			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17260018				2022-12-17	WOS:000247620000007
J	Cronauer, MV; Ince, Y; Engers, R; Rinnab, L; Weidemann, W; Suschek, CV; Burchardt, M; Kleinert, H; Wiedenmann, J; Sies, H; Ackermann, R; Kroncke, KD				Cronauer, M. V.; Ince, Y.; Engers, R.; Rinnab, L.; Weidemann, W.; Suschek, C. V.; Burchardt, M.; Kleinert, H.; Wiedenmann, J.; Sies, H.; Ackermann, R.; Kroencke, K.-D.			Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression	ONCOGENE			English	Article						androgen receptor; nitric oxide; prostate cancer; prostate specific antigen; zinc-finger	CARCINOMA-CELL LINE; GROWTH-FACTOR; UP-REGULATION; ZINC RELEASE; TUMOR-GROWTH; SYNTHASE-II; EXPRESSION; TRANSCRIPTION; PROTEIN; METALLOTHIONEIN	Chronic inflammation increases the risk of cancer and many cancers, including prostate cancer, arise at sites of chronic inflammation. Inducible nitric oxide synthase ( iNOS) is an enzyme dominantly expressed during inflammatory reactions. Although synthesis of high amounts of nitric oxide (NO) by iNOS has been demonstrated in pathophysiological processes, such as acute or chronic inflammation, autoimmune diseases or tumorigenesis, the role of iNOS activity in most of these diseases is poorly understood. Analysing prostate cancer biopsies by immunohistochemistry we found iNOS protein expression in tumor cells strongly paralleled by nitrotyrosine suggesting that iNOS is fully active. In vitro, NO inhibits androgen receptor-dependent promoter activity and prostate specific antigen production as well as DNA-binding activity of the androgen receptor (AR) in a concentration-dependent manner. Inhibition of the activity of androgen receptor-dependent reporter constructs is neither owing to diminished AR protein levels nor owing to an inhibition of its nuclear import. In addition, NO inhibits the proliferation of androgen receptor-positive prostate cancer cells significantly more efficiently than proliferation of androgen receptor-negative prostate cancer cells. In summary, our findings suggest that intratumoral iNOS activity favors development of prostate cancer cells that are able to proliferate androgen receptor-independently, thereby promoting prostate tumor progression.	Univ Dusseldorf, Inst Biochem & Mol Biol 1, Dept Urol, D-40225 Dusseldorf, Germany; Univ Ulm, Dept Gen Zool & Endocrinol, D-89069 Ulm, Germany; Univ Dusseldorf, Inst Biochem & Mol Biol 1, D-4000 Dusseldorf, Germany; Univ Dusseldorf, Inst Pathol, D-4000 Dusseldorf, Germany; Univ Ulm, Dept Urol & Pediat Urol, D-89069 Ulm, Germany; Univ Dusseldorf, Inst Biochem & Mol Biol 2, D-4000 Dusseldorf, Germany; Johannes Gutenberg Univ Mainz, Dept Pharmacol, D-6500 Mainz, Germany	Heinrich Heine University Dusseldorf; Ulm University; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Ulm University; Heinrich Heine University Dusseldorf; Johannes Gutenberg University of Mainz	Kroncke, KD (corresponding author), Univ Dusseldorf, Inst Biochem & Mol Biol 1, Dept Urol, Univ Str 1, D-40225 Dusseldorf, Germany.	kroencke@uni-duesseldorf.de	Cronauer, Marcus/AAG-7457-2021; Kleinert, Hartmut/M-2988-2018; Sies, Helmut/ABE-7355-2020; Sies, Helmut/B-7266-2008	Kleinert, Hartmut/0000-0003-2202-3548; Sies, Helmut/0000-0002-1000-3198				Aaltomaa SH, 2001, ANTICANCER RES, V21, P3101; Adam RM, 2002, ENDOCRINOLOGY, V143, P4599, DOI 10.1210/en.2002-220561; Attardi BJ, 2004, MOL CELL ENDOCRINOL, V222, P121, DOI 10.1016/j.mce.2004.04.013; Baltaci S, 2001, BJU INT, V88, P100, DOI 10.1046/j.1464-410x.2001.02231.x; Berendji D, 1997, FEBS LETT, V405, P37, DOI 10.1016/S0014-5793(97)00150-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bronte V, 2005, J EXP MED, V201, P1257, DOI 10.1084/jem.20042028; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Craft N, 1999, CANCER RES, V59, P5030; Cronauer MV, 2000, BRIT J CANCER, V82, P39; Cronauer MV, 2005, INT J ONCOL, V26, P1033; Cronauer MV, 2004, ONCOGENE, V23, P3541, DOI 10.1038/sj.onc.1207346; Cronauer MV, 2003, INT J ONCOL, V23, P1095; Ekmekcioglu S, 2005, CURR CANCER DRUG TAR, V5, P103, DOI 10.2174/1568009053202072; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Garban HJ, 2005, P NATL ACAD SCI USA, V102, P2632, DOI 10.1073/pnas.0409854102; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; GAST A, 1995, MOL CELL ENDOCRINOL, V111, P93, DOI 10.1016/0303-7207(95)03554-K; Gradini R, 1999, J PATHOL, V189, P224; Grune T, 2003, BIOCHEM BIOPH RES CO, V305, P709, DOI 10.1016/S0006-291X(03)00809-X; Hobisch A, 1996, PROSTATE, V28, P129; Hobisch A, 1998, CANCER RES, V58, P4640; Hongo F, 2005, BIOCHEM BIOPH RES CO, V336, P692, DOI 10.1016/j.bbrc.2005.08.150; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hrabie JA, 2000, J ORG CHEM, V65, P5745, DOI 10.1021/jo000600g; Huguenin S, 2004, PROSTATE, V61, P132, DOI 10.1002/pros.20081; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Klotz T, 1998, CANCER, V82, P1897, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1897::AID-CNCR12>3.0.CO;2-O; Kroncke KD, 2000, ANTIOXID REDOX SIGN, V2, P585, DOI 10.1089/15230860050192341; Kroncke KD, 2000, FASEB J, V14, P166; Kroncke KD, 2001, NITRIC OXIDE-BIOL CH, V5, P289, DOI 10.1006/niox.2001.0354; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; Le XD, 2005, P NATL ACAD SCI USA, V102, P8758, DOI 10.1073/pnas.0409581102; MARTH C, 1990, CANCER RES, V50, P7037; Michalaki V, 2004, BRIT J CANCER, V90, P2312, DOI 10.1038/sj.bjc.6601814; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nelson William G, 2004, J Urol, V172, pS6, DOI 10.1097/01.ju.0000142058.99614.ff; Nienhaus GU, 2006, PHOTOCHEM PHOTOBIOL, V82, P351, DOI 10.1562/2005-05-19-RA-533; Olson MV, 2006, CANCER GENE THER, V13, P676, DOI 10.1038/sj.cgt.7700941; PARK JG, 1987, CANCER RES, V47, P6710; Pearce LL, 2000, P NATL ACAD SCI USA, V97, P477, DOI 10.1073/pnas.97.1.477; Royle JS, 2004, J UROLOGY, V172, P338, DOI 10.1097/01.ju.0000132367.02834.41; Rudeck M, 2000, IUBMB LIFE, V49, P451; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Tepper CG, 2002, CANCER RES, V62, P6606; Thomsen LL, 1998, CANCER METAST REV, V17, P107, DOI 10.1023/A:1005912906436; Wang JZ, 2003, UROL ONCOL-SEMIN ORI, V21, P117, DOI 10.1016/S1078-1439(02)00208-9; Wiedenmann J, 2004, P NATL ACAD SCI USA, V101, P15905, DOI 10.1073/pnas.0403668101	50	54	56	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1875	1884		10.1038/sj.onc.1209984	http://dx.doi.org/10.1038/sj.onc.1209984			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	16983333				2022-12-17	WOS:000245117700005
J	Yang, G; Thompson, MA; Brandt, SJ; Hiebert, SW				Yang, G.; Thompson, M. A.; Brandt, S. J.; Hiebert, S. W.			Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein	ONCOGENE			English	Article						RUNX1; ETO; MTG8; histone deacetylase; t(8;21); corepressor	ACUTE MYELOID-LEUKEMIA; T-CELL LYMPHOMA; ABL TYROSINE KINASE; TRANS-RETINOIC ACID; ALPHA ONCOPROTEIN; TUMOR-SUPPRESSOR; ARSENIC TRIOXIDE; NUCLEAR-BODIES; CANCER-THERAPY; MURINE MODEL	The t(8; 21) chromosomal translocation that generates the fusion oncoprotein RUNX1-ETO predominates in leukemia patients of the French-American-British (FAB) class M2 subtype. The oncoprotein has the capacity to promote expansion of hematopoietic stem/progenitor cells and induces leukemia in association with other genetic alterations. Here, we show that RUNX1-ETO undergoes degradation in response to treatment with histone deacetylase inhibitors, one of which, depsipeptide (DEP), is currently undergoing phase II clinical testing in a variety of malignancies. These compounds induce turnover of RUNX1-ETO without affecting the stability of RUNX1-ETO partner proteins. In addition, RUNX1-ETO physically interacts with heat shock protein 90 (HSP90). DEP treatment interrupts the association of RUNX1-ETO with HSP90 and induces proteasomal degradation of RUNX1-ETO. DEP and the HSP90 antagonist 17-allylamino-geldanamycin (17-AAG) both triggered RUNX1-ETO degradation, but without any additive or cooperative effects. These findings may stimulate the development of more rational and effective approaches for treating t(8; 21) patients using histone deacetylase inhibitors or HSP90 inhibitors.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pathol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell & Dev Biol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Canc Biol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Tennessee Valley VA Healthcare Syst, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University	Hiebert, SW (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 512 Preston Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	scott.hiebert@vanderbilt.edu	Hiebert, Scott W/C-9979-2010		NCI NIH HHS [R01-CA64140, CA68485] Funding Source: Medline; NHLBI NIH HHS [R01-HL49118] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064140, P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aoyagi S, 2005, TRENDS CELL BIOL, V15, P565, DOI 10.1016/j.tcb.2005.09.003; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Blagosklonny MV, 2002, MOL CANCER THER, V1, P937; Byrd JC, 2005, BLOOD, V105, P959, DOI 10.1182/blood-2004-05-1693; Chen GQ, 1997, BLOOD, V89, P3345; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fenske TS, 2004, P NATL ACAD SCI USA, V101, P15184, DOI 10.1073/pnas.0400751101; Fuino L, 2003, MOL CANCER THER, V2, P971; Garrido SM, 2001, EXP HEMATOL, V29, P448, DOI 10.1016/S0301-472X(01)00612-9; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; George P, 2005, BLOOD, V105, P1768, DOI 10.1182/blood-2004-09-3413; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Kasashima K, 2004, BIOCHIMIE, V86, P713, DOI 10.1016/j.biochi.2004.08.003; Klisovic MI, 2003, LEUKEMIA, V17, P350, DOI 10.1038/sj.leu.2402776; Komori A, 1999, JPN J CANCER RES, V90, P60, DOI 10.1111/j.1349-7006.1999.tb00666.x; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Kozu T, 2000, GENES CELLS, V5, P637, DOI 10.1046/j.1365-2443.2000.00353.x; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Linggi BE, 2005, J CELL BIOCHEM, V96, P938, DOI 10.1002/jcb.20604; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Marshall John L, 2002, J Exp Ther Oncol, V2, P325, DOI 10.1046/j.1359-4117.2002.01039.x; MATSUSHITA H, 1995, BIOCHEM BIOPH RES CO, V215, P431, DOI 10.1006/bbrc.1995.2483; Muller S, 1998, BLOOD, V92, P4308, DOI 10.1182/blood.V92.11.4308.423k36_4308_4316; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Odenike OM, 2004, BLOOD, V104, p79A; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Pichardo DA, 2004, LEUKEMIA LYMPHOMA, V45, P1755, DOI 10.1080/10428190410001693560; Piekarz R, 2004, CURR PHARM DESIGN, V10, P2289, DOI 10.2174/1381612043383980; Piekarz RL, 2004, BLOOD, V103, P4636, DOI 10.1182/blood-2003-09-3068; Piekarz RL, 2001, BLOOD, V98, P2865, DOI 10.1182/blood.V98.9.2865; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; SANDRO V, 2002, CLIN CANCER RES, V8, P662; Sato N, 2004, INT J ONCOL, V24, P679; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Sutheesophon K, 2005, J CELL PHYSIOL, V203, P387, DOI 10.1002/jcp.20235; Szyrach M, 2001, EUR J BIOCHEM, V268, P3550, DOI 10.1046/j.1432-1327.2001.02259.x; Tabe Y, 2006, BLOOD, V107, P1546, DOI 10.1182/blood-2004-10-4126; Vanhaecke T, 2004, CURR MED CHEM, V11, P1629, DOI 10.2174/0929867043365099; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1999, CANCER RES, V59, P2766; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Yang GY, 2005, MOL CELL BIOL, V25, P5869, DOI 10.1128/MCB.25.14.5869-5879.2005; Yoshida H, 1996, CANCER RES, V56, P2945; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	68	54	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					91	101		10.1038/sj.onc.1209760	http://dx.doi.org/10.1038/sj.onc.1209760			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799637				2022-12-17	WOS:000243236500009
J	Brocke-Heidrich, K; Ge, B; Cvijic, H; Pfeifer, G; Loffler, D; Henze, C; McKeithan, TW; Horn, F				Brocke-Heidrich, K.; Ge, B.; Cvijic, H.; Pfeifer, G.; Loeffler, D.; Henze, C.; McKeithan, T. W.; Horn, F.			BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription	ONCOGENE			English	Article						BCL3; IL-6; Stat3; myeloma	NF-KAPPA-B; CANDIDATE PROTOONCOGENE BCL-3; MULTIPLE-MYELOMA CELLS; ONCOPROTEIN BCL-3; GENE-EXPRESSION; P50 HOMODIMERS; ENCODES; PHOSPHORYLATION; ACTIVATION; INDUCTION	BCL3 is a proto-oncogene affected by chromosomal translocations in some patients with chronic lymphocytic leukemia. It is an IKB family protein that is involved in transcriptional regulation of a number of NF-KB target genes. In this study, interleukin (IL)-6-induced BCL3 expression and its effect on survival of multiple myeloma ( MM) cells were examined. We demonstrate the upregulation of BCL3 by IL-6 in INA-6 and other MM cell lines. Sequence analysis of the BCL3 gene locus revealed four potential signal transducer and activator of transcription (Stat) binding sites within two conserved intronic enhancers regions: one located within enhancer HS3 and three within HS4. Chromatin immunoprecipitation experiments showed increased Stat3 binding to both enhancers upon IL-6 stimulation. Silencing Stat3 expression by small interfering RNA ( siRNA) abrogated BCL3 expression by IL-6. Using reporter gene assays, we demonstrate that BCL3 transcription depends on HS4. Mutation of the Stat motifs within HS4 abolished IL-6-dependent BCL3 induction. Furthermore, BCL3 transcription was inhibited by its own gene product. This repressive feedback is mediated by NF-KB sites within the promoter and HS3. Finally, we show that overexpression of BCL3 increases apoptosis, whereas BCL3-specific siRNA does not affect the viability of INA-6 cells suggesting that BCL3 is not essential for the survival of these cells.	Univ Leipzig, Inst Clin Immunol & Transfus Med, D-04103 Leipzig, Germany; Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68182 USA	Leipzig University; University of Nebraska System; University of Nebraska Medical Center	Brocke-Heidrich, K (corresponding author), Univ Leipzig, Inst Clin Immunol & Transfus Med, Johannisallee 30, D-04103 Leipzig, Germany.	kheid@medizin.uni-leipzig.de		McKeithan, Timothy/0000-0003-2242-3074				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Brocke-Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood-2003-04-1048; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Burger R, 2001, Hematol J, V2, P42, DOI 10.1038/sj.thj.6200075; Chatterjee M, 2004, BLOOD, V104, P3712, DOI 10.1182/blood-2004-04-1670; CHEN HM, 1995, ONCOGENE, V11, P1549; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Elliott SF, 2002, ARTHRITIS RHEUM-US, V46, P3230, DOI 10.1002/art.10675; Feinman R, 1999, BLOOD, V93, P3044; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Ge BS, 2003, J IMMUNOL, V171, P4210, DOI 10.4049/jimmunol.171.8.4210; Holtick U, 2005, LEUKEMIA, V19, P936, DOI 10.1038/sj.leu.2403750; INOUE J, 1993, ONCOGENE, V8, P2067; Jamaluddin M, 2005, J VIROL, V79, P15302, DOI 10.1128/JVI.79.24.15302-15313.2005; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; Kordula T, 1998, J BIOL CHEM, V273, P4112, DOI 10.1074/jbc.273.7.4112; Kuwata H, 2003, BLOOD, V102, P4123, DOI 10.1182/blood-2003-04-1228; MCKEITHAN TW, 1990, GENE CHROMOSOME CANC, V1, P247, DOI 10.1002/gcc.2870010310; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Mitchell TC, 2001, NAT IMMUNOL, V2, P397, DOI 10.1038/87692; Nishikori M, 2003, BLOOD, V101, P2789, DOI 10.1182/blood-2002-08-2464; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Ong ST, 1998, ONCOGENE, V16, P2333, DOI 10.1038/sj.onc.1201771; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; Thornburg NJ, 2003, CANCER RES, V63, P8293; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; Yamazaki S, 2005, J BIOL CHEM, V280, P1678, DOI 10.1074/jbc.M409983200	35	54	57	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7297	7304		10.1038/sj.onc.1209711	http://dx.doi.org/10.1038/sj.onc.1209711			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16732314				2022-12-17	WOS:000242244700008
J	Wang, G; Jones, SJM; Marra, MA; Sadar, MD				Wang, G.; Jones, S. J. M.; Marra, M. A.; Sadar, M. D.			Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen receptor; Affymetrix; LNCaP hollow fiber model; cross-talk; PKA	PROTEIN-KINASE; MOLECULAR CHARACTERIZATION; HORMONAL-REGULATION; EXPRESSION PROFILE; RESPONSIVE GENES; TUMOR-SUPPRESSOR; REGULATED GENES; DOWN-REGULATION; AMINO-TERMINUS; RECEPTOR	Progression of prostate cancer to androgen independence is suspected to involve the androgen and protein kinase A (PKA) signaling pathways. Here for the first time, the transcriptomes associated with each pathway and common transcriptional targets in response to stimulation of both pathways were identified in human prostate cancer cells using Affymetrix GeneChip technology (Human Genome U133 plus2). Statistically significant changes in the levels of 858 genes in response to androgen and 303 genes in response to activation of the PKA pathway were determined using GeneSpring software. Expression of a subset of these genes (22) that were transcriptional targets for the androgen and/or PKA pathways were validated by reverse transcriptase-polymerase chain reaction and Western blot analyses. Application of small interfering RNAs to the androgen receptor (AR) revealed that in addition to KLK3, levels of expression of KLK2 and SESN1 were regulated by AR activated by both the androgen and PKA signaling pathways. SESN1 was identified as a gene repressed by activated AR. These results provide a broad view of the effects of the androgen and PKA signaling pathways on the transcriptional program of prostate cancer cells and indicate that only a limited number of genes are targeted by cross-talk between AR and PKA pathways.	British Columbia Canc Agcy, Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency	Sadar, MD (corresponding author), British Columbia Canc Agcy, Genome Sci Ctr, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	msadar@bcgsc.ca	Marra, Marco A/B-5987-2008; Sadar, Marianne/E-9136-2012; Jones, Steven J/C-3621-2009	Marra, Marco A/0000-0001-7146-7175; Sadar, Marianne/0000-0003-0599-9215; Jones, Steven J/0000-0003-3394-2208	NCI NIH HHS [CA105403] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; Amler LC, 2000, CANCER RES, V60, P6134; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Bouchal J, 2005, J PHARM PHARMACOL, V57, P83, DOI 10.1211/0022357055164; Chen TS, 1999, CANCER RES, V59, P213; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Culig Z, 1997, PROSTATE, V32, P106, DOI 10.1002/(SICI)1097-0045(19970701)32:2<106::AID-PROS5>3.0.CO;2-K; DAGA A, 1993, J BIOL CHEM, V268, P8123; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; Day CL, 2004, BIOCHEM J, V377, P597, DOI 10.1042/BJ20031251; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; DePrimo SE, 2002, GENOME BIOL, V3; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Farini D, 2003, ENDOCRINOLOGY, V144, P1631, DOI 10.1210/en.2002-221009; Gobert GN, 2001, HISTOCHEM CELL BIOL, V115, P381; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022-5347(05)64820-3; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jung M, 2003, PROSTATE, V55, P89, DOI 10.1002/pros.10194; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; MORRIS DI, 1991, J BIOL CHEM, V266, P13377; Nakhla AM, 1999, STEROIDS, V64, P213, DOI 10.1016/S0039-128X(98)00084-1; Nantermet PV, 2004, J BIOL CHEM, V279, P1310, DOI 10.1074/jbc.M310206200; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Prins G S, 2000, Mayo Clin Proc, V75 Suppl, pS32; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Robles LD, 2002, J BIOL CHEM, V277, P25431, DOI 10.1074/jbc.M201199200; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sadar MD, 2002, MOL CANCER THER, V1, P629; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Segawa T, 2002, ONCOGENE, V21, P8749, DOI 10.1038/sj.onc.1205992; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Stroud RM, 1999, CURR OPIN STRUC BIOL, V9, P754, DOI 10.1016/S0959-440X(99)00040-8; Tao WK, 2001, GENE DEV, V15, P1796, DOI 10.1101/gad.894301; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Tepper CG, 2002, CANCER RES, V62, P6606; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Vilaboa N, 2004, NUCLEIC ACIDS RES, V32, P6454, DOI 10.1093/nar/gkh981; Waghray A, 2001, PROTEOMICS, V1, P1327, DOI 10.1002/1615-9861(200110)1:10<1327::AID-PROT1327>3.3.CO;2-2; Wang G, 2006, J CELL BIOCHEM, V98, P36, DOI 10.1002/jcb.20802; Wright ME, 2003, MOL ENDOCRINOL, V17, P1726, DOI 10.1210/me.2003-0031; Xu LL, 2001, INT J CANCER, V92, P322, DOI 10.1002/ijc.1196; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026; YOUNG CYF, 1991, CANCER RES, V51, P3748; Zeng CQ, 2000, MICROSC RES TECHNIQ, V49, P467, DOI 10.1002/(SICI)1097-0029(20000601)49:5<467::AID-JEMT9>3.3.CO;2-M; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; Zou ZQ, 2002, CLIN CANCER RES, V8, P1172; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	63	54	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7311	7323		10.1038/sj.onc.1209715	http://dx.doi.org/10.1038/sj.onc.1209715			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16751804				2022-12-17	WOS:000242244700010
J	Werbowetski-Ogilvie, TE; Sadr, MS; Jabado, N; Angers-Loustau, A; Agar, NYR; Wu, J; Bjerkvig, R; Antel, JP; Faury, D; Rao, Y; Del Maestro, RF				Werbowetski-Ogilvie, T. E.; Sadr, M. Seyed; Jabado, N.; Angers-Loustau, A.; Agar, N. Y. R.; Wu, J.; Bjerkvig, R.; Antel, J. P.; Faury, D.; Rao, Y.; Del Maestro, R. F.			Inhibition of medulloblastoma cell invasion by Slit	ONCOGENE			English	Article						Slit; medulloblastoma; glioma; invasion; inhibitor	ROUNDABOUT RECEPTOR; AXON GUIDANCE; CANCER-CELLS; TUMOR; MIGRATION; CDC42; GENE; PROTEINS; GLIOMAS; GROWTH	Invasion of brain tumor cells has made primary malignant brain neoplasms among the most recalcitrant to therapeutic strategies. We tested whether the secreted protein Slit2, which guides the projection of axons and developing neurons, could modulate brain tumor cell invasion. Slit2 inhibited the invasion of medulloblastoma cells in a variety of in vitro models. The effect of Slit2 was inhibited by the Robo ectodomain. Time-lapse videomicroscopy indicated that Slit2 reduced medulloblastoma invasion rate without affecting cell direction or proliferation. Both medulloblastoma and glioma tumors express Robo1 and Slit2, but only medulloblastoma invasion is inhibited by recombinant Slit2 protein. Downregulation of activated Cdc42 may contribute to this differential response. Our findings reinforce the concept that neurodevelopmental cues such as Slit2 may provide insights into brain tumor invasion.	Montreal Neurol Hosp & Inst, Brain Tumor Res Ctr, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Neurol Inst, Brain Tumor Res Ctr, Montreal, PQ, Canada; Montreal Childrens Hosp, Inst Res, Dept Pediat, Montreal, PQ H3H 1P3, Canada; Northwestern Univ, Feinberg Med Sch, Robert H Lurie Comprehens Canc Ctr, Ctr Genet Med, Chicago, IL 60611 USA; Univ Bergen, Dept Anat & Cell Biol, Bergen, Norway; McGill Univ, Montreal Neurol Inst, Neuroimmunol Unit, Montreal, PQ, Canada; Northwestern Univ, Feinberg Med Sch, Dept Neurol, Chicago, IL 60611 USA	McGill University; McGill University; McGill University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; University of Bergen; McGill University; Northwestern University; Feinberg School of Medicine	Del Maestro, RF (corresponding author), Montreal Neurol Hosp & Inst, Brain Tumor Res Ctr, 3801 Rue Univ St,BT 210, Montreal, PQ H3A 2B4, Canada.	y-rao@northwestern.edu; rolando.delmaestro@mcgill.ca	Xiao, Yang/B-5668-2012; Jabado, Nada/AAN-4026-2020	Angers-Loustau, Alexandre/0000-0003-1425-4143; antel, jack/0000-0002-5148-0636; Werbowetski-Ogilvie, Tamra/0000-0002-5469-0559	NCI NIH HHS [R01 CA114197-01A2, R01 CA114197] Funding Source: Medline; NEI NIH HHS [R01 EY014576, R01 EY014576-03] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967, R01 GM070967-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astuti D, 2004, BRIT J CANCER, V90, P515, DOI 10.1038/sj.bjc.6601447; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Corcoran A, 2003, NEUROSURGERY, V53, P174, DOI 10.1227/01.NEU.0000072442.26349.14; Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687; Dallol A, 2003, CANCER RES, V63, P1054; Dallol A, 2002, CANCER RES, V62, P5874; Del Duca D, 2004, J NEURO-ONCOL, V67, P295, DOI 10.1023/B:NEON.0000024220.07063.70; Del Maestro R, 2001, J NEURO-ONCOL, V53, P87, DOI 10.1023/A:1012236830230; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Fan XP, 2003, NEURON, V40, P113, DOI 10.1016/S0896-6273(03)00591-9; Gilthorpe JD, 2002, DEVELOPMENT, V129, P4719; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; JACOBSEN PF, 1985, J NEUROPATH EXP NEUR, V44, P472, DOI 10.1097/00005072-198509000-00003; Jen JC, 2004, SCIENCE, V304, P1509, DOI 10.1126/science.1096437; Joki T, 2001, NAT BIOTECHNOL, V19, P35, DOI 10.1038/83481; Keles GE, 1995, ONCOL RES, V7, P493; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Lundstrom A, 2004, GENE DEV, V18, P2161, DOI 10.1101/gad.310204; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Marillat V, 2004, NEURON, V43, P69, DOI 10.1016/j.neuron.2004.06.018; Marillat V, 2002, J COMP NEUROL, V442, P130, DOI 10.1002/cne.10068; Mason HA, 2001, J NEUROSCI, V21, P7654, DOI 10.1523/JNEUROSCI.21-19-07654.2001; Nguyen-Ba-Charvet KT, 2004, J NEUROSCI, V24, P1497, DOI 10.1523/JNEUROSCI.4729-03.2004; Palazzo AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4; Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6; Prasad A, 2004, J BIOL CHEM, V279, P9115, DOI 10.1074/jbc.M308083200; RAFFEL C, 1993, NEUROSURGERY, V33, P301, DOI 10.1227/00006123-199308000-00018; Raffel C, 2004, NEOPLASIA, V6, P310, DOI 10.1593/neo.03454; RAFFEL C, 1995, NEUROSURGERY, V36, P971, DOI 10.1227/00006123-199505000-00013; Read TA, 2001, NAT BIOTECHNOL, V19, P29, DOI 10.1038/83471; Rossi MR, 2005, GENE, V356, P85, DOI 10.1016/j.gene.2005.04.018; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Ruffini F, 2004, AM J PATHOL, V165, P2167, DOI 10.1016/S0002-9440(10)63266-X; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Werbowetski T, 2004, J NEUROBIOL, V60, P71, DOI 10.1002/neu.10335; Werbowetski-Ogilvie TE, 2006, CANCER RES, V66, P1464, DOI 10.1158/0008-5472.CAN-05-1913; Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616; Zhao YX, 2004, ANAL CHEM, V76, P1817, DOI 10.1021/ac0354037	43	54	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5103	5112		10.1038/sj.onc.1209524	http://dx.doi.org/10.1038/sj.onc.1209524			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16636676	Green Accepted			2022-12-17	WOS:000240063700003
J	McCabe, M; Low, JA; Imperiale, MJ; Day, ML				McCabe, M; Low, JA; Imperiale, MJ; Day, ML			Human polyomavirus BKV transcriptionally activates DNA methyltransferase 1 through the pRb/E2F pathway	ONCOGENE			English	Article						virus; DNA methylation; DNMT1; E2F; kidney	LARGE-T-ANTIGEN; DE-NOVO METHYLATION; ABERRANT METHYLATION; GENE-EXPRESSION; HUMAN-PAPILLOMAVIRUS; TRANSFORMED-CELLS; SIMIAN VIRUS-40; DOWN-REGULATION; TUMOR-ANTIGEN; CADHERIN GENE	Many DNA tumor virus oncogenes are capable of activating and highjacking the host cell's DNA replication machinery for its own reproduction purposes through targeting and inactivation of the retinoblastoma pocket protein family. Pocket proteins function to regulate cell cycle progression and DNA synthesis through inhibitory interactions with the E2F transcription factors. The interaction of viral oncogenes with the pocket proteins is crucial for their transforming activity. We recently demonstrated that the DNA methyltransferase 1 (DNMT1) gene is an E2F target gene that is transcriptionally activated in cells lacking the retinoblastoma gene (Rb-/-). Overexpression of DNMT1 is implicated in tumor suppressor gene hypermethylation which is associated with tumorigenesis. Given that viral oncogenes potently stimulate E2F activity, we hypothesized that viral infection might activate DNMT1 and thereby promote transformation. Herein, we demonstrate that DNMT1 is strongly activated by the human polyomavirus BKV large T antigen (TAg) and adenovirus E1a. Viral oncogene mutants incapable of binding the pocket proteins are ineffective at activating DNMT1 compared to their wildtype counterparts. Additionally, mutation of the E2F sites within the DNMT1 promoters dramatically abrogates transcriptional activation. These data suggest that viral induction of DNMT1 through modulation of the pRB/E2F pathway may be involved in viral transformation.	Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; Univ Michigan, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Day, ML (corresponding author), Univ Michigan, Dept Urol, 6219 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mday@umich.edu			NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061488] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09676] Funding Source: Medline; NIAID NIH HHS [AI060584] Funding Source: Medline; NIDDK NIH HHS [DK61488] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200; AZZI A, 1994, BONE MARROW TRANSPL, V14, P235; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; Biniszkiewicz D, 2002, MOL CELL BIOL, V22, P2124, DOI 10.1128/MCB.22.7.2124-2135.2002; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; BOUCHARD J, 1990, ANTIMICROB AGENTS CH, V34, P206, DOI 10.1128/AAC.34.2.206; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CRAWFORD L, 1982, J VIROL, V41, P709, DOI 10.1128/JVI.41.2.709-709.1982; Das D, 2004, ONCOGENE, V23, P7031, DOI 10.1038/sj.onc.1207920; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; El-Osta A, 2000, GENE EXPRESSION, V9, P63; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOORHA R, 1984, VIROLOGY, V138, P94, DOI 10.1016/0042-6822(84)90150-8; GUNTHERT U, 1976, P NATL ACAD SCI USA, V73, P3923, DOI 10.1073/pnas.73.11.3923; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; HELLER H, 1995, P NATL ACAD SCI USA, V92, P5515, DOI 10.1073/pnas.92.12.5515; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Hohlweg U, 2003, VIRUS RES, V98, P45, DOI 10.1016/j.virusres.2003.08.012; Humes HD, 2002, AM J KIDNEY DIS, V39, P1078, DOI 10.1053/ajkd.2002.32792; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jarrard DF, 1997, CLIN CANCER RES, V3, P2121; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSONTHOMPSON M, 1988, IN VITRO CELL DEV B, V24, P1114; KAYE AM, 1967, J MOL BIOL, V24, P475, DOI 10.1016/0022-2836(67)90233-1; Khalili K, 2003, ONCOGENE, V22, P5181, DOI 10.1038/sj.onc.1206559; KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x; Low J, 2004, VIROLOGY, V323, P182, DOI 10.1016/j.virol.2004.03.027; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; Mikovits JA, 1998, MOL CELL BIOL, V18, P5166, DOI 10.1128/MCB.18.9.5166; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; Munger K, 2002, FRONT BIOSCI-LANDMRK, V7, pD641, DOI 10.2741/munger; NAKSHATRI H, 1988, J VIROL, V62, P4613, DOI 10.1128/JVI.62.12.4613-4621.1988; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; Peterson EJ, 2003, CANCER RES, V63, P6579; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; Remus R, 1999, J VIROL, V73, P1010, DOI 10.1128/JVI.73.2.1010-1022.1999; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Santin AD, 2005, VIROLOGY, V331, P269, DOI 10.1016/j.virol.2004.09.045; Shivapurkar N, 2004, CANCER RES, V64, P3757, DOI 10.1158/0008-5472.CAN-03-3307; SINCLAIR AJ, 1995, J VIROL, V69, P1292, DOI 10.1128/JVI.69.2.1292-1295.1995; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; SUTTER D, 1980, P NATL ACAD SCI-BIOL, V77, P253, DOI 10.1073/pnas.77.1.253; Suzuki M, 2005, ONCOGENE, V24, P1302, DOI 10.1038/sj.onc.1208263; Syrjanen SM, 1999, ANN MED, V31, P175, DOI 10.3109/07853899909115976; Tognon M, 2003, ONCOGENE, V22, P5192, DOI 10.1038/sj.onc.1206550; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyooka S, 2001, CANCER RES, V61, P5727; Trabanelli C, 1998, VIROLOGY, V243, P492, DOI 10.1006/viro.1998.9080; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Vilchez RA, 2004, CLIN MICROBIOL REV, V17, P495, DOI [10.1128/CMR.17.3.495-508.2004, 10.1128/cmr.17.3.495-508.2004]; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	71	54	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2727	2735		10.1038/sj.onc.1209266	http://dx.doi.org/10.1038/sj.onc.1209266			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16547506				2022-12-17	WOS:000237272900004
J	Semba, S; Trapasso, F; Fabbri, M; McCorkell, KA; Volinia, S; Druck, T; Iliopoulos, D; Pekarsky, Y; Ishii, H; Garrison, PN; Barnes, LD; Croce, CM; Huebner, K				Semba, S.; Trapasso, F.; Fabbri, M.; McCorkell, K. A.; Volinia, S.; Druck, T.; Iliopoulos, D.; Pekarsky, Y.; Ishii, H.; Garrison, P. N.; Barnes, L. D.; Croce, C. M.; Huebner, K.			Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential	ONCOGENE			English	Article						Fhit; tyrosine 114 (Y114); Akt; survivin; lung cancer; apoptosis	FRAGILE HISTIDINE-TRIAD; EXPRESSION INDUCES APOPTOSIS; TUMOR-SUPPRESSOR; GENE; TUMORIGENICITY; CARCINOMA; KINASE; HYPERMETHYLATION; RESTORATION; COMPLEXES	The Fhit tumor suppressor binds and hydrolyses diadenosine polyphosphates and the Fhit - substrate complex has been proposed as a proapoptotic effector, as determined by infection of susceptible cancer cells with adenoviruses carrying wild- type fragile histidine triad ( FHIT) or catalytic site mutants. The highly conserved Fhit tyrosine 114 ( Y114), within the unstructured loop C- terminal of the catalytic site, can be phosphorylated by Src family tyrosine kinases, although endogenous phospho- Fhit is rarely detected. To explore the importance of Y114 and identify Fhit- mediated signaling events, wild- type and Y114 mutant FHIT- expressing adenoviruses were introduced into two human lung cancer cell lines. Caspase-dependent apoptosis was effectively induced only by wildtype but not Y114 mutant Fhit proteins. By expression proling of FHIT versus mutant FHIT- infected cells, we found that survivin, an Inhibitor of Apoptosis Protein ( IAP) family member, was significantly decreased by wildtype Fhit. In addition, Fhit inhibited activity of Akt, a key effector in the phosphatidylinositol 3- OH kinase ( PI3K) pathway; loss of endogenous Fhit expression caused increased Akt activity in vitro and in vivo, and overexpression of constitutively active Akt inhibited Fhit-induced apoptosis. The results indicate that the Fhit Y114 residue plays a critical role in Fhit- induced apoptosis, occurring through inactivation of the PI3K- Akt- survivin signal pathway.	Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Magna Graecia Univ Catanzaro, Med Sch Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy; Univ Ferrara, Telethon Facil, Data Min Anal DNA Microarrays, I-44100 Ferrara, Italy; Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat Mol Hematopoiesis, Minami Kawachi, Tochigi 32904, Japan; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78285 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Magna Graecia University of Catanzaro; University of Ferrara; Jichi Medical University; University of Texas System; University of Texas Health San Antonio	Huebner, K (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Room 455C Wiseman Hall,410 W 12th Ave, Columbus, OH 43210 USA.	kay.huebner@osumc.edu	Young, Richard A/F-6495-2012; Volinia, Stefano/A-3029-2010; Iliopoulos, Dimitrios/AAE-9106-2019; Volinia, Stefano/AAA-9264-2019	Young, Richard A/0000-0001-8855-8647; Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007780] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07780] Funding Source: Medline; Telethon [GTF03012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon)		Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Brenner C, 1997, PROTEIN ENG, V10, P1461, DOI 10.1093/protein/10.12.1461; Croce CM, 1999, J CLIN ONCOL, V17, P1618, DOI 10.1200/JCO.1999.17.5.1618; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dumon KR, 2001, CANCER RES, V61, P4827; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Fujishita T, 2004, BRIT J CANCER, V91, P1571, DOI 10.1038/sj.bjc.6602182; Garrison PN, 2005, BIOCHEMISTRY-US, V44, P6286, DOI 10.1021/bi047670s; Hao XP, 2000, CANCER RES, V60, P18; Hu BC, 2005, J CELL PHYSIOL, V202, P518, DOI 10.1002/jcp.20139; Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Iliopoulos D, 2005, ONCOGENE, V24, P1625, DOI 10.1038/sj.onc.1208398; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, CANCER RES, V59, P3333; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kato H, 2004, CLIN CANCER RES, V10, P7318, DOI 10.1158/1078-0432.CCR-04-0485; Kuroki T, 2003, CANCER RES, V63, P3724; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mori M, 2000, CANCER RES, V60, P1177; Nishizaki M, 2004, CANCER RES, V64, P5745, DOI 10.1158/0008-5472.CAN-04-0195; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Ottey M, 2004, BRIT J CANCER, V91, P1669, DOI 10.1038/sj.bjc.6602058; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 2004, P NATL ACAD SCI USA, V101, P3775, DOI 10.1073/pnas.0400481101; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Semba S, 2002, CLIN CANCER RES, V8, P3824; Sevignani C, 2003, CANCER RES, V63, P1183; Shi YF, 2000, BIOCHEM J, V352, P443, DOI 10.1042/0264-6021:3520443; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	44	54	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2860	2872		10.1038/sj.onc.1209323	http://dx.doi.org/10.1038/sj.onc.1209323			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407838				2022-12-17	WOS:000237448200004
J	Hara, T; Abe, M; Inoue, H; Yu, LR; Veenstra, TD; Kang, YH; Lee, KS; Miki, T				Hara, T; Abe, M; Inoue, H; Yu, LR; Veenstra, TD; Kang, YH; Lee, KS; Miki, T			Cytokinesis regulator ECT2 changes its conformation through phosphorylation at Thr-341 in G2/M phase	ONCOGENE			English	Article						exchange factor; Rho GTPases; Cdk1; interacting proteins; cell division	EXCHANGE FACTOR ECT2; RHOA; SPINDLE; MIDBODY; DOMAINS; GTPASES; CDK1; CDC2	The Rho activator ECT2 functions as a key regulator in cytokinesis. ECT2 is phosphorylated during G2/M phase, but the physiological significance of this event is not well known. In this study, we show that phosphorylation of ECT2 at threonine-341 (T341) affects the autoregulatory mechanism of ECT2. In G2/M phase, ECT2 was phosphorylated at T341 most likely by Cyclin B/Cyclindependent kinase 1 (Cdk1), and then dephosphorylated before cytokinesis. Depletion of ECT2 by RNA interference (RNAi) efficiently induced multinucleate cells. Expression of the phospho-deficient mutant of ECT2 at T341 suppressed the multinucleation induced by RNAi to ECT2, indicating that ECT2 is biologically active even when it is not phosphorylated at T341. However, the phospho-mimic mutation at T341 weakly stimulates the catalytic activity of ECT2 as detected by serum response element reporter gene assays. As T341 is located at the hinge region of the N-terminal regulatory domain and C-terminal catalytic domain, phosphorylation of T341 may help accessing downstream signaling molecules to further activate ECT2. We found that the phospho-mimic mutation T341D increases binding with itself or the N-terminal half of ECT2. These results suggest a conformational change of ECT2 upon phosphorylation at T341. Therefore, ECT2 activity might be regulated by the phosphorylation status of T341. We propose that T341 phosphorylation by Cyclin B/Cdk1 could be a trigger for further activation of ECT2.	NCI, Mol Tumor Biol Sect, Cell Biol Lab, Bethesda, MD 20892 USA; NCI, Lab Prote & Analyt Technol, SAIC Frederick Inc, Frederick, MD 21701 USA; NCI, Lab Metab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miki, T (corresponding author), NCI, Mol Tumor Biol Sect, Cell Biol Lab, Bldg 37,Room 2144,37 Convent Dr MSC 4256, Bethesda, MD 20892 USA.	toru@helix.nih.gov	Abe, Mitsuhiro/C-3602-2017	Yu, Li-Rong/0000-0001-6084-991X	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005548] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Echard A, 2003, CURR BIOL, V13, P373, DOI 10.1016/S0960-9822(03)00127-1; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirose K, 2001, J BIOL CHEM, V276, P5821, DOI 10.1074/jbc.M007252200; James P, 1996, GENETICS, V144, P1425; Kim JE, 2005, J BIOL CHEM, V280, P5733, DOI 10.1074/jbc.M409298200; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Liu XF, 2004, MOL CELL BIOL, V24, P6665, DOI 10.1128/mcb.24.15.6665-6675.2004; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; Lowery DM, 2004, CELL CYCLE, V3, P128; Matuliene J, 2004, MOL BIOL CELL, V15, P3083, DOI 10.1091/mbc.E03-12-0888; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; O'Keefe L, 2001, CELL STRUCT FUNCT, V26, P619, DOI 10.1247/csf.26.619; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Sakata H, 2000, HEPATOLOGY, V32, P193, DOI 10.1053/jhep.2000.8271; Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Wheatley SP, 1997, J CELL BIOL, V138, P385, DOI 10.1083/jcb.138.2.385; Yoshizaki H, 2004, J BIOL CHEM, V279, P44756, DOI 10.1074/jbc.M402292200	26	54	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					566	578		10.1038/sj.onc.1209078	http://dx.doi.org/10.1038/sj.onc.1209078			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16170345				2022-12-17	WOS:000234897400008
J	Mei, YD; Du, WJ; Yang, YH; Wu, MA				Mei, YD; Du, WJ; Yang, YH; Wu, MA			Puma* Mcl-1 interaction is not sufficient to prevent rapid degradation of Mcl-1	ONCOGENE			English	Article						apoptosis; colocalization; protein stabilization; Puma; Mcl-1	COLORECTAL-CANCER CELLS; HAMSTER OVARY CELLS; BCL-2 FAMILY; CYTOCHROME-C; DNA-DAMAGE; IN-VIVO; APOPTOSIS; P53; PROTEIN; DEATH	Although Puma (p53 upregulated modulator of apoptosis) was known as a principal mediator of cell death in response to diverse apoptotic signals, the molecular mechanism underlying its proapoptotic regulation remains largely uncharacterized. Here we reported that myeloid cell leukemia-1 (Mcl-1), an antiapoptotic member of the Bcl-2 family with a rapid turnover rate, interacts with Puma. The Puma/Mcl-1 interaction was verified by both yeast two-hybrid assay and co-immunoprecipation studies. Their binding sites were mapped to BH3 (Bcl-2 homology) domain of Puma and BH1 domain of Mcl-1, respectively. Mcl-1 and Puma was shown to colocalize at the mitochondria by immunostaining. The level of Mcl-1 was increased when coexpressed with Puma, indicating Puma is able to stabilize Mcl-1. Puma binding to Mcl-1 via its BH3 domain is the prerequisite for this effect, which is further supported by the finding that Puma mutant lacking BH3 domain no longer promotes Mcl-1 protein stability. This Puma-enhanced Mcl-1 stabilization was validated in vivo under nonoverexpression conditions. We also showed that BH1 domain is essential for Mcl-1 to inhibit Puma-induced apoptosis, since Mcl-1 mutant lacking BH1 domain completely abrogates its protective function. In addition, we concluded that binding of Puma to BH1 domain of Mcl-1 is necessary, but not sufficient to prevent rapid degradation of Mcl-1. In addition to PEST (proline, glutamic acid, serine, and threonine) and BH1 domain, some additional degradation signal is expected to reside in the C-terminal region of Mcl-1. In conclusion, our results provide the first evidence that the interaction between Mcl-1 and Puma may represent a novel mechanism by which Mcl-1 prevents apoptosis by increasing its stability through binding to Puma.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Wu, MA (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.	wumian88@yahoo.com	Wu, Mian/H-2494-2018; du, wenjing/A-2530-2013; Mei, Yide/M-4468-2013	du, wenjing/0000-0002-3967-9984; Wu, Mian/0000-0002-2714-0500				Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Prives C, 1999, J PATHOL, V187, P112; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J.F., 2000, MOL CLONING LAB MANU; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Unkila M, 2001, J BIOL CHEM, V276, P39132, DOI 10.1074/jbc.M104986200; VILLUNGER A, 2003, SCIENCE         0918; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yoon JH, 2002, CANCER RES, V62, P6500; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	37	54	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7224	7237		10.1038/sj.onc.1208873	http://dx.doi.org/10.1038/sj.onc.1208873			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16007132				2022-12-17	WOS:000232990100011
J	Di Stefano, V; Soddu, S; Sacchi, A; D'Orazi, G				Di Stefano, V; Soddu, S; Sacchi, A; D'Orazi, G			HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21(Waf1) after nonapoptotic DNA damage	ONCOGENE			English	Article						HIPK2; p53; acetylation; chromatin immunoprecipitation; DNA damage; PCAF	INTERACTING PROTEIN KINASE-2; APOPTOTIC TARGET GENES; CELL-CYCLE ARREST; INDUCED PHOSPHORYLATION; MUTANT P53; ACTIVATION; INHIBITION; RECRUITMENT; CHECKPOINT; RADIATION	The p53 tumor suppressor gene is activated in response to DNA damage resulting in either growth arrest or apoptosis. We previously demonstrated the specific involvement of homeodomain interacting protein-kinase 2 (HIPK2), a nuclear serine/threonine kinase, in inducing p53-dependent apoptosis through selective p53 phosphorylation at serine 46 after severe genotoxic damage. Here we show that HIPK2 contributes to p53 regulation, independently from serine 46 phosphorylation upon nonapoptotic DNA damage such as that induced by cytostatic doses of cisplatin. We show that HIPK2 depletion by RNA interference inhibits p53 binding to the p21(Waf1) promoter affecting its p53-induced transactivation thereby allowing cell proliferation. We found that nonapoptotic DNA damage induces p53 acetylation mediated by the HAT protein PCAF and this p53 post-translational modification is abolished by HIPK2 depletion. In this regard, we found that HIPK2 cooperates with PCAF to induce selectively p53 transcriptional activity toward the p21(Waf1) promoter while depletion of either HIPK2 or PCAF abolished this function. These data show that HIPK2 regulates the p53 growth arrest function through its PCAF-mediated acetylation.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, I-00185 Rome, Italy; Univ G DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; G d'Annunzio University of Chieti-Pescara	D'Orazi, G (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, Via Messi Doro 156, I-00185 Rome, Italy.	dorazi@ifo.it	Soddu, Silvia/ABH-6774-2020; Soddu, Silvia/K-2467-2018; D'Orazi, Gabriella/T-2792-2019	Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; D'Orazi, Gabriella/0000-0001-6876-9105				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Appella E, 2000, PATHOL BIOL, V48, P227; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; EL DW, 1993, CELL, V75, P817; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MIYASHITA T, 1995, CELL, V80, P293; Moller A, 2003, CANCER RES, V63, P4310; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Prives C, 1999, J PATHOL, V187, P112; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; VOGTSIONOV R, 1999, ONCOGENE, V18, P6145; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113	45	54	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5431	5442		10.1038/sj.onc.1208717	http://dx.doi.org/10.1038/sj.onc.1208717			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15897882				2022-12-17	WOS:000231222300004
J	Zhu, YL; Zhong, X; Zheng, S; Du, Q; Xu, WZ				Zhu, YL; Zhong, X; Zheng, S; Du, Q; Xu, WZ			Transformed immortalized gastric epithelial cells by virulence factor CagA of Helicobacter pylori through Erk mitogen-activated protein kinase pathway	ONCOGENE			English	Article						Helicobacter pylori; CagA protein; gastric epithelial cell; carcinogenesis; Erk pathway	SIGNAL-REGULATED KINASE; B-RAF; ONCOGENIC MUTATIONS; TUMOR-GROWTH; T-ANTIGEN; INFECTION; CANCER; DETERMINANT; DOWNSTREAM; TELOMERASE	CagA of Helicobacter pylori is a protein that has been closely associated with gastric cancer and that can intervene with signal pathways in cells. Its precise relationship with the occurrence of gastric cancer, however, remains unclear. The purpose of this study is to investigate whether CagA can promote transformation of normal gastric epithelial cells and to consider via what mechanisms CagA may exert its effects. Transformed colonies were merged in soft-agarose medium after immortalized gastric epithelial cells were transfected with recombinant pLHCX retrovirus with cagA and/or dimethylhydrazine. The number of transformed colonies in the group containing cagA/pLHCX retrovirus, combined with a subthreshold dose of dimethylhydrazine, was more than that for cagA/pLHCX retrovirus or dimethylhydrazine at a subthreshold dose alone. For cagA-transfected cells, only IQGAP-2, R-Ras and B-Raf of the Ras/mitogen-activated protein kinase signal pathway were markedly increased, and the activity of extracellular signal-regulated kinase 1/2 (Erk1/2) kinase was significantly higher than that in dimethylhydrazine-transformed cells or control cells. However, no evidence of alteration of any other molecules of the Ras superfamily was observed in cagA-transfected cells. These findings suggest that CagA can transform gastric epithelial cells through activation of the Erk1/2 pathway; this mechanism may, however, be independent of Ras activation.	Zhejiang Univ, Sch Med, Inst Canc, Hangzhou 310009, Zhejiang Prov, Peoples R China; Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Gastroenterol, Hangzhou 310027, Zhejiang Prov, Peoples R China	Zhejiang University; Zhejiang University	Zheng, S (corresponding author), Zhejiang Univ, Sch Med, Inst Canc, Jiefang Rd 88, Hangzhou 310009, Zhejiang Prov, Peoples R China.	zrxhsys@zju.edu.cn						Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brill S, 1996, MOL CELL BIOL, V16, P4869; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; COX AD, 1994, ONCOGENE, V9, P3281; Enroth H, 2000, CANCER EPIDEM BIOMAR, V9, P981; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; He YY, 2004, J BIOL CHEM, V279, P53867, DOI 10.1074/jbc.M405781200; Held M, 2004, HELICOBACTER, V9, P271, DOI 10.1111/j.1083-4389.2004.00222.x; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hindley A, 2002, J CELL SCI, V115, P1575; Huang RP, 1999, CARCINOGENESIS, V20, P485, DOI 10.1093/carcin/20.3.485; Hubbard SR, 2004, CELL, V116, P764, DOI 10.1016/S0092-8674(04)00256-9; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ikenoue T, 2003, CANCER RES, V63, P8132; Keates S, 1999, J IMMUNOL, V163, P5552; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kolb TM, 2004, TOXICOL SCI, V81, P233, DOI 10.1093/toxsci/kfh183; Kwong L, 2003, MOL CELL BIOL, V23, P933, DOI 10.1128/MCB.23.3.933-949.2003; MALE R, 1987, CARCINOGENESIS, V8, P1375, DOI 10.1093/carcin/8.10.1375; Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0; Narayan S, 2004, ONCOGENE, V23, P5880, DOI 10.1038/sj.onc.1207792; Nobuta A, 2004, ALIMENT PHARM THER, V20, P1, DOI 10.1111/j.1365-2036.2004.01976.x; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Okada T, 1999, MOL CELL BIOL, V19, P6057; Ostrowski J, 2000, BRIT J CANCER, V82, P1041; Panja A, 2000, LAB INVEST, V80, P1473, DOI 10.1038/labinvest.3780154; Quaroni A, 1997, GASTROENTEROLOGY, V113, P1198, DOI 10.1053/gast.1997.v113.pm9322515; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; Rieder G, 2003, INT J MED MICROBIOL, V293, P403, DOI 10.1078/1438-4221-00280; Rutten Michael J., 1996, Methods in Cell Science, V18, P269, DOI 10.1007/BF00127904; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Selbach M, 2003, EMBO J, V22, P515, DOI 10.1093/emboj/cdg050; Shin VY, 2004, CARCINOGENESIS, V25, P2487, DOI 10.1093/carcin/bgh266; Smoot Duane T., 2000, Methods in Cell Science, V22, P133, DOI 10.1023/A:1009846624044; Sugiyama K, 1998, JPN J CANCER RES, V89, P615, DOI 10.1111/j.1349-7006.1998.tb03263.x; TERANO A, 1983, DIGEST DIS SCI, V28, P595, DOI 10.1007/BF01299919; Tokieda M, 1999, CARCINOGENESIS, V20, P1261, DOI 10.1093/carcin/20.7.1261; Toouli CD, 2002, ONCOGENE, V21, P128, DOI 10.1038/sj.onc.1205014; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Whitehead RH, 1999, GASTROENTEROLOGY, V117, P858, DOI 10.1016/S0016-5085(99)70344-6; Zhang Lian, 1998, Zhonghua Yufang Yixue Zazhi, V32, P67; Zhu YL, 2004, CHINESE MED J-PEKING, V117, P1330; Zhu Yong-liang, 2004, Zhejiang Da Xue Xue Bao Yi Xue Ban, V33, P379; Zhu YL, 2005, WORLD J GASTROENTERO, V11, P880, DOI 10.3748/wjg.v11.i6.880	55	54	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3886	3895		10.1038/sj.onc.1208551	http://dx.doi.org/10.1038/sj.onc.1208551			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15856031				2022-12-17	WOS:000229435300004
J	Suraweera, N; Meijne, E; Moody, J; Carvajal-Carmona, LG; Yoshida, K; Pollard, P; Fitzgibbon, J; Riches, A; van Laar, T; Huiskamp, R; Rowan, A; Tomlinson, IPM; Silver, A				Suraweera, N; Meijne, E; Moody, J; Carvajal-Carmona, LG; Yoshida, K; Pollard, P; Fitzgibbon, J; Riches, A; van Laar, T; Huiskamp, R; Rowan, A; Tomlinson, IPM; Silver, A			Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia	ONCOGENE			English	Article						AML; PU.1; radiation induced; therapy related; Ets domain; mutation	TRANSCRIPTION FACTOR PU.1; EXPRESSION; MACROPHAGE; SPI-1; GENE; PROTOONCOGENE; RECOGNITION; DISRUPTION; INSIGHTS; BETA	Murine radiation-induced acute myeloid leukaemia (AML) is characterized by loss of one copy of chromosome 2. Previously, we positioned the critical haematopoietic specific transcription factor PU.1 within a minimally deleted region. We now report a high frequency (>65%) of missense mutation at codon 235 in the DNA-binding Ets domain of PU.1 in murine AML. Earlier studies, outside the context of malignancy, determined that conversion of arginine 235 (R235) to any other amino-acid residue leads to ablation of DNA-binding function and loss of expression of downstream targets. We show that mutation of R235 does not lead to protein loss, and occurs specifically in those AMLs showing loss of one copy of PU.1 (P=0.001, Fisher's exact test). PU.1 mutations were not found in the coding region, UTRs or promoter of human therapy-related AMLs. Potentially regulatory elements upstream of PU.1 were located but no mutations found. In conclusion, we have identified the cause of murine radiation-induced AML and have shown that loss of one copy of PU.1, as a consequence of flanking radiation-sensitive fragile domains on chromosome 2, and subsequent R235 conversion are highly specific to this mouse model. Such a mechanism does not operate, or is extremely rare, in human AML.	St Marks Hosp, Canc Res UK Labs, Harrow HA1 3UJ, Middx, England; Nucl Res & Consultancy Grp, Petten, Netherlands; Natl Radiol Protect Board, Didcot OX11 0RQ, Oxon, England; Canc Res UK, London Res Inst, Mol & Populat Genet Lab, London, England; Natl Inst Radiol Sci, Radiat Safety Res Ctr, Radiat Hazard Res Grp, Chiba 260, Japan; St Bartholomews Hosp, Canc Res UK, Med Oncol Unit, London, England; Univ St Andrews, Bute Med Sch, St Andrews, Fife, Scotland; Leiden Univ, Med Ctr, Dept Toxicogenet, NL-2300 RA Leiden, Netherlands	Cancer Research UK; Imperial College London; Nuclear Research & Consultancy Group; Cancer Research UK; National Institutes for Quantum Science & Technology; Cancer Research UK; University of London; Queen Mary University London; University of St Andrews; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Silver, A (corresponding author), St Marks Hosp, Canc Res UK Labs, Harrow HA1 3UJ, Middx, England.	andrew.silver@cancer.org.uk	Carvajal-Carmona, Luis G/B-3882-2010; Suraweera, Nirosha/E-5912-2012; Pollard, Patrick/F-7516-2012	Carvajal-Carmona, Luis G/0000-0001-7129-2918; Pollard, Patrick/0000-0002-4459-4993; van Laar, Theo/0000-0002-0990-6234; Fitzgibbon, Jude/0000-0002-9069-1866				Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; Bouffler SD, 1997, INT J RADIAT BIOL, V72, P181, DOI 10.1080/095530097143400; BRECKON G, 1991, GENE CHROMOSOME CANC, V3, P367, DOI 10.1002/gcc.2870030507; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; Clark DJ, 1996, GENE CHROMOSOME CANC, V16, P238, DOI 10.1002/(SICI)1098-2264(199608)16:4<238::AID-GCC3>3.3.CO;2-L; Dohner K, 2003, BLOOD, V102, P3850, DOI 10.1182/blood-2003-08-2654; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Finnon R, 2002, MOL CARCINOGEN, V34, P64, DOI 10.1002/mc.10054; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; HROMAS R, 1993, BLOOD, V82, P2998; Jia X, 1999, J MOL BIOL, V292, P1083, DOI 10.1006/jmbi.1999.3123; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; Lamandin C, 2002, BLOOD, V100, P4680, DOI 10.1182/blood-2002-08-2563; Leone G, 1999, HAEMATOLOGICA, V84, P937; Ley TJ, 2003, P NATL ACAD SCI USA, V100, P14275, DOI 10.1073/pnas.2335924100; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; McKercher SR, 2003, P NATL ACAD SCI USA, V100, P511, DOI 10.1073/pnas.0136910100; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; Mueller BU, 2003, BLOOD, V102, P3850; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SEKI M, 1991, RADIAT RES, V127, P146, DOI 10.2307/3577958; Silver A, 1999, GENE CHROMOSOME CANC, V24, P95, DOI 10.1002/(SICI)1098-2264(199902)24:2<95::AID-GCC1>3.3.CO;2-3; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Smith Roy E, 2003, Clin Breast Cancer, V4, P273, DOI 10.3816/CBC.2003.n.032; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Vegesna VA, 2002, LEUKEMIA RES, V26, P451, DOI 10.1016/S0145-2126(01)00150-3; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	40	54	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3678	3683		10.1038/sj.onc.1208422	http://dx.doi.org/10.1038/sj.onc.1208422			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15750630				2022-12-17	WOS:000229221800015
J	Jiang, F; Caraway, NP; Li, RY; Katz, RL				Jiang, F; Caraway, NP; Li, RY; Katz, RL			RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells	ONCOGENE			English	Article						SKP2; small interfering RNAs; lung cancer; apoptosis; centrosome	F-BOX PROTEIN; CYCLIN-E; GENETIC INSTABILITY; SKP2 OVEREXPRESSION; REGULATE P27(KIP1); NUCLEAR EXPORT; EXPRESSION; P27; DEGRADATION; DUPLICATION	The S-phase kinase-associated protein-2 (SKP2) plays a keyrole in ubiquitin-mediated proteolysis, which results in the progression of cells from a quiescence to proliferative state. SKP2 is overexpressed in a variety of tumors. In this study, we used small interfering RNAs (siRNAs) to inhibit the SKP2 expression in lung cancer cells and thereby investigate the role of SKP2 in lung tumorigenesis. Three lung cancer cell lines were transfected with siRNAs targeted against SKP2. SKP2-siRNAs specifically and efficiently reduced the levels of the SKP2 protein by 90% 48 h after transfection in all cell lines. In the A549 and H1792 cells, p27 expression was increased and the increase was inversely proportional to the level of SKP2; cell proliferation was reduced to 12 and 28%, respectively; apoptosis was increased to 36 and 30%, respectively; 36 and 28% of cells accumulated in the sub-G1 phase, respectively; and the population of cells in the G1 phase was decreased to 37 and 41%, respectively. In addition, the SKP2-depleted A549 and H1792 cells showed decreased levels of cyclin E/CDK2. Correspondingly, only 4 and 6% of the treated A549 and H1792 cells had multiple centrosomes, respectively, compared with 43 and 46% of the control cells, respectively. These results imply that SKP2 plays an oncogenic role in lung cancer and that SKP2 silencing maybe useful in the treatment of lung cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 53, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Jiang, F (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 53, 1515 Holcombe Blvd, Houston, TX 77030 USA.	fjiang@mail.mdanderson.org						Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Brambilla E, 1999, J PATHOL, V188, P351, DOI 10.1002/(SICI)1096-9896(199908)188:4<351::AID-PATH385>3.0.CO;2-W; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Foster JS, 2003, J BIOL CHEM, V278, P41355, DOI 10.1074/jbc.M302830200; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Fukuse T, 2000, CANCER RES, V60, P242; Gstaiger M, 1999, EXP CELL RES, V247, P554, DOI 10.1006/excr.1999.4386; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Jiang F, 2003, INT J CANCER, V106, P661, DOI 10.1002/ijc.11251; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; Kaye FJ, 2002, ONCOGENE, V21, P6908, DOI 10.1038/sj.onc.1205834; Kudo Y, 2001, CANCER RES, V61, P7044; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Lim MS, 2002, BLOOD, V100, P2950, DOI 10.1182/blood.V100.8.2950; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Martinez LA, 2002, P NATL ACAD SCI USA, V99, P14849, DOI 10.1073/pnas.222406899; Masuda T, 2002, CANCER RES, V62, P3819; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Murphy TD, 2003, J CELL SCI, V116, P2321, DOI 10.1242/jcs.00463; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Oliveira AM, 2003, J CLIN ONCOL, V21, P722, DOI 10.1200/JCO.2003.05.112; Pagano M, 2004, MOL CELL, V14, P414, DOI 10.1016/S1097-2765(04)00268-0; Park KH, 2001, LUNG CANCER-J IASLC, V31, P149, DOI 10.1016/S0169-5002(00)00195-1; Pihan GA, 1998, CANCER RES, V58, P3974; Piva R, 2002, MOL CELL BIOL, V22, P8375, DOI 10.1128/MCB.22.23.8375-8387.2002; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Shigemasa K, 2003, CLIN CANCER RES, V9, P1756; Shim EH, 2003, CANCER RES, V63, P1583; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Thyrell L, 2002, ONCOGENE, V21, P1251, DOI 10.1038/sj.onc.1205179; Vidwans SJ, 1999, J CELL BIOL, V147, P1371, DOI 10.1083/jcb.147.7.1371; Volm M, 1998, INT J CANCER, V79, P294, DOI 10.1002/(SICI)1097-0215(19980619)79:3<294::AID-IJC15>3.3.CO;2-0; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yeh KH, 2001, BIOCHEM BIOPH RES CO, V281, P884, DOI 10.1006/bbrc.2001.4442; Yokoi S, 2003, CANCER SCI, V94, P344, DOI 10.1111/j.1349-7006.2003.tb01444.x; Yokoi S, 2002, AM J PATHOL, V161, P207, DOI 10.1016/S0002-9440(10)64172-7; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470	62	54	68	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3409	3418		10.1038/sj.onc.1208459	http://dx.doi.org/10.1038/sj.onc.1208459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735730				2022-12-17	WOS:000229038800003
J	Minard, ME; Herynk, MH; Collard, JG; Gallick, GE				Minard, ME; Herynk, MH; Collard, JG; Gallick, GE			The guanine nucleotide exchange factor Tiam1 increases colon carcinoma growth at metastatic sites in an orthotopic nude mouse model	ONCOGENE			English	Article						Tiam1; colon carcinoma; migration; metastasis	PLECKSTRIN HOMOLOGY DOMAIN; RENAL-CELL CARCINOMAS; TUMOR PROGRESSION; RAC; INVASION; ACTIVATION; SRC; EXPRESSION; MIGRATION; CANCER	Alterations in migration and adhesion are critical to invasion and metastasis. To examine signaling pathways important for colon tumor metastasis, cells of increased migratory potential from the low migratory SW480 human colorectal carcinoma parental cell line were biologically selected by serial migration through modified Boyden chambers. Several sublines were obtained with statistically significantly increased migration relative to the parental cell line. One highly migratory population was single-cell cloned and characterized. The migratory clones exhibit a four- to five-fold increase in protein and mRNA expression of T-lymphoma invasion and metastasis gene 1 (Tiam1), a guanine nucleotide exchange factor. To determine directly the role of Tiam1 in the migration of these migratory sublines, the parental SW480 cell line was transfected with a plasmid encoding the Tiam1 protein, and single cell clones were established. Ectopic expression of Tiam1 in these clones led to morphologic changes identical to biologically selected clones and increased migration. Finally, the implantation of clones that overexpress Tiam1 into the cecum of athymic mice resulted in tumor growth in the spleen, liver, and lung, whereas parental cells do not form tumors by this route of injection. These results demonstrate that overexpression of Tiam1 contributes to the metastatic phenotype of colon cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX 77030 USA; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Netherlands Cancer Institute	Gallick, GE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holocombe Blvd,Box 173, Houston, TX 77030 USA.	ggallick@mdanderson.org			NATIONAL CANCER INSTITUTE [U54CA090810] Funding Source: NIH RePORTER; NCI NIH HHS [U54 CA 090810, 2 R01 CA25567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2001, J BIOL CHEM, V276, P28443, DOI 10.1074/jbc.M009769200; ALBINI A, 1987, CANCER RES, V47, P3239; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; Ehler E, 1997, MOL CELL NEUROSCI, V9, P1, DOI 10.1006/mcne.1997.0602; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; Engers R, 2000, INT J CANCER, V88, P369, DOI 10.1002/1097-0215(20001101)88:3<369::AID-IJC8>3.0.CO;2-K; Engers R, 2001, J BIOL CHEM, V276, P41889, DOI 10.1074/jbc.M105049200; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HABETS GGM, 1995, ONCOGENE, V10, P1371; Hewitt RE, 2000, J PATHOL, V192, P446; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Supriatno, 2003, ONCOL REP, V10, P527; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Wu Ming-fu, 2003, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V25, P434	33	54	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2568	2573		10.1038/sj.onc.1208503	http://dx.doi.org/10.1038/sj.onc.1208503			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735692				2022-12-17	WOS:000228180600014
J	Neben, K; Schnittger, S; Brors, B; Tews, B; Kokocinski, F; Haferlach, T; Muller, J; Hahn, M; Hiddemann, W; Eils, R; Lichter, P; Schoch, C				Neben, K; Schnittger, S; Brors, B; Tews, B; Kokocinski, F; Haferlach, T; Muller, J; Hahn, M; Hiddemann, W; Eils, R; Lichter, P; Schoch, C			Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype	ONCOGENE			English	Article						acute myeloid leukemia; normal karyotype; gene expression profiling; FLT3-activating mutations; NRAS-activating mutations	INTERNAL TANDEM DUPLICATION; HIGH-DOSE CYTARABINE; PROGNOSTIC-SIGNIFICANCE; NORMAL CYTOGENETICS; ADULT PATIENTS; AML 10; FLT3; APOPTOSIS; IDENTIFY; CYCLE	In acute myeloid leukemia (AML), constitutive activation of the FLT3 receptor tyrosine kinase, either by internal tandem duplications (FLT3-ITD) of the juxtamembrane region or by point mutations in the second tyrosine kinase domain (FLT3-TKD), as well as point mutations of the NRAS gene (NRAS-PM) are among the most frequent somatic gene mutations. To elucidate whether these mutations cause aberrant signal transduction in AML, we used gene expression pro. ling in a series of 110 newly diagnosed AML patients with normal karyotype. The different algorithms used for data analysis revealed highly concordant sets of genes, indicating that the identified gene signatures are specific for each analysed subgroup. Whereas samples with FLT3-ITD and FLT3-TKD could be separated with up to 100% accuracy, this did not apply for NRAS-PM and wild-type samples, suggesting that only FLT3-ITD and FLT3-TKD are associated with an apparent signature in AML. The set of discriminating genes included several known genes, which are involved in cell cycle control (CDC14A, WEE1), gene transcription (HOXB5, FOXA1), and signal transduction (SMG1). In conclusion, we showed that unique gene expression patterns can be correlated with FLT3-ITD and FLT3-TKD. This might lead to the identification of further pathogenetic relevant candidate genes particularly in AML with normal karyotype.	Deutsch Krebsforschungszentrum, Div Mol Genet B060, D-69120 Heidelberg, Germany; Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, Lab Leukemia Diagnost, D-81366 Munich, Germany; Deutsch Krebsforschungszentrum, Div Intelligent Bioinformat Syst B080, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ)	Lichter, P (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Genet B060, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	k.neben@dkfz.de	Brors, Benedikt/E-5620-2013; Eils, Roland/B-6121-2009	Brors, Benedikt/0000-0001-5940-3101; Eils, Roland/0000-0002-0034-4036; Kokocinski, Felix/0000-0002-8472-9207				BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Bishop Christopher M., 1995, NEURAL NETWORKS PATT; Bloomfield CD, 1998, CANCER RES, V58, P4173; Buchner T, 2003, J CLIN ONCOL, V21, P4496, DOI 10.1200/JCO.2003.02.133; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Dohner K, 2002, J CLIN ONCOL, V20, P3254, DOI 10.1200/JCO.2002.09.088; Epstein DJ, 1999, DEVELOPMENT, V126, P281; Frohling S, 2002, BLOOD, V100, P4372, DOI 10.1182/blood-2002-05-1440; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Griswold IJ, 2004, BLOOD, V104, P2912, DOI 10.1182/blood-2003-05-1669; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Kelly LM, 2002, CANCER CELL, V1, P421, DOI 10.1016/S1535-6108(02)00070-3; Kiyoi H, 1999, BLOOD, V93, P3074; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Korshunov A, 2003, AM J PATHOL, V163, P1721, DOI 10.1016/S0002-9440(10)63530-4; Korz C, 2002, BLOOD, V99, P4554, DOI 10.1182/blood.V99.12.4554; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Li YW, 2004, BLOOD, V104, P1137, DOI 10.1182/blood-2003-07-2585; Lin L, 2002, CANCER RES, V62, P5273; Lisovsky M, 1996, BLOOD, V88, P3987, DOI 10.1182/blood.V88.10.3987.bloodjournal88103987; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Mitelman F, 1995, INT SYSTEM HUMAN CYT; Nabney I. T., 2002, ADV PTRN RECOGNIT; Neben K, 2004, CANCER RES, V64, P3103, DOI 10.1158/0008-5472.CAN-03-3968; NEUBAUER A, 1994, BLOOD, V83, P1603; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ragg T, 2002, AI COMMUN, V15, P61; Reuter CWM, 2000, BLOOD, V96, P1655, DOI 10.1182/blood.V96.5.1655.h8001655_1655_1669; Schnittger S, 2000, LEUKEMIA, V14, P796, DOI 10.1038/sj.leu.2401773; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yamashita A, 2001, GENE DEV, V15, P2215, DOI 10.1101/gad.913001; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220	42	54	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1580	1588		10.1038/sj.onc.1208344	http://dx.doi.org/10.1038/sj.onc.1208344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674343				2022-12-17	WOS:000227218200011
J	Tsunoda, T; Koga, H; Yokomizo, A; Tatsugami, K; Eto, M; Inokuchi, J; Hirata, A; Masuda, K; Okumura, K; Naito, S				Tsunoda, T; Koga, H; Yokomizo, A; Tatsugami, K; Eto, M; Inokuchi, J; Hirata, A; Masuda, K; Okumura, K; Naito, S			Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP(3)R1) modulates the acouisition of cisplatin resistance in bladder cancer cell lines	ONCOGENE			English	Article						cisplatin resistance; IP(3)R1; apoptosis; bladder; cancer	UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; INCREASED EXPRESSION; INDUCED APOPTOSIS; CALCIUM SIGNALS; OVARIAN-CANCER; DNA-REPAIR; CIS-DIAMMINEDICHLOROPLATINUM(II); SENSITIVITY; MECHANISM	To investigate the molecules that regulate the acquisition of cis-diamminedichloroplatinum (11) (cisplatin) resistance, we performed cDNA microarrays using two pairs of parental and cisplatin-resistant bladder cancer cell lines. We found a markedly reduced expression of inositol 1,4,5-trisphosphate (IP3) receptor typel (IP(3)R1), endoplasmic reticulum membrane protein, in cisplatin-resistant cells. The suppression Of IP(3)R1 expression using small interfering RNA in parental cells prevented apoptosis and resulted in decreased sensitivity to cisplatin. Contrarily, overexpression Of IP(3)R1 in resistant cells induced apoptosis and increased sensitivity to cisplatin. These results suggest that cisplatin-induced downregulation of IP(3)R1 expression was closely associated with the acquisition of cisplatin resistance in bladder cancer cells. Published online 20 December 2004.	Kyushu Univ, Dept Urol, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Naito, S (corresponding author), Kyushu Univ, Dept Urol, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	naito@uro.med.Kyushu-u.ac.jp	Inokuchi, Junichi/AAO-3297-2020	Inokuchi, Junichi/0000-0002-6791-905X				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUBENIK J, 1973, INT J CANCER, V11, P765, DOI 10.1002/ijc.2910110327; Burger H, 1997, INT J CANCER, V73, P592, DOI 10.1002/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; EASTMAN A, 1988, BIOCHEMISTRY-US, V27, P4730, DOI 10.1021/bi00413a022; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; EASTMAN A, 1983, BIOCHEMISTRY-US, V22, P3927, DOI 10.1021/bi00285a031; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; Furutama D, 1996, J NEUROCHEM, V66, P1793; Hajnoczky G, 2000, CELL CALCIUM, V28, P349, DOI 10.1054/ceca.2000.0169; Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433; Hisano T, 1996, FEBS LETT, V397, P101, DOI 10.1016/S0014-5793(96)01150-7; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; KOTOH S, 1994, CANCER RES, V54, P3248; Kotoh S, 1997, J UROLOGY, V157, P1054, DOI 10.1016/S0022-5347(01)65140-1; Liang XJ, 2000, BIOSCIENCE REP, V20, P129, DOI 10.1023/A:1005530501137; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; MASUDA H, 1988, CANCER RES, V48, P5713; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; NIENDER H, 2001, MOL PHARMACOL, V60, P1153; Oubrahim H, 2002, J BIOL CHEM, V277, P20135, DOI 10.1074/jbc.C200226200; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Suzuki T, 2001, CURR DRUG METAB, V2, P367, DOI 10.2174/1389200013338289; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; TAYA T, 1977, JPN J UROL, V68, P1003, DOI 10.5980/jpnjurol1928.68.11_1003; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Vaisman A, 1997, CYTOMETRY, V27, P54, DOI 10.1002/(SICI)1097-0320(19970101)27:1<54::AID-CYTO7>3.0.CO;2-L; YOKOMIZO A, 1995, CANCER RES, V55, P4293	31	54	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1396	1402		10.1038/sj.onc.1208313	http://dx.doi.org/10.1038/sj.onc.1208313			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608674				2022-12-17	WOS:000227092600009
J	Mezquita, P; Parghi, SS; Brandvold, KA; Ruddell, A				Mezquita, P; Parghi, SS; Brandvold, KA; Ruddell, A			Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation	ONCOGENE			English	Article						Myc; VEGF; translational control; mammalian target of rapamycin; protein synthesis	ENDOTHELIAL GROWTH-FACTOR; RIBOSOME ENTRY SITES; C-MYC; VASCULAR-PERMEABILITY; FACTOR 4E; PROTEIN-SYNTHESIS; EXPRESSION; PHOSPHORYLATION; ANGIOGENESIS; VIRUS	Deregulated c-myc gene expression is associated with many human and animal cancers. Myc overexpression promotes the growth of blood and lymphatic vessels, which is due in part to induction of growth factors including vascular endothelial growth factor (VEGF). We determined that the P493-6 human B-cell line increases VEGF production 10-fold upon Myc overexpression. Myc overexpression in avian B cells similarly resulted in high level VEGF production. Real-time RT-PCR analyses showed that Myc did not alter the VEGF mRNA content of these cell lines, indicating that a post-transcriptional mechanism regulates VEGF production. VEGF mRNA translation was examined by RT-PCR analysis of monosome and polysome sucrose gradient fractions from Myc-on and Myc-off P493-6 cells. Myc increased VEGF mRNA translation initiation, as VEGF mRNA loading onto polysomes increased 14-fold in Myc-on cells, and the number of ribosomes loaded per VEGF mRNA increased threefold. This translational regulation is specific to VEGF mRNA, as total polysomes show the same sucrose gradient pro. le in Myc-on and Myc-off cells, with no change in the percent ribosomes in polysomes, or in the number of ribosomes per polysomal mRNA. Myc stimulates VEGF production by a rapamycin- and LY294002-sensitive pathway, which does not involve alteration of eIF4E activity.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,POB 19024,MS C2-023, Seattle, WA 98109 USA.	aruddell@fhcrc.org	Mezquita, Pau/AGN-4799-2022	Ruddell, Alanna/0000-0002-0195-5576	NATIONAL CANCER INSTITUTE [R01CA068328] Funding Source: NIH RePORTER; NCI NIH HHS [CA68328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Barr LF, 2000, CANCER RES, V60, P143; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Bellamy WT, 1999, CANCER RES, V59, P728; Bowers WJ, 1996, J VIROL, V70, P3051, DOI 10.1128/JVI.70.5.3051-3059.1996; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; Brandvold KA, 2001, ONCOGENE, V20, P3226, DOI 10.1038/sj.onc.1204431; Christinger HW, 1996, PROTEINS, V26, P353, DOI 10.1002/(SICI)1097-0134(199611)26:3<353::AID-PROT9>3.0.CO;2-E; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Davies E, 1995, METHOD CELL BIOL, V50, P209, DOI 10.1016/S0091-679X(08)61032-8; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; FLAMME I, 1995, DEV BIOL, V171, P399, DOI 10.1006/dbio.1995.1291; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; HUMPHRIES EH, 1984, CURR TOP MICROBIOL, V113, P47; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Ruddell A, 2003, AM J PATHOL, V163, P2233, DOI 10.1016/S0002-9440(10)63581-X; Satake S, 1998, BIOL CELL, V90, P161, DOI 10.1016/S0248-4900(98)80337-7; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SMITH DR, 1985, J VIROL, V56, P969, DOI 10.1128/JVI.56.3.969-977.1985; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; Tuxworth WJ, 2004, BIOCHEM J, V378, P73, DOI 10.1042/BJ20031027; Vacca A, 1999, BRIT J CANCER, V79, P965, DOI 10.1038/sj.bjc.6690154; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Willis AE, 1997, CURR TOP MICROBIOL, V224, P269	52	54	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					889	901		10.1038/sj.onc.1208251	http://dx.doi.org/10.1038/sj.onc.1208251			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580293	Green Accepted			2022-12-17	WOS:000226577100015
J	Sauane, M; Gopalkrishnan, RV; Choo, HT; Gupta, P; Lebedeva, IV; Yacoub, A; Dent, P; Fisher, PB				Sauane, M; Gopalkrishnan, RV; Choo, HT; Gupta, P; Lebedeva, IV; Yacoub, A; Dent, P; Fisher, PB			Mechanistic aspects of mda-7/IL-24 cancer cell selectivity analysed via a bacterial fusion protein	ONCOGENE			English	Article						cancer gene therapy; GST-MDA-7/IL-24; apoptosis; breast cancer; radiotherapy	DIFFERENTIATION-ASSOCIATED GENE; APOPTOSIS INDUCING CYTOKINE; GLUTATHIONE-S-TRANSFERASE; HUMAN-MELANOMA CELLS; PANCREATIC-CANCER; MDA-7 IL-24; SUPPRESSOR GENE; IN-VITRO; GROWTH; PATHWAYS	The human mda-7/IL-24 gene product is normally expressed in melanocytes and certain lymphocyte populations. Loss of expression, a distinctive feature of many tumor suppressor genes, has been documented at RNA and protein levels in association with melanoma progression both in vitro as well as in human tumor-derived material. The MDA-7/IL-24 protein undergoes post-translational processing, including removal of an amino-terminal 48-residue signal peptide and extensive glycosylation prior to its secretion by producing cells. Its inherent cytokine properties have been documented in multiple reports, which have identified and characterized its cognate receptors and activation of the JAK/STAT signaling pathway following ligand/receptor docking. A notable and incompletely understood property of MDA-7/IL-24 is its ability to induce apoptosis in transformed cells, while having marginal growth suppressive effects on normal primary or immortalized cell lines. MDA-7/IL-24 has been delivered to cells, tumor xenografts and patients in clinical trials via a nonreplicating adenovirus (Ad.mda-7). Studies utilizing eukaryotically expressed and purified MDA-7/ IL-24 protein from several sources have recapitulated some of the molecule's reported properties including receptor binding and JAK/STAT activation. Here, we report the properties and characteristics of a bacterially expressed and purified GST-MDA-7 fusion protein. These studies reveal that GST-MDA-7 retains its cancer-selective apoptosis-inducing properties, thereby providing a new reagent that will assist in de. ning the mechanism of action of this novel cytokine. In addition, retention of tumor-specific activity of GST-MDA-7 suggests that this protein may also have therapeutic applications.	Columbia Univ, Coll Phys & Surg, Dept Pathol, Med Ctr,Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Columbia Univ, Coll Phys & Surg, Dept Neurosurg, Med Ctr,Herbert Irving Comprehens Canc Ctr, New York, NY USA; Columbia Univ, Coll Phys & Surg, Dept Urol, Med Ctr,Herbert Irving Comprehens Canc Ctr, New York, NY USA	Columbia University; Virginia Commonwealth University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, Med Ctr,Herbert Irving Comprehens Canc Ctr, BB-1501,630 W 16th St, New York, NY 10027 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA097318, R01CA088906, R01CA098172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NCI NIH HHS [CA097318, CA098172, CA88906] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLASZKOWSKY L, 1998, FRONT BIOSCI, V3, P214; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Caudell EG, 2002, J IMMUNOL, V168, P6041, DOI 10.4049/jimmunol.168.12.6041; Chada S, 2001, CANCER GENE THER, V8, pS3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Hilgers W, 1999, GENE CHROMOSOME CANC, V26, P1; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kotenko SV, 2002, CYTOKINE GROWTH F R, V13, P223, DOI 10.1016/S1359-6101(02)00012-6; Lebedeva I, 2000, CANCER RES, V60, P6052; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Lin JJ, 1996, MOL CELL DIFFER, V4, P317; Lorenz M, 2000, EUR J CANCER, V36, P957, DOI 10.1016/S0959-8049(00)00073-3; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; Mhashilkar AM, 2003, MOL THER, V8, P207, DOI 10.1016/S1525-0016(03)00170-9; Namiki S, 2003, BIOCHEM BIOPH RES CO, V305, P592, DOI 10.1016/S0006-291X(03)00807-6; NEMUNITAIS J, 2003, CANCER GENE THER, V10, pS106; Novak JP, 2002, J BIOL CHEM, V277, P47517, DOI 10.1074/jbc.M205114200; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; PESTKA S, 2003, ENCY HORMONES, P507; Ramesh R, 2003, CANCER RES, V63, P5105; Regine William F., 1998, Frontiers in Bioscience, V3, pE186; Rosenberg L, 2000, DRUGS, V59, P1071, DOI 10.2165/00003495-200059050-00004; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sarkar D, 2002, BIOTECHNIQUES, P30; Sauane M, 2004, CANCER RES, V64, P2988, DOI 10.1158/0008-5472.CAN-04-0200; Sauane M, 2003, J CELL PHYSIOL, V196, P334, DOI 10.1002/jcp.10309; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Sieger KA, 2004, MOL THER, V9, P355, DOI 10.1016/j.ymthe.2003.11.014; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, MOL CANCER THER, V2, P623; YACOUB A, 2004, IN PRESS CANC BIOL T; Zhan Y, 2001, GENE, V281, P1, DOI 10.1016/S0378-1119(01)00797-1	46	54	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7679	7690		10.1038/sj.onc.1207958	http://dx.doi.org/10.1038/sj.onc.1207958			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15334067				2022-12-17	WOS:000224306700009
J	Wang, HM; Radjendirane, V; Wary, KK; Chakrabarty, S				Wang, HM; Radjendirane, V; Wary, KK; Chakrabarty, S			Transforming growth factor beta regulates cell-cell adhesion through extracellular matrix remodeling and activation of focal adhesion kinase in human colon carcinoma Moser cells	ONCOGENE			English	Article						TGFB; cell adhesion; colon cancer	C-ALPHA; CARCINOEMBRYONIC ANTIGEN; RECEPTOR EXPRESSION; CANCER CELLS; FIBRONECTIN; GROWTH-FACTOR-BETA-1; INDUCTION; DIFFERENTIATION; STIMULATION; REQUIREMENT	Transforming growth factor (TGF) beta is a potent regulator of cell-matrix and cell-cell adhesions (collectively termed cellular adhesions). Cellular adhesions play crucial roles in controlling the differentiation of epithelial cells and in maintaining the integrity of the epithelium. Loss of TGF beta-responsiveness is thought to be an important early initiating event in the malignant progression of epithelial cancer. In the TGFbeta-responsive human colon adenocarcinoma Moser cells, TGFbeta promotes cellular adhesions and suppresses their malignant phenotype. TGFbeta promotes cell-matrix adhesion by inducing the synthesis of extracellular matrix (ECM) adhesion molecules and the expression of integrin receptors for these molecules (termed ECM remodeling). TGFbeta promotes cell-cell adhesion through the induction of E-cadherin expression, an epithelial associated homotypic cell-cell adhesion molecule, which also functions as a tumor suppressor in colon cancer. How TGFbeta regulates E-cadherin expression is not known. In this study, we showed that the induction of E-cadherin by TGFbeta was mediated through the activation of focal adhesion kinase (FAK), a major signaling molecule in focal adhesion contacts and that the activation of FAK was due to ECM remodeling and increased cell-matrix interactions. Thus, TGFbeta regulates cell-cell adhesion through its ability to remodel the ECM and to activate FAK through ECM remodeling.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA; Texas A&M Univ Syst, Inst Biossci & Technol, Hlth Sci Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Chakrabarty, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Div Pathol & Lab Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.	schakrab@mdanderson.org		Wary, Kishore/0000-0001-8851-8565	NCI NIH HHS [R01 CA 47775] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047775] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009; BREEN E, 1995, ANN SURG ONCOL, V2, P378, DOI 10.1007/BF02306369; CHAKRABARTY S, 1989, CANCER RES, V49, P2112; Chakrabarty S, 1998, LAB INVEST, V78, P413; CHAKRABARTY S, 1995, J CELL PHYSIOL, V164, P148, DOI 10.1002/jcp.1041640119; CHAKRABARTY S, 1992, INT J CANCER, V50, P968, DOI 10.1002/ijc.2910500624; CHAKRABARTY S, 1988, CANCER RES, V48, P4059; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HUANG S, 1994, INT J CANCER, V57, P742, DOI 10.1002/ijc.2910570522; Ilyas M, 1999, P NATL ACAD SCI USA, V96, P3087, DOI 10.1073/pnas.96.6.3087; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Rajagopal S, 1997, J CELL PHYSIOL, V170, P138, DOI 10.1002/(SICI)1097-4652(199702)170:2<138::AID-JCP5>3.0.CO;2-P; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; TANG DG, 1995, J CELL PHYSIOL, V165, P291, DOI 10.1002/jcp.1041650210; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Varallo VM, 2003, ONCOGENE, V22, P3680, DOI 10.1038/sj.onc.1206415; Wang HM, 2001, J CELL PHYSIOL, V187, P188, DOI 10.1002/jcp.1068; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	27	54	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5558	5561		10.1038/sj.onc.1207701	http://dx.doi.org/10.1038/sj.onc.1207701			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15133493				2022-12-17	WOS:000222588400016
J	Chae, HD; Yun, J; Bang, YJ; Shin, DY				Chae, HD; Yun, J; Bang, YJ; Shin, DY			Cdk2-dependent phosphorylation of the NF-Y transcription factor is essential for the expression of the cell cycle-regulatory genes and cell cycle G1/S and G2/M transitions	ONCOGENE			English	Article						NF-Y; cell cycle; cdc2; cdk2; G1/G2	CCAAT-BINDING PROTEIN; MACROPHAGE DIFFERENTIATION; G(2) ARREST; KINASE; DNA; SENESCENCE; INHIBITION; COMPLEX; P53; ACTIVATION	We previously reported that cdk2 phosphorylates two serine residues near the DNA-binding domain of the YA subunit of NF-Y transcription factor and this phosphorylation is essential for DNA binding of NF-Y. In this study, we examined the effects of a phosphorylation-deficient mutant form of YA, YA-aa, in which the two serine residues are replaced with alanine, on the cell cycle and expression of the NF-Y target genes. Transient transfection assays show that YA-aa inhibits transcription from the NF-Y target promoters, such as cdc2, cyclin A, and cdc25C. Moreover, this inhibitory function of YA-aa can be suppressed by the expression of wild-type YA, implying that YA-aa inhibits transcription of those NF-Y target genes by inactivating wild-type YA. Since NF-Y target genes include the cell cycle-regulatory genes that ensure orderly progression of the cell cycle, we examined the effects of YA-aa in cell cycle progression. We constructed a recombinant adenovirus encoding YA-aa and found that YA-aa expression leads to repression of cell cycle-regulatory genes, such as cyclin A, RNR R2, DNA polymerase a, cdc2, cyclin B, and cdc25C. Consistently, YA-aa expression results in the inactivation of both cdc2 and cdk2. Furthermore, cell cycle analysis reveals that YA-aa induces cell cycle arrest at both G1 and G2/M. These results suggest that cdk2-dependent phosphorylation of NF-Y is essential for the expression of the cell cycle-regulatory genes and therefore for cell cycle progression at both G1/S and G2/M.	Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab, Cheonan 330714, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea	Dankook University; Seoul National University (SNU)	Shin, DY (corresponding author), Dankook Univ, Coll Med, Dept Microbiol & Immunol, Cheonan 330714, South Korea.	dreamer@dku.edu	Chae, Hee-Don/D-2620-2011; Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597				BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Currie RA, 1998, J BIOL CHEM, V273, P18220, DOI 10.1074/jbc.273.29.18220; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Gerrish K, 2001, J BIOL CHEM, V276, P47775, DOI 10.1074/jbc.M109244200; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; LI XY, 1992, J BIOL CHEM, V267, P8984; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Marziali G, 1999, BLOOD, V93, P519, DOI 10.1182/blood.V93.2.519.402a01_519_526; Matuoka K, 1999, EXP CELL RES, V253, P365, DOI 10.1006/excr.1999.4605; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PANG JH, 1993, J BIOL CHEM, V268, P2909; Park J S, 2001, Cancer Res Treat, V33, P236, DOI 10.4143/crt.2001.33.3.236; Park M, 2000, CANCER RES, V60, P542; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Sinha S, 1996, MOL CELL BIOL, V16, P328; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Yun JH, 2003, J BIOL CHEM, V278, P36966, DOI 10.1074/jbc.M305178200; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	28	54	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4084	4088		10.1038/sj.onc.1207482	http://dx.doi.org/10.1038/sj.onc.1207482			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064732				2022-12-17	WOS:000221520200006
J	Hildesheim, J; Belova, GI; Tyner, SD; Zhou, XW; Vardanian, L; Fornace, AJ				Hildesheim, J; Belova, GI; Tyner, SD; Zhou, XW; Vardanian, L; Fornace, AJ			Gadd45a regulates matrix metalloproteinases by suppressing Delta Np63 alpha and beta-catenin via p38 MAP kinase and APC complex activation	ONCOGENE			English	Article						Gadd45a; beta-catenin; Delta Np63 alpha; keratinocyte; UV	P63 EXPRESSION; P53 HOMOLOG; CYCLIN D1; SKIN; CANCER; MATRILYSIN; APOPTOSIS; PHOSPHORYLATION; PROTEIN; TARGET	The p53-regulated growth arrest and DNA damage-inducible gene product Gadd45a has been recently identified as a key factor protecting the epidermis against ultraviolet radiation (UVR)-induced skin tumors by activating p53 via the stress mitogen-activated protein kinase ( MAPK) signaling pathway. Herein we identify Gadd45a as an important negative regulator of two oncogenes commonly over-expressed in epithelial tumors: the p53 homologue DeltaNp63alpha and beta-catenin. DeltaNp63alpha is one of the several p63 isoforms and is the predominant species expressed in basal epidermal keratinocytes. DeltaNp63alpha lacks the N-terminal transactivation domain and behaves as a dominant-negative factor blocking expression of several p53-effector genes. DeltaNp63alpha also associates with and blocks activation of the adenomatous polyposis coli (APC) destruction complex that targets free cytoplasmic beta-catenin for degradation. While most beta-catenin protein is localized to the cell membrane and is involved in cell-cell adhesion, accumulation of free cytoplasmic beta-catenin will translocate into the nucleus where it functions in a bipartite transcription factor complex, whose targets include invasion and metastasis promoting endopeptidases, matrix metalloproteinases (MMP). We show that Gadd45a not only directly associates with two components of the APC complex, namely protein phosphatase 2A (PP2A) and glycogen synthase kinase 3beta (GSK3beta) but also promotes GSK3b dephosphorylation at Ser9, which is essential for GSK3b activation, and resultant activation of the APC destruction complex. We demonstrate that lack of Gadd45a not only prevents DeltaNp63alpha suppression and GSK3b dephosphorylation but also prevents free cytoplasmic beta-catenin degradation after UV irradiation. The inability of Gadd45a-null keratinocytes to suppress beta-catenin may contribute to the resulting observation of increased MMP expression and activity along with significantly faster keratinocyte migration in Matrigel in vitro and accelerated wound closure in vivo. Furthermore, epidermal keratinocytes treated with p38 MAPK inhibitors, both in vivo and in vitro, behave very similarly to Gadd45a-null keratinocytes after UVR. Similarly, Trp53-null mice are unable to attenuate DeltaNp63alpha expression in epidermal keratinocytes after such stress. These findings demonstrate a dependence on Gadd45a-mediated p38 MAPK and p53 activation for proper modulation of DeltaNp63alpha, GSK3beta, and beta-catenin after irradiation. Taken together, our results indicate that Gadd45a is able to repress DeltaNp63alpha, beta-catenin, and consequently MMP expression by two means: by maintaining UVR-induced p38 MAPK and p53 activation and also by associating with the APC complex. This implicates Gadd45a in the negative regulation of cell migration, and invasion.	NCI, Gene Response Sect, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fornace, AJ (corresponding author), NCI, Gene Response Sect, Ctr Canc Res, NIH, Bldg 37,Rm 6144,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	af6z@nih.gov	Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hildesheim J, 2002, CANCER RES, V62, P7305; Hu H, 2002, INT J CANCER, V102, P580, DOI 10.1002/ijc.10739; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; KARELINA TV, 1994, J INVEST DERMATOL, V103, P482, DOI 10.1111/1523-1747.ep12395596; Kusukawa J, 1996, ORAL ONCOL, V32B, P217, DOI 10.1016/0964-1955(96)00016-4; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Li G, 1996, AM J PATHOL, V148, P1113; Liefer KM, 2000, CANCER RES, V60, P4016; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Park BJ, 2000, CANCER RES, V60, P3370; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Pelosi G, 2002, J PATHOL, V198, P100, DOI 10.1002/path.1166; Polakis P, 2000, GENE DEV, V14, P1837; POWELL WC, 1993, CANCER RES, V53, P417; PYKE C, 1992, CANCER RES, V52, P1336; Quinn AG, 1997, BRIT J HOSP MED, V58, P261; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sakanaka C, 2002, J BIOCHEM, V132, P697, DOI 10.1093/oxfordjournals.jbchem.a003276; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsukifuji R, 1999, BRIT J CANCER, V80, P1087, DOI 10.1038/sj.bjc.6690468; Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; YAMAMOTO H, 1995, INT J CANCER, V61, P218, DOI 10.1002/ijc.2910610213; Yamasawa K, 2002, CLIN CANCER RES, V8, P2563; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	50	54	58	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1829	1837		10.1038/sj.onc.1207301	http://dx.doi.org/10.1038/sj.onc.1207301			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14647429				2022-12-17	WOS:000220129500004
J	Benoit, V; Relic, B; de Leval, X; Chariot, A; Merville, MP; Bours, V				Benoit, V; Relic, B; de Leval, X; Chariot, A; Merville, MP; Bours, V			Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2	ONCOGENE			English	Article						cyclooxygenase-2; HER-2; erbB-2; prostaglandin; PGE2; cancer	METASTATIC BREAST-CANCER; RECEPTOR-ENHANCED CHEMOSENSITIVITY; MAMMARY EPITHELIAL-CELLS; TUMOR NECROSIS FACTOR; TRASTUZUMAB HERCEPTIN; MONOCLONAL-ANTIBODY; NEU ONCOGENE; EGF RECEPTOR; PHASE-II; GROWTH	The oncoprotein HER-2/neu is a prosurvival factor and its overexpression has been correlated with adverse prognosis in breast cancers. High levels of the cyclooxygenase-2 (COX-2), a proinflammatory and antiapoptotic enzyme, were detected in HER-2-positive tumors and this observation was linked to an HER-2-mediated induction of COX-2 gene transcription. Here, we report that COX-2 expression, and synthesis of its major enzymatic product, PGE2, leads in turn to an enhanced HER-2 expression. Moreover, COX-2 enzymatic inhibition dramatically reduced HER-2 protein levels, efficiently increased the cancer cells sensitility to chemotherapeutic treatment and acted in synergy with HER-2 inhibitor, trastuzumab. Therefore, we propose an original model where HER-2 and COX-2 transcriptionally regulate each other in a positive loop.	Univ Liege, Ctr Mol & Cellular Therapy, Lab Rheumatol, B-4000 Liege, Belgium; Univ Liege, Nat & Synthet Drugs Res Ctr, B-4000 Liege, Belgium; Univ Liege, Ctr Mol & Cellular Therapy, Lab Med Chem & Human Genet, B-4000 Liege, Belgium	University of Liege; University of Liege; University of Liege	Bours, V (corresponding author), CHU, Lab Med Chem & Human Genet, B35, B-4000 Liege, Belgium.	vbours@ulg.ac.be		BENOIT, Valerie/0000-0002-1098-9452; Chariot, Alain/0000-0002-1691-4347				Baselga J, 1999, SEMIN ONCOL, V26, P78; Baselga J, 1998, CANCER RES, V58, P2825; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; GROOTECLAES M, 1994, CANCER RES, V54, P4193; Harris RE, 2000, CANCER RES, V60, P2101; Howe LR, 2002, CANCER RES, V62, P5405; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Kawamori T, 1998, CANCER RES, V58, P409; Kiguchi K, 2001, CANCER RES, V61, P6971; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Mann M, 2001, GASTROENTEROLOGY, V120, P1713, DOI 10.1053/gast.2001.24844; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pegram MD, 1999, SEMIN ONCOL, V26, P89; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; PRESS MF, 1993, CANCER RES, V53, P4960; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Sirica AE, 2002, SEMIN LIVER DIS, V22, P303, DOI 10.1055/s-2002-34507; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Tiano HF, 2002, CANCER RES, V62, P3395; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4	36	54	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1631	1635		10.1038/sj.onc.1207295	http://dx.doi.org/10.1038/sj.onc.1207295			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14985703	Green Published			2022-12-17	WOS:000189219500018
J	Liu, BY; Kim, YC; Leatherberry, V; Cowin, P; Alexander, CM				Liu, BY; Kim, YC; Leatherberry, V; Cowin, P; Alexander, CM			Mammary gland development requires syndecan-1 to create a beta-catenin/TCF-responsive mammary epithelial subpopulation	ONCOGENE			English	Article						Wnt-1; syndecan; mouse mammary gland; beta-catenin	HEPARAN-SULFATE PROTEOGLYCANS; SIGNAL-TRANSDUCTION; COLORECTAL-CANCER; WNT/BETA-CATENIN; TGF-BETA; WNT; WINGLESS; DROSOPHILA; PATHWAYS; PROTEIN	Mice with a null mutation in the cell surface heparan sulfate (HS) proteoglycan, syndecan-1 (Sdc1), develop almost normally, but resist mammary tumor development in response to Wnt-1. Here, we test the hypothesis that Sdc1 promotes Wnt-1- induced tumor development by interacting with the Wnt cell surface signaling complex. Thus, the response of Sdc1 -/- mammary epithelial cells (mecs) to the intracellular, activated Wnt signal transducer, DeltaNbeta-catenin, was assayed both in vitro and in vivo, to test whether beta-catenin/TCF transactivation was Sdc1-independent. Surprisingly, we found that the expression of a canonical Wnt pathway reporter, TOP-FLASH, was reduced by 50% in both unstimulated Sdc1-/- mecs and in stimulated cells responding to Wnt1 or DeltaNbeta-catenin. Tumor development in response to DeltaNbeta-catenin was also significantly delayed on a Sdc1-/- background. Furthermore, the average beta-catenin/TCF transactivation per cell was normal in Sdc1-/- mec cultures, but the number of responsive cells was reduced by 50%. Sdc1-/- mecs show compensatory changes that maintain the number of HS chains, hence these experiments cannot test the coreceptor activity of HS for Wnt signaling. We propose that TCF-dependent transactivational activity is suppressed in 50% of cells in Sdc1-/- glands, and conclude that the major effect of Sdc1 does not map to the activity of the Wnt signaling complex, but to another pathway to create or stabilize the beta-catenin/TCF-responsive tumor precursor cells in mouse mammary gland.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; NYU Med Ctr, Dept Cell Biol, New York, NY 10016 USA	University of Wisconsin System; University of Wisconsin Madison; New York University	Alexander, CM (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.			Kim, Young Chul/0000-0002-6782-2186; Cowin, Pamela/0000-0002-1827-1154	NATIONAL CANCER INSTITUTE [T32CA009135, R01CA090877, P30CA014520] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90877-01, T32 CA09135, P30 CA14520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Baeg GH, 2001, DEVELOPMENT, V128, P87; Baeg GH, 2000, CURR OPIN CELL BIOL, V12, P575, DOI 10.1016/S0955-0674(00)00134-4; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Behrens J, 2000, J CELL SCI, V113, P911; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Chan SK, 2002, CELL, V111, P265, DOI 10.1016/S0092-8674(02)01037-1; Clevers H, 2000, NAT GENET, V24, P206, DOI 10.1038/73396; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; EMERMAN JT, 1988, ADV CELL CULT, V6, P137; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/ng0501-53; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Letamendia A, 2001, J BONE JOINT SURG AM, V83A, pS31; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Payre F, 1999, NATURE, V400, P271, DOI 10.1038/22330; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Polakis P, 2000, GENE DEV, V14, P1837; Rasmussen SB, 2000, METHODS MAMMARY GLAN; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0	38	54	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2003	22	58					9243	9253		10.1038/sj.onc.1207217	http://dx.doi.org/10.1038/sj.onc.1207217			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681683				2022-12-17	WOS:000187400400006
J	Liu, LT; Peng, JP; Chang, HC; Hung, WC				Liu, LT; Peng, JP; Chang, HC; Hung, WC			RECK is a target of Epstein-Barr virus latent membrane protein 1	ONCOGENE			English	Article						RECK; Epstein-Barr virus; latent membrane protein 1; extracellular signal-regulated kinases; small interference RNA	MEMBRANE-PROTEIN 1; CANCER-CELL INVASION; NASOPHARYNGEAL CARCINOMA; EXTRACELLULAR-MATRIX; B-CELLS; EXPRESSION; ACTIVATION; MATRIX-METALLOPROTEINASE-9; TRANSFORMATION; METASTASIS	Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) has been suggested to be involved in tumor metastasis. However, the molecular mechanism of LMP1-induced metastasis is largely unknown. In this study, we investigated the effect of LMP1 on the expression of RECK, a metastasis suppressor gene, in an EBV-negative nasopharyngeal carcinoma (NPC) cell line. Our data demonstrated that LMP1 induced downregulation of RECK via transcription repression in TW04 cells. In addition, we found that LMP1 acted via an Sp1 site to inhibit RECK promoter activity. We next studied the signaling pathway that mediated the effect of LMP1 on RECK expression. Our results showed that LMP1 potently stimulated the activity of extracellular signal-regulated kinases (ERKs) and inhibition of ERK activity by PD98059 antagonized LMP1-induced downregulation of RECK. Conversely, the c-Jun N-terminal kinase inhibitor SP600125 and p38(HOG) kinase inhibitor SB203580 had little effect. We also found that the expression of LMP1 increased the invasive ability of TW04 cells. The importance of RECK in LMP1-induced invasiveness was supported by three observations. First, restoration of RECK expression by PD98059 reduced LMP1-induced release of active MMP-9. Second, suppression of PD98059-induced RECK expression by small interference RNA abolished the inhibitory action of PD98059 on LMP1-induced invasiveness. Third, coexpression of RECK with LMP1 in TW04 cells effectively suppressed cell invasiveness induced by LMP1. Taken together, these results suggest that LMP1 inhibits RECK expression via the ERK/Sp1 signaling pathway and this inhibition is a critical step for LMP1-induced tumor metastasis.	Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Dept Physiol, Kaohsiung, Taiwan; Cang Gung Univ, Chang Gung Mem Hosp, Dept Otolaryngol, Kaohsiung Med Ctr, Kaohsiung, Taiwan; Kaohsiung Med Univ, Grad Inst Med, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Chang Gung Memorial Hospital; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Univ, Sch Technol Med Sci, No 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.			Liu, Li-Teh/0000-0002-7993-7263				DERRICO A, 1991, MODERN PATHOL, V4, P239; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Horikawa T, 2000, CANCER-AM CANCER SOC, V89, P715, DOI 10.1002/1097-0142(20000815)89:4<715::AID-CNCR1>3.0.CO;2-9; HU LF, 1995, EUR J CANCER, V31A, P658, DOI 10.1016/0959-8049(94)00468-K; KIEFF E, 1995, NEW ENGL J MED, V333, P724, DOI 10.1056/NEJM199509143331110; KIEFF E, 1990, VIROLOGY, P1889; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kim KR, 2000, ONCOGENE, V19, P1764, DOI 10.1038/sj.onc.1203502; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; LIN CT, 1990, LAB INVEST, V62, P713; LIN CT, 1993, LAB INVEST, V68, P716; Liu LT, 2003, CANCER RES, V63, P3069; MILLER G, 1990, VIROLOGY, P1921; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; PALLESEN G, 1991, J PATHOL, V165, P289, DOI 10.1002/path.1711650404; Pan MR, 2002, J BIOL CHEM, V277, P32775, DOI 10.1074/jbc.M202334200; PENG M, 1992, ONCOGENE, V7, P1775; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEISS LM, 1991, AM J PATHOL, V139, P1259; Yang XH, 2000, ONCOGENE, V19, P2002, DOI 10.1038/sj.onc.1203515; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621	31	54	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8263	8270		10.1038/sj.onc.1207157	http://dx.doi.org/10.1038/sj.onc.1207157			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614450				2022-12-17	WOS:000186541500005
J	Sato, M; Girard, L; Sekine, I; Sunaga, N; Ramirez, RD; Kamibayashi, C; Minna, JD				Sato, M; Girard, L; Sekine, I; Sunaga, N; Ramirez, RD; Kamibayashi, C; Minna, JD			Increased expression and no mutation of the Flap endonuclease (FEN1) gene in human lung cancer	ONCOGENE			English	Article						Flap endonuclease 1 (FEN1); base excision repair; microsatellite instability; lung cancer	NONPOLYPOSIS COLORECTAL-CANCER; DNA-REPLICATION FORK; MICROSATELLITE INSTABILITY; CELL-LINES; EXCISION; REPAIR; PATHOGENESIS; CARCINOMAS; TUMORS; GENOME	The underlying molecular mechanisms leading to microsatellite alteration and mutations in human lung cancer remain unknown. Since Flap endonuclease1 (Fen1), which functions in the base excision repair system, has been shown to be involved in tumor progression of mouse models with microsatellite instability in a haplo-insufficient manner, we performed expression and mutation analyses for FEN1 in human lung cancer cell lines. Reverse transcriptase PCR analysis revealed that all 49 lung cancer cell lines ( 20 small cell lung cancers (SCLCs) and 29 non-small cell lung cancers (NSCLCs)) expressed FEN1. In addition, microarray analysis showed that FEN1 expression was elevated significantly by 1.65-fold ( P = 0.001) in SCLC cell lines compared to normal lung controls ( normal human lung cultures and immortalized normal human bronchial epithelial cell lines). FEN1 protein was abundantly expressed in all 23 lung cancer cell lines ( 10 SCLCs and 13 NSCLCs) and was expressed at lower levels in three of four normal lung epithelial culture controls. Direct sequencing of genomic DNAs revealed no FEN1 mutation in seven SCLCs and nine NSCLCs. As part of this analysis we discovered and sequenced a FEN1 pseudogene ( GenBank accession # AY249897) located at 1p22.2. This pseudogene is amplified from cDNA preparations contaminated with genomic DNA and must be taken into account in any FEN1 mutation analysis studies. Our results suggest that alterations of FEN1 are not likely to contribute to development of lung cancer.	Univ Texas, SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Minna, JD (corresponding author), Univ Texas, SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res NB8 206, 6000 HarryHines Blvd, Dallas, TX 75390 USA.	John.Minna@UTsouthwestern.edu	Sato, MITSUO/I-7280-2014	Sato, MITSUO/0000-0001-5458-9576	NCI NIH HHS [P50CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bhattacharyya N, 1999, DNA CELL BIOL, V18, P549, DOI 10.1089/104454999315097; Boland CR, 1998, CANCER RES, V58, P5248; Charbonnier F, 2002, CANCER RES, V62, P848; Chen KH, 1998, NUCLEIC ACIDS RES, V26, P2001, DOI 10.1093/nar/26.8.2001; Girard L, 2000, CANCER RES, V60, P4894; GUGGENHEIMER RA, 1984, J BIOL CHEM, V259, P7815; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; LINDAHL T, 1971, EUR J BIOCHEM, V18, P407, DOI 10.1111/j.1432-1033.1971.tb01257.x; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Phelps RM, 1996, J CELL BIOCHEM, P32; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Warbrick E, 1998, J PATHOL, V186, P319; Wijnen J, 1998, NAT GENET, V20, P326, DOI 10.1038/3795; Wistuba II, 1999, CLIN CANCER RES, V5, P991; Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828	28	54	60	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2003	22	46					7243	7246		10.1038/sj.onc.1206977	http://dx.doi.org/10.1038/sj.onc.1206977			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562054				2022-12-17	WOS:000185955000017
J	Lavia, P; Mileo, AM; Giordano, A; Paggi, MG				Lavia, P; Mileo, AM; Giordano, A; Paggi, MG			Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability	ONCOGENE			English	Review						E1A; E7; mitosis; genomic instability; cellular transformation	HUMAN-PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; CYCLIN-DEPENDENT KINASE; LARGE T-ANTIGEN; CENTROSOME DUPLICATION; ADENOVIRUS E1A; RAN-GTPASE; MITOTIC SPINDLE; MAMMALIAN-CELLS; AURORA-A	The small DNA virus proteins E1A and E1B from human Adenovirus, E6 and E7 from human papillomavirus, and large T and small T antigens from SV40, are multifaceted molecular tools that can carry out an impressive number of tasks in the host cell. These viral factors, collectively termed 'oncoproteins' for their ability to induce cancer, can be viewed as paradigmatic oncogenic factors which can disrupt checkpoint controls at multiple levels - they interfere with both 'gatekeeper' cellular functions, including major control pathways of cell cycle and apoptosis, and with 'caretaker' functions, thereby inducing mitotic abnormalities and increasing genomic instability. Both E1A and E7 have been recently found to interact physically with the Ran GTPase. This interaction is key in uncoupling the centrosome cycle from the cell cycle, highlighting a direct link between viral infection and the induction of genomic instability. Further expanding our current knowledge in this field will be crucial to elucidate viral strategies leading to cellular transformation and cancer progression, as well as design novel preventive or therapeutic approaches to human cancer.	Regina Elena Inst Canc Res, Ctr Expt Res, I-00158 Rome, Italy; CNR, Natl Res Council, Inst Mol Biol & Pathol, Rome, Italy; Temple Univ, Dept Biotechnol, Philadelphia, PA 19122 USA	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Paggi, MG (corresponding author), Regina Elena Inst Canc Res, Ctr Expt Res, Via Messi Oro 156, I-00158 Rome, Italy.	paggi@ccd.inemm.cnr.it	Paggi, Marco G./K-3494-2018; Lavia, Patrizia/AAL-3982-2021; Giordano, Antonio/F-1927-2010; Mileo, Anna Maria/J-3667-2016; Lavia, Patrizia/J-5793-2019	Giordano, Antonio/0000-0002-5959-016X; Mileo, Anna Maria/0000-0002-1970-3297; Lavia, Patrizia/0000-0003-3310-6701				Alazawi W, 2002, CANCER RES, V62, P6959; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; Balmain A, 2001, NAT REV CANCER, V1, P77, DOI 10.1038/35094086; Berger AJ, 2002, AM J PATHOL, V161, P603, DOI 10.1016/S0002-9440(10)64215-0; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CAPOROSSI D, 1990, J GEN VIROL, V71, P801, DOI 10.1099/0022-1317-71-4-801; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 2000, J CELL BIOCHEM, V76, P189, DOI 10.1002/(SICI)1097-4644(20000201)76:2<189::AID-JCB3>3.0.CO;2-J; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Clarke PR, 2001, TRENDS CELL BIOL, V11, P366, DOI 10.1016/S0962-8924(01)02071-2; CLAUDIO PP, 1994, CANCER RES, V54, P5556; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dasso M, 2002, CURR BIOL, V12, pR502, DOI 10.1016/S0960-9822(02)00970-3; De Luca A, 2003, CANCER RES, V63, P1430; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; DIFIORE B, 2003, IN PRESS J CELL SCI; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Duensing S, 2001, CANCER RES, V61, P2356; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fisk HA, 2002, CURR OPIN CELL BIOL, V14, P700, DOI 10.1016/S0955-0674(02)00385-X; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Frank SA, 2003, CURR BIOL, V13, pR261, DOI 10.1016/S0960-9822(03)00195-7; Frisch SM, 2001, ADV CANCER RES, V80, P39, DOI 10.1016/S0065-230X(01)80011-7; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Frisch SM, 1996, MUTAT RES-FUND MOL M, V350, P261, DOI 10.1016/0027-5107(95)00103-4; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; Gaillard S, 2001, J VIROL, V75, P9799, DOI 10.1128/JVI.75.20.9799-9807.2001; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Garrett S, 2002, CURR BIOL, V12, P2055, DOI 10.1016/S0960-9822(02)01277-0; Goepfert TM, 2002, CANCER RES, V62, P4115; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Guarguaglini G, 2000, CELL GROWTH DIFFER, V11, P455; Haase SB, 2001, NAT CELL BIOL, V3, P38, DOI 10.1038/35050543; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Hetzer M, 2002, NAT CELL BIOL, V4, pE177, DOI 10.1038/ncb0702-e177; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hortobagyi GN, 2001, J CLIN ONCOL, V19, P3422, DOI 10.1200/JCO.2001.19.14.3422; Hubberstey AV, 2002, CANCER GENE THER, V9, P321, DOI 10.1038/sj.cgt.7700436; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jackman M, 2002, MOL BIOL CELL, V13, P1030, DOI 10.1091/mbc.01-07-0361; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lavia P, 1999, BIOESSAYS, V21, P221; Lentini L, 2002, NEOPLASIA, V4, P380, DOI 10.1038/sj.neo.7900256; Leung D, 2003, NAT BIOTECHNOL, V21, P687, DOI 10.1038/nbt826; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MAYOL X, 1993, ONCOGENE, V8, P2561; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Moore JD, 2001, BIOESSAYS, V23, P77, DOI 10.1002/1521-1878(200101)23:1<77::AID-BIES1010>3.3.CO;2-5; Moore WJ, 2002, CURR BIOL, V12, P1442, DOI 10.1016/S0960-9822(02)01076-X; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Mymryk JS, 1996, ONCOGENE, V13, P1581; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nishimoto T, 2000, BIOL CHEM, V381, P397, DOI 10.1515/BC.2000.052; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Paggi MG, 2001, CANCER RES, V61, P4651; Piboonniyom SO, 2003, CANCER RES, V63, P476; Pihan GA, 1998, CANCER RES, V58, P3974; Pockwinse SM, 1997, P NATL ACAD SCI USA, V94, P3022, DOI 10.1073/pnas.94.7.3022; Raff JW, 2002, TRENDS CELL BIOL, V12, P222, DOI 10.1016/S0962-8924(02)02268-7; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; Sang NL, 2002, FRONT BIOSCI, V7, pD407, DOI 10.2741/sang; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SCHMEICHEL KL, 2002, BREAST CANCER RES, V5, P59; Severino Anna, 2003, P297; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; SHENK T, 1991, ADV CANCER RES, V57, P47; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Snaith HA, 1996, J CELL SCI, V109, P3001; Starostik P, 1996, MOL CELL BIOL, V16, P3606; Stiegler P, 1998, J CELL BIOCHEM, P30; Stiegler P, 1998, CANCER RES, V58, P5049; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292; TEODORO JG, 1995, ONCOGENE, V11, P467; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Vasseur Sophie, 2003, Mol Cancer, V2, P19, DOI 10.1186/1476-4598-2-19; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Yoo GH, 2001, CLIN CANCER RES, V7, P1237; Zatsepina OV, 1999, J CELL SCI, V112, P455; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwerschke W, 2000, ADV CANCER RES, V78, P1	122	54	55	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6508	6516		10.1038/sj.onc.1206861	http://dx.doi.org/10.1038/sj.onc.1206861			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528275				2022-12-17	WOS:000185700700007
J	Ribatti, D; Guidolin, D; Conconi, MT; Nico, B; Baiguera, S; Parnigotto, PP; Vacca, A; Nussdorfer, GG				Ribatti, D; Guidolin, D; Conconi, MT; Nico, B; Baiguera, S; Parnigotto, PP; Vacca, A; Nussdorfer, GG			Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo	ONCOGENE			English	Article						adrenomedullin; angiogenesis; antiangiogenesis; chorioallantoic membrane; Matrigel; vinblastine	MICE LACKING; ANTIANGIOGENESIS; ABNORMALITIES; GROWTH	Adrenomedullin (ADM) is protumorigenic by stimulating tumor cell growth and angiogenesis. In this context, ADM is identified as a novel target for antiangiogenic therapy. In this study, we addressed the possibility that vinblastine (VBL), as demonstrated in other experimental conditions, may act as an angiostatic molecule in the angiogenic response induced by ADM in two assays, such as Matrigel tube formation in vitro and angiogenesis in the chick embryo chorioallantoic membrane (CAM) in vivo. When tested on Matrigel, ADM caused a morphogenetic effect. In fact, endothelial cells spread and aligned with each other to form branching anastomosing tubes with multicentric junctions that gave rise to a meshwork of capillary-like structures. When ADM was administered in the presence of VBL, the capillary-like tubes were interrupted, most cells were spherical, either isolated or aggregated in small clumps. In the CAM assay, ADM induced a strong angiogenic response, which was counteracted by the treatment with VBL. Overall, these observations implicate ADM as a promoter of tumor growth and a possible target for anticancer strategies, such as the use of VBL at very low, nontoxic doses. Nevertheless, the antiangiogenic acitivity of low-dose VBL deserves further investigation, alone or together with other antiangiogenic agents for the treatment of tumors characterized by enhanced angiogenesis.	Univ Bari, Sch Med, Dept Human Anat & Histol, Bari, Italy; Univ Padua, Sch Med, Sect Anat, Dept Human Anat & Physiol, Padua, Italy; Univ Bari, Sch Med, Dept Biomed Sci & Human Oncol, Sect Internal Med & Clin Oncol, Bari, Italy	Universita degli Studi di Bari Aldo Moro; University of Padua; Universita degli Studi di Bari Aldo Moro	Ribatti, D (corresponding author), Policlin, Dept Human Anat & Histol, Piazza Giulio Cesare 11, I-70124 Bari, Italy.	ribatti@anatomia.uniba.it	Vacca, Angelo/AAC-9558-2022; Baiguera, Silvia/AAC-4738-2022	Vacca, Angelo/0000-0002-4567-8216; Baiguera, Silvia/0000-0002-6669-7061; Guidolin, Diego/0000-0003-2133-3552				Belloni AS, 2001, HISTOL HISTOPATHOL, V16, P1263, DOI 10.14670/HH-16.1263; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; ElHafny B, 1997, BIOCHEM PHARMACOL, V53, P1735, DOI 10.1016/S0006-2952(97)00093-2; Fujita Y, 2002, INT J UROL, V9, P285, DOI 10.1046/j.1442-2042.2002.00469.x; Hague S, 2000, CLIN CANCER RES, V6, P2808; Ishikawa T, 2003, ONCOGENE, V22, P1238, DOI 10.1038/sj.onc.1206207; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Martinez A, 2002, J NATL CANCER I, V94, P1226; Minamino N, 2000, CLIN HEMORHEOL MICRO, V23, P95; Nikitenko LL, 2002, TRENDS PHARMACOL SCI, V23, P101, DOI 10.1016/S0165-6147(00)01983-0; Oehler MK, 2002, ONCOGENE, V21, P2815, DOI 10.1038/sj.onc.1205374; Presta M, 2002, LEUKEMIA, V16, P1490, DOI 10.1038/sj.leu.2402646; Presta M, 1999, CANCER RES, V59, P2417; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Ribatti Domenico, 1999, Neoplasia (New York), V1, P293, DOI 10.1038/sj.neo.7900038; Shindo T, 2001, CIRCULATION, V104, P1964, DOI 10.1161/hc4101.097111; Vacca A, 1999, BLOOD, V94, P4143, DOI 10.1182/blood.V94.12.4143.424k26_4143_4155; Vacca A, 2002, J HEMATOTH STEM CELL, V11, P103, DOI 10.1089/152581602753448577; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768	20	54	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6458	6461		10.1038/sj.onc.1206789	http://dx.doi.org/10.1038/sj.onc.1206789			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508526				2022-12-17	WOS:000185535300016
J	Barnes, H; Ackermann, EJ; van der Geer, P				Barnes, H; Ackermann, EJ; van der Geer, P			v-Src induces Shc binding to tyrosine 63 in the cytoplasmic domain of the LDL receptor-related protein 1	ONCOGENE			English	Article						phosphorylation; kinase; PTB domain; signal transduction	DENSITY-LIPOPROTEIN RECEPTOR; GROWTH-FACTOR; C-SRC; SIGNAL-TRANSDUCTION; ADAPTER PROTEINS; FAMILY KINASES; PHOSPHORYLATION; ASSOCIATION; ACTIVATION; PP60C-SRC	We recently observed that the LDL receptor-related protein 1 (LRP-1) is tyrosine phosphorylated in v-Src-transformed cells. Using a GST-fusion protein containing the cytoplasmic domain of LRP-1, we show that LRP-1 is a direct substrate for v-Src in vitro. To study LRP-1 phosphorylation in vivo, we constructed an LRP-1 mini-receptor composed of the beta chain linked at the aminoterminus to a Myc epitope (Myc-LRPbeta). When expressed together with v-Src, Myc-LRPbeta becomes phosphorylated on tyrosine. Of the four tyrosine residues present in the cytoplasmic domain of LRP-1, only Tyr 63 is phosphorylated by v-Src in vivo or in vitro. Using fibroblasts deficient in Src, Yes and Fyn, we were able to show that there are multiple kinases present in the cell that can phosphorylate LRP-1. Tyrosine-phosphorylated LRP-1 associates with Shc, a PTB and SH2 domain containing signaling protein that is involved in the activation of Ras. Binding of the purified Shc PTB domain to Tyr 63 containing peptides shows that the interaction between LRP-1 and She is direct. We found that DAB, a PTB domain containing signaling protein that is involved in signaling by LDL receptor-related proteins in the nervous system, did not bind to full-length LRP-1. Our observations suggest that LRP-1 may be involved in normal and malignant signal transduction through a direct interaction with Shc adaptor proteins.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Neurogenet Inc, La Jolla, CA 92037 USA	University of California System; University of California San Diego	van der Geer, P (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.	geer@ucsd.edu			NATIONAL CANCER INSTITUTE [R29CA078629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA78629] Funding Source: Medline; NIDDK NIH HHS [DK 07233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/0968-0004(96)10033-5; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; Gellner K, 1999, GENOME RES, V9, P251; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lai KMV, 2000, GENE DEV, V14, P1132; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; MARTIN GS, 1970, NATURE, V227, P1021, DOI 10.1038/2271021a0; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; NIMPF J, 1994, J BIOL CHEM, V269, P212; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cellbio.9.1.129; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	54	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2003	22	23					3589	3597		10.1038/sj.onc.1206504	http://dx.doi.org/10.1038/sj.onc.1206504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789267				2022-12-17	WOS:000183399200009
J	Heliez, C; Baricault, L; Barboule, N; Valette, A				Heliez, C; Baricault, L; Barboule, N; Valette, A			Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells	ONCOGENE			English	Article						paclitaxel; p21 localization and phosphorylation	CYCLE ARREST; MICROTUBULE DISRUPTION; MITOTIC EXIT; P53; APOPTOSIS; G(1); P21(WAF1); INHIBITOR; G1; OVEREXPRESSION	CKI p21 is a regulator of cellular responses to microtubule damage induced by drugs such as paclitaxel (PTX). It mediates the G1 4N arrest postactivation of the spindle assembly checkpoint and protects cancer cells against PTX-induced cytotoxicity. We demonstrated here that low doses of PTX that are unable to activate the spindle assembly checkpoint, upregulate p21 by a p53-dependent pathway and induce its translocation to the cytoplasm. This cytoplasmic accumulation of p21 resulted from an AKT-dependent p21 phosphorylation leading to an association of p21 with 14-3-3. Furthermore, the cytoplasmic p21 accumulation observed in PTX-treated cells was inhibited by LY 294002, a specific PI-3 kinase inhibitor or by the expression of a dominant-negative AKT mutant. However, the kinase activity of AKT was unchanged in PTX-treated cells, suggesting that low doses of PTX could regulate p21 phosphorylation via inhibition of its dephosphorylation. As a functional consequence, we found that cytoplasmic accumulation of the phosphorylated form of p21 prevents the inhibitory effect of p21, enabling these cells to escape to the p53-dependent GI/S and G2/M checkpoints.	Univ Toulouse 3, CNRS, UMR 5088, IFR 109,LBCMCP, F-31062 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Valette, A (corresponding author), Univ Toulouse 3, CNRS, UMR 5088, IFR 109,LBCMCP, Bat 4R3B1,118 Route Narbonne, F-31062 Toulouse 4, France.	valette@cict.fr	Baricault, Laurent/G-3396-2017					Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blajeski AL, 2002, J CLIN INVEST, V110, P91, DOI 10.1172/JCI200213275; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen JG, 2002, CANCER RES, V62, P1935; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gorospe M, 1999, GENE EXPRESSION, V7, P377; HARPER JW, 1993, CELL, V75, P805; Jordan MA, 1996, CANCER RES, V56, P816; Khan SH, 1998, CANCER RES, V58, P396; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Li WW, 1999, MOL PHARMACOL, V55, P1088, DOI 10.1124/mol.55.6.1088; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Stewart ZA, 1999, CANCER RES, V59, P3831; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Torres K, 1998, CANCER RES, V58, P3620; Trielli MO, 1996, J CELL BIOL, V135, P689, DOI 10.1083/jcb.135.3.689; Vikhanskaya F, 1998, EXP CELL RES, V241, P96, DOI 10.1006/excr.1998.4018; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zugasti O, 2001, MOL CELL BIOL, V21, P6706, DOI 10.1128/MCB.21.19.6706-6717.2001	33	54	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3260	3268		10.1038/sj.onc.1206409	http://dx.doi.org/10.1038/sj.onc.1206409			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761496				2022-12-17	WOS:000183040000008
J	Glassford, J; Soeiro, I; Skarell, SM; Banerji, L; Holman, M; Klaus, GGB; Kadowaki, T; Koyasu, S; Lam, EWF				Glassford, J; Soeiro, I; Skarell, SM; Banerji, L; Holman, M; Klaus, GGB; Kadowaki, T; Koyasu, S; Lam, EWF			BCR targets cyclin D2 via Btk and the p85 alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells	ONCOGENE			English	Article						BCR; Btk; p85 alpha; cyclin D2; PKC beta; Ca2+ flux; cell cycle	BRUTONS-TYROSINE-KINASE; XID-LIKE IMMUNODEFICIENCY; FACTOR-KAPPA-B; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-2; T-CELL; PHOSPHATIDYLINOSITOL 3-KINASE; MEDIATED PROLIFERATION; ADAPTER PROTEIN; ACTIVATION	The p85alpha subunit of PI3-K and Btk are two crucial components of the B-cell receptor (BCR) signalling pathway. In the present study, we showed that primary splenic B cells from p85alpha null and xid (Btk-deficient) mice fail to induce cyclin D2 expression and enter early G1, but not S phase of the cell cycle in response to BCR engagement. Furthermore, these Btk or p85alpha null B cells displayed increased cell death compared with wild type following BCR engagement. These findings are further confirmed by studies showing that specific pharmacological inhibitors of Btk (LFM-A13), PI3-K (LY294002 and Wortmannin) and PLCgamma (U73122) also block cyclin D2 expression and S phase entry following BCR stimulation, as well as triggering apoptosis. Collectively, these data provide evidence for the concept that the B-cell signalosome (p85alpha, Btk, BLNK and PLCgamma) is involved in regulating cyclin D2 expression in response to BCR engagement. PKC and intracellular calcium are two major downstream effectors of the B-cell signalosome and can be activated by PMA and ionomycin, respectively. In small resting (GO) B cells, costimulation with PMA and ionomycin, but not PMA or ionomycin alone, induces cyclin D2 expression and cell-cycle progression. Consistent with this, we also showed that the BCR-mediated cyclin D2 induction could be abolished by pretreatment of resting B cells with specific inhibitors of capacitative Ca2+ entry (SK&F 96365) or PKC (Go6850). Our present results lead us to propose a model in which the B-cell signalosome targets cyclin D2 via the Ca2+ and PKC-dependent signalling cascades to mediate cell-cycle progression in response to BCR engagement.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Canc Re UK Labs, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Sect Canc Cell Biol,Dept Canc Med, London W12 0NN, England; Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England; Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo 1608582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	Imperial College London; Imperial College London; MRC National Institute for Medical Research; University of Tokyo; Keio University; Japan Science & Technology Agency (JST)	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Canc Re UK Labs, Du Cane Rd, London W12 0NN, England.	eric.lam@ic.ac.uk	Lam, Eric W-F/AAW-8566-2020; Koyasu, Shigeo/J-5583-2015	Lam, Eric W-F/0000-0003-1274-3576; Koyasu, Shigeo/0000-0001-9585-3038				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Baba Y, 2001, P NATL ACAD SCI USA, V98, P2582, DOI 10.1073/pnas.051626198; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Brorson K, 1997, J IMMUNOL, V159, P135; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cariappa A, 2002, CURR OPIN IMMUNOL, V14, P241, DOI 10.1016/S0952-7915(02)00328-X; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; DeFranco AL, 2001, NAT IMMUNOL, V2, P482, DOI 10.1038/88669; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fu C, 1997, J BIOL CHEM, V272, P27362, DOI 10.1074/jbc.272.43.27362; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Glassford J, 2001, J BIOL CHEM, V276, P41040, DOI 10.1074/jbc.M105305200; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Gulbranson-Judge A, 1999, EUR J IMMUNOL, V29, P477, DOI 10.1002/(SICI)1521-4141(199902)29:02&lt;477::AID-IMMU477&gt;3.0.CO;2-V; HAHNER L, 1991, FASEB J, V5, P2466, DOI 10.1096/fasebj.5.10.1648524; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; Johnson-Leger C, 1998, J IMMUNOL, V161, P4618; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; King LB, 1999, J IMMUNOL, V162, P2655; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; Klaus GGB, 1997, EUR J IMMUNOL, V27, P2749, DOI 10.1002/eji.1830271102; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lam EWF, 1999, EUR J IMMUNOL, V29, P3380, DOI 10.1002/(SICI)1521-4141(199910)29:10<3380::AID-IMMU3380>3.0.CO;2-C; Lam EWF, 1998, J BIOL CHEM, V273, P10051, DOI 10.1074/jbc.273.16.10051; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Mahajan S, 1999, J BIOL CHEM, V274, P9587, DOI 10.1074/jbc.274.14.9587; Mahajan S, 2001, J BIOL CHEM, V276, P31216, DOI 10.1074/jbc.M104874200; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MUTHUKKUMAR S, 1993, EUR J IMMUNOL, V23, P2419, DOI 10.1002/eji.1830231007; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Okkenhaug K, 2002, SCIENCE, V297, P1031; Petro JB, 2002, FEBS LETT, V532, P57, DOI 10.1016/S0014-5793(02)03623-2; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Saijo K, 2002, J EXP MED, V195, P1647, DOI 10.1084/jem.20020408; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Solvason N, 2000, INT IMMUNOL, V12, P631, DOI 10.1093/intimm/12.5.631; Solvason N, 1998, J EXP MED, V187, P1081, DOI 10.1084/jem.187.7.1081; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSUKADA S, 1994, CURR OPIN IMMUNOL, V6, P623, DOI 10.1016/0952-7915(94)90151-1; Tsukada S, 2001, ADV IMMUNOL, V77, P123, DOI 10.1016/S0065-2776(01)77016-2; VIHINEN M, 1995, IMMUNOL TODAY, V16, P460, DOI 10.1016/0167-5699(95)80027-1; Vihinen M, 1997, NUCLEIC ACIDS RES, V25, P166, DOI 10.1093/nar/25.1.166; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Williams CD, 1997, BLOOD, V90, P194; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	71	54	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2248	2259		10.1038/sj.onc.1206425	http://dx.doi.org/10.1038/sj.onc.1206425			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700661				2022-12-17	WOS:000182231500004
J	Yamasaki, S; Nishida, K; Yoshida, Y; Itoh, M; Hibi, M; Hirano, T				Yamasaki, S; Nishida, K; Yoshida, Y; Itoh, M; Hibi, M; Hirano, T			Gab1 is required for EGF receptor signaling and the transformation by activated ErbB2	ONCOGENE			English	Article						EGF; Gab1; ERK; transformation; signal transduction	GROWTH-FACTOR RECEPTORS; CELL ANTIGEN RECEPTORS; DOCKING PROTEIN GAB1; TYROSINE KINASE; C-MET; EPITHELIAL MORPHOGENESIS; PLECKSTRIN HOMOLOGY; SEVENLESS PROTEIN; REGULATED KINASE; IN-VIVO	Grb2-associated binder-1 (Gab1) is a pleckstrin homology (PH) domain-containing adapter molecule that is believed to function downstream of receptors for growth factors and cytokines. We previously found that deficiency in the mouse Gab1 gene led to embryonic lethality and defects in ERK activation in response to growth factors and cytokines. Here, we established immortalized Gab1-/- cell lines and analysed roles of Gab1 in growth factor-mediated signaling and oncogenesis. EGF-dependent activation of c-Raf and Mek1/2, which function upstream of ERKs, was perturbed in Gab1-/- cells. EGF-mediated upregulation of GTP-bound form of Ras was also reduced in these cells. EGF-dependent GTP/GDP exchange activity for Ras was suppressed in the Gab1-/- cells and expression of a constitutively active Sos restored ERK activation in these cells, indicating that Gab1 functions upstream of Ras. Furthermore, activated form of ErbB2 (active ErbB2)-mediated transformation, such as colony formation in soft agar and tumor formation in nude mice, was strongly suppressed when the Gab1-/- cells were transfected with active ErbB2, whereas the active Sos efficiently induced transformation of Gab1-/- cells. The data show that Gab1 plays an essential role in EGF-receptor/ErbB-mediated cell proliferation and oncogenesis.	Osaka Univ, Grad Sch Med, Dept Mol Oncol C7, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Lab Dev Immunol, Suita, Osaka 5650871, Japan; RIKEN, RCAI, Lab Cytokine Signaling, Yokohama, Kanagawa, Japan	Osaka University; Osaka University; RIKEN	Hirano, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Oncol C7, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Hibi, Masahiko/I-6215-2014; Hirano, Toshio/C-8194-2009	Hibi, Masahiko/0000-0002-9142-4444; 				AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bausenwein BS, 2000, MECH DEVELOP, V90, P205, DOI 10.1016/S0925-4773(99)00252-X; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Herbst R, 1999, EMBO J, V18, P6950, DOI 10.1093/emboj/18.24.6950; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	37	54	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1546	1556		10.1038/sj.onc.1206284	http://dx.doi.org/10.1038/sj.onc.1206284			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629518				2022-12-17	WOS:000181411900012
J	Alcivar, A; Hu, SM; Tang, J; Yang, XL				Alcivar, A; Hu, SM; Tang, J; Yang, XL			DEDD and DEDD2 associate with caspase-8/10 and signal cell death	ONCOGENE			English	Article						DEDD; DEDD2; caspase-8/10; apoptosis	ACTIVATION; OLIGOMERIZATION; APOPTOSIS	An apoptotic signal triggered by cell surface death receptors is disseminated to intracellular compartments through protein-protein interactions mediated by conserved domains such as the death effector domain (DED). A unique family of single DED-containing proteins, including DEDD and DEDD2, is targeted to the nucleolus. However, the role of DEDD/DEDD2 in apoptosis remains less understood. Here we show that DEDD and DEDD2 are highly conserved in diverse species, and that they are potent inducers of apoptosis in various cell types. Deletion analysis indicates that both the N-terminal DED domain and the C-terminal region of DEDD2 can induce apoptosis. The cell death activity of this family appears to be related to their nuclear localization. DEDD and DEDD2 bind to two tandem DED-containing caspases, caspase -8 and -10, that are engaged by death receptors. Consistent with the nuclear localization of this family, caspase-8 translocates to the nucleus during CD95-induced apoptosis. DEDD and DEDD2 also readily associate with themselves and with each other. These results suggest that DEDD and DEDD2 may be important mediators for death receptors and that they may target caspases to the nucleus.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Yang, XL (corresponding author), 421 Curie Blvd,Rm 610 BRB2-3, Philadelphia, PA 19104 USA.		Hu, Shimin/H-3427-2019	Hu, Shimin/0000-0001-7110-3814	NATIONAL CANCER INSTITUTE [R01CA088868] Funding Source: NIH RePORTER; NCI NIH HHS [CA88868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Roth W, 2002, J BIOL CHEM, V277, P7501, DOI 10.1074/jbc.M110749200; Schickling O, 2001, CELL DEATH DIFFER, V8, P1157, DOI 10.1038/sj.cdd.4400928; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zhan Y, 2002, CELL DEATH DIFFER, V9, P439, DOI 10.1038/sj.cdd.4401038; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	11	54	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					291	297		10.1038/sj.onc.1206099	http://dx.doi.org/10.1038/sj.onc.1206099			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527898				2022-12-17	WOS:000180322400014
J	Zhao, YL; Piao, CQ; Hei, TK				Zhao, YL; Piao, CQ; Hei, TK			Downregulation of Betaig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells	ONCOGENE			English	Article						asbestos; Betaig-h3; tumor suppression; human bronchial epithelial cells	GROWTH-FACTOR-BETA; SMOOTH-MUSCLE; MALIGNANT MESOTHELIOMA; EXTRACELLULAR-MATRIX; MAMMALIAN-CELLS; IN-VITRO; BETA-IG-H3; LOCALIZATION; EXPRESSION; PROTEIN	Although Betaig-h3 gene has been suggested to modulate cell adhesion and tumor formation, its physiological functions are not well understood. Using human papillomavirus immortalized human bronchial epithelial (BEP2D) cells, we found that Betaig-h3 expression was markedly decreased in asbestos-induced tumorigenic cells. Fusion of tumorigenic and control BEP2D cells resulted in the recovery of Betaig-h3 gene expression to control level and the loss of tumorigenic phenotype. Furthermore, ectopic expression of Betaig-h3 gene in asbestos-induced tumorigenic cells inhibited cell growth in vitro, anchorage independent phenotype, as well as tumorigenicity in nude mice. Betaig-h3 gene is ubiquitously expressed in various normal human tissues, with the exception of the brain, where there is little or no expression. In contrast, there was a decrease or absence in expression of the Betaig-h3 gene in 14 human tumor cell lines of diverse histological types examined, when compared with normal human cells or tissues. The result strongly suggests that loss of Betaig-h3 expression is a frequent event in human cancer and causally related to acquisition of tumorigenic phenotype in asbestos-treated BEP2D cells.	Columbia Univ, Coll Phys & Surg, Joseph Mailman Sch Publ Hlth, Ctr Radiol Res, New York, NY 10032 USA; Columbia Univ, Joseph Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA	Columbia University; Columbia University	Zhao, YL (corresponding author), Columbia Univ, Coll Phys & Surg, Joseph Mailman Sch Publ Hlth, Ctr Radiol Res, VC 11-128,630 W 168th St, New York, NY 10032 USA.	yz93@columbia.edu			NCI NIH HHS [CA49062] Funding Source: Medline; NIEHS NIH HHS [P30 ES 09089, ES07890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089, R01ES007890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Billings PC, 2000, AM J RESP CELL MOL, V22, P352, DOI 10.1165/ajrcmb.22.3.3732; Billings PC, 2000, J CELL BIOCHEM, V79, P261, DOI 10.1002/1097-4644(20001101)79:2<261::AID-JCB90>3.0.CO;2-#; Brezinova J, 2000, CANCER GENET CYTOGEN, V117, P45, DOI 10.1016/S0165-4608(99)00142-9; Brody AR, 1997, ENVIRON HEALTH PERSP, V105, P1165, DOI 10.2307/3433527; Bron AJ, 2000, CORNEA, V19, P699, DOI 10.1097/00003226-200009000-00015; FEARON ER, 1995, CANCER SURV, V24, P3; FITZPATRICK DR, 1995, AM J RESP CELL MOL, V12, P455, DOI 10.1165/ajrcmb.12.5.7742009; Genini M, 1996, INT J CANCER, V66, P571; GERWIN BI, 1994, AM J RESP CELL MOL, V11, P507, DOI 10.1165/ajrcmb.11.5.7946379; HEI TK, 1992, CANCER RES, V52, P6305; Hei TK, 2000, INHAL TOXICOL, V12, P141, DOI 10.1080/08958378.2000.11463207; Hei TK, 1997, ENVIRON HEALTH PERSP, V105, P1085, DOI 10.2307/3433513; HEINTZ NH, 1993, P NATL ACAD SCI USA, V90, P3299, DOI 10.1073/pnas.90.8.3299; Jagirdar J, 1997, ENVIRON HEALTH PERSP, V105, P1197, DOI 10.2307/3433532; Jaurand MC, 1997, ENVIRON HEALTH PERSP, V105, P1073, DOI 10.2307/3433512; Kamp DW, 1999, THORAX, V54, P638, DOI 10.1136/thx.54.7.638; Kane AB, 1996, IARC SCI PUBL, P11; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Mossman BT, 1996, CANCER INVEST, V14, P466, DOI 10.3109/07357909609018904; Mossman BT, 1997, ENVIRON HEALTH PERSP, V105, P1121, DOI 10.2307/3433519; Murthy SS, 1999, J CELL PHYSIOL, V180, P150, DOI 10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H; Ni ZY, 2000, MUTAT RES-GEN TOX EN, V468, P87, DOI 10.1016/S1383-5718(00)00043-7; Pass HI, 1996, J CELL BIOCHEM, P142; Peralta RC, 1998, INT J CANCER, V78, P600, DOI 10.1002/(SICI)1097-0215(19981123)78:5<600::AID-IJC12>3.0.CO;2-1; PERDUE TD, 1994, J HISTOCHEM CYTOCHEM, V42, P1061, DOI 10.1177/42.8.8027525; Piao CQ, 2001, ONCOGENE, V20, P7301, DOI 10.1038/sj.onc.1204908; Robledo R, 1999, J CELL PHYSIOL, V180, P158, DOI 10.1002/(SICI)1097-4652(199908)180:2<158::AID-JCP3>3.0.CO;2-R; Salih HR, 2001, EUR J MED RES, V6, P323; Schenker T, 1998, EXP CELL RES, V239, P161, DOI 10.1006/excr.1997.3896; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Suzuki M, 2001, INT J MOL MED, V8, P43; WILLEY JC, 1991, CANCER RES, V51, P5370; Wu XF, 1998, INT J CANCER, V79, P490, DOI 10.1002/(SICI)1097-0215(19981023)79:5<490::AID-IJC8>3.3.CO;2-D; Xu A, 1999, CANCER RES, V59, P5922; Zanella CL, 1996, CANCER RES, V56, P5334; Zhao YL, 2000, CARCINOGENESIS, V21, P2005, DOI 10.1093/carcin/21.11.2005	37	54	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7471	7477		10.1038/sj.onc.1205891	http://dx.doi.org/10.1038/sj.onc.1205891			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386809				2022-12-17	WOS:000178618200002
J	Dai, W; Wang, Q; Traganos, F				Dai, W; Wang, Q; Traganos, F			Polo-like kinases and centrosome regulation	ONCOGENE			English	Review						Polo; Polo-like kinases; centrosome; spindle pole body; microtubule organization center	CAENORHABDITIS-ELEGANS CONTAINS; SACCHAROMYCES-CEREVISIAE CDC5; PROTEIN-KINASE; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; SERINE/THREONINE KINASE; BODY DUPLICATION; BIPOLAR SPINDLE; XENOPUS-LAEVIS; GOLGI-COMPLEX		New York Med Coll, Brander Canc Inst, Dept Med, Valhalla, NY 10595 USA	New York Medical College	Dai, W (corresponding author), New York Med Coll, Brander Canc Inst, Dept Med, Valhalla, NY 10595 USA.	wei_dai@nymc.edu	Traganos, Frank/B-8021-2012					Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Blangy A, 1997, J BIOL CHEM, V272, P19418, DOI 10.1074/jbc.272.31.19418; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Chabin-Brion K, 2001, MOL BIOL CELL, V12, P2047, DOI 10.1091/mbc.12.7.2047; Chase D, 2000, DNA SEQUENCE, V11, P327, DOI 10.3109/10425170009033251; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; DESCAMPS S, 2001, SCI STKE, pE1; Donaldson MM, 2001, J CELL BIOL, V153, P663, DOI 10.1083/jcb.153.4.663; Donaldson MM, 2001, J CELL SCI, V114, P2357; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Duncan PI, 2001, EXP CELL RES, V270, P78, DOI 10.1006/excr.2001.5333; Feng Y, 2001, CELL GROWTH DIFFER, V12, P29; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Frenz LM, 2000, J CELL SCI, V113, P3399; Fry AM, 2000, J CELL SCI, V113, P1973; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; GOLAN A, 2002, IN PRESS J BIOL CHEM; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Gonzalez C, 1998, CHROMOSOMA, V107, P452, DOI 10.1007/s004120050329; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hinchcliffe EH, 2001, CURR BIOL, V11, pR698, DOI 10.1016/S0960-9822(01)00412-2; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lange BMH, 2000, EMBO J, V19, P1252, DOI 10.1093/emboj/19.6.1252; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Luca FC, 2001, MOL CELL BIOL, V21, P6972, DOI 10.1128/MCB.21.20.6972-6983.2001; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; Menssen R, 2001, CURR BIOL, V11, P345, DOI 10.1016/S0960-9822(01)00095-1; Mulvihill DP, 1999, MOL BIOL CELL, V10, P2771, DOI 10.1091/mbc.10.8.2771; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ouyang B, 1999, DNA SEQUENCE, V10, P109, DOI 10.3109/10425179909008427; Riparbelli MG, 2000, J CELL SCI, V113, P3341; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; SCHILD D, 1980, GENETICS, V96, P859; Schutz AR, 1997, J CELL BIOL, V136, P969, DOI 10.1083/jcb.136.5.969; Seemann J, 2002, SCIENCE, V295, P848, DOI 10.1126/science.1068064; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; SUNKEL CE, 1988, J CELL SCI, V89, P25; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wianny F, 1998, CHROMOSOMA, V107, P430, DOI 10.1007/s004120050327; Winey M, 1999, CURR BIOL, V9, pR449, DOI 10.1016/S0960-9822(99)80279-6; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200	64	54	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2002	21	40					6195	6200		10.1038/sj.onc.1205710	http://dx.doi.org/10.1038/sj.onc.1205710			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214249				2022-12-17	WOS:000177840500008
J	Kogerman, P; Krause, D; Rahnama, F; Kogerman, L; Unden, AB; Zaphiropoulos, PG; Toftgard, R				Kogerman, P; Krause, D; Rahnama, F; Kogerman, L; Unden, AB; Zaphiropoulos, PG; Toftgard, R			Alternative first exons of PTCH1 are differentially regulated in vivo and may confer different functions to the PTCH1 protein	ONCOGENE			English	Article						PTCH1 tumour suppressor gene; alternative first exons; SHH; Smoh	BASAL-CELL CARCINOMA; STEROL-SENSING DOMAIN; SONIC HEDGEHOG; HUMAN HOMOLOG; VESICULAR TRAFFICKING; SOMATIC MUTATIONS; PATCHED PROTEIN; GENE; RECEPTOR; REGION	The PTCH1 gene is a human tumour suppressor gene frequently mutated in basal cell carcinoma (BCC) and several other tumour types. It encodes a receptor for soluble factors of the hedgehog family. Binding of hedgehog to the receptor relieves its inhibitory action on the transmembrane co-receptor Smoh. In this study we describe alternative first exons of the PTCH1 tumour suppressor gene and show that they are differentially regulated in normal tissues, exon 1B being expressed at very low levels and the major mRNA species containing exon 1 or 1A. Exon 1B transcripts were found to be specifically upregulated in nodular BCCs. The different PTCH1 transcripts all encode proteins that interact with Smoh in doubly transfected cells. Furthermore, functional assays demonstrated that whereas all PTCH1 isoforms can inhibit the activity of SHH, only the PTCH1B isoform is capable of fully inhibiting Smoh activity. The results indicate that in tumour cells the PTCH1B promoter is specifically activated and importantly, that the N-terminal part of PTCH1 including exon 1B is required for full inhibition of Smoh signaling but not for physical interaction with Smoh.	Karolinska Inst, Novum, Dept Biosci, Huddinge, Sweden; Tallinn Univ Technol, NICPB, EE-200108 Tallinn, Estonia; Tallinn Univ Technol, Gene Technol Ctr, EE-200108 Tallinn, Estonia	Karolinska Institutet; National Institute of Chemical Physics & Biophysics (NICPB); Tallinn University of Technology; Tallinn University of Technology	Toftgard, R (corresponding author), Karolinska Inst, Novum, Dept Biosci, Huddinge, Sweden.	Rune.Toftgard@cnt.ki.se	Kogerman, Priit/B-6333-2008	Zaphiropoulos, Peter/0000-0003-4298-3861				Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Incardona JP, 2000, P NATL ACAD SCI USA, V97, P12044, DOI 10.1073/pnas.220251997; Ingham PW, 2000, CURR BIOL, V10, P1315, DOI 10.1016/S0960-9822(00)00755-7; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 2000, MOL CELL, V6, P467, DOI 10.1016/S1097-2765(00)00045-9; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Martin V, 2001, CURR BIOL, V11, P601, DOI 10.1016/S0960-9822(01)00178-6; McGarvey TW, 1998, ONCOGENE, V17, P1167, DOI 10.1038/sj.onc.1202045; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; RUIZ I, 1997, CELL, V90, P193; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Strutt H, 2001, CURR BIOL, V11, P608, DOI 10.1016/S0960-9822(01)00179-8; Unden AB, 1997, CANCER RES, V57, P2336; Vorechovsky I, 1997, CANCER RES, V57, P4677; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wang XQ, 2001, J BIOL CHEM, V276, P1311, DOI 10.1074/jbc.M005191200; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Zaphiropoulos PG, 1996, DNA CELL BIOL, V15, P1049, DOI 10.1089/dna.1996.15.1049	22	54	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6007	6016		10.1038/sj.onc.1205865	http://dx.doi.org/10.1038/sj.onc.1205865			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203113				2022-12-17	WOS:000177671300004
J	Nozell, S; Chen, XB				Nozell, S; Chen, XB			p21B, a variant of p21(Waf1/Cip1), is induced by the p53 family	ONCOGENE			English	Article						p53; p2l; p218; apoptosis	CELL-CYCLE ARREST; DNA-DAMAGE; BINDING PROTEIN; GENE; APOPTOSIS; P73; INHIBITOR; SIGNALS; IDENTIFICATION; TRANSCRIPT	Alternative splicing or expression from an alternate promoter can produce variants of a gene. To determine whether the p21(Waf1/Cip1) locus is regulated by these mechanisms, we searched for and found two transcripts, p21B and p21C, that are expressed from an alternate promoter in the first intron of the p21 gene. While p21C encodes the p21. cyclin-dependent kinase inhibitor, p21B encodes a novel protein and the transcript is ubiquitously expressed in 16 human tissues tested. Like p21, both p21B and p21C are induced by DNA damage, p53, and other p53 family members through a proximal p53 response element in the promoter of p21B and p21C. However, unlike p21, which induces cell cycle arrest, we found that overexpression of p21B induces apoptosis. These findings indicate that the p21 locus expresses at least two structurally distinct, but functionally related, variants of the p21 gene from discrete promoters.	Univ Alabama, Dept Cell Biol, UAB, Ctr Comprehens Canc,MCLM 656, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), Univ Alabama, Dept Cell Biol, UAB, Ctr Comprehens Canc,MCLM 656, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [R01CA076069, R01CA081237, R29CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [CA 81237, CA 76069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Benedict WF, 1999, ONCOGENE, V18, P1197, DOI 10.1038/sj.onc.1202452; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cain C, 2000, J BIOL CHEM, V275, P39944, DOI 10.1074/jbc.M002509200; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; DURO D, 1995, ONCOGENE, V11, P21; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARPER JW, 1993, CELL, V75, P805; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; MAO L, 1995, CANCER RES, V55, P2995; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; QUELLE DE, 1995, CELL, V83, P993; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; STONE S, 1995, CANCER RES, V55, P2988; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Tsubari M, 1997, CANCER RES, V57, P2966; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1998, CANCER RES, V58, P5061; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	46	54	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1285	1294		10.1038/sj.onc.1205191	http://dx.doi.org/10.1038/sj.onc.1205191			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850848				2022-12-17	WOS:000173729400016
J	Ljungman, M; O'Hagan, HM; Paulsen, MT				Ljungman, M; O'Hagan, HM; Paulsen, MT			Induction of ser15 and lys382 modifications of p53 by blockage of transcription elongation	ONCOGENE			English	Article						RNA polymerase II; inhibitors; DNA damage; UV light; Xeroderma pigmentosum; Cockayne's syndrome	RNA-POLYMERASE-II; DAMAGE-INDUCED PHOSPHORYLATION; CARBOXYL-TERMINAL DOMAIN; LIGHT-INDUCED APOPTOSIS; RING-FINGER DOMAIN; DNA-DAMAGE; ULTRAVIOLET-RADIATION; NUCLEAR EXPORT; UV-RADIATION; CELL-CYCLE	Blockage of transcription has been shown to induce the tumor suppressor p53 in human cells. We here show that RNA synthesis inhibitors blocking the phosphorylation of the carboxyl terminal domain (CTD) of RNA polymerase II, such as DRB and H7, induced rapid nuclear accumulation of p53 proteins that were not phosphorylated at ser15 or acetylated at lys382. In contrast, agents that inhibit the elongation phase of transcription, such as UV light, camptothecin or actinomycin D, induced the accumulation of nuclear p53 proteins that were modified at both of these sites. Furthermore, using a panel of DNA repair-deficient cells we show that persistent DNA lesions in the transcribed strand of active genes are responsible for the induction of the ser15 and lys382 modifications following UV-irradiation. We conclude that inhibition of transcription is sufficient for the accumulation of p53 in the nucleus regardless of whether the ser15 site of p53 is phosphorylated or not. Importantly, blockage of the elongation phase of transcription triggers a distinct signaling pathway leading to p53 modifications on ser15 and lys382. We propose that the elongating RNA polymerase complex may act as a sensor of DNA damage and as an integrator of cellular stress signals.	Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ljungman, M (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, 4306 CCGC,150 E Med Ctr Dr, Ann Arbor, MI 48109 USA.			O'Hagan, Heather/0000-0001-9750-5088	NATIONAL CANCER INSTITUTE [R01CA082376] Funding Source: NIH RePORTER; NCI NIH HHS [CA 82376-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1998, EXP CELL RES, V244, P54, DOI 10.1006/excr.1998.4193; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHRISTIANS FC, 1994, MUTAT RES, V323, P179, DOI 10.1016/0165-7992(94)90031-0; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; FISCELLA M, 1993, ONCOGENE, V8, P1519; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Groulx I, 2000, J BIOL CHEM, V275, P8991, DOI 10.1074/jbc.275.12.8991; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hirose Y, 2000, GENE DEV, V14, P1415; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Ljungman M, 1996, CARCINOGENESIS, V17, P31, DOI 10.1093/carcin/17.1.31; Lu X, 1996, ONCOGENE, V13, P413; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 2001, MUTAT RES-DNA REPAIR, V485, P93, DOI 10.1016/S0921-8777(00)00064-1; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Poele RHT, 1999, ONCOGENE, V18, P5765, DOI 10.1038/sj.onc.1202961; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883	56	54	54	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					5964	5971		10.1038/sj.onc.1204734	http://dx.doi.org/10.1038/sj.onc.1204734			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593403				2022-12-17	WOS:000171056300003
J	Wong, S; Witte, ON				Wong, S; Witte, ON			Modeling Philadelphia chromosome positive leukemias	ONCOGENE			English	Review						BCR-ABL; mouse model; leukemia	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; SEQUENCE-BINDING-PROTEIN; P210 BCR-ABL; COLONY-STIMULATING FACTOR; CHRONIC MYELOCYTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENE; MYELOPROLIFERATIVE DISEASE	The Ph chromosome has been genetically linked to CML and ALL. Its chimeric fusion gene product, BCR-ABL, can generate leukemia in mice. This review will discuss selected model systems developed to study BCR-ABL induced leukemia and focuses on what we have learned about the human disease from these models. Five main experimental approaches will be discussed including: (i) Reconstitution of mice with bone marrow cells retrovirally transduced with BCR-ABL; (ii) Transgenic mice expressing BCR-ABL; (iii) Knock-in mice with BCR-ABL expression driven from the endogenous ber locus; (iv) Development of CML-like disease in mice with loss of function mutations in heterologous genes; and (v) ES in vitro hematopoietic differentiation coupled with regulated BCR-ABL expression.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Witte, ON (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, 675 Charles E Young Dr S,Room 5-748 MRL Bldg, Los Angeles, CA 90095 USA.	owen@microbio.ucla.edu						ABELSON HT, 1970, CANCER RES, V30, P2213; Afar DEH, 1997, IMMUNITY, V6, P773, DOI 10.1016/S1074-7613(00)80452-5; AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Anderson SM, 1996, BLOOD, V87, P238; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; Cambier N, 1999, ONCOGENE, V18, P343, DOI 10.1038/sj.onc.1202302; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; Chung SW, 1996, ONCOGENE, V13, P2397; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLARK SS, 1993, J VIROL, V67, P6033, DOI 10.1128/JVI.67.10.6033-6046.1993; CLARKSON B, 1993, LEUKEMIA, V7, P1683; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; Colleoni GWB, 1996, AM J HEMATOL, V53, P277, DOI 10.1002/1096-8652(199612)53:4<277::AID-AJH2830530402>3.0.CO;2-Z; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; DEISSEROTH AB, 1994, BLOOD, V83, P3068, DOI 10.1182/blood.V83.10.3068.3068; Delforge M, 1999, BLOOD, V93, P284, DOI 10.1182/blood.V93.1.284.401k31_284_292; DIEKMANN L, 1994, ACTA HAEMATOL-BASEL, V92, P169; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1084; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ENGELMAN A, 1987, P NATL ACAD SCI USA, V84, P8021, DOI 10.1073/pnas.84.22.8021; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Fabbiano F, 1998, HAEMATOLOGICA, V83, P856; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FIALKOW PJ, 1967, P NATL ACAD SCI USA, V58, P1468, DOI 10.1073/pnas.58.4.1468; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; Ghaffari S, 1999, LEUKEMIA, V13, P1200, DOI 10.1038/sj.leu.2401467; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gross AW, 1999, MOL CELL BIOL, V19, P6918; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Haferlach T, 1997, BRIT J HAEMATOL, V99, P452, DOI 10.1046/j.1365-2141.1997.4203237.x; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HAWLEY RG, 1994, GENE THER, V1, P136; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; Kabarowski JHS, 2000, STEM CELLS, V18, P399, DOI 10.1002/stem.180399; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KANTARJIAN HM, 1991, BLOOD, V78, P2411, DOI 10.1182/blood.V78.9.2411.bloodjournal7892411; Kasprzyk A, 1999, LEUKEMIA, V13, P2000, DOI 10.1038/sj.leu.2401580; KELLIHER M, 1991, MOL CELL BIOL, V11, P4710, DOI 10.1128/MCB.11.9.4710; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, BLOOD, V70, P1584; LAZARIDOU A, 1994, LEUKEMIA, V8, P454; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; LI X, 1994, LEUKEMIA LYMPHOMA, V13, P65, DOI 10.3109/10428199409052678; Lim YM, 2000, P NATL ACAD SCI USA, V97, P12233, DOI 10.1073/pnas.210253497; LIU JX, 1993, ONCOGENE, V8, P101; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; LU D, 1993, BLOOD, V82, P1257; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANO H, 1990, ONCOGENE, V5, P1781; MARTIAT P, 1990, LEUKEMIA, V4, P751; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Maru Y, 1996, FEBS LETT, V379, P244, DOI 10.1016/0014-5793(95)01518-3; McCormack MP, 1999, ONCOGENE, V18, P7190, DOI 10.1038/sj.onc.1203226; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MELO JV, 1994, LEUKEMIA, V8, P208; Melo JV, 1996, BRIT J HAEMATOL, V92, P684, DOI 10.1046/j.1365-2141.1996.00350.x; MELO JV, 1993, BLOOD, V81, P2488; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MITANI K, 1990, BRIT J HAEMATOL, V76, P221, DOI 10.1111/j.1365-2141.1990.tb07875.x; MITELMAN F, 1993, LEUKEMIA LYMPHOMA, V11, P11, DOI 10.3109/10428199309047856; MOLLINEDO F, 1991, BIOCHEM J, V273, P477, DOI 10.1042/bj2730477; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; NOWELL PC, 1960, SCIENCE, V132, P1497; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Pajor L, 2000, LEUKEMIA, V14, P1122, DOI 10.1038/sj.leu.2401794; Pane F, 1996, BLOOD, V88, P2410, DOI 10.1182/blood.V88.7.2410.bloodjournal8872410; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Peters DG, 2001, BLOOD, V97, P1404, DOI 10.1182/blood.V97.5.1404; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RASKIND WH, 1987, ADV CANCER RES, V49, P127, DOI 10.1016/S0065-230X(08)60796-4; Reichert A, 2001, BLOOD, V97, P1399, DOI 10.1182/blood.V97.5.1399; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; ROVIRA A, 1995, ANN HEMATOL, V70, P129; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SAGLIO G, 1990, BLOOD, V76, P1819; Salloukh HF, 2000, ONCOGENE, V19, P4362, DOI 10.1038/sj.onc.1203804; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SECKERWALKER LM, 1988, BLOOD, V72, P784; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; SHARF R, 1995, J BIOL CHEM, V270, P13063, DOI 10.1074/jbc.270.22.13063; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Takahashi N, 1998, BLOOD, V92, P4758, DOI 10.1182/blood.V92.12.4758; Tauchi T, 1998, INT J ONCOL, V12, P1269; Thome KC, 1997, J VIROL, V71, P8149, DOI 10.1128/JVI.71.11.8149-8156.1997; Tiribelli M, 2000, BLOOD, V95, P4019; Unnikrishnan I, 1999, MOL CELL BIOL, V19, P4825, DOI 10.1128/mcb.19.7.4825; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Voncken JW, 1998, ONCOGENE, V16, P2029, DOI 10.1038/sj.onc.1201730; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; VONCKEN JW, 1992, CANCER RES, V52, P4534; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; WILSON G, 1997, BLOOD, V88, P2410; WilsonRawls J, 1996, CANCER RES, V56, P3426; WITTE ON, 1980, P NATL ACAD SCI-BIOL, V77, P4993, DOI 10.1073/pnas.77.8.4993; WITTE ON, 1981, J VIROL, V39, P870, DOI 10.1128/JVI.39.3.870-878.1981; YOFFE G, 1987, EXP HEMATOL, V15, P725; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Zhang XW, 2001, BLOOD, V97, P277, DOI 10.1182/blood.V97.1.277; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001; Zhao RC, 2001, BLOOD, V97, P2406, DOI 10.1182/blood.V97.8.2406; Zou XM, 2000, MOL CELL BIOL, V20, P628, DOI 10.1128/MCB.20.2.628-633.2000	152	54	63	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5644	5659		10.1038/sj.onc.1204638	http://dx.doi.org/10.1038/sj.onc.1204638			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607816				2022-12-17	WOS:000170887500007
J	Roopchand, DE; Lee, JM; Shahinian, S; Paquette, D; Bussey, H; Branton, PE				Roopchand, DE; Lee, JM; Shahinian, S; Paquette, D; Bussey, H; Branton, PE			Toxicity of human adenovirus E4orf4 protein in Saccharomyces cerevisiae results from interactions with the Cdc55 regulatory B subunit of PP2A	ONCOGENE			English	Article						protein phosphatase 2A; CDC55; adenovirus; E4orf4	PHOSPHATASE 2A; P53-INDEPENDENT APOPTOSIS; TUMOR-ANTIGENS; EARLY REGION-4; A-SUBUNIT; ACTIN CYTOSKELETON; TRANSFORMED-CELLS; DNA-REPLICATION; E1A PROTEINS; YEAST	The E4orf4 protein of human adenovirus induces p53-independent apoptosis, a process that may promote cell death and viral spread. When expressed alone, E4orf4 kills transformed cells but not normal human cells. The only clear target of E4orf4 in mammalian cells is the Ba (B55) subunit of protein phosphatase 2A (PP2A), a member of one of three classes of regulatory B subunits. Here we report the effects of E4orf4 in Saccharomyces cerevisiae, which encodes two PP2A regulatory B subunits, CDC55 and RTS1, that share homology with mammalian B and B' subunits, respectively. E4orf4 expression was found to be toxic in yeast, resulting in the accumulation of cells in G2/M phase that failed to grow upon removal of E4orf4. E4orf4-expressing yeast also displayed an elongated cell morphology similar to cdc55 deletion strains. E4orf4 required CDC55 to elicit its effect, whereas RTS1 was dispensable. The recruitment of the PP2A holoenzyme by E4orf4 was entirely dependent on Cdc55. These studies indicate that E4orf4-induced apoptosis in mammalian cells and cell death in yeast require functional interactions with B-type subunits of PP2A. However, some inhibition of growth by E4orf4 was observed in the cdc55 strain and with an E4orf4 mutant that fails to interact with Cdc55, indicating that E4orf4 may possess a second Cdc55-independent function affecting cell growth.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; GeminX Biotechnol Inc, Montreal, PQ H2W 2M9, Canada	McGill University; McGill University; McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Bldg,3655 Promenade Sir William Osle, Montreal, PQ H3G 1Y6, Canada.	branton@med.mcgill.ca						CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DIEN BS, 1994, METHOD CELL BIOL, V42, P457; Evans DRH, 1997, GENETICS, V145, P227; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; Lechward K, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1373; LIN FC, 1995, EMBO J, V14, P2745, DOI 10.1002/j.1460-2075.1995.tb07275.x; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 1996, J VIROL, V70, P6207, DOI 10.1128/JVI.70.9.6207-6215.1996; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; McCright B, 1996, GENOMICS, V36, P168, DOI 10.1006/geno.1996.0438; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MULLER U, 1992, J VIROL, V66, P5867; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; Shu YM, 1997, MOL CELL BIOL, V17, P3242, DOI 10.1128/MCB.17.6.3242; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; TEODORO JG, 1995, ONCOGENE, V11, P467; Tollefson AE, 1996, VIROLOGY, V220, P152, DOI 10.1006/viro.1996.0295; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; Zha HB, 1996, MOL CELL BIOL, V16, P6494; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	59	54	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5279	5290		10.1038/sj.onc.1204693	http://dx.doi.org/10.1038/sj.onc.1204693			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536041				2022-12-17	WOS:000170575500004
J	Schuringa, JJ; Wojtachnio, K; Hagens, W; Vellenga, E; Buys, CHCM; Hofstra, R; Kruijer, W				Schuringa, JJ; Wojtachnio, K; Hagens, W; Vellenga, E; Buys, CHCM; Hofstra, R; Kruijer, W			MEN2A-RET-induced cellular transformation by activation of STAT3	ONCOGENE			English	Article						Ret tyrosine kinase receptor; MEN2A; STAT3; cellular transformation	RECEPTOR TYROSINE KINASE; RET PROTOONCOGENE; DOCKING SITE; SIGNAL-TRANSDUCTION; GENE; MUTATIONS; ASSOCIATION; SRC; IDENTIFICATION; REQUIRES	The MEN2A oncogene encodes for a constitutive active member of the RET receptor tyrosine kinase family. Here, we report that MEN2A-RET activates Signal Transducer and Activator of Transcription 3 (STAT3) via two YxxV/Q STAT3 docking sites, Tyr752 and Tyr928. MEN2A-RET induces both Tyr705 and Ser727 phosphorylation of STAT3, and STAT3 serine phosphorylation is required for its maximal transcriptional activity. Stable NIH3T3 cell lines expressing both MEN2A-RET and STAT3 alpha but not STAT3 beta, are characterized by enhanced proliferation and cyclin-D1 promoter activity, and enhanced growth in soft agar. These data indicate that malignant cell growth induced by MEN2A-RET involves its activation of STAT3.	Univ Groningen, Biol Ctr Haren, Dept Dev Genet, NL-9751 NN Haren, Netherlands; Univ Groningen, Dept Hematol, NL-9751 NN Haren, Netherlands; Univ Groningen, Dept Med Genet, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen; University of Groningen	Kruijer, W (corresponding author), Univ Groningen, Biol Ctr Haren, Dept Dev Genet, Kerklaan 30, NL-9751 NN Haren, Netherlands.	W.Kruijer@biol.rug.nl		Hofstra, Robert/0000-0001-7498-3829				Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DELELLIS RA, 1995, LAB INVEST, V72, P494; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; GOODFELLOW PJ, 1995, J NATL CANCER I, V87, P1515, DOI 10.1093/jnci/87.20.1515; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HERBER B, 1994, ONCOGENE, V9, P1295; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Ponder BAJ, 1999, CANCER RES, V59, p1736S; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuringa JJ, 2000, BLOOD, V95, P3765, DOI 10.1182/blood.V95.12.3765; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Taraviras S, 1999, DEVELOPMENT, V126, P2785; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	51	54	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5350	5358		10.1038/sj.onc.1204715	http://dx.doi.org/10.1038/sj.onc.1204715			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536047				2022-12-17	WOS:000170575500010
J	Ahmad, N; Kalka, K; Mukhtar, H				Ahmad, N; Kalka, K; Mukhtar, H			In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy	ONCOGENE			English	Article						PDT; EGFR; Shc; cell cycle; apoptosis	ACTIVATED PROTEIN-KINASE; MEDIATED APOPTOSIS; INDUCED ABLATION; CARCINOMA-CELLS; MOUSE SKIN; HELA-CELLS; TUMORS; A431; INVOLVEMENT; PROGRESSION	PDT, a new therapeutic procedure for the management of many malignant conditions including skin cancer, involves the administration of a photosensitizing compound followed by illumination of the lesion with visible light, We earlier showed an involvement of: (i) WAF1/ p21-cyclins (D1 and E)-cdk (2 and 6) network; and (ii) Rb/E2F-DP machinery during silicon phthalocyanine (Pc4)-PDT-mediated cell cycle dysregulation and apoptosis of human epidermoid carcinoma (A431) cells, Here, we investigated the involvement of EGFR-pathway during antiproliferative responses of Pc4-PDT in A431 cells and during ablation of murine skin papillomas. Pc4-PDT of A431 cells was found to result in a time-dependent down-modulation of the protein expression and phosphorylation of EGFR and Shc (an immediate downstream molecule in EGFR-pathway), during progressive increase in apoptotic response. To establish the relevance of these in vitro findings to in vivo situations, we subjected chemically- as well as ultraviolet B radiation-induced squamous papillomas in SENCAR and SKH-1 hairless mice, respectively, to Pc4-PDT, and assessed its effect on EGFR-pathway during ablation of these tumors. Pc4-PDT was found to result in a time-dependent: (i) inhibition of protein expressions of EGFR; and (ii) tyrosine phosphorylation of EGFR and Shc; and (iii) induction of apoptosis, during the regression of these tumors, These data suggest the involvement of EGFR-pathway during the antiproliferative effects of PDT, It is tempting to speculate that inhibitors of EGFR could enhance the therapeutic efficacy of PDT.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA	Case Western Reserve University	Mukhtar, H (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA051802, P30CA043703, P01CA048735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 48735, P30 CA 43703, R01 CA 51802] Funding Source: Medline; NIAMS NIH HHS [P30 AR 39750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agarwal R, 1996, PHOTOCHEM PHOTOBIOL, V63, P547, DOI 10.1111/j.1751-1097.1996.tb03082.x; Ahmad N, 1999, ONCOGENE, V18, P1891, DOI 10.1038/sj.onc.1202493; Ahmad N, 1998, P NATL ACAD SCI USA, V95, P6977, DOI 10.1073/pnas.95.12.6977; Ahmad N, 1998, BIOCHEM BIOPH RES CO, V247, P294, DOI 10.1006/bbrc.1998.8748; Ahmad N, 2000, J INVEST DERMATOL, V115, P1041, DOI 10.1046/j.1523-1747.2000.00147.x; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Chiu SM, 2000, INT J ONCOL, V16, P423; Colussi VC, 1999, PHOTOCHEM PHOTOBIOL, V69, P236, DOI 10.1562/0031-8655(1999)069<0236:PPTOHO>2.3.CO;2; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Engbrecht BW, 1999, CANCER RES, V59, P4334; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Granville DJ, 1998, FEBS LETT, V437, P5, DOI 10.1016/S0014-5793(98)01193-4; Granville DJ, 1998, FEBS LETT, V422, P151, DOI 10.1016/S0014-5793(97)01616-5; Gupta S, 1998, CANCER RES, V58, P1785; Hansen LA, 2000, CANCER RES, V60, P3328; Kalka K, 2000, CANCER RES, V60, P5984; Kalka K, 2000, J AM ACAD DERMATOL, V42, P389, DOI 10.1016/S0190-9622(00)90209-3; Kawaguchi T, 2000, BRIT J CANCER, V82, P418; Kessler JJ, 1998, LAND DEGRAD DEV, V9, P95, DOI 10.1002/(SICI)1099-145X(199803/04)9:2<95::AID-LDR289>3.0.CO;2-Y; Kim HRC, 1999, CANCER RES, V59, P3429; Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x; Nakamura T, 1996, ONCOGENE, V13, P1111; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; Tajiri H, 1998, CANCER LETT, V128, P205, DOI 10.1016/S0304-3835(98)00066-4; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Whitacre CM, 2000, CLIN CANCER RES, V6, P2021; Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X; ZAIDI SIA, 1993, PHOTOCHEM PHOTOBIOL, V58, P771, DOI 10.1111/j.1751-1097.1993.tb04969.x; Zhang WG, 1999, CANCER LETT, V138, P189, DOI 10.1016/S0304-3835(99)00013-0	33	54	57	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2314	2317		10.1038/sj.onc.1204313	http://dx.doi.org/10.1038/sj.onc.1204313			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402326				2022-12-17	WOS:000168404500013
J	Bean, LJH; Stark, GR				Bean, LJH; Stark, GR			Phosphorylation of serines 15 and 37 is necessary for efficient accumulation of p53 following irradiation with UV	ONCOGENE			English	Article						HDM; p21; adriamycin; DNA damage; Li-Fraumeni syndrome	DEPENDENT PROTEIN-KINASE; CELL-CYCLE ARREST; DAMAGE-INDUCED PHOSPHORYLATION; P53-DEPENDENT G(1) ARREST; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING FUNCTION; WILD-TYPE P53; IONIZING-RADIATION; ATAXIA-TELANGIECTASIA; GENE AMPLIFICATION	Changes in the phosphorylation state of p53 are important in increasing its half-life and potency as a transcription factor. To investigate their roles, serine residues 15 and 37 were mutated to alanines and the mutated proteins were expressed stably at low basal levels in Li-Fraumeni-derived p53-null human fibroblasts, The accumulation of p53 after DNA damage was analysed quantitatively in multiple clones. Mutation of serine 15, serine 37 or both impaired the accumulation of the protein after exposing the cells to ultraviolet radiation (50-100% increase for the mutant proteins, 500% increase for wild-type p53) but not after treatment with adriamycin. The diminished accumulation of mutant p53 protein is due to a reduction of basal HDM association. Analysis of p53-dependent transcription revealed that phosphorylation of serine 15 is required to maintain basal levels of p21 mRNA. These results provide new evidence for an important function of serine 37 phosphorylation, dearly distinguish the pathways of p53 activation in response to ultraviolet radiation or DNA damage inflicted by adriamycin, and reveal that serine 15 is crucial to support the p53-mediated basal expression of p21.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Stark, GR (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008613, R01GM049345] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49345, 5-T32-GM08613] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham J, 1999, ONCOGENE, V18, P1521, DOI 10.1038/sj.onc.1202454; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen CYM, 1996, CANCER RES, V56, P3659; CHEN J, 1993, MOL CELL BIOL, V7, P2353; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Mayo LD, 1997, CANCER RES, V57, P5013; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Prives C, 1999, J PATHOL, V187, P112; Robinson GK., 1991, STAT SCI, V6, P15, DOI [10.1214/ss/1177011926, DOI 10.1214/SS/1177011926]; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMITH ML, 1995, ONCOGENE, V10, P1053; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; VANLAAR T, 1994, ONCOGENE, V9, P981; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; [No title captured]	72	54	54	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1076	1084		10.1038/sj.onc.1204204	http://dx.doi.org/10.1038/sj.onc.1204204			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314044				2022-12-17	WOS:000167232100007
J	Labuhn, M; Jones, G; Speel, EJM; Maier, D; Zweifel, C; Gratzl, O; Van Meir, EG; Hegi, ME; Merlo, A				Labuhn, M; Jones, G; Speel, EJM; Maier, D; Zweifel, C; Gratzl, O; Van Meir, EG; Hegi, ME; Merlo, A			Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas	ONCOGENE			English	Article						INK4A locus; P16(INK4A); p14(ARF); co-deletions; quantitative real-time PCR	CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; HOMOZYGOUS DELETION; INK4A LOCUS; P15(INK4B) GENE; HUMAN CANCERS; BRAIN-TUMORS; CPG ISLAND; LOW-GRADE; P53	In many human cancers, the INK4A locus is frequently mutated by homozygous deletions, By alternative splicing this locus encodes two non-related tumor suppressor genes, p16(INK4A) and p14(ARF) (p19(ARF) in mice), which regulate cell cycle and cell survival in the retinoblastoma protein (pRb) and p53 pathways, respectively, In mice, the role of p16(INK4A) as th, critical tumor suppressor gene at the INK4A locus was challenged when it was found that p19(ARF) only knock-out mice developed tumors, including gliomas, We have analysed the genetic status of the INK4A locus in 105 primary gliomas using both microsatellite mapping (MSM) and quantitative realtime PCR (QRT-PCR). Comparison of the results of the two methods revealed agreement in 67% of the tumors examined, In discordant cases, fluorescence in situ hybridization (FISH) analysis was always found to support QRT-PCR classification, Direct assessment of p14(ARF) exon 1 beta, p16(INK4A) exon 1 alpha and exon 2 by QRT-PCR revealed 43 (41%) homozygous and eight (7%) hemizygous deletions at the INK4A locus. In 49 (47%) gliomas, both alleles were retained, In addition, QRT-PCR, but not MSM, detected hyperploidy in five (5%) tumors, Deletion of p14(ARF) was always associated with co-deletion of p16(INK4A) and increased in frequency upon progression from low to high grade gliomas, Shorter survival was associated with homozygous deletions of INK4A in the subgroup of glioblastoma patients older than 50 years of age (P = 0.025, Anova test single factor, alpha =0.05).	Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; CHU Vaudois, Lab Tumor Biol & Genet, CH-1101 Lausanne, Switzerland; Emory Univ, Mol Neurooncol Lab, Atlanta, GA 30322 USA; Univ Maastricht, Dept Mol Cell Biol & Genet, NL-6200 MD Maastricht, Netherlands	University of Basel; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Emory University; Maastricht University	Merlo, A (corresponding author), Univ Basel Hosp, Dept Res, Schanzenstr 46, CH-4031 Basel, Switzerland.		Hegi, Monika/O-4796-2015	Hegi, Monika/0000-0003-0855-6495; Van Meir, Erwin G./0000-0003-2444-7707				CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; DURO D, 1995, ONCOGENE, V11, P21; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; GLENDENING JM, 1995, CANCER RES, V55, P5531; Gortz B, 1999, INT J CANCER, V80, P373, DOI 10.1002/(SICI)1097-0215(19990129)80:3<373::AID-IJC7>3.0.CO;2-B; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hegi ME, 1997, INT J CANCER, V73, P57, DOI 10.1002/(SICI)1097-0215(19970926)73:1<57::AID-IJC10>3.0.CO;2-2; Heyman M, 1996, BLOOD, V87, P1657, DOI 10.1182/blood.V87.4.1657.bloodjournal8741657; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; LI YJ, 1995, ONCOGENE, V11, P597; Lloyd AC, 2000, NAT CELL BIOL, V2, pE48, DOI 10.1038/35004078; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P2322; Newcomb EW, 1998, BRAIN PATHOL, V8, P655, DOI 10.1111/j.1750-3639.1998.tb00191.x; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; ROCCHI M, 1991, GENOMICS, V9, P517, DOI 10.1016/0888-7543(91)90419-F; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Speel EJM, 1997, J HISTOCHEM CYTOCHEM, V45, P1439, DOI 10.1177/002215549704501013; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Wang YW, 1997, ELECTROPHORESIS, V18, P1742, DOI 10.1002/elps.1150181007; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhuang ZP, 1997, CANCER RES, V57, P4682	42	54	58	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1103	1109		10.1038/sj.onc.1204197	http://dx.doi.org/10.1038/sj.onc.1204197			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314047				2022-12-17	WOS:000167232100010
J	Perez, S; Vial, E; van Dam, H; Castellazzi, M				Perez, S; Vial, E; van Dam, H; Castellazzi, M			Transcription factor ATF3 partially transforms chick embryo fibroblasts by promoting growth factor-independent proliferation	ONCOGENE			English	Article						ATF3; Jun; AP1; chicken embryo fibroblasts; cell transformation	FORMATION IN-VIVO; V-JUN; C-JUN; DNA-BINDING; CELLULAR-TRANSFORMATION; LIVER-REGENERATION; STRESS RESPONSES; DOWN-REGULATION; TARGET GENE; CELLS	Activating Transcription Factor 3 (ATF3) is a member of the bZip family of transcription factors. Previous studies in mammalian cells suggested that like other bZip family members e.g. Jun and Fos, ATF3 might play a role in the control of cell proliferation and participate in oncogenic transformation, To investigate this putative ATF3 function directly, the rat ATF3 protein was compared with v-Jun for its ability to transform primary cultures of chick embryo fibroblasts (CEFs). Like CEFs accumulating v-Jun, CEFs accumulating the ATF3 protein displayed a typical, fusiform morphology, associated with an enhanced capacity to grow in medium with reduced amount of serum. However, in contrast to v-Jun-transformed CEFs, the ATF3 overexpressing cells could not promote colony formation from single cells in agar. Partial transformation induced by ATF3 was found to be associated with repression of multiple cellular genes that are also down-regulated by v-Jun, including those coding for the extracellular components fibronectin, decorin, thrombospondin 2, and the pro-apoptotic protein Par-4. These data demonstrate that, at least in primary avian cells, rat ATF3 possesses an intrinsic oncogenic potential. Moreover, the results suggest that ATF3 might induce growth factor independence by down-regulating a subset of the genes repressed by v-Jun.	Ecole Normale Super Lyon, INSERM U412, Unite Virol Humaine, F-69364 Lyon 07, France; Leiden Univ, Med Ctr, Dept Mol Cell Biol, Sylvius Labs, NL-2300 RA Leiden, Netherlands	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Castellazzi, M (corresponding author), Ecole Normale Super Lyon, INSERM U412, Unite Virol Humaine, F-69364 Lyon 07, France.			van Dam, Hans/0000-0002-8307-4325				Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; BASSUK JA, 1993, EUR J BIOCHEM, V218, P117, DOI 10.1111/j.1432-1033.1993.tb18358.x; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Drysdale BE, 1996, MOL IMMUNOL, V33, P989, DOI 10.1016/S0161-5890(96)00043-0; FREEMAN T, 1998, EXPRESSION MAPPING M; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; GARCIA M, 1990, J VIROL, V64, P4684, DOI 10.1128/JVI.64.10.4684-4690.1990; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hai T, 1999, GENE EXPRESSION, V7, P321; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; HUGUES SH, 1987, J VIROL, V61, P3004; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Ishiguro T, 1996, CANCER RES, V56, P875; Ishiguro T, 2000, JPN J CANCER RES, V91, P833, DOI 10.1111/j.1349-7006.2000.tb01021.x; JOURDANLESAUX C, 1994, BIOCHEM BIOPH RES CO, V199, P587, DOI 10.1006/bbrc.1994.1269; JURDIC P, 1995, ONCOGENE, V11, P1699; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kilbey A, 1996, ONCOGENE, V12, P2409; LEHRACH H, 1978, P NATL ACAD SCI USA, V75, P5417, DOI 10.1073/pnas.75.11.5417; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MICHEL D, 1989, ONCOGENE RES, V4, P127; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; Qiu SG, 1999, ONCOGENE, V18, P7115, DOI 10.1038/sj.onc.1203199; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; TEMIN HM, 1960, VIROLOGY, V10, P182, DOI 10.1016/0042-6822(60)90038-6; Trower MK, 1996, P NATL ACAD SCI USA, V93, P1366, DOI 10.1073/pnas.93.4.1366; TUCKER RP, 1993, DEVELOPMENT, V117, P347; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDEL L, 1995, ONCOGENE, V10, P495; Venkatesh B, 2000, FEBS LETT, V476, P3, DOI 10.1016/S0014-5793(00)01659-8; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; VOGT PK, 1994, FOS JUN FAMILIES TRA, P203; WALCHLI C, 1994, J CELL SCI, V107, P669; WEIR E, 1994, HEPATOLOGY, V20, P955, DOI 10.1002/hep.1840200426; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700	52	54	55	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1135	1141		10.1038/sj.onc.1204200	http://dx.doi.org/10.1038/sj.onc.1204200			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314051				2022-12-17	WOS:000167232100014
J	Kataoka, H; Miura, Y; Joh, T; Seno, K; Tada, T; Tamaoki, T; Nakabayashi, H; Kawaguchi, M; Asai, K; Kato, T; Itoh, M				Kataoka, H; Miura, Y; Joh, T; Seno, K; Tada, T; Tamaoki, T; Nakabayashi, H; Kawaguchi, M; Asai, K; Kato, T; Itoh, M			Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1	ONCOGENE			English	Article						AFP (Alpha-fetoprotein); AFP-GC (AFP producing gastric cancer); ATBF1 (AT motif binding factor 1); HNF1 (hepatocyte nuclear factor 1)	CELL-LINES; GASTROINTESTINAL-TRACT; CLINICOPATHOLOGICAL FEATURES; CARCINOMA; EXPRESSION; ESTABLISHMENT; PROTEIN; LIVER; GENE; DIFFERENTIATION	Alpha-fetoprotein (AFP) producing gastric cancer (AFP-GC) is very malignant and highly metastatic compared with common gastric cancer. However, the causal relationship between AFP production and the high malignancy of AFP-GC is unclear. We investigated AFP gene regulation in AFP-GC by an active transcription factor, HNF1 (hapatocyte nuclear factor 1) and a repressive transcription factor, ATBF1 (AT motif binding factor 1), RNase protection assays revealed that the production of AFP in gastric cancer cells did not directly associate with HNF1 expression. An inverse relation between the expressions of ATBF1 and AFP was clearly observed in gastric cancer cells. CAT assays showed the direct inhibition of AFP gene expression by ATBF1, Methylation analysis of the AFP promoter region in gastric cancer cells suggested that methylation itself could not explain the silencing of the AFP gene. Immunohistochemistry of resected clinical samples revealed that AFP producing cells lacked ATBF1 immunoreactivity, Our data suggests that the absence of ATBF1 is responsible for AFP gene expression in gastric cancer, and the absence of ATBF1 is a distinct characteristic of AFP-GC and might be important for its highly malignant nature.	Nagoya City Univ, Sch Med, Dept Bioregulat Res, Mizuhi Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Nursing, Dept Pathol, Mizuhi Ku, Nagoya, Aichi 4678601, Japan; Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Hokkaido Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido 060, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Pathol, Toyama 9300194, Japan	Nagoya City University; Nagoya City University; Nagoya City University; University of Calgary; Hokkaido University; University of Toyama	Miura, Y (corresponding author), Nagoya City Univ, Sch Med, Dept Bioregulat Res, Mizuhi Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.		Asai, Kiyofumi/H-2356-2014	Asai, Kiyofumi/0000-0001-7015-2251				BOURREILLE J, 1970, PRESSE MED, V78, P1277; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CHANG YC, 1992, AM J GASTROENTEROL, V87, P321; CHANG YC, 1990, AM J GASTROENTEROL, V85, P1480; Chen HM, 1997, CRIT REV EUKAR GENE, V7, P11, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.20; DIGIOVANNI J, 1984, CANCER RES, V44, P2878; FUJIWARA T, 1993, INT J CANCER, V54, P965, DOI 10.1002/ijc.2910540617; GITLIN D, 1972, CANCER RES, V32, P979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hassan S, 1998, DIGEST DIS SCI, V43, P8, DOI 10.1023/A:1018851415704; Ido A, 1996, GENE, V168, P227, DOI 10.1016/0378-1119(95)00740-7; Kaspar P, 1999, J BIOL CHEM, V274, P14422, DOI 10.1074/jbc.274.20.14422; KOYAMA K, 1990, JPN J CANCER RES, V81, P967, DOI 10.1111/j.1349-7006.1990.tb03332.x; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; MCINTIRE KR, 1975, CANCER RES, V35, P991; MIURA Y, 1995, J BIOL CHEM, V270, P26840, DOI 10.1074/jbc.270.45.26840; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; NAKATA K, 1992, J BIOL CHEM, V267, P1331; PENG SY, 1993, HEPATOLOGY, V17, P35, DOI 10.1016/0270-9139(93)90188-S; Ramsay RG, 2000, CANCER RES, V60, P1805; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SEKIGUCHI M, 1978, JPN J EXP MED, V48, P61; TAKETA K, 1990, GASTROENTEROLOGY, V99, P508, DOI 10.1016/0016-5085(90)91034-4; TERASHIMA M, 1991, JPN J CANCER RES, V82, P883, DOI 10.1111/j.1349-7006.1991.tb01915.x; TYNER AL, 1990, J CELL BIOL, V110, P915, DOI 10.1083/jcb.110.4.915; YASUDA H, 1994, MOL CELL BIOL, V14, P1395, DOI 10.1128/MCB.14.2.1395	26	54	59	1	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					869	873		10.1038/sj.onc.1204160	http://dx.doi.org/10.1038/sj.onc.1204160			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314020				2022-12-17	WOS:000166924400010
J	Liu, XD; Sun, Y; Ehrlich, M; Lu, T; Kloog, Y; Weinberg, RA; Lodish, HF; Henis, YI				Liu, XD; Sun, Y; Ehrlich, M; Lu, T; Kloog, Y; Weinberg, RA; Lodish, HF; Henis, YI			Disruption of TGF-beta growth inhibition hy oncogenic ras is linked to p27(Kip1) mislocalization	ONCOGENE			English	Article						mislocalization of p27(Kip1); oncogenic Ras; p27(Kip1) partner switching; TGF-beta growth inhibition	CELL-CYCLE ARREST; EPITHELIAL-CELLS; SKI ONCOPROTEIN; CDK INHIBITORS; SMAD PROTEINS; CANCER CELLS; TUMOR-CELLS; C-MYC; RECEPTOR; GENE	Expression of oncogenic Ras in epithelial tumor cells is linked to the loss of transforming growth factor-beta (TGF-beta) anti-proliferative activity, and was proposed to involve inhibition of Smad2/3 nuclear translocation, Here we studied several epithelial cell lines expressing oncogenic N-Ras(K61) and show that TGF-beta -induced nuclear translocation of and transcriptional activation by Smad2/3,were unaffected. In contrast, oncogenic Ras mediated nuclear-to-cytoplasmic mislocalization of p27(Kip1) (p27) and of the cyclin-dependent kinase (CDK) CDK6, but not CDK2, Concomitantly, oncogenic Ras abrogated the ability of p27 and from to CDK6, to enhance its inhibit CDK2 activity. TGF-beta to binding to Inactivation of Ras by a specific antagonist restored the growth inhibitory response to TGF-beta with concurrent normalization of p27 and CDK6 localization. Therefore, the disruption of TGF-beta -mediated growth inhibition by oncogenic Ras appears to be due to lack of inhibition of CDK2, caused by the sequestration of p27 and CDK2 in different subcellular compartments and by the loss of TGF-beta -induced partner switching of p27 from CDK6 to CDK2.	Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Tel Aviv University; Massachusetts Institute of Technology (MIT)	Henis, YI (corresponding author), Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.			Ehrlich, Marcelo/0000-0002-2352-1808; Henis, Yoav/0000-0002-1408-3877; LIU, XUEDONG/0000-0001-7209-4964				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; BOS JL, 1989, CANCER RES, V49, P4682; Catzavelos C, 1999, CANCER RES, V59, P684; Constantinescu SN, 1999, EMBO J, V18, P3334, DOI 10.1093/emboj/18.12.3334; DeCoteau JF, 1997, P NATL ACAD SCI USA, V94, P5877, DOI 10.1073/pnas.94.11.5877; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FILMUS J, 1992, ONCOGENE, V7, P521; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOUCK KA, 1989, ONCOGENE, V4, P19; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LONGSTREET M, 1992, ONCOGENE, V7, P1549; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Schiemann WP, 1999, BLOOD, V94, P2854, DOI 10.1182/blood.V94.8.2854.420k07_2854_2861; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Singh SP, 1998, CANCER RES, V58, P1730; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; VALVERIUS EM, 1989, CANCER RES, V49, P6269; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Weis B, 1999, ONCOGENE, V18, P2579, DOI 10.1038/sj.onc.1202602; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	58	54	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5926	5935		10.1038/sj.onc.1203991	http://dx.doi.org/10.1038/sj.onc.1203991			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127824				2022-12-17	WOS:000165563100012
J	Susse, S; Janz, C; Janus, F; Deppert, W; Wiesmuller, L				Susse, S; Janz, C; Janus, F; Deppert, W; Wiesmuller, L			Role of heteroduplex joints in the functional interactions between human Rad51 and wild-type p53	ONCOGENE			English	Article						exonuclease; fidelity control; homologous recombination; mismatch correction; strand exchange	DOUBLE-STRAND BREAKS; INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; NUCLEOTIDE EXCISION-REPAIR; MOUSE L-CELLS; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; MUTANT P53; GENETIC-RECOMBINATION; TRANSACTIVATION ACTIVITY; REPLICATION FIDELITY	Our previous work (Dudenhoffer et al., 1999) unveiled a link between the capacity of p53 to regulate homologous recombination processes and to specifically bind to heteroduplex junction DNAs. Here, we show that p53 participates in ternary complex formation after preassembly of nucleoproteins, consisting of the human recombinase hRad51 and junction DNA, The cancer-related mutant p53(273H), which is defective in inhibiting recombination processes, displays a reduced capacity to associate with hRad51-DNA complexes, even under conditions which support DNA-binding, This suggests that hRad51-p53 contacts play a role in targeting p53 to heteroduplex joints and indicates an involvement in recombination immediately following hRad51-mediated strand transfer. To study the initial phase of strand exchange, when heteroduplex joints arise, we applied oligonucleotide based strand transfer assays. We observed that hRad51 stimulates exonucleolytic DNA degradation by p53, when it generates strand transfer intermediates. In agreement with this observation, artificial 3-stranded junction DNAs, designed to mimic nascent recombination intermediates, were found to represent preferred exonuclease substrates, especially when comprising a mismatch within the heteroduplex part. From our data, we propose a model according to which, p53-dependent correction of DNA exchange events is triggered by high-affinity binding to joint molecules and by stabilizing contacts with hRad51 oligomers.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Wiesmuller, L (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							Albor A, 1998, CANCER RES, V58, P2091; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1999, J MOL BIOL, V291, P363, DOI 10.1006/jmbi.1999.2954; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BELMAAZA A, 1994, MUTAT RES, V314, P199, DOI 10.1016/0921-8777(94)90065-5; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Bernstein C., 1991, AGING SEX DNA REPAIR; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BRAIN R, 1994, ONCOGENE, V9, P1775; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cleaver JE, 1999, CANCER RES, V59, P1102; Cox MM, 1997, P NATL ACAD SCI USA, V94, P11764, DOI 10.1073/pnas.94.22.11764; De Zutter SK, 1999, J MOL BIOL, V293, P769, DOI 10.1006/jmbi.1999.3200; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0165-1218(74)90185-2; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Grosse Frank, 1993, V16, P95; Gupta RC, 1999, MOL CELL, V4, P705, DOI 10.1016/S1097-2765(00)80381-0; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Gupta RC, 1999, J BIOL CHEM, V274, P1248, DOI 10.1074/jbc.274.3.1248; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Jean D, 1997, NUCLEIC ACIDS RES, V25, P4004, DOI 10.1093/nar/25.20.4004; Kanaar R, 1998, NATURE, V391, P335, DOI 10.1038/34790; Kawamura M, 1996, ONCOGENE, V12, P2361; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.biophys.20.1.539; KUCHERLAPATI R, 1988, GENETIC RECOMBINATIO; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; Namsaraev EA, 2000, J BIOL CHEM, V275, P3970, DOI 10.1074/jbc.275.6.3970; Namsaraev EA, 1998, BIOCHEMISTRY-US, V37, P11932, DOI 10.1021/bi9810297; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Palecek E, 1999, ONCOGENE, V18, P3617, DOI 10.1038/sj.onc.1202710; Paques F, 1997, MOL CELL BIOL, V17, P6765, DOI 10.1128/MCB.17.11.6765; PARK DJ, 1994, ONCOGENE, V9, P1899; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Prasad KAN, 1997, BIOCHEM BIOPH RES CO, V232, P14, DOI 10.1006/bbrc.1997.6212; RADDING CM, 1991, J BIOL CHEM, V266, P5355; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH ML, 1995, ONCOGENE, V10, P1053; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Tang W, 1999, CANCER RES, V59, P2562; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2476; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; Wiesmuller L, 1996, J VIROL, V70, P737; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	96	54	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2000	19	39					4500	4512		10.1038/sj.onc.1203809	http://dx.doi.org/10.1038/sj.onc.1203809			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002423				2022-12-17	WOS:000089236800007
J	Ono, Y; Nakanishi, H; Nishimura, M; Kakizaki, M; Takahashi, K; Miyahara, M; Satoh-Horikawa, K; Mandai, K; Takai, Y				Ono, Y; Nakanishi, H; Nishimura, M; Kakizaki, M; Takahashi, K; Miyahara, M; Satoh-Horikawa, K; Mandai, K; Takai, Y			Two actions of frabin: direct activation of Cdc42 and indirect activation of Rac	ONCOGENE			English	Article						frabin; Rac; Cdc42; filopodia; lamellipodia; membrane ruffles	PLECKSTRIN HOMOLOGY DOMAIN; NUCLEOTIDE EXCHANGE FACTOR; EXPRESSION CLONING; PROTEIN-KINASE; RHO; CYTOSKELETON; GTPASES; GENE; DBL; FILOPODIA	Frabin is an actin filament-binding protein which shows GDP/GTP exchange activity specific for Cdc42 small G protein and induces filopodium-like microspike formation and c-Jun N-terminal kinase (JNK) activation presumably through the activation of Cdc42. Frabin has one actin filament-binding (FAB) domain, one Dbl homology (DH) domain, first pleckstrin homology (PH) domain adjacent to the DH domain, one cysteine-rich FYVE domain, and second PH domain from the N-terminus to the C-terminus in this order. Different domains of frabin are involved in the microspike formation and the JNK activation, and the association of frabin with the actin cytoskeleton through the FAB domain is necessary for the microspike formation, but not for the JNK activation. We have found here that frabin induces the formation of not only filopodium-like microspikes but also lamellipodium-like structures in NIH3T3 and L fibroblasts. We have analysed the mechanism of frabin in these two actions and found that frabin induces filopodium-like microspike formation through the direct activation of Cdc42 and lamellipodium-like structure formation through the Cdc42-independent indirect activation of Pac small G protein. The FAB domain of frabin in addition to the DH domain and the first PH domain is necessary for the filopodium-like microspike formation, but not for the lamellipodium-like structure formation. The FYVE domain and the second PH domain in addition to the DH domain and the first PH domain are necessary for the lamellipodium-like structure formation. We show here these two actions of frabin in the regulation of cell morphology.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Mandai, Kenji/0000-0002-0115-6635; Nakanishi, Hiroyuki/0000-0002-9765-0266				Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Nagata K, 1998, J BIOL CHEM, V273, P15453, DOI 10.1074/jbc.273.25.15453; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Obaishi H, 1998, J BIOL CHEM, V273, P18697, DOI 10.1074/jbc.273.30.18697; Onishi M, 1996, EXP HEMATOL, V24, P324; PASTERIS NG, 1994, CELL, V79, P669; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Umikawa M, 1999, J BIOL CHEM, V274, P25197, DOI 10.1074/jbc.274.36.25197; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	21	54	57	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3050	3058		10.1038/sj.onc.1203631	http://dx.doi.org/10.1038/sj.onc.1203631			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871857				2022-12-17	WOS:000087903900002
J	Haik, S; Gauthier, LR; Granotier, C; Peyrin, JM; Lages, CS; Dormont, D; Boussin, FD				Haik, S; Gauthier, LR; Granotier, C; Peyrin, JM; Lages, CS; Dormont, D; Boussin, FD			Fibroblast growth factor 2 up regulates telomerase activity in neural precursor cells	ONCOGENE			English	Article						telomerase; neural precursor cells; fibroblast growth factor 2	MOUSE TELOMERASE; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; STEM-CELLS; NEURONAL DIFFERENTIATION; LYMPHOCYTE DEVELOPMENT; PROGENITOR CELLS; IMMORTAL CELLS; GLIOMA-CELLS; TUMOR-CELLS	During brain development, neuronal and glial cells are generated from neural precursors on a precise schedule involving steps of proliferation, fate commitment and differentiation. We report that telomerase activity is highly expressed during embryonic murine cortical neurogenesis and early steps of gliogenesis and progressively decreases thereafter during cortex maturation to be undetectable in the normal adult brain. We evidenced neural precursor cells (NPC) as the principal telomerase-expressing cells in primary cultures from E15 mouse embryo cortices, Their differentiation either in neurons or in glial cells lead to a down regulation of telomerase activity that was directly correlated to the decrease of telomerase core protein (mTERT) mRNA synthesis. Furthermore, we show that FGF2 (fibroblast growth factor 2), one of the main regulators of CNS development, induces a dose-dependant increase of both the proliferation of NPC and telomerase activity in primary cortical cultures without affecting the mTERT mRNA synthesis compared to that of glyceraldehyde-3-phosphate dehydrogenase (mGAPDH). Finally, we evidenced that AZT (3'-azido-2',3'-dideoxythymidine), known to inhibit telomerase activity, blocks in a dose dependant manner the FGF2-induced proliferation of NPC. Altogether, our results are in favor of an important role of telomerase activity during brain organogenesis.	CEA, Lab Radiopathol, DSV, DRR,IPSCI, F-92265 Fontenay Aux Roses, France; CEA, Serv Neurovirol, DSV, DRM,CRSSA,IPSC, F-92265 Fontenay Aux Roses, France	CEA; CEA; UDICE-French Research Universities; Universite Paris Saclay	Boussin, FD (corresponding author), CEA, Lab Radiopathol, DSV, DRR,IPSCI, BP 6, F-92265 Fontenay Aux Roses, France.		Gauthier, Laurent/ABC-7614-2021; Haik, Stephane/M-7247-2018	Gauthier, Laurent/0000-0003-4644-7660; GRANOTIER-BECKERS, Christine/0000-0003-1063-1159; Boussin, francois/0000-0003-3778-4403; Peyrin, Jean-Michel/0000-0002-8705-8672; Peyrin, Jean-Michel/0000-0002-0108-1266				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.3.CO;2-E; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; Engelhardt M, 1997, BLOOD, V90, P182; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; GIORDANO S, 1992, DEV BIOL, V152, P293, DOI 10.1016/0012-1606(92)90136-5; Gomez DE, 1998, BIOCHEM BIOPH RES CO, V246, P107, DOI 10.1006/bbrc.1998.8555; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Hiratochi M, 1998, DEV GROWTH DIFFER, V40, P59; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Ito H, 1998, CLIN CANCER RES, V4, P1603; JANET T, 1995, J NEUROSCI RES, V40, P707, DOI 10.1002/jnr.490400602; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kruk PA, 1996, BIOCHEM BIOPH RES CO, V224, P487, DOI 10.1006/bbrc.1996.1054; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Melana SM, 1998, CLIN CANCER RES, V4, P693; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miho Y, 1999, CELL DEATH DIFFER, V6, P463, DOI 10.1038/sj.cdd.4400506; Miyagi N, 1998, INT J ONCOL, V12, P1085; Multani AS, 1998, INT J ONCOL, V13, P923; MURPHY M, 1994, DEVELOPMENT, V120, P3519; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; OLIVERO OA, 1993, MOL CARCINOGEN, V8, P81, DOI 10.1002/mc.2940080204; Peyrin JM, 1999, NEUROREPORT, V10, P723, DOI 10.1097/00001756-199903170-00012; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; Ray J, 1997, P NATL ACAD SCI USA, V94, P7047, DOI 10.1073/pnas.94.13.7047; Reichman TW, 1997, J CELL BIOCHEM, V67, P13, DOI 10.1002/(SICI)1097-4644(19971001)67:1<13::AID-JCB2>3.0.CO;2-Z; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Strahl C, 1996, MOL CELL BIOL, V16, P53; Takakura M, 1998, CANCER RES, V58, P1558; Tian XX, 1999, J NEUROPATH EXP NEUR, V58, P472, DOI 10.1097/00005072-199905000-00006; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; Vaccarino FM, 1999, NAT NEUROSCI, V2, P246, DOI 10.1038/6350; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Weng NP, 1997, IMMUNOL REV, V160, P43, DOI 10.1111/j.1600-065X.1997.tb01026.x; Xu D, 1999, BRIT J CANCER, V80, P1156, DOI 10.1038/sj.bjc.6690480; Yamaguchi Y, 1998, EXP CELL RES, V242, P120, DOI 10.1006/excr.1998.4102; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	70	54	59	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 15	2000	19	26					2957	2966		10.1038/sj.onc.1203596	http://dx.doi.org/10.1038/sj.onc.1203596			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871847				2022-12-17	WOS:000087581400002
J	Mazumder, S; Gong, B; Almasan, A				Mazumder, S; Gong, B; Almasan, A			Cyclin E induction by genotoxic stress leads to apoptosis of hematopoietic cells	ONCOGENE			English	Article						Cyclin E; cyclin dependent kinase 2; apoptosis; ionizing radiation; caspase-3	S-PHASE ENTRY; THYMOCYTE APOPTOSIS; CDK INHIBITORS; ACTIVATION; KINASE; TRANSITION; CANCER; DEATH; P53; FIBROBLASTS	Cyclin E is essential for progression through the G1 phase of the cell cycle and initiation of DNA replication by interacting with, and activating its catalytic partner, the cyclin-dependent kinase 2 (Cdk2), We found a substantial increase in cyclin E mRNA, accompanied by increased production of cyclin E protein and cyclin E/ Cdk2 kinase activity in multiple myeloma and lymphoma cells following irradiation. Cyclin E expression increased early in a time and dose-dependent manner, with a threefold induction reached 8h following gamma-irradiation, Run-on analyses indicated a predominantly transcriptional regulation of cyclin E, Stable overexpression of cyclin E, but not cyclin D1, sensitized IM-9 cells to gamma-irradiation-induced apoptosis; in contrast, a dominant-negative Cdk2, prevented apoptosis. Irradiation of cyclin E overexpressing cells led to an enhanced caspase activation and exposure of the phosphatidylserine on the plasma membrane, two key markers of apoptosis, events which were completely abolished in cells expressing a dominant-negative Cdk2, This study identifies cyclin E as a target for activation by ionizing radiation and which plays a functional role in apoptosis of hematopoietic cells. Oncogene (2000) 19, 2828-2835.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Radiat Oncol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Almasan, A (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, NB40, Cleveland, OH 44195 USA.		Almasan, Alex/C-2715-2008	Almasan, Alex/0000-0002-8916-6650	NATIONAL CANCER INSTITUTE [R01CA081504, R01CA082858] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82858, CA81504, R01 CA082858, R01 CA081504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Gong BD, 1999, CELL GROWTH DIFFER, V10, P491; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lawrence TS, 1996, CANCER RES, V56, P3203; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Martin JMC, 1999, CANCER RES, V59, P1134; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; MAZARS GR, 1992, ONCOGENE, V7, P1015; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Sauter ER, 1999, CANCER RES, V59, P4876; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	38	54	59	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2828	2835		10.1038/sj.onc.1203623	http://dx.doi.org/10.1038/sj.onc.1203623			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851086	Green Accepted			2022-12-17	WOS:000087403600004
J	Kaykas, A; Sugden, B				Kaykas, A; Sugden, B			The amino-terminus and membrane-spanning domains of LMP-1 inhibit cell proliferation	ONCOGENE			English	Article						EBV; LMP-1; membrane-spanning domains; inhibition of proliferation	EPSTEIN-BARR-VIRUS; NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; BURKITT-LYMPHOMA LINE; GROWTH-FACTOR; LATENT MEMBRANE-PROTEIN-1; TRANSFORMING PROTEIN; CYTOPLASMIC DOMAIN; FLOW-CYTOMETRY; C-MYC	The LMP-I oncoprotein of EBV is required to maintain proliferation of infected B-cells and shares several features with CD40, TNF-R1, and related receptors, Members of this family can bind TRAF and TRADD molecules and activate NF-kappa B and AP-I, as can LMP-1, While CD40 and TNF-R1 are dependent on binding their ligands for their signaling, LMP-1 apparently is not, We have found that LMP-1 can act as a governor of cell proliferation and thereby limit its own activities, its inhibition of proliferation is not mediated by apoptosis but results in cytostasis in four cell lines tested. The structural moiety of LMP-I that distinguishes it from CD40 and TNF-R1, its amino-terminus and multiple membrane spanning segments, alone can mediate its cytostatic activity.	Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Sugden, B (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA.				NCI NIH HHS [T32-CA-09135, CA22443, CA07175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022443, T32CA009135, P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDERSON MR, 1994, INT IMMUNOL, V6, P1799, DOI 10.1093/intimm/6.11.1799; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; Bloss T, 1999, J GEN VIROL, V80, P3227, DOI 10.1099/0022-1317-80-12-3227; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; CAMPLEJOHN RS, 1994, J MICROSC-OXFORD, V176, P1, DOI 10.1111/j.1365-2818.1994.tb03493.x; CUOMO L, 1992, INT J CANCER, V51, P949, DOI 10.1002/ijc.2910510619; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEUSCHLE U, 1995, MOL CELL BIOL, V15, P1907; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JACOB MC, 1991, CYTOMETRY, V12, P550, DOI 10.1002/cyto.990120612; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; KNUTSON JC, 1987, ANAL BIOCHEM, V164, P44, DOI 10.1016/0003-2697(87)90365-4; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MARTIN J, 1991, CELL GROWTH DIFFER, V2, P653; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; Puls A, 1999, J CELL SCI, V112, P2983; Rooney RD, 1996, J BIOL CHEM, V271, P21498, DOI 10.1074/jbc.271.35.21498; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SCHLEISS MR, 1991, J VIROL, V65, P6782, DOI 10.1128/JVI.65.12.6782-6789.1991; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; SUGDEN B, 1979, J VIROL, V31, P590, DOI 10.1128/JVI.31.3.590-595.1979; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; WEIGEL R, 1983, VIROLOGY, V125, P287, DOI 10.1016/0042-6822(83)90202-7; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667	49	54	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1400	1410		10.1038/sj.onc.1203365	http://dx.doi.org/10.1038/sj.onc.1203365			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723131				2022-12-17	WOS:000085942700005
J	Poele, RHT; Okorokov, AL; Joel, SP				Poele, RHT; Okorokov, AL; Joel, SP			RNA synthesis block by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells	ONCOGENE			English	Article						5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole; (DRB); RNA synthesis; p53; apoptosis	P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; DNA-DAMAGE; GENE-MUTATIONS; BREAST-CANCER; POLYMERASE-II; TRANSCRIPTION; LEUKEMIA; PROTEIN; CYCLE	Most modern chemo- and radiotherapy treatments of human cancers use the DNA damage pathway, which induces a p53 response leading to either G1 arrest or apoptosis. However, such treatments can induce mutations and translocations leading to secondary malignancies or recurrent disease, which often have a poor prognosis because of resistance to therapy. Here we report that 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), an inhibitor of CDK7 TFIIH-associated kinase, CKI and CKII kinases, blocking RNA polymerase II in the early elongation stage, triggers p53-dependent apoptosis in human colon adenocarcinoma cells in a transcription independent manner. The fact that DRB kills tumour-derived cells without employment of DNA damage gives rise to the possibility of the development of a new alternative chemotherapeutic treatment of tumours expressing wild type p53, with a decreased risk of therapy-related, secondary malignancies.	St Bartholomews Hosp, ICRF Dept Med Oncol, Barry Reed Oncol Lab, London EC1A 7BE, England; Univ York, Dept Biol, Yorkshire Canc Res Res Grp P53, York YO10 5DD, N Yorkshire, England	University of London; Queen Mary University London; University of York - UK	Poele, RHT (corresponding author), St Bartholomews Hosp, ICRF Dept Med Oncol, Barry Reed Oncol Lab, London EC1A 7BE, England.			Okorokov, Andrei/0000-0003-2477-3254				AALTONEN LA, 1994, ANTICANCER RES, V14, P1657; Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BAKER SJ, 1990, CANCER RES, V50, P7717; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Dunton CJ, 1997, SEMIN ONCOL, V24, pS2; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; Elli R, 1996, CANCER GENET CYTOGEN, V87, P112, DOI 10.1016/0165-4608(95)00294-4; Felix CA, 1996, BLOOD, V87, P4376, DOI 10.1182/blood.V87.10.4376.bloodjournal87104376; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Froggatt NJ, 1996, J MED GENET, V33, P726, DOI 10.1136/jmg.33.9.726; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Gordon A, 1997, Clin Oncol (R Coll Radiol), V9, P338, DOI 10.1016/S0936-6555(05)80069-X; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gryfe R, 1997, CURR PROB CANCER, V21, P238, DOI 10.1016/S0147-0272(97)80003-7; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hiddemann W, 1995, EUR J CANCER, V31A, P2141, DOI 10.1016/0959-8049(95)00367-3; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1995, PHILOS T ROY SOC B, V347, P83, DOI 10.1098/rstb.1995.0013; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MEYN MS, 1995, CANCER RES, V55, P5991; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; Pui Ching-Hon, 1995, Current Opinion in Oncology, V7, P36; Reuss K, 1996, ANN ONCOL, V7, P109; ROLLEY N, 1995, ONCOGENE, V11, P763; SHUGAR D, 1994, CELL MOL BIOL RES, V40, P411; TISHLER RB, 1993, CANCER RES, V53, P2212; vanBasten JP, 1997, EUR J SURG ONCOL, V23, P354, DOI 10.1016/S0748-7983(97)90966-5; WILLIAMS AC, 1995, ONCOGENE, V11, P141; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; ZANDOMENI R, 1982, P NATL ACAD SCI-BIOL, V79, P3167, DOI 10.1073/pnas.79.10.3167	57	54	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5765	5772		10.1038/sj.onc.1202961	http://dx.doi.org/10.1038/sj.onc.1202961			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523857				2022-12-17	WOS:000083095100005
J	Kon, A; Vindevoghel, L; Kouba, DJ; Fujimura, Y; Uitto, J; Mauviel, A				Kon, A; Vindevoghel, L; Kouba, DJ; Fujimura, Y; Uitto, J; Mauviel, A			Cooperation between SMAD and NF-kappa B in growth factor regulated type VII collagen gene expression	ONCOGENE			English	Article						SMAD; NF-kappa B; TGF-beta; TNF-alpha; transcription; promoter	HUMAN DERMAL FIBROBLASTS; NECROSIS-FACTOR-ALPHA; FACTOR-BETA; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; DNA-BINDING; C-REL; PROTEINS; KERATINOCYTES; ACTIVATION	We have previously demonstrated that transforming growth factor-beta (TGF-beta) and pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) or interteukin-1 beta, synergistically enhance the expression of type VII collagen gene (COL7A1) in human dermal fibroblasts in culture (Mauviel rt nl., 1994), Recently, we identified a SMAD-containing complex, rapidly induced by TGF-beta and binding the region [-496/-444] of the COL7A1 promoter, responsible for COL7A1 gene transactivation (Vindevoghel rt al., 1998a), In this report, we demonstrate that TGF-beta and TNF-alpha response elements are distinct entities within the COL7A1 promoter. In particular, we demonstrate that the TNF-alpha effect is mediated by NF-kappa B1/RelA (p50/p65) and RelA/RelA (p65/p65) NF-kappa B complexes binding the TNF-alpha response element (TaRE) located in the region [-252/-230], with RelA acting as the transcriptional activator, Finally, we provide definitive evidence for the role of both TGF-beta and TNF-alpha response elements as enhancer sequences, functioning in the contest of a heterologous promoter in an additive manner in response to TGF-beta and TNF-alpha, This study provides the first identification of a functional interaction between the two immediate-early transcription factors, SMAD and NF-kappa B, to activate the expression of an extracellular matrix-related gene, COL7Al.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Inst Mol Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Allegheny Univ Hlth Sci, Dept Human Genet, Philadelphia, PA 19102 USA	Jefferson University; Jefferson University; Jefferson University; Jefferson University; Drexel University	Mauviel, A (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA.		MAUVIEL, Alain/F-6251-2013	Mauviel, Alain/0000-0002-0438-2793	NIAMS NIH HHS [R29-AR43751, R01-AR41439, T32-AR07651] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041439, R29AR043751] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; Chen Y.Q., 1994, J GERIATR DERMATOL, V2, P163; CHEN YQ, 1994, J INVEST DERMATOL, V102, P205, DOI 10.1111/1523-1747.ep12371763; CHRISTIANO AM, 1996, CURR OPIN DERMATOL, V3, P225; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Helenius M, 1996, BIOCHEM J, V318, P603, DOI 10.1042/bj3180603; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; IWASAKI T, 1993, BIOCHEM BIOPH RES CO, V193, P604, DOI 10.1006/bbrc.1993.1667; Kouba DJ, 1997, J INVEST DERMATOL, V108, P292; LANOIX J, 1994, ONCOGENE, V9, P841; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MAUVIEL A, 1993, WOUNDS, V5, P137; MAUVIEL A, 1994, J BIOL CHEM, V269, P25; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Sambrook J, 1989, MOL CLONING LAB MANU; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; Trebilcock GU, 1996, GERONTOLOGY, V42, P137, DOI 10.1159/000213785; UITTO J, 1998, PRINCIPLES MOL MED, P729; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vindevoghel L, 1997, J BIOL CHEM, V272, P10196; VINDEVOGHEL L, 1998, IN PRESS P NATL ACAD; WOODLEY DT, 1990, JAMA-J AM MED ASSOC, V263, P3057, DOI 10.1001/jama.263.22.3057	33	54	55	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1837	1844		10.1038/sj.onc.1202495	http://dx.doi.org/10.1038/sj.onc.1202495			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086338				2022-12-17	WOS:000079090000007
J	Tari, AM; Hung, MC; Li, KY; Lopez-Berestein, G				Tari, AM; Hung, MC; Li, KY; Lopez-Berestein, G			Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells	ONCOGENE			English	Article						Grb2; EGFR; ErbB2; MAP kinase; breast cancer	RECEPTOR TYROSINE KINASES; NUCLEOTIDE EXCHANGE FACTOR; SIGNALING GENE SEM-5; AUTOPHOSPHORYLATION SITES; ADAPTER PROTEIN; C-ERBB-2 GENE; PHOSPHATIDYLINOSITOL-3 KINASE; SEVENLESS GENE; NEU ONCOGENE; SH3 DOMAINS	Increased breast cancer growth has been associated with increased expression of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases (RTKs), Upon activation, RTKs may transmit their oncogenic signals by binding to the growth factor receptor bound protein-2 (Grb2), which in turn binds to SOS and activates the Ras/Raf/MEK/mitogen-activated protein (MAP) kinase pathway. Grb2 is important for the transformation of fibroblasts by EGFR and ErbB2; however, whether Grb2 is also important for the proliferation of breast cancer cells expressing these RTKs is unclear. We have used liposomes to deliver nuclease-resistant antisense oligodeoxynucleotides (oligos) specific for the GRB2 mRNA to breast cancer cells. Grb2 protein downregulation could inhibit breast cancer cell growth; the degree of growth inhibition was dependent upon the activation and/or endogenous levels of the RTKs. Grb2 inhibition led to MAP kinase inactivation in EGFR, but not in ErbB2, breast cancer cells, suggesting that different pathways might be used by EGFR and ErbB2 to regulate breast cancer growth.	Univ Texas, MD Anderson Cancer Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tari, AM (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Bioimmunotherapy, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V29, P29, DOI 10.1007/BF00666179; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DALY RJ, 1994, ONCOGENE, V9, P2723; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; FITZPATRICK SL, 1984, CANCER RES, V44, P3442; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; Heldin CH, 1996, CANCER SURV, V27, P7; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JANES PW, 1994, ONCOGENE, V9, P3601; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; Koenders P., 1992, Breast Cancer Research and Treatment, V23, P134; LI K, 1998, P AM ASSOC CANC RES, V39, P1404; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Marais R, 1996, CANCER SURV, V27, P101; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; NICHOLSON S, 1988, BRIT J CANCER, V58, P810, DOI 10.1038/bjc.1988.315; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELES E, 1992, J BIOL CHEM, V267, P12266; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PIETRAS R, 1995, ONCOGENE, V10, P2345; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGATTO O, 1993, ONCOGENE, V8, P2105; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; Tan M, 1997, CANCER RES, V57, P1199; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yu DH, 1996, ONCOGENE, V13, P1359; ZHANG LS, 1995, CANCER RES, V55, P3890	65	54	67	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1325	1332		10.1038/sj.onc.1202422	http://dx.doi.org/10.1038/sj.onc.1202422			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022814				2022-12-17	WOS:000078510900008
J	Kumagai, T; Miki, T; Kikuchi, M; Fukuda, T; Miyasaka, N; Kamiyama, R; Hirosawa, S				Kumagai, T; Miki, T; Kikuchi, M; Fukuda, T; Miyasaka, N; Kamiyama, R; Hirosawa, S			The proto-oncogene Bc16 inhibits apoptotic cell death in differentiation-induced mouse myogenic cells	ONCOGENE			English	Article						Bc16; apoptosis; muscle cell	GERMINAL-CENTER FORMATION; NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; CENTER B-CELLS; GROWTH-FACTOR; DNA-BINDING; MYOCYTE DIFFERENTIATION; 3Q27 TRANSLOCATION; BCL-6 GENE; EXPRESSION	The Bc16 gent is located at chromosomal band 3q27, a breakpoint for translocation that frequently occurs in B cell lymphomas. Bc16 has been found to be preferentially expressed in germinal center B cells, and expression of this gene has been shown to be essential for germinal center formation in vivo. The physiological function of Bc16 and its role in lymphomagenesis, however, are not yet known, Since significant expression of Bc16 has been demonstrated in skeletal muscle, we have utilized a differentiation-inducible mouse myogenic cell line, C2C12, to elucidate the function of the Bc16 gene product. Expression of Bc16 mRNA was very low in growing myocytes, but was increased in differentiating myocytes cultured in serum-started medium, Incubation of these cells with cytokines or chemicals that are known to block differentiation suppressed this increased Bc16 message abundance, indicating that Bc16 induction is related to the process of terminal differentiation in muscle cells. While a fraction of myocytes is known to undergo apoptosis after serum-starvation to induce differentiation, adenovirus-mediated overexpression of Bc16 enhanced the viability of the differentiating cells by preventing the apoptosis, High levels of Bc16 antisense mRNA expression induced substantial apoptosis during the differentiation of C2C12 cells, but this,vas effectively prevented by infection with adenovirus that expressed Bc16 sense mRNA, These results indicate that Bc16 acts to prevent apoptotic cell death in differentiating myocytes. The deregulation of expression of this anti-apoptotic gene may also contribute to the development of B cell lymphomas.	Tokyo Med & Dent Univ, Fac Med, Dept Internal Med 1, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Fac Med, Sch Allied Hlth Sci, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Hirosawa, S (corresponding author), Tokyo Med & Dent Univ, Fac Med, Dept Internal Med 1, Tokyo 1138519, Japan.							Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1992, BLOOD, V79, P2527; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BUSKIN JN, 1985, J MOL EVOL, V22, P334, DOI 10.1007/BF02115689; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DIBELLO PR, 1991, GENETICS, V129, P385; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; FUKUDA T, 1995, ONCOGENE, V11, P1657; GUO K, 1995, MOL CELL BIOL, V15, P3823; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KIM SJ, 1992, J BIOL CHEM, V267, P15140; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; MIKI T, 1994, BLOOD, V83, P217; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OFFIT K, 1989, BLOOD, V74, P1876; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; Okada S, 1998, J IMMUNOL, V160, P2590; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596	45	54	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					467	475		10.1038/sj.onc.1202306	http://dx.doi.org/10.1038/sj.onc.1202306			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927203				2022-12-17	WOS:000078166500019
J	Bahr, A; De Graeve, F; Kedinger, C; Chatton, B				Bahr, A; De Graeve, F; Kedinger, C; Chatton, B			Point mutations causing Bloom's syndrome abolish ATPase and DNA helicase activities of the BLM protein	ONCOGENE			English	Article						ATFa; BLM; Bloom's syndrome; helicase	HIGH-EFFICIENCY TRANSFORMATION; BASIC TRANSCRIPTION FACTOR; SYNDROME GENE-PRODUCT; WERNERS-SYNDROME; IN-VIVO; NUCLEAR-LOCALIZATION; REPAIR; CELLS; ATFA; SGS1	Bloom's syndrome (BS) is a rare human genetic disorder characterized by mutations within the BLM gene whose primary effects are excessive chromosome breakaoge and increased rates of sister chromatide interchange in somatic cells. We report the characterization of a murine protein (mBLM), highly related to the product of the human BLM gene. This protein exhibits an ATP-dependent DNA-helicase activity that unwinds DNA in a 3'-5' direction. Single aminoacid substitutions found in BS cells, abolish both ATPase and helicase activities of this protein, indicating that defects in these BLM functions may be primarily responsible for BS establishment. These results provide the first evidence suggesting that the enzymatic activities of the BLM product are implicated in the upholding of genomic integrity.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Kedinger, C (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP163, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.		CHATTON, Bruno/R-3813-2019	DE GRAEVE, Fabienne/0000-0002-3455-7507; CHATTON, Bruno/0000-0003-4515-7119				AUSUBUEL FM, 1989, CURR PROTOC MOL BIOL; Bocco JL, 1996, ONCOGENE, V12, P1971; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ELLIS NA, 1994, AM J HUM GENET, V55, P453; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, AM J HUM GENET, V57, P1019; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Foucault F, 1997, HUM MOL GENET, V6, P1427, DOI 10.1093/hmg/6.9.1427; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1992, GENETICS OF HEMATOLOGICAL DISORDERS, P241; GERMAN J, 1994, P NATL ACAD SCI USA, V91, P6669, DOI 10.1073/pnas.91.14.6669; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Kaneko H, 1997, BIOCHEM BIOPH RES CO, V240, P348, DOI 10.1006/bbrc.1997.7648; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KORN R, 1995, NATURE, V378, P557, DOI 10.1038/378557a0; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; Mandel JL, 1997, NATURE, V386, P767, DOI 10.1038/386767a0; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Richards RI, 1997, TRENDS BIOCHEM SCI, V22, P432, DOI 10.1016/S0968-0004(97)01108-0; ROY R, 1994, J BIOL CHEM, V269, P9826; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	43	54	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	1998	17	20					2565	2571		10.1038/sj.onc.1202389	http://dx.doi.org/10.1038/sj.onc.1202389			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840919				2022-12-17	WOS:000077058900003
J	Battista, S; de Nigris, F; Fedele, M; Chiappetta, G; Scala, S; Vallone, D; Pierantoni, GM; Megar, T; Santoro, M; Viglietto, G; Verde, P; Fusco, A				Battista, S; de Nigris, F; Fedele, M; Chiappetta, G; Scala, S; Vallone, D; Pierantoni, GM; Megar, T; Santoro, M; Viglietto, G; Verde, P; Fusco, A			Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo	ONCOGENE			English	Article						transformation; AP-1; fra-1; thyroid carcinomas	C-JUN; TRANSCRIPTIONAL ACTIVATION; NEOPLASTIC TRANSFORMATION; BINDING-ACTIVITY; DELETION MUTANT; DNA-BINDING; EXPRESSION; FOS; ONCOGENE; LINE	We have recently reported that neoplastic transformation of two rat thyroid epithelial cell lines by retroviruses carrying the v-mos and v-ras Ki oncogenes is associated with a drastic increase of AP-1 activity. The most important effects were represented by the dramatic junB and fra-1 gene induction, which was abolished by the block of the transformation-induced HMGI-C protein synthesis. Here, we have further characterized the transformation-dependent AP-1 activity, by analysing the expression of different jun- and fos-related components, in rat thyroid cell lines transformed by several oncogenes, in human thyroid carcinoma cell lines, and in naturally occurring human thyroid rumours. A significant increase of Fra-1 and JunB protein levels was detected in all oncogene transformed rat thyroid cell lines, Fra-1 gene induction was demonstrated to occur also in human thyroid carcinoma cell lines and tissues, Conversely, c-Jun and JunD proteins, rather than JunB, accumulated in human thyroid carcinoma cell lines. An induction of AP-1 target genes was also detected both in rat and human thyroid transformed cell lines. Therefore, in vivo and in vitro thyroid cell transformation is associated with important compositional changes in the AP-1 complex and an increased transcriptional activity.	Ist Nazl Tumori, Fdn Senatore Pascale Oncol Sperimentale D & E, I-80131 Naples, Italy; CNR, Ist Int Genet & Biofis, I-80125 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Reggio Calabria, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria	Fusco, A (corresponding author), Ist Nazl Tumori, Fdn Senatore Pascale Oncol Sperimentale D & E, Via M Semmola, I-80131 Naples, Italy.		Pierantoni, Giovanna Maria/O-7527-2015; Viglietto, Giuseppe/AAC-2852-2019; Scala, Stefania/K-1380-2016; Fedele, Monica/C-1417-2015; Battista, Sabrina/AAY-2981-2020	Pierantoni, Giovanna Maria/0000-0003-4078-8528; Viglietto, Giuseppe/0000-0003-2327-7515; Scala, Stefania/0000-0001-9524-2616; Fedele, Monica/0000-0002-9171-1312; Battista, Sabrina/0000-0001-5899-9759; Fusco, Alfredo/0000-0003-3332-5197; de nigris, filomena/0000-0002-2322-1557				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P2261, DOI 10.1128/MCB.8.5.2261; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN PH, 1993, ONCOGENE, V8, P877; Cerutti J, 1996, CLIN CANCER RES, V2, P119; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; DECESARE D, 1995, ONCOGENE, V11, P365; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GACK S, 1994, J BIOL CHEM, V269, P10363; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GRUDA MC, 1994, ONCOGENE, V9, P2537; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Joseloff E, 1997, MOL CARCINOGEN, V18, P26, DOI 10.1002/(SICI)1098-2744(199701)18:1<26::AID-MC4>3.0.CO;2-P; KARDALINOU E, 1993, J CELL BIOCHEM, V52, P375, DOI 10.1002/jcb.240520402; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li JJ, 1996, CANCER RES, V56, P483; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MATSUI M, 1990, ONCOGENE, V5, P249; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Rosenberger SF, 1996, ONCOGENE, V12, P2301; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SITTMAN DB, 1983, P NATL ACAD SCI-BIOL, V80, P1849, DOI 10.1073/pnas.80.7.1849; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Vandel L, 1996, MOL CELL BIOL, V16, P1881; VIGLIETTO G, 1995, ONCOGENE, V11, P1569	49	54	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	1998	17	3					377	385		10.1038/sj.onc.1201953	http://dx.doi.org/10.1038/sj.onc.1201953			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690519				2022-12-17	WOS:000074947500012
J	Shanmugam, M; Krett, NL; Peters, CA; Maizels, ET; Murad, FM; Kawakatsu, H; Rosen, ST; Hunzicker-Dunn, M				Shanmugam, M; Krett, NL; Peters, CA; Maizels, ET; Murad, FM; Kawakatsu, H; Rosen, ST; Hunzicker-Dunn, M			Association of PKC delta and active Src in PMA-treated MCF-7 human breast cancer cells	ONCOGENE			English	Article						Src; protein kinase C; breast cancer	PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; HIGH-AFFINITY RECEPTOR; TYROSINE PHOSPHORYLATION; 3T3 CELLS; SIGNAL-TRANSDUCTION; PHORBOL ESTER; ACTIVATION; IDENTIFICATION; STIMULATION	Phorbol ester treatment of MCF-7 cells led to the tyrosine phosphorylation and activation of PKC delta, However, through Western blot analysis and in vitro immunecomplex kinase assays, me detected a differential localization of tyrosine-phosphorylated PKC delta and catalytically active PK delta. Catalytically active PKC delta was concentrated in Triton X-100 solubilized-membrane fractions while tyrosine-phosphorylated PKC delta was localized to the cytosol fraction, Phorbol ester treatment of MCF-7 cells stimulated both the time-dependent in ville association of Src with PKC delta, evidenced in Src immunoprecipitates by the co-immunoprecipitation of PKC delta, and activation of Src, evidenced in Src immunoprecipitates as an increase in reactivity with a Src antibody (clone 28) reactive only with active Src (dephosphorylated on residue 530) and in Src and PKC delta immunoprecipitates by an increase in Src kinase activity. While our data are consistent with reports in the literature showing the activator/stimulus-dependent tyrosine phosphorylation of PKC delta, our data show that the tyrosine phosphorylation of PKC delta is not essential for kinase activity, These results are the first to demonstrate an in vivo association between PKC delta and active Src in the absence of over-expression of either PKC delta or Src, and support the association of Src and PKC delta towards a physiological function.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94110 USA	Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of California System; University of California San Francisco	Hunzicker-Dunn, M (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.		Shanmugam, Mala/M-6491-2019	Shanmugam, Mala/0000-0002-4415-8083; Maizels, Evelyn/0000-0001-9072-1095	NCI NIH HHS [P30 CA60553] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CUTLER RE, 1993, BIOCHIM BIOPHYS ACTA, V1179, P260, DOI 10.1016/0167-4889(93)90081-Y; DARBON JM, 1986, BIOCHEM PHARMACOL, V35, P2683, DOI 10.1016/0006-2952(86)90175-9; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DeVente JE, 1996, J BIOL CHEM, V271, P32276, DOI 10.1074/jbc.271.50.32276; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FAUCHER C, 1993, J BIOL CHEM, V268, P15168; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; ISSANDOU M, 1988, CANCER RES, V48, P6943; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; Kosaka C, 1996, AM J PHYSIOL-CELL PH, V270, pC170, DOI 10.1152/ajpcell.1996.270.1.C170; LEHEL C, 1994, J BIOL CHEM, V269, P4761; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISHIMA K, 1994, BIOCHEM BIOPH RES CO, V201, P363, DOI 10.1006/bbrc.1994.1710; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; OHMICHI M, 1993, BIOCHEM J, V295, P767, DOI 10.1042/bj2950767; OHNO S, 1994, J BIOL CHEM, V269, P17495; Owen PJ, 1996, EXP CELL RES, V225, P366, DOI 10.1006/excr.1996.0187; REDMOND T, 1992, CELL GROWTH DIFFER, V3, P567; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; ROOS W, 1986, P NATL ACAD SCI USA, V83, P991, DOI 10.1073/pnas.83.4.991; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; WALKER F, 1993, J BIOL CHEM, V268, P19552; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	40	54	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1649	1654		10.1038/sj.onc.1201684	http://dx.doi.org/10.1038/sj.onc.1201684			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582012				2022-12-17	WOS:000072807600002
J	Kim, SK; Su, LK; Oh, Y; Kemp, BL; Hong, WK; Mao, L				Kim, SK; Su, LK; Oh, Y; Kemp, BL; Hong, WK; Mao, L			Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines	ONCOGENE			English	Article						SCLC; PTEN/MMAC1; PTH2; chromosome 9; tumor suppressor	HOMOZYGOUS DELETION; CARCINOMA; MUTATIONS; RB; PROTEIN; CDKN2	Loss of heterozygosity (LOH) at chromosome 10q23-q25 is frequent in small cell lung cancer (SCLC), indicating the presence of putative tumor suppressor genes, PTEN/MMAC1, a newly cloned candidate tumor suppressor gene at 10q23, was mutated in multiple human cancers, We investigated whether mutations of PTEN/MMAC1 play an important role in SCLC tumorigenesis, We examined 16 SCLC cell lines for PTEN/MMAC1 mRNA expression by reverse-transcriptase polymerase chain reaction (RT-PCR) and potential mutations by sequencing analysis of the PTEN/MMAC1 coding region, No mutation was observed in PTEN/MMAC1 cDNAs in 15 cell lines expressing PTEN/MMAC1, One SCLC cell line, DMS79, did not have detectable PTEN/MMAC1 expression, Importantly, we identified a novel homologue of PTEN/MMAC1, termed PTH2, localized to chromosome 9p21-q13 and containing only ten amino acid substitutions compared with the PTEN/MMAC1 coding region, However, because the putative initiation codon for PTEN/MMAC1 gene was changed to arginine in PTH2, the translational initiation site of PTH2 is very likely to differ from that of the PTEN/MMAC1, PTH2 was expressed in two normal lung tissues and two normal colon tissues, but in only four of 16 SCLC cell lines, A missense mutation in PTH2 was identified in a SCLC cell line that did not express PTEN/MMAC1 mRNA, Our data suggest that inactivation of PTEN/MMAC1 is a rare event in SCLC tumorigenesis, However, the PTEN/MMAC1 homologue PTH2 may play a role in SCLC tumorigenesis.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mao, L (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358	NATIONAL CANCER INSTITUTE [P50CA070907, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA 70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; FEARON ER, 1990, CELL, V61, P757; HOSOE S, 1994, CANCER RES, V54, P1787; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; Kim SK, 1997, CANCER RES, V57, P400; Kim SK, 1996, CANCER RES, V56, P2519; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P2322; MERLO A, 1994, CANCER RES, V54, P640; MILLER CW, 1992, CANCER RES, V52, P1695; MORI N, 1990, ONCOGENE, V5, P1713; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Ohta M, 1996, INT J CANCER, V65, P762, DOI 10.1002/(SICI)1097-0215(19960315)65:6<762::AID-IJC9>3.0.CO;2-X; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; RIED T, 1994, CANCER RES, V54, P1801; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Wiest JS, 1997, CANCER RES, V57, P1; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	26	54	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					89	93		10.1038/sj.onc.1201512	http://dx.doi.org/10.1038/sj.onc.1201512			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467947	Bronze			2022-12-17	WOS:000071236800011
J	VarmehZiaie, S; Okan, I; Wang, YS; Magnusson, KP; Warthoe, P; Strauss, M; Wiman, KG				VarmehZiaie, S; Okan, I; Wang, YS; Magnusson, KP; Warthoe, P; Strauss, M; Wiman, KG			Wig-1, a new p53-induced gene encoding a zinc finger protein	ONCOGENE			English	Article						p53; differential display; zinc finger protein	WILD-TYPE P53; DIFFERENTIAL DISPLAY; MESSENGER-RNA; APOPTOSIS; EXPRESSION; ARREST; CELLS; BAX; IDENTIFICATION; ACTIVATION	Wild type p53 expressed from a temperature-sensitive (ts p53) construct induces both G1 cell cycle arrest and apoptosis in the p53-negative J3D mouse T lymphoma line (Wang et al., 1995). Using differential display analysis, we have identified one new p53-induced gene, wig-1 (for mild type p53-induced gene 1), whose 7.6 kb and 2.2 kb transcripts are upregulated in ts p53-transfected J3D cells following induction of wild type p53 expression by temperature shift to 32 degrees C. The wig-1 transcripts were also induced in irradiated NIH3T3 and p21(-/-) fibroblasts but not in irradiated p53(-/-) fibroblasts. Whole body gamma irradiation caused induction of both wig-1 transcripts in mouse brain, testis, kidney, spleen and lung. A basal wig-1 expression was detected in brain, testis and kidney. The WIG-1 protein contains three zinc finger motifs and a putative nuclear localization signal.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; DANISH CANC SOC,DIV CANC BIOL,DK-2100 COPENHAGEN,DENMARK	Karolinska Institutet; Danish Cancer Society			Magnusson, Kristinn P Pétur/X-4907-2019; Magnusson, Kristinn/A-6479-2011; Wiman, Klas/AAB-8399-2021	Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Magnusson, Kristinn/0000-0003-4528-6826; Wiman, Klas/0000-0002-7113-524X; Warthoe, peterwarthoe@gmail.com/0000-0003-3840-5460				BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUNT T, 1985, NATURE, V316, P580, DOI 10.1038/316580a0; ISRAELI D, 1997, IN PRESS EMBO J; KASTAN MB, 1991, CANCER RES, V51, P6304; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; MacCallum DE, 1996, ONCOGENE, V13, P2575; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MIYASHITA T, 1995, CELL, V80, P293; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PIENTENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sambrook J, 1989, MOL CLONING LAB MANU; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	25	54	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2699	2704		10.1038/sj.onc.1201454	http://dx.doi.org/10.1038/sj.onc.1201454			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400996				2022-12-17	WOS:A1997YH46800007
J	Baldassarre, G; Romano, A; Armenante, F; Rambaldi, M; Paoletti, I; Sandomenico, C; Pepe, S; Staibano, S; Salvatore, G; DeRosa, G; Persico, MG; Viglietto, G				Baldassarre, G; Romano, A; Armenante, F; Rambaldi, M; Paoletti, I; Sandomenico, C; Pepe, S; Staibano, S; Salvatore, G; DeRosa, G; Persico, MG; Viglietto, G			Expression of teratocarcinoma-derived growth factor-1 (TDGF-1) in testis germ cell tumors and its effects on growth and differentiation of embryonal carcinoma cell line NTERA2/D1	ONCOGENE			English	Article						TDGF-1; teratocarcinoma; seminoma; cell differentiation	HEXAMETHYLENE BISACETAMIDE HMBA; FACTOR-RELATED PROTEIN; RETINOIC ACID; FACTOR-ALPHA; COLORECTAL TUMORS; TGF-ALPHA; CANCER; CRIPTO; GENE; AMPHIREGULIN	The teratocarcinoma-derived growth factor-1 (TDGF-1) gene codes for a 188-aminoacid glycoprotein that shares structural homology with the epidermal growth factor (EGF) family of growth factors, TDGF-1 is highly expressed in the undifferentiated embryonal carcinoma stem cell line NTERA2 clone D1 (NT2/D1) and its expression is downregulated in response to differentiating agents such as retinoic acid (RA) and hexamethylen-bisacetamide (HMBA), To assess the role of TDGF-1 in the onset and/or progression of human germ cell tumors, we analysed TDGF-1 expression by Northern blot and immunostaining in a panel of 59 human germ cell tumors of different histological origins, We show that TDGF-1 expression is markedly elevated in a subset of human testicular germ cell tumors as compared to normal testes, TDGF-1 overexpression occurs in about 100% of tumors with non-seminomatous phenotype, such as embryonal carcinomas and malignant undifferentiated teratocarcinomas, To address the questions of how TDGF-1 (previously called CRIPTO) may affect the growth and/or the differentiation of embryonal carcinoma cells, we have characterized the effects of exogenous recombinant TDGF-1 protein on the proliferation rate and differentiation potential of NT2/D1, Exogenous TDGF-1 protein stimulated DNA synthesis and cell proliferation in both undifferentiated and differentiated NT2/D1 cells, However, TDGF-1 protein treatment was unable to block differentiation induced by both RA and HMBA, These results suggest that TDGF-1 growth factor may represent an autocrine growth factor that may be involved in the process of development of testicular neoplasms.	CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY; FDN SENATORE PASCALE,IST NAZL TUMORI NAPOLI,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,DIPARTIMENTO ENDOCRINOL & ONCOL SPERIMENTALE & CL,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,IST PATOL,I-80131 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); IRCCS Fondazione Pascale; University of Naples Federico II; University of Naples Federico II			Viglietto, Giuseppe/AAC-2852-2019; Baldassarre, Gustavo/K-1350-2016	Viglietto, Giuseppe/0000-0003-2327-7515; Baldassarre, Gustavo/0000-0002-9750-8825; DE ROSA, Gaetano/0000-0002-3635-5853; Sandomenico, Claudia/0000-0003-3709-0807				ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Baldassarre G, 1996, INT J CANCER, V66, P538, DOI 10.1002/(SICI)1097-0215(19960516)66:4<538::AID-IJC19>3.0.CO;2-3; BASELGA J, 1993, ONCOGENE, V8, P3257; BOS JL, 1989, CANCER RES, V49, P4682; BRANDT R, 1994, J BIOL CHEM, V269, P17320; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CIARDIELLO F, 1994, ONCOGENE, V9, P291; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DMITROVSKY E, 1990, ONCOGENE, V5, P534; DONO R, 1993, DEVELOPMENT, V118, P1157; KURIE JM, 1993, DIFFERENTIATION, V54, P115; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MURTY VVV, 1994, ONCOGENE, V9, P3228; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; SAEKI T, 1992, CANCER RES, V52, P3467; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SALOMON DS, 1995, CURRENT OPINION ENDO, V2, P500; Sambrook J, 1989, MOL CLONING LAB MANU; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPORN MB, 1992, ANN INTERN MED, V117, P408, DOI 10.7326/0003-4819-117-5-408; TIENARI J, 1995, DIFFERENTIATION, V59, P193, DOI 10.1046/j.1432-0436.1995.5930193.x; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; ULBRIGHT TM, 1994, DIAGNOSTIC SURG PATH, V46, P1885	38	54	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					927	936		10.1038/sj.onc.1201260	http://dx.doi.org/10.1038/sj.onc.1201260			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285688				2022-12-17	WOS:A1997XR76700006
J	Kim, E; Albrechtsen, N; Deppert, W				Kim, E; Albrechtsen, N; Deppert, W			DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53	ONCOGENE			English	Article						p53 DNA binding; DNA conformation; p53 conformation; p53 consensus sequence	WILD-TYPE; GENE-EXPRESSION; PROTEIN; TRANSCRIPTION; NUCLEI; IDENTIFICATION; ENHANCER; ELEMENT; DOMAIN; CELLS	Sequence-specific transactivation of target genes is one of the most important molecular properties of the tumor suppressor p53. Binding of p53 to its target DNAs is tightly regulated, with modifications in the carboxyterminal regulatory domain of the p53 protein playing an important role. In this study we examined the possible influence of DNA structure on sequence-specific DNA binding by p53, by analysing its binding to p53 consensus elements adopting different conformations. We found that p53 has the ability to bind to consensus elements which are present in a double-helical form, as well as to consensus elements which are located within alternative non-B-DNA structures. The ability of a consensus element to adopt either one of these conformations is dependent on its sequence symmetry, and is strongly influenced by its sequence environment. Our data suggest a model according to which the conformational status of the target DNA is an important determinant for sequence-specific DNA binding by p53. Modifications in the carboxy-terminal regulatory region of p53 possibly determine the preference of p53 for a given DNA conformation.	UNIV HAMBURG,HEINRICH PETTE INST EXPT VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY	Heinrich Pette Institute; University of Hamburg			Holst, Jens/AAA-8022-2022					Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DAYN A, 1992, NUCLEIC ACIDS RES, V20, P5991, DOI 10.1093/nar/20.22.5991; DELIC J, 1991, BIOCHEM BIOPH RES CO, V181, P818, DOI 10.1016/0006-291X(91)91263-C; Deppert W, 1996, J CELL BIOCHEM, V62, P172, DOI 10.1002/(SICI)1097-4644(199608)62:2<172::AID-JCB5>3.0.CO;2-P; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P185; DROGE P, 1994, BIOESSAYS, V16, P91, DOI 10.1002/bies.950160205; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Flaman JM, 1996, ONCOGENE, V12, P813; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HANKE JH, 1995, J MOL BIOL, V246, P63, DOI 10.1006/jmbi.1994.0066; Hecker D, 1996, ONCOGENE, V12, P953; HERBERT AG, 1993, P NATL ACAD SCI USA, V90, P3339, DOI 10.1073/pnas.90.8.3339; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LEITH IR, 1993, BIOCHEM BIOPH RES CO, V196, P601, DOI 10.1006/bbrc.1993.2292; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MAYFIELD C, 1994, NUCLEIC ACIDS RES, V22, P1909, DOI 10.1093/nar/22.10.1909; MCCLELLAN JA, 1990, P NATL ACAD SCI USA, V87, P8373, DOI 10.1073/pnas.87.21.8373; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MIYASHITA T, 1995, CELL, V80, P293; Muller BF, 1996, ONCOGENE, V12, P1941; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; PEARSON CE, 1995, EMBO J, V14, P1571, DOI 10.1002/j.1460-2075.1995.tb07143.x; PRIVES C, 1994, COLD SPRING HARB SYM, V59, P207, DOI 10.1101/SQB.1994.059.01.025; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SOLARO P, 1995, EUR J BIOCHEM, V230, P926, DOI 10.1111/j.1432-1033.1995.tb20638.x; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; SPIRO C, 1995, J BIOL CHEM, V270, P27702, DOI 10.1074/jbc.270.46.27702; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WANG Y, 1995, ONCOGENE, V10, P779; WARD GK, 1991, EXP CELL RES, V195, P92, DOI 10.1016/0014-4827(91)90503-M; WARD GK, 1990, EXP CELL RES, V188, P235, DOI 10.1016/0014-4827(90)90165-7; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Waterman MJF, 1996, CANCER RES, V56, P158; WEISSKER S, 1992, ONCOGENE, V7, P155; WITTIG B, 1989, J CELL BIOL, V108, P755, DOI 10.1083/jcb.108.3.755; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zhao JQ, 1996, ONCOGENE, V13, P293	70	54	55	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					857	869		10.1038/sj.onc.1201412	http://dx.doi.org/10.1038/sj.onc.1201412			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266973				2022-12-17	WOS:A1997XQ11700013
J	MarcosGutierrez, CV; Wilson, SW; Holder, N; Pachnis, V				MarcosGutierrez, CV; Wilson, SW; Holder, N; Pachnis, V			The zebrafish homologue of the ret receptor and its pattern of expression during embryogenesis	ONCOGENE			English	Article						tyrosine kinase receptor; zebrafish; c-ret proto-oncogene; nervous system; excretory system	TYROSINE KINASE; SIGNAL TRANSDUCTION; PROTO-ONCOGENE; RETICULOSPINAL NEURONS; AXONAL OUTGROWTH; PROTOONCOGENE; MUTATIONS; ACTIVATION; CADHERIN; EMBRYOS	The c-ret proto-oncogene, a member of the receptor tyrosine kinase gene superfamily, plays a critical role in the development of the excretory system and the enteric and autonomic nervous systems of mammalian embryos. To study the potential function of the c-vet locus in lower vertebrates, we have isolated its zebrafish homologue, ret1 and established its expression pattern during embryogenesis. Ret1 mRNA first appears during early somitogenesis in the presumptive brain, spinal cord and excretory system. Within the CNS, expression of ret1 is detected in primary motor and sensory (Rohon-Beard) neurons. Ret1 transcripts are also expressed in subsets of neural crest cells and cranial ganglia as well as in the enteric nervous system. In the excretory system, expression is detected in the developing nephric duct and the pronephros. Our findings reveal a remarkable similarity in the expression pattern of c-ret between higher and lower vertebrates, suggesting that the function of this locus has been conserved throughout vertebrate evolution. Furthermore, the conservation of ret1 expression in cell types which remain unaffected by the mammalian c-vet mutations, such as motor and sensory neurons, suggests a function of this receptor in these cell lineages.	NATL INST MED RES, DIV DEV NEUROBIOL, LONDON NW7 1AA, ENGLAND; UNIV LONDON KINGS COLL, RANDALL INST, DIV BIOMED SCI, RES CTR, LONDON WC2B 5RL, ENGLAND	MRC National Institute for Medical Research; University of London; King's College London			Wilson, Stephen W/B-9404-2008	Wilson, Stephen W/0000-0002-8557-5940; Pachnis, Vassilis/0000-0001-9733-7686				Appel B, 1995, DEVELOPMENT, V121, P4117; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; EISEN JS, 1990, J NEUROSCI, V10, P34; EISEN JS, 1991, SCIENCE, V252, P569, DOI 10.1126/science.1708527; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Green MC., 1989, GENETIC VARIANTS STR, P12; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUNTER T, 1990, ADV SEC MESS PHOSPH, V24, P260; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KORZH V, 1993, DEVELOPMENT, V118, P417; MASLAND RH, 1993, J NEUROSCI, V13, P5194, DOI 10.1523/JNEUROSCI.13-12-05194.1993; MENDELSON B, 1986, J COMP NEUROL, V251, P160, DOI 10.1002/cne.902510203; MENDELSON B, 1986, J COMP NEUROL, V251, P172, DOI 10.1002/cne.902510204; METCALFE WK, 1990, DEVELOPMENT, V110, P491; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MYERS PZ, 1986, J NEUROSCI, V6, P2278; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; ROBERTSON K, 1995, MECH DEVELOP, V53, P329, DOI 10.1016/0925-4773(95)00449-1; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; TSUZUKI T, 1995, ONCOGENE, V10, P191; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Weinberg E.S., 1992, Results and Problems in Cell Differentiation, V18, P91; Westerfield M, 1994, ZEBRAFISH BOOK; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; XU QL, 1994, DEVELOPMENT, V120, P287	52	54	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					879	889		10.1038/sj.onc.1201048	http://dx.doi.org/10.1038/sj.onc.1201048			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050987				2022-12-17	WOS:A1997WK34400001
J	Noble, JR; Rogan, EM; Neumann, AA; Maclean, K; Bryan, TM; Reddel, RR				Noble, JR; Rogan, EM; Neumann, AA; Maclean, K; Bryan, TM; Reddel, RR			Association of extended in vitro proliferative potential with loss of p16(INK4) expression	ONCOGENE			English	Article						p16(INK4); RB; telomeres; telomerase; senescence; immortalisation	TUMOR-SUPPRESSOR GENE; FRAUMENI SYNDROME FIBROBLASTS; HUMAN PAPILLOMAVIRUS TYPE-16; KINASE-4 INHIBITOR GENE; SQUAMOUS-CELL CARCINOMA; LARGE T-ANTIGEN; TELOMERASE ACTIVITY; EPITHELIAL-CELLS; HUMAN CANCER; FAMILIAL MELANOMA	This study addresses the question of whether loss of p16(INK4) expression contributes to the immortalization of human cells. in vitro immortalization usually proceeds through two phases. In the first phase (lifespan extension), cells continue proliferating and their telomeres continue shortening beyond the point at which normal cells become senescent. In the second phase (immortalization), the cells activate a telomere maintenance mechanism and acquire an unlimited proliferative potential. It has previously been shown that immortalized cells containing viral oncoproteins that bind and inactivate p110(RB) contain wild-type p16(INK4); we therefore examined the p16(INK4) status Of cell lines that became immortalized in vitro in the absence of these oncoproteins. Three such lines were identified: III-CF/ .2A1 and III-CF/E6A2 (both derived from Li-Fraumeni syndrome fibroblasts, probably by spontaneous immortalization) and MePV-23I (normal mesothelial cells transfected with HPV-16 E6/E7 genes that underwent deletion of these genes before immortalization). In each case p16(INK4) expression was lost at or before immortalization. Further, a cell strain was identified that had an extended but finite lifespan associated with loss of p16(INK4) (and p53) expression. Thus loss of p16(INK4) expression was associated with extended in vitro lifespan but was not sufficient for immortalization, even in the absence of wild-type p53.	CHILDRENS MED RES INST,WESTMEAD,NSW 2145,AUSTRALIA	Children's Medical Research Institute - Australia			Reddel, Roger R/A-6635-2014; Bryan, Tracy M/B-8468-2014; Neumann, Axel/D-3319-2012	Reddel, Roger R/0000-0002-6302-6107; Bryan, Tracy/0000-0002-7990-5501				AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; ARAP W, 1995, CANCER RES, V55, P1351; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BRENNER AJ, 1995, CANCER RES, V55, P2892; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHADENEAU C, 1995, CANCER RES, V55, P2533; CHENG JQ, 1994, CANCER RES, V54, P5547; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1995, TELOMERES, P265; DESILVA R, 1994, EXP CELL RES, V213, P418, DOI 10.1006/excr.1994.1218; DREYLING MH, 1995, CANCER RES, V55, P984; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JIN XM, 1995, CANCER RES, V55, P3250; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KE Y, 1989, AM J PATHOL, V134, P979; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LAVECK MA, 1988, IN VITRO CELL DEV B, V24, P1077; LI Y, 1994, CANCER RES, V54, P6078; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; MACLEAN K, 1994, ONCOGENE, V9, P719; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORI T, 1994, CANCER RES, V54, P3396; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUNGER K, 1989, J VIROL, V63, P4417; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; NILSSON P, 1994, ONCOGENE, V9, P3043; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; REED JA, 1995, CANCER RES, V55, P2713; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROSE BR, 1995, GYNECOL ONCOL, V56, P239, DOI 10.1006/gyno.1995.1039; SCHULZE A, 1994, ONCOGENE, V9, P3475; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAM SW, 1994, CANCER RES, V54, P5816; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; XU L, 1994, CANCER RES, V54, P5262; YEAGER T, 1995, CANCER RES, V55, P493; ZHANG SY, 1994, CANCER RES, V54, P5050	61	54	57	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1259	1268						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808700				2022-12-17	WOS:A1996VJ20200017
J	Milne, DM; McKendrick, L; Jardine, LJ; Deacon, E; Lord, JM; Meek, DW				Milne, DM; McKendrick, L; Jardine, LJ; Deacon, E; Lord, JM; Meek, DW			Murine p53 is phosphorylated within the PAb421 epitope by protein kinase C in vitro, but not in vivo, even after stimulation with the phorbol ester o-tetradecanoylphorbol 13-acetate	ONCOGENE			English	Article						p53; phosphorylation; protein kinase C; PAb421 epitope	WILD-TYPE P53; TUMOR SUPPRESSOR PROTEIN; CELL-CYCLE; GENE AMPLIFICATION; IRRADIATION; APOPTOSIS; ARREST	The p53 tumour suppressor protein is thought to play a major role in the defence of the cell against agents which damage DIVA, p53 is phosphorylated at multiple sites in vivo and by several different protein kinases in vitro. In this report, we have examined the phosphorylation of murine p53 by protein kinase C (PKC). Phosphopeptide mapping, phosphoamino acid analysis and radiosequence analysis of p53 phosphorylated by PKC in vitro indicated that serine 370 and threonine 377 were the major targets for phosphorylation and suggested that serine 372 and threonines 365 and 371 were minor phosphorylation sites, Site-directed mutagenesis confirmed that residues 370-372, all of which lie within the epitope for monoclonal antibody PAb421, were phosphorylated in vitro. The p53 from P-32-labelled SV3T3 cells showed a phosphopeptide pattern which includes peptides with mobilities similar to those arising from phosphorylation of residues 370-372 by PKC in vitro. Only two of these in vivo-labelled phosphopeptides co-migrated in two dimensions with peptides labelled in vitro within the PAb421 eptiope and their phosphorylation was not stimulated by the addition of the PKC activator o-tetradecanoylphorbol 13-acetate (TPA) to the cells, even though this treatment led to a fourfold stimulation of p53 phosphorylation by MAP kinase, Moreover, when the p53 proteins containing mutations at residues 370-372 were expressed in COS cells, there was no loss of any of the in vivo phosphopeptides, indicating that phosphorylation within the PAb421 epitope was undetectable in the cell, These data suggest that p53 and PKC may not interact in vivo. The two-dimensional migration pattern of the novel group of peptides is consistent with phosphorylation of previously uncharacterised sites within the central DNA binding region of p53.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, BIOMED RES CTR, DUNDEE DD1 9SY, SCOTLAND; UNIV BIRMINGHAM, SCH MED, DEPT IMMUNOL, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND	University of Dundee; University of Birmingham				Lord, Janet/0000-0003-1030-6786				BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCKENDRICK L, 1994, CELL MOL BIOL RES, V40, P555; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, ONCOGENE, V5, P1683; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Shaw P, 1996, ONCOGENE, V12, P921; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	29	54	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					205	211						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700548				2022-12-17	WOS:A1996UX31900024
J	Zhu, JG; Guo, SZ; Beggs, AH; Maruyama, T; Santarius, T; Dashner, K; Olsen, N; Wu, JK; Black, P				Zhu, JG; Guo, SZ; Beggs, AH; Maruyama, T; Santarius, T; Dashner, K; Olsen, N; Wu, JK; Black, P			Microsatellite instability analysis of primary human brain tumors	ONCOGENE			English	Article						brain neoplasms; polymerase chain reaction; microsatellite markers; loss of heterozygosity; replication errors; microsatellite instability	COLORECTAL-CANCER; GENETIC INSTABILITY; MUTATIONS; CARCINOMA; HOMOLOG; REPEAT; COLON; LOCUS; DNA	Microsatellite instability, as shown by the presence of additional alleles or shifts of electrophoretic mobility at simple sequence tandem repeat loci, has been demonstrated in hereditary and sporadic colorectal tumors and many other tumor types. To study microsatellite instability in human brain tumors, we examined a total of 144 sporadic neoplasms. These included 33 astrocytic tumors, 23 oligodendrogliomas, six gangliogliomas, 41 meningiomas, 10 vestibular schwannomas and 31 pituitary adenomas. Di-, tri- and tetranucleotide repeat microsatellite markers localized on chromosome 4 and 9, X, 13 and 22, respectively, were used to assess whether instability was a significant aspect of their abnormal chromosomal pattern. Instability of microsatellite markers was detected in four oligodendrogliomas (17.4%), one pituitary adenoma (3.2%), one meningioma (2.4%), one astrocytic tumor (3.0%) and not at all in gangliogliomas and schwannomas. Therefore, our results suggest that the microsatellite instability which occurs in colorectal cancers with defective mismatch repair is infrequent in many types of human brain tumors and that the lower level of instability observed in brain tumors may be reflective of other mechanisms of genetic instability.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHILDRENS HOSP,DANA FARBER CANC INST,NEUROSURG LABS,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHILDRENS HOSP,DANA FARBER CANC INST,BRAIN TUMOR CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHILDRENS HOSP,DIV GENET,BOSTON,MA 02115; TUFTS UNIV,NEW ENGLAND MED CTR,DEPT NEUROSURG,BOSTON,MA 02111	Harvard University; Boston Children's Hospital; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Tufts Medical Center; Tufts University				Beggs, Alan/0000-0001-8818-0568				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLACK PM, 1991, NEW ENGL J MED, V324, P1555, DOI 10.1056/NEJM199105303242205; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUETOW KH, 1993, GENOMICS, V18, P329, DOI 10.1006/geno.1993.1473; BURKS RT, 1994, ONCOGENE, V9, P1163; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; ICHIMURA K, 1994, CANCER RES, V54, P3127; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOTHE RA, 1993, CANCER RES, V53, P5849; MERIO A, 1994, CANCER RES, V54, P2098; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; Petrukhin Konstantin E., 1992, Human Molecular Genetics, V1, P349, DOI 10.1093/hmg/1.5.349; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SHAPIRO S, 1989, J NEUROSURG, V71, P77, DOI 10.3171/jns.1989.71.1.0077; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SUN Y, 1992, BIOTECHNIQUES, V12, P639; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VENTER DJ, 1991, ONCOGENE, V6, P445; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; Wu J K, 1992, Neurol Res, V14, P39; YANDELL DW, 1989, AM J HUM GENET, V45, P547; YEE CJ, 1994, CANCER RES, V54, P1641; ZHU JG, 1994, J CLIN ENDOCR METAB, V78, P922, DOI 10.1210/jc.78.4.922	43	54	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1417	1423						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622857				2022-12-17	WOS:A1996UF07600005
J	Biggs, PJ; Chapman, P; Lakhani, SR; Burn, J; Stratton, MR				Biggs, PJ; Chapman, P; Lakhani, SR; Burn, J; Stratton, MR			The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas	ONCOGENE			English	Article						cylindroma; cylindromatosis; tumour suppressor gene	BASAL-CELL ADENOMA; TURBAN TUMOR; PAROTID-GLAND; DERMAL CYLINDROMAS; RETINOBLASTOMA; PATIENT; CANCER	Hereditary cylindromatosis is a rare autosomal dominant disease characterised by the development of multiple benign neoplasms of the skin, We recently localised the gene responsible for this disease (cyld1) to chromosome 16q12-q13 and provided evidence that it is a tumour suppressor gene (Biggs et al., 1995). We have now examined polymorphic markers on every chromosome, some of which are close to known tumour suppressor genes, in 25 tumours from 4 individuals with familial cylindromatosis, No loss of heterozygosity (LOH) was detected other than at loci on chromosome 16q. This observation suggests that the cyld1 gene may be the only tumour suppressor gene implicated in the development of cylindromas. We have also demonstrated LOH using markers on chromosome 16q in 8/14 (57%) sporadic cylindromas, indicating that the cyld1 gene is likely to be involved in the genesis of both familial and sporadic cylindromas.	INST CANC RES,HADDOW LABS,MOLEC CARCINOGENESIS SECT,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV NEWCASTLE,DIV HUMAN GENET,NEWCASTLE TYNE NE2 4AA,TYNE & WEAR,ENGLAND; ROYAL MARSDEN NHS TRUST,DEPT HISTOPATHOL,SUTTON SM2 5PT,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK; Newcastle University - UK; Royal Marsden NHS Foundation Trust			Lakhani, Sunil R/I-1970-2018; Biggs, Patrick Jon/H-3355-2014	Lakhani, Sunil R/0000-0003-4067-2760; Biggs, Patrick Jon/0000-0002-0285-4101; Burn, John/0000-0002-9823-2322				ABENOZA P, 1990, NEOPLASMS ECCRINE DI, P253; ALAWI MH, 1982, BRIT J PLAST SURG, V35, P167, DOI 10.1016/0007-1226(82)90157-6; AUTIOHARMAINEN H, 1988, CANCER-AM CANCER SOC, V61, P161, DOI 10.1002/1097-0142(19880101)61:1<161::AID-CNCR2820610127>3.0.CO;2-1; BIGGS PJ, 1995, IN PRESS NATURE GENE; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; COLLINS N, 1995, ONCOGENE, V10, P1673; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; FABIAN RL, 1981, HEAD NECK SURG, V4, P165, DOI 10.1002/hed.2890040214; FERRANDIZ C, 1985, J CUTAN PATHOL, V12, P72, DOI 10.1111/j.1600-0560.1985.tb00432.x; FREEDMAN AM, 1989, ANN PLAS SURG, V22, P50, DOI 10.1097/00000637-198901000-00010; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Harper P S, 1971, Birth Defects Orig Artic Ser, V7, P338; HYMA BA, 1988, ARCH PATHOL LAB MED, V112, P209; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Lever W. F., 1990, HISTOPATHOLOGY SKIN; PINGITORE R, 1984, TUMORI, V70, P385, DOI 10.1177/030089168407000415; REINGOLD IM, 1977, CANCER, V40, P1702, DOI 10.1002/1097-0142(197710)40:4<1702::AID-CNCR2820400446>3.0.CO;2-A; SATO S, 1994, CANCER RES, V54, P5652; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; STRATTON MR, 1995, J PATHOL, V175, P195, DOI 10.1002/path.1711750207; VERNON HJ, 1988, J AM ACAD DERMATOL, V19, P397, DOI 10.1016/S0190-9622(88)70186-3; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	23	54	54	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1375	1377						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649842				2022-12-17	WOS:A1996UC06700025
J	Bonapace, IM; Addeo, R; Altucci, L; Cicatiello, L; Bifulco, M; Laezza, C; Salzano, S; Sica, V; Bresciani, F; Weisz, A				Bonapace, IM; Addeo, R; Altucci, L; Cicatiello, L; Bifulco, M; Laezza, C; Salzano, S; Sica, V; Bresciani, F; Weisz, A			17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation	ONCOGENE			English	Article						estrogen; cell cycle; mevalonate; HMG-CoA reductase; c-fos; ras	HUMAN-BREAST-CANCER; ESTROGEN RESPONSE ELEMENT; C-FOS PROTOONCOGENE; GROWTH-INHIBITION; RECEPTOR; IDENTIFICATION; LOVASTATIN; SERUM; GENE; LINE	HMG-CoA reductase inhibitors, such as Lovastatin and Simvastatin, cause cell cycle arrest by interfering with the mitogenic activity of mitogens present in culture media. Cells are induced to pause in G(1) and can readily resume growth upon removal of the enzymatic block. Estrogens, acting via their nuclear receptor, are mitogens for different normal and transformed cell types, where they foster cell cycle progression and cell division. In estrogen-responsive MCF-7 human breast cancer cells, but not in non responsive cells, 17 beta-estradiol (E(2)) induces cells arrested with Lovastatin or Simvastatin to proliferate in the presence of inhibitor, without restoring HMG-CoA reductase activity or affecting the protein prenylation pattern. Mitogenic stimulation of G(1)-arrested MCF-7 cells with E(2) includes primary transcriptional activation of c-fos, accompanied by transient binding in vivo of the estrogen receptor and/or other factors to the ERE and the estrogen-responsive DNA region of this proto-oncogene, as detected by dimethylsulphate genomic footprinting analysis. Mitogenic stimulation of growth-arrested MCF-7 cells by E(2) occurs, under these conditions, without evident activation of ERK-1 and -2 kinases, and thus independently from the mitogen-responsive signal transduction pathways that converge on these enzymes.	UNIV NAPLES 2, FAC MED & CHIRURG, IST PATOL GEN & ONCOL, I-80138 NAPLES, ITALY; UNIV NAPLES FEDERICO II, CNR, CEOS, NAPLES, ITALY; UNIV REGGIO CALABRIA, DIPARTIMENTO MED SPERIMENTALE & CLIN, CATANZARO, ITALY; UNIV NAPLES FEDERICO II, DIPARTIMENTO BIOL & PATOL CELLULARE & MOL L CALIF, NAPLES, ITALY	Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria; University of Naples Federico II			Altucci, Lucia/S-8031-2019; laez, chi/AAW-4437-2020; Weisz, Alessandro/A-1317-2014	Weisz, Alessandro/0000-0003-0455-2083; Bifulco, Maurizio/0000-0002-1771-4531; altucci, lucia/0000-0002-7312-5387; BONAPACE, IAN MARC/0000-0001-6580-8893				ABBONDANZA C, 1993, STEROIDS, V58, P4, DOI 10.1016/0039-128X(93)90011-B; AMBROSINO C, 1993, MOL ENDOCRINOL, V7, P1472, DOI 10.1210/me.7.11.1472; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; BARBU V, 1990, ONCOGENE, V5, P1077; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRIAND P, 1986, ANTICANCER RES, V6, P85; BRUNNER N, 1989, CANCER RES, V49, P1515; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CICATIELLO L, 1993, RECEPTOR, V3, P17; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAVIDSON NE, 1989, ONCOGENESIS, V1, P89; DECLUE JE, 1991, CANCER RES, V51, P712; DEY A, 1991, DNA CELL BIOL, V10, P537, DOI 10.1089/dna.1991.10.537; DOYLE A, 1994, CELL TISSUE CULTURE; DUBIK D, 1992, ONCOGENE, V7, P1587; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRIECO D, 1990, J BIOL CHEM, V265, P19343; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HU AW, 1994, MOL CELL BIOL, V14, P8202; HYDER SM, 1992, J BIOL CHEM, V267, P18047; IACOBELLI S, 1984, J STEROID BIOCHEM, V20, P747, DOI 10.1016/0022-4731(84)90079-7; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KNOWLER JT, 1985, ESSAYS BIOCHEM, V20, P1; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LARSSON O, 1989, CANCER RES, V49, P5605; LIPPMAN M, 1976, CANCER RES, V36, P4595; MARSHALL E, 1994, SCIENCE, V264, P1524, DOI 10.1126/science.8202702; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MATSUDA S, 1993, P NATL ACAD SCI USA, V90, P10803, DOI 10.1073/pnas.90.22.10803; Maxam A M, 1980, Methods Enzymol, V65, P499; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; NEMERE I, 1993, RECEPTOR, V3, P277; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OGASAWARA M, 1988, IN VITRO CELL DEV B, V24, P911; PERILLO B, 1995, J BIOL CHEM, V270, P15237, DOI 10.1074/jbc.270.25.15231; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; RICHARDFOY H, 1994, NATURE, V370, P417, DOI 10.1038/370417a0; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SCHULZ S, 1992, CANCER RES, V52, P1372; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; SHAFIE SM, 1980, SCIENCE, V209, P701, DOI 10.1126/science.6994231; SOULE HD, 1990, CANCER RES, V50, P6075; TAIT L, 1990, CANCER RES, V50, P6087; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; VINCENT TS, 1991, BIOCHEM BIOPH RES CO, V180, P1284, DOI 10.1016/S0006-291X(05)81334-8; WEIGEL RJ, 1993, CANCER RES, V53, P3472; WEISS W, 1991, INDAGAT MATH NEW SER, V2, P115, DOI 10.1016/0019-3577(91)90047-B; WEISZ A, 1993, CRIT REV ONCOGENESIS, V4, P361; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WEISZ A, 1988, MOL ENDOCRINOL, V2, P816, DOI 10.1210/mend-2-9-816; WEJDE J, 1993, J CELL PHYSIOL, V155, P539, DOI 10.1002/jcp.1041550312	65	54	55	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					753	763						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632897				2022-12-17	WOS:A1996TW68600006
J	Peverali, FA; Orioli, D; Tonon, L; Ciana, P; Bunone, G; Negri, M; DellaValle, G				Peverali, FA; Orioli, D; Tonon, L; Ciana, P; Bunone, G; Negri, M; DellaValle, G			Retinoic acid-induced growth arrest and differentiation of neuroblastoma cells are counteracted by N-myc and enhanced by max overexpressions	ONCOGENE			English	Article						differentiation; N-Myc; Max; neuroblastoma; proliferation; retinoic acid	HUMAN NEURO-BLASTOMA; C-MYC; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; EMBRYONIC LETHALITY; EXPRESSION; PROTEIN; LINES; GENE; PROGRESSION	N-myc expression is negatively regulated by retinoic acid (RA) which induces the growth arrest and differentiation of neuroblastoma (NB) cells. However, it has not been completely defined whether N-Myc promotes growth and/or antagonises neuronal differentiation of NE cells or whether the down regulation of N-myc occurs as a consequence of the onset of differentiation. By transfecting an N-myc gene construct into these cells, we found that the constitutive overexpression of N-myc stimulated proliferation in RA containing medium and, although these cells were still responsive to RA, they were no longer able to differentiate. Since N-Myc functions appear to be mediated by heterodimerization with Max, the ectopic overexpression of max in NE cells was also investigated, In contrast to N-Myc, Max strongly induced the differentiation by enhancing the effects of RA. Max-transfected cells rapidly arrested growth and differentiated fully within a few days of RA treatment. These findings suggest that the relative levels of N-Myc compared to Max appears to be crucial in stimulating neuroblastoma growth or differentiation, and may contribute to explain the remarkable clinical behaviour of neuroblastomas.	UNIV PAVIA,DIPARTIMENTO GENET & MICROBIOL A BUZZATI TRAV,I-27100 PAVIA,ITALY	University of Pavia			Ciana, Paolo/F-9224-2012; Peverali, Fiorenzo/J-2660-2012	Peverali, Fiorenzo/0000-0001-6717-6586; CIANA, PAOLO/0000-0001-5771-5638; ORIOLI, DONATA/0000-0002-3830-3408				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BIEDLER JL, 1978, CANCER RES, V38, P3751; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GHAZAL P, 1992, P NATL ACAD SCI USA, V89, P7630, DOI 10.1073/pnas.89.16.7630; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PEVERALI FA, 1990, DIFFERENTIATION, V45, P61, DOI 10.1111/j.1432-0436.1990.tb00458.x; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1988, EXP CELL BIOL, V56, P321; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	40	54	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					457	462						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570225				2022-12-17	WOS:A1996TR53800027
J	FUKUDA, T; MIKI, T; YOSHIDA, T; HATANO, M; OHASHI, K; HIROSAWA, S; TOKUHISA, T				FUKUDA, T; MIKI, T; YOSHIDA, T; HATANO, M; OHASHI, K; HIROSAWA, S; TOKUHISA, T			THE MURINE BCL6 GENE IS INDUCED IN ACTIVATED LYMPHOCYTES AS AN IMMEDIATE-EARLY GENE	ONCOGENE			English	Article						BCL6; LYMPHOCYTES; IMMEDIATE EARLY GENE	NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; B-CELL LYMPHOMAS; CHROMOSOME-TRANSLOCATION; MOLECULAR-CLONING; PROTO-ONCOGENE; REGION; BREAKPOINT; SEQUENCE; FOS	The chromosomal translocation involving 3q27 is often detected in human B-cell lymphomas, especially diffuse lymphomas with a large-cell component, The BCL6 gene has been isolated from the chromosomal breakpoint in these lymphomas. Here we cloned the murine BCL6 (mBCL6) cDNA from the muscle cDNA library using the human BCL6 (hBCL6) cDNA as a probe, The predicted amino acid sequence was 95% identical to that of hBCL6. It contains six repeats of the Kruppel-like zinc-finger motif that are completely identical to those of hBCL6, indicating that the BCL6 gene is well conserved between humans and mice, Expression of the mBCL6 gene was ubiquitously detected in adult mouse tissues including lymphatic organs, Furthermore, it was induced in lymphocytes activated with phorbol ester and Ca2+ ionophore within 30 min after stimulation, This induction was not inhibited by treatment of the cells with a protein synthesis inhibitor, cycloheximide. These results suggest that BCL6 plays a role in activated lymphocytes as an immediate early gene.	TOKYO MED & DENT UNIV,DEPT INTERNAL MED 1,TOKYO 113,JAPAN; CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV DEV GENET,CHIBA 260,JAPAN	Tokyo Medical & Dental University (TMDU); Chiba University								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAKHSHI A, 1985, CELL, V41, P889; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1992, BLOOD, V79, P2527; BASTARD C, 1994, BLOOD, V83, P2423; CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; HARRIS NL, 1994, BLOOD, V84, P1361; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LO CF, 1994, BLOOD, V83, P1757; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MIKI T, 1994, BLOOD, V83, P217; MIKI T, 1994, BLOOD, V83, P26; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OFFIT K, 1989, BLOOD, V74, P1876; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; TAKAO S, 1991, INT IMMUNOL, V3, P369, DOI 10.1093/intimm/3.4.369; TRAUB R, 1982, P NATL ACAD SCI USA, V79, P7837; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YE BHH, 1993, CANCER RES, V53, P2732	33	54	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1657	1663						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478591				2022-12-17	WOS:A1995TC53500025
J	GANJU, P; WALLS, E; BRENNAN, J; REITH, AD				GANJU, P; WALLS, E; BRENNAN, J; REITH, AD			CLONING AND DEVELOPMENTAL EXPRESSION OF NSK2, A NOVEL RECEPTOR TYROSINE KINASE IMPLICATED IN SKELETAL MYOGENESIS	ONCOGENE			English	Article						NSK2; RECEPTOR TYROSINE KINASE; MYOGENESIS; EPITHELIA; MOUSE CHROMOSOME 13; DEVELOPMENT	HEPATOCYTE GROWTH-FACTOR; GENE-EXPRESSION; PROTEIN; DIFFERENTIATION; MUSCLE; CELLS; IDENTIFICATION; PROTEASES; MODULES; FAMILY	The protein superfamily of transmembrane receptor tyrosine kinases (RTKs) are essential components of intercellular signalling pathways necessary for normal cellular regulation, We report the cloning and developmental expression pattern of NskZ, a novel, structurally distinct mammalian RTK characterised by a putative extracellular region bearing four immunoglobulin-like domains. The Nsk2 locus was mapped to the distal region of mouse chromosome 13 and was found to be expressed preferentially in skeletal muscle amongst adult mouse tissues. Moreover, increased steady-state levels of Nsk2 transcripts were apparent on terminal differentiation of committed skeletal myoblast cell lines in vitro and multiple isoforms of the NskZ RTK were identified in skeletal myotube cultures. RNA in situ hybridisation studies of mouse embryos confirmed skeletal myogenesis to be a major site of Nsk2 expression during normal embryogenesis, and identified other likely sites of Nsk2 function in ganglia of the developing peripheral nervous system and various embryonic epithelia, including those of kidney, lung and gut, during fetal development. Taken together, our data suggest normal functions for Nsk2 RTKs in distinctive aspects of skeletal muscle development, neurogenesis and mesenchymal-epithelial interactions during organ formation.	LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research				Brennan, Jane/0000-0003-3222-5485				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BARBACID M, 1993, ONCOGENE, V8, P2033; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BIRCHMEIER C, 1993, BIOESSAYS, V15, P185, DOI 10.1002/bies.950150307; BIRKENMEIER EH, 1992, MAMM GENOME, V3, P537, DOI 10.1007/BF00350618; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; ELLIOTT RW, 1991, MAMM GENOME, V1, P118, DOI 10.1007/BF02443788; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; FRANKEL WN, 1989, J VIROL, V63, P3810, DOI 10.1128/JVI.63.9.3810-3821.1989; GANJU P, 1994, ONCOGENE, V9, P1613; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KARP SL, 1994, P NATL ACAD SCI USA, V91, P5286, DOI 10.1073/pnas.91.12.5286; LEUDERS KK, 1993, MAMM GENOME, V4, P69; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MINOO P, 1994, ANNU REV PHYSIOL, V56, P13; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; OLSEN EN, 1992, DEV BIOL, V154, P261; OLSEN EN, 1994, GENE DEV, V8, P1; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; QU Z, 1990, NEURON, V2, P367; REITH AD, 1985, IN PRESS MAMM GENOME; REITH AD, 1991, GENOME ANAL, V3, P105; SAXEN L, 1992, CIBA F SYMP, V165, P183; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SZEBENYI G, 1991, J BIOL CHEM, V266, P5534; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	47	54	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					281	290						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624144				2022-12-17	WOS:A1995RK95700009
J	MARSTON, NJ; JENKINS, JR; VOUSDEN, KH				MARSTON, NJ; JENKINS, JR; VOUSDEN, KH			OLIGOMERIZATION OF FULL-LENGTH P53 CONTRIBUTES TO THE INTERACTION WITH MDM2 BUT NOT HPV E6	ONCOGENE			English	Article						P53; HPV E6; MDM2	HUMAN PAPILLOMAVIRUS TYPE-16; CYCLIN-DEPENDENT KINASES; WILD-TYPE; DNA-BINDING; MUTANT P53; PROTEIN; CONFORMATION; DEGRADATION; ONCOPROTEIN; EXPRESSION	The tumour suppressor protein p53 normally functions as a tetramer in a defined conformational state. Mutations within p53 which contribute to cancer development frequently induce a conformational shift in the protein which correlates with loss of wild type growth suppressor functions. Both the cell encoded mdm2 protein and the human papillomavirus oncoprotein E6 can regulate p53 function and we have examined the interaction of these proteins with p53. The E6/p53 association is sensitive to conformational alterations in the p53 protein, although oligomerisation is not necessary for this interaction to occur. Analysis of C-terminal p53 truncations has indicated that the region between residues 327 and 347 may play a role in E6 binding. Since monomeric forms of p53 retain transcriptional and transformation suppressor activities, our results indicate that E6 targets p53 proteins which retain these wild type functions. Conversely, the interaction of p53 with mdm2 is not dependent on the conformation of the p53 protein but is significantly impaired by loss of quaternary structure. It is possible that mdm2 plays a role in mediating activities of p53 which, unlike transcriptional activation, depend on oligomerisation.	ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; MARIE CURIE RES INST, CELL PROLIFERAT LAB, SURREY RH8 0TL, ENGLAND	Imperial College London; Ludwig Institute for Cancer Research								BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, LANCET, V79, P817; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Farthing Alan J., 1994, Trends in Microbiology, V2, P170, DOI 10.1016/0966-842X(94)90667-X; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1994, ONCOGENE, V9, P299; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TARUNINA M, 1993, ONCOGENE, V8, P3165; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	54	54	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1709	1715						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753547				2022-12-17	WOS:A1995QX46900003
J	NADA, S; OKADA, M; AIZAWA, S; NAKAGAWA, H				NADA, S; OKADA, M; AIZAWA, S; NAKAGAWA, H			IDENTIFICATION OF MAJOR TYROSINE-PHOSPHORYLATED PROTEINS IN CSK-DEFICIENT CELLS	ONCOGENE			English	Article							SRC FAMILY; EMBRYO FIBROBLASTS; P53-DEFICIENT MICE; ANTIGEN RECEPTOR; CD4 RECEPTOR; KINASES; SUBSTRATE; GENE; ASSOCIATION; ADHESION	Csk is a non-receptor protein-tyrosine kinase that acts as a negative regulator of Src family tyrosine kinases. Csk-deficient mouse embryos exhibited developmental defects including inability to turn and impaired formation of neural tube. In these embryos, an accumulation of tyrosine phosphorylated proteins was observed as a consequence of constitutive activation of Src family kinases. In order to identify those tyrosine phosphorylated proteins, we established a Csk-deficient cell line from embryos lacking both Csk and the anti-oncogene product p53. On surveying several proteins known as Src substrates, we found that phosphorylation level of p80/85 (cortactin) was markedly elevated in the Csk-deficient cells. Enhancement of cortactin phosphorylation was also seen in Csk-deficient embryos. Furthermore, immunoprecipitated Src was able to directly phosphorylate cortactin in vitro. Thus, we suggest that cortactin is a good substrate of activated Src family kinases in vivo and may play important roles in signaling pathways mediated by Src family kinases.	KUMAMOTO UNIV, SCH MED, INST MOLEC EMBRYOL & GENET, DEPT MORPHOGENESIS, KUMAMOTO 860, JAPAN	Kumamoto University	NADA, S (corresponding author), OSAKA UNIV, INST PROT RES, DIV PROT METAB, 3-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN.							BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; EISEMAN E, 1992, NATURE, V355, P78; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HARVEY M, 1993, ONCOGENE, V8, P2457; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KOZMA LM, 1990, MOL CELL BIOL, V10, P837, DOI 10.1128/MCB.10.2.837; MAA MC, 1992, ONCOGENE, V7, P2429; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; SATO N, 1992, J CELL SCI, V103, P131; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; TSUKADA T, 1993, ONCOGENE, V8, P3313; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631	38	54	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3571	3578						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7526315				2022-12-17	WOS:A1994PT39200020
J	MCVICAR, DW; LAL, BK; LLOYD, A; KAWAMURA, M; CHEN, YQ; ZHANG, XY; STAPLES, JE; ORTALDO, JR; OSHEA, JJ				MCVICAR, DW; LAL, BK; LLOYD, A; KAWAMURA, M; CHEN, YQ; ZHANG, XY; STAPLES, JE; ORTALDO, JR; OSHEA, JJ			MOLECULAR-CLONING OF LSK, A CARBOXYL-TERMINAL SRC KINASE (CSK) RELATED GENE, EXPRESSED IN LEUKOCYTES	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; NATURAL-KILLER-CELLS; SH3 DOMAINS; SIGNAL TRANSDUCTION; LYMPHOCYTES-T; NK CELLS; PHOSPHORYLATES; RECEPTORS; P50(CSK); ENCODES	Regulation of the activity of src-family kinases is thought to occur, in part, through the phosphorylation of conserved carboxyl-terminal tyrosine residues. Although the src-family includes several molecules with tissue or cell-type restricted expression, the only kinase implicated in the regulatory phosphorylation of these enzymes is p50(csk). Herein we report the molecular cloning of a tissue specific p50(csk)-related gene. Like p50(csk), the deduced protein sequence of this novel cDNA includes a tyrosine kinase catalytic domain, SH2 and SH3 domains, a short amino terminus, and no autophosphorylation or carboxyl-terminal tyrosine residues. Additionally, neither this novel kinase nor p50(csk) contain the amino-terminal myristoylation site characteristic of the src-family. However, whereas csk is ubiquitously expressed, mRNA corresponding to this novel gene is expressed in brain, natural killer (NK) cells, and activated T cells but not in a variety of other tissues and cell lines. In agreement with the mRNA expression pattern, antiserum reactive with the predicted carboxyl-terminus of the cDNA recognizes a 57 kDa polypeptide in immunoblots of NK cells and PHA-activated T cells, Because of its limited expression and high homology to p50(csk), we named this gene lsk; leukocyte carboxyl-terminal src kinase related gene. Identification of a molecule like lsk suggests the existence of tissue specific src-regulatory pathways that function in activated lymphocytes.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, MOLEC IMMUNOREGULAT LAB, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	MCVICAR, DW (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, LEUKOCYTE CELL BIOL SECT, EXPTL IMMUNOL LAB, FREDERICK, MD 21702 USA.		McVicar, Daniel/G-1970-2015; Lal, Brajesh/AAA-2620-2022; Lloyd, Andrew/AAF-6071-2022; Lloyd, Andrew/AFJ-8960-2022; Lloyd, Andrew/E-7334-2017	Lloyd, Andrew/0000-0001-6277-8887; Lloyd, Andrew/0000-0001-6277-8887; McVicar, Daniel/0000-0002-1112-5111				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; BROOKER GW, 1993, CELL, V73, P813; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOKE M P, 1989, New Biologist, V1, P66; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LANIER LL, 1992, IMMUNOL TODAY, V13, P392, DOI 10.1016/0167-5699(92)90087-N; LANIER LL, 1986, J IMMUNOL, V136, P4480; LI M, 1993, FOCUS, V15, P19; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACAULEY A, 1993, ONCOGENE, V8, P117; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; ORTALDO JR, 1986, J EXP MED, V164, P1193, DOI 10.1084/jem.164.4.1193; OSHEA JJ, 1992, J IMMUNOL, V148, P2497; PARTANEN J, 1991, ONCOGENE, V6, P2013; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; REIF AE, 1964, J EXP MED, V120, P413, DOI 10.1084/jem.120.3.413; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAKEYA T, 1983, CELL, V47, P277; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YOUNG HA, 1987, J IMMUNOL, V139, P724	40	54	57	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2037	2044						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	7516063				2022-12-17	WOS:A1994NR68500028
J	ISSHIKI, K; SENG, BA; ELDER, DE; GUERRY, D; LINNENBACH, AJ				ISSHIKI, K; SENG, BA; ELDER, DE; GUERRY, D; LINNENBACH, AJ			CHROMOSOME-9 DELETION IN SPORADIC AND FAMILIAL MELANOMAS IN-VIVO	ONCOGENE			English	Article							HUMAN-MALIGNANT MELANOMA; HOMOZYGOUS DELETIONS; COLORECTAL-CANCER; TUMOR PROGRESSION; DYSPLASTIC NEVUS; CELL-LINES; SHORT ARM; LOCUS; GENE; LINKAGE	Twenty microsatellite loci on chromosome 9 were analysed for allelic losses in DNAs from 30 uncultured melanomas from 25 patients, relative to DNA from autologous peripheral blood lymphocytes. All patients were constitutionally heterozygous at several loci, and loss of heterozygosity (LOH) affecting 9p was observed in melanoma DNAs from 18 individuals (72%). Observations of losses of identical alleles in different metastatic lesions from the same patients, and of LOH in a vertical growth phase primary melanoma, were consistent with previous reports of chromosome 9 deletion early in melanoma development. LOH data suggested the loss of entire copies of chromosome 9 in 11 cases, and the terminal deletion of all or a portion of 9p in six cases. A somatic interstitial deletion of 9p between D9S162 and D9S169 was seen in a familial melanoma. This 21 cM deleted region corresponded with the previously reported positions of homozygous deletions in melanoma cell lines, and of the familial melanoma susceptibility locus (MLM). As 16 of the 18 cases of 9p LOH in the present study were observed in individuals with no family history of melanoma, it is likely that the MLM locus plays a role in the development of most sporadic melanomas.	WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, CTR CANC, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NCI NIH HHS [CA25874, CA10815, CA25298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA025298, P30CA010815, P01CA025874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; Cowan J M, 1991, Cancer Treat Res, V54, P3; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DRACOPOLI NC, 1987, CANCER RES, V47, P3995; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; DRACOPOLI NC, 1985, P NATL ACAD SCI USA, V82, P1470, DOI 10.1073/pnas.82.5.1470; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; Greene MH, 1979, HUMAN MALIGNANT MELA, P139; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISSHIKI K, 1993, GENE CHROMOSOME CANC, V8, P178, DOI 10.1002/gcc.2870080307; JAMES CD, 1993, CANCER RES, V53, P3674; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; LINNENBACH AJ, 1994, NATURE, V367, P419, DOI 10.1038/367419b0; LITT M, 1989, AM J HUM GENET, V44, P397; MILLIKIN D, 1991, CANCER RES, V51, P5449; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1993, CANCER RES, V53, P2410; Parmiter A., 1988, MALIGNANT MELANOMA B, P47; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PETTY EM, 1993, AM J HUM GENET, V53, P96; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOLKENANDT M, 1991, PIGM CELL RES, V4, P35, DOI 10.1111/j.1600-0749.1991.tb00311.x; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	32	54	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1649	1653						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183559				2022-12-17	WOS:A1994NL81500016
J	ETIEMBLE, J; DEGOTT, C; RENARD, CA; FOUREL, G; SHAMOON, B; VITVITSKITREPO, L; HSU, TY; TIOLLAIS, P; BABINET, C; BUENDIA, MA				ETIEMBLE, J; DEGOTT, C; RENARD, CA; FOUREL, G; SHAMOON, B; VITVITSKITREPO, L; HSU, TY; TIOLLAIS, P; BABINET, C; BUENDIA, MA			LIVER-SPECIFIC EXPRESSION AND HIGH ONCOGENIC EFFICIENCY OF A C-MYC TRANSGENE ACTIVATED BY WOODCHUCK HEPATITIS-VIRUS INSERTION	ONCOGENE			English	Article							SURFACE-ANTIGEN GENE; B VIRUS; HEPATOCELLULAR-CARCINOMA; N-MYC; INFECTED WOODCHUCKS; RAT-LIVER; MICE; ENHANCER; TUMORS; DNA	The high oncogenic efficiency of woodchuck hepatitis virus (WHV) has been correlated with the ability of this virus to provoke insertional activation of mye family genes. To assess the impact of viral integration on liver cell transformation, we have generated transgenic mice carrying the mutated c-mye gene and adjacent viral DNA from a woodchuck tumor, in original configuration. Virtually all mice from two different strains developed hepatocellular carcinoma with a mean latency period of 8-12 months. The c-mye transgene was expressed transiently in neonatal livers, and re-expressed at preneoplastic and neoplastic stages in adult livers. Woodchuck c-mye mRNA driven by the normal P1 and P2 promoters and WHV-specific transcripts encoding viral surface antigens were produced in a strictly co-regulated fashion during development and tumorigenesis, indicating a predominant regulatory influence of the viral enhancer. Furthermore, the activity of the viral enhancer in response to various biological stimuli was apparently modulated by glucose uptake and glucogon/insulin balance in differentiated hepatocytes. In this model, a viral integration event selected from a naturally occurring tumor proved to be determinant for induction of hepatocarcinogenesis, although enforced, liver-specific expression of c-mye was limited to a particular developmental stage.	INST PASTEUR, INSERM, U163, UNITE RECOMBINAISON & EXPRESS GENET, F-75724 PARIS 15, FRANCE; INST PASTEUR, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE; HOP BEAUJON, ANATOMOPATHOL LAB, CLICHY, FRANCE; HOP ST LOUIS, UNITE RECOMBINAISON GENET, CNRS, UPR 41, PARIS, FRANCE; INSERM, U271, UNITE RECH HEPATITES, LYON, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)								ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ARAKI K, 1989, P NATL ACAD SCI USA, V86, P207, DOI 10.1073/pnas.86.1.207; BABINET C, 1985, SCIENCE, V230, P1160, DOI 10.1126/science.3865370; BEASLEY RP, 1981, LANCET, V2, P1129; BULLA GA, 1988, J VIROL, V62, P1437, DOI 10.1128/JVI.62.4.1437-1441.1988; CARTIER N, 1992, ONCOGENE, V7, P1413; CHANDAR N, 1989, P NATL ACAD SCI USA, V86, P2703, DOI 10.1073/pnas.86.8.2703; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DELOIA JA, 1989, J VIROL, V63, P4069, DOI 10.1128/JVI.63.9.4069-4073.1989; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FARZA H, 1988, J VIROL, V62, P4144, DOI 10.1128/JVI.62.11.4144-4152.1988; FARZA H, 1987, P NATL ACAD SCI USA, V84, P1187, DOI 10.1073/pnas.84.5.1187; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GARCIARUIZ JP, 1978, P NATL ACAD SCI USA, V75, P4189; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; HANSEN LJ, 1993, MOL CELL BIOL, V13, P659, DOI 10.1128/MCB.13.1.659; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KORBA BE, 1987, J VIROL, V61, P1318, DOI 10.1128/JVI.61.5.1318-1324.1987; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; MAKINO R, 1984, BIOCHEM BIOPH RES CO, V119, P1096, DOI 10.1016/0006-291X(84)90887-8; MARION PL, 1986, P NATL ACAD SCI USA, V83, P4543, DOI 10.1073/pnas.83.12.4543; MCGRANE MM, 1992, TRENDS BIOCHEM SCI, V17, P40, DOI 10.1016/0968-0004(92)90426-A; MORIYAMA T, 1990, SCIENCE, V248, P361, DOI 10.1126/science.1691527; MOROY T, 1985, EMBO J, V4, P1507, DOI 10.1002/j.1460-2075.1985.tb03810.x; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MURAKAMI H, 1993, CANCER RES, V53, P1719; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; RUTHER U, 1993, ONCOGENE, V8, P87; SANDGREN EP, 1989, ONCOGENE, V4, P715; SEEGER C, 1991, J VIROL, V65, P1673, DOI 10.1128/JVI.65.4.1673-1679.1991; SHAMOON BM, 1991, J GEN VIROL, V72, P421, DOI 10.1099/0022-1317-72-2-421; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; SZUMUNESS W, 1978, PROG MED VIROL, V24, P40; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TRANSY C, 1992, P NATL ACAD SCI USA, V89, P3874, DOI 10.1073/pnas.89.9.3874; TRUJILLO MA, 1991, P NATL ACAD SCI USA, V88, P3797, DOI 10.1073/pnas.88.9.3797; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANNICE JL, 1988, J VIROL, V62, P1305, DOI 10.1128/JVI.62.4.1305-1313.1988; VITVITSKI L, 1988, VIRAL HEPATITIS LIVE, P341; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545	53	54	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					727	737						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108115				2022-12-17	WOS:A1994MW55100007
J	HOFMANN, W; ROYER, HD; DRECHSLER, M; SCHNEIDER, S; ROYERPOKORA, B				HOFMANN, W; ROYER, HD; DRECHSLER, M; SCHNEIDER, S; ROYERPOKORA, B			CHARACTERIZATION OF THE TRANSCRIPTIONAL REGULATORY REGION OF THE HUMAN WT1 GENE	ONCOGENE			English	Article							WILMS-TUMOR GENE; ZINC-FINGER PROTEIN; FACTOR-A-CHAIN; PROMOTER REGION; GENITOURINARY DEVELOPMENT; ADENOSINE-DEAMINASE; HOMOZYGOUS DELETION; BINDING PROTEINS; SUPPRESSOR WT1; RECEPTOR GENE	Specific control of the expression of the Wilms tumor gene WT1 is important for normal development of the kidney. In order to characterise the transcriptional control region of the WT1 gene we have isolated genomic clones spanning the upstream region, the first WT1 exon and the 5' end of the Wit1 gene. DNA sequencing revealed that the WT1 promoter lacks a TATA box or CCAAT motif and has a GC content of 71%. Four transcriptional start sites are clustered within a 32 bp region. GC-boxes are present at nucleotide positions - 413, - 160, + 84 and + 158. DNAaseI protection assays with purified Sp1 protein revealed the existence of 11 different binding sites in the WT1 promoter. WT1 and Wit1 promoter activities were tested in COS-7 cells with luciferase reporter gene constructs either containing or lacking an SV40 enhancer. WT1 promoter activity was found in a fragment extending from 449 bp upstream to 201 bp downstream of the WT1 start site. It was 26 fold lower in the absence of the SV40 enhancer than in the presence. Cotransfection with a Sp1 expression vector stimulated both constructs 3-4 fold. Wit1 promoter activity was identified in a DNA fragment extending from 200 bp upstream of the putative Wit1 TATA box to 130 bp downstream. Several potential recognition sites for WT1/EGR, Pax-8, and GAGA-like transcription factors are present in the WT1 promoter.	UNIV HEIDELBERG, INST HUMAN GENET, IMNEVENHEIMER FELD 328, W-6900 HEIDELBERG, GERMANY; MAX DELBRUCK CTR MOLEC MED, BERLIN, GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Royer, Hans-dieter/AAH-6293-2019					ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; AVIVI A, 1992, ONCOGENE, V7, P1957; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRENNER B, 1992, ONCOGENE, V7, P1431; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COMPTON DA, 1990, GENOMICS, V6, P309, DOI 10.1016/0888-7543(90)90571-B; COWELL JK, 1991, ONCOGENE, V6, P595; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; Hastie Nicholas D., 1992, Human Molecular Genetics, V1, P293; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; KUSHNER L, 1992, J UROLOGY, V148, P555, DOI 10.1016/S0022-5347(17)36652-1; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maniatis T., 1982, MOL CLONING COLD SPR; MATSUNAGA E, 1981, HUM GENET, V57, P231; MATSUZAWA Y, 1991, ONCOGENE, V6, P1561; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; MIWA H, 1992, LEUKEMIA, V6, P405; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; POLEEV A, 1992, DEVELOPMENT, V116, P611; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROYERPOKORA B, 1991, GENE CHROMOSOME CANC, V3, P89, DOI 10.1002/gcc.2870030203; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER S, 1993, IN PRESS HUM GENET; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TADOKORO K, 1992, ONCOGENE, V7, P1215; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	68	54	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					3123	3132						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414514				2022-12-17	WOS:A1993MC09300029
J	CRENON, I; BERAUD, C; SIMARD, P; MONTAGNE, J; VESCHAMBRE, P; JALINOT, P				CRENON, I; BERAUD, C; SIMARD, P; MONTAGNE, J; VESCHAMBRE, P; JALINOT, P			THE TRANSCRIPTIONALLY ACTIVE FACTORS MEDIATING THE EFFECT OF THE HTLV-I TAX TRANSACTIVATOR ON THE IL-2R-ALPHA KAPPA-B ENHANCER INCLUDE THE PRODUCT OF THE C-REL PROTOONCOGENE	ONCOGENE			English	Article							RECEPTOR GENE-EXPRESSION; DNA-BINDING SUBUNIT; CELLULAR PROTEINS; 65-KD SUBUNIT; ALPHA-GENE; ACTIVATION; FAMILY; HIV; POLYPEPTIDE; INHIBITION	The transactivator HTLV-1 Tax activates the promoter of the gene coding for the interleukin 2 alpha-chain receptor (IL-2Ralpha) via a kappaB site that can bind several protein species of the rel family. Tax1 strongly activates the enhancer activity of this motif, in both epithelial HeLa and lymphoid Jurkat cells. This activation was not observed in undifferentiated embryocarcinoma F9 cells. Overexpression of the p50, p65 and Rel proteins in these cells showed that significant activation of the IL-2Ralpha kappaB site was observed only with Rel and Rel plus p65. Moreover, whereas both Tax and phorbol 12-myristate 13-acetate (PMA) are able to efficiently induce the binding of NF-kappaB to the IL-2Ralpha kappaB site, PMA is functionally inactive. Using the DNA affinity precipitation assay, we observed that Tax1 is able to efficiently induce the binding of Rel, whereas PMA is not. This established a clear difference between both stimuli, indicating that Rel is the functionally active factor. We conclude from these results that the functional activity of members of the rel family is regulated by their interaction with DNA and that Rel can be a potent transcriptional activator on specific kappaB sites.	ECOLE NORMALE SUPER LYON,BIOL MOLEC & CELLULAIRE LAB,46 ALLEE ITALIE,F-69364 LYON 7,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON)				Philippe, Veschambre/0000-0001-6094-6795				ALEXANDRE C, 1991, J VIROL, V6, P543; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BERAUD C, 1991, EMBO J, V10, P3795, DOI 10.1002/j.1460-2075.1991.tb04949.x; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BROWNELL E, 1989, ONCOGENE, V4, P935; CHEVALLIERGRECO A, 1989, J VIROL, V63, P615, DOI 10.1128/JVI.63.2.615-623.1989; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HASKILL LK, 1991, CELL, V65, P1281; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LEE JH, 1991, ONCOGENE, V6, P665; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; NAKAMURA M, 1989, NUCLEIC ACIDS RES, V17, P5207, DOI 10.1093/nar/17.13.5207; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PAN D, 1992, EMBO J, V11, P1837, DOI 10.1002/j.1460-2075.1992.tb05235.x; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, TRENDS CELL BIOL, V10, P3805; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6	45	54	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					867	875						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455941				2022-12-17	WOS:A1993KT22000007
J	SHARMA, SV				SHARMA, SV			MELITTIN-INDUCED HYPERACTIVATION OF PHOSPHOLIPASE-A2 ACTIVITY AND CALCIUM INFLUX IN RAS-TRANSFORMED CELLS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; A431 CELLS; MEMBRANE; PROTEINS; VENOM; DIACYLGLYCEROL; FACILITATION; FLUORESCENCE; LIPOXYGENASE; FIBROBLASTS	The activated ras oncogene is a key mediator of cellular transformation and is present in a wide variety of primary human neoplasms. The biochemical role of the ras oncogene in cellular transformation is at present unclear, and hence approaches to control its activities in transformed cells have met with limited success. Previous studies have demonstrated the ability of melittin, a 26 amino acid amphipathic peptide from bee venom, to specifically counterselect for cells in culture that express high levels of the ras oncogene product. The biochemical basis for this counterselection is currently unknown. This study demonstrates the ability of melittin to hyperactivate phospholipase A2 (PLA2) in ras-transformed cells by the mediation of enhanced influx of calcium ions (Ca2+). This hyperactivation of PLA2 and Ca2+ mobilization in ras-transformed cells by melittin is mimicked by the calcium ionophore, A23187. Both melittin- and A23187-mediated PLA2 hyperactivation require Ca2+. However, the action of melittin is strongly dependent on extracellular Ca2+, whereas that of A23187 is not. Melittin-induced Ca2+ influx and PLA2 hyperactivation is inhibited by manganese ions (Mn2+). These studies reveal a close correlation between the extent of PLA2 hyperactivation and Ca2+ mobilization, suggesting a causal relationship.			SHARMA, SV (corresponding author), UNIV TENNESSEE CTR HLTH SCI, DEPT MICROBIOL & IMMUNOL, MEMPHIS, TN 38163 USA.				NATIONAL CANCER INSTITUTE [R01CA055983] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55983] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1989, ANTICANCER RES, V9, P1427; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BARSAGI D, 1988, J CELL BIOL, V106, P1649, DOI 10.1083/jcb.106.5.1649; BATENBURG AM, 1987, BIOCHIM BIOPHYS ACTA, V903, P155, DOI 10.1016/0005-2736(87)90165-9; BOS JL, 1989, CANCER RES, V49, P4682; CHANG JP, 1988, J BIOL CHEM, V263, P18614; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DUFOURCQ J, 1977, BIOCHIM BIOPHYS ACTA, V467, P1, DOI 10.1016/0005-2736(77)90236-X; FLETCHER JE, 1991, BIOCHEM CELL BIOL, V69, P274, DOI 10.1139/o91-042; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GONZALEZ FA, 1988, J CELL PHYSIOL, V135, P269, DOI 10.1002/jcp.1041350214; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL A, 1989, G PROTEINS MEDIATORS; KUNOS G, 1984, P NATL ACAD SCI-BIOL, V81, P6178, DOI 10.1073/pnas.81.19.6178; LACHOWIEZ RM, 1988, FEBS LETT, V234, P195, DOI 10.1016/0014-5793(88)81332-2; LOMBARDO D, 1985, J BIOL CHEM, V260, P7234; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MACARA IG, 1986, J BIOL CHEM, V261, P9321; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; METZ SA, 1986, BIOCHEM PHARMACOL, V35, P3371, DOI 10.1016/0006-2952(86)90438-7; MIX LL, 1984, BIOCHEM BIOPH RES CO, V119, P69, DOI 10.1016/0006-291X(84)91619-X; MOLLAY C, 1976, BIOCHIM BIOPHYS ACTA, V426, P317, DOI 10.1016/0005-2736(76)90340-0; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MUFSON RA, 1979, NATURE, V280, P73; PANDIELLA A, 1989, J BIOL CHEM, V264, P12914; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; Rasmussen H, 1990, Curr Top Cell Regul, V31, P1; ROZENGURT E, 1981, CELL, V23, P781, DOI 10.1016/0092-8674(81)90442-6; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SESSA G, 1969, J BIOL CHEM, V244, P3575; SHAH GV, 1990, ENDOCRINOLOGY, V127, P613, DOI 10.1210/endo-127-2-613; SHARMA SV, 1992, ONCOGENE, V7, P193; SHIER WT, 1979, P NATL ACAD SCI USA, V76, P195, DOI 10.1073/pnas.76.1.195; SHIER WT, 1980, P NATL ACAD SCI-BIOL, V77, P137, DOI 10.1073/pnas.77.1.137; SNIDER RM, 1984, P NATL ACAD SCI-BIOL, V81, P3905, DOI 10.1073/pnas.81.12.3905; VINCENTINI LM, 1984, J BIOL CHEM, V259, P6912; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHEELER LA, 1987, J BIOL CHEM, V262, P6531; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; YUNES R, 1977, ARCH BIOCHEM BIOPHYS, V183, P105, DOI 10.1016/0003-9861(77)90424-6	46	54	56	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					939	947						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455945				2022-12-17	WOS:A1993KT22000016
J	KLINGELHUTZ, AJ; SMITH, PP; GARRETT, LR; MCDOUGALL, JK				KLINGELHUTZ, AJ; SMITH, PP; GARRETT, LR; MCDOUGALL, JK			ALTERATION OF THE DCC TUMOR-SUPPRESSOR GENE IN TUMORIGENIC HPV-18 IMMORTALIZED HUMAN KERATINOCYTES TRANSFORMED BY NITROSOMETHYLUREA	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; SQUAMOUS-CELL CARCINOMA; HUMAN FORESKIN KERATINOCYTES; OPEN READING FRAMES; NEOPLASTIC TRANSFORMATION; CERVICAL-CARCINOMA; CHROMOSOME CHANGES; EPITHELIAL-CELLS; DNA; IDENTIFICATION	A human papillomavirus type 18 (HPV-18)-immortalized human keratinocyte cell line (1811) has been transformed to tumorigenicity in nude mice by treatment with the carcinogen nitrosomethylurea (NMU). The NMU transformants (1811-NMU-T) showed additional chromosome alterations as compared with parental 1811 cells, including 18q deletion in two of two 1811-NMU-T lines analysed. Restriction fragment length polymorphism (RFLP) analysis indicated that both 1811-NMU-T lines had lost one allele of the 18q deleted in colon cancer (DCC) tumor-suppressor gene. Reverse transcriptase polymerase chain reaction (RT-PCR) showed that DCC expression was absent or barely detectable in the 1811-NMU-T cells as compared with 1811 or normal keratinocytes, suggesting that the remaining DCC allele in the 1811-NMU-T cells was also altered. These studies indicate that reduction or loss of DCC expression may be an important step in NMU transformation of HPV-immortalized cells to tumorigenicity.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	KLINGELHUTZ, AJ (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV CANC BIOL,M616,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.		Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046				ATKIN NB, 1991, CANCER GENET CYTOGEN, V55, P153, DOI 10.1016/0165-4608(91)90071-2; ATKIN NB, 1990, CANCER GENET CYTOGEN, V44, P229, DOI 10.1016/0165-4608(90)90052-C; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEVILEE P, 1991, ONCOGENE, V6, P311; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GARRETT LR, 1993, IN PRESS CARCINOGENE; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HORIKOSHI T, 1992, CANCER RES, V52, P108; HOWLEY PM, 1991, CANCER RES, V51, pS5019; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KAUR P, 1989, VIROLOGY, V173, P302, DOI 10.1016/0042-6822(89)90247-X; KAUR P, 1989, J GEN VIROL, V70, P1261, DOI 10.1099/0022-1317-70-5-1261; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; LORINCZ AT, 1987, J NATL CANCER I, V79, P671; MARLHENS F, 1987, NUCLEIC ACIDS RES, V15, P1348, DOI 10.1093/nar/15.3.1348; MUNGER K, 1989, J VIROL, V63, P4417; NARAYANAN R, 1992, ONCOGENE, V7, P553; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; PECORARO G, 1991, AM J PATHOL, V138, P1; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH PP, 1989, INT J CANCER, V44, P1124, DOI 10.1002/ijc.2910440631; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; UCHINO S, 1992, CANCER RES, V52, P3099; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WORSHAM MJ, 1991, GENE CHROMOSOME CANC, V3, P420, DOI 10.1002/gcc.2870030604; WU SQ, 1991, CANCER RES, V51, P3323	42	54	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					95	99						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380923				2022-12-17	WOS:A1993KN00500011
J	WOLDA, SL; MOON, RT				WOLDA, SL; MOON, RT			CLONING AND DEVELOPMENTAL EXPRESSION IN XENOPUS-LAEVIS OF 7 ADDITIONAL MEMBERS OF THE WNT FAMILY	ONCOGENE			English	Article							PROTO-ONCOGENE INT-1; MOUSE DEVELOPMENT; NEURAL-TUBE; EMBRYOS; GENE; PROTOONCOGENE; INSERTION; PRODUCTS; PROTEINS; SEQUENCE	Degenerate oligonucleotide primers encoding highly conserved regions of Wnt-related proteins were used with the polymerase chain reaction (PCR) to amplify cDNA derived from Xenopus laevis embryos. cDNA sequences partially encoding seven additional members of the Xwnt gene family were isolated using this strategy. These cDNAs have been given the designation Xwnt-2, Xwnt-6, Xwnt-7A, Xwnt-7B, Xwnt-7C, Xwnt-8B and Xwnt-10 based on their amino acid identity with previously described Wnts. With regard to the timing of expression of these Xwnts during embryonic development, Xwnt-2, the least abundant transcript, was first detected during the neurula stage, while Xwnt-8B transcripts were first detected at the gastrula stage, and decreased by the tailbud stage. Multiple transcripts of Xwnt-6 were detected at varied times during development beginning at the gastrula stage. In contrast, Xwnt-7A, -7B and -10 transcripts were not detected until the tailbud stage. With regard to expression in adult tissues, Xwnt-6, -7A, -7B, -8B and -10 were all expressed abundantly in the brain, and to a lesser extent in a variety of other tissues. Whole-mount in situ hybridization was then employed to monitor the spatial expression of selected Xwnts. Xwnt-7A and -10 transcripts were detected in distinct areas of the developing brain of tailbud-stage embryos. The temporal and spatial differences in expression suggest different roles for these new Xwnt family members in Xenopus development.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Moon, Randall T/B-1743-2014	Moon, Randall T/0000-0002-9352-1408	NHLBI NIH HHS [T32HL07312] Funding Source: Medline; NIAMS NIH HHS [K04AR1837] Funding Source: Medline; NICHD NIH HHS [R01HD27525] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027525] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001837] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KELLY GM, 1991, METHOD CELL BIOL, V36, P389; Maniatis T., 1982, MOL CLONING; MCGREW LL, 1992, IN PRESS DEVELOPMENT; MCMAHON AP, 1989, DEVELOPMENT, V107, P161; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MCMAHON AP, 1992, ADV DEV BIOL, V1, P31; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; Moon R. T., 1989, TECHNIQUE, V1, P76; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	35	54	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1941	1947						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408135				2022-12-17	WOS:A1992JP42400006
J	SHARMA, SV				SHARMA, SV			MELITTIN RESISTANCE - A COUNTERSELECTION FOR RAS TRANSFORMATION	ONCOGENE			English	Article							SACCHAROMYCES-CEREVISIAE; SARCOMA-VIRUS; BEE VENOM; H-RAS; PROTEINS; MEMBRANE; CELLS; ONCOGENES; PHOSPHOLIPASE-A2; GENES	The prevalence of activated ras oncogenes in human primary tumors suggests a central role for this oncogene in human cancer. Despite its ubiquitous distribution, the biochemical role of the oncogene remains unclear, and hence attempts to control its activity have been frustrated. This study demonstrates the ability of melittin, a 26 amino acid, amphipathic peptide from bee venom, to specifically select against cells in culture that express high levels of the ras oncogene. Acquisition of resistance to increasing concentrations of melittin is accompanied by corresponding decreases in the levels of expression of the ras oncoprotein and the number of copies of the ras gene. This results in a concomitant reversion of transformed cells to a normal morphology in a strict dose-dependent manner. Melittin is a known activator of cellular phospholipase A2 (PLA2), and these results suggest an interrelationship between ras and PLA2. In addition these studies indicate that melittin preferentially hyperactivates PLA2 in ras oncogene-transformed cells, resulting in their selective destruction.			SHARMA, SV (corresponding author), UNIV TENNESSEE CTR HLTH SCI, DEPT MICROBIOL & IMMUNOL, MEMPHIS, TN 38163 USA.							ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1989, ANTICANCER RES, V9, P1427; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BARSAGI D, 1988, J CELL BIOL, V106, P1649, DOI 10.1083/jcb.106.5.1649; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHANG JP, 1988, J BIOL CHEM, V263, P18614; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DUFOURCQ J, 1977, BIOCHIM BIOPHYS ACTA, V467, P1, DOI 10.1016/0005-2736(77)90236-X; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KILLION JJ, 1986, BIOCHEM BIOPH RES CO, V139, P222, DOI 10.1016/S0006-291X(86)80102-4; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KREIL G, 1967, BIOCHEM BIOPH RES CO, V27, P275, DOI 10.1016/S0006-291X(67)80074-3; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; KUNOS G, 1984, P NATL ACAD SCI-BIOL, V81, P6178, DOI 10.1073/pnas.81.19.6178; LACHOWIEZ RM, 1988, FEBS LETT, V234, P195, DOI 10.1016/0014-5793(88)81332-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MARSHALL CJ, 1989, ONCOGENES; MAULET Y, 1982, ANAL BIOCHEM, V127, P61, DOI 10.1016/0003-2697(82)90144-0; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MOLLAY C, 1976, BIOCHIM BIOPHYS ACTA, V426, P317, DOI 10.1016/0005-2736(76)90340-0; MUFSON RA, 1979, NATURE, V280, P73; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SESSA G, 1969, J BIOL CHEM, V244, P3575; SHARMA S, 1985, EMBO J, V4, P1479, DOI 10.1002/j.1460-2075.1985.tb03806.x; SHIER WT, 1979, P NATL ACAD SCI USA, V76, P195, DOI 10.1073/pnas.76.1.195; SHIER WT, 1980, P NATL ACAD SCI-BIOL, V77, P137, DOI 10.1073/pnas.77.1.137; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; TOOZE J, 1980, MOL BIOL TUMOR VIRUS; TOSTESON MT, 1987, BIOCHEMISTRY-US, V26, P6627, DOI 10.1021/bi00395a010; VINCENTINI LM, 1984, J BIOL CHEM, V259, P6912; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; YUNES R, 1977, ARCH BIOCHEM BIOPHYS, V183, P105, DOI 10.1016/0003-9861(77)90424-6	57	54	56	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1992	7	2					193	201						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549345				2022-12-17	WOS:A1992HG98200001
J	BECKER, D; BEEBE, SJ; HERLYN, M				BECKER, D; BEEBE, SJ; HERLYN, M			DIFFERENTIAL EXPRESSION OF PROTEIN-KINASE-C AND CAMP-DEPENDENT PROTEIN-KINASE IN NORMAL HUMAN MELANOCYTES AND MALIGNANT MELANOMAS	ONCOGENE			English	Article									EASTERN VIRGINIA MED SCH,DEPT OBSTET & GYNECOL,NORFOLK,VA 23510; WISTAR INST,PHILADELPHIA,PA 19104	Eastern Virginia Medical School; The Wistar Institute	BECKER, D (corresponding author), UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT TUMOR BIOL,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [P01CA025874] Funding Source: NIH RePORTER; NCI NIH HHS [CA 25874] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER D, 1984, MOL CELL BIOL, V4, P2247, DOI 10.1128/MCB.4.11.2247; BECKER D, 1989, GENOMICS, V4, P97, DOI 10.1016/0888-7543(89)90320-0; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CLARK WH, 1988, ARCH DERMATOL, V124, P1207, DOI 10.1001/archderm.124.8.1207; CLARK WH, 1986, HUM PATHOL, V17, P443, DOI 10.1016/S0046-8177(86)80032-6; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; FEIGE JJ, 1989, P NATL ACAD SCI USA, V86, P3174, DOI 10.1073/pnas.86.9.3174; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIALLONGO A, 1986, P NATL ACAD SCI USA, V83, P6741, DOI 10.1073/pnas.83.18.6741; GORDON PR, 1986, J INVEST DERMATOL, V87, P723, DOI 10.1111/1523-1747.ep12456842; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HALABAN R, 1988, ONCOGENE RES, V3, P177; HERLYN M, 1988, EXP CELL RES, V179, P322, DOI 10.1016/0014-4827(88)90271-6; HERLYN M, 1987, CANCER RES, V47, P3057; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPEUCH CJ, 1983, P NATL ACAD SCI-BIOL, V80, P6858; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LINNENBACH AJ, 1988, P NATL ACAD SCI USA, V85, P74, DOI 10.1073/pnas.85.1.74; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MELBER K, 1989, CANCER RES, V49, P3650; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NISHIZUKA Y, 1988, NATURE, V334, P662; OKEEFE E, 1974, P NATL ACAD SCI USA, V71, P2500, DOI 10.1073/pnas.71.6.2500; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1988, J BIOL CHEM, V263, P6927; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; PARKER PJ, 1985, EUR J BIOCHEM, V148, P579, DOI 10.1111/j.1432-1033.1985.tb08879.x; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PHILLIPS MA, 1983, J BIOL CHEM, V258, P2875; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; SALUSTRI A, 1985, BIOL REPROD, V33, P797, DOI 10.1095/biolreprod33.4.797; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SOLANKI V, 1981, P NATL ACAD SCI-BIOL, V78, P1722, DOI 10.1073/pnas.78.3.1722; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; ULLRICH A, 1986, COLD SPRING HARB SYM, V51, P713, DOI 10.1101/SQB.1986.051.01.084; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; YOUNG S, 1988, EUR J BIOCHEM, V173, P247, DOI 10.1111/j.1432-1033.1988.tb13991.x; ZIEGLERHEITBROCK HWL, 1985, CANCER RES, V45, P1344	49	54	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1133	1139						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2392322				2022-12-17	WOS:A1990DX36100004
J	CHIU, IM; WANG, WP; LEHTOMA, K				CHIU, IM; WANG, WP; LEHTOMA, K			ALTERNATIVE SPLICING GENERATES 2 FORMS OF MESSENGER-RNA CODING FOR HUMAN HEPARIN-BINDING GROWTH FACTOR-I	ONCOGENE			English	Article									OHIO STATE UNIV, MOLEC CELLULAR & DEV BIOL PROGRAM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR COMPREHENS CANC, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	CHIU, IM (corresponding author), OHIO STATE UNIV, DAVIS MED RES CTR, DEPT INTERNAL MED, ROOM S2052, 480 W 9TH AVE, COLUMBUS, OH 43210 USA.		Chiu, Ing-Ming/B-1534-2008		NCI NIH HHS [CA45611] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045611] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BUGAISKY L, 1986, HEART CARDIOVASCULAR, P1491; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURRUS LW, 1989, J BIOL CHEM, V264, P18647; CARAS IW, 1989, SCIENCE, V243, P1196, DOI 10.1126/science.2466338; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU IM, 1990, GENET ANAL-BIOMOL E, V7, P18, DOI 10.1016/0735-0651(90)90039-I; CHIU IM, 1990, IN PRESS TROPHIC FAC; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; DEFERRA F, 1985, CELL, V43, P721, DOI 10.1016/0092-8674(85)90245-4; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DISORBO D, 1988, BIOCHEM BIOPH RES CO, V157, P1007, DOI 10.1016/S0006-291X(88)80974-4; DOBNER PR, 1981, P NATL ACAD SCI-BIOL, V78, P2230, DOI 10.1073/pnas.78.4.2230; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GOODRICH SP, 1989, NUCLEIC ACIDS RES, V17, P2867, DOI 10.1093/nar/17.7.2867; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; GOUGH N, 1987, TRENDS GENET, V3, P238, DOI 10.1016/0168-9525(87)90252-6; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; GUSSOW D, 1987, IMMUNOL TODAY, V8, P220, DOI 10.1016/0167-5699(87)90170-8; HALL JA, 1989, IN PRESS J CELL BIOC; HALLEY C, 1988, NUCLEIC ACIDS RES, V16, P10913, DOI 10.1093/nar/16.22.10913; HUANG JS, 1986, J BIOL CHEM, V261, P1600; HUANG SS, 1986, J BIOL CHEM, V261, P9568; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOSEPHSILVERSTEIN J, 1989, J CELL BIOL, V108, P2459, DOI 10.1083/jcb.108.6.2459; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KLAGSBRUN M, 1987, P NATL ACAD SCI USA, V84, P1839, DOI 10.1073/pnas.84.7.1839; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LOBB RR, 1986, BIOCHEM BIOPH RES CO, V139, P861, DOI 10.1016/S0006-291X(86)80257-1; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MANASEK FJ, 1971, DEV BIOL, V26, P42, DOI 10.1016/0012-1606(71)90106-0; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; NUDEL U, 1989, NATURE, V337, P76, DOI 10.1038/337076a0; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; PASYK S, 1982, AM J PHYSIOL, V242, P1031; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1989, J BIOL CHEM, V264, P17606; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; WINKLES JA, 1987, P NATL ACAD SCI USA, V84, P7124, DOI 10.1073/pnas.84.20.7124; WITTE DP, 1989, LAB INVEST, V60, P353; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	70	54	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1990	5	5					755	762						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	1693186				2022-12-17	WOS:A1990DG37400017
J	CROUCH, DH; LANG, C; GILLESPIE, DAF				CROUCH, DH; LANG, C; GILLESPIE, DAF			THE LEUCINE ZIPPER DOMAIN OF AVIAN CMYC IS REQUIRED FOR TRANSFORMATION AND AUTOREGULATION	ONCOGENE			English	Article									BEATSON INST CANC RES,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND	Beatson Institute			Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Cleveland J L, 1988, Oncogene Res, V3, P357; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANG CV, 1989, MOL CELL BIOL, V9, P2477, DOI 10.1128/MCB.9.6.2477; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; ENRIETTO PJ, 1989, VIROLOGY, V168, P256, DOI 10.1016/0042-6822(89)90265-1; FRYKBERG L, 1987, ONCOGENE, V1, P415; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MOORE JP, 1987, ONCOGENE RES, V2, P65; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PATSCHINSKY T, 1986, J VIROL, V59, P341, DOI 10.1128/JVI.59.2.341-353.1986; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUBACH W, 1984, NATURE, V307, P702, DOI 10.1038/307702a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7	37	54	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					683	689						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2189105				2022-12-17	WOS:A1990DG37400008
J	STACHOWIAK, MK; SAR, M; TUOMINEN, RK; JIANG, HK; AN, S; IADAROLA, MJ; POISNER, AM; HONG, JS				STACHOWIAK, MK; SAR, M; TUOMINEN, RK; JIANG, HK; AN, S; IADAROLA, MJ; POISNER, AM; HONG, JS			STIMULATION OF ADRENAL-MEDULLARY CELLS INVIVO AND INVITRO INDUCES EXPRESSION OF C-FOS PROTO-ONCOGENE	ONCOGENE			English	Article									UNIV KANSAS, MED CTR, KANSAS CITY, KS 66103 USA; NIEHS, MOLEC & INTEGRAT NEUROSCI LAB, RES TRIANGLE PK, NC 27709 USA; UNIV N CAROLINA, DEPT CELL BIOL, CHAPEL HILL, NC 27599 USA; NIDR, NEUROBIOL & ANESTHESIOL BRANCH, BETHESDA, MD 20492 USA	University of Kansas; University of Kansas Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Poisner, Alan/Q-8226-2019; Hong, Jau-shyong/F-1920-2019; Poisner, Alan/AAC-8152-2022	Hong, Jau-shyong/0000-0002-3056-8401; Poisner, Alan/0000-0002-0161-8238	NINDS NIH HHS [NS-17479] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017479] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARKA T, 1987, ONCOGENE, V1, P439; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1987, ONCOGENE, V2, P79; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; DRAGUNOW M, 1987, EUR J PHARMACOL, V135, P113, DOI 10.1016/0014-2999(87)90767-9; DRAISCI G, 1989, IN PRESS MOL BRAIN R; EIDEN LE, 1984, NATURE, V312, P661, DOI 10.1038/312661a0; FAUSCHER FJ, 1988, CELL, V52, P471; Feldberg W, 1934, J PHYSIOL-LONDON, V81, P286, DOI 10.1113/jphysiol.1934.sp003136; FRANZA BR, 1987, ONCOGENE, V1, P213; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GUBITS RM, 1988, MOL BRAIN RES, V3, P197, DOI 10.1016/0169-328X(88)90067-8; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; KANAMATSU T, 1986, P NATL ACAD SCI USA, V83, P9242; KAPLAN BB, 1979, BIOCHEM J, V183, P181, DOI 10.1042/bj1830181; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MILLER R, 1987, ONCOGENE RES, V2, P19; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; SAR M, 1984, SCIENCE, V223, P938, DOI 10.1126/science.6141639; SAR M, 1985, TECHNIQUES IMMUNOCYT, V3, P43; STACHOWIAK M, 1985, BRAIN RES, V359, P356, DOI 10.1016/0006-8993(85)91450-7; STACHOWIAK M, 1988, MOL BRAIN RES, V3, P193, DOI 10.1016/0169-328X(88)90066-6; STACHOWIAK MK, 1988, MOL BRAIN RES, V3, P275, DOI 10.1016/0169-328X(88)90050-2; STACHOWIAK MK, 1989, J CELL BIOL, pA506; WILSON SP, 1981, EXP CELL RES, V133, P159, DOI 10.1016/0014-4827(81)90366-9; ZIMLICHMAN R, 1987, CELL CALCIUM, V8, P315, DOI 10.1016/0143-4160(87)90006-6	31	54	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1990	5	1					69	73						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2108403				2022-12-17	WOS:A1990CM62000010
J	SORRENTINO, V; BANDYOPADHYAY, S				SORRENTINO, V; BANDYOPADHYAY, S			TGF-BETA INHIBITS GO/S-PHASE TRANSITION IN PRIMARY FIBROBLASTS - LOSS OF RESPONSE TO THE ANTIGROWTH EFFECT OF TGF-BETA IS OBSERVED AFTER IMMORTALIZATION	ONCOGENE			English	Article											SORRENTINO, V (corresponding author), EUROPEAN MOLEC BIOL LAB, MEYERHOFSTR 1, D-6900 HEIDELBERG, GERMANY.		Sorrentino, Vincenzo/A-4793-2014	Sorrentino, Vincenzo/0000-0002-8573-8631				ANZANO MA, 1986, J CELL PHYSIOL, V126, P312, DOI 10.1002/jcp.1041260223; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CHAMBARD JC, 1988, J CELL PHYSIOL, V135, P101, DOI 10.1002/jcp.1041350114; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; EBSWORTH N, 1986, EXP CELL RES, V165, P255, DOI 10.1016/0014-4827(86)90549-5; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; EINAT M, 1988, ONCOGENE, V2, P485; FANGER BO, 1986, BIOCHEMISTRY-US, V25, P3083, DOI 10.1021/bi00359a003; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAMLIN JL, 1976, EXP CELL RES, V100, P265, DOI 10.1016/0014-4827(76)90147-6; HUME CR, 1988, ONCOGENE, V2, P223; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; KOHASE M, 1986, CELL, V45, P659, DOI 10.1016/0092-8674(86)90780-4; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; LOO DT, 1987, SCIENCE, V236, P200, DOI 10.1126/science.3494308; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MOSES HL, 1987, J CELL PHYSIOL, P1, DOI 10.1002/jcp.1041330403; MOUGNEAU E, 1988, ONCOGENE RES, V2, P177; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PARDEE AB, 1987, J CELL PHYSIOL, P107; RIZZINO A, 1988, CANCER RES, V48, P4266; ROBERTS AB, 1985, NATURE, V315, P237, DOI 10.1038/315237a0; ROBERTS AB, 1983, BIOCHEMISTRY-US, V22, P5692, DOI 10.1021/bi00294a002; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SORRENTINO V, 1987, P NATL ACAD SCI USA, V84, P4131, DOI 10.1073/pnas.84.12.4131; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; TAINSKY MA, 1984, SCIENCE, V225, P643, DOI 10.1126/science.6740333; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; TENDIJKE P, 1988, P NATL ACAD SCI USA, V85, P4715; TOMINAGA S, 1985, J BIOL CHEM, V260, P1975; ZERLIN M, 1987, ONCOGENE, V1, P19	45	54	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1989	4	5					569	574						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2498805				2022-12-17	WOS:A1989U768800006
J	TADOKORO, K; UEDA, M; OHSHIMA, T; FUJITA, K; RIKIMARU, K; TAKAHASHI, N; ENOMOTO, S; TSUCHIDA, N				TADOKORO, K; UEDA, M; OHSHIMA, T; FUJITA, K; RIKIMARU, K; TAKAHASHI, N; ENOMOTO, S; TSUCHIDA, N			ACTIVATION OF ONCOGENES IN HUMAN ORAL-CANCER CELLS - A NOVEL CODON-13 MUTATION OF C-H-RAS-1 AND CONCURRENT AMPLIFICATIONS OF C-ERBB-1 AND C-MYC	ONCOGENE			English	Article									TOKYO MED & DENT UNIV,FAC DENT,DEPT ORAL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,DEPT ORAL & MAXILLOFACIAL SURG 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								ANDERSEN PR, 1981, CELL, V26, P129, DOI 10.1016/0092-8674(81)90041-6; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; DOTTO GP, 1985, NATURE, V318, P472; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HIRAI H, 1987, NATURE, V327, P430, DOI 10.1038/327430a0; KOIKE K, 1983, NUCLEIC ACIDS RES, V11, P5391, DOI 10.1093/nar/11.16.5391; KOZMA SC, 1987, NUCLEIC ACIDS RES, V15, P5963; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LOENEN WAM, 1980, GENE, V10, P249, DOI 10.1016/0378-1119(80)90054-2; Maniatis T., 1982, MOL CLONING; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MIYAKI M, 1980, GANN, V71, P797; Momose F., 1986, J JPN STOMATOL SOC, V35, P485, DOI [10.11277/stomatology1952.35.485, DOI 10.11277/STOMATOLOGY1952.35.485]; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NAMBA M, 1986, INT J CANCER, V37, P419, DOI 10.1002/ijc.2910370314; PATER A, 1986, J VIROL, V58, P680, DOI 10.1128/JVI.58.2.680-683.1986; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; RHIM JS, 1975, INT J CANCER, V16, P840, DOI 10.1002/ijc.2910160516; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RUBIN CM, 1980, NATURE, V284, P372, DOI 10.1038/284372a0; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TAYA Y, 1984, EMBO J, V3, P2943, DOI 10.1002/j.1460-2075.1984.tb02236.x; TSUCHIDA N, 1981, J VIROL, V38, P720, DOI 10.1128/JVI.38.2.720-727.1981; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WEISS R, 1985, RNA TUMOR VIRUSES, V2; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YAMAMOTO T, 1986, CANCER RES, V46, P414; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	58	54	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					499	505						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2654810				2022-12-17	WOS:A1989U567700015
J	HALEY, JD; HSUAN, JJ; WATERFIELD, MD				HALEY, JD; HSUAN, JJ; WATERFIELD, MD			ANALYSIS OF MAMMALIAN FIBROBLAST TRANSFORMATION BY NORMAL AND MUTATED HUMAN EGF RECEPTORS	ONCOGENE			English	Article									LUDWIG INST CANC RES,LONDON W1 8PT,ENGLAND	Ludwig Institute for Cancer Research			Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564				BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BASSIRI M, 1986, J VIROL, V59, P525, DOI 10.1128/JVI.59.2.525-530.1986; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BEUG H, 1986, ONCOGENES GROWTH CON, P85; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRUGGE JS, 1986, CELL, V46, P149, DOI 10.1016/0092-8674(86)90729-4; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CLARK S, 1988, J CELL PHYSIOL, V134, P421, DOI 10.1002/jcp.1041340313; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HALEY J, 1987, ONCOGENE RES, V1, P375; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1984, NATURE, V311, P414, DOI 10.1038/311414a0; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1985, EMBO J, V4, P3179, DOI 10.1002/j.1460-2075.1985.tb04062.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NG M, 1986, J VIROL, V58, P542, DOI 10.1128/JVI.58.2.542-553.1986; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; REISS N, 1986, BIOCHEM J, V239, P691, DOI 10.1042/bj2390691; RIEDEL H, 1987, SCIENCE, V236, P197, DOI 10.1126/science.3494307; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT JA, 1985, EMBO J, V4, P105, DOI 10.1002/j.1460-2075.1985.tb02323.x; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WANG LH, 1987, P NATL ACAD SCI USA, V84, P5725, DOI 10.1073/pnas.84.16.5725; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	63	54	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					273	283						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2784850				2022-12-17	WOS:A1989U567600002
J	FRYKBERG, L; GRAF, T; VENNSTROM, B				FRYKBERG, L; GRAF, T; VENNSTROM, B			THE TRANSFORMING ACTIVITY OF THE CHICKEN-C-MYC GENE CAN BE POTENTIATED BY MUTATIONS	ONCOGENE			English	Article									EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAM,POSTFACH 102209,MEYERHOFSTR 1,D-6900 HEIDELBERG,FED REP GER	European Molecular Biology Laboratory (EMBL)			Graf, Thomas/B-4252-2015	Graf, Thomas/0000-0003-2774-4117				ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; Favaloro J, 1980, Methods Enzymol, V65, P718; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HACKETT PB, 1982, J VIROL, V41, P527, DOI 10.1128/JVI.41.2.527-534.1982; HACKETT PB, 1981, VIROLOGY, V112, P714, DOI 10.1016/0042-6822(81)90316-0; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HAYMAN MJ, 1983, CURR TOP MICROBIOL, V103, P109; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; Ivanov X., 1964, Izvestiya na Instituta po Sravnitelna Patologiya na Domashnite Zhivotni, V10, P5; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LINIAL M, 1985, P NATL ACAD SCI US, V82, P5357; MANIATIS T, 1982, MOL CLONING LABORATO; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; MLADENOV Z, 1967, JNCI-J NATL CANCER I, V38, P251; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PATSCHINSKY T, 1986, J VIROL, V59, P341, DOI 10.1128/JVI.59.2.341-353.1986; PAYNE GS, 1981, CELL, V23, P311, DOI 10.1016/0092-8674(81)90127-6; PFEIFER S, 1983, J VIROL, V46, P347, DOI 10.1128/JVI.46.2.347-354.1983; RAMSAY GM, 1982, J VIROL, V41, P745, DOI 10.1128/JVI.41.3.745-753.1982; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; SHAW J, 1985, J VIROL, V56, P953; SHIH CK, 1984, P NATL ACAD SCI-BIOL, V81, P4697, DOI 10.1073/pnas.81.15.4697; STOW ND, 1976, J GEN VIROL, V33, P447, DOI 10.1099/0022-1317-33-3-447; VENNSTROM B, 1987, ONCOGENE, V1, P271; VENNSTROM B, 1981, J VIROL, V39, P625; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; VENNSTROM B, 1980, J VIROL, V36, P575; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WEAVER RF, 1979, NUCLEIC ACIDS RES, V6, P6251; ZERLIN M, 1987, ONCOGENE, V1, P19	50	54	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	4					415	421						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	3330784				2022-12-17	WOS:A1987K748300011
J	WONG, DTW; BISWAS, DK				WONG, DTW; BISWAS, DK			EXPRESSION OF C-ERBB PROTO-ONCOGENE DURING DIMETHYLBENZANTHRACENE-INDUCED TUMORIGENESIS IN HAMSTER-CHEEK POUCH	ONCOGENE			English	Article									HARVARD UNIV,SCH DENT MED,PHARMACOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032034] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32034] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BISWAS DK, 1982, NUCLEIC ACIDS RES, V10, P3995, DOI 10.1093/nar/10.13.3995; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; Bruce S. A., 1984, BIOCH BASIS CHEM CAR, P159; FARBER E, 1975, NEW ENGL J MED, V303, P1379; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HARPER JR, 1986, MOL CELL BIOL, V6, P3144, DOI 10.1128/MCB.6.9.3144; HEIDELBERGER C, 1975, ANNU REV BIOCHEM, V44, P79, DOI 10.1146/annurev.bi.44.070175.000455; KOURI RE, 1980, GENETIC DIFFERENCES, P22; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE MA, 1984, P NATL ACAD SCI-BIOL, V81, P2227, DOI 10.1073/pnas.81.7.2227; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MCCARTHY PL, 1980, DISEASES ORAL MUCOSA, P428; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; MORRIS AL, 1961, J DENT RES, V40, P3, DOI 10.1177/00220345610400012001; ODUKOYA O, 1983, J NATL CANCER I, V71, P1253; OZANNE B, 1985, CANCER CELL, V3, P41; SALLEY JJ, 1954, J DENT RES, V33, P253, DOI 10.1177/00220345540330021201; Shafer W. G., 1983, TXB ORAL PATHOLOGY, P86; SHKLAR G, 1972, PROG EXP TUMOR RES, V16, P518; Shklar G, 1984, ORAL CANCER, P41; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; ULRICH A, 1984, NATURE, V309, P418; VARMUS HE, 1984, ANNU REV GENET, V18, P553; VENNSTROM B, 1980, J VIROL, V36, P575; WEINBERG RA, 1982, ADV CANCER RES, V36, P149, DOI 10.1016/S0065-230X(08)60424-8; YAMAMOTO M, 1983, P NATL ACAD SCI-BIOL, V80, P7524, DOI 10.1073/pnas.80.24.7524; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	31	54	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	2	1					67	72						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	L4813	3125508				2022-12-17	WOS:A1987L481300010
J	Cannataro, VL; Gaffney, SG; Sasaki, T; Issaeva, N; Grewal, NKS; Grandis, JR; Yarbrough, WG; Burtness, B; Anderson, KS; Townsend, JP				Cannataro, Vincent L.; Gaffney, Stephen G.; Sasaki, Tomoaki; Issaeva, Natalia; Grewal, Nicholas K. S.; Grandis, Jennifer R.; Yarbrough, Wendell G.; Burtness, Barbara; Anderson, Karen S.; Townsend, Jeffrey P.			APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma	ONCOGENE			English	Article							PAPILLOMAVIRUS-ASSOCIATED HEAD; FBW7 UBIQUITIN LIGASE; CYTOSINE DEAMINATION; OROPHARYNGEAL CANCER; SOMATIC MUTATIONS; GERMLINE VARIANTS; GENETIC LANDSCAPE; GENOMIC ANALYSIS; STRUCTURAL BASIS; DNA CYTOSINE	Recent studies have revealed the mutational signatures underlying the somatic evolution of cancer, and the prevalences of associated somatic genetic variants. Here we estimate the intensity of positive selection that drives mutations to high frequency in tumors, yielding higher prevalences than expected on the basis of mutation and neutral drift alone. We apply this approach to a sample of 525 head and neck squamous cell carcinoma exomes, producing a rank-ordered list of gene variants by selection intensity. Our results illustrate the complementarity of calculating the intensity of selection on mutations along with tallying the prevalence of individual substitutions in cancer: while many of the most prevalently-altered genes were heavily selected, their relative importance to the cancer phenotype differs from their prevalence and from their P value, with some infrequent variants exhibiting evidence of strong positive selection. Furthermore, we extend our analysis of effect size by quantifying the degree to which mutational processes (such as APOBEC mutagenesis) contributes mutations that are highly selected, driving head and neck squamous cell carcinoma. We calculate the substitutions caused by APOBEC mutagenesis that make the greatest contribution to cancer phenotype among patients. Lastly, we demonstrate via in vitro biochemical experiments that the APOBEC3B protein can deaminate the cytosine bases at two sites whose mutant states are subject to high net realized selection intensities-PIK3CA E545K and E542K. By quantifying the effects of mutations, we deepen the molecular understanding of carcinogenesis in head and neck squamous cell carcinoma.	[Cannataro, Vincent L.; Gaffney, Stephen G.; Townsend, Jeffrey P.] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT 06510 USA; [Sasaki, Tomoaki; Anderson, Karen S.] Yale Univ, Dept Pharmacol, New Haven, CT USA; [Issaeva, Natalia; Yarbrough, Wendell G.; Burtness, Barbara; Anderson, Karen S.] Yale Univ, Yale Canc Ctr, New Haven, CT USA; [Issaeva, Natalia; Yarbrough, Wendell G.] Yale Sch Med, Dept Surg, Div Otolaryngol, New Haven, CT USA; [Grewal, Nicholas K. S.; Townsend, Jeffrey P.] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA; [Grandis, Jennifer R.] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA USA; [Yarbrough, Wendell G.] Yale Univ, Yale Sch Med, Dept Pathol, New Haven, CT USA; [Burtness, Barbara] Yale Univ, Yale Sch Med, Dept Med, New Haven, CT USA; [Anderson, Karen S.] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT USA; [Townsend, Jeffrey P.] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University; Yale University; University of California System; University of California San Francisco; Yale University; Yale University; Yale University; Yale University	Townsend, JP (corresponding author), Yale Sch Publ Hlth, Dept Biostat, New Haven, CT 06510 USA.; Townsend, JP (corresponding author), Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA.; Townsend, JP (corresponding author), Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA.	Jeffrey.Townsend@Yale.edu	; Townsend, Jeffrey/D-6457-2017	Cannataro, Vincent/0000-0002-6364-7747; Gaffney, Stephen/0000-0002-5490-2945; Townsend, Jeffrey/0000-0002-9890-3907; Issaeva, Natalia/0000-0001-5483-6610; Grewal, Nicholas/0000-0001-5118-7774	Yale Cancer Center TTARE pilot award; American Cancer Society; NIH [R01DE023685, P50CA097190]; Department of Defence [W81XWH-15-1-0290]; Notsew Orm Sands Foundation; Gilead Sciences, Inc; NATIONAL CANCER INSTITUTE [P50CA097190, R35CA231998, T32CA193200] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE023685] Funding Source: NIH RePORTER	Yale Cancer Center TTARE pilot award; American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defence; Notsew Orm Sands Foundation; Gilead Sciences, Inc(Gilead Sciences); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This research was funded by a Yale Cancer Center TTARE pilot award to WGY and BB, by grants from The American Cancer Society and NIH grants R01DE023685 and P50CA097190 to JRG, by award W81XWH-15-1-0290 from the Department of Defence to KA, and by support from the Notsew Orm Sands Foundation to JPT. Whole-exome sequencing of tumor tissue was supported by funding from Gilead Sciences, Inc to JRG and JPT. Funders had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication.	Adolph MB, 2017, NUCLEIC ACIDS RES, V45, P11925, DOI 10.1093/nar/gkx832; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Alexandrov LB, 2015, NAT GENET, V47, P1402, DOI 10.1038/ng.3441; Alexandrov LB, 2014, CURR OPIN GENET DEV, V24, P52, DOI 10.1016/j.gde.2013.11.014; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Applebaum KM, 2007, JNCI-J NATL CANCER I, V99, P1801, DOI 10.1093/jnci/djm233; Bhatia A, 2015, J CLIN ONCOL, V33, P3243, DOI 10.1200/JCO.2015.61.2358; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Cannataro VL, 2018, ONCOGENE, V37, P2444, DOI 10.1038/s41388-017-0105-z; Cao S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28294; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chaussade C, 2009, BIOCHEM BIOPH RES CO, V381, P577, DOI 10.1016/j.bbrc.2009.02.081; Chelico L, 2006, NAT STRUCT MOL BIOL, V13, P392, DOI 10.1038/nsmb1086; Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; Faden DL, 2017, ORAL ONCOL, V74, P8, DOI 10.1016/j.oraloncology.2017.09.002; Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; Flores-Obando RE, 2010, BIOMARKERS, V15, P379, DOI 10.3109/13547501003797664; Fousteri M, 2008, CELL RES, V18, P73, DOI 10.1038/cr.2008.6; Fu Y, 2015, BIOCHEM J, V471, P25, DOI 10.1042/BJ20150382; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Glaser AP, 2018, ONCOTARGET, V9, P4537, DOI 10.18632/oncotarget.23344; Grossman RL, 2016, NEW ENGL J MED, V375, P1109, DOI 10.1056/NEJMp1607591; Hajek M, 2017, CANCER-AM CANCER SOC, V123, P1778, DOI 10.1002/cncr.30570; Hammerman PS, 2015, CANCER DISCOV, V5, P239, DOI 10.1158/2159-8290.CD-14-1205; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; Hayes DN, 2015, J CLIN ONCOL, V33, P3227, DOI 10.1200/JCO.2015.62.1086; Hayes DN, 2015, J CLIN INVEST, V125, P462, DOI 10.1172/JCI68339; Hedberg ML, 2016, J CLIN INVEST, V126, P169, DOI 10.1172/JCI82066; Henderson S, 2014, CELL REP, V7, P1833, DOI 10.1016/j.celrep.2014.05.012; Hoopes JI, 2016, CELL REP, V14, P1273, DOI 10.1016/j.celrep.2016.01.021; Huang KL, 2018, CELL, V173, P355, DOI 10.1016/j.cell.2018.03.039; Jiron J, 2014, AM J OTOLARYNG, V35, P147, DOI 10.1016/j.amjoto.2013.09.004; Kazanov MD, 2015, CELL REP, V13, P1103, DOI 10.1016/j.celrep.2015.09.077; Kox C, 2010, LEUKEMIA, V24, P2005, DOI 10.1038/leu.2010.203; Krupar R, 2014, EUR ARCH OTO-RHINO-L, V271, P1737, DOI 10.1007/s00405-013-2693-8; Kwon YW, 2012, MOL CANCER RES, V10, P834, DOI 10.1158/1541-7786.MCR-12-0025; Lawrence M, 2009, BIOINFORMATICS, V25, P1841, DOI 10.1093/bioinformatics/btp328; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; LECHNER M, 2013, GENOME MED, V5; Lewis JS, 2018, ARCH PATHOL LAB MED, V142, P559, DOI 10.5858/arpa.2017-0286-CP; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; Martin D, 2014, ONCOTARGET, V5, P8906, DOI 10.18632/oncotarget.2417; Martincorena I, 2017, CELL, V171, P1029, DOI 10.1016/j.cell.2017.09.042; McGranahan N., 2015, SCI TRANSL MED, V7; Mirghani H, 2018, CLIN TRANSL RAD ONCO, V8, P4, DOI 10.1016/j.ctro.2017.10.005; Montgomery ND, 2018, J MOL DIAGN, V20, P123, DOI 10.1016/j.jmoldx.2017.09.008; Mori S, 2017, J VIROL, V91, DOI 10.1128/JVI.02413-16; Mori S, 2015, BIOCHEM BIOPH RES CO, V460, P555, DOI 10.1016/j.bbrc.2015.03.068; Mroz EA, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001786; Nik-Zainal S, 2014, NAT GENET, V46, P487, DOI 10.1038/ng.2955; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Ramakodi MP, 2017, CANCER-AM CANCER SOC, V123, P849, DOI 10.1002/cncr.30457; Ramakodi MP, 2016, GENOMICS, V107, P76, DOI 10.1016/j.ygeno.2015.12.004; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; Roberts SA, 2012, MOL CELL, V46, P424, DOI 10.1016/j.molcel.2012.03.030; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310; Shi K, 2017, NAT STRUCT MOL BIOL, V24, P131, DOI 10.1038/nsmb.3344; Stamatoyannopoulos JA, 2009, NAT GENET, V41, P393, DOI 10.1038/ng.363; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sun W, 2018, NUCLEIC ACIDS RES, V46, P3009, DOI 10.1093/nar/gky131; Teng CL, 2012, CELL CYCLE, V11, P4059, DOI 10.4161/cc.22381; Theurer JA, 2016, PATHOL ONCOL RES, V22, P35, DOI 10.1007/s12253-015-9970-3; Venkatesan S, 2018, ANN ONCOL, V29, P563, DOI 10.1093/annonc/mdy003; Vieira VC, 2014, MBIO, V5, DOI 10.1128/mBio.02234-14; VIEIRA VC, 2013, BIOMED RES INT, V2013, P1; Wang XJ, 2011, J VIROL, V85, P3142, DOI 10.1128/JVI.02049-10; Weinberger PM, 2006, J CLIN ONCOL, V24, P736, DOI 10.1200/JCO.2004.00.3335; Weiss RA, 2011, J EXP MED, V208, P2351, DOI 10.1084/jem.20112160; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wu ES, 2016, HEAD NECK-J SCI SPEC, V38, P1234, DOI 10.1002/hed.24420	78	53	53	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3475	3487		10.1038/s41388-018-0657-6	http://dx.doi.org/10.1038/s41388-018-0657-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30647454	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000466610000011
J	Karsch-Bluman, A; Feiglin, A; Arbib, E; Stern, T; Shoval, H; Schwob, O; Berger, M; Benny, O				Karsch-Bluman, Adi; Feiglin, Ariel; Arbib, Eliran; Stern, Tal; Shoval, Hila; Schwob, Ouri; Berger, Michael; Benny, Ofra			Tissue necrosis and its role in cancer progression	ONCOGENE			English	Article							CELL SURVIVAL; TUMOR-CELLS; MOLECULAR-PATTERNS; METABOLIC STRESS; HYPOXIA; ADHESION; EXPRESSION; MEDIATORS; INVASION; PROLIFERATION	Great efforts have been made in revealing the mechanisms governing cancer resistance and recurrence. The in-situ effects of cell death, caused by hypoxia and metabolic stress, were largely studied in association with inflammation. However, in this work, we focused on the direct effects of necrosis on cancer promotion and on the tumor microenvironment. The conditions leading to cell necrosis, upon nutrient and oxygen deprivation, were recapitulated in-vitro and were used to generate samples for computational proteomic analysis. Under these conditions, we identified clusters of enriched pathways that may be involved in tumor resistance, leading to cancer recurrence. We show that the content of necrotic cells enhances angiogenesis and proliferation of endothelial cells, induces vasculature, as well as increases migration, invasion, and cell-cell interactions. In-vivo studies, where MDA-MB-231 xenografts were exposed to necrotic lysates, resulted in an increase in both proliferation and angiogenesis. Histological analysis of tumor tissues revealed high expression levels of key mediators that were identified by proteomic analysis. Moreover, when cells were injected systemically, coupled with necrotic lysates, a higher number of large lesions was detected in the lung. Finally, using xenografts, we demonstrated that combining an antagonist of a necrotic signal with an anticancer treatment potentiates the prolonged therapeutic effect. This approach suggests a paradigm shift in which targeting late necrotic-secreted factors may increase survival and enhance the efficacy of anticancer therapy.	[Karsch-Bluman, Adi; Stern, Tal; Shoval, Hila; Schwob, Ouri; Benny, Ofra] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Inst Drug Res, Jerusalem, Israel; [Feiglin, Ariel] Harvard Med Sch, Dept Biomed Informat, Boston, MA 02115 USA; [Arbib, Eliran; Berger, Michael] Hebrew Univ Jerusalem, Fac Med, Lautenberg Ctr Immunol & Canc Res, IMRIC,Concern Fdn Labs, Jerusalem, Israel	Hebrew University of Jerusalem; Harvard University; Harvard Medical School; Hebrew University of Jerusalem	Benny, O (corresponding author), Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Inst Drug Res, Jerusalem, Israel.	ofrab@ekmd.huji.ac.il	Benny, Ofra/AAB-3294-2021		Marie Curie Career Integration Grants (CIG) [0305116]; Israel Cancer Association (ICA) [0394691]; Israel Foundation of Science (ISF) [0394883]; David R. Blum Center for Pharmacy at The Hebrew University; Shukor Gladi fund; Frances Brody fund; Eliyahu Pen Fund	Marie Curie Career Integration Grants (CIG); Israel Cancer Association (ICA); Israel Foundation of Science (ISF); David R. Blum Center for Pharmacy at The Hebrew University; Shukor Gladi fund; Frances Brody fund; Eliyahu Pen Fund	This study was kindly supported by grants from the Marie Curie Career Integration Grants (CIG) (No. 0305116), Israel Cancer Association (ICA) (No. 0394691), Israel Foundation of Science (ISF) (No. 0394883), David R. Blum Center for Pharmacy at The Hebrew University, The Shukor Gladi fund, The Frances Brody fund, and Eliyahu Pen Fund. We thank Dr. Gil Hornung and The De Botton Protein Profiling Institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, for their support of the proteomic data generating process.	Aalinkeel R, 2004, CANCER RES, V64, P5311, DOI 10.1158/0008-5472.CAN-2506-2; Ahn SH, 2016, SCI REP-UK, V6, DOI 10.1038/srep24552; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Bredholt G, 2015, ONCOTARGET, V6, P39676, DOI 10.18632/oncotarget.5344; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Caino MC, 2013, J CLIN INVEST, V123, P2907, DOI 10.1172/JCI67841; Chen MJ, 2008, J EXP MED, V205, P2791, DOI 10.1084/jem.20080767; Chung TW, 2017, J ETHNOPHARMACOL, V195, P309, DOI 10.1016/j.jep.2016.11.036; Comito G, 2014, ONCOGENE, V33, P2423, DOI 10.1038/onc.2013.191; Crowley LC, 2016, COLD SPRING HARB PRO, V2016; Cuvier C, 1997, CLIN EXP METASTAS, V15, P19; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Esmatabadi MJD, 2016, J BIOSCIENCES, V41, P497, DOI 10.1007/s12038-016-9624-y; Eustace A, 2013, RADIOTHER ONCOL, V108, P40, DOI 10.1016/j.radonc.2013.05.017; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; Forte D, 2017, ONCOTARGET, V8, P2261, DOI 10.18632/oncotarget.13664; Franco M, 2011, BLOOD, V118, P2906, DOI 10.1182/blood-2011-01-331694; Gho YS, 2001, CANCER RES, V61, P4253; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hernandez C, 2016, ONCOGENE, V35, P5931, DOI 10.1038/onc.2016.104; Herszenyi L, 2012, DIGEST DIS, V30, P249, DOI 10.1159/000336914; Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769; Howard K, 2014, J SURG RES, V187, P19, DOI 10.1016/j.jss.2013.11.001; Indovina P, 2008, ANTICANCER RES, V28, P1013; Janakiram NB, 2009, CURR MOL MED, V9, P565, DOI 10.2174/156652409788488748; Kaczmarek A, 2013, IMMUNITY, V38, P209, DOI 10.1016/j.immuni.2013.02.003; Karsch-Bluman A, 2017, ONCOTARGET, V8, P32706, DOI 10.18632/oncotarget.16188; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kevil CG, 2004, J BIOL CHEM, V279, P19230, DOI 10.1074/jbc.M312025200; Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654; Land Walter G, 2015, Sultan Qaboos Univ Med J, V15, pe157; Li W, 2013, MOL MED, V19, P203, DOI 10.2119/molmed.2013.00064; Liu H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-583; Liu R, 2009, MOL CELL PROTEOMICS, V8, P70, DOI 10.1074/mcp.M800195-MCP200; Liu WD, 2012, ONCOL LETT, V4, P1315, DOI 10.3892/ol.2012.940; Martinive P, 2006, CANCER RES, V66, P11736, DOI 10.1158/0008-5472.CAN-06-2056; Maurer AJ, 2015, INFLAMM RES, V64, P185, DOI 10.1007/s00011-015-0796-y; McIntosh A, 2007, AM J CLIN ONCOL-CANC, V30, P146, DOI 10.1097/01.coc.0000251357.45879.7f; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Nagelkerke A, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3373; Pang C, 2008, AM J PHYSIOL-ENDOC M, V295, pE313, DOI 10.1152/ajpendo.90296.2008; Polychronidis Alexandros C, 2003, Folia Med (Plovdiv), V45, P20; Rahman M, 2015, METABOLITES, V5, P571, DOI 10.3390/metabo5040571; Riffle S, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3319-0; Rosette C, 2005, CARCINOGENESIS, V26, P943, DOI 10.1093/carcin/bgi070; Rundqvist H, 2013, J INTERN MED, V274, P105, DOI 10.1111/joim.12091; Schroder C, 2011, J CANCER RES CLIN, V137, P1193, DOI 10.1007/s00432-011-0984-2; Shoval H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10699-y; Simard S, 2013, J CANCER SURVIV, V7, P300, DOI 10.1007/s11764-013-0272-z; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sulciner ML, 2018, J EXP MED, V215, P115, DOI 10.1084/jem.20170681; Sun Y, 2016, CANCER LETT, V380, P205, DOI 10.1016/j.canlet.2015.07.044; Sunami E, 2000, Oncologist, V5, P108, DOI 10.1634/theoncologist.5-2-108; Tomes L, 2003, BREAST CANCER RES TR, V81, P61, DOI 10.1023/A:1025476722493; Wellen KE, 2010, MOL CELL, V40, P323, DOI 10.1016/j.molcel.2010.10.004; Yang DG, 2016, SCI REP-UK, V6, DOI 10.1038/srep35316; Yang M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.144; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Yodkeeree S, 2010, EUR J PHARMACOL, V627, P8, DOI 10.1016/j.ejphar.2009.09.052; Zhang Q, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00071	62	53	53	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1920	1935		10.1038/s41388-018-0555-y	http://dx.doi.org/10.1038/s41388-018-0555-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30390074				2022-12-17	WOS:000461164400010
J	Zhou, Y; Huang, T; Zhang, J; Wong, CC; Zhang, B; Dong, Y; Wu, F; Tong, JHM; Wu, WKK; Cheng, ASL; Yu, J; Kang, W; To, KF				Zhou, Y.; Huang, T.; Zhang, J.; Wong, C. C.; Zhang, B.; Dong, Y.; Wu, F.; Tong, J. H. M.; Wu, W. K. K.; Cheng, A. S. L.; Yu, J.; Kang, W.; To, K. F.			TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis	ONCOGENE			English	Article							INHIBITS CELL-PROLIFERATION; GROWTH-FACTOR CTGF; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC TARGET; TUMOR-SUPPRESSOR; CANCER GENOMICS; BREAST-CANCER; EXPRESSION; CLASSIFICATION; YAP1	TEA domain (TEAD) transcription factors are key components of the Hippo-YAP1 signaling pathway, but their functional role and regulatory mechanisms remain unclear. This study aims to comprehensively explore the expression pattern and functional role of TEAD family in gastric carcinogenesis and investigate its regulation by microRNAs (miRNAs). The mRNA and protein expression of TEAD family were examined by quantitative reverse transcription-PCR (qRT-PCR) and western blot. Their functional roles were determined by in vitro and in vivo studies. The clinicopathological association of TEAD4 in gastric cancer (GC) was studied using immunohistochemistry on tissue microarray. The prediction of miRNAs, which potentially target TEAD1/4, was performed by TargetScan and miRDB. The regulation of TEAD1/4 by miRNAs was confirmed by qRT-PCR, western blot and luciferase assays. TEAD1/4 were overexpressed in GC cell lines and primary GC tissues. Knockdown of TEAD1/4 induced a significant anticancer effect in vitro and in vivo. TEAD1 was confirmed to be a direct target of miR-377-3p and miR-4269, while TEAD4 was negatively regulated by miR-1343-3p and miR-4269. Among them, miR-4269 was the most effective inhibitor of TEAD1/4. Ectopic expression of these miRNAs substantiated their tumor-suppressive effects. In primary GC tumors, downregulation of miR-4269 was associated with poor disease-specific survival and showed a negative correlation with TEAD4. TEAD1 and TEAD4 are oncogenic factors, whose aberrant activation are, in part, mediated by the silence of miR-377-3p, miR-1343-3p and miR-4269. For the first time, the nuclear accumulated TEAD4 and downregulated miR-4269 are proposed to serve as novel prognostic biomarkers in GC.	[Zhou, Y.; Huang, T.; Zhang, J.; Wu, F.; Tong, J. H. M.; Kang, W.; To, K. F.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Oncol South China, Shatin, Hong Kong, Peoples R China; [Zhou, Y.; Huang, T.; Zhang, J.; Wong, C. C.; Dong, Y.; Wu, W. K. K.; Yu, J.; Kang, W.; To, K. F.] Chinese Univ Hong Kong, Inst Digest Dis, Partner State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Zhou, Y.; Huang, T.; Zhang, J.; Tong, J. H. M.; Kang, W.; To, K. F.] Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Huang, T.; Cheng, A. S. L.; Yu, J.; Kang, W.; To, K. F.] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China; [Zhang, B.] Nanjing Univ, Affiliated Drum Tower Hosp, Dept Gastroenterol, Med Sch, Nanjing, Jiangsu, Peoples R China; [Wu, W. K. K.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China; [Cheng, A. S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Yu, J.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; State Key Lab Oncology South China; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen; Nanjing University; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Oncol South China, Shatin, Hong Kong, Peoples R China.	weikang@cuhk.edu.hk; kfto@cuhk.edu.hk	Wong, Chi Chun/C-4636-2016; KANG, Wei/C-5451-2016; Wu, William K.K./A-3277-2009; Cheng, Alfred SL/C-3327-2014; Jun, Yu/D-8569-2015	KANG, Wei/0000-0002-4651-677X; Wu, William K.K./0000-0002-5662-5240; Cheng, Alfred SL/0000-0003-2345-6951; Jun, Yu/0000-0001-5008-2153	General Research Fund (RGC) from Research Grants Council of Hong Kong [CUHK14114414, CUHK14110016]	General Research Fund (RGC) from Research Grants Council of Hong Kong	We acknowledge the TCGA research Network (http://cancergenome.nih.gov/), The UCSC Cancer Genomics Browser (https://genome-cancer.ucsc.edu/) and NCI Center for Cancer Genomics Office (http://gdc.nci.nih.gov/) for providing the gastric cancer data set and analysis. This study is supported by General Research Fund (RGC Reference No. CUHK14114414 and CUHK14110016) from The Research Grants Council of Hong Kong.	Bai N, 2013, CANCER BIOL THER, V14, P511, DOI 10.4161/cbt.24345; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen GL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117714; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; Chu CY, 2008, J BIOMED SCI, V15, P675, DOI 10.1007/s11373-008-9264-9; de la Cova C, 2006, SEMIN CANCER BIOL, V16, P303, DOI 10.1016/j.semcancer.2006.07.010; Ding L, 2010, CELL RES, V20, P784, DOI 10.1038/cr.2010.79; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Guo C, 2015, INT J CLIN EXP PATHO, V8, P1690; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Huang TT, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0493-7; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Kang W, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0323-3; Kang W, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0281-3; Kang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033919; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Knight JF, 2008, BRIT J CANCER, V99, P1849, DOI 10.1038/sj.bjc.6604774; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Li N, 2015, AM J CANCER RES, V5, P1158; Lim B, 2014, CARCINOGENESIS, V35, P1020, DOI 10.1093/carcin/bgt409; Mao B, 2014, ONCOGENE, V33, P1468, DOI 10.1038/onc.2013.88; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Murray-Stewart T, 2016, ONCOGENE, V35, P5480, DOI 10.1038/onc.2016.91; Nowee ME, 2007, J PATHOL, V213, P46, DOI 10.1002/path.2217; Perra A, 2014, J HEPATOL, V61, P1088, DOI 10.1016/j.jhep.2014.06.033; Pobbati AV, 2013, CANCER BIOL THER, V14, P390, DOI 10.4161/cbt.23788; Qian ZL, 2014, GENE CHROMOSOME CANC, V53, P883, DOI 10.1002/gcc.22196; Qiao Y, 2016, ONCOGENE, V35, P2664, DOI 10.1038/onc.2015.338; Sala-Torra O, 2007, BLOOD, V109, P3080, DOI 10.1182/blood-2006-06-031096; Schutte U, 2014, TRANSL ONCOL, V7, P309, DOI 10.1016/j.tranon.2014.02.005; Shin G, 2011, CANCER INFORM, V10, P149, DOI 10.4137/CIN.S7226; Skotheim RI, 2006, CELL ONCOL, V28, P315; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170; Wang CY, 2015, ONCOTARGET, V6, P17685, DOI 10.18632/oncotarget.3779; Wang RY, 2015, BIOMED PHARMACOTHER, V70, P64, DOI 10.1016/j.biopha.2015.01.012; Wanjin H, 2014, PLOS ONE, V9; Xia JT, 2012, J PATHOL, V227, P470, DOI 10.1002/path.4030; Zehentmayr F, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0198-1; Zhang XT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116979; ZHOU YH, 2016, INT J MOL SCI, V17	48	53	54	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6518	6530		10.1038/onc.2017.257	http://dx.doi.org/10.1038/onc.2017.257			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28759040	Green Published, hybrid			2022-12-17	WOS:000416049200002
J	Song, W; Hwang, Y; Youngblood, VM; Cook, RS; Balko, JM; Chen, J; Brantley-Sieders, DM				Song, W.; Hwang, Y.; Youngblood, V. M.; Cook, R. S.; Balko, J. M.; Chen, J.; Brantley-Sieders, D. M.			Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASE; METASTATIC PROGRESSION; MAMMARY ADENOCARCINOMA; TUMOR ANGIOGENESIS; SIGNALING AXIS; T-ANTIGEN; MYC; DISEASE; MICE; GENE	Basal-like/triple-negative breast cancers (TNBCs) are among the most aggressive forms of breast cancer, and disproportionally affects young premenopausal women and women of African descent. Patients with TNBC suffer a poor prognosis due in part to a lack of molecularly targeted therapies, which represents a critical barrier for effective treatment. Here, we identify EphA2 receptor tyrosine kinase as a clinically relevant target for TNBC. EphA2 expression is enriched in the basal-like molecular subtype in human breast cancers. Loss of EphA2 function in both human and genetically engineered mouse models of TNBC reduced tumor growth in culture and in vivo. Mechanistically, targeting EphA2 impaired cell cycle progression through S-phase via downregulation of c-Myc and stabilization of the cyclin-dependent kinase inhibitor p27/KIP1. A small molecule kinase inhibitor of EphA2 effectively suppressed tumor cell growth in vivo, including TNBC patient-derived xenografts. Thus, our data identify EphA2 as a novel molecular target for TNBC.	[Song, W.; Hwang, Y.; Chen, J.; Brantley-Sieders, D. M.] Vanderbilt Univ, Sch Med, Dept Med, T-3107A MCN,1161 21st Ave South, Nashville, TN 37232 USA; [Youngblood, V. M.; Cook, R. S.; Balko, J. M.; Chen, J.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; [Cook, R. S.; Balko, J. M.; Chen, J.; Brantley-Sieders, D. M.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [Chen, J.] Vanderbilt Univ, Sch Med, Dept Cellular & Dev Biol, Nashville, TN 37212 USA; [Chen, J.] Vet Affairs Med Ctr, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Chen, J; Brantley-Sieders, DM (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, T-3107A MCN,1161 21st Ave South, Nashville, TN 37232 USA.; Chen, J (corresponding author), Vanderbilt Univ, Sch Med, T-3107A MCN,1161 21st Ave South, Nashville, TN 37232 USA.	jin.chen@vanderbilt.edu; dana.brantley@vanderbilt.edu		Chen, Jin/0000-0002-5557-2079; Hwang, Yoonha/0000-0001-7420-4477	NIH/NCI [R01 CA148934, R01 CA177681, R01 CA95004]; CTSA (via Vanderbilt Institute of Clinical and Translational Research (VICTR)) from the National Center for Advancing Translational Sciences [UL1TR000445, VR10608]; US Department of Veterans Affairs VA Merit Award [5I01BX000134]; NCI Cancer Center Support Grant [P30 CA068485]; NATIONAL CANCER INSTITUTE [R01CA177681, P30CA068485, R01CA148934, R01CA095004] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000134] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CTSA (via Vanderbilt Institute of Clinical and Translational Research (VICTR)) from the National Center for Advancing Translational Sciences; US Department of Veterans Affairs VA Merit Award; NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Veterans Affairs(US Department of Veterans Affairs)	We thank Dr Bojana Jovanovic (Dana-Farber Cancer Institute) and Dr Tammy Sobolik (Vanderbilt University) for helpful discussions on the research. This work was supported by NIH/NCI Grants R01 CA148934 (DMB-S); R01 CA177681, and R01 CA95004 (JC). Acquisition of PDX models from the Huntsman Cancer Institute was supported by CTSA award UL1TR000445 (via Vanderbilt Institute of Clinical and Translational Research (VICTR) Grant VR10608 (DMB-S)) from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. JC is also supported by US Department of Veterans Affairs VA Merit Award (5I01BX000134). This work was also supported in part by the NCI Cancer Center Support Grant # P30 CA068485 utilizing the Translational Pathology Shared Resources.	Amato KR, 2016, CANCER RES, V76, P305, DOI 10.1158/0008-5472.CAN-15-0717; Arnato KR, 2014, J CLIN INVEST, V124, P2037, DOI 10.1172/JCI72522; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154; Brantley-Sieders DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024426; Brantley-Sieders DM, 2011, CANCER RES, V71, P976, DOI 10.1158/0008-5472.CAN-10-3396; Brantley-Sieders DM, 2005, FASEB J, V19, P1884, DOI 10.1096/fj.05-4038fje; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Caldon CE, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-2; Chavez Kathryn J, 2010, Breast Dis, V32, P35, DOI 10.3233/BD-2010-0307; Choi Y, 2009, BIOORG MED CHEM LETT, V19, P4467, DOI 10.1016/j.bmcl.2009.05.029; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Dillon JL, 2016, BREAST, V29, P202, DOI 10.1016/j.breast.2016.06.018; Fosu-Mensah N, 2015, FUTURE MED CHEM, V7, P2019, DOI 10.4155/fmc.15.129; Foulkes WD, 2010, NAT REV CLIN ONCOL, V7, P348, DOI 10.1038/nrclinonc.2010.39; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Guo ZM, 2015, INT J PHARMACEUT, V493, P380, DOI 10.1016/j.ijpharm.2015.05.051; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Haibe-Kains B., GENEFU R PACKAGE REL; Hartl M, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00132; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Hutcheson J, 2015, CELL CYCLE, V14, P3812, DOI 10.1080/15384101.2015.1010922; Knudsen ES, 2015, CELL CYCLE, V14, P109, DOI 10.4161/15384101.2014.967118; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Larsen AB, 2007, MOL CANCER RES, V5, P283, DOI 10.1158/1541-7786.MCR-06-0321; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Le Du F, 2015, ONCOTARGET, V6, P12890, DOI 10.18632/oncotarget.3849; Lehmann BD, 2015, BREAST, V24, pS36, DOI 10.1016/j.breast.2015.07.009; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Moccia M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128364; Murria R, 2015, AM J CANCER RES, V5, P2330; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180; Tsouko E, 2015, CARCINOGENESIS, V36, P1051, DOI 10.1093/carcin/bgv087; Vaught D, 2009, MOL BIOL CELL, V20, P2572, DOI 10.1091/mbc.E08-04-0378; Weisman PS, 2016, MODERN PATHOL, V29, P476, DOI 10.1038/modpathol.2016.39; Young CD, 2015, MOL CELL PROTEOMICS, V14, P1959, DOI 10.1074/mcp.M115.049783; Youngblood VM, 2016, CANCER RES, V76, P1825, DOI 10.1158/0008-5472.CAN-15-0847; Zardavas D, 2015, NAT REV CLIN ONCOL, V12, P381, DOI 10.1038/nrclinonc.2015.73	47	53	54	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5620	5630		10.1038/onc.2017.170	http://dx.doi.org/10.1038/onc.2017.170			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581527	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000412293600006
J	Foo, TK; Tischkowitz, M; Simhadri, S; Boshari, T; Zayed, N; Burke, KA; Berman, SH; Blecua, P; Riaz, N; Huo, Y; Ding, YC; Neuhausen, SL; Weigelt, B; Reis, JS; Foulkes, WD; Xia, B				Foo, T. K.; Tischkowitz, M.; Simhadri, S.; Boshari, T.; Zayed, N.; Burke, K. A.; Berman, S. H.; Blecua, P.; Riaz, N.; Huo, Y.; Ding, Y. C.; Neuhausen, S. L.; Weigelt, B.; Reis-Filho, J. S.; Foulkes, W. D.; Xia, B.			Compromised BRCA1-PALB2 interaction is associated with breast cancer risk	ONCOGENE			English	Article							HOMOLOGOUS RECOMBINATION; SOMATIC MUTATIONS; FANCONI-ANEMIA; FALLOPIAN-TUBE; COPY NUMBER; PALB2; GENES; BRCA2; LANDSCAPE; GERMLINE	The major breast cancer suppressor proteins BRCA1 and BRCA2 play essential roles in homologous recombination (HR)-mediated DNA repair, which is thought to be critical for tumor suppression. The two BRCA proteins are linked by a third tumor suppressor, PALB2, in the HR pathway. While truncating mutations in these genes are generally pathogenic, interpretation of missense variants remains a challenge. To date, patient-derived missense variants that disrupt PALB2 binding have been identified in BRCA1 and BRCA2; however, there has not been sufficient evidence to prove their pathogenicity in humans, and no variants in PALB2 that disrupt either its BRCA1 or BRCA2 binding have been reported. Here we report on the identification of a novel PALB2 variant, c.104T>C (p.L35P), that segregates in a family with a strong history of breast cancer. Functional analyses showed that L35P abrogates the PALB2-BRCA1 interaction and completely disables its abilities to promote HR and confer resistance to platinum salts and PARP inhibitors. Whole-exome sequencing of a breast cancer from a c.104T>C carrier revealed a second, somatic, truncating mutation affecting PALB2, and the tumor displays hallmark genomic features of tumors with BRCA mutations and HR defects, cementing the pathogenicity of L35P. Parallel analyses of other germline variants in the PALB2 N-terminal BRCA1-binding domain identified multiple variants that affect HR function to varying degrees, suggesting their possible contribution to cancer development. Our findings establish L35P as the first pathogenic missense mutation in PALB2 and directly demonstrate the requirement of the PALB2-BRCA1 interaction for breast cancer suppression.	[Foo, T. K.; Simhadri, S.; Huo, Y.; Xia, B.] Rutgers Canc Inst New Jersey, Dept Radiat Oncol, 195 Little Albany St, New Brunswick, NJ 08903 USA; [Tischkowitz, M.] Univ Cambridge, Dept Med Genet, Cambridge, England; [Boshari, T.; Zayed, N.; Foulkes, W. D.] McGill Univ, Dept Med Genet, Jewish Gen Hosp, Montreal, PQ, Canada; [Boshari, T.; Zayed, N.; Foulkes, W. D.] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada; [Burke, K. A.; Berman, S. H.; Weigelt, B.; Reis-Filho, J. S.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Blecua, P.; Riaz, N.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA; [Ding, Y. C.; Neuhausen, S. L.] Beckman Res Inst City Hope, Dept Populat Sci, Duarte, CA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of Cambridge; McGill University; Lady Davis Institute; McGill University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; City of Hope; Beckman Research Institute of City of Hope	Xia, B (corresponding author), Rutgers Canc Inst New Jersey, Dept Radiat Oncol, 195 Little Albany St, New Brunswick, NJ 08903 USA.	xiabi@cinj.rutgers.edu	Tischkowitz, Marc/O-4452-2018; Blecua, Pedro/AAA-4589-2019; Foo, Tzeh Keong/AAE-5830-2021; Foulkes, William D./AAR-9586-2021	Tischkowitz, Marc/0000-0002-7880-0628; Blecua, Pedro/0000-0002-1012-0300; Foo, Tzeh Keong/0000-0003-0168-7054; Foulkes, William D./0000-0001-7427-4651; HUO, YANYING/0000-0003-4747-4951; Boshari, Talia/0000-0002-4838-9276; Riaz, Nadeem/0000-0001-9873-5862	National Cancer Institute [R0A138804, R01CA188096, R01CA184585, P30CA008748]; Susan G Komen; Quebec Breast Cancer Foundation; European Union Seventh Framework Program [2007Y2013]; European Research Council [310018]; Flow Cytometry Core Facility of Rutgers Robert Wood Johnson Medical School; Shared Resource of The Rutgers Cancer Institute of New Jersey [P30CA072720]; NIH Shared Instrumentation Grant [1 S10 RR025468]; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA138804, R01CA184585, R01CA188096] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen(Susan G. Komen Breast Cancer Foundation); Quebec Breast Cancer Foundation; European Union Seventh Framework Program(European Commission); European Research Council(European Research Council (ERC)European Commission); Flow Cytometry Core Facility of Rutgers Robert Wood Johnson Medical School; Shared Resource of The Rutgers Cancer Institute of New Jersey; NIH Shared Instrumentation Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Olga Aleynikova MD, Andrew Shuen MD, Nelly Sabbaghian MSc, Sonya Zaor MSc and Nancy Hamel MSc for their assistance. BX is supported by the National Cancer Institute (R0A138804 and R01CA188096). WDF is funded by Susan G Komen and the Quebec Breast Cancer Foundation. KAB, SHB, BW and JRF are supported in part by a Cancer Center Support Grant of the National Cancer Institute (grant No P30CA008748). MT is funded by the European Union Seventh Framework Program (2007Y2013)/European Research Council (Grant No. 310018). SLN is supported by Morris and Horowitz Endowed Professorship and the National Cancer Institute (R01CA184585). NZ is a Mitch Garber Postdoctoral Fellow. This research was supported by the Flow Cytometry Core Facility of Rutgers Robert Wood Johnson Medical School, a Shared Resource of The Rutgers Cancer Institute of New Jersey (P30CA072720), and a NIH Shared Instrumentation Grant (1 S10 RR025468).	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Antoniou AC, 2014, NEW ENGL J MED, V371, P497, DOI [10.1056/NEJMoa1400382, 10.1056/NEJMc1410673]; Blanco A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067538; Bogdanova N, 2011, BREAST CANCER RES TR, V126, P545, DOI 10.1007/s10549-010-1290-4; Buisson R, 2012, NUCLEIC ACIDS RES, V40, P10312, DOI 10.1093/nar/gks807; Carter H, 2009, CANCER RES, V69, P6660, DOI 10.1158/0008-5472.CAN-09-1133; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Casadei S, 2011, CANCER RES, V71, P2222, DOI 10.1158/0008-5472.CAN-10-3958; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Ding YC, 2011, BREAST CANCER RES TR, V126, P771, DOI 10.1007/s10549-010-1195-2; Ding YC, 2011, BREAST CANCER RES TR, V126, P227, DOI 10.1007/s10549-010-1271-7; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Hartford SA, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006236; Ho AS, 2013, NAT GENET, V45, P791, DOI 10.1038/ng.2643; Hu Y, 2014, CANCER INFORM, V13, P13, DOI 10.4137/CIN.S13495; Huo YY, 2013, CANCER DISCOV, V3, P894, DOI 10.1158/2159-8290.CD-13-0011; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kohsaka S, 2014, NAT GENET, V46, P595, DOI 10.1038/ng.2969; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Livraghi L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0425-1; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Oliver AW, 2009, EMBO REP, V10, P990, DOI 10.1038/embor.2009.126; Pennington KP, 2014, CLIN CANCER RES, V20, P764, DOI 10.1158/1078-0432.CCR-13-2287; Piscuoglio S, 2016, CLIN CANCER RES, V22, P4045, DOI 10.1158/1078-0432.CCR-15-2840; Piscuoglio S, 2016, J PATHOL, V238, P381, DOI 10.1002/path.4675; Popova T, 2012, CANCER RES, V72, P5454, DOI 10.1158/0008-5472.CAN-12-1470; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Shihab HA, 2013, HUM MUTAT, V34, P57, DOI 10.1002/humu.22225; Simhadri S, 2014, J BIOL CHEM, V289, P24617, DOI 10.1074/jbc.M114.566141; Sy SMH, 2009, J BIOL CHEM, V284, P18302, DOI 10.1074/jbc.M109.016717; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Telli ML, 2016, CLIN CANCER RES, V22, P3764, DOI 10.1158/1078-0432.CCR-15-2477; Teo ZL, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3392; Tischkowitz M, 2008, PROSTATE, V68, P675, DOI 10.1002/pros.20729; Tischkowitz M, 2007, P NATL ACAD SCI USA, V104, P6788, DOI 10.1073/pnas.0701724104; Tischkowitz M, 2012, HUM MUTAT, V33, P674, DOI 10.1002/humu.22022; Tischkowitz M, 2010, CANCER RES, V70, P7353, DOI 10.1158/0008-5472.CAN-10-1012; Tu ND, 2015, BREAST CANCER RES TR, V149, P547, DOI 10.1007/s10549-014-3260-8; Walsh T, 2011, P NATL ACAD SCI USA, V108, P18032, DOI 10.1073/pnas.1115052108; Wang L, 2014, INT J BIOL SCI, V10, P563, DOI 10.7150/ijbs.8579; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Zhang F, 2009, MOL CANCER RES, V7, P1110, DOI 10.1158/1541-7786.MCR-09-0123; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018; Zheng YL, 2012, CANCER-AM CANCER SOC, V118, P1362, DOI 10.1002/cncr.26388	55	53	57	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4161	4170		10.1038/onc.2017.46	http://dx.doi.org/10.1038/onc.2017.46			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319063	Green Submitted, Green Accepted			2022-12-17	WOS:000405835800007
J	Pemov, A; Li, H; Patidar, R; Hansen, NF; Sindiri, S; Hartley, SW; Wei, JS; Elkahloun, A; Chandrasekharappa, SC; Boland, JF; Bass, S; Mullikin, JC; Khan, J; Widemann, BC; Wallace, MR; Stewart, DR				Pemov, A.; Li, H.; Patidar, R.; Hansen, N. F.; Sindiri, S.; Hartley, S. W.; Wei, J. S.; Elkahloun, A.; Chandrasekharappa, S. C.; Boland, J. F.; Bass, S.; Mullikin, J. C.; Khan, J.; Widemann, B. C.; Wallace, M. R.; Stewart, D. R.		NISC Comparative Sequencing; NCI DCEG Canc Genomics Res Lab	The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas	ONCOGENE			English	Article							NERVE SHEATH TUMORS; SCHWANN-CELLS; EXPRESSION; CANCER; GENES; MUTATIONS; CHILDREN; BENIGN; PIRFENIDONE; FRAMEWORK	Neurofibromatosis type 1 (NF1) is a common tumor-predisposition disorder due to germline mutations in the tumor suppressor gene NF1. A virtually pathognomonic finding of NF1 is the plexiform neurofibroma (PN), a benign, likely congenital tumor that arises from bi-allelic inactivation of NF1. PN can undergo transformation to a malignant peripheral nerve sheath tumor, an aggressive soft-tissue sarcoma. To better understand the non-NF1 genetic contributions to PN pathogenesis, we performed whole-exome sequencing, RNASeq profiling and genome-wide copy-number determination for 23 low-passage Schwann cell cultures established from surgical PN material with matching germline DNA. All resected tumors were derived from routine debulking surgeries. None of the tumors were considered at risk for malignant transformation at the time; for example, there was no pain or rapid growth. Deep (similar to 500X) NF1 exon sequencing was also conducted on tumor DNA. Non-NF1 somatic mutation verification was performed using the Ampliseq/IonTorrent platform. We identified 100% of the germline NF1 mutations and found somatic NF1 inactivation in 74% of the PN. One individual with three PNs had different NF1 somatic mutations in each tumor. The median number of somatic mutations per sample, including NF1, was one (range 0-8). NF1 was the only gene that was recurrently somatically inactivated in multiple tumors. Gene Set Enrichment Analysis of transcriptome-wide tumor RNA sequencing identified five significant (FDR < 0.01) and seven trending (0.01 <= FDR < 0.02) gene sets related to DNA replication, telomere maintenance and elongation, cell cycle progression, signal transduction and cell proliferation. We found no recurrent non-NF1 locus copy-number variation in PN. This is the first multi-sample whole-exome and whole-transcriptome sequencing study of NF1-associated PN. Taken together with concurrent copy-number data, our comprehensive genetic analysis reveals the primacy of NF1 loss as the driver of PN tumorigenesis.	[Pemov, A.; Stewart, D. R.] NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, Rockville, MD USA; [Li, H.; Wallace, M. R.] Univ Florida, UF Hlth Canc Ctr, UF Genet Inst, Dept Mol Genet & Microbiol, Gainesville, FL USA; [Patidar, R.; Sindiri, S.; Wei, J. S.; Khan, J.] NCI, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Hansen, N. F.; Elkahloun, A.; Chandrasekharappa, S. C.; Mullikin, J. C.] NHGRI, Canc Genet & Comparat Genom Branch, Rockville, MD USA; [Hartley, S. W.] NCI, Human Genet Program, Div Canc Epidemiol & Genet, Rockville, MD USA; [Mullikin, J. C.; NISC Comparative Sequencing] NHGRI, NIH, Intramural Sequencing Ctr, Rockville, MD USA; [Boland, J. F.; Bass, S.; NCI DCEG Canc Genomics Res Lab] NCI, Canc Genom Res Lab, Div Canc Epidemiol & Genet, Rockville, MD USA; [Widemann, B. C.] NCI, Pediat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University System of Florida; University of Florida; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stewart, DR (corresponding author), NCI, Div Canc Epidemiol & Genet, 9609 Med Ctr Dr,Rm 6E450, Bethesda, MD 20892 USA.	drstewart@mail.nih.gov	Khan, Javed/P-9157-2014; Patidar, Rajesh/G-9389-2019; Patidar, Rajesh/M-5520-2019	Patidar, Rajesh/0000-0003-3578-8208; Patidar, Rajesh/0000-0003-3578-8208; sindiri, sivasish/0000-0003-2516-969X	National Human Genome Research Institute; Center for Cancer Research of the National Cancer Institute; Division of Cancer Epidemiology and Genetics of the National Cancer Institute; Department of Defense [DAMD17-98-1-8609, DAMD17-00-1-0549]; National Institutes of Health [R29 NS31550]; Children's Tumor Foundation; NATIONAL CANCER INSTITUTE [ZIABC010801, ZIACP010144] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZICHG200346, ZICHG200365, ZIAHG200330, ZIAHG000029, ZIBHG000196] Funding Source: NIH RePORTER	National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Center for Cancer Research of the National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Division of Cancer Epidemiology and Genetics of the National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Tumor Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	Funding provided by the Intramural Research Programs of the National Human Genome Research Institute, the Center for Cancer Research of the National Cancer Institute and the Division of Cancer Epidemiology and Genetics of the National Cancer Institute. We thank the members of the NISC Comparative Sequencing Program: Betty Barnabas, PhD, Robert Blakesley, PhD, Gerry Bouffard, PhD, Shelise Brooks, BS, Holly Coleman, MSc, Mila Dekhtyar, MSc, Michael Gregory, MSc, Xiaobin Guan, PhD, Jyoti Gupta, MSc, Joel Han, BS, Shi-ling Ho, BS, Richelle Legaspi, MSc, Quino Maduro, BS, Cathy Masiello, MSc, Baishali Maskeri, PhD, Jenny McDowell, PhD, Casandra Montemayor, MSc, Morgan Park, PhD, Nancy Riebow, BS, Karen Schandler, MSc, Brian Schmidt, BS, Christina Sison, BS, Mal Stantripop, BS, James Thomas, PhD, Pam Thomas, PhD, Meg Vemulapalli, MSc, Alice Young, BA. We also thank the members of the NCI DCEG Cancer Genomics Research Laboratory: Michael Beerman, Aaron J Bouk, Seth Brodie, Laurie Burdett, Salma Chowdhury, Charles Chung, Nathan Cole, Michael Cullen, Casey Dagnall, Danielle Debacker, Sadie Frary, Chris Hautman, Belynda Hicks, Herb Higson, Keisha Hines-Harris, Amy Hutchinson, Kristie Jones, Eric Karlins, Sally Larson, Kerrie Lashley, Hyo Jung Lee, Shengchao Li, Tong Li, Wen Luo, Mike Malasky, Michelle Manning, Charles McCoy, Jason Mitchell, Adri O'Neil, Padma Ramya Packirisamy, Timothy Pelc, David Roberson, Aaron Rodriguez, Marianne Siler, Shalabh Suman, Kedest Teshome, Julio Tun, Sue Turner, Bill Utermahlen, Aurelie Vogt, Sarah Wagner, Mingyi Wang, Zhaoming Wang, Kathleen Wyatt, Qi Yang, Meredith Yeager, Sherry Yu, Xijun Zhang, Weiyin Zhou, Bin Zhu. MRW acknowledges funding from the Department of Defense (DAMD17-98-1-8609, DAMD17-00-1-0549), the National Institutes of Health (R29 NS31550), and the Children's Tumor Foundation supporting the development of the PN cultures over a 17-year span. Finally, we thank the patients who enlisted the help of their physicians to contribute tissues to research.	[Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; Babovic-Vuksanovic D, 2007, PEDIATR NEUROL, V36, P293, DOI 10.1016/j.pediatrneurol.2007.01.009; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Beert E, 2011, GENE CHROMOSOME CANC, V50, P1021, DOI 10.1002/gcc.20921; Buchstaller J, 2012, NEUROFIBROMATOSIS TY; Castle B, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.10.e109; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; COLMAN SD, 1995, NAT GENET, V11, P90, DOI 10.1038/ng0995-90; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Dewan R, 2014, NEURO-ONCOLOGY, V17, P566; Dode C, 2003, NAT GENET, V33, P463, DOI 10.1038/ng1122; Emi M, 1998, JPN J CANCER RES, V89, P12, DOI 10.1111/j.1349-7006.1998.tb00472.x; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hirbe AC, 2015, CLIN CANCER RES, V21, P4201, DOI 10.1158/1078-0432.CCR-14-3049; Hsu F, 2006, BIOINFORMATICS, V22, P1036, DOI 10.1093/bioinformatics/btl048; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; Jett K, 2010, GENET MED, V12, P1, DOI 10.1097/GIM.0b013e3181bf15e3; Kannan K, 2012, ONCOTARGET, V3, P1194; Kim A, 2009, NEUROLOGY, V73, P1273, DOI 10.1212/WNL.0b013e3181bd1326; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Laycock-van Spyk Sebastian, 2011, Human Genomics, V5, P623; Le LQ, 2011, CANCER RES, V71, P4686, DOI 10.1158/0008-5472.CAN-10-4577; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Levy P, 2007, CLIN CANCER RES, V13, P398, DOI 10.1158/1078-0432.CCR-06-0182; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Luscan A, 2014, CLIN CANCER RES, V20, P358, DOI 10.1158/1078-0432.CCR-13-0780; Maertens O, 2006, HUM MUTAT, V27, P1030, DOI 10.1002/humu.20389; Mautner VF, 2008, NEURO-ONCOLOGY, V10, P593, DOI 10.1215/15228517-2008-011; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Muir D, 2001, AM J PATHOL, V158, P501, DOI 10.1016/S0002-9440(10)63992-2; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pasmant E, 2011, J NATL CANCER I, V103, P1713, DOI 10.1093/jnci/djr416; Pasmant E, 2010, J NEUROPATH EXP NEUR, V69, P60, DOI 10.1097/NEN.0b013e3181c79bff; PELTONEN J, 1988, LAB INVEST, V59, P760; Pemov A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004575; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Sabbagh A, 2009, HUM MOL GENET, V18, P2768, DOI 10.1093/hmg/ddp212; Serra E, 2000, HUM MOL GENET, V9, P3055, DOI 10.1093/hmg/9.20.3055; Smithson LJ, 2016, SEMIN CELL DEV BIOL, V58, P118, DOI 10.1016/j.semcdb.2016.06.002; StemmerRachamimov A, 2012, NEUROFIBROMATOSIS TY, P429; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Teer JK, 2012, BIOINFORMATICS, V28, P599, DOI 10.1093/bioinformatics/btr711; Teer JK, 2010, GENOME RES, V20, P1420, DOI 10.1101/gr.106716.110; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Upadhyaya M, 2008, HUM MUTAT, V29, P74, DOI [10.1002/humu.20601, 10.1002/humu.20793]; Upadhyaya M, 2012, HUM MUTAT, V33, P763, DOI 10.1002/humu.22044; Uusitalo E, 2016, J CLIN ONCOL, V34, P1978, DOI 10.1200/JCO.2015.65.3576; Van Loo P, 2012, METHODS MOL BIOL, V802, P57, DOI 10.1007/978-1-61779-400-1_4; Wallace MR, 2000, GENE CHROMOSOME CANC, V27, P117, DOI 10.1002/(SICI)1098-2264(200002)27:2<117::AID-GCC1>3.0.CO;2-H; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Weiss B, 2014, PEDIATR BLOOD CANCER, V61, P982, DOI 10.1002/pbc.24873; Widemann BC, 2014, PEDIATR BLOOD CANCER, V61, P1598, DOI 10.1002/pbc.25041; Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102; Youn A, 2011, BIOINFORMATICS, V27, P175, DOI 10.1093/bioinformatics/btq630; Zhang M, 2014, NAT GENET, V46, P1170, DOI 10.1038/ng.3116	57	53	54	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3168	3177		10.1038/onc.2016.464	http://dx.doi.org/10.1038/onc.2016.464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28068329	Green Accepted			2022-12-17	WOS:000402617900009
J	Vaquero, J; Ho-Bouldoires, THN; Claperon, A; Fouassier, L				Vaquero, J.; Nguyen Ho-Bouldoires, T. H.; Claperon, A.; Fouassier, L.			Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance	ONCOGENE			English	Review							BINDING PHOSPHOPROTEIN 50; ACTIN CYTOSKELETON REORGANIZATION; CXCR2 MACROMOLECULAR COMPLEX; CAMP-MEDIATED INHIBITION; BORDER NA+/H+ EXCHANGER; NUCLEAR NHERF1; CELL-PROLIFERATION; FACTOR-1 NHERF1; ASSOCIATING PROTEIN; KINASE ACTIVATION	The transmission of cellular information requires fine and subtle regulation of proteins that need to interact in a coordinated and specific way to form efficient signaling networks. The spatial and temporal coordination relies on scaffold proteins. Thanks to protein interaction domains such as PDZ domains, scaffold proteins organize multiprotein complexes enabling the proper transmission of cellular information through intracellular networks. NHERF1/EBP50 is a PDZ-scaffold protein that was initially identified as an organizer and regulator of transporters and channels at the apical side of epithelia through actin-binding ezrinmoesin-radixin proteins. Since, NHERF1/EBP50 has emerged as a major regulator of cancer signaling network by assembling cancerrelated proteins. The PDZ-scaffold EBP50 carries either anti-tumor or pro-tumor functions, two antinomic functions dictated by EBP50 expression or subcellular localization. The dual function of NHERF1/EBP50 encompasses the regulation of several major signaling pathways engaged in cancer, including the receptor tyrosine kinases PDGFR and EGFR, PI3K/PTEN/AKT and Wnt-beta-catenin pathways.	[Vaquero, J.; Nguyen Ho-Bouldoires, T. H.; Claperon, A.; Fouassier, L.] UPMC Univ Paris 06, Sorbonne Univ, CRSA, INSERM, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France; [Vaquero, J.; Nguyen Ho-Bouldoires, T. H.] Fdn ARC, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Fouassier, L (corresponding author), UPMC Univ Paris 06, Sorbonne Univ, CRSA, INSERM, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	laura.fouassier@inserm.fr	Vaquero, Javier/B-7147-2019; Fouassier, Laura/M-7556-2017	Vaquero, Javier/0000-0002-6020-6962; Fouassier, Laura/0000-0001-6377-5610	Ministere de l'Enseignement Superieur et de la Recherche; Fondation de France [2011-00025574, 2014 00047502]; Fondation ARC [DOC20130606463, PDF2014601431]; La Ligue National contre le Cancer [RS14/75-112]; GEFLUC; Spanish Association for the Study of the Liver (AEEH)	Ministere de l'Enseignement Superieur et de la Recherche; Fondation de France(Fondation de France); Fondation ARC; La Ligue National contre le Cancer; GEFLUC; Spanish Association for the Study of the Liver (AEEH)	THB was supported by the 'Ministere de l'Enseignement Superieur et de la Recherche', Fondation de France No. 2011-00025574 and Fondation ARC No. DOC20130606463. LF is supported by grants from Fondation de France (No. 2014 00047502), La Ligue National contre le Cancer (No. RS14/75-112) and GEFLUC. JV is recipient of two following postdoctoral fellowships from the Spanish Association for the Study of the Liver (AEEH) and the Fondation ARC No. PDF2014601431. The authors thank Yves Chretien for the graphic support.	Abeysundara N, 2014, DEV DYNAM, V243, P1554, DOI 10.1002/dvdy.24187; Accardi R, 2011, J VIROL, V85, P8208, DOI 10.1128/JVI.00114-11; Lacalle RA, 2007, J CELL BIOL, V179, P1539, DOI 10.1083/jcb.200705044; Baeyens N, 2011, J CELL BIOCHEM, V112, P2574, DOI 10.1002/jcb.23183; Bartholow TL, 2011, BMC UROL, V11, DOI 10.1186/1471-2490-11-12; Bellizzi A, 2015, INT J ONCOL, V46, P1214, DOI 10.3892/ijo.2014.2805; Bellizzi A, 2011, HISTOPATHOLOGY, V58, P1086, DOI 10.1111/j.1365-2559.2011.03844.x; Beltrami S, 2013, ANTICANCER RES, V33, P1; Boratko A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035595; Broere N, 2009, PFLUG ARCH EUR J PHY, V457, P1079, DOI 10.1007/s00424-008-0579-1; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Bryant DM, 2014, DEV CELL, V31, P171, DOI 10.1016/j.devcel.2014.08.027; Cardone RA, 2007, MOL BIOL CELL, V18, P1768, DOI 10.1091/mbc.E06-07-0617; Cardone RA, 2012, MOL BIOL CELL, V23, P2028, DOI 10.1091/mbc.E11-11-0911; Chen JY, 2012, CELL DEATH DIFFER, V19, P1027, DOI 10.1038/cdd.2012.4; Cheng H, 2009, STRUCTURE, V17, P660, DOI 10.1016/j.str.2009.03.009; Cheng S, 2013, FEBS LETT, V587, P3289, DOI 10.1016/j.febslet.2013.08.026; Chiba H, 2006, J CELL BIOL, V175, P971, DOI 10.1083/jcb.200608012; Claperon A, 2007, ONCOGENE, V26, P3143, DOI 10.1038/sj.onc.1210408; Claperon A, 2012, ONCOGENE, V31, P1376, DOI 10.1038/onc.2011.334; Cornez I, 2010, FEBS LETT, V584, P2681, DOI 10.1016/j.febslet.2010.04.056; Cortese MS, 2008, PROG BIOPHYS MOL BIO, V98, P85, DOI 10.1016/j.pbiomolbio.2008.05.007; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Custer M, 1997, AM J PHYSIOL-RENAL, V273, pF801, DOI 10.1152/ajprenal.1997.273.5.F801; Dai JL, 2004, ONCOGENE, V23, P8681, DOI 10.1038/sj.onc.1207962; Dard N, 2006, BIOESSAYS, V28, P146, DOI 10.1002/bies.20351; Demoulin JB, 2003, BIOCHEM J, V376, P505, DOI 10.1042/BJ20030385; Du GF, 2016, ANTICANCER RES, V36, P1165; Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732; Ediger TR, 2002, MOL ENDOCRINOL, V16, P1828, DOI 10.1210/me.2001-0290; Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976; Fang X-Y, 2015, J INVEST DERMATOL, V135, P1; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Fouassier L, 2005, EXP CELL RES, V306, P264, DOI 10.1016/j.yexcr.2005.02.011; Fouassier L, 2001, HEPATOLOGY, V33, P166, DOI 10.1053/jhep.2001.21143; Fouassier L, 2009, AM J PATHOL, V174, P869, DOI 10.2353/ajpath.2009.080079; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Garbett D, 2010, J CELL BIOL, V191, P397, DOI 10.1083/jcb.201004115; Garcia GG, 2007, J IMMUNOL, V179, P6403, DOI 10.4049/jimmunol.179.10.6403; Garcia-Mata R, 2007, TRENDS CELL BIOL, V17, P36, DOI 10.1016/j.tcb.2006.11.004; Georgescu MM, 2016, NEOPLASIA, V18, P512, DOI 10.1016/j.neo.2016.07.003; Georgescu MM, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0197-z; Georgescu MM, 2014, NEOPLASIA, V16, P365, DOI 10.1016/j.neo.2014.04.004; Georgescu MM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1992; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Good MC, 2011, SCIENCE, V332, P680, DOI 10.1126/science.1198701; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hanono A, 2006, J CELL BIOL, V175, P803, DOI 10.1083/jcb.200604046; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; Hayashi Y, 2010, NEOPLASIA, V12, P1013, DOI 10.1593/neo.10780; He JQ, 2001, J BIOL CHEM, V276, P41559, DOI 10.1074/jbc.M106859200; Ho-Bouldoires THN, 2015, FREE RADICAL BIO MED, V89, P34, DOI 10.1016/j.freeradbiomed.2015.07.011; Hou YN, 2015, STEM CELL RES, V14, P133, DOI 10.1016/j.scr.2014.12.001; Hsu YH, 2010, AM J PATHOL, V176, P3050, DOI 10.2353/ajpath.2010.090539; Hughes SC, 2010, J CELL SCI, V123, P1099, DOI 10.1242/jcs.059469; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Ingraffea J, 2002, EUR J CELL BIOL, V81, P61, DOI 10.1078/0171-9335-00218; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Ji MY, 2012, J MOL HISTOL, V43, P517, DOI 10.1007/s10735-012-9424-0; Jiang YY, 2014, BIOCHEM BIOPH RES CO, V446, P638, DOI 10.1016/j.bbrc.2014.03.028; Karn T, 2011, BREAST CANCER RES TR, V130, P409, DOI 10.1007/s10549-010-1333-x; Katzenellenbogen BS, 2000, J STEROID BIOCHEM, V74, P279, DOI 10.1016/S0960-0760(00)00104-7; Kishore R, 2005, J CLIN INVEST, V115, P1785, DOI 10.1172/JCI22849; Kislin KL, 2009, NEOPLASIA, V11, P377, DOI 10.1593/neo.81572; Kocher O, 1999, LAB INVEST, V79, P1161; Kostenko S, 2009, CELL MOL LIFE SCI, V66, P3289, DOI 10.1007/s00018-009-0086-3; Kreimann EL, 2007, ONCOGENE, V26, P5290, DOI 10.1038/sj.onc.1210336; Kremer KN, 2015, J BIOL CHEM, V290, P29478, DOI 10.1074/jbc.M115.668160; Langeberg LK, 2015, NAT REV MOL CELL BIO, V16, P232, DOI 10.1038/nrm3966; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239; Lee HH, 2015, AM J CANCER RES, V5, P2944; Leslie KL, 2013, J BIOL CHEM, V288, P36426, DOI 10.1074/jbc.M113.483339; Li HL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0162-x; Li JQ, 2007, J BIOL CHEM, V282, P27086, DOI 10.1074/jbc.M702019200; Lim H, 2016, ONCOTARGET, V7, P10283, DOI 10.18632/oncotarget.7184; Lin YY, 2012, J CLIN INVEST, V122, P1881, DOI 10.1172/JCI45661; Liu H, 2015, IEEE T IND INFORM, V11, P406, DOI 10.1109/TII.2015.2397878; Liu L, 2012, J BIOL CHEM, V287, P43312, DOI 10.1074/jbc.M112.422766; Kreimann EL, 2015, ONCOL LETT, V10, P3722, DOI 10.3892/ol.2015.3796; Lu G., 2013, SCI WORLD J, V2013, P1, DOI DOI 10.1016/J.M0L-MET.2013.07.005.(IN; Malfettone A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-106; Malfettone A, 2012, EXP MOL PATHOL, V92, P296, DOI 10.1016/j.yexmp.2012.03.004; Mangia A, 2015, CANCER BIOL THER, V16, P1140, DOI 10.1080/15384047.2015.1056414; Mangia A, 2015, MOL BIOTECHNOL, V57, P549, DOI 10.1007/s12033-015-9848-3; Mangia A, 2012, ONCOL REP, V28, P889, DOI 10.3892/or.2012.1895; Mangia A, 2009, HISTOPATHOLOGY, V55, P600, DOI 10.1111/j.1365-2559.2009.03424.x; Mangia A, 2011, HUM PATHOL, V42, P1589, DOI 10.1016/j.humpath.2011.01.010; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Meng R, 2016, ONCOTARGET; Meng WY, 2002, J BIOL CHEM, V277, P37401, DOI 10.1074/jbc.C200418200; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; Molina JR, 2010, CANCER RES, V70, P6697, DOI 10.1158/0008-5472.CAN-10-1271; Morales FC, 2007, MOL CELL BIOL, V27, P2527, DOI 10.1128/MCB.01372-06; Morales FC, 2004, P NATL ACAD SCI USA, V101, P17705, DOI 10.1073/pnas.0407974101; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Nourry Claire, 2003, Sci STKE, V2003, pRE7; Pan Y, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1846; Paradiso A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.439; Peng ZQ, 2016, INT J ONCOL, V49, P1737, DOI 10.3892/ijo.2016.3655; Raghuram V, 2003, P NATL ACAD SCI USA, V100, P9620, DOI 10.1073/pnas.1633250100; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Rangwala R, 2005, J BIOL CHEM, V280, P11790, DOI 10.1074/jbc.M414154200; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Saotome I, 2004, DEV CELL, V6, P855, DOI 10.1016/j.devcel.2004.05.007; Schirosi L, 2016, ONCOTARGET; Schroeder TM, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-362; Scott RO, 2002, J BIOL CHEM, V277, P22934, DOI 10.1074/jbc.M202434200; Sheng R, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2221; Shenolikar S, 2001, FEBS LETT, V489, P233, DOI 10.1016/S0014-5793(01)02109-3; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Smith PM, 2003, ENDOCRINE, V22, P119, DOI 10.1385/ENDO:22:2:119; Song GJ, 2015, J BIOL CHEM, V290, P2879, DOI 10.1074/jbc.M114.609768; Song GJ, 2012, J MOL CELL CARDIOL, V53, P809, DOI 10.1016/j.yjmcc.2012.08.022; Song GJ, 2012, ARTERIOSCL THROM VAS, V32, P33, DOI 10.1161/ATVBAHA.111.235200; Song J, 2007, HISTOPATHOLOGY, V51, P40, DOI 10.1111/j.1365-2559.2007.02730.x; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stalker TJ, 2009, J THROMB HAEMOST, V7, P1886, DOI 10.1111/j.1538-7836.2009.03606.x; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Stokka AJ, 2010, BIOCHEM J, V425, P381, DOI 10.1042/BJ20091136; Sun CY, 2013, MOL CELLS, V36, P47, DOI 10.1007/s10059-013-0014-0; Sun LC, 2016, FASEB J, V30, P578, DOI 10.1096/fj.15-275586; Tabrizi AD, 2010, INT J GYNECOL PATHOL, V29, P99, DOI 10.1097/PGP.0b013e3181bbbcc1; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Tan PC, 2006, STEM CELLS, V24, P1150, DOI 10.1634/stemcells.2005-0426; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vitureira N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012003; Voltz JW, 2007, J BIOL CHEM, V282, P33879, DOI 10.1074/jbc.M703481200; Vondriska TM, 2004, J MOL CELL CARDIOL, V37, P391, DOI 10.1016/j.yjmcc.2004.04.021; Wang B, 2008, MOL BIOL CELL, V19, P1637, DOI 10.1091/mbc.E07-11-1114; Wang L, 2014, EUR REV MED PHARMACO, V18, P3854; Wang S, 2013, TRANSL ONCOL, V6, P216, DOI 10.1593/tlo.13133; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Weber HO, 2005, ONCOGENE, V24, P1965, DOI 10.1038/sj.onc.1208389; Weinman EJ, 2010, J BIOL CHEM, V285, P25134, DOI 10.1074/jbc.M110.132423; Weinman EJ, 2010, J BIOL CHEM, V285, P13454, DOI 10.1074/jbc.M109.094359; Weinman EJ, 2006, ANNU REV PHYSIOL, V68, P491, DOI 10.1146/annurev.physiol.68.040104.131050; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; Wheeler DS, 2011, ONCOGENE, V30, P32, DOI 10.1038/onc.2010.389; Wu YN, 2012, J BIOL CHEM, V287, P5744, DOI 10.1074/jbc.M111.315762; Yang LY, 2011, ENDOCRINOLOGY, V152, P4537, DOI 10.1210/en.2011-1207; Yao WF, 2012, AMINO ACIDS, V43, P2027, DOI 10.1007/s00726-012-1277-z; Yin G, 2011, BRIT J DERMATOL, V164, P1043, DOI 10.1111/j.1365-2133.2010.10192.x; Yonglitthipagon P, 2012, HUM PATHOL, V43, P1719, DOI 10.1016/j.humpath.2011.11.021; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	151	53	57	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3067	3079		10.1038/onc.2016.462	http://dx.doi.org/10.1038/onc.2016.462			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28068322				2022-12-17	WOS:000402617900001
J	Hou, J; Deng, Q; Zhou, J; Zou, J; Zhang, Y; Tan, P; Zhang, W; Cui, H				Hou, J.; Deng, Q.; Zhou, J.; Zou, J.; Zhang, Y.; Tan, P.; Zhang, W.; Cui, H.			CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR	ONCOGENE			English	Article							PHASE-II TRIAL; COP9 SIGNALOSOME; MALIGNANT GLIOMAS; BREAST-CANCER; GROWTH; PHOSPHORYLATION; CLASSIFICATION; SUBUNIT-6; ERLOTINIB; CHAPERONE	CSN6, a critical subunit of the constitutive photomorphogenesis 9 (COP9) signalosome (CSN), has received attention as a regulator of the degradation of cancer-related proteins such as p53, c-myc and c-Jun, through the ubiquitin-proteasome system, suggesting its importance in cancerogenesis. However, the biological functions and molecular mechanisms of CSN6 in glioblastoma (GBM) remain poorly understood. Here, we report that GBM tumors overexpressed CSN6 compared with normal brain tissues and that CSN6 promoted GBM cell proliferation, migration, invasion and tumorigenesis. Erlotinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, was used to reveal that the proliferative and metastatic effects of CSN6 on GBM cells were EGFR dependent. We also found that CSN6 positively regulated EGFR stability via reduced levels of EGFR ubiquitination, thereby elevating steady expression of EGFR. In addition, this study is the first description of a novel role for the CSN6-interacting E3 ligase, CHIP (carboxyl terminus of heat-shock protein 70-interacting protein), regulating EGFR ubiquitination in cancer cells. We showed that CSN6 associated with CHIP and led to CHIP destabilization by increasing CHIP self-ubiquitination. Moreover, CSN6 decreased CHIP expression and increased EGFR expression in the tumor samples. Deregulation of this axis promoted GBM cell's proliferation and metastasis. Thus, our study provides insights into the applicability of using the CSN6-CHIP-EGFR axis as a potential therapeutic target in cancer.	[Hou, J.; Deng, Q.; Zou, J.; Zhang, Y.; Tan, P.; Zhang, W.; Cui, H.] Southwest Univ, Cell Biol Lab, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China; [Zhou, J.] Chinese Peoples Liberat Army, Rocket Force Gen Hosp, Dept Neurosurg, Beijing, Peoples R China	Southwest University - China	Cui, H (corresponding author), Southwest Univ, Cell Biol Lab, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China.	hongjuan.cui@gmail.com			Research Fund for the Doctoral Program of Higher Education of China [20130182110003]; National Basic Research Program of China [2012cb114603]; National Natural Science Foundation of China [81502574, 31501100]	Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Research Fund for the Doctoral Program of Higher Education of China (20130182110003), the National Basic Research Program of China (No. 2012cb114603) and the National Natural Science Foundation of China (81502574 and 31501100).	Ahmed SF, 2012, J BIOL CHEM, V287, P15996, DOI 10.1074/jbc.M111.321083; Cao Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116934; Chen J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6384; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Fang LK, 2015, CANCER CELL, V28, P183, DOI 10.1016/j.ccell.2015.07.004; Forozan F, 2000, CANCER RES, V60, P4519; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gao SJ, 2015, ONCOTARGET, V6, P28026, DOI 10.18632/oncotarget.4731; Gusmaroli G, 2007, PLANT CELL, V19, P564, DOI 10.1105/tpc.106.047571; HSUAN JJ, 1993, ANTICANCER RES, V13, P2521; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lee M. H., 2011, CELL CYCLE, V10, P3057, DOI [DOI 10.4161/CC.10.18, 10.4161/cc.10.18.17320, DOI 10.4161/CC.10.18.17320]; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li L, 2003, TRENDS CELL BIOL, V13, P507, DOI 10.1016/j.tcb.2003.08.002; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Lin DC, 2015, CANCER RES, V75, P1815, DOI 10.1158/0008-5472.CAN-14-1433; Lipkowitz S, 2003, BREAST CANCER RES, V5, P8, DOI 10.1186/bcr541; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Olar A, 2014, J PATHOL, V232, P165, DOI 10.1002/path.4282; Peng ZH, 2001, PLANT CELL, V13, P2393, DOI 10.1105/tpc.13.11.2393; Raizer JJ, 2010, NEURO-ONCOLOGY, V12, P95, DOI 10.1093/neuonc/nop015; Riddick G, 2011, NAT REV NEUROL, V7, P439, DOI 10.1038/nrneurol.2011.100; Ronnebaum SM, 2013, MOL CELL BIOL, V33, P4461, DOI 10.1128/MCB.00480-13; van den Bent MJ, 2009, J CLIN ONCOL, V27, P1268, DOI 10.1200/JCO.2008.17.5984; Wang TX, 2014, ONCOTARGET, V5, P1969, DOI 10.18632/oncotarget.1890; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Xuan F, 2016, NEURO-ONCOLOGY, V18, P819, DOI 10.1093/neuonc/nov281; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	34	53	54	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1134	1144		10.1038/onc.2016.280	http://dx.doi.org/10.1038/onc.2016.280			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27546621				2022-12-17	WOS:000395371500011
J	Lakshmanan, I; Rachagani, S; Hauke, R; Krishn, SR; Paknikar, S; Seshacharyulu, P; Karmakar, S; Nimmakayala, RK; Kaushik, G; Johansson, SL; Carey, GB; Ponnusamy, MP; Kaur, S; Batra, SK; Ganti, AK				Lakshmanan, I.; Rachagani, S.; Hauke, R.; Krishn, S. R.; Paknikar, S.; Seshacharyulu, P.; Karmakar, S.; Nimmakayala, R. K.; Kaushik, G.; Johansson, S. L.; Carey, G. B.; Ponnusamy, M. P.; Kaur, S.; Batra, S. K.; Ganti, A. K.			MUC5AC interactions with integrin beta 4 enhances the migration of lung cancer cells through FAK signaling	ONCOGENE			English	Article							FOCAL ADHESION KINASE; HUMAN PANCREATIC-CANCER; BREAST-CANCER; GROWTH-FACTOR; EXPRESSION PATTERNS; MUCIN EXPRESSION; REGULATED KINASE; TUMOR-GROWTH; ADENOCARCINOMA; RESISTANCE	MUC5AC is a secretory mucin aberrantly expressed in various cancers. In lung cancer, MUC5AC is overexpressed in both primary and metastatic lesions; however, its functional role is not well understood. The present study was aimed at evaluating mechanistic role of MUC5AC on metastasis of lung cancer cells. Clinically, the overexpression of MUC5AC was observed in lung cancer patient tissues and was associated with poor survival. In addition, the overexpression of Muc5ac was also observed in genetically engineered mouse lung adenocarcinoma tissues (Kras(G12D); Trp53(R172H/+); AdCre) in comparison with normal lung tissues. Our functional studies showed that MUC5AC knockdown resulted in significantly decreased migration in two lung cancer cell lines (A549 and H1437) as compared with scramble cells. Expression of integrins (alpha 5, beta 1, beta 3, beta 4 and beta 5) was decreased in MUC5AC knockdown cells. As both integrins and MUC5AC have a von Willebrand factor domain, we assessed for possible interaction of MUC5AC and integrins in lung cancer cells. MUC5AC strongly interacted only with integrin beta 4. The co-localization of MUC5AC and integrin beta 4 was observed both in A549 lung cancer cells as well as genetically engineered mouse adenocarcinoma tissues. Activated integrins recruit focal adhesion kinase (FAK) that mediates metastatic downstream signaling pathways. Phosphorylation of FAK (Y397) was decreased in MUC5AC knockdown cells. MUC5AC/integrin beta 4/FAK-mediated lung cancer cell migration was confirmed through experiments utilizing a phosphorylation (Y397)specific FAK inhibitor. In conclusion, overexpression of MUC5AC is a poor prognostic marker in lung cancer. MUC5AC interacts with integrin beta 4 that mediates phosphorylation of FAK at Y397 leading to lung cancer cell migration.	[Lakshmanan, I.; Rachagani, S.; Hauke, R.; Krishn, S. R.; Seshacharyulu, P.; Karmakar, S.; Nimmakayala, R. K.; Kaushik, G.; Ponnusamy, M. P.; Kaur, S.; Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Paknikar, S.; Ganti, A. K.] Univ Nebraska Med Ctr, Dept Internal Med, Div Hematol Oncol, Omaha, NE 68198 USA; [Johansson, S. L.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Johansson, S. L.; Ponnusamy, M. P.; Batra, S. K.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA; [Carey, G. B.] Univ Chicago, Dept Med, Hematol Oncol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Ganti, A. K.] VA Nebraska Western Iowa Hlth Care Syst, Dept Internal Med, Omaha, NE USA; [Ganti, A. K.] Univ Nebraska Med Ctr, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Ganti, AK (corresponding author), Univ Nebraska Med Ctr, Dept Internal Med, Div Hematol Oncol, Omaha, NE 68198 USA.	sbatra@unmc.edu; aganti@unmc.edu	Ganti, Apar Kishor/D-5498-2015; Seshacharyulu, Parthasarathy/AGL-7648-2022; KRISHN, SHIV RAM/K-1949-2019; Nimmakayala, Rama Krishna/CAG-5670-2022; Kaushik, Garima/AAO-7279-2021	Ganti, Apar Kishor/0000-0003-3724-2671; Seshacharyulu, Parthasarathy/0000-0002-2348-3901; KRISHN, SHIV RAM/0000-0002-4770-6671; Nimmakayala, Rama Krishna/0000-0003-4637-4828; Kaushik, Garima/0000-0002-7631-4028; Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X; lakshmanan, Imayavaramban/0000-0003-1733-2223	National Institutes of Health [P50 CA127297, U54 CA163120, RO1 CA183459, RO1 CA195586, K22 CA175260, P20 GM103480]; US Department of Veterans' Affairs; UNMC Department of Internal Medicine Summer Undergraduate Research Program and Fred & Pamela Buffett Cancer Center Support Grant [P30CA036727]; NATIONAL CANCER INSTITUTE [R01CA195586, K22CA175260, P30CA036727, U54CA163120, R01CA183459, P50CA127297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103480] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Veterans' Affairs(US Department of Veterans Affairs); UNMC Department of Internal Medicine Summer Undergraduate Research Program and Fred & Pamela Buffett Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge the valuable technical support from Mrs Kavita Mallya and Ms Lynette Smith. We also thank Janice A Tayor and James R Talaska, of the confocal laser scanning microscope core facility at UNMC, for their support. The work is partly supported by grants from the US Department of Veterans' Affairs, UNMC Department of Internal Medicine Summer Undergraduate Research Program and Fred & Pamela Buffett Cancer Center Support Grant (P30CA036727) and National Institutes of Health (P50 CA127297, U54 CA163120, RO1 CA183459, RO1 CA195586, K22 CA175260 and P20 GM103480).	Adsay NV, 2003, AM J SURG PATHOL, V27, P571, DOI 10.1097/00000478-200305000-00002; Andrianifahanana M, 2006, BBA-REV CANCER, V1765, P189, DOI 10.1016/j.bbcan.2006.01.002; Awaya H, 2004, AM J CLIN PATHOL, V121, P644, DOI 10.1039/U4WGE9EBFJN6CM8R; Azim HA, 2006, CANCER TREAT REV, V32, P630, DOI 10.1016/j.ctrv.2006.07.014; Bafna S, 2009, BRIT J CANCER, V101, P1155, DOI 10.1038/sj.bjc.6605285; Corfield AP, 2015, BBA-GEN SUBJECTS, V1850, P236, DOI 10.1016/j.bbagen.2014.05.003; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Eberwein P, 2015, BBA-MOL CELL RES, V1853, P2183, DOI 10.1016/j.bbamcr.2015.06.004; Evans CM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7281; Evans CM, 2009, CURR OPIN PULM MED, V15, P4, DOI 10.1097/MCP.0b013e32831da8d3; Glavey SV, 2015, BLOOD REV, V29, P269, DOI 10.1016/j.blre.2015.01.003; Golubovskaya VM, 2008, J MED CHEM, V51, P7405, DOI 10.1021/jm800483v; Guan JL, 2010, IUBMB LIFE, V62, P268, DOI 10.1002/iub.303; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hata H, 2014, J EUR ACAD DERMATOL, V28, P727, DOI 10.1111/jdv.12156; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Jonckheere N, 2014, BBA-REV CANCER, V1846, P142, DOI 10.1016/j.bbcan.2014.04.008; Kang JH, 2015, IMMUNOLOGY, V144, P79, DOI 10.1111/imm.12352; Kharbanda A, 2013, MOL CANCER RES, V11, P714, DOI 10.1158/1541-7786.MCR-12-0668; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lakshmanan I, 2012, ONCOGENE, V31, P805, DOI 10.1038/onc.2011.297; Lakshmanan I, 2015, ONCOTARGET, V6, P21085, DOI 10.18632/oncotarget.3912; Lakshmanan I, 2015, J THORAC ONCOL, V10, P19, DOI 10.1097/JTO.0000000000000404; Leteurtre E, 2004, BIOL CELL, V96, P145, DOI 10.1016/j.biolcel.2003.12.005; Lopez-Ferrer A, 2001, AM J RESP CELL MOL, V24, P22, DOI 10.1165/ajrcmb.24.1.4294; MacDermed DM, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-16; Majhi PD, 2013, J THORAC ONCOL, V8, P398, DOI 10.1097/JTO.0b013e3182829e06; Mariani CR, 1990, CANCER RES, V50, P6107; Mimeault M, 2010, CANCER LETT, V295, P69, DOI 10.1016/j.canlet.2010.02.015; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Nishiumi N, 2003, CLIN CANCER RES, V9, P5616; O'Connor KL, 2012, AM J PHYSIOL-CELL PH, V302, pC605, DOI 10.1152/ajpcell.00095.2011; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Rachagani S, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-68; Rossi G, 2012, HISTOPATHOLOGY, V60; Roy MG, 2014, NATURE, V505, P412, DOI 10.1038/nature12807; Roy MG, 2011, AM J RESP CELL MOL, V44, P755, DOI 10.1165/rcmb.2010-0020OC; Sanada Y, 2006, ONCOL REP, V15, P1157; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Seshacharyulu P, 2015, ONCOTARGET, V6, P5164, DOI 10.18632/oncotarget.3286; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Stewart RL, 2015, LAB INVEST, V95, P976, DOI 10.1038/labinvest.2015.82; Thai P, 2008, ANNU REV PHYSIOL, V70, P405, DOI 10.1146/annurev.physiol.70.113006.100441; Thornton DJ, 2008, ANNU REV PHYSIOL, V70, P459, DOI 10.1146/annurev.physiol.70.113006.100702; Trehoux S, 2015, BIOCHEM BIOPH RES CO, V456, P757, DOI 10.1016/j.bbrc.2014.12.025; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Yamazoe S, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-53; Yu CJ, 1996, INT J CANCER, V69, P457, DOI 10.1002/(SICI)1097-0215(19961220)69:6<457::AID-IJC7>3.0.CO;2-3; Yu CJ, 2005, LUNG CANCER, V47, P59, DOI 10.1016/j.lungcan.2004.05.018; Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001	56	53	54	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4112	4121		10.1038/onc.2015.478	http://dx.doi.org/10.1038/onc.2015.478			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26751774	Green Accepted			2022-12-17	WOS:000381020900009
J	Wang, G; Yu, Y; Sun, C; Liu, T; Liang, T; Zhan, L; Lin, X; Feng, XH				Wang, G.; Yu, Y.; Sun, C.; Liu, T.; Liang, T.; Zhan, L.; Lin, X.; Feng, X-H			STAT3 selectively interacts with Smad3 to antagonize TGF-beta signalling	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; CANCER; CELLS; TRANSCRIPTION; ROLES; PHOSPHORYLATION; SUPPRESSION; INHIBITION; EXPRESSION; GENERATION	Smad and STAT proteins are critical signal transducers and transcription factors in controlling cell growth and tumorigenesis. Here we report that the STAT3 signaling pathway attenuates transforming growth factor-beta (TGF-beta)-induced responses through a direct Smad3-STAT3 interplay. Activated STAT3 blunts TGF-beta-mediated signaling. Depletion of STAT3 promotes TGF-beta-mediated transcriptional and physiological responses, including cell cycle arrest, apoptosis and epithelial-to-mesenchymal transition. STAT3 directly interacts with Smad3 in vivo and in vitro, resulting in attenuation of the Smad3-Smad4 complex formation and suppression of DNA-binding ability of Smad3. The N-terminal region of DNA-binding domain of STAT3 is responsible for the STAT3-Smad3 interaction and also indispensable for STAT3-mediated inhibition of TGF-beta signaling. Thus, our finding illustrates a direct crosstalk between the STAT3 and Smad3 signaling pathways that may contribute to tumor development and inflammation.	[Wang, G.; Yu, Y.; Liu, T.; Feng, X-H] Zhejiang Univ, Inst Life Sci, Hangzhou, Zhejiang, Peoples R China; [Wang, G.; Yu, Y.; Liu, T.; Feng, X-H] Zhejiang Univ, Innovat Ctr Cell Signaling Network, Hangzhou, Zhejiang, Peoples R China; [Wang, G.; Lin, X.; Feng, X-H] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; [Sun, C.; Feng, X-H] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Liang, T.] Zhejiang Univ, Dept Hepatobiliary & Pancreat Surg, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Liang, T.] Zhejiang Univ, Affiliated Hosp 2, Key Lab Canc Prevent & Intervent, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Zhan, L.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai, Peoples R China; [Feng, X-H] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Sun, C.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Zhejiang University; Zhejiang University; Baylor College of Medicine; Baylor College of Medicine; Zhejiang University; Zhejiang University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Baylor College of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Feng, XH (corresponding author), Zhejiang Univ, Inst Life Sci, Hangzhou, Zhejiang, Peoples R China.; Feng, XH (corresponding author), Baylor Coll Med, Dept Surg, One Baylor Plaza,Rm R712, Houston, TX 77030 USA.	xhfeng@zju.edu.cn			MOST [2012CB966600]; NSFC [31571447, 31090360]; NIH [R01GM63773, R01 AR053591, R01CA108454, R01DK073932]; Project 985; Fundamental Research Funds for Central Universities; Project 111; NATIONAL CANCER INSTITUTE [R21CA112939, R01CA108454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER	MOST; NSFC(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Project 985; Fundamental Research Funds for Central Universities(Fundamental Research Funds for the Central Universities); Project 111(Ministry of Education, China - 111 Project); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank David Luskutoff for p800 (PAI-1)-luc, Peter ten Dijke for CAGA-luc, Bert Vogelstein for WWP1 (p21)-luc and SBE-luc and Xiao-Fan Wang for p15-luc. We are grateful to colleagues in our laboratories for helpful discussion and technical assistance. This research was partly supported by grants from MOST (2012CB966600) and NSFC (31571447; 31090360), NIH (R01GM63773, R01 AR053591, R01CA108454 and R01DK073932), Project 111, Project 985 and the Fundamental Research Funds for the Central Universities.	Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Campbell JDM, 2001, J IMMUNOL, V167, P553, DOI 10.4049/jimmunol.167.1.553; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Dai FY, 2009, DEV CELL, V16, P345, DOI 10.1016/j.devcel.2009.01.022; Deheuninck J, 2009, CELL RES, V19, P47, DOI 10.1038/cr.2008.324; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2007, THE TGF BETA FAMILY, P1; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Dunfield LD, 2003, ONCOGENE, V22, P4745, DOI 10.1038/sj.onc.1206617; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Flavell RA, 2010, NAT REV IMMUNOL, V10, P554, DOI 10.1038/nri2808; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Gunaje Jagadambika J., 2000, Molecular Cell Biology Research Communications, V4, P151, DOI 10.1006/mcbr.2001.0272; Han SU, 2004, ONCOGENE, V23, P1333, DOI 10.1038/sj.onc.1207259; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hirai H, 2001, CANCER CHEMOTH PHARM, V48, pS35, DOI 10.1007/s002800100303; Huang D, 2014, CONNECT TISSUE RES, V55, P391, DOI 10.3109/03008207.2014.959118; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Kim SG, 2005, MOL BIOL CELL, V16, P4672, DOI 10.1091/mbc.E05-01-0054; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lin X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Luwor RB, 2013, ONCOGENE, V32, P2433, DOI 10.1038/onc.2012.260; Martinez GJ, 2010, J BIOL CHEM, V285, P29039, DOI 10.1074/jbc.C110.155820; Martinez GJ, 2009, J BIOL CHEM, V284, P35283, DOI 10.1074/jbc.C109.078238; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Ogata H, 2006, ONCOGENE, V25, P2520, DOI 10.1038/sj.onc.1209281; Okita Keisuke, 2006, Curr Stem Cell Res Ther, V1, P103, DOI 10.2174/157488806775269061; Schmierer B, 2003, J BIOL CHEM, V278, P21197, DOI 10.1074/jbc.M212425200; Ungefroren H, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-67; Walia B, 2003, FASEB J, V17, P2130, DOI 10.1096/fj.02-1211fje; Wang DG, 2008, CANCER RES, V68, P783, DOI 10.1158/0008-5472.CAN-07-0008; Wierenga ATJ, 2002, LEUKEMIA, V16, P675, DOI 10.1038/sj.leu.2402425; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Wrighton KH, 2009, CELL RES, V19, P8, DOI 10.1038/cr.2008.327; Wu MY, 2009, DEV CELL, V16, P329, DOI 10.1016/j.devcel.2009.02.012; Yamamoto T, 2001, FEBS LETT, V492, P247, DOI 10.1016/S0014-5793(01)02258-X; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zauberman A, 2001, J BIOL CHEM, V276, P24719, DOI 10.1074/jbc.M005813200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zheng R, 2008, CELL BIOCHEM FUNCT, V26, P548, DOI 10.1002/cbf.1464	50	53	55	3	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4388	4398		10.1038/onc.2015.446	http://dx.doi.org/10.1038/onc.2015.446			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26616859	Green Accepted, Green Submitted			2022-12-17	WOS:000382152100010
J	Radogna, F; Cerella, C; Gaigneaux, A; Christov, C; Dicato, M; Diederich, M				Radogna, F.; Cerella, C.; Gaigneaux, A.; Christov, C.; Dicato, M.; Diederich, M.			Cell type-dependent ROS and mitophagy response leads to apoptosis or necroptosis in neuroblastoma	ONCOGENE			English	Article							OXIDATIVE STRESS; CANCER-CELLS; CARDIAC-GLYCOSIDES; CALOTROPIS-PROCERA; JNK ACTIVATION; AUTOPHAGY; DEATH; UNBS1450; TARGET; CROSSTALK	A limiting factor in the therapeutic outcome of children with high-risk neuroblastoma is the intrinsic and acquired resistance to common chemotherapeutic treatments. Here we investigated the molecular mechanisms by which the hemisynthetic cardiac glycoside UNBS1450 overcomes this limitation and induces differential cell death modalities in both neuroblastic and stromal neuroblastoma through stimulation of a cell-type-specific autophagic response eventually leading to apoptosis or necroptosis. In neuroblastic SH-SY5Y cells, we observed a time-dependent production of reactive oxygen species that affects lysosomal integrity inducing lysosome-associated membrane protein 2 degradation and cathepsin B and L activation. Subsequent mitochondrial membrane depolarization and accumulation of mitochondria in phagophores occurred after 8h of UNBS1450 treatment. Results were confirmed by mitochondrial mass analysis, electron microscopy and co-localization of mitochondria with GFP-LC3, suggesting the impaired clearance of damaged mitochondria. Thus, a stress-induced defective autophagic flux and the subsequent lack of clearance of damaged mitochondria sensitized SH-SY5Y cells to UNBS1450-induced apoptosis. Inhibition of autophagy with small inhibitory RNAs against ATG5, ATG7 and Beclin-1 protected SH-SY5Y cells against the cytotoxic effect of UNBS1450 by inhibiting apoptosis. In contrast, autophagy progression towards the catabolic state was observed in stromal SK-N-AS cells: here reactive oxygen species (ROS) generation remained undetectable preserving intact lysosomes and engulfing damaged mitochondria after UNBS1450 treatment. Moreover, autophagy inhibition determined sensitization of SK-N-AS to apoptosis. We identified efficient mitophagy as the key mechanism leading to failure of activation of the apoptotic pathway that increased resistance of SK-N-AS to UNBS1450, triggering rather necroptosis at higher doses. Altogether we characterize here the differential modulation of ROS and mitophagy as a main determinant of neuroblastoma resistance with potential relevance for personalized anticancer therapeutic approaches.	[Radogna, F.; Cerella, C.; Gaigneaux, A.; Dicato, M.] Hop Kirchberg, Lab Biol Mol & Cellulaire Canc, Luxembourg, Luxembourg; [Christov, C.] Univ Lorraine Vandoeuvre Les Nancy, Med Nancy, Nancy, France; [Diederich, M.] Seoul Natl Univ, Coll Pharm, Seoul, South Korea	Universite de Lorraine; Seoul National University (SNU)	Diederich, M (corresponding author), Seoul Natl Univ, Coll Pharm, Dept Pharm, Seoul 151742, South Korea.	marcdiederich@snu.ac.kr	Diederich, Marc/O-7335-2015; Radogna, Flavia/AAL-5698-2020	Diederich, Marc/0000-0003-0115-4725; Cerella, Claudia/0000-0001-9308-8176; Radogna, Flavia/0000-0003-0385-3335	ThinkPinkLux; Europadonna Luxembourg; Televie grant (Fonds National de la Recherche Scientifique, Belgium); 'Waxweiler grant for cancer prevention research' from the Action LIONS 'Vaincre le Cancer'; Fondation de Recherche Cancer et Sang; Recherches Scientifiques Luxembourg association; 'Een Haerz fir kriibskrank Kanner' association; Action LIONS 'Vaincre le Cancer' association; Televie Luxembourg; National Research Foundation (NRF) by the MEST of Korea for Tumor Microenvironment Global Core Research Center (GCRC) grant [2012-0001184]; Brain Korea (BK21) PLUS program	ThinkPinkLux; Europadonna Luxembourg; Televie grant (Fonds National de la Recherche Scientifique, Belgium); 'Waxweiler grant for cancer prevention research' from the Action LIONS 'Vaincre le Cancer'; Fondation de Recherche Cancer et Sang; Recherches Scientifiques Luxembourg association; 'Een Haerz fir kriibskrank Kanner' association; Action LIONS 'Vaincre le Cancer' association; Televie Luxembourg; National Research Foundation (NRF) by the MEST of Korea for Tumor Microenvironment Global Core Research Center (GCRC) grant; Brain Korea (BK21) PLUS program	FR thanks 'Een Haerz fir kriibskrank Kanner' association for initial support. This manuscript is dedicated to the memory of Marian Aldred. The authors are very thankful to ThinkPinkLux and Europadonna Luxembourg for their generous support. FR and AG are supported by a Televie grant (Fonds National de la Recherche Scientifique, Belgium). CC is supported by a 'Waxweiler grant for cancer prevention research' from the Action LIONS 'Vaincre le Cancer'. Research at LBMCC is financially supported by the Fondation de Recherche Cancer et Sang, the Recherches Scientifiques Luxembourg association, the 'Een Haerz fir kriibskrank Kanner' association, the Action LIONS 'Vaincre le Cancer' association and the Televie Luxembourg. Research at SNU is supported by the National Research Foundation (NRF) by the MEST of Korea for Tumor Microenvironment Global Core Research Center (GCRC) grant (grant number 2012-0001184) and by Brain Korea (BK21) PLUS program. The authors thank Justine Paoli for technical assistance with electron microscopy.	Abhari BA, 2013, ONCOGENE, V32, P3263, DOI 10.1038/onc.2012.337; Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310; Castino R, 2011, TOXICOL SCI, V123, P523, DOI 10.1093/toxsci/kfr179; Cerella C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.134; Cerella C, 2015, CANCER LETT, V356, P251, DOI 10.1016/j.canlet.2014.02.008; Cerella C, 2014, BIOTECHNOL ADV, V32, P1111, DOI 10.1016/j.biotechadv.2014.03.006; Cerella Claudia, 2013, Int J Cell Biol, V2013, P639401, DOI 10.1155/2013/639401; Cerella C, 2013, MITOCHONDRION, V13, P225, DOI 10.1016/j.mito.2012.06.003; Cerella C, 2009, APOPTOSIS, V14, P641, DOI 10.1007/s10495-009-0328-8; Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233; Cheng P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.17; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Goldsmith KC, 2005, CANCER LETT, V228, P133, DOI 10.1016/j.canlet.2005.01.048; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hashem SI, 2015, STEM CELLS, V33, P2343, DOI 10.1002/stem.2015; Hu FL, 2014, APOPTOSIS, V19, P210, DOI 10.1007/s10495-013-0914-7; Jasty R, 2001, NEOPLASIA, V3, P304, DOI 10.1038/sj.neo.7900171; Juncker T, 2011, BIOCHEM PHARMACOL, V81, P13, DOI 10.1016/j.bcp.2010.08.025; Juncker T, 2009, BIOCHEM PHARMACOL, V78, P1, DOI 10.1016/j.bcp.2009.01.018; Klose J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095970; Lang FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129196; Lefranc F, 2008, NEUROSURGERY, V62, P211, DOI 10.1227/01.NEU.0000311080.43024.0E; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li L, 2013, CELL SIGNAL, V25, P50, DOI 10.1016/j.cellsig.2012.09.020; Li Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093928; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Menger L, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003807; Mijatovic T, 2006, MOL CANCER THER, V5, P391, DOI 10.1158/1535-7163.MCT-05-0367; Mora J, 2001, CANCER RES, V61, P6892; Muller F, 2015, CURR MED CHEM, V22, P3447, DOI 10.2174/0929867322666150716115435; Newman RA, 2006, J EXP THER ONCOL, V5, P167; Olenych SG., 2007, CURR PROTOC CELL BIO, V33; Ostenfeld MS, 2008, AUTOPHAGY, V4, P487, DOI 10.4161/auto.5774; Parganlija D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095288; Pavlides S, 2012, ANTIOXID REDOX SIGN, V16, P1264, DOI 10.1089/ars.2011.4243; Radogna F, 2015, MITOCHONDRION, V21, P113, DOI 10.1016/j.mito.2015.02.003; Radogna F, 2009, TOXICOL APPL PHARM, V238, P170, DOI 10.1016/j.taap.2009.05.011; Radogna F, 2015, BIOCHEM PHARMACOL, V94, P1, DOI 10.1016/j.bcp.2014.12.018; Radogna F, 2009, TOXICOL APPL PHARM, V239, P37, DOI 10.1016/j.taap.2009.05.012; Salcher S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-224; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Schnekenburger M, 2011, BIOCHEM PHARMACOL, V81, P364, DOI 10.1016/j.bcp.2010.10.013; Sengupta A, 2011, J BIOL CHEM, V286, P7468, DOI 10.1074/jbc.M110.179242; Slingerland M, 2013, INVEST NEW DRUG, V31, P1087, DOI 10.1007/s10637-013-9984-1; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Van Quaquebeke E, 2005, J MED CHEM, V48, P849, DOI 10.1021/jm049405a; Vucicevic L, 2014, AUTOPHAGY, V10, P2362, DOI 10.4161/15548627.2014.984270; Wang Y, 2015, MOL CARCINOGEN, V54, pE26, DOI 10.1002/mc.22147; Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016; Zhang T, 2012, AUTOPHAGY, V8, P559, DOI 10.4161/auto.18867	51	53	58	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3839	3853		10.1038/onc.2015.455	http://dx.doi.org/10.1038/onc.2015.455			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26640148				2022-12-17	WOS:000380753200009
J	Shinderman-Maman, E; Cohen, K; Weingarten, C; Nabriski, D; Twito, O; Baraf, L; Hercbergs, A; Davis, PJ; Werner, H; Ellis, M; Ashur-Fabian, O				Shinderman-Maman, E.; Cohen, K.; Weingarten, C.; Nabriski, D.; Twito, O.; Baraf, L.; Hercbergs, A.; Davis, P. J.; Werner, H.; Ellis, M.; Ashur-Fabian, O.			The thyroid hormone-alpha v beta 3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; CELL-SURFACE RECEPTOR; ALPHA-V; ALPHA(V)BETA(3) INTEGRIN; GROWTH-FACTOR; TETRAIODOTHYROACETIC ACID; ALPHA-V-BETA-3 INTEGRIN; HORMONE STIMULATION; PLASMA-MEMBRANE; UP-REGULATION	Ovarian carcinoma is the fifth common cause of cancer death in women, despite advanced therapeutic approaches. alpha v beta 3 integrin, a plasma membrane receptor, binds thyroid hormones (L-thyroxine, T4; 3,5,3'-triiodo-L-thyronine, T3) and is overexpressed in ovarian cancer. We have demonstrated selective binding of fluorescently labeled hormones to alpha v beta 3-positive ovarian cancer cells but not to integrin-negative cells. Physiologically relevant T3 (1 nM) and T4 (100 nM) concentrations in OVCAR-3 (high alpha v beta 3) and A2780 (low alpha v beta 3) cells promoted alpha v and beta 3 transcription in association with basal integrin levels. This transcription was effectively blocked by RGD (Arg-Gly-Asp) peptide and neutralizing alpha v beta 3 antibodies, excluding T3-induced beta 3 messenger RNA, suggesting subspecialization of T3 and T4 binding to the integrin receptor pocket. We have provided support for extracellular regulated kinase (ERK)-mediated transcriptional regulation of the alpha v monomer by T3 and of beta 3 monomer by both hormones and documented a rapid (30-120 min) and dose-dependent (0.1-1000 nM) ERK activation. OVCAR-3 cells and alpha v beta 3-deficient HEK293 cells treated with alpha v beta 3 blockers confirmed the requirement for an intact thyroid hormone-integrin interaction in ERK activation. In addition, novel data indicated that T4, but not T3, controls integrin's outside-in signaling by phosphorylating tyrosine 759 in the beta 3 subunit. Both hormones induced cell proliferation (cell counts), survival (Annexin-PI), viability (WST-1) and significantly reduced the expression of genes that inhibit cell cycle (p21, p16), promote mitochondrial apoptosis (Nix, PUMA) and tumor suppression (GDF-15, IGFBP-6), particularly in cells with high integrin expression. At last, we have confirmed that hypothyroid environment attenuated ovarian cancer growth using a novel experimental platform that exploited paired euthyroid and severe hypothyroid serum samples from human subjects. To conclude, our data define a critical role for thyroid hormones as potent alpha v beta 3-ligands, driving ovarian cancer cell proliferation and suggest that disruption of this axis may present a novel treatment strategy in this aggressive disease.	[Shinderman-Maman, E.; Cohen, K.; Weingarten, C.; Ellis, M.; Ashur-Fabian, O.] Meir Med Ctr, Translat Hematooncol Lab, Inst Hematol, Tchernichovsky 59, IL-6997801 Kefar Sava, NA, Israel; [Shinderman-Maman, E.; Cohen, K.; Weingarten, C.; Ellis, M.; Ashur-Fabian, O.] Meir Med Ctr, Blood Bank, Tchernichovsky 59, IL-6997801 Kefar Sava, NA, Israel; [Shinderman-Maman, E.; Cohen, K.; Weingarten, C.; Werner, H.; Ashur-Fabian, O.] Tel Aviv Univ, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel; [Shinderman-Maman, E.; Cohen, K.; Weingarten, C.; Nabriski, D.; Werner, H.; Ellis, M.; Ashur-Fabian, O.] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Nabriski, D.; Twito, O.; Baraf, L.] Meir Med Ctr, Dept Endocrinol, IL-6997801 Kefar Sava, NA, Israel; [Hercbergs, A.] Cleveland Clin, Radiat Oncol, Cleveland, OH 44106 USA; [Davis, P. J.] Albany Med Coll, Dept Med, Albany, NY 12208 USA	Tel Aviv University; Tel Aviv University; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Cleveland Clinic Foundation; Albany Medical College	Ashur-Fabian, O (corresponding author), Meir Med Ctr, Translat Hematooncol Lab, Inst Hematol, Tchernichovsky 59, IL-6997801 Kefar Sava, NA, Israel.; Ashur-Fabian, O (corresponding author), Meir Med Ctr, Blood Bank, Tchernichovsky 59, IL-6997801 Kefar Sava, NA, Israel.	osnataf@gmail.com	Ashur, Osnat/AAC-1417-2020	Ashur-Fabian, Osnat/0000-0001-8624-3182; twito, orit/0000-0002-8865-3860	Li Ka Shing Foundation (LKSF)	Li Ka Shing Foundation (LKSF)	The work of Elena Shinderman Maman and Keren Cohen was done in partial fulfillment of the requirements for a PhD degree and of Chen Weingarten MSc degree from the Sackler Faculty of Medicine, Tel Aviv University, Israel. This work was partially supported by the Li Ka Shing Foundation (LKSF). We are grateful to Professor Jean-Luc Col (Institut Albert Bonniot and Universite Joseph Fourier, France) for HEK293 beta 3 and beta 1 cells.	Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bach LA, 2015, J CELL COMMUN SIGNAL, V9, P189, DOI 10.1007/s12079-015-0288-4; Bassett JHD, 2003, MOL CELL ENDOCRINOL, V213, P1, DOI 10.1016/j.mce.2003.10.033; Beral V, 2007, LANCET, V369, P1703, DOI 10.1016/S0140-6736(07)60534-0; Bergh JJ, 2005, ENDOCRINOLOGY, V146, P2864, DOI 10.1210/en.2005-0102; Blystone SD, 2002, J BIOL CHEM, V277, P46886, DOI 10.1074/jbc.M209506200; Boger C, 2013, APPL IMMUNOHISTO M M, V21, P553, DOI 10.1097/PAI.0b013e318284a03a; Brinton LA, 2007, GYNECOL ONCOL, V107, P487, DOI 10.1016/j.ygyno.2007.08.002; Brix K, 2011, THYROID RES, V4, DOI 10.1186/1756-6614-4-S1-S9; CANNISTRA SA, 1995, GYNECOL ONCOL, V58, P216, DOI 10.1006/gyno.1995.1214; Carduner L, 2014, CLIN EXP METASTAS, V31, P675, DOI 10.1007/s10585-014-9658-1; Chambery D, 2000, GROWTH HORM IGF RES, V10, P349, DOI 10.1054/ghir.2000.0179; Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007; Cody V, 2007, STEROIDS, V72, P165, DOI 10.1016/j.steroids.2006.11.008; Cohen K, 2015, LEUKEMIA LYMPHOMA, V56, P1107, DOI 10.3109/10428194.2014.947612; Cohen K, 2014, ONCOTARGET, V5, P6312, DOI 10.18632/oncotarget.2205; Cohen K, 2011, MOL CANCER RES, V9, P1385, DOI 10.1158/1541-7786.MCR-11-0187; Colombo R, 2012, J MED CHEM, V55, P10460, DOI 10.1021/jm301058f; Courter DL, 2005, J BIOL CHEM, V280, P12145, DOI 10.1074/jbc.M412555200; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Datta A, 2002, J BIOL CHEM, V277, P3943, DOI 10.1074/jbc.M109536200; Davis FB, 2006, CANCER RES, V66, P7270, DOI 10.1158/0008-5472.CAN-05-4365; Davis PJ, 2015, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00240; Davis PJ, 2014, ONCOTARGETS THER, V7, P1619, DOI 10.2147/OTT.S67393; Davis PJ, 2013, HORM CANCER-US, V4, P335, DOI 10.1007/s12672-013-0156-8; Davis PJ, 2011, ANNU REV PHARMACOL, V51, P99, DOI 10.1146/annurev-pharmtox-010510-100512; Davis PJ, 2000, J BIOL CHEM, V275, P38032, DOI 10.1074/jbc.M002560200; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dijkgraaf I, 2007, INT J CANCER, V120, P605, DOI 10.1002/ijc.22297; Dittrich R, 2011, J REPROD IMMUNOL, V90, P58, DOI 10.1016/j.jri.2011.02.009; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Edson MA, 2009, ENDOCR REV, V30, P624, DOI 10.1210/er.2009-0012; Freindorf M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/959057; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hall LC, 2008, J STEROID BIOCHEM, V109, P57, DOI 10.1016/j.jsbmb.2007.12.008; Hanna L, 2006, BEST PRACT RES CL OB, V20, P339, DOI 10.1016/j.bpobgyn.2005.10.016; Hapke S, 2003, BIOL CHEM, V384, P1073, DOI 10.1515/BC.2003.120; Hercbergs A, 2015, ONCOLOGIST, V20, P72, DOI 10.1634/theoncologist.2014-0308; Hercbergs AH, 2010, CURR OPIN ENDOCRINOL, V17, P432, DOI 10.1097/MED.0b013e32833d9710; Huang CY, 2011, J CELL PHYSIOL, V226, P1274, DOI 10.1002/jcp.22455; Huang YC, 2007, BIOCHEM PHARMACOL, V74, P1702, DOI 10.1016/j.bcp.2007.08.025; Illario M, 2005, J CLIN ENDOCR METAB, V90, P2865, DOI 10.1210/jc.2004-1520; Incerpi S, 1999, ENDOCRINOLOGY, V140, P683, DOI 10.1210/en.140.2.683; Incerpi S, 2005, ENDOCRINOLOGY, V146, P2861, DOI 10.1210/en.2005-0394; Janssen ML, 2002, CANCER RES, V62, P6146; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kang JH, 2013, OBSTET GYNECOL INT, V2013, DOI 10.1155/2013/743721; Krassas GE, 2010, ENDOCR REV, V31, P702, DOI 10.1210/er.2009-0041; Landen CN, 2008, NEOPLASIA, V10, P1259, DOI 10.1593/neo.08740; Liapis H, 1997, HUM PATHOL, V28, P443, DOI 10.1016/S0046-8177(97)90033-2; Lin HY, 2008, CARCINOGENESIS, V29, P62, DOI 10.1093/carcin/bgm239; Lin HY, 2007, STEROIDS, V72, P180, DOI 10.1016/j.steroids.2006.11.014; Lin HY, 2013, FASEB J, V27, P3209, DOI 10.1096/fj.12-227132; Lin HY, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001073; Lin HY, 2009, AM J PHYSIOL-CELL PH, V296, pC980, DOI 10.1152/ajpcell.00305.2008; Lin HY, 1998, J IMMUNOL, V161, P843; Liu J, 2014, CLIN CANCER RES, V20, P5150, DOI 10.1158/1078-0432.CCR-14-1312; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Martinez MB, 2000, ANTICANCER RES, V20, P4141; Miller CR, 2014, GYNECOL ONCOL, V133, P128, DOI 10.1016/j.ygyno.2014.01.008; Moeller LC, 2011, THYROID RES, V4, DOI 10.1186/1756-6614-4-S1-S6; Moriggi G, 2011, ANTICANCER RES, V31, P89; Mousa SA, 2012, LUNG CANCER, V76, P39, DOI 10.1016/j.lungcan.2011.10.003; Ness RB, 2000, EPIDEMIOLOGY, V11, P111, DOI 10.1097/00001648-200003000-00006; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Pascual A, 2013, BBA-GEN SUBJECTS, V1830, P3908, DOI 10.1016/j.bbagen.2012.03.012; Rae MT, 2007, J CLIN ENDOCR METAB, V92, P322, DOI 10.1210/jc.2006-1522; Rathinam R, 2010, CANCER METAST REV, V29, P223, DOI 10.1007/s10555-010-9211-x; Saegusa M, 2001, CANCER, V92, P1177, DOI 10.1002/1097-0142(20010901)92:5<1177::AID-CNCR1436>3.0.CO;2-5; Scanlan TS, 2004, NAT MED, V10, P638, DOI 10.1038/nm1051; Scarlett A, 2008, J ENDOCRINOL, V196, P509, DOI 10.1677/JOE-07-0344; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; SIEGRISTKAISER CA, 1990, J BIOL CHEM, V265, P5296; Sterle HA, 2014, J ENDOCRINOL, V222, P243, DOI 10.1530/JOE-14-0159; Storey NM, 2006, P NATL ACAD SCI USA, V103, P5197, DOI 10.1073/pnas.0600089103; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Tang HY, 2004, ENDOCRINOLOGY, V145, P3265, DOI 10.1210/en.2004-0308; Theodossiou C, 1999, CANCER, V86, P1596, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1596::AID-CNCR30>3.0.CO;2-C; Verga Falzacappa C, 2006, J CELL PHYSIOL, V206, P309, DOI 10.1002/jcp.20460; Wang XY, 2013, BIOCHEM PHARMACOL, V85, P597, DOI 10.1016/j.bcp.2012.11.025; Wang YF, 2011, INT J MOL SCI, V12, P3409, DOI 10.3390/ijms12063409; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Wu W, 2013, J LIPID RES, V54, P936, DOI 10.1194/jlr.M031450; Xi XD, 2006, J BIOL CHEM, V281, P29426, DOI 10.1074/jbc.C600039200; Xiong SB, 1998, P NATL ACAD SCI USA, V95, P12260, DOI 10.1073/pnas.95.21.12260; Yalcin M, 2013, HORM CANCER-US, V4, P176, DOI 10.1007/s12672-013-0137-y; Yamauchi M, 2008, MOL ENDOCRINOL, V22, P893, DOI 10.1210/me.2007-0249; Yehuda-Shnaidman E, 2014, ENDOCR REV, V35, P35, DOI 10.1210/er.2013-1006; Yu YC, 2013, ONCOL RES, V21, P217, DOI 10.3727/096504014X13907540404879; Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16; Zhao YS, 2007, CANCER RES, V67, P5821, DOI 10.1158/0008-5472.CAN-06-4499	93	53	53	0	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1977	1987		10.1038/onc.2015.262	http://dx.doi.org/10.1038/onc.2015.262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26165836				2022-12-17	WOS:000374010300010
J	Teng, Y; Ren, X; Li, H; Shull, A; Kim, J; Cowell, JK				Teng, Y.; Ren, X.; Li, H.; Shull, A.; Kim, J.; Cowell, J. K.			Mitochondrial ATAD3A combines with GRP78 to regulate the WASF3 metastasis-promoting protein	ONCOGENE			English	Article							DOMAIN-CONTAINING 3A; ATPASE FAMILY; CANCER-CELLS; LAMELLIPODIA FORMATION; GENE; SUPPRESSION; WAVE3; TRANSLOCATION; LOCALIZATION; INACTIVATION	AAA domain containing 3A (ATAD3A) is an integral mitochondrial membrane protein with unknown function, although we now show that high-level expression is associated with poor survival in breast cancer patients. Using a mass spectrometry approach we have demonstrated that ATAD3A interacts with the WASF3 metastasis-promoting protein. Knockdown of ATAD3A leads to decreased WASF3 protein levels in breast and colon cancer cells. Silencing ATAD3A also results in loss of both cell anchorageindependent growth and invasion and suppression of tumor growth and metastasis in vivo using immuno-compromised mice. HSP70 is responsible for stabilizing WASF3 in the cytoplasm, but inactivation of HSP70 does not lead to the loss of WASF3 stability at the mitochondrial membrane, where presumably it is protected through its interaction with ATAD3A. In response to endoplasmic reticulum (ER) stress, increases in the GRP78 protein level leads to increased WASF3 protein levels. We also show that ATAD3A was present in a WASF3-GRP78 complex, and suppression of GRP78 led to destabilization of WASF3 at the mitochondrial membrane, which was ATAD3A dependent. Furthermore, ATAD3A-mediated suppression of CDH1/E-cadherin occurs through its regulation of GRP78-mediated WASF3 stability. Proteolysis experiments using isolated mitochondria demonstrates the presence of the N-terminal end of WASF3 within the mitochondria, which is the interaction site with the N-terminal end of ATAD3A. It appears, therefore, that stabilization of WASF3 function occurs through its interaction with ATAD3A and GRP78, which may provide a bridge between the ER and mitochondria, allowing communication between the two organelles. These findings also suggest that pharmacologic inhibition of ATAD3A could be an effective therapeutic strategy to treat human cancer.	[Teng, Y.; Ren, X.; Li, H.; Shull, A.; Cowell, J. K.] Georgia Regents Univ, Canc Ctr, 1120 15th St, Augusta, GA 30912 USA; [Teng, Y.; Li, H.] Georgia Regents Univ, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Kim, J.] Georgia Regents Univ, Dept Biostat & Epidemiol, Augusta, GA USA; [Kim, J.] Sungkyunkwan Univ, Dept Stat, Seoul, South Korea	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Sungkyunkwan University (SKKU)	Teng, Y (corresponding author), Georgia Regents Univ, Canc Ctr, 1120 15th St, Augusta, GA 30912 USA.	yteng@gru.edu	Teng, Yong/AAK-4160-2020	Teng, Yong/0000-0002-1856-7289	Department of Defense [W81XWH-14-1-0412]; National Institutes of Health [CA120510]; NATIONAL CANCER INSTITUTE [R01CA120510] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by grant W81XWH-14-1-0412 from Department of Defense and grant CA120510 from the National Institutes of Health. We would like to thank Yun Mei, James Ross and the staff of Cancer Center Shared Resources at GRU for the technical assistance.	Beene DL, 2007, CURR OPIN CELL BIOL, V19, P192, DOI 10.1016/j.ceb.2007.02.011; Bellot G, 2007, CELL DEATH DIFFER, V14, P785, DOI 10.1038/sj.cdd.4402055; Bisi S, 2013, CURR OPIN CELL BIOL, V25, P565, DOI 10.1016/j.ceb.2013.04.001; Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200; Chen TC, 2011, INT J MOL MED, V28, P689, DOI 10.3892/ijmm.2011.743; Chiang SF, 2012, INT J MOL MED, V29, P365, DOI 10.3892/ijmm.2011.849; Dahl JP, 2003, J NEUROSCI, V23, P3343; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Dong DZ, 2011, CANCER RES, V71, P2848, DOI 10.1158/0008-5472.CAN-10-3151; Fang HY, 2010, J CELL SCI, V123, P1171, DOI 10.1242/jcs.062034; Gilquin B, 2010, MOL CELL BIOL, V30, P1984, DOI 10.1128/MCB.00007-10; Goller T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054799; Grkovic S, 2013, ONCOGENE, V32, P2412, DOI 10.1038/onc.2012.264; He JY, 2007, J CELL BIOL, V176, P141, DOI 10.1083/jcb.200609158; Hoffmann M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007644; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hubstenberger A, 2008, EXP CELL RES, V314, P2870, DOI 10.1016/j.yexcr.2008.06.017; Iorns E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047995; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Li N, 2013, ONCOGENE, V32, P1933, DOI 10.1038/onc.2012.212; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Maitre JL, 2013, CURR BIOL, V23, pR626, DOI 10.1016/j.cub.2013.06.019; Merle N, 2012, MITOCHONDRION, V12, P441, DOI 10.1016/j.mito.2012.05.005; Ogaeri T, 2009, STEM CELLS, V27, P1120, DOI 10.1002/stem.42; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rawe VY, 2004, HUM REPROD, V19, P2594, DOI 10.1093/humrep/deh513; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Rotty JD, 2013, NAT REV MOL CELL BIO, V14, P7, DOI 10.1038/nrm3492; Sossey-Alaoui K, 2005, J BIOL CHEM, V280, P21748, DOI 10.1074/jbc.M500503200; Sossey-Alaoui K, 2003, MAMM GENOME, V14, P314, DOI 10.1007/s00335-002-2247-7; Sossey-Alaoui K, 2002, ONCOGENE, V21, P5967, DOI 10.1038/sj.onc.1205734; Sossey-Alaoui K, 2007, J BIOL CHEM, V282, P26257, DOI 10.1074/jbc.M701484200; Sossey-Alaoui K, 2007, AM J PATHOL, V170, P2112, DOI 10.2353/ajpath.2007.060975; Sotomayor M, 2014, TRENDS CELL BIOL, V24, P524, DOI 10.1016/j.tcb.2014.03.007; Sun FC, 2006, BIOCHEM J, V396, P31, DOI 10.1042/BJ20051916; Teng Y, 2014, ONCOGENE, V33, P203, DOI 10.1038/onc.2012.565; Teng Y, 2010, BRIT J CANCER, V103, P1066, DOI 10.1038/sj.bjc.6605850; Teng Y, 2013, CARCINOGENESIS, V34, P1994, DOI 10.1093/carcin/bgt167; Teng Y, 2012, J BIOL CHEM, V287, P10051, DOI 10.1074/jbc.M111.335000; Teng Y, 2011, INT J CANCER, V129, P2825, DOI 10.1002/ijc.25964; Yang J, 2010, J THEOR BIOL, V266, P231, DOI 10.1016/j.jtbi.2010.06.009; You WC, 2013, NEURO-ONCOLOGY, V15, P1342, DOI 10.1093/neuonc/not077	44	53	54	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					333	343		10.1038/onc.2015.86	http://dx.doi.org/10.1038/onc.2015.86			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25823022	Green Accepted			2022-12-17	WOS:000369055300007
J	Chen, Z; Wang, Z; Guo, W; Zhang, Z; Zhao, F; Zhao, Y; Jia, D; Ding, J; Wang, H; Yao, M; He, X				Chen, Z.; Wang, Z.; Guo, W.; Zhang, Z.; Zhao, F.; Zhao, Y.; Jia, D.; Ding, J.; Wang, H.; Yao, M.; He, X.			TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma	ONCOGENE			English	Article							NUCLEAR TRANSLOCATION; GENE-TRANSCRIPTION; B-BOX; PKM2; PROMOTES; PHOSPHORYLATION; DIFFERENTIATION; PROLIFERATION; PROTEIN; GROWTH	Tripartite motif-containing protein 35 (TRIM35) is a member of RBCC family, which has a highly conserved order consisting of a RING domain followed by one or two B-Box domains and then a coiled-coil domain. We previously identified TRIM35 as a novel tumor suppressor in human hepatocellular carcinoma (HCC). However, the molecular mechanism that TRIM35 uses to suppress tumorigenicity is largely unknown. Pyruvate kinase isoform M2 (PKM2) has been demonstrated to have a central role in metabolic reprogramming during cancer progression. Phosphorylation of PKM2 tyrosine residue 105 (Y105) regulates PKM2 to provide a metabolic advantage to tumor cells, thereby promoting tumor growth. In the present work, mass spectrometry analysis demonstrated an interaction between TRIM35 and PKM2. Co-IP experiments confirmed that TRIM35 interacts with PKM2 and that the coiled-coil domain is required for such an interaction. Furthermore, the coiled-coil domain mediates decreases in the Warburg effect and in the cell proliferation of HCC cells. In addition, TRIM35 suppresses the tumorigenicity of HCC cells through the blockade of PKM2 Y105 phosphorylation. Collectively, our data reveal a new function for TRIM35, which is to regulate the Warburg effect and tumorigenicity through interaction with PKM2 in HCC.	[Chen, Z.; Zhao, Y.; Jia, D.; Ding, J.; He, X.] Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; [Chen, Z.; Zhao, Y.; Jia, D.; Ding, J.; He, X.] Inst Biomed Sci, Shanghai 200433, Peoples R China; [Chen, Z.; Zhao, Y.; Jia, D.; Ding, J.; He, X.] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Chen, Z.; Guo, W.; Zhang, Z.; Zhao, F.; Wang, H.; Yao, M.; He, X.] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Med, Shanghai 200032, Peoples R China; [Wang, Z.] Fudan Univ, Minist Educ, Liver Canc Inst, Zhongshan Hosp, Shanghai 200433, Peoples R China; [Wang, Z.] Fudan Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai 200433, Peoples R China	Fudan University; Fudan University; Shanghai Jiao Tong University; Fudan University; Fudan University	He, X (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Med, 25-Ln 2200,Xie Tu Rd, Shanghai 200032, Peoples R China.	xhhe@shsci.org	Chen, Zhiao/AAO-1087-2021; He, Xianghuo/I-1497-2014; Jia, Deshui/U-9732-2019	Chen, Zhiao/0000-0003-4105-8674; He, Xianghuo/0000-0001-8872-668X; 	National 973 Key Basic Research Program [2013CB910504]; Shanghai Natural Science Fund for Youth Scholars [12ZR1449900]; Shanghai Rising-Star Program [12QA1403100]; Shanghai 'Promising Youth Medical Worker' Project [XYQ2011042]; National Natural Science Foundation of China [81201538, 81125016, 81171942]	National 973 Key Basic Research Program(National Basic Research Program of China); Shanghai Natural Science Fund for Youth Scholars; Shanghai Rising-Star Program; Shanghai 'Promising Youth Medical Worker' Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We are grateful for Dr T Didier's gifts of the pWPXL, psPAX2 and pMD2. G lentivirus plasmids. We thank Qunying Lei for discussions throughout this study. We thank Jianhua Zhu for use of the scintillation counter. We thank Feng Wang and Ping Zhang for technical assistance. This work was supported by grants from the National 973 Key Basic Research Program (2013CB910504), Shanghai Natural Science Fund for Youth Scholars (12ZR1449900), Shanghai Rising-Star Program (12QA1403100), Shanghai 'Promising Youth Medical Worker' Project (XYQ2011042), National Natural Science Foundation of China (81201538, 81125016, 81171942).	ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; Baek YM, 2008, PROTEOMICS, V8, P4748, DOI 10.1002/pmic.200800094; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; Dombrauckas JD, 2005, BIOCHEMISTRY-US, V44, P9417, DOI 10.1021/bi0474923; Endersby R, 2008, BLOOD, V111, P1946, DOI 10.1182/blood-2007-04-085746; Figeac N, 2014, DEV BIOL, V386, P135, DOI 10.1016/j.ydbio.2013.11.017; Freeman KW, 2003, CANCER RES, V63, P6237; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; He HC, 2013, MOL BIOL REP, V40, P3799, DOI 10.1007/s11033-012-2458-2; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hoshino A, 2007, J BIOL CHEM, V282, P17706, DOI 10.1074/jbc.M700094200; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jia DS, 2011, HEPATOLOGY, V54, P1227, DOI 10.1002/hep.24495; Kimura F, 2003, J BIOL CHEM, V278, P25046, DOI 10.1074/jbc.M303438200; Lalonde JP, 2004, J BIOL CHEM, V279, P8181, DOI 10.1074/jbc.M306751200; Lee JW, 2008, INT J BIOCHEM CELL B, V40, P1043, DOI 10.1016/j.biocel.2007.11.009; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Maluccio M, 2012, CA-CANCER J CLIN, V62, P394, DOI 10.3322/caac.21161; Mazurek S, 2005, SEMIN CANCER BIOL, V15, P300, DOI 10.1016/j.semcancer.2005.04.009; Mcnab FW, 2011, CURR OPIN IMMUNOL, V23, P46, DOI 10.1016/j.coi.2010.10.021; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Welm BE, 2002, J CELL BIOL, V157, P703, DOI 10.1083/jcb.200107119; Yang WW, 2013, CELL CYCLE, V12, P3154, DOI 10.4161/cc.26182; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598	31	53	57	0	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3946	3956		10.1038/onc.2014.325	http://dx.doi.org/10.1038/onc.2014.325			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25263439				2022-12-17	WOS:000358544200007
J	Aranda, F; Bloy, N; Pesquet, J; Petit, B; Chaba, K; Sauvat, A; Kepp, O; Khadra, N; Enot, D; Pfirschke, C; Pittet, M; Zitvogel, L; Kroemer, G; Senovilla, L				Aranda, F.; Bloy, N.; Pesquet, J.; Petit, B.; Chaba, K.; Sauvat, A.; Kepp, O.; Khadra, N.; Enot, D.; Pfirschke, C.; Pittet, M.; Zitvogel, L.; Kroemer, G.; Senovilla, L.			Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer	ONCOGENE			English	Article							MULTICENTER PHASE-II; CALRETICULIN EXPOSURE; VITAMIN-B6 METABOLISM; DOSE EPIRUBICIN; CHEMOTHERAPY; THERAPY; MECHANISM; DEATH; IMMUNOGENICITY; EFFICACY	cis-Diamminedichloroplatinum(II) (CDDP), which is mostly referred to as cisplatin, is a widely used antineoplastic. The efficacy of cisplatin can be improved by combining it with the vitamin B6 precursor pyridoxine. Here, we evaluated the putative synergistic interaction of CDDP with pyridoxine in the treatment of an orthotopic mouse model of non-small-cell lung cancer (NSCLC). CDDP and pyridoxine exhibited hyperadditive therapeutic effects. However, this synergy was only observed in the context of an intact immune system and disappeared when the otherwise successful drug combination was applied to the same NSCLC cancer implanted in the lungs of athymic mice (which lack T lymphocytes). Immunocompetent mice that had been cured from NSCLC by the combined regimen of CDDP plus pyridoxine became resistant against subcutaneous rechallenge with the same (but not with an unrelated) cancer cell line. In vitro, CDDP and pyridoxine did not only cause synergistic killing of NSCLC cells but also elicited signs of immunogenic cell death including an endoplasmic reticulum stress response and exposure of calreticulin at the surface of the NSCLC cells. NSCLC cells treated with CDDP plus pyridoxine in vitro elicited a protective anticancer immune response upon their injection into immunocompetent mice. Altogether, these results suggest that the combined regimen of cisplatin plus pyridoxine mediates immune-dependent antineoplastic effects against NSCLC.	[Aranda, F.; Bloy, N.; Pesquet, J.; Chaba, K.; Sauvat, A.; Kepp, O.; Khadra, N.; Enot, D.; Kroemer, G.; Senovilla, L.] Ctr Rech Cordeliers, INSERM U1138, Equipe Labellisee Pas Ligue Natl Canc 11, F-75006 Paris, France; [Aranda, F.; Bloy, N.; Pesquet, J.; Chaba, K.; Sauvat, A.; Kepp, O.; Khadra, N.; Enot, D.; Kroemer, G.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Aranda, F.; Bloy, N.; Pesquet, J.; Sauvat, A.; Kepp, O.; Khadra, N.; Enot, D.; Kroemer, G.; Senovilla, L.] Metab & Cell Biol Platforms, Villejuif, France; [Bloy, N.; Zitvogel, L.] Univ Paris 11, Villejuif, France; [Petit, B.] INSERM, U1030, Villejuif, France; [Pfirschke, C.; Pittet, M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol,Pittet Lab, Boston, MA USA; [Zitvogel, L.; Senovilla, L.] INSERM, U1015, Villejuif, France; [Zitvogel, L.] Ctr Invest Clin Biotherapie CICBT 507, Villejuif, France; [Kroemer, G.] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Harvard University; Harvard Medical School; Massachusetts General Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Ctr Rech Cordeliers, INSERM U1138, Equipe Labellisee Pas Ligue Natl Canc 11, 15 Rue Ecole Med, F-75006 Paris, France.	kroemer@orange.fr; laurasenovilla@hotmail.com	Aranda, Fernando/N-2112-2014; Aranda, Fernando/N-9649-2019; Kroemer, Guido/AAY-9859-2020; Kepp, Oliver/GPX-8627-2022; KROEMER, Guido/B-4263-2013; Kepp, Oliver/N-2763-2017; Senovilla, Laura/AAX-5599-2021	Aranda, Fernando/0000-0002-9364-474X; Aranda, Fernando/0000-0002-9364-474X; KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; Senovilla, Laura/0000-0001-6887-2436; ZITVOGEL, laurence/0000-0003-1596-0998	Deutsche Forschungsgemeinschaft (DFG) [PF809/1-1]; Fondation Tourre; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale (FRM); European Commission (ArtForce); European Research Council (ERC); LabEx Immuno-Oncology; Paris Alliance of Cancer Research Institutes (PACRI)	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Fondation Tourre; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Ligue contre le Cancer (equipe labelisee)(Ligue nationale contre le cancer); Agence National de la Recherche (ANR)(French National Research Agency (ANR)); Association pour la recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Canceropole Ile-de-France(Region Ile-de-France); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Fondation Bettencourt-Schueller; Fondation de France(Fondation de France); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); European Commission (ArtForce)(European CommissionEuropean Commission Joint Research Centre); European Research Council (ERC)(European Research Council (ERC)); LabEx Immuno-Oncology; Paris Alliance of Cancer Research Institutes (PACRI)	We are indepted to Dr Gonin (Gustave Roussy) for help in mouse experiments. CP is supported by the Deutsche Forschungsgemeinschaft (DFG) PF809/1-1. LS is supported by the Fondation Tourre, the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE) and the SIRIC Cancer Research and Personalized Medicine (CARPEM). GK is supported by the Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).	Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Atmaca A, 2013, BRIT J CANCER, V108, P265, DOI 10.1038/bjc.2012.555; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Chao MP, 2012, NAT REV CANCER, V12, P58, DOI 10.1038/nrc3171; Chao MP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001375; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Feldman DR, 2008, JAMA-J AM MED ASSOC, V299, P672, DOI 10.1001/jama.299.6.672; Finn OJ, 2012, ANN ONCOL, V23, P6, DOI 10.1093/annonc/mds256; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Galanski M, 2006, RECENT PAT ANTI-CANC, V1, P285, DOI 10.2174/157489206777442287; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Galluzzi L, 2013, CELL CYCLE, V12, P417, DOI 10.4161/cc.23275; Galluzzi L, 2012, CELL REP, V2, P257, DOI 10.1016/j.celrep.2012.06.017; Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626; Hsu C, 2008, LUNG CANCER, V62, P334, DOI 10.1016/j.lungcan.2008.03.010; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kelland LR, 2004, EUR J CANCER, V40, P827, DOI 10.1016/j.ejca.2003.11.028; KELMAN AD, 1979, CANCER TREAT REP, V63, P1445; Kepp O, 2011, CANCER METAST REV, V30, P61, DOI 10.1007/s10555-011-9273-4; Kim D, 2007, HUM GENE THER, V18, P575, DOI 10.1089/hum.2007.038; Koberle B, 2010, BBA-REV CANCER, V1806, P172, DOI 10.1016/j.bbcan.2010.07.004; Lebwohl D, 1998, EUR J CANCER, V34, P1522, DOI 10.1016/S0959-8049(98)00224-X; Li QQ, 2013, ANTICANCER RES, V33, P1421; Martins I, 2011, ONCOGENE, V30, P1147, DOI 10.1038/onc.2010.500; Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026; MAYO JG, 1972, CANCER CHEMOTH REP 2, V3, P325; McDonnell AM, 2011, SEMIN IMMUNOPATHOL, V33, P353, DOI 10.1007/s00281-011-0246-z; Menard C, 2008, CANCER IMMUNOL IMMUN, V57, P1579, DOI 10.1007/s00262-008-0505-6; Mordant P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026073; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Otterson GA, 2010, CLIN CANCER RES, V16, P2466, DOI 10.1158/1078-0432.CCR-09-3015; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Phernambucq ECJ, 2006, BRIT J CANCER, V95, P470, DOI 10.1038/sj.bjc.6603289; PRESTAYKO AW, 1979, CANCER TREAT REV, V6, P17, DOI 10.1016/S0305-7372(79)80057-2; Sanderson BJS, 1996, MUTAT RES-FUND MOL M, V355, P59, DOI 10.1016/0027-5107(96)00022-X; Senovilla L, 2012, SCIENCE, V337, P1678, DOI 10.1126/science.1224922; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Talmadge JE, 2007, AM J PATHOL, V170, P793, DOI 10.2353/ajpath.2007.060929; Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Winter C, 2011, NAT REV ENDOCRINOL, V7, P43, DOI 10.1038/nrendo.2010.196; Zitvogel L, 2013, IMMUNITY, V39, P74, DOI 10.1016/j.immuni.2013.06.014; Zitvogel L, 2011, NAT REV CLIN ONCOL, V8, P151, DOI 10.1038/nrclinonc.2010.223; Zitvogel L, 2010, CLIN CANCER RES, V16, P3100, DOI 10.1158/1078-0432.CCR-09-2891	46	53	55	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					3053	3062		10.1038/onc.2014.234	http://dx.doi.org/10.1038/onc.2014.234			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25065595				2022-12-17	WOS:000356100500010
J	Li, H; Li, J; Su, Y; Fan, Y; Guo, X; Li, L; Su, X; Rong, R; Ying, J; Mo, X; Liu, K; Zhang, Z; Yang, F; Jiang, G; Wang, J; Zhang, Y; Ma, D; Tao, Q; Han, W				Li, H.; Li, J.; Su, Y.; Fan, Y.; Guo, X.; Li, L.; Su, X.; Rong, R.; Ying, J.; Mo, X.; Liu, K.; Zhang, Z.; Yang, F.; Jiang, G.; Wang, J.; Zhang, Y.; Ma, D.; Tao, Q.; Han, W.			A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth	ONCOGENE			English	Article						CMTM7; 3p22; tumor-suppressor gene; methylation; LOH	CHEMOKINE-LIKE FACTOR-1; TUMOR-SUPPRESSOR GENE; EPSTEIN-BARR-VIRUS; NASOPHARYNGEAL CARCINOMA; CPG METHYLATION; GASTRIC-CANCER; APOPTOSIS; RECEPTOR; PROTEIN; IDENTIFICATION	Deletion of 3p12-22 is frequent in multiple cancer types, indicating the presence of critical tumor-suppressor genes (TSGs) at this region. We studied a novel candidate TSG, CMTM7, located at the 3p22.3 CMTM-gene cluster, for its tumor-suppressive functions and related mechanisms. The three CMTM genes, CMTM6, 7 and 8, are broadly expressed in human normal adult tissues and normal epithelial cell lines. Only CMTM7 is frequently silenced Or downregulated in esophageal and nasopharyngeal cell lines, but uncommon in other carcinoma cell lines. Immunostaining of tissue microarrays for CMTM7 protein showed its downregulation or absence in esophageal, gastric, pancreatic, liver, lung and cervix tumor tissues. Promoter CpG methylation and loss of heterozygosity were both found contributing to CMTM7 downregulation. Ectopic expression of CMTM7 in carcinoma cells inhibits cell proliferation, motility and tumor formation in nude mice, but not in immortalized normal cells, suggesting a tumor inhibitory role of CMTM7. The tumor-suppressive function of CMTM7 is associated with its role in G1/S cell cycle arrest, through upregulating p27 and downregulating cyclin-dependent kinase 2 (CDK2) and 6 (CDK6). Moreover, CMTM7 could promote epidermal growth factor receptor (EGFR) internalization, and further suppress AKT signaling pathway. Thus, our findings suggest that CMTM7 is a novel 3p22 tumor suppressor regulating G1/S transition and EGFR/AKT signaling during tumor pathogenesis.	[Li, H.; Su, Y.; Guo, X.; Mo, X.; Liu, K.; Zhang, Y.; Ma, D.; Han, W.] Peking Univ, Dept Immunol, Ctr Human Dis Genom, Key Lab Med Immunol,Minist Hlth,Sch Basic Med Sci, Beijing 100191, Peoples R China; [Li, H.] Peking Univ, Peoples Hosp, Dept Clin Lab, Beijing 100191, Peoples R China; [Li, J.; Fan, Y.; Li, L.; Su, X.; Rong, R.; Tao, Q.] Chinese Univ Hong Kong, Canc Epigenet Lab, State Key Lab Oncol South China, Dept Clin Oncol,Sir YK Pao Ctr Canc, Shatin, Hong Kong, Peoples R China; [Li, J.; Fan, Y.; Li, L.; Su, X.; Rong, R.; Tao, Q.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Li, J.; Fan, Y.; Li, L.; Su, X.; Rong, R.; Tao, Q.] Chinese Univ Hong Kong, Shenzhen Res Inst, Shatin, Hong Kong, Peoples R China; [Ying, J.] Peking Union Med Coll, Dept Pathol, Beijing 100021, Peoples R China; [Ying, J.] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Zhang, Z.] Guangxi Med Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, Nanning, Peoples R China; [Yang, F.; Jiang, G.; Wang, J.] Peking Univ, Peoples Hosp, Dept Thorac Surg, Beijing 100191, Peoples R China	Peking University; Peking University; Chinese University of Hong Kong; State Key Lab Oncology South China; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Guangxi Medical University; Peking University	Tao, Q (corresponding author), Chinese Univ Hong Kong, Dept Clin Oncol, Ctr Canc, PWH, Shatin, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk; hanwl@bjmu.edu.cn	Guo, Xiaohuan/I-3710-2017; Li, Lili/Q-5750-2018; Tao, Qian/T-4743-2018	Guo, Xiaohuan/0000-0001-5152-3010; Li, Lili/0000-0002-0292-5889; Tao, Qian/0000-0001-5383-4808	National Natural Science Foundation of China [30972780, 30928012]; Program for Innovation of new drug [2009ZX09503-004]; Specialized Research Fund for the Doctoral Program of Higher Education [20100001110050]; Hong Kong RGC [474710]; Chinese University of Hong Kong	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Innovation of new drug; Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Hong Kong RGC(Hong Kong Research Grants Council); Chinese University of Hong Kong(Chinese University of Hong Kong)	We thank Bert Vogelstein, George Tsao and Sun Young Rha for some tumor cell lines and samples, and DSMZ (German Collection of Microorganisms and Cell Cultures) for the KYSE cell lines (Shimada et at, Cancer 69: 277-284, 1992). This work was supported by grants from the National Natural Science Foundation of China (no. 30972780 and no. 30928012), Program for Innovation of new drug (no. 2009ZX09503-004); the Specialized Research Fund for the Doctoral Program of Higher Education (no. 20100001110050), Hong Kong RGC (no. 474710) and the Group Research Scheme of The Chinese University of Hong Kong.	Aviel-Ronen S, 2008, P NATL ACAD SCI USA, V105, P10155, DOI 10.1073/pnas.0709618105; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Buffart TE, 2008, BRIT J CANCER, V99, P1802, DOI 10.1038/sj.bjc.6604777; Cheng YD, 2010, CANCER RES, V70, P6516, DOI 10.1158/0008-5472.CAN-09-4566; Cheung ST, 1999, INT J CANCER, V83, P121, DOI 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Guo XH, 2009, BIOCHEM BIOPH RES CO, V387, P139, DOI 10.1016/j.bbrc.2009.06.148; Han WL, 2003, GENOMICS, V81, P609, DOI 10.1016/S0888-7543(03)00095-8; Han WL, 2001, BIOCHEM J, V357, P127, DOI 10.1042/0264-6021:3570127; Harari PM, 2004, ENDOCR-RELAT CANCER, V11, P689, DOI 10.1677/erc.1.00600; Hu XT, 2009, ONCOGENE, V28, P2466, DOI 10.1038/onc.2009.92; Jin CN, 2007, J CELL PHYSIOL, V211, P112, DOI 10.1002/jcp.20914; Jin CN, 2005, FEBS LETT, V579, P6375, DOI 10.1016/j.febslet.2005.10.021; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Li D, 2007, INT J BIOCHEM CELL B, V39, P2107, DOI 10.1016/j.biocel.2007.06.002; Li HN, 2010, BMB REP, V43, P182, DOI 10.5483/BMBRep.2010.43.3.182; Li L, 2012, ONCOGENE, V31, P3901, DOI 10.1038/onc.2011.541; Li T, 2006, LIFE SCI, V79, P519, DOI 10.1016/j.lfs.2006.01.042; Lind GE, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-13; Lo PHY, 2006, CANCER LETT, V234, P184, DOI 10.1016/j.canlet.2005.03.036; Ma S, 2012, GASTROENTEROLOGY, V143, P675, DOI 10.1053/j.gastro.2012.06.007; Maddika S, 2007, DRUG RESIST UPDATE, V10, P13, DOI 10.1016/j.drup.2007.01.003; Mao L, 1996, CANCER RES, V56, P5128; Martin TA, 2010, INT J MOL MED, V26, P721, DOI 10.3892/ijmm_00000519; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Miyazaki A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031829; Nakayama J, 2009, BLOOD, V113, P1483, DOI 10.1182/blood-2008-07-166355; Niu J, 2010, LEUKEMIA RES, V35, P771; Odintsova E, 2003, J CELL SCI, V116, P4557, DOI 10.1242/jcs.00793; Plate M, 2010, MOL CELLS, V29, P355, DOI 10.1007/s10059-010-0038-7; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; REMMELE W, 1987, PATHOLOGE, V8, P138; Sanchez-Pulido L, 2002, TRENDS BIOCHEM SCI, V27, P599, DOI 10.1016/S0968-0004(02)02229-6; Shao L, 2007, CLIN CANCER RES, V13, P5756, DOI 10.1158/1078-0432.CCR-06-3082; Shao LN, 2010, CELL IMMUNOL, V263, P188, DOI 10.1016/j.cellimm.2010.03.015; Shao LN, 2009, BIOCHEM BIOPH RES CO, V379, P866, DOI 10.1016/j.bbrc.2008.12.126; Sharp TV, 2008, P NATL ACAD SCI USA, V105, P19932, DOI 10.1073/pnas.0805003105; Shi S, 2005, INT J BIOCHEM CELL B, V37, P1633, DOI 10.1016/j.biocel.2004.04.028; Sinha S, 2008, CANCER SCI, V99, P1984, DOI 10.1111/j.1349-7006.2008.00952.x; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Wang Y, 2006, LIFE SCI, V78, P614, DOI 10.1016/j.lfs.2005.05.070; Wang Y, 2008, BIOCHEM BIOPH RES CO, V371, P54, DOI 10.1016/j.bbrc.2008.03.143; Wang Y, 2009, CANCER RES, V69, P5194, DOI 10.1158/0008-5472.CAN-08-3694; WEINBERG RA, 1994, CA-CANCER J CLIN, V44, P160, DOI 10.3322/canjclin.44.3.160; Ying J, 2009, BRIT J CANCER, V100, P663, DOI 10.1038/sj.bjc.6604888; Zhong J, 2006, J BIOCHEM MOL BIOL, V39, P537	48	53	58	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3109	3118		10.1038/onc.2013.282	http://dx.doi.org/10.1038/onc.2013.282			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23893243				2022-12-17	WOS:000338410000004
J	Soria-Valles, C; Gutierrez-Fernandez, A; Guiu, M; Mari, B; Fueyo, A; Gomis, RR; Lopez-Otin, C				Soria-Valles, C.; Gutierrez-Fernandez, A.; Guiu, M.; Mari, B.; Fueyo, A.; Gomis, R. R.; Lopez-Otin, C.			The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21	ONCOGENE			English	Article						extracellular matrix; metalloprotease; metastasis; miRNA; TGF-beta	TUMOR-SUPPRESSOR GENE; MATRIX METALLOPROTEINASE-8; MICRORNA-21 TARGETS; LUNG-CANCER; METASTASIS; EXPRESSION; MODULATION; PROTEASES; CLEAVAGE; ROLES	Matrix metalloproteinases (MMPs) have been traditionally implicated in cancer progression because of their ability to degrade the extracellular matrix. However, some members of the MMP family have recently been identified as proteases with antitumor properties. Thus, it has been described that collagenase-2 (MMP-8) has a protective role in tumor and metastasis progression, but the molecular mechanisms underlying these effects are unknown. We show herein that Mmp8 expression causes a decrease in miR-21 levels that in turn leads to a reduction in tumor growth and lung metastasis formation by MDA-MB-231 (4175) breast cancer cells. By using both in vitro and in vivo models, we demonstrate that the mechanism responsible for these MMP-8 beneficial effects involves cleavage of decorin by MMP-8 and a subsequent reduction of transforming growth factor beta (TGF-beta) signaling that controls miR-21 levels. In addition, miR-21 downregulation induced by MMP-8 increases the levels of tumor suppressors such as programmed cell death 4, which may also contribute to the decrease in tumor formation and metastasis of breast cancer cells overexpressing this metalloproteinase. These findings reveal a new signaling pathway for cancer regulation controlled by MMP-8, and contribute to clarify the molecular mechanisms by which tumor-defying proteases may exert their protective function in cancer and metastasis.	[Soria-Valles, C.; Gutierrez-Fernandez, A.; Lopez-Otin, C.] Univ Oviedo, IUOPA, Fac Med, Dept Bioquim & Biol Mol, Oviedo 33006, Spain; [Guiu, M.; Gomis, R. R.] Inst Res Biomed IRB Barcelona, Barcelona, Spain; [Mari, B.] CNRS, Valbonne, France; [Mari, B.] Univ Nice, Inst Pharmacol Mol & Cellulaire, Valbonne, France; [Fueyo, A.] Univ Oviedo, IUOPA, Fac Med, Dept Biol,Area Fisiol, Oviedo, Spain	University of Oviedo; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Oviedo	Lopez-Otin, C (corresponding author), Univ Oviedo, IUOPA, Fac Med, Dept Bioquim & Biol Mol, C Fernando Bongera S-N, Oviedo 33006, Spain.	clo@uniovi.es	Fueyo, Antonio/ABH-3243-2020; Mari, Bernard P/GVS-3100-2022; López-Otín, Carlos/AAB-2106-2020; Gomis, Roger R/E-9788-2016; Mari, Bernard P/F-8960-2013; Gutierrez-Fernandez, Ana/ABG-6678-2020; Gutierrez-Fernandez, Ana/AAS-9954-2021; Mari, Bernard P/D-7445-2015; Mari, Bernard/Q-5832-2019	Fueyo, Antonio/0000-0002-7121-9398; Mari, Bernard P/0000-0002-0422-9182; López-Otín, Carlos/0000-0001-6964-1904; Gomis, Roger R/0000-0001-6473-2858; Mari, Bernard P/0000-0002-0422-9182; Gutierrez-Fernandez, Ana/0000-0002-9287-8843; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182	Ministerio de Economia y Competitividad-Spain; RTICC-Instituto de Salud Carlos III-Spain; European Union; BBVA foundation [2009 SGR1429, SAF2010-21171]; Obra Social Cajastur-Asturias	Ministerio de Economia y Competitividad-Spain; RTICC-Instituto de Salud Carlos III-Spain; European Union(European Commission); BBVA foundation(BBVA Foundation); Obra Social Cajastur-Asturias	We are very grateful to Dr JMP Freije and FG Osorio for helpful comments and to C Garabaya, MF Suarez y S Alvarez for their excellent technical assistance. We also thank the excellent support of the Nice-Sophia Antipolis Functional Genomics Platform. This work was supported by grants from Ministerio de Economia y Competitividad-Spain, RTICC-Instituto de Salud Carlos III-Spain, and European Union (FP7-Microenvimet). BBVA foundation, 2009 SGR1429 and SAF2010-21171 support to RRG was provided. The Instituto Universitario de Oncologia is supported by Obra Social Cajastur-Asturias. CL-O is an Investigator of the Botin Foundation.	Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Fanjul-Fernandez M, 2013, J BIOL CHEM, V288, P14647, DOI 10.1074/jbc.M112.439893; Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608; Gutierrez-Fernandez A, 2008, CANCER RES, V68, P2755, DOI 10.1158/0008-5472.CAN-07-5154; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Knauper V, 1997, FEBS LETT, V405, P60, DOI 10.1016/S0014-5793(97)00158-0; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6; Korpi JT, 2008, BRIT J CANCER, V98, P766, DOI 10.1038/sj.bjc.6604239; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Lopez-Otin C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Merline R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001868; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Montel V, 2004, CANCER RES, V64, P1687, DOI 10.1158/0008-5472.CAN-03-2047; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Noel A, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00140; Pan XA, 2010, CANCER BIOL THER, V10, P1224, DOI 10.4161/cbt.10.12.14252; Puissegur MP, 2011, CELL DEATH DIFFER, V18, P465, DOI 10.1038/cdd.2010.119; Qian BY, 2009, BREAST CANCER RES TR, V117, P131, DOI 10.1007/s10549-008-0219-7; Tester AM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000312; Turk B, 2012, EMBO J, V31, P1630, DOI 10.1038/emboj.2012.42; Van Lint P, 2006, CYTOKINE GROWTH F R, V17, P217, DOI 10.1016/j.cytogfr.2006.04.001; Yan LX, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2803; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhen EY, 2008, ARTHRITIS RHEUM-US, V58, P2420, DOI 10.1002/art.23654; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	35	53	56	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3054	3063		10.1038/onc.2013.267	http://dx.doi.org/10.1038/onc.2013.267			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23851508				2022-12-17	WOS:000337232200012
J	Rimessi, A; Marchi, S; Patergnani, S; Pinton, P				Rimessi, A.; Marchi, S.; Patergnani, S.; Pinton, P.			H-Ras-driven tumoral maintenance is sustained through caveolin-1-dependent alterations in calcium signaling	ONCOGENE			English	Article						calcium signaling; caveolin-1; mitochondria; apoptosis; oncogenic H-Ras	MITOCHONDRIA-ASSOCIATED MEMBRANES; OXIDATIVE STRESS; CANCER-CELLS; ONCOGENIC TRANSFORMATION; MURINE FIBROBLASTS; PLASMA-MEMBRANE; GENE-EXPRESSION; DOWN-REGULATION; CAVEOLAE; METABOLISM	A growing body of research has highlighted the complex range of tumoral traits acquired during H-Ras-driven transformation and maintenance, which include proliferative signaling, growth suppressor evasion and resistance to cell death. Clear molecular information about these processes is not yet available, but recent evidence has provided solid support for the importance of mitochondria. Here, we show that the induction of oncogenic H-Ras leads to changes in intracellular calcium (Ca2+), evaluate the temporal relationship between oncogene expression and mitochondrial physiology, and demonstrate that Ca2+ homeostasis is altered by caveolin-1, a protein that has a key role in tumor maintenance. Our results indicate that tumor-suppressor caveolin-1 is a core component of the Ca2+-dependent apoptotic pathway and participates in the regulation of critical mitochondrial functions during tumor development. The compromised caveolin-1/Ca2+ axis contributes to failure in both mitochondrial metabolism and apoptosis, thereby sustaining the neoplastic phenotype. These results illustrate a direct link between Ca2+ regulation and mitochondrial biology in cancer.	[Rimessi, A.; Marchi, S.; Patergnani, S.; Pinton, P.] Univ Ferrar, Lab Technol Adv Therapies LTTA, Dept Morphol Surg & Expt Med, Sect Gen Pathol,Interdisciplinary Ctr Study Infla, I-44121 Ferrara, Italy		Pinton, P (corresponding author), Univ Ferrar, Lab Technol Adv Therapies LTTA, Dept Morphol Surg & Expt Med, Sect Gen Pathol,Interdisciplinary Ctr Study Infla, Via Borsari 46, I-44121 Ferrara, Italy.	pnp@unife.it	Marchi, Saverio/AAK-3308-2021; Rimessi, Alessandro/K-5420-2016; rimessi, alessandro/O-3335-2019; Marchi, Saverio/K-5997-2016; Pinton, Paolo/J-8025-2012; Patergnani, Simone/AAK-2929-2021; Patergnani, Simone/AAC-3969-2021	Marchi, Saverio/0000-0003-2708-1843; Rimessi, Alessandro/0000-0001-7091-5765; rimessi, alessandro/0000-0001-7091-5765; Marchi, Saverio/0000-0003-2708-1843; Pinton, Paolo/0000-0001-7108-6508; Patergnani, Simone/0000-0001-7951-9267; 	Italian Ministry of Health; FISM (Fondazione Italiana Sclerosi Multipla) research fellowship [2012/B/11]; FIRC (Fondazione Italiana Ricerca sul Cancro) fellowship; Italian Association for Cancer Research (AIRC), Telethon [GGP09128, GGP11139B]; local funds from the University of Ferrara; Italian Ministry of Education, University and Research (COFIN, FIRB and Futuro in Ricerca); Italian Cystic Fibrosis Research Foundation	Italian Ministry of Health(Ministry of Health, Italy); FISM (Fondazione Italiana Sclerosi Multipla) research fellowship; FIRC (Fondazione Italiana Ricerca sul Cancro) fellowship(Fondazione AIRC per la ricerca sul cancro); Italian Association for Cancer Research (AIRC), Telethon(Fondazione AIRC per la ricerca sul cancroFondazione Telethon); local funds from the University of Ferrara; Italian Ministry of Education, University and Research (COFIN, FIRB and Futuro in Ricerca)(Ministry of Education, Universities and Research (MIUR)); Italian Cystic Fibrosis Research Foundation(Ministry of Health, ItalyItalian Cystic Fibrosis Research Foundation)	This research was supported by: the Italian Ministry of Health to AR. SP is supported by a FISM (Fondazione Italiana Sclerosi Multipla) research fellowship (2012/B/11), whereas SM by FIRC (Fondazione Italiana Ricerca sul Cancro) fellowship. PP is financed by Italian Association for Cancer Research (AIRC), Telethon (GGP09128 and GGP11139B), local funds from the University of Ferrara, the Italian Ministry of Education, University and Research (COFIN, FIRB and Futuro in Ricerca), the Italian Cystic Fibrosis Research Foundation and Italian Ministry of Health.	Adebiyi A, 2011, J BIOL CHEM, V286, P4341, DOI 10.1074/jbc.M110.179747; Bender F, 2002, BIOL RES, V35, P151, DOI 10.4067/S0716-97602002000200006; Berridge MV, 2010, REJUV RES, V13, P139, DOI 10.1089/rej.2009.0948; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Ferdek PE, 2012, CURR BIOL, V22, P1241, DOI 10.1016/j.cub.2012.05.002; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GALLIMORE PH, 1986, ANTICANCER RES, V6, P499; Giorgi C, 2012, CELL CALCIUM, V52, P36, DOI 10.1016/j.ceca.2012.02.008; Giorgi C, 2012, MITOCHONDRION, V12, P77, DOI 10.1016/j.mito.2011.07.004; Giorgi C, 2009, INT J BIOCHEM CELL B, V41, P1817, DOI 10.1016/j.biocel.2009.04.010; Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Hayer A, 2010, J CELL BIOL, V191, P615, DOI 10.1083/jcb.201003086; Hu YM, 2012, CELL RES, V22, P399, DOI 10.1038/cr.2011.145; Hulit J, 2000, J BIOL CHEM, V275, P21203, DOI 10.1074/jbc.M000321200; Isshiki M, 2002, J CELL SCI, V115, P475; Isshiki M, 2003, TRAFFIC, V4, P717, DOI 10.1034/j.1600-0854.2003.00130.x; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Krejci P, 2010, BONE, V47, P102, DOI 10.1016/j.bone.2010.03.021; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Liu XG, 2009, INT J BIOCHEM CELL B, V41, P1972, DOI 10.1016/j.biocel.2009.05.013; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3256, DOI 10.4161/cc.9.16.12553; Murata T, 2007, J BIOL CHEM, V282, P16631, DOI 10.1074/jbc.M607948200; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Park DS, 2001, BIOCHEMISTRY-US, V40, P3354, DOI 10.1021/bi002787b; Patel HH, 2008, ANNU REV PHARMACOL, V48, P359, DOI 10.1146/annurev.pharmtox.48.121506.124841; Patergnani S, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-19; Pavlides S, 2010, AGING-US, V2, P185, DOI 10.18632/aging.100134; Peng TI, 2010, ANN NY ACAD SCI, V1201, P183, DOI 10.1111/j.1749-6632.2010.05634.x; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2007, METHOD CELL BIOL, V80, P297, DOI 10.1016/S0091-679X(06)80015-4; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Rajjayabun PH, 2001, UROLOGY, V58, P811, DOI 10.1016/S0090-4295(01)01337-1; Ralph SJ, 2010, MOL ASPECTS MED, V31, P145, DOI 10.1016/j.mam.2010.02.008; Razani B, 2000, J CELL SCI, V113, P2103; Rimessi A, 2008, BBA-BIOENERGETICS, V1777, P808, DOI 10.1016/j.bbabio.2008.05.449; Sano R, 2009, MOL CELL, V36, P500, DOI 10.1016/j.molcel.2009.10.021; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Thomas CM, 2008, J CELL MOL MED, V12, P796, DOI 10.1111/j.1582-4934.2008.00295.x; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Wiechen K, 2001, AM J PATHOL, V158, P833, DOI 10.1016/S0002-9440(10)64031-X; Wieckowski MR, 2009, NAT PROTOC, V4, P1582, DOI 10.1038/nprot.2009.151; Williams TM, 2004, ANN MED, V36, P584, DOI 10.1080/07853890410018899	60	53	54	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2329	2340		10.1038/onc.2013.192	http://dx.doi.org/10.1038/onc.2013.192			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23728347				2022-12-17	WOS:000335451800006
J	Shamanna, RA; Hoque, M; Pe'ery, T; Mathews, MB				Shamanna, R. A.; Hoque, M.; Pe'ery, T.; Mathews, M. B.			Induction of p53, p21 and apoptosis by silencing the NF90/NF45 complex in human papilloma virus-transformed cervical carcinoma cells	ONCOGENE			English	Article						Apoptosis; human papilloma virus; transcription; p53; p21; NF90/NF45	DOUBLE-STRANDED-RNA; TUMOR-SUPPRESSOR P53; IL-2 MESSENGER-RNA; BINDING-PROTEIN; GENE-EXPRESSION; NUCLEAR EXPORT; TRANSLATIONAL CONTROL; NEGATIVE REGULATOR; E6 ONCOPROTEIN; CYCLE ARREST	The heterodimeric nuclear factor (NF) 90/NF45 complex (NF90/NF45) binds nucleic acids and is a multifunctional regulator of gene expression. Here we report that depletion of NF90/NF45 restores the expression of the p53 and p21 proteins in cervical carcinoma cells infected with high-risk human papillomaviruses (HPVs). Knockdown of either NF90 or NF45 by RNA interference led to greatly elevated levels of p53 and p21 proteins in HPV-derived HeLa and SiHa cells but not in other cancerous or normal cell lines. In HeLa cells, p21 messenger-RNA (mRNA) increased concomitantly but the level of p53 mRNA was unaffected. RNA interference directed against p53 prevented the induction of both proteins. These results indicated that the upregulation of p21 is due to p53-dependent transcription, whereas p53 is regulated post-transcriptionally. Proteasome-mediated turnover of p53 is accelerated by the HPV E6 and cellular E6AP proteins. We therefore examined the hypothesis that this pathway is regulated by NF90/NF45. Indeed, depletion of NF90 attenuated the expression of E6 RNA and inhibited transcription from the HPV early promoter, revealing a new role for NF90/NF45 in HPV gene expression. The transcription inhibition was largely independent of the reduction of P-TEFb (positive transcription elongation factor b) levels caused by NF90 depletion. Consistent with p53 derepression, NF90/NF45-depleted HeLa cells displayed elevated poly ADP-ribose polymerase (PARP) cleavage and susceptibility to camptothecin-induced apoptosis. We conclude that high-risk strains of HPV utilize the cellular NF90/NF45 complex for viral E6 expression in infected cervical carcinoma cell lines. Interference with NF90/NF45 function could assist in controlling cervical carcinoma.	[Shamanna, R. A.; Hoque, M.; Mathews, M. B.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07101 USA; [Shamanna, R. A.; Pe'ery, T.; Mathews, M. B.] Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Newark, NJ 07103 USA; [Pe'ery, T.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Mathews, MB (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, POB 1709, Newark, NJ 07101 USA.	mathews@umdnj.edu			NIH [R01 AI034552]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034552] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Dr Edward Goodwin for pGL3-HPV18URR-Firefly luciferase plasmid and Dr Betsy Barnes for HCT 116 cell lines. We are indebted to Dr Raymond Birge and Dr Edouard Azzam for discussions and helpful suggestions. The early stages of this work were supported by NIH Grant R01 AI034552 to MBM.	Agbottah ET, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-41; Austin D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036327; Barber GN, 2009, RNA BIOL, V6, P35, DOI 10.4161/rna.6.1.7565; BAUKNECHT T, 1995, J VIROL, V69, P1; Bednarek PH, 1998, J VIROL, V72, P708, DOI 10.1128/JVI.72.1.708-716.1998; Bose SK, 2006, BIOCHEM J, V396, P99, DOI 10.1042/BJ20051548; Brantley-Finley C, 2003, BIOCHEM PHARMACOL, V66, P459, DOI 10.1016/S0006-2952(03)00255-7; Cazanove O, 2008, BIOCHEMISTRY-US, V47, P8350, DOI 10.1021/bi7008486; Chang JTC, 2010, CANCER GENE THER, V17, P827, DOI 10.1038/cgt.2010.38; Chen T, 2004, MOL CELL BIOL, V24, P6608, DOI 10.1128/mcb.24.15.6608-6619.2004; Chesnokov IN, 2003, P NATL ACAD SCI USA, V100, P9150, DOI 10.1073/pnas.1633580100; Chow LT, 2010, APMIS, V118, P422, DOI 10.1111/j.1600-0463.2010.02625.x; Collavin L, 2010, CELL DEATH DIFFER, V17, P901, DOI 10.1038/cdd.2010.35; Corso C, 2011, NUCLEIC ACIDS RES, V39, P7263, DOI 10.1093/nar/gkr278; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; Dey A, 2008, BRIT J CANCER, V98, P4, DOI 10.1038/sj.bjc.6604098; Eldridge AG, 2006, CELL, V124, P367, DOI 10.1016/j.cell.2005.10.038; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2009, BIOFACTORS, V35, P161, DOI 10.1002/biof.26; Gomila RC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016687; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; Graber TE, 2010, CELL DEATH DIFFER, V17, P719, DOI 10.1038/cdd.2009.164; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Guan DY, 2008, MOL CELL BIOL, V28, P4629, DOI 10.1128/MCB.00120-08; Gwizdek C, 2004, J BIOL CHEM, V279, P884, DOI 10.1074/jbc.M306808200; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Harashima A, 2010, GENE DEV, V24, P2640, DOI 10.1101/gad.1965010; Hoque M, 2011, J MOL BIOL, V410, P917, DOI 10.1016/j.jmb.2011.03.060; Howie HL, 2009, VIROLOGY, V384, P324, DOI 10.1016/j.virol.2008.11.017; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Isken O, 2004, RNA, V10, P1637, DOI 10.1261/rna.7290904; Isken O, 2003, EMBO J, V22, P5655, DOI 10.1093/emboj/cdg562; Isken O, 2007, RNA, V13, P1675, DOI 10.1261/rna.594207; Karmakar S, 2010, EMBO J, V29, P3260, DOI 10.1038/emboj.2010.204; Kiesler P, 2010, J BIOL CHEM, V285, P8256, DOI 10.1074/jbc.M109.041004; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; Kreis NN, 2010, ONCOGENE, V29, P5591, DOI 10.1038/onc.2010.290; Kuwano Y, 2008, MOL CELL BIOL, V28, P4562, DOI 10.1128/MCB.00165-08; Kuwano Y, 2010, NUCLEIC ACIDS RES, V38, P225, DOI 10.1093/nar/gkp861; Lace MJ, 2009, J VIROL, V83, P7457, DOI 10.1128/JVI.00285-09; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lee CH, 2007, CANCER SCI, V98, P795, DOI 10.1111/j.1349-7006.2007.00473.x; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Liao HJ, 1998, P NATL ACAD SCI USA, V95, P8514, DOI 10.1073/pnas.95.15.8514; Lopez-Saavedra A, 2009, ARCH VIROL, V154, P747, DOI 10.1007/s00705-009-0362-4; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Merrill MK, 2006, J VIROL, V80, P6936, DOI 10.1128/JVI.00243-06; Merrill MK, 2006, J VIROL, V80, P3147, DOI 10.1128/JVI.80.7.3147-3156.2006; Molchadsky A, 2010, CARCINOGENESIS, V31, P1501, DOI 10.1093/carcin/bgq101; Munoz-Fontela C, 2011, J IMMUNOL, V187, P6428, DOI 10.4049/jimmunol.1101459; Nair JS, 2009, MOL BIOL CELL, V20, P2218, DOI 10.1091/mbc.E08-08-0885; Narisawa-Saito M, 2007, CANCER SCI, V98, P1505, DOI 10.1111/j.1349-7006.2007.00546.x; Nie YZ, 2005, MOL CELL BIOL, V25, P6956, DOI 10.1128/MCB.25.16.6956-6963.2005; Pajunk HS, 1997, J GEN VIROL, V78, P3287, DOI 10.1099/0022-1317-78-12-3287; Parker LM, 2001, J BIOL CHEM, V276, P32522, DOI 10.1074/jbc.M104408200; Parrott AM, 2005, J MOL BIOL, V348, P281, DOI 10.1016/j.jmb.2005.02.047; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; Pei Y, 2008, J IMMUNOL, V180, P222, DOI 10.4049/jimmunol.180.1.222; Pfeifer I, 2008, P NATL ACAD SCI USA, V105, P4173, DOI 10.1073/pnas.0711222105; Ranpura SA, 2008, J ANDROL, V29, P186, DOI 10.2164/jandrol.107.003756; Reichman TW, 2002, MOL CELL BIOL, V22, P343, DOI 10.1128/MCB.22.1.343-356.2002; Reichman TW, 2003, CELL SIGNALING HDB, V3, P335; Rezai-Zadeh N, 2003, GENE DEV, V17, P1019, DOI 10.1101/gad.1068003; Saha B, 2012, ONCOGENE, V31, P173, DOI 10.1038/onc.2011.234; Sakamoto S, 1999, BIOCHEMISTRY-US, V38, P3355, DOI 10.1021/bi982099g; Sakamoto S, 2009, MOL CELL BIOL, V29, P3754, DOI 10.1128/MCB.01836-08; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shabman RS, 2011, J INFECT DIS, V204, pS911, DOI 10.1093/infdis/jir343; Shamanna RA, 2011, MOL CELL BIOL, V31, P4832, DOI 10.1128/MCB.05849-11; Shi LF, 2005, J BIOL CHEM, V280, P18981, DOI 10.1074/jbc.M411034200; Shi LF, 2007, J EXP MED, V204, P971, DOI 10.1084/jem.20052078; Shi LF, 2007, NUCLEIC ACIDS RES, V35, P2302, DOI 10.1093/nar/gkm117; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; Shin HJ, 2002, ARCH VIROL, V147, P471, DOI 10.1007/s007050200001; Shiohama A, 2007, EXP CELL RES, V313, P4196, DOI 10.1016/j.yexcr.2007.07.020; Smith NL, 2011, CELL PROLIFERAT, V44, P147, DOI 10.1111/j.1365-2184.2011.00742.x; Stricker RLO, 2010, J VIROL, V84, P10592, DOI 10.1128/JVI.02506-09; Suzuki K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/978312; Tan S, 2012, MOL PHARMACOL, V81, P701, DOI 10.1124/mol.111.076539; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Tommasino M, 2003, HUM MUTAT, V21, P307, DOI 10.1002/humu.10178; Tran H, 2004, MOL CELL, V13, P101, DOI 10.1016/S1097-2765(03)00481-7; Ulke-Lemee A, 2007, BBA-PROTEINS PROTEOM, V1774, P1339, DOI 10.1016/j.bbapap.2007.07.015; Urcuqui-Inchima S, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-83; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vumbaca F, 2008, MOL CELL BIOL, V28, P772, DOI 10.1128/MCB.02078-06; Wang P, 2009, J VIROL, V83, P7850, DOI 10.1128/JVI.00735-09; Wang XH, 2011, J VIROL, V85, P8080, DOI 10.1128/JVI.00670-11; WANG XW, 1995, CANCER RES, V55, P6012; Yan JP, 2010, J VIROL, V84, P76, DOI 10.1128/JVI.01647-09; Zheltukhin AO, 2010, BIOCHEMISTRY-MOSCOW+, V75, P1692, DOI 10.1134/S0006297910130110; Zhu P, 2010, J IMMUNOL, V185, P5140, DOI 10.4049/jimmunol.1000849; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	105	53	55	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2013	32	43					5176	5185		10.1038/onc.2012.533	http://dx.doi.org/10.1038/onc.2012.533			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240JY	23208500	Green Accepted			2022-12-17	WOS:000326093200005
J	Di, K; Linskey, ME; Bota, DA				Di, K.; Linskey, M. E.; Bota, D. A.			TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth	ONCOGENE			English	Article						TRIM11; oncogene; EGFR; malignant glioma; tumor formation	GLIOBLASTOMA STEM-CELLS; MALIGNANT GLIOMAS; PROGENITOR CELLS; EXPRESSION; CANCER; IDENTIFICATION; RECEPTOR; SYSTEM; NESTIN; GENE	TRIM11 (tripartite motif-containing protein 11), an E3 ubiquitin ligase, is known to be involved in the development of the central nervous system. However, very little is known regarding the role of TRIM11 in cancer biology. Here, we examined the expression profile of TRIM11, along with two stem cell markers CD133 and nestin, in multiple glioma patient specimens, glioma primary cultures derived from tumors taken at surgery and normal neural stem/progenitor cells (NSCs). The oncogenic function of TRIM11 in glioma biology was investigated by knockdown and/or overexpression in vitro and in vivo experiments. Our results showed that TRIM11 expression levels were upregulated in malignant glioma specimens and in high-grade glioma-derived primary cultures, whereas remaining low in glioblastoma multiforme (GBM) stable cell lines, low-grade glioma-derived primary cultures and NSCs. The expression pattern of TRIM11 strongly correlated with that of CD133 and nestin and differentiation status of malignant glioma cells. Knock down of TRIM11 inhibited proliferation, migration and invasion of GBM cells, significantly decreased epidermal growth factor receptor (EGFR) levels and mitogen-activated protein kinase activity, and downregulated HB-EGF (heparin-binding EGF-like growth factor) mRNA levels. Meanwhile, TRIM11 overexpression promoted a stem-like phenotype in vitro (tumorsphere formation) and enhanced glial tumor growth in immunocompromised mice. These findings suggest that TRIM11 might be an indicator of glioma malignancy and has an oncogenic function mediated through the EGFR signaling pathway. TRIM11 overexpression potentially leads to a more aggressive glioma phenotype, along with increased malignant tumor growth and poor survival. Taken together, clarification of the biological function of TRIM11 and pathways it affects may provide novel therapeutic strategies for treating malignant glioma patients.	[Di, K.; Linskey, M. E.; Bota, D. A.] UC Irvine Sch Med, Dept Neurol Surg, Orange, CA 92868 USA; [Linskey, M. E.; Bota, D. A.] UC Irvine Chao Family Comprehens Canc Ctr, Orange, CA USA; [Bota, D. A.] UC Irvine Sch Med, Dept Neurol, Orange, CA 92868 USA		Bota, DA (corresponding author), UC Irvine Sch Med, UC Irvine Med Ctr, 101 City Dr South,Shanbrom Hall,Suite 121, Orange, CA 92868 USA.	dbota@uci.edu		Bota, Daniela/0000-0002-9680-9060	Community Foundation of Jewish Federation; University of California, Irvine; UCI Cancer Center from the National Cancer Institute [P30CA062203]; NATIONAL CANCER INSTITUTE [P30CA062203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS072234] Funding Source: NIH RePORTER	Community Foundation of Jewish Federation; University of California, Irvine(University of California System); UCI Cancer Center from the National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Xing Gong for the preparation of glioma primary cultures, Dr Ronald C Kim for the neuropathological diagnosis of tumor samples and Dr Abhishek Chaturbedi for the organization of the tumor list used in the study. This work was supported by research funds donated by Ralph and Suzanne Stern and the Community Foundation of Jewish Federation. This study was also supported, in part, by start-up funds to DAB from the University of California, Irvine and the UCI Cancer Center Award Number P30CA062203 from the National Cancer Institute.	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; BIGNER SH, 1990, CANCER RES, V50, P8017; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Corn BW, 2009, J NEURO-ONCOL, V95, P247, DOI 10.1007/s11060-009-9923-3; Dey M, 2011, STEM CELL REV REP, V7, P119, DOI 10.1007/s12015-010-9132-7; Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872; FREDENS K, 1986, HISTOCHEMISTRY, V84, P247, DOI 10.1007/BF00495790; Gladson CL, 2010, ANNU REV PATHOL-MECH, V5, P33, DOI 10.1146/annurev-pathol-121808-102109; Gong X, 2011, NEUROLOGY, V76, P1126, DOI 10.1212/WNL.0b013e318212a89f; Griguer CE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003655; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Hong SJ, 2008, BIOCHEM BIOPH RES CO, V368, P650, DOI 10.1016/j.bbrc.2008.01.165; Ishikawa H, 2006, FEBS LETT, V580, P4784, DOI 10.1016/j.febslet.2006.07.066; Kordes C, 2007, BIOCHEM BIOPH RES CO, V352, P410, DOI 10.1016/j.bbrc.2006.11.029; Kurihara H, 2000, GENE THER, V7, P686, DOI 10.1038/sj.gt.3301129; Li ZZ, 2009, J BIOL CHEM, V284, P16705, DOI 10.1074/jbc.R900013200; Lim DA, 2007, NEURO-ONCOLOGY, V9, P424, DOI 10.1215/15228517-2007-023; Ma YH, 2008, J NEURO-ONCOL, V86, P31, DOI 10.1007/s11060-007-9439-7; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Mishima K, 1998, ACTA NEUROPATHOL, V96, P322, DOI 10.1007/s004010050901; Niikura T, 2003, EUR J NEUROSCI, V17, P1150, DOI 10.1046/j.1460-9568.2003.02553.x; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Pistollato F, 2009, STEM CELLS, V27, P7, DOI 10.1634/stemcells.2008-0402; Raab G, 1997, BBA-REV CANCER, V1333, pF179, DOI 10.1016/S0304-419X(97)00024-3; Rao RD, 2003, FRONT BIOSCI-LANDMRK, V8, pE270, DOI 10.2741/897; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmidinger M, 2003, J NEURO-ONCOL, V63, P55, DOI 10.1023/A:1023740303162; Schwartz PH, 2003, J NEUROSCI RES, V74, P838, DOI 10.1002/jnr.10854; Sherman JH, 2011, J NEUROSCI METH, V198, P99, DOI 10.1016/j.jneumeth.2011.03.003; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Suo ZH, 2002, INT J SURG PATHOL, V10, P91, DOI 10.1177/106689690201000202; Tarbe N, 2002, ANTICANCER RES, V22, P2015; Tuoc TC, 2008, GENE DEV, V22, P1972, DOI 10.1101/gad.471708; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; von Deimling A, 2011, BRAIN PATHOL, V21, P74, DOI 10.1111/j.1750-3639.2010.00454.x; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Zhang MY, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-85; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhou XD, 2009, J INT MED RES, V37, P503, DOI 10.1177/147323000903700226; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	46	53	56	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5038	5047		10.1038/onc.2012.531	http://dx.doi.org/10.1038/onc.2012.531			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23178488	Green Accepted, Green Submitted			2022-12-17	WOS:000325937900005
J	Deeraksa, A; Pan, J; Sha, Y; Liu, XD; Eissa, NT; Lin, SH; Yu-Lee, LY				Deeraksa, A.; Pan, J.; Sha, Y.; Liu, X-D; Eissa, N. T.; Lin, S-H; Yu-Lee, L-y			Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis	ONCOGENE			English	Article						Plk1; BI2536; mitotic catastrophe; necroptosis; autophagy; prostate cancer	POLO-LIKE KINASES; MITOTIC CATASTROPHE; DEATH PATHWAY; LNCAP MODEL; PHOSPHORYLATION; IDENTIFICATION; CYTOKINESIS; KINETOCHORE; PROGRESSION; INDUCTION	Castration-resistant prostate cancer (PCa) is refractory to hormone therapy and new strategies for treatment are urgently needed. We found that androgen-insensitive (AI) PCa cells, LNCaP-AI, are reprogrammed to upregulate the mitotic kinase Plk1 (Polo-like kinase 1) and other M-phase cell-cycle proteins, which may underlie AI PCa growth. In androgen-depleted media, LNCaP-AI cells showed exquisite sensitivity to growth inhibition by subnanomolar concentrations of a small molecule inhibitor of Plk1, BI2536, suggesting that these cells are dependent on Plk1 for growth. In contrast, the androgen-responsive parental LNCaP cells showed negligible responses to BI2536 treatment under the same condition. BI2536 treatment of LNCaP-AI cells resulted in an increase in cell death marker PARP-1 (polymerase-1) but did not activate caspase-3, an apoptosis marker, suggesting that the observed cell death was caspase-independent. BI2536-treated LNCaP-AI cells formed multinucleated giant cells that contain clusters of nuclear vesicles indicative of mitotic catastrophe. Live-cell time-lapse imaging revealed that BI2536-treated giant LNCaP-AI cells underwent necroptosis, as evidenced by 'explosive' cell death and partial reversal of cell death by a necroptosis inhibitor. Our studies suggest that LNCaP-AI cells underwent reprogramming in both their cell growth and cell death pathways, rendering them highly sensitive to Plk1 inhibition that induces necroptosis. Harnessing necroptosis through Plk1 inhibition may be explored for therapeutic intervention of castration-resistant PCa.	[Deeraksa, A.; Pan, J.; Yu-Lee, L-y] Dept Med, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Sha, Y.; Liu, X-D; Eissa, N. T.] Dept Med, Sect Pulm Crit Care & Sleep Med, Houston, TX 77030 USA; [Lin, S-H] UT Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX USA; [Yu-Lee, L-y] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Yu-Lee, LY (corresponding author), Dept Med, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA.	yulee@bcm.edu		Liu, xiande/0000-0002-9639-0458	NIH [T32-AI07495, T32-DK07696, HL080205, CA111479, DK53176, AI071130]; DOD [PC080847, PC093132]; Dan L Duncan Cancer Center; Alkek Award in Experimental Therapeutics; NATIONAL CANCER INSTITUTE [R01CA111479] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI071130, T32AI007495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053176, T32DK007696] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); Dan L Duncan Cancer Center; Alkek Award in Experimental Therapeutics; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Anna Ferrari of New York University for the LNCaP-AI cells and Ms Shenyan Zeng for FACS analysis. This work was supported by NIH training Grants T32-AI07495 and T32-DK07696 for AD and Grants from the NIH (HL080205 to NTE; CA111479 to S-HL; DK53176, AI071130 to L-yY-L), DOD (PC080847, PC093132 to S-HL), Dan L Duncan Cancer Center (L-yY-L and S-HL) and Alkek Award in Experimental Therapeutics (L-yY-L and S-HL).	Alano CC, 2006, TRENDS BIOCHEM SCI, V31, P309, DOI 10.1016/j.tibs.2006.04.006; Artus C, 2010, EMBO J, V29, P1585, DOI 10.1038/emboj.2010.43; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bastos RN, 2010, J CELL BIOL, V191, P751, DOI 10.1083/jcb.201008108; Brennan IM, 2007, P NATL ACAD SCI USA, V91, P5046; Caserta TM, 2003, VIROLOGY, V191, P589; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Guan R, 2005, CANCER RES, V65, P2698, DOI 10.1158/0008-5472.CAN-04-2131; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kurasawa Y, 2010, MOL BIOL CELL, V21, P1188, DOI 10.1091/mbc.E09-11-0950; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lenart P, 2007, CURR BIOL, V17, P1; Li J, 2010, J GENET GENOMICS, V37, P159, DOI 10.1016/S1673-8527(09)60034-5; Liu XS, 2010, PROTEIN CELL, V1, P999, DOI 10.1007/s13238-010-0131-x; Macy B, 2009, CELL CYCLE, V8, P35, DOI 10.4161/cc.8.1.7327; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nishino M, 2006, CURR BIOL, V16, P1414, DOI 10.1016/j.cub.2006.05.052; Park JE, 2011, P NATL ACAD SCI USA, V108, P8200, DOI 10.1073/pnas.1102020108; Reagan-Shaw S, 2005, FASEB J, V19, P611, DOI 10.1096/fj.04-2910fje; Schmit TL, 2009, J INVEST DERMATOL, V129, P2843, DOI 10.1038/jid.2009.172; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Speirs CK, 2011, AM J CANCER RES, V1, P43; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Takaki T, 2008, CURR OPIN CELL BIOL, V20, P650, DOI 10.1016/j.ceb.2008.10.005; THALMANN GN, 1994, CANCER RES, V54, P2577; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Wang LG, 2004, ONCOGENE, V23, P5175, DOI 10.1038/sj.onc.1207654; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	41	53	59	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2973	2983		10.1038/onc.2012.309	http://dx.doi.org/10.1038/onc.2012.309			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22890325	Green Accepted			2022-12-17	WOS:000320369700007
J	Zheng, HX; Cai, YD; Wang, YD; Cui, XB; Xie, TT; Li, WJ; Peng, L; Zhang, Y; Wang, ZQ; Wang, J; Jiang, B				Zheng, H. X.; Cai, Y. D.; Wang, Y. D.; Cui, X. B.; Xie, T. T.; Li, W. J.; Peng, L.; Zhang, Y.; Wang, Z. Q.; Wang, J.; Jiang, B.			Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer	ONCOGENE			English	Article						Fas signaling; metastasis; motility; epithelial-mesenchymal transition	COLORECTAL CANCER.; TUMOR PROGRESSION; GLIOMA-CELLS; CD95; EXPRESSION; COLON; MECHANISMS; CARCINOMA; RESECTION; SURVIVAL	Fas signaling was reported to participate in cell apoptosis. However, this pathway has also been shown to promote tumor cell motility, leading to the hypothesis that Fas signaling may induce epithelial mesenchymal transition (EMT) to promote metastasis. The effects of Fas-ligand (FasL) treatment and inhibition of Fas signaling on colorectal and gastric cancer cells were tested using motility assay, immunofluorescence, RT-PCR and immunoblot analyses. Fas signaling downregulated epithelial markers, upregulated mesenchymal markers and promoted motility in gastrointestinal (GI) cancer cells. FasL treatment also increased the expression of EMT transcriptional factors in the nucleus and induced a spindle shape cell morphology in these cells. Knockdown of Snail or Twist expression significantly decreased FasL-induced motility. The ERK1/2 pathway was activated by Fas signaling and is required for FasL-induced EMT and motility. Moreover, oxaliplatin, a chemotherapeutic agent, induced EMT partly through Fas signaling. Evaluation of human GI clinical specimens showed that FasL expression increased whereas E-cadherin expression decreased during GI cancer progression. Both markers were significantly inversely correlated. Tissue samples with a non-EMT phenotype were mainly distributed in patients with early cancer stages, whereas samples with an EMT phenotype were mostly distributed in patients with advanced cancer stages. A non-EMT phenotype significantly correlated with better prognosis. Altogether, these data indicate that Fas signaling may induce EMT to promote tumor motility and metastasis in GI cancer in vivo and in vitro. Oncogene (2013) 32, 1183-1192; doi:0.1038/onc.2012.126; published online 16 April 2012	[Zheng, H. X.; Cai, Y. D.; Wang, Y. D.; Cui, X. B.; Xie, T. T.; Li, W. J.; Peng, L.; Zhang, Y.; Wang, Z. Q.; Wang, J.; Jiang, B.] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China; [Cai, Y. D.] China Acad Chinese Med Sci, Xiyuan Hosp, Dept Gastroenterol, Beijing, Peoples R China; [Peng, L.] Mt Sinai Sch Med, Dept Med, Inst Immunol, New York, NY USA; [Zhang, Y.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Wang, Z. Q.] Mt Sinai Sch Med, Dept Pathol, New York, NY USA	Southern Medical University - China; China Academy of Chinese Medical Sciences; Xiyuan Hospital, CACMS; Icahn School of Medicine at Mount Sinai; Harvard University; Dana-Farber Cancer Institute; Icahn School of Medicine at Mount Sinai	Jiang, B (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guanzhoudabaobei 1838, Guangzhou 510515, Guangdong, Peoples R China.	prof.jiang@yahoo.com.cn	Cui, XiaoBing/K-8159-2012	Cui, XiaoBing/0000-0002-5460-0357	Science and Technology Project of Guangzhou [2009Z1-E051]; Nanfang Hospital President Foundation [2011C015]	Science and Technology Project of Guangzhou; Nanfang Hospital President Foundation	This study was supported by Science and Technology Project of Guangzhou (2009Z1-E051) and Nanfang Hospital President Foundation(2011C015).	Adam R, 2004, ANN SURG, V240, P1052, DOI 10.1097/01.sla.0000145964.08365.01; Ametller E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-161; Barnhart BC, 2004, EMBO J, V23, P3175, DOI 10.1038/sj.emboj.7600325; Chen L, 2010, NATURE, V465, P492, DOI 10.1038/nature09075; Choi C, 2001, CANCER RES, V61, P3084; Curtin JF, 2003, CELL SIGNAL, V15, P983, DOI 10.1016/S0898-6568(03)00093-7; Desbarats J, 2000, NAT MED, V6, P920, DOI 10.1038/78688; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; GRIFFIN MR, 1987, CANCER-AM CANCER SOC, V60, P2318, DOI 10.1002/1097-0142(19871101)60:9<2318::AID-CNCR2820600934>3.0.CO;2-B; Higgs HN, 2005, MOL BIOL CELL, V16, P1, DOI 10.1091/mbc.E04-07-0565; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kleber S, 2008, CANCER CELL, V13, P235, DOI 10.1016/j.ccr.2008.02.003; Lavrik IN, 2007, J BIOL CHEM, V282, P13664, DOI 10.1074/jbc.M700434200; Li HC, 2008, AM J PHYSIOL-GASTR L, V294, pG263, DOI 10.1152/ajpgi.00267.2007; Li HC, 2011, GASTROENTEROLOGY, V140, pS162; Li HC, 2009, GASTROENTEROLOGY, V137, P934, DOI 10.1053/j.gastro.2009.06.004; Medici D, 2006, MOL BIOL CELL, V17, P1871, DOI 10.1091/mbc.E05-08-0767; Mitsiades N, 2001, CANCER RES, V61, P577; O'Brien DI, 2005, EXPERT OPIN THER TAR, V9, P1031, DOI 10.1517/14728222.9.5.1031; Park DR, 2003, J IMMUNOL, V170, P6209, DOI 10.4049/jimmunol.170.12.6209; Pryczynicz A, 2010, FOLIA HISTOCHEM CYTO, V48, P425, DOI 10.2478/v10042-010-0058-3; Przybylo JA, 2007, INT J BIOCHEM CELL B, V39, P1082, DOI 10.1016/j.biocel.2007.03.002; Shinohara H, 2000, CANCER RES, V60, P1766; Soumaoro LT, 2004, CLIN CANCER RES, V10, P8465, DOI 10.1158/1078-0432.CCR-04-0653; Tsanou E, 2008, ANTICANCER RES, V28, P3815; Turley EA, 2008, NAT CLIN PRACT ONCOL, V5, P280, DOI 10.1038/ncponc1089; Wang J, 2009, J HISTOCHEM CYTOCHEM, V57, P363, DOI 10.1369/jhc.2008.953091; Yan W, 2009, BIOCHEM BIOPH RES CO, V382, P631, DOI 10.1016/j.bbrc.2009.03.088; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Zhu Q, 2006, EUR J GASTROEN HEPAT, V18, P1071, DOI 10.1097/01.meg.0000231750.68513.6c	33	53	53	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1183	1192		10.1038/onc.2012.126	http://dx.doi.org/10.1038/onc.2012.126			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22508480	Bronze			2022-12-17	WOS:000316428800012
J	Wang, Y; Moncayo, G; Morin, P; Xue, G; Grzmil, M; Lino, MM; Clement-Schatlo, V; Frank, S; Merlo, A; Hemmings, BA				Wang, Y.; Moncayo, G.; Morin, P., Jr.; Xue, G.; Grzmil, M.; Lino, M. M.; Clement-Schatlo, V.; Frank, S.; Merlo, A.; Hemmings, B. A.			Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme	ONCOGENE			English	Article						glioblastoma multiforme (GBM); MerTK; invasiveness; apoptosis; actomyosin contractility	STEM-LIKE CELLS; MYOSIN-II; SIGNALING PATHWAY; APOPTOTIC CELLS; GLIOMA INVASION; NDR KINASE; C-MER; CANCER; IDENTIFICATION; EXPRESSION	The infiltration of glioma cells into adjacent tissue is one of the major obstacles in the therapeutic management of malignant brain tumours, in most cases precluding complete surgical resection. Consequently, malignant glioma patients almost invariably experience tumour recurrences. Within the brain, glioma cells migrate rapidly either amoeboidly or mesenchymally to invade surrounding structures, in dependence on the extracellular environment. In addition, radiotherapy, frequently applied as adjuvant therapeutic modality, may enhance tumour cell mobility. Here, we show that the receptor tyrosine kinase Mer (MerTK) is overexpressed in glioblastoma multiforme (GBM) and that this is accompanied with increased invasive potential. MerTK expression is maintained in primary GBM-derived tumour spheres under stem cell culture conditions but diminishes significantly in serum-containing cultures with concomitant downregulation of Nestin and Sox2. Depletion of MerTK disrupts the rounded morphology of glioma cells and decreases their invasive capacity. Furthermore, the expression and phosphorylation of myosin light chain 2 are strongly associated with MerTK activity, indicating that the effect of MerTK on glionna cell invasion is mediated by actomyosin contractility. Finally, DNA damage robustly triggers the upregulation and phosphorylation of MerTK, which protects cells from apoptosis. This effect is strongly impaired upon MerTK depletion or overexpression of an inactive MerTK mutant. Collectively, our data suggests that MerTK is a novel therapeutic target in the treatment of the malignant gliomas. Oncogene (2013) 32, 872-882; doi:10.1038/onc.2012.104; published online 2 April 2012	[Wang, Y.; Moncayo, G.; Morin, P., Jr.; Xue, G.; Grzmil, M.; Hemmings, B. A.] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; [Lino, M. M.; Merlo, A.] Univ Basel, Dept Res & Surg, Mol Neurooncol Lab, Basel, Switzerland; [Clement-Schatlo, V.] Univ Hosp Geneva, Dept Clin Neurosci, Div Neurosurg, Geneva, Switzerland; [Clement-Schatlo, V.] Univ Geneva, Geneva, Switzerland; [Frank, S.] Univ Basel, Dept Neuropathol, Inst Pathol, Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; University of Basel; University of Geneva; University of Geneva; University of Basel	Hemmings, BA (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	brian.hemmings@fmi.ch		Grzmil, Michal/0000-0002-7866-8145	Oncosuisse CCRP Grant [KFP OCS-01613-12-2004]; Swiss National Science Foundation [SNF 31003A_130838]	Oncosuisse CCRP Grant; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	We thank Sandrine Bichet and Hubertus Kohler for helping with immunohistochemistry and FACS experiments, respectively, Susanne Schenk for the generation of the MerTK monoclonal antibody, Douglass Vollrath for the pcDNA3.1(-)-MerTK construct, Janis Liebetanz and Doriano Fabbro for the GST-hMerTK (amino acids 536-999) construct and Patrick King for editing the manuscript. This research was funded by Oncosuisse CCRP Grant KFP OCS-01613-12-2004. G Xue is supported by the Swiss National Science Foundation SNF 31003A_130838. The FMI is part of the Novartis Research Foundation.	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Beadle C, 2008, MOL BIOL CELL, V19, P3357, DOI 10.1091/mbc.E08-03-0319; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Clement V, 2010, NAT METHODS, V7, P224, DOI [10.1038/nmeth.1430, 10.1038/NMETH.1430]; Cohen PL, 2002, J EXP MED, V196, P135, DOI 10.1084/jem.20012094; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Duncan JL, 2003, ADV EXP MED BIOL, V533, P165; Ek S, 2002, CANCER RES, V62, P4398; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Graham DK, 2006, CLIN CANCER RES, V12, P2662, DOI 10.1158/1078-0432.CCR-05-2208; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; Grzmil M, 2011, CANCER RES, V71, P2392, DOI 10.1158/0008-5472.CAN-10-3112; Gunther HS, 2008, ONCOGENE, V27, P2897, DOI 10.1038/sj.onc.1210949; Guttridge KL, 2002, J BIOL CHEM, V277, P24057, DOI 10.1074/jbc.M112086200; Gyorffy B, 2007, J INVEST DERMATOL, V127, P394, DOI 10.1038/sj.jid.5700543; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hambardzumyan D, 2006, CANCER CELL, V10, P454, DOI 10.1016/j.ccr.2006.11.008; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hergovich A, 2007, MOL CELL, V25, P625, DOI 10.1016/j.molcel.2007.01.020; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Keating AK, 2010, MOL CANCER THER, V9, P1298, DOI 10.1158/1535-7163.MCT-09-0707; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Ling L, 1996, J BIOL CHEM, V271, P18355, DOI 10.1074/jbc.271.31.18355; LING L, 1995, MOL CELL BIOL, V15, P6582; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; McCord AM, 2009, CLIN CANCER RES, V15, P5145, DOI 10.1158/1078-0432.CCR-09-0263; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Nakada M, 2007, CELL MOL LIFE SCI, V64, P458, DOI 10.1007/s00018-007-6342-5; Pankova K, 2010, CELL MOL LIFE SCI, V67, P63, DOI 10.1007/s00018-009-0132-1; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Rao JY, 2004, CURR CANCER DRUG TAR, V4, P345, DOI 10.2174/1568009043332998; Rogers AEJ, 2012, ONCOGENE, V31, P4171, DOI 10.1038/onc.2011.588; Ropolo M, 2009, MOL CANCER RES, V7, P383, DOI 10.1158/1541-7786.MCR-08-0409; Sather S, 2007, BLOOD, V109, P1026, DOI 10.1182/blood-2006-05-021634; Strick DJ, 2009, INVEST OPHTH VIS SCI, V50, P2427, DOI 10.1167/iovs.08-3058; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vichalkovski A, 2008, CURR BIOL, V18, P1889, DOI 10.1016/j.cub.2008.10.060; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632; Wu YM, 2004, CANCER RES, V64, P7311, DOI 10.1158/0008-5472.CAN-04-0972; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Zhai GG, 2006, J NEURO-ONCOL, V76, P227, DOI 10.1007/s11060-005-6499-4; Zhang M, 2005, INVEST OPHTH VIS SCI, V46, P4130, DOI 10.1167/iovs.05-0164	49	53	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2013	32	7					872	882		10.1038/onc.2012.104	http://dx.doi.org/10.1038/onc.2012.104			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22469987	hybrid			2022-12-17	WOS:000316581100007
J	Yuan, W; Stawiski, E; Janakiraman, V; Chan, E; Durinck, S; Edgar, KA; Kljavin, NM; Rivers, CS; Gnad, F; Roose-Girma, M; Haverty, PM; Fedorowicz, G; Heldens, S; Soriano, RH; Zhang, Z; Wallin, JJ; Johnson, L; Merchant, M; Modrusan, Z; Stern, HM; Seshagiri, S				Yuan, W.; Stawiski, E.; Janakiraman, V.; Chan, E.; Durinck, S.; Edgar, K. A.; Kljavin, N. M.; Rivers, C. S.; Gnad, F.; Roose-Girma, M.; Haverty, P. M.; Fedorowicz, G.; Heldens, S.; Soriano, R. H.; Zhang, Z.; Wallin, J. J.; Johnson, L.; Merchant, M.; Modrusan, Z.; Stern, H. M.; Seshagiri, S.			Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations	ONCOGENE			English	Article						Pik3ca; H1047R; knock-in; mammary gland; Trp53; exome sequencing	TO-MESENCHYMAL TRANSITION; BREAST-CANCER; HIGH-FREQUENCY; PIK3CA GENE; PI3K; EXPRESSION; MICE; P110-ALPHA; INHIBITION; CARCINOMA	Oncogenic mutations in PIK3CA, which encodes the phosphoinositide-3-kinase (PI3K) catalytic subunit p110 alpha, occur in similar to 25% of human breast cancers. In this study, we report the development of a knock-in mouse model for breast cancer where the endogenous Pik3ca allele was modified to allow tissue-specific conditional expression of a frequently found Pik3ca(H1047R) (pik3ca(e20H1047R)) mutant allele. We found that activation of the latent Pik3ca(H1047R) allele resulted in breast tumors with multiple histological types. Whole-exome analysis of the Pik3ca(H1047R)-driven mammary tumors identified multiple mutations, including Trp53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors. Further, we used this model to test the efficacy of GDC-0941, a PI3K inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition. Oncogene (2013) 32, 318-326; doi:10.1038/onc.2012.53; published online 27 February 2012	[Yuan, W.; Stawiski, E.; Janakiraman, V.; Durinck, S.; Kljavin, N. M.; Rivers, C. S.; Roose-Girma, M.; Fedorowicz, G.; Heldens, S.; Soriano, R. H.; Johnson, L.; Modrusan, Z.; Seshagiri, S.] Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; [Chan, E.; Merchant, M.] Genentech Inc, Dept Translat Oncol, San Francisco, CA 94080 USA; [Edgar, K. A.; Wallin, J. J.] Genentech Inc, Dept Canc Signaling, San Francisco, CA 94080 USA; [Gnad, F.; Haverty, P. M.; Zhang, Z.] Genentech Inc, Dept Bioinformat & Computat Biol, San Francisco, CA 94080 USA; [Stern, H. M.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Seshagiri, S (corresponding author), Genentech Inc, Dept Mol Biol, 1 DNA Way, San Francisco, CA 94080 USA.	sekar@gene.com		Wallin, Jeffrey/0000-0002-5952-3813; Gnad, Florian/0000-0002-2287-2251; Seshagiri, Somasekar/0000-0003-4272-6443; Merchant, Mark/0000-0003-0690-8581				Adams JR, 2011, CANCER RES, V71, P2706, DOI 10.1158/0008-5472.CAN-10-0738; Amikura T, 2006, GYNECOL ONCOL, V100, P365, DOI 10.1016/j.ygyno.2005.09.010; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Boyault S, 2012, BREAST CANCER RES TR, V132, P29, DOI 10.1007/s10549-011-1518-y; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carter MR, 2006, AM J SURG PATHOL, V30, P300; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Fishler T, 2010, ONCOGENE, V29, P4007, DOI 10.1038/onc.2010.163; Folkes A, 2007, PCT Int Appl, P206, Patent No. [WO 2007127175 A2 20071108, 2007127175]; Grochova D, 2008, ONCOGENE, V27, P1243, DOI 10.1038/sj.onc.1210748; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Horn S, 2008, ONCOGENE, V27, P4096, DOI 10.1038/onc.2008.40; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Hynes NE, 2009, CANCER CELL, V15, P353, DOI 10.1016/j.ccr.2009.04.004; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Khan HN, 2003, EUR J SURG ONCOL, V29, P600, DOI 10.1016/S0748-7983(03)00107-0; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Li G, 2002, DEVELOPMENT, V129, P4159; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Meyer DS, 2011, CANCER RES, V71, P4344, DOI 10.1158/0008-5472.CAN-10-3827; Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Pinheiro J, 2008, R PACKAGE VERSION, V57, P1; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Salphati L, 2010, DRUG METAB DISPOS, V38, P1436, DOI 10.1124/dmd.110.032912; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Singh M, 2010, NAT BIOTECHNOL, V28, P585, DOI 10.1038/nbt.1640; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Stephens P, 2005, NAT GENET, V37, P590, DOI 10.1038/ng1571; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tiede B, 2011, CELL RES, V21, P245, DOI 10.1038/cr.2011.11; Tuveson D, 2011, NATURE, V471, P316, DOI 10.1038/471316a; Ullman-Cullere MH, 1999, LAB ANIM SCI, V49, P319; Vanhaesebroeck B, 2005, TRENDS BIOCHEM SCI, V30, P194, DOI 10.1016/j.tibs.2005.02.008; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Walrath JC, 2010, ADV CANCER RES, V106, P113, DOI 10.1016/S0065-230X(10)06004-5; Weigelt B, 2009, NAT REV CLIN ONCOL, V6, P718, DOI 10.1038/nrclinonc.2009.166; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105	53	53	53	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					318	326		10.1038/onc.2012.53	http://dx.doi.org/10.1038/onc.2012.53			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22370636	Green Published, hybrid			2022-12-17	WOS:000314736600006
J	Fassl, A; Tagscherer, KE; Richter, J; Diaz, MB; Llaguno, SRA; Campos, B; Kopitz, J; Herold-Mende, C; Herzig, S; Schmidt, MHH; Parada, LF; Wiestler, OD; Roth, W				Fassl, A.; Tagscherer, K. E.; Richter, J.; Diaz, M. Berriel; Llaguno, S. R. Alcantara; Campos, B.; Kopitz, J.; Herold-Mende, C.; Herzig, S.; Schmidt, M. H. H.; Parada, L. F.; Wiestler, O. D.; Roth, W.			Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1	ONCOGENE			English	Article						glioblastoma; apoptosis; Notch1; Mcl-1; EGFR	GROWTH-FACTOR RECEPTOR; NEURAL STEM-CELLS; MALIGNANT GLIOMA; BRAIN-TUMORS; EXPRESSION; PATHWAY; ACTIVATION; ORIGIN; BCL-2; P53	The Notch1-mediated signaling pathway has a central role in the maintenance of neural stem cells and contributes to growth and progression of glioblastomas, the most frequent malignant brain tumors in adults. Here, we demonstrate that the Notch1 receptor promotes survival of glioblastoma cells by regulation of the anti-apoptotic Mcl-1 protein. Notch1-dependent regulation of Mcl-1 occurs cell type dependent at a transcriptional or post-translational level and is mediated by the induction of epidermal growth factor receptor (EGFR). Inhibition of the Notch1 pathway overcomes apoptosis resistance and sensitizes glioblastoma cells to apoptosis induced by ionizing radiation, the death ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) or the Bcl-2/Bcl-XL inhibitor ABT-737. In conclusion, targeting Notch1 might represent a promising novel strategy in the treatment of glioblastomas.	[Diaz, M. Berriel; Herzig, S.] Univ Heidelberg, Ctr Mol Biol, DKFZ, Joint Div Mol Metab Control, D-6900 Heidelberg, Germany; [Diaz, M. Berriel; Herzig, S.] Univ Heidelberg Hosp, Heidelberg, Germany; [Llaguno, S. R. Alcantara; Parada, L. F.] Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA; [Campos, B.; Herold-Mende, C.] Univ Heidelberg, Dept Neurosurg, Heidelberg, Germany; [Kopitz, J.; Roth, W.] Univ Heidelberg, Inst Pathol, D-6900 Heidelberg, Germany; [Schmidt, M. H. H.] Goethe Univ Frankfurt, Inst Neurol, Frankfurt, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Texas System; University of Texas Southwestern Medical Center Dallas; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Goethe University Frankfurt	Roth, W (corresponding author), German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	W.Roth@dkfz.de	Tagscherer, Katrin/AAS-3809-2021; Parada, luis F/B-9400-2014; Schmidt, Mirko H. H./ABI-6650-2020; Fassl, Anne/AAA-5249-2022; Diaz, Mauricio Berriel/AAF-8285-2021	Tagscherer, Katrin/0000-0002-0657-6399; Schmidt, Mirko H. H./0000-0001-7411-8835; Berriel Diaz, Mauricio/0000-0003-4670-919X; Herzig, Stephan/0000-0003-3950-3652; Alcantara, Sheila/0000-0002-1586-4384	Deutsche Krebshilfe (German Cancer Aid)	Deutsche Krebshilfe (German Cancer Aid)(Deutsche Krebshilfe)	We thank Tabea Sinkovic and Martina Keith for technical assistance. We further thank Anja Reimann (Molecular Metabolic Control, DKFZ, Heidelberg, Germany) for help with purification of recombinant adenoviruses, David Capper, David Reuss and Andreas v Deimling (Department of Neuropathology, University of Heidelberg, Germany) for providing histological sections of glioblastomas and Tamara Quandel, Lodovica Borghese, Philipp Koch and Oliver Brustle (Institute of Reconstructive Neurobiology, Life and Brain, Bonn, Germany) for providing cell pellets and RNA from neural stem cells. This work was supported by a grant from the Deutsche Krebshilfe to WR (German Cancer Aid, Max Eder Program).	Arbour N, 2008, J NEUROSCI, V28, P6068, DOI 10.1523/JNEUROSCI.4940-07.2008; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baumgart A, 2010, CANCER RES, V70, P5368, DOI 10.1158/0008-5472.CAN-09-3763; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Campos B, 2010, CLIN CANCER RES, V16, P2715, DOI 10.1158/1078-0432.CCR-09-1800; Capper D, 2009, ACTA NEUROPATHOL, V117, P445, DOI 10.1007/s00401-009-0494-3; Chen J, 2010, RADIAT PROT DOSIM, V142, P1, DOI 10.1093/rpd/ncq205; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Henson ES, 2003, J CELL BIOCHEM, V89, P1177, DOI 10.1002/jcb.10597; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Kanamori M, 2007, J NEUROSURG, V106, P417, DOI 10.3171/jns.2007.106.3.417; Karcher S, 2006, INT J CANCER, V118, P2182, DOI 10.1002/ijc.21648; Koch P, 2009, P NATL ACAD SCI USA, V106, P3225, DOI 10.1073/pnas.0808387106; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Krajewski S, 1997, AM J PATHOL, V150, P805; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Liu WH, 2007, EMBO J, V26, P1660, DOI 10.1038/sj.emboj.7601611; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Masuoka HC, 2009, J BIOL CHEM, V284, P30039, DOI 10.1074/jbc.M109.039545; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Mungamuri SK, 2006, CANCER RES, V66, P4715, DOI 10.1158/0008-5472.CAN-05-3830; Oishi K, 2004, DEV BIOL, V276, P172, DOI 10.1016/j.ydbio.2004.08.039; Opferman JT, 2006, CELL DEATH DIFFER, V13, P1260, DOI 10.1038/sj.cdd.4401978; Pierfelice TJ, 2008, COLD SH Q B, V73, P367, DOI 10.1101/sqb.2008.73.013; Purow BW, 2008, CARCINOGENESIS, V29, P918, DOI 10.1093/carcin/bgn079; Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Schmidt MHH, 2009, NAT CELL BIOL, V11, P873, DOI 10.1038/ncb1896; Schultz A, 2003, CELL DEATH DIFFER, V10, P662, DOI 10.1038/sj.cdd.4401235; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Sheng Z, 2010, NAT MED, V16, P671, DOI 10.1038/nm.2158; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tagscherer KE, 2008, ONCOGENE, V27, P6646, DOI 10.1038/onc.2008.259; Thomas LW, 2010, FEBS LETT, V584, P2981, DOI 10.1016/j.febslet.2010.05.061; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; van Tetering G, 2009, J BIOL CHEM, V284, P31018, DOI 10.1074/jbc.M109.006775; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Xu P, 2010, J NEURO-ONCOL, V97, P41, DOI 10.1007/s11060-009-0007-1; Yoon JH, 2002, CANCER RES, V62, P6500; Zhang XP, 2008, MOL CELL BIOCHEM, V307, P101, DOI 10.1007/s11010-007-9589-0; Zhu Y, 2005, CANCER CELL, V8, P119, DOI 10.1016/j.ccr.2005.07.004	50	53	55	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	44					4698	4708		10.1038/onc.2011.615	http://dx.doi.org/10.1038/onc.2011.615			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22249262				2022-12-17	WOS:000310724400005
J	Sahraei, M; Roy, LD; Curry, JM; Teresa, TL; Nath, S; Besmer, D; Kidiyoor, A; Dalia, R; Gendler, SJ; Mukherjee, P				Sahraei, M.; Roy, L. D.; Curry, J. M.; Teresa, T. L.; Nath, S.; Besmer, D.; Kidiyoor, A.; Dalia, R.; Gendler, S. J.; Mukherjee, P.			MUC1 regulates PDGFA expression during pancreatic cancer progression	ONCOGENE			English	Article						pancreatic cancer; MUC1; PDGFA; beta-catenin	GROWTH-FACTOR RECEPTOR; CELL-SURFACE; SIGNAL-TRANSDUCTION; TUMOR PROGRESSION; CYTOPLASMIC TAIL; RANDOMIZED-TRIAL; MOUSE MODEL; MUCINS; ADENOCARCINOMA; CARCINOMA	Pancreatic ductal adenocarcinoma (PDA) has one of the worst prognoses of all cancers. Mucin 1 (MUC1), a transmembrane mucin glycoprotein, is a key modulator of several signaling pathways that affect oncogenesis, motility and metastasis. Its expression is known to be associated with poor prognosis in patients. However, the precise mechanism remains elusive. We report a novel association of MUC1 with platelet-derived growth factor-A (PDGFA). PDGFA is one of the many drivers of tumor growth, angiogenesis and metastasis in PDA. Using mouse PDA models as well as human samples, we show clear evidence that MUC1 regulates the expression and secretion of PDGFA. This, in turn, influences proliferation and invasion of pancreatic cancer cells leading to higher tumor burden in vivo. In addition, we reveal that MUC1 overexpressing cells are heavily dependent on PDGFA both for proliferation and invasion, whereas MUC1-null cells are not. Moreover, PDGFA and MUC1 are critical for translocation of beta catenin to the nucleus for oncogenesis to ensue. Finally, we elucidate the underlying mechanism by which MUC1 regulates PDGFA expression and secretion in pancreatic cancer cells. We show that MUC1 associates with Hif1-alpha, a known transcription factor involved in controlling PDGFA expression. Furthermore, MUC1 facilitates Hif1-alpha translocation to the nucleus. In summary, we have demonstrated that MUC1-induced invasion and proliferation occurs via increased exogenous production of PDGFA. Thus, impeding MUC1 regulation of PDGFA signaling may be therapeutically beneficial for patients with PDA.	[Sahraei, M.; Roy, L. D.; Curry, J. M.; Teresa, T. L.; Nath, S.; Besmer, D.; Kidiyoor, A.; Dalia, R.; Mukherjee, P.] Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA; [Gendler, S. J.] Mayo Clin, Ctr Canc, Dept Biochem & Mol Biol, Scottsdale, AZ USA	University of North Carolina; University of North Carolina Charlotte; Mayo Clinic; Mayo Clinic Phoenix	Mukherjee, P (corresponding author), Univ N Carolina, Dept Biol, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	pmukherj@uncc.edu	Nath, Sritama/J-7725-2019		NIH;  [RO1 CA118944];  [P50CA102701]; NATIONAL CANCER INSTITUTE [P50CA102701, R01CA118944] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Drs Mukherjee's and Gendler's work has been funded by the NIH. The remaining authors declare no conflict of interest.; We acknowledge the Mayo Clinic Histology Core and the UNC-Charlotte vivarium staff for maintaining our mouse colonies. This study is supported by RO1 CA118944 and P50CA102701.	Adsay NV, 2005, SEMIN RADIAT ONCOL, V15, P254, DOI 10.1016/j.semradonc.2005.04.001; Adsay NV, 2002, MODERN PATHOL, V15, P1087, DOI 10.1097/01.MP.0000028647.98725.8B; Al Masri A, 2005, ONCOGENE, V24, P5799, DOI 10.1038/sj.onc.1208738; Al-Batran SE, 2007, CANCER, V109, P1897, DOI 10.1002/cncr.22622; Appelmann I, 2010, RECENT RESULTS CANC, V180, P51, DOI 10.1007/978-3-540-78281-0_5; Baldus SE, 1998, CANCER, V82, P1019, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1019::AID-CNCR3>3.0.CO;2-9; Behrens ME, 2010, ONCOGENE, V29, P5667, DOI 10.1038/onc.2010.327; Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Carson DD, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127pe35; Castaneda CA, 2010, CANCER METAST REV, V29, P751, DOI 10.1007/s10555-010-9261-0; Chhieng DC, 2003, CANCER CYTOPATHOL, V99, P365, DOI 10.1002/cncr.11857; Fischer ANM, 2007, ONCOGENE, V26, P3395, DOI 10.1038/sj.onc.1210121; Fujimoto K, 1998, EUR J CANCER, V34, P1439, DOI 10.1016/S0959-8049(98)00069-0; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Hellberg C, 2010, RECENT RESULTS CANC, V180, P103, DOI 10.1007/978-3-540-78281-0_7; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hoffmann AC, 2008, NEOPLASIA, V10, P674, DOI 10.1593/neo.08292; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hwang RF, 2003, CLIN CANCER RES, V9, P6534; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; LAN MS, 1990, CANCER RES, V50, P2997; Levi E, 2004, J CLIN PATHOL, V57, P456, DOI 10.1136/jcp.2003.013292; Mantur Maria, 2008, Pol Merkur Lekarski, V24, P173; Moniaux N, 2004, BRIT J CANCER, V91, P1633, DOI 10.1038/sj.bjc.6602163; Moon SW, 2009, BIOCHEM BIOPH RES CO, V388, P167, DOI 10.1016/j.bbrc.2009.07.144; Mukherjee P, 2009, J IMMUNOL, V182, P216, DOI 10.4049/jimmunol.182.1.216; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Reiser-Erkan C, 2008, CANCER BIOL THER, V7, P1352, DOI 10.4161/cbt.7.9.6418; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016/S1072-7515(99)00075-7; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh PK, 2008, J BIOL CHEM, V283, P26985, DOI 10.1074/jbc.M805036200; Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Society AC, 2010, AM CANC SOC CANC FAC; SPICER AP, 1995, J BIOL CHEM, V270, P30093; Szajda SD, 2011, BIOCHEM SOC T, V39, P340, DOI 10.1042/BST0390340; Thompson EJ, 2006, MOL CANCER RES, V4, P489, DOI 10.1158/1541-7786.MCR-06-0038; Tinder TL, 2008, J IMMUNOL, V181, P3116, DOI 10.4049/jimmunol.181.5.3116; Wang CC, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.4	44	53	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	47					4935	4945		10.1038/onc.2011.651	http://dx.doi.org/10.1038/onc.2011.651			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041VU	22266848	Green Accepted			2022-12-17	WOS:000311430200005
J	Rygiel, TP; Karnam, G; Goverse, G; van der Marel, APJ; Greuter, MJ; van Schaarenburg, RA; Visser, WF; Brenkman, AB; Molenaar, R; Hoek, RM; Mebius, RE; Meyaard, L				Rygiel, T. P.; Karnam, G.; Goverse, G.; van der Marel, A. P. J.; Greuter, M. J.; van Schaarenburg, R. A.; Visser, W. F.; Brenkman, A. B.; Molenaar, R.; Hoek, R. M.; Mebius, R. E.; Meyaard, L.			CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor	ONCOGENE			English	Article						CD200R; immune regulation; anti-tumor responses; skin carcinogenesis; inhibitory receptors	REGULATORY T-CELLS; PROGNOSTIC-FACTOR; DENDRITIC CELLS; MOUSE SKIN; TH17 CELLS; TGF-BETA; HA-RAS; TOLERANCE; ANTIGEN; CANCER	Expression of CD200, the gene encoding the ligand for the inhibitory immune receptor CD200R, is an independent prognostic factor for various forms of leukemia predicting worse overall survival of the patients. The enhanced expression of CD200 on the tumors implies that anti-tumor responses can be enhanced by blockage of the CD200-CD200R interaction. Indeed, antibody-mediated blockade of the CD200-CD200R inhibitory axis is currently evaluated in clinical tests to boost immune responses against CD200-expressing tumors. Here, we show that mice lacking CD200, the exclusive ligand for CD200R, are resistant to chemical skin carcinogenesis. Importantly, CD200R controls tumor outgrowth independently of CD200 expression by the tumor cells themselves. Furthermore, Cd200(-/-) mice do not become tolerant to intranasally administered antigens, suggesting that tumor rejection is normally suppressed through CD200-induced immune tolerance. Decreased tumor outgrowth is accompanied by increased expression of the proinflammatory cytokines interleukin (IL)-1 beta and IL-6 by the lymph node (LN) dendritic cells. During carcinogenesis, skin-draining LNs of Cd200(-/-) mice contain increased numbers of IL-17-producing FoxP3(+) cells, which preferentially home to the tumors. Thus, the CD200-CD200R axis induces tolerance to external and tumor antigens and influences the T-regulatory/Th17 cell ratio. We demonstrate for the first time that the absence of CD200R signaling inhibits outgrowth of an endogenous tumor irrespective of CD200 expression by the tumor cells. This important paradigm shift leads to a much broader applicability of CD200-blockade in the treatment of tumors.	[Rygiel, T. P.; Karnam, G.; van Schaarenburg, R. A.; Meyaard, L.] Univ Med Ctr Utrecht, Dept Immunol, NL-3584 EA Utrecht, Netherlands; [Goverse, G.; van der Marel, A. P. J.; Greuter, M. J.; Molenaar, R.; Mebius, R. E.] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands; [Visser, W. F.; Brenkman, A. B.] Netherlands Metabol Ctr, Utrecht, Netherlands; [Visser, W. F.; Brenkman, A. B.] Dept Metab & Endocrine Dis, Utrecht, Netherlands; [Hoek, R. M.] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam	Meyaard, L (corresponding author), Univ Med Ctr Utrecht, Dept Immunol, Lundlaan 6,Room KC02-085-2, NL-3584 EA Utrecht, Netherlands.	l.meyaard@umcutrecht.nl		Rygiel, Tomasz/0000-0003-4746-6505; Meyaard, Linde/0000-0003-0707-4793; Mebius, Reina/0000-0003-0451-7464	Association for International Cancer Research [AICR 07-0086]; VICI [918.56.612]; Netherlands Organization for Scientific Research	Association for International Cancer Research; VICI(Netherlands Organization for Scientific Research (NWO)); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	We thank Gerrit Spierenburg for cell sorting, Serge van de Pavert for assistance with the confocal microscope and Lewis Lanier, Frank Miedema, Berent Prakken and Erik Hack for critical review of versions of this manuscript. This research was supported by the Association for International Cancer Research (AICR 07-0086) to LM and TPR and by a VICI grant (918.56.612) (from the Netherlands Organization for Scientific Research) to REM, MJG and RM.	Baban B, 2009, J IMMUNOL, V183, P2475, DOI 10.4049/jimmunol.0900986; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Chung Y, 2009, IMMUNITY, V30, P576, DOI 10.1016/j.immuni.2009.02.007; Fallarino F, 2004, J IMMUNOL, V173, P3748, DOI 10.4049/jimmunol.173.6.3748; Finch JS, 1996, CARCINOGENESIS, V17, P2551, DOI 10.1093/carcin/17.12.2551; Fouser LA, 2008, IMMUNOL REV, V226, P87, DOI 10.1111/j.1600-065X.2008.00712.x; Gorczynski RM, 1999, J IMMUNOL, V163, P1654; Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768; Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967; Kretz-Rommel A, 2007, J IMMUNOL, V178, P5595, DOI 10.4049/jimmunol.178.9.5595; Kryczek I, 2009, BLOOD, V114, P357, DOI 10.1182/blood-2008-09-177360; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Maniati E, 2010, ONCOGENE, V29, P5653, DOI 10.1038/onc.2010.367; Martin-Orozco N, 2009, IMMUNITY, V31, P787, DOI 10.1016/j.immuni.2009.09.014; McWhirter JR, 2006, P NATL ACAD SCI USA, V103, P1041, DOI 10.1073/pnas.0510081103; Meyer KC, 2008, BRIT J DERMATOL, V159, P1077, DOI 10.1111/j.1365-2133.2008.08818.x; Min WP, 2003, J IMMUNOL, V170, P1304, DOI 10.4049/jimmunol.170.3.1304; Molenaar R, 2009, J IMMUNOL, V183, P6395, DOI 10.4049/jimmunol.0900311; Moreaux J, 2006, BLOOD, V108, P4194, DOI 10.1182/blood-2006-06-029355; Mukhopadhyay S, 2010, CELL HOST MICROBE, V8, P236, DOI 10.1016/j.chom.2010.08.005; Murphy KM, 2010, NAT IMMUNOL, V11, P674, DOI 10.1038/ni.1899; Pallasch CP, 2009, LEUKEMIA RES, V33, P460, DOI 10.1016/j.leukres.2008.08.021; Petermann KB, 2007, J CLIN INVEST, V117, P3922, DOI 10.1172/JCI32163; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Ralph C, 2010, CLIN CANCER RES, V16, P1662, DOI 10.1158/1078-0432.CCR-09-2870; Rijkers ESK, 2008, MOL IMMUNOL, V45, P1126, DOI 10.1016/j.molimm.2007.07.013; Rosenblum MD, 2004, J INVEST DERMATOL, V123, P880, DOI 10.1111/j.0022-202X.2004.23461.x; Sharma MD, 2010, IMMUNITY, V33, P942, DOI 10.1016/j.immuni.2010.11.022; Sharma MD, 2009, BLOOD, V113, P6102, DOI 10.1182/blood-2008-12-195354; Siva A, 2008, CANCER IMMUNOL IMMUN, V57, P987, DOI 10.1007/s00262-007-0429-6; Snelgrove RJ, 2008, NAT IMMUNOL, V9, P1074, DOI 10.1038/ni.1637; Taylor N, 2005, J IMMUNOL, V174, P143, DOI 10.4049/jimmunol.174.1.143; Tonks A, 2007, LEUKEMIA, V21, P566, DOI 10.1038/sj.leu.2404559; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Unger WWJ, 2003, J IMMUNOL, V171, P4592, DOI 10.4049/jimmunol.171.9.4592; Unger WWJ, 2003, INT IMMUNOL, V15, P731, DOI 10.1093/intimm/dxg069; van der Marel APJ, 2007, J IMMUNOL, V179, P894, DOI 10.4049/jimmunol.179.2.894; Wang L, 2010, CANCER RES, V70, P10112, DOI 10.1158/0008-5472.CAN-10-0775; Wilke CM, 2011, CARCINOGENESIS, V32, P643, DOI 10.1093/carcin/bgr019; Wolvers DAW, 1997, IMMUNOLOGY, V92, P328, DOI 10.1046/j.1365-2567.1997.00356.x; Wong KK, 2010, J LEUKOCYTE BIOL, V88, P361, DOI 10.1189/jlb.1009686; Wright GJ, 2001, IMMUNOLOGY, V102, P173, DOI 10.1046/j.1365-2567.2001.01163.x; Xu LL, 2007, J IMMUNOL, V178, P6725, DOI 10.4049/jimmunol.178.11.6725; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878	44	53	53	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	24					2979	2988		10.1038/onc.2011.477	http://dx.doi.org/10.1038/onc.2011.477			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	22020332				2022-12-17	WOS:000305388400007
J	Miyake, T; Parsons, SJ				Miyake, T.; Parsons, S. J.			Functional interactions between Choline kinase alpha, epidermal growth factor receptor and c-Src in breast cancer cell proliferation	ONCOGENE			English	Article						choline kinase; proliferation; c-Src; EGFR; breast cancer; tyrosine phosphorylation	TYROSINE KINASES; PHOSPHORYLATION; ACTIVATION; SITES; EGFR; OVEREXPRESSION; ONCOGENESIS; EXPRESSION; LUNG; Y845	Epidermal growth factor receptor (EGFR) family members and c-Src are co-overexpressed in many cancers. The synergistic effect of EGFR and c-Src has been shown in the tumorigenesis of breast and other cancers. Reported mechanisms of synergy include transcriptional regulation by STAT5b and the regulation of cellular ATP production by mitochondrial protein COX II. Here, we report a new mechanism of EGFR-c-Src synergy through choline kinase alpha (CHKA). The first enzyme of the phosphatidyl choline production pathway, CHKA, is overexpressed in many cancers, and the product of the enzyme, phosphocholine, is also increased in tumor cells. In this report, we find that CHKA forms a complex with EGFR in a c-Src-dependent manner. Endogenous CHKA and EGFR co-immunoprecipitated from a variety of breast cancer cell lines and immortalized mammary epithelial cells. CHKA interacted with the EGFR kinase domain upon c-Src co-overexpression and was phosphorylated in a c-Src-dependent manner on Y197 and Y333. Overexpression of EGFR and c-Src increased total cellular activity and protein levels of CHKA. Mutation of CHKA Y197 and Y333 reduced complex formation, EGFR-dependent activation of CHKA enzyme activity and epidermal growth factor (EGF)-dependent DNA synthesis. Furthermore, small interfering RNA-mediated knockdown of CHKA in MCF-7 and MCF-10A cells reduced EGF-dependent cell proliferation. Together, these results strongly implicate a new c-Src-dependent link between CHKA and EGFR, which contributes to the regulation of cell proliferation and tumorigenesis. Oncogene (2012) 31, 1431-1441; doi:10.1038/onc.2011.332; published online 8 August 2011	[Parsons, S. J.] Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; [Parsons, S. J.] Univ Virginia Hlth Syst, Ctr Canc, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Parsons, SJ (corresponding author), Univ Virginia Hlth Syst, Dept Microbiol, POB 800734,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	sap@virginia.edu			NIH-NCI [R01CA123037]; NATIONAL CANCER INSTITUTE [R01CA123037] Funding Source: NIH RePORTER	NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Nicholas E Sherman in the WM Keck Biomedical Mass Spectrometry Laboratory for analysis of CHKA2 phosphorylation sites, and Drs Jill Slack-Davis and John DaSilva for their critical comments. We also thank members of Sarah J Parsons' laboratory and the Women's Oncology Group in the University of Virginia Cancer Center for helpful discussions. This work was supported by NIH-NCI grant R01CA123037(SJP).	Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; Chua BT, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-131; CUADRADO A, 1993, ONCOGENE, V8, P2959; de Molina AR, 2002, ONCOGENE, V21, P4317, DOI 10.1038/sj.onc.1205556; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Demory ML, 2009, J BIOL CHEM, V284, P36592, DOI 10.1074/jbc.M109.000760; Dimri M, 2007, CANCER RES, V67, P4164, DOI 10.1158/0008-5472.CAN-06-2580; Glunde K, 2006, MOL PHARMACEUT, V3, P496, DOI 10.1021/mp060067e; Grigera PR, 2005, J CELL SCI, V118, P4931, DOI 10.1242/jcs.02696; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Hernando E, 2009, ONCOGENE, V28, P2425, DOI 10.1038/onc.2009.91; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; ISHIDATE K, 1992, METHOD ENZYMOL, V209, P121; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Ishizawar RC, 2007, ONCOGENE, V26, P3503, DOI 10.1038/sj.onc.1210138; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Krishnamachary B, 2009, CANCER RES, V69, P3464, DOI 10.1158/0008-5472.CAN-08-4120; Liao HN, 2006, BBA-MOL CELL BIOL L, V1761, P111, DOI 10.1016/j.bbalip.2006.01.005; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Malito E, 2006, J MOL BIOL, V364, P136, DOI 10.1016/j.jmb.2006.08.084; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Morse DL, 2009, NMR BIOMED, V22, P114, DOI 10.1002/nbm.1318; Peisach D, 2003, STRUCTURE, V11, P703, DOI 10.1016/S0969-2126(03)00094-7; Qiu C, 2009, BIOCHEMISTRY-US, V48, P6624, DOI 10.1021/bi900755n; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Ramirez de Molina A, 2004, CANCER RES, V64, P6732, DOI 10.1158/0008-5472.CAN-04-0489; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; Ramirez de Molina A, 2007, LANCET ONCOL, V8, P889, DOI 10.1016/S1470-2045(07)70279-6; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Uchida T, 1996, BBA-LIPID LIPID MET, V1304, P89, DOI 10.1016/S0005-2760(96)00109-9; Wright JD, 1996, BBA-MOL CELL RES, V1312, P85, DOI 10.1016/0167-4889(96)00027-4; Wu GS, 2010, BIOCHEM CELL BIOL, V88, P559, DOI 10.1139/O09-160; Yalcin A, 2010, ONCOGENE, V29, P139, DOI 10.1038/onc.2009.317; Yanga S, 2008, EXP CELL RES, V314, P413, DOI 10.1016/j.yexcr.2007.09.002	42	53	55	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	11					1431	1441		10.1038/onc.2011.332	http://dx.doi.org/10.1038/onc.2011.332			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21822308	Green Accepted			2022-12-17	WOS:000301780000010
J	Huang, B; Qu, Z; Ong, CW; Tsang, YHN; Xiao, G; Shapiro, D; Salto-Tellez, M; Ito, K; Ito, Y; Chen, LF				Huang, B.; Qu, Z.; Ong, C. W.; Tsang, Y-H N.; Xiao, G.; Shapiro, D.; Salto-Tellez, M.; Ito, K.; Ito, Y.; Chen, L-F			RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha	ONCOGENE			English	Article						breast cancer; degradation; ER alpha; RUNX3; tumor suppressor	EPITHELIAL-CELLS; EXPRESSION; PROTEASOME; BETA; TRANSACTIVATION; TUMORIGENESIS; TURNOVER; DEGRADATION; APOPTOSIS; GROWTH	Transcription factor RUNX3 is inactivated in a number of malignancies, including breast cancer, and is suggested to function as a tumor suppressor. How RUNX3 functions as a tumor suppressor in breast cancer remains undefined. Here, we show that about 20% of female Runx3(+/-) mice spontaneously developed ductal carcinoma at an average age of 14.5 months. Additionally, RUNX3 inhibits the estrogen-dependent proliferation and transformation potential of ER alpha-positive MCF-7 breast cancer cells in liquid culture and in soft agar and suppresses the tumorigenicity of MCF-7 cells in severe combined immunodeficiency mice. Furthermore, RUNX3 inhibits ER alpha-dependent transactivation by reducing the stability of ER alpha. Consistent with its ability to regulate the levels of ER alpha, expression of RUNX3 inversely correlates with the expression of ER alpha in breast cancer cell lines, human breast cancer tissues and Runx3(+/-) mouse mammary tumors. By destabilizing ER alpha, RUNX3 acts as a novel tumor suppressor in breast cancer. Oncogene (2012) 31, 527-534; doi: 10.1038/onc.2011.252; published online 27 June 2011	[Ito, K.] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528588, Japan; [Chen, L-F] Univ Illinois, Dept Biochem, Coll Med, Urbana, IL 61801 USA; [Qu, Z.; Xiao, G.] Univ Pittsburgh, Med Ctr, Inst Canc, Pittsburgh, PA USA; [Ong, C. W.; Salto-Tellez, M.] Natl Univ Singapore, Dept Pathol, Singapore 117548, Singapore; [Ong, C. W.; Salto-Tellez, M.; Ito, Y.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Tsang, Y-H N.; Ito, Y.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore	Nagasaki University; University of Illinois System; University of Illinois Urbana-Champaign; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Ito, K (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528588, Japan.	itok@nagasaki-u.ac.jp; lfchen@life.illinois.edu		Salto-Tellez, Manuel/0000-0001-8586-282X	UIUC; NIH [DK-085158, CA116616, DK-071909]; NATIONAL CANCER INSTITUTE [R01CA116616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071909, R01DK085158] Funding Source: NIH RePORTER	UIUC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank W Xu for reagents; W Xu, A Nardulli and members in the Chen lab for discussion. This work is supported in part by fund provided by UIUC (to LFC) and NIH grants DK-085158 (to LFC), CA116616 (to GTX) and DK-071909 (to DS). YHT is an A*STAR-Illinois Partnership fellow.	Anderson E, 2002, BREAST CANCER RES, V4, P197, DOI 10.1186/bcr452; Cheskis BJ, 2007, J CELL PHYSIOL, V213, P610, DOI 10.1002/jcp.21253; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Ekena K, 1996, J BIOL CHEM, V271, P20053, DOI 10.1074/jbc.271.33.20053; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Frech MS, 2005, CANCER RES, V65, P681; Ito K, 2009, ONCOGENE, V28, P1379, DOI 10.1038/onc.2008.496; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Jerry DJ, 2010, CELL MOL LIFE SCI, V67, P1017, DOI 10.1007/s00018-009-0244-7; Jiang Y, 2008, PATHOBIOLOGY, V75, P244, DOI 10.1159/000132385; Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78; KHAN SA, 1994, CANCER RES, V54, P993; LaMarca HL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1740; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Sakuma A, 2008, MOL REPROD DEV, V75, P1653, DOI 10.1002/mrd.20904; Shoker BS, 2000, J CLIN PATHOL, V53, P778, DOI 10.1136/jcp.53.10.778; Subramaniam MM, 2009, BBA-REV CANCER, V1796, P315, DOI 10.1016/j.bbcan.2009.07.004; Subramaniam MM, 2009, BREAST CANCER RES TR, V113, P113, DOI 10.1007/s10549-008-9917-4; Tateishi Y, 2004, EMBO J, V23, P4813, DOI 10.1038/sj.emboj.7600472; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yan PR, 2009, BLOOD, V113, P4370, DOI 10.1182/blood-2008-10-185660; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05; Zhang DH, 2003, LIFE SCI, V73, P3189, DOI 10.1016/j.lfs.2003.05.006	28	53	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	4					527	534		10.1038/onc.2011.252	http://dx.doi.org/10.1038/onc.2011.252			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21706051	Green Accepted			2022-12-17	WOS:000300219300011
J	Min, Y; Ghose, S; Boelte, K; Li, J; Yang, L; Lin, PC				Min, Y.; Ghose, S.; Boelte, K.; Li, J.; Yang, L.; Lin, P. C.			C/EBP-delta regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1 alpha	ONCOGENE			English	Article						C/EBP-delta; VEGF-C; HIF-1 alpha; lymphangiogenesis; metastasis	BINDING-PROTEIN-DELTA; GROWTH-FACTOR-C; LYMPHATIC ENDOTHELIAL-CELLS; FACTOR-ALPHA-RECEPTOR; SMOOTH-MUSCLE-CELLS; NODE METASTASIS; GENE-EXPRESSION; BREAST-CANCER; TUMOR LYMPHANGIOGENESIS; MICE LACKING	CCAAT/enhancer-binding protein-delta (C/EBP-delta), a transcription factor, is elevated in carcinoma compared with that in normal tissue. This study reports a novel function of C/EBP-delta in lymphangiogenesis and tumor metastasis. Genetic deletion of C/EBP-delta in mice resulted in a significant reduction of lymphangiogenesis and pulmonary metastases, with a dramatic reduction of vascular endothelial growth factor-C (VEGF-C) and its cognate receptor VEGF receptor-3 (VEGFR3) in lymphatic endothelial cells (LECs). By contrast, no difference of VEGF-C in tumor tissues and bone marrow was observed between null and wild-type mice. Consistently, forced expression of C/EBP-delta increased VEGF-C and VEGFR3 expression in cultured LECs. These findings suggest a specific and important role of C/EBP-delta in the regulation of VEGFR3 signaling in LECs. Furthermore, expression of C/EBP-delta in cultured LECs significantly increased cell motility, and knockdown of C/EBP-delta inhibited cell motility and lymphatic vascular network formation in vitro. Forced expression of VEGF-C, but not recombinant VEGF-C, rescued the knockdown of C/EBP-delta-induced cell apoptosis, indicative of autonomous VEGF-C autocrine signaling essential for LEC survival. Moreover, hypoxia induces C/EBP-delta expression and C/EBP-delta regulates HIF-1 alpha expression. Blocking HIF-1 alpha activity totally blocked CEBP-delta-induced VEGF-C and VEGFR3 expression in LECs. Together, these findings uncover a new function of CEBP-delta in lymphangiogenesis through regulation of VEGFR3 signaling in LECs. Oncogene (2011) 30, 4901-4909; doi:10.1038/onc.2011.187; published online 13 June 2011	[Min, Y.; Yang, L.; Lin, P. C.] NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21702 USA; [Ghose, S.; Li, J.] Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Nashville, TN USA; [Boelte, K.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University; Vanderbilt University	Lin, PC (corresponding author), NCI, Mouse Canc Genet Program, Ctr Canc Res, 1050 Boyles St,Bldg 560,Room 12-89, Frederick, MD 21702 USA.	p.lin@nih.edu			NIH [CA108856, NS45888, AR053718]; NATIONAL CANCER INSTITUTE [R01CA108856, ZIABC011390] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045888] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported in part by grants from NIH (CA108856, NS45888 and AR053718).	Akagi K, 2000, BRIT J CANCER, V83, P887, DOI 10.1054/bjoc.2000.1396; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Helotera H, 2007, CELL, V130, P591, DOI 10.1016/j.cell.2007.08.012; Irigoyen M, 2007, BBA-MOL CELL RES, V1773, P880, DOI 10.1016/j.bbamcr.2007.03.001; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Kamiyama M, 2006, ONCOGENE, V25, P7019, DOI 10.1038/sj.onc.1209694; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Katsuta M, 2005, EXP MOL PATHOL, V78, P123, DOI 10.1016/j.yexmp.2004.11.002; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Kitami Y, 1999, CIRC RES, V84, P64; Kurokawa T, 2003, BRIT J CANCER, V89, P1042, DOI 10.1038/sj.bjc.6601186; Kuwai T, 2003, INT J CANCER, V105, P176, DOI 10.1002/ijc.11068; Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; Ota H, 2007, FEBS LETT, V581, P5220, DOI 10.1016/j.febslet.2007.10.009; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Rabek JP, 1998, BBA-GENE STRUCT EXPR, V1398, P137, DOI 10.1016/S0167-4781(98)00038-4; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Schoppmann SF, 2006, BREAST CANCER RES TR, V99, P135, DOI 10.1007/s10549-006-9190-3; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Simiantonaki N, 2008, INT J ONCOL, V32, P585; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2002, NAT REV CANCER, V2, P573, DOI 10.1038/nrc863; Sterneck E, 1998, P NATL ACAD SCI USA, V95, P10908, DOI 10.1073/pnas.95.18.10908; Takata Y, 2002, CIRC RES, V91, P427, DOI 10.1161/01.RES.0000031271.20771.4F; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Tang Y, 2006, NEUROBIOL DIS, V21, P18, DOI 10.1016/j.nbd.2005.06.002; Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050; Yang ZH, 2001, CIRC RES, V89, P503, DOI 10.1161/hh1801.096265; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823	35	53	56	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2011	30	49					4901	4909		10.1038/onc.2011.187	http://dx.doi.org/10.1038/onc.2011.187			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YI	21666710	Green Accepted			2022-12-17	WOS:000298346400006
J	Shields, DJ; Murphy, EA; Desgrosellier, JS; Mielgo, A; Lau, SKM; Barnes, LA; Lesperance, J; Huang, M; Schmedt, C; Tarin, D; Lowy, AM; Cheresh, DA				Shields, D. J.; Murphy, E. A.; Desgrosellier, J. S.; Mielgo, A.; Lau, S. K. M.; Barnes, L. A.; Lesperance, J.; Huang, M.; Schmedt, C.; Tarin, D.; Lowy, A. M.; Cheresh, D. A.			Oncogenic Ras/Src cooperativity in pancreatic neoplasia	ONCOGENE			English	Article						pancreatic cancer; Src; Ras; oncogenic cooperativity	EPIDERMAL-GROWTH-FACTOR; SRC FAMILY KINASES; DUCTAL ADENOCARCINOMA; TYROSINE KINASE; C-SRC; HUMAN CANCER; INTRAEPITHELIAL NEOPLASIA; TUMOR PROGRESSION; TRANSGENIC MICE; MOUSE MODEL	Pancreas cancer is one of the most lethal malignancies and is characterized by activating mutations of Kras, present in 95% of patients. More than 60% of pancreatic cancers also display increased c-Src activity, which is associated with poor prognosis. Although loss of tumor suppressor function (for example, p16, p53, Smad4) combined with oncogenic Kras signaling has been shown to accelerate pancreatic duct carcinogenesis, it is unclear whether elevated Src activity contributes to Kras-dependent tumorigenesis or is simply a biomarker of disease progression. Here, we demonstrate that in the context of oncogenic Kras, activation of c-Src through deletion of C-terminal Src kinase (CSK) results in the development of invasive pancreatic ductal adenocarcinoma (PDA) by 5-8 weeks. In contrast, deletion of CSK alone fails to induce neoplasia, while oncogenic Kras expression yields PDA at low frequency after a latency of 12 months. Analysis of cell lines derived from Ras/Src-induced PDA's indicates that oncogenic Ras/Src cooperativity may lead to genomic instability, yet Ras/Src-driven tumor cells remain dependent on Src signaling and as such, Src inhibition suppresses growth of Ras/Src-driven tumors. These findings demonstrate that oncogenic Ras/Src cooperate to accelerate PDA onset and support further studies of Src-directed therapies in pancreatic cancer. Oncogene (2011) 30, 2123-2134; doi:10.1038/onc.2010.589; published online 17 January 2011	[Shields, D. J.; Murphy, E. A.; Desgrosellier, J. S.; Mielgo, A.; Lau, S. K. M.; Barnes, L. A.; Lesperance, J.; Huang, M.; Tarin, D.; Cheresh, D. A.] Moores UCSD Canc Ctr, Dept Pathol, La Jolla, CA 92093 USA; [Schmedt, C.] Novartis Res Fdn, Genom Inst, San Diego, CA USA; [Lowy, A. M.] Moores UCSD Canc Ctr, Dept Surg, La Jolla, CA 92093 USA	Novartis	Cheresh, DA (corresponding author), Moores UCSD Canc Ctr, Dept Pathol, Room 2344,3855 Hlth Sci Dr,MC 0803, La Jolla, CA 92093 USA.	dcheresh@ucsd.edu	Desgrosellier, Jay S/A-8756-2008	Huang, Miller/0000-0002-3371-0100; Lau, Steven/0000-0002-6433-8735	NIH [R21CA104898, P01-CA078045]; Moores UCSD Cancer Center; NATIONAL CANCER INSTITUTE [T32CA121938, P01CA078045, P01CA104898] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Moores UCSD Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Charles Yi and Dana Wu for excellent technical assistance. We acknowledge Richard Aspinall, Lisette Acevedo, Josh Greenberg and David Tuveson for valuable discussions, Greg Boivin for histological analysis, as well as Richard Levenson and Kristin Lane for NuBrio imaging. This work was supported by NIH grants R21CA104898, P01-CA078045 (DAC) and Collaborative Translational Research grants from Moores UCSD Cancer Center (DAC, DJS and AML).	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; BARTON CM, 1991, J PATHOL, V163, P111, DOI 10.1002/path.1711630206; Billadeau DD, 2006, J GASTROINTEST CANC, V37, P110, DOI 10.1007/s12029-007-0011-7; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Broome MA, 2000, ONCOGENE, V19, P2867, DOI 10.1038/sj.onc.1203608; Desgrosellier JS, 2009, NAT MED, V15, P1163, DOI 10.1038/nm.2009; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Grimm J, 2003, INT J CANCER, V106, P806, DOI 10.1002/ijc.11281; HALL PA, 1990, J PATHOL, V161, P195, DOI 10.1002/path.1711610305; Hernandez-Munoz I, 2008, PANCREATOLOGY, V8, P462, DOI 10.1159/000151537; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Hruban RH, 2004, AM J SURG PATHOL, V28, P977, DOI 10.1097/01.pas.0000126675.59108.80; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kabil A, 2008, CARCINOGENESIS, V29, P1862, DOI 10.1093/carcin/bgn138; Kasahara K, 2007, J BIOL CHEM, V282, P5327, DOI 10.1074/jbc.M608396200; Kline CLB, 2008, INT J CANCER, V122, P2665, DOI 10.1002/ijc.23445; Koreckij T, 2009, BRIT J CANCER, V101, P263, DOI 10.1038/sj.bjc.6605178; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Maddalena AS, 1999, BRAIN PATHOL, V9, P627; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Matsumoto T, 2004, MOL CARCINOGEN, V40, P189, DOI 10.1002/mc.20027; Morton JP, 2010, GASTROENTEROLOGY, V139, P292, DOI 10.1053/j.gastro.2010.03.034; Murphy EA, 2008, P NATL ACAD SCI USA, V105, P9343, DOI 10.1073/pnas.0803728105; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Ricono JM, 2009, CANCER RES, V69, P1383, DOI 10.1158/0008-5472.CAN-08-3612; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; Rucci N, 2006, J PHARMACOL EXP THER, V318, P161, DOI 10.1124/jpet.106.102004; Schmedt C, 1998, NATURE, V394, P901, DOI 10.1038/29802; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thomas RM, 2008, GUT, V57, P1555, DOI 10.1136/gut.2007.143941; Thomas RM, 2007, CANCER RES, V67, P6075, DOI 10.1158/0008-5472.CAN-06-4128; Trevino JG, 2006, AM J PATHOL, V168, P962, DOI 10.2353/ajpath.2006.050570; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Vitali R, 2009, INT J CANCER, V125, P2547, DOI 10.1002/ijc.24606; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Yezhelyev MV, 2004, CLIN CANCER RES, V10, P8028, DOI 10.1158/1078-0432.CCR-04-0621	51	53	58	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	18					2123	2134		10.1038/onc.2010.589	http://dx.doi.org/10.1038/onc.2010.589			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21242978	Green Accepted			2022-12-17	WOS:000290249600004
J	Yang, Y; Tse, AKW; Li, P; Ma, Q; Xiang, S; Nicosia, SV; Seto, E; Zhang, X; Bai, W				Yang, Y.; Tse, A. K-W; Li, P.; Ma, Q.; Xiang, S.; Nicosia, S. V.; Seto, E.; Zhang, X.; Bai, W.			Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation	ONCOGENE			English	Article						androgen receptor; androgens; HDAC4; prostate cancer; SUMOylation; SUMO E3 ligase	PROSTATE-CANCER CELLS; TRANSCRIPTIONAL ACTIVITY; DEPENDENT TRANSCRIPTION; HDAC4 DEACETYLASE; COMPLEMENTARY-DNA; SUPERFAMILY; ACTIVATION; PHOSPHORYLATION; ACETYLATION; APOPTOSIS	The transcriptional activity of the androgen receptor (AR) is regulated by both ligand binding and post-translational modifications, including acetylation and small ubiquitin-like modifier (SUMO)ylation. Histone deacetylases (HDACs) are known to catalyze the removal of acetyl groups from both histones and non-histone proteins. In this study, we report that HDAC4 binds to and inhibits the activity of the AR. This inhibition was found to depend on the SUMOylation, instead of deacetylation, of the AR. Consistently, HDAC4 increases the level of AR SUMOylation in both whole-cell and cell-free assay systems, raising the possibility that the deacetylase may act as an E3 ligase for AR SUMOylation. Knock down of HDAC4 increases the activity of endogenous AR and androgen induction of prostate-specific antigen expression and prostate cancer cell growth, which is associated with decreased SUMOylation of the receptor. Overall, the studies identify HDAC4 as a positive regulator for AR SUMOylation, revealing a deacetylase-independent mechanism of HDAC action in prostate cancer cells. Oncogene (2011) 30, 2207-2218; doi:10.1038/onc.2010.600; published online 17 January 2011	[Yang, Y.; Tse, A. K-W; Li, P.; Ma, Q.; Xiang, S.; Nicosia, S. V.; Zhang, X.; Bai, W.] Univ S Florida, Dept Pathol & Cell Biol, Coll Med, Tampa, FL 33612 USA; [Nicosia, S. V.; Seto, E.; Zhang, X.; Bai, W.] Univ S Florida, Dept Oncol Sci, Coll Med, Tampa, FL 33612 USA; [Seto, E.; Zhang, X.; Bai, W.] Univ S Florida, H Lee Moffitt Canc Ctr, Programs Mol Oncol, Tampa, FL 33682 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Bai, W (corresponding author), Univ S Florida, Dept Pathol & Cell Biol, Coll Med, 12901 Bruce B Downs Blvd,MDC 11, Tampa, FL 33612 USA.	wbai@health.usf.edu	XIANG, SHENGYAN/C-3176-2013; Bai, Wenlong/A-8977-2013	XIANG, SHENGYAN/0000-0002-6940-3559; Bai, Wenlong/0000-0002-9536-0556	Public Health Service [CA93666, CA111334]; DOD [DAMD17-02-1-0140]; Florida Department of Health [09KT-03, 06BCBG1]; NATIONAL CANCER INSTITUTE [R01CA093666, R01CA111334] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); DOD(United States Department of Defense); Florida Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs XJ Yang for HDAC4 vector, RJ Matusik for probasin-based AR reporter genes, PR Rennie for the PSA-based reporter gene, G Jenster for GST-AR-NT construct, JJ Palvimo for AR SUMOylation mutants and AP Lieberman for AR acetylation mutants. The work was supported by the Public Health Service Grants CA93666 and CA111334 (WB), a DOD Prostate Cancer Grant DAMD17-02-1-0140 (WB) and Grants 09KT-03 and 06BCBG1 (W.B) from the Florida Department of Health.	Bai WL, 1996, J BIOL CHEM, V271, P12801, DOI 10.1074/jbc.271.22.12801; Blok LJ, 1996, ENDOCR RES, V22, P197, DOI 10.3109/07435809609030508; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; Dai Y, 2007, MOL ENDOCRINOL, V21, P1807, DOI 10.1210/me.2006-0467; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fu MF, 2006, MOL CELL BIOL, V26, P8122, DOI 10.1128/MCB.00289-06; Fu MF, 2004, BIOCHEM PHARMACOL, V68, P1199, DOI 10.1016/j.bcp.2004.05.037; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Ghisletti S, 2007, MOL CELL, V25, P57, DOI 10.1016/j.molcel.2006.11.022; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Jeong BC, 2004, MOL ENDOCRINOL, V18, P13, DOI 10.1210/me.2003-0065; Jones PL, 2003, CURR TOP MICROBIOL, V274, P237; Kaikkonen S, 2009, MOL ENDOCRINOL, V23, P292, DOI 10.1210/me.2008-0219; Karvonen U, 2006, EXP CELL RES, V312, P3165, DOI 10.1016/j.yexcr.2006.06.018; Kasper S, 1999, J MOL ENDOCRINOL, V22, P313, DOI 10.1677/jme.0.0220313; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Lee H, 2000, MOL ENDOCRINOL, V14, P1882, DOI 10.1210/me.14.11.1882; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Lin DY, 2004, MOL CELL BIOL, V24, P10529, DOI 10.1128/MCB.24.24.10529-10541.2004; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; ONATE SA, 1995, SCIENCE, V270, P1354; Pan Y, 2005, BIOCHEM BIOPH RES CO, V332, P702, DOI 10.1016/j.bbrc.2005.05.012; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Snoek R, 1998, PROSTATE, V36, P256; Thomas M, 2004, J BIOL CHEM, V279, P8389, DOI 10.1074/jbc.M311761200; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Xu Jianming, 2002, Rev Endocr Metab Disord, V3, P185, DOI 10.1023/A:1020016208071; Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004; Zhao X, 2005, MOL CELL BIOL, V25, P8456, DOI 10.1128/MCB.25.19.8456-8464.2005	39	53	54	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	19					2207	2218		10.1038/onc.2010.600	http://dx.doi.org/10.1038/onc.2010.600			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21242980	Green Accepted			2022-12-17	WOS:000290514600004
J	Brenner, C; Subramaniam, K; Pertuiset, C; Pervaiz, S				Brenner, C.; Subramaniam, K.; Pertuiset, C.; Pervaiz, S.			Adenine nucleotide translocase family: four isoforms for apoptosis modulation in cancer	ONCOGENE			English	Review						cancer; cell death; mitochondria; ADP/ATP carrier; mitochondrial membrane permeabilization	PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; CELL-DEATH MACHINERY; ADP/ATP CARRIER; GLIOMA-CELLS; DIFFERENTIAL EXPRESSION; TRANSCRIPTIONAL ELEMENT; ADENYLATE TRANSLOCATOR; BAX TRANSLOCATION	Mitochondria have important functions in mammalian cells as the energy powerhouse and integrators of the mitochondrial pathway of apoptosis. The adenine nucleotide translocase (ANT) is a family of proteins involved in cell death pathways that perform distinctly opposite functions to regulate cell fate decisions. On the one hand, ANT catalyzes the adenosine triphosphate export from the mitochondrial matrix to the intermembrane space with the concomitant import of ADP from the intermembrane space to the matrix. On the other hand, during periods of stress, ANT could function as a lethal pore and trigger the process of mitochondrial membrane permeabilization, which leads irreversibly to cell death. In human, ANT is encoded by four homologous genes, whose expression is not only tissue specific, but also varies according to the pathophysiological state of the cell. Recent evidence revealed a differential role of the ANT isoforms in apoptosis and a deregulation of their expression in cancer. In this review, we introduce the current knowledge of ANT in apoptosis and cancer cells and propose a novel classification of ANT isoforms. Oncogene (2011) 30, 883-895; doi:10.1038/onc.2010.501; published online 15 November 2010	[Brenner, C.] Univ Paris 11, Fac Pharm, INSERM, UMR S 769, F-92290 Chatenay Malabry, France; [Brenner, C.; Pertuiset, C.] PRES UniverSud Paris, Chatenay Malabry, France; [Subramaniam, K.; Pervaiz, S.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Apoptosis ROS & Canc Biol Program, Singapore 117595, Singapore; [Pervaiz, S.] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore; [Pervaiz, S.] Duke NUS Grad Med Sch, Singapore, Singapore; [Pervaiz, S.] Singapore MIT Alliance, Singapore, Singapore	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; National University of Singapore; National University of Singapore; National University of Singapore; Massachusetts Institute of Technology (MIT); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Singapore-MIT Alliance for Research & Technology Centre (SMART)	Brenner, C (corresponding author), Univ Paris 11, Fac Pharm, INSERM, UMR S 769, 5 Rue J-B Clement, F-92290 Chatenay Malabry, France.	catherine.brenner-jan@u-psud.fr	Pervaiz, Shazib/C-4188-2015		le Centre National de la Recherche Scientifique (CNRS); l'Agence Nationale de la Recherche (ANR) [ANR-08PCVI-0008-01]; l'Institut National pour le Cancer (INCa) [2008-1-PL BIO-04-CNS ON1]; l'Universite Paris Sud	le Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); l'Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); l'Institut National pour le Cancer (INCa)(Institut National du Cancer (INCA) France); l'Universite Paris Sud	The work of CB and CP are supported by le Centre National de la Recherche Scientifique (CNRS) and l'Agence Nationale de la Recherche (ANR, ANR-08PCVI-0008-01). CB is also supported by l'Institut National pour le Cancer (INCa, 2008-1-PL BIO-04-CNS ON1) and l'Universite Paris Sud (Programme Attractivite). CB thanks M Nunez for the help in the preparation of Figure 2 and current and past laboratory members for their invaluable contribution.	Adante A, 2008, BBA-BIOENERGETICS, V1777, P1289, DOI 10.1016/j.bbabio.2008.07.004; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Azzu V, 2008, BIOCHEM J, V413, P323, DOI 10.1042/BJ20080321; Baines CP, 2009, J MOL CELL CARDIOL, V46, P969, DOI 10.1016/j.yjmcc.2009.01.016; Barath P, 2004, EUR J BIOCHEM, V271, P1781, DOI 10.1111/j.1432-1033.2004.04090.x; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Beckner ME, 2005, LAB INVEST, V85, P1457, DOI 10.1038/labinvest.3700355; Bellance N, 2009, FRONT BIOSCI-LANDMRK, V14, P4015, DOI 10.2741/3509; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Belzacq AS, 2001, CANCER RES, V61, P1260; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Bouchier-Hayes L, 2005, J CLIN INVEST, V115, P2640, DOI 10.1172/JCI26274; Bouzier AK, 1998, DEV NEUROSCI-BASEL, V20, P331, DOI 10.1159/000017328; BRANDOLIN G, 1980, BIOCHIM BIOPHYS ACTA, V592, P592, DOI 10.1016/0005-2728(80)90103-6; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Brenner C, 2010, BIOCHEM BIOPH RES CO, V391, P248, DOI 10.1016/j.bbrc.2009.11.044; Brower JV, 2009, REPRODUCTION, V138, P463, DOI 10.1530/REP-09-0201; Brower JV, 2009, BBA-GENE REGUL MECH, V1789, P198, DOI 10.1016/j.bbagrm.2008.12.005; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Chen C, 2004, J BIOL CHEM, V279, P31761, DOI 10.1074/jbc.M401353200; Chevrollier A, 2005, J BIOENERG BIOMEMBR, V37, P307, DOI 10.1007/s10863-005-8642-5; Chevrollier A, 2005, MOL CARCINOGEN, V42, P1, DOI 10.1002/mc.20059; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Crichton PG, 2010, BIOSCIENCE REP, V30, P187, DOI 10.1042/BSR20090063; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Deniaud E, 2006, ONCOGENE, V25, P7096, DOI 10.1038/sj.onc.1209696; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Doerner A, 1997, FEBS LETT, V414, P258, DOI 10.1016/S0014-5793(97)01000-4; Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Gallerne C, 2010, INT J BIOCHEM CELL B, V42, P623, DOI 10.1016/j.biocel.2009.12.024; Gazaryan IG, 2007, NEUROCHEM RES, V32, P917, DOI 10.1007/s11064-006-9252-2; Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Griguer CE, 2007, J NEURO-ONCOL, V81, P9, DOI 10.1007/s11060-006-9201-6; Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Haouzi D, 2002, APOPTOSIS, V7, P395, DOI 10.1023/A:1020026923038; HENDERSON PJ, 1970, J BIOL CHEM, V245, P1319; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jacotot E, 2006, BBA-BIOENERGETICS, V1757, P1312, DOI 10.1016/j.bbabio.2006.07.002; Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935; Jang JY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1857; Jang JY, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-160; Jastroch M, 2010, ESSAYS BIOCHEM, V47, P53, DOI [10.1042/BSE0470053, 10.1042/bse0470053]; Kehoe SM, 2008, BIOL REPROD, V79, P921, DOI 10.1095/biolreprod.108.067645; Khailova LS, 2006, BBA-BIOENERGETICS, V1757, P1324, DOI 10.1016/j.bbabio.2006.04.024; Klingenberg M, 2008, BBA-BIOMEMBRANES, V1778, P1978, DOI 10.1016/j.bbamem.2008.04.011; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Lauquin G J, 1979, Methods Enzymol, V56, P414; Le Bras M, 2006, CANCER RES, V66, P9143, DOI 10.1158/0008-5472.CAN-05-4407; Lee J, 2009, BBA-BIOENERGETICS, V1787, P364, DOI 10.1016/j.bbabio.2009.01.014; Leung AWC, 2008, J BIOL CHEM, V283, P26312, DOI 10.1074/jbc.M805235200; LI K, 1989, J BIOL CHEM, V264, P13998; LI K, 1990, J BIOL CHEM, V265, P20585; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; Luciakova K, 2008, BIOCHEM J, V412, P123, DOI 10.1042/BJ20071440; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; LUNARDI J, 1992, J BIOL CHEM, V267, P15267; Machida K, 2002, J BIOL CHEM, V277, P31243, DOI 10.1074/jbc.M204564200; Malorni W, 2009, CELL DEATH DIFFER, V16, P1480, DOI 10.1038/cdd.2009.100; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Nadtochiy SM, 2006, BIOCHEM J, V395, P611, DOI 10.1042/BJ20051927; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; Notario B, 2003, MOL PHARMACOL, V63, P224, DOI 10.1124/mol.63.1.224; O'Brien TM, 2008, TOXICOL APPL PHARM, V227, P184, DOI 10.1016/j.taap.2007.10.016; Ong SB, 2010, CIRCULATION, V121, P2012, DOI 10.1161/CIRCULATIONAHA.109.906610; Ortega R, 2009, J BIOENERG BIOMEMBR, V41, P41, DOI 10.1007/s10863-009-9198-6; Palmieri F, 2010, ESSAYS BIOCHEM, V47, P37, DOI [10.1042/BSE0470037, 10.1042/bse0470037]; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Pereira C, 2007, MOL MICROBIOL, V66, P571, DOI 10.1111/j.1365-2958.2007.05926.x; Pereira CV, 2008, TOXICOL SCI, V105, P408, DOI 10.1093/toxsci/kfn131; PFAFF E, 1968, EUR J BIOCHEM, V6, P66, DOI 10.1111/j.1432-1033.1968.tb00420.x; PFAFF E, 1969, EUR J BIOCHEM, V10, P484, DOI 10.1111/j.1432-1033.1969.tb00715.x; Queiroga CSF, 2010, J BIOL CHEM, V285, P17077, DOI 10.1074/jbc.M109.065052; Rasola A, 2010, FEBS LETT, V584, P1989, DOI 10.1016/j.febslet.2010.02.022; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Rial E, 2010, BBA-BIOENERGETICS, V1797, P800, DOI 10.1016/j.bbabio.2010.04.001; Rodic N, 2005, STEM CELLS, V23, P1314, DOI 10.1634/stemcells.2005-0119; Rodriguez-Enriquez S, 2010, INT J BIOCHEM CELL B, V42, P1744, DOI 10.1016/j.biocel.2010.07.010; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; SABOVA L, 1993, EUR J BIOCHEM, V213, P547, DOI 10.1111/j.1432-1033.1993.tb17793.x; Schonfeld P, 1996, EUR J BIOCHEM, V240, P387, DOI 10.1111/j.1432-1033.1996.0387h.x; Shen QF, 2009, MOL CELL BIOL, V29, P3881, DOI 10.1128/MCB.01509-08; Smiraglia DJ, 2008, CANCER BIOL THER, V7, P1182, DOI 10.4161/cbt.7.8.6215; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; Toime LJ, 2010, FREE RADICAL BIO MED, V49, P606, DOI 10.1016/j.freeradbiomed.2010.05.010; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; VIGNAIS PV, 1973, BIOCHEMISTRY-US, V12, P1508, DOI 10.1021/bi00732a007; VIGNY HF, 1996, MOL CARCINOG, V16, P165; Vyssokikh MY, 2003, ACTA BIOCHIM POL, V50, P389; Vyssokikh MY, 2001, BIOCHEM J, V358, P349, DOI 10.1042/0264-6021:3580349; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1924, BIOCHEM Z, V152, P319; Watabe M, 2000, CANCER RES, V60, P5214; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; Zamarin Dmitriy, 2005, PLoS Pathogens, V1, P40; Zamora M, 2004, J BIOL CHEM, V279, P38415, DOI 10.1074/jbc.M404928200; Zamora M, 2004, FEBS LETT, V563, P155, DOI 10.1016/S0014-5793(04)00293-5; Zhivotovsky B, 2009, CELL DEATH DIFFER, V16, P1419, DOI 10.1038/cdd.2009.118; Zoratti M, 2005, BBA-BIOENERGETICS, V1706, P40, DOI 10.1016/j.bbabio.2004.10.006; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	115	53	54	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					883	895		10.1038/onc.2010.501	http://dx.doi.org/10.1038/onc.2010.501			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	21076465				2022-12-17	WOS:000287695900001
J	Balzer, EM; Whipple, RA; Thompson, K; Boggs, AE; Slovic, J; Cho, EH; Matrone, MA; Yoneda, T; Mueller, SC; Martin, SS				Balzer, E. M.; Whipple, R. A.; Thompson, K.; Boggs, A. E.; Slovic, J.; Cho, E. H.; Matrone, M. A.; Yoneda, T.; Mueller, S. C.; Martin, S. S.			c-Src differentially regulates the functions of microtentacles and invadopodia	ONCOGENE			English	Article						microtentacle; invadopodia; Src; breast cancer; microtubule; actin	CANCER-CELLS; EXTRACELLULAR-MATRIX; TUMOR-CELLS; METASTASIS; PODOSOMES; INVASION; DEGRADATION; ADHESION; GROWTH; ACTIN	During metastasis, invading cells produce various actin-based membrane protrusions that promote directional migration and proteolysis of extracellular matrix (ECM). Observations of actin staining within thin, tubulin-based microtentacle (McTN) protrusions in suspended MDA-MB-231 tumor cells, prompted an investigation of whether McTNs are structural or functional analogs of invadopodia. We show here that MDA-MB-231 cells are capable of producing invadopodia and McTNs, both of which contain F-actin. Invadopodium formation was enhanced by the expression of a constitutively active c-Src kinase, and repressed by the expression of dominant-negative, catalytically inactive form of c-Src. In contrast, expression of inactive c-Src significantly increased McTN formation. Direct inhibition of c-Src with the SU6656 inhibitor compound also significantly enhanced McTN formation, but suppressed invadopodia, including the appearance of F-actin cores and phospho-cortactin foci, as well as completely blocking focal degradation of ECM. In addition, silencing of Tks5 in Src-transformed fibroblasts blocked invadopodia without affecting McTNs. Genetic modification of c-Src activity that promoted McTN formation augmented capillary retention of circulating tumor cells in vivo and rapid re-attachment of suspended cells in vitro, even though invadopodia were strongly suppressed. These results indicate that McTNs are capable of enhancing tumor cell reattachment, even in the absence of Tks5 and active Src, and define separate cytoskeletal mechanisms and functions for McTNs and invadopodia. Oncogene (2010) 29, 6402-6408; doi:10.1038/onc.2010.360; published online 18 October 2010	[Balzer, E. M.; Whipple, R. A.; Thompson, K.; Cho, E. H.; Matrone, M. A.; Martin, S. S.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum NCI Canc Ctr, Dept Physiol, Baltimore, MD 21201 USA; [Balzer, E. M.; Boggs, A. E.; Slovic, J.; Cho, E. H.; Matrone, M. A.; Martin, S. S.] Univ Maryland, Sch Med, Program Mol Med, Baltimore, MD 21201 USA; [Yoneda, T.] Osaka Univ, Grad Sch Dent, Dept Biochem, Osaka, Japan; [Mueller, S. C.] Georgetown Univ, Sch Med, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Osaka University; Georgetown University	Martin, SS (corresponding author), Univ Maryland, Sch Med, Marlene & Stewart Greenebaum NCI Canc Ctr, Dept Physiol, 655 W Baltimore St,Room 10-029, Baltimore, MD 21201 USA.	ssmartin@som.umaryland.edu	Cho, Edward/B-3727-2012	Cho, Edward/0000-0002-0278-334X	National Cancer Institute [R01-CA124704]; USA Medical Research and Materiel Command [BC061047]; Susan G Komen investigator-initiated grant [KG100240]; NATIONAL CANCER INSTITUTE [R01CA124704, P30CA134274] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); USA Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Susan G Komen investigator-initiated grant(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by R01-CA124704 grant from the National Cancer Institute, Breast Cancer Idea Award from USA Medical Research and Materiel Command (BC061047) and a Susan G Komen investigator-initiated grant (KG100240). We are very grateful to Darren Seals and Sara Courtneidge for generously providing cell lines and reagents to examine the role of Tks5.	Balzer EM, 2010, BREAST CANCER RES TR, V121, P65, DOI 10.1007/s10549-009-0457-3; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Buccione R, 2009, CANCER METAST REV, V28, P137, DOI 10.1007/s10555-008-9176-1; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Clark ES, 2008, EUR J CELL BIOL, V87, P581, DOI 10.1016/j.ejcb.2008.01.008; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; GUPTON SL, 2007, SCI STKE, pRE5, DOI DOI 10.1126/STKE.4002007RE5; Korb T, 2004, EXP CELL RES, V299, P236, DOI 10.1016/j.yexcr.2004.06.001; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mendoza M, 2009, INT J BIOCHEM CELL B, V41, P1452, DOI 10.1016/j.biocel.2009.01.015; Miles FL, 2008, CLIN EXP METASTAS, V25, P305, DOI 10.1007/s10585-007-9098-2; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Whipple RA, 2008, CANCER RES, V68, P5678, DOI 10.1158/0008-5472.CAN-07-6589; Whipple RA, 2007, EXP CELL RES, V313, P1326, DOI 10.1016/j.yexcr.2007.02.001; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0	20	53	54	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6402	6408		10.1038/onc.2010.360	http://dx.doi.org/10.1038/onc.2010.360			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20956943	Green Accepted			2022-12-17	WOS:000284874700010
J	Aguilar, H; Sole, X; Bonifaci, N; Serra-Musach, J; Islam, A; Lopez-Bigas, N; Mendez-Pertuz, M; Beijersbergen, RL; Lazaro, C; Urruticoechea, A; Pujana, MA				Aguilar, H.; Sole, X.; Bonifaci, N.; Serra-Musach, J.; Islam, A.; Lopez-Bigas, N.; Mendez-Pertuz, M.; Beijersbergen, R. L.; Lazaro, C.; Urruticoechea, A.; Pujana, M. A.			Biological reprogramming in acquired resistance to endocrine therapy of breast cancer	ONCOGENE			English	Article						aromatase inhibition; breast cancer; estrogen receptor; fibroblast growth factor receptor; long-term estrogen-deprived; MCF7	ESTROGEN-RECEPTOR-ALPHA; REGULATORY FACTOR-I; ONCOLOGY TECHNOLOGY-ASSESSMENT; ACTIVATED PROTEIN-KINASE; GENOME-WIDE ASSOCIATION; ESR1 GENE AMPLIFICATION; AROMATASE INHIBITOR; TAMOXIFEN-RESISTANT; ESTRADIOL HYPERSENSITIVITY; ADAPTIVE HYPERSENSITIVITY	Endocrine therapies targeting the proliferative effect of 17 beta-estradiol through estrogen receptor alpha (ER alpha) are the most effective systemic treatment of ER alpha-positive breast cancer. However, most breast tumors initially responsive to these therapies develop resistance through molecular mechanisms that are not yet fully understood. The long-term estrogen-deprived (LTED) MCF7 cell model has been proposed to recapitulate acquired resistance to aromatase inhibitors in postmenopausal women. To elucidate this resistance, genomic, transcriptomic and molecular data were integrated into the time course of MCF7-LTED adaptation. Dynamic and widespread genomic changes were observed, including amplification of the ESR1 locus consequently linked to an increase in ER alpha. Dynamic transcriptomic profiles were also observed that correlated significantly with genomic changes and were predicted to be influenced by transcription factors known to be involved in acquired resistance or cell proliferation (for example, interferon regulatory transcription factor 1 and E2F1, respectively) but, notably, not by canonical ER alpha transcriptional function. Consistently, at the molecular level, activation of growth factor signaling pathways by EGFR/ERBB/AKT and a switch from phospho-Ser118 (pS118)- to pS167-ER alpha were observed during MCF7-LTED adaptation. Evaluation of relevant clinical settings identified significant associations between MCF7-LTED and breast tumor transcriptome profiles that characterize ER alpha-negative status, early response to letrozole and tamoxifen, and recurrence after tamoxifen treatment. In accordance with these profiles, MCF7-LTED cells showed increased sensitivity to inhibition of FGFR-mediated signaling with PD173074. This study provides mechanistic insight into acquired resistance to endocrine therapies of breast cancer and highlights a potential therapeutic strategy. Oncogene (2010) 29, 6071-6083; doi:10.1038/onc.2010.333; published online 16 August 2010	[Aguilar, H.; Urruticoechea, A.; Pujana, M. A.] Bellvitge Inst Biomed Res IDIBELL, Catalan Inst Oncol, Translat Res Lab, Barcelona, Spain; [Sole, X.; Bonifaci, N.; Serra-Musach, J.; Pujana, M. A.] IDIBELL, Catalan Inst Oncol, Biomarkers & Susceptibil Unit, Barcelona, Spain; [Sole, X.; Bonifaci, N.; Serra-Musach, J.; Pujana, M. A.] IDIBELL, Catalan Inst Oncol, Biomed Res Ctr Network Epidemiol & Publ Hlth, Barcelona, Spain; [Islam, A.; Lopez-Bigas, N.] Pompeu Fabra Univ, Dept Expt & Hlth Sci, Res Unit Biomed Informat, Barcelona, Spain; [Mendez-Pertuz, M.] Spanish Natl Canc Res Ctr, Mol Pathol Programme, Epithelial Carcinogenesis Grp, Madrid, Spain; [Beijersbergen, R. L.] Netherlands Canc Inst, Ctr Biomed Genet, Div Mol Carcinogenesis, Amsterdam, Netherlands; [Beijersbergen, R. L.] Netherlands Canc Inst, Canc Genom Ctr, Amsterdam, Netherlands; [Lazaro, C.] IDIBELL, Catalan Inst Oncol, Hereditary Canc Program, Mol Diagnost Unit, Barcelona, Spain	Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Pompeu Fabra University; Centro Nacional de Investigaciones Oncologicas (CNIO); Netherlands Cancer Institute; Netherlands Cancer Institute; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona	Urruticoechea, A (corresponding author), Bellvitge Inst Biomed Res, Catalan Inst Oncol, Translat Res Lab, Gran Via 199-203, Barcelona 08907, Spain.	anderu@iconcologia.net; mapujana@iconcologia.net	Lopez-Bigas, Nuria/F-6193-2011; bonifaci, nuria/B-8104-2019; Solé, Xavier/AAF-3015-2019; GARCIA, CONXI LAZARO/Q-2410-2016; Pujana, Miquel Angel/N-3127-2014; Gasull, Martina/J-4076-2019	Lopez-Bigas, Nuria/0000-0003-4925-8988; bonifaci, nuria/0000-0002-8193-6825; Solé, Xavier/0000-0002-2197-3325; GARCIA, CONXI LAZARO/0000-0002-7198-5906; Pujana, Miquel Angel/0000-0003-3222-4044; Beijersbergen, Roderick/0000-0003-0116-4130; Urruticoechea, Ander/0000-0003-0359-3641; Islam, Abul/0000-0002-7274-0855	Spanish Ministry of Health CIBERESP; Ministry of Science and Innovation (MICINN) [SAF06/05399]	Spanish Ministry of Health CIBERESP; Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	This study was funded by the Spanish Ministry of Health CIBERESP and grant 06/0545 and the Ministry of Science and Innovation (MICINN) grant SAF06/05399. HA was supported by a MICINN postdoctoral fellowship and MAP was a 'Ramon y Cajal' Researcher with the MICINN.	Adelaide J, 2008, INT J CANCER, V123, P2970, DOI 10.1002/ijc.23786; Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Ahn BY, 2010, CANCER RES, V70, P3013, DOI 10.1158/0008-5472.CAN-09-3108; Alvarez MJ, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-12-r143; Balciunaite E, 2005, MOL CELL BIOL, V25, P8166, DOI 10.1128/MCB.25.18.8166-8178.2005; Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391; Beeram M, 2007, ANN ONCOL, V18, P1323, DOI 10.1093/annonc/mdm170; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Bowie ML, 2004, ONCOGENE, V23, P8743, DOI 10.1038/sj.onc.1208120; Brown LA, 2008, NAT GENET, V40, P806, DOI 10.1038/ng0708-806; Bryne JC, 2008, NUCLEIC ACIDS RES, V36, pD102, DOI 10.1093/nar/gkm955; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chan CMW, 2002, J STEROID BIOCHEM, V81, P333, DOI 10.1016/S0960-0760(02)00074-2; Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483; Chia S, 2008, J CLIN ONCOL, V26, P1664, DOI 10.1200/JCO.2007.13.5822; Chlebowski RT, 2002, J CLIN ONCOL, V20, P3328, DOI 10.1200/JCO.2002.06.029; Clarke M, 1998, LANCET, V351, P1451; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Dey JH, 2010, CANCER RES, V70, P4151, DOI 10.1158/0008-5472.CAN-09-4479; Dowsett M, 2005, J STEROID BIOCHEM, V95, P167, DOI 10.1016/j.jsbmb.2005.04.022; Dowsett M, 2005, BREAST CANCER RES TR, V93, pS11, DOI 10.1007/s10549-005-9037-3; Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Ellis MJ, 2006, J CLIN ONCOL, V24, P3019, DOI 10.1200/JCO.2005.04.3034; Galan-Caridad JM, 2007, CELL, V129, P345, DOI 10.1016/j.cell.2007.03.014; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Geisler J, 2002, J CLIN ONCOL, V20, P751, DOI 10.1200/JCO.2002.20.3.751; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Ghayad SE, 2010, INT J CANCER, V126, P545, DOI 10.1002/ijc.24750; Gu ZP, 2002, CANCER RES, V62, P3428; Hoch RV, 1999, INT J CANCER, V84, P122; Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006; Horlings HM, 2008, NAT GENET, V40, P807, DOI 10.1038/ng0708-807; Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; Jelovac D, 2005, CANCER RES, V65, P5380, DOI 10.1158/0008-5472.CAN-04-4502; Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164; Johnston SRD, 2005, J STEROID BIOCHEM, V95, P173, DOI 10.1016/j.jsbmb.2005.04.004; JOHNSTON SRD, 1995, CANCER RES, V55, P3331; Johnston S, 2009, J CLIN ONCOL, V27, P5538, DOI 10.1200/JCO.2009.23.3734; JONAT W, 1995, EUR J CANCER, V31A, P137, DOI 10.1016/0959-8049(94)00415-2; Kanai M, 2009, GENE, V438, P49, DOI 10.1016/j.gene.2009.03.004; KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Korc M, 2009, CURR CANCER DRUG TAR, V9, P639, DOI 10.2174/156800909789057006; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Lewis-Wambi JS, 2008, EUR J CANCER, V44, P1770, DOI 10.1016/j.ejca.2008.05.016; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Martin LA, 2005, ENDOCR-RELAT CANCER, V12, pS75, DOI 10.1677/erc.1.01023; Martin LA, 2003, J BIOL CHEM, V278, P30458, DOI 10.1074/jbc.M305226200; MASAMURA S, 1995, J CLIN ENDOCR METAB, V80, P2918, DOI 10.1210/jc.80.10.2918; Masri S, 2008, CANCER RES, V68, P4910, DOI 10.1158/0008-5472.CAN-08-0303; Massarweh S, 2007, CLIN CANCER RES, V13, P1950, DOI 10.1158/1078-0432.CCR-06-2540; Massarweh S, 2006, ENDOCR-RELAT CANCER, V13, pS15, DOI 10.1677/erc.1.01273; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; McClelland RA, 2001, ENDOCRINOLOGY, V142, P2776, DOI 10.1210/en.142.7.2776; Meyer KB, 2008, PLOS BIOL, V6, P1098, DOI 10.1371/journal.pbio.0060108; Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016; Miller WR, 2007, PHARMACOGENET GENOM, V17, P813, DOI 10.1097/FPC.0b013e32820b853a; Normanno N, 2005, ENDOCR-RELAT CANCER, V12, P721, DOI 10.1677/erc.1.00857; Osborne CK, 2005, CLIN CANCER RES, V11, p865S; Pique-Regi R, 2008, BIOINFORMATICS, V24, P309, DOI 10.1093/bioinformatics/btm601; Reis-Filho JS, 2008, NAT GENET, V40, P809, DOI 10.1038/ng0708-809b; Rose C, 2003, EUR J CANCER, V39, P2318, DOI 10.1016/S0959-8049(03)00630-0; Sabnis GJ, 2005, CANCER RES, V65, P3903, DOI 10.1158/0008-5472.CAN-04-4092; Sadler AJ, 2009, J STEROID BIOCHEM, V114, P21, DOI 10.1016/j.jsbmb.2008.12.017; Santen R, 2001, J STEROID BIOCHEM, V79, P115, DOI 10.1016/S0960-0760(01)00151-0; Santen RJ, 2008, ADV EXP MED BIOL, V630, P19; Santen RJ, 2005, ENDOCR-RELAT CANCER, V12, pS61, DOI 10.1677/erc.1.01018; Schild-Hay LJ, 2009, CANCER RES, V69, P1150, DOI 10.1158/0008-5472.CAN-08-2806; Schones DE, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-19; Shaw LE, 2006, J STEROID BIOCHEM, V99, P19, DOI 10.1016/j.jsbmb.2005.11.005; Shen RL, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-28; Shim WS, 2000, ENDOCRINOLOGY, V141, P396, DOI 10.1210/en.141.1.396; Sole X, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004544; Song RXD, 2006, ENDOCR-RELAT CANCER, V13, pS3, DOI 10.1677/erc.1.01322; Stamm S, 2006, NUCLEIC ACIDS RES, V34, pD46, DOI 10.1093/nar/gkj031; Stephen R, 2000, BRIT J CANCER, V83, P1183, DOI 10.1054/bjoc.2000.1388; Stephen RL, 2001, J BIOL CHEM, V276, P40080, DOI 10.1074/jbc.M105892200; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tashiro E, 2003, ONCOGENE, V22, P5630, DOI 10.1038/sj.onc.1206636; Tomita S, 2009, CANCER SCI, V100, P1012, DOI 10.1111/j.1349-7006.2009.01145.x; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vincent-Salomon A, 2008, NAT GENET, V40, P809, DOI 10.1038/ng0708-809a; WELSHONS WV, 1987, EUR J CANCER CLIN ON, V23, P1935, DOI 10.1016/0277-5379(87)90062-9; Winer EP, 2002, J CLIN ONCOL, V20, P3317, DOI 10.1200/JCO.2002.06.020; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Xu XQ, 2007, GENOME RES, V17, P1550, DOI 10.1101/gr.6783507; Yu JX, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-182; Yue W, 2005, INT J CANCER, V117, P746, DOI 10.1002/ijc.21222; Yue W, 2003, J STEROID BIOCHEM, V86, P265, DOI 10.1016/S0960-0760(03)00366-2; Zhang Z, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-331	98	53	54	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6071	6083		10.1038/onc.2010.333	http://dx.doi.org/10.1038/onc.2010.333			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20711236				2022-12-17	WOS:000284108700009
J	Salem, H; Rachmin, I; Yissachar, N; Cohen, S; Amiel, A; Haffner, R; Lavi, L; Motro, B				Salem, H.; Rachmin, I.; Yissachar, N.; Cohen, S.; Amiel, A.; Haffner, R.; Lavi, L.; Motro, B.			Nek7 kinase targeting leads to early mortality, cytokinesis disturbance and polyploidy	ONCOGENE			English	Article						NIMA; kinase; gene targeting; early lethality; cytokinesis; mitosis	NIMA-FAMILY KINASE; POLYCYSTIC KIDNEY-DISEASE; MITOTIC SPINDLE FORMATION; CELL-CYCLE; PROTEIN-KINASES; ASPERGILLUS-NIDULANS; MAMMALIAN-CELLS; MURINE KINASES; PRIMARY CILIA; CENTROSOME	The mammalian NIMA-related kinases (Neks) are commonly referred to as mitotic kinases, although a definitive in vivo verification of this definition is largely missing. Reduction in the activity of Nek7 or its close paralog, Nek6, has previously been shown to arrest cells in mitosis, mainly at metaphase. In this study, we investigate the developmental and cellular roles of Nek7 kinase through the generation and analysis of Nek7-deficient mice. We show that absence of Nek7 leads to lethality in late embryogenesis or at early post-natal stages and to severe growth retardation. Mouse embryonic fibroblasts (MEFs) derived from Nek7(-/-) embryos show increase tendency for chromosomal lagging, micronuclei formation and cytokinesis failure. Tetraploidy and aneuploidy were commonly observed and their prevalence arises with MEFs passages. The frequency of multicentrosomal cells in the mutant's MEF cells was higher, and it commonly occurred concurrently with a binuclear phenotype, suggesting cytokinesis failure etiology. Lastly, the percentage of mutant MEF cells bearing primary cilia (PC) was low, whereas a cell population having two cilia appeared in the mutant MEFs. Taken together, these results confirm Nek7 as a regulator of cell division, and reveal it as an essential component for mammalian growth and survival. The intimate connection between tetraploidy, aneuploidy and cancer development suggests that Nek7 deregulation can induce oncogenesis. Oncogene (2010) 29, 4046-4057; doi:10.1038/onc.2010.162; published online 17 May 2010	[Salem, H.; Rachmin, I.; Yissachar, N.; Cohen, S.; Amiel, A.; Lavi, L.; Motro, B.] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel; [Amiel, A.] Meir Med Ctr, Genet Inst, Kefar Sava, Israel; [Haffner, R.] Weizmann Inst Sci, Dept Vet Resources, IL-76100 Rehovot, Israel	Bar Ilan University; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science	Motro, B (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel.	motro@mail.biu.ac.il	/ABF-8487-2022	Yissachar, Nissan/0000-0002-7647-9754	Bar-Ilan Rector	Bar-Ilan Rector	We thank G Damari and A Berkovitz from the Transgenic Unit of the Weizmann Institute for generation of chimeras. We also thank S Madar, Weizmann Institute, for real time RT-PCR analyses; R Palmiter, University of Washington, for providing the pNeoZTK2 vector. This study is supported by funds from Bar-Ilan Rector.	Akhter S, 2004, MOL CELL BIOL, V24, P10448, DOI 10.1128/MCB.24.23.10448-10455.2004; Aleem Eiman, 2006, V42, P271, DOI 10.1007/023; Alieva IB, 2004, CELL BIOL INT, V28, P139, DOI 10.1016/j.cellbi.2003.11.013; Barr FA, 2007, CELL, V131, P847, DOI 10.1016/j.cell.2007.11.011; Belham C, 2003, J BIOL CHEM, V278, P34897, DOI 10.1074/jbc.M303663200; Capra M, 2006, CANCER RES, V66, P8147, DOI 10.1158/0008-5472.CAN-05-3489; Castillo A, 2007, CANCER RES, V67, P10138, DOI 10.1158/0008-5472.CAN-07-0326; De Souza CPC, 2003, GENETICS, V165, P1071; EPSTEIN CJ, 1967, P NATL ACAD SCI USA, V57, P327, DOI 10.1073/pnas.57.2.327; Feige E, 2002, MECH DEVELOP, V110, P219, DOI 10.1016/S0925-4773(01)00573-1; FRY AM, 1995, CURR BIOL, V5, P1122, DOI 10.1016/S0960-9822(95)00227-2; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Glotzer M, 2009, NAT REV MOL CELL BIO, V10, P9, DOI 10.1038/nrm2609; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Kandli M, 2000, GENOMICS, V68, P187, DOI 10.1006/geno.2000.6293; Kim S, 2007, BIOCHEM BIOPH RES CO, V360, P56, DOI 10.1016/j.bbrc.2007.05.206; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Lee MY, 2008, CELL CYCLE, V7, P2705, DOI 10.4161/cc.7.17.6551; Liu SM, 2002, DEVELOPMENT, V129, P5839, DOI 10.1242/dev.00173; Mahjoub MR, 2005, J AM SOC NEPHROL, V16, P3485, DOI 10.1681/ASN.2005080824; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; O'Connell MJ, 2003, TRENDS CELL BIOL, V13, P221, DOI 10.1016/S0962-8924(03)00056-4; O'Regan L, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-25; O'Regan L, 2009, MOL CELL BIOL, V29, P3975, DOI 10.1128/MCB.01867-08; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; Parker JDK, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001076; Rapley J, 2008, J CELL SCI, V121, P3912, DOI 10.1242/jcs.035360; Roig J, 2005, MOL BIOL CELL, V16, P4827, DOI 10.1091/mbc.E05-04-0315; Roig J, 2002, GENE DEV, V16, P1640, DOI 10.1101/gad.972202; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Shalom O, 2008, FEBS LETT, V582, P1465, DOI 10.1016/j.febslet.2008.03.036; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smith LA, 2006, J AM SOC NEPHROL, V17, P2821, DOI 10.1681/ASN.2006020136; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Storchova Z, 2008, J CELL SCI, V121, P3859, DOI 10.1242/jcs.039537; Upadhya P, 2000, P NATL ACAD SCI USA, V97, P217, DOI 10.1073/pnas.97.1.217; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; White MC, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-29; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6; Yin MJ, 2003, J BIOL CHEM, V278, P52454, DOI 10.1074/jbc.M308080200; Yissachar N, 2006, FEBS LETT, V580, P6489, DOI 10.1016/j.febslet.2006.10.069	45	53	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4046	4057		10.1038/onc.2010.162	http://dx.doi.org/10.1038/onc.2010.162			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20473324				2022-12-17	WOS:000279892400005
J	Santhanam, AN; Baker, AR; Hegamyer, G; Kirschmann, DA; Colburn, NH				Santhanam, A. N.; Baker, A. R.; Hegamyer, G.; Kirschmann, D. A.; Colburn, N. H.			Pdcd4 repression of lysyl oxidase inhibits hypoxia-induced breast cancer cell invasion	ONCOGENE			English	Article						PDCD4; lysyl oxidase; breast cancer; hypoxia	TRANSFORMATION SUPPRESSOR PDCD4; TUMOR-SUPPRESSOR; PROTEIN PDCD4; INDUCIBLE FACTOR-1-ALPHA; EUKARYOTIC TRANSLATION; GENE-EXPRESSION; CARCINOMA; AKT; METASTASIS; ACTIVATION	Metastasis to bone, liver and lungs is the primary cause of death in breast cancer patients. Our studies have revealed that the novel tumor suppressor Pdcd4 inhibits breast cancer cell migration and invasion in vitro. Loss of Pdcd4 in human nonmetastatic breast cancer cells increased the expression of lysyl oxidase (LOX) mRNA. LOX is a hypoxia-inducible amine oxidase, the activity of which enhances breast cancer cell invasion in vitro and in vivo. Specific inhibition of LOX activity by beta-aminopropionitrile or small interfering RNA decreased the invasiveness of T47D and MCF7 breast cancer cells attenuated for Pdcd4 function. Most significantly, loss of Pdcd4 augments hypoxia induction of LOX as well. Conversely, overexpression of Pdcd4 significantly reversed the hypoxia induction of LOX expression in T47D cells attenuated for Pdcd4. However, Pdcd4 did not affect hypoxia-inducible factor-1 (HIF-1) protein expression or HIF-1-responsive element-luciferase activity in response to hypoxia, suggesting that Pdcd4 regulation of LOX occurs through an HIF-independent mechanism. Nevertheless, the loss of Pdcd4 early in cancer progression may have an important role in the increased sensitivity of cancer cells to hypoxia through increased LOX activity and concomitant enhanced invasiveness. Oncogene (2010) 29, 3921-3932; doi:10.1038/onc.2010.158; published online 24 May 2010	[Santhanam, A. N.; Baker, A. R.; Hegamyer, G.; Colburn, N. H.] NCI, Gene Regulat Sect, Lab Canc Prevent, Ctr Canc Res, Frederick, MD 21702 USA; [Kirschmann, D. A.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Childrens Mem Res Ctr,Canc Biol & Epigen Program, Chicago, IL 60611 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Santhanam, AN (corresponding author), NCI, Gene Regulat Sect, Lab Canc Prevent, Ctr Canc Res, Boyles St, Frederick, MD 21702 USA.	santhanama@ncifcrf.gov			NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010026] Funding Source: NIH RePORTER	NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Giovanni Melillo and Annamaria Rapisarda (Tumor Hypoxia Laboratory, NCI-Frederick) for helpful suggestions and for the use of reagents and hypoxia chambers. We also thank members of the Gene Regulation Section, Laboratory of Cancer Prevention, for helpful discussions. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	Arsham AM, 2004, CANCER RES, V64, P3500, DOI 10.1158/0008-5472.CAN-03-2239; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Atsawasuwan P, 2008, J BIOL CHEM, V283, P34229, DOI 10.1074/jbc.M803142200; Bedogni B, 2005, CANCER CELL, V8, P443, DOI 10.1016/j.ccr.2005.11.005; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Chen HHW, 2007, BREAST CANCER RES TR, V103, P167, DOI 10.1007/s10549-006-9360-3; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Csiszar K, 1996, MOL BIOL REP, V23, P97, DOI 10.1007/BF00424435; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Erler JT, 2006, CANCER RES, V66, P10238, DOI 10.1158/0008-5472.CAN-06-3197; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Goke R, 2004, ANN NY ACAD SCI, V1014, P220, DOI 10.1196/annals.1294.024; Goke R, 2004, AM J PHYSIOL-CELL PH, V287, pC1541, DOI 10.1152/ajpcell.00025.2004; Ivan M, 2008, J CELL MOL MED, V12, P1426, DOI 10.1111/j.1582-4934.2008.00398.x; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; Jeay S, 2003, MOL CELL BIOL, V23, P2251, DOI 10.1128/MCB.23.7.2251-2263.2003; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; Kang YB, 2005, EXPERT REV MOL DIAGN, V5, P385, DOI 10.1586/14737159.5.3.385; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kirschmann DA, 2002, CANCER RES, V62, P4478; Kronblad A, 2006, INT J CANCER, V118, P2609, DOI 10.1002/ijc.21676; Kulshreshtha R, 2008, CELL DEATH DIFFER, V15, P667, DOI 10.1038/sj.cdd.4402310; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Li T, 2009, BIOCHEM BIOPH RES CO, V383, P280, DOI 10.1016/j.bbrc.2009.03.077; Li YM, 2005, CANCER RES, V65, P3257, DOI 10.1158/0008-5472.CAN-04-1284; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Lundgren K, 2007, CELL MOL LIFE SCI, V64, P3233, DOI 10.1007/s00018-007-7390-6; Melillo G, 1999, CANCER RES, V59, P5433; Min CY, 2007, CANCER RES, V67, P1105, DOI 10.1158/0008-5472.CAN-06-3867; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Nieves-Alicea R, 2009, BREAST CANCER RES TR, V114, P203, DOI 10.1007/s10549-008-9993-5; PASTOREK J, 1994, ONCOGENE, V9, P2877; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Postovit LM, 2008, J CELL BIOCHEM, V103, P1369, DOI 10.1002/jcb.21517; Rucker RB, 1998, AM J CLIN NUTR, V67, p996S, DOI 10.1093/ajcn/67.5.996S; Schindl M, 2002, CLIN CANCER RES, V8, P1831; Schmid T, 2008, CANCER RES, V68, P1254, DOI 10.1158/0008-5472.CAN-07-1719; Schmitz KJ, 2004, MODERN PATHOL, V17, P15, DOI 10.1038/modpathol.3800002; Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9; Tan RSP, 1996, CANCER RES, V56, P2417; van der Groep P, 2008, BREAST CANCER RES TR, V111, P475, DOI 10.1007/s10549-007-9817-z; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; Waters LC, 2007, ONCOGENE, V26, P4941, DOI 10.1038/sj.onc.1210305; Wen YH, 2007, ONCOL REP, V18, P1387; Yagata H, 2003, PATHOL INT, V53, P501, DOI 10.1046/j.1440-1827.2003.01514.x; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Zakowicz H, 2005, RNA, V11, P261, DOI 10.1261/rna.7191905; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	62	53	59	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2010	29	27					3921	3932		10.1038/onc.2010.158	http://dx.doi.org/10.1038/onc.2010.158			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20498644	Green Accepted			2022-12-17	WOS:000279603200005
J	Ooki, A; Yamashita, K; Kikuchi, S; Sakuramoto, S; Katada, N; Kokubo, K; Kobayashi, H; Kim, MS; Sidransky, D; Watanabe, M				Ooki, A.; Yamashita, K.; Kikuchi, S.; Sakuramoto, S.; Katada, N.; Kokubo, K.; Kobayashi, H.; Kim, M. S.; Sidransky, D.; Watanabe, M.			Potential utility of HOP homeobox gene promoter methylation as a marker of tumor aggressiveness in gastric cancer	ONCOGENE			English	Article						HOP homeobox; gastric cancer; methylation; prognosis	ABERRANT METHYLATION; DNA METHYLATION; EXPRESSION; HYPERMETHYLATION; ESTROGEN; PGP9.5; INACTIVATION; CHEMOTHERAPY; MANAGEMENT; SCORE	HOP homeobox (HOPX) is an unusual homeobox gene encoding three spliced transcript variants, among which the only HOPX-beta promoter harbors CpG islands. The characteristics of its promoter methylation was analyzed using bisulfite sequencing and quantitative-methylation-specific polymerase chain reaction (Q-MSP), and the effects of HOPX expression were also examined. HOPX-beta expression was silenced in all gastric cancer cell lines tested; its expression could be restored by treatment with demethylating agent. On Q-MSP, HOPX-beta hypermethylation (cut-off value of 3.55) was found in 84% (67 out of 80) of primary tumor tissues and 10% (8 out of 80) of the corresponding normal tissues and could discriminate normal from tumor tissues (P<0.0001). The prognosis of the advanced cases with HOPX-beta hypermethylation was as poor as those with stage IV disease when cut-off value was set at 11.28. This finding was validated in an independent cohort of 90 advanced gastric cancers. The HOPX-beta hypermethylation was also an independent prognostic factor (P = 0.029) on multivariate analysis. Exogenous HOPX expression significantly inhibited cell proliferation, colony formation and invasion as well as enhanced apoptosis. Taken together, HOPX-beta promoter methylation is a frequent and cancer-specific event in gastric cancer. Quantitative assessment of HOPX-beta methylation has great clinical potential as a marker of tumor aggressiveness. Oncogene (2010) 29, 3263-3275; doi: 10.1038/onc.2010.76; published online 15 March 2010	[Ooki, A.; Yamashita, K.; Kikuchi, S.; Sakuramoto, S.; Katada, N.; Watanabe, M.] Kitasato Univ Hosp, Dept Surg, Kanagawa, Japan; [Kokubo, K.; Kobayashi, H.] Kitasato Univ, Sch Allied Hlth Sci, Dept Med Engn & Technol, Kanagawa 2288555, Japan; [Kim, M. S.; Sidransky, D.] Johns Hopkins Univ, Dept Otolaryngol, Head & Neck Canc Res Inst, Baltimore, MD USA	Kitasato University; Kitasato University; Johns Hopkins University	Ooki, A (corresponding author), Kitasato Univ, Dept Surg, Kitasato 1-15-1, Kanagawa 2288555, Japan.	sp9y9tq9@piano.ocn.ne.jp; gekaw@med.kitasato-u.ac.jp	Kokubo, Kenichi/E-6667-2011	Kokubo, Kenichi/0000-0003-0922-7933	Ministry of Health, Labour and Welfare of Japan; Japanese Foundation for Multidisciplinary Treatment of Cancer	Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Japanese Foundation for Multidisciplinary Treatment of Cancer(Japanese Foundation for Multidisciplinary Treatment of Cancer)	This work was supported, in part, by the Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan and by the Japanese Foundation for Multidisciplinary Treatment of Cancer.	Brena RM, 2006, J MOL MED, V84, P365, DOI 10.1007/s00109-005-0034-0; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Chen Y, 2007, INT J CANCER, V121, P1021, DOI 10.1002/ijc.22753; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Japanese Gastric Cancer Association, 1998, Gastric Cancer, V1, P10; Kee HJ, 2007, J BIOL CHEM, V282, P7700, DOI 10.1074/jbc.M611198200; Kook H, 2006, BIOCHEMISTRY-US, V45, P10584, DOI 10.1021/bi060641s; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lehnert T, 2002, BRIT J SURG, V89, P471, DOI 10.1046/j.0007-1323.2002.02067.x; Liu JW, 2007, INT J CANCER, V121, P1994, DOI 10.1002/ijc.22934; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lowy AM, 1999, ANN SURG, V229, P303, DOI 10.1097/00000658-199903000-00001; Mandelker DL, 2005, CANCER RES, V65, P4963, DOI 10.1158/0008-5472.CAN-04-3923; Miotto E, 2004, CANCER RES, V64, P8156, DOI 10.1158/0008-5472.CAN-04-3000; Nakajima Toshifusa, 2002, Gastric Cancer, V5, P1, DOI 10.1007/s101200200000; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; OOKI A, 2009, INT J CANC IN PRESS; Oshimo Y, 2004, INT J CANCER, V110, P212, DOI 10.1002/ijc.20090; Oshimo Y, 2004, PATHOBIOLOGY, V71, P137, DOI 10.1159/000076468; Park J, 2004, ONCOGENE, V23, P3474, DOI 10.1038/sj.onc.1207470; REMMELE W, 1987, PATHOLOGE, V8, P138; REMMELE W, 1993, PATHOL RES PRACT, V189, P862; Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252; Sotiriou C, 2007, NAT REV CANCER, V7, P545, DOI 10.1038/nrc2173; Takahashi T, 2005, INT J CANCER, V115, P503, DOI 10.1002/ijc.20910; Tokumaru Y, 2003, ONCOGENE, V22, P6954, DOI 10.1038/sj.onc.1206403; Tokumaru Y, 2008, INT J CANCER, V123, P753, DOI 10.1002/ijc.23354; Tomii K, 2007, INT J CANCER, V120, P566, DOI 10.1002/ijc.22341; Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142; Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Yamaguchi S, 2009, INT J CANCER, V124, P2577, DOI 10.1002/ijc.24217; Yamashita K, 2006, CANCER RES, V66, P3921, DOI 10.1158/0008-5472.CAN-05-1511; Yamashita K, 2008, MOL CANCER RES, V6, P31, DOI 10.1158/1541-7786.MCR-07-0213; Yamashita K, 2009, CANCER SCI, V100, P195, DOI 10.1111/j.1349-7006.2008.01022.x; Zhang YJ, 2008, J GASTROEN HEPATOL, V23, P856, DOI 10.1111/j.1440-1746.2007.05140.x; Zou B, 2006, GASTROENTEROLOGY, V131, P1835, DOI 10.1053/j.gastro.2006.09.050	39	53	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3263	3275		10.1038/onc.2010.76	http://dx.doi.org/10.1038/onc.2010.76			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20228841				2022-12-17	WOS:000278321100009
J	Marcel, V; Vijayakumar, V; Fernandez-Cuesta, L; Hafsi, H; Sagne, C; Hautefeuille, A; Olivier, M; Hainaut, P				Marcel, V.; Vijayakumar, V.; Fernandez-Cuesta, L.; Hafsi, H.; Sagne, C.; Hautefeuille, A.; Olivier, M.; Hainaut, P.			p53 regulates the transcription of its Delta 133p53 isoform through specific response elements contained within the TP53 P2 internal promoter	ONCOGENE			English	Article						p53; Delta 133p53 isoform; promoter; transcriptional regulation; genotoxic stress	CANCER-CELLS; GENE; ACTIVATION; ZEBRAFISH; DIFFERENTIATION; DELTA-113P53; SUPPRESSION; EXPRESSION; DELTA-NP73; MUTATIONS	The tumor suppressor p53 protein is activated by genotoxic stress and regulates genes involved in senescence, apoptosis and cell-cycle arrest. Nine p53 isoforms have been described that may modulate suppressive functions of the canonical p53 protein. Among them, Delta 133p53 lacks the 132 proximal residues and has been shown to modulate p53-induced apoptosis and cell-cycle arrest. Delta 133p53 is expressed from a specific mRNA, p53I4, driven by an alternative promoter P2 located between intron 1 and exon 5 of TP53 gene. Here, we report that the P2 promoter is regulated in a p53-dependent manner. Delta 133p53 expression is increased in response to DNA damage by doxorubicin in p53 wild-type cell lines, but not in p53-mutated cells. Chromatin immunoprecipitation and luciferase assays using P2 promoter deletion constructs indicate that p53 binds functional response elements located within the P2 promoter. We also show that Delta 133p53 does not bind specifically to p53 consensus DNA sequence in vitro, but competes with wild-type p53 in specific DNA-binding assays. Finally, we report that Delta 133p53 counteracts p53-dependent growth suppression in clonogenic assays. These observations indicate that D133p53 is a novel target of p53 that may participate in a negative feedback loop controlling p53 function. Oncogene (2010) 29, 2691-2700; doi:10.1038/onc.2010.26; published online 1 March 2010	[Marcel, V.; Vijayakumar, V.; Fernandez-Cuesta, L.; Hafsi, H.; Sagne, C.; Hautefeuille, A.; Olivier, M.; Hainaut, P.] Int Agcy Res Canc, Mol Carcinogenesis Grp, F-69372 Lyon 08, France	World Health Organization; International Agency for Research on Cancer (IARC)	Hainaut, P (corresponding author), Int Agcy Res Canc, Mol Carcinogenesis & Biomarkers Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	Fernandez-Cuesta, Lynnette/O-2415-2017; MARCEL, Virginie/ABF-1904-2020; Fernandez-Cuesta, Lynnette/Z-1875-2019; Marcel, Virginie/H-3037-2011; Olivier, Magali/G-3728-2010; Hainaut, Pierre/B-6018-2012	Fernandez-Cuesta, Lynnette/0000-0002-0724-6703; MARCEL, Virginie/0000-0002-9557-8221; Fernandez-Cuesta, Lynnette/0000-0002-0724-6703; Marcel, Virginie/0000-0002-9557-8221; Olivier, Magali/0000-0002-8202-342X; Hainaut, Pierre/0000-0002-1303-1610; Vijayakumar, Vineetha/0000-0002-4295-7009	Association for International Cancer Research (AICR); Ligue Regionale du Rhone Contre le Cancer	Association for International Cancer Research (AICR); Ligue Regionale du Rhone Contre le Cancer	VM is supported by la Ligue National Contre le Cancer. LF-C is supported by The Association for International Cancer Research (AICR). This project is funded by la Ligue Regionale du Rhone Contre le Cancer.	Bacus SS, 1996, ONCOGENE, V12, P2535; Boldrup L, 2007, EUR J CANCER, V43, P617, DOI 10.1016/j.ejca.2006.10.019; Bourdon JC, 2007, BRIT J CANCER, V97, P277, DOI 10.1038/sj.bjc.6603886; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chen J, 2005, GENE DEV, V19, P2900, DOI 10.1101/gad.1366405; Chen J, 2009, GENE DEV, V23, P278, DOI 10.1101/gad.1761609; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Danilova N, 2008, BLOOD, V112, P5228, DOI 10.1182/blood-2008-01-132290; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hurd C, 1997, ONCOGENE, V15, P991, DOI 10.1038/sj.onc.1201233; Ishimoto O, 2002, CANCER RES, V62, P636; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Marcel V, 2009, CELL MOL LIFE SCI, V66, P391, DOI 10.1007/s00018-008-8336-3; Menendez D, 2007, ONCOGENE, V26, P2191, DOI 10.1038/sj.onc.1210277; MIYASHITA T, 1995, CELL, V80, P293; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; WALDMAN T, 1995, CANCER RES, V55, P5187; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	31	53	57	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2691	2700		10.1038/onc.2010.26	http://dx.doi.org/10.1038/onc.2010.26			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190805				2022-12-17	WOS:000277354600009
J	Mamidipudi, V; Cartwright, CA				Mamidipudi, V.; Cartwright, C. A.			A novel pro-apoptotic function of RACK1: suppression of Src activity in the intrinsic and Akt pathways	ONCOGENE			English	Article						RACK1; Src; apoptosis; mitochondrial cell death; intrinsic pathway; Akt cell survival pathway	PROTEIN-KINASE-C; RECEPTOR-INTERACTING PROTEIN; TRANSCRIPTION FACTORS; INHIBITS APOPTOSIS; BCL-2 PROTEINS; CELL-MIGRATION; CANCER-CELLS; GROWTH; ACTIVATION; ADHESION	Earlier we showed that RACK1 regulates growth of human colon cells by suppressing Src activity at G(1) and mitotic checkpoints. Here, we show that RACK1 also induces apoptosis of the cells, partly by inhibiting Src. In the intrinsic pathway, RACK1 inhibits expression of anti-apoptotic Bcl-2 and Bcl-X-L, induces expression of proapoptotic Bim, targets Bim and Bax to the mitochondria, induces oligomerization of Bax (which requires Bim and inhibition of Src), depolarizes mitochondria membranes, releases cytochrome c, and activates caspases-9 and -3 and death substrates. Bax and Bim are required for RACK1-mediated mitochondrial cell death. RACK1-induced oligomerization of Bax is required for staurosporine-mediated cell death. RACK1 also induces apoptosis by blocking Src activation of the Akt cell survival pathway. This leads to activation of the transcription factor FOXO3, a potent inducer of apoptosis and G(1) arrest. Collectively, our results show that RACK1, partly by inhibiting Src, promotes mitochondrial cell death and blocks Akt-mediated cell survival. Thus, RACK1 inhibits growth and induces death of colon cells. Exploitation of these dual functions could lead to novel colon cancer therapies that mimic RACK1 function. Oncogene (2009) 28, 4421-4433; doi:10.1038/onc.2009.293; published online 21 September 2009	[Cartwright, C. A.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA	Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Dept Med, Sch Med, M211 Alway Bldg,MC 5187,300 Pasteur Dr, Stanford, CA 94305 USA.	chris.cartwright@stanford.edu			National Institutes of Health [DK43743]; Broad Medical Research Program [IBD-0068]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043743] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Broad Medical Research Program; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Jenny Cheng and Gayathri Swaminathan for many helpful discussions and critical review of the data and manuscript. This work was supported by a grant from the National Institutes of Health to CAC (DK43743). Preliminary studies were supported by a pilot grant from the Broad Medical Research Program (IBD-0068).	Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Arimoto K, 2008, NAT CELL BIOL, V10, P1324, DOI 10.1038/ncb1791; Buensuceso CS, 2001, J CELL SCI, V114, P1691; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Cox EA, 2003, MOL BIOL CELL, V14, P658, DOI 10.1091/mbc.E02-03-0142; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; Galluzzi L, 2008, CELL DEATH DIFFER, V15, P1113, DOI 10.1038/cdd.2008.28; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Golubovskaya VM, 2003, MOL CANCER RES, V1, P755; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Griffiths GJ, 2004, J BIOL CHEM, V279, P46113, DOI 10.1074/jbc.M408550200; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Inagaki K, 2006, CARDIOVASC RES, V70, P222, DOI 10.1016/j.cardiores.2006.02.015; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Kang BPS, 2003, AM J PHYSIOL-RENAL, V285, pF1013, DOI 10.1152/ajprenal.00209.2003; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Liou JY, 2005, EXP CELL RES, V306, P75, DOI 10.1016/j.yexcr.2005.01.011; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Makin G, 2003, TRENDS MOL MED, V9, P251, DOI 10.1016/S1471-4914(03)00084-4; Mamidipudi V, 2007, ONCOGENE, V26, P2914, DOI 10.1038/sj.onc.1210091; Mamidipudi V, 2004, MOL CELL BIOL, V24, P6788, DOI 10.1128/MCB.24.15.6788-6798.2004; Mamidipudi V, 2004, FEBS LETT, V567, P321, DOI 10.1016/j.febslet.2004.03.125; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Miyazaki T, 2003, J CELL BIOL, V160, P709, DOI 10.1083/jcb.200209098; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Oberst A, 2008, CELL DEATH DIFFER, V15, P1139, DOI 10.1038/cdd.2008.65; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; SUN Y, 2002, CANCER RES, V21, P6323; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vomastek T, 2007, MOL CELL BIOL, V27, P8296, DOI 10.1128/MCB.00598-07; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	54	53	57	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	2009	28	50					4421	4433		10.1038/onc.2009.293	http://dx.doi.org/10.1038/onc.2009.293			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19767770				2022-12-17	WOS:000272876500002
J	Lai, CPK; Bechberger, JF; Naus, CC				Lai, C. P. K.; Bechberger, J. F.; Naus, C. C.			Pannexin2 as a novel growth regulator in C6 glioma cells	ONCOGENE			English	Article						Panx2; pannexins; gap junction; intercellular communication; C6 glioma	GAP-JUNCTIONS; INTERLEUKIN-1-BETA RELEASE; EXPRESSION; HEMICHANNELS; DEGRADATION; COMMUNICATION; CONNEXIN-43; DELETION; FAMILY; BRAIN	Connexins (Cxs), the gap junction proteins, have been found to be downregulated in many types of cancers including gliomas. By restoring gap junctional communication in cancer cell models, the neoplastic phenotype can be reversed, suggesting Cxs are tumor suppressors. Pannexin2 (Panx2) is a member of the novel gap junction protein family, Panxs, and it has been proposed as a brain-specific protein. Recently, gene array analysis showed an overall reduction of Panx2 in gliomas, and a direct correlation was observed between Panx2 expression and post-diagnosis survival in patients. In this study, we explored the potential inverse correlation between Panx2 and glioma oncogenicity. A decrease or absence of Panx2 expression in a panel of human glioma cell lines was found, whereas an appreciable amount of Panx2 was detected in both human brain and astrocytes. Stable Panx2 expression revealed a flattened morphology and increased cell-cell contacts in rat C6 glioma cells similar to Panx1. However, in contrast to Panx1 and Panx3, Panx2 was predominately detected in the cytoplasm in vesicle-like patterns but not at the plasma membrane. Coexpression of Panx2 and Panx1 did not show colocalization of both Panxs. Strikingly, restoration of Panx2 expression significantly reduced in vitro oncogenicity parameters, including monolayer saturation density and anchorage-independent growth, as well as in vivo tumor growth. This study suggests a role of aberrant Panx2 expression during gliomagenesis, and that Panx2 independently functions as a negative growth regulator without Panx1. Oncogene (2009) 28, 4402-4408; doi: 10.1038/onc.2009.283; published online 14 September 2009	[Lai, C. P. K.; Bechberger, J. F.; Naus, C. C.] Univ British Columbia, Inst Life Sci, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Naus, CC (corresponding author), Univ British Columbia, Inst Life Sci, Dept Cellular & Physiol Sci, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	cnaus@interchange.ubc.ca	Lai, Charles Pin-Kuang/D-5442-2017	Lai, Charles Pin-Kuang/0000-0001-8050-7060	Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The research was supported by the Canadian Institutes of Health Research. The authors thank Dr WC Sin for the critical review of the paper, Dr L Matsuuchi for the insightful data discussions, as well as Lynne Bechberger for proofreading the paper. CCN is a recipient of a Canada Research Chair.	Baranova A, 2004, GENOMICS, V83, P706, DOI 10.1016/j.ygeno.2003.09.025; Barth RF, 1998, J NEURO-ONCOL, V36, P91, DOI 10.1023/A:1005805203044; Berthoud VA, 2004, CARDIOVASC RES, V62, P256, DOI 10.1016/j.cardiores.2003.12.021; Boengler K, 2005, CARDIOVASC RES, V67, P234, DOI 10.1016/j.cardiores.2005.04.014; Bruzzone R, 2005, J NEUROCHEM, V92, P1033, DOI 10.1111/j.1471-4159.2004.02947.x; Bruzzone R, 2003, P NATL ACAD SCI USA, V100, P13644, DOI 10.1073/pnas.2233464100; Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023; D'Abaco GM, 2007, J CLIN NEUROSCI, V14, P1041, DOI 10.1016/j.jocn.2007.06.019; Das Sarma J, 2005, CELL COMMUN ADHES, V12, P237, DOI 10.1080/15419060500511875; Hu J, 2004, CHINESE MED J-PEKING, V117, P456; Huang YJ, 2007, P NATL ACAD SCI USA, V104, P6436, DOI 10.1073/pnas.0611280104; Ino Y, 1999, J NEUROPATH EXP NEUR, V58, P881, DOI 10.1097/00005072-199908000-00010; Lai CPK, 2007, CANCER RES, V67, P1545, DOI 10.1158/0008-5472.CAN-06-1396; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Li H, 2002, AM J PHYSIOL-HEART C, V282, pH2124, DOI 10.1152/ajpheart.01028.2001; Litvin O, 2006, J CELL MOL MED, V10, P613, DOI 10.1111/j.1582-4934.2006.tb00424.x; Locovei S, 2006, P NATL ACAD SCI USA, V103, P7655, DOI 10.1073/pnas.0601037103; LOEWENSTEIN WR, 1987, CELL, V48, P725, DOI 10.1016/0092-8674(87)90067-5; Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4; Naus CC, 2005, GAP JUNCTIONS IN DEVELOPMENT AND DISEASE, P253, DOI 10.1007/3-540-28621-7_12; Naus CCG, 2002, CAN J PHYSIOL PHARM, V80, P136, DOI 10.1139/Y02-009; NAUS CCG, 1991, NEUROSCI LETT, V126, P33, DOI 10.1016/0304-3940(91)90364-Y; Oskam NT, 2000, INT J CANCER, V85, P336, DOI 10.1002/(SICI)1097-0215(20000201)85:3<336::AID-IJC7>3.0.CO;2-9; Pelegrin P, 2007, J BIOL CHEM, V282, P2386, DOI 10.1074/jbc.M610351200; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Qin H, 2003, J BIOL CHEM, V278, P30005, DOI 10.1074/jbc.M300614200; Ray A, 2006, CEREBELLUM, V5, P189, DOI 10.1080/14734220500530082; Romanov RA, 2007, EMBO J, V26, P657, DOI 10.1038/sj.emboj.7601526; Schulz R, 2007, HEART FAIL REV, V12, P261, DOI 10.1007/s10741-007-9032-3; Skerrett IM, 2004, FASEB J, V18, P860, DOI 10.1096/fj.03-0763fje; Thomas T, 2005, J CELL SCI, V118, P4451, DOI 10.1242/jcs.02569; Thompson RJ, 2006, SCIENCE, V312, P924, DOI 10.1126/science.1126241; Trosko JE, 2002, CURR DRUG TARGETS, V3, P465, DOI 10.2174/1389450023347371; Vogt A, 2005, MOL BRAIN RES, V141, P113, DOI 10.1016/j.molbrainres.2005.08.002; Wang XH, 2009, J COMP NEUROL, V512, P336, DOI 10.1002/cne.21898; Zappala A, 2007, NEUROSCIENCE, V148, P653, DOI 10.1016/j.neuroscience.2007.06.028; Zheng L, 2007, INT J INF SECUR, V6, P67, DOI 10.1007/s10207-007-0019-9	38	53	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4402	4408		10.1038/onc.2009.283	http://dx.doi.org/10.1038/onc.2009.283			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19749789				2022-12-17	WOS:000272876400009
J	Olaussen, KA; Commo, F; Tailler, M; Lacroix, L; Vitale, I; Raza, SQ; Richon, C; Dessen, P; Lazar, V; Soria, JC; Kroemer, G				Olaussen, K. A.; Commo, F.; Tailler, M.; Lacroix, L.; Vitale, I.; Raza, S. Q.; Richon, C.; Dessen, P.; Lazar, V.; Soria, J-C; Kroemer, G.			Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines	ONCOGENE			English	Article						pazopanib; lapatinib; TKIs; apoptosis; kinome; transcriptome	EPIDERMAL-GROWTH-FACTOR; TUMOR-CELLS; FACTOR RECEPTOR-1; DUAL INHIBITION; MESSENGER-RNA; RIBOSOMAL-RNA; DRUG INSIGHT; C-MET; CANCER; EXPRESSION	Pazopanib and lapatinib are two tyrosine kinase inhibitors that have been designed to inhibit the VEGF tyrosine kinase receptors 1, 2 and 3 (pazopanib), and the HER1 and HER2 receptors in a dual manner (lapatinib). Pazopanib has also been reported to mediate inhibitory effect on a selected panel of additional tyrosine kinases such as PDGFR and c-kit. Here, we report that pazopanib and lapatinib act synergistically to induce apoptosis of A549 non-small-cell lung cancer cells. Systematic assessment of the kinome revealed that both pazopanib and lapatinib inhibited dozens of different tyrosine kinases and that their combination could suppress the activity of some tyrosine kinases (such as c-Met) that were not or only partially affected by either of the two agents alone. We also found that pazopanib and lapatinib induced selective changes in the transcriptome of A549 cells, some of which were specific for the combination of both agents. Analysis of a panel of unrelated human carcinoma cell lines revealed a signature of 52 genes whose up- or downregulation reflected the combined action of pazopanib and lapatinib. Indeed, pazopanib and lapatinib exerted synergistic cytotoxic effects on several distinct non-small-cell lung cancer cells as well as on unrelated carcinomas. Altogether, these results support the contention that combinations of tyrosine kinase inhibitors should be evaluated for synergistic antitumor effects. Such combinations may lead to a 'collapse' of pro-survival signal transduction pathways that leads to apoptotic cell death. Oncogene (2009) 28, 4249-4260; doi: 10.1038/onc.2009.277; published online 14 September 2009	[Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Olaussen, K. A.; Commo, F.; Lacroix, L.; Soria, J-C] Inst Gustave Roussy, Lab Rech Translat, F-94805 Villejuif, France; [Olaussen, K. A.; Tailler, M.; Vitale, I.; Raza, S. Q.; Soria, J-C; Kroemer, G.] Univ Paris 11, Paris, France; [Richon, C.; Dessen, P.; Lazar, V.] Inst Gustave Roussy, Unite Genom Fonct & Bioinformat, F-94805 Villejuif, France; [Soria, J-C] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Lazar, Vladimir/AAV-2087-2020; Kroemer, Guido/AAY-9859-2020; Raza, Syed/G-3158-2016; Vitale, Ilio/M-3960-2017; Soria, Jean-Charles/F-3619-2014; KROEMER, Guido/B-4263-2013; Lazar, Vladimir/AAQ-2086-2020	Raza, Syed/0000-0003-3536-6611; Vitale, Ilio/0000-0002-5918-1841; KROEMER, Guido/0000-0002-9334-4405; RICHON, Catherine/0000-0002-3556-3941; Olaussen, Ken/0000-0002-3115-8914	Ligue Nationale contre le Cancer; Agence Nationale de Recherche; Institut National contre le Cancer; Canceropole Ile-de France; European Union; Fondation pour la Recherche Medicale	Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Agence Nationale de Recherche(French National Research Agency (ANR)); Institut National contre le Cancer; Canceropole Ile-de France(Region Ile-de-France); European Union(European Commission); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	GK received grants from Ligue Nationale contre le Cancer (equipe labellisee), Agence Nationale de Recherche, Institut National contre le Cancer, Canceropole Ile-de France, European Union (Active p53, ApoSys, ChemoRes, DeathTrain, RIGHT, TransDeath) and Fondation pour la Recherche Medicale.	Barnes CJ, 2003, CANCER METAST REV, V22, P301, DOI 10.1023/A:1023726827771; Bianco R, 2008, CLIN CANCER RES, V14, P5069, DOI 10.1158/1078-0432.CCR-07-4905; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; Bozec A, 2007, BRIT J CANCER, V97, P65, DOI 10.1038/sj.bjc.6603791; Calandrella N, 2007, J EXP CLIN CANC RES, V26, P405; Cameron DA, 2008, NAT CLIN PRACT ONCOL, V5, P512, DOI 10.1038/ncponc1156; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chien AJ, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3595; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Danilov AV, 2005, BRIT J HAEMATOL, V128, P472, DOI 10.1111/j.1365-2141.2004.05346.x; Donnem T, 2007, CLIN CANCER RES, V13, P6649, DOI 10.1158/1078-0432.CCR-07-0414; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1037; Edinger AL, 2007, BIOCHEM J, V406, P1, DOI 10.1042/BJ20070490; Fan F, 2005, ONCOGENE, V24, P2647, DOI 10.1038/sj.onc.1208246; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Fransson A, 2003, J BIOL CHEM, V278, P6495, DOI 10.1074/jbc.M208609200; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Golubovskaya V, 2002, J BIOL CHEM, V277, P38978, DOI 10.1074/jbc.M205002200; Harris PA, 2008, J MED CHEM, V51, P4632, DOI 10.1021/jm800566m; Hayashida N, 2006, EMBO J, V25, P4773, DOI 10.1038/sj.emboj.7601370; Hegde PS, 2007, MOL CANCER THER, V6, P1629, DOI 10.1158/1535-7163.MCT-05-0399; Helfrich BA, 2006, CLIN CANCER RES, V12, P7117, DOI 10.1158/1078-0432.CCR-06-0760; HOUGE G, 1995, MOL CELL BIOL, V15, P2051; Hulit J, 2002, BIOCHEM PHARMACOL, V64, P827, DOI 10.1016/S0006-2952(02)01145-0; Hurwitz HI, 2009, CLIN CANCER RES, V15, P4220, DOI 10.1158/1078-0432.CCR-08-2740; Johnson SA, 2005, NAT METHODS, V2, P17, DOI 10.1038/NMETH731; Joo JH, 2007, CANCER RES, V67, P7929, DOI 10.1158/0008-5472.CAN-07-0931; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; KLAWITTER J, 2009, BIOMED CHROMATOGR; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kumar R, 2007, MOL CANCER THER, V6, P2012, DOI 10.1158/1535-7163.MCT-07-0193; Lee TH, 2007, PLOS MED, V4, P1101, DOI 10.1371/journal.pmed.0040186; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; Mourali J, 2006, MOL CELL BIOL, V26, P6209, DOI 10.1128/MCB.01515-05; Nadano D, 2000, J BIOL CHEM, V275, P13967, DOI 10.1074/jbc.275.18.13967; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Oberst MD, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-189; Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078-0432.CCR-06-0818; Petit AMV, 1997, AM J PATHOL, V151, P1523; Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315; Podar K, 2006, P NATL ACAD SCI USA, V103, P19478, DOI 10.1073/pnas.0609329103; Press MF, 2008, CLIN CANCER RES, V14, P7861, DOI 10.1158/1078-0432.CCR-08-1056; Puri N, 2007, CANCER RES, V67, P3529, DOI 10.1158/0008-5472.CAN-06-4416; Puri Neelu, 2008, J Carcinog, V7, P9; Riely GJ, 2009, J CLIN ONCOL, V27, P264, DOI 10.1200/JCO.2008.17.4656; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Simiantonaki N, 2008, INT J ONCOL, V32, P585; Sini P, 2008, CANCER RES, V68, P1581, DOI 10.1158/0008-5472.CAN-06-4685; Sleijfer S, 2008, NAT CLIN PRACT ONCOL, V5, P102, DOI 10.1038/ncponc1037; Sloan B, 2008, CURR OPIN INVEST DR, V9, P1324; Sonpavde G, 2008, EXPERT OPIN INV DRUG, V17, P253, DOI 10.1517/13543784.17.2.253; Storey John D, 2003, Methods Mol Biol, V224, P149; Storniolo AM, 2008, J CLIN ONCOL, V26, P3317, DOI 10.1200/JCO.2007.13.5202; Thompson HJ, 2004, CANCER RES, V64, P1541, DOI 10.1158/0008-5472.CAN-03-3108; Vitale I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001337; Wettenhall JM, 2004, BIOINFORMATICS, V20, P3705, DOI 10.1093/bioinformatics/bth449; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Wu BL, 2006, BIOINFORMATICS, V22, P472, DOI 10.1093/bioinformatics/bti827; ZAMZAMI N, 2003, METH MOL B, V282, P103	64	53	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4249	4260		10.1038/onc.2009.277	http://dx.doi.org/10.1038/onc.2009.277			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19749798				2022-12-17	WOS:000272876300003
J	Cimmino, F; Schulte, JH; Zollo, M; Koster, J; Versteeg, R; Iolascon, A; Eggert, A; Schramm, A				Cimmino, F.; Schulte, J. H.; Zollo, M.; Koster, J.; Versteeg, R.; Iolascon, A.; Eggert, A.; Schramm, A.			Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness	ONCOGENE			English	Article						neuroblastoma; Galectin-1; TrkB; neurotrophin receptors	NEUROTROPHIC FACTOR; CLASSICAL HODGKIN; TUMOR PROGRESSION; IMMUNE PRIVILEGE; GENE-EXPRESSION; H-RAS; CELLS; CANCER; TARGET; INVASIVENESS	Expression of Trk receptors is an important prognostic factor in neuroblastoma (NB) and other cancers. TrkB and its ligand brain-derived neurotrophic factor (BDNF) are preferentially expressed in NB with poor prognosis, conferring invasive and metastatic potential to the tumor cells as well as enhancing therapy resistance. Galectin-1 (Gal-1) has emerged as an interesting cancer target, as it is involved in modulating cell proliferation, cell death and cell migration, all of which are linked to cancer initiation and progression. We previously identified Gal-1 mRNA to be upregulated in patients with aggressive, relapsing NB and found that Gal-1 protein was upregulated in human SY5Y NB cells on activation of ectopically expressed TrkB (SY5Y-TrkB), but not TrkA (SY5Y-TrkA). Here, we report that Gal-1 mRNA levels positively correlated with TrkB expression and anticorrelated with TrkA expression in a cohort of 102 primary NB. Immunohistochemical analyses of 92 primary NB specimens revealed high Gal-1 expression in stromal septae and in neuroblasts. BDNF-mediated activation of TrkB enhanced invasiveness and migration in vitro, which could be impaired by transient transfection using Gal-1-specific siRNA or a neutralizing antibody directed against Gal-1. The addition of recombinant Gal-1 (rGal-1) in the absence of BDNF partially restored migration and invasive capacity. Using the Trk inhibitor K252a, we could show that the upregulation of Gal-1 protein strictly depended on activated TrkB. Our data suggest that targeting Gal-1 might be a promising strategy for the treatment of aggressive NB. Oncogene (2009) 28, 2015-2023; doi:10.1038/onc.2009.70; published online 13 April 2009	[Cimmino, F.; Zollo, M.; Iolascon, A.] Univ Naples Federico 2, Dipartimento Biochim & Biotecnol Med, Ctr Ingn Genet CEINGE Biotecnol Avanzate, Naples, Italy; [Koster, J.; Versteeg, R.] AMC Amsterdam, Dept Human Genet, Amsterdam, Netherlands; [Cimmino, F.; Schulte, J. H.; Eggert, A.; Schramm, A.] Univ Childrens Hosp Essen, Div Hematol Oncol, Essen, Germany	CEINGE Biotecnologie Avanzate; University of Naples Federico II; University of Amsterdam; Academic Medical Center Amsterdam; University of Duisburg Essen	Schramm, A (corresponding author), Univ Childrens Hosp Essen, Div Hematol Oncol, Hufelandstr 55, D-45122 Essen Nrw, Germany.	alexander.schramm@uni-due.de	Schulte, Johannes H./V-2474-2018; Schulte, Johannes H/G-3981-2010; Schramm, Alexander/G-5688-2010; Versteeg, Rogier/AAQ-1765-2020; Eggert, Angelika/AAE-6907-2022; Koster, Jan/C-5934-2008; Iolascon, Achille/A-4461-2014; Cimmino, Flora/AAA-2378-2020; Cimmino, FLORA/K-6205-2016	Schramm, Alexander/0000-0001-7670-7529; Eggert, Angelika/0000-0003-3476-8184; Koster, Jan/0000-0002-0890-7585; Cimmino, Flora/0000-0003-1538-9285; Cimmino, FLORA/0000-0003-1538-9285; Versteeg, Rogier/0000-0001-7172-0388; iolascon, achille/0000-0002-9558-0356; Schulte, Johannes Hubertus/0000-0003-0671-1201	European Union [037260]	European Union(European Commission)	This study was supported by the 6th framework program of the European Union, Grant no. 037260 (EET-Pipeline).	Belanis L, 2008, MOL BIOL CELL, V19, P1404, DOI 10.1091/mbc.E07-10-1053; Chiang WF, 2008, ORAL ONCOL, V44, P325, DOI 10.1016/j.oraloncology.2007.03.004; Cimmino F, 2007, J PROTEOME RES, V6, P2550, DOI 10.1021/pr060701g; Eggert A, 2001, CANCER RES, V61, P1314; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He JL, 2004, J BIOL CHEM, V279, P4705, DOI 10.1074/jbc.M311183200; Hecht M, 2005, CARCINOGENESIS, V26, P2105, DOI 10.1093/carcin/bgi192; Hecht M, 2004, CANCER RES, V64, P6109, DOI 10.1158/0008-5472.CAN-04-1014; Ho R, 2002, CANCER RES, V62, P6462; Hughes RC, 2001, BIOCHIMIE, V83, P667; Jaboin J, 2002, CANCER RES, V62, P6756; Jung EJ, 2007, INT J CANCER, V120, P2331, DOI 10.1002/ijc.22434; Juszczynski P, 2007, P NATL ACAD SCI USA, V104, P13134, DOI 10.1073/pnas.0706017104; Le Mercier M, 2008, J NEUROPATH EXP NEUR, V67, P456, DOI 10.1097/NEN.0b013e318170f892; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Lucarelli E, 1997, EUR J CANCER, V33, P2068, DOI 10.1016/S0959-8049(97)00266-9; Mathieu V, 2007, J INVEST DERMATOL, V127, P2399, DOI 10.1038/sj.jid.5700869; MATSUMOTO K, 1995, CANCER RES, V55, P1798; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Rabinovich GA, 2005, BRIT J CANCER, V92, P1188, DOI 10.1038/sj.bjc.6602493; Rodig SJ, 2008, CLIN CANCER RES, V14, P3338, DOI 10.1158/1078-0432.CCR-07-4709; Rubinstein N, 2004, CANCER CELL, V5, P241, DOI 10.1016/S1535-6108(04)00024-8; Salatino M, 2008, EXPERT OPIN BIOL TH, V8, P45, DOI 10.1517/14712598.8.1.45; Schramm A, 2005, ONCOGENE, V24, P7902, DOI 10.1038/sj.onc.1208936; Schramm A, 2005, CANCER LETT, V228, P143, DOI 10.1016/j.canlet.2005.02.051; Schulte JH, 2005, ONCOGENE, V24, P165, DOI 10.1038/sj.onc.1208000; Schulte JH, 2008, CANCER LETT, V271, P56, DOI 10.1016/j.canlet.2008.05.039; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Sitek B, 2005, MOL CELL PROTEOMICS, V4, P291, DOI 10.1074/mcp.M400188-MCP200; Stephan H, 2008, PEDIATR BLOOD CANCER, V50, P218, DOI 10.1002/pbc.21369; TAPLEY P, 1992, ONCOGENE, V7, P371; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thijssen VLJL, 2007, BLOOD, V110, P2819, DOI 10.1182/blood-2007-03-077792; Thijssen VLJL, 2006, P NATL ACAD SCI USA, V103, P15975, DOI 10.1073/pnas.0603883103; Yamashiro DJ, 1997, EUR J CANCER, V33, P2054, DOI 10.1016/S0959-8049(97)00309-2	37	53	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2009	28	19					2015	2023		10.1038/onc.2009.70	http://dx.doi.org/10.1038/onc.2009.70			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445BF	19363525				2022-12-17	WOS:000266023900002
J	Tomaic, V; Gardiol, D; Massimi, P; Ozbun, M; Myers, M; Banks, L				Tomaic, V.; Gardiol, D.; Massimi, P.; Ozbun, M.; Myers, M.; Banks, L.			Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators	ONCOGENE			English	Article						papillomavirus; oncoproteins; PDZ domains; Par3	PAPILLOMAVIRUS E6 PROTEINS; MEDIATED DEGRADATION; ACTIVATED RAS; ONCOPROTEIN; SCRIBBLE; SUPPRESSOR; SEQUENCE; RHPV-1; DOMAIN; MOTIF	A unique feature of the cancer-causing mucosotropic human papillomaviruses (HPVs) is the ability of their E6 proteins to interact with a number of PDZ domain-containing cellular substrates, including the cell polarity regulators hDlg and hScrib. These interactions are essential for the ability of these viruses to induce malignant progression. Rhesus papillomaviruses (RhPV) are similar to their human counterparts in that they also cause anogenital malignancy in their host, the Rhesus Macaque. However, unlike HPV E6, the RhPV E6 has no PDZ-binding motif. We now show that such a motif is present on the RhPV E7 oncoprotein. This motif specifically confers PDZ-binding activity and directs the interaction of RhPV E7 with the cell polarity regulator Par3, which it targets for proteasome-mediated degradation. These results demonstrate an amazing evolutionary conservation of function between the RhPV and the HPV oncoproteins, where both target proteins of the same cell polarity control network, although through different components and pathways.	[Tomaic, V.; Gardiol, D.; Massimi, P.; Myers, M.; Banks, L.] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, TS, Italy; [Ozbun, M.] Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); University of New Mexico	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, TS, Italy.	banks@icgeb.org	Ozbun, Michelle Adair/Q-4158-2017; Ozbun, Michelle/AAN-2922-2021	Ozbun, Michelle Adair/0000-0001-8551-4606; Ozbun, Michelle/0000-0001-8551-4606	NIH [CA103645]; NATIONAL CANCER INSTITUTE [R21CA103645] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000164] Funding Source: NIH RePORTER; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	This work was supported in part by a research grant from the Associazione Italiana per la Ricerca sul Cancro to LB and from a Public Health Service Grant from the NIH CA103645 (MAO) to MO.	Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee CH, 2004, J VIROL, V78, P12366, DOI 10.1128/JVI.78.22.12366-12377.2004; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nguyen MM, 2003, MOL CELL BIOL, V23, P8970, DOI 10.1128/MCB.23.24.8970-8981.2003; OSTROW RS, 1991, VIROLOGY, V181, P424; OSTROW RS, 1993, VIROLOGY, V196, P861, DOI 10.1006/viro.1993.1547; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1996, ONCOGENE, V13, P471; Watson RA, 2003, J CELL SCI, V116, P4925, DOI 10.1242/jcs.00809; Wood CE, 2007, J VIROL, V81, P6339, DOI 10.1128/JVI.00233-07; Zhang Y, 2007, J VIROL, V81, P3618, DOI 10.1128/JVI.02044-06; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	23	53	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					1	8		10.1038/onc.2008.365	http://dx.doi.org/10.1038/onc.2008.365			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18820705	Green Accepted			2022-12-17	WOS:000262294100001
J	Gallimore, AM; Simon, AK				Gallimore, A. M.; Simon, A. K.			Positive and negative influences of regulatory T cells on tumour immunity	ONCOGENE			English	Review						tumour; cancer; regulatory T cells; development of regulatory T cells; Th17; Il-23	IMMUNOLOGICAL SELF-TOLERANCE; GROWTH-FACTOR-BETA; THYMIC EPITHELIAL-CELLS; TGF-BETA; CUTTING EDGE; DENDRITIC-CELLS; IN-VIVO; MEDIATED SUPPRESSION; LUNG-CANCER; OVARIAN-CARCINOMA	Clinicians and scientists have long questioned whether the immune system has a role in destroying cancerous tissue. Studies performed in animal models have, however, recently revealed that the immune system can, at least in principle, effectively control tumours. In parallel with these findings, a large body of evidence indicates that although the immune system has the capacity to control tumours, there are also regulatory mechanisms that subdue these responses. A major challenge of tumour immunotherapy, therefore, is to find ways of disabling these regulatory functions while restoring or priming any immune responses that are protective.	[Gallimore, A. M.] Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales; [Simon, A. K.] John Radcliffe Hosp, Weatherall Inst Mol Med, NIHR Biomed Res Ctr, Nuffield Dept Med, Oxford OX3 9DU, England	Cardiff University; University of Oxford	Gallimore, AM (corresponding author), Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales.	gallimoream@cardiff.ac.uk		Simon, Anna Katharina/0000-0002-4077-7995; Gallimore, Awen/0000-0001-6675-7004	Association for International Cancer Research; NIHR Biomedical Research Centre; MRC [G117/488] Funding Source: UKRI; Medical Research Council [G117/488] Funding Source: researchfish	Association for International Cancer Research; NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	AMG is a Medical Research Council Non-Clinical Senior research Fellow and AKS is funded by the Association for International Cancer Research and by the NIHR Biomedical Research Centre. We thank Nick Willcox and Kerstin Luhn for carefully reading the manuscript.	Antony PA, 2005, J IMMUNOL, V174, P2591, DOI 10.4049/jimmunol.174.5.2591; Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816; Aschenbrenner K, 2007, NAT IMMUNOL, V8, P351, DOI 10.1038/ni1444; Asselin-Paturel C, 1998, INT J CANCER, V77, P7, DOI 10.1002/(SICI)1097-0215(19980703)77:1<7::AID-IJC2>3.0.CO;2-Y; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Azuma T, 2003, CANCER RES, V63, P4516; Betti M, 2006, ANN ONCOL, V17, P235; Betts G, 2007, BRIT J CANCER, V96, P1849, DOI 10.1038/sj.bjc.6603824; Betts GJ, 2006, ADV DRUG DELIVER REV, V58, P948, DOI 10.1016/j.addr.2006.05.006; Beyer M, 2006, BLOOD, V107, P3940, DOI 10.1182/blood-2005-09-3671; Bopp T, 2007, J EXP MED, V204, P1303, DOI 10.1084/jem.20062129; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Bui JD, 2006, CANCER RES, V66, P7301, DOI 10.1158/0008-5472.CAN-06-0556; Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Clarke SL, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000129; Conrad CT, 1999, J EXP CLIN CANC RES, V18, P225; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Curti A, 2007, BLOOD, V109, P2871, DOI 10.1182/blood-2006-07-036863; Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947; Darnell RB, 2003, NEW ENGL J MED, V349, P1543, DOI 10.1056/NEJMra023009; Davidson TS, 2007, J IMMUNOL, V178, P4022, DOI 10.4049/jimmunol.178.7.4022; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Derbinski J, 2001, NAT IMMUNOL, V2, P1032, DOI 10.1038/ni723; DiPaolo RJ, 2007, J IMMUNOL, V179, P4685, DOI 10.4049/jimmunol.179.7.4685; Erdman SE, 2005, CANCER RES, V65, P3998, DOI 10.1158/0008-5472.CAN-04-3104; Erdman SE, 2003, AM J PATHOL, V162, P691, DOI 10.1016/S0002-9440(10)63863-1; Fantini MC, 2007, EUR J IMMUNOL, V37, P3155, DOI 10.1002/eji.200737766; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Ghiringhelli F, 2005, J EXP MED, V202, P1075, DOI 10.1084/jem.20051511; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Gondek DC, 2005, J IMMUNOL, V174, P1783, DOI 10.4049/jimmunol.174.4.1783; Hsieh CS, 2004, IMMUNITY, V21, P267, DOI 10.1016/j.immuni.2004.07.009; Ichihara F, 2003, CLIN CANCER RES, V9, P4404; Itoh M, 1999, J IMMUNOL, V162, P5317; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kelchtermans H, 2005, ARTHRITIS RES THER, V7, pR402, DOI 10.1186/ar1500; Kryczek I, 2000, BRIT J CANCER, V82, P621; Kryczek I, 2007, J IMMUNOL, V178, P6730, DOI 10.4049/jimmunol.178.11.6730; La Cava A, 2006, TRENDS IMMUNOL, V27, P322, DOI 10.1016/j.it.2006.05.003; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Leong PP, 2006, IMMUNOL LETT, V102, P229, DOI 10.1016/j.imlet.2005.09.006; Lewkowicz P, 2006, J IMMUNOL, V177, P7155, DOI 10.4049/jimmunol.177.10.7155; Lim HW, 2005, J IMMUNOL, V175, P4180, DOI 10.4049/jimmunol.175.7.4180; Liu VC, 2007, J IMMUNOL, V178, P2883, DOI 10.4049/jimmunol.178.5.2883; Nishikawa H, 2003, P NATL ACAD SCI USA, V100, P10902, DOI 10.1073/pnas.1834479100; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Pacholczyk R, 2007, IMMUNITY, V27, P493, DOI 10.1016/j.immuni.2007.07.019; Peluso I, 2007, J IMMUNOL, V178, P732, DOI 10.4049/jimmunol.178.2.732; Piccirillo CA, 2001, J IMMUNOL, V167, P1137, DOI 10.4049/jimmunol.167.3.1137; Romagnani C, 2005, EUR J IMMUNOL, V35, P2452, DOI 10.1002/eji.200526069; Roncador G, 2005, LEUKEMIA, V19, P2247, DOI 10.1038/sj.leu.2403965; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Sharma S, 2005, CANCER RES, V65, P5211, DOI 10.1158/0008-5472.CAN-05-0141; Simon AK, 2007, EUR J IMMUNOL, V37, P758, DOI 10.1002/eji.200636593; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Smyth MJ, 2006, J IMMUNOL, V176, P1582, DOI 10.4049/jimmunol.176.3.1582; Somasundaram R, 2002, CANCER RES, V62, P5267; Taams LS, 2005, HUM IMMUNOL, V66, P222, DOI 10.1016/j.humimm.2004.12.006; Tadokoro CE, 2006, J EXP MED, V203, P505, DOI 10.1084/jem.20050783; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Tang QZ, 2006, NAT IMMUNOL, V7, P83, DOI 10.1038/ni1289; Trzonkowski P, 2004, CLIN IMMUNOL, V112, P258, DOI 10.1016/j.clim.2004.04.003; Valzasina B, 2006, CANCER RES, V66, P4488, DOI 10.1158/0008-5472.CAN-05-4217; Veldhoen M, 2006, NAT IMMUNOL, V7, P1151, DOI 10.1038/ni1391; Wang G, 2003, CANCER RES, V63, P9016; Wang HY, 2004, IMMUNITY, V20, P107, DOI 10.1016/S1074-7613(03)00359-5; Wang ZJ, 2006, J CLIN INVEST, V116, P2434, DOI 10.1172/JCI25826; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Yee C, 2000, J EXP MED, V192, P1637, DOI 10.1084/jem.192.11.1637; Zeng R, 2005, J EXP MED, V201, P139, DOI 10.1084/jem.20041057; Zheng SG, 2007, J IMMUNOL, V178, P2018, DOI 10.4049/jimmunol.178.4.2018; Zhou G, 2007, J IMMUNOL, V178, P2155, DOI 10.4049/jimmunol.178.4.2155; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	78	53	56	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 6	2008	27	45					5886	5893		10.1038/onc.2008.269	http://dx.doi.org/10.1038/onc.2008.269			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836469				2022-12-17	WOS:000259722600003
J	Ehrhardt, H; Hacker, S; Wittmann, S; Maurer, M; Borkhardt, A; Toloczko, A; Debatin, KM; Fulda, S; Jeremias, I				Ehrhardt, H.; Haecker, S.; Wittmann, S.; Maurer, M.; Borkhardt, A.; Toloczko, A.; Debatin, K-M; Fulda, S.; Jeremias, I.			Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells	ONCOGENE			English	Article						caspase-8; p53; cytotoxic drugs; TRAIL; TRAIL-R1; TRAIL-R2	MUTANT P53; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; DEATH RECEPTORS; CANCER-CELLS; EXPRESSION; TRAIL; RESTORATION; THERAPY; PROLIFERATION	Apoptosis resistance is crucially involved in cancer development and progression, represents the leading cause for failure of anticancer therapy and is caused, for example, by downregulation of proapoptotic intracellular signaling molecules such as caspase-8. We found that the cytotoxic drugs methotrexate (MTX) and 5-fluorouracil (5-FU) were both able to sensitize resistant tumor cells for induction of apoptosis by p53-mediated upregulation of caspase-8. Increase in caspase-8 messenger RNA and protein expression disabled tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced proliferation and restored sensitivity toward TRAIL-induced apoptosis which was inhibited by transfection of p53 decoy oligonucleotides, p53 shRNA and caspase-8 shRNA. Upregulation of caspase-8 and sensitization toward TRAIL-induced apoptosis was found both in a broad panel of tumor cell lines with downregulated caspase-8 and in TRAIL-resistant primary tumor cells of children with acute leukemia. Taken together, we have identified caspase-8 as an important p53 target gene regulated by cytotoxic drugs. These findings highlight a new drug-induced modulation of physiological apoptosis pathways, which may be involved in successful anticancer therapy using MTX and 5-FU in leukemia and solid tumors over decades.	[Ehrhardt, H.; Wittmann, S.; Maurer, M.; Borkhardt, A.; Jeremias, I.] Univ Munich, Dr Von Haunerschen Kinderspital, Dept Hematol Oncol, D-80337 Munich, Germany; [Haecker, S.; Debatin, K-M; Fulda, S.] Klin Kinder & Jugendmed, Ulm, Germany; [Toloczko, A.; Jeremias, I.] GSF Res Ctr Environm & Hlth, Munich, Germany; [Ehrhardt, H.] Univ Munich, Dept Obstet & Gynecol, Div Neonatol, Munich, Germany	University of Munich; University of Munich	Jeremias, I (corresponding author), GSF Forschungszentrum Umwelt & Gesundheit, Abt Genvektoren, Marchioninistr 25, D-81377 Munich, Germany.	I.Jeremias@lrz.uni-muenchen.de	Ehrhardt, Harald/L-9007-2018; Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014; Jeremias, Irmela/Q-5934-2019; Jeremias, Irmela/C-6090-2015	Ehrhardt, Harald/0000-0003-4587-1734; Debatin, Klaus-Michael/0000-0002-8397-1886; Jeremias, Irmela/0000-0003-1773-7677; Fulda, Simone/0000-0002-0459-6417				Ashley DM, 2005, CANCER-AM CANCER SOC, V104, P1487, DOI 10.1002/cncr.21323; Baader E, 2005, CANCER RES, V65, P7888, DOI 10.1158/0008-5472.CAN-04-4278; Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Ehrhardt H, 2004, LEUKEMIA, V18, P1406, DOI 10.1038/sj.leu.2403406; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Fuster JJ, 2007, TRENDS MOL MED, V13, P192, DOI 10.1016/j.molmed.2007.03.002; Gomez-Lazaro M, 2004, J PHYSIOL BIOCHEM, V60, P287, DOI 10.1007/BF03167075; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Liedtke C, 2003, J BIOL CHEM, V278, P27593, DOI 10.1074/jbc.M304077200; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; MILNER J, 1987, ONCOGENE, V1, P453; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Ohnishi T, 1999, INT J RADIAT BIOL, V75, P1095; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232	31	53	54	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					783	793		10.1038/sj.onc.1210666	http://dx.doi.org/10.1038/sj.onc.1210666			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17637740				2022-12-17	WOS:000252884500007
J	Li, ZG; Yang, J; Vazquez, ES; Rose, D; Vakar-Lopez, F; Mathew, P; Lopez, A; Logothetis, CJ; Lin, SH; Navone, NM				Li, Z. G.; Yang, J.; Vazquez, E. S.; Rose, D.; Vakar-Lopez, F.; Mathew, P.; Lopez, A.; Logothetis, C. J.; Lin, S-H; Navone, N. M.			Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone	ONCOGENE			English	Article						WNT; WNT7b; prostate cancer; bone metastases; osteoblasts; DKK1	METASTASES; OSTEOBLASTS; DICKKOPF-1; PROTEINS; HEDGEHOG; CATENIN; LESIONS	The tendency of prostate cancer to produce osteoblastic bone metastases suggests that cancer cells and osteoblasts interact in ways that contribute to cancer progression. To identify factors that mediate these interactions, we compared gene expression patterns between two bone-derived prostate cancer cell lines that produce osteoblastic (MDA PCa 2b) or osteolytic lesions (PC-3). Both cell lines expressed Wnt ligands, including WNT7b, a canonical Wnt implicated in osteogenesis. PC-3 cells expressed 50 times more Dickkopf-1 (DKK1), an inhibitor of Wnt pathways, than did MDA PCa 2b cells. Evaluation of the functional role of these factors (in cocultures of prostate cancer cells with primary mouse osteoblasts (PMOs) or in bone organ cultures) showed that MDA PCa 2b cells activated Wnt canonical signaling in PMOs and that DKK1 blocked osteoblast proliferation and new bone formation induced by MDA PCa 2b cells. MDA PCa 2b cells did not induce bone formation in calvaria from mice lacking the Wnt co-receptor Lrp5. In human specimens, WNT7b was not expressed in normal prostate but was expressed in areas of high-grade prostate intraepithelial neoplasia, in three of nine primary prostate tumor specimens and in 16 of 38 samples of bone metastases from prostate cancer. DKK1 was not expressed in normal or cancerous tissue but was expressed in two of three specimens of osteolytic bone metastases (P = 0.0119). We conclude that MDA PCa 2b induces new bone formation through Wnt canonical signaling, that LRP5 mediates this effect, and that DKK1 is involved in the balance between bone formation and resorption that determines lesion phenotype.	[Li, Z. G.; Yang, J.; Rose, D.; Mathew, P.; Logothetis, C. J.; Navone, N. M.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, Houston, TX 77230 USA; [Vazquez, E. S.] Univ Buenos Aires, CONICET, Sch Sci, Dept Biol Chem, RA-1053 Buenos Aires, DF, Argentina; [Vakar-Lopez, F.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77230 USA; [Lopez, A.] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77230 USA; [Lin, S-H] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77230 USA	University of Texas System; UTMD Anderson Cancer Center; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Navone, NM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, 1515 Holcombe Blvd,POB 301439, Houston, TX 77230 USA.	nnavone@mdanderson.org	; Vazquez, Elba/D-5134-2019	Lopez, Adriana/0000-0001-9169-800X; Vazquez, Elba/0000-0002-0460-0236	NATIONAL CANCER INSTITUTE [R01CA096797, R01CA111479, P50CA090270] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA111479, R01CA096797, P50CA90270] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; COOK GB, 1968, J UROLOGY, V99, P87, DOI 10.1016/S0022-5347(17)62647-8; Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891; Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802; Ferrari SL, 2005, CURR OPIN LIPIDOL, V16, P207, DOI 10.1097/01.mol.0000162326.62419.e4; Fizazi K, 2003, CLIN CANCER RES, V9, P2587; Freshney RI, 1994, CULTURE ANIMAL CELLS; GARRETT R, 2003, METHODS MOL MED, P183; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008-5472.CAN-05-1317; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kolpakova E, 2005, DEV CELL, V8, P626, DOI 10.1016/j.devcel.2005.04.008; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Loberg RD, 2005, J CLIN ONCOL, V23, P8232, DOI 10.1200/JCO.2005.03.0841; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; YANG BC, 2001, J E CHINA NORMAL U N, V1, P61; Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677-4684.2004	27	53	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					596	603		10.1038/sj.onc.1210694	http://dx.doi.org/10.1038/sj.onc.1210694			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17700537				2022-12-17	WOS:000252674900004
J	Craft, CS; Romero, D; Vary, CPH; Bergan, RC				Craft, C. S.; Romero, D.; Vary, C. P. H.; Bergan, R. C.			Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway	ONCOGENE			English	Article						transforming growth factor beta; prostate cancer; motility; endoglin; smad1; ALK2	GROWTH-FACTOR-BETA; MATRIX-METALLOPROTEINASE TYPE-2; HUMAN ENDOTHELIAL-CELLS; RECEPTOR-LIKE KINASE-2; TGF-BETA; SIGNAL-TRANSDUCTION; CELLULAR-RESPONSES; EPITHELIAL-CELLS; II RECEPTORS; ACTIVIN	Endoglin is a transforming growth factor beta (TGF beta) superfamily auxiliary receptor. We had previously shown that it suppressed prostate cancer (PCa) cell motility, and that its expression was lost during PCa progression. The mechanism by which endoglin inhibits PCa cell motility is unknown. Here we demonstrate that endoglin abrogates TGF beta-mediated cell motility, but does not alter cell surface binding of TGF beta. By measuring Smad-specific phosphorylation and Smad-responsive promoter activity, endoglin was shown to constitutively activate Smad1, with little-to-no effect upon Smad3. Knockdown of Smad1 increased motility and abrogated endoglin's effects. As type I activin receptor-like kinases (ALKs) are necessary for Smad activation, we went on to show that knockdown of ALK2, but not TGF beta RI (ALK5), abrogated endoglin-mediated decreases in cell motility and constitutively active ALK2 was sufficient to restore a low-motility phenotype in endoglin deficient cells. These findings provide the first evidence that endoglin decreases PCa cell motility through activation of the ALK2-Smad1 pathway.	Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Maine Medical Center	Bergan, RC (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Olson 8321, 710 N Fairbanks, Chicago, IL 60611 USA.	r-bergan@northwestern.edu	Romero, Diana/GWU-9250-2022		NATIONAL CANCER INSTITUTE [T32CA009560, P50CA090386] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015555] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083151] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA090386, T32 CA009560, CA90386, T32CA09560] Funding Source: Medline; NCRR NIH HHS [P20 RR015555-076459, P20 RR015555, P20 RR015555-076465] Funding Source: Medline; NHLBI NIH HHS [R01 HL083151, R01 HL083151-01A2S1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bergan R, 1996, CLIN EXP METASTAS, V14, P389, DOI 10.1007/BF00123398; Bergan R, 1996, BLOOD, V88, P731, DOI 10.1182/blood.V88.2.731.bloodjournal882731; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Blanco FJ, 2005, J CELL PHYSIOL, V204, P574, DOI 10.1002/jcp.20311; CARROLL PR, 2001, CANC PRINCIPLES PRAC, P1418; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Desgrosellier JS, 2005, DEV BIOL, V280, P201, DOI 10.1016/j.ydbio.2004.12.037; Ding Y, 2006, PROSTATE CANCER P D, V9, P379, DOI 10.1038/sj.pcan.4500888; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Hayes SA, 2003, ONCOGENE, V22, P4841, DOI 10.1038/sj.onc.1206730; Huang XK, 2005, CANCER RES, V65, P3470, DOI 10.1158/0008-5472.CAN-04-2807; Jovanovic B D, 2001, Am J Pharmacogenomics, V1, P145, DOI 10.2165/00129785-200101020-00007; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Liu YQ, 2001, PROSTATE CANCER P D, V4, P81, DOI 10.1038/sj.pcan.4500506; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Monteiro RM, 2004, J CELL SCI, V117, P4653, DOI 10.1242/jcs.01337; Pece-Barbara N, 2005, J BIOL CHEM, V280, P27800, DOI 10.1074/jbc.M503471200; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Ward SM, 2002, J BIOL CHEM, V277, P50183, DOI 10.1074/jbc.M209668200; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337	37	53	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7240	7250		10.1038/sj.onc.1210533	http://dx.doi.org/10.1038/sj.onc.1210533			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17496924	Green Accepted			2022-12-17	WOS:000250955600008
J	Sundvall, M; Peri, L; Maatta, JA; Tvorogov, D; Paatero, I; Savisalo, M; Silvennoinen, O; Yarden, Y; Elenius, K				Sundvall, M.; Peri, L.; Maatta, J. A.; Tvorogov, D.; Paatero, I.; Savisalo, M.; Silvennoinen, O.; Yarden, Y.; Elenius, K.			Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains	ONCOGENE			English	Article						cancer; gamma-secretase; HER; neuregulin; nuclear shuttling; ubiquitin	GROWTH-FACTOR RECEPTOR; GAMMA-SECRETASE CLEAVAGE; BREAST-CANCER CELLS; TYROSINE KINASE; ESTROGEN-RECEPTOR; ISOFORM; ACTIVATION; PHOSPHORYLATION; TRANSACTIVATION; UBIQUITYLATION	Cleavable isoforms of the ErbB4 receptor tyrosine kinase release a soluble intracellular domain (ICD) that may translocate to the nucleus and regulate signaling. However, ErbB4 gene is alternatively spliced generating CYT-1 and CYT-2 isoforms with different cytoplasmic tails. Here, we addressed whether the two alternative ErbB4 ICDs of either CYT4 (ICD1) or CYT-2 (ICD2) type differ in signaling to the nucleus. Confocal microscopy and extraction of nuclear cell fractions indicated that significantly more ICD2 translocated to the nuclei when compared to ICD1. Unlike the membrane-anchored 80 kDa fragments derived from full-length ErbB4 isoforms, the two ICDs did not differ from each other in metabolic stability or ubiquitylation. However, ICD2 was phosphorylated at tyrosine residues to a higher extent and demonstrated greater in vitro kinase activity than ICDI. Mutating the ATP-binding site within ICD2 kinase domain (ICD2 K751R) blocked its tyrosine phosphorylation and significantly reduced its nuclear translocation. When expressed in the context of full-length ErbB4, ICD2 was also more efficient than ICD1 in promoting transcriptional activation of the STAT5 target gene beta-casein. These findings indicate that the two alternative ICDs of ErbB4 differ in their nuclear accumulation, and that the mechanism involves differential kinase activity but not ubiquitin-regulated ICD stability.	Univ Turku, Dept Med Biochem & Mol Biol, FIN-20520 Turku, Finland; Univ Turku, Medicity Res Lab, Turku, Finland; Univ Turku, Turku Grad Sch Biomed Sci, Turku, Finland; Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Clin Microbiol, Tampere, Finland; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Turku Univ, Cent Hosp, Dept Oncol, Turku, Finland	University of Turku; University of Turku; University of Turku; Tampere University; Tampere University; Tampere University Hospital; Weizmann Institute of Science; University of Turku	Elenius, K (corresponding author), Univ Turku, Dept Med Biochem & Mol Biol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	klaus.elenius@utu.fi	Elenius, Klaus/AAI-7594-2021; YARDEN, YOSEF/K-1467-2012; Paatero, Ilkka/A-6391-2009; Paatero, Ilkka/AAE-7542-2019	Elenius, Klaus/0000-0001-5700-0827; Paatero, Ilkka/0000-0001-5926-2396; Maatta, Jorma/0000-0001-8752-6862; Tvorogov, Denis/0000-0002-2009-1347; Sundvall, Maria H/0000-0002-0494-2965				Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Arasada RR, 2005, J BIOL CHEM, V280, P30783, DOI 10.1074/jbc.M506057200; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Gullick WJ, 2003, J PATHOL, V200, P279, DOI 10.1002/path.1335; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2000, TRENDS CARDIOVAS MED, V10, P304, DOI 10.1016/S1050-1738(01)00065-2; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Linggi B, 2006, ONCOGENE, V25, P160, DOI 10.1038/sj.onc.1209003; Litterst CM, 2003, J BIOL CHEM, V278, P45340, DOI 10.1074/jbc.M303644200; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Muraoka-Cook RS, 2006, MOL BIOL CELL, V17, P4118, DOI 10.1091/mbc.E06-02-0101; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Ni CY, 2003, J BIOL CHEM, V278, P4561, DOI 10.1074/jbc.M210504200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Pircher TJ, 1997, MOL CELL ENDOCRINOL, V133, P169, DOI 10.1016/S0303-7207(97)00164-0; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Srinivasan R, 2000, CANCER RES, V60, P1483; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhu Y, 2006, CANCER RES, V66, P7991, DOI 10.1158/0008-5472.CAN-05-4397	36	53	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6905	6914		10.1038/sj.onc.1210501	http://dx.doi.org/10.1038/sj.onc.1210501			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486069				2022-12-17	WOS:000250188400006
J	Lalier, L; Cartron, PF; Pedelaborde, F; Olivier, C; Loussouarn, D; Martin, SA; Meflah, K; Menanteau, J; Vallette, FM				Lalier, L.; Cartron, P-F; Pedelaborde, F.; Olivier, C.; Loussouarn, D.; Martin, S. A.; Meflah, K.; Menanteau, J.; Vallette, F. M.			Increase in PGE(2) biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme	ONCOGENE			English	Article						gliomas; cyclooxygenase; prostaglandin synthase; apoptosis; Bax; PGE(2)	PROSTAGLANDIN-E SYNTHASE; CYCLOOXYGENASE-2 EXPRESSION; PROGNOSTIC-SIGNIFICANCE; PARKINSONS-DISEASE; COLON-CANCER; DEATH; NEURODEGENERATION; NEUROTOXICITY; INHIBITION; CELLS	Prostaglandin E-2 plays multiple roles both in the physiology and the physiopathology of human brain, which are not completely understood. We have identi. ed in a subset of human glioblastoma multiforme (GBM) tumors, the most common form of adult brain cancer, an increased expression of mPGES-1, the enzyme which catalyses the isomerization of PGH(2) into PGE(2) downstream of cyclooxygenase 2 (COX-2). The sensitivity of primary cultures of GBM to apoptosis was augmented by the overexpression of mPGES-1, whereas the knockdown of its expression by shRNA decreased the apoptotic threshold in vitro and stimulated tumor growth in vivo. Adding extracellular PGE(2) in the culture medium failed to reproduce mPGES-1 effect on the cell viability in vitro. However, the intracellular injection of PGE2 induced a dose-dependent apoptosis in GBM cultures, which was dependent on the presence of Bax, a pro-apoptotic protein. We show that PGE(2) physically associates with Bax, triggering its apoptotic-like change in conformation and its subsequent association with mitochondria. Our results raise questions about the role of PGE(2) in the control of apoptosis and in its potential impact in central nervous system pathologies.	INSERM, U601, F-44035 Nantes 01, France; Univ Nantes, Fac Med, F-44035 Nantes, France; CHU Nantes, G&R Laennec Hosp, Dept Anatomopathol, F-44035 Nantes 01, France; CHU Nantes, G&R Laennec Hosp, Dept Neurosurg, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Vallette, FM (corresponding author), INSERM, U601, 9 Quai MONSOUSU, F-44035 Nantes 01, France.	francois.vallette@univ-nantes.fr	Lalier, Lisenn/K-9230-2015; Cartron, Pierre Francois/K-9802-2015; OLIVIER, Christophe/L-1598-2015; Vallette, Francois M/K-9047-2015; Vallette, Francois/N-2361-2018	Vallette, Francois M/0000-0002-3296-8572; Cartron, Pierre-Francois/0000-0002-3393-784X				BERRY CN, 1983, BIOCHEM PHARMACOL, V32, P2863, DOI 10.1016/0006-2952(83)90390-8; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Brown DM, 1996, J IMMUNOL, V157, P1359; Buccoliero AM, 2006, CLIN NEUROPATHOL, V25, P59; Cartron PF, 2004, FEBS LETT, V578, P41, DOI 10.1016/j.febslet.2004.10.080; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cha YI, 2006, DEV BIOL, V289, P263, DOI 10.1016/j.ydbio.2005.10.013; Chen Z, 2005, CELL METAB, V1, P93, DOI 10.1016/j.cmet.2004.12.009; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Gasparini G, 2003, LANCET ONCOL, V4, P605, DOI 10.1016/S1470-2045(03)01220-8; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hara A, 2004, ACTA NEUROPATHOL, V108, P43, DOI 10.1007/s00401-004-0860-0; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Hinz B, 2004, MOL PHARMACOL, V66, P1643, DOI 10.1124/mol.104.002618; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Juin P, 1998, J BIOL CHEM, V273, P17559, DOI 10.1074/jbc.273.28.17559; Kawai N, 2002, PROSTAG OTH LIPID M, V68-9, P187, DOI 10.1016/S0090-6980(02)00030-8; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; Krunic N, 2000, DEV BRAIN RES, V121, P145, DOI 10.1016/S0165-3806(00)00033-X; Kudo I, 2005, J BIOCHEM MOL BIOL, V38, P633; Manabe Y, 2004, ANN NEUROL, V55, P668, DOI 10.1002/ana.20078; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; Musiek ES, 2005, BRAIN PATHOL, V15, P149; Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016; Patsos HA, 2005, GUT, V54, P1741, DOI 10.1136/gut.2005.073403; Perez-Sala D, 2003, J BIOL CHEM, V278, P51251, DOI 10.1074/jbc.M309409200; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reid G, 2003, P NATL ACAD SCI USA, V100, P9244, DOI 10.1073/pnas.1033060100; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Shono T, 2001, CANCER RES, V61, P4375; Takadera T, 2002, NEUROSCI LETT, V317, P61, DOI 10.1016/S0304-3940(01)02449-1; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Tessner TG, 2004, J CLIN INVEST, V114, P1676, DOI 10.1172/JCI200422218; Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Yucel-Lindberg T, 2006, CELL SIGNAL, V18, P2131, DOI 10.1016/j.cellsig.2006.04.003	43	53	54	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	34					4999	5009		10.1038/sj.onc.1210303	http://dx.doi.org/10.1038/sj.onc.1210303			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17369862				2022-12-17	WOS:000248322500012
J	Mohankumar, KM; Xu, XQ; Zhu, T; Kannan, N; Miller, LD; Liu, ET; Gluckman, PD; Sukumar, S; Emerald, BS; Lobie, PE				Mohankumar, K. M.; Xu, X. Q.; Zhu, T.; Kannan, N.; Miller, L. D.; Liu, E. T.; Gluckman, P. D.; Sukumar, S.; Emerald, B. S.; Lobie, P. E.			HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells	ONCOGENE			English	Article						HOXA1; gene expression; p44/42 MAP kinase; MEK; oncogenicity	HUMAN GROWTH-HORMONE; GENE-EXPRESSION; BREAST; PHOSPHORYLATION; TRANSACTIVATION; TRANSFORMATION; PROLIFERATION; ACTIVATION; SURVIVAL; HOXA1	Expression of homeobox A1 ( HOXA1) results in oncogenic transformation of immortalized human mammary epithelial cells with aggressive tumor formation in vivo. However, the mechanisms by which HOXA1 mediates oncogenic transformation is not well defined. To identify molecules that could potentially be involved in HOXA1-mediated oncogenic transformation, microarray analysis was utilized to characterize and compare the gene expression pattern in response to forced expression or depletion of HOXA1 in human mammary carcinoma cells. Gene expression pro. ling identified that genes involved in the p44/42 mitogen-activated protein ( MAP) kinase activation pathway ( GRB2, MAP kinase kinase ( MEK1) and SDFR1) or p44/42 MAP kinase-regulated genes ( IER3, EPAS1, PCNA and catalase) are downstream expression targets of HOXA1. Forced expression of HOXA1 increased GRB2 and MEK1 mRNA and protein expression and increased p44/42 MAP kinase phosphorylation, activity and Elk-1-mediated transcription. Use of a MEK1 inhibitor demonstrated that increased p44/42 MAP kinase activity is required for the HOXA1-mediated increase in cell proliferation, survival, oncogenicity and oncogenic transformation. Thus, modulation of the p44/42 MAP kinase pathway is one mechanism by which HOXA1 mediates oncogenic transformation of the human mammary epithelial cell.	Univ Auckland, Liggins Inst, Auckland, New Zealand; Univ Auckland, Natl Res Ctr Growth & Dev, Auckland, New Zealand; Genome Inst Singapore, Singapore, Singapore; Johns Hopkins Univ, Breast Canc Program, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	University of Auckland; University of Auckland; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Johns Hopkins University; Johns Hopkins Medicine	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave,Private Bag 92019, Auckland, New Zealand.	p.lobie@auckland.ac.nz	Miller, Lance/A-5633-2009; Kumarasamypet Murugesan, Mohankumar/F-4231-2012; David, Starling Emerald Bright/R-6034-2019; Liu, Edison/C-4141-2008	David, Starling Emerald Bright/0000-0001-6875-2258; Miller, Lance/0000-0003-3799-2528; KM, Mohankumar/0000-0001-9407-1800; Kannan, Nagarajan/0000-0002-8825-2178				Bajetto A, 2001, J NEUROCHEM, V77, P1226, DOI 10.1046/j.1471-4159.2001.00350.x; Chariot A, 1996, BIOCHEM BIOPH RES CO, V222, P292, DOI 10.1006/bbrc.1996.0737; Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Clark JH, 1999, GREEN CHEM, V1, P1, DOI 10.1039/a807961g; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Grill C, 2004, BIOCHEM J, V381, P635, DOI 10.1042/BJ20031688; Hattori R, 2001, J MOL CELL CARDIOL, V33, P1929, DOI 10.1006/jmcc.2001.1456; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Rinehart J, 2004, J CLIN ONCOL, V22, P4456, DOI 10.1200/JCO.2004.01.185; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Salh B, 1999, ANTICANCER RES, V19, P731; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Wang CX, 2006, CELL DEATH DIFFER, V13, P1203, DOI 10.1038/sj.cdd.4401804; Xu XQ, 2005, J BIOL CHEM, V280, P23987, DOI 10.1074/jbc.M503869200; Yu FQ, 2005, FRONT BIOSCI-LANDMRK, V10, P896, DOI 10.2741/1584; Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200; Zhu T, 2005, CANCER RES, V65, P317; Zhu Z, 2005, ONCOGENE, V24, P3774, DOI 10.1038/sj.onc.1208541	30	53	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					3998	4008		10.1038/sj.onc.1210180	http://dx.doi.org/10.1038/sj.onc.1210180			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213808				2022-12-17	WOS:000247144500010
J	Tai, KY; Shiah, SG; Shieh, YS; Kao, YR; Chi, CY; Huang, E; Lee, HS; Chang, LC; Yang, PC; Wu, CW				Tai, K-Y; Shiah, S-G; Shieh, Y-S; Kao, Y-R; Chi, C-Y; Huang, E.; Lee, H-S; Chang, L-C; Yang, P-C; Wu, C-W			DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression	ONCOGENE			English	Article						Ep-CAM; invasion; promoter methylation	EP-CAM; LUNG ADENOCARCINOMA; BREAST-CANCER; EXPRESSION; CARCINOMA; EPCAM; ANTIGEN; MARKERS; TARGET; INHIBITION	Epithelial cell adhesion molecule ( Ep-CAM) is believed to have a critical role in carcinogenesis and cell proliferation. However, the association of Ep-CAM with cancer invasion and progression is less clear. We found that EpCAM was highly expressed on low-invasive cells compared with highly invasive cells. Forced expression of Ep-CAM decreased cancer invasiveness, and silencing Ep-CAM expression elevated cancer invasiveness. EpCAM expression was associated with promoter methylation. Treatment with a demethylating agent, and/or the histone deacetylase inhibitor reactivated Ep-CAM expression in Ep-CAM-negative cells and inhibited cancer invasiveness. Using a promoter-reporter construct, we demonstrated methylation of the promoter fragment drive Ep-CAM-silenced transcription. Additionally, silenced Ep-CAM gene in cancer cells was enriched for hyper-methylated histone 3 lysine 9. When unmethylated and active, this promoter was associated with acetylated histone 3 lysine 9. Furthermore, we observed an increased association of Ep-CAM promoter with repression components as tumor invasiveness increased. In cancer tissues, Ep-CAM expression significantly correlated with tumor progression and associated with promoter methylation. Our data support the idea that modulation of Ep-CAM plays a pivotal role in tumor invasion and progression. Moreover, aberrant DNA methylation of Ep-CAM is implicated in enhancing invasive/metastatic proclivity of tumors.	Inst Canc Res, Natl Hlth Res Inst, Miaoli, Taiwan; Natl Def Med Ctr, Sch Dent, Taipei, Taiwan; Natl Def Med Ctr, Canc Epigenet Lab, Taipei, Taiwan; Tri Serv Gen Hosp, Dept Oral Diag, Taipei, Taiwan; Tri Serv Gen Hosp, Dept Pathol, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan	National Health Research Institutes - Taiwan; National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital; Tri-Service General Hospital; National Taiwan University; National Taiwan University Hospital	Wu, CW (corresponding author), Inst Canc Res, Natl Hlth Res Inst, Miaoli, Taiwan.	ken@nhri.org.tw	Yang, Pan-Chyr/B-8808-2009; Shiah, Shine-Gwo/D-2087-2010	Tai, Kang-Yu/0000-0001-6867-3365; YANG, PAN-CHYR/0000-0001-6330-6048; Shiah, Shine-Gwo/0000-0002-1003-973X				Armstrong A, 2003, CANCER BIOL THER, V2, P320, DOI 10.4161/cbt.2.4.451; Basak S, 1998, JNCI-J NATL CANCER I, V90, P691, DOI 10.1093/jnci/90.9.691; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Drapkin R, 2004, HUM PATHOL, V35, P1014, DOI 10.1016/j.humpath.2004.04.014; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Gastl G, 2000, LANCET, V356, P1981, DOI 10.1016/S0140-6736(00)03312-2; Jojovic M, 1998, HISTOCHEM J, V30, P723, DOI 10.1023/A:1003486630314; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Joo M, 2005, J GASTROEN HEPATOL, V20, P1039, DOI 10.1111/j.1440-1746.2005.03842.x; Kim JH, 2003, CLIN CANCER RES, V9, P4782; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Kumble S, 1996, INT J CANCER, V66, P48, DOI 10.1002/(SICI)1097-0215(19960328)66:1<48::AID-IJC9>3.0.CO;2-Z; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; McLaughlin PMJ, 2004, CANCER GENE THER, V11, P603, DOI 10.1038/sj.cgt.7700725; Munz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; Rao CG, 2005, INT J ONCOL, V27, P49; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Seligson DB, 2004, CLIN CANCER RES, V10, P2659, DOI 10.1158/1078-0432.CCR-1132-03; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Songun I, 2005, BRIT J CANCER, V92, P1767, DOI 10.1038/sj.bjc.6602519; Spizzo G, 2007, CANCER LETT, V246, P253, DOI 10.1016/j.canlet.2006.03.002; Takes RP, 2001, J PATHOL, V194, P298, DOI 10.1002/1096-9896(200107)194:3<298::AID-PATH900>3.0.CO;2-Q; Takes RP, 1997, ARCH OTOLARYNGOL, V123, P412; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; Went P, 2005, AM J SURG PATHOL, V29, P83, DOI 10.1097/01.pas.0000.146028.70868.7a; Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/j.humpath.2003.08.026; Winter MJ, 2003, AM J PATHOL, V163, P2139, DOI 10.1016/S0002-9440(10)63570-5	29	53	53	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					3989	3997		10.1038/sj.onc.1210176	http://dx.doi.org/10.1038/sj.onc.1210176			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213811				2022-12-17	WOS:000247144500009
J	Liu, W; Wei, W; Winer, D; Bamberger, AM; Bamberger, C; Wagener, C; Ezzat, S; Asa, SL				Liu, W.; Wei, W.; Winer, D.; Bamberger, A.-M.; Bamberger, C.; Wagener, C.; Ezzat, S.; Asa, S. L.			CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases	ONCOGENE			English	Article						CEACAM1; thyroid cancer; cell adhesion; tumor invasion; metastases	CELL-ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN FAMILY; BILIARY GLYCOPROTEIN GENE; C-CAM; TUMOR-SUPPRESSOR; PROSTATE-CANCER; CD66A BGP; CYTOPLASMIC DOMAIN; ENHANCES INVASION; EPITHELIAL-CELLS	CEACAM1, also known as biliary glycoprotein (BGP), CD66a, pp120 and C-CAM1, is a member of the CEA immunoglobulin superfamily. CEACAM1 is a putative tumor suppressor based on diminished expression in some solid neoplasms such as colorectal carcinoma. However, CEACAM1 is overexpressed in some tumors such as non-small cell lung cancer. To clarify the mechanism of action of this cell adhesion molecule, we studied thyroid carcinoma that has a spectrum of morphologies and variable behavior allowing separation of proliferation from invasion and metastasis. CEACAM1 is expressed in thyroid carcinoma cell lines derived from tumors that exhibit aggressive behavior. Introduction of CEACAM1 into endogenously deficient WRO cells resulted in reduced cell cycle progression associated with p21 upregulation and diminished Rb phosphorylation. Forced CEACAM1 expression enhanced cell-matrix adhesion and migration and promoted tumor invasiveness. Conversely, small interfering RNA (siRNA)-mediated downregulation of CEACAM1 expression in MRO cells accelerated cell cycle progression and significantly enhanced tumor size in xenografted mice. CEACAM1 is not appreciably expressed in normal thyroid tissue or benign thyroid tumors. In a human thyroid tissue array, CEACAM1 reactivity was associated with metastatic spread but not with increased tumor size. These findings identify CEACAM1 as a unique mediator that restricts tumor growth whereas increasing metastatic potential. Our data highlight a complex repertoire of actions providing a putative mechanism underlying the spectrum of biologic behaviors associated with thyroid cancer.	Univ Hlth Network, Dept Pathol, Toronto, ON, Canada; Toronto Med Labs, Toronto, ON, Canada; Ontario Canc Inst, Toronto, ON M4X 1K9, Canada; Univ Toronto, Toronto, ON, Canada; Univ Hosp Hamburg Eppendorf, Dept Pathol, Hamburg, Germany; Univ Hosp Hamburg Eppendorf, Dept Internal Med, Hamburg, Germany; Univ Hosp Hamburg Eppendorf, Dept Clin Chem, Toronto, ON, Canada; Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Asa, SL (corresponding author), Univ Toronto, Dept Pathol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	sylvia.asa@uhn.on.ca		Asa, Sylvia/0000-0001-8418-5054				Bamberger AM, 2006, AM J PATHOL, V168, P141, DOI 10.2353/ajpath.2006.050167; Bamberger AM, 2000, AM J PATHOL, V156, P1165, DOI 10.1016/S0002-9440(10)64985-1; Bamberger AM, 1998, AM J PATHOL, V152, P1401; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; Beauchemin N, 1999, EXP CELL RES, V252, P243; Briese J, 2005, J CLIN ENDOCR METAB, V90, P5407, DOI 10.1210/jc.2004-2434; BRUMMER J, 1995, ONCOGENE, V11, P1649; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; DeLellis RA, 2004, PATHOLOGY GENETICS T; Ebrahimnejad A, 2004, AM J PATHOL, V165, P1781, DOI 10.1016/S0002-9440(10)63433-5; Estrera VT, 1999, BIOCHEM BIOPH RES CO, V263, P797, DOI 10.1006/bbrc.1999.1443; Estrera VT, 2001, J BIOL CHEM, V276, P15547, DOI 10.1074/jbc.M008156200; Ezzat S, 1996, THYROID, V6, P409, DOI 10.1089/thy.1996.6.409; FAGIN JA, 1992, J CLIN ENDOCR METAB, V75, P1398, DOI 10.1210/jc.75.6.1398; Fournes B, 2001, ONCOGENE, V20, P219, DOI 10.1038/sj.onc.1204058; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; HSIEH JT, 1995, CANCER RES, V55, P190; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Khoo MLC, 2002, ARCH OTOLARYNGOL, V128, P253, DOI 10.1001/archotol.128.3.253; Khoo MLC, 2002, J CLIN ENDOCR METAB, V87, P1814, DOI 10.1210/jcem.87.4.8353; Kinugasa T, 1998, INT J CANCER, V76, P148, DOI 10.1002/(SICI)1097-0215(19980330)76:1<148::AID-IJC23>3.3.CO;2-J; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Kunath T, 1995, ONCOGENE, V11, P2375; Leung N, 2006, ONCOGENE, V25, P5527, DOI 10.1038/sj.onc.1209541; Liu W, 2005, MOL ENDOCRINOL, V19, P2349, DOI 10.1210/me.2005-0117; Luo WP, 1999, CANCER GENE THER, V6, P313, DOI 10.1038/sj.cgt.7700055; Muenzner P, 2005, J CELL BIOL, V170, P825, DOI 10.1083/jcb.200412151; Muller MM, 2005, BLOOD, V105, P3925, DOI 10.1182/blood-2004-09-3618; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; OHWADA A, 1994, AM J RESP CELL MOL, V11, P214, DOI 10.1165/ajrcmb.11.2.8049082; OIKAWA S, 1992, BIOCHEM BIOPH RES CO, V186, P881, DOI 10.1016/0006-291X(92)90828-9; OLSEN A, 1994, GENOMICS, V23, P659, DOI 10.1006/geno.1994.1555; Piersanti M, 2003, ENDOCR PATHOL, V14, P183, DOI 10.1385/EP:14:3:183; PIGNATELLI M, 1994, HUM PATHOL, V25, P849, DOI 10.1016/0046-8177(94)90002-7; Plunkett TA, 2002, J CLIN ONCOL, V20, P4273, DOI 10.1200/JCO.2002.20.21.4273; Powell DJ, 1998, CANCER RES, V58, P5523; Prall F, 1996, J HISTOCHEM CYTOCHEM, V44, P35, DOI 10.1177/44.1.8543780; Riethdorf L, 1997, J HISTOCHEM CYTOCHEM, V45, P957, DOI 10.1177/002215549704500705; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; Singer BB, 2000, CANCER RES, V60, P1236; STOFFEL A, 1993, J IMMUNOL, V150, P4978; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Takanishi K, 1997, ONCOLOGY, V54, P231; Thies A, 2002, J CLIN ONCOL, V20, P2530, DOI 10.1200/JCO.2002.05.033; Wang L, 2000, CLIN CANCER RES, V6, P2988	50	53	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2747	2758		10.1038/sj.onc.1210077	http://dx.doi.org/10.1038/sj.onc.1210077			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17057731				2022-12-17	WOS:000246210600009
J	Vincan, E; Darcy, PK; Farrelly, CA; Faux, MC; Brabletz, T; Ramsay, RG				Vincan, E.; Darcy, P. K.; Farrelly, C. A.; Faux, M. C.; Brabletz, T.; Ramsay, R. G.			Frizzled-7 dictates three-dimensional organization of colorectal cancer cell carcinoids	ONCOGENE			English	Article						frizzled-7; Wnt signalling; colorectal cancer; carcinoma morphogenesis	EPITHELIAL-MESENCHYMAL TRANSITIONS; LAMININ-5 GAMMA-2 CHAIN; BETA-CATENIN EXPRESSION; TRANSCRIPTIONAL ACTIVATION; EPIGENETIC INACTIVATION; SIGNALING CONTROLS; WNT; DIFFERENTIATION; RECEPTOR; XENOPUS	Progression of colorectal cancer (CRC) involves spatial and temporal occurrences of epithelial-mesenchymal transition (EMT), whereby tumour cells acquire a more invasive and metastatic phenotype. Subsequently, the disseminated mesenchymal tumour cells must undergo a reverse transition (mesenchymal-epithelial transition, MET) at the site of metastases, as most metastases recapitulate the pathology of their corresponding primary tumours. Importantly, initiation of tumour growth at the secondary site is the rate-limiting step in metastasis. However, investigation of this dynamic reversible EMT and MET that underpins CRC morphogenesis has been hindered by a lack of suitable in vitro models. To this end, we have established a unique in vitro model of CRC morphogenesis, which we term LIM1863-Mph (morphogenetic). LIM1863-Mph cells spontaneously undergo cyclic transitions between two-dimensional monolayer (migratory, mesenchymal) and three-dimensional sphere (carcinoid, epithelial) states. Using RNAi, we demonstrate that FZD7 is necessary for MET of the monolayer cells as loss of FZD7 results in the persistence of a mesenchymal state (increased SNAI2/decreased E-cadherin). Moreover, FZD7 is also required for migration of the LIM1863-Mph monolayer cells. During development, FZD7 orchestrates either migratory or epithelialization events depending on the context. Our findings strongly implicate similar functional diversity for FZD7 during CRC morphogenesis.	Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic 3001, Australia; Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Ludwig Inst Canc Res, Parkville, Vic, Australia; Univ Erlangen Nurnberg, Dept Pathol, Erlangen, Germany	Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; Ludwig Institute for Cancer Research; University of Erlangen Nuremberg	Vincan, E (corresponding author), Peter MacCallum Canc Ctr, Div Res, St Andrews Pl, Melbourne, Vic 3001, Australia.	Elizabeth.Vincan@petermac.org	Ramsay, Robert G/C-3291-2015	Ramsay, Robert G/0000-0001-5003-0433; Darcy, Phillip/0000-0002-5303-9561; Vincan, Elizabeth/0000-0002-8607-4849				Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; BATES R, 2005, 2 EMT M VANC; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Burstyn-Cohen T, 2004, DEVELOPMENT, V131, P5327, DOI 10.1242/dev.01424; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carroll TJ, 2005, DEV CELL, V9, P283, DOI 10.1016/j.devcel.2005.05.016; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; De Calisto J, 2005, DEVELOPMENT, V132, P2587, DOI 10.1242/dev.01857; Djiane A, 2000, DEVELOPMENT, V127, P3091; Eckhardt BL, 2005, MOL CANCER RES, V3, P1; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gilles C, 2001, J CELL SCI, V114, P2967; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; HAYWARD IP, 1995, IMMUNOL CELL BIOL, V73, P249, DOI 10.1038/icb.1995.41; HAYWARD IP, 1992, INT J CANCER, V50, P752, DOI 10.1002/ijc.2910500515; Heath JK, 1997, P NATL ACAD SCI USA, V94, P469, DOI 10.1073/pnas.94.2.469; Hlubek F, 2004, INT J CANCER, V108, P321, DOI 10.1002/ijc.11522; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kao KR, 1998, BIOL CELL, V90, P585, DOI 10.1016/S0248-4900(99)80016-1; Kirchner T, 2000, AM J PATHOL, V157, P1113, DOI 10.1016/S0002-9440(10)64626-3; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhl M, 2002, SEMIN CELL DEV BIOL, V13, P243, DOI 10.1016/S1084-9521(02)00050-2; Linker C, 2005, DEVELOPMENT, V132, P3895, DOI 10.1242/dev.01961; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mariadason JM, 2005, GASTROENTEROLOGY, V128, P1081, DOI 10.1053/j.gastro.2005.01.054; Minobe S, 2000, DEV GENES EVOL, V210, P258, DOI 10.1007/s004270050312; Nagayama S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780; PYKE C, 1995, CANCER RES, V55, P4132; Sagara N, 1998, BIOCHEM BIOPH RES CO, V252, P117, DOI 10.1006/bbrc.1998.9607; Schmidt C, 2004, DEV BIOL, V271, P198, DOI 10.1016/j.ydbio.2004.03.016; Schubert FR, 2002, MECH DEVELOP, V114, P143, DOI 10.1016/S0925-4773(02)00039-4; Shioiri M, 2006, BRIT J CANCER, V94, P1816, DOI 10.1038/sj.bjc.6603193; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tada M, 2002, SEMIN CELL DEV BIOL, V13, P251, DOI 10.1016/S1084-9521(02)00052-6; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; THOMPSON EW, 1993, CLIN EXP METASTAS, V11, P15, DOI 10.1007/BF00880062; Thompson MA, 1998, CANCER RES, V58, P5168; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Vincan E, 2005, DIFFERENTIATION, V73, P142, DOI 10.1111/j.1432-0436.2005.00015.x; Vincan E, 2004, FRONT BIOSCI-LANDMRK, V9, P1023, DOI 10.2741/1311; WHITEHEAD RH, 1987, CANCER RES, V47, P2683; Winklbauer R, 2001, NATURE, V413, P856, DOI 10.1038/35101621	53	53	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2340	2352		10.1038/sj.onc.1210026	http://dx.doi.org/10.1038/sj.onc.1210026			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016432				2022-12-17	WOS:000245466000010
J	Bacon, AL; Fox, S; Turley, H; Harris, AL				Bacon, A. L.; Fox, S.; Turley, H.; Harris, A. L.			Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer	ONCOGENE			English	Article						BNIP3; hypoxia; histone deacetylation; HIF; silencing	CELL-DEATH; PROTEIN BNIP3; TUMOR HYPOXIA; EXPRESSION; NECROSIS; BREAST; P53; MEDIATOR; GROWTH; HEAD	Hypoxia, via the hypoxia-inducible factors 1 and 2 (HIF-1 and HIF-2), upregulates many genes involved in cell survival. However, proapoptotic pathways are also induced. BCL-2/adenovirus E1B-19kDa-interacting protein 3 (BNIP3) represents a paradigm of a cell death protein that is hypoxically upregulated via HIF-1 in most cancers. We found that in contrast to many other cell types, 6/8 colorectal cancer (CRC) cell lines show little hypoxic induction of BNIP3 despite an intact HIF signalling system. Colorectal tumour tissue also loses BNIP3 expression relative to matched normal samples. Downregulation of hypoxic BNIP3 in CRC cells was independent of the expression of other BCL-2 family members, or BNIP3L. That BNIP3 plays a functional role in hypoxic survival in CRC cells was demonstrated by the fact that CRC cell lines that do not upregulate BNIP3 or have been treated with BNIP3 RNA interference were insensitive to hypoxia-induced cell death. Promoter methylation and histone deacetylation were shown to silence BNIP3 in these CRC cell lines. Of significance, hypoxic induction of BNIP3 was restored in 4/6 cell lines by trichostatin-A treatment alone. These data suggest that BNIP3 plays an important role in hypoxic cell death and epigenetic mechanisms selectively silence its expression in CRC.	Univ Oxford, John Radcliffe Hosp, Mol Oncol Lab, Weatherall Inst Mol Med,Canc Res UK, Oxford OX3 9DU, England	Cancer Research UK; University of Oxford	Harris, AL (corresponding author), Univ Oxford, John Radcliffe Hosp, Mol Oncol Lab, Weatherall Inst Mol Med,Canc Res UK, Oxford OX3 9DU, England.	aharris.lab@cancer.org.uk	Harris, Adrian L/ABA-3343-2020; Fox, Stephen/G-9719-2016	Harris, Adrian L/0000-0003-1376-8409; Fox, Stephen/0000-0002-7648-8896				Bacon AL, 2004, ANN MED, V36, P530, DOI 10.1080/07853890410018231; Beasley NJP, 2002, CANCER RES, V62, P2493; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P5566, DOI 10.1158/1078-0432.CCR-04-0076; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hockel M, 1998, INT J CANCER, V79, P365; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Knowles HJ, 2001, BREAST CANCER RES, V3, P318, DOI 10.1186/bcr314; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Lee MJ, 2004, MOL CELL BIOL, V24, P3918, DOI 10.1128/MCB.24.9.3918-3927.2004; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Murai M, 2005, BRIT J CANCER, V92, P1165, DOI 10.1038/sj.bjc.6602422; Murai M, 2005, CLIN CANCER RES, V11, P1021; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rubin H, 2001, ADV CANCER RES, V83, P159, DOI 10.1016/S0065-230X(01)83006-2; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sowter HM, 2003, J PATHOL, V201, P573, DOI 10.1002/path.1486; Sowter HM, 2001, CANCER RES, V61, P6669; Stadler P, 1999, INT J RADIAT ONCOL, V44, P749, DOI 10.1016/S0360-3016(99)00115-7; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tomes L, 2003, BREAST CANCER RES TR, V81, P61, DOI 10.1023/A:1025476722493; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wykoff CC, 2000, CANCER RES, V60, P7075; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327	39	53	57	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					132	141		10.1038/sj.onc.1209761	http://dx.doi.org/10.1038/sj.onc.1209761			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799636				2022-12-17	WOS:000243236500013
J	Tilki, D; Irmak, S; Oliveira-Ferrer, L; Hauschild, J; Miethe, K; Atakaya, H; Hammerer, P; Friedrich, MG; Schuch, G; Galalae, R; Stief, CG; Kilic, E; Huland, H; Ergun, S				Tilki, D.; Irmak, S.; Oliveira-Ferrer, L.; Hauschild, J.; Miethe, K.; Atakaya, H.; Hammerer, P.; Friedrich, M. G.; Schuch, G.; Galalae, R.; Stief, C. G.; Kilic, E.; Huland, H.; Ergun, S.			CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer	ONCOGENE			English	Article						CEACAM1; prostate cancer; angiogenesis; Ang1; siRNA; vascular destabilization	ENDOTHELIAL GROWTH-FACTOR; BILIARY GLYCOPROTEIN; C-CAM; COLORECTAL CARCINOMAS; CD66A BGP; CEACAM1; EXPRESSION; ANTIGEN; FAMILY; MECHANISMS	We demonstrate here that epithelial carcinoembryonic antigen (CEA)-related cell adhesion molecule-1 (CEACAM1) downregulation in prostate intraepithelial neoplasia (PIN) is inversely correlated with its upregulation in adjacent blood vessels. CEACAM1 silencing in prostate cancer cell line DU-145 via small interfering ribonucleic acid (siRNA) increased but its overexpression suppressed the expression of angiogenic/lymphangiogenic factors such as vascular endothelial growth factor (VEGF)-A, -C and -D, and angiogenic inhibitor collagen 18/endostatin. Furthermore, CEACAM1 overexpression in DU-145 cells increased but CEACAM1 silencing reduced angiopoietin-1 expression. Inverse relation was found for angiopoietin-2. Supernatant of CEACAM1-overexpressing DU-145 suppressed but that of CEACAM1-silenced increased the VEGF-induced endothelial tubes. Electron microscopically the majority of PIN-associated blood vessels was structurally destabilized exhibiting endothelial fenestration, trans- and inter-endothelial gaps. In some PIN areas, invasion of single tumor cells into the destabilized blood vessels was observed. These data show that disappearance of epithelial CEACAM1 in PIN is accompanied by its upregulation in adjacent vasculature which apparently correlates with vascular destabilization and increased vascularization of prostate cancer. Strategies to either conserve the epithelial CEACAM1 or to target endothelial CEACAM1 might be useful for an anti-angiogenic therapy of prostate cancer.	Univ Hamburg Hosp, Ctr Expt Med, Inst Anat, D-20246 Hamburg, Germany; Univ Hamburg Hosp, Ctr Surg, Urol Clin, D-20246 Hamburg, Germany; Univ Hamburg Hosp, Ctr Theoret Med, Inst Pathol, D-20246 Hamburg, Germany; Univ Hamburg Hosp, Dept Haematol & Oncol, Ctr Internal Med, D-20246 Hamburg, Germany; Univ Hosp Kiel, Dept Radiat Oncol, Kiel, Germany; Univ Hosp, Dept Urol, Munich, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Kiel; Schleswig Holstein University Hospital; University of Munich	Ergun, S (corresponding author), Univ Hamburg Hosp, Ctr Expt Med, Inst Anat, Martinistr 52, D-20246 Hamburg, Germany.	erguen@uke.uni-hamburg.de						Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Bamberger AM, 1998, AM J PATHOL, V152, P1401; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; Brummer J, 2001, AM J PATHOL, V159, P537, DOI 10.1016/S0002-9440(10)61725-7; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; Cao RH, 2004, CIRC RES, V94, P664, DOI 10.1161/01.RES.0000118600.91698.BB; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chalajour F, 2004, EXP CELL RES, V298, P455, DOI 10.1016/j.yexcr.2004.04.034; Ebrahimnejad A, 2000, EXP CELL RES, V260, P365, DOI 10.1006/excr.2000.5026; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Ergun S, 1996, CELL TISSUE RES, V286, P93, DOI 10.1007/s004410050678; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HIXSON DC, 1985, CANCER RES, V45, P3742; Hong YK, 2004, NAT GENET, V36, P683, DOI 10.1038/ng1383; Huss WJ, 2001, CANCER RES, V61, P2736; Iijima H, 2004, J EXP MED, V199, P471, DOI 10.1084/jem.20030437; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Kilic N, 2005, J BIOL CHEM, V280, P2361, DOI 10.1074/jbc.M409407200; KILIC N, 2001, METASTASIS RES PROTO; KUROKI M, 1991, BIOCHEM BIOPH RES CO, V176, P578, DOI 10.1016/S0006-291X(05)80223-2; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; Lin SH, 1999, SEMIN ONCOL, V26, P227; Luo WP, 1999, CANCER GENE THER, V6, P313, DOI 10.1038/sj.cgt.7700055; Mazzucchelli R, 2000, PROSTATE, V45, P72; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nollau P, 1997, AM J PATHOL, V151, P521; Nollau P, 1997, CANCER RES, V57, P2354; Oh P, 2004, NATURE, V429, P629, DOI 10.1038/nature02580; Oliveira-Ferrer L, 2004, CANCER RES, V64, P8932, DOI 10.1158/0008-5472.CAN-04-0505; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Riethdorf L, 1997, J HISTOCHEM CYTOCHEM, V45, P957, DOI 10.1177/002215549704500705; ROBERTS WG, 1995, J CELL SCI, V108, P2369; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; Saaristo A, 2002, FASEB J, V16, P1041, DOI 10.1096/fj.01-1042com; Singer BB, 2000, CANCER RES, V60, P1236; Volpert O, 2002, J BIOL CHEM, V277, P35696, DOI 10.1074/jbc.M205319200; Wagener C, 2000, EXP CELL RES, V261, P19, DOI 10.1006/excr.2000.5038	39	53	58	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2006	25	36					4965	4974		10.1038/sj.onc.1209514	http://dx.doi.org/10.1038/sj.onc.1209514			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568082				2022-12-17	WOS:000239921300002
J	Boisvert-Adamo, K; Aplin, AE				Boisvert-Adamo, K.; Aplin, A. E.			B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis	ONCOGENE			English	Article						adhesion; apoptosis; collagen; ERK1/2; fibronectin; melanoma	GLYCOGEN-SYNTHASE KINASE-3; ONCOGENIC MUTATIONS; BRAF MUTATIONS; NEVUS CELLS; SURVIVAL; PATHWAY; ACTIVATION; APOPTOSIS; AKT; GROWTH	A hallmark feature of cancer is resistance to anoikis, apoptosis induced when cells either lose contact with or encounter an inappropriate extracellular matrix. Melanoma is inherently associated with a high degree of resistance to apoptosis. Mutations in B-RAF are prevalent in melanoma and promote constitutive MEK-ERK1/2 signaling and cell transformation. Acquisition of B-RAF mutations correlates with vertical phase growth when melanoma cells invade into the dermis, a collagen-rich environment that also contains fibronectin matrix. In addition, alterations in phosphoinositide-3 kinase (PI-3 kinase) signaling that lead to activation of AKT are detected in advanced melanomas. Here we show that knockdown of B-RAF expression by siRNA or pharmacological inhibition of MEK rendered melanoma cells susceptible to anoikis. Furthermore, adhesion to fibronectin but not collagen protected melanoma cells from anoikis through a PI-3 kinase-dependent pathway. Therefore, melanoma cells require either B-RAF or PI-3 kinase activation for protection from anoikis. Notably, AKT signaling in melanoma cells is substrate specific. These findings demonstrate that melanoma cells utilize multiple signaling pathways to provide resistance to apoptosis.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, MC-165,47 New Scotland Ave, Albany, NY 12208 USA.	aplina@mail.amc.edu			NIGMS NIH HHS [GM067893] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alanko T, 2000, J INVEST DERMATOL, V115, P286, DOI 10.1046/j.1523-1747.2000.00045.x; Alanko T, 1999, J INVEST DERMATOL, V113, P111, DOI 10.1046/j.1523-1747.1999.00636.x; Alonso SR, 2004, AM J PATHOL, V164, P193, DOI 10.1016/S0002-9440(10)63110-0; Bataille V, 2003, EUR J CANCER, V39, P1341, DOI 10.1016/S0959-8049(03)00313-7; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies MA, 1998, CANCER RES, V58, P5285; DEL PL, 1997, SCIENCE, V278, P687; Dong JL, 2003, CANCER RES, V63, P3883; Eisenmann KM, 2003, CANCER RES, V63, P8330; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Gaggioli C, 2005, ONCOGENE, V24, P1423, DOI 10.1038/sj.onc.1208318; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gill M, 2005, J AM ACAD DERMATOL, V53, P108, DOI 10.1016/j.jaad.2005.04.013; Guldberg P, 1997, CANCER RES, V57, P3660; Hingorani SR, 2003, CANCER RES, V63, P5198; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Marshman E, 2003, J CELL SCI, V116, P675, DOI 10.1242/jcs.00263; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; REGINATO MJ, 2003, NAT CELL BIOL, V6, P6; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schulze A, 2004, MOL BIOL CELL, V15, P3450, DOI 10.1091/mbc.E03-11-0807; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stahl JM, 2003, CANCER RES, V63, P2881; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433	54	53	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4848	4856		10.1038/sj.onc.1209493	http://dx.doi.org/10.1038/sj.onc.1209493			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547495				2022-12-17	WOS:000239687100003
J	Yao, H; Dashner, EJ; van Golen, CM; van Golen, KL				Yao, H; Dashner, EJ; van Golen, CM; van Golen, KL			RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility	ONCOGENE			English	Article						RhoC GTPase; Rac1 GTPase; insulin-like growth factor-1; collagen 1	INFLAMMATORY BREAST-CANCER; GROWTH-FACTOR-I; ACTIVATED PROTEIN-KINASE; ACTIN STRESS FIBERS; BINDING PROTEINS; BOTULINUM ADP-RIBOSYLTRANSFERASE-C3; METASTATIC VARIANTS; CYCLE PROGRESSION; GENE-EXPRESSION; FACTOR RECEPTOR	It is projected that in 2005, approximately 220 900 men will be newly diagnosed with carcinoma of the prostate (CaP). Men who are diagnosed with locally advanced or metastatic disease undergo androgen ablation therapy and most will relapse and progress within 18 months. Metastasis to bone is the major clinical concern during CaP progression, as it is associated with intractable pain, bone fracture and paralysis resulting from spinal cord compression. Therefore, an understanding of the key mechanisms involved in CaP cell bone metastasis is vital to development of novel treatments. The Rho GTPases are molecular switches involved in cell survival, motility and invasion. Increased expression of RhoC GTPase is linked to enhanced metastatic potential in multiple cancers; however, the role of RhoC GTPase in CaP metastasis has not been addressed. In the current study, we demonstrate that RhoC GTPase is expressed and active in PC-3 CaP cells. RhoC inhibition, either pharmacologically with C3 exotransferase or molecularly through expression of a dominant-negative RhoC, promotes IGF-I stimulated random motility but decreases in vitro invasion and experimental metastases. Inhibition of RhoC activity results in drastic morphologic changes and alterations in the expression and distribution of focal adhesion-related proteins. These data suggest that RhoC inhibition leads to activation of other GTPases involved in nondirected motility and that expression of active RhoC is required for the invasive phenotype of PC-3 cells.	Univ Michigan, Ctr Comprehens Canc, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	van Golen, KL (corresponding author), Univ Michigan, Ctr Canc, Dept Internal Med, 200 Zina Pitcher Pl,R-4048A Kresge 2, Ann Arbor, MI 48109 USA.	Kgolen@umich.edu			NATIONAL CANCER INSTITUTE [P50CA069568, P30CA046592] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA69568, 5 P30 CA46592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Alcover J, 1994, Actas Urol Esp, V18 Suppl, P409; Bockhorn M, 2004, CANCER RES, V64, P2469, DOI 10.1158/0008-5472.CAN-03-0256; Carr KM, 2003, ONCOGENE, V22, P3076, DOI 10.1038/sj.onc.1206448; Chang FM, 2003, INT J ONCOL, V22, P469; Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cooper CR, 2000, PROSTATE CANCER P D, V3, P6, DOI 10.1038/sj.pcan.4500387; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; del Peso L, 1997, ONCOGENE, V15, P3047; DIEKMANN D, 1995, METHOD ENZYMOL, V256, P207; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Evers EE, 2000, METHOD ENZYMOL, V325, P403; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Garber K, 2005, J NATL CANCER I, V97, P790, DOI 10.1093/jnci/97.11.790; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; Greenberg DL, 2003, BIOCHEMISTRY-US, V42, P702, DOI 10.1021/bi027100x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hellawell GO, 2002, CANCER RES, V62, P2942; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; Hodge JC, 2003, CANCER RES, V63, P1359; Horiuchi A, 2003, LAB INVEST, V83, P861, DOI 10.1097/01.LAB.0000073128.16098.31; Imamura F, 1999, CLIN EXP METASTAS, V17, P141, DOI 10.1023/A:1006598531238; IWAMURA M, 1993, PROSTATE, V22, P243, DOI 10.1002/pros.2990220307; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kaverina I, 2002, INT J BIOCHEM CELL B, V34, P746, DOI 10.1016/S1357-2725(01)00171-6; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kiefer JA, 2001, MATRIX BIOL, V20, P429, DOI 10.1016/S0945-053X(01)00159-7; Kimura G, 1996, Int J Urol, V3, P39; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kleer CG, 2002, AM J PATHOL, V160, P579, DOI 10.1016/S0002-9440(10)64877-8; Kondo T, 2004, PATHOBIOLOGY, V71, P19, DOI 10.1159/000072958; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Marionnet C, 2003, ONCOGENE, V22, P3500, DOI 10.1038/sj.onc.1206571; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Mitsiades CS, 2005, EXPERT REV ANTICANC, V5, P487, DOI 10.1586/14737140.5.3.487; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; MOSCOW JA, 1994, ONCOGENE, V9, P189; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1996, J MOL MED-JMM, V74, P563, DOI 10.1007/s001090050060; PIENTA KJ, 1999, CANC MANAGEMENT MULT, P193; Price LS, 2001, SEMIN CANCER BIOL, V11, P167, DOI 10.1006/scbi.2000.0367; RIDLEY AJ, 1992, COLD SPRING HARB SYM, V57, P661, DOI 10.1101/SQB.1992.057.01.072; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, J CELL SCI, V114, P2713; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rubin J, 2004, PROSTATE, V58, P41, DOI 10.1002/pros.10299; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Shinto Eiji, 2003, Nihon Rinsho, V61 Suppl 7, P215; Somlyo AV, 2003, FASEB J, V17, P223, DOI 10.1096/fj.02-0655com; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tanno S, 2001, CANCER RES, V61, P589; Thalmann GN, 2000, PROSTATE, V44, P91; Turner CE, 2000, J CELL SCI, V113, P4139; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; van Golen KL, 2003, BREAST CANCER RES, V5, P174, DOI 10.1186/bcr598; van Golen KL, 2002, MOL CANCER THER, V1, P575; van Golen KL, 2002, CLIN EXP METASTAS, V19, P301, DOI 10.1023/A:1015518114931; van Golen KL, 2000, NEOPLASIA, V2, P418, DOI 10.1038/sj.neo.7900115; Wang W, 2003, WORLD J GASTROENTERO, V9, P1950, DOI 10.3748/wjg.v9.i9.1950; WEST K, 2004, J CELL BIOL, V154, P161, DOI DOI 10.1083/JCB.200101039; Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; Zhang H, 2004, EXPERT OPIN INV DRUG, V13, P1569, DOI 10.1517/13543784.13.12.1569; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775; 1999, CANC MANAGEMENT MULT	78	53	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2285	2296		10.1038/sj.onc.1209260	http://dx.doi.org/10.1038/sj.onc.1209260			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16314838				2022-12-17	WOS:000236764300001
J	Ichimura, K; Mungall, AJ; Fiegler, H; Pearson, DM; Dunham, I; Carter, NP; Collins, VP				Ichimura, K; Mungall, AJ; Fiegler, H; Pearson, DM; Dunham, I; Carter, NP; Collins, VP			Small regions of overlapping deletions on 6q26 in human astrocytic tumours identified using chromosome 6 tile path array-CGH	ONCOGENE			English	Article						brain tumour; molecular cytogenetics; array-CGH; glioblastoma; astrocytoma	COMPARATIVE GENOMIC HYBRIDIZATION; RECESSIVE JUVENILE PARKINSONISM; SUPPRESSOR GENE; WAF1/CIP1 GENE; OVARIAN-CANCER; EXPRESSION; MUTATIONS; GLIOMAS; ABNORMALITIES; MICROARRAY	Deletions of chromosome 6 are a common abnormality in diverse human malignancies including astrocytic tumours, suggesting the presence of tumour suppressor genes (TSG). In order to help identify candidate TSGs, we have constructed a chromosome 6 tile path microarray. The array contains 1780 clones (778 P1-derived artificial chromosome and 1002 bacterial artificial chromosome) that cover 98.3% of the published chromosome 6 sequences. A total of 104 adult astrocytic tumours (10 diffuse astrocytomas, 30 anaplastic astrocytomas (AA), 64 glioblastomas (GB)) were analysed using this array. Single copy number change was successfully detected and the result was in general concordant with a microsatellite analysis. The pattern of copy number change was complex with multiple interstitial deletions/ gains. However, a predominance of telomeric 6q deletions was seen. Two small common and overlapping regions of deletion at 6q26 were identified. One was 1002 kb in size and contained PACRG and QKI, while the second was 199 kb and harbours a single gene, AR1D1B. The data show that the chromosome 6 tile path array is useful in mapping copy number changes with high resolution and accuracy. We confirmed the high frequency of chromosome 6 deletions in AA and GB, and identified two novel commonly deleted regions that may harbour TSGs.	Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Mol Histopathol, Cambridge CB2 2QQ, England; Wellcome Trust Sanger Inst, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Wellcome Trust Sanger Institute	Ichimura, K (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Mol Histopathol, Level 3,Lab Block,Box 231, Cambridge CB2 2QQ, England.	ki212@cam.ac.uk	Mungall, Andrew J./U-7067-2018	Mungall, Andrew J./0000-0002-0905-2742; Dunham, Ian/0000-0003-2525-5598	Cancer Research UK [A6618] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Acquati F, 2001, ONCOGENE, V20, P980, DOI 10.1038/sj.onc.1204178; Bentley DR, 2001, NATURE, V409, P942, DOI 10.1038/35057165; BHATIA K, 1995, CANCER RES, V55, P1431; BIGNER SH, 1988, CANCER RES, V48, P405; Buschges R, 1999, BRAIN PATHOL, V9, P435; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Chibon F, 2004, GENE CHROMOSOME CANC, V40, P32, DOI 10.1002/gcc.20012; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Cowell JK, 2004, CANCER GENET CYTOGEN, V151, P36, DOI 10.1016/j.cancergencyto.2003.09.012; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Ekong R, 2004, HUM MUTAT, V24, P76, DOI 10.1002/humu.20059; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; GAO X, 1995, ONCOGENE, V11, P1395; Hardy RJ, 1996, J NEUROSCI, V16, P7941; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Ichimura K, 2000, CANCER RES, V60, P417; Ichimura K, 1996, ONCOGENE, V13, P1065; Ichimura K, 2004, J NEURO-ONCOL, V70, P137, DOI 10.1007/s11060-004-2747-2; Imai Y, 2003, J BIOL CHEM, V278, P51901, DOI 10.1074/jbc.M309655200; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Kleihues P, 2000, PATHOLOGY GENETICS T; KOOPMANN J, 1995, BRIT J CANCER, V72, P1230, DOI 10.1038/bjc.1995.491; Li ZZ, 2002, JPN J CANCER RES, V93, P167, DOI 10.1111/j.1349-7006.2002.tb01255.x; Liu L, 2000, J NEUROPATH EXP NEUR, V59, P1087, DOI 10.1093/jnen/59.12.1087; Liu Y, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-20; Miyakawa A, 2000, BRIT J CANCER, V82, P543; Mungall AJ, 2003, NATURE, V425, P805, DOI 10.1038/nature02055; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Seng TJ, 2005, GENE CHROMOSOME CANC, V43, P181, DOI 10.1002/gcc.20181; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Sonoki T, 2001, BLOOD, V98, P2837, DOI 10.1182/blood.V98.9.2837; Steinemann D, 2003, GENE CHROMOSOME CANC, V37, P421, DOI 10.1002/gcc.10231; Stewart CA, 2004, GENOME RES, V14, P1176, DOI 10.1101/gr.2188104; Tagawa H, 2004, CANCER RES, V64, P5948, DOI 10.1158/0008-5472.CAN-03-4056; Tchinda J, 2004, BRIT J HAEMATOL, V126, P495, DOI 10.1111/j.1365-2141.2004.05082.x; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vissers LELM, 2003, AM J HUM GENET, V73, P1261, DOI 10.1086/379977; Wang XM, 2004, BIOCHEM J, V383, P319, DOI 10.1042/BJ20040524; West AB, 2003, J MOL BIOL, V326, P11, DOI 10.1016/S0022-2836(02)01376-1; Wu JI, 2002, P NATL ACAD SCI USA, V99, P4233, DOI 10.1073/pnas.072090399	43	53	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1261	1271		10.1038/sj.onc.1209156	http://dx.doi.org/10.1038/sj.onc.1209156			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205629	Green Accepted			2022-12-17	WOS:000235537500013
J	Pazzaglia, S; Tanori, M; Mancuso, M; Rebessi, S; Leonardi, S; Di Majo, V; Covelli, V; Atkinson, MJ; Hahn, H; Saran, A				Pazzaglia, S; Tanori, M; Mancuso, M; Rebessi, S; Leonardi, S; Di Majo, V; Covelli, V; Atkinson, MJ; Hahn, H; Saran, A			Linking DNA damage to medulloblastoma tumorigenesis in patched heterozygous knockout mice	ONCOGENE			English	Article						ionizing radiation; apoptosis; LOH; p53; PI3K-Akt/Pkb pathway	MODULATES HOMOLOGOUS RECOMBINATION; CENTRAL-NERVOUS-SYSTEM; BASAL-CELL CARCINOMA; SONIC HEDGEHOG; MOLECULAR-GENETICS; P53; GROWTH; CEREBELLUM; APOPTOSIS; PROTEIN	Hemizygous Ptc1 mice have many features of Gorlin syndrome, including predisposition to medulloblastoma development. Ionizing radiation synergize with Ptc1 mutation to induce medulloblastoma only in neonatally exposed mice. To explore the mechanisms underlying age-dependent susceptibility, we irradiated Ptc(neo67/+) mice at postnatal day 1 (P1) or 10 (P10). We observed a dramatic difference in medulloblastoma incidence, which ranged from 81% in the cerebellum irradiated at P1 to 3% in the cerebellum irradiated at P10. A stricking difference was also detected in the frequency of cerebellar preneoplastic lesions (100 versus 14%). Our data also show significantly lower induction of apoptosis in the cerebellum of medulloblastoma-susceptible (P1) compared to resistant (P10) mice, strongly suggesting that medulloblastoma formation in Ptc1 mutants may be associated with resistance to radiation-induced cell killing. Furthermore, in marked contrast with P10 mice, cerebellum at P1 displays substantially increased activation of the cell survival-promoting Akt/Pkb protein, and markedly decreased p53 levels in response to radiation-induced genotoxic stress. Overall, these results show that developing cerebellar granule neuron precursors' (CGNPs) radiosensitivity to radiation-induced cell death increases with progressing development and inversely correlates with their ability to neoplastically transform.	ENEA, Biotechnol Unit, I-00060 Rome, Italy; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; ENEA, CR Casaccia, Radiat Protect Unit, Rome, Italy; Univ Goettingen, Inst Human Genet, Gottingen, Germany	Italian National Agency New Technical Energy & Sustainable Economics Development; Fondazione IRCCS Istituto Nazionale Tumori Milan; Italian National Agency New Technical Energy & Sustainable Economics Development; University of Gottingen	Pazzaglia, S (corresponding author), ENEA, Biotechnol Unit, Via Anguillarese 301, I-00060 Rome, Italy.	pazzaglia@casaccia.enea.it	Atkinson, Michael/AAU-5127-2020; Atkinson, Michael J/E-5537-2011	Atkinson, Michael/0000-0003-3358-2089; Atkinson, Michael J/0000-0003-3358-2089; Saran, Anna/0000-0002-5587-064X				ANDERSON WJ, 1977, J COMP NEUROL, V171, P17, DOI 10.1002/cne.901710103; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Blackburn AC, 2004, CANCER RES, V64, P5140, DOI 10.1158/0008-5472.CAN-03-3435; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; CERDA H, 1983, INT J RADIAT BIOL, V44, P113, DOI 10.1080/09553008314550911; Chrysis D, 2001, J NEUROSCI, V21, P1481, DOI 10.1523/JNEUROSCI.21-05-01481.2001; Dahmane N, 1999, DEVELOPMENT, V126, P3089; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Lee Y, 2002, CANCER RES, V62, P6395; Linke SP, 2003, CANCER RES, V63, P2596; MacDonald TJ, 2003, ONCOLOGIST, V8, P174, DOI 10.1634/theoncologist.8-2-174; Mancuso M, 2004, CANCER RES, V64, P934, DOI 10.1158/0008-5472.CAN-03-2460; Marino S, 2000, GENE DEV, V14, P994; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Raffel C, 1997, CANCER RES, V57, P842; Raffel C, 2004, NEOPLASIA, V6, P310, DOI 10.1593/neo.03454; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602; Stark JM, 2003, MOL CELL BIOL, V23, P733, DOI 10.1128/MCB.23.2.733-743.2003; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wetmore C, 2000, CANCER RES, V60, P2239; Wetmore C, 2001, CANCER RES, V61, P513; WOOD KA, 1995, J NEUROSCI, V15, P5851; Ye P, 1996, DEV BRAIN RES, V95, P44; Zindy F, 2003, CANCER RES, V63, P5420; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	42	53	53	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 23	2006	25	8					1165	1173		10.1038/sj.onc.1209032	http://dx.doi.org/10.1038/sj.onc.1209032			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16407852				2022-12-17	WOS:000235537500004
J	Cerone, MA; Autexier, C; Londono-Vallejo, JA; Bacchetti, S				Cerone, MA; Autexier, C; Londono-Vallejo, JA; Bacchetti, S			A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT	ONCOGENE			English	Article						telomere; ALT; telomerase	IMMORTAL HUMAN-CELLS; MUTANT TELOMERASE; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; RNA COMPONENT; RECOMBINATION; MAINTENANCE; RECONSTITUTION; EXPRESSION; MECHANISM	In human somatic cells proliferation results in telomere shortening due to the end replication problem and the absence of adequate levels of telomerase activity. The progressive loss of telomeric DNA has been associated with replicative senescence. Maintenance of telomere structure and function is, therefore, an essential requisite for cells that proliferate indefinitely. Human cells that have acquired the immortal phenotype mostly rely on telomerase to compensate for telomere shortening with cell division. However, a certain percentage of immortalized cell lines and human tumors maintain their telomeres by Alternative Lengthening of Telomeres (ALT), a mechanism not fully understood but apparently based on homologous recombination. Here, we report the isolation of an immortal human cell line that is derived from an ALT cell line but maintains telomeres in the absence of key features of ALT and of telomerase. The properties of these cells suggest that the identification of ALT cells may not be reliably based on known ALT markers. This finding is of relevance for discriminating between the mortal and immortal phenotype among telomerase-negative cells in vitro and in vivo, particularly in regard to the development of pharmacological approaches for cancer treatment based on telomerase inhibition.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B4, Canada; Jewish Gen Hosp, Bloomfield Ctr Res Aging, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada; Inst Curie, Telomeres & Canc Lab, F-75248 Paris, France; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McGill University; Lady Davis Institute; McGill University; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; McMaster University	Bacchetti, S (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Via Messi Oro 156, I-00158 Rome, Italy.	bacchett@mcmaster.ca	Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563				Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; BACCHETTI S, 1995, INT J ONCOL, V7, P423; Bailey SM, 2004, CYTOGENET GENOME RES, V107, P14, DOI 10.1159/000079565; Bailey SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Bechter OE, 2004, CANCER RES, V64, P3444, DOI 10.1158/0008-5472.CAN-04-0323; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Cesare AJ, 2004, MOL CELL BIOL, V24, P9948, DOI 10.1128/MCB.24.22.9948-9957.2004; Chen QJ, 2001, MOL CELL BIOL, V21, P1819, DOI 10.1128/MCB.21.5.1819-1827.2001; Chute I, 1997, GENOMICS, V46, P51, DOI 10.1006/geno.1997.5007; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; Cornforth MN, 2001, MUTAGENESIS, V16, P85, DOI 10.1093/mutage/16.1.85; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Fasching CL, 2005, CANCER RES, V65, P2722, DOI 10.1158/0008-5472.CAN-04-2881; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; Grobelny JV, 2000, J CELL SCI, V113, P4577; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Henson JD, 2005, CLIN CANCER RES, V11, P217; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; Jiang WQ, 2005, MOL CELL BIOL, V25, P2708, DOI 10.1128/MCB.25.7.2708-2721.2005; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kurenova EV, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1242; Lee SR, 2003, J BIOL CHEM, V278, P52531, DOI 10.1074/jbc.M311359200; Lin CY, 2005, EUKARYOT CELL, V4, P327, DOI 10.1128/EC.4.2.327-336.2005; Londono-Vallejo JA, 2004, CANCER RES, V64, P2324, DOI 10.1158/0008-5472.CAN-03-4035; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Marciniak RA, 2005, CANCER RES, V65, P2730, DOI 10.1158/0008-5472.CAN-04-2888; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(00)00092-7; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Topcu Z, 2005, P NATL ACAD SCI USA, V102, P3348, DOI 10.1073/pnas.0408770102; Ulaner GA, 2003, CANCER RES, V63, P1759; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Yeager TR, 1999, CANCER RES, V59, P4175; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	57	53	57	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7893	7901		10.1038/sj.onc.1208934	http://dx.doi.org/10.1038/sj.onc.1208934			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16116482				2022-12-17	WOS:000233463000008
J	Barnes, DJ; Schultheis, B; Adedeji, S; Melo, JV				Barnes, DJ; Schultheis, B; Adedeji, S; Melo, JV			Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia	ONCOGENE			English	Article						chronic myeloid leukemia; Bcr-Abl; growth factor dependence; tumorigenicity; adhesion	CHRONIC MYELOGENOUS LEUKEMIA; MURINE HEMATOPOIETIC-CELLS; INTEGRIN-MEDIATED ADHESION; TYROSINE KINASE-ACTIVITY; BONE-MARROW; PROGENITOR CELLS; NOD/SCID MICE; CD34(+) CELLS; CHRONIC-PHASE; EXPRESSION	Chronic myeloid leukemia (CML) is caused by Bcr-Abl, an activated tyrosine kinase. The amounts of Bcr-Abl mRNA and protein in cells from patients in blast crisis (BC) are higher than in those chronic phase (CP), indicating that their expression rises with disease progression. In order to study this phenomenon on cells with the same genetic background, we transfected the 32D cell line with the BCR-ABL transgene and selected clones with graded expression of Bcr-Abl within the range found in cells from CP to BC. In vitro, we found that Bcr-Abl exerted dose-dependent effects upon growth factor dependence, clonogenicity and migration. How ever, the relationship between Bcr-Abl expression and cellular adhesion to fibronectin was more complex: rather than a direct positive correlation, clones that expressed low, but not high, levels of Bcr-Abl were less adhesive than growth factor stimulated, parental BCR-ABL-negative 32D cells. This finding parallels the situation with normal and CML-CP progenitors where the latter exhibit defective adhesion to fibronectin. Treatment with the tyrosine kinase inhibitor imatinib mesylate reversed the adhesion deficient phenotype of clones expressing low levels of Bcr-Abl. When injected subcutaneously into syngeneic mice, cell lines expressing high levels of Bcr-Abl rapidly induced tumors, whereas low-expressing clones led to tumor formation only after a prolonged latency. These findings suggest that the level of Bcr-Abl may be essential in determining the phenotype of the leukemic clone at different stages of the disease.	Hammersmith Hosp, Imperial Coll London, Fac Med, Dept Haematol, London W12 0NN, England	Imperial College London	Melo, JV (corresponding author), Hammersmith Hosp, Imperial Coll London, Fac Med, Dept Haematol, Du Cane Rd, London W12 0NN, England.	j.melo@imperial.ac.uk	Schultheis, Beate/M-5889-2017	Barnes, David/0000-0002-7937-2004				AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Bhatia R, 1998, BLOOD, V91, P3414, DOI 10.1182/blood.V91.9.3414.3414_3414_3422; Bhatia R, 1998, LEUKEMIA, V12, P1708, DOI 10.1038/sj.leu.2401193; Bhatia R, 2001, BRIT J HAEMATOL, V115, P845, DOI 10.1046/j.1365-2141.2001.03192.x; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Dazzi F, 1998, BLOOD, V92, P1390, DOI 10.1182/blood.V92.4.1390.416k09_1390_1396; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Elmaagacli AH, 2000, ANN HEMATOL, V79, P424, DOI 10.1007/s002770000169; GAIGER A, 1995, BLOOD, V86, P2371, DOI 10.1182/blood.V86.6.2371.bloodjournal8662371; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; GUO JQ, 1991, CANCER RES, V51, P3048; HURLEY RW, 1995, J CLIN INVEST, V96, P511, DOI 10.1172/JCI118063; Issaad C, 2000, LEUKEMIA, V14, P662, DOI 10.1038/sj.leu.2401730; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LEVESQUE JP, 1995, J EXP MED, V181, P1805, DOI 10.1084/jem.181.5.1805; Lewis ID, 1998, BLOOD, V91, P630, DOI 10.1182/blood.V91.2.630.630_630_640; Lin F, 1996, BLOOD, V87, P4473, DOI 10.1182/blood.V87.10.4473.bloodjournal87104473; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Ramaraj P, 2004, CANCER RES, V64, P5322, DOI 10.1158/0008-5472.CAN-03-3656; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Schleuning M, 1999, EUR J HAEMATOL, V62, P149; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; Wang JCY, 1998, BLOOD, V91, P2406, DOI 10.1182/blood.V91.7.2406.2406_2406_2414; Wertheim JA, 2003, BLOOD, V102, P2220, DOI 10.1182/blood-2003-01-0062; Wertheim JA, 2002, BLOOD, V99, P4122, DOI 10.1182/blood.V99.11.4122; Zhao RC, 2001, BLOOD, V97, P2406, DOI 10.1182/blood.V97.8.2406	32	53	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6432	6440		10.1038/sj.onc.1208796	http://dx.doi.org/10.1038/sj.onc.1208796			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007188				2022-12-17	WOS:000232038200010
J	Chae, HD; Choi, TS; Kim, BM; Jung, JH; Bang, YJ; Shin, DY				Chae, HD; Choi, TS; Kim, BM; Jung, JH; Bang, YJ; Shin, DY			Oocyte-based screening of cytokinesis inhibitors and identication of pectenotoxin-2 that induces Bim/Bax-mediated apoptosis in p53-deficient tumors	ONCOGENE			English	Article						p53; apoptosis; actin inhibitor; chemosensitivity; Bim; Bax	WILD-TYPE P53; Y TRANSCRIPTION FACTOR; BCL-2 FAMILY-MEMBERS; CELL-LINES; ANTICANCER AGENTS; GENE-EXPRESSION; IN-VIVO; ACTIVATION; CYCLE; ARREST	In this study, we demonstrate that a loss of p53 sensitizes tumor cells to actin damage. Using a novel oocyte-based screening system, we identified natural compounds that inhibit cytokinesis. Among these, pectenotoxin-2 (PTX2), which was first identified as a cytotoxic entity in marine sponges, which depolymerizes actin. laments, was found to be highly effective and more potent to activate an intrinsic pathway of apoptosis in p53-deficient tumor cells compared to those with functional p53 both in vitro and in vivo. Other agents that depolymerize or knot actin. laments were also found to be toxic to p53-deficient tumors. In p53-deficient cells, PTX-2 triggers apoptosis through mitochondrial dysfunction, and this is followed by the release of proapoptotic factors and caspase activation. Furthermore, we observed Bax activation and Bim induction only in p53-deficient cells after PTX-2 treatment. RNA interference of either Bim or Bax resulted in the inhibition of caspases and apoptosis induced by PTX2. However, the small interfering RNAs (SiRNA) of Bim blocked a conformational change of Bax, but Bax SiRNA did not affect Bim expression. Therefore, these results suggest that Bim triggers apoptosis by activating Bax in p53-deficient tumors upon actin damage, and that actin inhibitors may be potent chemotherapeutic agents against p53-deficient tumors.	Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab, Cheonan 330714, South Korea; Seoul Natl Univ, Canc Res Inst, Seoul 110799, South Korea; GenCross Biotech Inst, Anseo 330714, Cheonan, South Korea; Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea	Dankook University; Seoul National University (SNU); Pusan National University	Shin, DY (corresponding author), Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab, Anseo 29, Cheonan 330714, South Korea.	dreamer@dku.edu	Bang, Yung Jue/J-2759-2012; Chae, Hee-Don/D-2620-2011	Bang, Yung Jue/0000-0001-6000-4597; 				Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chae HD, 2004, ONCOGENE, V23, P4084, DOI 10.1038/sj.onc.1207482; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHOI T, 1991, DEVELOPMENT, V113, P789; Debernardis D, 1997, CANCER RES, V57, P870; Draisci R, 1996, TOXICON, V34, P923, DOI 10.1016/0041-0101(96)00030-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1994, CANCER RES, V54, P5824; Fan SJ, 1998, CLIN CANCER RES, V4, P1047; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hori M, 1999, Nihon Yakurigaku Zasshi, V114 Suppl 1, p225P; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Masui Y, 1996, Prog Cell Cycle Res, V2, P1; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; OConnor PM, 1997, CANCER RES, V57, P4285; Park M, 2000, CANCER RES, V60, P542; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Spector I, 1999, MICROSC RES TECHNIQ, V47, P18, DOI 10.1002/(SICI)1097-0029(19991001)47:1<18::AID-JEMT3>3.0.CO;2-E; Trielli MO, 1996, J CELL BIOL, V135, P689, DOI 10.1083/jcb.135.3.689; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Valavanis C, 2001, METHOD CELL BIOL, V66, P417; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; YUN J, 2003, J BIOL CHEM; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	42	53	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4813	4819		10.1038/sj.onc.1208640	http://dx.doi.org/10.1038/sj.onc.1208640			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870701				2022-12-17	WOS:000230477900008
J	Harland, M; Taylor, CF; Chambers, PA; Kukalizch, K; Randerson-Moor, JA; Gruis, NA; de Snoo, FA; ter Huurne, JAC; Goldstein, AM; Tucker, MA; Bishop, DT; Bishop, JAN				Harland, M; Taylor, CF; Chambers, PA; Kukalizch, K; Randerson-Moor, JA; Gruis, NA; de Snoo, FA; ter Huurne, JAC; Goldstein, AM; Tucker, MA; Bishop, DT; Bishop, JAN			A mutation hotspot at the p14ARF splice site	ONCOGENE			English	Article						CDKN2A; p14ARF; p16INK4a; melanoma; mutation; splicing	GERMLINE MUTATIONS; MELANOMA FAMILIES; CDKN2A; SENESCENCE; GENE; LOCUS; RECOMBINATION; FIBROBLASTS; EXPRESSION; PROTEINS	Germline mutations of CDKN2A that affect the p16INK4a transcript have been identified in numerous melanoma pedigrees worldwide. In the UK, over 50% of pedigrees with three or more cases of melanoma have been found to carry mutations of CDKN2A. Mutations that affect p14ARF exon 1 beta exclusively are very rare. This has led to the suggestion that it is p16INK4a and not p14ARF that plays the critical role in melanoma predisposition. We report the identification of a cluster of five different germline mutations at the p14ARF exon 1 beta splice donor site in melanoma pedigrees. All the five splice site variants showed evidence of being causal mutations. Three of the variants were demonstrated to result in aberrant splicing of the p14ARF mRNA, confirming their role in melanoma predisposition. No other point mutations were identified in the coding region of p14ARF. The p14ARF transcript of CDKN2A is clearly important in disease predisposition in a subset of melanoma pedigrees. Curiously, the only mutations so far reported to affect p14ARF exon 1 beta exclusively have been knockout mutations. Further investigation into the spectrum of mutations observed in this gene may help clarify the exact role of p14ARF in melanoma predisposition.	St James Univ Hosp, Canc Res UK Clin Ctr, Genet Epidemiol Div, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Canc Res UK Clin Ctr, Mutat Detect Facil, Leeds LS9 7TF, W Yorkshire, England; Leiden Univ, Ctr Med, Dept Dermatol, NL-9600 PB Leiden, Netherlands; Leiden Univ, Ctr Med, Ctr Human & Clin Genet, NL-9600 PB Leiden, Netherlands; NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Bethesda, MD 20892 USA	Cancer Research UK; Saint James's University Hospital; University of Leeds; Cancer Research UK; Saint James's University Hospital; University of Leeds; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bishop, JAN (corresponding author), St James Univ Hosp, Canc Res UK Clin Ctr, Genet Epidemiol Div, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	j.newton-bishop@cancer.org.uk	Tucker, Margaret A/B-4297-2015	Bishop, Tim/0000-0002-8752-8785; Randerson-Moor, Juliette/0000-0003-0303-0072; Newton-Bishop, Julia/0000-0001-9147-6802; Gruis, Nelleke/0000-0002-5210-9150; Chambers, Philip/0000-0002-0926-717X	NATIONAL CANCER INSTITUTE [Z01CP004410, R01CA083115, ZIACP004410] Funding Source: NIH RePORTER; NCI NIH HHS [IR01 CA083115] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446; Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; Clurman BE, 1998, NEW ENGL J MED, V338, P910, DOI 10.1056/NEJM199803263381312; den Dunnen JT, 2001, HUM GENET, V109, P121, DOI 10.1007/s004390100505; Dracopoli NC, 1996, CANCER SURV, V26, P115; Goldstein AM, 2000, J NATL CANCER I, V92, P1006, DOI 10.1093/jnci/92.12.1006; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hara E, 1996, MOL CELL BIOL, V16, P859; Harland M, 2005, GENE CHROMOSOME CANC, V43, P128, DOI 10.1002/gcc.20177; Harland M, 2000, GENE CHROMOSOME CANC, V28, P45, DOI 10.1002/(SICI)1098-2264(200005)28:1<45::AID-GCC6>3.3.CO;2-6; Harland M, 1997, HUM MOL GENET, V6, P2061, DOI 10.1093/hmg/6.12.2061; Hayward Nicholas K., 1996, Current Opinion in Oncology, V8, P136, DOI 10.1097/00001622-199603000-00011; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Hilleren PJ, 2003, MOL CELL, V12, P1453, DOI 10.1016/S1097-2765(03)00488-X; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Jones AC, 1999, CLIN CHEM, V45, P1133; MEYERHANS A, 1990, NUCLEIC ACIDS RES, V18, P1687, DOI 10.1093/nar/18.7.1687; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PAABO S, 1990, J BIOL CHEM, V265, P4718; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; QUELLE DE, 1995, CELL, V83, P993; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Reese MG, 1997, J COMPUT BIOL, V4, P311, DOI 10.1089/cmb.1997.4.311; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Robertson KD, 1999, ONCOGENE, V18, P3810, DOI 10.1038/sj.onc.1202737; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; STONE S, 1995, CANCER RES, V55, P2988; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; Zaphiropoulos PG, 1998, NUCLEIC ACIDS RES, V26, P2843, DOI 10.1093/nar/26.12.2843; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	34	53	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4604	4608		10.1038/sj.onc.1208678	http://dx.doi.org/10.1038/sj.onc.1208678			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856016				2022-12-17	WOS:000230157100015
J	van Doorn-Khosrovani, SBV; Spensberger, D; de Knegt, Y; Tang, M; Lowenberg, B; Delwel, R				van Doorn-Khosrovani, SBV; Spensberger, D; de Knegt, Y; Tang, M; Lowenberg, B; Delwel, R			Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia	ONCOGENE			English	Article						ETV6; TEL; AML	CHRONIC MYELOMONOCYTIC LEUKEMIA; MESSENGER-RNA DECAY; GENE; FUSION; EXPRESSION; BETA; DIFFERENTIATION; OLIGOMERIZATION; CLASSIFICATION; IDENTIFICATION	ETV6 (ets translocation variant gene 6) TEL ( translocation ets leukemia), encoding a transcriptional repressor, is involved in various translocations associated with human malignancies. Strikingly, the nonrearranged ETV6 allele is often deleted or inactivated in cells harboring these translocations. Although ETV6 translocations are infrequent in acute myeloid leukemia (AML), mutations or deregulated expression of ETV6 may contribute to leukemogenesis. To investigate the involvement of ETV6 in AML, we analysed 300 newly diagnosed patients for mutations in the coding region of the gene. Furthermore, we studied protein expression in 77 patients using two ETV6-specific antibodies. Five somatic heterozygous mutations were detected, which affected either the homodimerization- or the DNA-binding domain of ETV6. The proteins translated from the cDNAs of these mutants were unable to repress transcription and showed dominant-negative effects. In addition, we demonstrate that one-third of AML patients have deficient ETV6 protein expression, which is not related to ETV6 mRNA expression levels. In conclusion, we demonstrate that ETV6 abnormalities are not restricted to translocations and occur more frequently in AML than previously thought. Additional comprehensive studies are required to de. ne the clinical consequence of ETV6 loss of function in AML.	Erasmus MC, Dept Hematol, NL-3015 GE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Delwel, R (corresponding author), Erasmus MC, Dept Hematol, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.	h.delwel@erasmusmc.nl		Spensberger, Dominik/0000-0002-9798-2949; Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar/0000-0003-1239-9867				Agape P, 1997, BRIT J HAEMATOL, V98, P234, DOI 10.1046/j.1365-2141.1997.1973014.x; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Alexander FE, 2001, CANCER RES, V61, P2542; Andreasson P, 2001, CANCER GENET CYTOGEN, V130, P93, DOI 10.1016/S0165-4608(01)00518-0; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; BUIJS A, 1995, ONCOGENE, V10, P1511; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Goseki-Sone M, 2001, J BONE MINER METAB, V19, P263, DOI 10.1007/s007740170030; Hermans MHA, 2003, BLOOD, V101, P2584, DOI 10.1182/blood-2002-07-2062; Hernandez JM, 2000, HAEMATOLOGICA, V85, P31; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Iwase S, 1998, INT J HEMATOL, V67, P361; Joosten M, 2004, J BIOL CHEM, V279, P38169, DOI 10.1074/jbc.M401283200; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kibel AS, 1999, GENE CHROMOSOME CANC, V25, P270, DOI 10.1002/(SICI)1098-2264(199907)25:3<270::AID-GCC9>3.3.CO;2-Q; Kibel AS, 2002, PROSTATE, V52, P305, DOI 10.1002/pros.10112; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lamba JK, 2003, HUM MOL GENET, V12, P99, DOI 10.1093/hmg/ddg011; Liu TC, 2000, AM J HEMATOL, V63, P170, DOI 10.1002/(SICI)1096-8652(200004)63:4<170::AID-AJH2>3.0.CO;2-0; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; LOWENBERG B, 1985, BLOOD, V66, P1225; Odero MD, 2001, GENE CHROMOSOME CANC, V31, P134, DOI 10.1002/gcc.1127; Patel N, 2003, BRIT J HAEMATOL, V122, P94, DOI 10.1046/j.1365-2141.2003.04399.x; Perrin-Vidoz L, 2002, HUM MOL GENET, V11, P2805, DOI 10.1093/hmg/11.23.2805; Plaschke Jens, 2004, Hum Mutat, V23, P285, DOI 10.1002/humu.9217; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Poirel H, 1998, ONCOGENE, V16, P2895, DOI 10.1038/sj.onc.1201817; Romana SP, 1996, LEUKEMIA, V10, P167; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Schell T, 2002, GENOME BIOL, V3; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459; Waga K, 2003, ONCOGENE, V22, P59, DOI 10.1038/sj.onc.1206072; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wlodarska I, 1996, LEUKEMIA LYMPHOMA, V23, P287, DOI 10.3109/10428199609054831; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100	48	53	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4129	4137		10.1038/sj.onc.1208588	http://dx.doi.org/10.1038/sj.onc.1208588			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806161				2022-12-17	WOS:000229680300011
J	Shibata, A; Kamada, N; Masumura, K; Nohmi, T; Kobayashi, S; Teraoka, H; Nakagama, H; Sugimura, T; Suzuki, H; Masutani, M				Shibata, A; Kamada, N; Masumura, K; Nohmi, T; Kobayashi, S; Teraoka, H; Nakagama, H; Sugimura, T; Suzuki, H; Masutani, M			Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent	ONCOGENE			English	Article						Parp-1; gpt delta; deletion; mutation; recombination; rearrangement	BASE-EXCISION-REPAIR; STRAND BREAK REPAIR; DEPENDENT PROTEIN-KINASE; DELTA TRANSGENIC MOUSE; DNA-POLYMERASE-LAMBDA; POLY(ADP-RIBOSE) POLYMERASE; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; SPI(-) SELECTION; ADP-RIBOSYLATION	Accumulated evidence suggests that Parp-1 is involved in DNA repair processes, including base excision repair, single-strand and double-strand break repairs. To understand the precise role of Parp-1 in genomic stability in vivo, we carried out mutation analysis using Parp-1 knockout (Parp-1(-/-)) mice harboring two marker genes, gpt and red/gam genes. Spontaneous mutant frequencies of both genes in the bone marrows and livers did not differ significantly between Parp-1(-/-) and Parp-1(+/+) mice (P > 0.05). After treatment with an alkylating agent, N-nitrosobis(2-hydroxypropyl)amine (BHP), the mutant frequency of the red/gam genes in the liver in Parp-1(-/-) mice was 1.6-fold higher than that in Parp-1(+/+) mice (P<0.05). Categorization of the mutations revealed that deletions larger than 1 kb or those accompanying 1-5 lip insertions at the deletion junctions, as well as rearrangements, were more frequently observed in Parp-1(-/-) than in Parp-1(+/+) mice (P<0.05, respectively). In contrast, mutant frequencies of the gpt gene in the livers of Parp-1(-/-) and Parp-1(+/+) mice after BHP treatment were both elevated and there was no significant difference between the genotypes. These results indicate that Parp-I is implicated in suppressing deletion mutations in vivo, especially those accompanying small insertions or rearrangements. Published online 20 December 2004.	Natl Canc Ctr, Res Inst, Div Biochem, Chuo Ku, Tokyo 1040045, Japan; Kyoritsu Coll Pharmaceut Sci, Minato Ku, Tokyo, Japan; Tokyo Med & Dent Univ, Med Res Inst, Chiyoda Ku, Tokyo, Japan; Chugai Pharmaceut Co Ltd, Shizuoka, Japan; Natl Inst Hlth Sci, Div Genet & Mutagenesis, Tokyo 158, Japan	National Cancer Center - Japan; Tokyo Medical & Dental University (TMDU); Chugai Pharmaceutical Co., Ltd.; Roche Holding; National Institute of Health Sciences - Japan	Masutani, M (corresponding author), Natl Canc Ctr, Res Inst, Div Biochem, Chuo Ku, 5-1-1 Chuo Ku, Tokyo 1040045, Japan.	mmasutan@gan2.res.ncc.go.jp	Masumura, Kenichi/J-7936-2019; Shibata, Atsushi/AAX-1283-2021	Masumura, Kenichi/0000-0002-7907-164X; Shibata, Atsushi/0000-0001-8912-6977				ADOLPH KW, 1985, BIOCHEMISTRY-US, V24, P345, DOI 10.1021/bi00323a017; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Blaisdell JO, 2001, P NATL ACAD SCI USA, V98, P7426, DOI 10.1073/pnas.131077798; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BUKI KG, 1995, J BIOL CHEM, V270, P3370, DOI 10.1074/jbc.270.7.3370; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; DOLL R, 1962, GERONTOL CLIN, V4, P211, DOI 10.1159/000244746; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; GREEN U, 1980, CANCER LETT, V9, P257, DOI 10.1016/0304-3835(80)90096-8; Harrison L, 1999, J MOL BIOL, V290, P667, DOI 10.1006/jmbi.1999.2892; KOKKINAKIS DM, 1992, CARCINOGENESIS, V13, P759, DOI 10.1093/carcin/13.5.759; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; Li BM, 2004, J BIOL CHEM, V279, P13659, DOI 10.1074/jbc.M311606200; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Masumura K, 1999, ENVIRON MOL MUTAGEN, V34, P1, DOI 10.1002/(SICI)1098-2280(1999)34:1<1::AID-EM1>3.0.CO;2-P; Masumura K, 2002, ENVIRON MOL MUTAGEN, V40, P207, DOI 10.1002/em.10108; Masutani M, 1999, P NATL ACAD SCI USA, V96, P2301, DOI 10.1073/pnas.96.5.2301; Masutani M, 2000, MUTAT RES-REV MUTAT, V462, P159, DOI 10.1016/S1383-5742(00)00033-8; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Nivard MJM, 2003, MUTAT RES-FUND MOL M, V529, P95, DOI 10.1016/S0027-5107(03)00111-8; Nohmi T, 1999, ENVIRON MOL MUTAGEN, V34, P9, DOI 10.1002/(SICI)1098-2280(1999)34:1<9::AID-EM2>3.0.CO;2-E; Nohmi T, 2004, ADV BIOPHYS, V38, P97, DOI 10.1016/S0065-227X(04)80106-0; Nohmi T, 1996, ENVIRON MOL MUTAGEN, V28, P465, DOI 10.1002/(SICI)1098-2280(1996)28:4<465::AID-EM24>3.0.CO;2-C; Nozaki T, 2003, CANCER SCI, V94, P497, DOI 10.1111/j.1349-7006.2003.tb01472.x; OIKAWA A, 1980, BIOCHEM BIOPH RES CO, V97, P1311, DOI 10.1016/S0006-291X(80)80009-X; Okada N, 1999, ENVIRON MOL MUTAGEN, V34, P106; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; Oshima J, 2002, CANCER RES, V62, P547; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Sanderson RJ, 2002, DNA REPAIR, V1, P547, DOI 10.1016/S1568-7864(02)00054-X; Sasaki S, 2003, ONCOGENE, V22, P3792, DOI 10.1038/sj.onc.1206589; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Semionov A, 2003, BIOCHEM CELL BIOL, V81, P17, DOI 10.1139/O02-172; Semionov A, 1999, NUCLEIC ACIDS RES, V27, P4526, DOI 10.1093/nar/27.22.4526; Shibata A, 2004, ENVIRON MOL MUTAGEN, V43, P204, DOI 10.1002/em.20008; Shibata A, 2003, ENVIRON MOL MUTAGEN, V41, P370, DOI 10.1002/em.10159; SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570; Susse S, 2004, NUCLEIC ACIDS RES, V32, P669, DOI 10.1093/nar/gkh227; Tong WM, 2002, CANCER RES, V62, P6990; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Vispe S, 2003, J BIOL CHEM, V278, P35279, DOI 10.1074/jbc.M303448200; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; WALDMAN BC, 1990, NUCLEIC ACIDS RES, V18, P5981, DOI 10.1093/nar/18.20.5981; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491; YOSHIHARA K, 1977, BIOCHEM BIOPH RES CO, V78, P1281, DOI 10.1016/0006-291X(77)91431-0	58	53	54	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1328	1337		10.1038/sj.onc.1208289	http://dx.doi.org/10.1038/sj.onc.1208289			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608683				2022-12-17	WOS:000227092600003
J	Ivanov, VN; Hei, TK				Ivanov, VN; Hei, TK			Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway	ONCOGENE			English	Article						melanoma; EGFR; arsenite; ERK; AKT; TRAIL	NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; HEME OXYGENASE-1 GENE; HYPOXIA-INDUCIBLE FACTOR; TRAIL-INDUCED APOPTOSIS; CELL LUNG-CANCER; THERAPEUTIC TARGET; TRANSCRIPTION FACTOR; MEDIATED APOPTOSIS; TYROSINE KINASES	Epidermal growth factor receptor (EGFR) is expressed, albeit at low or intermediate levels, in human melanomas at the different stages of tumor progression. Coexpression of EGFR with its ligand TGFalpha indicates their role in paracrine and autocrine growth regulation of melanomas. As it was previously observed for several types of cancer, specific inhibitors of EGFR-mediated signaling may reduce antiapoptotic properties of cancer cells and sensitize them to cytotoxic drugs. We recently reported that arsenite, particularly in combination with inhibitors of the PI3K-AKT and mitogen-activated protein kinase (MAPK) kinase (MEK)-extracellular signal-regulated kinase (ERK) pathways, induces high levels of apoptosis in different melanomas. Since EGFR signaling operates via activation of the PI3K-AKTand MEK-ERK pathways, we suggested that the combination of arsenite and EGFR inhibitors might also effectively induce apoptosis in melanoma. Here, we demonstrate that a moderate concentration of arsenite (5 - 10 muM) indeed upregulates apoptosis induced by EGFR inhibitors in EGFR-positive melanomas. In contrast, induction of apoptosis in melanomas with negligible surface expression of EGFR or with defective EGFR signaling requires direct suppression of the PI3K-AKTand MAPK pathways by specific pharmacological inhibitors in the presence of arsenite. Under these conditions, metastatic melanoma cell lines undergo TNF-related apoptosis-inducing ligand ( TRAIL)and tumor necrosis factor alpha (TNFalpha)- mediated apoptosis. Taken together, these data provide additional approaches in sensitizing melanomas to the cytotoxic effects of specific inhibitors of survival pathways.	Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA	Columbia University; Columbia University	Ivanov, VN (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St,VC11-218, New York, NY 10032 USA.	vni3@columbia.edu	Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774	NIEHS NIH HHS [P42 ES010349, P30 ES 09089, R01 ES011804, P30 ES009089, ES 05786, ES 11804, F32 ES005786, P42 ES 10349, R01 ES005786] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011804, R01ES005786, P42ES010349, P30ES009089, F32ES005786] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alam J, 2003, CURR PHARM DESIGN, V9, P2499, DOI 10.2174/1381612033453730; ALAM J, 1992, J BIOL CHEM, V267, P21894; Amit S, 2003, SEMIN CANCER BIOL, V13, P15, DOI 10.1016/S1044-579X(02)00096-2; Berking C, 2001, CANCER RES, V61, P8306; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Blackledge G, 2004, BRIT J CANCER, V90, P566, DOI 10.1038/sj.bjc.6601550; Bode AM, 2002, CRIT REV ONCOL HEMAT, V42, P5, DOI 10.1016/S1040-8428(01)00215-3; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Cheng HYY, 2004, ONCOGENE, V23, P3603, DOI 10.1038/sj.onc.1207466; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; Dancey JE, 2004, CANCER CELL, V5, P411, DOI 10.1016/S1535-6108(04)00122-9; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Durante W, 2003, J CELL PHYSIOL, V195, P373, DOI 10.1002/jcp.10274; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001; Gong PF, 2002, ARCH BIOCHEM BIOPHYS, V405, P265, DOI 10.1016/S0003-9861(02)00404-6; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Halaban R, 1996, SEMIN ONCOL, V23, P673; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hayashi T, 2003, BRIT J HAEMATOL, V120, P10, DOI 10.1046/j.1365-2141.2003.03929.x; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; Hershko DD, 2002, J CELL BIOCHEM, V84, P687, DOI 10.1002/jcb.10083; Huerta-Yepez S, 2004, ONCOGENE, V23, P4993, DOI 10.1038/sj.onc.1207655; IVANOV V, 1994, J IMMUNOL, V153, P2394; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Ivanov VN, 2004, J BIOL CHEM, V279, P22747, DOI 10.1074/jbc.M314131200; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Krasilnikov M, 2003, ONCOGENE, V22, P4092, DOI 10.1038/sj.onc.1206598; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li G, 2003, ONCOGENE, V22, P6891, DOI 10.1038/sj.onc.1206819; Li G, 2001, CANCER RES, V61, P3819; Li MY, 2002, J CELL BIOCHEM, V87, P29, DOI 10.1002/jcb.10269; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Liu J, 2001, TOXICOL SCI, V61, P314, DOI 10.1093/toxsci/61.2.314; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; MYKLEBUST AT, 1994, J NEURO-ONCOL, V21, P215, DOI 10.1007/BF01063770; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Perlis C, 2004, ONCOLOGIST, V9, P182, DOI 10.1634/theoncologist.9-2-182; Rea MA, 2003, CARCINOGENESIS, V24, P747, DOI 10.1093/carcin/bgg010; Reifenberger J, 2004, INT J CANCER, V109, P377, DOI 10.1002/ijc.11722; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Satyamoorthy K, 2003, CANCER RES, V63, P756; SATYAMOORTHY K, 1997, MELANOMA RES S2, V7, P35; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; von Willebrand M, 2003, CANCER RES, V63, P1420; Wakeling AE, 1996, BREAST CANCER RES TR, V38, P67, DOI 10.1007/BF01803785; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yih LH, 2002, CARCINOGENESIS, V23, P867, DOI 10.1093/carcin/23.5.867; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427; Zheng XH, 2003, TOXICOLOGY, V187, P39, DOI 10.1016/S0300-483X(03)00025-8	82	53	55	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2005	24	4					616	626		10.1038/sj.onc.1208125	http://dx.doi.org/10.1038/sj.onc.1208125			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580309	Green Published, Green Accepted			2022-12-17	WOS:000226420400009
J	Solari, F; Bourbon-Piffaut, A; Masse, I; Payrastre, B; Chan, AML; Billaud, M				Solari, F; Bourbon-Piffaut, A; Masse, I; Payrastre, B; Chan, AML; Billaud, M			The human tumour suppressor PTEN regulates longevity and dauer formation in Caenorhabditis elegans	ONCOGENE			English	Article						PTEN; insulin pathway; longevity; C. elegans	CELL-CYCLE ARREST; INSULIN-RECEPTOR; LIFE-SPAN; PHOSPHATASE-ACTIVITY; FAMILY-MEMBER; PDZ DOMAIN; HOMOLOG; KINASE; PHOSPHORYLATION; DAF-16	The PTEN tumour suppressor is a phosphatase that dephosphorylates phosphatidylinositol 3, 4, 5 triphosphate (PIP3) and protein substrates. PTEN function is modulated by its carboxy-terminal region, which contains several clustered phosphorylation sites and a PDZ-binding motif (PDZbm). Although PTEN growth suppression effect is well demonstrated, its additional biological roles are less well understood. DAF-18, a Caenorhabditis elegans homologue PTEN, is a component of the insulin/IGF-I signalling pathway that controls entry to the dauer larval stage and adult longevity. To further explore the role of PTEN in the insulin signalling cascade and its possible involvement in the mechanisms of ageing, we undertook a study of PTEN function in C. elegans. We now report that human PTEN can substitute for DAF-18 and restores the dauer and longevity phenotypes in worms devoid of DAF-18. Furthermore, we provide genetic and biochemical evidence that dauer and lifespan control depends on PTEN-mediated regulation of PIP3 levels. Finally, we established that phosphorylation sites in the C-terminus of PTEN and its PDZbm are necessary for PTEN control of the insulin/IGF-I pathway. These results demonstrate that PTEN negatively regulates the insulin/IGF pathway in a whole organism and raise the hypothesis that PTEN may be involved in mammalian ageing.	Univ Lyon 1, Lab Genet & Canc, CNRS, FRE 2692, F-69373 Lyon 08, France; Hop Purpan, IFR30, Dept Oncogenese & Signalisat Cellules Hematopoiet, INSERM,U563, F-31059 Toulouse, France; CUNY Mt Sinai Sch Med, Derald H Ruttenber Canc Ctr, New York, NY 10029 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Billaud, M (corresponding author), Univ Lyon 1, Lab Genet & Canc, CNRS, FRE 2692, Domaine Rockefeller,8 Ave Rockefeller, F-69373 Lyon 08, France.	billaud@univ-lyon1.fr	Chan, Andrew Man-Lok/J-9497-2013; Billaud, Marc N/M-6954-2013; Chan, Andrew/AAC-1145-2020; Solari, Florence/G-8907-2017	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464; Solari, Florence/0000-0002-4173-8314; , Bernard/0000-0002-8693-0190; MASSE, Ingrid/0000-0003-3193-970X	NATIONAL CANCER INSTITUTE [R01CA095063] Funding Source: NIH RePORTER; NCI NIH HHS [CA95063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adey NB, 2000, CANCER RES, V60, P35; Birle D, 2002, J IMMUNOL, V169, P286, DOI 10.4049/jimmunol.169.1.286; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Bossinger O, 2001, DEV BIOL, V230, P29, DOI 10.1006/dbio.2000.0113; BRENNER S, 1974, GENETICS, V77, P71; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; DORMAN JB, 1995, GENETICS, V141, P1399; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Furnari FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gil EB, 1999, P NATL ACAD SCI USA, V96, P2925, DOI 10.1073/pnas.96.6.2925; GOTTLIEB S, 1994, GENETICS, V137, P107; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; LARSEN PL, 1995, GENETICS, V139, P1567; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Mihaylova VT, 1999, P NATL ACAD SCI USA, V96, P7427, DOI 10.1073/pnas.96.13.7427; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Niebuhr K, 2002, EMBO J, V21, P5069, DOI 10.1093/emboj/cdf522; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Riddle DL, 1997, C ELEGANS, P739; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	52	53	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					20	27		10.1038/sj.onc.1207978	http://dx.doi.org/10.1038/sj.onc.1207978			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637588				2022-12-17	WOS:000226125800004
J	Soejima, H; Nakagawachi, T; Zhao, W; Higashimoto, K; Urano, T; Matsukura, S; Kitajima, Y; Takeuchi, M; Nakayama, M; Oshimura, M; Miyazaki, K; Joh, K; Mukai, T				Soejima, H; Nakagawachi, T; Zhao, W; Higashimoto, K; Urano, T; Matsukura, S; Kitajima, Y; Takeuchi, M; Nakayama, M; Oshimura, M; Miyazaki, K; Joh, K; Mukai, T			Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer	ONCOGENE			English	Article						imprinting control region; differentially methylated region; CDKN1C; CpG methylation; histone H3 lysine 9 methylation	BECKWITH-WIEDEMANN-SYNDROME; DEPENDENT KINASE INHIBITOR; SQUAMOUS-CELL CARCINOMA; DNA METHYLATION; CHROMOSOME 11P15.5; REDUCED EXPRESSION; HUMAN P57(KIP2); GASTRIC-CANCER; CONTROL REGION; WILMS-TUMORS	The putative tumor suppressor CDKN1C is an imprinted gene at 11p15.5, a well-known imprinted region often deleted in tumors. The absence of somatic mutations and the frequent diminished expression in tumors would suggest that CDKN1C expression is regulated epigenetically. It has been, however, controversial whether the diminution is caused by imprinting disruption of the CDKN1C/LIT1 domain or by promoter hypermethylation of CDKN1C itself. To clarify this, we investigated the CpG methylation index of the CDKN1C promoter and the differentially methylated region of the LIT1 CpG island (differentially methylated region (DMR)-LIT1), an imprinting control region of the domain, and CDKN1C expression in esophageal cancer cell lines. CDKN1C expression was diminished in 10 of 17 lines and statistically correlated with the loss of methylation at DMR-LIT1 in all but three. However, there was no statistical correlation between CDKN1C promoter MI and CDKN1C expression. Furthermore, loss of CpG methylation was associated with loss of histone H3 lysine 9 (H3K9) methylation at DMR-LIT1. Histone modi. cations at CDKN1C promoter were not correlated with CDKN1C expression. The data suggested that the diminished CDKN1C expression is associated with the loss of methylation of CpG and H3K9 at DMR-LIT1, not by its own promoter CpG methylation, and is involved in esophageal cancer, implying that DMR-LIT1 epigenetically regulates CDKN1C expression not through histone modifications at CDKN1C promoter, but through that of DMR-LIT1.	Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, Saga 8498501, Japan; Nagoya Univ, Grad Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4668550, Japan; Saga Med Sch, Dept Surg, Div Gen Surg, Saga 8498501, Japan; Osaka Med Ctr, Osaka 5941101, Japan; Res Inst Maternal & Child Hlth, Osaka 5941101, Japan; Tottori Univ, Grad Sch Med Sci, Dept Biomed Sci, Yonago, Tottori 6838503, Japan	Saga University; Nagoya University; Saga University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Tottori University	Soejima, H (corresponding author), Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, 5-1-1 Nabeshima, Saga 8498501, Japan.	soejimah@post.saga-med.ac.jp		Soejima, Hidenobu/0000-0001-5076-6563; Urano, Takeshi/0000-0003-3383-3554				Baffa R, 1996, CANCER RES, V56, P268; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Bliek J, 2001, HUM MOL GENET, V10, P467, DOI 10.1093/hmg/10.5.467; Diaz-Meyer N, 2003, J MED GENET, V40, P797, DOI 10.1136/jmg.40.11.797; Du MJ, 2003, HUM MOL GENET, V12, P1927, DOI 10.1093/hmg/ddg194; Feinberg AD, 2000, J CLIN INVEST, V106, P739, DOI 10.1172/JCI10911; Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; Higashimoto K, 2003, AM J HUM GENET, V73, P948, DOI 10.1086/378595; Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kikuchi T, 2002, ONCOGENE, V21, P2741, DOI 10.1038/sj.onc.1205376; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lam WWK, 1999, J MED GENET, V36, P518; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; Li YH, 2002, BLOOD, V100, P2572, DOI 10.1182/blood-2001-11-0026; Mancini-DiNardo D, 2003, HUM MOL GENET, V12, P283, DOI 10.1093/hmg/ddg024; Matsumoto M, 2000, ANTICANCER RES, V20, P1947; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; OKeefe D, 1997, AM J HUM GENET, V61, P295, DOI 10.1086/514854; Oya M, 2000, BRIT J CANCER, V83, P626, DOI 10.1054/bjoc.2000.1298; Scelfo RAM, 2002, ONCOGENE, V21, P2564, DOI 10.1038/sj.onc.1205336; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Shin JY, 2000, CANCER RES, V60, P262; Shin JY, 2000, EXP MOL MED, V32, P79, DOI 10.1038/emm.2000.14; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Thakur N, 2003, J BIOL CHEM, V278, P9514, DOI 10.1074/jbc.M212203200; Thompson JS, 1996, CANCER RES, V56, P5723; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Ueijma H, 2000, NAT GENET, V25, P375, DOI 10.1038/78040; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Weksberg R, 2001, HUM MOL GENET, V10, P2989, DOI 10.1093/hmg/10.26.2989; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yatsuki H, 2002, GENOME RES, V12, P1860, DOI 10.1101/gr.110702	47	53	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4380	4388		10.1038/sj.onc.1207576	http://dx.doi.org/10.1038/sj.onc.1207576			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15007390				2022-12-17	WOS:000221661300004
J	Hubalek, MM; Widschwendter, A; Erdel, M; Gschwendtner, A; Fiegl, HM; Muller, HM; Goebel, G; Mueller-Holzner, E; Marth, C; Spruck, CH; Reed, SI; Widschwendter, M				Hubalek, MM; Widschwendter, A; Erdel, M; Gschwendtner, A; Fiegl, HM; Muller, HM; Goebel, G; Mueller-Holzner, E; Marth, C; Spruck, CH; Reed, SI; Widschwendter, M			Cyclin E dysregulation and chromosomal instability in endometrial cancer	ONCOGENE			English	Article						cyclin E; dysregulation; chromosomal instability; endometrial cancer	BREAST-CANCER; CELL-LINES; PHOSPHORYLATION; CARCINOMAS; ACTIVATION; TRANSITION; INDUCTION	Deregulation of cyclin E, an activator of cyclin-dependent kinase 2 (Cdk2), has been associated with a broad spectrum of human malignancies. Yet the mechanism linking abnormal cyclin E expression to carcinogenesis is largely unknown. The gene encoding the F-box protein hCdc4, a key component of the molecular machinery that targets cyclin E for degradation, is frequently mutated in endometrial cancer, leading to deregulation of cyclin E expression. Here we show that hCDC4 gene mutation and hyperphosphorylation of cyclin E, a parameter that usually correlates with hCDC4 mutation, have a strong statistically significant association with polypoidy and aneuploidy in endometrial cancer. On the contrary, elevated expression of cyclin E by itself was not significantly correlated with polyploidy or aneuploidy when tumors of similar grade are evaluated. These data suggest that impairment of cell cycle regulated proteolysis of cyclin E may be linked to carcinogenesis by promoting genomic instability.	Univ Innsbruck Hosp, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Pathol, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Biostat & Documentat, A-6020 Innsbruck, Austria; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Medical University of Innsbruck; University of Innsbruck; University of Innsbruck; University of Innsbruck; Scripps Research Institute	Widschwendter, M (corresponding author), Univ Innsbruck Hosp, Dept Obstet & Gynecol, Anichstr 35, A-6020 Innsbruck, Austria.	martin.widschwendter@uibk.ac.at	Goebel, Georg/P-6909-2015; Hubalek, Michael/ABD-8041-2021; Fiegl, Heidi/K-4445-2017	Fiegl, Heidi/0000-0002-1236-6806; Widschwendter, Martin/0000-0002-7778-8380	NCI NIH HHS [CA78343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078343, R56CA078343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blegen H, 2003, ANAL CELL PATHOL, V25, P103, DOI 10.1155/2003/491362; BOCKING A, 1994, STATIC DNA CYTOMETRY, P107; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Erlanson M, 1998, CYTOMETRY, V32, P214, DOI 10.1002/(SICI)1097-0320(19980701)32:3<214::AID-CYTO8>3.3.CO;2-N; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Haroske G, 2001, ANAL CELL PATHOL, V23, P89, DOI 10.1155/2001/657642; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; MIKUZ G, 1985, ANAL QUANT CYTOL, V7, P343; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Reed SI, 1996, BBA-REV CANCER, V1287, P151, DOI 10.1016/0304-419X(96)00006-6; Reed SI, 1997, CANCER SURV, V29, P7; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Suzuki A, 1997, HUM GENET, V100, P629, DOI 10.1007/s004390050565; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x	25	53	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	2004	23	23					4187	4192		10.1038/sj.onc.1207560	http://dx.doi.org/10.1038/sj.onc.1207560			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048079				2022-12-17	WOS:000221520200019
J	Hecker, TP; Ding, Q; Rege, TA; Hanks, SK; Gladson, CL				Hecker, TP; Ding, Q; Rege, TA; Hanks, SK; Gladson, CL			Overexpression of FAK promotes Ras activity through the formation of a FAK/p120RasGAP complex in malignant astrocytoma cells	ONCOGENE			English	Article						focal adhesion kinase (FAK); Ras; RasGAP; astrocytoma; glioma; glioblastoma; proliferation	FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; SRC TRANSFORMATION; P21 GTPASE; V-SRC; ACTIVATION; GAP; PATHWAY; DOMAIN; PROLIFERATION	Focal adhesion kinase (FAK) signaling may be mediated through the modulation of Ras activity. We have shown previously that grade III malignant astrocytoma biopsy samples exhibit elevated levels of FAK, and that overexpression of FAK in U-251MG malignant astrocytoma cells promotes the phosphorylation of Shc, a potential upstream mediator of Ras activity. Here, we report that overexpression of FAK promotes Ras activity in U-251MG malignant astrocytoma cells cultured in aggregate suspension or as monolayers adherent to vitronectin. The overexpression of FAK also promoted the association of FAK with p120RasGAP, which is a negative regulator of Ras activity, in the U-251MG cells cultured in aggregate suspension, with this association being abrogated upon plating of the cells onto vitronectin. An association of FAK with p120RasGAP also was observed in malignant astrocytoma biopsy samples, but not in normal brain samples. As overexpression of FAK in U-251MG cells in aggregate suspension culture reduced the amount of p120RasGAP complexed with active Ras, we hypothesize that the association of FAK with p120 RasGAP may facilitate Ras activity. The overexpression of a mutated FAK in which the Y397 had been mutated to F did not result in the formation of the FAK/p120RasGAP complex and did not promote Ras activity, indicating that the Y397 residue of FAK plays a role in the formation of this complex and in the activation of Ras. Moreover, the overexpression of mutated FAK (397F) was found to inhibit anchorage-independent growth. These data provide the basis for a previously undescribed mechanism in which the elevated expression of FAK can promote Ras activity through its competitive recruitment of p120RasGAP, thereby diminishing the association of p120RasGAP with active Ras.	Univ Alabama, Dept Pathol, Div Neuropathol, LHRB 567, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Med Scientist Training Program, Birmingham, AL 35294 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Vanderbilt University	Gladson, CL (corresponding author), Univ Alabama, Dept Pathol, Div Neuropathol, LHRB 567, 701 S 19th St, Birmingham, AL 35294 USA.	gladson@uab.edu			NATIONAL CANCER INSTITUTE [R01CA059958, R01CA097100] Funding Source: NIH RePORTER; NCI NIH HHS [CA59958, CA97100] Funding Source: Medline; NIGMS NIH HHS [GM49882] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; Ding H, 2001, CANCER RES, V61, P3826; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Guha A, 1998, CAN J NEUROL SCI, V25, P267, DOI 10.1017/S0317167100034272; Hecker TP, 2002, CANCER RES, V62, P2699; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; LIEUBEAUTEILLET R, 1995, CANCER RES, V58, P4957; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; Mohan PM, 1999, CANCER RES, V59, P3369; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Serpente N, 1996, MOL CELL NEUROSCI, V7, P391, DOI 10.1006/mcne.1996.0028; Sieg DJ, 1999, J CELL SCI, V112, P2677; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Wang DY, 2000, J CELL SCI, V113, P4221; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413	34	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3962	3971		10.1038/sj.onc.1207541	http://dx.doi.org/10.1038/sj.onc.1207541			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15077193				2022-12-17	WOS:000221382000008
J	Yang, O; Zhang, R; Wang, XW; Linke, SP; Sengupta, S; Hickson, ID; Pedrazzi, G; Perrera, C; Stagljar, I; Littman, SJ; Modrich, P; Harris, CC				Yang, O; Zhang, R; Wang, XW; Linke, SP; Sengupta, S; Hickson, ID; Pedrazzi, G; Perrera, C; Stagljar, I; Littman, SJ; Modrich, P; Harris, CC			The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase	ONCOGENE			English	Article						p53; Rad51; homologous recombination; DNA repair	SYNDROME GENE-PRODUCT; MODULATES HOMOLOGOUS RECOMBINATION; DOUBLE-STRAND BREAKS; HOLLIDAY JUNCTIONS; MAMMALIAN-CELLS; REPLICATION FORKS; SYNDROME PROTEIN; BULGED BASES; TUMOR-CELLS; S-PHASE	The human MSH2/6 complex is essential for mismatch recognition during the repair of replication errors. Although mismatch repair components have been implicated in DNA homologous recombination repair, the exact function of hMSH2/6 in this pathway is unclear. Here, we show that the recombinant hMSH2/6 protein complex stimulated the ability of the Bloom's syndrome gene product, BLM, to process Holliday junctions in vitro, an activity that could also be regulated by p53. Consistent with these observations, hMSH6 colocalized with BLM and phospho-ser15-p53 in hydroxyurea-induced RAD51 nuclear foci that may correspond to the sites of presumed stalled DNA replication forks and more likely the resultant DNA double-stranded breaks. In addition, we show that hMSH2 and hMSH6 coimmunoprecipitated with BLM, p53, and RAD51. Bot h the number of RAD51 foci and the amount of the BLM-p53-RAD51 complex are increased in hMSH2- or hMSH6-deficient cells. These data suggest that hMSH2/6 formed a complex with BLM-p53-RAD51 in response to the damaged DNA forks during double-stranded break repair.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Univ Oxford, John Radcliffe Hosp, Canc Res UK, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Mol Canc Res, CH-8006 Zurich, Switzerland; Duke Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cancer Research UK; University of Oxford; University of Zurich; University of Zurich; Duke University; Duke University; Howard Hughes Medical Institute	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bldg 37,Rm 3068,37 Convent Dr, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov	Sengupta, Sagar/AGR-1063-2022; Hickson, Ian/AAJ-7548-2020; Wang, Xin Wei/B-6162-2009	Sengupta, Sagar/0000-0002-6365-1770; Wang, Xin Wei/0000-0001-9735-606X	NIGMS NIH HHS [GM45190] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005795, ZIABC005795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Chen SH, 2001, P NATL ACAD SCI USA, V98, P13802, DOI 10.1073/pnas.241508098; Davalos AR, 2003, J CELL BIOL, V162, P1197, DOI 10.1083/jcb.200304016; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Franchitto A, 2003, ONCOGENE, V22, P2110, DOI 10.1038/sj.onc.1206254; Frei C, 2000, GENE DEV, V14, P81; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Langland G, 2001, J BIOL CHEM, V276, P30031, DOI 10.1074/jbc.M009664200; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Linke SP, 2003, CANCER RES, V63, P2596; Marsischky GT, 1999, J BIOL CHEM, V274, P7200, DOI 10.1074/jbc.274.11.7200; McGlynn P, 1999, NUCLEIC ACIDS RES, V27, P3049, DOI 10.1093/nar/27.15.3049; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Pedrazzi G, 2003, BIOL CHEM, V384, P1155, DOI 10.1515/BC.2003.128; Pedrazzi G, 2001, NUCLEIC ACIDS RES, V29, P4378, DOI 10.1093/nar/29.21.4378; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Subramanian D, 2002, NUCLEIC ACIDS RES, V30, P2427, DOI 10.1093/nar/30.11.2427; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Umar A, 1997, CANCER RES, V57, P3949; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wang Y, 2000, GENE DEV, V14, P927; Warnick CT, 2001, J BIOL CHEM, V276, P27363, DOI 10.1074/jbc.M103088200; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	58	53	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3749	3756		10.1038/sj.onc.1207462	http://dx.doi.org/10.1038/sj.onc.1207462			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15064730				2022-12-17	WOS:000221242500002
J	Garnis, C; Coe, BP; Zhang, LW; Rosin, MP; Lam, WL				Garnis, C; Coe, BP; Zhang, LW; Rosin, MP; Lam, WL			Overexpression of LRP12, a gene contained within an 8q22 amplicon identified by high-resolution array CGH analysis of oral squamous cell carcinomas	ONCOGENE			English	Article						head and neck; array CGH; 8q; premalignant	COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER; EXPRESSION; DISTINCT; NECK; HEAD	Chromosome 8q amplification is a common event observed in cancer. In this study, we used high-resolution array comparative genomic hybridization to resolve two neighboring regions on 8q that are both amplified in oral cancer. One region (at 8q24) contains the MYC oncogene, which is frequently overexpressed in many cancers, while the other region (at 8q22) represents a novel amplicon. The alignment of array comparative genomic hybridization profiles of 20 microdissected oral squamous cell carcinomas (OSCCs) revealed a similar to5 Mbp region of frequent copy number alteration. This region harbors 16 known genes. Gene expression analysis comparing 15 microdissected OSCC with 16 normal epithelium samples revealed overexpression specific to LRP12 but not the neighboring genes, dihydropyrimidinase and FOG2, suggesting that LRP12 may function as an oncogene in oral tumors.	British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada; Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 2B5, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia	Garnis, C (corresponding author), British Columbia Canc Res Ctr, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	cgarnis@bccancer.bc.ca	Zhang, Lewei/AAP-4757-2021; Coe, Bradley/A-2878-2009; Garnis, Cathie/A-3888-2009	Zhang, Lewei/0000-0003-3594-598X; Coe, Bradley/0000-0001-8471-4016	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013124] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE13124] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Battle MA, 2003, BIOCHEMISTRY-US, V42, P7270, DOI 10.1021/bi034081y; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Dong SM, 2002, CLIN CANCER RES, V8, P2939; Garnis C, 2004, GENE CHROMOSOME CANC, V39, P93, DOI 10.1002/gcc.10294; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; KRAJINA Z, 1975, LARYNGOSCOPE, V85, P1155, DOI 10.1288/00005537-197507000-00006; LOWRY WS, 1975, LARYNGOSCOPE, V85, P1275, DOI 10.1288/00005537-197508000-00001; Martinez-Climent JA, 2003, BLOOD, V101, P3109, DOI 10.1182/blood-2002-07-2119; Ng IOL, 2000, ORAL ONCOL, V36, P484, DOI 10.1016/S1368-8375(00)00040-3; Paris PL, 2003, AM J PATHOL, V162, P763, DOI 10.1016/S0002-9440(10)63873-4; Qing J, 1999, ONCOGENE, V18, P335, DOI 10.1038/sj.onc.1202290; Rosin MP, 2000, CLIN CANCER RES, V6, P357; Veltman JA, 2003, CANCER RES, V63, P2872; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Weiss MM, 2003, ONCOGENE, V22, P1872, DOI 10.1038/sj.onc.1206350; Zhang LW, 1997, AM J PATHOL, V151, P323	16	53	55	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2582	2586		10.1038/sj.onc.1207367	http://dx.doi.org/10.1038/sj.onc.1207367			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676824				2022-12-17	WOS:000220558000017
J	Kauraniemi, P; Hautaniemi, S; Autio, R; Astola, J; Monni, O; Elkahloun, A; Kallioniemi, A				Kauraniemi, P; Hautaniemi, S; Autio, R; Astola, J; Monni, O; Elkahloun, A; Kallioniemi, A			Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines	ONCOGENE			English	Article						HER2; herceptin; amplification; breast cancer; cDNA microarray	MONOCLONAL-ANTIBODY; C-FOS; MUTATIONS; KIT; CHEMOTHERAPY; TRASTUZUMAB; ACTIVATION; ESTROGEN; EFFICACY; AMPLICON	Herceptin is a humanized monoclonal antibody targeted against the extracellular domain of the HER2 oncogene, which is amplified and overexpressed in 10-34% of breast cancers. Herceptin therapy provides effective treatment in HER2-positive metastatic breast cancer, although a favorable treatment response is not achieved in all cases. Here, we show that Herceptin treatment induces a dose-dependent growth reduction in breast cancer cell lines with HER2 amplification, whereas nonamplified cell lines are practically resistant. Time-course analysis of global gene expression patterns in amplified and nonamplified cell tines indicated a major change in transcript levels between 24 and 48 h of Herceptin treatment. A step-wise gene selection algorithm revealed a set of 439 genes whose temporal expression profiles differed most between the amplified and nonamplified cell lines. The discriminatory power of these genes was confirmed by both hierarchical clustering and self-organizing map analyses. In the amplified cell lines, the Herceptin treatment induced the expression of several genes involved in RNA processing and DNA repair, while cell adhesion mediators and known oncogenes, such as e-FOS and c-KIT, were downregulated. These results provide additional clues to the downstream effects of blocking the HER2 pathway in breast cancer and may provide new targets for more effective treatment.	Univ Tampere, Inst Med Technol, Canc Genet Lab, FIN-33520 Tampere, Finland; Tampere Univ Hosp, FIN-33520 Tampere, Finland; Tampere Univ Technol, Inst Signal Proc, FIN-33101 Tampere, Finland; Univ Helsinki, Biomedicum Helsinki, Biomedicum Biochip Ctr, FIN-00290 Helsinki, Finland; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	Tampere University; Tampere University; Tampere University Hospital; Tampere University; University of Helsinki; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Kallioniemi, A (corresponding author), Univ Tampere, Inst Med Technol, Canc Genet Lab, FIN-33520 Tampere, Finland.	anne.kallioniemi@uta.fi	Astola, Jaakko T/G-4297-2014; Autio, Reija/D-2037-2014; Hautaniemi, Sampsa/CAG-0362-2022; Hautaniemi, Sampsa/A-3122-2009	Hautaniemi, Sampsa/0000-0002-7749-2694; Hautaniemi, Sampsa/0000-0002-7749-2694; Astola, Jaakko/0000-0002-2750-5311; Autio, Reija/0000-0002-6519-2715				Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Duan RQ, 2002, BIOCHEM BIOPH RES CO, V294, P384, DOI 10.1016/S0006-291X(02)00499-0; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Hautaniemi S, 2003, MACH LEARN, V52, P45, DOI 10.1023/A:1023941307670; HAUTANIEMI S, 2003, STRATEGY IDENTIFYING; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hyman E, 2002, CANCER RES, V62, P6240; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kohonen T, 2001, SELF ORG MAPS, Vthird, DOI DOI 10.1007/978-3-642-56927-2; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; Molina MA, 2001, CANCER RES, V61, P4744; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Mousses S, 2000, PRACT APPROACH SER, P113; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; Vesanto J., 2000, SOM TOOLBOX MATLAB 5; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; WILDING G, 1988, CANCER RES, V48, P802; Yakes FM, 2002, CANCER RES, V62, P4132; Yang YH, 2001, PROC SPIE, V4266, P141, DOI 10.1117/12.427982	27	53	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					1010	1013		10.1038/sj.onc.1207200	http://dx.doi.org/10.1038/sj.onc.1207200			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647448				2022-12-17	WOS:000188486600018
J	Philipp-Staheli, J; Kim', KH; Liggitt, D; Gurley, KE; Longton, G; Kemp, CJ				Philipp-Staheli, J; Kim', KH; Liggitt, D; Gurley, KE; Longton, G; Kemp, CJ			Distinct roles for p53, p27(Kip1), and p21(Cip1) during tumor development	ONCOGENE			English	Article						tumor suppressor gene; lymphoma; sarcoma haploinsufficiency; epistasis	DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; MAMMARY-CANCER MODEL; CDK INHIBITOR; MICE LACKING; P53-DEFICIENT MICE; P27; EXPRESSION; TUMORIGENESIS; DEGRADATION	Mutations in p53 and reduced expression of the Cdk inhibitor P27(Kip1) are frequently observed in a wide variety of human cancers, but it is not known whether alterations in these tumor suppressors interact to influence tumor progression. To address this, we measured tumor latency and spectrum in p53 and p27 single and compound mutant mice. p53-/- (null) mice developed T-cell lymphomas and soft-tissue sarcomas, while p27-/- mice developed adenomas of the pituitary and lung, but with much longer latency. The latency for tumor development in p53-/- p27-/- and p53 -/- p27 +/- compound mutant mice was significantly reduced, by 15-30%, compared to single mutant p53-/- mice. The tumor spectrum in the compound mutants was similar to that of p53-/- mice, and additional tumors of diverse histotypes. In tumors from p53-/- mice, p27 protein levels were reduced to a greater extent than were mRNA levels, indicating that p27 is downregulated in tumors at the transcriptional as well as post-transcriptional levels. In contrast, mice deficient in another Cdk inhibitor p21(Cip1), which is also a transcriptional target and effector of p53, showed only a marginal increase in tumor predisposition in response to ENU treatment. Thus, downregulation of p27 is a common feature in p53-/- tumors. Germline deletion of one or both alleles of p27 accelerates tumor development and associated mortality in p53-/- mice, indicating potent synergy between loss of p27 and p53. Although p21 is functionally similar to both p53 and p27, it plays a lesser role in tumor suppression. These results further highlight the highly cooperative nature of p27 and its central role in tumor suppression.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Kemp, CJ (corresponding author), Fred Hutchinson Canc Res Ctr, C1-015,1100 Fairview Ave N, Seattle, WA 98109 USA.	cjkemp@fhcrc.org			NCI NIH HHS [CA70414] Funding Source: Medline; NIEHS NIH HHS [ES011045] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011045] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Bearss DJ, 2002, CANCER RES, V62, P2077; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BULLRICH F, 1995, CANCER RES, V55, P1199; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Ciaparrone M, 1998, CANCER RES, V58, P114; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDIERY WS, 2001, NAT CELL BIOL, V3, P71; Erlanson M, 1998, BLOOD, V92, P770; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Geisen C, 2003, ONCOGENE, V22, P1724, DOI 10.1038/sj.onc.1206340; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson RJ, 2003, CANCER RES, V63, P3021; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Kalbfleish J., 1980, STAT ANAL FAILURE TI; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Maronpot R, 1999, PATHOLOGY MOUSE; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Masciullo V, 1999, CANCER RES, V59, P3790; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Moller MB, 2000, LEUKEMIA LYMPHOMA, V39, P19, DOI 10.3109/10428190009053535; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; PIETENPOL JA, 1995, CANCER RES, V55, P1206; Piva R, 1999, J NEUROPATH EXP NEUR, V58, P691, DOI 10.1097/00005072-199907000-00002; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Quintanilla-Martinez L, 1998, AM J PATHOL, V153, P175, DOI 10.1016/S0002-9440(10)65558-7; SanchezBeato M, 1997, AM J PATHOL, V151, P151; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Singh SP, 1998, CANCER RES, V58, P1730; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; TIMME TL, 1994, BIOTECHNIQUES, V17, P462; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Yang WC, 2001, CANCER RES, V61, P565; Yasui W, 1997, JPN J CANCER RES, V88, P625, DOI 10.1111/j.1349-7006.1997.tb00428.x	63	53	56	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					905	913		10.1038/sj.onc.1207220	http://dx.doi.org/10.1038/sj.onc.1207220			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647411				2022-12-17	WOS:000188486600005
J	Zou, WG; Luo, CX; Zhang, ZL; Liu, J; Gu, JF; Pei, ZF; Qian, C; Liu, XY				Zou, WG; Luo, CX; Zhang, ZL; Liu, J; Gu, JF; Pei, ZF; Qian, C; Liu, XY			A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent	ONCOGENE			English	Article						oncolytic adenovirus; E1A gene; hTERT promoter; telomerase; cancer	REPLICATION-COMPETENT ADENOVIRUS; SUICIDE GENE-THERAPY; EXPRESSING BACTERIAL NITROREDUCTASE; REVERSE-TRANSCRIPTASE PROMOTER; CATALYTIC SUBUNIT HTERT; HUMAN CANCER-CELLS; HUMAN BONE-MARROW; PROSTATE-CANCER; HEPATOCELLULAR-CARCINOMA; BAX GENE	Telomerase is a therapeutic target for cancer. Human telomerase reverse transcriptase (hTERT), the catalytic subunit of the telomerase, is transcriptionaly upregulated exclusively in about 90#37; of cancer cells. Previous studies have demonstrated that hTERT promoter can control the expression of exogenous genes to the telomerase-positive cancer cells, thus hTERT promoter is an excellent candidate for generating cancer-specific oncolytic adenovirus. In this study, we devised a novel oncolytic adenovirus (Ad.TERT) by replacing the normal E1A regulatory elements with hTERT promoter. Ad.TERT displays cancer-specific E1A expression, virus replication and cytolysis in in vitro experiments. In animal experiments, intratumoral administration of Ad.TERT demonstrates potent antitumoral efficacy at least in two xenograft models (Bcap37 and BEL7404). Ad.TERT was targeted by the telomerase activity in cancer cells and has potent antitumoral efficacy in vivo, and since telomerase activity is a wide-ranged tumor marker, Ad.TERT could be a powerful therapeutic agent for a variety of cancers.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Univ Navarra, Sch Med, Dept Med, E-31080 Pamplona, Spain	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Navarra	Liu, XY (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	xyliu@sibs.ac.cn	zhang, zl/D-9716-2012					Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; Bilsland AE, 2003, ONCOGENE, V22, P370, DOI 10.1038/sj.onc.1206168; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Curiel DT, 2000, CLIN CANCER RES, V6, P3395; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Freytag SO, 1998, HUM GENE THER, V9, P1323, DOI 10.1089/hum.1998.9.9-1323; Gu J, 2000, CANCER RES, V60, P5359; Gu J, 2002, ONCOGENE, V21, P4757, DOI 10.1038/sj.onc.1205582; Hallenbeck PL, 1999, HUM GENE THER, V10, P1721, DOI 10.1089/10430349950017725; Hernandez-Alcoceba R, 2002, HUM GENE THER, V13, P1737, DOI 10.1089/104303402760293574; HORWITZ MS, 1996, FIELDS VIROLOGY, P2149; Ichikawa T, 2001, CANCER RES, V61, P5336; Jakubczak JL, 2003, CANCER RES, V63, P1490; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirch HC, 2002, ONCOGENE, V21, P7991, DOI 10.1038/sj.onc.1205965; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Komata T, 2002, ONCOGENE, V21, P656, DOI 10.1038/sj.onc.1205072; Kruyt FAE, 2002, HUM GENE THER, V13, P485, DOI 10.1089/10430340252809784; Kurihara T, 2000, J CLIN INVEST, V106, P763, DOI 10.1172/JCI9180; Li YH, 2001, CANCER RES, V61, P6428; Lin TY, 2002, ONCOGENE, V21, P8020, DOI 10.1038/sj.onc.1205926; Liu J, 2002, INT J ONCOL, V21, P661; Matsubara S, 2001, CANCER RES, V61, P6012; MCKINNON RD, 1982, GENE, V19, P33, DOI 10.1016/0378-1119(82)90186-X; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Motoi F, 2000, HUM GENE THER, V11, P223, DOI 10.1089/10430340050015978; Nakamura Y, 1999, MOL CARCINOGEN, V26, P312, DOI 10.1002/(SICI)1098-2744(199912)26:4<312::AID-MC10>3.3.CO;2-1; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Nettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2; Plumb JA, 2001, ONCOGENE, V20, P7797, DOI 10.1038/sj.onc.1204954; Post DE, 2003, ONCOGENE, V22, P2065, DOI 10.1038/sj.onc.1206464; Ramirez RD, 1997, J INVEST DERMATOL, V108, P113, DOI 10.1111/1523-1747.ep12285654; Rodriguez R, 1997, CANCER RES, V57, P2559; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Takakura M, 1999, CANCER RES, V59, P551; Tsukuda K, 2002, CANCER RES, V62, P3438; Wang JH, 2002, BIOCHEM BIOPH RES CO, V290, P1454, DOI 10.1006/bbrc.2002.6373; Watanabe T, 1996, BLOOD, V87, P5032, DOI 10.1182/blood.V87.12.5032.bloodjournal87125032; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Wildner O, 1999, GENE THER, V6, P57, DOI 10.1038/sj.gt.3300810; Yasumoto S, 1996, ONCOGENE, V13, P433; Yu DC, 1999, CANCER RES, V59, P4200; Yu DC, 2001, CANCER RES, V61, P517	46	53	67	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					457	464		10.1038/sj.onc.1207033	http://dx.doi.org/10.1038/sj.onc.1207033			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724574				2022-12-17	WOS:000188098300016
J	Dohoney, KM; Guillerm, C; Whiteford, C; Elbi, C; Lambert, PF; Hager, GL; Brady, JN				Dohoney, KM; Guillerm, C; Whiteford, C; Elbi, C; Lambert, PF; Hager, GL; Brady, JN			Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage	ONCOGENE			English	Article						p53; PP2A; phosphatase; DNA damage; serine 37	PROTEIN PHOSPHATASE 2A; CELL-CYCLE CHECKPOINT; CATALYTIC SUBUNIT; BINDING-SITE; OKADAIC ACID; T-ANTIGEN; MDM2; TRANSACTIVATION; INHIBITION; EXPRESSION	The p53 tumor suppressor protein plays a critical role in mediating cellular response to stress. Upon DNA damage, post-translational modifications stabilize and activate this nuclear phosphoprotein. To determine the effect of phosphorylation site mutants in the context of the whole p53 protein, we performed reporter assays in p53 and MDM2 knockout mouse embryonic fibroblasts transfected with full-length p53 constructs. We show that mutation of S37 causes a decrease in p53 transcriptional activity compared to wild-type p53. Our data further suggest that the dephosphorylation of p53 at S37 is a regulated event involving protein phosphatase 2A (PP2A). Coimmunoprecipitation and immunofluorescence microscopy studies demonstrate that PP2A and p53 associate with one another in vivo following gamma-irradiation. Consistent with these observations, phosphorylated S37 accumulates in cell extracts prepared from gamma-irradiated Molt-4 cells in the presence of okadaic acid. Furthermore, in vitro phosphatase assays show that PP2A dephosphorylates p53 at S37. These results suggest that dephosphorylation of p53 at S37 plays a role in the transcriptional regulation of the p53 protein in response to DNA damage.	NCI, Basic Res Lab, Virus Tumor Biol Sect, NIH, Bethesda, MD 20892 USA; NCI, Ctr Adv Technol, Ctr Canc Res, Gaithersburg, MD 20892 USA; NCI, Lab Receptor Biol & Gene Express, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Flinders Univ S Australia, Sch Med, Bedford Pk, SA 5042, Australia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Flinders University South Australia	Brady, JN (corresponding author), NCI, Basic Res Lab, Virus Tumor Biol Sect, NIH, Bldg 41,Room B 201,41 Lib Dr MSC 5055, Bethesda, MD 20892 USA.	bradyj@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC010308, Z01BC005450, ZIABC005450, ZIABC005691, Z01BC005691, Z01BC010308] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1989, J BIOL CHEM, V264, P21435; COHEN P, 1991, METHOD ENZYMOL, V201, P389; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Elbi C, 2002, MOL BIOL CELL, V13, P2001, DOI 10.1091/mboc.13.6.mk0602002001; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; GUY GR, 1992, J BIOL CHEM, V267, P1846; HARPER JW, 1993, CELL, V75, P805; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; MIYASHITA T, 1995, CELL, V80, P293; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHONTHAL AH, 1998, FRONT BIOSCI, V3, P1262; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; vanSteensel B, 1996, J CELL SCI, V109, P787; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Wilson NJ, 1999, BIOCHEM J, V339, P517, DOI 10.1042/0264-6021:3390517; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	47	53	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					49	57		10.1038/sj.onc.1207005	http://dx.doi.org/10.1038/sj.onc.1207005			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712210				2022-12-17	WOS:000187895300006
J	Xue, LY; Chiu, SM; Fiebig, A; Andrews, DW; Oleinick, NL				Xue, LY; Chiu, SM; Fiebig, A; Andrews, DW; Oleinick, NL			Photodamage to multiple Bcl-xL isoforms by photodynamic therapy with the phthalocyanine photosensitizer Pc 4	ONCOGENE			English	Article						Bcl-xL; Bcl-2; apoptosis; photodynamic; therapy; Pc 4	ENDOPLASMIC-RETICULUM; INDUCED APOPTOSIS; CELLS; BCL-X(L); OVEREXPRESSION; ONCOPROTEIN; RESISTANCE; INDUCTION; MEMBERS; FAMILY	The antiapoptotic oncoprotein Bcl-2 is now a recognized phototarget of photodynamic therapy (PDT) with the phthalocyanine Pc 4 and with other mitochondrion-targeting photosensitizers. Photodamage, observed on Western blots as the loss of the native 26-kDa Bcl-2 protein, is PDT dose dependent and occurs in multiple cell lines, in the cold, and immediately upon photoirradiation. In our initial study, no photochemical damage was observed to Bcl-xL, in spite of its similarity in size, sequence, location and function to Bcl-2. The original study used a commercial anti-Bcl-xS/L antibody. We have revisited this issue by examining Western blots developed using one of three epitope-specific anti-Bcl-xL antibodies from commercial sources, a polyclonal antibody generated to the entire protein, as well as the antibody used previously. All five Bcl-xL antibodies recognized bacterially expressed Bcl-xL, but not Bcl-2, whereas an anti-Bcl-2 antibody recognized Bcl-2 and not Bcl-xL. All five Bcl-xL antibodies recognized at least one protein migrating at similar to30 kDa; two of the antibodies recognized an additional band, migrating at similar to33 or similar to24 kDa. We now observe Pc 4-PDT-induced photo-damage to all Bcl-xL-related proteins, except the 33-kDa species, in several human cancer cell lines. The results indicate that, in addition to the expected quantitative differences that may reflect exposure of individual epitopes, the antibodies also detect proteins of different apparent molecular weights that may be distinct isoforms or post-translationally modified forms of Bcl-xL. No evidence for PDT-induced phosphorylation or degradation was observed. Bcl-xL localized to mitochondria was considerably more sensitive to photodamage than was Bcl-xL in the cytosol, indicating that as previously found for Bcl-2, Bcl-xL must be membrane localized to be photosensitive.	Case Western Reserve Univ, Sch Med BRB324, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, CWRU Ireland Comprehens Canc Ctr, Cleveland, OH USA; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	Case Western Reserve University; Case Western Reserve University; McMaster University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med BRB324, Dept Radiat Oncol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	nlo@po.cwru.edu		Andrews, David/0000-0002-9266-7157	NATIONAL CANCER INSTITUTE [R01CA083917, P01CA048735, P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA83917, P01 CA48735, P30 CA43703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; FANG W, 1994, J IMMUNOL, V153, P4388; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P318, DOI 10.1562/0031-8655(2001)074<0318:ETBITT>2.0.CO;2; Kim HRC, 1999, CANCER RES, V59, P3429; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200; Li XY, 2001, CANCER RES, V61, P1699; Liu QY, 1997, CLIN CANCER RES, V3, P2039; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; Srivastava M, 2001, J BIOL CHEM, V276, P15481, DOI 10.1074/jbc.M006920200; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; Usuda J, 2003, PHOTOCHEM PHOTOBIOL, V78, P1, DOI 10.1562/0031-8655(2003)078<0001:ABTPLO>2.0.CO;2; Usuda J, 2003, J BIOL CHEM, V278, P2021, DOI 10.1074/jbc.M205219200; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; Ye QR, 2002, J EXP MED, V196, P87, DOI 10.1084/jem.20012084	32	53	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9197	9204		10.1038/sj.onc.1207019	http://dx.doi.org/10.1038/sj.onc.1207019			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681679				2022-12-17	WOS:000187400400001
J	Balachandran, R; Welsh, MJ; Day, BW				Balachandran, R; Welsh, MJ; Day, BW			Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells	ONCOGENE			English	Article						stathmin; p21(WAF1); microtubules; p53	HUMAN BREAST-CANCER; MICROTUBULE DYNAMICS; DOWN-REGULATION; IN-VIVO; PROTEIN; EXPRESSION; PHOSPHORYLATION; TUBULIN; P53; ONCOPROTEIN-18	Two paclitaxel(Ptx)-resistant ovarian cancer cell lines, 1A9/Ptx-10 and 1A9/Ptx-22, isolated from the 1A9 cell line (a clone of the A2780 line) by continuous exposure to Ptx and verapamil, have point mutations in their major beta-tubulin gene and in one or both alleles of their TP53 gene. These cells were examined for alterations in cell cycle regulators and the tubulin-binding protein stathmin. Unlike parental cells, neither 1A9/Ptx-10 nor 1A9/Ptx-22 expressed detectable levels of p21(WAF1/Cip1), a putative transcriptional regulator of stathmin, but did overexpress stathmin and Bcl2. No differences were noted in the expression levels of proliferative cell nuclear antigen or tyrosine-phosphorylated p34(Cdc2). Ptx treatment altered little the expression of stathmin in the parental cell line, although it increased p21(WAF1/Cip1) levels several-fold. Infection of Ptx-resistant lines with a wild-type TP53-bearing adenovirus (AdWTp53) changed cell cycle distribution and increased the levels of p21(WAF1/Cip1), but caused no changes in stathmin levels. Microtubule drug resistance in ovarian carcinoma may be associated with altered p53/21(WAF1/Cip1) regulatory pathways for stathmin expression and function.	Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Day, BW (corresponding author), 721 Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA.			Day, Billy/0000-0001-6208-9950	NCI NIH HHS [CA 78039] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078039] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Alli E, 2002, CANCER RES, V62, P6864; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Andersen SSL, 1999, BIOESSAYS, V21, P53, DOI 10.1002/(SICI)1521-1878(199901)21:1<53::AID-BIES7>3.0.CO;2-L; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; Brattsand G, 2000, BRIT J CANCER, V83, P311, DOI 10.1054/bjoc.2000.1264; Cheon MS, 2001, J NEURAL TRANSM-SUPP, P281; Curmi PA, 2000, BRIT J CANCER, V82, P142, DOI 10.1054/bjoc.1999.0891; DiPaolo G, 1996, J CELL BIOL, V133, P1383, DOI 10.1083/jcb.133.6.1383; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; EUSTACE W, 1995, FEBS LETT, V364, P309, DOI 10.1016/0014-5793(95)00416-7; FRIEDRICH B, 1995, PROSTATE, V27, P102, DOI 10.1002/pros.2990270207; Gavet O, 1998, J CELL SCI, V111, P3333; Giannakakou P, 2000, ONCOGENE, V19, P3078, DOI 10.1038/sj.onc.1203642; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Howell B, 1999, J CELL SCI, V112, P3713; Hummert TW, 2000, J CELL BIOCHEM, V79, P150, DOI 10.1002/1097-4644(2000)79:1<150::AID-JCB140>3.3.CO;2-2; Iancu C, 2000, CANCER RES, V60, P3537; JI H, 1993, J BIOL CHEM, V268, P13396; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Johnsson A, 2000, BRIT J CANCER, V83, P1047, DOI 10.1054/bjoc.2000.1420; Katayose D, 1995, CLIN CANCER RES, V1, P889; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; Larsson NL, 1999, MOL CELL BIOL, V19, P2242; Lawler S, 1998, CURR BIOL, V8, pR212, DOI 10.1016/S0960-9822(98)70128-9; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; Liedtke W, 2002, AM J PATHOL, V160, P469, DOI 10.1016/S0002-9440(10)64866-3; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Mistry SJ, 2001, J BIOL CHEM, V276, P31209, DOI 10.1074/jbc.M011654200; Moreno FJ, 1998, MOL CELL BIOCHEM, V183, P201, DOI 10.1023/A:1006807814580; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Poruchynsky MS, 2001, BIOCHEM PHARMACOL, V62, P1469, DOI 10.1016/S0006-2952(01)00804-8; Price DK, 2000, CANCER INVEST, V18, P722, DOI 10.3109/07357900009012204; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; ROWLANDS DC, 1995, LAB INVEST, V72, P100; Steinman RA, 2000, LEUKEMIA RES, V24, P601, DOI 10.1016/S0145-2126(00)00020-5; Vancompernolle K, 2000, J BIOL CHEM, V275, P33876, DOI 10.1074/jbc.M004785200; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Wallon G, 2000, EMBO J, V19, P213, DOI 10.1093/emboj/19.2.213	45	53	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8924	8930		10.1038/sj.onc.1207060	http://dx.doi.org/10.1038/sj.onc.1207060			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654788				2022-12-17	WOS:000186982200013
J	Schiller, M; Verrecchia, F; Mauviel, A				Schiller, M; Verrecchia, F; Mauviel, A			Cyclic adenosine 3 ',5 '-monophosphate-elevating agents inhibit transforming growth factor-beta-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism	ONCOGENE			English	Article						cAMP; CREB; gene regulation; PAI-1; PKA; SMAD signaling; TGF-beta	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLON-CANCER CELLS; TGF-BETA; GENE-EXPRESSION; ANTISENSE OLIGONUCLEOTIDE; DERMAL FIBROBLASTS; PROSTAGLANDIN E-2; FACTOR CREB; C-JUN; COACTIVATOR	Transforming growth factor-beta (TGF-beta) plays complex roles in carcinogenesis, as it may exert both tumor suppressor and pro-oncogenic activities depending on the stage of the tumor. SMAD proteins transduce signals from the TGF-beta receptors to regulate the transcription of specific target genes. Crosstalks with other signaling pathways may contribute to the speci. city of TGF-beta effects. In this report, we have investigated the effects of cyclic adenosine 3',5'-monophosphate (cAMP), a key second messenger in the cellular response to various hormones, on SMAD-dependent signaling in human HaCaT keratinocytes. Using either an artificial SMAD3/4-dependent reporter construct or the natural TGF-beta target, plasminogen activator inhibitor-1, we show that membrane-permeable dibutyryl cAMP, and other intracellular cAMP-elevating agents such as the phosphodiesterase inhibitor isobutyl-methylxanthine, the adenylate cyclase activator forskolin, or exogenous prostaglandin E-2 (PGE(2)), interfere with TGF-beta-induced SMAD-specific gene transactivation. Inhibition of protein kinase A (PKA), the main downstream effector of cAMP, with H-89, suppressed cAMP-dependent repression of SMAD-driven gene expression. Inversely, coexpression of either an active PKA catalytic subunit or that of the cAMP response element (CRE)-binding protein (CREB) blocked SMAD-driven gene transactivation. cAMP-elevating agents did not inhibit nuclear translocation and DNA binding of SMAD3/4complexes, but abolished the interactions of SMAD3 with the transcription coactivators CREB-binding protein (CBP) and p300 in a PKA-dependent manner. These results suggest that suppression of TGF-beta/SMAD signaling and resulting gene transactivation by cAMP-inducing agents occurs via PKA-dependent, CREB-mediated, disruption of SMAD-CBP/p300 complexes.	Univ Paris 07, Hop St Louis, Inst Rech Peau, INSERM,U532, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Mauviel, A (corresponding author), Hop St Louis, Inst Rech Peau, INSERM, U532, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.	mauviel@chu-stlouis.fr	MAUVIEL, Alain/F-6251-2013; Verrecchia, Franck/G-5535-2018	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bianco C, 2000, CLIN CANCER RES, V6, P4343; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Corley DA, 2003, GASTROENTEROLOGY, V124, P47, DOI 10.1053/gast.2003.50008; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johnson TW, 2002, CANCER EPIDEM BIOMAR, V11, P1586; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Leask A, 2001, J CLIN PATHOL-MOL PA, V54, P180, DOI 10.1136/mp.54.3.180; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Rodeck U, 1999, CANCER RES, V59, P547; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Smalley W, 1999, ARCH INTERN MED, V159, P161, DOI 10.1001/archinte.159.2.161; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; Tortora G, 1997, P NATL ACAD SCI USA, V94, P12586, DOI 10.1073/pnas.94.23.12586; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Verrecchia F, 2003, J BIOL CHEM, V278, P1585, DOI 10.1074/jbc.M206927200; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	44	53	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8881	8890		10.1038/sj.onc.1206871	http://dx.doi.org/10.1038/sj.onc.1206871			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654784				2022-12-17	WOS:000186982200009
J	Repovic, P; Fears, CY; Gladson, CL; Benveniste, EN				Repovic, P; Fears, CY; Gladson, CL; Benveniste, EN			Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells	ONCOGENE			English	Article						oncostatin-M; VEGF; angiogenesis; astroglioma	HYPOXIA-INDUCIBLE FACTOR-1; NECROSIS-FACTOR-ALPHA; IN-VITRO; GENE-TRANSCRIPTION; SIGNALING PATHWAY; NERVOUS-SYSTEM; FACTOR VEGF; ASTROCYTES; RECEPTOR; INTERLEUKIN-6	Oncostatin-M (OSM), a hematopoietic cytokine, and vascular endothelial growth factor (VEGF), a quintessential angiogenic signal, are coexpressed in development, cancer and inflammation. Here, we report that OSM treatment of human astroglioma cell lines increases VEGF levels by similar tothreefold. Interleukin-1beta (IL-1beta), in combination with OSM, induces up to sevenfold higher VEGF expression, without significantly inducing VEGF on its own. Specifically examining the OSM contribution to VEGF expression, neutralizing antibodies to OSM receptor subunits gp130 and OSMRbeta, but not LIFRbeta, inhibited OSM induction of VEGF, indicating that the OSM-specific receptor OSMRbeta/gp130 transduces the OSM signal for VEGF synthesis. OSM induction of VEGF promoter activity maps to the (-1171, -786) region of the VEGF promoter, which contains a STAT-3-binding site. STAT-3 is indeed essential for this response, since overexpression of a dominant-negative STAT-3 blocks OSM induction of VEGF promoter activity, as well as endogenous VEGF expression. Finally, we demonstrate that OSM is expressed in glioblastoma multiforme tumor biopsies, a particularly malignant form of brain tumor. This novel mechanism of VEGF regulation in astroglioma cells may be active in pathophysiological states where both OSM and IL-1beta are present.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Benveniste, EN (corresponding author), Univ Alabama, Dept Cell Biol, MCLM 395,1918 Univ Blvd, Birmingham, AL 35294 USA.		Repovic, Pavle/AAV-1594-2020		NCI NIH HHS [CA97247, CA59958, CA97110] Funding Source: Medline; NIMH NIH HHS [MH63650] Funding Source: Medline; NINDS NIH HHS [NS39954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059958, P50CA097247, R01CA097110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hao CH, 2002, ACTA NEUROPATHOL, V103, P171; Hecker TP, 2002, CANCER RES, V62, P2699; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kordula T, 1998, J BIOL CHEM, V273, P4112, DOI 10.1074/jbc.273.7.4112; Lilja A, 2001, INT J ONCOL, V19, P495; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Mukouyama YS, 1998, IMMUNITY, V8, P105, DOI 10.1016/S1074-7613(00)80463-X; Murphy M, 1997, PROG NEUROBIOL, V52, P355, DOI 10.1016/S0301-0082(97)00020-8; Nagashima G, 2002, CLIN NEUROL NEUROSUR, V104, P125, DOI 10.1016/S0303-8467(01)00197-4; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Pietsch T, 1997, ACTA NEUROPATHOL, V93, P109, DOI 10.1007/s004010050591; RADKA SF, 1993, J IMMUNOL, V150, P5195; Repovic P, 2003, GLIA, V42, P433, DOI 10.1002/glia.10182; Repovic P, 2002, J NEUROSCI, V22, P5334; Ruprecht K, 2001, J NEUROPATH EXP NEUR, V60, P1087, DOI 10.1093/jnen/60.11.1087; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Schaefer LK, 2000, CYTOKINE, V12, P1647, DOI 10.1006/cyto.2000.0774; Shono T, 2001, CANCER RES, V61, P4375; Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Taga T, 1997, ANN MED, V29, P63, DOI 10.3109/07853899708998744; Tai YT, 2002, BLOOD, V99, P1419, DOI 10.1182/blood.V99.4.1419; Tanaka T, 2000, J MOL CELL CARDIOL, V32, P1955, DOI 10.1006/jmcc.2000.1228; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Van Wagoner NJ, 2000, J NEUROCHEM, V75, P563, DOI 10.1046/j.1471-4159.2000.0750563.x; Vasse M, 1999, ARTERIOSCL THROM VAS, V19, P1835, DOI 10.1161/01.ATV.19.8.1835; Xu L, 2002, J BIOL CHEM, V277, P11368, DOI 10.1074/jbc.M108347200; Yao Y, 2001, ACTA NEUROCHIR, V143, P159, DOI 10.1007/s007010170122	41	53	58	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8117	8124		10.1038/sj.onc.1206922	http://dx.doi.org/10.1038/sj.onc.1206922			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603252				2022-12-17	WOS:000186403400006
J	Augenlicht, L; Shi, L; Mariadason, J; Laboisse, C; Velcich, A				Augenlicht, L; Shi, L; Mariadason, J; Laboisse, C; Velcich, A			Repression of MUC2 gene expression by butyrate, a physiological regulator of intestinal cell maturation	ONCOGENE			English	Article						human MUC2 gene; MUC2 expression; sodium butyrate and differentiation; goblet cell lineage	CHAIN FATTY-ACIDS; COLON-CARCINOMA-CELLS; SODIUM-BUTYRATE; CARCINOEMBRYONIC ANTIGEN; HISTONE ACETYLATION; PROTEIN PHOSPHATASE; TRICHOSTATIN-A; MESSENGER-RNA; DIFFERENTIATION; APOPTOSIS	Sodium butyrate (NaB) inhibits proliferation, stimulates apoptosis, and promotes differentiation of human colon cancer cells along the absorptive phenotype. In vitro, butyrate induces a switch from cells with a secretory to an absorptive phenotype. Here, we report that NaB specifically represses the expression of the MUC2 gene, a differentiation marker of the secretory goblet cell lineage, in forskolin- and 12-O-tetradecanoylphorbol 13-acetate-induced HT29 cells, and Cl.16E cells, a clonal derivative of HT29 cells that spontaneously differentiates into goblet cells. Thus, NaB repression is independent of the nature of the stimulus that triggers MUC2 expression. Further, repression was independent of new protein synthesis. Our results suggest that inhibition of MUC2 is linked to the ability of butyrate to repress histone deacetylase activity, since trichostatin A, another inhibitor of histone deacetylases, also inhibited MUC2 expression in induced HT29 cells. Finally, we demonstrate that the NaB effect is specific for this marker of the secretory cell lineage, since carcinoembryonic antigen, which is expressed in both the secretory and absorptive cells, is induced by NaB. Thus, the NaB repression of a definitive function of the secretory cell lineage is a further mechanism, in addition to the effects on proliferation and apoptotic pathways, through which butyrate can regulate intestinal homeostasis.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Fac Med, INSERM, U539, F-44035 Nantes, France	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm)	Velcich, A (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.		Mariadason, John/N-2003-2013	Mariadason, John/0000-0001-9123-7684	NATIONAL CANCER INSTITUTE [R01CA090808, R01CA068965, P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA-13330, CA-68965, CA-90808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen A, 1998, INT J BIOCHEM CELL B, V30, P797, DOI 10.1016/S1357-2725(98)00028-4; AUGENLICHT LH, 1987, CANCER RES, V47, P3763; Augenlicht LH, 1999, CANCER RES, V59, P6005; AUGERON C, 1984, CANCER RES, V44, P3961; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; Csordas A., 1995, ROLE GUT BACTERIA HU, P105; Cuisset L, 1998, BIOCHEM BIOPH RES CO, V246, P760, DOI 10.1006/bbrc.1998.8698; Cuisset L, 1997, J BIOL CHEM, V272, P24148, DOI 10.1074/jbc.272.39.24148; Debailleul V, 1998, J BIOL CHEM, V273, P881, DOI 10.1074/jbc.273.2.881; DeRubertis F, 1996, NATURE, V384, P589; Espinos E, 1999, MOL CELL BIOL, V19, P3474; GUM JR, 1987, J BIOL CHEM, V262, P1092; Hague A, 1997, GASTROENTEROLOGY, V112, P1036, DOI 10.1053/gast.1997.v112.agast971036; Hass R, 1997, GASTROENTEROLOGY, V112, P875, DOI 10.1053/gast.1997.v112.pm9041249; HEERDT BG, 1994, CANCER RES, V54, P3288; HILL MJ, 1995, EUR J CANCER PREV, V4, P353, DOI 10.1097/00008469-199510000-00004; Iacomino G, 2001, BIOCHEM BIOPH RES CO, V285, P1280, DOI 10.1006/bbrc.2001.5323; Ilantzis C, 1997, LAB INVEST, V76, P703; JARRY A, 1994, EUR J PHARM-MOLEC PH, V267, P95, DOI 10.1016/0922-4106(94)90229-1; Laboisse C. L., 1989, CELL MOL BIOL COLON, P27; Lee HW, 2002, J BIOL CHEM, V277, P32624, DOI 10.1074/jbc.M200353200; Mariadason JM, 2000, CANCER RES, V60, P4561; Matthews JB, 1998, J CLIN INVEST, V101, P2072, DOI 10.1172/JCI1042; NAP M, 1988, TUMOR BIOL, V9, P145, DOI 10.1159/000217555; PAULUS U, 1993, J CELL SCI, V106, P473; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; ROWE WA, 1992, GASTROENTEROLOGY, V103, P336, DOI 10.1016/0016-5085(92)91133-O; SCHEPPACH W, 1994, GUT, V35, pS35, DOI 10.1136/gut.35.1_Suppl.S35; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Singh B, 1997, CARCINOGENESIS, V18, P1265, DOI 10.1093/carcin/18.6.1265; Taupin D, 1999, GASTROENTEROLOGY, V116, P1072, DOI 10.1016/S0016-5085(99)70010-7; TRAN C, 1998, AM J PHYSIOL, pG85; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Velcich A, 1997, J BIOL CHEM, V272, P7968, DOI 10.1074/jbc.272.12.7968; VELCICH A, 1993, J BIOL CHEM, V268, P13956; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; VELCICH A, 1995, CELL GROWTH DIFFER, V6, P749; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Weiss AA, 1996, J HISTOCHEM CYTOCHEM, V44, P1161, DOI 10.1177/44.10.8813081; Wu JT, 2001, AM J PHYSIOL-GASTR L, V280, pG482, DOI 10.1152/ajpgi.2001.280.3.G482; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	44	53	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					4983	4992		10.1038/sj.onc.1206521	http://dx.doi.org/10.1038/sj.onc.1206521			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902981				2022-12-17	WOS:000184578900006
J	Bartunek, P; Kralova, J; Blendinger, G; Dvorak, M; Zenke, M				Bartunek, P; Kralova, J; Blendinger, G; Dvorak, M; Zenke, M			GATA-1 and c-myb crosstalk during red blood cell differentiation through GATA-1 binding sites in the c-myb promoter	ONCOGENE			English	Article						c-myb; proto-oncogene; GATA-1; GATA factor; erythropoiesis; red blood cell	TRANSCRIPTION FACTOR GATA-1; EMBRYONIC STEM-CELLS; ZINC-FINGER PROTEIN; ERYTHROID PROGENITORS; HEMATOPOIETIC-CELLS; IN-VITRO; DNA-BINDING; TERMINAL DIFFERENTIATION; ERYTHROPOIETIN RECEPTOR; GLUCOCORTICOID RECEPTOR	GATA-1 and c-Myb transcription factors represent key regulators of red blood cell development. GATA-1 is upregulated and c-myh proto-oncogene expression is downregulated when red cell progenitors differentiate into erythrocytes. Here we have employed a culture system, that faithfully recapitulates red blood cell differentiation in vitro, to follow the kinetics of GATA-1 and c-myb expression. We show that c-myb proto-oncogene expression is high in progenitors and effectively downregulated at the time when nuclear GATA-1 accumulates and cells differentiate into erythrocytes. Additionally, we identified two GATA-1 binding sites within the c-myb promoter and demonstrate that GATA-I protein binds to these sites in vitro. Furthermore, GATA-1 represses c-myb expression through one of the GATA-1 binding sites in transient transfection experiments and this requires FOG-1. Thus, our study provides evidence for a direct molecular link between GATA-1 activity and c-myb proto-oncogene expression during terminal red cell differentiation.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Inst Mol Genet, Prague 16637 6, Czech Republic	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Zenke, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.		Dvořák, Michal/I-9939-2014; Bartunek, Petr/J-3897-2014; Kralova, Jarmila/G-3834-2014; Dvorak, Michal/G-5861-2014	Bartunek, Petr/0000-0002-6202-7650; Kralova, Jarmila/0000-0002-4735-8857; 				AIRD WC, 1994, J BIOL CHEM, V269, P883; Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; Bartunek P, 2002, ONCOGENE, V21, P400, DOI 10.1038/sj/onc/1205103; Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; Bartunek P, 1998, MOL ENDOCRINOL, V12, P1269, DOI 10.1210/mend.12.9.0173; BARTUNEK P, 1992, VIROLOGY, V190, P882, DOI 10.1016/0042-6822(92)90930-N; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; BEUG H, 1995, METHOD ENZYMOL, V254, P41; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Briegel K, 1996, DEVELOPMENT, V122, P3839; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Campanero MR, 1999, MOL CELL BIOL, V19, P8442; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; Deconinck AE, 2000, DEVELOPMENT, V127, P2031; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; Dolznig H, 2002, CURR BIOL, V12, P1076, DOI 10.1016/S0960-9822(02)00930-2; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; DVORAK M, 1989, NUCLEIC ACIDS RES, V17, P5651; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FIBACH E, 1991, INT J CELL CLONING, V9, P57, DOI 10.1002/stem.5530090108; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KOZMIK Z, 1990, GENE, V90, P287, DOI 10.1016/0378-1119(90)90192-T; LYON JJ, 1995, DIFFERENTIATION, V59, P171, DOI 10.1046/j.1432-0436.1995.5930171.x; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; PERROTTI D, 1995, MOL CELL BIOL, V15, P6075; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SOBIESZCZUK PW, 1989, NUCLEIC ACIDS RES, V17, P9593, DOI 10.1093/nar/17.23.9593; Sullivan J, 1997, J BIOL CHEM, V272, P1943, DOI 10.1074/jbc.272.3.1943; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; URBANEK P, 1988, NUCLEIC ACIDS RES, V16, P11521, DOI 10.1093/nar/16.24.11521; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang DY, 2001, EXP HEMATOL, V29, P1278, DOI 10.1016/S0301-472X(01)00725-1	56	53	57	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1927	1935		10.1038/sj.onc.1206281	http://dx.doi.org/10.1038/sj.onc.1206281			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673198				2022-12-17	WOS:000181967700003
J	Ferrara, P; Andermarcher, E; Bossis, G; Acquaviva, C; Brockly, F; Jariel-Encontre, I; Piechaczyk, M				Ferrara, P; Andermarcher, E; Bossis, G; Acquaviva, C; Brockly, F; Jariel-Encontre, I; Piechaczyk, M			The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression	ONCOGENE			English	Article						c-Fos; protein degradation; proteasome	IN-VITRO; PROTOONCOGENE PRODUCT; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; V-FOS; JUN; AP-1; PHOSPHORYLATION; TRANSCRIPTION; KINASE	c-fos gene is expressed constitutively in a number of tissues as well as in certain tumor cells and is inducible, in general rapidly and transiently, in virtually all other cell types by a variety of stimuli. Its protein product, c-Fos, is a short-lived transcription factor that heterodimerizes with various protein partners within the AP-1 transcription complex via leucine zipper/leucine zipper interactions for binding to specific DNA sequences. It is mostly, if not exclusively, degraded by the proteasome. To localize the determinant(s) responsible for its instability, we have conducted a genetic analysis in which the half-lives of c-Fos mutants and chimeras made with the stable EGFP reporter protein were compared under two experimental conditions taken as example of continous and inducible expression. Those were constitutive expression in asynchronously growing Balb/C 3T3 mouse embryo fibroblasts and transient induction in the same cells undergoing the G0/G1 phase transition upon stimulation by serum. Our work shows that c-Fos is degraded faster in synchronous-than in asynchronous cells. This difference in turnover is primarily accounted for by several mechanisms. First, in asynchronous cells, a unique C-terminal destabilizer is active whereas, in serum-stimulated cells two destabilizers located at both extremities of the protein are functional. Second, heterodimerization and/or binding to DNA accelerates protein degradation only during the G0/G1 phase transition. Adding another level of complexity to turnover control, phosphorylation at serines 362 and 374, which are c-Fos phosphorylation sites largely modified during the G0/G1 phase transition, stabilizes c-Fos much more efficiently in asynchronous than in serum-stimulated cells. In both cases, the reduced degradation rate is due to inhibition of the activity of the C-terminal destabilizer. However, in serum-stimulated cells, this effect is partially masked by the activation of the N-terminal destabilizer and basic domain/leucine zipper-dependent mechanisms. Taken together, our data show that multiple degradation mechanisms, differing according to the conditions of expression, may operate on c-Fos to ensure a proper level and/or timing of expression. Moreover, they also indicate that the half-life of c-Fos during the G0/G1 phase transition is determined by a delicate balance between opposing stabilizing and destabilizing mechanisms operating at the same time.	CNRS, UMR 5535, Inst Mol Genet, IFR24, F-34293 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Piechaczyk, M (corresponding author), CNRS, UMR 5535, Inst Mol Genet, IFR24, 1919 Route Mende, F-34293 Montpellier 05, France.	piechaczyk@igm.cnrs-mop.fr	Bossis, Guillaume/C-7172-2012; Acquaviva, Claire/N-4306-2017; PIECHACZYK, Marc/E-7896-2013	Acquaviva, Claire/0000-0002-0227-9813; PIECHACZYK, Marc/0000-0003-1367-2597; bossis, guillaume/0000-0002-3349-8250				ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; Acquaviva C, 2001, ONCOGENE, V20, P7563, DOI 10.1038/sj.onc.1204880; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Chaussepied M, 1998, MOL BIOCHEM PARASIT, V94, P215, DOI 10.1016/S0166-6851(98)00070-X; Chen JS, 1997, J NEUROSCI, V17, P4933; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Coux Olivier, 2002, Prog Mol Subcell Biol, V29, P85; Curran T, 1988, ONCOGENE HDB, P307; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; EIBL B, 1995, CYTOKINES MOL THER, V1, P29; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; FUJII M, 1991, ONCOGENE, V6, P1023; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; GRUDA MC, 1994, ONCOGENE, V9, P2537; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; HUANG TS, 1995, CANCER LETT, V96, P1, DOI 10.1016/0304-3835(95)03918-M; IWAHASHI M, 1994, BRIT J HAEMATOL, V86, P193, DOI 10.1111/j.1365-2141.1994.tb03275.x; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KANAITSUKA T, 1988, ACTA PATHOL JAPON, V38, P1523; Kanaitsuka T, 1987, Nihon Naika Gakkai Zasshi, V76, P1595; Kim YH, 2000, BRAIN RES, V872, P227, DOI 10.1016/S0006-8993(00)02477-X; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Masuyama H, 1998, J CELL BIOCHEM, V71, P429, DOI 10.1002/(SICI)1097-4644(19981201)71:3<429::AID-JCB11>3.0.CO;2-P; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Perkins G, 2001, EMBO J, V20, P4836, DOI 10.1093/emboj/20.17.4836; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RECH J, 1989, NUCLEIC ACIDS RES, V17, P2874, DOI 10.1093/nar/17.7.2874; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; Rubio N, 1996, J NEUROVIROL, V2, P167, DOI 10.3109/13550289609146879; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Sambrook J., 1989, MOL CLONING; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Su KH, 2000, BIOCHEM J, V348, P281, DOI 10.1042/0264-6021:3480281; Tajima S, 2002, J VIROL, V76, P2557, DOI 10.1128/JVI.76.5.2557-2562.2002; Tansey WP, 2001, GENE DEV, V15, P1045, DOI 10.1101/gad.896501; Thomas D, 2000, CURR BIOL, V10, pR341, DOI 10.1016/S0960-9822(00)00462-0; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Zhang JH, 2002, NAT GENET, V30, P416, DOI 10.1038/ng859	70	53	53	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1461	1474		10.1038/sj.onc.1206266	http://dx.doi.org/10.1038/sj.onc.1206266			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629509				2022-12-17	WOS:000181411900003
J	Nelson, HH; Kelsey, KT				Nelson, HH; Kelsey, KT			The molecular epidemiology of asbestos and tobacco in lung cancer	ONCOGENE			English	Article						lung cancer; asbestos; tobacco	PLEURAL MESOTHELIAL CELLS; SISTER-CHROMATID EXCHANGE; OXIDATIVE DNA-DAMAGE; K-RAS MUTATIONS; MAN-MADE FIBERS; CROCIDOLITE ASBESTOS; EPITHELIAL-CELLS; MAMMALIAN-CELLS; HUMAN-LYMPHOCYTES; CEMENT WORKERS	Asbestos is a well-known toxin and lung carcinogen. Epidemiologic studies have established tobacco smoke and asbestos exposures synergistically interact to enhance lung cancer risk. The biologic mechanism responsible for this interaction has been the subject of considerable debate. Studies have suggested that asbestos may act as a carcinogen by generating free radical and reactive oxygen species, by inducing tissue injury and subsequent cellular growth, via large-scale chromosome loss and by enhancing delivery of tobacco carcinogens to the respiratory epithelium. Recent molecular epidemiologic approaches further suggest that asbestos enhances the mutagenicity of tobacco carcinogens and that it acts, at least in part, independent of the tissue damage responsible for fibrosis.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environ Epidemiol Program, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Kelsey, KT (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave,Bldg 1,Rm 207, Boston, MA 02115 USA.	Kelsey@hsph.harvard.edu	Kelsey, Karl T/I-1252-2014	Nelson, Heather/0000-0003-1901-9513	NATIONAL CANCER INSTITUTE [R01CA082354, R01CA057494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, P42ES005947, P42ES007373] Funding Source: NIH RePORTER; NCI NIH HHS [CA57494, CA82354] Funding Source: Medline; NIEHS NIH HHS [ES0002, P42ES07373, P42ES5947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADACHI S, 1994, CARCINOGENESIS, V15, P753, DOI 10.1093/carcin/15.4.753; ADACHI S, 1992, INT ARCH OCC ENV HEA, V63, P553, DOI 10.1007/BF00386345; AUERBACH O, 1979, CANCER, V43, P636, DOI 10.1002/1097-0142(197902)43:2<636::AID-CNCR2820430234>3.0.CO;2-7; AUERBACH O, 1984, CANCER, V54, P3017, DOI 10.1002/1097-0142(19841215)54:12<3017::AID-CNCR2820541233>3.0.CO;2-9; AULT JG, 1995, CANCER RES, V55, P792; BLOT WJ, 1996, CANC EPIDEMIOLOGY PR, P637; BOTH K, 1994, INT J CANCER, V59, P538, DOI 10.1002/ijc.2910590417; Brodkin CA, 1997, AM J IND MED, V32, P582, DOI 10.1002/(SICI)1097-0274(199712)32:6<582::AID-AJIM2>3.0.CO;2-S; BROWN RC, 1983, ENVIRON HEALTH PERSP, V51, P315, DOI 10.2307/3429770; BROWNE K, 1986, BRIT J IND MED, V43, P145; Chao CC, 1996, ARCH BIOCHEM BIOPHYS, V326, P152, DOI 10.1006/abbi.1996.0059; Chen Q, 1996, CARCINOGENESIS, V17, P2525, DOI 10.1093/carcin/17.11.2525; CHURG A, 1995, AM J RESP CRIT CARE, V151, P1409, DOI 10.1164/ajrccm.151.5.7735593; CHURG A, 1985, JAMA-J AM MED ASSOC, V253, P2984, DOI 10.1001/jama.253.20.2984; COLE RW, 1991, CANCER RES, V51, P4942; CRAIGHEAD JE, 1982, NEW ENGL J MED, V306, P1446, DOI 10.1056/NEJM198206173062403; deKlerk NH, 1996, OCCUP ENVIRON MED, V53, P157, DOI 10.1136/oem.53.3.157; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DONG HY, 1994, CARCINOGENESIS, V15, P1251, DOI 10.1093/carcin/15.6.1251; Donmez H, 1996, MUTAT RES-ENVIR MUTA, V361, P129, DOI 10.1016/S0165-1161(96)90247-2; DOPP E, 1995, ENVIRON HEALTH PERSP, V103, P268, DOI 10.2307/3432547; FATMA N, 1991, BRIT J IND MED, V48, P103; Fubini B, 1995, TOXICOL LETT, V82-3, P951, DOI 10.1016/0378-4274(95)03531-1; Fung H, 1997, CARCINOGENESIS, V18, P825, DOI 10.1093/carcin/18.4.825; GERDE P, 1988, BRIT J IND MED, V45, P682; GERDE P, 1989, ENVIRON HEALTH PERSP, V79, P249; GOODGLICK LA, 1986, CANCER RES, V46, P5558; HEI TK, 1992, CANCER RES, V52, P6305; HEI TK, 1995, CARCINOGENESIS, V16, P1573, DOI 10.1093/carcin/16.7.1573; HESTERBERG TW, 1985, CARCINOGENESIS, V6, P473, DOI 10.1093/carcin/6.3.473; HILLERDAL G, 1983, BRIT J IND MED, V40, P380; HIRAO T, 2002, IN PRESS CARCINOGENE; HOURIHANE DO, 1966, POSTGRAD MED J, V42, P613, DOI 10.1136/pgmj.42.492.613; Huncharek Michael, 1993, Journal of Public Health Policy, V14, P51, DOI 10.2307/3342826; Husgafvel-Pursiainen K, 1999, AM J RESP CELL MOL, V20, P667, DOI 10.1165/ajrcmb.20.4.3404; HUSGAFVELPURSIAINEN K, 1993, INT J CANCER, V53, P250, DOI 10.1002/ijc.2910530213; HUSGAFVELPURSIAINEN K, 1995, J OCCUP ENVIRON MED, V37, P69, DOI 10.1097/00043764-199501000-00010; HUUSKONEN MS, 1978, SCAND J WORK ENV HEA, V4, P265, DOI 10.5271/sjweh.2699; JACOB G, 1965, ANN NY ACAD SCI, V132, P536, DOI 10.1111/j.1749-6632.1965.tb41134.x; JAURAND MC, 1986, MUTAT RES, V169, P141, DOI 10.1016/0165-1218(86)90093-5; Jensen CG, 1996, CARCINOGENESIS, V17, P2013, DOI 10.1093/carcin/17.9.2013; JOHANSSON L, 1992, BRIT J IND MED, V49, P626; KAMP DW, 1992, FREE RADICAL BIO MED, V12, P293, DOI 10.1016/0891-5849(92)90117-Y; KANNERST.M, 1972, CANCER, V30, P14, DOI 10.1002/1097-0142(197207)30:1<14::AID-CNCR2820300104>3.0.CO;2-9; KARJALAINEN A, 1993, SCAND J WORK ENV HEA, V19, P102, DOI 10.5271/sjweh.1490; KARJALAINEN A, 1994, SCAND J WORK ENV HEA, V20, P243, DOI 10.5271/sjweh.1401; Kazan-Allen L, 2001, INT J HEALTH SERV, V31, P481, DOI 10.2190/R5WM-Q78P-E5XQ-34E8; Kim DH, 2001, CANCER RES, V61, P3419; KODAMA Y, 1993, CARCINOGENESIS, V14, P691, DOI 10.1093/carcin/14.4.691; KORKINA LG, 1992, MUTAT RES, V265, P245, DOI 10.1016/0027-5107(92)90053-5; LAKOWICZ JR, 1980, BIOCHIM BIOPHYS ACTA, V629, P243, DOI 10.1016/0304-4165(80)90098-7; Lee BW, 1998, AM J RESP CRIT CARE, V157, P748, DOI 10.1164/ajrccm.157.3.9707025; LILIS R, 1991, AM J IND MED, V20, P145, DOI 10.1002/ajim.4700200203; Liu BC, 1998, BIOMED ENVIRON SCI, V11, P226; LUND LG, 1992, CARCINOGENESIS, V13, P637, DOI 10.1093/carcin/13.4.637; MAPLES KR, 1992, CARCINOGENESIS, V13, P2035, DOI 10.1093/carcin/13.11.2035; Marczynski B, 2000, MUTAT RES-GEN TOX EN, V468, P195, DOI 10.1016/S1383-5718(00)00053-X; MARCZYNSKI B, 1994, HUM EXP TOXICOL, V13, P3, DOI 10.1177/096032719401300102; MENRAD H, 1986, ENVIRON RES, V40, P84; MOLLO F, 1995, INT J CANCER, V60, P289; MOSSMAN B, 1983, ANNU REV PHARMACOL, V23, P595, DOI 10.1146/annurev.pa.23.040183.003115; MOSSMAN BT, 1986, LAB INVEST, V54, P204; MurataKamiya N, 1997, INT ARCH OCC ENV HEA, V70, P321, DOI 10.1007/s004200050225; NEJJARI A, 1993, BRIT J IND MED, V50, P501; Nelson HH, 1998, CANCER RES, V58, P1804; Nelson HH, 1999, CANCER RES, V59, P4570; NUORVA K, 1994, AM J RESP CRIT CARE, V150, P528, DOI 10.1164/ajrccm.150.2.8049841; Okayasu R, 1999, BRIT J CANCER, V79, P1319, DOI 10.1038/sj.bjc.6690213; PALEKAR LD, 1987, CARCINOGENESIS, V8, P553, DOI 10.1093/carcin/8.4.553; Park SH, 1998, CANCER RES, V58, P1144; Pylkkanen L, 2002, INT J ONCOL, V20, P285; RAFFN E, 1993, BRIT J IND MED, V50, P85; ROM WN, 1983, JNCI-J NATL CANCER I, V70, P45; ROM WN, 1998, ENV OCCUPATIONAL MED, P349; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V103, P506, DOI 10.1093/oxfordjournals.aje.a112252; RUSSI MB, 1994, TXB CLIN OCCUPATIONA, P543; Sanchez-Cespedes M, 2001, CANCER RES, V61, P2092; SCHAPIRA RM, 1994, AM J RESP CELL MOL, V10, P573, DOI 10.1165/ajrcmb.10.5.8179922; Sekhon H, 1995, INT J EXP PATHOL, V76, P411; SELIKOFF IJ, 1968, J AMER MED ASSOC, V204, P106, DOI 10.1001/jama.204.2.106; SINCOCK A, 1975, NATURE, V257, P56, DOI 10.1038/257056a0; SOUTAR CA, 1974, BRIT J DIS CHEST, V68, P235; Takahashi, 1997, Int J Occup Environ Health, V3, P111; TAKEUCHI T, 1994, CARCINOGENESIS, V15, P635, DOI 10.1093/carcin/15.4.635; TALCOTT JA, 1988, CURR PROB CANCER, V12, P133; VAINIO H, 1994, SCAND J WORK ENV HEA, V20, P235, DOI 10.5271/sjweh.1402; VALERIO F, 1983, MUTAT RES, V122, P397, DOI 10.1016/0165-7992(83)90026-X; WANG X, 1995, CANCER EPIDEM BIOMAR, V4, P543; WEISS W, 1988, J OCCUP ENVIRON MED, V30, P33; WEISS W, 1988, BRIT J IND MED, V45, P544; WEITZMAN SA, 1984, ARCH BIOCHEM BIOPHYS, V228, P373, DOI 10.1016/0003-9861(84)90078-X; WHITWELL F, 1974, BRIT J IND MED, V31, P298; WILT J, 1998, OCCUPATIONAL LUNG DI, P119; Xu A, 1999, CANCER RES, V59, P5922; YEGLES M, 1993, AM J RESP CELL MOL, V9, P186, DOI 10.1165/ajrcmb/9.2.186; ZALMA R, 1987, CAN J CHEM, V65, P2338, DOI 10.1139/v87-390; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	97	53	56	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7284	7288		10.1038/sj.onc.1205804	http://dx.doi.org/10.1038/sj.onc.1205804			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379872				2022-12-17	WOS:000178618000002
J	Hecquet, C; Lefevre, G; Valtink, M; Engelmann, K; Mascarelli, F				Hecquet, C; Lefevre, G; Valtink, M; Engelmann, K; Mascarelli, F			CAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1/2 in a PKA-independent manner	ONCOGENE			English	Article						retinal pigment epithelium; signal transduction	MAP KINASE ERK; SIGNALING PATHWAYS; ACTIVE-TRANSPORT; PROTEIN; PHOSPHORYLATION; ACTIVATION; RAF-1; COMPLEXITY; SECRETION; REQUIRES	Retinal pigmented epithelial (RPE) cell integrity is critical to the maintenance of retina functions and RPE cells do not proliferate in adults. The activation of RPE results in cell proliferation which may be associated with proliferative retinopathy and choroidal melanoma. Mitogen-activated protein kinase (MAPK) is believed to be a key participant in the response to mitogenic stimuli. We therefore investigated the involvement of the extracellular signal-regulated protein kinase (ERK) I and 2 during the induction of RPE cell proliferation. After foetal calf serum (FCS) stimulation activation of the Ras/Raf/ERK signalling pathway was detected by Western blotting and immunochemistry, with specific anti-phosphosignalling protein antibodies. Pharmacological and antisense (AS) oligonucleotide (ODN) strategies were used to analyse the signalling involved in FCS-induced RPE cell proliferation. Activation of the small G protein Ras and, to a lesser extent of Raf-1, the kinase directly downstream from Ras, was necessary to FCS-induced cell proliferation. MEK1/2 and ERK1/2 were activated during cell proliferation. Inhibition of MEK1/2 with UO 126 completely abolished ERK1/2 activation and reduced cell proliferation by 33-43%. ERK1/2 depletion by an AS ODN approach reduced cell proliferation by 27-33%, confirming the role of ERK1/2 in the FCS stimulation of RPE cells. We also investigated the role of PKA/cAMP, one of the major inhibitory pathways of ERK1/2. PKA blockade did not modify ERK1/2 activation or cell proliferation. In contrast, agents that increased cAMP concentration, abolished RPE proliferation, and MEK/ERK activation. Moreover, inhibition of the cAMP-activated small G protein Rap1, partially reversed the inhibitory effects of cAMP on cell proliferation and MEK/ERK activation. The requirement for Ras and ERK1/2, the lack of ERK1/2 regulation by PKA and the cAMP/Rap1 counter-regulatory pathway for ERK-mediated cell proliferation suggest complex regulation of signalling in RPE cells. These data may have important implications for the development of more selective models for retinal anti-proliferative therapies.	CNRS, Ctr Biomed Cordeliers, INSERM U450, F-75006 Paris, France; Univ Klinikum Hamburg Eppendorf, Dept Ophthalmol, Cornea Bank Transplantat Lab, D-20246 Hamburg, Germany	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; University of Hamburg; University Medical Center Hamburg-Eppendorf	Mascarelli, F (corresponding author), CNRS, Ctr Biomed Cordeliers, INSERM U450, 15 Rue Ecole Med, F-75006 Paris, France.	fmascar@infobiogen.fr	Mascarelli, Frederic/L-8916-2018; Valtink, Monika/I-1507-2013	Valtink, Monika/0000-0003-3205-1876				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Bornfeldt KE, 1999, CELL SIGNAL, V11, P465, DOI 10.1016/S0898-6568(99)00020-0; Bryckaert M, 2000, ONCOGENE, V19, P4917, DOI 10.1038/sj.onc.1203872; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Enzmann V, 1998, OPHTHALMIC RES, V30, P189, DOI 10.1159/000055473; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; Monia BP, 1996, P NATL ACAD SCI USA, V93, P15481, DOI 10.1073/pnas.93.26.15481; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Valtink H, 1999, GRAEF ARCH CLIN EXP, V237, P1001, DOI 10.1007/s004170050336; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231; Zubilewicz A, 2001, INVEST OPHTH VIS SCI, V42, P488	27	53	55	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6101	6112		10.1038/sj.onc.1205765	http://dx.doi.org/10.1038/sj.onc.1205765			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203122	Bronze			2022-12-17	WOS:000177671300013
J	Wang, YD; De Vos, J; Jourdan, M; Couderc, G; Lu, ZY; Rossi, JF; Klein, B				Wang, YD; De Vos, J; Jourdan, M; Couderc, G; Lu, ZY; Rossi, JF; Klein, B			Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells	ONCOGENE			English	Article						CD9; HB-EGF; ErbB1; IL-6; myeloma	HUMAN MULTIPLE-MYELOMA; DIPHTHERIA-TOXIN RECEPTOR; FACTOR (EGF)-LIKE DOMAIN; SIGNAL TRANSDUCER GP130; MONOCLONAL-ANTIBODY; GENE-EXPRESSION; SURVIVAL FACTOR; IFN-ALPHA; LINES; PROLIFERATION	Interleukin-6 (IL-6) is a major survival and proliferation factor of human malignant plasma cells and IL-6 dependent myeloma cell lines can be obtained from patients with terminal disease. We show here that mutated diphtheria toxin, a specific inhibitor of heparin-binding epidermal growth factor-like growth factor (HB-EGF), blocked the IL-6-induced growth of two myeloma cell lines (XG-1 and XG-14) and did not significantly affect that of two other cell lines (XG-6 and XG-13). The IL-6 mediated growth of myeloma cells was also inhibited by antibodies to ErbB1, a receptor for HB-EGF. The XG-1 and XG-14 cell lines that are sensitive to HB-EGF inhibitors overexpressed HB-EGF and EGF receptor (ErbB1) genes. They also overexpressed CD9, a tetraspanin that binds to the heparin-binding domain of HB-EGF and is critical for promoting ErbB1 activation by HB-EGF. The XG-6 and XG-13 myeloma cells that were not significantly sensitive to HB-EGF antagonists, poorly expressed HB-EGF, ErbB1 and CD9 genes or proteins. We demonstrated that recombinant HB-EGF supported the long-term growth of myeloma cells, as did IL-6. The myeloma cell growth factor activity of HB-EGF was completely inhited by antibodies to ErbB1, but also by antibodies to gp130 IL-6 transducer or to IL-6. These data indicate that in the XG-1 and XG-14 IL-6-dependent myeloma cell lines, the CD9/HB-EGF/erbB1 and the IL-6/IL-6R/ gp130 pathways cooperate synergistically to trigger myeloma cell growth. They suggest that inhibitors of the EGF receptor or HB-EGF may be useful for inducing myeloma cell apoptosis in patients with multiple myeloma.	CHU Montpellier, INSERM, U475, F-34197 Montpellier, France; CHU Montpellier, Unit Cellular Therapy, F-34197 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	Klein, B (corresponding author), CHU Montpellier, INSERM, U475, 99 Rue Puech Villa, F-34197 Montpellier, France.	Klein@montp.inserm.fr	DE VOS, John/A-5703-2010	DE VOS, John/0000-0003-1880-4130				Badache A, 2001, CANCER RES, V61, P383; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Costes V, 1998, BRIT J HAEMATOL, V103, P1152, DOI 10.1046/j.1365-2141.1998.01101.x; Costes V, 1999, HUM PATHOL, V30, P1405, DOI 10.1016/S0046-8177(99)90160-0; DAVISFLEISCHER KM, 1998, FRONT BIOSCI, V3, P288; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Ferlin-Bezombes M, 1998, J IMMUNOL, V161, P2692; Gaillard JP, 1997, EUR J IMMUNOL, V27, P3332, DOI 10.1002/eji.1830271232; Garcia-Sanz R, 1999, BLOOD, V93, P1032, DOI 10.1182/blood.V93.3.1032.403a15_1032_1037; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; Gu ZJ, 2000, LEUKEMIA, V14, P188, DOI 10.1038/sj.leu.2401632; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hirata M, 2001, BIOCHEM BIOPH RES CO, V283, P915, DOI 10.1006/bbrc.2001.4879; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; Jelinek DF, 1997, J IMMUNOL, V159, P487; JOURDAN M, 1991, J IMMUNOL, V147, P4402; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Jourdan M, 1999, EUR CYTOKINE NETW, V10, P65; Kaefer M, 2000, J UROLOGY, V163, P580, DOI 10.1016/S0022-5347(05)67936-0; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 1991, BLOOD, V78, P1198; LOKHORST HM, 1994, BLOOD, V84, P2269; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Nakamura K, 2000, J BIOL CHEM, V275, P18284, DOI 10.1074/jbc.M907971199; PORTIER M, 1991, EUR J IMMUNOL, V21, P1759, DOI 10.1002/eji.1830210727; PORTIER M, 1993, BRIT J HAEMATOL, V85, P514; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Rebouissou C, 1998, BLOOD, V91, P4727, DOI 10.1182/blood.V91.12.4727.412k35_4727_4737; SHIMIZU S, 1989, J EXP MED, V169, P339, DOI 10.1084/jem.169.1.339; Westendorf JJ, 1996, LEUKEMIA, V10, P866; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040-8428(00)00134-7; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337; ZHANG XG, 1994, BLOOD, V83, P3654	41	53	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2584	2592		10.1038/sj.onc.1205355	http://dx.doi.org/10.1038/sj.onc.1205355			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971193				2022-12-17	WOS:000174918400015
J	Koul, D; Jasser, SA; Lu, YL; Davies, MA; Shen, RJ; Shi, YX; Mills, GB; Yung, WKA				Koul, D; Jasser, SA; Lu, YL; Davies, MA; Shen, RJ; Shi, YX; Mills, GB; Yung, WKA			Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity	ONCOGENE			English	Article						MMAC; PTEN; phosphatidylinositol phosphatase; growth inhibition	FOCAL ADHESION KINASE; GLIOMA-CELLS; AKT PROTOONCOGENE; PDZ DOMAIN; PTEN; GROWTH; ONCOGENE; BREAST; PHOSPHORYLATION; INHIBITION	The tumor suppressor gene, MMAC/PTEN, has phosphatase, C2, and PDZ-binding domains as well as potential sites of regulation by phosphorylation, including tyrosine phosphorylation, which may contribute to its ability to modulate cell growth and viability. Several obvious and significant motifs were found in MMAC/PTEN, including most notably, a catalytic domain of tyrosine phosphatase (IHCxxGxxRS/T) and several potential tyrosine phosphorylation sites. To examine the functional significance of tyrosine phosphorylation of MMAC/PTEN, retroviral constructs were generated with mutations at two putative tyrosine phosphorylation sites (Y240A/Y240F and Y315A/Y315F). Stable expression of wild-type MMAC/PTEN in U251 human glioma cells (which do not normally produce a functional MMAC/PTEN gene product) resulted in a significant reduction of tumor growth in nude mice, decreased growth rate, saturation density, and colony formation in vitro, as well as dephosphorylation of D3-phosphorylated phosphatidylinositols (PtdIns) in vitro. Mutation of Y240 or Y315 to either alanine or phenylalanine abrogated the ability of MMAC/PTEN to alter growth rate, saturation density, and colony formation in vitro. The ability of MMAC/PTEN to limit tumor growth in nude mice was markedly decreased but not abrogated by mutation of Y240 or Y315 to alanine. Thus, Y240 and Y315 are required for MMAC/PTEN to decrease tumor growth in vitro and in vivo. In contrast to wild-type MMAC/PTEN, mutant MMAC/PTEN containing Y240A or Y315A was unable to dephosphorylate D3-phosphorylated PtdIns in vitro. Thus, Y240A and Y315A are involved in the ability of MMAC/PTEN to dephosphorylate PtdIns and regulate tumor cell growth in vitro and in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Brain Tumor Ctr, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yung, WKA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Brain Tumor Ctr, Box 100,1515 Holcombe Blvd, Houston, TX 77030 USA.	wyung@manderson.org	Davies, Michael/GWV-2527-2022		NCI NIH HHS [R01 CA82716, CA-16672, R01 CA51148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082716, P30CA016672, R01CA051148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BESSON A, 1999, EUR J BIOCHEM, V263, P237; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 1998, CANCER RES, V58, P5285; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; LI DM, 1999, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Pluskota E, 2000, J BIOL CHEM, V275, P30029, DOI 10.1074/jbc.M000240200; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	38	53	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2357	2364		10.1038/sj/onc/1205296	http://dx.doi.org/10.1038/sj/onc/1205296			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948419				2022-12-17	WOS:000174635600008
J	Katsuda, K; Kataoka, M; Uno, F; Murakami, T; Kondo, T; Roth, JA; Tanaka, N; Fujiwara, T				Katsuda, K; Kataoka, M; Uno, F; Murakami, T; Kondo, T; Roth, JA; Tanaka, N; Fujiwara, T			Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells	ONCOGENE			English	Article						p16; adenovirus vector; apoptosis; caspase-3	RETINOBLASTOMA GENE-PRODUCT; KINASE-4 INHIBITOR GENE; S-PHASE ENTRY; POLY(ADP-RIBOSE) POLYMERASE; PROTEIN; EXPRESSION; P53; P16(INK4A); MDM2; P16	The p16 tumor suppressor gene is frequently inactivated in human cancer tissues and cell lines. We previously reported that wild-type p16 expression from an adenovirus vector (Adv/p16) induced p53-dependent apoptotic cell death in non-small cell lung cancer (NSCLC) cell fines. Here we show the potential mechanism of apoptosis induced by Adv/p16 infection. Infection of human NSCLC cell line A549, which carries the wild-type p53 gene, with Adv/p16 resulted in activation of caspase-3, accompanied by the cleavage of its substrate poly (ADP-ribose) polymerase (PARP), on day 3 of infection. The retinoblastoma (Rb) cell cycle regulator protein was also cleaved after activation of caspase-3; when the levels of Rb significantly diminished, apoptosis began. When A549 cells were pretreated with the caspase-inhibitory peptide N-acetyl-asp-Glu-Val-Asp-CHO (aldehyde) (Ac-DEVD-CHO), Adv/p16-mediated apoptosis and Rb cleavage were greatly inhibited. Furthermore, MDM2, a negative regulator of p53 expression was upregulated 3 days after Adv/p16 infection, and MDM2 was subsequently cleaved by caspase-3; MDM2 cleavage was inhibited by Ac-DEVD-CHO treatment. These data implied that cleavage of Rb, in addition to activation of caspase-3, represented a mechanism by which Adv/p16 induced apoptotic cell death in human NSCLC cells. Our results support the clinical relevance of Adv/p16 as a treatment for p16-null human NSCLC that express wild-type p53.	Okayama Univ, Grad Sch Med & Dent, Dept Surg, Div Surg Oncol, Okayama 7008558, Japan; Natl Canc Ctr, Res Inst, Canc Proteom Project, Tokyo 1040045, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA	Okayama University; National Cancer Center - Japan; University of Texas System; UTMD Anderson Cancer Center	Fujiwara, T (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Surg, Div Surg Oncol, Okayama 7008558, Japan.	toshi_f@md.okayama-u.ac.jp			NATIONAL CANCER INSTITUTE [P01CA078778, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, 2P50-CA70970-04, P01 CA78778-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; An B, 1996, CANCER RES, V56, P438; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Hara E, 1996, MOL CELL BIOL, V16, P859; HAUPT Y, 1995, ONCOGENE, V10, P1563; Herman JG, 1996, CANCER RES, V56, P722; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hu YX, 1997, CLIN CANCER RES, V3, P1473; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; JEN J, 1994, CANCER RES, V54, P6353; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Kawabe S, 2000, ONCOGENE, V19, P5359, DOI 10.1038/sj.onc.1203935; Kim M, 2000, CELL DEATH DIFFER, V7, P706, DOI 10.1038/sj.cdd.4400703; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MAO L, 1995, CANCER RES, V55, P2995; McConkey DJ, 1996, ONCOGENE, V13, P1693; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORI T, 1994, CANCER RES, V54, P3396; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Steiner MS, 2000, CANCER GENE THER, V7, P360, DOI 10.1038/sj.cgt.7700151; Takeuchi H, 1997, CLIN CANCER RES, V3, P2229; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang J, 1997, CANCER RES, V57, P351; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954	50	53	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2108	2113		10.1038/sj.onc.1205272	http://dx.doi.org/10.1038/sj.onc.1205272			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960384	Green Submitted			2022-12-17	WOS:000174827000018
J	Liberto, M; Cobrinik, D; Minden, A				Liberto, M; Cobrinik, D; Minden, A			Rho regulates p21(CIP1) cyclin D1, and checkpoint control in mammary epithelial cells	ONCOGENE			English	Article						Rho; p21(CIP1); cyclin D1; MCF10A; epithelial cells	ADP-RIBOSYLATION; CDC42 GTPASES; DBL FAMILY; EXPRESSION; KINASE; RAC; TRANSFORMATION; ACTIVATION; OVEREXPRESSION; GROWTH	The small GTPase Rho is important for cell cycle progression and Ras transformation in fibroblasts. However, it is unclear whether Rho is needed for proliferation in other cell types, and its targets in promoting normal cell cycle progression are unknown. Here, we demonstrate that Rho is required for G1 to S progression in MCF10A mammary epithelial cells, both in response to EGF and in response to oncogenic Ras. We describe two effects of Rho, the repression of p21(CIP1) and the induction of cyclin D1, that may underlie its role in promoting S phase entry. The Rho inhibitor, C3 exotransferase, induced p21(CIP1) both in EGF-stimulated and V12Ras-expressing cells. In addition, C3 blocked EGF-stimulated cyclin D1 promoter activity whereas V14RhoA induced the cyclin D1 promoter and cooperated with V12Ras in cyclin D1 induction. Finally, a high proportion of cells co-expressing V14RhoA and V12Ras displayed lobulated, polyploid nuclei that were actively synthesizing DNA. Our results demonstrate that Rho plays a fundamental role in promoting Ras-dependent S phase entry in mammary epithelial cells, whether in response to normal or oncogenic signaling, and indicate that in cells expressing oncogenic Ras, the activation of Rho diminishes p21(CIP1) expression, increases cyclin D1 promoter activity, and uncouples DNA synthesis from mitosis.	Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Sherman Fairchild Ctr, New York, NY 10027 USA	Columbia University; Columbia University	Cobrinik, D (corresponding author), Columbia Univ, Coll Phys & Surg, 650 W 168th St,BB20-09, New York, NY 10032 USA.	dc197@columbia.edu; agm24@columbia.edu			NATIONAL CANCER INSTITUTE [R01CA076342] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76342] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GILLETT C, 1994, CANCER RES, V54, P1812; GUDAS J, 1995, ONCOGENE, V11, P253; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kerkhoff E, 1998, CANCER RES, V58, P1636; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KHOSRAVIFAR R, 1997, ADV CANCER RES, V72, P72; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; LI Y, 1994, ONCOGENE, V9, P2261; Liberto M, 2000, CANCER LETT, V154, P151, DOI 10.1016/S0304-3835(00)00378-5; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MICHIELI P, 1994, CANCER RES, V54, P3391; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; SOULE HD, 1990, CANCER RES, V50, P6075; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Tombes RM, 1998, BIOCHEM J, V330, P1451; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VAN AL, 1997, GENE DEV, V11, P2295; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhou P, 1996, CANCER RES, V56, P36	48	53	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1590	1599		10.1038/sj.onc.1205242	http://dx.doi.org/10.1038/sj.onc.1205242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896588				2022-12-17	WOS:000173956800015
J	Henry, H; Thomas, A; Shen, Y; White, E				Henry, H; Thomas, A; Shen, Y; White, E			Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death	ONCOGENE			English	Article						p53; apoptosis; Bcl-2 family; caspase	CYTOCHROME-C RELEASE; TUMOR-SUPPRESSOR P53; PORE-FORMING DOMAIN; ADENOVIRUS E1B 19K; BCL-2 FAMILY; P53-DEPENDENT APOPTOSIS; 19-KILODALTON PROTEIN; CONFORMATIONAL CHANGE; DELTA-ENDOTOXIN; BAX GENE	The p53 tumor suppressor protein inhibits tumor formation, in part by inducing apoptosis, which is inhibited by anti-apoptotic Bcl-2 family members Bcl-2 and adenovirus E1B 19K. We have identified p53-apoptotic signaling events which are targeted for inhibition by E1B 19K. Apoptotic signaling by p53 induced a Bid-independent conformational change in Bax, a Bax-Bak interaction, release of cytochrome c and Smac/DIABLO from mitochondria, caspase-9 and 3 activation, cleavage of known caspase substrates, and apoptosis. When p53-dependent apoptosis was blocked by E1B 19K expression, E1B 19K bound Bak, and the Bax-Bak interaction was inhibited. Cytochrome c and Smac/DIABLO release from mitochondria was also inhibited in E1B 19K expressing cells and cells remained viable. After a prolonged p53 death stimulus, the inhibition of the mitochondrial death checkpoint by E1B 19K failed, and cytochrome c and Smac/DIABLO were released from mitochondria, and became degraded. Despite this eventual failure to inhibit the mitochondrial checkpoint, caspase-9 and -3 were not activated, and cells remained viable even upon treatment with an exogenous death stimulus. Thus, p53 induces apoptosis in part through Bax and Bak, and even an incomplete inhibition of this mitochondrial checkpoint may be sufficient to confer resistance to cell death.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Canc Inst New Jersey, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	White, E (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, Howard Hughes Med Inst, 679 Hoes Lane, Piscataway, NJ 08854 USA.		White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA53370, CA60088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053370, R01CA060088, R01CA053370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; BOYD JM, 1995, ONCOGENE, V11, P1921; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Gao CF, 2001, EXP CELL RES, V265, P145; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; SUNDARARAJAN R, 2001, IN PRESS J BIOL CHEM, V276; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tan YJ, 1999, BIOCHEM BIOPH RES CO, V255, P334, DOI 10.1006/bbrc.1999.0222; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	54	53	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					748	760		10.1038/sj.onc.1205125	http://dx.doi.org/10.1038/sj.onc.1205125			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850803				2022-12-17	WOS:000173427000006
J	Gentile, M; Ahnstrom, M; Schon, F; Wingren, S				Gentile, M; Ahnstrom, M; Schon, F; Wingren, S			Candidate tumour suppressor genes at 11q23-q24 in breast cancer: evidence of alterations in PIG8, a gene involved in p53-induced apoptosis	ONCOGENE			English	Article						11q23-q24; early onset; breast cancer; PIG8; CHK1; LOH11CR2A	ATAXIA-TELANGIECTASIA; EARLY-ONSET; ATM GENE; SPORADIC BREAST; PPP2R1B GENE; MUTATIONS; HETEROZYGOSITY; REGION; IDENTIFICATION; DELETION	One of the most consistently deleted chromosomal regions in solid tumours is 11q23-q25, which consequently has been postulated to harbour one or more tumour suppressor loci. Despite large efforts to identify the responsible genes, the goal remains elusive, but as knowledge accumulates new candidates are emerging. The present study was undertaken in an attempt to assess the possible implication of four genes residing at 11q23-q24, in a population of early onset breast cancer (n = 41). The coding sequence of PIG8, CHK1, LOH11CR2A and PPP2R1B were screened for mutations using the protein truncation test or single-strand conformational polymorphism, in combination with direct DNA sequencing. Varying proportions of alterations were detected, ranging from 6% in PPP2R1B to 39% in PIG8. Many of these changes were deletions, in some cases corresponding to complete exons, thus likely to represent splice variants, while others were presumed to arise from aberrant splicing, since they occurred at sites with resemblance to exon/intron borders. Considering only bona fide mutations, the highest alteration frequency (17%) was again found in PIG8. Most of these alterations were likely to have an adverse impact on the translated protein as they either altered the reading frame or affected phylogenetically conserved residues. Our data represent the first evidence of alterations in the PIG8 gene in human malignancies, a finding that substantiates its role as a potential tumour suppressor gene as suggested by its involvement in p53-induced apoptosis.	Linkoping Univ Hosp, Div Oncol, Dept Biomed & Surg, S-58185 Linkoping, Sweden	Linkoping University	Wingren, S (corresponding author), Linkoping Univ Hosp, Div Oncol, Dept Biomed & Surg, S-58185 Linkoping, Sweden.	sten.wingren@onk.liu.se						Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Bebb DG, 1999, BRIT J CANCER, V80, P1979, DOI 10.1038/sj.bjc.6690630; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bertoni F, 1999, GENE CHROMOSOME CANC, V26, P176, DOI 10.1002/(SICI)1098-2264(199910)26:2<176::AID-GCC11>3.3.CO;2-V; Broeks A, 2000, AM J HUM GENET, V66, P494, DOI 10.1086/302746; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; Evans MF, 1998, ONCOGENE, V16, P2557, DOI 10.1038/sj.onc.1202039; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gentile M, 1999, EUR J CANCER, V35, P1202, DOI 10.1016/S0959-8049(99)00121-5; Gentile M, 2001, INT J CANCER, V92, P208, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1169>3.0.CO;2-4; Gentile M, 1999, BRIT J CANCER, V80, P843, DOI 10.1038/sj.bjc.6690430; Gu Z, 2000, CYTOGENET CELL GENET, V89, P230, DOI 10.1159/000015620; Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000; HAMPTON GM, 1994, CANCER RES, V54, P4586; Haruki N, 2000, CANCER RES, V60, P4689; HAYASHI K, 1993, HUM MUTAT, V2, P338, DOI 10.1002/humu.1380020503; Herbst RA, 1999, INT J CANCER, V80, P205, DOI 10.1002/(SICI)1097-0215(19990118)80:2<205::AID-IJC8>3.0.CO;2-J; Hui ABY, 1996, CANCER RES, V56, P3225; Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X; Izatt L, 1999, EUR J HUM GENET, V7, P310, DOI 10.1038/sj.ejhg.5200288; Janin N, 1999, BRIT J CANCER, V80, P1042, DOI 10.1038/sj.bjc.6690460; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; Koreth J, 1997, ONCOGENE, V14, P431, DOI 10.1038/sj.onc.1200847; Laake K, 1999, GENE CHROMOSOME CANC, V25, P212, DOI 10.1002/(SICI)1098-2264(199907)25:3<212::AID-GCC3>3.3.CO;2-7; Laake K, 2000, BRIT J CANCER, V83, P1650, DOI 10.1054/bjoc.2000.1519; Lehar SM, 1996, ONCOGENE, V12, P1181; Liu WG, 1997, NAT GENET, V16, P328, DOI 10.1038/ng0897-328; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; NEGRINI M, 1995, CANCER RES, V55, P3003; Olsen JH, 2001, JNCI-J NATL CANCER I, V93, P121, DOI 10.1093/jnci/93.2.121; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Siah SP, 2000, BREAST CANCER RES TR, V60, P135, DOI 10.1023/A:1006315315060; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268; Valentine CR, 1998, MUTAT RES-REV MUTAT, V411, P87, DOI 10.1016/S1383-5742(98)00010-6; Vorechovsky I, 1996, CANCER RES, V56, P2726; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017	45	53	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2001	20	53					7753	7760		10.1038/sj.onc.1204993	http://dx.doi.org/10.1038/sj.onc.1204993			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753653				2022-12-17	WOS:000172161700006
J	Meyer, GE; Shelden, E; Kim, B; Feldman, EL				Meyer, GE; Shelden, E; Kim, B; Feldman, EL			Insulin-like growth factor I stimulates motility in human neuroblastoma cells	ONCOGENE			English	Article						PI3-K; MAP kinase; insulin receptor substrate; PTEN	KINASE TYROSINE PHOSPHORYLATION; FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; CYTOSKELETAL REORGANIZATION; DIFFERENTIAL REGULATION; RECEPTOR SUBSTRATE-2; NEURITE OUTGROWTH; SIGNALING SYSTEM; RAC	Motility is an important process that contributes to cancer cell spread. Growth factors are key regulators of motility in many cell types. Insulin-like growth factor I (IGF-I) causes SH-SY5Y human neuroblastoma cells to undergo dynamic morphological changes, leading to the extension of lamellipodia. IGF-I stimulated lamellipodia extension requires signaling through both phosphatidylinositol 3-kinase (P13-K) and MAP kinase pathways. IGF-I, over a period of hours, stimulates SH-SY5Y and SHEP neuroblastoma cells to become more motile. While SH-SY5Y and SHEP cells use different insulin receptor substrate (IRS) isoforms to transduce signals from the IGF-I receptor, IGF-I has the same relative effect on the motility of both cell lines. Blocking the P13-K and MAP kinase pathways attenuates the ability of IGF-I to increase motility. Overexpression of PTEN also attenuates IGF-I mediated motility. These results delineate some of the proximal events in the signaling mechanism utilized by IGF-I to stimulate cell motility.	Univ Michigan, Dept Neurol, Program Neurosci, Ann Arbor, MI 48109 USA; Univ Michigan, Med Sci Training Program, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, Program Neurosci, 4414 Kresge III,200 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.		, Eric/GWC-7636-2022	Feldman, Eva/0000-0002-9162-2694	NCI NIH HHS [5T32 CA 09676] Funding Source: Medline; NIGMS NIH HHS [5T32 GM 07863] Funding Source: Medline; NINDS NIH HHS [R01 NS 38849] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038849] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; Cheng HL, 2000, J BIOL CHEM, V275, P27197; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; JACKSON JG, 1999, END SOC 81 ANN M, P479; Keller HU, 2000, CELL MOTIL CYTOSKEL, V46, P247, DOI 10.1002/1097-0169(200008)46:4<247::AID-CM2>3.0.CO;2-8; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kim B, 1998, ENDOCRINOLOGY, V139, P4881, DOI 10.1210/en.139.12.4881; Kim BS, 1998, J NEUROCHEM, V71, P1333; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mira E, 1999, ENDOCRINOLOGY, V140, P1657, DOI 10.1210/en.140.4.1657; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOHAN S, 1991, CLIN ORTHOP RELAT R, P30; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; PANAGAKOS FS, 1993, BIOCHIMIE, V75, P991, DOI 10.1016/0300-9084(93)90150-Q; Shelden EA, 2000, J NEUROSCI METH, V102, P143, DOI 10.1016/S0165-0270(00)00286-7; Singleton JR, 1996, CANCER RES, V56, P4522; SUMANTRAN VN, 1993, ENDOCRINOLOGY, V132, P2017, DOI 10.1210/en.132.5.2017; TANABE M, 1995, MED PEDIATR ONCOL, V24, P292, DOI 10.1002/mpo.2950240505; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; Van Golen CM, 2000, J CELL PHYSIOL, V182, P24, DOI 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; YAMAMOTO M, 1993, NEUROSCI LETT, V152, P37, DOI 10.1016/0304-3940(93)90477-3; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	38	53	54	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7542	7550		10.1038/sj.onc.1204927	http://dx.doi.org/10.1038/sj.onc.1204927			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709726				2022-12-17	WOS:000171976900011
J	Banerji, L; Glassford, J; Lea, NC; Thomas, NSB; Klaus, GGB; Lam, EWF				Banerji, L; Glassford, J; Lea, NC; Thomas, NSB; Klaus, GGB; Lam, EWF			BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells	ONCOGENE			English	Article						cyclin D2; p27(Kip1); proliferation; apoptosis; WEHI 231; PI3-K	ANTIGEN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; DEPENDENT KINASE; LYMPHOMA-CELLS; G(1) CYCLIN; IN-VITRO; ACTIVATION	Cross-linking of the B cell antigen receptor (BCR) on immature WEHI 231 B cells results in GI cell cycle arrest and apoptosis. Here we investigated the, molecular mechanisms that are necessary and sufficient for these changes to occur., We show that BCR stimulation of WEHI 231 cells results in down-regulation of cyclin D2 and up-regulation of p27(Kip1), which are associated with pocket protein hypophosphorylation and E2F inactivation. Ectopic expression of p27(Kip1) by TAT-fusion protein or retroviral transduction is sufficient to cause G1 cell cycle arrest, followed by apoptosis. In contrast, overt expression of cyclin D2 overcomes, the cell cycle arrest and apoptosis induced by anti-IgM, indicating that downregulation of cyclin D2 is necessary for the cell cycle arrest and apoptosis activated by BCR stimulation. Thus, cyclin D2 and p27(Kip1) have opposing roles in these pathways and our data also suggest that cyclin D2 functions upstream of p27(Kip1) and the pRB pathway and therefore plays an essential part in integrating the signals from BCR with the cell cycle machinery. We next investigated which signal transduction pathways triggered by the BCR regulate cell proliferation and apoptosis. via cyclin D2 and p27(Kip1). Inhibition of PI3-K signalling by LY294002 down-regulated cyclin D2 and up-regulated p27(Kip1) expression at both, protein and RNA levels, mimicking the effects of BCR-stimulation. Furthermore, ectopic expression of a constitutively active form of AKT blocked the cell cycle arrest and apoptosis triggered by anti-IgM and also, abrogated downregulation of cyclin D2 and up-regulation of p27(Kip1) expression induced by BCR-engagement. These results indicate that BCR activation targets: p27(Kip1) and cyclin D2 to mediate cell cycle arrest and apoptosis and that down-regulation of PI3-K/AKT activity post BCR stimulation is necessary for these to occur.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, CRC,Lab Canc Cell Biol, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, CRC,Sect Canc Cell Biol, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, London W2 1PG, England; Guys Kings St Thomas Sch Med, Rayne Inst, Dept Haematol, London, England; Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England	Imperial College London; Imperial College London; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; University of London; King's College London; MRC National Institute for Medical Research	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, CRC,Lab Canc Cell Biol, Du Cane Rd, London W12 0NN, England.	eric.lam@ic.ac.uk	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576				AagaardTillery KM, 1996, J IMMUNOL, V156, P4543; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Birkeland ML, 1997, CRIT REV IMMUNOL, V17, P353, DOI 10.1615/CritRevImmunol.v17.i3-4.50; Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; Boonen GJJC, 1999, EUR J IMMUNOL, V29, P789; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; Carey GB, 2001, J IMMUNOL, V166, P1618, DOI 10.4049/jimmunol.166.3.1618; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Craxton A, 2000, CELL IMMUNOL, V200, P56, DOI 10.1006/cimm.2000.1616; Craxton A, 1999, J BIOL CHEM, V274, P30644, DOI 10.1074/jbc.274.43.30644; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Donjerkovic D, 1999, CELL GROWTH DIFFER, V10, P695; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; GOLD MR, 1994, J IMMUNOL, V152, P42; Gold MR, 1999, J IMMUNOL, V163, P1894; Gold MR, 2000, IMMUNOL REV, V176, P47; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Klaus G G, 1997, Int Rev Immunol, V15, P5, DOI 10.3109/08830189709068169; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Kuwahara K, 1996, INT IMMUNOL, V8, P1273, DOI 10.1093/intimm/8.8.1273; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lam EWF, 1998, J BIOL CHEM, V273, P10051, DOI 10.1074/jbc.273.16.10051; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li HL, 1999, P NATL ACAD SCI USA, V96, P6890, DOI 10.1073/pnas.96.12.6890; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Monroe JG, 2000, CURR TOP MICROBIOL, V245, P1; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Padmore L, 1997, CELL IMMUNOL, V177, P119, DOI 10.1006/cimm.1997.1102; PARADA Y, 2001, J BIOL CHEM, V25, P25; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sakata A, 1999, IMMUNOL LETT, V68, P301, DOI 10.1016/S0165-2478(99)00053-X; Sakata N, 1999, EUR J IMMUNOL, V29, P2999, DOI 10.1002/(SICI)1521-4141(199909)29:09<2999::AID-IMMU2999>3.0.CO;2-L; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wu M, 1999, J IMMUNOL, V163, P6530	62	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7352	7367		10.1038/sj.onc.1204951	http://dx.doi.org/10.1038/sj.onc.1204951			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704865				2022-12-17	WOS:000171894200008
J	Sayed, M; Pelech, S; Wong, C; Marotta, A; Salh, B				Sayed, M; Pelech, S; Wong, C; Marotta, A; Salh, B			Protein kinase CK2 is involved in G2 arrest and apoptosis following spindle damage in epithelial cells	ONCOGENE			English	Article						CK2; p53; spindle checkpoint; apoptosis	DNA-DAMAGE; P53 PROTEIN; NEUROBLASTOMA-CELLS; SUPPRESSOR PROTEIN; MOUSE FIBROBLASTS; CYCLE CHECKPOINT; G(2) CHECKPOINT; GAMMA-RADIATION; II SITE; PHOSPHORYLATION	p53 undergoes phosphorylation on several residues in response to cellular stresses that include UV and ionizing radiation, however the influence of spindle damage on this parameter is relatively unclear. Consequently, the effect of nocodazole on serine 392 phosphorylation was examined in two epithelial cell lines. We show that this process is dependent upon the stepwise activation of p38 mitogen-activated protein kinase (p38 MAPK) and protein kinase casein kinase 2 (CK2). Furthermore, this activation correlated with the biochemical regulation of the maturation-promoting factor (MPF, cdc2/cyclin B), as both DRB and antisense depletion of CK2, as well as SB203580 were associated with an inhibition of its activation in response to nocodazole. Strikingly, when the cell cycle characteristics of nocodazole treated cells were examined, we observed that depletion or inhibition of the catalytic subunit of CK2, in the presence of microtubule inhibitors, resulted in a compromise of the G2 arrest (spindle checkpoint). Furthermore, CK2-depleted, nocodazole treated cells demonstrated a dramatic reduction in the apoptotic cell fraction, confirming that these cells had been endowed with oncogenic properties. These changes were observed in both HeLa cells and HCT116 cells. We also show that this effect is dependent on the presence of functional wild-type p53, as this phenomenon is not apparent in HCT116 p53 /(-) cells. Collectively, our results indicate two novel roles for CK2 in the spindle checkpoint arrest, in concert with p53. Firstly, to maintain increased cyclinB/cdc2 kinase activity, as a component of G2 arrest, and secondly, a role in p53-mediated apoptosis. These findings may have implications for an improved understanding of abnormalities of the spindle checkpoint in human cancers, which is a prerequisite for defining future therapies.	Univ British Columbia, Jack Bell Res Ctr, Dept Expt Med, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z3, Canada; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of British Columbia; University of British Columbia; Memorial Sloan Kettering Cancer Center	Salh, B (corresponding author), Univ British Columbia, Dept Med, 100-2647 Willow St, Vancouver, BC V5Z 3P1, Canada.			Pelech, Steven/0000-0003-1112-903X				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butz K, 1999, ONCOGENE, V18, P2381, DOI 10.1038/sj.onc.1202557; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Di Leonardo A, 1997, CANCER RES, V57, P1013; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISCELLA M, 1993, ONCOGENE, V8, P1519; Gotz C, 1999, MOL CELL BIOCHEM, V191, P111, DOI 10.1023/A:1006886727248; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERRMANN CPE, 1991, ONCOGENE, V6, P877; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang LC, 1996, CANCER RES, V56, P2940; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Mayo LD, 1997, CANCER RES, V57, P5013; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MIYASHITA T, 1995, CELL, V80, P293; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Prives C, 1999, J PATHOL, V187, P112; ROLLEY N, 1994, ONCOGENE, V9, P3067; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHICH SY, 1997, CELL, V91, P325; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; ULLOA L, 1994, CELL MOL NEUROBIOL, V14, P407, DOI 10.1007/BF02088827; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Xu X, 1999, MOL CELL BIOCHEM, V191, P65, DOI 10.1023/A:1006866412652; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	62	53	57	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					6994	7005		10.1038/sj.onc.1204894	http://dx.doi.org/10.1038/sj.onc.1204894			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704824				2022-12-17	WOS:000171739300003
J	Little, NA; Jochemsen, AG				Little, NA; Jochemsen, AG			Hdmx and Mdm2 can repress transcription activation by p53 but not by p63	ONCOGENE			English	Article						p53; p63; Mdmx; Mdm2; transcriptional activation	PROTEIN; HOMOLOG; P73; DEGRADATION; ONCOPROTEIN; PRODUCTS; MUTANTS; LIGASE; LIMB	The p53 protein is involved in cell cycle arrest and apoptosis. To ensure that cells under non-stressed conditions are able to grow, p53 sets up a negative feedback loop by inducing Mdm2. Mdm2 is able to both inhibit the transcriptional regulation by p53 and to degrade it, thus maintaining p53 inactive until it is required. The Mdm2 related protein, Hdmx, has also been shown to inhibit the transcriptional activation of p53 but is unable to degrade it. A few years ago, the p53 family member, p63 was identified. Like p53, p63 is able to induce p53 target genes and it was shown to be able to cause cell cycle arrest and apoptosis. In this study we report that, despite the similarities between p53 and p63, neither Hdmx nor Mdm2 are able to interact with p63, to repress p63-induced transcription or to affect its half-life.	Leiden Univ, Med Ctr, Dept Mol & Cell Biol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Jochemsen, AG (corresponding author), Leiden Univ, Med Ctr, Dept Mol & Cell Biol, POB 9503, NL-2300 RA Leiden, Netherlands.	a.g.jochemsen@lumc.nl						Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Kojima T, 2001, BIOCHEM BIOPH RES CO, V281, P1170, DOI 10.1006/bbrc.2001.4486; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Lee LA, 1999, J INVEST DERMATOL, V113, P146, DOI 10.1046/j.1523-1747.1999.00651.x; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1995, CELL, V80, P293; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shimada A, 1999, CANCER RES, V59, P2781; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stad R, 2000, J BIOL CHEM, V275, P28039; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; van der Eb A J, 1980, Methods Enzymol, V65, P826; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	36	53	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4576	4580		10.1038/sj.onc.1204615	http://dx.doi.org/10.1038/sj.onc.1204615			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494153				2022-12-17	WOS:000170074900015
J	Benedit, P; Paciucci, R; Thomson, TM; Valeri, M; Nadal, M; Caceres, C; de Torres, I; Estivill, X; Lozano, JJ; Morote, J; Reventos, J				Benedit, P; Paciucci, R; Thomson, TM; Valeri, M; Nadal, M; Caceres, C; de Torres, I; Estivill, X; Lozano, JJ; Morote, J; Reventos, J			PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks	ONCOGENE			English	Article						prostate; prostate adenocarcinoma; androgens; molecular markers	DIFFERENTIALLY EXPRESSED GENES; INTRAEPITHELIAL NEOPLASIA; SERINE-PROTEASE; ANDROGEN RECEPTOR; TUMOR-SUPPRESSOR; CARCINOMA; TISSUE; DISPLAY; SEARCH; FAMILY	In a search for molecular markers of progression in prostate cancer by means of differential display, me have identified a new gene, which we have designated PTO VI, Semiquantitative RT-PCR has established that nine out of 11 tumors overexpress PTOV1 at levels significantly higher than benign prostatic hyperplasia or normal prostate tissue. The human PTOV1 protein consists almost entirely of two repeated blocks of homology of 151 and 147 amino acids, joined by a short linker peptide, and is encoded by a 12-exon gene localized in chromosome 19q13.3, A Drosophila melanogaster PTOV1 homolog also contains two tandemly arranged PTOV blocks. A second gene, PTOV2, was identified in humans and Drosophila, coding for proteins with a single PTOV homology block and unrelated amino- and carboxyl-terminal extensions. A 1.8-Kb PTOV1 transcript was detected abundantly in normal human brain, heart, skeletal muscle, kidney and liver, and at low levels in normal prostate. Immunocytochemical analysis and expression of chimeric GFP-PTOV1 proteins in cultured cells showed a predominantly perinuclear localization of PTOV1, In normal prostate tissue and in prostate adenomas, PTOV1 was undetectable or expressed at low levels, whereas nine out of 11 prostate adenocarcinomas showed a strong immunoreactivity, with a focal distribution in areas of carcinoma and prostatic intraepithelial neoplasia, Therefore, PTOV1 is a previously unknown gene, overexpressed in early and late stages of prostate cancer. The PTOV homology block represents a new class of conserved sequence blocks present in human, rodent and fly proteins.	Hosp Gen Valle Hebron, Hosp Materno Infantil, Unitat Rec Biomed, Barcelona, Spain; CSIC, Inst Mol Biol, Barcelona, Spain; Inst Rec Oncol, Ctr Genet Mol, Barcelona, Spain; Hosp Gen Valle Hebron, Serv Anat Patol, Barcelona, Spain; Inst Municipal Invest Med, Inst Rec Informat Med, Barcelona, Spain; Univ Pompeu Fabra, Barcelona, Spain; Hosp Gen Valle Hebron, Urol Serv, Barcelona, Spain	Hospital Universitari Vall d'Hebron; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Hospital Universitari Vall d'Hebron; Pompeu Fabra University; Hospital Universitari Vall d'Hebron	Thomson, TM (corresponding author), Hosp Gen Valle Hebron, Hosp Materno Infantil, Unitat Rec Biomed, Barcelona, Spain.		Estivill, Xavier/E-2957-2012; Paciucci, Rosanna/AGP-3844-2022; Reventos, Jaume/I-1633-2012; Morote, Juan/M-6914-2017; Estivill, Xavier/A-3125-2013; Thomson, Timothy/Z-6271-2019	Paciucci, Rosanna/0000-0001-5651-5933; Morote, Juan/0000-0002-2168-323X; Estivill, Xavier/0000-0002-0723-2256; Thomson, Timothy/0000-0002-4670-9440; Lozano, Juan Jose/0000-0001-7613-3908; Nadal, Marga/0000-0002-5739-1693				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLOK LJ, 1995, PROSTATE, V26, P213, DOI 10.1002/pros.2990260407; Bostwick DG, 1998, CANCER, V83, P1995, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO;2-2; Bostwick DG, 1996, CANCER, V78, P330, DOI 10.1002/(SICI)1097-0142(19960715)78:2<330::AID-CNCR22>3.0.CO;2-W; Bostwick DG, 1997, PROSTATE, V33, P32, DOI 10.1002/(SICI)1097-0045(19970915)33:1<32::AID-PROS6>3.0.CO;2-B; Brooks JD, 1996, CANCER RES, V56, P3814; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chang GTG, 1997, CANCER RES, V57, P4075; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Fernandez PL, 1999, J PATHOL, V187, P563, DOI 10.1002/(SICI)1096-9896(199904)187:5<563::AID-PATH292>3.0.CO;2-3; Gottlieb B, 1999, HUM MUTAT, V14, P103, DOI 10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.3.CO;2-1; Goyal J, 1998, CANCER RES, V58, P4782; Guate JL, 1999, BJU INT, V84, P495; GUIGO R, 1992, J MOL BIOL, V226, P141, DOI 10.1016/0022-2836(92)90130-C; Harper ME, 1998, J PATHOL, V186, P169, DOI 10.1002/(SICI)1096-9896(1998100)186:2<169::AID-PATH164>3.0.CO;2-W; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Jenster G, 1999, SEMIN ONCOL, V26, P407; Johnson MI, 1998, PROSTATE, V37, P223, DOI 10.1002/(SICI)1097-0045(19981201)37:4<223::AID-PROS3>3.0.CO;2-O; Kallioniemi OP, 1996, ADV CANCER RES, V68, P225, DOI 10.1016/S0065-230X(08)60355-3; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lin BY, 1999, CANCER RES, V59, P4180; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; Lucas S, 1998, CANCER RES, V58, P743; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Meyers FJ, 1998, CANCER, V83, P2534, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2534::AID-CNCR19>3.3.CO;2-M; Montironi R, 1999, J CLIN PATHOL, V52, P350, DOI 10.1136/jcp.52.5.350; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Reiter RE, 1998, P NATL ACAD SCI USA, V95, P1735, DOI 10.1073/pnas.95.4.1735; Rondinelli RH, 1999, CLIN CANCER RES, V5, P1595; SHEN RQ, 1995, P NATL ACAD SCI USA, V92, P6778, DOI 10.1073/pnas.92.15.6778; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Stubbs AP, 1999, AM J PATHOL, V154, P1335, DOI 10.1016/S0002-9440(10)65387-4; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; Sun YL, 1997, CANCER RES, V57, P18; TROYER JK, 1995, INT J CANCER, V62, P552, DOI 10.1002/ijc.2910620511; Wang FL, 1996, CANCER RES, V56, P3634; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Yousef GM, 2000, GENOMICS, V63, P88, DOI 10.1006/geno.1999.6072; Yousef GM, 1999, GENOMICS, V62, P251, DOI 10.1006/geno.1999.6012; ZHAU HYE, 1992, MOL CARCINOGEN, V5, P320, DOI 10.1002/mc.2940050413	43	53	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2001	20	12					1455	1464		10.1038/sj.onc.1204233	http://dx.doi.org/10.1038/sj.onc.1204233			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313889				2022-12-17	WOS:000167595200006
J	Simoneau, M; LaRue, H; Aboulkassim, TO; Meyer, F; Moore, L; Fradet, Y				Simoneau, M; LaRue, H; Aboulkassim, TO; Meyer, F; Moore, L; Fradet, Y			Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest	ONCOGENE			English	Article						bladder cancer; LOH; recurrence; prognostic; chromosome 9	TRANSITIONAL-CELL CARCINOMA; TUMOR-SUPPRESSOR LOCI; URINARY-BLADDER; HUMAN HOMOLOG; GENE; PROGRESSION; MUTATIONS; ANTIGENS; SMOKING; MARKERS	In a previous study, loss of heterozygosity (LOH) of 28 chromosome 9 microsatellite markers was assessed on 139 Ta/T1 bladder tumors. LOH at one or more loci was detected in 67 tumors, 62 presenting subchromosomal deletions. One hundred and thirty-three of these patients have now been followed for up to 8 years. The purpose of the present study was to evaluate the potential biological significance of chromosome 9 deletions in superficial bladder tumors at initial diagnosis. High grade was associated with LOH (P=0.004). Large tumors carried more frequently 9p deletions (P = 0.022). Female patients had more chromosome 9q LOH than male patients did (P = 0.010), Chromosome 9 LOH at all loci was associated with an elevated risk of recurrence but four regions were associated with a particularly high risk of recurrence. Multivariate analysis taking into account grade, stage, size and number of tumors showed that tumors deleted in the regions 9ptr-p22, 9q22.3, 9q33, and 9q34 recurred significantly more rapidly than those without deletions (Recurrence rate ratio=2.32, 2.53, 2.52 and 2.43 respectively). Log-rank statistics comparing Kaplan-Meier survival curves for the same chromosomal regions confirmed the correlation (P = 0.0002, 0.010, 0.002 and 0.009 respectively). Only four patients progressed to muscle-invasive disease. They all had extensive deletions on 9q but none had deletions at 9ptr-p22. This study suggests a link between chromosome 9 anomalies and recurrence of superficial bladder cancer.	Univ Laval, Ctr Hosp Univ Quebec, Ctr Rech Cancerol, Quebec City, PQ, Canada	Laval University	Fradet, Y (corresponding author), CHUQ LHotel Dieu Quebec, Ctr Rech, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.			Fradet, Yves/0000-0002-7581-2500	NATIONAL CANCER INSTITUTE [R01CA047526, U01CA047526] Funding Source: NIH RePORTER; NCI NIH HHS [CA47526] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allard P, 1998, BRIT J UROL, V81, P692; Allard P, 1995, CLIN CANCER RES, V1, P1195; Bartlett JMS, 1998, BRIT J CANCER, V77, P2193, DOI 10.1038/bjc.1998.365; Bartlett JMS, 1997, ANN HUM GENET, V61, P207; Czerniak B, 1999, ONCOGENE, V18, P1185, DOI 10.1038/sj.onc.1202385; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; Erbersdobler A, 1998, ONCOL RES, V10, P415; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Hills, 1993, STAT MODELS EPIDEMIO; Hornigold N, 1999, ONCOGENE, V18, P2657, DOI 10.1038/sj.onc.1202854; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KEEN AJ, 1994, ONCOGENE, V9, P2083; Kleinbaum DG, 1987, APPL REGRESSION ANAL; LaRue H, 2000, CARCINOGENESIS, V21, P101, DOI 10.1093/carcin/21.1.101; Lee E, 1997, J UROLOGY, V157, P1070, DOI 10.1016/S0022-5347(01)65143-7; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Micheli A, 1998, EUR J CANCER, V34, P2271, DOI 10.1016/S0959-8049(98)00324-4; Orlow I, 1999, AM J PATHOL, V155, P105, DOI 10.1016/S0002-9440(10)65105-X; POWELL I, 1990, CANCER GENET CYTOGEN, V50, P97, DOI 10.1016/0165-4608(90)90242-3; RAO JY, 1993, P NATL ACAD SCI USA, V90, P8287, DOI 10.1073/pnas.90.17.8287; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Simoneau AR, 1996, CANCER RES, V56, P5039; Simoneau M, 1999, ONCOGENE, V18, P157, DOI 10.1038/sj.onc.1202277; SPRUCK CH, 1994, CANCER RES, V54, P784; TSAI YC, 1990, CANCER RES, V50, P44; Uchida T, 1996, INT J CANCER, V69, P142, DOI 10.1002/(SICI)1097-0215(19960422)69:2<142::AID-IJC13>3.3.CO;2-N; Van Tilborg AAG, 1998, INT J CANCER, V75, P9, DOI 10.1002/(SICI)1097-0215(19980105)75:1<9::AID-IJC2>3.3.CO;2-I; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; Zhang ZF, 1997, CANCER EPIDEM BIOMAR, V6, P321; Zhang Zuo-Feng, 1997, P215; Zhao JM, 1999, CANCER RES, V59, P4658	34	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6317	6323		10.1038/sj.onc.1204022	http://dx.doi.org/10.1038/sj.onc.1204022			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175346				2022-12-17	WOS:000166210500015
J	Wang, DY; Yamamoto, S; Hijiya, N; Benveniste, EN; Gladson, CL				Wang, DY; Yamamoto, S; Hijiya, N; Benveniste, EN; Gladson, CL			Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions	ONCOGENE			English	Article						osteopontin; promoter; transcriptional regulation; malignant astrocytoma; astrocytes; glioma	C-MYC; GENE-EXPRESSION; IN-VIVO; NEOPLASTIC TRANSFORMATION; EXTRACELLULAR-MATRIX; MESSENGER-RNA; CELLS; VITRONECTIN; MECHANISM; CLONING	Synthesis of cell attachment proteins and cytokines, such as osteopontin (OPN), can promote tumor cell remodeling of the extracellular matrix into an environment that promotes tumor cell attachment and migration, We investigated the transcriptional regulation of OPN in the U-251MG and U-87MG human malignant astrocytoma cell lines. Deletion and mutagenesis analyses of the OPN promoter region identified a proximal promoter clement (-24 to -94 relative to the transcription initiation site) that is essential for maintaining high levels of OPN expression in the tumor cells. This clement, designated RE-1, consists of two cis-acting elements, RE-la (-55 to -86) and RE-lb (-22 to -45), which act synergistically to regulate the activity of the OPN promoter, Gel shift assays using nuclear extracts of U-251MG cells demonstrated that RE-la contains binding sites for transcription factors Spl, the glucocorticoid receptor, and the E-box-binding factors, whereas RE-lh contains a binding site for the octamer motif-binding protein (OCT-1/OCT-2), Inclusion of antibodies directed toward Myc and OCT-1 in the gel shift assays indicated that Myc and OCT-1 participate in forming DNA-protein complexes on the RE-la and RE-lb elements, respectively. Our results identify two previously unrecognized elements in the OPN promoter that act synergistically to promote upregulation of OPN synthesis by tumor cells but are regulated by different transcription factors.	Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Oita Med Univ, Dept Pathol, Oita 87955, Japan	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Oita University	Gladson, CL (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, LHRB 567,701 19th St S, Birmingham, AL 35294 USA.				NCI NIH HHS [CA75682, CA59958] Funding Source: Medline; NINDS NIH HHS [NS 34856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059958, R01CA075682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BENVENISTE EN, 1991, J BIOL CHEM, V266, P18119; Broaddus WC, 1997, NEUROSURGERY, V41, P908, DOI 10.1097/00006123-199710000-00027; BROWN LF, 1994, AM J PATHOL, V145, P610; CASTAGNOLA P, 1991, J BIOL CHEM, V266, P9944; Chackalaparampil I, 1996, ONCOGENE, V12, P1457; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CHANG PL, 1993, CANCER RES, V53, P2217; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; ENGELHARD HH, 1989, J NEUROSURG, V71, P224, DOI 10.3171/jns.1989.71.2.0224; GARDNER HAR, 1994, ONCOGENE, V9, P2321; Gladson CL, 1999, J NEUROPATH EXP NEUR, V58, P1029, DOI 10.1097/00005072-199910000-00001; GLADSON CL, 1995, J CELL SCI, V108, P947; Gladson CL, 2000, NEUROSCI LETT, V283, P157, DOI 10.1016/S0304-3940(00)00876-4; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIJIYA N, 1994, BIOCHEM J, V303, P255, DOI 10.1042/bj3030255; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Manji SS, 1998, J CELL PHYSIOL, V176, P1; NODA M, 1988, J BIOL CHEM, V263, P13916; ORIAN JM, 1992, BRIT J CANCER, V66, P106, DOI 10.1038/bjc.1992.225; Pijuan-Thompson V, 1999, EXP CELL RES, V249, P86, DOI 10.1006/excr.1999.4458; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P83; SAITOH Y, 1995, LAB INVEST, V72, P55; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SENGER DR, 1988, CANCER RES, V48, P5770; SINGH K, 1995, J BIOL CHEM, V270, P28471; SMITH JH, 1987, J CELL BIOCHEM, V34, P13, DOI 10.1002/jcb.240340103; Stein GS, 1999, J CELL BIOCHEM, P24; SU LC, 1995, ONCOGENE, V10, P2163; Tezuka KI, 1996, J BIOL CHEM, V271, P22713, DOI 10.1074/jbc.271.37.22713; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	39	53	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5801	5809		10.1038/sj.onc.1203917	http://dx.doi.org/10.1038/sj.onc.1203917			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126367				2022-12-17	WOS:000165477700012
J	Williams, BO; Barish, GD; Klymkowsky, MW; Varmus, HE				Williams, BO; Barish, GD; Klymkowsky, MW; Varmus, HE			A comparative evaluation of beta-catenin and plakoglobin signaling activity	ONCOGENE			English	Article						beta-catenin; plakoglobin; Wnt; LEF/TCF	F-BOX PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; TUMOR-SUPPRESSOR PROTEIN; XENOPUS EMBRYOS; AXIS FORMATION; HEPATOCELLULAR CARCINOMAS; FUNCTIONAL INTERACTION; NUCLEAR-LOCALIZATION; NEGATIVE REGULATOR	Vertebrates have two Armadillo-like proteins, beta -catenin and plakoglobin. Mutant forms of beta -catenin with oncogenic activity are found in many human tumors, but plakoglobin mutations are not commonly found, In fact, plakoglobin has been proposed to suppress tumorigenesis, To assess differences between beta -catenin and plakoglobin, we compared several of their biochemical properties, After transient transfection of 293T cells with an expression vector encoding either of the two proteins, soluble wild type beta -catenin does not significantly accumulate, whereas soluble wild type plakoglobin is readily detected. As anticipated, beta -catenin is stabilized by the oncogenic mutation S37A; however, the analogous mutation in plakoglobin (S28A) does not alter its half-life. S37A-beta -catenin activates a TCF/LEF-dependent reporter 20-fold more potently than wild type beta -catenin, and similar to5-fold more potently than wild type or S28A plakoglobin. These differences may be attributable to an enhanced affinity of S37A beta -catenin for LEF1 and TCF4, as observed here by immunoprecipitation assays. We show that the carboxyl-terminal domain is largely responsible for the difference in signaling and that the Armadillo repeats account for the remainder of the difference, The relatively weak signaling by plakoglobin and the failure of the S28A mutation to enhance its stability, may explain why plakoglobin mutations are infrequent in malignancies.	NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Univ Colorado, Boulder, CO 80309 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Colorado System; University of Colorado Boulder	Williams, BO (corresponding author), Van Andel Res Inst, 333 Bostwick NE, Grand Rapids, MI 49503 USA.		Williams, Bart/A-3539-2013	Williams, Bart/0000-0002-5261-5301; Klymkowsky, Mike/0000-0001-5816-9771	NIGMS NIH HHS [GM54001] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; ABERLE H, 1995, P NATL ACAD SCI USA, V92, P6384, DOI 10.1073/pnas.92.14.6384; Barker N, 2000, ADV CANCER RES, V77, P1; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bierkamp C, 1999, DEVELOPMENT, V126, P371; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Carnac G, 1996, DEVELOPMENT, V122, P3055; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dale TC, 1998, BIOCHEM J, V329, P209; Denk C, 1997, CANCER LETT, V120, P185, DOI 10.1016/S0304-3835(97)00308-X; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Fan MJ, 1998, P NATL ACAD SCI USA, V95, P5626, DOI 10.1073/pnas.95.10.5626; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Gradl D, 1999, MOL CELL BIOL, V19, P5576; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kessler DS, 1997, P NATL ACAD SCI USA, V94, P13017, DOI 10.1073/pnas.94.24.13017; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kikuchi A, 1999, CYTOKINE GROWTH F R, V10, P255, DOI 10.1016/S1359-6101(99)00017-9; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Klymkowsky MW, 1999, MOL BIOL CELL, V10, P3151, DOI 10.1091/mbc.10.10.3151; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; Kolligs FT, 2000, GENE DEV, V14, P1319; Kondo Y, 1999, JPN J CANCER RES, V90, P1301, DOI 10.1111/j.1349-7006.1999.tb00712.x; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Laurent MN, 1997, DEVELOPMENT, V124, P4905; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Miyoshi Y, 1998, CANCER RES, V58, P2524; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Ogawa K, 1999, CANCER RES, V59, P1830; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Pantel K, 1998, J CLIN ONCOL, V16, P1407, DOI 10.1200/JCO.1998.16.4.1407; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Rubenstein A, 1997, DEV GENET, V20, P91, DOI 10.1002/(SICI)1520-6408(1997)20:2<91::AID-DVG2>3.0.CO;2-3; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wahl JK, 1996, J CELL SCI, V109, P1143; White P, 1998, J CELL BIOL, V140, P183, DOI 10.1083/jcb.140.1.183; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Witcher LL, 1996, J BIOL CHEM, V271, P10904, DOI 10.1074/jbc.271.18.10904; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; ZHURINSKY J, 2000, IN PRESS MOL CELL BI; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2; [No title captured]	87	53	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5720	5728		10.1038/sj.onc.1203921	http://dx.doi.org/10.1038/sj.onc.1203921			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126358				2022-12-17	WOS:000165477700003
J	Blaydes, JP; Craig, AL; Wallace, M; Ball, HML; Traynor, NJ; Gibbs, NK; Hupp, TR				Blaydes, JP; Craig, AL; Wallace, M; Ball, HML; Traynor, NJ; Gibbs, NK; Hupp, TR			Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways	ONCOGENE			English	Article						p53; cdk; ionizing; radiation; DRB; Roscovitine	TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; DEPENDENT KINASE INHIBITORS; NORMAL HUMAN FIBROBLASTS; DNA-BINDING FUNCTION; RNA-POLYMERASE-II; WILD-TYPE P53; PROTEIN-KINASE; IONIZING-RADIATION; MOUSE FIBROBLASTS	High level activation of p53-dependent transcription occurs following cellular exposure to genotoxic damaging agents such as UV-C, while ionizing radiation damage does not induce a similarly potent induction of p53-dependent gene expression. Reasoning that one of the major differences between UV-C and ionizing radiation damage is that the latter does not inhibit general transcription, we attempted to reconstitute p53-dependent gene expression in ionizing irradiated cells by co-treatment with selected transcription inhibitors that alone do not activate p53. p53-dependent transcription can be dramatically enhanced by the treatment of ionizing irradiated cells with low doses of DRB, which on its own does not induce p53 activity, The mechanism of ionizing radiation-dependent activation of p53-dependent transcription using DRB is more likely due to inhibition of gene transcription rather than prolonged DNA damage, as the non-genotoxic and general transcription inhibitor Roscovitine also synergistically activates p53 function in ionizing irradiated cells, These results identify two distinct signal transduction pathways that cooperate to fully activate p53-dependent gene expression: one responding to lesions induced by ionizing radiation and the second being a kinase pathway that regulates general RNA Polymerase it activity.	Univ Dundee, Ninewells Med Sch, Dundee Canc Res Ctr, Canc Res Campaign Labs,Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Med Sch, Dundee Canc Res Ctr, Canc Res Campaign Labs,Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Med Sch, Dundee Canc Res Ctr, Canc Res Campaign Labs,Dept Photobiol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Hupp, TR (corresponding author), Univ Dundee, Ninewells Med Sch, Dundee Canc Res Ctr, Canc Res Campaign Labs,Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209; Gibbs, Neil K./0000-0003-2311-2489				ABARZUA P, 1995, CANCER RES, V55, P3490; Abraham J, 2000, J MOL BIOL, V295, P853, DOI 10.1006/jmbi.1999.3415; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; Bellamy COC, 1997, J PATHOL, V183, P177, DOI 10.1002/(SICI)1096-9896(199710)183:2<177::AID-PATH909>3.0.CO;2-E; Bellamy COC, 1997, FASEB J, V11, P591, DOI 10.1096/fasebj.11.7.9212083; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLAYDES J, 2000, STRESS RESPONSES MET; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bond J, 1996, ONCOGENE, V13, P2097; Bond JA, 1999, ONCOGENE, V18, P3788, DOI 10.1038/sj.onc.1202733; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chang D, 1999, CELL GROWTH DIFFER, V10, P155; Chehab NH, 2000, GENE DEV, V14, P278; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; David-Pfeuty T, 1999, ONCOGENE, V18, P7409, DOI 10.1038/sj.onc.1203103; de Fromentel CC, 1999, ONCOGENE, V18, P551, DOI 10.1038/sj.onc.1202338; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hajduch M, 1999, ADV EXP MED BIOL, V457, P341; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Hardmeier R, 1997, P NATL ACAD SCI USA, V94, P7572, DOI 10.1073/pnas.94.14.7572; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Hughes PE, 1997, NEUROREPORT, V8, pR5; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lavin Martin F., 1999, Cancer Research, V59, P3845; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Poele RHT, 1999, ONCOGENE, V18, P5765, DOI 10.1038/sj.onc.1202961; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; Reavy HJ, 1997, PHOTOCHEM PHOTOBIOL, V66, P368, DOI 10.1111/j.1751-1097.1997.tb03160.x; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Sakhi S, 1997, EXP NEUROL, V145, P81, DOI 10.1006/exnr.1997.6451; Sankrithi N, 1999, J NEUROCHEM, V72, P605, DOI 10.1046/j.1471-4159.1999.0720605.x; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STONEWOLFF DS, 1981, MUTAT RES, V82, P147, DOI 10.1016/0027-5107(81)90146-9; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wesierska-Gadek J, 1999, CANCER RES, V59, P28; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; YAMADA T, 1994, SEMICOND SCI TECH, V9, P775, DOI 10.1088/0268-1242/9/5S/102; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; Yuan ZM, 1999, ONCOGENE, V18, P5714, DOI 10.1038/sj.onc.1202930; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883	75	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3829	3839		10.1038/sj.onc.1203773	http://dx.doi.org/10.1038/sj.onc.1203773			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951576				2022-12-17	WOS:000088614300001
J	Zohn, IE; Klinger, M; Karp, X; Kirk, H; Symons, M; Chrzanowska-Wodnicka, M; Der, CJ; Kay, RJ				Zohn, IE; Klinger, M; Karp, X; Kirk, H; Symons, M; Chrzanowska-Wodnicka, M; Der, CJ; Kay, RJ			G2A is an oncogenic G protein-coupled receptor	ONCOGENE			English	Article						G protein-coupled receptor; Rho; G alpha(12); G alpha(13)	GTP-BINDING PROTEIN; SERUM RESPONSE FACTOR; NUCLEOTIDE EXCHANGE FACTORS; STRESS FIBER FORMATION; MUTANT ALPHA-SUBUNIT; RHO-FAMILY GTPASES; THROMBIN RECEPTOR; RAS TRANSFORMATION; NEOPLASTIC TRANSFORMATION; LYSOPHOSPHATIDIC ACID	G2A is a heptahelical cell surface protein that has recently been described as a potential tumor suppressor, based on its ability to counteract transformation of pre-B cells and fibroblasts by Bcr-Abl, an oncogenic tyrosine kinase, We have isolated cDNAs encoding G2A in the course of screening libraries for clones that cause oncogenic transformation of NIH3T3 fibroblasts, When expressed at high levels in NIH3T3 cells by retroviral transduction, G2A induced a full range of phenotypes characteristic of oncogenic transformation, including loss of contact inhibition, anchorage-independent survival and proliferation, reduced dependence on serum, and tumorigenicity in mice. When expressed by transfection, G2A greatly enhanced the ability of a weakly oncogenic form of Raf-1 to transform NIH3T3 cells. These results demonstrate that G2A is potently oncogenic both on its own and in cooperation with another oncogene, Expression of G2A in fibroblasts and endothelial cells resulted in changes in cell morphology and cytoskeleton structure that were equivalent to those induced by the G protein subunit G alpha(13), Transformation of NIH3T3 cells via G2A expression,vas completely suppressed by co-expression of LscRGS, a GTPase activating protein that suppresses signaling by G alpha(12) and G alpha(13). Hyperactivity of G alpha(12) or G alpha(13) has previously been shown to result in activation of Rho GTPases, G2A expression resulted in activation of Rho, and transformation via G2A was suppressed by a dominant negative form of RhoA, These results indicate that G2A may be directly coupled to G alpha(13), and that it is the activation of this Rho-activating Ga protein which is responsible for the ability of G2A to transform fibroblasts.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 4E6, Canada; Onyx Pharmaceut, Richmond, CA 94806 USA	British Columbia Cancer Agency; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of British Columbia	Kay, RJ (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.		Karp, Xantha/AAU-9847-2021	Der, Channing/0000-0002-7751-2747; Zohn, Irene/0000-0001-7688-682X; Karp, Xantha/0000-0001-6602-5583; Chrzanowska, Magdalena/0000-0003-4182-2126	NATIONAL CANCER INSTITUTE [R01CA063071, R01CA055008, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA55008, CA42978, CA63071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; GLUKHOVA MA, 1990, DEV BIOL, V141, P193, DOI 10.1016/0012-1606(90)90114-X; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Joyce DE, 1997, BLOOD, V90, P1893, DOI 10.1182/blood.V90.5.1893; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MARI B, 1994, J BIOL CHEM, V269, P8517; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Maulon L, 1998, BLOOD, V91, P4232, DOI 10.1182/blood.V91.11.4232.411k32_4232_4241; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Offermanns S, 1998, ONCOGENE, V17, P1375, DOI 10.1038/sj.onc.1202173; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PYSZNIAK AM, 1994, J IMMUNOL, V152, P5241; Reif K, 1998, IMMUNITY, V8, P395, DOI 10.1016/S1074-7613(00)80545-2; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.biochem.63.1.101; TORDAI A, 1993, J IMMUNOL, V150, P4876; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P5339, DOI 10.1073/pnas.85.14.5339; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	70	53	59	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3866	3877		10.1038/sj.onc.1203731	http://dx.doi.org/10.1038/sj.onc.1203731			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951580				2022-12-17	WOS:000088614300005
J	Nesbit, CE; Tersak, JM; Grove, LE; Drzal, A; Choi, H; Prochownik, EV				Nesbit, CE; Tersak, JM; Grove, LE; Drzal, A; Choi, H; Prochownik, EV			Genetic dissection of c-myc apoptotic pathways	ONCOGENE			English	Article						IL-3; cDNA microarrays; interferon-gamma; max	IN-VIVO; TRANSCRIPTIONAL ACTIVATION; ORNITHINE DECARBOXYLASE; TRANSACTIVATION DOMAIN; LUNG-CARCINOMA; DNA-BINDING; CELL-GROWTH; PROTEIN; MAX; EXPRESSION	All biological functions mediated by the c-myc oncoprotein require an intact transactivation domain (TAD). We compared TAD mutants for their ability to promote apoptosis of 32D myeloid cells in response to interleukin-3 (IL-3) deprivation and exposure to chemotherapeutic drugs, and to activate ornithine decarboxylase, an endogenous c-myc target. Different sub-regions of the TAD were required to mediate each function. cDNA microarrays were then used to identify multiple c-myc-regulated transcripts, some of which were also modulated by IL-3 or cytotoxic drugs, as well as by specific sub-regions of the TAD. Several of the c-myc-regulated transcripts had also been previously identified as targets for IFN-gamma. The functional consequences of their deregulation were manifested by a marked sensitivity of c-myc-overexpressing cells to IFN-gamma-mediated apoptosis, Our results establish that several well-characterized functions of c-myc are separable and correlate with the expression of a novel group of target genes, some of which also mediate the apoptotic action of IFN-gamma.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Program Mol Oncol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, 3705 5th ave, Pittsburgh, PA 15213 USA.				NATIONAL CANCER INSTITUTE [R01CA078259] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NCI NIH HHS [CA78259] Funding Source: Medline; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; Aoyama K, 1999, BLOOD, V93, P2586, DOI 10.1182/blood.V93.8.2586.408k23_2586_2594; ASKEW DS, 1991, ONCOGENE, V6, P1915; Barr LF, 1998, CANCER RES, V58, P5537; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bonfil RD, 1998, ONCOL RES, V10, P15; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Cook GA, 1999, EXP CELL RES, V251, P356, DOI 10.1006/excr.1999.4596; Dang CV, 1999, MOL CELL BIOL, V19, P1; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KIJIMOTOOCHIAI S, 1995, GLYCOBIOLOGY, V5, P443, DOI 10.1093/glycob/5.4.443; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Krause T, 1999, CLIN EXP METASTAS, V17, P183, DOI 10.1023/A:1006626500852; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 1998, BLOOD, V92, P1003; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; Okochi H, 1997, BRIT J DERMATOL, V137, P856, DOI 10.1046/j.1365-2133.1997.19782088.x; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Prochownik EV, 1998, GENE CHROMOSOME CANC, V22, P295, DOI 10.1002/(SICI)1098-2264(199808)22:4<295::AID-GCC5>3.3.CO;2-R; PULVERER BJ, 1994, ONCOGENE, V9, P59; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Rosenfeld ME, 1998, SEMIN REPROD ENDOCR, V16, P249, DOI 10.1055/s-2007-1016285; Sakamuro D, 1995, ONCOGENE, V11, P2411; SHUMAKER DK, 1994, EXP CELL RES, V214, P440, DOI 10.1006/excr.1994.1280; Smits P, 1999, GENE, V226, P253, DOI 10.1016/S0378-1119(98)00558-7; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Thompson A, 1996, J BIOL CHEM, V271, P22976, DOI 10.1074/jbc.271.38.22976; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P7227, DOI 10.1073/pnas.94.14.7227; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZHAO Q, 1998, GENE DEV, V12, P3803	63	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3200	3212		10.1038/sj.onc.1203636	http://dx.doi.org/10.1038/sj.onc.1203636			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918575				2022-12-17	WOS:000088019200009
J	Wery-Zennaro, S; Zugaza, JL; Letourneur, M; Bertoglio, J; Pierre, J				Wery-Zennaro, S; Zugaza, JL; Letourneur, M; Bertoglio, J; Pierre, J			IL-4 regulation of IL-6 production involves Rac/Cdc42-and p38 MAPK-dependent pathways in keratinocytes	ONCOGENE			English	Article						mRNA stabilization; cytokines; p38 MAP kinase; Rho family GTPase	ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA DEGRADATION; WISKOTT-ALDRICH-SYNDROME; UA-RICH SEQUENCES; NF-KAPPA-B; FACTOR-ALPHA; TRANSCRIPTIONAL ACTIVATION; INTERLEUKIN-6 PRODUCTION; SELECTIVE ACTIVATION	The stress-activated pathways leading to activation of p38 MAP kinase (p38 MAPK) and c-jun N-terminal kinases (JNK) have been shown to be activated by proinflammatory cytokines, physical and chemical stresses as well as a, variety of hematopoietic growth factors. One exception is interleukin (IL)-4, which does not activate this pathway in hematopoietic cell. We report here that in A431, a keratinocytic cell line, IL-4 activates Rac and Cdc42 and their downstream effector p21-activated kinase (PAK). Pac and Cdc42 appear to regulate a protein kinase cascade initiated at the level of PAK and leading to activation of p38 MAPK, since IL-4 stimulates tyrosine phosphorylation of p38 MAPK and increases its catalytic activity. As A431 cells are able to produce IL-6 in response to IL-4 stimulation, we assessed the involvement of p38 MAPK in IL-6 gene expression. A pyrimidazole compound, SB203580, a specific inhibitor of p38 MAPK, inhibits production and gene expression of IL-6. SB203580 reduced significantly the stability of IL-6 mRNA, Here we provide evidence that p38 MAPK is activated in response to IL-4 and is involved in IL-6 synthesis by stabilizing IL-6 mRNA.	Fac Pharm, INSERM, U461, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Pierre, J (corresponding author), Fac Pharm, INSERM, U461, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.		Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Bennett BL, 1997, J BIOL CHEM, V272, P10212; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Blanque R, 1997, DRUG EXP CLIN RES, V23, P63; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chomarat P, 1997, EUR CYTOKINE NETW, V8, P333; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DEROCQ JM, 1994, FEBS LETT, V343, P32, DOI 10.1016/0014-5793(94)80601-2; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Duncliffe KN, 1997, IMMUNITY, V6, P175, DOI 10.1016/S1074-7613(00)80424-0; ELIAS JA, 1990, J IMMUNOL, V145, P161; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; ERNST P, 1995, IMMUNITY, V2, P311, DOI 10.1016/1074-7613(95)90139-6; FEGHALI CA, 1992, CLIN IMMUNOL IMMUNOP, V63, P182, DOI 10.1016/0090-1229(92)90011-C; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Gollob JA, 1999, J IMMUNOL, V162, P4472; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HOWELLS G, 1991, EUR J IMMUNOL, V21, P97, DOI 10.1002/eji.1830210115; Jackson JR, 1998, J PHARMACOL EXP THER, V284, P687; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KRUEGER J, 1991, J CELL BIOCHEM, V45, P327, DOI 10.1002/jcb.240450404; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KUPPER TS, 1989, ANN NY ACAD SCI, V557, P454; KUPPER TS, 1990, J CLIN INVEST, V86, P1783, DOI 10.1172/JCI114907; LANG P, 1993, BIOCHEM BIOPH RES CO, V196, P1522, DOI 10.1006/bbrc.1993.2424; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; NEUNER P, 1991, J INVEST DERMATOL, V97, P27, DOI 10.1111/1523-1747.ep12477880; NG SB, 1994, J BIOL CHEM, V269, P19021; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; PRICHETT W, 1995, J INFLAMM, V45, P97; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rhodes K, 1998, J BIOL CHEM, V273, P26534, DOI 10.1074/jbc.273.41.26534; Ridley SH, 1997, J IMMUNOL, V158, P3165; Ruckdeschel K, 1997, J BIOL CHEM, V272, P15920, DOI 10.1074/jbc.272.25.15920; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Wery S, 1996, J BIOL CHEM, V271, P8529, DOI 10.1074/jbc.271.15.8529; Wery-Zennaro S, 1999, FEBS LETT, V464, P91, DOI 10.1016/S0014-5793(99)01680-4; YAMAMOTO T, 1995, J INVEST DERMATOL, V104, P784, DOI 10.1111/1523-1747.ep12606990; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	75	53	55	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1596	1604		10.1038/sj.onc.1203458	http://dx.doi.org/10.1038/sj.onc.1203458			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734320				2022-12-17	WOS:000086108100013
J	Delgado, MD; Vaque, JP; Arozarena, I; Lopez-Ilasaca, MA; Martinez, C; Crespo, P; Leon, J				Delgado, MD; Vaque, JP; Arozarena, I; Lopez-Ilasaca, MA; Martinez, C; Crespo, P; Leon, J			H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21(WAF1)-dependent mechanism	ONCOGENE			English	Article						Ras; p21(WAF1); myeloid leukemia cells	CYCLE ARREST; P53; EXPRESSION; PATHWAY; GENE; SENESCENCE; DIFFERENTIATION; P16(INK4A)/MTS1; P21(WAF1/CIP1); SUPPRESSION	Mutated ras genes are frequently found in human cancer, However, it has been shown that oncogenic ras inhibits growth of primary cells, through pathways involving p53 and the cell cycle inhibitors p16(INK4a) and p19(ARF). We have analysed the effect of the ectopic expression of the three mammalian ras genes on the proliferation of K562 leukemia cells, which are deficient for p53, p16(INK4a), p15(INK4b) and p19(ARF) genes. We have found that high expression levels of both wild-type and oncogenic H-, K- and N-ras inhibit the clonogenic growth of K562 cells, Induction of H-rasV12 expression in K562 transfectants retards growth and this effect is accompanied with an increase of p21(WAF1) mRNA and protein levels, Furthermore, p21(WAF1) promoter is activated potently by oncogenic ras and less pronounced by wild-type ras, This induction is p53-independent since a p21(WAF1) promoter devoid of the p53 responsive elements is still activated by Ras, Finally, inhibition of p21(WAF1) expression by an antisense construct partially overcomes the growth inhibitory action of oncogenic H-ras. Altogether, these results indicate that the antiproliferative effect of ras in myeloid leukemia cells is associated to the induction of p21(WAF1) expression and suggest the existence of p19(ARF) and p16(INK4a)-independent pathways for ras-mediated growth inhibition.	Univ Cantabria, Grp Biol Mol Canc, Dept Mol Biol, Fac Med, Santander 39011, Spain; Univ Cantabria, Unidad Asociada Ctr Invest Biol, CSIC, Santander 39011, Spain	Universidad de Cantabria; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria	Leon, J (corresponding author), Univ Cantabria, Grp Biol Mol Canc, Dept Mol Biol, Fac Med, Santander 39011, Spain.		Arozarena, Imanol/A-5981-2017; Vaqué, José P/H-8413-2015; Leon, Javier/K-4615-2014; Crespo, Piero/M-3273-2014; Delgado, M. Dolores/K-9056-2014	Arozarena, Imanol/0000-0001-6349-2442; Vaqué, José P/0000-0002-3913-2495; Crespo, Piero/0000-0003-2825-7783; Leon, Javier/0000-0001-5803-0112; Delgado, M. Dolores/0000-0003-4682-4040				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Beaupre DM, 1999, J CLIN ONCOL, V17, P1071, DOI 10.1200/JCO.1999.17.3.1071; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DELGADO MD, 1992, CANCER RES, V52, P5979; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; HAWLEY RG, 1995, ONCOGENE, V11, P1113; Juan G, 1998, LEUKEMIA, V12, P1241, DOI 10.1038/sj.leu.2401100; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; Leon J., 1993, RAS SUPERFAMILY GTPA, P3; LERGA A, 1995, BIOCHEM BIOPH RES CO, V215, P889, DOI 10.1006/bbrc.1995.2547; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; Maher J, 1996, LEUKEMIA, V10, P83; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; OTSUKI T, 1995, CANCER RES, V55, P1436; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PIERCE JH, 1985, MOL CELL BIOL, V5, P667, DOI 10.1128/MCB.5.4.667; Quincoces AF, 1997, FEBS LETT, V416, P317, DOI 10.1016/S0014-5793(97)01229-5; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; TODD AV, 1991, LEUKEMIA LYMPHOMA, V3, P293, DOI 10.3109/10428199109107917; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; WATZINGER F, 1994, CANCER RES, V54, P3934; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	40	53	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2000	19	6					783	790		10.1038/sj.onc.1203384	http://dx.doi.org/10.1038/sj.onc.1203384			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698496				2022-12-17	WOS:000085192100008
J	Horstmann, S; Ferrari, S; Klempnauer, KH				Horstmann, S; Ferrari, S; Klempnauer, KH			Regulation of B-Myb activity by cyclin D1	ONCOGENE			English	Article						B-Myb; cell cycle regulation; cyclin D1; phosphorylation; trans-activation	CELL-CYCLE; A-MYB; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; DEPENDENT-KINASE; ESTROGEN-RECEPTOR; GENE ACTIVATION; DNA-BINDING; C-MYB; EXPRESSION	Evidence obtained during recent years suggests that B-Myb, a highly conserved member of the Myb transcription factor family, plays a key role in cell proliferation. We have shown previously that the activity of B-Myb is stimulated by cyclin A/Cdk2-dependent phosphorylation of the carboxyl-terminus of B-Myb, We have now investigated in more detail the effect of other cyclins on B-Myb, Here, we show that cyclin D1, in contrast to cyclin A, strongly inhibits the activity of B-Myb. This inhibitory effect does not involve increased phosphorylation of B-Myb but seems to rely on the formation of a specific complex of B-Myb and cyclin D1, Our work identifies B-Myb as an interacting partner for cyclin D1 and suggest that the activity of B-Myb during the cell cycle is controlled by the antagonistic effects of cyclin D1 and A. The results presented here suggest a more general role of cyclin D1 as regulator of transcription in addition to the known effect on RE phosphorylation.	Univ Munster, Inst Biochem, D-48149 Munster, Germany; Inst Expt Canc Res, Tumor Biol Ctr, D-79011 Freiburg, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.		Buchinger, Sebastian/M-3003-2013; Ferrari, Stefano/I-7357-2016	Buchinger, Sebastian/0000-0003-4859-8972; Ferrari, Stefano/0000-0002-6607-215X				ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Kamano H, 1995, ONCOGENE, V11, P2575; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MASSAGUE J, 1995, CURR OPIN CELL BIOL, V7, P769, DOI 10.1016/0955-0674(95)80059-X; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Robinson C, 1996, ONCOGENE, V12, P1855; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sitzmann J, 1996, ONCOGENE, V12, P1889; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	49	53	53	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					298	306		10.1038/sj.onc.1203302	http://dx.doi.org/10.1038/sj.onc.1203302			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645009				2022-12-17	WOS:000084844400016
J	Qiu, SG; Krishnan, S; El-Guendy, N; Rangnekar, VM				Qiu, SG; Krishnan, S; El-Guendy, N; Rangnekar, VM			Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation	ONCOGENE			English	Article						Ras; Par-4; ERK; transformation	PROTEIN-KINASE-C; MAMMALIAN-CELL; GROWTH ARREST; GENE; PHOSPHORYLATION; APOPTOSIS; ACTIVATION; SURVIVAL; INHIBITION; EXPRESSION	Oncogenic variants of the cellular Ras protein are often associated with different types of human cancers. However, the mechanisms by which oncogenic Ras induces transformation are not fully established. Expression of the transcriptional repressor Par-4 was downregulated by oncogenic Ras via the Raf-MEK-ERK pathway. Restoration of Par-4 levels by abrogation of the Raf-MEK-ERK pathway with the MEK-inhibitor PD98059 or by ectopic Par-4, that acted to inhibit ERK expression and activation, was sufficient to suppress oncogenic Ras-induced transformation. These findings identify Par-4 as a novel target that has to be downmodulated by oncogenic Ras for successful transformation.	Univ Kentucky, Dept Surg, Lexington, KY 40536 USA; Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Rangnekar, VM (corresponding author), Univ Kentucky, Dept Surg, Combs Res Bldg,Room 303,800 Rose St, Lexington, KY 40536 USA.			El-Guendy, Nadia/0000-0002-0770-3740	NCI NIH HHS [R01 CA60872] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060872] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; BOS JL, 1989, CANCER RES, V49, P4682; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; Cook J, 1999, ONCOGENE, V18, P1205, DOI 10.1038/sj.onc.1202416; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GALANG CK, 1994, ONCOGENE, V9, P2913; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; KISS Z, 1995, FEBS LETT, V357, P279, DOI 10.1016/0014-5793(94)01371-7; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LIN XY, 1995, MOL CELL BIOL, V15, P2754; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; Muthukkumar S, 1996, J BIOL CHEM, V271, P5733, DOI 10.1074/jbc.271.10.5733; PARK M, 1998, GENETIC BASIS HUMAN, P205; Qiu GF, 1999, ONCOGENE, V18, P623, DOI 10.1038/sj.onc.1202344; RANGNEKAR VV, 1992, J BIOL CHEM, V267, P6240; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	35	53	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7115	7123		10.1038/sj.onc.1203199	http://dx.doi.org/10.1038/sj.onc.1203199			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597313				2022-12-17	WOS:000083901900019
J	Okano, H; Saito, Y; Miyazawa, T; Shinbo, T; Chou, DZ; Kosugi, S; Takahashi, Y; Odani, S; Niwa, O; Kominami, R				Okano, H; Saito, Y; Miyazawa, T; Shinbo, T; Chou, DZ; Kosugi, S; Takahashi, Y; Odani, S; Niwa, O; Kominami, R			Homozygous deletions and point mutations of the Ikaros gene in gamma-ray-induced mouse thymic lymphomas	ONCOGENE			English	Article						tumor suppressor gene; Ikaros; allelic loss (or LOH) analysis; somatic mutation; gamma-ray-induced thymic lymphoma	TUMOR-SUPPRESSOR GENES; DNA-BINDING PROTEINS; CENTROMERIC HETEROCHROMATIN; TRANSCRIPTION FACTOR; P53; FAMILY; CANCER; CELLS; MICE; CHROMOSOME-16	Our previous genome-wide analysis of allelic loss for thymic lymphomas that were induced by gamma-irradiation in F-1 hybrid mice between BALB/c and MSM strains suggested the centromeric region on chromosome 11 as a site harboring a tumor suppressor gene. Interestingly, to this region the mouse Ikaros gene was mapped which was postulated to participate in oncogenic process from the study of Ikaros knockout mice. Here we show fine allelic loss mapping in the vicinity of Ikaros in 191 lymphomas, indicating that the critical region of allelic loss was centered at the Ikaros locus. PCR analysis revealed that nine lymphomas failed to give PCR-amplification for either of two exon primer pairs, indicative of homozygous deletion, Six and five mutations were detected in the N-terminal zinc finger domain and the activation domain of Ikaros, respectively, and six of the eleven were frameshift or nonsense mutations that resulted in truncation of Ikaros protein. The results strongly suggest a direct role for Ikaros in development of mouse thymic lymphomas, This provides the experimental basis for further analysis of Ikaros mutations in human cancer.	Niigata Univ, Sch Med, Dept Biochem, Niigata 9518122, Japan; Niigata Univ, Grad Sch Sci & Technol, Div Life Sci, Niigata 9502181, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyou Ku, Yoshida Konoecho 6068315, Japan	Niigata University; Niigata University; Kyoto University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem, Asahimachi 1-757, Niigata 9518122, Japan.		Kosugi, S./K-5142-2019	Kosugi, Shin-ichi/0000-0002-6602-7412				BONHOMME F, 1989, GENETIC VARIANTS STR, P658; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Ghebranious N, 1998, ONCOGENE, V17, P3385, DOI 10.1038/sj.onc.1202573; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HALEVY O, 1991, ONCOGENE, V6, P1593; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAYASHI T, 1993, GENOMICS, V17, P490, DOI 10.1006/geno.1993.1352; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; KEMP CJ, 1993, CANCER RES, V53, P6022; Klug CA, 1998, P NATL ACAD SCI USA, V95, P657, DOI 10.1073/pnas.95.2.657; KNUDSON AG, 1985, CANCER RES, V45, P1437; Koide N, 1999, MOL CARCINOGEN, V24, P57, DOI 10.1002/(SICI)1098-2744(199901)24:1<57::AID-MC8>3.0.CO;2-5; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Little JB, 1997, RADIAT RES, V148, P299, DOI 10.2307/3579514; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Molnar A, 1996, J IMMUNOL, V156, P585; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Sato S, 1998, ONCOGENE, V17, P105, DOI 10.1038/sj.onc.1201913; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shinbo T, 1999, ONCOGENE, V18, P4131, DOI 10.1038/sj.onc.1202767; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; THACKER J, 1992, ADV RADIAT BIOL, V16, P77; TSUKADA T, 1993, ONCOGENE, V8, P3313; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1	40	53	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6677	6683		10.1038/sj.onc.1203100	http://dx.doi.org/10.1038/sj.onc.1203100			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597273				2022-12-17	WOS:000083792000007
J	Palecek, E; Brazdova, M; Cernocka, H; Vlk, D; Brazda, V; Vojtesek, B				Palecek, E; Brazdova, M; Cernocka, H; Vlk, D; Brazda, V; Vojtesek, B			Effect of transition metals on binding of p53 protein to supercoiled DNA and to consensus sequence in DNA fragments	ONCOGENE			English	Article						p53; DNA-p53 interaction; sc DNA; divalent cation; gel electrophoresis	TUMOR-SUPPRESSOR PROTEIN; ASTERISK-H-DNA; WILD-TYPE; STRUCTURAL ASPECTS; CELL-CYCLE; ZINC; DOMAIN; IONS; METALLOTHIONEIN; CONFORMATION	Recently we have shown that mild-type human p53 protein binds preferentially to supercoiled (sc) DNA in vitro in both the presence and absence of the p53 consensus sequence (p53CON). This binding produces a ladder of retarded bands on an agarose gel. Using immunoblotting with the antibody DO-1, me show that the bands obtained correspond to ethidium-stained DNA, suggesting that each band of the ladder contains a DNA-p53 complex. The intensity and the number of these bands are decreased by physiological concentrations of zinc ions. At higher zinc concentrations, binding of p53 to scDNA is completely inhibited. The binding of additional zinc ions to p53 appears much weaker than the binding of the intrinsic zinc ion in the DNA binding site of the core domain. In contrast to previously published data suggesting that 100 mu M zinc ions do not influence p53 binding to p53CON in a DNA oligonucleotide, we show that 5-20 mu M zinc efficiently inhibits binding of p53 to p53CON in DNA fragments. We also show that relatively low concentrations of dithiothreitol but not of 2-mercaptoethanol decrease the concentration of free zinc ions, thereby preventing their inhibitory effect on binding of p53 to DNA. Nickel and cobalt ions inhibit binding of p53 to scDNA and to its consensus sequence in linear DNA fragments less efficiently than zinc; cobalt ions are least efficient, requiring > 100 mu M Co2+ for full inhibition of p53 binding. Modulation of binding of p53 to DNA by physiological concentrations of zinc might represent a novel pathway that regulates p53 activity in vivo.	Acad Sci Czech Republ, Inst Biophys, CS-61265 Brno, Czech Republic; Masaryk Mem Canc Inst, Brno 65653, Czech Republic	Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences; Masaryk Memorial Cancer Institute	Palecek, E (corresponding author), Acad Sci Czech Republ, Inst Biophys, Kralovopolska 135, CS-61265 Brno, Czech Republic.		Brazdova, Marie/H-1924-2014; Václav, Brázda/F-9582-2011; Vlk, Daniel/A-1413-2014; Brazda, Vaclav/ABH-9460-2020; Palecek, Emil/C-1075-2013; Černocká, Hana/H-1926-2014	Václav, Brázda/0000-0003-2837-4226; Brazda, Vaclav/0000-0003-2837-4226; Palecek, Emil/0000-0003-2561-8336; Cernocka, Hana/0000-0002-1673-1305				Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BELTRAN R, 1993, J MOL BIOL, V230, P966, DOI 10.1006/jmbi.1993.1213; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BERNUES J, 1989, EMBO J, V8, P2087, DOI 10.1002/j.1460-2075.1989.tb03617.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; COFFER AI, 1994, BBA-PROTEIN STRUCT M, V1209, P279, DOI 10.1016/0167-4838(94)90197-X; CORNELL NW, 1972, ANAL BIOCHEM, V47, P203, DOI 10.1016/0003-2697(72)90293-X; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; EBADI M, 1994, GEN PHARMACOL-VASC S, V25, P1297, DOI 10.1016/0306-3623(94)90152-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELLEDGE RM, 1995, BIOESSAYS, V17, P923, DOI 10.1002/bies.950171105; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1995, ONCOGENE, V10, P27; Han WH, 1997, P NATL ACAD SCI USA, V94, P10565, DOI 10.1073/pnas.94.20.10565; Han WH, 1997, NATURE, V386, P563, DOI 10.1038/386563a0; HARLOW E, 1988, ANTIBODIES LABORATOR, P497; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Klevickis C, 1996, MET IONS BIOL SYST, V32, P1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAUNDON CH, 1987, BIOCHEMISTRY-US, V26, P3759, DOI 10.1021/bi00387a003; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTINEZBALBAS A, 1993, NUCLEIC ACIDS RES, V21, P2557, DOI 10.1093/nar/21.11.2557; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; NAGEL WW, 1995, P NATL ACAD SCI USA, V92, P579, DOI 10.1073/pnas.92.2.579; ORTIZLOMBARDIA M, 1995, BIOCHEMISTRY-US, V34, P14408, DOI 10.1021/bi00044a018; Palecek E, 1997, ELECTROANAL, V9, P990, DOI 10.1002/elan.1140091305; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; Palecek E, 1997, ONCOGENE, V15, P2201, DOI 10.1038/sj.onc.1201398; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Sabat M, 1996, MET IONS BIOL SYST, V33, P143; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Tomschik M, 1998, ELECTROANAL, V10, P403, DOI 10.1002/(SICI)1521-4109(199805)10:6<403::AID-ELAN403>3.3.CO;2-U; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; VLK D, 1997, THESIS ACAD SCI CZEC; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791	48	53	54	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	1999	18	24					3617	3625		10.1038/sj.onc.1202710	http://dx.doi.org/10.1038/sj.onc.1202710			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380883				2022-12-17	WOS:000080891700007
J	Yoshikawa, H; Nagashima, M; Khan, MA; McMenamin, MG; Hagiwara, K; Harris, CC				Yoshikawa, H; Nagashima, M; Khan, MA; McMenamin, MG; Hagiwara, K; Harris, CC			Mutational analysis of p73 and p53 in human cancer cell lines	ONCOGENE			English	Article						p73; mutation; deletion	TUMOR-SUPPRESSOR GENE; RAS MUTATIONS; LUNG-CANCER; COLORECTAL-CANCER; CARCINOMAS; FREQUENT; PROTEIN; EXPRESSION; INHIBITOR; KINASES	p73 is a candidate tumor suppressor gene with substantial DNA and protein homology to the p53 tumor suppressor gene. We have investigated two hypotheses: (a) p73 is mutated in diverse types of human cancer, and (b) p73 is functionally redundant with p53 in carcinogenesis so that mutations would be exclusive in these two genes. The entire coding region and intronic splice junctions of p73 were examined in 54 cancer cell lines. Three lung cancer cell lines contained mutations that affected the amino acid sequence. One amino acid substitution was in a region with homology to the specific DNA binding region of p53 and two microdeletions were outside the region of homology. Two of the cell lines with p73 mutations also carried p53 mutations. Although our results are inconsistent with the two hypotheses tested, p73 mutations may contribute infrequently to the molecular pathogenesis of human lung cancer.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bldg 37,Room 2CD5, Bethesda, MD 20892 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC005794] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BODNER SM, 1992, ONCOGENE, V7, P743; CAAMANO J, 1993, AM J PATHOL, V142, P1131; EL DW, 1993, CELL, V75, P817; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Greenblatt MS, 1996, CANCER RES, V56, P2130; Hagiwara K, 1996, NUCLEIC ACIDS RES, V24, P2460, DOI 10.1093/nar/24.12.2460; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTRINAKIS WV, 1995, ONCOGENE, V11, P647; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; LEHMAN TA, 1991, CANCER RES, V51, P4090; Mai M, 1998, CANCER RES, V58, P2347; METCALF RA, 1992, CANCER RES, V52, P2610; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MURAKAMI Y, 1991, CANCER RES, V51, P3356; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nomoto S, 1998, CANCER RES, V58, P1380; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PEINADO MA, 1993, INT J ONCOL, V2, P123; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RUGGERI B, 1992, ONCOGENE, V7, P1503; RUSSELL SJ, 1995, CANCER, V75, P1339, DOI 10.1002/1097-0142(19950315)75:6<1339::AID-CNCR2820750616>3.0.CO;2-F; SOMERS KD, 1992, CANCER RES, V52, P5997; Takahashi H, 1998, CANCER RES, V58, P2076; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	28	53	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3415	3421		10.1038/sj.onc.1202677	http://dx.doi.org/10.1038/sj.onc.1202677			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362363				2022-12-17	WOS:000080589300013
J	Care, A; Valtieri, M; Mattia, G; Meccia, E; Masella, B; Luchetti, L; Felicetti, F; Colombo, MP; Peschle, C				Care, A; Valtieri, M; Mattia, G; Meccia, E; Masella, B; Luchetti, L; Felicetti, F; Colombo, MP; Peschle, C			Enforced expression of HOXB7 promotes hematopoietic stem cell proliferation and myeloid-restricted progenitor differentiation	ONCOGENE			English	Article						homeobox genes; hematopoietic progenitors; retroviral vector expression	NATURAL-KILLER LYMPHOCYTES; FIBROBLAST GROWTH-FACTOR; HUMAN PERIPHERAL-BLOOD; HOMEOBOX GENES; FUNCTIONAL-ROLE; LEUKEMIA; OVEREXPRESSION; EXPANSION	Hematopoietic progenitor/stem cells (HPCs/HSCs) purified from human adult peripheral blood (PB) were triggered into cycling, retrovirally transduced with HOXB7 and then functionally assayed in vitro. HPCs were assayed in multi- and unilineage differentiation cultures in either liquid phase or semisolid medium, primitive HPCs in the high proliferative potential colony-forming cell (HPP-CFC) evaluation system and putative HSCs in Dexter type long-term culture (LTC) as LTC initiating cells (LTC-ICs), Control experiments ensured that the exogenous HOXB7 gene was constantly expressed, while the endogenous one was barely or not transcribed. Enforced expression of the gene markedly modulated the proliferation/differentiation program of the entire HSC/HPC population, Enforced HOXB7 expression exerted a potent stimulatory effect on the proliferation of the primitive HPC and putative HSC subsets, assayed as HPP-CFCs and LTC-ICs respectively. While not modifying the total number of HPCs, exogenous HOXB7 induced an increase of the number of granulo-monocytic (GM) HPCs [colony-forming unit GM (CFU-GM) CFU-GM, CFU-C and CFU-M, as evaluated by clonogenic assays] and markedly amplified the progeny of both CFU-G and CFU-M, which showed a sustained proliferation through at least 1-2 months (as evaluated in liquid suspension culture). The prolonged proliferative stimulus induced by HOXB7 transfer into LTC, primitive and GM oriented HPC culture was characterized by persistent proliferation of a discrete population of blast cells and a large pool of differentiated myeloid precursors. Altogether, these results suggest the hypothesis that the proliferative stimulus exerted by exogenous HOXB7 in primitive and GM-oriented HPCs may represent a preleukemic immortalization step. Consistent with the functional role of HOXB7 in the initial ontogenetic phase, these studies indicate that ectopic HOXB7 expression in early HPCs and HSCs from adult PB stimulates their self renewal, sustained proliferation and myeloid differentiation.	Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy; Ist Nazl Tumori, I-20133 Milan, Italy; T Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA USA	Istituto Superiore di Sanita (ISS); Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University	Care, A (corresponding author), Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy.		Felicetti, Federica/N-7077-2017; CARE', Alessandra/H-5090-2016; felli, nadia/G-2088-2012; Mattia, Gianfranco/K-5194-2016; Colombo, Mario P./V-7166-2017; valtieri, mauro/H-1044-2016	Felicetti, Federica/0000-0003-4628-0696; CARE', Alessandra/0000-0003-4106-3342; felli, nadia/0000-0001-6763-3361; Mattia, Gianfranco/0000-0001-7047-6360; Colombo, Mario P./0000-0003-0042-7955; valtieri, mauro/0000-0002-9139-6754; meccia, ettore/0000-0003-2076-5951				BLATT C, 1992, CELL GROWTH DIFFER, V3, P671; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Care A, 1998, ONCOGENE, V16, P3285, DOI 10.1038/sj.onc.1201875; CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; Care A, 1996, MOL CELL BIOL, V16, P4842; DEGUCHI Y, 1991, BLOOD, V78, P445; DESCHAMPS J, 1992, Critical Reviews in Oncogenesis, V3, P117; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LICHTY BD, 1995, LEUKEMIA LYMPHOMA, V16, P209, DOI 10.3109/10428199509049759; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAVILIO F, 1993, EUR J BIOCHEM, V212, P273, DOI 10.1111/j.1432-1033.1993.tb17660.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PETRINI M, 1992, BLOOD, V80, P185; Quaranta MT, 1996, J IMMUNOL, V157, P2462; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; Shimamoto T, 1998, INT J HEMATOL, V67, P339; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Tocci A, 1996, BLOOD, V88, P2878, DOI 10.1182/blood.V88.8.2878.bloodjournal8882878; UDOMSAKDI C, 1992, BLOOD, V80, P2513; VALTIERI M, 1994, CANCER RES, V54, P4398; Valtieri M, 1998, CANCER RES, V58, P562; Ziegler B, 1998, Stem Cells, V16 Suppl 1, P51	32	53	56	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1993	2001		10.1038/sj.onc.1202498	http://dx.doi.org/10.1038/sj.onc.1202498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208421				2022-12-17	WOS:000079191300009
J	Habelhah, H; Okada, F; Kobayashi, M; Nakai, K; Choi, SK; Hamada, J; Moriuchi, T; Kaya, M; Yoshida, K; Fujinaga, K; Hosokawa, M				Habelhah, H; Okada, F; Kobayashi, M; Nakai, K; Choi, SK; Hamada, J; Moriuchi, T; Kaya, M; Yoshida, K; Fujinaga, K; Hosokawa, M			Increased E1AF expression in mouse fibrosarcoma promotes metastasis through induction of MT1-MMP expression	ONCOGENE			English	Article						mouse-fibrosarcoma; metastasis; MMP-2; MT1-MMP; E1AF	METALLOPROTEINASE GENE-EXPRESSION; TRANSFORMING GROWTH FACTOR-BETA-1; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; TRANSCRIPTION FACTORS; IV COLLAGENASE; GELATINASE-A; TUMOR-CELLS; 72-KDA GELATINASE; HUMAN FIBROBLASTS	In this study, we investigated the role of E1AF, a member of ets family transcription factor, in the acquisition of metastatic capacity by non-metastatic mouse fibrosarcoma cell clone, QR-32, The QR-32 cell clone grows progressively after co-implantation with gelatin sponge in syngeneic C57BL/6 mice. The cell lines (QRsP) established from arising tumors after the co-implantation exhibited enhanced tumorigenicity and pulmonary metastasis in vivo as compared with parent QR-32 cells. The enhanced pulmonary metastasis of QRsP cells was correlated well with augmented production of matrix metalloproteinase-2 (MMP-2) and increased expression of membrane-type 1-IMMP (MT1-MMP). The QRsP cells also acquired higher chemokinetic activities to fibronectin and higher invasive activities through a reconstituted basement membrane. Furthermore we observed the elevated mRNA expression of E1AF in QRsP cells compared to parent QR-32 cells. Therefore, we transfected QR-32 cells with E1AF cDNA. Overexpression of E1AF in the QR-32 cells resulted in the induction of MT1-MMP expression and converting an exogenously added precursor MMP-2 into active form. E1AF transfectants exhibited more motile and invasive activities, and moderately increased pulmonary metastatic activities than parental QR-32 cells in vivo, although their metastatic activities were lower than those of QRsP cells. These findings suggest that the increased expression of E1AF in fibrosarcoma contributes to invasive phenotypes including MT1-MIMP expression and enhanced cell migration, but not sufficient for exhibiting highly metastatic activity in vivo.	Hokkaido Univ, Sch Med, Inst Canc, Pathol Lab,Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Sch Med, Inst Canc, Div Cell Biol,Kita Ku, Sapporo, Hokkaido 0608638, Japan; Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sch Med,Chuo Ku, Sapporo, Hokkaido 0600061, Japan	Hokkaido University; Hokkaido University; Sapporo Medical University	Hosokawa, M (corresponding author), Hokkaido Univ, Sch Med, Inst Canc, Pathol Lab,Kita Ku, Sapporo, Hokkaido 0608638, Japan.		Hamada, Jun-ichi/D-7452-2012	Okada, Futoshi/0000-0003-4733-1037; Habelhah, Hasem/0000-0003-4097-1007				ALBINI A, 1987, CANCER RES, V47, P3239; ASCHER NL, 1979, TRANSPLANTATION, V27, P254, DOI 10.1097/00007890-197904000-00010; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chen JH, 1996, ONCOGENE, V13, P1667; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Imai K, 1997, AM J PATHOL, V151, P245; Imai K, 1996, CANCER RES, V56, P2707; Kadono Y, 1998, CANCER RES, V58, P2240; Kaya M, 1996, ONCOGENE, V12, P221; KOHN EC, 1994, J BIOL CHEM, V269, P21505; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONSKY WL, 1993, CANCER RES, V53, P3159; OHagan RC, 1996, ONCOGENE, V13, P1323; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; OKADA F, 1992, BRIT J CANCER, V66, P635, DOI 10.1038/bjc.1992.329; OVERALL CM, 1994, ANN NY ACAD SCI, V732, P51, DOI 10.1111/j.1749-6632.1994.tb24724.x; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; SALO T, 1991, J BIOL CHEM, V266, P11436; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Shindoh M, 1996, AM J PATHOL, V148, P693; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; Taguchi K, 1997, JPN J CANCER RES, V88, P394, DOI 10.1111/j.1349-7006.1997.tb00395.x; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Turck J, 1996, J BIOL CHEM, V271, P15074, DOI 10.1074/jbc.271.25.15074; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEITZMAN SA, 1990, BLOOD, V76, P655	40	53	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1771	1776		10.1038/sj.onc.1202465	http://dx.doi.org/10.1038/sj.onc.1202465			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208438				2022-12-17	WOS:000079025000012
J	Kanoe, H; Nakayama, T; Hosaka, T; Murakami, H; Yamamoto, H; Nakashima, Y; Tsuboyama, T; Nakamura, T; Ron, D; Sasaki, MS; Toguchida, J				Kanoe, H; Nakayama, T; Hosaka, T; Murakami, H; Yamamoto, H; Nakashima, Y; Tsuboyama, T; Nakamura, T; Ron, D; Sasaki, MS; Toguchida, J			Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocation	ONCOGENE			English	Article						TLS; CHOP; liposarcoma; topoisomerase II; Translin	ROUND-CELL LIPOSARCOMA; ACUTE MYELOID-LEUKEMIA; RNA-BINDING PROTEIN; MYXOID LIPOSARCOMA; CHROMOSOMAL TRANSLOCATIONS; DNA-SEQUENCE; BCR GENE; ONCOGENIC TRANSFORMATION; CLUSTER REGION; RECOMBINATION	Fusion of TLS/FUS and CHOP gene by reciprocal translocation t(12;16)(q32;q16) is a common genetic event found in myxoid and round-cell liposarcomas, Characterization of this genetic event was performed by three methods, Southern blot, RT-PCR, and genomic long-distance PCR in nine myxoid and three round-cell liposarcomas. All but one tumors showed genetic alternations indicating the fusion of TLS/FUS and CHOP gene, Two novel types of fusion transcripts were found, of which one lacked exon 2 sequence of CHOP gene, and the other lacked 3' half of exon 5 of TLS gene, The latter case was caused by a cryptic splicing site which,vas created by the genomic fusion, Detailed analyses genomic fusion points revealed several sequence characteristics surrounding the fusion points, Homology analyses of breakpoint sequences with known sequence motifs possibly involve in the process of translocation uncovered Translin binding sequences at both of TLS/ FUS and CHOP breakpoints in two cases. Translocations were always associated with other genetic alterations, such as deletions, duplications, or insertions. Short direct repeats were almost always found at both ends of deleted or duplicated fragments some of which had apparently been created by joining of sequences that flank the rearrangement. Finally, consensus topoisomerase II cleavage sites were found at breakpoints in all cases analysed, suggesting a role of this enzyme in creating staggered ends at the breakpoint, These data suggested that sequence characteristics may play an important role to recruit several factors such as Translin and topoisomerase II in the process of chromosomal translation in liposarcomas.	Kyoto Univ, Dept Orthopaed Surg, Kyoto 606, Japan; Kyoto Univ, Dept Pathol, Kyoto 606, Japan; Kyoto Univ, Ctr Radiat Biol, Kyoto 606, Japan; Kyoto Univ, Inst Frontier Med Sci, Kyoto 606, Japan; NYU Med Ctr, Skirball Inst Biomol Med, New York, NY 10016 USA	Kyoto University; Kyoto University; Kyoto University; Kyoto University; New York University	Toguchida, J (corresponding author), Kyoto Univ, Dept Orthopaed Surg, Kyoto 606, Japan.			Ron, David/0000-0002-3014-5636	NATIONAL CANCER INSTITUTE [R01CA060945] Funding Source: NIH RePORTER; NCI NIH HHS [CA60945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI K, 1994, ONCOGENE, V9, P1109; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; Chalk JG, 1997, ONCOGENE, V15, P1199, DOI 10.1038/sj.onc.1201285; CHEN SJ, 1989, ONCOGENE, V4, P195; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CROWTHER PJ, 1991, NUCLEIC ACIDS RES, V19, P2395, DOI 10.1093/nar/19.9.2395; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; KASAI M, 1994, INT IMMUNOL, V6, P1017, DOI 10.1093/intimm/6.7.1017; KNIGHT JC, 1995, CANCER RES, V55, P24; Kovalchuk AL, 1997, ONCOGENE, V15, P2369, DOI 10.1038/sj.onc.1201409; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; KURODA M, 1995, AM J PATHOL, V147, P1221; Kuroda M, 1997, AM J PATHOL, V151, P735; NILBERT M, 1994, CANCER GENET CYTOGEN, V72, P155, DOI 10.1016/0165-4608(94)90133-3; Panagopoulos I, 1996, GENE CHROMOSOME CANC, V17, P102, DOI 10.1002/(SICI)1098-2264(199610)17:2<102::AID-GCC5>3.0.CO;2-9; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; Panagopoulos I, 1997, ONCOGENE, V15, P1357, DOI 10.1038/sj.onc.1201281; Panagopoulos I, 1996, ONCOGENE, V12, P489; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; Sambrook J, 1989, MOL CLONING LAB MANU; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SOWERBY SJ, 1993, ONCOGENE, V8, P1679; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; SPTIZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; ZHANG JG, 1995, BRIT J HAEMATOL, V90, P138, DOI 10.1111/j.1365-2141.1995.tb03392.x; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	40	53	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					721	729		10.1038/sj.onc.1202364	http://dx.doi.org/10.1038/sj.onc.1202364			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989822	Green Submitted			2022-12-17	WOS:000078394400017
J	Konishi, H; Takahashi, T; Kozaki, K; Yatabe, Y; Mitsudomi, T; Fujii, Y; Sugiura, T; Matsuda, H; Takahashi, T; Takahashi, T				Konishi, H; Takahashi, T; Kozaki, K; Yatabe, Y; Mitsudomi, T; Fujii, Y; Sugiura, T; Matsuda, H; Takahashi, T; Takahashi, T			Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers	ONCOGENE			English	Article						17p13.3; LOH; p53; tumor suppressor gene; lung cancer	DINUCLEOTIDE REPEAT POLYMORPHISM; SQUAMOUS-CELL CARCINOMA; SHORT ARM; CHROMOSOME 17P13.3; BREAST-CANCER; HUMAN GENOME; ALLELE LOSS; MUTATIONS; DISTINCT; 17P	The short arm of chromosome 17 is one of the most frequently affected chromosomal regions in lung cancers, while there is solid evidence that the p53 gene at 17p13.1 is a target for frequent 17p deletions. In the present study, we re-evaluated 17p deletions in lung cancers by conducting a detailed analysis of the minimum deleted region(s) on 17p with reference to the p53 gene status in each 100 primary lung cancer cases. In addition to the p53 locus at 17p13.1, the presence of an independent, commonly deleted region(s) at 17p13.3 was identified, Furthermore, loss of heterozygosity (LOH) at 17p13.3 was shown to be even more frequent than that at 17p13.1 and it appeared to occur in the absence of p53 mutation and/or 17p13.1 deletion. These results suggest that in addition to the p53 gene at 17p13.1, an as yet unidentified tumor suppressor gene(s) residing at 17p13.3 might play a role in lung carcinogenesis possibly in an earlier phase than the p53 gene. This would warrant future studies to identify the putative tumor suppressor gene at 17p13.3 in order to gain a better understanding of the molecular pathogenesis of this fatal disease.	Aichi Canc Ctr, Res Inst, Ultrastruct Res Lab, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Immunol Lab, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Clin Labs, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Internal Med, Chikusa Ku, Nagoya, Aichi 464, Japan; Osaka Univ, Sch Med, Dept Surg 1, Suita, Osaka 565, Japan; Gifu Univ, Sch Med, Dept Surg 2, Gifu 500, Japan; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 467, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Osaka University; Gifu University; Nagoya City University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Ultrastruct Res Lab, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 464, Japan.		Kozaki, Ken-ichi/M-6281-2014; Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014	Kozaki, Ken-ichi/0000-0003-3286-819X; Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X; Konishi, Hiroyuki/0000-0003-1131-4905; Mitsudomi, Tetsuya/0000-0001-9860-8505				BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; BIEGEL JA, 1992, CANCER RES, V52, P3391; CARROZZO R, 1993, HUM MOL GENET, V2, P615, DOI 10.1093/hmg/2.5.615; CHIBA I, 1990, ONCOGENE, V5, P1603; Chung GTY, 1995, ONCOGENE, V11, P2591; COGEN PH, 1992, AM J HUM GENET, V50, P584; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CORNELIS RS, 1994, CANCER RES, V54, P4200; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FUJIMORI M, 1991, CANCER RES, V51, P89; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GERKEN SC, 1995, AM J HUM GENET, V56, P484; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Haataja L, 1997, CANCER RES, V57, P32; HIBI K, 1992, ONCOGENE, V7, P445; HORIO Y, 1994, ONCOGENE, V9, P1231; HORIO Y, 1993, CANCER RES, V53, P1; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kondo M, 1996, ONCOGENE, V12, P1365; LEDBETTER SA, 1990, GENOMICS, V7, P264, DOI 10.1016/0888-7543(90)90549-A; LUDWIG CU, 1991, INT J CANCER, V49, P661, DOI 10.1002/ijc.2910490506; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MERLO GR, 1994, CANCER GENET CYTOGEN, V76, P106, DOI 10.1016/0165-4608(94)90458-8; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; OLIPHANT AR, 1991, NUCLEIC ACIDS RES, V19, P4794; PARK SY, 1995, CANCER GENET CYTOGEN, V79, P74, DOI 10.1016/0165-4608(94)00103-I; Phillips NJ, 1996, CANCER RES, V56, P606; RADFORD DM, 1995, CANCER RES, V55, P3399; SATO T, 1990, CANCER RES, V50, P7184; SAXENA A, 1992, CANCER RES, V52, P6716; Schultz DC, 1996, CANCER RES, V56, P1997; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; Todd S, 1997, CANCER RES, V57, P1344; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WILLIAMSON MP, 1994, GENE CHROMOSOME CANC, V9, P108, DOI 10.1002/gcc.2870090206; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOYAMA S, 1992, CANCER RES, V52, P873	49	53	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2095	2100		10.1038/sj.onc.1202128	http://dx.doi.org/10.1038/sj.onc.1202128			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798680				2022-12-17	WOS:000076540900008
J	Rosel, M; Claas, C; Seiter, S; Herlevsen, M; Zoller, M				Rosel, M; Claas, C; Seiter, S; Herlevsen, M; Zoller, M			Cloning and functional characterization of a new phosphatidyl-inositol anchored molecule of a metastasizing rat pancreatic tumor	ONCOGENE			English	Article						rat; metastasis; phosphatidyl-inositol anchor; matrix degradation	UROKINASE PLASMINOGEN-ACTIVATOR; CELL-SURFACE RECEPTOR; COLON-CARCINOMA CELLS; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; CANCER METASTASIS; GLYCOSYL-PHOSPHATIDYLINOSITOL; SIGNAL TRANSDUCTION; LAMININ DEGRADATION; ADHESION MOLECULES	We have described recently a panel of metastasis-associated antigens expressed on a rat pancreatic tumor. One of these molecules, recognized by the monoclonal antibody C4.4 and named accordingly C4.4A, was under physiological conditions expressed only in the gravid uterus and on epithelial of the upper gastrointestinal tract. The cDNA of the antigen has been isolated and cloned. The 1,637 b cDNA codes for a 352 amino acid long glycosylphosphatidy-inositol (GP) anchored molecule, whose molecular weight varies in different cells between 94-98 kD according to the degree of N- and O-glycosylation. Data base searches have revealed a low degree of homology to the receptor for the plasminogen activator (uPAR). After intrafootpad and intravenous application of C4.4A transfected and mocktransfected tumor cells, an increased number of lung nodules was detected with the former, whereby the individual metastatic nodules amalgamated without any encapsulation of the tumor tissue. Furthermore, C4.4A is involved in adhesion to laminin and, although transfection of a non-metastasizing tumor line with the molecule was not sufficient, constitutively C4.4A-positive tumor cells penetrated through matrigel. This process could be completely prevented by C4.4. Finally, we could demonstrate that uPA, albeit weakly, bound to the C4.4A molecule. In view of the observed influence of C4.4A on metastasis formation and matrix penetration it is tempting to speculate that this newly described metastasis-associated molecule may exert functional activity similar to the uPAR, i.e. via activation of matrix degrading enzymes. By the very restricted expression of the molecule in the adult organism, modulation of C4.4A could well be of therapeutic interest.	German Canc Res Ctr, Dept Tumor Progress & Immune Def, D-69120 Heidelberg, Germany; Univ Karlsruhe, Dept Appl Genet, D-78000 Karlsruhe, Germany; Univ Hosp, Dept Dermatol, D-66424 Homburg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Karlsruhe Institute of Technology; Universitatsklinikum des Saarlandes	Zoller, M (corresponding author), German Canc Res Ctr, Dept Tumor Progress & Immune Def, D-69120 Heidelberg, Germany.							Anderson R G, 1994, Semin Immunol, V6, P89, DOI 10.1006/smim.1994.1013; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BEHRENS J, 1993, BREAST CANCER RES TR, V24, P175, DOI 10.1007/BF01833258; BERGSAGEL PL, 1992, J IMMUNOL, V148, P590; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BURGLE M, 1997, BIOL CHEM, V378, P3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Claas C, 1996, CELL GROWTH DIFFER, V7, P663; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; COOK RG, 1992, CELL IMMUNOL, V144, P367, DOI 10.1016/0008-8749(92)90252-K; CRAWFORD HC, 1994, INVAS METAST, V14, P234; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Dasgupta A, 1996, BIOCHEM BIOPH RES CO, V227, P110, DOI 10.1006/bbrc.1996.1475; De Clerck Yves A., 1993, P121; DeClerck YA, 1996, ENZYME PROTEIN, V49, P72, DOI 10.1159/000468617; DIMANCHEBOITREL MT, 1994, INT J CANCER, V56, P512, DOI 10.1002/ijc.2910560410; DURLIAT M, 1992, BRIT J CANCER, V66, P51, DOI 10.1038/bjc.1992.215; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; EVANS CW, 1992, CELL BIOL INT REP, V16, P1, DOI 10.1016/S0309-1651(06)80150-5; FAZIOLI F, 1994, TRENDS PHARMACOL SCI, V15, P25, DOI 10.1016/0165-6147(94)90130-9; FERGUSON RM, 1988, CLIN TRANSPLANT, V2, P285; FIDLER IJ, 1990, J NATL CANCER I, V82, P166, DOI 10.1093/jnci/82.3.166; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GLINSKY GV, 1993, CRIT REV ONCOL HEMAT, V14, P229, DOI 10.1016/1040-8428(93)90011-R; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUBE M, 1994, EUR J IMMUNOL, V24, P731; Jardi M, 1996, THROMB HAEMOSTASIS, V76, P1009; Jones PH, 1996, CELL ADHES COMMUN, V4, P297, DOI 10.3109/15419069609010773; KHOKHA R, 1993, J NEUROONCOL, V18, P123; KO YG, 1995, ANAL BIOCHEM, V224, P166, DOI 10.1006/abio.1995.1024; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LIOTTA LA, 1983, LAB INVEST, V49, P636; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Malek T R, 1994, Semin Immunol, V6, P105, DOI 10.1006/smim.1994.1015; Mareel M. M., 1991, MECH INVASION METAST; MAREEL MM, 1993, CRIT REV ONCOGENESIS, V4, P559; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATZKU S, 1983, INVAS METAST, V3, P109; MATZKU S, 1989, CANCER RES, V49, P1294; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOLLER LB, 1993, BLOOD COAGUL FIBRIN, V4, P293; MOLLER LB, 1992, FEBS LETT, V301, P493; MORGAN BP, 1993, EUR J IMMUNOL, V23, P2841, DOI 10.1002/eji.1830231118; Nagase H, 1997, BIOL CHEM, V378, P151; NazihSanderson F, 1997, BBA-LIPID LIPID MET, V1346, P45, DOI 10.1016/S0005-2760(97)00017-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OSSOWSKI L, 1992, CANCER RES, V52, P6754; PLOUG M, 1991, J BIOL CHEM, V266, P1926; REISSER D, 1993, INT J CANCER, V53, P651, DOI 10.1002/ijc.2910530421; Resta R, 1997, CELL SIGNAL, V9, P131, DOI 10.1016/S0898-6568(96)00132-5; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLECHTE JW, 1990, CANCER COMMUN, V2, P261, DOI 10.3727/095535490820874245; SCHLECHTE W, 1989, CANCER RES, V49, P6064; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SOLBERG H, 1992, EUR J BIOCHEM, V205, P451, DOI 10.1111/j.1432-1033.1992.tb16799.x; SORDAT BC, 1995, INVAS METAST, V14, P223; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Strohmeier GR, 1997, J CLIN INVEST, V99, P2588, DOI 10.1172/JCI119447; SUH TT, 1994, J BIOL CHEM, V269, P25992; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRYGVASSON K, 1989, INFLUENCE TUMOR DEV, P72; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; ZOLLER M, 1978, BRIT J CANCER, V37, P61, DOI 10.1038/bjc.1978.9; ZOLLER M, 1992, J NUCL MED, V33, P1366; Zoller M, 1996, CURR TOP MICROBIOL, V213, P215	76	53	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1989	2002		10.1038/sj.onc.1202079	http://dx.doi.org/10.1038/sj.onc.1202079			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788443				2022-12-17	WOS:000076423500013
J	von Knethen, A; Lotero, A; Brune, B				von Knethen, A; Lotero, A; Brune, B			Etoposide and cisplatin induced apoptosis in activated RAW264.7 macrophages is attenuated by cAMP-induced gene expression	ONCOGENE			English	Article						cisplatin; etoposide; resistance; macrophages; p53; cAMP	PROSTAGLANDIN-H SYNTHASE-2; OXIDE-INDUCED APOPTOSIS; CELL-DEATH; CYCLOOXYGENASE EXPRESSION; INDUCIBLE CYCLOOXYGENASE; ALVEOLAR MACROPHAGES; TRANSCRIPTION FACTOR; THYMOCYTE APOPTOSIS; COLORECTAL-CANCER; DNA-REPAIR	Previous observations suggest expression of cyclooxygenase-2 to convey macrophage protection towards apoptotic cell death. We reasoned prostaglandin formation and in turn a cAMP increase as the underlying protective principle. Here we report that exposure of macrophages to lipopolysaccharide/interferon-gamma or lipophilic cAMP analogs such as dibutyryl-cAMP or 8-bromo-cAMP for 15 h attenuated DNA fragmentation and accumulation of the tumor suppressor p53 in response to the chemotherapeutic agents cisplatin and etoposide, compared to cells that received chemotherapeutic agents only. In contrast, a Ih lasting preexposure period revealed no protection. The demand for a long incubation period with cAMP-derivates implied cAMP-mediated gene activation as the underlying principle, Therefore, we treated cells with oligonucleotides containing a cAMP-response element (CRE) binding site. Using this decoy-approach we scavanged activated cAMP response element binding protein prior to its promoter activating ability. Incubating macrophages with decoy, but not with control oligonucleotides, reduced cAMP evoked protection and simultanously restored p53 accumulation in response to chemotherapeutic agents. Our studies demonstrate that cAMP-initiated gene activation regulates the sensitivity towards DNA damaging agents via inhibition of a p53 dependent pathway.	Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, D-91054 Erlangen, Germany; Univ Alcala de Henares, Fac Med, Dept Biochem & Mol Biol, Alcala De Henares 28871, Spain	University of Erlangen Nuremberg; Universidad de Alcala	Brune, B (corresponding author), Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, Loschgestr 8, D-91054 Erlangen, Germany.							ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; Brune B, 1996, BIOCHEM BIOPH RES CO, V229, P396, DOI 10.1006/bbrc.1996.1816; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; Chen ZH, 1996, CANCER RES, V56, P5224; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; DiBattista JA, 1997, J CELL BIOCHEM, V65, P408, DOI 10.1002/(SICI)1097-4644(19970601)65:3<408::AID-JCB10>3.3.CO;2-H; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DuBois RN, 1996, CANCER RES, V56, P733; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Eischen Christine M., 1997, Blood, V90, P935; Fladmark KE, 1997, BIOCHEM BIOPH RES CO, V232, P20, DOI 10.1006/bbrc.1997.6214; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; Fulda S, 1997, CANCER RES, V57, P3823; Gallagher WM, 1997, ONCOGENE, V14, P185; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; Karim S, 1997, BIOCHEM J, V326, P593, DOI 10.1042/bj3260593; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1992, J BIOL CHEM, V267, P25934; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJNO G, 1995, AM J PATHOL, V146, P3; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MCDONNELL TJ, 1995, SEMIN CANCER BIOL, V6, P53, DOI 10.1006/scbi.1995.0007; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; Pang LH, 1997, BIOCHEM PHARMACOL, V53, P493, DOI 10.1016/S0006-2952(96)00737-X; Perego P, 1996, CANCER RES, V56, P556; PETERSON HI, 1983, INVAS METAST, V3, P151; Quinn MR, 1996, IMMUNOL LETT, V50, P185, DOI 10.1016/0165-2478(96)02542-4; Ramanathan RK, 1997, SEMIN ONCOL, V24, P440; REDDY BS, 1987, CANCER RES, V47, P5340; REDDY ST, 1994, J BIOL CHEM, V269, P15473; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; Ruchaud S, 1997, ONCOGENE, V15, P827, DOI 10.1038/sj.onc.1201248; Sandler AB, 1997, SEMIN ONCOL, V24, P463; SANO H, 1995, CANCER RES, V55, P3785; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Sharma HW, 1996, ANTICANCER RES, V16, P589; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Torgersen KM, 1997, J BIOL CHEM, V272, P5495, DOI 10.1074/jbc.272.9.5495; Tortora G, 1997, P NATL ACAD SCI USA, V94, P12586, DOI 10.1073/pnas.94.23.12586; Tortora G, 1997, CANCER RES, V57, P5107; Trump BF, 1997, TOXICOL PATHOL, V25, P82, DOI 10.1177/019262339702500116; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VASSAULT A, 1983, METHOD ENZYMAT AN, V1, P118; VonKnethen A, 1997, FASEB J, V11, P887; Walker BAM, 1997, J IMMUNOL, V158, P2926; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang YM, 1996, ONCOGENE, V12, P2223; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; ZHANG F, 1995, BIOCHEM J, V312, P135, DOI 10.1042/bj3120135	73	53	54	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	1998	17	3					387	394		10.1038/sj.onc.1201926	http://dx.doi.org/10.1038/sj.onc.1201926			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690520				2022-12-17	WOS:000074947500013
J	Benkhelifa, S; Provot, S; Lecoq, O; Pouponnot, C; Calothy, G; Felder-Schmittbuhl, MP				Benkhelifa, S; Provot, S; Lecoq, O; Pouponnot, C; Calothy, G; Felder-Schmittbuhl, MP			mafA, a novel member of the maf proto-oncogene family, displays developmental regulation and mitogenic capacity in avian neuroretina cells	ONCOGENE			English	Article						maf; neuroretina; transcription factor; oncogene	RETINA-SPECIFIC GENE; ZIPPER TRANSCRIPTION FACTOR; NUCLEAR ONCOPROTEIN; BASIC DOMAIN; FACTOR NF-E2; FACTOR NRL; V-MAF; PROTEINS; EXPRESSION; FOS	Transcription factors of the Maf proto-oncogene family have been shown to participate in the regulation of several differentiation specific genes. We previously reported that a member(s) of this family is involved in the regulation of the neuroretina specific gene, QR1, through a promoter region, designated the A box, that is closely related to the Maf recognition element (MARE). We undertook an identification of Maf family genes expressed in the quail neuroretina (QNR) and we report the isolation of mafA, a gene encoding a novel member of the large Maf proteins subgroup. Expression of this gene is developmentally regulated in the neuroretina, MafA is able to bind to MARE sequence and to heterodimerize with v-Maf, MafB, Jun and Fos, but not with the small MafF and MafK proteins. Accordingly, it is able to transactivate the QR1 promoter A box. We also show that increased expression of mafA induces sustained proliferation of postmitotic QNR cells.	Inst Curie, UMR 145 CNRS, F-91405 Orsay, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Felder-Schmittbuhl, MP (corresponding author), Inst Curie, UMR 145 CNRS, F-91405 Orsay, France.			Benkhelifa-Ziyyat, Sofia/0000-0002-8088-5288; PROVOT, SYLVAIN/0000-0003-4087-4450				ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BARNSTABLE CJ, 1987, MOL NEUROBIOL, V1, P9, DOI 10.1007/BF02935263; BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Casado FJ, 1996, MECH DEVELOP, V54, P237, DOI 10.1016/0925-4773(95)00482-3; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; CRISANTICOMBES P, 1977, CELL TISSUE RES, V185, P159; EYCHENE A, 1992, ONCOGENE, V7, P1315; Farjo Q, 1997, GENOMICS, V45, P395, DOI 10.1006/geno.1997.4964; FARJO Q, 1993, GENOMICS, V18, P216, DOI 10.1006/geno.1993.1458; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 1996, ONCOGENE, V12, P53; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Kurschner C, 1997, BIOCHEM BIOPH RES CO, V231, P333, DOI 10.1006/bbrc.1997.6097; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; Liu Q, 1996, ONCOGENE, V12, P207; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PIERANI A, 1995, MOL CELL BIOL, V15, P642; PIERANI A, 1993, MOL CELL BIOL, V13, P3401, DOI 10.1128/MCB.13.6.3401; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Sakai M, 1997, ONCOGENE, V14, P745, DOI 10.1038/sj.onc.1200869; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266	40	53	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					247	254		10.1038/sj.onc.1201898	http://dx.doi.org/10.1038/sj.onc.1201898			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674710				2022-12-17	WOS:000074706700014
J	Erhardt, JA; Pittman, RN				Erhardt, JA; Pittman, RN			p21(WAF1) induces permanent growth arrest and enhances differentiation, but does not alter apoptosis in PC12 cells	ONCOGENE			English	Article						p21(WAF1); PC12; NGF; apoptosis; differentiation; proliferation	CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; IN-VIVO; TERMINAL DIFFERENTIATION; SYMPATHETIC NEURONS; TUMOR SUPPRESSION; HUMAN FIBROBLASTS; PROTEIN-KINASES; G(1) ARREST; P21	p21(WAF1) cyclin-dependent kinase inhibitor has been implicated in the control of proliferation, differentiation, and death in, various cell lines, To further examine p21 regulation of the transitions between these cellular processes, an inducible p21 vector (lac operon system) was transfected into the rat pheochromocytoma (PC12) neural cell line, Induction of p21 led to permanent growth arrest, as evidenced by cell counts, FACS analysis, and thymidine incorporation, This arrest was maintained, even after removal of the inducing signal (IPTG). Northern analysis revealed that endogenous p21 mRNA increased following IPTG removal, which may be responsible for the continued growth arrest despite the decrease in ectopic p21 expression, p21 overexpression did not directly lead to a differentiated phenotype; however, differentiation in response to nerve growth factor (NGF) was greatly accelerated. To examine effects on cell, death, and specifically test the hypothesis that apoptosis caused by withdrawal of trophic support results from inappropriate entry into cell cycle, serum was removed from proliferating and p21-arrested PC12 cells, The rate of apoptotic death was not affected by p21, nor was it effective in altering the extent of death following other apoptotic stimuli.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Erhardt, JA (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.				AHRQ HHS [HS32465] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ATTARDI D, 1996, EMBO J, V15, P3696; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Buchkovich K, 1994, MOL BIOL CELL, V5, P1226; Chen J, 1996, ONCOGENE, V13, P1395; CHEN YQ, 1995, CANCER RES, V55, P4536; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FERRARI G, 1995, J NEUROSCI, V15, P2857; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Givol I, 1995, ONCOGENE, V11, P2609; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GRANA X, 1995, ONCOGENE, V11, P211; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUO K, 1995, MOL CELL BIOL, V15, P3823; GUPTA M, 1987, BRAIN RES BULL, V18, P555, DOI 10.1016/0361-9230(87)90119-5; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HUPPI K, 1994, ONCOGENE, V9, P3017; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; Mills JC, 1997, EXP CELL RES, V231, P337, DOI 10.1006/excr.1997.3474; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Poluha W, 1996, MOL CELL BIOL, V16, P1335; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; STEIN GS, 1994, CELL BIOL LAB HDB, P282; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Teng KK, 1994, CELL BIOL LAB HDB, P218; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanGrunsven LA, 1996, ONCOGENE, V12, P855; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Woodgett JR, 1996, CANCER SURV, V27, P127; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAN GZ, 1995, J NEUROSCI, V15, P6200; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG BW, 1996, CURR BIOL, V6, P606	67	53	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					443	451		10.1038/sj.onc.1201577	http://dx.doi.org/10.1038/sj.onc.1201577			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484833				2022-12-17	WOS:000071739400002
J	Iravani, M; Dhat, R; Price, CM				Iravani, M; Dhat, R; Price, CM			Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15(INK4B)) in childhood acute lymphoblastic leukemia	ONCOGENE			English	Article						MTS1; p16(INK4A); MTS2; p15(INK4B); methylation; childhood leukemia	DEPENDENT KINASE INHIBITORS; CELL-CYCLE ARREST; DNA METHYLATION; HUMAN CANCERS; TGF-BETA; P16; INACTIVATION; HYPERMETHYLATION; EXPRESSION; FREQUENCY	The multi tumor suppressor genes MTS1 (CDKN2 p16(INK4A)) and MTS2 (CDKN1, p15(INK4B)) located at 9p21-22 are inactivated in some human cancers via several mechanisms including deletion and hypermethylation, We have investigated the deletion and methylation status of MTS1 and MTS2 in childhood acute lymphoblastic leukemia (ALL) of both T-cell (17 cases) and B-cell phenotypes (29 cases), and p16(INK4A) and p15(INK4B) mRNA expression in 36 of these cases, Biallelic or monoallelic loss of both MTS1 and MTS2 was observed in 12 cases of B-ALL and nine cases of T-ALL. Two cases of T-ALL showed deletion of MTS1 but not MTS2 The 5' CpG region of MTS2 was hypermethylated in 12 cases of precursor B-ALL and eight cases of T-ALL but no hypermethylation was found in the 5' CPG region of MTS1, All cases with homozygous deletion of MTS1 or MTS2 had no or low levels of mRNA expression and similar low levels of expression were found in cases in which MTS2 was present but fully methylated, Thus hypermethylation of MTS2, in contrast to MTS1, is frequent in childhood ALL, Furthermore our data show that although inactivation of MTS1 by deletion is common, inactivation of MTS2 by a combination of deletion and hypermethylation is more frequent in both B-ALL (20/29, 69%) and T-ALL (17/17, 100%), This suggests that both MTS1 and MTS2 are important targets of the 9p21-22 deletion.	INST CANC RES,CHESTER BEATTY LABS,LEUKAEMIA RES FUND CTR,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Costello JF, 1996, CANCER RES, V56, P2405; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; GREGER V, 1994, HUM GENET, V94, P491; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAIDAR MA, 1995, BLOOD, V86, P311, DOI 10.1182/blood.V86.1.311.bloodjournal861311; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; HIRAMA T, 1995, BLOOD, V86, P841; Jamal R, 1996, LEUKEMIA, V10, P629; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LI Y, 1994, CANCER RES, V54, P6078; Lo KW, 1996, CANCER RES, V56, P2721; MARCO JAG, 1996, BLOOD, V88, P1568; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nagatake M, 1996, CANCER RES, V56, P1886; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; PRICE CM, 1992, BLOOD, V80, P1033; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; Reed AL, 1996, CANCER RES, V56, P3630; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sambrook J, 1989, MOL CLONING LAB MANU; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Schwaller J, 1997, LEUKEMIA, V11, P54, DOI 10.1038/sj.leu.2400522; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; ZULUETA MG, 1995, CANCER RES, V55, P4531	39	53	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2609	2614		10.1038/sj.onc.1201428	http://dx.doi.org/10.1038/sj.onc.1201428			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399648				2022-12-17	WOS:A1997YG73200010
J	Gottgens, B; McLaughlin, F; Bockamp, EO; Fordham, JL; Begley, CG; Kosmopoulos, K; Elefanty, AG; Green, AR				Gottgens, B; McLaughlin, F; Bockamp, EO; Fordham, JL; Begley, CG; Kosmopoulos, K; Elefanty, AG; Green, AR			Transcription of the SCL gene in erythroid and CD34 positive primitive myeloid cells is controlled by a complex network of lineage-restricted chromatin-dependent and chromatin-independent regulatory elements	ONCOGENE			English	Article						SCL/TAL-1; transcription; regulation; chromatin; enhancer; silencer	LOCUS-CONTROL REGION; LOOP-HELIX PROTEIN; BETA-GLOBIN GENE; FACTOR GATA-1; HEMATOPOIETIC LINEAGES; HOMEODOMAIN PROTEIN; TRANSGENIC MICE; TAL-1 GENE; DIFFERENTIATION; EXPRESSION	The SCL gene (also known as TAL-1) encodes a basic helix-loop-helix transcription factor that is essential for the development of all haematopoietic lineages, and ectopic expression of which results in T cell leukaemia, SCL is expressed in normal pluripotent haematopoietic stem cells and its expression is maintained during differentiation along erythroid, mast and megakaryocytic lineages, but is extinguished following commitment to other cell types, The mechanisms responsible for this pattern of expression are poorly understood, but are likely to illuminate the molecular basis for stem cell development and lineage commitment. We have identified multiple lineage-restricted DNase I hypersensitive sites in a 45 kb region spanning the murine SCL locus, Committed erythroid cells and CD34 positive primitive myeloid cells exhibited both shared and unique DNase I hypersensitive sites whereas none were found in T cells, The function of each hypersensitive site was studied using both transient and stable reporter assays in erythroid, primitive myeloid and T cells, Multiple positive and negative regulatory elements were characterised and found to display lineage-specificity, promoter-specificity and/or chromatin-dependence. These results represent the first description of key components of a complex network of regulatory elements controlling SCL expression during haematopoiesis.	UNIV CAMBRIDGE, CTR MRC, DEPT HAEMATOL, CAMBRIDGE CB2 2QH, ENGLAND; WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA	University of Cambridge; Walter & Eliza Hall Institute			Elefanty, Andrew G/A-6066-2008	Gottgens, Berthold/0000-0001-6302-5705; Green, Anthony/0000-0002-9795-0218; Bockamp, Ernesto/0000-0002-6181-1734; Elefanty, Andrew/0000-0001-6448-8314	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BENZ EJ, 1980, P NATL ACAD SCI-BIOL, V77, P3509, DOI 10.1073/pnas.77.6.3509; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; Bockamp EO, 1997, J BIOL CHEM, V272, P8781, DOI 10.1074/jbc.272.13.8781; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BONIFER C, 1994, NUCLEIC ACIDS RES, V22, P4202, DOI 10.1093/nar/22.20.4202; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CROSS MA, 1994, ONCOGENE, V9, P3013; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; ERNST P, 1995, IMMUNITY, V2, P311, DOI 10.1016/1074-7613(95)90139-6; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; GOLDFARB AN, 1992, BLOOD, V58, P537; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HWANG LY, 1993, ONCOGENE, V8, P3043; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LECOINTE N, 1994, ONCOGENE, V9, P2623; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; LEROYVIARD K, 1994, BLOOD, V84, P3819, DOI 10.1182/blood.V84.11.3819.bloodjournal84113819; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MAY G, 1995, EMBO J, V14, P564, DOI 10.1002/j.1460-2075.1995.tb07032.x; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MOUTHON MA, 1993, BLOOD, V81, P647; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TAPSCOTT SJ, 1992, MOL CELL BIOL, V12, P4994, DOI 10.1128/MCB.12.11.4994; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, ONCOGENE, V6, P187; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZEHETNER G, 1994, NATURE, V367, P489, DOI 10.1038/367489a0; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	79	53	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	1997	15	20					2419	2428		10.1038/sj.onc.1201426	http://dx.doi.org/10.1038/sj.onc.1201426			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395238				2022-12-17	WOS:A1997YE96300004
J	Dirks, PB; Patel, K; Hubbard, SL; Ackerley, C; Hamel, PA; Rutka, JT				Dirks, PB; Patel, K; Hubbard, SL; Ackerley, C; Hamel, PA; Rutka, JT			Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells	ONCOGENE			English	Article						astrocytoma; cyclins; cyclin-dependent kinases; GFAP; retinoic acid; p16; p21	RETINOBLASTOMA PROTEIN; POTENTIAL MEDIATOR; TUMOR SUPPRESSION; GENE-EXPRESSION; MAMMALIAN-CELLS; CDK INHIBITOR; MICE LACKING; P27(KIP1); ARREST; GROWTH	We have characterized the expression and activity of the cell cycle regulatory machinery and the organization of the cytoskeleton of the p16(ink4a)-deficient astrocytoma cell line, U343 MG-a (U343), following retinoic acid (RA) treatment, RA causes cell cycle arrest at low cell density and significant morphological changes in U343 cells, reflected by reorganization of the intermediate filament, GFAP, and actin, RA-induced cell cycle arrest is also associated with induction of p27(Kip1) expression, inhibition of cdk2-associated kinase activity and alteration of the phosphorylation state of the pRB-family proteins, We next determined the effect of inducing expression of the cyclin dependent kinase inhibitors (CKI's), p16(Ink4a), p21(Cip1/Waf1) or p27(Kip1) on the proliferation and morphology of these malignant astrocytoma cells in the absence and presence of RA, Induction of p16, p21 or p27, using the tetracycline repressor system, potently inhibits proliferation of U343 cells, However, rather than resembling RA-treated cells, CKI-induced U343 cells become flat with abundant cytoplasm and perinuclear vacuolization, CKI-induced morphological alterations are accompanied by a significant reorganization of glial filaments within the cytoplasm, Interestingly, when U343 cells are arrested by p16, p21 or p27 induction and with RA, a dramatic morphological cells acquiring multiple long, tapering processes reminiscent of primary astrocytes, This rearrangement is accompanied by reorganization of GFAP, vimentin and actin, Vimentin specifically relocalizes to the tips of the long processes which form, The arrangement of intermediate filaments in these cells is, in fact, indistinguishable from their arrangement in primary human astrocytes, These data demonstrate that when a strong proliferative block, produced by CKI expression, occurs in conjunction with the morphogenic signals generated by RA, these p16-deficient malignant astrocytoma cells are induced to phenotypically resemble normal astrocytes.	HOSP SICK CHILDREN,DIV NEUROSURG,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Ichimura K, 1996, ONCOGENE, V13, P1065; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LIU L, 1995, ONCOGENE, V11, P405; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGLIARO LC, 1995, CELL GROWTH DIFFER, V6, P673; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RUTKA JT, 1988, INT J CANCER, V53, P3634; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WALDMAN T, 1995, CANCER RES, V55, P5187; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YANO T, 1991, BIOCHEM BIOPH RES CO, V175, P1144, DOI 10.1016/0006-291X(91)91685-6	41	53	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2037	2048		10.1038/sj.onc.1201392	http://dx.doi.org/10.1038/sj.onc.1201392			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366521				2022-12-17	WOS:A1997YC28400005
J	Koch, G; Tanaka, K; Masuda, T; Yamochi, W; Nonaka, H; Takai, Y				Koch, G; Tanaka, K; Masuda, T; Yamochi, W; Nonaka, H; Takai, Y			Association of the Rho family small GTP-binding proteins with Rho GDP dissociation inhibitor (Rho GDI) in Saccharomyces cerevisiae	ONCOGENE			English	Article						small GTP binding protein; Rho GDI; Rho; S-cerevisiae	GDP/GTP EXCHANGE PROTEIN; REGULATORY PROTEIN; CELL POLARITY; MOLECULAR-CLONING; ADP-RIBOSYLATION; ONCOGENE PRODUCT; BUD FORMATION; YEAST-CELLS; PURIFICATION; CYTOSOL	The small GTP-binding proteins of the Rho family, consisting of the Rho, Rac, and Cdc42 subfamilies, are implicated in various cell functions, such as cell shape change, cell motility and cytokinesis, through reorganization of actin cytoskeleton. Rho GDI is a general regulator which forms a complex with the GDP-bound inactive form of the Rho family members and inhibits their activation. We have purified Rho GDI from the yeast Saccharomyces cerevisiae, cloned its gene, and named it RD11 (Rho GD). In this study, we have further characterized Beast Rho GDI, Rho GDI was found in the cytosol by immunoblot and immunofluorescence microscopic analyses. Rho1p and Cdc42p were co-immunoprecipitated with Rho GDI from the cytosol. This immunoprecipitated Rho1p was mainly bound to GDP. In the disruption mutant of Rho GDI, which did not show any apparent phenotype, both Rho1p and Cdc42p were also present in the cytosol. These results indicate that yeast Rho GDI possesses properties similar to those of mammalian Rho GDI, and that there is a cytosolic factor which functionally substitutes for Rho GDI in yeast.	OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN	Osaka University								ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BACKLUND PS, 1993, BIOCHEM BIOPH RES CO, V196, P534, DOI 10.1006/bbrc.1993.2283; BOIVIN D, 1995, AM J PHYSIOL, V269, P180; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOURMEYSTER N, 1992, BIOCHEMISTRY-US, V31, P12863, DOI 10.1021/bi00166a022; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hirano H, 1996, MOL CELL BIOL, V16, P4396; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; IMAMURA H, 1997, IN PRESS EMBO J; ISOMURA M, 1991, ONCOGENE, V6, P119; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; Mack D, 1996, MOL CELL BIOL, V16, P4387; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MASUDA T, 1994, J BIOL CHEM, V269, P19713; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; Rubin G M, 1975, Methods Cell Biol, V12, P45; Sambrook J, 1989, MOL CLONING LAB MANU; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Sherman F., 1986, METHODS YEAST GENETI; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAPON M, 1997, CURR OPIN CELL BIOL, V9, P86; UEDA T, 1990, J BIOL CHEM, V265, P9373; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366	45	53	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					417	422		10.1038/sj.onc.1201194	http://dx.doi.org/10.1038/sj.onc.1201194			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242378				2022-12-17	WOS:A1997XM23800006
J	Makino, K; Kuwahara, H; Masuko, N; Nishiyama, Y; Morisaki, T; Sasaki, J; Nakao, M; Kuwano, A; Nakata, M; Ushio, Y; Saya, H				Makino, K; Kuwahara, H; Masuko, N; Nishiyama, Y; Morisaki, T; Sasaki, J; Nakao, M; Kuwano, A; Nakata, M; Ushio, Y; Saya, H			Cloning and characterization of NE-dlg: A novel human homolog of the Drosophila discs large (dlg) tumor suppressor protein interacts with the APC protein	ONCOGENE			English	Article						tumor suppressor genes; two-hybrid screening; chromosome Xq13; EST	MOLECULAR CHARACTERIZATION; GENE-PRODUCT; HUMAN GENOME; TIGHT; ZO-1; ASSOCIATION; JUNCTIONS; SEPTATE; SAP90	We have cloned a cDNA for a novel human homolog of the Dvosophila discs large (dig) tumor suppressor protein, termed NE-dlg (neuronal and endocrine dig). Northern blot analysis revealed that the gene is highly expressed in neuronal and endocrine tissues. Fluorescence in situ hybridization (FISH) and radiation hybrid mapping studies localized the NE-dlg gene to chromosome Xq13. We also found that the NE-dlg gene encoded a 100 kDa protein. Immunolocalization studies using an NE-dlg antibody showed that the protein tended to be expressed in non-proliferating cells, such as neurons, cells in Langerhans islets of the pancreas, myocytes of the heart muscles, and the prickle and functional layer cells of the esophageal epithelium. Proliferative cells, including various cultured cancer cell lines and basal cells in the esophageal epithelium, showed little expression of the NE-dlg protein. In addition, yeast true-hybrid screening and in vitro binding assays revealed that the NE-dlg interacted with the carboxyl-terminal region of the APC tumor suppressor protein. These data suggest that NE-dlg negatively regulates cell proliferation through its interaction with the APC protein.	KUMAMOTO UNIV, SCH MED, DEPT TUMOR GENET & BIOL, KUMAMOTO 860, JAPAN; KUMAMOTO UNIV, SCH MED, DEPT NEUROSURG, KUMAMOTO 860, JAPAN; EHIME UNIV, SCH MED, DEPT HYG EHIME, SHIGENOBU, EHIME 79102, JAPAN; SUMITOMO ELECT IND LTD, BIOMED R&D DEPT, YOKOHAMA, KANAGAWA 244, JAPAN	Kumamoto University; Kumamoto University; Ehime University; Sumitomo Electric Industries			Saya, Hideyuki/J-4325-2013					ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUWANO A, 1991, AM J HUM GENET, V49, P707; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MONROE KR, 1995, NAT MED, V1, P827, DOI 10.1038/nm0895-827; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; WATSON KL, 1994, J CELL SCI, P19; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7	34	53	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2425	2433		10.1038/sj.onc.1201087	http://dx.doi.org/10.1038/sj.onc.1201087			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188857				2022-12-17	WOS:A1997WZ68000006
J	Murakami, M; Sonobe, MH; Ui, M; Kabuyama, Y; Watanabe, H; Wada, T; Handa, H; Iba, H				Murakami, M; Sonobe, MH; Ui, M; Kabuyama, Y; Watanabe, H; Wada, T; Handa, H; Iba, H			Phosphorylation and high level expression of Fra-2 in v-src transformed cells: A pathway of activation of endogenous AP-1	ONCOGENE			English	Article						AP-1; Fra-2; phosphorylation; transformation; v-src; ERK2	DNA-BINDING ACTIVITY; GROWTH-STIMULATING ACTIVITY; AFFINITY LATEX-PARTICLES; PROTEIN-KINASE; C-JUN; MAP KINASE; FOS GENE; SIGNAL-TRANSDUCTION; CELLULAR-TRANSFORMATION; TRANSCRIPTION FACTOR	Chicken embryo fibroblasts (CEF) transformed with v-src were previously reported to revert to normal phenotype after the introduction of dominant-negative mutants of Fos or Jun, indicating that endogenous AP-1 activity is essential for the cellular transformation, The major changes in the expression levels of fos and jun family genes induced by v-src were the elevation of fra-2 and c-jun transcripts. We show here that extensive phosphorylation of the AP-1 component Fra-2 is a major qualitative change in v-src transformed CEF and that several Ser and Thr residues in a C-terminal region of Fra-2 (amino acids 266-323) are phosphorylated specifically. The induced kinase activity was detected at the position of 42 kDa by in gel kinase assay using the Fra-2 C-terminal region as a substrate, and it was identified as chicken ERK2. JNK1 and JNK2, other members of the MAP kinase family, were not significantly activated in v-src transformed CEF and Fra-2 was not a good substrate for JNKs. fra-2 promoter analysis indicated that this promoter activity is elevated in v-src transformed CEP via two AP-1 binding sites and CRE-like sequence. We propose that phosphorylation of Fra-2 by ERK2 converts it from an inefficient transcriptional activator to an active one and further that fra-2 expression is autoregulated in response to the phosphorylation status of its gene product.	UNIV TOKYO,INST MED SCI,DEPT GENE REGULAT,MINATO KU,TOKYO 108,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	University of Tokyo; Tokyo Institute of Technology			Sonobe, Martha/I-2877-2015; Watanabe, Hirotaka/GZA-8002-2022					ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; CATLING AD, 1993, ONCOGENE, V8, P1875; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FOLETTA VC, 1994, ONCOGENE, V9, P3305; FUJIWARA KT, 1987, J VIROL, V61, P4012, DOI 10.1128/JVI.61.12.4012-4018.1987; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; Greulich H, 1996, ONCOGENE, V12, P1689; GRUDA MC, 1994, ONCOGENE, V9, P2537; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARTL M, 1991, ONCOGENE, V6, P1623; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOSHI M, 1988, J BIOL CHEM, V263, P5396; IBA H, 1988, ONCOGENE RES, V2, P121; INOMATA Y, 1992, ANAL BIOCHEM, V206, P109, DOI 10.1016/S0003-2697(05)80018-1; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAWAGUCHI H, 1989, NUCLEIC ACIDS RES, V17, P6229, DOI 10.1093/nar/17.15.6229; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MATSUI M, 1990, ONCOGENE, V5, P249; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIDA E, 1992, INT REV CYTOL, V138, P211, DOI 10.1016/S0074-7696(08)61589-2; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKUNO H, 1991, ONCOGENE, V6, P1491; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SONOBE MH, 1995, ONCOGENE, V10, P689; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; YOSHIDA T, 1989, ONCOGENE RES, V5, P79; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	56	53	53	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2435	2444		10.1038/sj.onc.1201077	http://dx.doi.org/10.1038/sj.onc.1201077			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188858				2022-12-17	WOS:A1997WZ68000007
J	Xian, WJ; Rosenberg, MP; DiGiovanni, J				Xian, WJ; Rosenberg, MP; DiGiovanni, J			Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: Possible role in mouse skin tumor promotion	ONCOGENE			English	Article						erbB2; c-src; phosphorylation; tumor promotion	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; NEU-ONCOGENE; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; HUMAN-BREAST; MOLECULAR-CLONING; CARCINOMA-CELLS; MAMMARY-TUMORS; PROTO-ONCOGENE	In recent work eve showed that the EGF receptor (EGFr) was activated in tumor promoter treated mouse epidermis (Cell Growth & Differentiation, 6: 1447-1455, 1995). In the present study, we have investigated the possible role of other erbB family members in the process of tumor promotion. Both erbB2 and erbB3, but not erbB4, were expressed in cultured mouse keratinocytes and in mouse epidermis in vivo. In cultured mouse keratinocytes, EGF stimulated rapid tyrosine phosphorylation of erbB2 followed by a time-dependent degradation of erbB2 protein. Furthermore, an increase in erbB2:EGFr heterodimer formation was also induced by EGF. In contrast to the results with erbB2, EGF did not induce tyrosine phosphorylation, the degradation of erbB3, or erbB3:EGFr heterodimer formation in cultured keratinocytes. Further analyses revealed that c-src kinase activity was dramatically elevated in cultured mouse keratinocytes exposed to EGF. In mouse epidermis following multiple treatments with 12-O-tetradecanoylphorbol-13-acetate (TPA), the phosphotyrosine content of erbB2 was significantly elevated in a dose-dependent manner. Concomittantly, erbB2:EGFr heterodimer formation and c-src kinase activity were also elevated in TPA-treated epidermis. Structure-activity relationships with several phorbol ester analogs showed that the elevated phosphorylation of erbB2 in mouse epidermis followed closely with tumor promoting ability. Activation of erbB2 and c-src kinase were also observed in the epidermis of TGF alpha transgenic mice where expression of human TGF alpha was targeted to basal keratinocytes with the human K14 promoter. Collectively, the current data suggest that the activation of erbB2 in phorbol ester treated skin can be explained solely by a mechanism involving elevation of EGFr ligands and activation of the EGFr. In addition, activation of c-spe may be an important downstream effector in mouse keratinocytes both in vivo and in vitro, following activation of the EGFr, erbB2, or both.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CARCINOGENESIS, DIV SCI PK RES, SMITHVILLE, TX 78957 USA; GLAXO WELLCOME INC, RES TRIANGLE PK, NC 27709 USA	University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline					NATIONAL CANCER INSTITUTE [P01CA057596, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA57596, CA16672] Funding Source: Medline; NIEHS NIH HHS [ES 07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALDAZ CM, 1985, CANCER RES, V45, P2753; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; BLUMBERG PM, 1988, CANCER RES, V48, P1; BOUTWELL RK, 1976, CANCER RES, V36, P2631; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOUGALL WC, 1994, ONCOGENE, V9, P2109; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EWING MW, 1988, CARCINOGENESIS, V9, P405, DOI 10.1093/carcin/9.3.405; EWING MW, 1988, CANCER RES, V48, P7048; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; IMAMOTO A, 1991, MOL CARCINOGEN, V4, P52, DOI 10.1002/mc.2940040109; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KIGUCHI K, 1995, MOL CARCINOGEN, V12, P225, DOI 10.1002/mc.2940120407; Kiguchi K., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P149; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAEMMLI UK, 1970, NATURE, V301, P621; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MASON S, 1995, BREAST, V4, P11, DOI 10.1016/0960-9776(95)90022-5; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; PARKINSON EK, 1985, BRIT J CANCER, V52, P479, DOI 10.1038/bjc.1985.219; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; RAICK AN, 1972, CANCER RES, V32, P1562; RHO OY, 1994, MOL CARCINOGEN, V11, P19, DOI 10.1002/mc.2940110105; SAWYER TW, 1988, CARCINOGENESIS, V9, P1197, DOI 10.1093/carcin/9.7.1197; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLAGA T J, 1989, P1; SLAGA TJ, 1983, ENVIRON HEALTH PERSP, V50, P3, DOI 10.2307/3429529; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; XIAN WJ, 1995, CELL GROWTH DIFFER, V6, P1447; YUSPA SH, 1994, CANCER RES, V54, P1178	61	53	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1435	1444		10.1038/sj.onc.1200980	http://dx.doi.org/10.1038/sj.onc.1200980			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136987				2022-12-17	WOS:A1997WT58400006
J	Fan, JG; Bertino, JR				Fan, JG; Bertino, JR			Functional roles of E2F in cell cycle regulation	ONCOGENE			English	Article						E2F; cell cycle; gene regulation	DEPENDENT KINASE INHIBITORS; RETINOBLASTOMA PROTEIN; S-PHASE; TUMOR-SUPPRESSOR; IN-VIVO; GROWTH SUPPRESSION; GENE-EXPRESSION; MAMMALIAN-CELLS; DNA-REPLICATION; CDK6 INHIBITOR	The E2F family of transcription factors play a key role in G1-S progression. A dominant negative mutant (E2F97) of E2F1 containing the DNA binding domain of E2F1 under the control of a tetracycline-responsive promoter was constructed. Stable transfectants were produced in the pRb-lacking SaOS-2 cell line and SV40-transformed VA-13 cell line, respectively. Induction of E2F97 by tetracycline withdrawal resulted in strong inhibition of the E2F transcriptional activity and a decreased percentage of cells in S-phase, To understand the mechanism(s) by which E2F97 exerts its effect on the cell cycle, the effect of E2F97 on expression of various cell cycle proteins was examined. Upon induction of E2F97, a significant decrease in the levels of both dihydrofolate reductase and thymidylate synthase was observed in transfectants derived from both cell lines. Induction of E2F97 also led to a decrease in cyclin A and D1 protein levels. Regulation of cyclin A by E2F97 occurred at the transcriptional level. In addition, in VA13 cells, induction of E2F97 resulted in downregulation of the tumor suppressor protein p53. These data suggest that E2F regulates both G1 and S-phase cyclins and that there may be a potential positive feedback regulatory loop between E2F and cyclin D1.	MEM SLOAN KETTERING CANC CTR, PROGRAM MOL PHARMACOL & THERAPEUT, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [T32CA062948, P01CA047179] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-47179, CA62948-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCK V, 1995, ONCOGENE, V11, P31; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Geng Y, 1996, ONCOGENE, V12, P1173; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERBER B, 1994, ONCOGENE, V9, P1295; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRAMA T, 1995, BLOOD, V86, P841; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSON LF, 1994, J CELL BIOCHEM, V54, P387, DOI 10.1002/jcb.240540405; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; LI Y, 1994, ONCOGENE, V9, P2261; LOWKVIST B, 1986, DEV BIOL, V116, P291, DOI 10.1016/0012-1606(86)90132-6; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MAYOL X, 1995, ONCOGENE, V11, P801; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; North S, 1996, CELL GROWTH DIFFER, V7, P339; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OSWALD F, 1994, ONCOGENE, V9, P2029; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETERS G, 1994, J CELL SCI, P89; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	86	53	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	1997	14	10					1191	1200		10.1038/sj.onc.1200940	http://dx.doi.org/10.1038/sj.onc.1200940			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121768				2022-12-17	WOS:A1997WM78200008
J	Takenoshita, S; Tani, M; Nagashima, M; Hagiwara, K; Bennett, WP; Yokota, J; Harris, CC				Takenoshita, S; Tani, M; Nagashima, M; Hagiwara, K; Bennett, WP; Yokota, J; Harris, CC			Mutation analysis of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human colon cancer using genomic DNA and Intron primers	ONCOGENE			English	Article						transforming growth factor beta type II receptor; colon carcinogenesis; tumor biology	MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; CARCINOMA-CELLS; TGF-BETA	Mutations in the transforming growth factor beta type II receptor (TGF beta RII) gene have been detected in several human cancers exhibiting microsatellite instability. To extend analyses of this gene, we previously investigated the exon-intron organization of the TGF beta RII. gene and defined seven exons and flanking intron sequences. In this study, we further determined the nucleotide sequences surrounding these seven exons and designed eight sets of intron-based primers to examine the entire coding region of the TGF beta RII gene. Using these primers, we screened genomic DNA sequences from 30 sporadic colorectal cancers for mutations of the TGF beta RII. gene. TGF beta RII mutations were detected in two of 30 tumors and both displayed microsatellite instability. One had a deletion in a polyadenine tract in exon 3 and the other had a point mutation in the kinase domain located in exon 7. There were no mutations in exons 1, 2, 4, 5 and 6. These results further implicate the polyadenine tract and kinase domain as mutational hotspots in the TGF beta RII gene in cells,vith genomic instability and suggest that TGF beta RII gene mutations occur rarely in cells lacking genomic instability.	NCI,HUMAN CARCINOGENESIS LAB,NIH,BETHESDA,MD 20892; NATL CANC CTR,RES INST,DIV BIOL,TOKYO 104,JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Japan								GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; Hagiwara K, 1996, NUCLEIC ACIDS RES, V24, P2460, DOI 10.1093/nar/24.12.2460; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ISHIMARU G, 1995, INT J CANCER, V64, P153, DOI 10.1002/ijc.2910640302; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Takenoshita S, 1996, GENOMICS, V36, P341, DOI 10.1006/geno.1996.0471; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044	12	53	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1255	1258		10.1038/sj.onc.1200938	http://dx.doi.org/10.1038/sj.onc.1200938			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121777				2022-12-17	WOS:A1997WM78200017
J	Adachi, Y; Matsubara, S; Pedraza, C; Ozawa, M; Tsutsui, J; Takamatsu, H; Noguchi, H; Akiyama, T; Muramatsu, T				Adachi, Y; Matsubara, S; Pedraza, C; Ozawa, M; Tsutsui, J; Takamatsu, H; Noguchi, H; Akiyama, T; Muramatsu, T			Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1)	ONCOGENE			English	Article						Wilms' tumor; WT1; midkine	ACID-RESPONSIVE GENE; GROWTH-DIFFERENTIATION FACTOR; EMBRYONAL CARCINOMA-CELLS; ZINC FINGER PROTEIN; FACTOR-II GENE; FACTOR-A-CHAIN; MOUSE EMBRYOGENESIS; KIDNEY DEVELOPMENT; CHLORAMPHENICOL ACETYLTRANSFERASE; TERATOCARCINOMA SYSTEM	Midkine (MK) is a heparin-binding growth factor which is strongly expressed during the midgestation period of mouse embryogenesis. Wilms' tumor is an embryonal kidney malignancy in infants, and WT1 has been identified as its tumor suppressor gene. The high expression level of MK in all Wilms' tumor specimens so far examined and the presence of two WT1 elements (5-GCGGGGGCG-3') in the human MK promoter region led us to examine the possible role of the WT1 gene product in the regulation of MK gene expression. A gel shift assay verified the complex formation between the WT1 gene product and WT1 consensus sequence of MK gene. DNase1 footprint analysis also demonstrated that the downstream WT1 element was protected from DNase1 cleavage by the addition of the WT1 protein. The human MK promoter fused with the chloramphenicol acetyltransferase gene (phMK2.3kCAT) was cotransfected with an effector plasmid containing the WT1 gene into several cell lines. Transient transfection assays showed suppression of the MK promoter by WT1 co-transfection in recipient cells; deletion of the WT1 binding site abolished the suppression. The evidence reported in this study indicates that MK gene is a newly identified WT1 target gene.	KAGOSHIMA UNIV,FAC MED,DEPT PEDIAT SURG,KAGOSHIMA 890,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,SCH MED,DEPT BIOCHEM,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Kagoshima University; Osaka University; Nagoya University	Adachi, Y (corresponding author), KAGOSHIMA UNIV,FAC MED,DEPT BIOCHEM,8-35-1 SAKURAGAOKA,KAGOSHIMA 890,JAPAN.							ARIDOME K, 1995, JPN J CANCER RES, V86, P655, DOI 10.1111/j.1349-7006.1995.tb02449.x; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; BRENNER B, 1992, ONCOGENE, V7, P1431; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1993, J PEDIATR-US, V123, P673, DOI 10.1016/S0022-3476(05)80839-X; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FRAIZER GE, 1987, J CELL PHYSIOL, V133, P169, DOI 10.1002/jcp.1041330122; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; GANSLER T, 1989, AM J PATHOL, V135, P961; GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOODYER P, 1995, ONCOGENE, V10, P1125; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P227; HANAOKA K, 1991, DIFFERENTIATION, V48, P183, DOI 10.1111/j.1432-0436.1991.tb00256.x; HARBOMEL P, 1984, CELL, V39, P653; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KADOMATSU K, 1990, J CELL BIOL, V110, P607, DOI 10.1083/jcb.110.3.607; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEISENRING WM, 1994, CANCER RES, V54, P4680; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUBARA S, 1994, J BIOCHEM-TOKYO, V115, P1088, DOI 10.1093/oxfordjournals.jbchem.a124462; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS JF, 1991, ONCOGENE, V6, P2339; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; MURAMATSU T, 1993, INT J DEV BIOL, V37, P183; NAKAMOTO M, 1992, J BIOCHEM-TOKYO, V112, P346, DOI 10.1093/oxfordjournals.jbchem.a123903; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PEDRAZA C, 1995, J BIOCHEM-TOKYO, V117, P845; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; RYAN G, 1995, DEVELOPMENT, V121, P867; SAWAI S, 1991, NEW BIOL, V3, P861; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; TOMOMURA M, 1990, J BIOL CHEM, V265, P10765; TSUTSUI J, 1993, CANCER RES, V53, P1281; UEHARA K, 1992, J BIOCHEM-TOKYO, V111, P563, DOI 10.1093/oxfordjournals.jbchem.a123797; WABER PG, 1993, CANCER, V72, P3732, DOI 10.1002/1097-0142(19931215)72:12<3732::AID-CNCR2820721228>3.0.CO;2-U; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1992, J BIOL CHEM, V267, P21999	53	53	60	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2197	2203						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950987				2022-12-17	WOS:A1996VV14500017
J	Muller, BF; Paulsen, D; Deppert, W				Muller, BF; Paulsen, D; Deppert, W			Specific binding of MAR/SAR DNA-elements by mutant p53	ONCOGENE			English	Review						oncogenic function of mutant p53; MAR/SAR DNA-elements; binding of MAR/SAR DNA-elements by mutant p53	WILD-TYPE P53; SCAFFOLD-ATTACHED REGIONS; LARGE-T-ANTIGEN; CHROMOSOMAL LOOP ANCHORAGE; TUMOR SUPPRESSOR GENE; AMINO-ACID-SEQUENCE; CELL-CYCLE CONTROL; A MOUSE CELLS; SIMIAN VIRUS-40; MONOCLONAL-ANTIBODY	Inactivation of the tumor suppressor p53 by single missense point mutations characterizes a large number of human tumors, At least some mutant p53 proteins not only have lost the tumor suppressor function, but at the same time reveal a variety of dominant oncogenic properties. The molecular basis of this 'gain of function' is still unknown. In this report we describe a new biochemical activity of mutant p53, the specific high-affinity interaction with MAR/SAR DNA-elements (nuclear matrix/scaffold attachment regions). This DNA-binding activity can be distinguished from the previously reported DNA-binding activities of p53 by its specificity for mutant p53, the high binding affinity, and the domains of the mutant p53 molecule involved in MAR/SAR DNA-binding. The MAR/SAR-binding region of mutant p53 maps to a bipartite domain consisting of the mutated core region and the C-terminal 60 amino acids, carrying the unspecific DNA-binding domain and the oligomerization motif. MAR/SAR elements are considered as important regulatory elements in a variety of nuclear processes. We propose a model according to which the specific interaction of mutant p53 with MAR/SAR elements might interfere with these processes, thereby exerting pleiotropic oncogenic effects.	UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, D-20251 HAMBURG, GERMANY	Heinrich Pette Institute; University of Hamburg								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ANDERSON JN, 1986, NUCLEIC ACIDS RES, V14, P8513, DOI 10.1093/nar/14.21.8513; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARTEK J, 1990, ONCOGENE, V5, P893; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; BERTHOLD H, 1992, PROTEIN EXPRES PURIF, V3, P50, DOI 10.1016/1046-5928(92)90055-2; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; Bode J, 1995, INT REV CYTOL, V162A, P389; BOULIKAS T, 1992, J CELL BIOCHEM, V50, P111, DOI 10.1002/jcb.240500202; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P513, DOI 10.1002/jcb.240550411; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; BRAIN R, 1994, ONCOGENE, V9, P1775; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DEPPERT W, 1990, ONCOGENE, V5, P1701; DEPPERT W, 1994, INT CONGR SER, V1050, P11; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Gai X X, 1988, Oncogene Res, V3, P377; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HERBOMEL P, 1990, NEW BIOL, V39, P937; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIESER A, 1994, ONCOGENE, V9, P963; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEGROS Y, 1994, ONCOGENE, V9, P3689; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MAH DCW, 1993, J CELL SCI, V105, P807; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; POLACK A, 1991, ONCOGENE, V6, P2033; POLJAK L, 1994, NUCLEIC ACIDS RES, V22, P4386, DOI 10.1093/nar/22.21.4386; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reed Michael, 1993, Gene Expression, V3, P95; ROVINSKI B, 1988, ONCOGENE, V2, P445; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHMIEG FI, 1993, ONCOGENE, V8, P2043; SCHWYZER M, 1977, C INSERM, V69, P63; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1991, CANCER RES, V51, P5232; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TARUNINA M, 1993, ONCOGENE, V8, P3165; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEIDT G, 1994, J IMMUNOL, V153, P2554; WEISSKER SN, 1992, ONCOGENE, V7, P1921; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZERRAHN J, 1992, ONCOGENE, V7, P1371; ZHIVOTOVSKY B, 1994, FEBS LETT, V351, P150, DOI 10.1016/0014-5793(94)00827-2; ZHIVOTOVSKY B, 1994, INT ARCH ALLERGY IMM, V105, P333, DOI 10.1159/000236778; ZHIVOTOVSKY B, 1994, BIOCHEM BIOPH RES CO, V202, P120, DOI 10.1006/bbrc.1994.1901	121	53	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1941	1952						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649855				2022-12-17	WOS:A1996UK49800013
J	Patel, AM; Incognito, LS; Schechter, GL; Wasilenko, WJ; Somers, KD				Patel, AM; Incognito, LS; Schechter, GL; Wasilenko, WJ; Somers, KD			Amplification and expression of EMS-1 (cortactin) in head and neck squamous cell carcinoma cell lines	ONCOGENE			English	Article						cortactin; amplification; head and neck cancer	BREAST-CANCER; CYCLIN D1; GENES; SUBSTRATE; ONCOGENE; IDENTIFICATION; INT-2; ABNORMALITIES; CLONING; REGION	Amplification of chromosome 11q13 DNA sequences is detected in approximately 30% of primary head and neck squamous cell carcinomas (HNSCC). The amplified region includes genes for cyclin D1, hst-1, int-2, and more recently, ems-1, Ems-1 encodes an 80/85kd cytoskeletal associated protein termed cortactin, which has been shown to bind F-actin and is a pp60src substrate. We investigated 16 HNSCC cell Lines for ems-1 DNA amplification and gene expression by western blotting and immunofluorescence using mAb 4F11. Amplification of ems-1 DNA was detected in 8/16 (50%) cell lines and was related directly to overexpression of cortactin by western blotting and immunofluorescence, Western blotting detected both forms of cortactin, p80 and p85, at equal intensity. Immunofluorescent staining revealed low levels of cortactin localized to the cytoplasm and surface membrane in normal bronchial epithelial cells and tumor cell cultures with single copy ems-1 DNA. In contrast, tumor cell cultures with ems-1 DNA amplification demonstrated intense, homogeneous cortactin cytoplasmic staining. These results suggest that overexpression of p80/85 may be a useful marker to identify 11q13 amplification, a molecular alteration correlated with the presence of lymph node metastasis in head and neck cancer.	EASTERN VIRGINIA MED SCH,DEPT MICROBIOL & IMMUNOL,NORFOLK,VA 23501; EASTERN VIRGINIA MED SCH,DEPT OTOLARYNGOL HEAD & NECK SURG,NORFOLK,VA 23501; EASTERN VIRGINIA MED SCH,HEAD & NECK TUMOR BIOL PROGRAM,NORFOLK,VA 23501	Eastern Virginia Medical School; Eastern Virginia Medical School; Eastern Virginia Medical School								ADELAIDE J, 1988, ONCOGENE, V2, P413; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; Field J K, 1992, Eur J Cancer B Oral Oncol, V28B, P67, DOI 10.1016/0964-1955(92)90016-T; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P430; LOVEC H, 1994, ONCOGENE, V9, P323; MAA MC, 1992, ONCOGENE, V7, P2429; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER D, 1994, ORAL ONCOL, V30B, P113; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; SOMERS KD, 1992, CANCER RES, V52, P5997; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; TSUDA T, 1989, CANCER RES, V49, P5505; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; XU L, 1994, INT J CANCER, V59, P383, DOI 10.1002/ijc.2910590316; ZHAN X, 1993, J BIOL CHEM, V268, P24427	33	53	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					31	35						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552396				2022-12-17	WOS:A1996TQ01400004
J	Cooper, HM; Armes, P; Britto, J; Gad, J; Wilks, AF				Cooper, HM; Armes, P; Britto, J; Gad, J; Wilks, AF			Cloning of the mouse homologue of the deleted in colorectal cancer gene (mDCC) and its expression in the developing mouse embryo	ONCOGENE			English	Article						DCC; tumorigenesis; sequence; embryogenesis; neural tube	TUMOR-SUPPRESSOR GENE; ADHESION MOLECULE NCAM; MESSENGER-RNA; FREQUENT LOSS; DCC; HETEROZYGOSITY; CARCINOMAS; GROWTH	Loss of DCC gene expression has now been demonstrated in a wide variety of metastatic cancers. Here we present the nucleotide sequence and predicted amino acid sequence of mouse DCC, Mouse and human DCC share 96% identity at the amino acid level, Analysis of DCC mRNA expression throughout the mid to late stages of gestation in the mouse, demonstrated that DCC mRNA is expressed at significantly higher levels in the developing mouse embryo than in any adult tissue, In addition, we show that an embryo-specific, alternatively spliced, form of DCC is expressed in day 9.5 through day 18.5 embryos. The expression of both alternatively spliced forms of DCC is developmentally regulated such that the embryonic form of DCC predominates in day 9.5 and 10.5 embryos. In the later stage embryos the expression of this alternatively spliced form of DCC is down-regulated with respect to that of the adult form, Whole-mount in situ hybridization of day 11.5 mouse embryos revealed that DCC mRNA is expressed at high levels in the developing brain and the neural tube, However, no DCC mRNA could be detected in any other embryonic tissue at this stage of development, These observations suggest that during embryogenesis DCC may play a pivotal role in the development of the central nervous system.	ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Cooper, HM (corresponding author), LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA.		Wilks, Andrew F/R-5542-2019; Cooper, Helen/G-3505-2010; COOPER, HOWARD/M-7304-2014; Cooper, Helen M/AAA-2182-2019	Cooper, Helen M/0000-0001-9838-5743; Wilks, Andrew F/0000-0002-8554-2399				Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BIXBY JL, 1991, ANNU REV CELL BIOL, V7, P117, DOI 10.1146/annurev.cellbio.7.1.117; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CHOWCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; CONLON RA, 1992, DEVELOPMENT, V116, P357; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DEVILEE P, 1991, ONCOGENE, V6, P311; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; ENOMOTO T, 1995, BRIT J CANCER, V71, P462, DOI 10.1038/bjc.1995.94; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GAO X, 1993, CANCER RES, V53, P2723; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; HUANG Y, 1992, CANCER RES, V52, P6525; IONO H, 1994, CANCER, V73, P1324; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; MIYAKE K, 1993, BLOOD, V82, P927; MIYAKE S, 1994, CANCER RES, V54, P3007; OELERICHS RB, 1993, ONCOGENE, V8, P11; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; PIERCEALL WE, 1994, DEV BIOL, V166, P654, DOI 10.1006/dbio.1994.1345; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; PORFIRI E, 1993, BLOOD, V81, P2696; REALE MA, 1994, CANCER RES, V54, P4493; RUGH R, 1991, MOUSE ITS REPRODUCTI; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECK AC, 1993, CANCER RES, V53, P5605; UCHINO S, 1992, CANCER RES, V52, P3099; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; ZORN AM, 1992, DEV BIOL, V149, P197, DOI 10.1016/0012-1606(92)90276-M	42	53	55	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2243	2254						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570174				2022-12-17	WOS:A1995TK70200007
J	Kobayashi, T; Consoli, U; Andreeff, M; Shiku, H; Deisseroth, AB; Zhang, W				Kobayashi, T; Consoli, U; Andreeff, M; Shiku, H; Deisseroth, AB; Zhang, W			Activation of p21(WAF1/Cip1) expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis	ONCOGENE			English	Article						p21; temperature-sensitive p53; K562 cells; apoptosis	WILD-TYPE P53; CELL-LINE; INHIBITION; GROWTH; TRANSFORMATION; SUPPRESSION; KINASES; P21	The cyclin-dependent kinase inhibitor p21(WAF1/Cip1) (p21) inhibits cellular proliferation and has been implicated in p53-dependent apoptosis. In this study, we examined the regulation of p21 in the K562 erythroleukemia cell line using a human temperature-sensitive mutant of p53, 143Ala. We showed that 143Ala at the permissive temperature (32 degrees C) activated the expression of p21. Stable cell lines expressing 143Ala or other p53 mutants were established. We then examined whether elevation of p21 promotes apoptosis and sensitizes cells to radiation-induced apoptosis. Our results showed that p21 elevation did not promote or sensitize K562 cells to apoptosis.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT NEUROONCOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT HEMATOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA; MIE UNIV, SCH MED, DEPT INTERNAL MED 2, TSU, MIE 514, JAPAN	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Mie University			Consoli, Ugo/ADT-6954-2022		NATIONAL CANCER INSTITUTE [R01CA057639, P30CA016672, P01CA055164] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA55164, CA57639, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; GORCZYCA W, 1993, CANCER RES, V53, P1945; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JUNG JM, 1995, CELL GROWTH DIFFER, V6, P909; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LINDENBOIM L, 1995, CANCER RES, V55, P1242; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PROSSER J, 1990, ONCOGENE, V5, P1573; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAMQVIST T, 1993, ONCOGENE, V8, P1495; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHANG W, 1995, CANCER RES, V55, P668	43	53	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2311	2316						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570182				2022-12-17	WOS:A1995TK70200015
J	Takahashi, K; Stamenkovic, I; Cutler, M; Saya, H; Tanabe, KK				Takahashi, K; Stamenkovic, I; Cutler, M; Saya, H; Tanabe, KK			CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas	ONCOGENE			English	Article						CD44; hyaluronate; colon carcinoma; adhesion molecule; metastases	LYMPHOCYTE-HOMING RECEPTOR; CELL-SURFACE GLYCOPROTEIN; NON-HODGKINS-LYMPHOMA; MONOCLONAL-ANTIBODIES; TUMOR-GROWTH; FIBRONECTIN RECEPTOR; ACID BINDING; EXPRESSION; ADHESION; VARIANT	CD44 is a cell surface receptor for hyaluronate that is implicated in the regulation of tumor growth and metastatic potential. Transformation of colon mucosa to carcinoma is associated with overexpression of several CD44 alternative splice variants. The functional roles of CD44 isoforms in colon carcinoma tumor progression remain unclear. CD44H expression is downregulated in colon carcinomas compared to paired normal mucosa. In the present study we demonstrate that reintroduction of CD44H back into colon carcinoma cells by stable transfection reduces their in vitro growth rate and tumorigenicity. Examination of several colon carcinoma cell lines and use of mutant CD44H reveal that this in vitro and irt vivo growth reduction requires the ability of CD44H to bind hyaluronate. These observations indicate that the CD44H downregulation associated with transformation of mucosa to colon carcinoma may provide the carcinoma cells with a growth advantage. Furthermore, the reduction in tumor growth rate mediated by reintroduction of CD44H into colon carcinoma cells is dependent on its ability to bind hyaluronate.	MASSACHUSETTS GEN HOSP, DEPT SURG, DIV SURG ONCOL, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA; KUMAMOTO UNIV, SCH MED, DEPT ONCOL, KUMAMOTO 860, JAPAN	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Kumamoto University			Saya, Hideyuki/J-4325-2013		NCI NIH HHS [CA64454, CA55735] Funding Source: Medline; NIDDK NIH HHS [DK433351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064454, R01CA055735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BIRCH M, 1991, CANCER RES, V51, P6660; BROWN PJ, 1985, SCIENCE, V228, P1448, DOI 10.1126/science.4012302; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CANNISTRA SA, 1993, CANCER RES, V53, P3830; COOPER DL, 1992, BIOCHEM BIOPH RES CO, V182, P569, DOI 10.1016/0006-291X(92)91770-Q; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; FOX SB, 1994, CANCER RES, V54, P4539; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P4654, DOI 10.1073/pnas.86.12.4654; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUO YJ, 1994, CANCER RES, V54, P422; GUO YJ, 1994, CANCER RES, V54, P1561; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1991, CANCER RES, V51, P5292; HORST E, 1990, LEUKEMIA, V4, P595; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; JALKANEN S, 1991, J CLIN INVEST, V87, P1835, DOI 10.1172/JCI115205; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; JOENSUU H, 1993, AM J PATHOL, V143, P867; JOENSUU H, 1993, BRIT J CANCER, V68, P428, DOI 10.1038/bjc.1993.354; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MORIKAWA K, 1988, CANCER RES, V48, P1943; MULDER JWR, 1994, LANCET, V344, P1470, DOI 10.1016/S0140-6736(94)90290-9; NAGASAKA S, 1995, J NEUROSURG, V82, P858, DOI 10.3171/jns.1995.82.5.0858; PALS ST, 1989, BLOOD, V73, P885; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; SCHREINER C, 1991, CANCER RES, V51, P1738; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; SY MS, 1992, J EXP MED, V176, P623, DOI 10.1084/jem.176.2.623; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TANABE KK, 1995, ANN SURG, V222, P493; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TANABE KK, 1993, MOL CARCINOGEN, V7, P212, DOI 10.1002/mc.2940070403; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; TOLG C, 1993, NUCLEIC ACIDS RES, V21, P1225, DOI 10.1093/nar/21.5.1225; TOOLE BP, 1979, P NATL ACAD SCI USA, V76, P6299, DOI 10.1073/pnas.76.12.6299; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; WIELENGA VJM, 1993, CANCER RES, V53, P4754; ZHANG LR, 1995, CANCER RES, V55, P428	56	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2223	2232						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570172				2022-12-17	WOS:A1995TK70200005
J	PRICE, BD; HUGHESDAVIES, L; PARK, SJ				PRICE, BD; HUGHESDAVIES, L; PARK, SJ			CDK2 KINASE PHOSPHORYLATES SERINE-315 OF HUMAN P53 IN-VITRO	ONCOGENE			English	Article						P53; CDK2; PHOSPHORYLATION; DNA DAMAGE; TRANSCRIPTION	CELL-CYCLE CONTROL; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; MAMMALIAN-CELLS; GENE; INHIBITION; P34CDC2	DNA damage increases p53 protein levels and activates transcription of the p21 gene. The p21 protein binds to and inhibits cdk2 kinase, causing G1 arrest. Here, we have investigated if a p53 fusion protein is a substrate for cdk2 kinase in vitro. Cdk2 kinase was immunoprecipitated from NIH3T3 cells and allowed to phosphorylate a human p53-GST (glutathione-s-transferase) fusion protein. Cdk2 and cyclin E-cdk2 efficiently phosphorylated both wild-type (wt) and mutant p53-GST. Cdk2 immunoprecipitated from cells in Go and early G1 exhibited minimal p53 kinase activity, whereas cells in S-phase displayed high levels of p53 kinase activity. If NIH3T3 cells were X-ray irradiated to induce DNA damage, cdk2 p53 kinase activity was rapidly inhibited within 1 h, but had recovered by 4 h post irradiation. Mutation of serine 315 of p53 to alanine (p53-S315A) abolished phosphorylation by cdk2 kinase. However, wtp53 and p53-S315A were equally effective at activating transcription when cotransfected with a p53 reporter construct. The results demonstrate that ser 315 of p53 is phosphorylated by cdk2 in vitro. However, ser 315 of wtp53 is not required for transcriptional activity in vivo, suggesting that cdk2 phosphorylation of p53 may be involved in regulating other cellular functions of wtp53.			PRICE, BD (corresponding author), DANA FARBER CANC INST,JOINT CTR RADIAT THERAPY,STRESS PROT GRP,44 BINNEY ST,BOSTON,MA 02115, USA.				NCI NIH HHS [CA64585] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BADER SB, 1992, J CELL PHYSIOL, V151, P56, DOI 10.1002/jcp.1041510110; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHO Y, 1994, NATURE, V265, P346; CROOK T, 1994, EMBO J, V79, P817; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUERBITZ SJ, 1991, SCIENCE, V252, P1708; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIN X, 1993, MOL CELL BIOL, V13, P3291; LOCK RB, 1990, CANCER RES, V50, P3761; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRICE BD, 1994, CANCER RES, V54, P896; PRICE BD, 1993, ONCOGENE, V8, P3055; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEVENSON MA, 1994, CANCER RES, V54, P12; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TARUNINA M, 1993, ONCOGENE, V8, P3165; TISHLER RB, 1993, CANCER RES, V53, P2212; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHANG W, 1994, CELL GROWTH DIFFER, V5, P705	55	53	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					73	80						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624134				2022-12-17	WOS:A1995RJ29500009
J	LICHTNER, RB; KAUFMANN, AM; KITTMANN, A; ROHDESCHULZ, B; WALTER, J; WILLIAMS, L; ULLRICH, A; SCHIRRMACHER, V; KHAZAIE, K				LICHTNER, RB; KAUFMANN, AM; KITTMANN, A; ROHDESCHULZ, B; WALTER, J; WILLIAMS, L; ULLRICH, A; SCHIRRMACHER, V; KHAZAIE, K			LIGAND-MEDIATED ACTIVATION OF ECTOPIC EGF RECEPTOR PROMOTES MATRIX PROTEIN ADHESION AND LUNG COLONIZATION OF RAT MAMMARY ADENOCARCINOMA CELLS	ONCOGENE			English	Article						EGF RECEPTOR; METASTASIS; MATRIX	EPIDERMAL-GROWTH-FACTOR; HUMAN-BREAST CANCER; CARCINOMA-CELLS; TRANSGENIC MICE; TGF-ALPHA; METASTATIC PROPERTIES; DUCTAL MORPHOGENESIS; EXTRACELLULAR-MATRIX; ESTROGEN-RECEPTORS; EXPRESSION	Increased expression of EGF receptor (EGFR) in metastases of human mammary carcinoma as compared to cells of the primary cancer suggests a contribution of EGFR to mammary carcinoma metastasis. To test for a positive causative link, we investigated 13762NF rat mammary adenocarcinoma cloned tumor cell lines of high (MTLn3) or low (MTC) metastatic potential, While MTC cells expressed barely detectable amounts of EGFR, MTLn3 cells expressed readily detectable levels of functional receptors. A full length cDNA of the human EGFR (HER) was introduced by infection with a retroviral vector into MTC cells, Expression of HER was stable and receptors were functional with respect to surface expression, ligand binding and EGF-stimulated phosphorylation, Independent clones of the transfectants were isolated and characterized. Ligand stimulation of MTC HER cells and derived clones led to enhanced adhesion of tells to extracellular matrix proteins. Implantation of cells intravenously into female nu/nu mice revealed ligand-dependent enhancement of lung colonizing potential of EGFR-expressing cells.	GERMAN CANC RES CTR, DIV CELLULAR IMMUNOL, D-69120 HEIDELBERG, GERMANY; ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE, VIC 3050, AUSTRALIA; MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Max Planck Society	LICHTNER, RB (corresponding author), SCHERING AG, RES LABS, MULLERSTR 170-178, D-13342 BERLIN, GERMANY.			Kaufmann, Andreas/0000-0001-7732-3009				ADELMANNGRILL BC, 1990, EUR J CELL BIOL, V51, P322; BARKER S, 1989, BRIT J CANCER, V60, P673, DOI 10.1038/bjc.1989.338; BATTAGLIA F, 1988, EUR J CANCER CLIN ON, V24, P1685, DOI 10.1016/0277-5379(88)90068-5; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; BOYD D, 1989, CANCER RES, V49, P2427; CAMPOSGONZALEZ R, 1990, CELL MOTIL CYTOSKEL, V15, P34, DOI 10.1002/cm.970150106; CHAUDHRY A, 1994, CANCER RES, V54, P981; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; DITTADI R, 1993, BRIT J CANCER, V67, P7, DOI 10.1038/bjc.1993.2; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; ENGSTROM W, 1986, J CELL SCI, V86, P47; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HART IR, 1991, BRIT J CANCER, V63, P9, DOI 10.1038/bjc.1991.4; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KAUFMANN AM, 1994, INT J ONCOL, V4, P1149; KERBEL RS, 1987, P NATL ACAD SCI USA, V84, P1263, DOI 10.1073/pnas.84.5.1263; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KHAZAIE K, 1991, ONCOGENE, V6, P21; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LAIHO M, 1989, CANCER RES, V49, P2533; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEWIS S, 1990, J CLIN PATHOL, V43, P385, DOI 10.1136/jcp.43.5.385; LICHTNER RB, 1993, CLIN EXP METASTAS, V11, P113, DOI 10.1007/BF00880072; LICHTNER RB, 1992, J BIOL CHEM, V267, P11872; LICHTNER RB, 1988, J CELL PHYSIOL, V137, P285, DOI 10.1002/jcp.1041370211; LICHTNER RB, 1989, EXP CELL BIOL, V57, P146; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NERI A, 1982, J NATL CANCER I, V68, P507; NICHOLSON RI, 1994, BREAST CANCER RES TR, V29, P117, DOI 10.1007/BF00666187; NICHOLSON S, 1991, BRIT J CANCER, V63, P146, DOI 10.1038/bjc.1991.30; NICOLSON G L, 1986, Cancer Reviews, V3, P25; NICOLSON GL, 1992, ONCOGENE, V7, P1127; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; NICOLSON GL, 1983, INT REV EXP PATHOL, V25, P77; NICOLSON GL, 1990, ONCOGENE, V5, P747; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; ROHDESCHULZ B, 1995, IN PRESS INVASION ME; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAINSBURY JRC, 1985, LANCET, V1, P364; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SCHIRRMACHER V, 1985, ADV CANCER RES, V43, P1, DOI 10.1016/S0065-230X(08)60942-2; SCHIRRMACHER V, 1980, IMMUNOBIOLOGY, V157, P89, DOI 10.1016/S0171-2985(80)80091-X; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YU DH, 1994, CANCER RES, V54, P3260	63	53	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1823	1832						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753557				2022-12-17	WOS:A1995QX46900015
J	TASHIRO, S; TAKEMOTO, Y; HANDA, H; ISHII, S				TASHIRO, S; TAKEMOTO, Y; HANDA, H; ISHII, S			CELL-TYPE-SPECIFIC TRANSACTIVATION BY THE B-MYB GENE-PRODUCT - REQUIREMENT OF THE PUTATIVE COFACTOR BINDING TO THE C-TERMINAL CONSERVED DOMAIN	ONCOGENE			English	Article						B-MYB; TRANSACTIVATOR; CELL TYPE SPECIFICITY	NUCLEOTIDE-SEQUENCE; V-MYB; EXPRESSION; TRANSACTIVATION; TRANSFORMATION; PROLIFERATION; PROTOONCOGENE; ONCOGENE; LEUKEMIA; PROTEIN	The myb gene family has three members, c-myb, A-myb and B-myb. We have examined the trans-activating capacity of the B-myb gene product (B-Myb) in various types of cells. B-Myb functions as a transcriptional activator in CV-1 and HeLa cells, but not in NIH3T3 cells, indicating that B-Myb is a cell type-specific transcriptional activator. Deletion analyses of B-Myb have demonstrated that the region conserved between three members of the myb gene family (CR for conserved region) is necessary for trans-activation by B-Myb. An in vivo competition assay suggests that regulatory factor(s) that binds to the CR of B-Myb is required for transactivation. Analyses using an affinity resin show that multiple proteins bind to the CR of B-Myb and that the CR-binding proteins in CV-1 and HeLa cells are different from those in NIH3T3 cells. These results suggest that the CR-binding cofactor(s) is critical for the cell type-specific trans-activation by B-Myb.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; TOKYO INST TECHNOL,FAC LIFE SCI & TECHNOL,DEPT BIOSYST,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	RIKEN; Tokyo Institute of Technology			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				ARSURA M, 1992, BLOOD, V79, P2708; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BROWN KE, 1992, J BIOL CHEM, V267, P4625; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FURUTA Y, 1993, TRANSGENIC RES, V2, P199, DOI 10.1007/BF01977350; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIGUCHI R, 1990, PCR TECHNOLOGY PRINC, P61; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LAM EWF, 1992, ONCOGENE, V7, P1885; MAEKAWA T, 1991, ONCOGENE, V6, P627; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; TAKEMOTO Y, 1994, FEBS LETT, V350, P55, DOI 10.1016/0014-5793(94)00733-0; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; TIJAN R, 1994, CELL, V77, P5; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	44	53	53	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1699	1707						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753546				2022-12-17	WOS:A1995QX46900002
J	CASTAGNINO, P; BIESOVA, Z; WONG, WT; FAZIOLI, F; GILL, GN; DIFIORE, PP				CASTAGNINO, P; BIESOVA, Z; WONG, WT; FAZIOLI, F; GILL, GN; DIFIORE, PP			DIRECT BINDING OF EPS8 TO THE JUXTAMEMBRANE DOMAIN OF EGFR IS PHOSPHOTYROSINE-INDEPENDENT AND SH2-INDEPENDENT	ONCOGENE			English	Article						EPS8; EGFR; JUXTAMEMBRANE; BINDING	GROWTH-FACTOR RECEPTOR; SIGNALING PROTEINS; TYROSINE KINASES; SH3 DOMAINS; PHOSPHORYLATION; SPECIFICITY; THREONINE; ERBB-2	Several signal transducers bind through their SH2 domains to phosphotyrosine-containing motifs present in receptor tyrosine kinases (RTKs). However, the juxtamembrane regions of the epidermal growth factor receptor (EGFR) and of the related erbB-2 protein, while important in mitogenic signaling, lack demonstrable tyrosine phosphorylation sites, suggesting that other modalities of receptor-transducer interactions exist. A candidate for investigating this type of association is p97(eps8), a recently described substrate for RTKs. p97(eps8) is phosphorylated by several RTKs, associates with EGFR in vivo and, upon overexpression, enhances the transduction of EGFR-mediated mitogenic signals. Here we report that eps8 binds directly to the juxtamembrane region of EGFR through a domain that does not bear resemblance to SH2 domains and by a mechanism that does not require the presence of phosphotyrosine residues. Thus, the physical association between EGFR and eps8 represents a novel interaction between RTKs and their substrates.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; FAC MED & CHIRURG BARI, IST MICROBIOL, BARI, ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego; Universita degli Studi di Bari Aldo Moro			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013149, R01DK013149] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 13149] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COCHET C, 1991, J BIOL CHEM, V266, P637; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHLESSINGER J, 1992, COLD SPRING HARB SYM, V57, P67, DOI 10.1101/SQB.1992.057.01.009; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WONG WT, 1994, ONCOGENE, V9, P3057; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	53	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					723	729						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7532293				2022-12-17	WOS:A1995QH61200012
J	SAPI, E; FLICK, MB; GILMOREHEBERT, M; RODOV, S; KACINSKI, BM				SAPI, E; FLICK, MB; GILMOREHEBERT, M; RODOV, S; KACINSKI, BM			TRANSCRIPTIONAL REGULATION OF THE C-FMS (CSF-1R) PROTOONCOGENE IN HUMAN BREAST-CARCINOMA CELLS BY GLUCOCORTICOIDS	ONCOGENE			English	Article						C-FMS; PROTOONCOGENE; GLUCOCORTICOIDS; BREAST NEOPLASMS; TRANSCRIPTIONAL REGULATION RU486	COLONY-STIMULATING FACTOR; GENE-EXPRESSION; RECEPTOR GENE; MESSENGER-RNA; GROWTH-FACTOR; V-FMS; ADENOCARCINOMAS; MONOCYTES; INVITRO; PRODUCT	Expression of the macrophage colony stimulating factor CSF-1 and its receptor, the c-fms proto-oncogene, has been observed in macrophages, trophoblast and in a variety of neoplasms of epithelial origin including those of the breast. We have reported earlier (Oncogene, 1991, 6: 941-952) that c-fms transcript and protein expression were dramatically increased in several breast carcinoma cell lines by glucocorticoids which are essential humoral regulators of normal mammary epithelial cell differentiation. In this communication, we demonstrate that levels of c-fms transcript and protein increased significantly within the first few hours of glucocorticoid treatment, and that these increases were completely abolished by pretreatment of cells with mifepristone (RU486). We also demonstrate that such early increases in c-fms transcript levels could not be attributed to prolongation of transcript half-life. Both promoters of the c-fms gene were found to exhibit some basal activity in breast carcinoma cell lines and both were stimulated 2-3-fold by glucocorticoids. However the first promoter was shown to be responsible for more than 95% of the observed c-fms transcription. Sequence upstream of both promoters was found to contain potential 'glucocorticoid response elements' (GREs), and in each case, elimination of the GRE closest to the promoter abolished glucocorticoid stimulation. Our observations suggest that one mechanism by which glucocorticoids regulate the proliferation and differentiation of neoplastic mammary epithelial cells is through their regulation of transcription of the gene for the receptor of a ubiquitous cytokine, CSF-1.	YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University					NATIONAL CANCER INSTITUTE [R01CA047292] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-47292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKKER GH, 1987, CANCER TREAT REP, V71, P1021; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BRUCKNER A, 1992, CANCER RES, V52, P3043; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CHAMBERS SK, 1993, EXP HEMATOL, V21, P1328; CHAMBERS SK, 1994, STEROIDS, V59, P514, DOI 10.1016/0039-128X(94)90069-8; COPE CL, 1972, ADRENAL STEROIDS DIS; COUSSENS L, 1986, NATURE, V320, P180; DAITER E, 1992, J CLIN ENDOCR METAB, V74, P850, DOI 10.1210/jc.74.4.850; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FILDERMAN AE, 1992, CANCER RES, V52, P3661; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAGNE D, 1985, J STEROID BIOCHEM, V23, P247, DOI 10.1016/0022-4731(85)90401-7; GAILLARD RC, 1985, J CLIN ENDOCR METAB, V61, P1009, DOI 10.1210/jcem-61-6-1009; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GUSELLA GL, 1990, J IMMUNOL, V111, P3571; HALL RE, 1990, INT J CANCER, V46, P1081, DOI 10.1002/ijc.2910460622; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HEISTERKAMP N, 1983, VIROLOGY, V126, P248, DOI 10.1016/0042-6822(83)90476-2; HORIGUCHI J, 1988, BIOCHEM BIOPH RES CO, V157, P395, DOI 10.1016/S0006-291X(88)80060-3; KACINSKI BM, 1988, INT J RADIAT ONCOL, V15, P823, DOI 10.1016/0360-3016(88)90113-7; KACINSKI BM, 1991, ONCOGENE, V6, P941; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KLIJN JGM, 1989, CANCER RES, V49, P2851; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MANDELONDE T, 1987, HORMONAL MANIPULATIO; Maniatis T., 1982, MOL CLONING; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROBERTS WM, 1992, BLOOD, V79, P586; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; SHERR CJ, 1985, CELL, V41, P666; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WEBER B, 1989, MOL CELL BIOL, V9, P768; WILLIAMS TM, 1989, ANAL BIOCHEM, V176, P28, DOI 10.1016/0003-2697(89)90267-4; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	49	53	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					529	542						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845678				2022-12-17	WOS:A1995QF64800014
J	DAWSON, CW; ELIOPOULOS, AG; DAWSON, J; YOUNG, LS				DAWSON, CW; ELIOPOULOS, AG; DAWSON, J; YOUNG, LS			BHRF1, A VIRAL HOMOLOG OF THE BCL-2 ONCOGENE, DISTURBS EPITHELIAL-CELL DIFFERENTIATION	ONCOGENE			English	Article						BHRF1; BCL-2; EBV; APOPTOSIS; EPITHELIAL	EPSTEIN-BARR-VIRUS; ORAL HAIRY LEUKOPLAKIA; TERMINAL DIFFERENTIATION; HUMAN KERATINOCYTES; B-CELLS; NASOPHARYNGEAL CARCINOMA; GENE-EXPRESSION; INFECTED-CELLS; REPLICATION; PROTEIN	Epstein-Barr virus (EBV) is associated with tumours of both lymphoid and epithelial origin. Whilst a role for EBV latent genes in the development of these malignancies is accepted, it is also possible that viral proteins involved in EBV replication may influence the oncogenic process. BHRF1 is an immediate early protein which has homology with the Bcl-2 oncogene and can protect B cells from apoptosis. In vivo this protein is most abundantly expressed in the upper layers of oral 'hairy' leukoplakia (HL), a benign hyperparakeratotic tongue lesion which represents a focus EBV replication. We have transfected BHRF1 into the human squamous cell carcinoma line SCC12F which retains several features of normal keratinocytes behaviour in vitro. BHRF1 expression in these epithelial cells is associated with a delay in the commitment of cells to terminal differentiation, increased resistance to the DNA damaging drug, cis-platin and enhanced survival under conditions of serum deprivation. As the differentiation of epithelial cells is an apoptotic process, this data strongly suggests that BHRF1 expression delays the terminal differentiation of epithelial cells through the prevention of apoptosis. This effect of BHRF1, which may normally function to promote productive EBV infection, could contribute to the development of EBV-associated tumours.	UNIV BIRMINGHAM, SCH MED, INST CANC STUDIES, BIRMINGHAM B15 2TJ, W MIDLANDS, ENGLAND	University of Birmingham			ELIOPOULOS, ARISTIDES/R-9449-2018; Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/ABI-6632-2020	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COCHET C, 1993, VIROLOGY, V197, P358, DOI 10.1006/viro.1993.1597; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIGILEITNER O, 1986, DIFFERENTIATION, V31, P191, DOI 10.1111/j.1432-0436.1986.tb00400.x; GILLIGAN K, 1990, P NATL ACAD SCI USA, V87, P8790, DOI 10.1073/pnas.87.22.8790; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; GUTSCH DE, 1994, MOL CELL BIOL, V14, P1939, DOI 10.1128/MCB.14.3.1939; HELLER M, 1981, J VIROL, V38, P632, DOI 10.1128/JVI.38.2.632-648.1981; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HICKISH T, 1994, CANCER RES, V54, P2808; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; LEE MA, 1992, J VIROL, V66, P1899, DOI 10.1128/JVI.66.4.1899-1906.1992; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MARCHINI A, 1991, J VIROL, V65, P5991, DOI 10.1128/JVI.65.11.5991-6000.1991; MCCALL CA, 1991, J INVEST DERMATOL, V97, P111, DOI 10.1111/1523-1747.ep12478519; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MILLER G, 1990, J INFECT DIS, V161, P833, DOI 10.1093/infdis/161.5.833; MILLER G, 1990, VIROLOGY, P1921; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NIEDOBITEK G, 1991, J GEN VIROL, V72, P3035, DOI 10.1099/0022-1317-72-12-3035; OITVAI ZN, 1993, CELL, V74, P609; PALLESEN G, 1991, J PATHOL, V165, P289, DOI 10.1002/path.1711650404; PALLESEN G, 1991, BLOOD, V78, P1162; PARKINSON FK, 1983, CARCINOGENESIS, V4, P857, DOI 10.1093/carcin/4.7.857; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; Raab-Traub N, 1992, Semin Cancer Biol, V3, P297; RHEINWALD JG, 1981, CANCER RES, V41, P1657; SANDVEJ K, 1992, HISTOPATHOLOGY, V20, P387, DOI 10.1111/j.1365-2559.1992.tb01008.x; SHIBATA D, 1992, AM J PATHOL, V140, P769; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; THOMAS JA, 1991, AM J PATHOL, V139, P1369; THOMAS JA, 1991, ADV CANCER RES, V57, P329; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YOUNG LS, 1991, J VIROL, V65, P2868, DOI 10.1128/JVI.65.6.2868-2874.1991; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	47	53	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					69	77						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824280				2022-12-17	WOS:A1995QA98000009
J	SHIPLEY, JM; CLARK, J; CREW, AJ; BIRDSALL, S; ROCQUES, PJ; GILL, S; CHELLY, J; MONACO, AP; ABE, S; GUSTERSON, BA; COOPER, CS				SHIPLEY, JM; CLARK, J; CREW, AJ; BIRDSALL, S; ROCQUES, PJ; GILL, S; CHELLY, J; MONACO, AP; ABE, S; GUSTERSON, BA; COOPER, CS			THE T(X18)(P11.2Q11.2) TRANSLOCATION FOUND IN HUMAN SYNOVIAL SARCOMAS INVOLVES 2 DISTINCT LOCI ON THE X-CHROMOSOME	ONCOGENE			English	Article							BREAKPOINT; LIBRARIES	A high proportion of synovial sarcomas contain the reciprocal translocation t(X;18)(p11.2;q11.2). We have previously localized the breakpoint on the X chromosome between the X chromosome marker DXS255 and an ornithine aminotransferase (OAT) pseudogene region designated OATL2. Subsequently by fluorescence in situ hybridization (FISH) we provided evidence that YACs corresponding to the OATL2 locus spanned the breakpoint. In order to confirm the position of this breakpoint cosmids corresponding to the OATL2 region were isolated. Most of these cosmids mapped to four cosmid contigs designated C1-C4. Analysis of two contigs, C1-and C4, using FISH established that in four of six synovial sarcomas examined the breakpoint occurs between these two contigs: C1 lies distal to the breakpoint while C4 is proximal. In contrast we provide evidence that the breakpoint in the remaining two tumours mapped to a second pseudogene region called OATL1 that is telomeric to the OATL2 locus. This heterogeneity of the breakpoint position on the X chromosome explains why in previous mapping studies there have been discrepancies between the results obtained by different laboratories.	INST CANC RES, MOLEC CARCINOGENESIS SECT, SUTTON SM2 5NG, SURREY, ENGLAND; JOHN RADCLIFFE HOSP, IMPERIAL CANC RES FUND, HUMAN GENET LAB, OXFORD OX3 9DU, ENGLAND; HOKKAIDO UNIV, FAC SCI, CHROMOSOME RES UNIT, SAPPORO, HOKKAIDO, JAPAN	University of London; Institute of Cancer Research - UK; University of Oxford; Hokkaido University	SHIPLEY, JM (corresponding author), INST CANC RES, CELL BIOL & EXPTL PATHOL SECT, 15 COTSWOLD RD, SUTTON SM2 5NG, SURREY, ENGLAND.		gusterson, barry a/D-3752-2009; Monaco, Anthony P/A-4495-2010; Chelly, Jamel/J-7528-2015	Monaco, Anthony P/0000-0001-7480-3197; Chelly, Jamel/0000-0002-0939-8719; Shipley, Janet/0000-0001-6748-8678				BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; COOPER CS, 1993, ADV CANCER RES, V60, P75; COOPER CS, 1991, CARCINOGENESIS, V12, P155, DOI 10.1093/carcin/12.2.155; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; Coulson Alan, 1988, P19; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELEEUW B, 1993, ONCOGENE, V8, P1457; DELEEUW B, 1993, GENE CHROMOSOME CANC, V6, P182, DOI 10.1002/gcc.2870060309; Enzinger RM., 2011, SOFT TISSUE TUMORS, P1178; GERAGHTY MT, 1993, GENOMICS, V16, P440, DOI 10.1006/geno.1993.1208; GILGENKRANTZ S, 1990, ONCOGENE, V5, P1063; GREIG GM, 1993, HUM MOL GENET, V2, P1611; KNIGHT JC, 1992, HUM MOL GENET, V1, P633, DOI 10.1093/hmg/1.8.633; KNIGHT JC, 1992, INT J ONCOL, V1, P747; LAFRENIERE RG, 1991, GENOMICS, V10, P276, DOI 10.1016/0888-7543(91)90512-D; LIMON J, 1991, GENE CHROMOSOME CANC, V3, P338, DOI 10.1002/gcc.2870030504; LITTLE PFR, 1987, DNA CLONING PRACTICA, V3, P19; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; NOJIMA T, 1990, ACTA PATHOL JAPON, V40, P486; REEVES BR, 1989, ONCOGENE, V4, P373; RUBIN CM, 1988, P NATL ACAD SCI USA, V85, P2795, DOI 10.1073/pnas.85.8.2795; SHENG WW, 1987, CANCER GENET CYTOGEN, V29, P179, DOI 10.1016/0165-4608(87)90048-3; SHIPLEY JM, 1993, CYTOGENET CELL GENET, V64, P233, DOI 10.1159/000133585; SMITH S, 1987, CANCER GENET CYTOGEN, V26, P179, DOI 10.1016/0165-4608(87)90147-6; SONOBE H, 1992, LAB INVEST, V67, P498; TACHIBANA K, 1993, GENE, V124, P231, DOI 10.1016/0378-1119(93)90398-M; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160	29	53	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1994	9	5					1447	1453						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152806				2022-12-17	WOS:A1994NH40100017
J	CHAN, AML; MCGOVERN, ES; CATALANO, G; FLEMING, TP; MIKI, T				CHAN, AML; MCGOVERN, ES; CATALANO, G; FLEMING, TP; MIKI, T			EXPRESSION CDNA CLONING OF A NOVEL ONCOGENE WITH SEQUENCE SIMILARITY TO REGULATORS OF SMALL GTP-BINDING PROTEINS	ONCOGENE			English	Article							SIGNAL TRANSDUCTION; VAV PROTOONCOGENE; SACCHAROMYCES-CEREVISIAE; TRANSFORMING ACTIVITY; GENE-PRODUCT; CELL-CYCLE; PROTO-DBL; CANCER; CDC24; RECEPTOR	We generated a cDNA expression library from a human mammary epithelial cell line for detection of novel oncogenes by focus formation assay in NIH3T3 cells. A morphologically unique focus was identified and the transforming plasmid was isolated. The transforming gene, designated TIM, encoded a predicted protein species of 60 kDa containing a Dbl-Homology (DH) motif. This motif is also present in other growth regulatory molecules including Bcr, Cdc24, Vav, Ras-grf, and Ect2 which have been implicated as regulators of small GTP-binding proteins. NIH3T3 cells transfected with TIM expression plasmid showed altered growth properties in vitro and were tumorigenic when injected into nude mice. The 6.5 kilobasepair (kb) transcript of the TIM gene was mainly expressed in kidney, liver, pancreas, lung, and placenta. By analysing a panel of human-hamster somatic celt hybrids, we localized the TIM gene to human chromosome 7.			CHAN, AML (corresponding author), NCI, CELLULAR & MOLEC BIOL LAB, BLDG 37, 1E24, BETHESDA, MD 20892 USA.		Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464				ADAMS JM, 1992, ONCOGENE, V7, P611; BOS JL, 1989, CANCER RES, V49, P4682; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AML, 1993, ONCOGENE, V8, P1329; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; DOWNWARD J, 1992, NATURE, V358, P282, DOI 10.1038/358282a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Maniatis T., 1982, MOL CLONING; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1067; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	33	53	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1057	1063						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134109				2022-12-17	WOS:A1994NC04800008
J	HORIO, Y; SUZUKI, H; UEDA, R; KOSHIKAWA, T; SUGIURA, T; ARIYOSHI, Y; SHIMOKATA, K; TAKAHASHI, T; TAKAHASHI, T				HORIO, Y; SUZUKI, H; UEDA, R; KOSHIKAWA, T; SUGIURA, T; ARIYOSHI, Y; SHIMOKATA, K; TAKAHASHI, T; TAKAHASHI, T			PREDOMINANTLY TUMOR-LIMITED EXPRESSION OF A MUTANT ALLELE IN A JAPANESE FAMILY CARRYING A GERMLINE P53 MUTATION	ONCOGENE			English	Note							LI-FRAUMENI SYNDROME; CANCER-PRONE FAMILY; CELL LUNG-CANCER; MESSENGER-RNA; BREAST-CANCER; WILD-TYPE; GENE; SARCOMA; ABNORMALITIES; LESIONS	Germline mutations of p53 have been implicated as a cause of cancer susceptibility in the Li-Fraumeni syndrome. Since inactivation of p53 has been suggested to play an important causative role in lung cancer, the present study of the prevalence of germline mutations in 148 patients with this neoplasm was performed. None of 138 randomly chosen patients were found to carry such mutations, while a single patient had a nonsense mutation at codon 213 among 10 patients selected for early onset and/or occurrence of multiple primary cancers. In contrast to the previous report of biallelic expression of p53 in a case with a germline missense mutation, preferential expression of the wild-type allele was observed in the heterozygous state in both normal lung and peripheral blood lymphocytes of our case, whereas expression of mutant mRNA was readily detectable in her lung cancer in the absence of the remaining wild-type allele. Interestingly, the family history of the proband showed a mild aggregation of adulthood cancers and a high prevalence of stomach cancer, a rare component in American families affected by the syndrome. These observations suggest the presence of heterogeneity with regard to molecular and clinical features of germline p53 mutations.	AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,CLIN LABS,CHIKUSA KU,NAGOYA 464,JAPAN; AICHI CANC CTR HOSP,DEPT INTERNAL MED,CHIKUSA KU,NAGOYA 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nagoya University			Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Horio, Yoshitsugu/0000-0003-4661-6399				CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FELIX CA, 1993, ONCOGENE, V8, P1203; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; HORIO Y, 1993, CANCER RES, V53, P1; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KUROISHI T, 1992, JPN J CLIN ONCOL, V22, P365; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LYNCH HT, 1978, CANCER, V41, P2055, DOI 10.1002/1097-0142(197805)41:5<2055::AID-CNCR2820410554>3.0.CO;2-X; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MATSUDA R, 1993, AM J PATHOL, V142, P339; MINNA JD, 1991, MOL MECHANISMS THEIR, P63; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; UCHINO S, 1993, INT J CANCER, V54, P759, DOI 10.1002/ijc.2910540509; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; 1992, CANCER INCIDENCE 5 C, V6, P876	30	53	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1231	1235						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134126				2022-12-17	WOS:A1994NC04800027
J	NG, IOL; CHUNG, LP; TSANG, SWY; LAM, CL; LAI, ECS; FAN, ST; NG, M				NG, IOL; CHUNG, LP; TSANG, SWY; LAM, CL; LAI, ECS; FAN, ST; NG, M			P53 GENE MUTATION SPECTRUM IN HEPATOCELLULAR CARCINOMAS IN HONG-KONG CHINESE	ONCOGENE			English	Note							TUMOR-SUPPRESSOR GENE; CELL-LINES; CANCER; EXPRESSION; OVEREXPRESSION; AFLATOXIN; INVITRO	To examine the significance of mutation of the p53 tumour suppressor gene in the development of human hepatocellular carcinoma in a high-prevalence area for hepatitis B viral infection but a low-exposure area for aflatoxin B1, the spectrum of p53 gene mutations was examined in 21 tumour samples from Hong Kong Chinese patients, all of whom were HBsAg positive. DNA sequencing covering exons 5 to 9 of the p53 gene and Hae III restriction enzyme digestion for preliminary assessment of mutation at codon 249 were performed. Immunohistochemical staining with anti-p53 monoclonal antibodies was done on both tumour and nontumour liver tissues. Six tumours (28.6%) showed a p53 mutation and all were point mutations. Of the six point mutations, two (9.5%) were at codon 249 and both were G to T transversions (AGG-->ATG and AGG-->AGT transversions). The remaining point mutations were transversions scattered at codon 172 (exon 5), 214 (exon 6), 273 (exon 8) and 330 (exon 9). Mutated p53 protein was detected in five of these six cases with demonstrable point mutations by DNA sequencing, in contrast to none detected in all of the 15 cases without demonstrable point mutations. The presence of p53 mutations, including those at codon 249, did not show a significant association with tumour size, sex, age, tumour invasiveness in terms of liver invasion, microsatellites and venous permeation, cirrhosis and encapsulation, but tumours with low cellular differentiation tended to have a higher incidence (71%) of point mutations than those with high cellular differentiation (8%). In conclusion, both the overall p53 mutation rate and that at codon 249 in HCC in Hong Kong Chinese are lower than those reported in tumours from China and sub-Saharan Africa. The low mutation rate at codon 249 is compatible with a low aflatoxin exposure. A special type of p53 mutation has not been found to be associated with hepatitis B viral infection. Mutations of p53 gene tends to occur in tumours with low cellular differentiation, suggesting a late occurrence in the event of tumour progression.	UNIV HONG KONG,QUEEN MARY HOSP,DEPT SURG,HONG KONG,HONG KONG; UNIV HONG KONG,QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG	University of Hong Kong; University of Hong Kong	NG, IOL (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT PATHOL,HONG KONG,HONG KONG.		Fan, Sheung Tat/C-4138-2009	Ng, Irene Oi-lin/0000-0001-7532-2029				BAKER SJ, 1990, CANCER RES, V50, P7717; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; CAAMANO J, 1991, AM J PATHOL, V139, P839; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHALLEN C, 1992, HEPATOLOGY, V16, P1362, DOI 10.1002/hep.1840160610; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; HARRIS AL, 1991, NATURE, V350, P377, DOI 10.1038/350377a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KASTAN MB, 1991, CANCER RES, V51, P4279; KOHLER MF, 1992, CANCER RES, V52, P1622; LAURENTPUIG P, 1992, HEPATOLOGY, V16, P1171, DOI 10.1016/0270-9139(92)90010-7; LEUNG NWY, 1992, CANCER, V70, P40, DOI 10.1002/1097-0142(19920701)70:1<40::AID-CNCR2820700107>3.0.CO;2-P; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINSELL CA, 1977, T ROY SOC TROP MED H, V71, P471, DOI 10.1016/0035-9203(77)90136-5; LOK ASF, 1990, HEPATOLOGY, V12, P582, DOI 10.1002/hep.1840120322; MURAKAMI Y, 1991, CANCER RES, V51, P3356; NIGRO JM, 1989, NATURE, V342, P505; ODA T, 1992, CANCER RES, V52, P6358; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; SCORSONE KA, 1992, CANCER RES, V52, P1635; SHANK RC, 1972, FOOD COSMET TOXICOL, V10, P51, DOI 10.1016/S0015-6264(72)80046-4; SHANK RC, 1972, FOOD COSMET TOXICOL, V10, P61, DOI 10.1016/S0015-6264(72)80047-6; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; WALKER GJ, 1991, CANCER RES, V51, P4367; 1983, WHO TECH REP SER, V691, P7; 1991, HONG KONG ANN DEP RE; 1992, DATA DEPT HLTH	33	53	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					985	990						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108145				2022-12-17	WOS:A1994MW55100039
J	FREUND, R; BRONSON, RT; BENJAMIN, TL				FREUND, R; BRONSON, RT; BENJAMIN, TL			SEPARATION OF IMMORTALIZATION FROM TUMOR-INDUCTION WITH POLYOMA LARGE T-MUTANTS THAT FAIL TO BIND THE RETINOBLASTOMA GENE-PRODUCT	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; ADENOVIRUS E1A PROTEINS; MIDDLE-T; CELL-CYCLE; TRANSCRIPTION FACTOR; SUSCEPTIBILITY GENE; KINASE-ACTIVITY; EMBRYO FIBROBLASTS; SIMIAN VIRUS-40; WILD-TYPE	The mouse polyomavirus encodes a tumor-suppressor gene inactivator in its large T protein and a proto-oncogene activator in its middle T protein. We have used site-directed mutagenesis to selectively inactivate the former function without affecting the latter. Two mutant viruses were constructed to encode altered large T proteins that fail to bind the retinoblastoma tumor-suppressor gene product pRB, along with normal small and middle T proteins. The pRB-binding mutants proved to be defective in immortalization of primary rat embryo fibroblasts by a variety of tests. Yet they proved capable of transforming both primary and established fibroblasts in culture. Most importantly, the inability of these mutants to bind pRB had little effect on their ability to induce tumors in mice. We conclude that induction of multiple tumor types in this system does not depend on large T-pRB interactions but rather on middle T-dependent pathways. In addition, the ability of this virus to immortalize cells in culture is not essential to its ability to induce tumors in the animal.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NCI NIH HHS [R35-CA44343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BENJAMIN T, 1990, VIROLOGY, P317; BENJAMIN TL, 1970, P NATL ACAD SCI USA, V67, P394, DOI 10.1073/pnas.67.1.394; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; CHESTERS PM, 1990, J GEN VIROL, V71, P449, DOI 10.1099/0022-1317-71-2-449; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; COWIE A, 1986, MOL CELL BIOL, V6, P4344, DOI 10.1128/MCB.6.12.4344; DAWE CJ, 1987, AM J PATHOL, V127, P243; DEBENSKY TW, 1984, J VIROL, V50, P779; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUBENSKY TW, 1991, J VIROL, V65, P342, DOI 10.1128/JVI.65.1.342-349.1991; DYSON N, 1989, CANCER CEL, V7, P235; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ECKHART W, 1969, VIROLOGY, V38, P120, DOI 10.1016/0042-6822(69)90133-0; ECKHART W, 1977, VIROLOGY, V77, P589, DOI 10.1016/0042-6822(77)90484-6; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEUTEUN J, 1976, P NATL ACAD SCI USA, V73, P4169; FLUCK MM, 1979, VIROLOGY, V96, P205, DOI 10.1016/0042-6822(79)90185-5; FLUCK MM, 1977, VIROLOGY, V77, P610, DOI 10.1016/0042-6822(77)90486-X; FREUND R, 1991, J VIROL, V65, P335, DOI 10.1128/JVI.65.1.335-341.1991; FREUND R, 1987, J VIROL, V61, P2232, DOI 10.1128/JVI.61.7.2232-2239.1987; FRIED M, 1965, P NATL ACAD SCI USA, V53, P486, DOI 10.1073/pnas.53.3.486; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARTRIDGE JF, 1991, EMBO J, V10, P3819, DOI 10.1002/j.1460-2075.1991.tb04951.x; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SILVER J, 1978, CELL, V15, P485, DOI 10.1016/0092-8674(78)90018-1; STANELONI RJ, 1977, VIROLOGY, V77, P598, DOI 10.1016/0042-6822(77)90485-8; TALMAGE DA, 1992, VIROLOGY, V187, P734, DOI 10.1016/0042-6822(92)90476-6; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1991, CELL GROWTH DIFFER, V2, P51; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	73	53	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1979	1987						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328987				2022-12-17	WOS:A1992JP42400011
J	LUBBERT, M; MIRRO, J; KITCHINGMAN, G; MCCORMICK, F; MERTELSMANN, R; HERRMANN, F; KOEFFLER, HP				LUBBERT, M; MIRRO, J; KITCHINGMAN, G; MCCORMICK, F; MERTELSMANN, R; HERRMANN, F; KOEFFLER, HP			PREVALENCE OF N-RAS MUTATIONS IN CHILDREN WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID-LEUKEMIA	ONCOGENE			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; GENE-MUTATIONS; OLIGONUCLEOTIDE PROBES; ONCOGENE ACTIVATION; TUMOR INITIATION; CARCINOGENESIS; PROGRESSION; ADENOCARCINOMA; MECHANISMS; CHILDHOOD	The ras proto-oncogene family encodes a group of 21 kDa nucleotide-binding proteins. Activating mutations of ras genes are associated with certain types of malignancies, indicating that they are related in some way to the malignant process. We have examined bone marrow cells from nine children with myelodysplastic syndromes (MDS) and 35 with acute myeloid leukemia (AML) for activating point mutations of ras genes by in vitro amplification using polymerase chain reaction (PCR), oligonucleotide hybridization and sequencing of PCR products. We found N-ras mutations in cells from 3 of 9 children (33%) with MDS and only 2 of 35 children with AML (6%; 95% confidence interval is 0.7-19%). All mutations the second nucleotide of codon 12 or the first nucleotide of codon 61 of N-ras. There was no apparent correlation with clinical or laboratory characteristics, including karyotype; however, an association of N-ras activation with the most aggressive type of MDS was noted. Among the patients with MDS, 2 of 6 with monosomy 7 had N-ras mutations; however, three children with monosomy 7 which presented with AML lacked ras mutations. One patient was studied at time of diagnosis of MDS and again after progression to AML. At the preleukemic stage of disease, an N-ras mutation was identified; however, after development of AML this mutation was not present in the leukemic clone. In conclusion, these data show that ras mutations, while not necessary for leukemic transformation, may be important for the initiation of preleukemias evolving into overt AML.	UNIV PITTSBURGH, SCH MED, DIV PEDIAT HEMATOL ONCOL, PITTSBURGH, PA 15213 USA; ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38101 USA; CETUS CORP, DEPT MOLEC BIOL, EMERYVILLE, CA 94608 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90048 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; St Jude Children's Research Hospital; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	LUBBERT, M (corresponding author), UNIV FREIBURG, MED CTR, DEPT HEMATOL ONCOL, W-7800 FREIBURG, GERMANY.				NCI NIH HHS [CA42710, CA33936] Funding Source: Medline; PHS HHS [AZ6038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042710, P30CA042710, R01CA033936] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTRAM CR, 1989, LEUKEMIA, V3, P247; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLOOMFIELD CD, 1987, SEMIN ONCOL, V14, P372; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HARDY KJ, 1985, P NATL ACAD SCI USA, V82, P8173, DOI 10.1073/pnas.82.23.8173; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LUBBERT M, 1990, ONCOGENE, V5, P583; LUBBERT M, 1990, BLOOD, V75, P1163; LYONS J, 1988, BLOOD, V71, P1707; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; NEUBAUER A, 1991, BLOOD, V77, P594; PADUA RA, 1988, LEUKEMIA, V2, P503; PEDERSENBJERGAARD J, 1988, CANCER RES, V48, P1812; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1986, BLOOD, V67, P1698; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAISONBEHMOARAS T, 1991, EMBO J, V10, P1111, DOI 10.1002/j.1460-2075.1991.tb08051.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOUSDEN KH, 1984, EMBO J, V3, P913, DOI 10.1002/j.1460-2075.1984.tb01905.x	34	53	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					263	268						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549347				2022-12-17	WOS:A1992HG98200009
J	FRAME, MC; WILKIE, NM; DARLING, AJ; CHUDLEIGH, A; PINTZAS, A; LANG, JC; GILLESPIE, DAF				FRAME, MC; WILKIE, NM; DARLING, AJ; CHUDLEIGH, A; PINTZAS, A; LANG, JC; GILLESPIE, DAF			REGULATION OF AP-1/DNA COMPLEX-FORMATION INVITRO	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; JUN PROTO-ONCOGENE; DNA-BINDING; RAT FIBROBLASTS; GENE; EXPRESSION; PROMOTER; FOS; TPA; IDENTIFICATION	The level of AP-1 DNA-binding activity exhibited in vitro by unfractionated extracts of Hela nuclei can be stimulated by a low molecular weight fraction from rabbit reticulocyte lysate. Stimulation also requires a heat labile component of the nuclear extract, probably a protein. Stimulated and unstimulated extracts with high and low AP-1 DNA-binding activities contain the same levels of proteins reactive with antisera against Jun and Fos, proteins which are shown to be involved in the AP-1/DNA complexes detected in vitro. The low molecular weight fraction from reticulocyte lysate can be substituted by the reducing agent dithiothreitol (DTT) in the stimulation reaction and conversely oxidised glutathione greatly reduces formation of AP-1/DNA complexes. The binding activities of transcription factors SP-1, NF-1 and CBP are unaffected by DTT or oxidised glutathione. These observations, taken together, suggest that the efficiency with which pre-existing Fos and Jun proteins can bind an AP-1 target sequence in vitro can be controlled by a nuclear activity which is sensitive to oxidation/reduction and that this control mechanism is specific for AP-1.			FRAME, MC (corresponding author), BEATSON INST CANC RES,BEATSON LABS,CANC RES CAMPAIGN,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND.		Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				Abate C, 1990, Semin Cancer Biol, V1, P19; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARNHART KM, 1988, MOL CELL BIOL, V8, P3215, DOI 10.1128/MCB.8.8.3215; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; FULTON R, 1990, J VIROL, V64, P1675, DOI 10.1128/JVI.64.4.1675-1682.1990; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Maniatis T., 1982, MOL CLONING; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MULLER R, 1987, ONCOGENE RES, V2, P19; NISHIMURA T, 1988, ONCOGENE, V3, P659; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P63; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WELHAM MJ, 1990, ONCOGENE, V5, P161	25	53	53	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					205	209						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900354				2022-12-17	WOS:A1991FZ13400004
J	HIRVONEN, H; MAKELA, TP; SANDBERG, M; KALIMO, H; VUORIO, E; ALITALO, K				HIRVONEN, H; MAKELA, TP; SANDBERG, M; KALIMO, H; VUORIO, E; ALITALO, K			EXPRESSION OF THE MYC PROTOONCOGENES IN DEVELOPING HUMAN FETAL BRAIN	ONCOGENE			English	Article							HUMAN NEURO-BLASTOMA; CELL LUNG-CANCER; HUMAN N-MYC; EMBRYONAL CARCINOMA-CELLS; CENTRAL NERVOUS-SYSTEM; C-MYC; NUCLEOTIDE-SEQUENCE; MESSENGER-RNAS; PROTOONCOGENE EXPRESSION; INSITU HYBRIDIZATION	We have analysed c-myc, N-myc and L-myc gene expression in developing human fetal brain by Northern hybridization, RNAase protection and in situ hybridization. The unique zonal organization of the developing fetal brain allows a particularly good assessment of the coupling of myc gene expression to cell proliferation and differentiation in vivo. By Northern and in situ hybridization, L-myc as well as c-myc and N-myc transcripts in the brain were found in the post-mitotic cortical and intermediate layers, as well as in the mitotically active layers containing the neuroepithelial precursor cells. Consistent results were also obtained for L-myc using RNAase protection analysis. Both the 3.6 and 3.8 kb forms of the L-myc mRNA, resulting from alternative splicing of intron I, were detected in layers of neuroectodermal origin, but not in the meninges or choroid plexus. We also extended L-myc expression and splicing analyses to other developing human fetal tissues. L-myc mRNA was expressed in several other fetal tissues, particularly in fetal skin. Predominantly intron I containing L-myc mRNA was observed in fetal striated and cardiac muscle. Thus, L-myc is expressed in a wider spectrum of developing tissues than previously known. Our findings also, show that L-myc as well as N-myc and c-myc expression is uncoupled from cell division in developing brain.	UNIV TURKU,DEPT PATHOL,SF-20520 TURKU 52,FINLAND; UNIV HELSINKI,DEPT VIROL,CANC BIOL LAB,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,DEPT PATHOL,CANC BIOL LAB,SF-00290 HELSINKI 29,FINLAND	University of Turku; University of Helsinki; University of Helsinki	HIRVONEN, H (corresponding author), UNIV TURKU,DEPT MED BIOCHEM,KIINAMYLLYNKATU 10,SF-20520 TURKU 52,FINLAND.		makela, tomi/B-3734-2009; Alitalo, Kari K/J-5013-2014	makela, tomi/0000-0002-4869-8044; Alitalo, Kari K/0000-0002-7331-0902; Vuorio, Eero/0000-0003-3404-2439				ADAMSON ED, 1987, DEVELOPMENT, V99, P449; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; ALT FW, 1986, MOL BIOL HOMO SAPIEN, P931; AMATRUDA TT, 1985, BIOCHEM BIOPH RES CO, V126, P1189, DOI 10.1016/0006-291X(85)90311-0; BARTLETT PF, 1988, P NATL ACAD SCI USA, V85, P3255, DOI 10.1073/pnas.85.9.3255; BERNARD O, 1989, J NEUROSCI RES, V24, P9, DOI 10.1002/jnr.490240104; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CAUBET JF, 1989, MOL CELL BIOL, V9, P2269, DOI 10.1128/MCB.9.5.2269; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DEPINHO R, 1990, IN PRESS ONCOGENES; DOWNS KM, 1989, GENE DEV, V3, P860, DOI 10.1101/gad.3.6.860; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRADY EF, 1987, CANCER RES, V47, P2931; HANLEY MR, 1988, NEURON, V1, P175, DOI 10.1016/0896-6273(88)90137-7; HERSCHKOWITZ N, 1988, BIOL NEONATE, V54, P1; HIRVONEN H, 1989, J CELL BIOL, V108, P1093, DOI 10.1083/jcb.108.3.1093; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; JOHNSON BE, 1988, CANCER RES, V48, P5163; JOHNSTON JG, 1989, P NATL ACAD SCI USA, V86, P1066, DOI 10.1073/pnas.86.3.1066; KADURRAHDAOUK R, 1987, GENE DEV, V1, P347; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MAPLES JA, 1985, AM J CLIN PATHOL, V83, P356, DOI 10.1093/ajcp/83.3.356; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NOWAKOWSKI RS, 1981, J COMP NEUROL, V196, P129, DOI 10.1002/cne.901960110; OFVERSTEDT LG, 1984, BIOCHIM BIOPHYS ACTA, V782, P120, DOI 10.1016/0167-4781(84)90014-9; ONCLERCQ R, 1989, NUCLEIC ACIDS RES, V17, P735, DOI 10.1093/nar/17.2.735; ONCLERCQ R, 1988, J VIROL, V62, P4533, DOI 10.1128/JVI.62.12.4533-4537.1988; PERREAU J, 1988, GENE, V62, P7, DOI 10.1016/0378-1119(88)90575-6; PFEIFEROHLSSON S, 1985, P NATL ACAD SCI USA, V82, P5050, DOI 10.1073/pnas.82.15.5050; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; ROUAH E, 1989, CANCER RES, V49, P1797; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; SAKSELA K, 1989, INT J CANCER, V44, P182, DOI 10.1002/ijc.2910440132; SAKSELA K, 1987, ONCOGENE, V1, P291; SANDBERG M, 1987, J CELL BIOL, V104, P1077, DOI 10.1083/jcb.104.4.1077; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1986, ONCOGENES GROWTH CON, P332; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEMSEI I, 1989, ONCOGENE, V4, P465; SIDMAN RL, 1973, BRAIN RES, V62, P1, DOI 10.1016/0006-8993(73)90617-3; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STANTON LW, 1987, MOL CELL BIOL, V7, P4266, DOI 10.1128/MCB.7.12.4266; STARNAUD R, 1988, ONCOGENE, V3, P553; SUDOL M, 1988, BRAIN RES REV, V13, P391, DOI 10.1016/0165-0173(88)90014-8; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1988, EXP CELL BIOL, V56, P321; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	69	53	54	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1787	1797						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2284098				2022-12-17	WOS:A1990ET43600008
J	DEPPERT, W; STEINMAYER, T; RICHTER, W				DEPPERT, W; STEINMAYER, T; RICHTER, W			COOPERATION OF SV40 LARGE T-ANTIGEN AND THE CELLULAR PROTEIN-P53 IN MAINTENANCE OF CELL-TRANSFORMATION	ONCOGENE			English	Article									UNIV ULM,BIOCHEM ABT,D-7900 ULM,FED REP GER	Ulm University	DEPPERT, W (corresponding author), UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,D-2000 HAMBURG 20,FED REP GER.		Richter, Wiltrud/V-3217-2017	Richter, Wiltrud/0000-0003-4694-2768				BOUCK N, 1984, J VIROL, V49, P997, DOI 10.1128/JVI.49.3.997-1001.1984; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; CRAWFORD LV, 1986, INT REV EXP PATHOL, V25, P1; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DEPPERT W, 1989, NATO ASI SER, V434, P399; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINZPETER M, 1987, ONCOGENE, V1, P119; JENKINS JR, 1988, ONCOGENE HDB; KELLEY S, 1980, J VIROL, V33, P550, DOI 10.1128/JVI.33.1.550-552.1980; LINZER DIH, 1979, VIROLOGY, V98, P308, DOI 10.1016/0042-6822(79)90554-3; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MONTENARH M, 1984, J VIROL, V49, P658, DOI 10.1128/JVI.49.3.658-664.1984; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PINTEL D, 1981, J VIROL, V38, P518, DOI 10.1128/JVI.38.2.518-528.1981; RASSOULZADEGAN M, 1978, J VIROL, V28, P421, DOI 10.1128/JVI.28.2.421-426.1978; RASSOULZADEGAN M, 1978, J VIROL, V28, P1; Rigby P. W. J., 1983, ADV VIRAL ONCOL, V3, P31; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; TOOZE J, 1981, MOL BIOL TUMOR VIRUS, V2	24	53	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1103	1110						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674854				2022-12-17	WOS:A1989AM53100008
J	RICHON, VM; RAMSAY, RG; RIFKIND, RA; MARKS, PA				RICHON, VM; RAMSAY, RG; RIFKIND, RA; MARKS, PA			MODULATION OF THE C-MYB, C-MYC AND P53 MESSENGER-RNA AND PROTEIN-LEVELS DURING INDUCED MURINE ERYTHROLEUKEMIA CELL-DIFFERENTIATION	ONCOGENE			English	Article									CORNELL UNIV,GRAD SCH MED SCI,SLOAN KETTERING DIV,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,MEM SLOAN KETTERING CANC CTR,DEWITT WALLACE RES LAB,NEW YORK,NY 10021	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center			Ramsay, Robert G/C-3291-2015	Ramsay, Robert G/0000-0001-5003-0433	NCI NIH HHS [CA-08748, CA 31768-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA031768] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDER TP, 1987, J IMMUNOL, V139, P3822; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN ZX, 1982, P NATL ACAD SCI-BIOL, V79, P471, DOI 10.1073/pnas.79.2.471; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CRAIG RW, 1984, CANCER RES, V44, P442; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIBACH E, 1977, CANCER RES, V37, P440; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; KHOCHBIN S, 1988, J MOL BIOL, V200, P55, DOI 10.1016/0022-2836(88)90333-6; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1987, BLOOD, V69, P1542; Maniatis T., 1982, MOL CLONING; MARKS PA, 1987, CANCER RES, V47, P659; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NUDEL U, 1977, CELL, V12, P463, DOI 10.1016/0092-8674(77)90122-2; OREN M, 1983, P NATL ACAD SCI-BIOL, V80, P56, DOI 10.1073/pnas.80.1.56; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; SHEFFERY M, 1984, J MOL BIOL, V172, P417, DOI 10.1016/S0022-2836(84)80015-7; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHEN DW, 1983, P NATL ACAD SCI-BIOL, V80, P5919, DOI 10.1073/pnas.80.19.5919; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TODOKORO K, 1986, BIOCHEM BIOPH RES CO, V135, P1112, DOI 10.1016/0006-291X(86)91043-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WINGROVE TG, 1988, J BIOL CHEM, V263, P8918; YENOFSKY R, 1983, MOL CELL BIOL, V3, P1197, DOI 10.1128/MCB.3.7.1197; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	52	53	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					165	173						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2648254				2022-12-17	WOS:A1989U567500007
J	BERNARD, O; LARSEN, CJ; HAMPE, A; MAUCHAUFFE, M; BERGER, R; MATHIEUMAHUL, D				BERNARD, O; LARSEN, CJ; HAMPE, A; MAUCHAUFFE, M; BERGER, R; MATHIEUMAHUL, D			MOLECULAR MECHANISMS OF A T(8-14)(Q24-Q11) TRANSLOCATION JUXTAPOSING C-MYC AND TCR-ALPHA GENES IN A T-CELL LEUKEMIA - INVOLVEMENT OF A V-ALPHA INTERNAL HEPTAMER	ONCOGENE			English	Article									HOP ST LOUIS,CTR HAYEM,INSERM,UNITE 301,F-75475 PARIS 10,FRANCE; HOP ST LOUIS,CTR HAYEM,HEMATOL EXPTL LAB,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			Mathieu, Daniele/G-6092-2012; Bernard, Olivier A./E-5721-2016					BERGER R, 1986, CHROMOSOMES HEMATOLO, P104; CAUBET JF, 1985, CR ACAD SCI III-VIE, V300, P171; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; EARLY P, 1982, MOL CELL BIOL, V2, P829, DOI 10.1128/MCB.2.7.829; ERIKSON J, 1986, SCIENCE, V232, P884, DOI 10.1126/science.3486470; ERIKSON J, 1985, SCIENCE, V229, P784, DOI 10.1126/science.3875152; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; FUJIMOTO S, 1987, NATURE, V327, P242, DOI 10.1038/327242a0; HAYASHI Y, 1986, NEW ENGL J MED, V314, P650, DOI 10.1056/NEJM198603063141018; HOPE TJ, 1986, SCIENCE, V231, P1141, DOI 10.1126/science.3003919; KATAOKA T, 1984, NUCLEIC ACIDS RES, V12, P5995, DOI 10.1093/nar/12.15.5995; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LEBEAU MM, 1986, P NATL ACAD SCI USA, V83, P9744; MALISSEN M, 1986, NATURE, V319, P28, DOI 10.1038/319028a0; MATHIEUMAHUL D, 1986, J EXP MED, V163, P1308, DOI 10.1084/jem.163.5.1308; MATHIEUMAHUL D, 1986, INT J CANCER, V38, P835, DOI 10.1002/ijc.2910380609; MATHIEUMAHUL D, 1985, EMBO J, V4, P3427, DOI 10.1002/j.1460-2075.1985.tb04100.x; MCKEITHAN TW, 1986, P NATL ACAD SCI USA, V83, P6636, DOI 10.1073/pnas.83.17.6636; RETH M, 1986, NATURE, V322, P840, DOI 10.1038/322840a0; RIVIERE D, 1983, NOUV REV FR HEMATOL, V25, P175; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHIMA EA, 1986, P NATL ACAD SCI USA, V83, P3439, DOI 10.1073/pnas.83.10.3439; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; YOSHIKAI Y, 1986, J EXP MED, V164, P90, DOI 10.1084/jem.164.1.90	25	53	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					195	200						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	2966921				2022-12-17	WOS:A1988M086000014
J	He, D; Wang, D; Lu, P; Yang, N; Xue, ZG; Zhu, XM; Zhang, P; Fan, GP				He, Di; Wang, Di; Lu, Ping; Yang, Nan; Xue, Zhigang; Zhu, Xianmin; Zhang, Peng; Fan, Guoping			Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations	ONCOGENE			English	Article							NF-KAPPA-B; ETS TRANSCRIPTION FACTOR; NONCODING RNA; NECROSIS-FACTOR; CANCER; EXPRESSION; METASTASIS; PROGRESSION; INDUCTION; ACTIVATOR	Lung adenocarcinoma (LUAD) harboring EGFR mutations prevails in Asian population. However, the inter-patient and intra-tumor heterogeneity has not been addressed at single-cell resolution. Here we performed single-cell RNA sequencing (scRNA-seq) of total 125,674 cells from seven stage-I/II LUAD samples harboring EGFR mutations and five tumor-adjacent lung tissues. We identified diverse cell types within the tumor microenvironment (TME) in which myeloid cells and T cells were the most abundant stromal cell types in tumors and adjacent lung tissues. Within tumors, accompanied by an increase in CD1C(+) dendritic cells, the tumor-associated macrophages (TAMs) showed pro-tumoral functions without signature gene expression of defined M1 or M2 polarization. Tumor-infiltrating T cells mainly displayed exhausted and regulatory T-cell features. The adenocarcinoma cells can be categorized into different subtypes based on their gene expression signatures in distinct pathways such as hypoxia, glycolysis, cell metabolism, translation initiation, cell cycle, and antigen presentation. By performing pseudotime trajectory, we found that ELF3 was among the most upregulated genes in more advanced tumor cells. In response to secretion of inflammatory cytokines (e.g., IL1B) from immune infiltrates, ELF3 in tumor cells was upregulated to trigger the activation of PI3K/Akt/NF-kappa B pathway and elevated expression of proliferation and anti-apoptosis genes such as BCL2L1 and CCND1. Taken together, our study revealed substantial heterogeneity within early-stage LUAD harboring EGFR mutations, implicating complex interactions among tumor cells, stromal cells and immune infiltrates in the TME.	[He, Di; Zhu, Xianmin; Fan, Guoping] ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China; [He, Di; Wang, Di; Zhu, Xianmin; Zhang, Peng] Tongji Univ, Shanghai Pulm Hosp, Sch Life Sci & Technol, Dept Thorac Surg, Shanghai 200433, Peoples R China; [Lu, Ping; Xue, Zhigang] Tongji Univ, Tongji Hosp, Translat Ctr Stem Cell Res, Dept Regenerat Med,Sch Med, Shanghai 200065, Peoples R China; [Yang, Nan] Zhangjiang High Tech Pk Ltd, PharmaLegacy Labs Shanghai Co, Bldg 7,388 Jialilue Rd, Shanghai 201203, Peoples R China; [Fan, Guoping] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA	ShanghaiTech University; Tongji University; Tongji University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Zhu, XM; Fan, GP (corresponding author), ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China.; Zhu, XM; Zhang, P (corresponding author), Tongji Univ, Shanghai Pulm Hosp, Sch Life Sci & Technol, Dept Thorac Surg, Shanghai 200433, Peoples R China.; Fan, GP (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.	xianminzhu@hotmail.com; zhangpeng1121@aliyun.com; gfan@mednet.ucla.edu	Zhu, Xianmin/M-6437-2017	Zhu, Xianmin/0000-0003-1405-9700; Fan, Guoping/0000-0001-5235-6410; Lu, Ping/0000-0002-0127-3911	National Program on Key Basic Research Project (973 Program) [2015CB964702, 2015CB964601]; National Natural Science Foundation of China [81570521, 81470244, 81622001, 81430026, 91642108, 31871288]; Experimental Animal Research Fund, Science and Technology Commission of Shanghai Municipality [18140903900, 15140903900]; Fundamental Research Funds for the Central Universities	National Program on Key Basic Research Project (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Experimental Animal Research Fund, Science and Technology Commission of Shanghai Municipality; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	We thank Wei Jiang at Genergy Bio-technology (Shanghai) Co., Ltd and Minghui Li at Sinotech Genomics (Shenzhen) Co., Ltd for their contribution in library construction, sequencing and data analysis. The work was supported by National Program on Key Basic Research Project (973 Program 2015CB964702, 2015CB964601); National Natural Science Foundation of China (81570521, 81470244, 81622001, 81430026, 91642108, 31871288); Experimental Animal Research Fund, Science and Technology Commission of Shanghai Municipality (18140903900, 15140903900); Fundamental Research Funds for the Central Universities (Xianmin Zhu and Peng Zhang).	Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; AlHossiny M, 2016, CANCER RES, V76, P3376, DOI 10.1158/0008-5472.CAN-15-2654; Altorki NK, 2019, NAT REV CANCER, V19, P9, DOI 10.1038/s41568-018-0081-9; Apostolopoulos V, 2015, CELL MOL LIFE SCI, V72, P4475, DOI 10.1007/s00018-015-2014-z; Apte RN, 2006, EUR J CANCER, V42, P751, DOI 10.1016/j.ejca.2006.01.010; Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060; Bishop JA, 2010, HUM PATHOL, V41, P20, DOI 10.1016/j.humpath.2009.06.014; Bouillez A, 2017, ONCOGENE, V36, P4037, DOI 10.1038/onc.2017.47; Campbell MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079114; Campbell MJ, 2011, BREAST CANCER RES TR, V128, P703, DOI 10.1007/s10549-010-1154-y; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chen HM, 2019, ONCOL REP, V41, P570, DOI 10.3892/or.2018.6807; Chiossone L, 2018, NAT REV IMMUNOL, V18, P671, DOI 10.1038/s41577-018-0061-z; Chittezhath M, 2014, IMMUNITY, V41, P815, DOI 10.1016/j.immuni.2014.09.014; Cortot AB, 2014, EUR RESPIR REV, V23, P356, DOI 10.1183/09059180.00004614; Dong PX, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00471; Enfield KSS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13295-y; Engblom C, 2016, NAT REV CANCER, V16, P447, DOI 10.1038/nrc.2016.54; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Goossens P, 2019, CELL METAB, V29, P1376, DOI 10.1016/j.cmet.2019.02.016; Grall F, 2003, ARTHRITIS RHEUM, V48, P1249, DOI 10.1002/art.10942; Guha A, 2012, P NATL ACAD SCI USA, V109, P12592, DOI 10.1073/pnas.1204710109; Guo XY, 2018, NAT MED, V24, P978, DOI 10.1038/s41591-018-0045-3; Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Hu P, 2017, MOL CELL, V68, P1006, DOI 10.1016/j.molcel.2017.11.017; Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Klein AM, 2015, CELL, V161, P1187, DOI 10.1016/j.cell.2015.04.044; Lambrechts D, 2018, NAT MED, V24, P1277, DOI 10.1038/s41591-018-0096-5; Lanitis E, 2017, ANN ONCOL, V28, P18, DOI 10.1093/annonc/mdx238; Laoui D, 2014, CANCER RES, V74, P24, DOI 10.1158/0008-5472.CAN-13-1196; Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014; Li HJ, 2019, CELL, V176, P775, DOI 10.1016/j.cell.2018.11.043; Longoni N, 2013, CANCER RES, V73, P4533, DOI 10.1158/0008-5472.CAN-12-4537; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Milette S, 2019, J PATHOL, V247, P589, DOI 10.1002/path.5241; Min JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135817; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mukhtar RA, 2012, ANN SURG ONCOL, V19, P3979, DOI 10.1245/s10434-012-2415-2; Murdoch C, 2005, INT J CANCER, V117, P701, DOI 10.1002/ijc.21422; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Oliver JR, 2012, LAB INVEST, V92, P320, DOI 10.1038/labinvest.2011.186; Oliver JR, 2011, LAB INVEST, V91, P1514, DOI 10.1038/labinvest.2011.100; Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055; Ozes ON, 1999, NATURE, V401, P82; Peng JY, 2019, CELL RES, V29, P725, DOI 10.1038/s41422-019-0195-y; Peterson VM, 2017, NAT BIOTECHNOL, V35, P936, DOI 10.1038/nbt.3973; Pocha K, 2020, CLIN CANCER RES, V26, P2231, DOI 10.1158/1078-0432.CCR-19-2184; Psallidas I, 2013, ONCOGENE, V32, P528, DOI 10.1038/onc.2012.57; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Reynolds SD, 2002, AM J RESP CRIT CARE, V166, P1498, DOI 10.1164/rccm.200204-285OC; Seow WJ, 2017, HUM MOL GENET, V26, P454, DOI 10.1093/hmg/ddw414; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun Y, 2019, CANCERS, V216, P1; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Torre LA, 2016, ADV EXP MED BIOL, V893, P1, DOI 10.1007/978-3-319-24223-1_1; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Wang H, 2018, INT J BIOCHEM CELL B, V94, P98, DOI 10.1016/j.biocel.2017.12.002; Wang JL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.206; Wang YQ, 2017, GENOM PROTEOM BIOINF, V15, P14, DOI 10.1016/j.gpb.2017.01.001; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Wu J, 2008, CELL RES, V18, P649, DOI 10.1038/cr.2008.57; Xiao G, 2012, P NATL ACAD SCI USA, V109, P15419, DOI 10.1073/pnas.1206370109; Xu X, 2012, P NATL ACAD SCI USA, V109, P4910, DOI 10.1073/pnas.1112499109; Zacharias WJ, 2018, NATURE, V555, P251, DOI 10.1038/nature25786; Zhang L, 2019, ARTIF CELL NANOMED B, V47, P2516, DOI 10.1080/21691401.2019.1626409; Zhang YM, 2014, INFLAMMATION, V37, P1240, DOI 10.1007/s10753-014-9851-z; Zhang Z, 2019, NUCLEIC ACIDS RES, V47, pD8, DOI 10.1093/nar/gky993; Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049; Zheng LB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0399-y; Zheng PM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0465-5	77	52	53	5	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					355	368		10.1038/s41388-020-01528-0	http://dx.doi.org/10.1038/s41388-020-01528-0		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33144684	hybrid, Green Published			2022-12-17	WOS:000585016500001
J	Liang, Y; Hou, LD; Li, LJ; Li, L; Zhu, LM; Wang, Y; Huang, X; Hou, YC; Zhu, DX; Zou, HM; Gu, Y; Weng, XL; Wang, YY; Li, Y; Wu, TQ; Yao, MF; Gross, I; Gaiddon, C; Luo, M; Wang, JH; Meng, XJ				Liang, Yu; Hou, Lidan; Li, Linjing; Li, Lei; Zhu, Liming; Wang, Yu; Huang, Xin; Hou, Yichao; Zhu, Danxi; Zou, Huimin; Gu, Yan; Weng, Xiaoling; Wang, Yingying; Li, Yue; Wu, Tianqi; Yao, Mengfei; Gross, Isabelle; Gaiddon, Christian; Luo, Meng; Wang, Jianhua; Meng, Xiangjun			Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway	ONCOGENE			English	Article							PYRUVATE-DEHYDROGENASE; DRUG-RESISTANCE; INHIBITION; MICRORNAS; APOPTOSIS; GLYCOLYSIS; AXIS; DCA; FLUOROURACIL; STATISTICS	The development of chemoresistance remains a major challenge that accounts for colorectal cancer (CRC) lethality. Dichloroacetate (DCA) was originally used as a metabolic regulator in the treatment of metabolic diseases; here, DCA was assayed to identify the mechanisms underlying the chemoresistance of CRC. We found that DCA markedly enhanced chemosensitivity of CRC cells to fluorouracil (5-FU), and reduced the colony formation due to high levels of apoptosis. Using the microarray assay, we noted that miR-149-3p was involved in the chemoresistance of CRC, which was modulated by wild-type p53 after DCA treatment. In addition, PDK2 was identified as a direct target of miR-149-3p. Mechanistic analyses showed that overexpression of miR-149-3p enhanced 5-FU-induced apoptosis and reduced glucose metabolism, similar to the effects of PDK2 knockdown. In addition, overexpression of PDK2 partially reversed the inhibitory effect of miR-149-3p on glucose metabolism. Finally, both DCA treatment and miR-149-3p overexpression in 5-FU-resistant CRC cells were found to markedly sensitize the chemotherapeutic effect of 5-FU in vivo, and this effect was also validated in a small retrospective cohort of CRC patients. Taken together, we determined that the p53/miR-149-3p/PDK2 signaling pathway can potentially be targeted with DCA treatment to overcome chemoresistant CRC.	[Liang, Yu; Hou, Lidan; Li, Linjing; Li, Lei; Zhu, Liming; Wang, Yu; Huang, Xin; Hou, Yichao; Zhu, Danxi; Zou, Huimin; Meng, Xiangjun] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China; [Gu, Yan; Luo, Meng] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Gen Surg, Sch Med, Shanghai, Peoples R China; [Weng, Xiaoling; Wu, Tianqi; Yao, Mengfei; Wang, Jianhua] Fudan Univ, Inst Canc, Shanghai Canc Ctr, Shanghai, Peoples R China; [Weng, Xiaoling] Ningbo Aitagene Technol Co LTD, Shanghai, Peoples R China; [Wang, Yingying] Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, Sch Med, Shanghai, Peoples R China; [Li, Yue] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Pathol Ctr, Sch Med, Shanghai, Peoples R China; [Gross, Isabelle] INSERM, UMR S1113, F-67200 Strasbourg, France; [Gross, Isabelle] Univ Strasbourg, FMTS, F-67000 Strasbourg, France; [Gaiddon, Christian] Univ Strasbourg, INSERM, UMR S1113, IRFAC,Lab Stress Response & Innovat Therapy Strei, F-67200 Strasbourg, France; [Gaiddon, Christian] CLCC Paul Strauss, Strasbourg, France	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fudan University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UNICANCER; Centre Paul Strauss	Meng, XJ (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China.; Luo, M (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Gen Surg, Sch Med, Shanghai, Peoples R China.; Wang, JH (corresponding author), Fudan Univ, Inst Canc, Shanghai Canc Ctr, Shanghai, Peoples R China.	luotysy@sina.com; jianhuaw2007@qq.com; meng_xiangjun@yahoo.com	Gross, Isabelle/P-9859-2019; Gaiddon, Christian/F-7321-2012	Gross, Isabelle/0000-0002-2783-8773; Gaiddon, Christian/0000-0003-4315-3851	National Natural Science Foundation of China [81272745, 81872419, 81272404]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning	This work was supported by the National Natural Science Foundation of China (81272745, 81872419, and 81272404) and the Program for Professor of Special Appointment (Eastern Scholar to JW) at Shanghai Institutions of Higher Learning. We thank Dr Yanhong Gu for providing the 5-FU resistant HCT116 cell lines and Dr Hua Lu for providing the p53 plasmid.	Abbot EL, 2005, FEBS J, V272, P3004, DOI 10.1111/j.1742-4658.2005.04713.x; Adekola K, 2012, CURR OPIN ONCOL, V24, P650, DOI 10.1097/CCO.0b013e328356da72; Allen KT, 2015, FREE RADICAL BIO MED, V89, P263, DOI 10.1016/j.freeradbiomed.2015.08.006; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bellazzo A, 2018, CELL DEATH DIFFER, V25, P1224, DOI 10.1038/s41418-018-0088-5; Benci JL, 2016, CELL, V167, P1540, DOI 10.1016/j.cell.2016.11.022; Bertoli G, 2015, THERANOSTICS, V5, P1122, DOI 10.7150/thno.11543; Bhattacharya B, 2014, BRIT J PHARMACOL, V171, P3255, DOI 10.1111/bph.12668; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cao DH, 2016, ONCOTARGET, V7, P71960, DOI 10.18632/oncotarget.12443; Chen D, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00502; Chen WQ, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.04.05; Chu QSC, 2015, INVEST NEW DRUG, V33, P603, DOI 10.1007/s10637-015-0221-y; Contractor T, 2012, CANCER RES, V72, P560, DOI 10.1158/0008-5472.CAN-11-1215; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gnanapradeepan K, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00124; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Guo WJ, 2015, HEPATOLOGY, V62, P1132, DOI 10.1002/hep.27929; Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hlouschek J, 2018, CANCER LETT, V439, P24, DOI 10.1016/j.canlet.2018.09.002; Huang SL, 2010, PROTEIN CELL, V1, P916, DOI 10.1007/s13238-010-0116-9; Hulse M, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007394; Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175; Kankotia S, 2014, BBA-REV CANCER, V1846, P617, DOI 10.1016/j.bbcan.2014.08.005; Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004; Kluza J, 2012, CANCER RES, V72, P5035, DOI 10.1158/0008-5472.CAN-12-0979; Li G, 2017, ONCOGENE, V36, P989, DOI 10.1038/onc.2016.265; Madhok BM, 2010, BRIT J CANCER, V102, P1746, DOI 10.1038/sj.bjc.6605701; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Papandreou I, 2011, INT J CANCER, V128, P1001, DOI 10.1002/ijc.25728; Qiu ZP, 2015, GASTROENTEROLOGY, V149, P1587, DOI 10.1053/j.gastro.2015.07.050; Roh JL, 2016, CANCER LETT, V371, P20, DOI 10.1016/j.canlet.2015.11.023; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Shahrzad S, 2010, CANCER LETT, V297, P75, DOI 10.1016/j.canlet.2010.04.027; Shaw RJ, 2006, CURR OPIN CELL BIOL, V18, P598, DOI 10.1016/j.ceb.2006.10.005; Shen YC, 2013, BRIT J CANCER, V108, P72, DOI 10.1038/bjc.2012.559; Shroads AL, 2008, J PHARMACOL EXP THER, V324, P1163, DOI 10.1124/jpet.107.134593; Si LL, 2017, BRIT J PHARMACOL, V174, P553, DOI 10.1111/bph.13718; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Stacpoole PW, 2003, J CLIN PHARMACOL, V43, P683, DOI 10.1177/0091270003254637; STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6; Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002; Sutendra G, 2013, ONCOGENE, V32, P1638, DOI 10.1038/onc.2012.198; Van Dang C, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-1; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868; Xu RH, 2005, CANCER RES, V65, P613; Xuan Y, 2014, EXP CELL RES, V321, P219, DOI 10.1016/j.yexcr.2013.12.009; Zhang Y, 2017, BIOL CHEM, V398, P929, DOI 10.1515/hsz-2016-0308; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60	60	52	54	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					469	485		10.1038/s41388-019-1035-8	http://dx.doi.org/10.1038/s41388-019-1035-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31597953	hybrid, Green Published			2022-12-17	WOS:000507766400016
J	He, MJ; Jin, QN; Chen, C; Liu, YF; Ye, XS; Jiang, YL; Ji, FH; Qian, HS; Gan, DL; Yue, SJ; Zhu, W; Chen, TM				He, Mengjia; Jin, Qianni; Chen, Cong; Liu, Yifeng; Ye, Xiangsen; Jiang, Yulin; Ji, Feihu; Qian, Husun; Gan, Delu; Yue, Shujun; Zhu, Wei; Chen, Tingmei			The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells	ONCOGENE			English	Article							COLORECTAL-CANCER; MICRORNA; GROWTH; EPIREGULIN; SENSITIVITY; ACTIVATION; MECHANISMS; EXPRESSION; PATHWAY; GENE	Tamoxifen resistance is one of the major challenges for its medical uses in estrogen receptor (ER)-positive breast cancer. Aerobic glycolysis, an anomalous characteristic of glucose metabolism in cancer cells, has been shown to associate with the resistance to chemotherapeutic agents. It remains, however, largely unclear whether and how tamoxifen resistance contributes to aerobic glycolysis in breast cancer. Here, we report that tamoxifen resistance is associated with enhanced glycolysis in ER-positive breast cancer cells. We demonstrate that EREG, an agonist of EGFR, has an important role in enhancing glycolysis via activating EGFR signaling and its downstream glycolytic genes in tamoxifen-resistant breast cancer cells. We further show that EREG is a direct target of miR-186-3p and that downregulation of miR-186-3p by tamoxifen results in EREG upregulation in tamoxifen-resistant breast cancer cells. Importantly, systemic delivery of cholesterolmodified agomiR-186-3p to mice bearing tamoxifen-resistant breast tumors effectively attenuates both tumor growth and [F-18]-fluoro-deoxyglucose ([F-18]-FDG) uptake. Together, our results reveal a novel molecular mechanism of resistance to hormone therapies in which the miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in ER-positive breast cancer, suggesting targeting miR-186-3p as a promising strategy for therapeutic intervention in endocrineresistant breast tumors.	[He, Mengjia] Chongqing Med Univ, Coll Clin Med, Chongqing 400016, Peoples R China; [Jin, Qianni; Liu, Yifeng; Ye, Xiangsen; Jiang, Yulin; Ji, Feihu; Qian, Husun; Gan, Delu; Yue, Shujun; Chen, Tingmei] Chongqing Med Univ, Minist Educ, Key Lab Diagnost Med Designated, Chongqing 400016, Peoples R China; [Jin, Qianni; Liu, Yifeng; Ye, Xiangsen; Jiang, Yulin; Ji, Feihu; Qian, Husun; Gan, Delu; Yue, Shujun; Chen, Tingmei] Chongqing Med Univ, Dept Lab Med, Chongqing 400016, Peoples R China; [Chen, Cong; Zhu, Wei] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai 200032, Peoples R China	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University; Fudan University	Chen, TM (corresponding author), Chongqing Med Univ, Minist Educ, Key Lab Diagnost Med Designated, Chongqing 400016, Peoples R China.; Chen, TM (corresponding author), Chongqing Med Univ, Dept Lab Med, Chongqing 400016, Peoples R China.; Zhu, W (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai 200032, Peoples R China.	zhu.wei1@zs-hospital.sh.cn; tingmeichen@cqmu.edu.cn	liu, yi/GXE-9662-2022	Chen, Tingmei/0000-0003-4250-674X	National Natural Science Foundation of China [81272544, 81502267]; Foundation and frontier science and technology project of Yuzhong district science and technology commission, Chongqing, China [20150121]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation and frontier science and technology project of Yuzhong district science and technology commission, Chongqing, China	We thank members of the Chen's and Zhu's labs for helpful comments. This work was supported by grants from the National Natural Science Foundation of China (81272544 and 81502267) and Foundation and frontier science and technology project of Yuzhong district science and technology commission, Chongqing, China (20150121).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; [Anonymous], ASN00022011 ANSIATCC; Bhattacharya B, 2016, BRIT J PHARMACOL, V173, P970, DOI 10.1111/bph.13422; Connor CE, 2001, CANCER RES, V61, P2917; Daurio NA, 2016, CANCER RES, V76, P3295, DOI 10.1158/0008-5472.CAN-15-2197; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Gambhir SS, 2000, P NATL ACAD SCI USA, V97, P2785, DOI 10.1073/pnas.97.6.2785; Gee JMW, 2003, ENDOCRINOLOGY, V144, P5105, DOI 10.1210/en.2003-0705; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Iorns E, 2009, BIOCHEM J, V417, P361, DOI 10.1042/BJ20081682; JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Johnston SRD, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv212; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li CF, 2017, BIOCHEM BIOPH RES CO, V491, P552, DOI 10.1016/j.bbrc.2017.03.042; Lim SO, 2016, CANCER RES, V76, P1284, DOI 10.1158/0008-5472.CAN-15-2478; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu L, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.35; Ma CX, 2009, ONCOLOGY-NY, V23, P133; Ma J, 2010, CANCER GENE THER, V17, P523, DOI 10.1038/cgt.2010.18; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Miao Y, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.72; Mills JN, 2018, CURR OPIN PHARMACOL, V41, P59, DOI 10.1016/j.coph.2018.04.009; Mishra S, 2016, CRIT REV ONCOL HEMAT, V98, P12, DOI 10.1016/j.critrevonc.2015.10.003; Morandi A, 2017, BBA-REV CANCER, V1868, P1, DOI 10.1016/j.bbcan.2016.12.004; Park WC, 2005, INT J ONCOL, V27, P1459; Peifer Christian, 2009, Biochem J, V417, pe5, DOI 10.1042/BJ20082243; Poliakova M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0798-9; Qu X, 2016, ONCOGENE, V35, P6403, DOI 10.1038/onc.2016.170; Revillion F, 2008, ANN ONCOL, V19, P73, DOI 10.1093/annonc/mdm431; Santen RJ, 2009, STEROIDS, V74, P586, DOI 10.1016/j.steroids.2008.11.020; Schneider MR, 2009, J CELL PHYSIOL, V218, P460, DOI 10.1002/jcp.21635; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Sun P, 2014, ASIAN PAC J CANCER P, V15, P4245, DOI 10.7314/APJCP.2014.15.10.4245; Sunaga N, 2013, ONCOGENE, V32, P4034, DOI 10.1038/onc.2012.402; Swietach P, 2007, CANCER METAST REV, V26, P299, DOI 10.1007/s10555-007-9064-0; Thrane S, 2015, ONCOGENE, V34, P4199, DOI 10.1038/onc.2014.351; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Torring N, 2000, ANTICANCER RES, V20, P91; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Wang L, 2014, CANCER RES, V74, P4720, DOI 10.1158/0008-5472.CAN-14-0960; Ye JJ, 2016, MOL BIOSYST, V12, P3417, DOI 10.1039/c6mb00576d; Zhang LF, 2017, CELL MOL LIFE SCI, V74, P2929, DOI 10.1007/s00018-017-2508-y; Zhang LF, 2015, EMBO J, V34, P2671, DOI 10.15252/embj.201591803; Zhao S, 2009, SCI CHINA SER C, V52, P1111, DOI 10.1007/s11427-009-0152-y; Zhu X, 2016, ONCOGENE, V35, P323, DOI 10.1038/onc.2015.84; Zhu ZW, 2000, BIOCHEM BIOPH RES CO, V273, P1019, DOI 10.1006/bbrc.2000.3033	50	52	53	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5551	5565		10.1038/s41388-019-0817-3	http://dx.doi.org/10.1038/s41388-019-0817-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	30967627				2022-12-17	WOS:000474845100001
J	Naito, Y; Yamamoto, Y; Sakamoto, N; Shimomura, I; Kogure, A; Kumazaki, M; Yokoi, A; Yashiro, M; Kiyono, T; Yanagihara, K; Takahashi, RU; Hirakawa, K; Yasui, W; Ochiya, T				Naito, Yutaka; Yamamoto, Yusuke; Sakamoto, Naoya; Shimomura, Iwao; Kogure, Akiko; Kumazaki, Minami; Yokoi, Akira; Yashiro, Masakazu; Kiyono, Tohru; Yanagihara, Kazuyoshi; Takahashi, Ryou-u; Hirakawa, Kosei; Yasui, Wataru; Ochiya, Takahiro			Cancer extracellular vesicles contribute to stromal heterogeneity by inducing chemokines in cancer-associated fibroblasts	ONCOGENE			English	Article							TGF-BETA; CELLS; RECRUITMENT; EXPRESSION; CARCINOMA; GROWTH; CXCL1; CHEMORESISTANCE; INTERLEUKIN-8; LOCALIZATION	Cancer-associated fibroblasts (CAFs), one of the major components of a tumour microenvironment, comprise heterogeneous populations involved in tumour progression. However, it remains obscure how CAF heterogeneity is governed by cancer cells. Here, we show that cancer extracellular vesicles (EVs) induce a series of chemokines in activated fibroblasts and contribute to the formation of the heterogeneity. In a xenograft model of diffuse-type gastric cancer, we showed two distinct fibroblast subpopulations with alpha-smooth muscle actin (alpha-SMA) expression or chemokine expression. MicroRNAs (miRNAs) profiling of the EVs and the transfection experiment suggested that several miRNAs played a role in the induction of chemokines such as CXCL1 and CXCL8 in fibroblasts, but not for the myofibroblastic differentiation. Clinically, aberrant activation of CXCL1 and CXCL8 in CAFs correlated with poorer survival in gastric cancer patients. Thus, this link between chemokine expression in CAFs and tumour progression may provide novel targets for anticancer therapy.	[Naito, Yutaka; Yamamoto, Yusuke; Shimomura, Iwao; Kogure, Akiko; Kumazaki, Minami; Yokoi, Akira; Takahashi, Ryou-u; Ochiya, Takahiro] Natl Canc Ctr, Div Mol & Cellular Med, Tokyo, Japan; [Sakamoto, Naoya; Yasui, Wataru] Hiroshima Univ, Dept Mol Pathol, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan; [Yashiro, Masakazu; Hirakawa, Kosei] Osaka City Univ, Mol Oncol & Therapeut, Grad Sch Med, Osaka, Japan; [Kiyono, Tohru] Natl Canc Ctr, Div Carcinogenesis & Canc Prevent, Tokyo, Japan; [Yanagihara, Kazuyoshi] Natl Canc Ctr, Div Biomarker Discovery, Exploratory Oncol & Clin Trial Ctr, Chiba, Japan; [Takahashi, Ryou-u] Hiroshima Univ, Dept Cellular & Mol Biol, Div Integrated Med Sci, Grad Sch Biomed Sci, Hiroshima, Japan; [Ochiya, Takahiro] Tokyo Med Univ, Dept Mol & Cellular Med, Inst Med Sci, Tokyo, Japan	National Cancer Center - Japan; Hiroshima University; Osaka Metropolitan University; National Cancer Center - Japan; National Cancer Center - Japan; Hiroshima University; Tokyo Medical University	Ochiya, T (corresponding author), Natl Canc Ctr, Div Mol & Cellular Med, Tokyo, Japan.; Ochiya, T (corresponding author), Tokyo Med Univ, Dept Mol & Cellular Med, Inst Med Sci, Tokyo, Japan.	tochiya@ncc.go.jp	Asada, Akiko/ABF-7324-2020; Ochiya, Takahiro/AAH-7585-2019		JSPS KAKENHI Grant [15K21646, 17H04991, 17K19625]; JSPS [15J10473]; Center of Open Innovation Network for Smart Health (COINS); Council for Science; Japan Agency for Medical Research and development, AMED; Naito foundation	JSPS KAKENHI Grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Center of Open Innovation Network for Smart Health (COINS); Council for Science; Japan Agency for Medical Research and development, AMED(Japan Agency for Medical Research and Development (AMED)); Naito foundation(Naito Memorial Foundation)	We thank Mr. Shinichi Norimura in Hiroshima University for his excellent technical assistance. This work was supported by JSPS KAKENHI Grant Number 15K21646, 17H04991 and 17K19625, and JSPS Fellows 15J10473 and in part by a Grant-in-Aid for the Japan Science and Technology Agency (JST) through the Center of Open Innovation Network for Smart Health (COINS) initiated by the Council for Science, a Grant-in-Aid for the Project for Cancer Research And Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and development, AMED; and the research grant from Naito foundation.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Al-Alwan LA, 2013, J IMMUNOL, V191, P2731, DOI 10.4049/jimmunol.1203421; Anderberg C, 2009, CANCER RES, V69, P369, DOI 10.1158/0008-5472.CAN-08-2724; Asfaha S, 2013, GASTROENTEROLOGY, V144, P155, DOI 10.1053/j.gastro.2012.09.057; Baroni S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.224; Belli C, 2018, CANCER TREAT REV, V65, P22, DOI 10.1016/j.ctrv.2018.02.004; Bhattacharyya S, 2011, J BIOL CHEM, V286, P11604, DOI 10.1074/jbc.M110.198390; Cheng WL, 2011, ANN ONCOL, V22, P2267, DOI 10.1093/annonc/mdq739; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; De Filippo K, 2013, BLOOD, V121, P4930, DOI 10.1182/blood-2013-02-486217; Eck M, 2003, CLIN EXP IMMUNOL, V134, P508, DOI 10.1111/j.1365-2249.2003.02305.x; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Givel AM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03348-z; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jackson DG, 2001, TRENDS IMMUNOL, V22, P317, DOI 10.1016/S1471-4906(01)01936-6; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kasashima H, 2016, AM J PATHOL, V186, P3028, DOI 10.1016/j.ajpath.2016.07.024; Kawajiri H, 2008, CLIN CANCER RES, V14, P2850, DOI 10.1158/1078-0432.CCR-07-1634; Kitadai Y, 1998, AM J PATHOL, V152, P93; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; MIZOI T, 1993, CANCER RES, V53, P183; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Paggetti J, 2015, BLOOD, V126, P1106, DOI 10.1182/blood-2014-12-618025; Powell DR, 2016, TRENDS IMMUNOL, V37, P41, DOI 10.1016/j.it.2015.11.008; Raja UM, 2017, CYTOKINE, V89, P82, DOI 10.1016/j.cyto.2016.08.032; Roswall P, 2018, NAT MED, V24, P463, DOI 10.1038/nm.4494; Shinto O, 2010, BRIT J CANCER, V102, P844, DOI 10.1038/sj.bjc.6605561; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Sugimoto H, 2014, CANCER BIOL THER, V5, P1640; Tominaga N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7716; Verbeke H, 2011, CANCER LETT, V302, P54, DOI 10.1016/j.canlet.2010.12.013; Webber JP, 2015, ONCOGENE, V34, P319, DOI 10.1038/onc.2013.560; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Wu RF, 2018, J CLIN INVEST, V128, P2551, DOI 10.1172/JCI97426; Yamaguchi H, 2015, CANCERS, V7, P2054, DOI 10.3390/cancers7040876; Yanagihara K, 2004, CANCER SCI, V95, P575, DOI 10.1111/j.1349-7006.2004.tb02489.x; Yanagihara K, 2006, CANCER RES, V66, P7532, DOI 10.1158/0008-5472.CAN-05-3259; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007; Zomer A, 2015, CELL, V161, P1046, DOI 10.1016/j.cell.2015.04.042	48	52	53	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5566	5579		10.1038/s41388-019-0832-4	http://dx.doi.org/10.1038/s41388-019-0832-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31147602	Green Published, hybrid			2022-12-17	WOS:000474845100002
J	Nakano, M; Kikushige, Y; Miyawaki, K; Kunisaki, Y; Mizuno, S; Takenaka, K; Tamura, S; Okumura, Y; Ito, M; Ariyama, H; Kusaba, H; Nakamura, M; Maeda, T; Baba, E; Akashi, K				Nakano, Michitaka; Kikushige, Yoshikane; Miyawaki, Kohta; Kunisaki, Yuya; Mizuno, Shinichi; Takenaka, Katsuto; Tamura, Shingo; Okumura, Yuta; Ito, Mamoru; Ariyama, Hiroshi; Kusaba, Hitoshi; Nakamura, Masafumi; Maeda, Takahiro; Baba, Eishi; Akashi, Koichi			Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer	ONCOGENE			English	Article							HUMAN COLON; MESENCHYMAL TRANSITION; INITIATING CELLS; TUMOR INITIATION; EMT; IDENTIFICATION; METASTASIS; EXPRESSION; PLASTICITY; SIGNATURE	Cancer stem cells (CSCs) possess the capacity for self-renewal and the potential to differentiate into non-CSCs. The recent discoveries of dynamic equilibrium between CSCs and non-CSCs revealed the significance of acquiring CSC-like properties in non-CSCs as an important process in progression of cancer. The mechanism underlying acquisition of CSC-like properties has mainly been investigated in the context of epithelial-mesenchymal transition. Here, we demonstrate the dedifferentiation process may be an alternative mechanism in acquisition of CSC-like properties in human colorectal cancer cells. By exploring the single-cell gene expression analysis of organoids developed from CD44(+) CSCs, we identified TWIST1 as a key molecule for maintaining the undifferentiated state of cancer cells. Consistent with the finding, we found that TGF-beta signaling pathway, a regulator of TWIST1, was specifically activated in the undifferentiated CD44(+) CSCs in human colorectal cancer using microarray-based gene expression analysis and quantitative pathology imaging system. Furthermore, we showed that external stimulation with TGF-beta and the induction of TWIST1 converted CD44(-) non-CSCs into the undifferentiated CD44(+) CSCs, leading to the significant increment of CSCs in xenograft models. This study strongly suggests dedifferentiation driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer.	[Nakano, Michitaka; Kikushige, Yoshikane; Miyawaki, Kohta; Kunisaki, Yuya; Mizuno, Shinichi; Takenaka, Katsuto; Tamura, Shingo; Okumura, Yuta; Ito, Mamoru; Ariyama, Hiroshi; Kusaba, Hitoshi; Maeda, Takahiro; Baba, Eishi; Akashi, Koichi] Kyushu Univ, Dept Med & Biosyst Sci, Grad Sch Med Sci, Fukuoka, Fukuoka, Japan; [Baba, Eishi] Kyushu Univ, Dept Comprehens Clin Oncol, Fac Med Sci, Fukuoka, Fukuoka, Japan; [Nakamura, Masafumi] Kyushu Univ, Dept Surg & Oncol, Grad Sch Med Sci, Fukuoka, Fukuoka, Japan	Kyushu University; Kyushu University; Kyushu University	Baba, E (corresponding author), Kyushu Univ, Dept Med & Biosyst Sci, Grad Sch Med Sci, Fukuoka, Fukuoka, Japan.; Baba, E (corresponding author), Kyushu Univ, Dept Comprehens Clin Oncol, Fac Med Sci, Fukuoka, Fukuoka, Japan.	e-baba@intmed1.med.kyushu-u.ac.jp	Maeda, Takahiro/AAC-4563-2019	Maeda, Takahiro/0000-0003-4530-6460; Nakano, Michitaka/0000-0003-1049-5791; Okumura, Yuta/0000-0002-7825-8373	JSPS [16H06391, 16H02662, 15K08970, 16H06250, 25860542, 15H04859]; MEXT, Japan [25115002]; Japan Agency for Medical Research and development, AMED [18cm0106507h0003, 18ck0106196h0003]; Shinnihon Foundation of Advanced Medical Treatment Research; AstraZeneca KK (AZKK Science Promotion Grant)	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Agency for Medical Research and development, AMED(Japan Agency for Medical Research and Development (AMED)); Shinnihon Foundation of Advanced Medical Treatment Research; AstraZeneca KK (AZKK Science Promotion Grant)	We especially thank N Torada, T Ueki, and T Manabe, S Nagai from the Department of Surgery and Oncology, Kyushu University, for providing clinical colorectal cancer tissues. They sincerely thank T. Isobe for development of methods and wonderful lecture. They also thank A. Yurino for providing mice, Yasufumi Uehara for taking confocal microscopy images, T Sugio, T Jiroumaru for performing microarray analysis. Co-workers at our labs, F Hanamura, Yumiko Uehara, K Yamaguchi, K Sagara, K Tsuchihashi, S Arita, supported this work. This study was supported in part by a Grant-in-Aid for Scientific Research (S) (to KA, #16H06391), a Grant-in-Aid for Scientific Research (A) (to KA, #16H02662), a Grant-in-Aid for Scientific Research (C) (to EB, #15K08970), a Grant-in-Aid for Young Scientists (A) (to Y Kikushige #16H06250), a Grant-in-Aid for Young Scientists (B) (to SA, #25860542), a Grant-in-Aid for Scientific Research (B) (to Y Kunisaki, #15H04859), from the JSPS, and a Grant-in-Aid for Scientific Research on Innovative Areas "Stem Cell Aging and Disease" (to TM and Y Kikushige, #25115002) from MEXT, Japan, and the "Project for Cancer Research and Therapeutic Evolution" (to KA, 18cm0106507h0003), and the "Practical Research for Innovative Cancer Control" (to Y Kikushige, 18ck0106196h0003) from Japan Agency for Medical Research and development, AMED, and the Shinnihon Foundation of Advanced Medical Treatment Research (to HA, Y Kikushige, and Y Kunisaki), and a collaborative research grant from AstraZeneca KK (to MN, AZKK Science Promotion Grant).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Barriga FM, 2017, CELL STEM CELL, V20, P801, DOI 10.1016/j.stem.2017.02.007; Beck B, 2015, CELL STEM CELL, V16, P67, DOI 10.1016/j.stem.2014.12.002; Beerling E, 2016, CELL REP, V14, P2281, DOI 10.1016/j.celrep.2016.02.034; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; de Sousa e Melo F, 2011, CELL STEM CELL, V9, P476, DOI 10.1016/j.stem.2011.10.008; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008-5472.CAN-12-2706; Foroutan M, 2017, MOL CANCER RES, V15, P619, DOI 10.1158/1541-7786.MCR-16-0313; Fujii M, 2016, CELL STEM CELL, V18, P827, DOI 10.1016/j.stem.2016.04.003; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Jiang JM, 2008, CELL STEM CELL, V3, P127, DOI 10.1016/j.stem.2008.07.011; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Jung P, 2015, STEM CELL REP, V5, P979, DOI 10.1016/j.stemcr.2015.10.003; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kim J, 2011, GENOME MED, V3, DOI 10.1186/gm291; Lee CJ, 2008, J CLIN ONCOL, V26, P2806, DOI 10.1200/JCO.2008.16.6702; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Medema JP, 2011, NATURE, V474, P318, DOI 10.1038/nature10212; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Mullen AC, 2011, CELL, V147, P565, DOI 10.1016/j.cell.2011.08.050; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oshimori N, 2012, CELL STEM CELL, V11, P751, DOI 10.1016/j.stem.2012.11.001; Ovadya Y, 2015, NAT MED, V21, P975, DOI 10.1038/nm.3938; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Pino MS, 2010, GASTROENTEROLOGY, V138, P1406, DOI 10.1053/j.gastro.2009.12.010; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Shvab A, 2016, ONCOGENE, V35, P549, DOI 10.1038/onc.2015.127; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wang DW, 2018, ONCOL REP, V39, P31, DOI 10.3892/or.2017.6076; Wu Y, 2017, BREAST CANCER RES TR, V163, P449, DOI 10.1007/s10549-017-4211-y; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Zhang BX, 2010, GASTROENTEROLOGY, V138, P969, DOI 10.1053/j.gastro.2009.11.004; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364; Zhu PP, 2015, J CLIN INVEST, V125, P3795, DOI 10.1172/JCI81979	52	52	54	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					780	793		10.1038/s41388-018-0480-0	http://dx.doi.org/10.1038/s41388-018-0480-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30181548	Green Accepted			2022-12-17	WOS:000458006300002
J	Ferro, R; Adamska, A; Lattanzio, R; Mavrommati, I; Edling, CE; Arifin, SA; Fyffe, CA; Sala, G; Sacchetto, L; Chiorino, G; De Laurenzi, V; Piantelli, M; Sansom, OJ; Maffucci, T; Falasca, M				Ferro, R.; Adamska, A.; Lattanzio, R.; Mavrommati, I; Edling, C. E.; Arifin, S. A.; Fyffe, C. A.; Sala, G.; Sacchetto, L.; Chiorino, G.; De Laurenzi, V; Piantelli, M.; Sansom, O. J.; Maffucci, T.; Falasca, M.			GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine	ONCOGENE			English	Article							CANNABINOID RECEPTOR GPR55; LYSOPHOSPHATIDYLINOSITOL; RESISTANCE; PROGRESSION; EXPRESSION; MIGRATION; KRAS	The life expectancy for pancreatic cancer patients has seen no substantial changes in the last 40 years as very few and mostly just palliative treatments are available. As the five years survival rate remains around 5%, the identification of novel pharmacological targets and development of new therapeutic strategies are urgently needed. Here we demonstrate that inhibition of the G protein-coupled receptor GPR55, using genetic and pharmacological approaches, reduces pancreatic cancer cell growth in vitro and in vivo and we propose that this may represent a novel strategy to inhibit pancreatic ductal adenocarcinoma (PDAC) progression. Specifically, we show that genetic ablation of Gpr55 in the KRAS(WT/G12D)/TP53(WT/)(R172H)/Pdx1-Cre(+/+) (KPC) mouse model of PDAC significantly prolonged survival. Importantly, KPC mice treated with a combination of the GPR55 antagonist Cannabidiol (CBD) and gemcitabine (GEM, one of the most used drugs to treat PDAC), survived nearly three times longer compared to mice treated with vehicle or GEM alone. Mechanistically, knockdown or pharmacologic inhibition of GPR55 reduced anchorage-dependent and independent growth, cell cycle progression, activation of mitogen-activated protein kinase (MAPK) signalling and protein levels of ribonucleotide reductases in PDAC cells. Consistent with this, genetic ablation of Gpr55 reduced proliferation of tumour cells, MAPK signalling and ribonucleotide reductase M1 levels in KPC mice. Combination of CBD and GEM inhibited tumour cell proliferation in KPC mice and it opposed mechanisms involved in development of resistance to GEM in vitro and in vivo. Finally, we demonstrate that the tumour suppressor p53 regulates GPR55 protein expression through modulation of the microRNA miR34b-3p. Our results demonstrate the important role played by GPR55 downstream of p53 in PDAC progression. Moreover our data indicate that combination of CBD and GEM, both currently approved for medical use, might be tested in clinical trials as a novel promising treatment to improve PDAC patients' outcome.	[Ferro, R.; Mavrommati, I; Edling, C. E.; Arifin, S. A.; Fyffe, C. A.; Maffucci, T.; Falasca, M.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, Ctr Cell Biol & Cutaneous Res, 4 Newark St, London E1 2AT, England; [Adamska, A.; De Laurenzi, V; Falasca, M.] Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Pharm & Biomed Sci, Metab Signalling Grp, Perth, WA 6102, Australia; [Lattanzio, R.; Sala, G.; De Laurenzi, V; Piantelli, M.] Univ G dAnnunzio, Dipartimento Sci Med Orali & Biotecnol, CeSI MeT, Ctr Studi Invecchiamento, I-66100 Chieti, Italy; [Sacchetto, L.; Chiorino, G.] Fdn Edo & Elvo Tempia, Canc Genom Lab, Biella, Italy; [Sansom, O. J.] Canc Res UK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland	University of London; Queen Mary University London; Curtin University; G d'Annunzio University of Chieti-Pescara; Beatson Institute	Falasca, M (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, Ctr Cell Biol & Cutaneous Res, 4 Newark St, London E1 2AT, England.; Falasca, M (corresponding author), Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Pharm & Biomed Sci, Metab Signalling Grp, Perth, WA 6102, Australia.	marco.falasca@curtin.edu.au	Ferro, Riccardo/AAD-3882-2019; Sala, Gianluca/C-2056-2017; Lattanzio, Rossano/K-1927-2018; Chiorino, Giovanna/K-5037-2016; Falasca, Marco/S-4020-2016	Ferro, Riccardo/0000-0001-6532-4856; Sala, Gianluca/0000-0002-4494-915X; Lattanzio, Rossano/0000-0001-9803-4476; Chiorino, Giovanna/0000-0002-9502-6400; Falasca, Marco/0000-0002-9801-7235; SACCHETTO, LIDIA/0000-0001-6590-325X; Sansom, Owen J./0000-0001-9540-3010	Pancreatic Cancer Research Fund; Avner Pancreatic Cancer Foundation; Curtin International Postgraduate Research Scholarship (CIPRS)/Health Sciences Faculty International Research Scholarship (HSFIRS); Ministero Sanita Finalizzata 2011/2012; AIRC [IG 15196.c]	Pancreatic Cancer Research Fund; Avner Pancreatic Cancer Foundation; Curtin International Postgraduate Research Scholarship (CIPRS)/Health Sciences Faculty International Research Scholarship (HSFIRS); Ministero Sanita Finalizzata 2011/2012; AIRC(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Pancreatic Cancer Research Fund and Avner Pancreatic Cancer Foundation (grants to MF). RF, CAF, CEE were supported by Pancreatic Cancer Research Fund (grants to MF). AA is supported by Curtin International Postgraduate Research Scholarship (CIPRS)/Health Sciences Faculty International Research Scholarship (HSFIRS). GS was supported by Ministero Sanita Finalizzata 2011/2012. VDL was supported by AIRC IG 15196.c. We thank Prof David A. Tuveson and Prof David Baker for KC/KPC and GPR55<SUP>-/-</SUP> mice respectively; Dr Massimo Broggini for p53 mutants constructs; Prof Hemant Kocher for HPDE cells; GW Pharmaceuticals for providing the cannabidiol used in this study; the Pathology Core facility of the Blizard Institute for helping with IHC. AA, VDL and MF also acknowledge the infrastructure and staff support provided by CHIRI, School of Pharmacy & Biomedical Sciences and by Faculty of Health Sciences, Curtin University.	Andradas C, 2011, ONCOGENE, V30, P245, DOI 10.1038/onc.2010.402; Andradas C, 2016, ONCOTARGET, V7, P47565, DOI 10.18632/oncotarget.10206; Bergman AM, 2005, CANCER RES, V65, P9510, DOI 10.1158/0008-5472.CAN-05-0989; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Davidson JD, 2004, CANCER RES, V64, P3761, DOI 10.1158/0008-5472.CAN-03-3363; Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215; Falasca M, 1998, ONCOGENE, V16, P2357, DOI 10.1038/sj.onc.1201758; FALASCA M, 1995, ONCOGENE, V10, P2113; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; Falasca M, 2016, BBA-REV CANCER, V1865, P123, DOI 10.1016/j.bbcan.2016.01.001; Ford LA, 2010, BRIT J PHARMACOL, V160, P762, DOI 10.1111/j.1476-5381.2010.00743.x; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hofmann NA, 2015, BRIT J PHARMACOL, V172, P4107, DOI 10.1111/bph.13196; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816; Kargl J, 2016, BRIT J PHARMACOL, V173, P142, DOI 10.1111/bph.13345; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Oka S, 2007, BIOCHEM BIOPH RES CO, V362, P928, DOI 10.1016/j.bbrc.2007.08.078; Paul RK, 2014, BIOCHEM PHARMACOL, V87, P547, DOI 10.1016/j.bcp.2013.11.020; Peixoto RD, 2017, AM J CLIN ONCOL-CANC, V40, P507, DOI 10.1097/COC.0000000000000193; Perez-Gomez E, 2013, ONCOGENE, V32, P2534, DOI 10.1038/onc.2012.278; Pineiro R, 2011, ONCOGENE, V30, P142, DOI 10.1038/onc.2010.417; Romero-Zerbo SY, 2011, J ENDOCRINOL, V211, P177, DOI 10.1530/JOE-11-0166; Ross RA, 2011, TRENDS PHARMACOL SCI, V32, P265, DOI 10.1016/j.tips.2011.01.005; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; SCARPA A, 1993, AM J PATHOL, V142, P1534; Sisay S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076907; Suresh Kp, 2011, J Hum Reprod Sci, V4, P8, DOI 10.4103/0974-1208.82352; Sutphen R, 2004, CANCER EPIDEM BIOMAR, V13, P1185; Vaccaro V, 2011, NEW ENGL J MED, V365, P768, DOI 10.1056/NEJMc1107627; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Vogt M, 2011, VIRCHOWS ARCH, V458, P313, DOI 10.1007/s00428-010-1030-5; Zheng CN, 2013, J INT MED RES, V41, P300, DOI 10.1177/0300060512474128	36	52	55	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2018	37	49					6368	6382		10.1038/s41388-018-0390-1	http://dx.doi.org/10.1038/s41388-018-0390-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HD3AP	30061636	Green Accepted, Green Submitted			2022-12-17	WOS:000452384400007
J	Berns, K; Caumanns, JJ; Hijmans, EM; Gennissen, AMC; Severson, TM; Evers, B; Wisman, GBA; Meersma, GJ; Lieftink, C; Beijersbergen, RL; Itamochi, H; van der Zee, AGJ; de Jong, S; Bernards, R				Berns, Katrien; Caumanns, Joseph J.; Hijmans, E. Marielle; Gennissen, Annemiek M. C.; Severson, Tesa M.; Evers, Bastiaan; Wisman, G. Bea A.; Meersma, Gert Jan; Lieftink, Cor; Beijersbergen, Roderick L.; Itamochi, Hiroaki; van der Zee, Ate G. J.; de Jong, Steven; Bernards, Rene			ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors	ONCOGENE			English	Article							COLON-CANCER; RESISTANCE; ACTIVATION; LANDSCAPE; MYC	Current treatment for advanced stage ovarian clear cell cancer is severely hampered by a lack of effective systemic therapy options, leading to a poor outlook for these patients. Sequencing studies revealed that ARID1A is mutated in over 50% of ovarian clear cell carcinomas. To search for a rational approach to target ovarian clear cell cancers with ARID1A mutations, we performed kinome-centered lethality screens in a large panel of ovarian clear cell carcinoma cell lines. Using the largest OCCC cell line panel established to date, we show here that BRD2 inhibition is predominantly lethal in ARID1A mutated ovarian clear cell cancer cells. Importantly, small molecule inhibitors of the BET (bromodomain and extra terminal domain) family of proteins, to which BRD2 belongs, specifically inhibit proliferation of ARID1A mutated cell lines, both in vitro and in ovarian clear cell cancer xenografts and patient-derived xenograft models. BET inhibitors cause a reduction in the expression of multiple SWI/SNF members including ARID1B, providing a potential explanation for the observed lethal interaction with ARID1A loss. Our data indicate that BET inhibition may represent a novel treatment strategy for a subset of ARID1A mutated ovarian clear cell carcinomas.	[Berns, Katrien; Hijmans, E. Marielle; Gennissen, Annemiek M. C.; Severson, Tesa M.; Evers, Bastiaan; Lieftink, Cor; Beijersbergen, Roderick L.; Bernards, Rene] Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [Berns, Katrien; Hijmans, E. Marielle; Gennissen, Annemiek M. C.; Severson, Tesa M.; Evers, Bastiaan; Lieftink, Cor; Beijersbergen, Roderick L.; Bernards, Rene] Netherlands Canc Inst, Oncode Inst, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [Caumanns, Joseph J.; Wisman, G. Bea A.; Meersma, Gert Jan; van der Zee, Ate G. J.] Univ Groningen, Univ Med Ctr Groningen, Canc Res Ctr Groningen, Gynaecol Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands; [Itamochi, Hiroaki] Iwate Med Univ, Sch Med, Dept Obstet & Gynaecol, Morioka, Iwate 0208505, Japan; [de Jong, Steven] Univ Groningen, Univ Med Ctr Groningen, Canc Res Ctr Groningen, Med Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; University of Groningen; Iwate Medical University; University of Groningen	Berns, K; Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.; Berns, K; Bernards, R (corresponding author), Netherlands Canc Inst, Oncode Inst, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	k.berns@nki.nl; r.bernards@nki.nl		Beijersbergen, Roderick/0000-0003-0116-4130	Dutch Cancer Society (KWF) [RUG2012-5477]; Cancer Genomics Center Netherlands through the Netherlands Organization for Scientific Research (NWO)	Dutch Cancer Society (KWF)(KWF Kankerbestrijding); Cancer Genomics Center Netherlands through the Netherlands Organization for Scientific Research (NWO)	We thank pathologist E.W. Duiker from UMCG for her contributions on OCCC pathology, H. Maat (Department of Experimental Hematology, UMCG) for her help with ChIP experiments, the people from the Genomics Core Facility of the Netherlands Cancer Institute for their technical support, and members of the Bernards lab for their helpful discussions. This research was supported by grants from the Dutch Cancer Society (KWF, RUG2012-5477) and the Cancer Genomics Center Netherlands through the Netherlands Organization for Scientific Research (NWO).	Alkema NG, 2015, SCI REP-UK, V5, DOI 10.1038/srep14495; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Bitler BG, 2017, NAT CELL BIOL, V19, P962, DOI 10.1038/ncb3582; Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799; Braicu EI, 2011, BRIT J CANCER, V105, P1818, DOI 10.1038/bjc.2011.455; Cheung KL, 2017, MOL CELL, V65, P1068, DOI 10.1016/j.molcel.2016.12.022; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Denis GV, 1996, GENE DEV, V10, P261, DOI 10.1101/gad.10.3.261; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gad H, 2014, NATURE, V508, P215, DOI 10.1038/nature13181; Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480; Herold MJ, 2008, P NATL ACAD SCI USA, V105, P18507, DOI 10.1073/pnas.0806213105; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Khursheed M, 2013, BRIT J CANCER, V108, P2056, DOI 10.1038/bjc.2013.200; Kurman RJ, 2008, INT J GYNECOL PATHOL, V27, P151, DOI 10.1097/PGP.0b013e318161e4f5; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062; Miller RE, 2016, MOL CANCER THER, V15, P1472, DOI 10.1158/1535-7163.MCT-15-0554; Murakami R, 2017, AM J PATHOL, V187, P2246, DOI 10.1016/j.ajpath.2017.06.012; Prahallad A, 2015, CELL REP, V12, P1978, DOI 10.1016/j.celrep.2015.08.037; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Prat J, 2012, ANN ONCOL, V23, P111, DOI 10.1093/annonc/mds300; Shao Q, 2014, CANCER RES, V74, P7090, DOI 10.1158/0008-5472.CAN-14-0305; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068	29	52	54	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4611	4625		10.1038/s41388-018-0300-6	http://dx.doi.org/10.1038/s41388-018-0300-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29760405	Green Published, hybrid			2022-12-17	WOS:000441736700009
J	Zhou, HH; Liu, YS; Zhu, R; Ding, F; Cao, XF; Lin, DX; Liu, ZH				Zhou, Honghong; Liu, Yongshuo; Zhu, Rui; Ding, Fang; Cao, Xiufeng; Lin, Dongxin; Liu, Zhihua			OTUB1 promotes esophageal squamous cell carcinoma metastasis through modulating Snail stability	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR SNAIL; BREAST-CANCER; POOR-PROGNOSIS; DEGRADATION; INVASION; EMT; DEUBIQUITINATION; PROGRESSION; ENZYME	Snail is a key regulator of epithelial-mesenchymal transition (EMT) and plays an important role in tumor progression and metastasis. Snail is rapidly degraded in the cells and its protein level is critically controlled. Although several E3 ligases regulating Snail degradation have been defined, the deubiquitinases (DUBs) responsible for Snail deubiquitination are less studied. We identified ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 (OTUB1) as a DUB that stabilizes Snail through preventing its ubiquitination and proteasomal degradation. Functionally, OTUB1 facilitates metastasis of esophageal squamous cell carcinoma (ESCC) through promoting Snail protein stability. Moreover, OTUB1 is highly expressed in ESCC and higher expression of OTUB1 predicts poor prognosis. These findings suggest that OTUB1 is an essential regulator of Snail and plays a critical role in facilitating esophageal cancer progression.	[Zhou, Honghong; Liu, Yongshuo; Zhu, Rui; Ding, Fang; Lin, Dongxin; Liu, Zhihua] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, State Key Lab Mol Oncol, Beijing, Peoples R China; [Zhou, Honghong; Liu, Yongshuo; Zhu, Rui; Ding, Fang; Lin, Dongxin; Liu, Zhihua] Peking Union Med Coll, Beijing, Peoples R China; [Zhou, Honghong; Lin, Dongxin] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Dept Etiol & Carcinogenesis, Beijing, Peoples R China; [Cao, Xiufeng] Nanjing Med Univ, Nanjing Hosp 1, Dept Surg Oncol, Nanjing, Jiangsu, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Nanjing Medical University	Liu, ZH (corresponding author), Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, State Key Lab Mol Oncol, Beijing, Peoples R China.; Liu, ZH (corresponding author), Peking Union Med Coll, Beijing, Peoples R China.	liuzh@cicams.ac.cn	Liu, Yongshuo/AGZ-8274-2022; Liu, Yongshuo/GRX-6416-2022	Liu, Yongshuo/0000-0001-8190-0139; Liu, Yongshuo/0000-0001-8190-0139; Lin, Dongxin/0000-0002-8723-8868	National Key R&D Program of China [2016YFC1302100]; National Science Foundation of China [81420108025]; CAMS Initiative for Innovative Medicine [2016-I2M-1-001]	National Key R&D Program of China; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Initiative for Innovative Medicine	This work was supported by National Key R&D Program of China (2016YFC1302100), National Science Foundation of China (81420108025), and CAMS Initiative for Innovative Medicine (2016-I2M-1-001). We thank Dr. Shimada Y. (Kyoto University, Kyoto, Japan) for kindly providing the ESCC cell lines.	Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67; Baietti MF, 2016, EMBO MOL MED, V8, P288, DOI 10.15252/emmm.201505972; Balakirev MY, 2003, EMBO REP, V4, P517, DOI 10.1038/sj.embor.embor824; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Edelmann MJ, 2010, FEBS J, V277, P2515, DOI 10.1111/j.1742-4658.2010.07665.x; Edelmann MJ, 2009, BIOCHEM J, V418, P379, DOI 10.1042/BJ20081318; Guzik P, 2013, CLIN AUTON RES, V23, P91, DOI 10.1007/s10286-013-0188-8; Herhaus L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3519; Iglesias-Gato D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0280-2; Jin Y, 2015, CANCER LETT, V362, P70, DOI 10.1016/j.canlet.2015.03.037; Karunarathna U, 2016, ONCOGENE, V35, P1433, DOI 10.1038/onc.2015.208; Lander R, 2011, J CELL BIOL, V194, P17, DOI 10.1083/jcb.201012085; Li S, 2010, J BIOL CHEM, V285, P4291, DOI 10.1074/jbc.M109.074971; Li YH, 2014, J BIOL CHEM, V289, P5097, DOI 10.1074/jbc.M113.533109; Lin YW, 2017, ONCOTARGET, V8, P75127, DOI 10.18632/oncotarget.20561; Liu TZ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13923; Liu X, 2014, PATHOL RES PRACT, V210, P770, DOI 10.1016/j.prp.2014.05.008; Luo AP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096610; Matysiak M, 2017, ARCH GYNECOL OBSTET, V295, P817, DOI 10.1007/s00404-017-4304-1; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Sun XX, 2012, EMBO J, V31, P576, DOI 10.1038/emboj.2011.434; Tian YY, 2010, J BIOL CHEM, V285, P7986, DOI 10.1074/jbc.M109.062877; Wang M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-225; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Wang YQ, 2016, ONCOTARGET, V7, P36681, DOI 10.18632/oncotarget.9160; Weng WW, 2016, AM J TRANSL RES, V8, P2234; Wu YD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14228; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhou H, 2017, ONCOGENE, V36, P3312, DOI 10.1038/onc.2016.479; Zhou Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-258	37	52	55	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3356	3368		10.1038/s41388-018-0224-1	http://dx.doi.org/10.1038/s41388-018-0224-1			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29559747				2022-12-17	WOS:000436411300003
J	Lourenco, AR; Coffer, PJ				Lourenco, A. R.; Coffer, P. J.			A tumor suppressor role for C/EBP alpha in solid tumors: more than fat and blood	ONCOGENE			English	Review							BINDING-PROTEIN-ALPHA; HUMAN HEPATOCELLULAR-CARCINOMA; BREAST-CANCER CELLS; GROWTH-INHIBITORY ACTIVITY; ACUTE MYELOID LEUKEMIAS; DOWN-REGULATION; LUNG-CANCER; GENE-EXPRESSION; FACTOR-RECEPTOR; C-MYC	The transcription factor CCAAT/enhancer-binding protein alpha (C/EBP alpha) plays a critical role during embryogenesis and is thereafter required for homeostatic glucose metabolism, adipogenesis and myeloid development. Its ability to regulate the expression of lineage-specific genes and induce growth arrest contributes to the terminal differentiation of several cell types, including hepatocytes, adipocytes and granulocytes. CEBPA loss of-function mutations contribute to the development of similar to 10% of acute myeloid leukemia (AML), stablishing a tumor suppressor role for C/EBP alpha. Deregulation of C/EBP alpha expression has also been reported in a variety of additional human neoplasias, including liver, breast and lung cancer. However, functional CEBPA mutations have not been found in solid tumors, suggesting that abrogation of C/EBP alpha function in non-hematopoietic tissues is regulated by alternative mechanisms. Here we review the function of C/EBP alpha in solid tumors and focus on the molecular mechanisms underlying its tumor suppressive role.	[Lourenco, A. R.; Coffer, P. J.] Univ Med Ctr Utrecht, Ctr Mol Med, Utrecht, Netherlands; [Coffer, P. J.] Univ Med Ctr Utrecht, Regenerat Med Ctr, Uppsalalaan 6, NL-3584 CT Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Coffer, PJ (corresponding author), Univ Med Ctr Utrecht, Regenerat Med Ctr, Uppsalalaan 6, NL-3584 CT Utrecht, Netherlands.	P.J.Coffer@umcutrecht.nl	Coffer, Paul/AAF-7970-2020					Adams BD, 2009, ENDOCRINOLOGY, V150, P14, DOI 10.1210/en.2008-0984; Anand S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112073; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Basseres DS, 2006, MOL CELL BIOL, V26, P1109, DOI 10.1128/MCB.26.3.1109-1123.2006; Bennett KL, 2007, CANCER RES, V67, P4657, DOI 10.1158/0008-5472.CAN-06-4793; Bennett KL, 2009, INT J CANCER, V124, P1285, DOI 10.1002/ijc.24087; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Calkhoven CF, 2000, GENE DEV, V14, P1920; Cappellen D, 2007, EMBO REP, V8, P70, DOI 10.1038/sj.embor.7400849; Cassel TN, 2000, ANN NY ACAD SCI, V923, P300; Chattopadhyay S, 2006, MOL ENDOCRINOL, V20, P984, DOI 10.1210/me.2005-0240; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Cheng JW, 2007, J BIOL CHEM, V282, P30535, DOI 10.1074/jbc.M704829200; Costa DB, 2007, LUNG CANCER, V56, P97, DOI 10.1016/j.lungcan.2006.11.023; Costa DB, 2006, LUNG CANCER, V53, P253, DOI 10.1016/j.lungcan.2006.04.011; D'Alo F, 2003, BLOOD, V102, P3163, DOI 10.1182/blood-2003-02-0479; Datta J, 2007, CANCER RES, V67, P2736, DOI 10.1158/0008-5472.CAN-06-4433; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Dhawan P, 2009, J BIOL CHEM, V284, P3086, DOI 10.1074/jbc.M803602200; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Esteller M, 2000, CANCER RES, V60, P2368; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Foka P, 2009, INT J BIOCHEM CELL B, V41, P1189, DOI 10.1016/j.biocel.2008.10.024; Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797; Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271; Gaykalova DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093102; Gery S, 2005, CLIN CANCER RES, V11, P3184, DOI 10.1158/1078-0432.CCR-04-2625; Girard L, 2000, CANCER RES, V60, P4894; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Grandinetti KB, 2011, ONCOGENE, V30, P3328, DOI 10.1038/onc.2011.57; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; Guo BH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-10; Hall JR, 2014, CELL CYCLE, V13, P3602, DOI 10.4161/15384101.2014.962957; Halmos B, 2004, CANCER RES, V64, P4137, DOI 10.1158/0008-5472.CAN-03-4052; Halmos B, 2002, CANCER RES, V62, P528; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; House JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009837; Huan HB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153117; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jeon BN, 2008, J BIOL CHEM, V283, P33199, DOI 10.1074/jbc.M802935200; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266; Kato N, 2011, BLOOD, V117, P221, DOI 10.1182/blood-2010-02-270181; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kim YH, 2013, EXP MOL PATHOL, V94, P360, DOI 10.1016/j.yexmp.2012.12.002; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; Kumagai T, 2009, INT J CANCER, V124, P827, DOI 10.1002/ijc.23994; Latha K, 2005, MOL CELL BIOL, V25, P1737, DOI 10.1128/MCB.25.5.1737-1748.2005; Lefterova MI, 2008, GENE DEV, V22, P2941, DOI 10.1101/gad.1709008; Leroy H, 2005, LEUKEMIA, V19, P329, DOI 10.1038/sj.leu.2403614; Li JN, 2011, ANTICANCER RES, V31, P2683; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Lin TC, 2011, LEUKEMIA, V25, P32, DOI 10.1038/leu.2010.222; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Loomis KD, 2007, CANCER RES, V67, P6768, DOI 10.1158/0008-5472.CAN-07-0139; Lopez RG, 2009, NAT CELL BIOL, V11, P1181, DOI 10.1038/ncb1960; Lu GD, 2010, GASTROENTEROLOGY, V139, P632, DOI 10.1053/j.gastro.2010.03.051; Lynes MA, 2014, CELL STRESS CHAPERON, V19, P605, DOI 10.1007/s12192-014-0501-z; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; Miller M, 2003, J BIOL CHEM, V278, P15178, DOI 10.1074/jbc.M300417200; Ming J, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150167; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Murata K, 2005, MOL CELL BIOL, V25, P4262, DOI 10.1128/MCB.25.10.4262-4271.2005; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; Nerlov C, 2004, NAT REV CANCER, V4, P394, DOI 10.1038/nrc1363; Oeztuerk-Winder F, 2012, EMBO J, V31, P3431, DOI 10.1038/emboj.2012.192; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Osada S, 1996, J BIOL CHEM, V271, P3891; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Ozenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pan ZM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-417; Patrick BA, 2012, ONCOGENE, V31, P4362, DOI 10.1038/onc.2011.600; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; Reebye V, 2014, HEPATOLOGY, V59, P216, DOI 10.1002/hep.26669; Roe JS, 2014, J EXP MED, V211, P1, DOI 10.1084/jem.20132530; Roepman P, 2005, NAT GENET, V37, P182, DOI 10.1038/ng1502; Rosen ED, 2000, GENE DEV, V14, P1293; Ruttkay-Nedecky B, 2013, INT J MOL SCI, V14, P6044, DOI 10.3390/ijms14036044; Saramaki A, 2006, NUCLEIC ACIDS RES, V34, P543, DOI 10.1093/nar/gkj460; Sato A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057013; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Schuster MB, 2006, BBA-REV CANCER, V1766, P88, DOI 10.1016/j.bbcan.2006.02.003; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Seifeddine R, 2008, CANCER RES, V68, P2158, DOI 10.1158/0008-5472.CAN-07-1190; Shi DB, 2015, CANCER LETT, V369, P376, DOI 10.1016/j.canlet.2015.08.029; Shi YC, 2013, DIGEST LIVER DIS, V45, P844, DOI 10.1016/j.dld.2013.03.013; Shim M, 2005, CANCER RES, V65, P861; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Soriano HE, 1998, HEPATOLOGY, V27, P392, DOI 10.1002/hep.510270212; Sugahara K, 2001, CELL TISSUE RES, V306, P57, DOI 10.1007/s004410100420; Sun CC, 2016, ONCOTARGET, V7, P35960, DOI 10.18632/oncotarget.8482; Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093; Takai N, 2005, MOL CANCER RES, V3, P261, DOI 10.1158/1541-7786.MCR-04-0110; Tan EH, 2005, CANCER RES, V65, P10330, DOI 10.1158/0008-5472.CAN-04-4486; Tang SH, 2010, CANCER BIOL THER, V9, P88, DOI 10.4161/cbt.9.2.10283; Taylor BS, 2011, CANCER DISCOV, V1, P587, DOI 10.1158/2159-8290.CD-11-0181; Thompson EA, 2011, J INVEST DERMATOL, V131, P1339, DOI 10.1038/jid.2011.31; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Tomizawa M, 2003, ANTICANCER RES, V23, P351; Tomizawa M, 2002, INT J MOL MED, V9, P597; Tomizawa M, 2007, ONCOL REP, V17, P341; Tseng HH, 2009, J CANCER RES CLIN, V135, P241, DOI 10.1007/s00432-008-0448-5; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Wang CG, 2014, CHINESE J CANCER RES, V26, P17, DOI 10.3978/j.issn.1000-9604.2014.01.01; Wang GL, 2006, MOL CELL BIOL, V26, P2570, DOI 10.1128/MCB.26.7.2570-2582.2006; Wang GL, 2005, MOL CELL BIOL, V25, P1325, DOI 10.1128/MCB.25.4.1325-1338.2005; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; Wang GL, 2008, EXP CELL RES, V314, P1626, DOI 10.1016/j.yexcr.2008.01.028; Wang GL, 2010, J CLIN INVEST, V120, P2549, DOI 10.1172/JCI41933; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang QA, 2015, NAT CELL BIOL, V17, P1099, DOI 10.1038/ncb3217; Watkins PJ, 1996, CANCER RES, V56, P1063; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Wu YV, 2012, GENE CHROMOSOME CANC, V51, P313, DOI 10.1002/gcc.21917; Yin H, 2005, PROSTATE, V62, P209, DOI 10.1002/pros.20136; Yin H, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-158; Yin H, 2009, PROSTATE, V69, P1001, DOI 10.1002/pros.20947; Yoon K, 2004, MOL CELL BIOL, V24, P10650, DOI 10.1128/MCB.24.24.10650-10660.2004; Yoon S, 2016, MOL THER, V24, P1106, DOI 10.1038/mt.2016.60; Zaragoza K, 2010, MOL CELL BIOL, V30, P2293, DOI 10.1128/MCB.01619-09; Zeng CX, 2010, HEPATOLOGY, V52, P1702, DOI 10.1002/hep.23875; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang J, 2010, ONCOGENE, V29, P723, DOI 10.1038/onc.2009.373; Zhang JX, 2015, INT J CLIN EXP PATHO, V8, P14472; Zhang J, 2008, PROSTATE, V68, P1206, DOI 10.1002/pros.20779; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006; Zhang SJ, 2012, J MOL MED, V90, P1069, DOI 10.1007/s00109-012-0879-y; Zhao Y, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-23	146	52	53	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5221	5230		10.1038/onc.2017.151	http://dx.doi.org/10.1038/onc.2017.151			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28504718				2022-12-17	WOS:000410671700001
J	Colicchia, V; Petroni, M; Guarguaglini, G; Sardina, F; Sahun-Roncero, M; Carbonari, M; Ricci, B; Heil, C; Capalbo, C; Belardinilli, F; Coppa, A; Peruzzi, G; Screpanti, I; Lavia, P; Gulino, A; Giannini, G				Colicchia, V.; Petroni, M.; Guarguaglini, G.; Sardina, F.; Sahun-Roncero, M.; Carbonari, M.; Ricci, B.; Heil, C.; Capalbo, C.; Belardinilli, F.; Coppa, A.; Peruzzi, G.; Screpanti, I.; Lavia, P.; Gulino, A.; Giannini, G.			PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma	ONCOGENE			English	Article							POLY(ADP-RIBOSE) POLYMERASE; N-MYC; METASTATIC NEUROBLASTOMA; THERAPEUTIC STRATEGY; GENOMIC INSTABILITY; COMBINATION THERAPY; DNA-REPLICATION; FORK REVERSAL; C-MYC; CELLS	High-risk and MYCN-amplified neuroblastomas are among the most aggressive pediatric tumors. Despite intense multimodality therapies, about 50% of these patients succumb to their disease, making the search for effective therapies an absolute priority. Due to the important functions of poly (ADP-ribose) polymerases, PARP inhibitors have entered the clinical settings for cancer treatment and are being exploited in a variety of preclinical studies and clinical trials. PARP inhibitors based combination schemes have also been tested in neuroblastoma preclinical models with encouraging results. However, the expression of PARP enzymes in human neuroblastoma and the biological consequences of their inhibition remained largely unexplored. Here, we show that high PARP1 and PARP2 expression is significantly associated with high-risk neuroblastoma cases and poor survival, highlighting its previously unrecognized prognostic value for human neuroblastoma. In vitro, PARP1 and 2 are abundant in MYCN amplified and MYCN-overexpressing cells. In this context, PARP inhibitors with high 'PARP trapping' potency, such as olaparib or talazoparib, yield DNA damage and cell death preceded by intense signs of replication stress. Notwithstanding the activation of a CHK1-CDC25A replication stress response, PARP-inhibited MYCN amplified and overexpressing cells fail to sustain a prolonged checkpoint and progress through mitosis in the presence of damaged DNA, eventually undergoing mitotic catastrophe. CHK1-targeted inhibition of the replication stress checkpoint exacerbated this phenotype. These data highlight a novel route for cell death induction by PARP inhibitors and support their introduction, together with CHK1 inhibitors, in therapeutic approaches for neuroblastomas with high MYC(N) activity.	[Colicchia, V.; Sardina, F.; Sahun-Roncero, M.; Ricci, B.; Heil, C.; Capalbo, C.; Belardinilli, F.; Screpanti, I.; Gulino, A.; Giannini, G.] Univ Roma La Sapienza, Dept Mol Med, Viale Regina Elena 291, I-00161 Rome, Italy; [Petroni, M.; Peruzzi, G.] Ist Italiano Tecnol, Ctr Life Nano Sci Sapienza, Rome, Italy; [Guarguaglini, G.; Lavia, P.] Univ Roma La Sapienza, Inst Mol Biol & Pathol, CNR, Rome, Italy; [Carbonari, M.] Univ Roma La Sapienza, Dept Clin Med, Rome, Italy; [Coppa, A.] Univ Roma La Sapienza, Dept Expt Med, Rome, Italy; [Giannini, G.] Univ Roma La Sapienza, Dept Mol Med, Ist Pasteur, Fdn Cenci Bolognetti, Rome, Italy	Sapienza University Rome; Istituto Italiano di Tecnologia - IIT; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome	Giannini, G (corresponding author), Univ Roma La Sapienza, Dept Mol Med, Viale Regina Elena 291, I-00161 Rome, Italy.	giuseppe.giannini@uniroma1.it	Sardina, Francesca/AAC-2143-2022; coppa, anna/N-3274-2016; Giannini, Giuseppe/B-5672-2013; Lavia, Patrizia/J-5793-2019; Ricci, Biancamaria/AAT-9935-2021; Lavia, Patrizia/AAL-3982-2021; petroni, marialaura/AAB-8637-2019	Giannini, Giuseppe/0000-0003-0299-4056; Lavia, Patrizia/0000-0003-3310-6701; petroni, marialaura/0000-0002-6021-1657; Belardinilli, Francesca/0000-0003-4966-7044; Ricci, Biancamaria/0000-0003-1574-6043; coppa, anna/0000-0001-9758-5444; Peruzzi, Giovanna/0000-0002-6517-9107	Associazione Italiana per la Ricerca sul Cancro [IG17734, IG14723, IG14535]; AIRC [MFAG13350, 5XMILLE]; Ministry of University and Research (FIRB and PRIN); Italian Institute of Technology; FIRC	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); Ministry of University and Research (FIRB and PRIN)(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Italian Institute of Technology(Istituto Italiano di Tecnologia - IIT); FIRC(Fondazione AIRC per la ricerca sul cancro)	Time-lapse experiments were performed at the Nikon Reference Center for Central-Southern Italy at IBPM-CNR. Financial Support: This work was supported by grants from: Associazione Italiana per la Ricerca sul Cancro IG17734 (G. Giannini), IG14723 (A. Gulino) and IG14535 (P. Lavia); AIRC MFAG13350 (G. Guarguaglini); AIRC 5XMILLE (A. Gulino); Ministry of University and Research (FIRB and PRIN projects) (A. Gulino and G. Giannini); Italian Institute of Technology (A. Gulino). M.P. has been recipient of a FIRC fellowship David Raffaelli.	Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Bagatell R, 2009, J CLIN ONCOL, V27, P365, DOI 10.1200/JCO.2008.17.9184; Ben-Yosef T, 1998, ONCOGENE, V17, P165, DOI 10.1038/sj.onc.1201939; Berti M, 2013, NAT STRUCT MOL BIOL, V20, P347, DOI 10.1038/nsmb.2501; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bryant HE, 2009, EMBO J, V28, P2601, DOI 10.1038/emboj.2009.206; Canete A, 2009, J CLIN ONCOL, V27, P1014, DOI 10.1200/JCO.2007.14.5839; Carbonari M, 2016, CYTOM PART A, V89A, P498, DOI 10.1002/cyto.a.22823; Chaudhuri AR, 2012, NAT STRUCT MOL BIOL, V19, P417, DOI 10.1038/nsmb.2258; Chayka O, 2015, J BIOL CHEM, V290, P2198, DOI 10.1074/jbc.M114.624056; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Daniel RA, 2009, CLIN CANCER RES, V15, P1241, DOI 10.1158/1078-0432.CCR-08-1095; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Feng FY, 2015, MOL CELL, V58, P925, DOI 10.1016/j.molcel.2015.04.016; Ferrao PT, 2012, ONCOGENE, V31, P1661, DOI 10.1038/onc.2011.358; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Judware R, 1995, ONCOGENE, V11, P2599; Kuzyk A, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014373; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Lupo B, 2014, BBA-REV CANCER, V1846, P201, DOI 10.1016/j.bbcan.2014.07.004; Lutz W, 1996, ONCOGENE, V13, P803; Massimi I, 2013, MOL CARCINOGEN, V52, P526, DOI 10.1002/mc.21887; McCluskey AG, 2012, J NUCL MED, V53, P1146, DOI 10.2967/jnumed.111.095943; McNeil EM, 2013, DNA REPAIR, V12, P1000, DOI 10.1016/j.dnarep.2013.08.017; Mueller S, 2013, ANTICANCER RES, V33, P755; Murai J, 2014, J PHARMACOL EXP THER, V349, P408, DOI 10.1124/jpet.113.210146; Murai J, 2014, MOL CANCER THER, V13, P433, DOI 10.1158/1535-7163.MCT-13-0803; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Neelsen KJ, 2013, J CELL BIOL, V200, P699, DOI 10.1083/jcb.201212058; Neiman PE, 2006, ONCOGENE, V25, P6325, DOI 10.1038/sj.onc.1209646; Norris RE, 2014, PEDIATR BLOOD CANCER, V61, P145, DOI 10.1002/pbc.24697; Petroni M, 2016, CELL DEATH DIFFER, V23, P197, DOI 10.1038/cdd.2015.81; Petroni M, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00141; Petroni M, 2011, MOL CANCER RES, V9, P67, DOI 10.1158/1541-7786.MCR-10-0227; Ray S, 2006, CANCER RES, V66, P6598, DOI 10.1158/0008-5472.CAN-05-3115; Rohban S, 2015, BBA-GENE REGUL MECH, V1849, P517, DOI 10.1016/j.bbagrm.2014.04.008; Sonnenblick A, 2015, NAT REV CLIN ONCOL, V12, P27, DOI 10.1038/nrclinonc.2014.163; Srinivasan SV, 2013, CELL REP, V3, P1629, DOI 10.1016/j.celrep.2013.04.002; Utani K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010089; Valentijn LJ, 2012, P NATL ACAD SCI USA, V109, P19190, DOI 10.1073/pnas.1208215109; Veschi V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.68; Veschi V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049139; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Zellweger R, 2015, J CELL BIOL, V208, P563, DOI 10.1083/jcb.201406099	50	52	52	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4682	4691		10.1038/onc.2017.40	http://dx.doi.org/10.1038/onc.2017.40			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394338				2022-12-17	WOS:000407702400002
J	Mi, L; Zhu, F; Yang, X; Lu, J; Zheng, Y; Zhao, Q; Wen, X; Lu, A; Wang, M; Zheng, M; Ji, J; Sun, J				Mi, L.; Zhu, F.; Yang, X.; Lu, J.; Zheng, Y.; Zhao, Q.; Wen, X.; Lu, A.; Wang, M.; Zheng, M.; Ji, J.; Sun, J.			The metastatic suppressor NDRG1 inhibits EMT, migration and invasion through interaction and promotion of caveolin-1 ubiquitylation in human colorectal cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; RNA-POLYMERASE-II; PROSTATE-CANCER; PROTEASOMAL DEGRADATION; INDUCED UBIQUITINATION; ELEVATED EXPRESSION; LUNG ADENOCARCINOMA; SIGNALING PATHWAYS; GENE-EXPRESSION; DOWN-REGULATION	N-myc downstream-regulated gene 1 (NDRG1) has been reported to act as a key regulatory molecule in tumor progression-related signaling pathways, especially in tumor metastasis. However, the related mechanism has not been fully discovered yet. Herein we demonstrated that the novel molecule of cell migration and invasion, caveolin-1, has direct interaction with NDRG1 in human colorectal cancer (CRC) cells. Moreover, we discovered that NDRG1 reduces caveolin-1 protein expression through promoting its ubiquitylation and subsequent degradation via the proteasome in CRC cells. In addition, caveolin-1 mediates the suppressive function of NDRG1 in epithelial-mesenchymal transition, migration and invasion in vitro and metastasis in vivo. These results help to fulfill the potential mechanisms of NDRG1 in anti-metastatic treatment for human colorectal cancer.	[Mi, L.; Zhu, F.; Yang, X.; Lu, J.; Lu, A.; Wang, M.; Zheng, M.; Sun, J.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gen Surg, Shanghai 200025, Peoples R China; [Mi, L.; Zhu, F.; Yang, X.; Lu, J.; Lu, A.; Wang, M.; Zheng, M.; Sun, J.] Shanghai Minimally Invas Surg Ctr, Shanghai, Peoples R China; [Mi, L.; Ji, J.] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Surg, Beijing, Peoples R China; [Mi, L.; Wen, X.; Ji, J.] Peking Univ, Canc Hosp & Inst, Div Gastrointestinal Canc Translat Res Lab, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China; [Zheng, Y.; Zhao, Q.] Shanghai Jiao Tong Univ, Sch Med, Dept Pathophysiol, Key Lab Cell Differentiat & Apoptosis,Minist Educ, Shanghai, Peoples R China	Shanghai Jiao Tong University; Peking University; Peking University; Shanghai Jiao Tong University	Wang, M; Zheng, M; Sun, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gen Surg, Shanghai 200025, Peoples R China.	mingliang-99@hotmail.com; zmhtiger@yeah.net; jingsun1982@sina.cn			National High-tech Research and Development Projects (863) [2012AA021103]; National Natural Science Foundation of China (NSFC) [81402423, 81572818]; Science and Technology Commission of Shanghai Municipality [13JC1404100, 14YF1402800]	National High-tech Research and Development Projects (863); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	The study is financially supported by National High-tech Research and Development Projects (863) (2012AA021103), National Natural Science Foundation of China (NSFC) (81402423, 81572818), Science and Technology Commission of Shanghai Municipality (13JC1404100, 14YF1402800).	[Anonymous], MEMBRANE MICRODOMAIN; Bartz R, 2008, INT J CANCER, V122, P520, DOI 10.1002/ijc.23142; Bender F, 2002, BIOL RES, V35, P151, DOI 10.4067/S0716-97602002000200006; Bender FC, 2000, CANCER RES, V60, P5870; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Burgermeister E, 2008, CANCER LETT, V268, P187, DOI 10.1016/j.canlet.2008.03.055; Chen ZQ, 2012, J BIOL CHEM, V287, P17016, DOI 10.1074/jbc.M112.350470; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; Fine SW, 2001, AM J CLIN PATHOL, V115, P719; Galbiati F, 2000, J BIOL CHEM, V275, P37702, DOI 10.1074/jbc.M006657200; Goetz JG, 2008, CANCER METAST REV, V27, P715, DOI 10.1007/s10555-008-9160-9; Gonzalez E, 2004, J BIOL CHEM, V279, P40659, DOI 10.1074/jbc.M407051200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayer A, 2010, J CELL BIOL, V191, P615, DOI 10.1083/jcb.201003086; He JM, 2010, BIOCHEM BIOPH RES CO, V397, P513, DOI 10.1016/j.bbrc.2010.05.146; Hill MM, 2008, CELL, V132, P113, DOI 10.1016/j.cell.2007.11.042; Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2; Hosoi F, 2009, CANCER RES, V69, P4983, DOI 10.1158/0008-5472.CAN-08-4882; Jin RS, 2014, J CELL SCI, V127, P3116, DOI 10.1242/jcs.147835; Joshi B, 2008, CANCER RES, V68, P8210, DOI 10.1158/0008-5472.CAN-08-0343; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karam JA, 2007, PROSTATE, V67, P614, DOI 10.1002/pros.20557; Kok LF, 2010, ARCH GYNECOL OBSTET, V281, P293, DOI 10.1007/s00404-009-1094-0; Koo CL, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-25; Kovacevic Z, 2008, BBA-MOL CELL RES, V1783, P1981, DOI 10.1016/j.bbamcr.2008.05.016; Kovacevic Z, 2013, ANTIOXID REDOX SIGN, V18, P874, DOI 10.1089/ars.2011.4273; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Liu W, 2012, EMBO MOL MED, V4, P93, DOI 10.1002/emmm.201100190; Liu W, 2011, J BIOL CHEM, V286, P18949, DOI 10.1074/jbc.M111.232637; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Luan TY, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0644-5; Mao ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068206; Navarro A, 2004, FASEB J, V18, P1801, DOI 10.1096/fj.04-2516rev; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122; Patel HH, 2008, ANNU REV PHARMACOL, V48, P359, DOI 10.1146/annurev.pharmtox.48.121506.124841; Patlolla JMR, 2004, ONCOL REP, V11, P957; Pearce LR, 2011, BIOCHEM J, V436, P169, DOI 10.1042/BJ20102103; Quest AFG, 2013, CURR MOL MED, V13, P266; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Razani B, 2001, J BIOL CHEM, V276, P38121; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sun J, 2013, CARCINOGENESIS, V34, P1943, DOI 10.1093/carcin/bgt163; Sun J, 2013, MOL PHARMACOL, V83, P454, DOI 10.1124/mol.112.083097; Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099; Torres VA, 2007, MOL CELL BIOL, V27, P7703, DOI 10.1128/MCB.01991-06; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; van Golen KL, 2006, EXPERT OPIN THER TAR, V10, P709, DOI 10.1517/14728222.10.5.709; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200; Yang G, 1998, CLIN CANCER RES, V4, P1873; Yang G, 2007, HUM PATHOL, V38, P1688, DOI 10.1016/j.humpath.2007.03.024; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199; Zhu MJ, 2010, ANTICANCER RES, V30, P3451	59	52	58	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4323	4335		10.1038/onc.2017.74	http://dx.doi.org/10.1038/onc.2017.74			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28346422	hybrid, Green Published			2022-12-17	WOS:000406360600009
J	Hanse, EA; Ruan, C; Kachman, M; Wang, D; Lowman, XH; Kelekar, A				Hanse, E. A.; Ruan, C.; Kachman, M.; Wang, D.; Lowman, X. H.; Kelekar, A.			Cytosolic malate dehydrogenase activity helps support glycolysis in actively proliferating cells and cancer	ONCOGENE			English	Article							LACTIC-DEHYDROGENASE; ALPHA-KETOGLUTARATE; METABOLISM; GROWTH; LACTATE; PATHWAY; GLUCOSE; SENSITIVITY; ACTIVATION; GENOMICS	Increased glucose consumption is a hallmark of cancer cells. The increased consumption and subsequent metabolism of glucose during proliferation creates the need for a constant supply of NAD, a co-factor in glycolysis. Regeneration of the NAD required to support enhanced glycolysis has been attributed to the terminal glycolytic enzyme, lactate dehydrogenase (LDH). However, loss of glucose carbons to biosynthetic pathways early in glycolysis reduces the carbon supply to LDH. Thus, alternative routes for NAD regeneration must exist to support the increased glycolytic rate while allowing for the diversion of glucose to generate biomass and support proliferation. Here we demonstrate, using a variety of cancer cell lines as well as activated primary T cells, that cytosolic malate dehydrogenase 1 (MDH1) is an alternative to LDH as a supplier of NAD. Moreover, our results indicate that MDH1 generates malate with carbons derived from glutamine, thus enabling utilization of glucose carbons for glycolysis and for biomass. Amplification of MDH1 occurs at an impressive frequency in human tumors and correlates with poor prognosis. Together, our findings suggest that proliferating cells rely on both MDH1 and LDH to replenish cytosolic NAD, and that therapies designed at targeting glycolysis must consider both dehydrogenases.	[Hanse, E. A.; Lowman, X. H.; Kelekar, A.] Univ Minnesota, Dept Lab Med & Pathol, 420 SE Washington Ave,MCB 5-126, Minneapolis, MN 55455 USA; [Hanse, E. A.; Lowman, X. H.; Kelekar, A.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Ruan, C.; Kachman, M.; Wang, D.] Univ Michigan, Michigan Reg Comprehens Metab Res Core, Ann Arbor, MI 48109 USA; [Lowman, X. H.] City Hope Canc Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan; City of Hope; Beckman Research Institute of City of Hope	Kelekar, A (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, 420 SE Washington Ave,MCB 5-126, Minneapolis, MN 55455 USA.	ameeta@umn.edu		Hanse, Eric/0000-0002-1234-0198	University of Minnesota Academic Health Center; National Institutes of Health (NIH) [R01 CA157971, 3002751553]; T32 training fellowship [CA009138]; F31 award [CA177119]; NIH Common Funds Project [U24 DK097153]; NATIONAL CANCER INSTITUTE [T32CA009138, P30CA077598, F31CA177119, T32CA186895, R01CA157971] Funding Source: NIH RePORTER	University of Minnesota Academic Health Center; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); T32 training fellowship; F31 award; NIH Common Funds Project(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs David Sabatini and Kivanc Birsoy for the MDH1 KO Jurkat cells, and Hong-Duk Youn for the MDH1 construct. We would also like to thank Todd Rappe and University of Minnesota Nuclear Magnetic Resonance Core for help with nuclear magnetic resonance analysis. We are grateful to Dr David Bernlohr, Michael Downey, Yan Yan and Dr Jenna Benson for stimulating discussions. We also thank Drs Lucas Sullivan and Sandra Armstrong for valuable suggestions. This study was supported by a Seed Grant and an Infrastructure grant from the University of Minnesota Academic Health Center (to AK), National Institutes of Health (NIH) grant R01 CA157971, P/F grant, 3002751553, through the NIH-funded RCMC in Michigan (to AK), and by T32 training fellowship, CA009138, and F31 award, CA177119 (to EAH). The study utilized Metabolomics Core Services supported by grant U24 DK097153 of NIH Common Funds Project to the University of Michigan.	Augoff K, 2015, CANCER LETT, V358, P1, DOI 10.1016/j.canlet.2014.12.035; Billiard J, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-19; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Calvo MN, 2006, FEBS LETT, V580, P3308, DOI 10.1016/j.febslet.2006.04.093; Carr EL, 2010, J IMMUNOL, V185, P1037, DOI 10.4049/jimmunol.0903586; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Fendt SM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3236; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; GOLDBERG EB, 1965, J BIOL CHEM, V240, P2786; GOLDMAN RD, 1964, CANCER RES, V24, P389; Gui DY, 2016, CELL METAB, V24, P716, DOI 10.1016/j.cmet.2016.09.006; Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457; Lamesch P, 2007, GENOMICS, V89, P307, DOI 10.1016/j.ygeno.2006.11.012; Lee SM, 2009, CELL DEATH DIFFER, V16, P738, DOI 10.1038/cdd.2009.5; Lewis CA, 2014, MOL CELL, V55, P253, DOI 10.1016/j.molcel.2014.05.008; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Liu L, 2016, NAT CHEM BIOL, V12, P345, DOI [10.1038/NCHEMBIO.2047, 10.1038/nchembio.2047]; Liu PP, 2014, CELL DEATH DIFFER, V21, P124, DOI 10.1038/cdd.2013.131; Lorenz MA, 2011, ANAL CHEM, V83, P3406, DOI 10.1021/ac103313x; Lowman XH, 2010, MOL CELL, V40, P823, DOI 10.1016/j.molcel.2010.11.035; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Menzies KJ, 2016, NAT REV ENDOCRINOL, V12, P43, DOI 10.1038/nrendo.2015.181; Rani R, 2016, J MED CHEM, V59, P487, DOI 10.1021/acs.jmedchem.5b00168; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Wang YJ, 2016, J MENINGITIS, V1, P1, DOI DOI 10.1016/J.BMC1.2015.12.021; Winer LSP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109916; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003; Yang ZR, 2003, J BIOL CHEM, V278, P8804, DOI 10.1074/jbc.M211892200	33	52	54	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3915	3924		10.1038/onc.2017.36	http://dx.doi.org/10.1038/onc.2017.36			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263970	Green Accepted			2022-12-17	WOS:000404848200011
J	Escoll, M; Gargini, R; Cuadrado, A; Anton, IM; Wandosell, F				Escoll, M.; Gargini, R.; Cuadrado, A.; Anton, I. M.; Wandosell, F.			Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ	ONCOGENE			English	Article							WASP-INTERACTING PROTEIN; HIPPO PATHWAY; T-CELL; ACTIN ORGANIZATION; TISSUE-GROWTH; ORGAN GROWTH; F-ACTIN; TAZ; YAP; INVASION	Wild-type p53 (wtp53) is described as a tumour suppressor gene; mutations in this gene occur in many human cancers and promote oncogenic capacity. Here, we establish that the oncogenic activity of mutant p53 (mtp53) is driven by the WASP-interacting protein (WIP). WIP knockdown from mtp53-expressing glioblastoma and breast cancer cells (BCC) greatly reduced proliferation and growth capacity of cancer stem cell (CSC)-like cells and decreased CSC-like markers (CD133, CD44 or YAP/TAZ). mtp53 overexpression in human astrocytes enhanced their proliferative capacity in suspension culture and increased expression of CSC markers and WIP. WIP knockdown compromised tumour glioblastoma and BCC growth capacity in vivo. We show that WIP is phosphorylated by AKT2 and is regulated by mtp53/p63 through enhancement of PI3K/AKT2-mediated integrin/receptor recycling pathways. WIP regulates this oncogenic pathway by controlling YAP/TAZ stability. We thus establish a new CSC signalling pathway downstream of mtp53 in which AKT2 regulates WIP and controls YAP/TAZ stability.	[Escoll, M.; Wandosell, F.] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa CSIC UAM, Nicolas Cabrera 1, E-28049 Madrid, Spain; [Escoll, M.; Cuadrado, A.; Anton, I. M.; Wandosell, F.] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Valderrebollo 5, Madrid, Spain; [Gargini, R.; Anton, I. M.] Ctr Nacl Biotecnol CNB CSIC, Dept Mol & Cellular Biol, Darwin 3, Madrid 28049, Spain; [Cuadrado, A.] Inst Invest Biomed Alberto Sols CSIC UAM, Inst Invest Sanitaria La Paz IdiPaz, Madrid, Spain; [Cuadrado, A.] Univ Autonoma Madrid, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); CIBERNED; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Wandosell, F (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa CSIC UAM, Nicolas Cabrera 1, E-28049 Madrid, Spain.; Anton, IM (corresponding author), Ctr Nacl Biotecnol CNB CSIC, Dept Mol & Cellular Biol, Darwin 3, Madrid 28049, Spain.	ianton@cnb.csic.es; fwandosell@cbm.csic.es	Wandosell, Francisco/AAV-6391-2020; Gargini, Ricardo/AAA-3542-2020; Anton, Ines M/G-6090-2015; Wandosell, Francisco/G-6105-2015	Anton, Ines M/0000-0002-2935-5919; Wandosell, Francisco/0000-0001-6537-2321; Cuadrado, Antonio/0000-0002-4039-7140; Escoll, Maribel/0000-0003-0043-6878	MICINN; Plan Nacional of the Direccio General de Ciencia y Tecnologia [SAF2012-39148-C03-01, SAF2013-45937-R, SAF2015-70368-R, SAF2013-43271-R]; European Union [EU-FP7-2009-CT222887]; Instituto de Salud Carlos III Centro de Investigacion Biomedica en Red (CIBERNED)	MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Plan Nacional of the Direccio General de Ciencia y Tecnologia; European Union(European Commission); Instituto de Salud Carlos III Centro de Investigacion Biomedica en Red (CIBERNED)	We thank Catherine Mark for editorial assistance. The proteomic analysis was performed in the proteomics facility of Centro Nacional de Biotecnolog~a that belongs to ProteoRed, PRB2-ISCIII; we particularly acknowledge the exceptional work of Rosana Navajas. This work was supported by grants from the MICINN, the Plan Nacional of the Direccio General de Ciencia y Tecnologia (SAF2012-39148-C03-01 to FW, SAF2013-45937-R to IMA and SAF2015-70368-R to both and SAF2013-43271-R to AC), the European Union (EU-FP7-2009-CT222887 to FW) and the Instituto de Salud Carlos III Centro de Investigacion Biomedica en Red (CIBERNED).	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Anton IM, 2002, IMMUNITY, V16, P193, DOI 10.1016/S1074-7613(02)00268-6; Anton IM, 2007, TRENDS CELL BIOL, V17, P555, DOI 10.1016/j.tcb.2007.08.005; Aspenstrom P, 2005, FEBS LETT, V579, P5253, DOI 10.1016/j.febslet.2005.08.053; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027; Banon-Rodriguez I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070364; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110; Fernandez BG, 2011, DEVELOPMENT, V138, P2337, DOI 10.1242/dev.063545; Franco A, 2012, CEREB CORTEX, V22, P1191, DOI 10.1093/cercor/bhr199; Gallego MD, 2006, INT IMMUNOL, V18, P221, DOI 10.1093/intimm/dxh310; Garcia E, 2014, EUR J CELL BIOL, V93, P413, DOI 10.1016/j.ejcb.2014.07.008; Garcia E, 2012, EUR J CELL BIOL, V91, P869, DOI 10.1016/j.ejcb.2012.06.002; Gargini R, 2016, CELL REP, V17, P1962, DOI 10.1016/j.celrep.2016.10.064; Gargini R, 2015, STEM CELLS, V33, P646, DOI 10.1002/stem.1904; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hiemer SE, 2013, BBA-GEN SUBJECTS, V1830, P2323, DOI 10.1016/j.bbagen.2012.07.005; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Imajo M, 2015, NAT CELL BIOL, V17, P7, DOI 10.1038/ncb3084; Kim NG, 2015, J CELL BIOL, V210, P503, DOI 10.1083/jcb.201501025; Klein C, 2011, ANNU REV IMMUNOL, V29, P399, DOI 10.1146/annurev-immunol-030409-101259; Lanzardo S, 2007, INT J BIOCHEM CELL B, V39, P262, DOI 10.1016/j.biocel.2006.08.011; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Le Bras S, 2009, P NATL ACAD SCI USA, V106, P7519, DOI 10.1073/pnas.0806410106; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lian I, 2010, GENE DEV, V24, P1106, DOI 10.1101/gad.1903310; Lucas EP, 2013, J CELL BIOL, V201, P875, DOI 10.1083/jcb.201210073; Mizuarai S, 2006, CANCER RES, V66, P6319, DOI 10.1158/0008-5472.CAN-05-4629; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Nagpal J, 2006, ANTICANCER RES, V26, P4633; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Piccolo S, 2013, CLIN CANCER RES, V19, P4925, DOI 10.1158/1078-0432.CCR-12-3172; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Powell E, 2014, CANCER DISCOV, V4, P405, DOI 10.1158/2159-8290.CD-13-0136; Rada P, 2011, MOL CELL BIOL, V31, P1121, DOI 10.1128/MCB.01204-10; Rainero E, 2012, J CELL BIOL, V196, P277, DOI 10.1083/jcb.201109112; Sansores-Garcia L, 2011, EMBO J, V30, P2325, DOI 10.1038/emboj.2011.157; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Shiraishi S, 2002, CANCER-AM CANCER SOC, V95, P249, DOI 10.1002/cncr.10677; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Staub E, 2009, J MOL MED, V87, P633, DOI 10.1007/s00109-009-0467-y; Sturm D, 2014, NAT REV CANCER, V14, P92, DOI 10.1038/nrc3655; Suh YA, 2011, CANCER RES, V71, P7168, DOI 10.1158/0008-5472.CAN-11-0459; Thanabalu T, 2007, FEBS J, V274, P4103, DOI 10.1111/j.1742-4658.2007.05936.x; Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Werbowetski-Ogilvie TE, 2006, CANCER RES, V66, P1464, DOI 10.1158/0008-5472.CAN-05-1913; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001	65	52	53	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3515	3527		10.1038/onc.2016.518	http://dx.doi.org/10.1038/onc.2016.518			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166194				2022-12-17	WOS:000403878600002
J	Faiao-Flores, F; Alves-Fernandes, DK; Pennacchi, PC; Sandri, S; Vicente, ALSA; Scapulatempo-Neto, C; Vazquez, VL; Reis, RM; Chauhan, J; Goding, CR; Smalley, KS; Maria-Engler, SS				Faiao-Flores, F.; Alves-Fernandes, D. K.; Pennacchi, P. C.; Sandri, S.; Vicente, A. L. S. A.; Scapulatempo-Neto, C.; Vazquez, V. L.; Reis, R. M.; Chauhan, J.; Goding, C. R.; Smalley, K. S.; Maria-Engler, S. S.			Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; BRAF INHIBITOR RESISTANCE; TGF-BETA; MESENCHYMAL TRANSITION; ACQUIRED-RESISTANCE; DRUG-RESISTANCE; MEK INHIBITION; IN-VITRO; PATHWAY; EXPRESSION	BRAF inhibitor (BRAFi) therapy for melanoma patients harboring the V600E mutation is initially highly effective, but almost all patients relapse within a few months. Understanding the molecular mechanisms underpinning BRAFi-based therapy is therefore an important issue. Here we identified a previously unsuspected mechanism of BRAFi resistance driven by elevated Hedgehog (Hh) pathway activation that is observed in a cohort of melanoma patients after vemurafenib treatment. Specifically, we demonstrate that melanoma cell lines, with acquired in vitro-induced vemurafenib resistance, show increased levels of glioma-associated oncogene homolog 1 and 2 (GLI1/GLI2) compared with naive cells. We also observed these findings in clinical melanoma specimens. Moreover, the increased expression of the transcription factors GLI1/GLI2 was independent of canonical Hh signaling and was instead correlated with the noncanonical Hh pathway, involving TGF beta/SMAD (transforming growth factor-beta/Sma- and Mad-related family) signaling. Knockdown of GLI1 and GLI2 restored sensitivity to vemurafenib-resistant cells, an effect associated with both growth arrest and senescence. Treatment of vemurafenib-resistant cells with the GLI1/GLI2 inhibitor Gant61 led to decreased invasion of the melanoma cells in a three-dimensional skin reconstruct model and was associated with a decrease in metalloproteinase (MMP2/MMP9) expression and microphthalmia transcription factor upregulation. Gant61 monotherapy did not alter the drug sensitivity of naive cells, but could reverse the resistance of melanoma cells chronically treated with vemurafenib. We further noted that alternating dosing schedules of Gant61 and vemurafenib prevented the onset of BRAFi resistance, suggesting that this could be a potential therapeutic strategy for the prevention of therapeutic escape. Our results suggest that targeting the Hh pathway in BRAFi-resistant melanoma may represent a viable therapeutic strategy to restore vemurafenib sensitivity, reducing or even inhibiting the acquired chemoresistance in melanoma patients.	[Faiao-Flores, F.; Alves-Fernandes, D. K.; Pennacchi, P. C.; Sandri, S.; Maria-Engler, S. S.] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Chem & Toxicol Anal, 580 Prof Lineu Prestes Ave,Bldg 17,Room 114, BR-05508000 Sao Paulo, Brazil; [Vicente, A. L. S. A.; Scapulatempo-Neto, C.; Vazquez, V. L.; Reis, R. M.] Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil; [Scapulatempo-Neto, C.] Barretos Canc Hosp, Dept Pathol, Barretos, Brazil; [Vazquez, V. L.] Barretos Canc Hosp, Dept Surg Melanoma Sarcoma, Barretos, Brazil; [Reis, R. M.] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Hlth Sci, Braga, Portugal; [Reis, R. M.] 3Bs PT Govt Associate Lab, Braga, Guimaraes, Portugal; [Chauhan, J.; Goding, C. R.] Univ Oxford, Ludwig Inst Canc Res, Nuffield Dept Clin Med, Oxford, England; [Smalley, K. S.] H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, Tampa, FL USA	Universidade de Sao Paulo; Hospital de Cancer de Barretos; Hospital de Cancer de Barretos; Hospital de Cancer de Barretos; Universidade do Minho; Ludwig Institute for Cancer Research; University of Oxford; H Lee Moffitt Cancer Center & Research Institute	Maria-Engler, SS (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Chem & Toxicol Anal, 580 Prof Lineu Prestes Ave,Bldg 17,Room 114, BR-05508000 Sao Paulo, Brazil.	silvya@usp.br	de lima vazquez, Vinicius/O-7780-2019; Vicente, Anna Luiza SA/E-3660-2017; Vazquez, Vinicius L/F-3574-2012; Reis, Rui Manuel/AAD-6470-2020; Alves-Fernandes, Débora Kristina/AAQ-3385-2020; Maria-Engler, Silvya/ABC-2016-2020; Alves-Fernandes, Debora Kristina/AAC-5983-2019; Engler, Silvya Stuchi Maria/K-5936-2016; Pennacchi, Paula/L-2220-2015; Sandri, Silvana/A-1650-2015; Faião-Flores, Fernanda/F-7111-2012; Reis, Rui Manuel/B-1744-2018	de lima vazquez, Vinicius/0000-0002-0325-5514; Vicente, Anna Luiza SA/0000-0003-3902-7772; Vazquez, Vinicius L/0000-0002-0325-5514; Reis, Rui Manuel/0000-0002-9639-7940; Alves-Fernandes, Débora Kristina/0000-0002-0917-9292; Maria-Engler, Silvya/0000-0003-4771-6041; Engler, Silvya Stuchi Maria/0000-0003-4771-6041; Pennacchi, Paula/0000-0003-0875-0263; Faião-Flores, Fernanda/0000-0003-3449-9930; Reis, Rui Manuel/0000-0002-9639-7940; Goding, Colin/0000-0002-1614-3909; Smalley, Keiran/0000-0003-1089-9307; Scapulatempo-Neto, Cristovam/0000-0002-8920-6579	Fapesp [2012/04194-1, 2013/05172-4, 2014/24400-0, 2015/10821-7]; CNPq [150447/2013-2, 471512/2013-3]; PRODOC [3193-32/2010]; National Institutes of Health [R01 CA161107, R21 CA198550]; Skin SPORE [P50 CA168536]; NATIONAL CANCER INSTITUTE [P50CA168536, R21CA198550, R01CA161107] Funding Source: NIH RePORTER	Fapesp(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); PRODOC; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Skin SPORE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Walter Turato for help with technical advice and support in colony formation studies and Renata Albuquerque for the FACS analyses. This work was supported by Fapesp-grant number 2012/04194-1, 2013/05172-4, 2014/24400-0 and 2015/10821-7, CNPq-grant number 150447/2013-2 and 471512/2013-3 and PRODOC-grant no 3193-32/2010. Work in the lab of KS Smalley was supported by the National Institutes of Health grants R01 CA161107, R21 CA198550, and Skin SPORE grant P50 CA168536.	Alexaki VI, 2010, JNCI-J NATL CANCER I, V102, P1148, DOI 10.1093/jnci/djq257; Brohem CA, 2012, PIGM CELL MELANOMA R, V25, P354, DOI 10.1111/j.1755-148X.2012.00992.x; Brohem CA, 2011, PIGM CELL MELANOMA R, V24, P35, DOI 10.1111/j.1755-148X.2010.00786.x; Carlino MS, 2014, MOL ONCOL, V8, P544, DOI 10.1016/j.molonc.2014.01.003; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chioni AM, 2008, FIBROGENESIS TISSUE, V1, DOI 10.1186/1755-1536-1-8; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Dennler S, 2007, CANCER RES, V67, P6981, DOI 10.1158/0008-5472.CAN-07-0491; Dennler S, 2009, J BIOL CHEM, V284, P31523, DOI 10.1074/jbc.M109.059964; Dugo M, 2015, ONCOTARGET, V6, P5118, DOI 10.18632/oncotarget.3007; Eichhorn PJA, 2012, NAT MED, V18, P429, DOI 10.1038/nm.2619; Faiao-Flores F, 2013, TUMOR BIOL, V34, P1235, DOI 10.1007/s13277-013-0666-6; Fan HX, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0041-5; Fan YH, 2016, ONCOGENE, V35, P116, DOI 10.1038/onc.2015.67; Fedorenko IV, 2015, J INVEST DERMATOL, V135, P3115, DOI 10.1038/jid.2015.329; Fernandez Y, 2006, J BIOL CHEM, V281, P1107, DOI 10.1074/jbc.M511607200; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gary RK, 2005, ANAL BIOCHEM, V343, P329, DOI 10.1016/j.ab.2005.06.003; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Gonnissen A, 2015, ONCOTARGET, V6, P13899, DOI 10.18632/oncotarget.4224; Green DR, 2013, NAT MED, V19, P131, DOI 10.1038/nm.3076; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Huang LL, 2014, CLIN CANCER RES, V20, P1566, DOI 10.1158/1078-0432.CCR-13-2195; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Javelaud D, 2008, PIGM CELL MELANOMA R, V21, P123, DOI 10.1111/j.1755-148X.2008.00450.x; Javelaud D, 2012, FEBS LETT, V586, P2016, DOI 10.1016/j.febslet.2012.05.011; Javelaud D, 2011, PIGM CELL MELANOMA R, V24, P932, DOI 10.1111/j.1755-148X.2011.00893.x; Javelaud D, 2011, CANCER RES, V71, P5606, DOI 10.1158/0008-5472.CAN-11-1194; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Lasfar A, 2010, CARCINOGENESIS, V31, P1710, DOI 10.1093/carcin/bgq155; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lei JJ, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-66; Li X, 2006, ONCOGENE, V25, P609, DOI 10.1038/sj.onc.1209077; Long B, 2016, CELL PHYSIOL BIOCHEM, V38, P1288, DOI 10.1159/000443075; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Long GV, 2016, J CLIN ONCOL, V34, P871, DOI 10.1200/JCO.2015.62.9345; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; Meani RE, 2014, AUSTRALAS J DERMATOL, V55, P218, DOI 10.1111/ajd.12196; Menon Dinoop R, 2013, Pigment Cell Melanoma Res, V26, P912, DOI 10.1111/pcmr.12139; Menzies AM, 2015, CANCER-AM CANCER SOC, V121, P3826, DOI 10.1002/cncr.29586; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Narita S, 2008, CLIN CANCER RES, V14, P5769, DOI 10.1158/1078-0432.CCR-07-4282; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Niehr F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-76; O'Connell MP, 2013, CANCER DISCOV, V3, P1378, DOI 10.1158/2159-8290.CD-13-0005; Palle K, 2015, CANCERS, V7, P2330, DOI 10.3390/cancers7040894; Pan D, 2012, LEUKEMIA RES, V36, P742, DOI 10.1016/j.leukres.2012.02.012; Paraiso KHT, 2010, BRIT J CANCER, V102, P1724, DOI 10.1038/sj.bjc.6605714; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Penna I, 2016, ONCOTARGET, V7, P3947, DOI 10.18632/oncotarget.6600; Pennacchi PC, 2015, TISSUE ENG PT A, V21, P2417, DOI [10.1089/ten.tea.2015.0009, 10.1089/ten.TEA.2015.0009]; Pierrat MJ, 2012, J BIOL CHEM, V287, P17996, DOI 10.1074/jbc.M112.358341; Queiroz KCS, 2010, ONCOGENE, V29, P6314, DOI 10.1038/onc.2010.375; Ruiz I, 2002, NAT REV CANCER, V2, P361, DOI DOI 10.1038/NRC796; Sabbatino F, 2014, ONCOTARGET, V5, P1926, DOI 10.18632/oncotarget.1878; Sandri S, 2016, PHARMACOL RES, V111, P523, DOI 10.1016/j.phrs.2016.07.017; Sims-Mourtada J, 2007, ONCOGENE, V26, P5674, DOI 10.1038/sj.onc.1210356; Smalley KM, 2007, BRIT J CANCER, V96, P445, DOI 10.1038/sj.bjc.6603596; Smalley KSM, 2006, IN VITRO CELL DEV-AN, V42, P242; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Steg AD, 2012, MOL CANCER THER, V11, P1587, DOI 10.1158/1535-7163.MCT-11-1058; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Tauro M, 2013, BIOORGAN MED CHEM, V21, P6456, DOI 10.1016/j.bmc.2013.08.054; Tirino V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.144; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wickstrom M, 2013, INT J CANCER, V132, P1516, DOI 10.1002/ijc.27820; Xu M, 2015, CANCER LETT, V369, P124, DOI 10.1016/j.canlet.2015.08.005; Yu H, 2009, AM J PATHOL, V174, P2367, DOI 10.2353/ajpath.2009.081057; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhou HM, 2012, IUBMB LIFE, V64, P889, DOI 10.1002/iub.1080; Zhou JC, 2016, CANCER LETT, V370, P313, DOI 10.1016/j.canlet.2015.11.006	84	52	53	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1849	1861		10.1038/onc.2016.348	http://dx.doi.org/10.1038/onc.2016.348			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27748762	hybrid, Green Published			2022-12-17	WOS:000398128900010
J	Xu, LZ; Li, SS; Zhou, W; Kang, ZJ; Zhang, QX; Kamran, M; Xu, J; Liang, DP; Wang, CL; Hou, ZJ; Wan, XB; Wang, HJ; Lam, EWF; Zhao, ZW; Liu, Q				Xu, L-Z; Li, S-S; Zhou, W.; Kang, Z-J; Zhang, Q-X; Kamran, M.; Xu, J.; Liang, D-P; Wang, C-L; Hou, Z-J; Wan, X-B; Wang, H-J; Lam, E. W-F; Zhao, Z-W; Liu, Q.			p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA	ONCOGENE			English	Article							TUBEROUS SCLEROSIS COMPLEX; C-MYC; PROSPECTIVE IDENTIFICATION; INITIATING CELLS; BINDING PROTEIN; AURORA KINASE; P62; EXPRESSION; PHOSPHORYLATION; OVEREXPRESSION	Aberrant p62 overexpression has been implicated in breast cancer development. Here, we found that p62 expression was elevated in breast cancer stem cells (BCSCs), including CD44(+)CD24(-) fractions, mammospheres, ALDH1(+) populations and side population cells. Indeed, short-hairpin RNA (shRNA)-mediated knockdown of p62 impaired breast cancer cells from self-renewing under anchorageindependent conditions, whereas ectopic overexpression of p62 enhanced the self-renewal ability of breast cancer cells in vitro. Genetic depletion of p62 robustly inhibited tumor-initiating frequencies, as well as growth rates of BCSC-derived tumor xenografts in immunodeficient mice. Consistently, immunohistochemical analysis of clinical breast tumor tissues showed that high p62 expression levels were linked to poorer clinical outcome. Further gene expression profiling analysis revealed that p62 was positively correlated with MYC expression level, which mediated the function of p62 in promoting breast cancer stem-like properties. MYC mRNA level was reduced upon p62 deletion by siRNA and increased with p62 overexpression in breast cancer cells, suggesting that p62 positively regulated MYC mRNA. Interestingly, p62 did not transactivate MYC promoter. Instead, p62 delayed the degradation of MYC mRNA by repressing the expression of let-7a and let-7b, thus promoting MYC mRNA stabilization at the post-transcriptional level. Consistently, let-7a and let-7b mimics attenuated p62-mediated MYC mRNA stabilization. Together, these findings unveiled a previously unappreciated role of p62 in the regulation of BCSCs, assigning p62 as a promising therapeutic target for breast cancer treatments.	[Xu, L-Z; Li, S-S; Zhou, W.; Kang, Z-J; Kamran, M.; Xu, J.; Liang, D-P; Wang, C-L; Hou, Z-J; Liu, Q.] Dalian Med Univ, Inst Canc Stem Cell, Affiliated Hosp 2, 9 Western Sect,Lvshun South St, Dalian 116044, Liaoning, Peoples R China; [Xu, L-Z; Li, S-S; Zhou, W.; Kang, Z-J; Kamran, M.; Xu, J.; Liang, D-P; Wang, C-L; Hou, Z-J; Liu, Q.] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Zhang, Q-X] Guangdong Pharmaceut Univ, Dept Oncol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Wan, X-B] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Radiat Oncol, Guangzhou, Guangdong, Peoples R China; [Wang, H-J] Dalian Med Univ, Affiliated Hosp 1, Dept Breast Surg, Dalian, Peoples R China; [Lam, E. W-F] Imperial Coll London, Dept Surg & Canc, London, England; [Zhao, Z-W] Dalian Med Univ, Affiliated Hosp 2, Dept Breast Surg, 467 Zhongshan Rd, Dalian 116000, Liaoning, Peoples R China	Dalian Medical University; State Key Lab Oncology South China; Sun Yat Sen University; Guangdong Pharmaceutical University; Sun Yat Sen University; Dalian Medical University; Imperial College London; Dalian Medical University	Liu, Q (corresponding author), Dalian Med Univ, Inst Canc Stem Cell, Affiliated Hosp 2, 9 Western Sect,Lvshun South St, Dalian 116044, Liaoning, Peoples R China.; Zhao, ZW (corresponding author), Dalian Med Univ, Affiliated Hosp 2, Dept Breast Surg, 467 Zhongshan Rd, Dalian 116000, Liaoning, Peoples R China.	dlzhaozw@163.com; liuq9@mail.sysu.edu.cn	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; KAMRAN, MUHAMMAD/0000-0002-5157-5459	National Basic Research Program of China (973 Program) [2012CB967000]; National Natural Science Foundation of China [81573025, 81201686, 81402445]; National Natural Science Foundation of Liaoning [NSF2014029102]; CRUK [A12011]; Breast Cancer Now [2012MayPR070, 2012NovPhD016]; Biotechnology and Biological Sciences Research Council [BBS/B/03785] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Engineering and Physical Sciences Research Council [1234732] Funding Source: researchfish; Medical Research Council [MR/N012097/1] Funding Source: researchfish; MRC [MR/N012097/1] Funding Source: UKRI	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Liaoning; CRUK(Cancer Research UK); Breast Cancer Now; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Quentin Liu's laboratory members for their critical commends and technical support. We also thank them for their critical reading of the manuscript. This work is supported by the National Basic Research Program of China (973 Program; No. 2012CB967000 to QL), National Natural Science Foundation of China (No. 81573025 to QL), the Liaoning (NSF2014029102 to QL), National Natural Science Foundation of China (No. 81201686 to JX), National Natural Science Foundation of China (No. 81402445 to C- LW). EW-FL's work is supported by CRUK (A12011) and Breast Cancer Now (2012MayPR070; 2012NovPhD016). See Supplementary Materials and Methods.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Filipova A, 2014, TUMORI J, V100, P363, DOI 10.1700/1636.17886; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Gaffan J, 2006, J CLIN ONCOL, V24, P1932, DOI 10.1200/JCO.2005.02.6617; Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111; Geula S, 2015, SCIENCE, V347, P1002, DOI 10.1126/science.1261417; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Guan JL, 2013, AUTOPHAGY, V9, P830, DOI 10.4161/auto.24132; Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Inoue D, 2012, CANCER SCI, V103, P760, DOI 10.1111/j.1349-7006.2012.02216.x; Ioannidis P, 2003, ANTICANCER RES, V23, P2179; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Karunarathna U, 2016, ONCOGENE, V35, P1433, DOI 10.1038/onc.2015.208; Kim HH, 2009, GENE DEV, V23, P1743, DOI 10.1101/gad.1812509; Kitamura H, 2006, HISTOPATHOLOGY, V48, P157, DOI 10.1111/j.1365-2559.2005.02313.x; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Lafon I, 1998, ONCOGENE, V16, P3413, DOI 10.1038/sj.onc.1201895; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Li CW, 2009, METHODS MOL BIOL, V568, P161, DOI 10.1007/978-1-59745-280-9_10; Li LJ, 2013, CANCER CELL, V24, P738, DOI 10.1016/j.ccr.2013.10.025; Lin Y, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-59; Linares JF, 2011, MOL CELL BIOL, V31, P105, DOI 10.1128/MCB.00620-10; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Liu YC, 2012, BIOCHEM BIOPH RES CO, V417, P371, DOI 10.1016/j.bbrc.2011.11.119; Loi S, 2010, P NATL ACAD SCI USA, V107, P10208, DOI 10.1073/pnas.0907011107; Luo Rong-Zhen, 2013, Onco Targets Ther, V6, P883, DOI 10.2147/OTT.S46222; Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood-2003-09-3064; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Nadiminty N, 2012, J BIOL CHEM, V287, P1527, DOI 10.1074/jbc.M111.278705; Nigam A, 2013, INDIAN J SURG, V75, P170, DOI 10.1007/s12262-012-0616-3; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Parkhitko A, 2011, P NATL ACAD SCI USA, V108, P12455, DOI 10.1073/pnas.1104361108; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rolland P, 2007, ENDOCR-RELAT CANCER, V14, P73, DOI 10.1677/erc.1.01312; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Schmidt EV, 2009, CELL CYCLE, V8, P1344, DOI 10.4161/cc.8.9.8215; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Weidensdorfer D, 2009, RNA, V15, P104, DOI 10.1261/rna.1175909; Wong TS, 2011, J CANCER RES CLIN, V137, P415, DOI 10.1007/s00432-010-0898-4; Xia MH, 2014, INT J ONCOL, V45, P2341, DOI 10.3892/ijo.2014.2669; Xu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056919; Xu LZ, 2014, ONCOTARGET, V5, P7498, DOI 10.18632/oncotarget.2241; Yang XJ, 2015, ONCOL REP, V33, P1723, DOI 10.3892/or.2015.3757; Zheng FM, 2014, MOL CANCER THER, V13, P1991, DOI 10.1158/1535-7163.MCT-13-1029	62	52	53	2	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					304	317		10.1038/onc.2016.202	http://dx.doi.org/10.1038/onc.2016.202			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27345399	Green Published, hybrid			2022-12-17	WOS:000394166000002
J	Yang, XZ; Li, XX; Zhang, YJ; Rodriguez-Rodriguez, L; Xiang, MQ; Wang, HY; Zheng, XFS				Yang, X-Z; Li, X-X; Zhang, Y-J; Rodriguez-Rodriguez, L.; Xiang, M-Q; Wang, H-Y; Zheng, X. F. S.			Rab1 in cell signaling, cancer and other diseases	ONCOGENE			English	Review							GTP-BINDING PROTEIN; ENDOPLASMIC-RETICULUM STRESS; ALPHA-SYNUCLEIN; MAMMALIAN TARGET; HEPATOCELLULAR CARCINOMAS; TRAPP COMPLEXES; SMALL GTPASES; EXPRESSION; MTORC1; LOCALIZATION	The endoplasmic reticulum (ER) and Golgi membrane system have major roles in cell signaling and regulation of the biosynthesis/transport of proteins and lipids in response to environmental cues such as amino acid and cholesterol levels. Rab1 is the founding member of the Rab small GTPase family, which is known to mediate dynamic membrane trafficking between ER and Golgi. Growing evidence indicate that Rab1 proteins have important functions beyond their classical vesicular transport functions, including nutrient sensing and signaling, cell migration and presentation of cell-surface receptors. Moreover, deregulation of RAB1 expression has been linked to a myriad of human diseases such as cancer, cardiomyopathy and Parkinson's disease. Further investigating these new physiological and pathological functions of Rab1 should provide new opportunities for better understanding of the disease processes and may lead to more effective therapeutic interventions.	[Yang, X-Z; Li, X-X; Wang, H-Y; Zheng, X. F. S.] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Zhang, Y-J; Rodriguez-Rodriguez, L.; Wang, H-Y; Zheng, X. F. S.] Rutgers State Univ, Robert Wood Johnson Med Sch, Rutgers Canc Inst New Jersey, New Brunswick, NJ USA; [Zhang, Y-J] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Oncol Dept, Shanghai, Peoples R China; [Rodriguez-Rodriguez, L.] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ USA; [Xiang, M-Q] Rutgers State Univ, Ctr Adv Biotechnol & Med, New Brunswick, NJ USA; [Xiang, M-Q] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ USA; [Xiang, M-Q] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China; [Wang, H-Y; Zheng, X. F. S.] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pharmacol, 195 Little Albany St, New Brunswick, NJ 08903 USA	State Key Lab Oncology South China; Sun Yat Sen University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Shanghai Jiao Tong University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Sun Yat Sen University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Zheng, XFS (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pharmacol, 195 Little Albany St, New Brunswick, NJ 08903 USA.; Zheng, XFS (corresponding author), Rutgers State Univ, Rutgers Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08903 USA.	zhengst@cinj.rutgers.edu	Li, Xiao-xing/B-9114-2008	Li, Xiao-xing/0000-0001-8791-7505	NIH R01 grants [CA123391, CA166575, CA173519]; National Natural Science Foundation of China [81171891, 81270035, 81572440]; Recruitment Program of Global Experts; Lead Talent of Guangdong Province; Natural Science Foundation of Guangdong Province [2015A030306047]; Research Fund of State Key Laboratory of Oncology in South China; Shanghai Pujiang Program [15PJ1404900]; NATIONAL CANCER INSTITUTE [R01CA123391, R01CA166575, R01CA099004, R01CA173519] Funding Source: NIH RePORTER	NIH R01 grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Recruitment Program of Global Experts; Lead Talent of Guangdong Province; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Research Fund of State Key Laboratory of Oncology in South China; Shanghai Pujiang Program(Shanghai Pujiang Program); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Related work in authors' laboratories was supported by NIH R01 grants CA123391, CA166575 and CA173519, the National Natural Science Foundation of China, grant nos: 81171891, 81270035 and 81572440, the Recruitment Program of Global Experts, the Lead Talent of Guangdong Province, the Natural Science Foundation of Guangdong Province for Distinguished Young Scholar (no: 2015A030306047), the Research Fund of State Key Laboratory of Oncology in South China, and Shanghai Pujiang Program 15PJ1404900.	Abd Elmageed ZY, 2014, STEM CELLS, V32, P983, DOI 10.1002/stem.1619; Abraham RT, 2015, SCIENCE, V347, P128, DOI 10.1126/science.aaa4570; ALEXANDER KR, 1984, BRIT J OPHTHALMOL, V68, P561, DOI 10.1136/bjo.68.8.561; Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; Bao ZS, 2014, CNS NEUROSCI THER, V20, P112, DOI 10.1111/cns.12171; Barrowman J, 2010, NAT REV MOL CELL BIO, V11, P759, DOI 10.1038/nrm2999; Cervigne NK, 2014, HUM MOL GENET, V23, P2618, DOI 10.1093/hmg/ddt657; Charng WL, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001777; Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012; Cooper AA, 2006, SCIENCE, V313, P324, DOI 10.1126/science.1129462; Coune PG, 2011, J PARKINSON DIS, V1, P373, DOI 10.3233/JPD-2011-11058; Dehay B, 2015, LANCET NEUROL, V14, P855, DOI 10.1016/S1474-4422(15)00006-X; Demmel L, 2008, MOL BIOL CELL, V19, P1046, DOI 10.1091/mbc.E07-02-0134; Diao A, 2003, J CELL BIOL, V160, P201, DOI 10.1083/jcb.200207045; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Efeyan A, 2012, TRENDS MOL MED, V18, P524, DOI 10.1016/j.molmed.2012.05.007; Filipeanu CM, 2008, METHOD ENZYMOL, V438, P217, DOI 10.1016/S0076-6879(07)38015-4; Frasa MAM, 2012, NAT REV MOL CELL BIO, V13, P67, DOI 10.1038/nrm3267; Han JB, 2015, NATURE, V524, P243, DOI 10.1038/nature14557; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; He H, 2002, GENE EXPRESSION, V10, P231, DOI 10.3727/000000002783992406; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Huang W, 2009, VISUAL NEUROSCI, V26, P443, DOI 10.1017/S0952523809990277; Hutagalung AH, 2011, PHYSIOL REV, V91, P119, DOI 10.1152/physrev.00059.2009; Huttenlocher A, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005074; Hwang YS, 2012, BIOL PHARM BULL, V35, P289, DOI 10.1248/bpb.35.289; Jiang HL, 2015, ONCOTARGET, V6, P16352, DOI 10.18632/oncotarget.3877; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Kopan Raphael, 2012, Cold Spring Harb Perspect Biol, V4, DOI 10.1101/cshperspect.a011213; Kumar A, 2004, MOL VIS, V10, P399; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Li H, 2006, NATURE, V442, P1058, DOI 10.1038/nature05020; Li L, 2010, J BIOL CHEM, V285, P19705, DOI 10.1074/jbc.C110.102483; Liu XY, 2007, MOL BIOL CELL, V18, P1073, DOI 10.1091/mbc.E06-05-0406; Zoppino FCM, 2010, TRAFFIC, V11, P1246, DOI 10.1111/j.1600-0854.2010.01086.x; Meiling-Wesse K, 2005, J BIOL CHEM, V280, P33669, DOI 10.1074/jbc.M501701200; Muller MP, 2010, SCIENCE, V329, P946, DOI 10.1126/science.1192276; Mukherjee S, 2011, NATURE, V477, P103, DOI 10.1038/nature10335; Nalesnik MA, 2012, AM J PATHOL, V180, P1495, DOI 10.1016/j.ajpath.2011.12.021; Neunuebel MR, 2011, SCIENCE, V333, P453, DOI 10.1126/science.1207193; Nikoshkov A, 2015, INT J ONCOL, V46, P107, DOI 10.3892/ijo.2014.2724; Park JS, 2014, DNA CELL BIOL, V33, P155, DOI 10.1089/dna.2013.2213; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Puria R, 2008, P NATL ACAD SCI USA, V105, P7194, DOI 10.1073/pnas.0801087105; Roberg KJ, 1997, GENETICS, V147, P1569; Sanchez-Gurmaches J, 2014, CANCER CELL, V26, P601, DOI 10.1016/j.ccell.2014.10.011; SARASTE J, 1995, J CELL SCI, V108, P1541; Satoh A, 2003, TRAFFIC, V4, P153, DOI 10.1034/j.1600-0854.2003.00103.x; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; Sciarretta S, 2014, CIRC RES, V114, P549, DOI 10.1161/CIRCRESAHA.114.302022; Sherwood RK, 2013, CELL HOST MICROBE, V14, P256, DOI 10.1016/j.chom.2013.08.010; Shimada K, 2005, BRIT J CANCER, V92, P1915, DOI 10.1038/sj.bjc.6602594; Stein MP, 2012, TRAFFIC, V13, P1565, DOI 10.1111/tra.12000; Sun T, 2014, ONCOGENE, V33, P2790, DOI 10.1038/onc.2013.230; Thomas JD, 2014, CANCER CELL, V26, P754, DOI 10.1016/j.ccell.2014.09.008; TOUCHOT N, 1989, FEBS LETT, V256, P79, DOI 10.1016/0014-5793(89)81722-3; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; Tsang CK, 2007, EMBO J, V26, P448, DOI 10.1038/sj.emboj.7601488; VIELH E, 1989, NUCLEIC ACIDS RES, V17, P1770, DOI 10.1093/nar/17.4.1770; Wang CR, 2010, J BIOL CHEM, V285, P29398, DOI 10.1074/jbc.M110.141440; Wang J, 2015, J CELL BIOL, V210, P273, DOI 10.1083/jcb.201408075; Wang J, 2013, P NATL ACAD SCI USA, V110, P9800, DOI 10.1073/pnas.1302337110; Wei LX, 2015, J CARDIOVASC PHARM, V65, P357, DOI 10.1097/FJC.0000000000000203; Winslow AR, 2010, J CELL BIOL, V190, P1023, DOI 10.1083/jcb.201003122; Wu GY, 2008, METHOD ENZYMOL, V438, P227, DOI 10.1016/S0076-6879(07)38016-6; Wu GY, 2001, CIRC RES, V89, P1130, DOI 10.1161/hh2401.100427; Xu BH, 2015, ONCOTARGET, V6, P20813, DOI 10.18632/oncotarget.5175; Yang Y, 2015, ONCOTARGET, V6, P16227, DOI 10.18632/oncotarget.3970; Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167; Zhuang XL, 2010, ENDOCRINOLOGY, V151, P5114, DOI 10.1210/en.2010-0422	72	52	52	4	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5699	5704		10.1038/onc.2016.81	http://dx.doi.org/10.1038/onc.2016.81			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27041585	Green Accepted			2022-12-17	WOS:000386998400001
J	Zhai, W; Sun, Y; Jiang, M; Wang, M; Gasiewicz, TA; Zheng, J; Chang, C				Zhai, W.; Sun, Y.; Jiang, M.; Wang, M.; Gasiewicz, T. A.; Zheng, J.; Chang, C.			Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2 alpha/C-MYC axis under hypoxia	ONCOGENE			English	Article							CLEAR-CELL; NONCODING RNAS; BINDING; GENE; HIF; CARCINOMA; CANCER; EPIDEMIOLOGY; SPECIFICITY; PROGRESSION	It is well established that hypoxia contributes to tumor progression in a hypoxia inducible factor-2 alpha (HIF-2 alpha)-dependent manner in renal cell carcinoma (RCC), yet the role of long noncoding RNAs (LncRNAs) involved in hypoxia-mediated RCC progression remains unclear. Here we demonstrate that LncRNA-SARCC (Suppressing Androgen Receptor in Renal Cell Carcinoma) is differentially regulated by hypoxia in a von Hippel-Lindau (VHL)-dependent manner both in RCC cell culture and clinical specimens. LncRNA-SARCC can suppress hypoxic cell cycle progression in the VHL-mutant RCC cells while derepress it in the VHL-restored RCC cells. Mechanism dissection reveals that LncRNA-SARCC can post-transcriptionally regulate androgen receptor (AR) by physically binding and destablizing AR protein to suppress AR/HIF-2 alpha/C-MYC signals. In return, HIF-2 alpha can transcriptionally regulate the LncRNA-SARCC expression via binding to hypoxia-responsive elements on the promoter of LncRNA-SARCC. The negative feedback modulation between LncRNA-SARCC/AR complex and HIF-2 alpha signaling may then lead to differentially modulated RCC progression in a VHL-dependent manner. Together, these results may provide us a new therapeutic approach via targeting this newly identified signal from LncRNA-SARCC to AR-mediated HIF-2 alpha/C-MYC signals against RCC progression.	[Zhai, W.; Zheng, J.] Tongji Univ, Shanghai Peoples Hosp 10, Dept Urol, Shanghai, Peoples R China; [Zhai, W.; Sun, Y.; Wang, M.; Chang, C.] Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA; [Zhai, W.; Sun, Y.; Wang, M.; Chang, C.] Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA; [Zhai, W.; Sun, Y.; Wang, M.; Chang, C.] Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA; [Zhai, W.; Sun, Y.; Wang, M.; Chang, C.] Univ Rochester, Med Ctr, Wilmot Canc Ctr, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA; [Jiang, M.] Nantong Univ, Sch Med, Lab Nucl Receptors & Canc Res, Nantong, Jiangsu, Peoples R China; [Gasiewicz, T. A.] Univ Rochester, Med Ctr, Dept Environm Med, Rochester, NY 14642 USA; [Chang, C.] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung, Taiwan	Tongji University; University of Rochester; University of Rochester; University of Rochester; University of Rochester; Nantong University; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan	Zheng, J; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.; Zheng, J; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.; Zheng, J; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.; Zheng, J; Chang, C (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Ctr, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	zhengjh0471@sina.com.cn; chang@urmc.rochester.edu		Jiang, Ming/0000-0003-3361-9881	NIH [CA155477, CA156700]; George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial, Research Center of Excellence [DOH99-TD-B-111-004]; National Science Foundation of China [31570775]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial, Research Center of Excellence; National Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by NIH grants (CA155477 and CA156700), George Whipple Professorship Endowment and Taiwan Department of Health Clinical Trial, Research Center of Excellence (DOH99-TD-B-111-004 to China Medical University, Taichung, Taiwan) and the National Science Foundation of China (31570775). We also gratefully acknowledged the help from Mr Jason Walrath of Department of Environmental Medicine of URMC for hypoxia experiments using In ViVo<INF>2</INF> hypoxic workstation. We thank Karen Wolf for help preparing the manuscript.	Cabianca DS, 2012, CELL, V149, DOI 10.1016/j.cell.2012.03.035; Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611; Chen Y, 2015, ONCOTARGET, V6, P31203, DOI 10.18632/oncotarget.4522; Chow WH, 2010, NAT REV UROL, V7, P245, DOI 10.1038/nrurol.2010.46; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Ding JH, 2012, P NATL ACAD SCI USA, V109, P2654, DOI 10.1073/pnas.1121374109; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Ghosh G, 2010, J CLIN INVEST, V120, P4141, DOI 10.1172/JCI42980; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Harrison L, 2004, ONCOLOGIST, V9, P31, DOI 10.1634/theoncologist.9-90005-31; Harrison LRE, 2011, J CLIN INVEST, V121, P1075, DOI 10.1172/JCI43505; He DL, 2014, CANCER RES, V74, P4420, DOI 10.1158/0008-5472.CAN-13-2681; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Kuo HP, 2009, BIOCHEM BIOPH RES CO, V389, P640, DOI 10.1016/j.bbrc.2009.09.042; Linehan WM, 2010, NAT REV UROL, V7, P277, DOI 10.1038/nrurol.2010.47; Lipworth L, 2006, J UROLOGY, V176, P2353, DOI 10.1016/j.juro.2006.07.130; Lu W, 2015, MOL BIOL CELL, V26, P1296, DOI 10.1091/mbc.E14-10-1423; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mitani T, 2011, J STEROID BIOCHEM, V123, P58, DOI 10.1016/j.jsbmb.2010.10.009; Moon EJ, 2007, ANTIOXID REDOX SIGN, V9, P1237, DOI 10.1089/ars.2007.1623; Moreno-Manzano V, 2010, J BIOL CHEM, V285, P1333, DOI 10.1074/jbc.M109.008326; Muller H, 2007, BIOORGAN MED CHEM, V15, P7470, DOI 10.1016/j.bmc.2007.07.024; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Park SY, 2006, CANCER RES, V66, P5121, DOI 10.1158/0008-5472.CAN-05-1341; Parker AS, 2005, UROLOGY, V65, P1090, DOI 10.1016/j.urology.2004.12.040; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Shen C, 2013, SEMIN CANCER BIOL, V23, P18, DOI 10.1016/j.semcancer.2012.06.001; Stone Louise, 2015, Nat Rev Urol, V12, P125, DOI 10.1038/nrurol.2015.26; Takahashi K, 2014, J CELL SCI, V127, P1585, DOI 10.1242/jcs.141069; Verrijdt G, 2000, J BIOL CHEM, V275, P12298, DOI 10.1074/jbc.275.16.12298; Verrijdt G, 1999, MOL ENDOCRINOL, V13, P1558, DOI 10.1210/me.13.9.1558; Wang J, 2014, MOL ENDOCRINOL, V28, P239, DOI 10.1210/me.2013-1258; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992; Wennemers M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2934; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Yang LQ, 2011, CELL, V147, P773, DOI 10.1016/j.cell.2011.08.054; Yao M, 2002, JNCI-J NATL CANCER I, V94, P1569; Yu G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042377	52	52	53	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4866	4880		10.1038/onc.2016.19	http://dx.doi.org/10.1038/onc.2016.19			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26973243				2022-12-17	WOS:000383330700005
J	Grun, D; Adhikary, G; Eckert, RL				Grun, D.; Adhikary, G.; Eckert, R. L.			VEGF-A acts via neuropilin-1 to enhance epidermal cancer stem cell survival and formation of aggressive and highly vascularized tumors	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR NEUROPILIN-1; SKIN-CANCER; ANGIOGENESIS; EXPRESSION; OVEREXPRESSION; PROMOTE; PROGRESSION; ACTIVATION; INDUCTION	We identify a limited subpopulation of epidermal cancer stem cells (ECS cells), in squamous cell carcinoma, that form rapidly growing, invasive and highly vascularized tumors, as compared with non-stem cancer cells. These ECS cells grow as non-attached spheroids, and display enhanced migration and invasion. We show that ECS cell-produced vascular endothelial growth factor (VEGF)-A is required for the maintenance of this phenotype, as knockdown of VEGF-A gene expression or treatment with VEGF-A-inactivating antibody reduces these responses. In addition, treatment with bevacizumab reduces tumor vascularity and growth. Surprisingly, the classical mechanism of VEGF-A action via interaction with VEGF receptors does not mediate these events, as these cells lack VEGFR1 and VEGFR2. Instead, VEGF-A acts via the neuropilin-1 (NRP-1) co-receptor. Knockdown of NRP-1 inhibits ECS cell spheroid formation, invasion and migration, and attenuates tumor formation. These studies suggest that VEGF-A acts via interaction with NRP-1 to trigger intracellular events leading to ECS cell survival and formation of aggressive, invasive and highly vascularized tumors.	[Grun, D.; Adhikary, G.; Eckert, R. L.] Univ Maryland, Sch Med, Dept Biochem, Baltimore, MD 21201 USA; [Grun, D.; Adhikary, G.; Eckert, R. L.] Univ Maryland, Sch Med, Dept Mol Biol, Baltimore, MD 21201 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD 21201 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Reprod Biol, Baltimore, MD 21201 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Marlene, Baltimore, MD 21201 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Stewart Greenebaum Canc, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Eckert, RL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 North Greene St,Rm 103, Baltimore, MD 21201 USA.	reckert@umaryland.edu		Grun, Daniel/0000-0003-4261-7765	Maryland Stem Cell Research Foundation; National Institutes of Health [CA131074, CA184027]; pilot grant from Greenebaum Cancer Center [P30 CA134274]; NATIONAL CANCER INSTITUTE [P30CA134274, R01CA131074, R01CA211909, R01CA184027] Funding Source: NIH RePORTER	Maryland Stem Cell Research Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); pilot grant from Greenebaum Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the Maryland Stem Cell Research Foundation (RLE) and the National Institutes of Health (RLE - CA131074, CA184027) and a pilot grant from the Greenebaum Cancer Center (P30 CA134274).	Adhikary G, 2015, CARCINOGENESIS, V36, P800, DOI 10.1093/carcin/bgv064; Adhikary G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084324; Akagi M, 2003, BRIT J CANCER, V88, P796, DOI 10.1038/sj.bjc.6600811; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Bachelder RE, 2001, CANCER RES, V61, P5736; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Bickers DR, 2006, J AM ACAD DERMATOL, V55, P490, DOI 10.1016/j.jaad.2006.05.048; Borriello L, 2014, CANCER LETT, V349, P120, DOI 10.1016/j.canlet.2014.04.004; Boukamp P, 2005, CARCINOGENESIS, V26, P1657, DOI 10.1093/carcin/bgi123; Cao Y, 2012, CANCER RES, V72, P3912, DOI 10.1158/0008-5472.CAN-11-4058; Casanova ML, 2002, CANCER RES, V62, P3402; Chew YC, 2013, J BIOL CHEM, V288, P17759, DOI 10.1074/jbc.M113.477133; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; Djordjevic S, 2013, DRUG DISCOV TODAY, V18, P447, DOI 10.1016/j.drudis.2012.11.013; Eckert RL, 2013, BBA-GEN SUBJECTS, V1830, P2427, DOI 10.1016/j.bbagen.2012.07.002; Folkman J, 1992, Semin Cancer Biol, V3, P65; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Gray MJ, 2005, CANCER RES, V65, P3664, DOI 10.1158/0008-5472.CAN-04-2229; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Jarvis A, 2010, J MED CHEM, V53, P2215, DOI 10.1021/jm901755g; Jia H, 2010, BRIT J CANCER, V102, P541, DOI 10.1038/sj.bjc.6605539; Johnson KE, 2012, J SKIN CANCER, V2012, DOI 10.1155/2012/483439; Kawakami T, 2002, CANCER, V95, P2196, DOI 10.1002/cncr.10936; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301; Lampropoulou A, 2014, BIOCHEM SOC T, V42, P1623, DOI 10.1042/BST20140244; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Li M, 2004, CANCER-AM CANCER SOC, V101, P2341, DOI 10.1002/cncr.20634; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Linde N, 2012, J PATHOL, V227, P17, DOI 10.1002/path.3989; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; Man XY, 2006, MOL MED, V12, P127, DOI 10.2119/2006-00024.Man; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Mueller MM, 2002, DIFFERENTIATION, V70, P486, DOI 10.1046/j.1432-0436.2002.700903.x; Nissen JC, 2013, J NEUROCHEM, V127, P394, DOI 10.1111/jnc.12404; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; Parikh AA, 2003, CANCER, V98, P720, DOI 10.1002/cncr.11560; Pincelli C, 2010, J CELL PHYSIOL, V225, P310, DOI 10.1002/jcp.22275; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Rogers HW, 2010, ARCH DERMATOL, V146, P283, DOI 10.1001/archdermatol.2010.19; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899; Tosetti F, 2002, FASEB J, V16, P2, DOI 10.1096/fj.01-0300rev; Vanveldhuizen PJ, 2003, ONCOL REP, V10, P1067; Wilgus TA, 2005, AM J PATHOL, V167, P1257, DOI 10.1016/S0002-9440(10)61213-8; Yang XH, 2006, BIOCHEM BIOPH RES CO, V349, P31, DOI 10.1016/j.bbrc.2006.07.213; Zhao Y, 2011, INT J DEV BIOL, V55, P477, DOI 10.1387/ijdb.103225yz; Zhu JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055463; Zhu JW, 2012, INT J BIOCHEM CELL B, V44, P246, DOI 10.1016/j.biocel.2011.10.022	56	52	55	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4379	4387		10.1038/onc.2015.507	http://dx.doi.org/10.1038/onc.2015.507			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26804163	Green Accepted			2022-12-17	WOS:000382152100009
J	Lin, KY; Ye, H; Han, BW; Wang, WT; Wei, PP; He, B; Li, XJ; Chen, YQ				Lin, K-Y; Ye, H.; Han, B-W; Wang, W-T; Wei, P-P; He, B.; Li, X-J; Chen, Y-Q			Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinoma	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; NECROSIS-FACTOR-ALPHA; CELL-DIFFERENTIATION; SIGNAL TRANSDUCER; IN-VITRO; CANCER; STAT3; GROWTH; EXPRESSION; INTERLEUKIN-6	Cholangiocarcinoma (CCA), which is a poor prognosis malignancy that arises from the malignant transformation of cholangiocytes, is associated with chronic inflammation of the biliary epithelium. Thus far, the molecular mechanisms of the origin and neoplastic processes of CCA that are promoted by inflammation are still unclear and need to be fully elucidated. Here using small RNA sequencing to determine the microRNA (miRNA) expression profiles in CCA, we found that let-7c, miR-99a and miR-125b, which are three miRNAs of the same cluster, were downregulated in CCA and targeted interleukin 6 (IL-6), IL-6R and type 1 insulin-like growth factor, which are important cytokines and receptors of the IL-6/signal transducer and activator 3 (STAT3) pathway and have key roles in inflammation and CCA initiation. We also found that enforced expression of let-7c, miR-99a or miR-125b could reduce the activity of STAT3 and further suppress CCA tumorigenicity in vivo and inhibit the migration and invasion of CCA cells in vitro. Surprisingly, let-7c/miR-99a/miR-125b cluster also significantly decreased the ability of CCA cells for cancer stem cell-like mammosphere generation by downregulating CD133 and CD44, which suggests the pivotal roles of let-7c, miR-99a and miR-125b in CCA by regulating both inflammation and stem-like properties. Our findings showed potential links between miRNAs and inflammation, and provide a potential treatment strategy for developing an miRNA-based therapy via IL-6/STAT3 targeting for CCA.	[Lin, K-Y; Han, B-W; Wang, W-T; Wei, P-P; Li, X-J; Chen, Y-Q] Sun Yat Sen Univ, State Key Lab Biocontrol, Sch Life Sci, Key Lab Gene Engn,Minist Engn, Guangzhou, Guangdong, Peoples R China; [Ye, H.; He, B.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hepatobiliary, Guangzhou, Guangdong, Peoples R China; [Ye, H.; He, B.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Chen, YQ (corresponding author), Sun Yat Sen Univ, Biotechnol Res Ctr, Minist Educ, Key Lab Gene Engn, Guangzhou 510275, Guangdong, Peoples R China.	lsscyq@mail.sysu.edu.cn	Lin, Kangyu/I-8050-2016	Lin, Kangyu/0000-0003-0140-2557; Wang, Wen-Tao/0000-0003-3913-4455	National Science and Technology Department [973, 2011CB8113015, 2011CBA0110]; National Science Foundation of China [81270629]; Guangdong Province Key Laboratory of Computational Science; Guangdong Province Computational Science Innovative Research Team; National Science Foundation of Guangdong [2014A020212135]	National Science and Technology Department; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Province Key Laboratory of Computational Science; Guangdong Province Computational Science Innovative Research Team; National Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province)	This work was supported by the funds from National Science and Technology Department (973, 2011CB8113015 and 2011CBA0110), National Science Foundation of China (no. 81270629) and Guangdong (2014A020212135). This work is also supported in part by the Guangdong Province Key Laboratory of Computational Science and the Guangdong Province Computational Science Innovative Research Team.	Akiyama T, 1998, HEPATO-GASTROENTEROL, V45, P665; Alvaro D, 2006, AM J PATHOL, V169, P877, DOI 10.2353/ajpath.2006.050464; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Barton BE, 2004, MOL CANCER THER, V3, P1183; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Benckert C, 2003, CANCER RES, V63, P1083; Boonyanugomol W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077358; Brown BD, 2007, NAT BIOTECHNOL, V25, P1457, DOI 10.1038/nbt1372; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Falamarzian A, 2014, J BIOMED MATER RES A, V102, P3216, DOI 10.1002/jbm.a.34992; Fava G, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/630543; Furqan M, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-90; Gores GJ, 2003, HEPATOLOGY, V37, P961, DOI 10.1053/jhep.2003.50200; Groner B, 2008, SEMIN CELL DEV BIOL, V19, P341, DOI 10.1016/j.semcdb.2008.06.005; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Isomoto H, 2005, HEPATOLOGY, V42, P1329, DOI 10.1002/hep.20966; Isomoto H, 2007, GASTROENTEROLOGY, V132, P384, DOI 10.1053/j.gastro.2006.10.037; Isomoto H, 2009, DIGESTION, V79, P2, DOI 10.1159/000167859; Johnson Christopher, 2012, Transl Gastrointest Cancer, V1, P58; Khan SA, 2005, LANCET, V366, P1303, DOI 10.1016/S0140-6736(05)67530-7; Kimura F, 1999, HEPATO-GASTROENTEROL, V46, P1613; Kokuryo T, 2012, J HEPATO-BIL-PAN SCI, V19, P606, DOI 10.1007/s00534-012-0542-6; Landi S, 2003, CANCER RES, V63, P3560; Lazaridis KN, 2005, GASTROENTEROLOGY, V128, P1655, DOI 10.1053/j.gastro.2005.03.040; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Li S, 2012, CANCER RES, V72, P865, DOI 10.1158/0008-5472.CAN-11-1357; Li XJ, 2013, BRIT J CANCER, V109, P2189, DOI 10.1038/bjc.2013.562; Li Z, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-17; Lin KY, 2011, J BIOL CHEM, V286, P38253, DOI 10.1074/jbc.M111.269670; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; Meng F, 2008, ONCOGENE, V27, P378, DOI 10.1038/sj.onc.1210648; Mullokandov G, 2012, NAT METHODS, V9, P840, DOI [10.1038/NMETH.2078, 10.1038/nmeth.2078]; Munoz-Garrido P, 2012, WORLD J GASTROENTERO, V18, P6189, DOI 10.3748/wjg.v18.i43.6189; Park J, 1999, HEPATOLOGY, V29, P1037, DOI 10.1002/hep.510290423; Rojas A, 2011, ONCOGENE, V30, P2345, DOI 10.1038/onc.2010.605; Rosen HR, 1997, DIGEST DIS SCI, V42, P1290, DOI 10.1023/A:1018822628096; Scotte M, 1991, Eur Cytokine Netw, V2, P177; Shaib Y, 2004, SEMIN LIVER DIS, V24, P115, DOI 10.1055/s-2004-828889; Sirica AE, 2005, HEPATOLOGY, V41, P5, DOI 10.1002/hep.20537; Smith AD, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0070-8; Sun D, 2014, ONCOGENE, V33, P1448, DOI 10.1038/onc.2013.77; Sun YM, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-6; Sun Z, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-14; Thanan R, 2013, FREE RADICAL BIO MED, V65, P1464, DOI 10.1016/j.freeradbiomed.2013.07.034; Wang WT, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0086-0; Wang WT, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-6; Xie TX, 2006, CANCER RES, V66, P3188, DOI 10.1158/0008-5472.CAN-05-2674; Yang JH, 2011, NUCLEIC ACIDS RES, V39, pD202, DOI 10.1093/nar/gkq1056; Yazumi S, 2000, INT J CANCER, V86, P782; Zen Y, 2005, LAB INVEST, V85, P572, DOI 10.1038/labinvest.3700236; Zhang H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006849; Zhang KZ, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-28; Zheng TS, 2014, HEPATOLOGY, V59, P935, DOI 10.1002/hep.26705; Zheng YS, 2012, ONCOGENE, V31, P80, DOI 10.1038/onc.2011.208; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	57	52	52	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3376	3386		10.1038/onc.2015.396	http://dx.doi.org/10.1038/onc.2015.396			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26455324	Green Published, hybrid			2022-12-17	WOS:000379270100003
J	Taki, K; Ohmuraya, M; Tanji, E; Komatsu, H; Hashimoto, D; Semba, K; Araki, K; Kawaguchi, Y; Baba, H; Furukawa, T				Taki, K.; Ohmuraya, M.; Tanji, E.; Komatsu, H.; Hashimoto, D.; Semba, K.; Araki, K.; Kawaguchi, Y.; Baba, H.; Furukawa, T.			GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm	ONCOGENE			English	Article							FREQUENT GNAS MUTATIONS; STIMULATORY G-PROTEIN; ACTIVATING MUTATIONS; ADENOMA; ALPHA; GSP	Intraductal papillary mucinous neoplasm (IPMN), the most common pancreatic cystic neoplasm, is known to progress to invasive ductal adenocarcinoma. IPMNs commonly harbor activating somatic mutations in GNAS and KRAS, primarily GNAS(R201H) and KRAS(G12D). GNAS encodes the stimulatory G-protein alpha subunit (Gs alpha) that mediates a stimulatory signal to adenylyl cyclase to produce cyclic adenosine monophosphate (cAMP), subsequently activating cAMP-dependent protein kinase A. The GNAS(R201H) mutation results in constitutive activation of Gs alpha. To study the potential role of GNAS in pancreatic tumorigenesis in vivo, we generated lines of transgenic mice in which the transgene consisted of Lox-STOP-Lox (LSL)-GNAS(R201H) under the control of the CAG promoter (Tg(CAG-LSL-GNAS)). These mice were crossed with pancreatic transcription factor 1a (Ptf1a)-Cre mice (Ptf1a(Cre/+)), generating Tg(CAG-LSL-GNAS); Ptf1a(Cre/+) mice. This mouse line showed elevated cAMP levels, small dilated tubular complex formation, loss of acinar cells and fibrosis in the pancreas; however, no macroscopic tumorigenesis was apparent by 2 months of age. We then crossed Tg(CAG-LSL-GNAS); Ptf1a(Cre/+) mice with LSL-Kras(G12D) mice, generating Tg(CAG-LSL-GNAS); LSL-Kras(G12D); Ptf1a(Cre/+) mice. We used these mice to investigate a possible cooperative effect of GNAS(R201H) and Kras(G12D) in pancreatic tumorigenesis. Within 5 weeks, Tg(CAG-LSL-GNAS); LSL-Kras(G12D); Ptf1a(Cre/+) mice developed a cystic tumor consisting of marked dilated ducts lined with papillary dysplastic epithelia in the pancreas, which closely mimicked the human IPMN. Our data strongly suggest that activating mutations in GNAS and Kras cooperatively promote murine pancreatic tumorigenesis, which recapitulates IPMN. Our mouse model may serve as a unique in vivo platform to find biomarkers and effective drugs for diseases associated with GNAS mutations.	[Taki, K.; Ohmuraya, M.; Semba, K.; Araki, K.] Kumamoto Univ, Inst Resource Dev & Anal, Kumamoto, Japan; [Taki, K.; Hashimoto, D.; Baba, H.] Kumamoto Univ, Dept Gastroenterol Surg, Kumamoto, Japan; [Tanji, E.; Komatsu, H.; Furukawa, T.] Tokyo Womens Med Univ, Inst Integrated Med Sci, Tokyo 1628666, Japan; [Kawaguchi, Y.] Kyoto Univ, Ctr iPS Cell Res & Applicat CiRA, Kyoto, Japan	Kumamoto University; Kumamoto University; Tokyo Women's Medical University; Kyoto University	Furukawa, T (corresponding author), Tokyo Womens Med Univ, Inst Integrated Med Sci, Shinjuku Ku, 8-1 Kawadacho, Tokyo 1628666, Japan.	furukawa.toru@twmu.ac.jp	Hashimoto, Daisuke/AAE-7134-2020; Furukawa, Toru/AAF-5596-2021	Furukawa, Toru/0000-0002-1083-2324	Ministry of Education, Culture, Sports, Science and Technology [26110003]; Japan Society for the Promotion of Science [24659167]; Grants-in-Aid for Scientific Research [25640052] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Dr David A Tuveson (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA) for providing LSL-Kras<SUP>G12D</SUP> mouse, Dr Takeshi Tanaka and Dr Emiko Hayama (Department of Pediatric Cardiology, Tokyo Women's Medical University) for their work preparing the anti-Gs alpha antibody and Ms Yuko Fukuchi and Ms Michiyo Nakata (Institute of Resource Development and Analysis, Kumamoto University) for their technical assistance. This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas, Ministry of Education, Culture, Sports, Science and Technology (26110003) to MO and a Grant-in-Aid for Challenging Exploratory Research, Japan Society for the Promotion of Science (24659167) to TF.	Adsay NV, 2010, WHO CLASSIFICATION T, V4th edn, P304; Delaney D, 2009, MODERN PATHOL, V22, P718, DOI 10.1038/modpathol.2009.32; Dhanasekaran Danny N, 2006, Sci STKE, V2006, ppe31, DOI 10.1126/stke.3472006pe31; Fragoso MCBV, 1998, J CLIN ENDOCR METAB, V83, P2074, DOI 10.1210/jc.83.6.2074; Furukawa T, 2011, SCI REP-UK, V1, DOI 10.1038/srep00161; Furukawa T, 2011, GUT, V60, P509, DOI 10.1136/gut.2010.210567; Hata T, 2013, PANCREATOLOGY, V13, P615, DOI 10.1016/j.pan.2013.09.003; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Kalfa N, 2006, J UROLOGY, V176, P891, DOI 10.1016/j.juro.2006.04.023; Kawaguchi Y, 2002, NAT GENET, V32, P128, DOI 10.1038/ng959; Komatsu H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087875; Kuboki Y, 2015, PANCREAS, V44, P227, DOI 10.1097/MPA.0000000000000253; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Matsubara A, 2013, J PATHOL, V229, P579, DOI 10.1002/path.4153; Matthaei H, 2014, AM J SURG PATHOL, V38, P360, DOI 10.1097/PAS.0000000000000117; Nishikawa G, 2013, BRIT J CANCER, V108, P951, DOI 10.1038/bjc.2013.47; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; Semba K, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003204; Taniwaki T, 2005, DEV GROWTH DIFFER, V47, P163; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Wu J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002543; Yamada M, 2012, J PATHOL, V228, P113, DOI 10.1002/path.4012	22	52	54	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2407	2412		10.1038/onc.2015.294	http://dx.doi.org/10.1038/onc.2015.294			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26257060				2022-12-17	WOS:000376165000013
J	Lee, S; Axelsen, TV; Andersen, AP; Vahl, P; Pedersen, SF; Boedtkjer, E				Lee, S.; Axelsen, T. V.; Andersen, A. P.; Vahl, P.; Pedersen, S. F.; Boedtkjer, E.			Disrupting Na+, HCO3--cotransporter NBCn1 (Slc4a7) delays murine breast cancer development	ONCOGENE			English	Article							INTRACELLULAR PH; SUSCEPTIBILITY LOCI; COTRANSPORTER NBCN1; NHE1; METABOLISM; EXCHANGER; SKELETAL; CELLS; PROLIFERATION; GLYCOLYSIS	Increased metabolism and insufficient blood supply cause acidic waste product accumulation in solid cancers. During carcinogenesis, cellular acid extrusion is upregulated but the underlying molecular mechanisms and their consequences for cancer growth and progression have not been established. Genome-wide association studies have indicated a possible link between the Na+, HCO3--cotransporter NBCn1 (SLC4A7) and breast cancer. We tested the functional consequences of NBCn1 knockout (KO) for breast cancer development. NBCn1 protein expression increased 2.5-fold during breast carcinogenesis and was responsible for the increased net acid extrusion and alkaline intracellular pH of breast cancer compared with normal breast tissue. Genetic disruption of NBCn1 delayed breast cancer development: tumor latency was similar to 50% increased while tumor growth rate was similar to 65% reduced in NBCn1 KO compared with wild-type (WT) mice. Breast cancer histopathology in NBCn1 KO mice differed from that in WT mice and included less aggressive tumor types. The extracellular tumor microenvironment in NBCn1 KO mice contained higher concentrations of glucose and lower concentrations of lactate than that in WT mice. Independently of NBCn1 genotype, the cleaved fraction of poly(ADP-ribose) polymerase (PARP)-1 and expression of monocarboxylate transporter (MCT) 1 increased while phosphorylation of Akt and ERK1 decreased as functions of tumor volume. Cell proliferation, evaluated from Ki-67 and phosphohistone H-3 staining, was similar to 60% lower in breast cancer of NBCn1 KO than that of WT mice when corrected for variations in tumor size. We conclude that NBCn1 facilitates acid extrusion from breast cancer tissue, maintains the alkaline intracellular environment and promotes aggressive cancer development and growth.	[Lee, S.; Axelsen, T. V.; Boedtkjer, E.] Aarhus Univ, Dept Biomed, Ole Worms Alle 3,Bldg 1170, DK-8000 Aarhus C, Denmark; [Andersen, A. P.; Pedersen, S. F.] Univ Copenhagen, Dept Biol, Copenhagen, Denmark; [Vahl, P.] Aarhus Univ Hosp, Dept Pathol, DK-8000 Aarhus, Denmark	Aarhus University; University of Copenhagen; Aarhus University	Boedtkjer, E (corresponding author), Aarhus Univ, Dept Biomed, Ole Worms Alle 3,Bldg 1170, DK-8000 Aarhus C, Denmark.	eb@biomed.au.dk	Pedersen, Stine Falsig/O-1133-2019; Boedtkjer, Ebbe/O-8449-2019; Boedtkjer, Ebbe/B-7315-2008	Pedersen, Stine Falsig/0000-0002-3044-7714; Boedtkjer, Ebbe/0000-0002-5078-9279; Boedtkjer, Ebbe/0000-0002-5078-9279; Andersen, Anne Poder/0000-0002-6693-1524	Danish Council for Independent Research [10-094816, 12-127290]; Novo Nordisk Foundation [2131, 7393]; Danish Cancer Society [R72-A4273-13-S2]; MEMBRANES at Aarhus University; Novo Nordisk Fonden [NNF13OC0007393] Funding Source: researchfish; The Danish Cancer Society [R72-A4273] Funding Source: researchfish	Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish Cancer Society(Danish Cancer Society); MEMBRANES at Aarhus University; Novo Nordisk Fonden(Novo Nordisk Foundation); The Danish Cancer Society(Danish Cancer Society)	Financial support was provided from the Danish Council for Independent Research (10-094816 to EB and 12-127290 to SFP), Novo Nordisk Foundation (2131 and 7393 to EB), Danish Cancer Society (R72-A4273-13-S2 to EB) and MEMBRANES at Aarhus University. We thank Dr. Christian Aalkjaer (Aarhus University) for valuable discussions, Drs Frauke Alves and Roser Ufartes (Max Planck Institute for Experimental Medicine) for advice on chemical breast cancer induction and Dr Vibeke Dam, Jane Ronn and Ida Tvilling for expert technical assistance.	Aalkjaer C, 2014, COMPR PHYSIOL, V4, P1605, DOI 10.1002/cphy.c130005; Ahmed S, 2009, NAT GENET, V41, P585, DOI 10.1038/ng.354; Andersen AP, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0098; Balgi AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021549; Boedtkjer E, 2006, CIRC RES, V98, P515, DOI 10.1161/01.RES.0000204750.04971.76; Boedtkjer E, 2012, CURR PHARM DESIGN, V18, P1345, DOI 10.2174/138161212799504830; Boedtkjer E, 2013, INT J CANCER, V132, P1288, DOI 10.1002/ijc.27782; Boedtkjer E, 2011, CIRCULATION, V124, P1819, DOI 10.1161/CIRCULATIONAHA.110.015974; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; Brunner A, 2012, BRIT J CANCER, V107, P84, DOI 10.1038/bjc.2012.198; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Chen W, 2012, BREAST CANCER RES TR, V136, P847, DOI 10.1007/s10549-012-2309-9; Chiche J, 2012, INT J CANCER, V130, P1511, DOI 10.1002/ijc.26125; Currier N, 2005, TOXICOL PATHOL, V33, P726, DOI 10.1080/01926230500352226; Damkier HH, 2006, AM J PHYSIOL-HEART C, V290, pH172, DOI 10.1152/ajpheart.00713.2005; De Milito A, 2012, CURR PHARM DESIGN, V18, P1395, DOI 10.2174/138161212799504911; Eigenbrodt E, 1998, ANTICANCER RES, V18, P3267; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; FIDELMAN ML, 1982, AM J PHYSIOL, V242, pC87, DOI 10.1152/ajpcell.1982.242.1.C87; Freedman ML, 2011, NAT GENET, V43, P513, DOI 10.1038/ng.840; Gonzalez-Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495; Gorbatenko A, 2014, FASEB J, V28, P350, DOI 10.1096/fj.13-233288; Green DR, 2014, SCIENCE, V345, P1466, DOI 10.1126/science.1250256; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Han W, 2011, CANCER EPIDEM BIOMAR, V20, P793, DOI 10.1158/1055-9965.EPI-10-1282; Hulikova A, 2013, J CELL PHYSIOL, V228, P743, DOI 10.1002/jcp.24221; Inwald EC, 2013, BREAST CANCER RES TR, V139, P539, DOI 10.1007/s10549-013-2560-8; Jenkins CM, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.203661; Landis MD, 2006, ONCOGENE, V25, P3325, DOI 10.1038/sj.onc.1209365; Lauritzen G, 2010, EXP CELL RES, V316, P2538, DOI 10.1016/j.yexcr.2010.06.005; Lauritzen G, 2012, CANCER LETT, V317, P172, DOI 10.1016/j.canlet.2011.11.023; Lee S, 2015, PFLUG ARCH EUR J PHY, V467, P367, DOI 10.1007/s00424-014-1524-0; Long JR, 2010, CANCER EPIDEM BIOMAR, V19, P2357, DOI 10.1158/1055-9965.EPI-10-0054; Loo SY, 2012, CURR PHARM DESIGN, V18, P1372; Mortensen B, 2013, AM J PHYSIOL-ENDOC M, V304, pE1379, DOI 10.1152/ajpendo.00295.2012; Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; Pedersen SF, 2007, CELL PHYSIOL BIOCHEM, V20, P735, DOI 10.1159/000110434; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Robertson N, 2004, CANCER RES, V64, P6160, DOI 10.1158/0008-5472.CAN-03-2224; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Silva AS, 2009, CANCER RES, V69, P2677, DOI 10.1158/0008-5472.CAN-08-2394; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Sueta A, 2012, BREAST CANCER RES TR, V132, P711, DOI 10.1007/s10549-011-1904-5; Swietach P, 2009, J BIOL CHEM, V284, P20299, DOI 10.1074/jbc.M109.006478; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; VAUPEL P, 1989, CANCER RES, V49, P6449; Yalcin A, 2009, EXP MOL PATHOL, V86, P174, DOI 10.1016/j.yexmp.2009.01.003	50	52	53	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2112	2122		10.1038/onc.2015.273	http://dx.doi.org/10.1038/onc.2015.273			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26212013				2022-12-17	WOS:000374505600010
J	Kinugasa, H; Whelan, KA; Tanaka, K; Natsuizaka, M; Long, A; Guo, A; Chang, S; Kagawa, S; Srinivasan, S; Guha, M; Yamamoto, K; St Clair, DK; Avadhani, NG; Diehl, JA; Nakagawa, H				Kinugasa, H.; Whelan, K. A.; Tanaka, K.; Natsuizaka, M.; Long, A.; Guo, A.; Chang, S.; Kagawa, S.; Srinivasan, S.; Guha, M.; Yamamoto, K.; St Clair, D. K.; Avadhani, N. G.; Diehl, J. A.; Nakagawa, H.			Mitochondrial SOD2 regulates epithelial-mesenchymal transition and cell populations defined by differential CD44 expression	ONCOGENE			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; NF-KAPPA-B; OXIDATIVE STRESS; CANCER; EMT; PROMOTES; GROWTH; GENE; IDENTIFICATION; ACTIVATION	Epithelial-mesenchymal transition (EMT) promotes cancer cell invasion, metastasis and treatment failure. EMT may be activated in cancer cells by reactive oxygen species (ROS). EMT may promote conversion of a subset of cancer cells from a CD44(low)-CD24(high) (CD44L) epithelial phenotype to a CD44(high)-CD24(-/low) (CD44H) mesenchymal phenotype, the latter associated with increased malignant properties of cancer cells. ROS are required for cells undergoing EMT, although excessive ROS may induce cell death or senescence; however, little is known as to how cellular antioxidant capabilities may be regulated during EMT. Mitochondrial superoxide dismutase 2 (SOD2) is frequently overexpressed in oral and esophageal cancers. Here, we investigate mechanisms of SOD2 transcriptional regulation in EMT, as well as the functional role of this antioxidant in EMT. Using well-characterized genetically engineered oral and esophageal human epithelial cell lines coupled with RNA interference and flow cytometric approaches, we find that transforming growth factor (TGF)-beta stimulates EMT, resulting in conversion of CD44L to CD44H cells, the latter of which display SOD2 upregulation. SOD2 induction in transformed keratinocytes was concurrent with suppression of TGF-beta-mediated induction of both ROS and senescence. SOD2 gene expression appeared to be transcriptionally regulated by NF-kappa B and ZEB2, but not ZEB1. Moreover, SOD2-mediated antioxidant activity may restrict conversion of CD44L cells to CD44H cells at the early stages of EMT. These data provide novel mechanistic insights into the dynamic expression of SOD2 during EMT. In addition, we delineate a functional role for SOD2 in EMT via the influence of this antioxidant upon distinct CD44L and CD44H subsets of cancer cells that have been implicated in oral and esophageal tumor biology.	[Kinugasa, H.; Whelan, K. A.; Tanaka, K.; Natsuizaka, M.; Long, A.; Guo, A.; Chang, S.; Kagawa, S.; Diehl, J. A.; Nakagawa, H.] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; [Kinugasa, H.; Whelan, K. A.; Tanaka, K.; Natsuizaka, M.; Long, A.; Guo, A.; Chang, S.; Kagawa, S.; Diehl, J. A.; Nakagawa, H.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Kinugasa, H.; Yamamoto, K.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Okayama, Japan; [Natsuizaka, M.] Hokkaido Univ, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan; [Srinivasan, S.; Guha, M.; Avadhani, N. G.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; [Srinivasan, S.; Guha, M.; Avadhani, N. G.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; [St Clair, D. K.] Univ Kentucky, Coll Med, Dept Toxicol & Canc Biol, Lexington, KY USA; [Diehl, J. A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Okayama University; Hokkaido University; University of Pennsylvania; University of Pennsylvania; University of Kentucky; Medical University of South Carolina	Nakagawa, H (corresponding author), Univ Penn, Dept Med, Div Gastroenterol, 421Curie Blvd,956 BRB, Philadelphia, PA 19104 USA.	nakagawh@mail.med.upenn.edu		Natsuizaka, Mitsuteru/0000-0002-1819-1955	NIH [P01CA098101, F32CA174176, F30CA175133, K26RR032714, R01CA073599]; Pennsylvania CURE Program Grant; Edward P. Evans Foundation; University of Pennsylvania University Research Foundation Award; University of Pennsylvania, Abramson Cancer Center Pilot Project Grant; NATIONAL CANCER INSTITUTE [F31CA174176, R01CA073599, P30CA177558, R01CA022762, P01CA098101, F32CA174146] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K26RR032714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [K26OD011179] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania CURE Program Grant; Edward P. Evans Foundation; University of Pennsylvania University Research Foundation Award; University of Pennsylvania, Abramson Cancer Center Pilot Project Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are grateful to the Molecular Pathology & Imaging, Molecular Biology/Gene Expression and Cell Culture Core Facilities of the NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases (P30-DK050306) and of the NIH P01CA098101. This study was supported in part by NIH Grants P01CA098101 (to HK, KAW, KT, MN, AL, AG, SC, SK, JAD and HN), F32CA174176 (KAW), F30CA175133 (AL), K26RR032714 (HN), R01CA073599 (DKS) as well as Pennsylvania CURE Program Grant (HN), the Edward P. Evans Foundation (DKS), University of Pennsylvania University Research Foundation Award (HN) and University of Pennsylvania, Abramson Cancer Center Pilot Project Grant (HN).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bai XY, 2011, J AM SOC NEPHROL, V22, P1252, DOI 10.1681/ASN.2010040367; Chaudhuri L, 2012, ONCOGENE, V31, P1207, DOI 10.1038/onc.2011.325; Chen PM, 2013, CARCINOGENESIS, V34, P2655, DOI 10.1093/carcin/bgt220; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Connor KM, 2007, CANCER RES, V67, P10260, DOI 10.1158/0008-5472.CAN-07-1204; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Dhar SK, 2011, CANCER RES, V71, P6684, DOI 10.1158/0008-5472.CAN-11-1233; Dhar SK, 2012, FREE RADICAL BIO MED, V52, P2209, DOI 10.1016/j.freeradbiomed.2012.03.009; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Gammon L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062493; Giannoni E, 2012, ANTIOXID REDOX SIGN, V16, P1248, DOI 10.1089/ars.2011.4280; Guha M, 2014, ONCOGENE, V33, P5238, DOI 10.1038/onc.2013.467; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Ji GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069351; Ju XM, 2014, CANCER RES, V74, P508, DOI 10.1158/0008-5472.CAN-13-1313; Kagawa S, 2015, ONCOGENE, V34, P2347, DOI 10.1038/onc.2014.169; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455; Kriegel AJ, 2010, NUCLEIC ACIDS RES, V38, P8338, DOI 10.1093/nar/gkq718; Lambert AJ, 2009, METHODS MOL BIOL, V554, P165, DOI 10.1007/978-1-59745-521-3_11; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lin CH, 2013, INT J MOL SCI, V14, P13266, DOI 10.3390/ijms140713266; Liu Xiqiang, 2009, Cancer Genomics & Proteomics, V6, P131; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Meng XQ, 2013, GASTROENTEROLOGY, V145, P426, DOI 10.1053/j.gastro.2013.04.004; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nam EH, 2014, CARCINOGENESIS, V35, P302, DOI 10.1093/carcin/bgt340; Nam EH, 2012, CARCINOGENESIS, V33, P563, DOI 10.1093/carcin/bgs005; Natsuizaka M, 2014, AM J CANCER RES, V4, P29; Ohashi S, 2011, CANCER RES, V71, P6836, DOI 10.1158/0008-5472.CAN-11-0846; Ohashi S, 2010, CANCER RES, V70, P4174, DOI 10.1158/0008-5472.CAN-09-4614; Ovcharenko I, 2004, NUCLEIC ACIDS RES, V32, pW280, DOI 10.1093/nar/gkh355; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rhyu DY, 2005, J AM SOC NEPHROL, V16, P667, DOI 10.1681/ASN.2004050425; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957; Wang Q, 2008, FASEB J, V22, P4126, DOI 10.1096/fj.08-112326; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Yeh CC, 1998, DNA CELL BIOL, V17, P921, DOI 10.1089/dna.1998.17.921; Yoon YS, 2005, ONCOGENE, V24, P1895, DOI 10.1038/sj.onc.1208262; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X; Zhou GF, 2009, AM J PHYSIOL-LUNG C, V297, pL1120, DOI 10.1152/ajplung.00007.2009; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	52	52	53	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5229	5239		10.1038/onc.2014.449	http://dx.doi.org/10.1038/onc.2014.449			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25659582	Green Accepted			2022-12-17	WOS:000362575400003
J	Martin-Villar, E; Borda-d'Agua, B; Carrasco-Ramirez, P; Renart, J; Parsons, M; Quintanilla, M; Jones, GE				Martin-Villar, E.; Borda-d'Agua, B.; Carrasco-Ramirez, P.; Renart, J.; Parsons, M.; Quintanilla, M.; Jones, G. E.			Podoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stability	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; IN-VIVO; EXTRACELLULAR-MATRIX; REGULATES COFILIN; TUMOR-METASTASIS; PA2.26 ANTIGEN; ORAL-CANCER; TGF-BETA; INVASION; PODOSOMES	Invadopodia are actin-rich cell membrane projections used by invasive cells to penetrate the basement membrane. Control of invadopodia stability is critical for efficient degradation of the extracellular matrix (ECM); however, the underlying molecular mechanisms remain poorly understood. Here, we uncover a new role for podoplanin, a transmembrane glycoprotein closely associated with malignant progression of squamous cell carcinomas (SCCs), in the regulation of invadopodia-mediated matrix degradation. Podoplanin downregulation in SCC cells impairs invadopodia stability, thereby reducing the efficiency of ECM degradation. We report podoplanin as a novel component of invadopodia-associated adhesion rings, where it clusters prior to matrix degradation. Early podoplanin recruitment to invadopodia is dependent on lipid rafts, whereas ezrin/moesin proteins mediate podoplanin ring assembly. Finally, we demonstrate that podoplanin regulates invadopodia maturation by acting upstream of the ROCK-LIMK-Cofilin pathway through the control of RhoC GTPase activity. Thus, podoplanin has a key role in the regulation of invadopodia function in SCC cells, controlling the initial steps of cancer cell invasion.	[Martin-Villar, E.; Carrasco-Ramirez, P.; Renart, J.; Quintanilla, M.] Inst Invest Biomed Alberto Sols CSIC UAM, Madrid 28029, Spain; [Martin-Villar, E.; Borda-d'Agua, B.; Parsons, M.; Jones, G. E.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of London; King's College London	Martin-Villar, E (corresponding author), Inst Invest Biomed Alberto Sols CSIC UAM, Arturo Duperier 4, Madrid 28029, Spain.	emvillar@iib.uam.es; gareth.jones@kcl.ac.uk	Renart, Jaime/B-7661-2009; Martin-Villar, Ester/F-1982-2016; Quintanilla, Miguel/K-9293-2017; Jones, Gareth E/H-2282-2012; Parsons, Maddy/B-2203-2013	Renart, Jaime/0000-0001-6620-3706; Martin-Villar, Ester/0000-0003-2910-2345; Jones, Gareth E/0000-0001-5879-3048; Quintanilla, Miguel/0000-0002-2124-7657; Parsons, Maddy/0000-0002-2021-8379	Cancer Research UK [C7125/A9926, A13651]; Medical Research Council [G0401026]; Spanish Ministry of Economy and Competitiveness [SAF 2010-19152/SAF2013-46183R]; Community of Madrid [S2010/BMD-2359]; Fundacion Cientifica Asociacion Espanola Contra el Cancer (AECC); MRC [G1100041, G0401026] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Spanish Ministry of Economy and Competitiveness(Spanish Government); Community of Madrid(Comunidad de Madrid); Fundacion Cientifica Asociacion Espanola Contra el Cancer (AECC); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Professor Anne Ridley for critical advice and help with ERM, and Rho GTPase siRNAs; Dr Yolanda Calle for her support and helpful suggestions; Drs Asier Jayo and Patricia Costa for help with LIMK studies, technical advice and critical discussions on this work and Dr David Sarrio for critical reading of the manuscript. This work has been funded by grants from Cancer Research UK (C7125/A9926; A13651) to GEJ and EM-V, the Medical Research Council (G0401026) to GEJ and from the Spanish Ministry of Economy and Competitiveness (SAF 2010-19152/SAF2013-46183R) and Community of Madrid (S2010/BMD-2359, SkinModel-CM) to MQ. EM-V is currently a recipient of a Postdoctoral Research Contract from Fundacion Cientifica Asociacion Espanola Contra el Cancer (AECC).	Antelmi E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075113; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Astarita JL, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00283; Beaty BT, 2014, J CELL BIOL, V205, P737, DOI 10.1083/jcb.201312046; Beaty BT, 2013, MOL BIOL CELL, V24, P1661, DOI 10.1091/mbc.E12-12-0908; Beaty BT, 2014, EUR J CELL BIOL, DOI [10.1016/ j. ejcb. 2014. 07. 003, DOI 10.1016/J.EJCB.2014.07.003)]; Branch KM, 2012, BIOL OPEN, V1, P711, DOI 10.1242/bio.20121867; Bravo-Cordero JJ, 2013, NAT REV MOL CELL BIO, V14, P405, DOI 10.1038/nrm3609; Bravo-Cordero JJ, 2011, CURR BIOL, V21, P635, DOI 10.1016/j.cub.2011.03.039; Caldieri G, 2009, J CELL MOL MED, V13, P1728, DOI 10.1111/j.1582-4934.2008.00568.x; Clark ES, 2008, EUR J CELL BIOL, V87, P581, DOI 10.1016/j.ejcb.2008.01.008; Fernandez-Munoz B, 2011, INT J BIOCHEM CELL B, V43, P886, DOI 10.1016/j.biocel.2011.02.010; Gandarillas A, 1997, MOL CARCINOGEN, V20, P10, DOI 10.1002/(SICI)1098-2744(199709)20:1<10::AID-MC3>3.0.CO;2-M; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Hagedorn EJ, 2014, J CELL BIOL, V204, P1209, DOI 10.1083/jcb.201312098; Hagedorn EJ, 2013, J CELL BIOL, V201, P903, DOI 10.1083/jcb.201301091; Honma M, 2012, J DERMATOL SCI, V65, P134, DOI 10.1016/j.jdermsci.2011.11.011; Hoshino D, 2013, J CELL SCI, V126, P2979, DOI 10.1242/jcs.079475; Hwang YS, 2012, CARCINOGENESIS, V33, P2135, DOI 10.1093/carcin/bgs258; Inoue H, 2012, TUMOR BIOL, V33, P183, DOI 10.1007/s13277-011-0261-7; Kawaguchi H, 2008, J CLIN ONCOL, V26, P354, DOI 10.1200/JCO.2007.13.4072; Kelley LC, 2014, J CELL BIOL, V204, P291, DOI 10.1083/jcb.201311112; Leong HS, 2014, CELL REP, V8, P1558, DOI 10.1016/j.celrep.2014.07.050; Li A, 2010, CURR BIOL, V20, P339, DOI 10.1016/j.cub.2009.12.035; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; Linder S, 2009, J CELL SCI, V122, P3009, DOI 10.1242/jcs.032631; Magalhaes MAO, 2011, J CELL BIOL, V195, P903, DOI 10.1083/jcb.201103045; Mahtab EAF, 2008, DEV DYNAM, V237, P847, DOI 10.1002/dvdy.21463; Martin-Villar E, 2005, INT J CANCER, V113, P899, DOI 10.1002/ijc.20656; Martin-Villar E, 2006, J CELL SCI, V119, P4541, DOI 10.1242/jcs.03218; Martin-Villar E, 2010, MOL BIOL CELL, V21, P4387, DOI 10.1091/mbc.E10-06-0489; Monteiro P, 2013, J CELL BIOL, V203, P1063, DOI 10.1083/jcb.201306162; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Oser M, 2009, J CELL BIOCHEM, V108, P1252, DOI 10.1002/jcb.22372; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Parekh A, 2009, CELL ADHES MIGR, V3, P288, DOI 10.4161/cam.3.3.8888; Paz H, 2014, ONCOGENE, V33, P4193, DOI 10.1038/onc.2013.393; Pignatelli J, 2012, J CELL BIOL, V197, P421, DOI 10.1083/jcb.201108143; Ramirez MI, 2003, DEV BIOL, V256, P61, DOI 10.1016/S0012-1606(02)00098-2; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Sakurai-Yageta M, 2008, J CELL BIOL, V181, P985, DOI 10.1083/jcb.200709076; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Scholl FG, 1999, J CELL SCI, V112, P4601; Scott RW, 2010, J CELL BIOL, V191, P169, DOI 10.1083/jcb.201002041; Suzuki H, 2008, FEBS LETT, V582, P341, DOI 10.1016/j.febslet.2007.12.028; Toll A, 2012, J AM ACAD DERMATOL, V67, P1310, DOI 10.1016/j.jaad.2012.03.007; Tsuneki M, 2013, LAB INVEST, V93, P921, DOI 10.1038/labinvest.2013.86; Wicki A, 2006, CANCER CELL, V9, P261, DOI 10.1016/j.ccr.2006.03.010; Wicki A, 2007, BRIT J CANCER, V96, P1, DOI 10.1038/sj.bjc.6603518; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yamaguchi H, 2010, ONCOTARGET, V1, P320; Yamaguchi H, 2009, CANCER RES, V69, P8594, DOI 10.1158/0008-5472.CAN-09-2305; Yuan P, 2006, CANCER, V107, P563, DOI 10.1002/cncr.22061; Yurrita MM, 2014, INT J BIOCHEM CELL B, V46, P68, DOI 10.1016/j.biocel.2013.11.016; Zhao M, 2011, CLIN CANCER RES, V17, P7248, DOI 10.1158/1078-0432.CCR-11-0690	55	52	57	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4531	4544		10.1038/onc.2014.388	http://dx.doi.org/10.1038/onc.2014.388			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25486435	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000360189200012
J	Edmond, V; Dufour, F; Poiroux, G; Shoji, K; Malleter, M; Fouque, A; Tauzin, S; Rimokh, R; Sergent, O; Penna, A; Dupuy, A; Levade, T; Theret, N; Micheau, O; Segui, B; Legembre, P				Edmond, V.; Dufour, F.; Poiroux, G.; Shoji, K.; Malleter, M.; Fouque, A.; Tauzin, S.; Rimokh, R.; Sergent, O.; Penna, A.; Dupuy, A.; Levade, T.; Theret, N.; Micheau, O.; Segui, B.; Legembre, P.			Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility	ONCOGENE			English	Article							GENE-EXPRESSION PATTERNS; BREAST-CANCER; IN-VITRO; RECEPTOR; TRANSFORMATION; INVASION; RAFTS; SPHINGOLIPIDS; GANGLIOSIDE; PHENOTYPE	Epithelial-to-mesenchymal transition (EMT) promotes cell motility, which is important for the metastasis of malignant cells, and blocks CD95-mediated apoptotic signaling triggered by immune cells and chemotherapeutic regimens. CD95L, the cognate ligand of CD95, can be cleaved by metalloproteases and released as a soluble molecule (cl-CD95L). Unlike transmembrane CD95L, cl-CD95L does not induce apoptosis but triggers cell motility. Electron paramagnetic resonance was used to show that EMT and cl-CD95L treatment both led to augmentation of plasma membrane fluidity that was instrumental in inducing cell migration. Compaction of the plasma membrane is modulated, among other factors, by the ratio of certain lipids such as sphingolipids in the membrane. An integrative analysis of gene expression in NCI tumor cell lines revealed that expression of ceramide synthase-6 (CerS6) decreased during EMT. Furthermore, pharmacological and genetic approaches established that modulation of CerS6 expression/activity in cancer cells altered the level of C16-ceramide, which in turn influenced plasma membrane fluidity and cell motility. Therefore, this study identifies CerS6 as a novel EMT-regulated gene that has a pivotal role in the regulation of cell migration.	[Edmond, V.; Shoji, K.; Malleter, M.; Fouque, A.; Tauzin, S.; Sergent, O.; Penna, A.; Theret, N.; Legembre, P.] Univ Rennes 1, F-35043 Rennes, France; [Edmond, V.; Shoji, K.; Malleter, M.; Fouque, A.; Tauzin, S.; Sergent, O.; Penna, A.; Theret, N.; Legembre, P.] INSERM, UMR 1085, IRSET, Rennes, France; [Edmond, V.; Shoji, K.; Malleter, M.; Fouque, A.; Tauzin, S.; Penna, A.; Legembre, P.] Equipe Labellisee Ligue Contre Le Canc, Rennes, France; [Dufour, F.; Micheau, O.] INSERM, UMR 866, Dijon, France; [Poiroux, G.; Levade, T.; Segui, B.] INSERM, UMR 1037, Toulouse, France; [Poiroux, G.; Levade, T.; Segui, B.] Univ Toulouse 3, Toulouse, France; [Poiroux, G.; Levade, T.; Segui, B.] Equipe Labellisee Ligue Contre Le Canc, Toulouse, France; [Rimokh, R.] Univ Lyon, Ctr Rech Cancerol Lyon, CNRS UMR 5286, Ctr Leon Berard Lyon,Inserm U1052, Lyon, France; [Dupuy, A.] INSERM, U1048, Toulouse, France; [Legembre, P.] Ctr Eugene Marquis, Rennes, France	Universite de Rennes 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Eugene Marquis	Legembre, P (corresponding author), Univ Rennes 1, IRSET, U1085, INSERM, 2 Av Prof Leon Bernard, F-35043 Rennes, France.	patrick.legembre@inserm.fr	micheau, olivier/C-3574-2011; legembre, patrick/L-3475-2016; theret, nathalie/ABG-6780-2020; Guillaume, Poiroux/M-2854-2015; penna, aubin/AAD-2550-2019; Levade, Thierry/O-8948-2014; PENNA, aubin/E-2208-2018; Rimokh, Ruth/G-7506-2014; SERGENT, ODILE/K-1966-2015; Legembre, Patrick/U-1882-2019; Ségui, Bruno/O-8957-2014; Theret, Nathalie/I-2871-2015	micheau, olivier/0000-0001-8499-7984; legembre, patrick/0000-0001-6649-8049; theret, nathalie/0000-0002-5857-7828; Guillaume, Poiroux/0000-0002-6769-3716; penna, aubin/0000-0002-1070-5990; PENNA, aubin/0000-0002-1070-5990; Legembre, Patrick/0000-0001-6649-8049; Ségui, Bruno/0000-0002-6119-1889; Theret, Nathalie/0000-0002-5857-7828; Sergent, Odile/0000-0002-9488-2141	French National Research Agency (ANR) [ANR-11-LABX-0021-01-LipSTIC Labex]; Conseil General d'Ille-et-Vilaine, project Membratox [32508]; European union (FEDER)	French National Research Agency (ANR)(French National Research Agency (ANR)); Conseil General d'Ille-et-Vilaine, project Membratox; European union (FEDER)(European Commission)	We are grateful to the L3 and microscopy facilities of the SFR Biosit (Universite de Rennes-1, Rennes, France) for their technical assistance. We thank Nicole Therville and Julia Rochotte for their technical assistance. We also acknowledge the assistance of Dr Pauline Le Faouder and Dr Justine Bertrand-Michel from the lipidomic facilities (INSERM U1048, Toulouse, France). This work was supported by grants from the French Government managed by the French National Research Agency (ANR) and under the program 'Investissements d'Avenir' with reference ANR-11-LABX-0021-01-LipSTIC Labex, INCa, ARC, Canceropole Grand Ouest, Region Bretagne, Region Bourgogne, Rennes Metropole, Ligue Contre le Cancer (Comites d'Ille-et-Vilaine/du Morbihan/des Cotes d'Armor/du Maine et Loire et les comites du Doubs/de l'Yonne), Conseil General d'Ille-et-Vilaine, project Membratox (Grant number 32508) and the European union (FEDER).	Algeciras-Schimnich A, 2003, P NATL ACAD SCI USA, V100, P11445, DOI 10.1073/pnas.2034995100; ALONSO A, 1995, BBA-BIOMEMBRANES, V1237, P6, DOI 10.1016/0005-2736(95)00069-F; Asano S, 2012, MOL CELL BIOL, V32, P3242, DOI 10.1128/MCB.00121-12; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Goni FM, 2009, BBA-BIOMEMBRANES, V1788, P169, DOI 10.1016/j.bbamem.2008.09.002; Guan F, 2009, P NATL ACAD SCI USA, V106, P7461, DOI 10.1073/pnas.0902368106; Gulbins E, 2004, J MOL MED, V82, P357, DOI 10.1007/s00109-004-0539-y; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; HANAI N, 1988, J BIOL CHEM, V263, P6296; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hesling C, 2011, EMBO REP, V12, P665, DOI 10.1038/embor.2011.78; Hoogwater FJH, 2010, GASTROENTEROLOGY, V138, P2357, DOI 10.1053/j.gastro.2010.02.046; Jezequel P, 2013, DATABASE-OXFORD, DOI 10.1093/database/bas060; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kleber S, 2008, CANCER CELL, V13, P235, DOI 10.1016/j.ccr.2008.02.003; Konishi H, 2007, CANCER RES, V67, P8460, DOI 10.1158/0008-5472.CAN-07-0108; LUCIANO L, 1989, CELL TISSUE RES, V258, P339; Malleter M, 2013, CANCER RES, V73, P6711, DOI 10.1158/0008-5472.CAN-13-1794; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Mullen TD, 2012, BIOCHEM J, V441, P789, DOI 10.1042/BJ20111626; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NAKAZAWA I, 1989, TOHOKU J EXP MED, V157, P193, DOI 10.1620/tjem.157.193; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pewzner-Jung Y, 2010, J BIOL CHEM, V285, P10902, DOI 10.1074/jbc.M109.077594; Reilly LAO, 2009, NATURE, V461, P659, DOI 10.1038/nature08402; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sergent O, 2005, BIOMETALS, V18, P567, DOI 10.1007/s10534-005-8488-7; Silva LC, 2007, BIOPHYS J, V92, P502, DOI 10.1529/biophysj.106.091876; Silva LC, 2012, J LIPID RES, V53, P430, DOI 10.1194/jlr.M022715; Sok M, 2002, ANN THORAC SURG, V73, P1567, DOI 10.1016/S0003-4975(02)03458-6; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001; TARABOLETTI G, 1989, INT J CANCER, V44, P707, DOI 10.1002/ijc.2910440426; Tauzin S, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001090; VLASIC N, 1993, LIFE SCI, V53, P1053, DOI 10.1016/0024-3205(93)90258-5; WANG E, 1991, J BIOL CHEM, V266, P14486; Weinmann A, 2005, INT J MOL MED, V16, P905; Xu LJ, 2006, J BIOL CHEM, V281, P35567, DOI 10.1074/jbc.M607702200; Zeisig R, 2007, ARCH BIOCHEM BIOPHYS, V459, P98, DOI 10.1016/j.abb.2006.09.030	40	52	55	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					996	1005		10.1038/onc.2014.55	http://dx.doi.org/10.1038/onc.2014.55			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632610	Green Submitted			2022-12-17	WOS:000350121300006
J	Lahdaoui, F; Delpu, Y; Vincent, A; Renaud, F; Messager, M; Duchene, B; Leteurtre, E; Mariette, C; Torrisani, J; Jonckheere, N; Van Seuningen, I				Lahdaoui, F.; Delpu, Y.; Vincent, A.; Renaud, F.; Messager, M.; Duchene, B.; Leteurtre, E.; Mariette, C.; Torrisani, J.; Jonckheere, N.; Van Seuningen, I.			miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer	ONCOGENE			English	Article							CELL-PROLIFERATION; GENE MUC4; ADENOCARCINOMA; TRANSCRIPTION; PROMOTER; GROWTH; IDENTIFICATION; MICRORNAS; MIRNA	Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers in the world with one of the worst outcome. The oncogenic mucin MUC4 has been identified as an actor of pancreatic carcinogenesis as it is involved in many processes regulating pancreatic cancer cell biology. MUC4 is not expressed in healthy pancreas whereas it is expressed very early in pancreatic carcinogenesis. Targeting MUC4 in these early steps may thus appear as a promising strategy to slow-down pancreatic tumorigenesis. miRNA negative regulation of MUC4 could be one mechanism to efficiently downregulate MUC4 gene expression in early pancreatic neoplastic lesions. Using in silico studies, we found two putative binding sites for miR-219-1-3p in the 3'-UTR of MUC4 and showed that miR-219-1-3p expression is downregulated both in PDAC-derived cell lines and human PDAC tissues compared with their normal counterparts. We then showed that miR-219-1-3p negatively regulates MUC4 mucin expression via its direct binding to MUC4 3'-UTR. MiR-219-1-3p overexpression (transient and stable) in pancreatic cancer cell lines induced a decrease of cell proliferation associated with a decrease of cyclin D1 and a decrease of Akt and Erk pathway activation. MiR-219-1-3p overexpression also decreased cell migration. Furthermore, miR-219-1-3p expression was found to be conversely correlated with Muc4 expression in early pancreatic intraepithelial neoplasia lesions of Pdx1-Cre;LSL-Kras(G12D) mice. Most interestingly, in vivo studies showed that miR-219-1-3p injection in xenografted pancreatic tumors in mice decreased both tumor growth and MUC4 mucin expression. Altogether, these results identify miR-219-1-3p as a new negative regulator of MUC4 oncomucin that possesses tumor-suppressor activity in PDAC.	[Lahdaoui, F.; Vincent, A.; Renaud, F.; Messager, M.; Duchene, B.; Leteurtre, E.; Mariette, C.; Jonckheere, N.; Van Seuningen, I.] INSERM, UMR837, JPARC, Team Mucins 5, F-59045 Lille, France; [Lahdaoui, F.; Vincent, A.; Renaud, F.; Messager, M.; Duchene, B.; Leteurtre, E.; Mariette, C.; Jonckheere, N.; Van Seuningen, I.] Univ Lille Nord France, Lille, France; [Lahdaoui, F.; Vincent, A.; Renaud, F.; Messager, M.; Duchene, B.; Leteurtre, E.; Mariette, C.; Jonckheere, N.; Van Seuningen, I.] CHRU Lille, F-59037 Lille, France; [Delpu, Y.; Torrisani, J.] INSERM, Canc Res Ctr Toulouse, UMR 1037, F-59045 Lille, France; [Delpu, Y.; Torrisani, J.] Univ Toulouse 3, F-31062 Toulouse, France	Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Van Seuningen, I (corresponding author), INSERM, JPARC UMR837, Rue Polonovski, F-59045 Lille, France.	isabelle.vanseuningen@inserm.fr	Jonckheere, Nicolas/J-6028-2013; Vincent, Audrey/I-2934-2016; Renaud, Florence/V-5064-2019; Torrisani, Jérôme/M-6203-2014; VAN SEUNINGEN, Isabelle/N-6176-2016	Jonckheere, Nicolas/0000-0002-0496-0661; Vincent, Audrey/0000-0003-0058-2058; Torrisani, Jérôme/0000-0001-6880-9357; Duchene, Belinda/0000-0002-4810-4680; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; RENAUD, Florence/0000-0003-3614-1713	PhD fellowship of la Ligue Nationale Contre le Cancer; la Ligue Nationale Contre le Cancer (Equipe Labellisee Ligue IVS); 'Contrat Hospitalier de Recherche Translationnelle' (AVIESAN/CHRT)	PhD fellowship of la Ligue Nationale Contre le Cancer; la Ligue Nationale Contre le Cancer (Equipe Labellisee Ligue IVS); 'Contrat Hospitalier de Recherche Translationnelle' (AVIESAN/CHRT)	We thank D Tuveson (Cambridge Research Institute, England, UK) for the kind gift of LStopL-Kras<SUP>G12D</SUP> mouse model, Dr MS Tsao (University Health Network, Toronto, Canada) for the kind gift of human pancreatic ductal cells, MH Gevaert and R Siminsky (Department of Histology, Faculty of Medicine, University of Lille 2) for their technical help, Dr C Cauffiez (EA4483, University of Lille 2) and Dr M Perrais (Inserm UMR837, team 5, Lille) for the in situ hybridization studies, the technical platforms IFR114/IMPRT for luciferase measurements (A.S Drucbert) and the animal facility (D. Taillieu). FL is a recipient of a PhD fellowship of la Ligue Nationale Contre le Cancer. This work is supported by a grant from la Ligue Nationale Contre le Cancer (Equipe Labellisee Ligue 2013, IVS). IVS is the recipient of a 'Contrat Hospitalier de Recherche Translationnelle' (AVIESAN/CHRT).	Andrianifahanana M, 2005, ONCOGENE, V24, P6143, DOI 10.1038/sj.onc.1208756; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Cheng HYM, 2007, NEURON, V54, P813, DOI 10.1016/j.neuron.2007.05.017; du Rieu MC, 2010, CLIN CHEM, V56, P603, DOI 10.1373/clinchem.2009.137364; Dugas JC, 2010, NEURON, V65, P597, DOI 10.1016/j.neuron.2010.01.027; Furukawa T, 1996, AM J PATHOL, V148, P1763; Hruban RH, 2008, INT J CLIN EXP PATHO, V1, P306; Humeau M, 2013, CLIN BIOCHEM, V46, P933, DOI 10.1016/j.clinbiochem.2013.03.019; Jonckheere N, 2004, ONCOGENE, V23, P5729, DOI 10.1038/sj.onc.1207769; Jonckheere N, 2007, J BIOL CHEM, V282, P22638, DOI 10.1074/jbc.M700905200; Jonckheere N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032232; Jonckheere Nicolas, 2010, Cancers (Basel), V2, P1794, DOI 10.3390/cancers2041794; Jonckheere N, 2010, BIOCHIMIE, V92, P1, DOI 10.1016/j.biochi.2009.09.018; Jonckheere Nicolas, 2008, Critical Reviews in Oncogenesis, V14, P177; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Lal A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002363; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Lin MB, 2003, CHINESE MED J-PEKING, V116, P1156; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Olive KP, 2006, CLIN CANCER RES, V12, P5277, DOI 10.1158/1078-0432.CCR-06-0436; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Piessen G, 2007, BIOCHEM J, V402, P81, DOI 10.1042/BJ20061461; Rachagani S, 2012, CARCINOGENESIS, V33, P1953, DOI 10.1093/carcin/bgs225; Schultz NA, 2012, MODERN PATHOL, V25, P1609, DOI 10.1038/modpathol.2012.122; Singh AP, 2007, ONCOGENE, V26, P30, DOI 10.1038/sj.onc.1209764; Skrypek N, 2013, ONCOGENE, V32, P1714, DOI 10.1038/onc.2012.179; Srivastava SK, 2011, CARCINOGENESIS, V32, P1832, DOI 10.1093/carcin/bgr223; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228; Torrisani J, 2001, GASTROENTEROLOGY, V120, P200, DOI 10.1053/gast.2001.21192; Torrisani J, 2009, HUM GENE THER, V20, P831, DOI 10.1089/hum.2008.134; van der Sluis M, 2004, BIOCHEM BIOPH RES CO, V325, P952, DOI 10.1016/j.bbrc.2004.10.108; Van Seuningen I, 2000, BIOCHEM J, V348, P675; Vincent A, 2008, FASEB J, V22, P3035, DOI 10.1096/fj.07-103390; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Xu SB, 2007, J BIOL CHEM, V282, P25053, DOI 10.1074/jbc.M700501200; Yu J, 2012, CLIN CANCER RES, V18, P981, DOI 10.1158/1078-0432.CCR-11-2347; Zhang BZ, 2012, HUM GENE THER, V23, P1071, DOI 10.1089/hum.2012.070; Zhao XH, 2010, NEURON, V65, P612, DOI 10.1016/j.neuron.2010.02.018	45	52	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					780	788		10.1038/onc.2014.11	http://dx.doi.org/10.1038/onc.2014.11			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24608432	Green Published			2022-12-17	WOS:000348853800011
J	Baumgart, A; Mazur, PK; Anton, M; Rudelius, M; Schwamborn, K; Feuchtinger, A; Behnke, K; Walch, A; Braren, R; Peschel, C; Duyster, J; Siveke, JT; Dechow, T				Baumgart, A.; Mazur, P. K.; Anton, M.; Rudelius, M.; Schwamborn, K.; Feuchtinger, A.; Behnke, K.; Walch, A.; Braren, R.; Peschel, C.; Duyster, J.; Siveke, J. T.; Dechow, T.			Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model	ONCOGENE			English	Article						Notch; Ras; mouse model; beta-catenin; DUSP1	GROWTH-FACTOR RECEPTOR; E-CADHERIN; SECRETASE INHIBITION; IN-VITRO; ACTIVATION; EXPRESSION; PATHWAY; P53; TUMORIGENESIS; PHENOTYPE	Lung cancer is the leading cause of cancer-related deaths worldwide. Recently, we have shown that Notch1 inhibition resulted in substantial cell death of non-small cell lung cancer (NSCLC) cells in vitro. New compounds targeting Notch signal transduction have been developed and are now being tested in clinical trials. However, the tumorigenic role of individual Notch receptors in vivo remains largely unclear. Using a Kras(G12D)-driven endogenous NSCLC mouse model, we analyzed the effect of conditional Notch1 and Notch2 receptor deletion on NSCLC tumorigenesis. Notch1 deficiency led to a reduced early tumor formation and lower activity of MAPK compared with the controls. Unexpectedly, Notch2 deletion resulted in a dramatically increased carcinogenesis and increased MAPK activity. These mice died significantly earlier due to rapidly growing tumor burden. We found that Notch1 regulates Ras/MAPK pathway via HES1-induced repression of the DUSP1 promoter encoding a phosphatase specifically suppressing pERK1/2. Interestingly, Notch1 but not Notch2 ablation leads to decreased HES1 and DUSP1 expression. However, Notch2-depleted tumors showed an appreciable increase in beta-catenin expression, a known activator of HES1 and important lung cancer oncogene. Characteristically for beta-catenin upregulation, we found that the majority of Notch2-deficient tumors revealed an undifferentiated phenotype as determined by their morphology, E-Cadherin and TTF1 expression levels. In addition, these carcinomas showed aggressive growth patterns with bronchus invasion and obstruction. Together, we show that Notch2 mediates differentiation and has tumor suppressor functions during lung carcinogenesis, whereas Notch1 promotes tumor initiation and progression. These data are further supported by immunohistochemical analysis of human NSCLC samples showing loss or downregulation of Notch2 compared with normal lung tissue. In conclusion, this is the first study characterizing the in vivo functions of Notch1 and Notch2 in Kras(G12D)-driven NSCLC tumorigenesis. These data highlight the clinical importance of a thorough understanding of Notch signaling especially with regard to Notch-targeted therapies.	[Baumgart, A.; Behnke, K.; Peschel, C.; Dechow, T.] Tech Univ Munich, Dept Internal Med 3, D-81675 Munich, Germany; [Mazur, P. K.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Mazur, P. K.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; [Anton, M.] Tech Univ Munich, Dept Expt Oncol, D-81675 Munich, Germany; [Rudelius, M.; Schwamborn, K.] Tech Univ Munich, Dept Pathol, D-81675 Munich, Germany; [Feuchtinger, A.; Walch, A.] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Res Unit Analyt Pathol, Neuherberg, Germany; [Braren, R.] Tech Univ Munich, Inst Diagnost Imaging, D-81675 Munich, Germany; [Duyster, J.] Univ Klinikum Freiburg, Dept Internal Med 1, Freiburg, Germany; [Siveke, J. T.] Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany; [Dechow, T.] Onkol Ravensburg, Ravensburg, Germany	Technical University of Munich; University of Munich; Stanford University; Stanford University; Technical University of Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Freiburg; Technical University of Munich	Siveke, JT (corresponding author), Tech Univ Munich, Dept Internal Med 2, Ismaninger Str 22, D-81675 Munich, Germany.	jens.siveke@lrz.tum.de	Mazur, Pawel K./AAU-6343-2021; Feuchtinger, Annette/O-4569-2014; Braren, Rickmer/U-3254-2018; Siveke, Jens/AAQ-6170-2021; Walch, Axel/B-4554-2012	Mazur, Pawel K./0000-0002-5820-8344; Braren, Rickmer/0000-0001-6039-6957; Walch, Axel/0000-0001-5578-4023	Wilhelm Sander-Stiftung [2005.158.1]; Deutsche Krebshilfe [109606]; Deutsche Forschungsgemeinschaft [SI 1549/1-1]; Tobacco-Related Disease Research Program; Dean's Fellowship from Stanford University; Child Health Research Institute; Lucile Packard Foundation for Children's Health at Stanford	Wilhelm Sander-Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Tobacco-Related Disease Research Program(University of California System); Dean's Fellowship from Stanford University; Child Health Research Institute; Lucile Packard Foundation for Children's Health at Stanford	We would like to thank Dr Tibor Schuster for the help with statistical calculations, Nadya Mitova and Birgit Geist for her excellent technical help with the experiments and Joachim Alfer for providing histological pictures. We also thank Freddy Radtke for the Notch1<SUP>lox/lox</SUP> mice, Ursula Zimber-Strobl for the Notch2<SUP>lox/lox</SUP> mice and David Tuveson and Tyler Jacks for the Kras<SUP>+/LSL-G12D</SUP> mice. TD received a grant from the Wilhelm Sander-Stiftung (#2005.158.1). TD and JTS have been supported by grants from the Deutsche Krebshilfe (#109606 to TD and JTS) and the Deutsche Forschungsgemeinschaft (SI 1549/1-1 to JTS). PKM was supported by the Tobacco-Related Disease Research Program, a Dean's Fellowship from Stanford University and the Child Health Research Institute and Lucile Packard Foundation for Children's Health at Stanford.	Allen TD, 2011, CANCER RES, V71, P6010, DOI 10.1158/0008-5472.CAN-11-0595; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Asnaghi L, 2010, ONCOGENE, V29, P2760, DOI 10.1038/onc.2010.39; Baumgart A, 2010, CANCER RES, V70, P5368, DOI 10.1158/0008-5472.CAN-09-3763; Besseyrias V, 2007, J EXP MED, V204, P331, DOI 10.1084/jem.20061442; Bettstetter M, 2013, HUM PATHOL, V44, P829, DOI 10.1016/j.humpath.2012.08.005; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Bremnes RM, 2002, LUNG CANCER, V36, P115, DOI 10.1016/S0169-5002(01)00471-8; Huynh C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025264; Cheng HT, 2007, DEVELOPMENT, V134, P801, DOI 10.1242/dev.02773; Chu D, 2009, ANN SURG ONCOL, V16, P3259, DOI 10.1245/s10434-009-0655-6; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Eliasz S, 2010, ONCOGENE, V29, P2488, DOI 10.1038/onc.2010.7; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Graziani I, 2008, CANCER RES, V68, P9678, DOI 10.1158/0008-5472.CAN-08-0969; Hanlon L, 2010, CANCER RES, V70, P4280, DOI 10.1158/0008-5472.CAN-09-4645; Haruki N, 2005, CANCER RES, V65, P3555, DOI 10.1158/0008-5472.CAN-04-3132; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Kim HA, 2012, J CLIN INVEST, V122, P3248, DOI 10.1172/JCI61216; Kim MY, 2005, BIOCHEM BIOPH RES CO, V332, P609, DOI 10.1016/j.bbrc.2005.05.001; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Maraver A, 2012, ONCOTARGET, V3, P917; Maraver A, 2012, CANCER CELL, V22, P222, DOI 10.1016/j.ccr.2012.06.014; Mazur PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013578; Mazur PK, 2010, P NATL ACAD SCI USA, V107, P13438, DOI 10.1073/pnas.1002423107; Michie AM, 2007, INT IMMUNOL, V19, P1421, DOI 10.1093/intimm/dxm113; Myong Na-Hye, 2004, Cancer Res Treat, V36, P56, DOI 10.4143/crt.2004.36.1.56; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Osanyingbemi-Obidi J, 2011, MOL CANCER RES, V9, P1746, DOI 10.1158/1541-7786.MCR-11-0286; Pacheco-Pinedo EC, 2011, J CLIN INVEST, V121, P1935, DOI 10.1172/JCI44871; Peignon G, 2011, GUT, V60, P166, DOI 10.1136/gut.2009.204719; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; RODENHUIS S, 1988, CANCER RES, V48, P5738; Saad AG, 2008, CANCER-AM CANCER SOC, V113, P2129, DOI 10.1002/cncr.23826; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Sjolund J, 2008, J CLIN INVEST, V118, P217, DOI 10.1172/JCI32086; Slotta-Huspenina J, 2012, HAEMATOL-HEMATOL J, V97, P1422, DOI 10.3324/haematol.2011.055715; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Sriuranpong V, 2001, CANCER RES, V61, P3200; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wang XQ, 2009, MOL BIOL CELL, V20, P791, DOI 10.1091/mbc.E08-07-0732; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Westhoff B, 2009, P NATL ACAD SCI USA, V106, P22293, DOI 10.1073/pnas.0907781106; Wu Y, 2010, NATURE, V464, P1052, DOI 10.1038/nature08878; Zheng YY, 2013, CANCER CELL, V24, P59, DOI 10.1016/j.ccr.2013.05.021	55	52	53	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					578	588		10.1038/onc.2013.592	http://dx.doi.org/10.1038/onc.2013.592			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24509876				2022-12-17	WOS:000348853500005
J	Ballesteros-Arias, L; Saavedra, V; Morata, G				Ballesteros-Arias, L.; Saavedra, V.; Morata, G.			Cell competition may function either as tumour-suppressing or as tumour-stimulating factor in Drosophila	ONCOGENE			English	Article						cell competition; apoptosis; Rab5; tumour development; imaginal discs	CASPASE DRONC; ENDOCYTIC CONTROL; APOPTOTIC CELLS; GENETIC SCREEN; JNK; PROLIFERATION; SURVIVAL; MUTANTS; DEATH; RAS	Drosophila endocytosis-defective cells develop tumour overgrowths in the imaginal discs. We have analysed the tumorigenic potential of cells mutant for Rab5, a gene involved in endocytosis. We found that while a compartment entirely made by Rab5 mutant cells can grow indefinitely, clones of Rab5 cells surrounded by normal cells are eliminated by cell competition. However, when a group of about 400 cells are simultaneously made mutant for Rab5, they form an overgrowing tumour: mutant cells in the periphery are eliminated, but those inside survive and continue proliferating because they are beyond the range of cell competition. These results identify group protection as a mechanism to evade the tumour-suppressing function of cell competition in Drosophila. Furthermore, we find that the growth of the tumour depends to a large extent on the presence of apoptosis inside the tumour: cells doubly mutant for Rab5 and the proapoptotic gene dronc do not form overgrowing tumours. These results suggest that the apoptosis caused by cell competition acts as a tumour-stimulating factor, bringing about high levels of Jun N-terminal kinase and subsequently Wg/Dpp signalling and high proliferation levels in the growing tumour. We conclude that under these circumstances cell competition facilitates the progression of the tumour, thus reversing its normal antitumour role.	[Ballesteros-Arias, L.; Saavedra, V.; Morata, G.] Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Morata, G (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol, Nicolas Cabrera 1, E-28049 Madrid, Spain.	gmorata@cbm.uam.es		Morata, Gines/0000-0003-3274-5173; Ballesteros-Arias, Luna/0000-0002-5701-699X	Ministerio de Economia y Competitividad [BFU2008-03196, CSD2007-00008]; Comunidad de Madrid [CELDEV S2006/SAL-0190]; Fundacion Ramon Areces	Ministerio de Economia y Competitividad(Spanish Government); Comunidad de Madrid(Comunidad de Madrid); Fundacion Ramon Areces	We thank Ernesto Sanchez-Herrero and the members of the Morata laboratory for help during the work and comments on the manuscript. We also thank Kenneth Irvine for comments on the manuscript. We also thank Angelica Cantarero for general help. The work has been supported by the grants BFU2008-03196, CSD2007-00008 from the Ministerio de Economia y Competitividad, and CELDEV S2006/SAL-0190 from the Comunidad de Madrid. We also acknowledge the institutional grant from the Fundacion Ramon Areces to the Centro de Biologia Molecular.	Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Chen CL, 2012, P NATL ACAD SCI USA, V109, P484, DOI 10.1073/pnas.1113882109; Chew SK, 2004, DEV CELL, V7, P897, DOI 10.1016/j.devcel.2004.09.016; Daish TJ, 2004, DEV CELL, V7, P909, DOI 10.1016/j.devcel.2004.09.018; de Celis JF, 2009, INT J DEV BIOL, V53, P1385, DOI 10.1387/ijdb.072408jd; Devergne O, 2007, J CELL SCI, V120, P3457, DOI 10.1242/jcs.005926; Fischer JA, 2006, ANNU REV CELL DEV BI, V22, P181, DOI 10.1146/annurev.cellbio.22.010605.093205; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; Galliot B, 2010, TRENDS CELL BIOL, V20, P514, DOI 10.1016/j.tcb.2010.05.006; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hariharan IK, 2006, ANNU REV GENET, V40, P335, DOI 10.1146/annurev.genet.39.073003.100738; Herz HM, 2006, DEVELOPMENT, V133, P1871, DOI 10.1242/dev.02356; Huang Q, 2011, NAT MED, V17, P860, DOI 10.1038/nm.2385; Huh JR, 2004, CURR BIOL, V14, P1262, DOI 10.1016/j.cub.2004.06.015; Igaki T, 2009, DEV CELL, V16, P458, DOI 10.1016/j.devcel.2009.01.002; Leong GR, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-62; Li W, 2007, FLY, V1, P274, DOI 10.4161/fly.5247; Lu H, 2005, NAT CELL BIOL, V7, P1232, DOI 10.1038/ncb1324; Martin FA, 2009, INT J DEV BIOL, V53, P1341, DOI 10.1387/ijdb.072447fm; Martin FA, 2009, DEVELOPMENT, V136, P3747, DOI 10.1242/dev.038406; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Menendez J, 2010, P NATL ACAD SCI USA, V107, P14651, DOI 10.1073/pnas.1009376107; Menut L, 2007, GENETICS, V177, P1667, DOI 10.1534/genetics.107.078360; Moberg KH, 2005, DEV CELL, V9, P699, DOI 10.1016/j.devcel.2005.09.018; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Morata G, 2011, DEV GROWTH DIFFER, V53, P168, DOI 10.1111/j.1440-169X.2010.01225.x; Moreno E, 2002, NATURE, V416, P755, DOI 10.1038/416755a; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Perez-Garijo A, 2004, DEVELOPMENT, V131, P5591, DOI 10.1242/dev.01432; Perez-Garijo A, 2009, DEVELOPMENT, V136, P1169, DOI 10.1242/dev.034017; Ryoo HD, 2004, DEV CELL, V7, P491, DOI 10.1016/j.devcel.2004.08.019; Shivas JM, 2010, TRENDS CELL BIOL, V20, P445, DOI 10.1016/j.tcb.2010.04.003; Shlevkov E, 2012, CELL DEATH DIFFER, V19, P451, DOI 10.1038/cdd.2011.113; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Thompson BJ, 2005, DEV CELL, V9, P711, DOI 10.1016/j.devcel.2005.09.020; Torroja C, 2004, DEVELOPMENT, V131, P2395, DOI 10.1242/dev.01102; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401	39	52	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4377	4384		10.1038/onc.2013.407	http://dx.doi.org/10.1038/onc.2013.407			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24096487				2022-12-17	WOS:000341157800002
J	Chen, Z; Chen, J; Gu, Y; Hu, C; Li, JL; Lin, S; Shen, H; Cao, C; Gao, R; Li, J; Ha, PK; Kaye, FJ; Griffin, JD; Wu, L				Chen, Z.; Chen, J.; Gu, Y.; Hu, C.; Li, J-L; Lin, S.; Shen, H.; Cao, C.; Gao, R.; Li, J.; Ha, P. K.; Kaye, F. J.; Griffin, J. D.; Wu, L.			Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells	ONCOGENE			English	Article						salivary gland tumors; mucoepidermoid carcinoma; CRTC1-MAML2; AREG; EGFR	TRANSCRIPTIONAL COACTIVATORS; T(11/19) TRANSLOCATION; NOTCH RECEPTORS; LUNG-CANCER; WILD-TYPE; TUMORS; ONCOGENE; MASTERMIND; CETUXIMAB; CREB	Salivary gland tumors (SGT) are a group of highly heterogeneous head and neck malignancies with widely varied clinical outcomes and no standard effective treatments. The CRTC1-MAML2 fusion oncogene, encoded by a recurring chromosomal translocation t(11; 19)(q14-21; p12-13), is a frequent genetic alteration found in > 50% of mucoepidermoid carcinomas (MEC), the most common malignant SGT. In this study, we aimed to define the role of the CRTC1-MAML2 oncogene in the maintenance of MEC tumor growth and to investigate critical downstream target genes and pathways for therapeutic targeting of MEC. By performing gene expression analyses and functional studies via RNA interference and pharmacological modulation, we determined the importance of the CRTC1-MAML2 fusion gene and its downstream AREG-EGFR signaling in human MEC cancer cell growth and survival in vitro and in vivo using human MEC xenograft models. We found that CRTC1-MAML2 fusion oncogene was required for the growth and survival of fusion-positive human MEC cancer cells in vitro and in vivo. The CRTC1-MAML2 oncoprotein induced the upregulation of the epidermal growth factor receptor (EGFR) ligand Amphiregulin (AREG) by co-activating the transcription factor CREB, and AREG subsequently activated EGFR signaling in an autocrine manner that promoted MEC cell growth and survival. Importantly, CRTC1-MAML2-positive MEC cells were highly sensitive to EGFR signaling inhibition. Therefore, our study revealed that aberrantly activated AREG-EGFR signaling is required for CRTC1-MAML2-positive MEC cell growth and survival, suggesting that EGFR-targeted therapies will benefit patients with advanced, unresectable CRTC1-MAML2-positive MEC.	[Chen, Z.; Gu, Y.; Hu, C.; Lin, S.; Wu, L.] Univ Florida, Shands Canc Ctr, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; [Chen, J.; Griffin, J. D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Li, J-L] Sanford Burnham Med Res Inst Lake Nona, Orlando, FL USA; [Shen, H.] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China; [Cao, C.; Gao, R.; Kaye, F. J.] Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL USA; [Li, J.] Fujian Med Univ, Fujian Prov Tumor Hosp, Teaching Hosp, Fuzhou, Fujian, Peoples R China; [Ha, P. K.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA	State University System of Florida; University of Florida; Harvard University; Dana-Farber Cancer Institute; Sanford Burnham Prebys Medical Discovery Institute; Sun Yat Sen University; State University System of Florida; University of Florida; Fujian Medical University; Johns Hopkins University	Wu, L (corresponding author), Univ Florida, Shands Canc Ctr, Dept Mol Genet & Microbiol, 2033 Mowry Rd, Gainesville, FL 32610 USA.	lzwu@ufl.edu	Li, Jian-Liang/AAE-9315-2019; Li, J L/E-6100-2018; chen, zirong/S-4042-2016	Li, Jian-Liang/0000-0002-6487-081X; Li, J L/0000-0002-6487-081X; chen, zirong/0000-0002-0589-4619	University of Florida Shands Cancer Center Startup fund; Bankhead Coley Cancer Research Program; V foundation for Cancer Research	University of Florida Shands Cancer Center Startup fund; Bankhead Coley Cancer Research Program; V foundation for Cancer Research	We thank Marda Jorgensen for helping with immunohistochemical staining, Mei Zhang for helping with FACS analysis, and the Salivary Gland Tumor Biorepository (SGTB) for providing tumor specimens for this study. L Wu was supported by the University of Florida Shands Cancer Center Startup fund, Bankhead Coley Cancer Research Program, and the V foundation for Cancer Research.	Altarejos JY, 2011, NAT REV MOL CELL BIO, V12, P141, DOI 10.1038/nrm3072; Anzick SL, 2010, GENE CHROMOSOME CANC, V49, P59, DOI 10.1002/gcc.20719; Behboudi A, 2006, GENE CHROMOSOME CANC, V45, P470, DOI 10.1002/gcc.20306; Bell D, 2012, CURR ONCOL REP, V14, P166, DOI 10.1007/s11912-012-0220-5; Busser B, 2011, BBA-REV CANCER, V1816, P119, DOI 10.1016/j.bbcan.2011.05.003; Canettieri G, 2009, P NATL ACAD SCI USA, V106, P1445, DOI 10.1073/pnas.0808749106; Chiosea SI, 2012, LARYNGOSCOPE, V122, P1690, DOI 10.1002/lary.22419; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Coxon A, 2005, CANCER RES, V65, P7137, DOI 10.1158/0008-5472.CAN-05-1125; Enlund F, 2004, EXP CELL RES, V292, P21, DOI 10.1016/j.yexcr.2003.09.007; Eveson JW, 2011, PERIODONTOL 2000, V57, P150, DOI 10.1111/j.1600-0757.2011.00385.x; Fehr A, 2008, CANCER GENET CYTOGEN, V180, P135, DOI 10.1016/j.cancergencyto.2007.10.007; Grisanti Salvatore, 2008, J Med Case Rep, V2, P320, DOI 10.1186/1752-1947-2-320; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; Han SW, 2008, LUNG CANCER, V61, P30, DOI 10.1016/j.lungcan.2007.11.014; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Komiya T, 2006, ONCOGENE, V25, P6128, DOI 10.1038/sj.onc.1209627; Komiya T, 2010, ONCOGENE, V29, P1672, DOI 10.1038/onc.2009.453; Kumar V, 2005, ROBBINS COTRAN PATHO; Lujan B, 2010, BRIT J CANCER, V103, P510, DOI 10.1038/sj.bjc.6605788; McElhinny AS, 2008, ONCOGENE, V27, P5138, DOI 10.1038/onc.2008.228; O'Neill ID, 2009, LUNG CANCER, V64, P129, DOI 10.1016/j.lungcan.2009.01.003; O'Neill ID, 2009, ORAL ONCOL, V45, P2, DOI 10.1016/j.oraloncology.2008.03.012; O'Neill ID, 2009, J ORAL PATHOL MED, V38, P145, DOI 10.1111/j.1600-0714.2008.00676.x; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Raben D, 2005, CLIN CANCER RES, V11, P795; Seethala RR, 2010, AM J SURG PATHOL, V34, P1106, DOI 10.1097/PAS.0b013e3181de3021; Steiner P, 2007, CLIN CANCER RES, V13, P1540, DOI 10.1158/1078-0432.CCR-06-1887; Stenman G, 2005, SEMIN CANCER BIOL, V15, P224, DOI 10.1016/j.semcancer.2005.01.002; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu LZ, 2005, EMBO J, V24, P2391, DOI 10.1038/sj.emboj.7600719; Yonesaka K, 2008, CLIN CANCER RES, V14, P6963, DOI 10.1158/1078-0432.CCR-08-0957	34	52	53	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3869	3877		10.1038/onc.2013.348	http://dx.doi.org/10.1038/onc.2013.348			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23975434				2022-12-17	WOS:000339394100013
J	Chen, CH; Thai, P; Yoneda, K; Adler, KB; Yang, PC; Wu, R				Chen, C-H; Thai, P.; Yoneda, K.; Adler, K. B.; Yang, P-C; Wu, R.			A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis	ONCOGENE			English	Article						MARCKS; MANS peptide; migration; metastasis; lung cancer	PROTEIN-KINASE; IN-VITRO; THERAPEUTIC TARGET; TUMOR-METASTASIS; PLASMA-MEMBRANE; GENE-EXPRESSION; MOUSE MODEL; RHO-KINASE; PHOSPHORYLATION; CELLS	Myristoylated Alanine-Rich C Kinase Substrate (MARCKS), a substrate of protein kinase C, is a key regulatory molecule controlling mucus granule secretion by airway epithelial cells as well as directed migration of leukocytes, stem cells and fibroblasts. Phosphorylation of MARKCS may be involved in these responses. However, the functionality of MARCKS and its related phosphorylation in lung cancer malignancy have not been characterized. This study demonstrated elevated levels of MARCKS and phospho-MARCKS in highly invasive lung cancer cell lines and lung cancer specimens from non-small-cell lung cancer patients. siRNA knockdown of MARCKS expression in these highly invasive lung cancer cell lines reduced cell migration and suppressed PI3K (phosphatidylinositol 30-kinase)/Akt phosphorylation and Slug level. Interestingly, treatment with a peptide identical to the MARCKS N-terminus sequence (the MANS peptide) impaired cell migration in vitro and also the metastatic potential of invasive lung cancer cells in vivo. Mechanistically, MANS peptide treatment resulted in a coordination of increase of E-cadherin expression, suppression of MARCKS phosphorylation and AKT/Slug signalling pathway but not the expression of total MARCKS. These results indicate a crucial role for MARCKS, specifically its phosphorylated form, in potentiating lung cancer cell migration/metastasis and suggest a potential use of MARCKS-related peptides in the treatment of lung cancer metastasis.	[Chen, C-H; Thai, P.; Yoneda, K.; Wu, R.] Univ Calif Davis, Dept Internal Med, Div Pulm & Crit Care Med, Davis, CA 95616 USA; [Chen, C-H; Thai, P.; Yoneda, K.; Wu, R.] Univ Calif Davis, Ctr Comparat Resp Biol & Med, Davis, CA 95616 USA; [Adler, K. B.] N Carolina State Univ, Dept Mol Biomed Sci, Raleigh, NC 27695 USA; [Yang, P-C] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan	University of California System; University of California Davis; University of California System; University of California Davis; University of North Carolina; North Carolina State University; National Taiwan University	Wu, R (corresponding author), Univ Calif Davis, Dept Internal Med, Div Pulm & Crit Care Med, GBSF Room 6510-6523, Davis, CA 95616 USA.	rwu@ucdavis.edu	Tsou, YY/H-4160-2011	Tsou, YY/0000-0003-3345-4351; YANG, PAN-CHYR/0000-0001-6330-6048	NIH-NHLBI [HL077902, HL096373, HL36982]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036982, R01HL096373, R01HL036982, R01HL077902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009701] Funding Source: NIH RePORTER	NIH-NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was supported, in parts, by Grants from the NIH-NHLBI (HL077902, HL096373, and HL36982).	Botto L, 2004, FEBS LETT, V557, P143, DOI 10.1016/S0014-5793(03)01463-7; Brooks G, 1996, CARCINOGENESIS, V17, P683, DOI 10.1093/carcin/17.4.683; Chen JJW, 2001, CANCER RES, V61, P5223; Chen XY, 2010, CELL SIGNAL, V22, P1097, DOI 10.1016/j.cellsig.2010.03.003; Chen Y, 2011, CANCER RES, V71, P1721, DOI 10.1158/0008-5472.CAN-09-4683; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Eckert RE, 2010, AM J RESP CELL MOL, V42, P586, DOI 10.1165/rcmb.2008-0394OC; Fan T, 2007, CANCER RES, V67, P7901, DOI 10.1158/0008-5472.CAN-07-0090; Fenouille N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040378; Garcia J, 2012, EMBO REP, V13, P431, DOI 10.1038/embor.2012.29; Gonzalez-Guerrico AM, 2005, J BIOCHEM MOL BIOL, V38, P639; Hanigan Marie H, 2003, Cancer Ther, V1, P47; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Jarboe JS, 2012, CLIN CANCER RES, V18, P3030, DOI 10.1158/1078-0432.CCR-11-3091; Kalwa H, 2011, J BIOL CHEM, V286, P2320, DOI 10.1074/jbc.M110.196022; Kim J, 2011, ONCOGENE, V30, P323, DOI 10.1038/onc.2010.415; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Lukk M, 2010, NAT BIOTECHNOL, V28, P322, DOI 10.1038/nbt0410-322; McLaughlin S, 2005, NATURE, V438, P605, DOI 10.1038/nature04398; Micallef J, 2009, CANCER RES, V69, P7548, DOI 10.1158/0008-5472.CAN-08-4783; Michel S, 2010, MOL CARCINOGEN, V49, P175, DOI 10.1002/mc.20587; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; NAIRN AC, 1992, CIBA F SYMP, V164, P145; Naylor TL, 2011, CANCER RES, V71, P2643, DOI 10.1158/0008-5472.CAN-10-2525; Ohmitsu M, 1999, J BIOL CHEM, V274, P408, DOI 10.1074/jbc.274.1.408; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127; Reddy MM, 2011, LEUKEMIA, V25, P281, DOI 10.1038/leu.2010.263; Roffey J, 2009, CURR OPIN CELL BIOL, V21, P268, DOI 10.1016/j.ceb.2009.01.019; Rombouts K, 2013, CANCER LETT, V333, P244, DOI 10.1016/j.canlet.2013.01.040; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Singer M, 2004, NAT MED, V10, P193, DOI 10.1038/nm983; Takashi S, 2006, AM J RESP CELL MOL, V34, P647, DOI 10.1165/rcmb.2006-0030RC; Tanabe A, 2006, BIOCHEM BIOPH RES CO, V345, P156, DOI 10.1016/j.bbrc.2006.04.082; Tatsumi S, 2005, NEUROSCIENCE, V131, P491, DOI 10.1016/j.neuroscience.2004.10.022; Tauskela JS, 2009, NEUROSCI LETT, V466, P41, DOI 10.1016/j.neulet.2009.09.028; Techasen A, 2010, CANCER SCI, V101, P658, DOI 10.1111/j.1349-7006.2009.01427.x; Teicher BA, 2006, CLIN CANCER RES, V12, P5336, DOI 10.1158/1078-0432.CCR-06-0945; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Yamaguchi H, 2009, J CELL PHYSIOL, V220, P748, DOI 10.1002/jcp.21822; Yarmola EG, 2001, J BIOL CHEM, V276, P22351, DOI 10.1074/jbc.M101457200; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yokoyama Y, 1998, INT J CANCER, V75, P774, DOI 10.1002/(SICI)1097-0215(19980302)75:5<774::AID-IJC18>3.3.CO;2-P; Zhang K, 2012, DIS ESOPHAGUS, V25, P731, DOI 10.1111/j.1442-2050.2012.01323.x	49	52	57	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3696	3706		10.1038/onc.2013.336	http://dx.doi.org/10.1038/onc.2013.336			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23955080	Green Accepted			2022-12-17	WOS:000338942900009
J	Asuthkar, S; Velpula, KK; Nalla, AK; Gogineni, VR; Gondi, CS; Rao, JS				Asuthkar, S.; Velpula, K. K.; Nalla, A. K.; Gogineni, V. R.; Gondi, C. S.; Rao, J. S.			Irradiation-induced angiogenesis is associated with an MMP-9-miR-494-syndecan-1 regulatory loop in medulloblastoma cells	ONCOGENE			English	Article						matrix metalloproteinase-9 (MMP-9); syndecan-1 (SDC1); microRNA-494 (miR-494); ionizing radiation (IR); 3 '-untranslated region (3 '-UTR); CpG methylation	PLASMINOGEN-ACTIVATOR RECEPTOR; HISTONE ACETYLTRANSFERASE; TUMOR-GROWTH; SOLUBLE SYNDECAN-1; DNA METHYLATION; DOWN-REGULATION; CANCER; EXPRESSION; INVASION; GENE	Matrix metalloproteinase-9 (MMP-9) represents one of the most prominent proteins associated with tumorigenesis and is a modulator of the tumor microenvironment during angiogenesis. Recently, syndecan-1 (SDC1), a transmembrane heparan sulfatebearing proteoglycan, was also speculated to have a critical role in contributing to angiogenesis when associated with MMP-9. However, the mechanism behind their synergistic regulation is not fully understood. In the current study, we report for the first time that ionizing radiation (IR)-induced MMP-9 enhances SDC1 shedding, corroborating to tube-inducing ability of medulloblastoma (MB) cells. Furthermore, we observed that the tumor angiogenesis is associated with higher MMP-9-SDC1 interactions on both the cell surface and extracellular medium. Our results also revealed the existence of a novel regulatory mechanism where MMP-9 drives the suppression of miR-494, resulting in enhanced SDC1 shedding and angiogenesis. From the in situ hybridization analysis, we found that MMP-9-specific shRNA (shMMP-9) treatment of mouse intracranial tumors resulted in elevated expression of miR-494. This negative correlation between MMP-9 and miR-494 levels was observed to be dependent on the methylation status of a miR-494 promoter-associated CpG island region (- 186 to - 20), which was confirmed by bisulfite-sequencing and methylation-specific PCR (MSP) analysis. Further, validation of MMP-9 and SDC1 3 '-untranslated region (3 '-UTR) targets with luciferase reporter assay provided a more favorable result for miR-494-mediated regulation of SDC1 but not of MMP-9, suggesting that the 3 '-UTR of SDC1 mRNA is a direct target of miR-494. Overall, our results indicate that angiogenesis induced by radiotherapy is associated with an MMP-9-miR-494-SDC1 regulatory loop and that MMP-9-SDC1 activity creates a negative feedback loop by regulating the expression of miR-494.	[Asuthkar, S.; Velpula, K. K.; Nalla, A. K.; Gogineni, V. R.; Gondi, C. S.; Rao, J. S.] Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA; [Rao, J. S.] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Asuthkar, S (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, One Illini Dr, Peoria, IL 61605 USA.	asuthkar@uic.edu		Gondi, Christopher/0000-0002-3036-9920	National Cancer Institute Grant [CA138409]; NATIONAL CANCER INSTITUTE [R01CA138409] Funding Source: NIH RePORTER	National Cancer Institute Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Peggy Mankin and Noorjehan Ali for their technical assistance, Susan Renner and Debbie McCollum for manuscript preparation, and Diana Meister and Sushma Jasti for manuscript review. This research was supported by National Cancer Institute Grant CA138409 (to JSR).	ALIOSMAN F, 1990, CANCER RES, V50, P6976; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Artacho-Cordon F, 2012, SURG ONCOL, V21, pE143, DOI 10.1016/j.suronc.2012.06.001; Asuthkar S, 2012, J BIOL CHEM, V287, P20576, DOI 10.1074/jbc.M112.348888; Asuthkar S, 2011, NEURO-ONCOLOGY, V13, P1059, DOI 10.1093/neuonc/nor109; Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bhoopathi P, 2011, CANCER RES, V71, P4908, DOI 10.1158/0008-5472.CAN-10-3395; BIGNER SH, 1990, CANCER RES, V50, P2347; Brieger J, 2004, ANN NY ACAD SCI, V1030, P37, DOI 10.1196/annals.1329.005; Brule S, 2006, GLYCOBIOLOGY, V16, P488, DOI 10.1093/glycob/cwj098; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Enright AJ, 2004, GENOME BIOL, V5; Ezhilarasan R, 2009, INT J CANCER, V124, P306, DOI 10.1002/ijc.23951; Fandy TE, 2010, EPIGENOMICS-UK, V2, P221, DOI 10.2217/EPI.10.1; Fang JY, 2002, WORLD J GASTROENTERO, V8, P400, DOI 10.3748/wjg.v8.i3.400; Floer M, 2010, AM J PATHOL, V176, P146, DOI 10.2353/ajpath.2010.080639; Gondi CS, 2004, ONCOGENE, V23, P8486, DOI 10.1038/sj.onc.1207879; Han L, 2007, CANCER BIOL THER, V6, P1284; Huang YC, 2011, TOXICOL LETT, V201, P62, DOI 10.1016/j.toxlet.2010.12.006; Ibrahim SA, 2012, INT J CANCER, V131, pE884, DOI 10.1002/ijc.27629; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Khotskaya YB, 2009, J BIOL CHEM, V284, P26085, DOI 10.1074/jbc.M109.018473; Kim WK, 2011, CLIN CANCER RES, V17, P7584, DOI 10.1158/1078-0432.CCR-11-0166; Kishikawa Shotaro, 2002, Nucleic Acids Res Suppl, P209; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kunigal S, 2007, INT J CANCER, V121, P2307, DOI 10.1002/ijc.22962; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Li XH, 2011, ONCOL REP, V26, P1431, DOI 10.3892/or.2011.1437; Lindsey JC, 2007, BRIT J CANCER, V97, P267, DOI 10.1038/sj.bjc.6603852; Lindsey JC, 2004, CARCINOGENESIS, V25, P661, DOI 10.1093/carcin/bgh055; Liu SJ, 2008, BLOOD, V111, P2364, DOI 10.1182/blood-2007-08-110171; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Massimino M, 2012, J NEURO-ONCOL, V108, P163, DOI 10.1007/s11060-012-0822-7; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Nikolova V, 2009, CARCINOGENESIS, V30, P397, DOI 10.1093/carcin/bgp001; Oh JH, 2010, INT J GYNECOL CANCER, V20, P751, DOI 10.1111/IGC.0b013e3181e02faa; Oh JH, 2009, GYNECOL ONCOL, V114, P509, DOI 10.1016/j.ygyno.2009.05.027; Olaru AV, 2011, HEPATOLOGY, V54, P2089, DOI 10.1002/hep.24591; Purushothaman A, 2008, J BIOL CHEM, V283, P32628, DOI 10.1074/jbc.M806266200; Purushothaman A, 2011, J BIOL CHEM, V286, P30377, DOI 10.1074/jbc.M111.254789; Purushothaman A, 2010, BLOOD, V115, P2449, DOI 10.1182/blood-2009-07-234757; Seidel C, 2000, BLOOD, V96, P3139, DOI 10.1182/blood.V96.9.3139.h8003139_3139_3146; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Shan SQ, 2001, CLIN CANCER RES, V7, P2590; Sung B, 2008, BLOOD, V111, P4880, DOI 10.1182/blood-2007-10-117994; Taillandier L, 2011, REV NEUROL-FRANCE, V167, P431, DOI 10.1016/j.neurol.2011.01.014; Yang Y, 2007, J BIOL CHEM, V282, P13326, DOI 10.1074/jbc.M611259200; Yu Q, 2000, GENE DEV, V14, P163; Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743; Zhao CH, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-224	59	52	54	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1922	1933		10.1038/onc.2013.151	http://dx.doi.org/10.1038/onc.2013.151			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23728345				2022-12-17	WOS:000334346300005
J	Finger, EC; Cheng, CF; Williams, TR; Rankin, EB; Bedogni, B; Tachiki, L; Spong, S; Giaccia, AJ; Powell, MB				Finger, E. C.; Cheng, C-F; Williams, T. R.; Rankin, E. B.; Bedogni, B.; Tachiki, L.; Spong, S.; Giaccia, A. J.; Powell, M. B.			CTGF is a therapeutic target for metastatic melanoma	ONCOGENE			English	Article						connective tissue growth factor (CTGF); melanoma; invasion; metastasis; therapeutic target; hypoxia	TISSUE GROWTH-FACTOR; PANCREATIC TUMOR-GROWTH; GENE-EXPRESSION; MALIGNANT-MELANOMA; HYPOXIC INDUCTION; CANCER; PROGRESSION; PROTEINS; ANGIOGENESIS; MECHANISMS	Metastatic melanoma remains a devastating disease with a 5-year survival rate of less than five percent. Despite recent advances in targeted therapies for melanoma, only a small percentage of melanoma patients experience durable remissions. Therefore, it is critical to identify new therapies for the treatment of advanced melanoma. Here, we define connective tissue growth factor (CTGF) as a therapeutic target for metastatic melanoma. Clinically, CTGF expression correlates with tumor progression and is strongly induced by hypoxia through HIF-1 and HIF-2-dependent mechanisms. Genetic inhibition of CTGF in human melanoma cells is sufficient to significantly reduce orthotopic tumor growth, as well as metastatic tumor growth in the lung of severe combined immunodeficient (SCID) mice. Mechanistically, inhibition of CTGF decreased invasion and migration associated with reduced matrix metalloproteinase-9 expression. Most importantly, the anti-CTGF antibody, FG-3019, had a profound inhibitory effect on the progression of established metastatic melanoma. These results offer the first preclinical validation of anti-CTGF therapy for the treatment of advanced melanoma and underscore the importance of tumor hypoxia in melanoma progression.	[Finger, E. C.; Cheng, C-F; Williams, T. R.; Rankin, E. B.; Tachiki, L.; Giaccia, A. J.; Powell, M. B.] Stanford Univ, Div Radiat & Canc Biol, Dept Radiat Oncol, Stanford, CA 94305 USA; [Bedogni, B.] Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; [Spong, S.] FibroGen Inc, San Francisco, CA USA	Stanford University; Case Western Reserve University; FibroGen	Powell, MB (corresponding author), Stanford Univ, Div Radiat & Canc Biol, Dept Radiat Oncol, 269 Campus Dr,CCSR-S-1250, Stanford, CA 94305 USA.	mbp@stanford.edu		Rankin, Erinn/0000-0002-2045-2296	NIH [CA67166, CA116685, CA120526, T32 CA121940, T32 CA09302]; NATIONAL CANCER INSTITUTE [R01CA120526, R01CA116685, T32CA121940, T32CA009302, P01CA067166] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Giaccia Laboratory for their insightful discussions. We kindly thank Dr Boris C Bastian for discussions and review of our tissue array analysis methodology and Dr Adam J Krieg for his insights on the microarray analysis. We appreciate Kathy Brown's guiding hand with the low passage melanoma cell lines. This investigation was supported by NIH grants CA67166 and CA116685 (AJG), CA120526 (MBP), T32 CA121940 (ECF) and T32 CA09302 (TRW).	Aguissa-Toure AH, 2012, CELL MOL LIFE SCI, V69, P1475, DOI 10.1007/s00018-011-0878-0; Bedogni B, 2008, J CLIN INVEST, V118, P3660, DOI 10.1172/JCI36157; Bedogni B, 2009, PIGM CELL MELANOMA R, V22, P166, DOI 10.1111/j.1755-148X.2009.00553.x; Bennewith KL, 2009, CANCER RES, V69, P775, DOI 10.1158/0008-5472.CAN-08-0987; Bindra RS, 2005, ANN NY ACAD SCI, V1059, P184, DOI 10.1196/annals.1339.049; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Braig S, 2011, BRIT J CANCER, V105, P231, DOI 10.1038/bjc.2011.226; Chan DA, 2007, CANCER METAST REV, V26, P333, DOI 10.1007/s10555-007-9063-1; Chan DA, 2009, CANCER CELL, V15, P527, DOI 10.1016/j.ccr.2009.04.010; Chen PP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000534; Chu CY, 2008, J BIOMED SCI, V15, P675, DOI 10.1007/s11373-008-9264-9; Chujo S, 2009, J CELL PHYSIOL, V220, P189, DOI 10.1002/jcp.21750; Cicha I, 2009, BIOFACTORS, V35, P200, DOI 10.1002/biof.30; Dahl C, 2007, APMIS, V115, P1161, DOI 10.1111/j.1600-0463.2007.apm_855.xml.x; Dhar A., 2010, Experimental Oncology, V32, P2; Dornhofer N, 2006, CANCER RES, V66, P5816, DOI 10.1158/0008-5472.CAN-06-0081; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093; Hall-Glenn F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030562; Haluska FG, 2006, CLIN CANCER RES, V12, p2301S, DOI 10.1158/1078-0432.CCR-05-2518; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Higgins DF, 2004, AM J PHYSIOL-RENAL, V287, pF1223, DOI 10.1152/ajprenal.00245.2004; Hubble J, 2009, NUCLEIC ACIDS RES, V37, pD898, DOI 10.1093/nar/gkn786; Koliopanos A, 2002, WORLD J SURG, V26, P420, DOI 10.1007/s00268-001-0242-x; Kondo S, 2002, CARCINOGENESIS, V23, P769, DOI 10.1093/carcin/23.5.769; Lartigau E, 1997, MELANOMA RES, V7, P400, DOI 10.1097/00008390-199710000-00006; Liu LY, 2008, WORLD J GASTROENTERO, V14, P2110, DOI 10.3748/wjg.14.2110; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Norman JT, 2000, KIDNEY INT, V58, P2351, DOI 10.1046/j.1523-1755.2000.00419.x; PATEL B, 1994, BIOCHEM MOL BIOL INT, V34, P639; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Sala-Torra O, 2007, BLOOD, V109, P3080, DOI 10.1182/blood-2006-06-031096; Samarin J, 2010, J BIOL CHEM, V285, P4328, DOI 10.1074/jbc.M109.049650; Shakunaga T, 2000, CANCER, V89, P1466, DOI 10.1002/1097-0142(20001001)89:7<1466::AID-CNCR8>3.0.CO;2-G; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; Zhang B, 2010, DIABETES, V59, P1809, DOI 10.2337/db09-1056; Zhang H, 2003, BLOOD, V101, P2253, DOI 10.1182/blood-2002-02-0629	43	52	58	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1093	1100		10.1038/onc.2013.47	http://dx.doi.org/10.1038/onc.2013.47			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23435419	Green Accepted			2022-12-17	WOS:000331933800003
J	Byrne, FL; Yang, L; Phillips, PA; Hansford, LM; Fletcher, JI; Ormandy, CJ; McCarroll, JA; Kavallaris, M				Byrne, F. L.; Yang, L.; Phillips, P. A.; Hansford, L. M.; Fletcher, J. I.; Ormandy, C. J.; McCarroll, J. A.; Kavallaris, M.			RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model	ONCOGENE			English	Article						orthotopic xenograft; cytoskeleton; cofilin; tubulin	CELL-MIGRATION; POOR-PROGNOSIS; EARLY RECURRENCE; ACTIN DYNAMICS; CANCER CELLS; LIM KINASES; RHO-KINASE; TUMOR; INVASION; MOTILITY	Metastatic neuroblastoma is an aggressive childhood cancer of neural crest origin. Stathmin, a microtubule destabilizing protein, is highly expressed in neuroblastoma although its functional role in this malignancy has not been addressed. Herein, we investigate stathmin's contribution to neuroblastoma tumor growth and metastasis. Small interfering RNA (siRNA)-mediated stathmin suppression in two independent neuroblastoma cell lines, BE(2)-C and SH-SY5Y, did not markedly influence cell proliferation, viability or anchorage-independent growth. In contrast, stathmin suppression significantly reduced cell migration and invasion in both the neuroblastoma cell lines. Stathmin suppression altered neuroblastoma cell morphology and this was associated with changes in the cytoskeleton, including increased tubulin polymer levels. Stathmin suppression also modulated phosphorylation of the actin-regulatory proteins, cofilin and myosin light chain (MLC). Treatment of stathmin-suppressed neuroblastoma cells with the ROCKI and ROCKII inhibitor, Y-27632, ablated MLC phosphorylation and returned the level of cofilin phosphorylation and cell invasion back to that of untreated control cells. ROCKII inhibition (H-1152) and siRNA suppression also reduced cofilin phosphorylation in stathmin-suppressed cells, indicating that ROCKII mediates stathmin's regulation of cofilin phosphorylation. This data demonstrates a link between stathmin and the regulation of cofilin and MLC phosphorylation via ROCK. To examine stathmin's role in neuroblastoma metastasis, stathmin short hairpin RNA (shRNA)\luciferase-expressing neuroblastoma cells were injected orthotopically into severe combined immunodeficiency-Beige mice, and tumor growth monitored by bioluminescent imaging. Stathmin suppression did not influence neuroblastoma cell engraftment or tumor growth. In contrast, stathmin suppression significantly reduced neuroblastoma lung metastases by 71% (P<0.008) compared with control. This is the first study to confirm a role for stathmin in hematogenous spread using a clinically relevant orthotopic cancer model, and has identified stathmin as an important contributor of cell invasion and metastasis in neuroblastoma.	[Byrne, F. L.; Yang, L.; McCarroll, J. A.; Kavallaris, M.] Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Tumour Biol & Targeting Program, Randwick, NSW 2031, Australia; [Phillips, P. A.] Univ New S Wales, Sch Med Sci, Pancreat Canc Translat Res Grp, Randwick, NSW 2031, Australia; [Hansford, L. M.] Univ Toronto, Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Fletcher, J. I.] Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Expt Therapeut Program, Randwick, NSW 2031, Australia; [Ormandy, C. J.] St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; [McCarroll, J. A.; Kavallaris, M.] Univ New S Wales, Australian Ctr Nanomed, Randwick, NSW 2031, Australia	Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Children's Cancer Institute; University of New South Wales Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Kavallaris, M (corresponding author), Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Tumour Biol & Targeting Program, POB 81, Randwick, NSW 2031, Australia.	jmccarroll@ccia.unsw.edu.au; mkavallaris@ccia.unsw.edu.au	Kavallaris, Maria/J-5240-2014; Phillips, Phoebe A/E-6006-2010; McCarroll, Joshua/E-8481-2010; Ormandy, Chris/G-4165-2014; Fletcher, Jamie/V-4667-2019; Byrne, Frances/AAW-7748-2020	Phillips, Phoebe A/0000-0002-4481-8782; McCarroll, Joshua/0000-0001-8807-3623; Byrne, Frances/0000-0002-8897-8438; Ormandy, Christopher/0000-0002-2504-7919; Fletcher, Jamie/0000-0003-2949-9469	Children's Cancer Institute Australia for Medical Research; Anthony Rothe Memorial Trust; National Health and Medical Research Council (NHMRC); Cancer Council New South Wales Program Grant; Cure Cancer Australia Foundation Grant; Cancer Institute New South Wales Early Career Development Fellowship; NHMRC	Children's Cancer Institute Australia for Medical Research; Anthony Rothe Memorial Trust; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council New South Wales Program Grant(Cancer Council New South Wales); Cure Cancer Australia Foundation Grant; Cancer Institute New South Wales Early Career Development Fellowship; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	We thank Dr Vladimir Ponomarev (Memorial Sloan Kettering Cancer Center) for kindly providing the TGL reporter vector, Dr Michael Shum and Dr Toby Trahair for helpful discussions and Zillan Neiron for technical assistance. Biological Resources Imaging Laboratory and the Biomedical Imaging Facility, Mark Wainwright Analytical Center, University of New South Wales. This study was financially supported by: Children's Cancer Institute Australia for Medical Research, which is affiliated with the University of New South Wales and the Sydney Children's Hospital. Funding from the Anthony Rothe Memorial Trust (F Byrne, The Anthony Rothe Scholarship) and grants from the National Health and Medical Research Council (NHMRC) (M Kavallaris and J McCarroll), Cancer Council New South Wales Program Grant (M Kavallaris), Cure Cancer Australia Foundation Grant (J McCarroll), Cancer Institute New South Wales Early Career Development Fellowship (J McCarroll, J Fletcher), NHMRC Career Development Fellowship (P Phillips) and an NHMRC Senior Research Fellowship (M Kavallaris).	Ara T, 2006, CANCER METAST REV, V25, P645, DOI 10.1007/s10555-006-9028-9; Balasubramani M, 2011, MUTAT RES-GEN TOX EN, V722, P154, DOI 10.1016/j.mrgentox.2010.08.019; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Belletti B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894; Belletti B, 2010, MOL CELL BIOL, V30, P2229, DOI 10.1128/MCB.00723-09; Bernard O, 2007, INT J BIOCHEM CELL B, V39, P1071, DOI 10.1016/j.biocel.2006.11.011; Campostrini N, 2004, J CHROMATOGR B, V808, P279, DOI 10.1016/j.jchromb.2004.05.013; Curmi PA, 1999, CELL STRUCT FUNCT, V24, P345; Don S, 2004, MOL CANCER THER, V3, P1137; DuBois SG, 1999, J PEDIAT HEMATOL ONC, V21, P181, DOI 10.1097/00043426-199905000-00005; DuBois SG, 2008, PEDIATR BLOOD CANCER, V51, P589, DOI 10.1002/pbc.21684; Gutierrez JC, 2007, PEDIATR SURG INT, V23, P637, DOI 10.1007/s00383-007-1933-7; Gutjahr MC, 2005, EXP CELL RES, V308, P422, DOI 10.1016/j.yexcr.2005.05.001; HAILAT N, 1990, ONCOGENE, V5, P1615; Henriksson KC, 2004, CLIN EXP METASTAS, V21, P563, DOI 10.1007/s10585-004-4091-5; Hsieh SY, 2010, MOL CARCINOGEN, V49, P476, DOI 10.1002/mc.20627; Insall RH, 2009, DEV CELL, V17, P310, DOI 10.1016/j.devcel.2009.08.012; Jeon TY, 2010, BRIT J CANCER, V102, P710, DOI 10.1038/sj.bjc.6605537; Kadir S, 2011, J CELL SCI, V124, P2642, DOI 10.1242/jcs.087965; Khanna C, 2002, IN VIVO, V16, P77; McCarroll JA, 2010, CANCER RES, V70, P4995, DOI 10.1158/0008-5472.CAN-09-4487; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; Nevo I, 2008, NEOPLASIA, V10, P817, DOI 10.1593/neo.08402; Phillips PA, 2003, GUT, V52, P677, DOI 10.1136/gut.52.5.677; Ponomarev V, 2004, EUR J NUCL MED MOL I, V31, P740, DOI 10.1007/s00259-003-1441-5; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Sadow PM, 2008, ENDOCR PATHOL, V19, P97, DOI 10.1007/s12022-008-9028-0; Salvesen HB, 2009, P NATL ACAD SCI USA, V106, P4834, DOI 10.1073/pnas.0806514106; Scott RW, 2010, J CELL BIOL, V191, P169, DOI 10.1083/jcb.201002041; Singer S, 2009, CANCER RES, V69, P2234, DOI 10.1158/0008-5472.CAN-08-3338; Takahashi K, 2010, CELL SIGNAL, V22, P510, DOI 10.1016/j.cellsig.2009.11.005; Takahashi K, 2009, CELL SIGNAL, V21, P695, DOI 10.1016/j.cellsig.2009.01.007; Takesono A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008774; Tamura M, 2005, BBA-PROTEINS PROTEOM, V1754, P245, DOI 10.1016/j.bbapap.2005.06.015; Torka R, 2006, EXP CELL RES, V312, P3857, DOI 10.1016/j.yexcr.2006.08.025; Trovik J, 2011, CLIN CANCER RES, V17, P3368, DOI 10.1158/1078-0432.CCR-10-2412; Wittmann T, 2001, J CELL SCI, V114, P3795; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Yuan RH, 2006, J PATHOL, V209, P549, DOI 10.1002/path.2011	40	52	53	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					882	890		10.1038/onc.2013.11	http://dx.doi.org/10.1038/onc.2013.11			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23396365				2022-12-17	WOS:000331626900009
J	Xu, C; Fu, H; Gao, L; Wang, L; Wang, W; Li, J; Li, Y; Dou, L; Gao, X; Luo, X; Jing, Y; Chim, CS; Zheng, X; Yu, L				Xu, C.; Fu, H.; Gao, L.; Wang, L.; Wang, W.; Li, J.; Li, Y.; Dou, L.; Gao, X.; Luo, X.; Jing, Y.; Chim, C-S; Zheng, X.; Yu, L.			BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia	ONCOGENE			English	Article						microRNA; imatinib; chronic myeloid leukemia; BCR-ABL	SQUAMOUS-CELL CARCINOMA; CYCLE ARREST; BCR-ABL; MICRORNA; EXPRESSION; DIFFERENTIATION; ONCOGENE; MIR-138; TRANSCRIPTION; GATA-1	Abnormal expression of microRNAs (miRNAs) has been implicated in carcinogenesis. Here we report a novel BCR (breakpoint cluster region)-ABL (c-abl oncogene 1, non-receptor tyrosine kinase)/GATA1/microRNA-138 (miR-138) circuitry in chronic myeloid leukemia (CML). miR-138 expression is downregulated in K562 cells and primary CML samples, which is restored after imatinib treatment. The tumor suppressor activity of miR-138 is demonstrated by the induction of cell cycle arrest at G0/G1, inhibition of cell proliferation and colony forming unit granulocyte-macrophage colony formation and enhanced imatinib-induced apoptosis in K562 and Ku812 cells overexpressing miR-138. Moreover, overexpression of miR-138 led to the downregulation of BCR-ABL. Based on luciferase assay, ABL and BCR-ABL are shown to be the target genes regulated by miR-138. Furthermore, miR-138 binding to ABL was shown to localize to the coding region instead of 30-untranslated regions (30-UTR) of ABL mRNA. In addition, CCND3 is another target of miR-138, which represses CCND3 expression by binding to its 30-UTR. Finally, upregulation of miR-138 upon imatinib treatment is associated with the enhancement of GATA1 activity, which binds to the miR-138 promoter. In conclusion, miR-138 is a tumor suppressor miRNA underexpressed in CML. miR-138 represses expression of both BCR-ABL and CCND3 via binding to the coding region and 30-UTR, respectively. miR-138 expression is activated by GATA1, which in turn is repressed by BCR-ABL. Therefore, miR-138, by virtue of a BCR-ABL/GATA1/miR-138 circuitry, is a tumor suppressor miRNA implicated in the pathogenesis of CML and its clinical response to imatinib.	[Xu, C.; Gao, L.; Wang, L.; Wang, W.; Li, J.; Li, Y.; Dou, L.; Gao, X.; Luo, X.; Jing, Y.; Yu, L.] Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing 100853, Peoples R China; [Fu, H.; Zheng, X.] Beijing Inst Radiat Med, Dept Biochem & Mol Biol, Beijing, Peoples R China; [Chim, C-S] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China	Chinese People's Liberation Army General Hospital; Academy of Military Medical Sciences - China; University of Hong Kong	Yu, L (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, 28 Fuxing Rd, Beijing 100853, Peoples R China.	xfzheng100@126.com; chunhuiliyu@yahoo.com		Fu, Hanjiang/0000-0002-4352-1178; Yu, Li/0000-0001-6872-2665; Chim, CS/0000-0003-2427-915X	Chinese State Key Projects for Basic Research [2005CB522408, 2010CB912801]; Chinese National Natural Science Foundation [90919044, 81072021, 30971297, 81170518]; High and New Technology Program of PLA [2010gxjs091]; Capital Medical Development Scientific Research Fund [2007-2040]	Chinese State Key Projects for Basic Research; Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); High and New Technology Program of PLA; Capital Medical Development Scientific Research Fund	We thank C Li (Beijing Institute of Radiation Medicine, Beijing, China) for kindly providing the GATA1 expression vector. This work was supported partially by Chinese State Key Projects for Basic Research (2005CB522408 and 2010CB912801), Chinese National Natural Science Foundation Projects (90919044, 81072021, 30971297, and 81170518), High and New Technology Program of PLA (2010gxjs091) and Capital Medical Development Scientific Research Fund (no. 2007-2040).	Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Enright Anton J, 2003, Genome Biol, V5, pR1, DOI 10.1186/gb-2003-5-1-r1; Garzon R, 2007, ONCOGENE, V26, P4148, DOI 10.1038/sj.onc.1210186; Heckman KL, 2007, NAT PROTOC, V2, P924, DOI 10.1038/nprot.2007.132; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Huang DY, 2005, NUCLEIC ACIDS RES, V33, P5331, DOI 10.1093/nar/gki838; Jacquel A, 2003, FASEB J, V17, P2160, DOI 10.1096/fj.03-0322fje; Jiang L, 2011, HUM GENET, V129, P189, DOI 10.1007/s00439-010-0915-3; Kisliouk T, 2011, EUR J NEUROSCI, V33, P224, DOI 10.1111/j.1460-9568.2010.07493.x; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li S, 2009, HEPATOLOGY, V49, P1194, DOI 10.1002/hep.22757; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Liu XQ, 2011, BIOCHEM J, V440, P23, DOI 10.1042/BJ20111006; Mitomo S, 2008, CANCER SCI, V99, P280, DOI 10.1111/j.1349-7006.2007.00666.x; Morceau F, 2008, BIOFACTORS, V34, P313, DOI [10.1002/biof.5520340407, 10.3233/BIO-2009-1085]; Morton SU, 2008, P NATL ACAD SCI USA, V105, P17830, DOI 10.1073/pnas.0804673105; Nana-Sinkam SP, 2006, J THORAC ONCOL, V1, P929, DOI 10.1097/01243894-200611000-00002; O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484; Obernosterer G, 2006, RNA, V12, P1161, DOI 10.1261/rna.2322506; Pope NJ, 2010, NUCLEIC ACIDS RES, V38, P2190, DOI 10.1093/nar/gkp1159; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Spizzo R, 2009, CELL, V137, P586, DOI 10.1016/j.cell.2009.04.040; Suresh S, 2011, J CELL COMMUN SIGNAL, V5, P183, DOI 10.1007/s12079-011-0139-x; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Wang W, 2012, CARCINOGENESIS, V33, P1113, DOI 10.1093/carcin/bgs113; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; Xu CW, 2010, EUR J CANCER, V46, P2828, DOI 10.1016/j.ejca.2010.06.127; Yu M, 2009, MOL CELL, V36, P682, DOI 10.1016/j.molcel.2009.11.002; Zanette DL, 2007, BRAZ J MED BIOL RES, V40, P1435, DOI 10.1590/S0100-879X2007001100003	38	52	55	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					44	54		10.1038/onc.2012.557	http://dx.doi.org/10.1038/onc.2012.557			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23208504				2022-12-17	WOS:000329212000006
J	Kunkeaw, N; Jeon, SH; Lee, K; Johnson, BH; Tanasanvimon, S; Javle, M; Pairojkul, C; Chamgramol, Y; Wongfieng, W; Gong, B; Leelayuwat, C; Lee, YS				Kunkeaw, N.; Jeon, S. H.; Lee, K.; Johnson, B. H.; Tanasanvimon, S.; Javle, M.; Pairojkul, C.; Chamgramol, Y.; Wongfieng, W.; Gong, B.; Leelayuwat, C.; Lee, Y. S.			Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma	ONCOGENE			English	Article						nc886; cholangiocarcinoma; PKR; eIF2 alpha; NF-kappa B	GUANINE-NUCLEOTIDE EXCHANGE; INITIATION-FACTORS EIF-4E; UP-REGULATION; TRANSLATIONAL CONTROL; INCREASED EXPRESSION; CANCER CELLS; PKR ACTIVITY; VIRUS; INHIBITION; APOPTOSIS	We have recently identified nc886 (pre-miR-886 or vtRNA2-1) as a novel type of non-coding RNA that inhibits activation of protein kinase R (PKR). PKR's pro-apoptotic role through eukaryotic initiation factor 2 alpha (eIF2 alpha) phosphorylation is well established in the host defense against viral infection. Paradoxically, some cancer patients have elevated PKR activity; however, its cause and consequence are not understood. Initially, we evaluated the expression of nc886, PKR and eIF2 alpha in non-malignant cholangiocyte and cholangiocarcinoma (CCA) cells. nc886 is repressed in CCA cells and this repression is the cause of PKR's activation therein. nc886 alone is necessary and sufficient for suppression of PKR via direct physical interaction. Consistently, artificial suppression of nc886 in cholangiocyte cells activates the canonical PKR/eIF2 alpha cell death pathway, suggesting a potential significance of the nc886 suppression and the consequent PKR activation in eliminating pre-malignant cells during tumorigenesis. In comparison, active PKR in CCA cells does not induce phospho-eIF2 alpha nor apoptosis, but promotes the pro-survival nuclear factor-kappa B pathway. Thus, PKR has a dual life or death role during tumorigenesis. Similarly to the CCA cell lines, nc886 tends to be decreased but PKR tends to be activated in our clinical samples from CCA patients. Collectively from our data, we propose a tumor surveillance model for nc886's role in the PKR pathway during tumorigenesis.	[Kunkeaw, N.; Jeon, S. H.; Lee, K.; Johnson, B. H.; Lee, Y. S.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Kunkeaw, N.; Wongfieng, W.; Leelayuwat, C.] Khon Kaen Univ, Fac Associated Med Sci, Ctr Res & Dev, Med Diagnost Labs, Khon Kaen, Thailand; [Jeon, S. H.] Hallym Univ, Dept Life Sci, Chunchon, South Korea; [Tanasanvimon, S.] Chulalongkorn Univ, Fac Med, King Chulalongkorn Mem Hosp, Dept Med, Bangkok 10330, Thailand; [Tanasanvimon, S.] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA; [Javle, M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Pairojkul, C.; Chamgramol, Y.; Leelayuwat, C.] Khon Kaen Univ, Fac Med, Liver Fluke & Cholangiocarcinoma Res Ctr, Khon Kaen, Thailand; [Gong, B.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; Khon Kaen University; Hallym University; Chulalongkorn University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Khon Kaen University; University of Texas System; University of Texas Medical Branch Galveston	Lee, YS (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, 7-138H Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	yslee@utmb.edu	Jeon, Sung Ho/B-9728-2009; , Alsevier/V-1974-2019	Piwphankum, Jirawut/0000-0001-6129-8830	National Cancer Institute [CA16672]; American Cancer Society [RSG-12-187-01-RMC]; Sealy Center for Cancer Biology at the University of Texas Medical Branch; Royal Golden Jubilee (RGJ) scholarship of Thailand Research Fund (TRF) [PHD/0105/2550]; Basic Science Research Program through the National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2011-0022022]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Sealy Center for Cancer Biology at the University of Texas Medical Branch; Royal Golden Jubilee (RGJ) scholarship of Thailand Research Fund (TRF); Basic Science Research Program through the National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Sopit Wongkham, Dr Kanlayanee Sawanyawisuth and Ms Sirinapa Sribenja (Khon Kaen University) for CCA cells and helpful discussion; Dr Inhan Lee (miRcore, MI) for helpful advice; Research Histology Core Laboratory Facility, University of Texas, MD Anderson Cancer Center (funded by the National Cancer Institute Grant # CA16672) for tissue preparation and IHC. This work was supported by a Research Scholar Grant, RSG-12-187-01-RMC from the American Cancer Society to YSL, by start-up funding from the Sealy Center for Cancer Biology at the University of Texas Medical Branch to YSL, by the Royal Golden Jubilee (RGJ) scholarship (PHD/0105/2550) of Thailand Research Fund (TRF) to NK and the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0022022) to SHJ.	Alisi A, 2011, J HEPATOL, V54, P956, DOI 10.1016/j.jhep.2010.08.016; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Basu S, 1997, CANCER RES, V57, P943; Beretta L, 1996, ONCOGENE, V12, P1593; Blalock WL, 2009, J CELL PHYSIOL, V221, P232, DOI 10.1002/jcp.21848; Datta B, 2000, BIOCHIMIE, V82, P95, DOI 10.1016/S0300-9084(00)00383-7; Fabian JR, 1998, PROTEIN EXPRES PURIF, V13, P16, DOI 10.1006/prep.1998.0860; Garcia MA, 2007, BIOCHIMIE, V89, P799, DOI 10.1016/j.biochi.2007.03.001; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Haines GK, 1998, TUMOR BIOL, V19, P52, DOI 10.1159/000029974; Hiasa Y, 2003, AM J GASTROENTEROL, V98, P2528, DOI 10.1016/S0002-9270(03)01696-4; Hii SI, 2004, INT J CANCER, V109, P329, DOI 10.1002/ijc.11714; Ikegami T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000287; Jeon SH, 2012, FEBS LETT IN PRESS, DOI DOI 10.1016/J.FEBSLET.2012.07.076); Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lee K, 2011, RNA, V17, P1076, DOI 10.1261/rna.2701111; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; Li YJ, 2011, INT J MOL MED, V28, P215, DOI 10.3892/ijmm.2011.666; Lobo MVT, 2000, HISTOCHEM J, V32, P139, DOI 10.1023/A:1004091122351; Maruyama M, 2004, TRANSPLANTATION, V77, P446, DOI 10.1097/01.TP.0000110292.73873.25; Mounir Z, 2010, FUTURE ONCOL, V6, P643, DOI 10.2217/FON.10.45; Murad JM, 2005, BLOOD CELL MOL DIS, V34, P1, DOI 10.1016/j.bcmd.2004.08.025; Nandy C, 2009, J MOL BIOL, V388, P776, DOI 10.1016/j.jmb.2009.03.031; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Onori P, 2009, INT J CANCER, V125, P565, DOI 10.1002/ijc.24271; Pataer A, 2002, CANCER RES, V62, P2239; Pataer A, 2010, CLIN CANCER RES, V16, P5522, DOI 10.1158/1078-0432.CCR-10-0753; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Raught B, 1996, CANCER RES, V56, P4382; REICHEL PA, 1985, NATURE, V313, P196, DOI 10.1038/313196a0; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; Scheuner D, 2006, J BIOL CHEM, V281, P21458, DOI 10.1074/jbc.M603784200; Stadler PF, 2009, MOL BIOL EVOL, V26, P1975, DOI 10.1093/molbev/msp112; Tepsiri N, 2005, WORLD J GASTROENTERO, V11, P2748, DOI 10.3748/wjg.v11.i18.2748; Terada T, 2000, HUM PATHOL, V31, P817, DOI 10.1053/hupa.2000.8443; Treppendahl MB, 2012, BLOOD, V119, P206, DOI 10.1182/blood-2011-06-362541; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Yonglitthipagon P, 2010, INT J PARASITOL, V40, P1203, DOI 10.1016/j.ijpara.2010.05.002	47	52	56	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2013	32	32					3722	3731		10.1038/onc.2012.382	http://dx.doi.org/10.1038/onc.2012.382			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22926522	Green Accepted			2022-12-17	WOS:000322904400007
J	Bhandari, A; Gordon, W; Dizon, D; Hopkin, AS; Gordon, E; Yu, Z; Andersen, B				Bhandari, A.; Gordon, W.; Dizon, D.; Hopkin, A. S.; Gordon, E.; Yu, Z.; Andersen, B.			The Grainyhead transcription factor Grhl3/Get1 suppresses miR-21 expression and tumorigenesis in skin: modulation of the miR-21 target MSH2 by RNA-binding protein DND1	ONCOGENE			English	Article						mir-21; Grhl3; Dnd1; skin; tumorigenesis; MSH2	IN-VIVO; MESENCHYMAL TRANSITION; MICRORNA EXPRESSION; REPRESSORS ZEB1; CELL-MIGRATION; CANCER-CELLS; FAMILY; DIFFERENTIATION; MORPHOGENESIS; KERATINOCYTES	Epidermal differentiation and stratification, crucial for barrier formation, are regulated by a complex interplay of transcription factors, including the evolutionarily conserved Grainyhead-like 3 (Grhl3/Get1); Grhl3-deleted mice exhibit impaired epidermal differentiation and decreased expression of multiple differentiation genes. To test whether Grhl3 regulates epidermal genes indirectly by controlling the expression of specific microRNAs (miRs), we performed miR profiling and identified 11 miRs that are differentially regulated in Grhl3(-/-) skin, one of which is miR-21, previously shown to be upregulated in diseased skin, including in psoriasis and squamous cell skin cancer. We found that miR-21 is normally expressed in the post-mitotic suprabasal layers of the epidermis, overlapping with Grhl3. The miR-21 promoter is bound and repressed by Grhl3 indicating that these two factors are involved in a regulatory loop maintaining homeostasis in the epidermis. Although miR-21 overexpression in normal keratinocytes had mild effects on the expression of several known miR-21 targets, an enhanced downregulation of the miR-21 tumor-related targets, including MSH2, was observed in Ras-transformed keratinocytes. The increased sensitivity of transformed keratinocytes to miR-21's effects occurs in part through downregulation of the RNA-binding protein DND1 during the transformation process. Additionally, we observed increased tumorigenesis in mice subcutaneously injected with transformed keratinocytes lacking Grhl3. These findings indicate that decreased Grhl3 expression contributes to tumor progression and upregulation of the oncomir miR-21 in squamous cell carcinoma of the skin. Oncogene (2013) 32, 1497-1507; doi:10.1038/onc.2012.168; published online 21 May 2012	[Bhandari, A.; Gordon, W.; Dizon, D.; Hopkin, A. S.; Yu, Z.; Andersen, B.] Univ Calif Irvine, Dept Biol Chem, Dept Med, Irvine, CA 92697 USA; [Gordon, W.; Andersen, B.] Univ Calif Irvine, Ctr Complex Biol Syst, Irvine, CA 92697 USA; [Gordon, E.] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; [Gordon, E.] Univ Calif Irvine, Inst Genom & Bioinformat, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Andersen, B (corresponding author), Univ Calif Irvine, Dept Biol Chem, Dept Med, Sprague Hall,Room 206, Irvine, CA 92697 USA.	bogi@uci.edu	Hopkin, Amelia Soto/AAT-2609-2021; Dizon, Don Steven/I-3634-2019	Dizon, Don Steven/0000-0001-6541-9580; Yu, Zhengquan/0000-0001-8696-2013	NIH [AR44882, T32-HD60555]; Irving Weinstein Foundation; California Tobacco Related Disease Research Program [17DT-0192]; National Library of Medicine [LM07443]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD060555] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA062203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044882] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007443] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Irving Weinstein Foundation; California Tobacco Related Disease Research Program(University of California System); National Library of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank Stuart Yuspa and Andrew Ryscavage for the gift of mouse papilloma and carcinoma sample and the Ras virus. We also thank Reuven Agami for HA-DND1 expression plasmid. This work was supported by grants from the NIH (AR44882) and the Irving Weinstein Foundation (to BA); the California Tobacco Related Disease Research Program (17DT-0192 to AB); the NIH training program in Systems Biology of Development (T32-HD60555 to WG); the National Library of Medicine training grant (LM07443 to EG).	Ahmed MI, 2011, J CELL SCI, V124, P3399, DOI 10.1242/jcs.086710; Andl T, 2006, CURR BIOL, V16, P1041, DOI 10.1016/j.cub.2006.04.005; Antonini D, 2010, J INVEST DERMATOL, V130, P1249, DOI 10.1038/jid.2009.438; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Christoffersen NR, 2007, RNA, V13, P1172, DOI 10.1261/rna.586807; Cottonham CL, 2010, J BIOL CHEM, V285, P35293, DOI 10.1074/jbc.M110.160069; Darido C, 2011, CANCER CELL, V20, P635, DOI 10.1016/j.ccr.2011.10.014; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dziunycz P, 2010, J INVEST DERMATOL, V130, P2686, DOI 10.1038/jid.2010.169; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Hildebrand J, 2011, J INVEST DERMATOL, V131, P20, DOI 10.1038/jid.2010.268; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Jiang RC, 2009, NEOPLASIA, V11, P964, DOI 10.1593/neo.09706; Joyce CE, 2011, HUM MOL GENET, V20, P4025, DOI 10.1093/hmg/ddr331; Kedde M, 2007, CELL, V131, P1273, DOI 10.1016/j.cell.2007.11.034; Kira M, 2002, J BIOL CHEM, V277, P12931, DOI 10.1074/jbc.M110795200; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Koster MI, 2007, ANNU REV CELL DEV BI, V23, P93, DOI 10.1146/annurev.cellbio.23.090506.123357; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Lin KK, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000573; Ma XD, 2011, P NATL ACAD SCI USA, V108, P10144, DOI 10.1073/pnas.1103735108; Meira LB, 2002, DNA REPAIR, V1, P929, DOI 10.1016/S1568-7864(02)00143-X; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Rabinovich A, 2008, GENOME RES, V18, P1763, DOI 10.1101/gr.080622.108; Reitmair AH, 1996, CANCER RES, V56, P3842; Ribas J, 2010, CELL CYCLE, V9, P923, DOI 10.4161/cc.9.5.10930; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pW249, DOI 10.1093/nar/gkh372; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918; SHEIBANI N, 1991, CANCER RES, V51, P5967; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Sonkoly E, 2010, J INVEST DERMATOL, V130, P124, DOI 10.1038/jid.2009.294; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Ting SB, 2005, SCIENCE, V308, P411, DOI 10.1126/science.1107511; Ting Stephen B, 2005, Organogenesis, V2, P33; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang Y, 2009, J CELL MOL MED, V13, P12, DOI 10.1111/j.1582-4934.2008.00510.x; Yang X, 2011, INT J BIOL SCI, V7, P685, DOI 10.7150/ijbs.7.685; Yi R, 2006, NAT GENET, V38, P356, DOI 10.1038/ng1744; Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642; Yi R, 2009, P NATL ACAD SCI USA, V106, P498, DOI 10.1073/pnas.0810766105; Yu Y, 2010, MOL CANCER RES, V8, P1633, DOI 10.1158/1541-7786.MCR-10-0362; Yu ZQ, 2006, DEV BIOL, V299, P122, DOI 10.1016/j.ydbio.2006.07.015; Zhu R, 2011, BMC MOL BIOL, V12, DOI 10.1186/1471-2199-12-37; Zibert JR, 2010, J DERMATOL SCI, V58, P177, DOI 10.1016/j.jdermsci.2010.03.004	52	52	56	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1497	1507		10.1038/onc.2012.168	http://dx.doi.org/10.1038/onc.2012.168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22614019	Green Accepted			2022-12-17	WOS:000316456000003
J	Herroon, MK; Rajagurubandara, E; Rudy, DL; Chalasani, A; Hardaway, AL; Podgorski, I				Herroon, M. K.; Rajagurubandara, E.; Rudy, D. L.; Chalasani, A.; Hardaway, A. L.; Podgorski, I.			Macrophage cathepsin K promotes prostate tumor progression in bone	ONCOGENE			English	Article						cathepsin K; macrophages; osteoclasts; bone metastasis; prostate cancer; inflammation	MONOCYTE CHEMOATTRACTANT PROTEIN-1; RESISTANT ACID-PHOSPHATASE; CARCINOMA CELL-LINE; BREAST-CANCER; IN-VITRO; MATRIX-METALLOPROTEINASE; OSTEOCLAST; RESORPTION; EXPRESSION; INHIBITOR	Bone marrow macrophages (BMMs) share common progenitors with osteoclasts and are critical components of bone-tumor microenvironment; however, their function in prostate tumor growth in the skeleton has not been explored. BMMs are the major source of inflammatory factors and proteases, including cysteine protease cathepsin K (CTSK). In this study, utilizing mice deficient in CTSK, we demonstrate the critical involvement of this potent collagenase in tumor progression in bone. We present the evidence that tumor growth and progression in the bone are impaired in the absence of CTSK. Most importantly, we show for the first time that BMM-supplied CTSK may be involved in CCL2- and COX-2-driven pathways that contribute to tumor progression in bone. Together, our data unravel novel roles for CTSK in macrophage-regulated processes, and provide evidence for close interplay between inflammatory, osteolytic and tumor cell-driven events in the bone-tumor microenvironment. Oncogene (2013) 32, 1580-1593; doi:10.1038/onc.2012.166; published online 21 May 2012	[Herroon, M. K.; Rajagurubandara, E.; Rudy, D. L.; Chalasani, A.; Hardaway, A. L.; Podgorski, I.] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; [Podgorski, I.] Karmanos Canc Inst, Detroit, MI USA	Wayne State University; Barbara Ann Karmanos Cancer Institute	Podgorski, I (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield,Rm 6304, Detroit, MI 48201 USA.	ipodgors@med.wayne.edu			DOD [PC074031, PC030325]; Wayne State University;  [MICR: P30 CA 22453]; NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER	DOD(United States Department of Defense); Wayne State University; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully acknowledge Dr Lisa Coussens (UCSF, CA) for providing breeding pairs of immuno-deficient (FVB/N/N5, Rag-1 <SUP>/</SUP> , Cat K <SUP>/</SUP> (WT)) and (FVB/N/N5, Rag-1 <SUP>/</SUP> , Cat K<SUP>-/-</SUP> (CTSK KO)) mice, as well as immuno-competent (FVB/N/N5 Cat K<SUP>+/+</SUP> (WT)) and (FVB/N/N5 Cat K<SUP>-/-</SUP> (CTSK KO)) mice used in this study. We also thank Dr Bonnie Sloane for providing CTSB antibodies, Dr Kamiar Moin and the Microscopy, Imaging and Cytometry Resources Core for assistance with confocal and conventional light microscopy analyses, and Dr Karin list for critical review of this manuscript. Grant support was provided by DOD PC074031, DOD PC030325, Wayne State University start-up fund and MICR: P30 CA 22453.	Abedinpour P, 2011, PROSTATE, V71, P813, DOI 10.1002/pros.21297; Andresen C., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P148; Asagiri M, 2008, SCIENCE, V319, P624, DOI 10.1126/science.1150110; BALEY PA, 1995, J STEROID BIOCHEM, V52, P403, DOI 10.1016/0960-0760(95)00001-G; Bar-Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Boyce BF, 2009, CRIT REV EUKAR GENE, V19, P171, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.10; Bromme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661, 10.1517/13543780902832661 ]; Brubaker KD, 2003, J BONE MINER RES, V18, P222, DOI 10.1359/jbmr.2003.18.2.222; Buhling F, 2001, J PATHOL, V195, P375; Chao TY, 2010, CLIN CHIM ACTA, V411, P1553, DOI 10.1016/j.cca.2010.06.027; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Conti I, 2004, SEMIN CANCER BIOL, V14, P149, DOI 10.1016/j.semcancer.2003.10.009; Cook RJ, 2006, CLIN CANCER RES, V12, P3361, DOI 10.1158/1078-0432.CCR-06-0269; Cross AK, 1999, GLIA, V28, P183, DOI 10.1002/(SICI)1098-1136(199912)28:3<183::AID-GLIA2>3.0.CO;2-3; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Desmarais S, 2009, BIOL CHEM, V390, P941, DOI 10.1515/BC.2009.092; Galvez BG, 2005, J BIOL CHEM, V280, P1292, DOI 10.1074/jbc.M408673200; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Jensen AB, 2010, CLIN BREAST CANCER, V10, P452, DOI 10.3816/CBC.2010.n.059; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kawashima M, 2009, MOD RHEUMATOL, V19, P192, DOI 10.1007/s10165-008-0149-6; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Kiviranta R, 2005, BONE, V36, P159, DOI 10.1016/j.bone.2004.09.020; Kiviranta R, 2001, J BONE MINER RES, V16, P1444, DOI 10.1359/jbmr.2001.16.8.1444; Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015; Lean JM, 2000, BONE, V27, P29, DOI 10.1016/S8756-3282(00)00306-9; Lee RJ, 2010, CLIN GENITOURIN CANC, V8, P29, DOI 10.3816/CGC.2010.n.005; Lee RJ, 2011, BONE, V48, P88, DOI 10.1016/j.bone.2010.05.038; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386; Loberg RD, 2007, NEOPLASIA, V9, P556, DOI 10.1593/neo.07307; Lu Y, 2007, CANCER RES, V67, P3646, DOI 10.1158/0008-5472.CAN-06-1210; Lynch CC, 2011, BONE, V48, P44, DOI 10.1016/j.bone.2010.06.007; Mancini A, 2007, J CELL BIOCHEM, V101, P425, DOI 10.1002/jcb.21191; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marquis RW, 2001, J MED CHEM, V44, P1380, DOI 10.1021/jm000481x; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; McCabe NP, 2008, CLIN EXP METASTAS, V25, P581, DOI 10.1007/s10585-008-9175-1; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; Miyamoto K, 2009, BIOCHEM BIOPH RES CO, V383, P373, DOI 10.1016/j.bbrc.2009.04.020; Mizutani K, 2009, NEOPLASIA, V11, P1235, DOI 10.1593/neo.09988; MOIN K, 1992, BIOCHEM J, V285, P427, DOI 10.1042/bj2850427; Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298; Navone NM, 1997, CLIN CANCER RES, V3, P2493; New DC, 2003, ACTA BIOCH BIOPH SIN, V35, P779; Nonomura N, 2011, BJU INT, V107, P1918, DOI 10.1111/j.1464-410X.2010.09804.x; Palermo C, 2008, TRENDS PHARMACOL SCI, V29, P22, DOI 10.1016/j.tips.2007.10.011; Podgorski I, 2005, NEOPLASIA, V7, P207, DOI 10.1593/neo.04349; Podgorski I, 2009, FUTURE MED CHEM, V1, P21, DOI 10.4155/FMC.09.4; Podgorski I, 2009, AM J PATHOL, V175, P1255, DOI 10.2353/ajpath.2009.080906; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Porta C, 2007, ADV EXP MED BIOL, V604, P67, DOI 10.1007/978-0-387-69116-9_5; Punturieri A, 2000, J EXP MED, V192, P789, DOI 10.1084/jem.192.6.789; Qian BZ, 2011, NATURE; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Roato I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003627; Robichaud J, 2008, J MED CHEM, V51, P6410, DOI 10.1021/jm800610j; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Saftig P, 2000, ADV EXP MED BIOL, V477, P293; Saylor PJ, 2011, J CLIN ONCOL, V29, P3705, DOI 10.1200/JCO.2010.34.4994; SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0; Shiirevnyamba A, 2011, BRIT J CANCER, V104, P505, DOI 10.1038/sj.bjc.6606070; Singh B, 2007, ONCOGENE, V26, P3789, DOI 10.1038/sj.onc.1210154; Smith MR, 2008, UROL ONCOL-SEMIN ORI, V26, P420, DOI 10.1016/j.urolonc.2007.11.004; Smith MR, 2007, UROLOGY, V70, P315, DOI 10.1016/j.urology.2007.03.071; Smith MR, 2006, J CLIN ONCOL, V24, P2723, DOI 10.1200/JCO.2005.03.7804; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Tanaka S, 2006, GUT, V55, P54, DOI 10.1136/gut.2004.059824; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Valsecchi ME, 2009, CLIN BREAST CANCER, V9, P225, DOI 10.3816/CBC.2009.n.038; Weischenfeldt J, 2008, CSH PROTOC, V2008, DOI DOI 10.1101/PDB.PROT5080; Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200; Wilson TJ, 2008, BBA-REV CANCER, V1785, P85, DOI 10.1016/j.bbcan.2007.11.001; Wolf M, 2008, INT J BIOCHEM CELL B, V40, P1185, DOI 10.1016/j.biocel.2007.12.009; Yoon DS, 2010, STEM CELLS DEV, V19, P1523, DOI 10.1089/scd.2009.0393; Zenger S, 2007, BONE, V41, P820, DOI 10.1016/j.bone.2007.07.010; Zhang J, 2010, CYTOKINE GROWTH F R, V21, P41, DOI 10.1016/j.cytogfr.2009.11.009; Zhau HE, 2008, CLIN EXP METASTAS, V25, P601, DOI 10.1007/s10585-008-9183-1	83	52	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1580	1593		10.1038/onc.2012.166	http://dx.doi.org/10.1038/onc.2012.166			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22614014	Green Accepted			2022-12-17	WOS:000316456000011
J	Mackintosh, C; Garcia-Dominguez, DJ; Ordonez, JL; Ginel-Picardo, A; Smith, PG; Sacristan, MP; de Alava, E				Mackintosh, C.; Garcia-Dominguez, D. J.; Ordonez, J. L.; Ginel-Picardo, A.; Smith, P. G.; Sacristan, M. P.; de Alava, E.			WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells	ONCOGENE			English	Article						MLN4924; Ewing sarcoma; WEE1; cyclin A; cyclin E; P27	NEDD8-ACTIVATING ENZYME-INHIBITOR; UBIQUITIN LIGASE; BETA-TRCP; CANCER-CELLS; DEGRADATION; PHOSPHORYLATION; P27(KIP1); KINASES; P27; COMPLEX	Ewing sarcoma (ES) is an aggressive bone and soft tissue tumor of children and young adults in which finding effective new targeted therapies is imperative. Here, we report an in-depth preclinical study of the investigational cullin-RING ubiquitin ligase (CRL) inhibitor MLN4924 in ES, as we have recently demonstrated the implication of a CRL component in the ES pathogenesis. First, our results support a high sensitivity of ES cells to MLN4924 growth inhibition both in vitro (14 ES cell lines tested, median IC50 = 81 nM) and in tumor xenografts (tumor regression achieved with 60 mg/kg BID, subcutaneously, n = 9). Second, we report a dual mechanism of action of MLN4924 in ES cells: while a wide range of MLN4924 concentrations (similar to 30-300 nM) trigger a G2 arrest that can only be rescued by WEE1 kinase inhibition or depletion, saturating doses of the drug (>300 nM) cause a delay in S-phase progression concomitant with unbalanced CDK2-Cyclin E and CDK2-Cyclin A relative levels (accumulation of the first and depletion of the latter). The aberrant presence of CDC6 in the nucleus at late S-phase cell cycle stage confirmed the loss of CDK2-Cyclin A-specific functions. Remarkably, other mechanisms explored (P27 accumulation and DNA damage signaling pathways) were found unable to explain MLN4924 effects, strengthening the specificity of our findings and suggesting the absence of functionality of some CRL substrates accumulated in response to MLN4924. This study renders a rationale for clinical trials and contributes molecular mechanisms for a better understanding of this promising antitumoral agent. Oncogene (2013) 32, 1441-1451; doi:10.1038/onc.2012.153; published online 28 May 2012	[Mackintosh, C.; Garcia-Dominguez, D. J.; Ordonez, J. L.; de Alava, E.] IBSAL Ctr Invest Canc IBMCC USAL CSIC, Mol Pathol Program, Salamanca 37007, Spain; [Ginel-Picardo, A.] Ctr Invest Canc IBMCC USAL CSIC, Lab 1, Salamanca, Spain; [Smith, P. G.] Millennium Pharmaceut Inc, Discovery, Cambridge, MA USA; [Sacristan, M. P.] Ctr Invest Canc IBMCC USAL CSIC, Dept Mol & Genet, Salamanca 37007, Spain; [de Alava, E.] IBSAL Univ Hosp Salamanca, Dept Pathol, Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC)	Mackintosh, C (corresponding author), IBSAL Ctr Invest Canc IBMCC USAL CSIC, Mol Pathol Program, Campus Miguel de Unamuno S-N, Salamanca 37007, Spain.	cmackintosh@usal.es; edealava@usal.es	Sacristan, Maria/Y-4923-2019; Garcia, Daniel Jose/B-5366-2016; de Alava, Enrique/GOH-0368-2022; Garcia, Daniel Jose/X-6857-2019; Sacristán, María P/A-9587-2016; IBIS, SARCOMAS/O-1893-2015; Ordóñez, José Luis/B-6069-2017	Sacristan, Maria/0000-0003-2314-8430; Garcia, Daniel Jose/0000-0001-8150-2747; de Alava, Enrique/0000-0001-8400-046X; Sacristán, María P/0000-0003-2314-8430; Ordóñez, José Luis/0000-0002-3791-4215; Mackintosh, Carlos/0000-0002-6786-9558	Maria Garcia Estrada Foundation; Ministry of Economy and Competitiveness of Spain-FEDER [PI081828, RD06/0020/0059, PI1100018]; Ministry of Economy and Competitiveness of Spain-FEDER (ISCIII_postdoc grant) [CD06/00001]; European Commission [278742 EUROSARC]	Maria Garcia Estrada Foundation; Ministry of Economy and Competitiveness of Spain-FEDER; Ministry of Economy and Competitiveness of Spain-FEDER (ISCIII_postdoc grant); European Commission(European CommissionEuropean Commission Joint Research Centre)	We thank Cristina Teodosio and Martin Perez de Andres for their kind help in flow cytometry studies. Daniel J Garcia-Dominguez is supported by a grant from the Maria Garcia Estrada Foundation. Research in Enrique de Alava's lab is also supported by the Ministry of Economy and Competitiveness of Spain-FEDER (PI081828, RD06/0020/0059, PI1100018, ISCIII_postdoc grant CD06/00001) and the European Commission (FP7-HEALTH-2011-two-stage, Project ID 278742 EUROSARC).	Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bennett EJ, 2010, CELL, V143, P951, DOI 10.1016/j.cell.2010.11.017; Bernstein M, 2006, ONCOLOGIST, V11, P503, DOI 10.1634/theoncologist.11-5-503; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Duda DM, 2008, CELL, V134, P995, DOI 10.1016/j.cell.2008.07.022; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Haeusler J, 2010, CANCER-AM CANCER SOC, V116, P443, DOI 10.1002/cncr.24740; Jia LJ, 2011, NEOPLASIA, V13, P561, DOI 10.1593/neo.11420; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025; Liao H, 2011, MOL CELL PROTEOMICS, DOI [10.1074/mcp.M111.009183, DOI 10.1074/mcp.M111.009183]; Lin JJ, 2010, CANCER RES, V70, P10310, DOI 10.1158/0008-5472.CAN-10-2062; Mackintosh C, 2012, ONCOGENE, V31, P1287, DOI 10.1038/onc.2011.317; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Milhollen MA, 2011, CANCER RES, V71, P3042, DOI 10.1158/0008-5472.CAN-10-2122; Milhollen MA, 2010, BLOOD, V116, P1515, DOI 10.1182/blood-2010-03-272567; Mir SE, 2010, CANCER CELL, V18, P244, DOI 10.1016/j.ccr.2010.08.011; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nishitani H, 2006, EMBO J, V25, P1126, DOI 10.1038/sj.emboj.7601002; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Paolinelli R, 2009, NAT STRUCT MOL BIOL, V16, P412, DOI 10.1038/nsmb.1583; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Smith MA, 2012, PEDIATR BLOOD CANCER, V59, P246, DOI 10.1002/pbc.23357; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Susaki E, 2007, CELL CYCLE, V6, P3015, DOI 10.4161/cc.6.24.5087; Swords RT, 2010, BLOOD, V115, P3796, DOI 10.1182/blood-2009-11-254862; Syljuasen RG, 2006, CANCER RES, V66, P10253, DOI 10.1158/0008-5472.CAN-06-2144; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Wei DP, 2012, CANCER RES, V72, P282, DOI 10.1158/0008-5472.CAN-11-2866; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	40	52	53	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2013	32	11					1441	1451		10.1038/onc.2012.153	http://dx.doi.org/10.1038/onc.2012.153			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22641220				2022-12-17	WOS:000316455600010
J	Cortes-Sempere, M; de Miguel, MP; Pernia, O; Rodriguez, C; Carpeno, JD; Nistal, M; Conde, E; Lopez-Rios, F; Belda-Iniesta, C; Perona, R; Ibanez de Caceres, I				Cortes-Sempere, M.; de Miguel, M. P.; Pernia, O.; Rodriguez, C.; de Castro Carpeno, J.; Nistal, M.; Conde, E.; Lopez-Rios, F.; Belda-Iniesta, C.; Perona, R.; Ibanez de Caceres, I.			IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer	ONCOGENE			English	Article						NSCLC; cisplatin resistance; IGFIR; IGFBP-3; hypermethylation	GROWTH-FACTOR RECEPTOR; INDUCED DNA HYPERMETHYLATION; OXIDATIVE STRESS; DRUG-RESISTANCE; TUMOR-GROWTH; GENE; CHEMOTHERAPY; EXPRESSION; GEFITINIB; MUTATION	Although many cancers initially respond to cisplatin (CDDP)-based chemotherapy, resistance frequently develops. Insulin-like growth factor-binding protein-3 (IGFBP-3) silencing by promoter methylation is involved in the CDDP-acquired resistance process in non-small cell lung cancer (NSCLC) patients. Our purpose is to design a translational-based profile to predict resistance in NSCLC by studying the role of IGFBP-3 in the phosphatidyl inositol 3-kinase (PI3K) signaling pathway. We have first examined the relationship between IGFBP-3 expression regulated by promoter methylation and activation of the epidermal growth factor receptor (EGFR), insulin-like growth factor-I receptor (IGFIR) and PI3K/AKT pathways in 10 human cancer cell lines and 25 NSCLC patients with known IGFBP-3 methylation status and response to CDDP. Then, to provide a helpful tool that enables clinicians to identify patients with a potential response to CDDP, we have calculated the association between our diagnostic test and the true outcome of analyzed samples in terms of cisplatin IC50; the inhibitory concentration that kills 50% of the cell population. Our results suggest that loss of IGFBP-3 expression by promoter methylation in tumor cells treated with CDDP may activate the PI3K/AKT pathway through the specific derepression of IGFIR signaling, inducing resistance to CDDP. This study also provides a predictive test for clinical practice with an accuracy and precision of 0.84 and 0.9, respectively, (P = 0.0062). We present a biomarker test that could provide clinicians with a robust tool with which to decide on the use of CDDP, improving patient clinical outcomes.	[Cortes-Sempere, M.; Perona, R.] CSIC UAM, CIBER Enfermedades Raras CIBERER, Inst Invest Biomed, Madrid 28029, Spain; [Cortes-Sempere, M.; Pernia, O.; Rodriguez, C.; de Castro Carpeno, J.; Belda-Iniesta, C.; Perona, R.; Ibanez de Caceres, I.] Biomarkers & Expt Therapeut Canc IdiPAZ, Madrid, Spain; [de Miguel, M. P.] La Paz Univ Hosp, IdiPAZ, Lab Cellular Engn, Madrid, Spain; [Pernia, O.; Rodriguez, C.; Ibanez de Caceres, I.] La Paz Univ Hosp, INGEMM, Canc Epigenet Lab, Madrid, Spain; [Nistal, M.] La Paz Univ Hosp, Dept Pathol, Madrid, Spain; [Conde, E.] Madrid Norte Sanchinarro Univ Hosp, Dept Pathol, Madrid, Spain; [Belda-Iniesta, C.] Madrid Norte Sanchinarro Univ Hosp, Dept Med Oncol, Madrid, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Universitario La Paz; Hospital Universitario La Paz; Hospital Universitario La Paz	Perona, R (corresponding author), CSIC UAM, CIBER Enfermedades Raras CIBERER, Biomarkers & Expt Therapeut Canc IdiPAZ, Inst Invest Biomed, C Arturo Duperier 4, Madrid 28029, Spain.	rperona@iib.uam.es; inma.ibanezca@salud.madrid.org	Rodriguez-Antolin, Carlos/ABD-9119-2020	Rodriguez-Antolin, Carlos/0000-0001-6682-0771; Belda Iniesta, Cristobal/0000-0003-3254-7492	'Miguel Servet' program [CP08/000689, PI-717]; MINECO [SAF2010-19230]; FIS [PS09/00472, PI08-1485, FIS 11-00949]; Miguel Servet [PI-717, CP 08/000689];  [PI08/1485];  [PI11/00949]	'Miguel Servet' program; MINECO(Spanish Government); FIS(Instituto de Salud Carlos III); Miguel Servet; ; 	We thank J Siegfried for the English correction, F Dominguez for her technical help, the Health Investigation Funding to IIC through the 'Miguel Servet' program (CP08/000689; PI-717) and acknowledge the support of PI08/1485 and PS09/00472 and PI11/00949 projects. We thank MINECO for its support through SAF2010-19230 Grant. This work was supported by FIS PI08-1485, FIS 11-00949, PS09/00472 and Miguel Servet financial support to Ibanez de Caceres, I (CP 08/000689; PI-717).	Aleksic T, 2010, CANCER RES, V70, P6412, DOI 10.1158/0008-5472.CAN-10-0052; Attia SM, 2012, MUTAT RES-GEN TOX EN, V741, P22, DOI 10.1016/j.mrgentox.2011.10.008; Bai T, 2006, INT J ONCOL, V28, P497; Campos ACE, 2007, NEOPLASIA, V9, P1111, DOI 10.1593/neo.07712; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chakravarti A, 2002, CANCER RES, V62, P200; Chang XF, 2010, CANCER RES, V70, P2870, DOI 10.1158/0008-5472.CAN-09-3427; Chang YS, 2002, CLIN CANCER RES, V8, P3796; Chattopadhyay S, 2006, ONCOGENE, V25, P3335, DOI 10.1038/sj.onc.1209364; Chen HB, 2006, CANCER RES, V66, P9009, DOI 10.1158/0008-5472.CAN-06-0101; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Ferroni P, 2011, REJUV RES, V14, P293, DOI 10.1089/rej.2010.1141; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Hamano R, 2011, CLIN CANCER RES, V17, P3029, DOI 10.1158/1078-0432.CCR-10-2532; Ibanez de Caceres I, 2010, ONCOGENE, V29, P1681, DOI 10.1038/onc.2009.454; Ibanez de Caceres I, 2006, CANCER RES, V66, P5021, DOI 10.1158/0008-5472.CAN-05-3365; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; James SR, 2006, ONCOGENE, V25, P6975, DOI 10.1038/sj.onc.1209678; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Judde JG, 2007, INT J CANCER, V120, P1579, DOI 10.1002/ijc.22364; Khan R, 2012, TOXICOL APPL PHARM, V258, P315, DOI 10.1016/j.taap.2011.11.013; Koul S, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-16; Lawless MW, 2009, J CELL MOL MED, V13, P826, DOI 10.1111/j.1582-4934.2008.00571.x; Lawless MW, 2010, EXPERT OPIN THER TAR, V14, P1225, DOI 10.1517/14728222.2010.526933; Malinen M, 2011, NUCLEIC ACIDS RES, V39, P502, DOI 10.1093/nar/gkq820; Morgillo F, 2007, CLIN CANCER RES, V13, P2795, DOI 10.1158/1078-0432.CCR-06-2077; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Niu X, 2012, ONCOGENE, V31, P776, DOI 10.1038/onc.2011.266; NYCE J, 1989, CANCER RES, V49, P5829; Nyce JW, 1997, MUTAT RES-REV MUTAT, V386, P153, DOI 10.1016/S1383-5742(96)00051-8; Oliveras-Ferraros C, 2008, INT J ONCOL, V33, P1165, DOI 10.3892/ijo_00000106; Qiu YY, 2005, CANCER DETECT PREV, V29, P456, DOI 10.1016/j.cdp.2005.05.004; Romanelli RJ, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M704309200; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Sonnweber B, 2006, J CLIN PATHOL, V59, P255, DOI 10.1136/jcp.2005.027615; Takeda K, 2010, J CLIN ONCOL, V28, P753, DOI 10.1200/JCO.2009.23.3445; Tsai CM, 2011, J THORAC ONCOL, V6, P559, DOI 10.1097/JTO.0b013e3182021ff5; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Wiley A, 2006, INT J GYNECOL CANCER, V16, P210, DOI 10.1111/j.1525-1438.2006.00299.x; Yokomizo A, 1998, ONCOGENE, V17, P475, DOI 10.1038/sj.onc.1201956; Zeller C, 2012, ONCOGENE; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	47	52	55	0	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1274	1283		10.1038/onc.2012.146	http://dx.doi.org/10.1038/onc.2012.146			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22543588				2022-12-17	WOS:000316454500008
J	Mahata, B; Sundqvist, A; Xirodimas, DP				Mahata, B.; Sundqvist, A.; Xirodimas, D. P.			Recruitment of RPL11 at promoter sites of p53-regulated genes upon nucleolar stress through NEDD8 and in an Mdm2-dependent manner	ONCOGENE			English	Article						RPL11; nucleolar stress; NEDD8; Mdm2; p53	RIBOSOMAL-PROTEIN L11; P53 ACTIVATION; DNA-DAMAGE; ACTINOMYCIN-D; IN-VIVO; C-MYC; ACETYLATION; TRANSCRIPTION; UBIQUITIN; RNA	Ribosomal proteins (RPs) activate the p53 tumour-suppressor protein upon disruption of the nucleolus. However, the exact mechanisms for p53 transcriptional activation through RPs are not well understood. We show that the RPL11 is rapidly but transiently recruited at promoter sites of p53-regulated genes upon nucleolar stress induced by actinomycin D (ActD). Characterisation of molecular events at p53 promoter sites shows that L11 is required for the recruitment of p53 transcriptional co-activators p300/CBP and p53 K382 acetylation. We found that direct binding to Mdm2 E3 ligase and NEDDylation of L11 are critical regulators for L11 promoter recruitment. Our data suggest that binding of L11 to Mdm2 at the promoter results in relief from Mdm2-mediated transcriptional repression of p53. Analysis of chromatin and RNA polymerase II markers suggests that L11 is involved in the initiation step of transcriptional activation. Furthermore, analysis of 36 ActD-induced genes shows that L11 and NEDD8 are global regulators of the p53 activation response. The studies provide insights on how nucleolar stress through L11 and NEDD8 can activate the transcriptional activity of p53. Oncogene (2012) 31, 3060-3071; doi: 10.1038/onc.2011.482; published online 14 November 2011	[Xirodimas, D. P.] CNRS, Ctr Rech Biochim Macromol, UMR 5237, F-34293 Montpellier 5, France; [Mahata, B.; Sundqvist, A.; Xirodimas, D. P.] Univ Dundee, Coll Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Dundee, Scotland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; University of Dundee	Xirodimas, DP (corresponding author), CNRS, Ctr Rech Biochim Macromol, UMR 5237, F-34293 Montpellier 5, France.	dimitris.xirodimas@crbm.cnrs.fr		Mahata, Bidesh/0000-0002-4506-0184; Xirodimas, Dimitris/0000-0001-9275-1140	Association for International Cancer Research (AICR); INSERM	Association for International Cancer Research (AICR); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	Our research in the DPX laboratory is supported by the Association for International Cancer Research (AICR) and INSERM. DPX is an AICR Research Fellow.	Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Choong ML, 2009, CELL CYCLE, V8, P2810, DOI 10.4161/cc.8.17.9503; Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776; Dai MS, 2010, J BIOL CHEM, V285, P12587, DOI 10.1074/jbc.M109.056259; Dikic I, 2009, NAT REV MOL CELL BIO, V10, P659, DOI 10.1038/nrm2767; Donati G, 2011, ONCOGENE, V30, P3274, DOI 10.1038/onc.2011.48; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Espinosa JM, 2008, ONCOGENE, V27, P4013, DOI 10.1038/onc.2008.37; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fuchs SM, 2009, BBA-GENE REGUL MECH, V1789, P26, DOI 10.1016/j.bbagrm.2008.07.008; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Horn HF, 2008, ONCOGENE, V27, P5774, DOI 10.1038/onc.2008.189; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lennartsson A, 2009, BBA-GEN SUBJECTS, V1790, P863, DOI 10.1016/j.bbagen.2008.12.006; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Lindstrom MS, 2009, BIOCHEM BIOPH RES CO, V379, P167, DOI 10.1016/j.bbrc.2008.12.083; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Perry RP, 2007, GENE, V401, P1, DOI 10.1016/j.gene.2007.07.007; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Phatnani HP, 2006, GENE DEV, V20, P2922, DOI 10.1101/gad.1477006; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Rabut G, 2008, EMBO REP, V9, P969, DOI 10.1038/embor.2008.183; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Sun XX, 2010, J BIOL CHEM, V285, P25812, DOI 10.1074/jbc.M109.098442; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wang M, 2011, EXPERT OPIN THER TAR, V15, P253, DOI 10.1517/14728222.2011.550877; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Watson IR, 2011, CANCER CELL, V19, P168, DOI 10.1016/j.ccr.2011.01.002; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Xirodimas DP, 2008, BIOCHEM SOC T, V36, P802, DOI 10.1042/BST0360802; Xirodimas DP, 2008, EMBO REP, V9, P280, DOI 10.1038/embor.2008.10; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024	48	52	55	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	25					3060	3071		10.1038/onc.2011.482	http://dx.doi.org/10.1038/onc.2011.482			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22081073				2022-12-17	WOS:000305705900005
J	Walia, V; Yu, Y; Cao, D; Sun, M; McLean, JR; Hollier, BG; Cheng, J; Mani, SA; Rao, K; Premkumar, L; Elble, RC				Walia, V.; Yu, Y.; Cao, D.; Sun, M.; McLean, J. R.; Hollier, B. G.; Cheng, J.; Mani, S. A.; Rao, K.; Premkumar, L.; Elble, R. C.			Loss of breast epithelial marker hCLCA2 promotes epithelial-to-mesenchymal transition and indicates higher risk of metastasis	ONCOGENE			English	Article						hCLCA2; epithelial-to-mesenchymal transition; differentiation; breast; metastasis; chloride	TUMOR PROGRESSION; CANCER CELLS; E-CADHERIN; IN-VITRO; ION CHANNELS; CLAUDIN-LOW; EXPRESSION; GENE; PH; TRANSFORMATION	Transition between epithelial and mesenchymal states is a feature of both normal development and tumor progression. We report that expression of chloride channel accessory protein hCLCA2 is a characteristic of epithelial differentiation in the immortalized MCF10A and HMLE models, while induction of epithelial-to-mesenchymal transition by cell dilution, TGF beta or mesenchymal transcription factors sharply reduces hCLCA2 levels. Attenuation of hCLCA2 expression by lentiviral small hairpin RNA caused cell overgrowth and focus formation, enhanced migration and invasion, and increased mammosphere formation in methylcellulose. These changes were accompanied by downregulation of E-cadherin and upregulation of mesenchymal markers such as vimentin and fibronectin. Moreover, hCLCA2 expression is greatly downregulated in breast cancer cells with a mesenchymal or claudin-low profile. These observations suggest that loss of hCLCA2 may promote metastasis. We find that higher-than-median expression of hCLCA2 is associated with a one-third lower rate of metastasis over an 18-year period among breast cancer patients compared with lower-than- median (n = 344, unfiltered for subtype). Thus, hCLCA2 is required for epithelial differentiation, and its loss during tumor progression contributes to metastasis. Overexpression of hCLCA2 has been reported to inhibit cell proliferation and is accompanied by increases in chloride current at the plasma membrane and reduced intracellular pH (pHi). We found that knockdown cells have sharply reduced chloride current and higher pHi, both characteristics of tumor cells. These results suggest a mechanism for the effects on differentiation. Loss of hCLCA2 may allow escape from pHi homeostatic mechanisms, permitting the higher intracellular and lower extracellular pH that are characteristic of aggressive tumor cells. Oncogene (2012) 31, 2237-2246; doi:10.1038/onc.2011.392; published online 12 September 2011	[Walia, V.; Cao, D.; Premkumar, L.; Elble, R. C.] So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62794 USA; [Walia, V.; Yu, Y.; Cheng, J.; Rao, K.; Elble, R. C.] So Illinois Univ, Sch Med, Simmons Canc Inst, Springfield, IL 62794 USA; [Sun, M.] Univ Chicago, Comm Genet Genom & Syst Biol GGSB, Chicago, IL 60637 USA; [McLean, J. R.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA; [Hollier, B. G.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia; [Mani, S. A.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; University of Chicago; Vanderbilt University; Queensland University of Technology (QUT); University of Texas System; UTMD Anderson Cancer Center	Elble, RC (corresponding author), So Illinois Univ, Sch Med, Dept Pharmacol, POB 19629, Springfield, IL 62794 USA.	relble2@siumed.edu	Mani, Sendurai A./A-7244-2009; Cao, Deshou/G-8697-2014	Mani, Sendurai A./0000-0002-5918-4276; 	NIH [1R15CA151094-01, DK065742, DA028017]; Excellence in Academic Medicine [56252, 56253]; NATIONAL CANCER INSTITUTE [R15CA151094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065742, R56DK065742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA028017] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Excellence in Academic Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by the following grants: NIH grant 1R15CA151094-01 and Excellence in Academic Medicine grants 56252 and 56253 to RCE; and NIH grants DK065742 and DA028017 to LP.	Agiostratidou G, 2009, CANCER RES, V69, P5030, DOI 10.1158/0008-5472.CAN-08-4007; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Barriere H, 2001, AM J PHYSIOL-CELL PH, V281, pC810, DOI 10.1152/ajpcell.2001.281.3.C810; BARRY MA, 1992, BIOCHEM BIOPH RES CO, V186, P782, DOI 10.1016/0006-291X(92)90814-2; Beckley JR, 2004, J BIOL CHEM, V279, P41634, DOI 10.1074/jbc.M408334200; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Cheng JM, 2006, INT J CANCER, V118, P2957, DOI 10.1002/ijc.21739; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; D'Assoro AB, 2010, INT J ONCOL, V37, P1167, DOI 10.3892/ijo_00000768; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Elble RC, 2006, J BIOL CHEM, V281, P29448, DOI 10.1074/jbc.M605919200; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Enerback C, 2002, CANCER RES, V62, P43; Furlong IJ, 1997, J CELL SCI, V110, P653; Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Grigoriadis A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1604; Gruber AD, 1999, CANCER RES, V59, P5488; Hajra KM, 2002, CANCER RES, V62, P1613; Hamann M, 2009, J PHYSIOL-LONDON, V587, P2255, DOI 10.1113/jphysiol.2009.170159; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; Hsu YM, 2007, CANCER RES, V67, P11064, DOI 10.1158/0008-5472.CAN-07-2443; Jiang Z, 2010, J CLIN INVEST, V120, P3296, DOI 10.1172/JCI41490; Kogan-Sakin I, 2011, CELL DEATH DIFFER, V18, P271, DOI 10.1038/cdd.2010.94; Kunzelmann K, 2005, J MEMBRANE BIOL, V205, P159, DOI 10.1007/s00232-005-0781-4; Li XR, 2004, ONCOGENE, V23, P1474, DOI 10.1038/sj.onc.1207249; Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008-5472.CAN-06-4493; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Malo ME, 2007, J BIOL CHEM, V282, P6292, DOI 10.1074/jbc.M611073200; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marshall A, 2009, CELL TISSUE RES, V335, P383, DOI 10.1007/s00441-008-0719-0; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rao K, 2003, CANCER LETT, V201, P79, DOI 10.1016/S0304-3835(03)00423-3; Rao K, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-15; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008-5472.CAN-10-2855; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sontheimer H, 2008, EXP BIOL MED, V233, P779, DOI 10.3181/0711-MR-308; Tanaka H, 2006, INT J CANCER, V118, P1680, DOI 10.1002/ijc.21559; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Walia V, 2010, STEM CELLS DEV, V19, P1175, DOI 10.1089/scd.2009.0430; Walia V, 2009, CANCER RES, V69, P6624, DOI 10.1158/0008-5472.CAN-08-4101; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1	57	52	52	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	17					2237	2246		10.1038/onc.2011.392	http://dx.doi.org/10.1038/onc.2011.392			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21909135	Green Accepted			2022-12-17	WOS:000303415900011
J	Jiang, J; Liu, W; Guo, X; Zhang, R; Zhi, Q; Ji, J; Zhang, J; Chen, X; Li, J; Zhang, J; Gu, Q; Liu, B; Zhu, Z; Yu, Y				Jiang, J.; Liu, W.; Guo, X.; Zhang, R.; Zhi, Q.; Ji, J.; Zhang, J.; Chen, X.; Li, J.; Zhang, J.; Gu, Q.; Liu, B.; Zhu, Z.; Yu, Y.			IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer	ONCOGENE			English	Article						gastric carcinoma; IRX1; angiogenesis; vasculogenic mimicry; BDKRB2	VASCULAR CHANNEL FORMATION; ENDOTHELIAL GROWTH-FACTOR; TUMOR-CELL PLASTICITY; VASCULOGENIC MIMICRY; IN-VIVO; DOWN-REGULATION; FACTOR RECEPTOR; MELANOMA-CELLS; BREAST-CANCER; ANGIOGENESIS	The overexpression of IRX1 gene correlates with the growth arrest in gastric cancer. Furthermore, overexpression of IRX1 gene suppresses peritoneal spreading and long distance metastasis. To explore the precise mechanisms, we investigated whether restoring IRX1 expression affects the angiogenesis or vasculogenic mimicry (VM). Human umbilical vein endothelial cells (HUVECs) and chick embryo and SGC-7901 gastric cancer cells were used for angiogenesis and VM analysis. Small interfering RNA was used for analyzing the function of BDKRB2, a downstream target gene of IRX1. As results, the remarkable suppression on peritoneal spreading and pulmonary metastasis of SGC-7901 cells by IRX1 transfectant correlates to reduced angiogenesis as well as VM formation. Using the supernatant from SGC-7901/ IRX1 cells, we found a strong inhibiting effect on angiogenesis both in vitro and in chick embryo. SGC-7901/IRX1 cells revealed strong inhibiting effect on VM formation too. By gene-specific RNA interference for BDKRB2, or its effector PAK1, we got an effective inhibition on tube formation, cell proliferation, cell migration and invasion in vitro. In conclusion, enforcing IRX1 expression effectively suppresses peritoneal spreading and pulmonary metastasis via anti-angiogenesis and anti-VM mechanisms, in addition to previously found cell growth and invasion. BDKRB2 and its downstream effector might be potential targets for anti-cancer strategy. Oncogene (2011) 30, 4498-4508; doi:10.1038/onc.2011.154; published online 23 May 2011	Shanghai Jiao Tong Univ, Sch Med, Dept Surg, Shanghai Ruijin Hosp, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Digest Surg, Shanghai Key Lab Diag & Treatment Gastr Canc, Shanghai 200025, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yu, Y (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Surg, Ruijin Er Rd 197, Shanghai 200025, Peoples R China.	surgeryzhu@yahoo.com.cn; yingyan3y@yahoo.com.cn	Liu, Bingya/GMW-5655-2022	Liu, Bingya/0000-0002-4406-3762	National Natural Science Foundation of China [30572127, 30770961, 30973486]; Chinese National High Tech Program [863-2006AA02A402, 2006AA02A301]; Shanghai Science and Technology Commission [09DZ1950101, 09JC1409600]; Shanghai Charity Foundation for Cancer Research	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese National High Tech Program(National High Technology Research and Development Program of China); Shanghai Science and Technology Commission(Shanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Charity Foundation for Cancer Research	This work was supported, in part, by grants from the National Natural Science Foundation of China (30572127, 30770961 and 30973486), the Chinese National High Tech Program (863-2006AA02A402 and 2006AA02A301), Key Research Project from Shanghai Science and Technology Commission (09DZ1950101 and 09JC1409600) and Shanghai Charity Foundation for Cancer Research.	Alarcon P, 2008, DEVELOPMENT, V135, P3197, DOI 10.1242/dev.023697; Altundag K, 2004, CANCER, V100, P1768, DOI 10.1002/cncr.20175; Andoh T, 2010, PEPTIDES, V31, P238, DOI 10.1016/j.peptides.2009.12.003; Basu GD, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1626; Becker MB, 2001, MECH DEVELOP, V106, P155, DOI 10.1016/S0925-4773(01)00412-9; Bennett KL, 2008, CANCER RES, V68, P4494, DOI 10.1158/0008-5472.CAN-07-6509; Bennett KL, 2009, CANCER RES, V69, P9301, DOI 10.1158/0008-5472.CAN-09-3073; Bessard A, 2008, ONCOGENE, V27, P5315, DOI 10.1038/onc.2008.163; Cai XZ, 2009, CANCER BIOL THER, V8, P1360, DOI 10.4161/cbt.8.14.8720; Calderon Adrian J, 2005, P R Health Sci J, V24, P27; Deryugina EI, 2008, METHOD ENZYMOL, V444, P21, DOI 10.1016/S0076-6879(08)02802-4; Deryugina EI, 2008, HISTOCHEM CELL BIOL, V130, P1119, DOI 10.1007/s00418-008-0536-2; Fryer BH, 2005, CANCER LETT, V229, P13, DOI 10.1016/j.canlet.2004.12.009; Fujimoto A, 2006, ANTICANCER RES, V26, P59; Moya EMG, 2009, CELL SIGNAL, V21, P1727, DOI 10.1016/j.cellsig.2009.08.006; Gartel AL, 2006, BIOMOL ENG, V23, P17, DOI 10.1016/j.bioeng.2006.01.002; Getmanova EV, 2006, CHEM BIOL, V13, P549, DOI 10.1016/j.chembiol.2005.12.009; Gu Wenyi, 2008, V442, P159, DOI 10.1007/978-1-59745-191-8_12; Guo X, 2010, ONCOGENE, V29, P3908, DOI 10.1038/onc.2010.143; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hao Xishan, 2002, Zhonghua Yi Xue Za Zhi, V82, P1298; Ikeda Y, 2004, CANCER RES, V64, P5178, DOI 10.1158/0008-5472.CAN-03-3589; Ishihara K, 2002, INT IMMUNOPHARMACOL, V2, P499, DOI 10.1016/S1567-5769(01)00193-X; Kramarenko II, 2010, MOL PHARMACOL, V78, P126, DOI 10.1124/mol.110.064840; Krankel N, 2008, CIRC RES, V103, P1335, DOI 10.1161/CIRCRESAHA.108.179952; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Li XD, 2010, EXPERT OPIN THER TAR, V14, P419, DOI 10.1517/14728221003642019; Liu FN, 2009, INT J CANCER, V125, P2511, DOI 10.1002/ijc.24588; Lorch JH, 2007, CANCER RES, V67, P727, DOI 10.1158/0008-5472.CAN-06-2162; Lu Y, 2005, CANCER LETT, V224, P329, DOI 10.1016/j.canlet.2004.11.057; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Masamune A, 2008, AM J PHYSIOL-GASTR L, V295, pG709, DOI 10.1152/ajpgi.90356.2008; Matsuda KM, 2000, CANCER GENE THER, V7, P589, DOI 10.1038/sj.cgt.7700147; Mirshahi P, 2009, LEUKEMIA, V23, P1039, DOI 10.1038/leu.2009.10; Nogueras S, 2008, AM J PHYSIOL-HEART C, V294, pH708, DOI 10.1152/ajpheart.00466.2007; Oleinikov AV, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni091; Sharma N, 2002, PROSTATE, V50, P189, DOI 10.1002/pros.10048; Shirakawa K, 2003, BREAST CANCER RES, V5, P136, DOI 10.1186/bcr585; Sood AK, 2001, AM J PATHOL, V158, P1279, DOI 10.1016/S0002-9440(10)64079-5; Su M, 2008, INT J GYNECOL CANCER, V18, P476, DOI 10.1111/j.1525-1438.2007.01034.x; Sun BC, 2008, HUM PATHOL, V39, P444, DOI 10.1016/j.humpath.2007.07.018; Sun BC, 2006, ONCOL REP, V16, P693; Sun BC, 2004, INT J ONCOL, V25, P1609; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; van der Schaft DWJ, 2005, CANCER RES, V65, P11520, DOI 10.1158/0008-5472.CAN-05-2468; Veeravalli KK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011583; Wu J, 2002, INT J CANCER, V98, P29, DOI 10.1002/ijc.10142; Yue WY, 2005, J HISTOCHEM CYTOCHEM, V53, P997, DOI 10.1369/jhc.4A6521.2005; Zhang J, 2008, J CHONGQING MED U, V33, P1603; Zhang SW, 2007, CANCER LETT, V254, P157, DOI 10.1016/j.canlet.2006.12.036; Zhang WP, 2008, MOL CANCER RES, V6, P1946, DOI 10.1158/1541-7786.MCR-07-2197	51	52	59	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	44					4498	4508		10.1038/onc.2011.154	http://dx.doi.org/10.1038/onc.2011.154			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	844FN	21602894	Green Published, hybrid			2022-12-17	WOS:000296733200005
J	Giordano, C; Catalano, S; Panza, S; Vizza, D; Barone, I; Bonofiglio, D; Gelsomino, L; Rizza, P; Fuqua, SAW; Ando, S				Giordano, C.; Catalano, S.; Panza, S.; Vizza, D.; Barone, I.; Bonofiglio, D.; Gelsomino, L.; Rizza, P.; Fuqua, S. A. W.; Ando, S.			Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression	ONCOGENE			English	Article						FXR; breast cancer; tamoxifen resistance; HER2; NF-kappa B	ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR; CROSS-TALK; IDENTIFICATION; AMPLIFICATION; HER-2/NEU; PROMOTER; THERAPY; TARGET; FXR	Tamoxifen (Tam) treatment is a first-line endocrine therapy for estrogen receptor-alpha-positive breast cancer patients. Unfortunately, resistance frequently occurs and is often related with overexpression of the membrane tyrosine kinase receptor HER2. This is the rationale behind combined treatments with endocrine therapy and novel inhibitors that reduce HER2 expression and signaling and thus inhibit Tam-resistant breast cancer cell growth. In this study, we show that activation of farnesoid X receptor (FXR), by the primary bile acid chenodeoxycholic acid (CDCA) or the synthetic agonist GW4064, inhibited growth of Tam-resistant breast cancer cells (termed MCF-7 TR1), which was used as an in vitro model of acquired Tam resistance. Our results demonstrate that CDCA treatment significantly reduced both anchorage-dependent and anchorage-independent epidermal growth factor (EGF)-induced growth in MCF-7 TR1 cells. Furthermore, results from western blot analysis and real-time reverse transcription-PCR revealed that CDCA treatment reduced HER2 expression and inhibited EGF-mediated HER2 and p42/44 mitogen-activated protein kinase (MAPK) phosphorylation in these Tam-resistant breast cancer cells. Transient transfection experiments, using a vector containing the human HER2 promoter region, showed that CDCA treatment downregulated basal HER2 promoter activity. This occurred through an inhibition of nuclear factor-kappa B transcription factor binding to its specific responsive element located in the HER2 promoter region as revealed by mutagenesis studies, electrophoretic mobility shift assay and chromatin immunoprecipitation analysis. Collectively, these data suggest that FXR ligand-dependent activity, blocking HER2/MAPK signaling, may overcome anti-estrogen resistance in human breast cancer cells and could represent a new therapeutic tool to treat breast cancer patients that develop resistance. Oncogene (2011) 30, 4129-4140; doi:10.1038/onc.2011.124; published online 18 April 2011	[Barone, I.; Rizza, P.; Ando, S.] Univ Calabria, Dept Cell Biol, I-87036 Arcavacata Di Rende, Italy; [Giordano, C.; Catalano, S.; Barone, I.; Bonofiglio, D.; Ando, S.] Univ Calabria, Ctr Sanit, I-87036 Arcavacata Di Rende, Italy; [Catalano, S.; Panza, S.; Vizza, D.; Bonofiglio, D.; Gelsomino, L.] Univ Calabria, Dept Pharmacobiol, I-87036 Arcavacata Di Rende, Italy; [Fuqua, S. A. W.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Fuqua, S. A. W.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA	University of Calabria; University of Calabria; University of Calabria; Baylor College of Medicine; Baylor College of Medicine	Ando, S (corresponding author), Univ Calabria, Dept Cell Biol, Via P Bucci, I-87036 Arcavacata Di Rende, Italy.	sebastiano.ando@unical.it	Bonofiglio, Daniela/AAV-8371-2020	BONOFIGLIO, Daniela/0000-0002-4142-0496; GIORDANO, Cinzia/0000-0003-4969-0607; BARONE, Ines/0000-0002-9769-1615; Gelsomino, Luca/0000-0003-3076-3482; CATALANO, Stefania/0000-0002-6352-9628; RIZZA, Pietro/0000-0002-1267-3910	AIRC; MIUR; Lilli Funaro Foundation; NIH/NCI [R01 CA72038]; Cancer Prevention and Research Institute of Texas (SAWF) [RP101251]; NATIONAL CANCER INSTITUTE [R01CA072038] Funding Source: NIH RePORTER	AIRC(Fondazione AIRC per la ricerca sul cancro); MIUR(Ministry of Education, Universities and Research (MIUR)); Lilli Funaro Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention and Research Institute of Texas (SAWF); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by AIRC grants, MIUR Ex 60% 2009, PRIN 2009 and Lilli Funaro Foundation. NIH/NCI R01 CA72038 and RP101251 from the Cancer Prevention and Research Institute of Texas (SAWF). We thank Dr Mien-Chie Hung for providing the pNeuLite plasmid and Dr T. A. Kocarek for providing the FXR-responsive reporter gene and FXR-DN expression plasmids. We also thank Dr Rachel Schiff for providing the MCF-7/HER2-18 cells.	ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arpino G, 2004, CLIN CANCER RES, V10, P5670, DOI 10.1158/1078-0432.CCR-04-0110; Arpino G, 2008, ENDOCR REV, V29, P217, DOI 10.1210/er.2006-0045; BARONE I, 2011, J NATL CANC IN PRESS; Barone I, 2009, CANCER RES, V69, P4724, DOI 10.1158/0008-5472.CAN-08-4194; Bishop-Bailey D, 2004, DRUG NEWS PERSPECT, V17, P499, DOI 10.1358/dnp.2004.17.8.863693; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Catalano S, 2010, J BIOL CHEM, V285, P5581, DOI 10.1074/jbc.M109.052670; Chung YL, 2002, INT J CANCER, V97, P306, DOI 10.1002/ijc.1614; Claudel T, 2002, J CLIN INVEST, V109, P961; De Laurentiis M, 2005, CLIN CANCER RES, V11, P4741, DOI 10.1158/1078-0432.CCR-04-2569; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Giordano C, 2010, BREAST CANCER RES TR, V119, P71, DOI 10.1007/s10549-009-0334-0; Glockner S, 2001, LAB INVEST, V81, P565, DOI 10.1038/labinvest.3780265; Gradishar WJ, 2004, ONCOLOGIST, V9, P378, DOI 10.1634/theoncologist.9-4-378; Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172; He FT, 2006, CIRC RES, V98, P192, DOI 10.1161/01.RES.0000200400.55539.85; Herynk MH, 2006, MOL CANCER THER, V5, P3023, DOI 10.1158/1535-7163.MCT-06-0394; Hurst HC, 2001, BREAST CANCER RES, V3, P395, DOI 10.1186/bcr329; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; Johnston SRD, 2009, CLIN BREAST CANCER, V9, pS28, DOI 10.3816/CBC.2009.s.003; Journe F, 2008, BREAST CANCER RES TR, V107, P49, DOI 10.1007/s10549-007-9535-6; Kalaany NY, 2006, ANNU REV PHYSIOL, V68, P159, DOI 10.1146/annurev.physiol.68.033104.152158; Kirkegaard T, 2007, CLIN CANCER RES, V13, P1405, DOI 10.1158/1078-0432.CCR-06-1933; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Kocarek TA, 2002, J PHARMACOL TOXICOL, V47, P177, DOI 10.1016/S1056-8719(03)00002-9; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Meng SD, 2004, P NATL ACAD SCI USA, V101, P9393, DOI 10.1073/pnas.0402993101; Morelli C, 2004, ONCOGENE, V23, P7517, DOI 10.1038/sj.onc.1208014; Nicholson RI, 2004, ENDOCR-RELAT CANCER, V11, P623, DOI 10.1677/erc.1.00778; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Sabnis GJ, 2005, CANCER RES, V65, P3903, DOI 10.1158/0008-5472.CAN-04-4092; Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Sirianni R, 2007, CANCER RES, V67, P8368, DOI 10.1158/0008-5472.CAN-06-4064; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Staka CM, 2005, ENDOCR-RELAT CANCER, V12, pS85, DOI 10.1677/erc.1.01006; Swales KE, 2006, CANCER RES, V66, P10120, DOI 10.1158/0008-5472.CAN-06-2399; Vavassori P, 2009, J IMMUNOL, V183, P6251, DOI 10.4049/jimmunol.0803978; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396	49	52	54	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	39					4129	4140		10.1038/onc.2011.124	http://dx.doi.org/10.1038/onc.2011.124			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21499302	Green Accepted			2022-12-17	WOS:000295357500008
J	Sangster-Guity, N; Conrad, BH; Papadopoulos, N; Bunz, F				Sangster-Guity, N.; Conrad, B. H.; Papadopoulos, N.; Bunz, F.			ATR mediates cisplatin resistance in a p53 genotype-specific manner	ONCOGENE			English	Article						p53; ATR; cisplatin; synthetic lethality; gene targeting	HUMAN CANCER-CELLS; DNA-DAMAGE RESPONSE; REPLICATION CHECKPOINT; ATAXIA-TELANGIECTASIA; CYCLE CHECKPOINTS; SECKEL-SYNDROME; ACTIVATION; SURVIVAL; PATHWAY; PHOSPHORYLATION	The protein kinase encoded by the ataxia telangiectasia and Rad3-related (ATR) gene is activated by DNA-damaging agents that are frequently used as anticancer therapeutics. Inhibition of ATR expression in cultured cancer cells has been demonstrated to increase sensitivity to chemotherapeutic drugs, including the DNA-cross-linking agent cisplatin. Cisplatin is a widely used and effective drug, but its use is associated with significant toxicity. Here, we demonstrate that genetic inhibition of ATR expression selectively enhanced cisplatin sensitivity in human colorectal cancer cells with inactivated p53. A knock-in strategy was used to restore wild-type p53 in cells harboring wild-type or mutant ATR alleles. Knock-in of functional p53 in ATR-deficient cells restored checkpoint function, suppressed apoptotic pathways and markedly increased clonogenic survival after cisplatin treatment. These results suggest that a strategy that combines specific inhibitors of ATR and conventional therapies might promote synthetic lethality in p53-deficient tumors, and thus minimize toxicity to normal tissues. Oncogene (2011) 30, 2526-2533; doi:10.1038/onc.2010.624; published online 24 January 2011	[Sangster-Guity, N.; Conrad, B. H.; Bunz, F.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21231 USA; [Sangster-Guity, N.; Papadopoulos, N.; Bunz, F.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Bunz, F (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, David H Koch Canc Res Bldg,1550 Orleans St,Room 4, Baltimore, MD 21231 USA.	fbunz@jhmi.edu	Papadopoulos, Nickolas/K-7272-2012	Conrad, Bogdan/0000-0002-2984-099X	Flight Attendant Medical Research Institute; NCI [T32CA121937]; NATIONAL CANCER INSTITUTE [T32CA121937, R01CA104253] Funding Source: NIH RePORTER	Flight Attendant Medical Research Institute; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the Flight Attendant Medical Research Institute and the NCI (T32CA121937).	Alderton GK, 2004, HUM MOL GENET, V13, P3127, DOI 10.1093/hmg/ddh335; Blasina A, 2008, MOL CANCER THER, V7, P2394, DOI 10.1158/1535-7163.MCT-07-2391; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cho SH, 2005, CELL CYCLE, V4, P131, DOI 10.4161/cc.4.1.1299; Chung JH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000863; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Collis SJ, 2003, CANCER RES, V63, P1550; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Hurley PJ, 2007, ONCOGENE, V26, P2535, DOI 10.1038/sj.onc.1210049; Hurley PJ, 2007, CELL CYCLE, V6, P414, DOI 10.4161/cc.6.4.3886; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Jirmanova L, 2005, CELL CYCLE, V4, P1428, DOI 10.4161/cc.4.10.2055; Karnitz LM, 2005, MOL PHARMACOL, V68, P1636, DOI 10.1124/mol.105.012716; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kodama M, 2010, MOL CELL BIOL, V30, P1620, DOI 10.1128/MCB.00810-09; Li QX, 2009, NAT CELL BIOL, V11, P1128, DOI 10.1038/ncb1927; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Murga M, 2009, NAT GENET, V41, P891, DOI 10.1038/ng.420; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Pabla N, 2008, J BIOL CHEM, V283, P6572, DOI 10.1074/jbc.M707568200; Pirollo KF, 2000, ANTI-CANCER DRUG, V11, P419, DOI 10.1097/00001813-200007000-00002; Rago C, 2007, NAT PROTOC, V2, P2734, DOI 10.1038/nprot.2007.408; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Robinson HMR, 2006, ONCOGENE, V25, P5359, DOI 10.1038/sj.onc.1209532; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Ruzankina Y, 2009, NAT GENET, V41, P1144, DOI 10.1038/ng.441; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Topaloglu O, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni160; Tse AN, 2007, CLIN CANCER RES, V13, P1955, DOI 10.1158/1078-0432.CCR-06-2793; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wagner JM, 2010, PHARMACEUTICALS, V3, P1311, DOI 10.3390/ph3051311; Wagner JM, 2009, MOL PHARMACOL, V76, P208, DOI 10.1124/mol.109.055178; WALDMAN T, 1995, CANCER RES, V55, P5187; Wilsker D, 2007, MOL CANCER THER, V6, P1406, DOI 10.1158/1535-7163.MCT-06-0679; Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106; Zenvirt S, 2010, ONCOGENE, V29, P6149, DOI 10.1038/onc.2010.343; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039	49	52	54	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	22					2526	2533		10.1038/onc.2010.624	http://dx.doi.org/10.1038/onc.2010.624			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21258400	Green Accepted			2022-12-17	WOS:000291198400004
J	Cha, B; Kim, W; Kim, YK; Hwang, BN; Park, SY; Yoon, JW; Park, WS; Cho, JW; Bedford, MT; Jho, EH				Cha, B.; Kim, W.; Kim, Y. K.; Hwang, B. N.; Park, S. Y.; Yoon, J. W.; Park, W. S.; Cho, J. W.; Bedford, M. T.; Jho, E-h			Methylation by protein arginine methyltransferase 1 increases stability of Axin, a negative regulator of Wnt signaling	ONCOGENE			English	Article						Axin; PRMT1; Wnt; protein methylation; GSK3 beta	BETA-CATENIN; COLORECTAL-CANCER; PATHWAY; PHOSPHORYLATION; UBIQUITINATION; ACTIVATION; COMPLEX; BINDING; PRMT1; INHIBITION	Axin, a negative regulator of Wnt signaling, is a key scaffold protein for the beta-catenin destruction complex. It has been previously shown that multiple post-translational modification enzymes regulate the level of Axin. Here, we provide evidence that protein arginine methyltransferase 1 (PRMT1) directly interacts with and methylates the 378th arginine residue of Axin both in vitro and in vivo. We found that the transient expression of PRMT1 led to an increased level of Axin and that knockdown of endogenous PRMT1 by short hairpin RNA reduced the level of Axin. These results suggest that methylation by PRMT1 enhanced the stability of Axin. Methylation of Axin by PRMT1 also seemingly enhanced the interaction between Axin and glycogen synthase kinase 3 beta, leading to decreased ubiquitination of Axin. Consistent with the role of PRMT1 in the regulation of Axin, knockdown of PRMT1 enhanced the level of cytoplasmic beta-catenin as well as beta-catenin-dependent transcription activity. In summary, we show that the methylation of Axin occurred in vivo and controlled the stability of Axin. Therefore, methylation of Axin by PRMT1 may serve as a finely tuned regulation mechanism for Wnt/beta-catenin signaling. Oncogene (2011) 30, 2379-2389; doi: 10.1038/onc.2010.610; published online 17 January 2011	[Cha, B.; Kim, W.; Hwang, B. N.; Jho, E-h] Univ Seoul, Dept Life Sci, Seoul 130743, South Korea; [Kim, Y. K.; Bedford, M. T.] Univ Texas MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX USA; [Park, S. Y.; Cho, J. W.] Yonsei Univ, Dept Biol, Seoul 120749, South Korea; [Park, S. Y.; Cho, J. W.] Yonsei Univ, Dept Integrated OMICS Biomed Sci, World Class Univ Program, Seoul 120749, South Korea; [Yoon, J. W.; Park, W. S.] Catholic Univ Korea, Dept Pathol, Coll Med, Seoul, South Korea	University of Seoul; University of Texas System; UTMD Anderson Cancer Center; Yonsei University; Yonsei University; Catholic University of Korea	Jho, EH (corresponding author), Univ Seoul, Dept Life Sci, 90 Jeonnong Dong, Seoul 130743, South Korea.	ej70@uos.ac.kr	Bedford, Mark T/E-7856-2011	Jho, Eek-hoon/0000-0003-2414-6234	Korea Research Foundation [C00339]; Ministry for Health and Welfare, Republic of Korea [1020240]; Brain Korea 21 program; Seoul Science Fellowship	Korea Research Foundation(National Research Foundation of Korea); Ministry for Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); Brain Korea 21 program(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); Seoul Science Fellowship	This work was supported by grants from the Korea Research Foundation (C00339) and the National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea (1020240) to E Jho B Cha, W Kim and B Hwang were supported by the Brain Korea 21 program. B Cha and W Kim were recipients of the Seoul Science Fellowship.	Bedford MT, 2007, J CELL SCI, V120, P4243, DOI 10.1242/jcs.019885; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BOISVERT FM, 2005, SCI STKE, pRE2, DOI DOI 10.1126/STKE.2712005RE2; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Dajani R, 2003, EMBO J, V22, P494, DOI 10.1093/emboj/cdg068; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Goulet I, 2007, J BIOL CHEM, V282, P33009, DOI 10.1074/jbc.M704349200; Gupta P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002658; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Jernigan KK, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000647; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; Jung H, 2009, EXP MOL MED, V41, P695, DOI 10.3858/emm.2009.41.10.076; Kim MJ, 2008, FASEB J, V22, P3785, DOI 10.1096/fj.08-113910; Kim S, 2010, J BIOL CHEM, V285, P36420, DOI 10.1074/jbc.M110.137471; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Luo W, 2004, NEUROSIGNALS, V13, P99, DOI 10.1159/000076563; Luo W, 2007, EMBO J, V26, P1511, DOI 10.1038/sj.emboj.7601607; Lyu J, 2008, DEV CELL, V15, P773, DOI 10.1016/j.devcel.2008.10.004; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(01)00269-0; Nicholson TB, 2009, PHARMACOL RES, V60, P466, DOI 10.1016/j.phrs.2009.07.006; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Polakis P, 2000, GENE DEV, V14, P1837; Rui HL, 2002, J BIOL CHEM, V277, P42981, DOI 10.1074/jbc.M208099200; Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shimizu Y, 2002, GENE CHROMOSOME CANC, V33, P73, DOI 10.1002/gcc.1226; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Teyssier C, 2005, GENE DEV, V19, P1466, DOI 10.1101/gad.1295005; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yu ZB, 2009, MOL CELL BIOL, V29, P2982, DOI 10.1128/MCB.00042-09; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540; Zhao X, 2008, GENE DEV, V22, P640, DOI 10.1101/gad.1632608	51	52	52	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	20					2379	2389		10.1038/onc.2010.610	http://dx.doi.org/10.1038/onc.2010.610			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21242974				2022-12-17	WOS:000290789200009
J	Kim, J; Thorne, SH; Sun, L; Huang, B; Mochly-Rosen, D				Kim, J.; Thorne, S. H.; Sun, L.; Huang, B.; Mochly-Rosen, D.			Sustained inhibition of PKC alpha reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model	ONCOGENE			English	Article						bioluminescence; mammary cancer; metastasis; protein kinase C	PROTEIN-KINASE-C; BREAST-CANCER METASTASIS; MATRIX METALLOPROTEINASES; EPITHELIAL-CELLS; BETA-II; EXPRESSION; ACTIVATION; PEPTIDES; INVASION; THERAPY	Metastasis is the major reason for breast cancer-related deaths. Although there is a host of indirect evidence for a role of protein kinase C (PKC) alpha in primary breast cancer growth, its role in the molecular pathways leading to metastasis has not been studied comprehensively. By treating mice with alpha V5-3, a novel peptide inhibitor selective for PKC alpha, we were able to determine how PKC alpha regulates metastasis of mammary cancer cells using a syngeneic and orthotopic model. The primary tumor growth was not affected by alpha V5-3 treatment. However, the mortality rate was reduced and metastasis in the lung decreased by more than 90% in the alpha V5-3-treated mice relative to the control-treated mice. alpha V5-3 treatment reduced intravasation by reducing matrix metalloproteinase-9 activities. alpha V5-3 treatment also reduced lung seeding of tumor cells and decreased cell migration, effects that were accompanied by a reduction in nuclear factor kappa B activity and cell surface levels of the CXCL12 receptor, CXCR4. alpha V5-3 treatment caused no apparent toxicity in non-tumor-bearing naive mice. Rather, inhibiting PKC alpha protected against liver damage and increased the number of immune cells in tumor-bearing mice. Importantly, alpha V5-3 showed superior efficacy relative to anti-CXCR4 antibody in reducing metastasis in vivo. Together, these data show that pharmacological inhibition of PKC alpha effectively reduces mammary cancer metastasis by targeting intravasation and lung seeding steps in the metastatic process and suggest that PKC alpha-specific inhibitors, such as alpha V5-3, can be used to study the mechanistic roles of PKC alpha specifically and may provide a safe and effective treatment for the prevention of lung metastasis of breast cancer patients. Oncogene (2011) 30, 323-333; doi:10.1038/onc.2010.415; published online 20 September 2010	[Kim, J.; Sun, L.; Mochly-Rosen, D.] Stanford Univ, Sch Med, Dept Chem & Syst Biol, Stanford, CA 94305 USA; [Thorne, S. H.] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; [Thorne, S. H.; Huang, B.] Univ Pittsburgh, Div Surg Oncol, Inst Canc, Pittsburgh, PA USA	Stanford University; Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Mochly-Rosen, D (corresponding author), Stanford Univ, Sch Med, Dept Chem & Syst Biol, Room 3145-A,269 Campus Dr, Stanford, CA 94305 USA.	mochly@stanford.edu		Mochly-Rosen, Daria/0000-0002-6691-8733; Kim, Jeewon/0000-0002-1063-0239	National Cancer Institute, DHHS [CA09151]; NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052141] Funding Source: NIH RePORTER	National Cancer Institute, DHHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Erinn Bruno Rankin in Dr Amato Giaccia's lab at the Department of Radiation Oncology at Stanford University for generous technical support and Dr Adrienne Gordon for critical reading of the paper. This work was supported in part by PHS Grant Number CA09151, awarded by the National Cancer Institute, DHHS (to JK).	Affara NI, 2007, CELL, V129, P25, DOI 10.1016/j.cell.2007.03.029; Alsayed Y, 2007, BLOOD, V109, P2708, DOI 10.1182/blood-2006-07-035857; Assender JW, 2007, J CLIN PATHOL, V60, P1216, DOI 10.1136/jcp.2006.041616; Begley R, 2004, BIOCHEM BIOPH RES CO, V318, P949, DOI 10.1016/j.bbrc.2004.04.121; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chen L, 2001, CHEM BIOL, V8, P1123, DOI 10.1016/S1074-5521(01)00076-X; Christofori G, 2007, NATURE, V446, P735, DOI 10.1038/446735a; Cindoruk M, 2007, BMC GASTROENTEROL, V7, DOI 10.1186/1471-230X-7-44; Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062; Frankel LB, 2007, BREAST CANCER RES TR, V104, P165, DOI 10.1007/s10549-006-9399-1; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Gross S, 2005, NAT METHODS, V2, P607, DOI 10.1038/NMETH779; Harvey JR, 2007, CLIN CANCER RES, V13, P1562, DOI 10.1158/1078-0432.CCR-06-1987; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Inagaki K, 2005, CIRCULATION, V111, P44, DOI 10.1161/01.CIR.0000151614.22282.F1; Kawakami A, 2007, ARTERIOSCL THROM VAS, V27, P219, DOI 10.1161/01.ATV.0000249620.68705.0d; Ke ZJ, 2006, INT J CANCER, V119, P8, DOI 10.1002/ijc.21769; Kim JW, 2008, CANCER RES, V68, P6831, DOI 10.1158/0008-5472.CAN-07-6195; Kim YM, 2000, CANCER RES, V60, P5410; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; Martiny-Baron G, 2007, PHARMACOL RES, V55, P477, DOI 10.1016/j.phrs.2007.04.001; Mi ZY, 2006, CARCINOGENESIS, V27, P1134, DOI 10.1093/carcin/bgi352; Mimeault M, 2007, CANCER METAST REV, V26, P203, DOI 10.1007/s10555-007-9052-4; Mochly-Rosen D, 1998, FASEB J, V12, P35; Molckovsky A, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-20; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Noel A, 2008, SEMIN CELL DEV BIOL, V19, P52, DOI 10.1016/j.semcdb.2007.05.011; OBRIAN CA, 1989, CANCER RES, V49, P3215; Pan Q, 2005, CANCER RES, V65, P8366, DOI 10.1158/0008-5472.CAN-05-0553; Peter M, 2005, BIOPHYS J, V88, P1224, DOI 10.1529/biophysj.104.050153; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Shin Y, 2007, EXP MOL MED, V39, P97, DOI 10.1038/emm.2007.11; Sledge GW, 2006, SEMIN ONCOL, V33, pS15, DOI 10.1016/j.seminoncol.2006.03.019; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; Taichman RS, 2002, CANCER RES, V62, P1832; Tester AM, 2001, CLIN EXP METASTAS, V18, P553, DOI 10.1023/A:1011953118186; Thorne SH, 2005, P IEEE, V93, P750, DOI 10.1109/JPROC.2005.844261; Tonetti DA, 2003, BRIT J CANCER, V88, P1400, DOI 10.1038/sj.bjc.6600923; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; YEE JK, 1987, P NATL ACAD SCI USA, V84, P5197, DOI 10.1073/pnas.84.15.5197; Zorzi D, 2007, BRIT J SURG, V94, P274, DOI 10.1002/bjs.5719; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	48	52	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					323	333		10.1038/onc.2010.415	http://dx.doi.org/10.1038/onc.2010.415			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20856202	Green Accepted			2022-12-17	WOS:000286418800007
J	Erenpreisa, J; Cragg, MS				Erenpreisa, J.; Cragg, M. S.			MOS, aneuploidy and the ploidy cycle of cancer cells	ONCOGENE			English	Review						polyploidy; MOS; aneuploidy; DNA damage; tumor resistance; life cycle	MEIOSIS-SPECIFIC GENES; VIDEO TIME-LAPSE; MITOTIC CATASTROPHE; GIANT-CELLS; CHROMOSOME SEGREGATION; TUMOR-CELLS; C-MOS; UP-REGULATION; SELF-RENEWAL; POLYPLOIDY	After DNA or spindle damage, p53-defective tumor cells undergo a complex cycle of reversible polyploidy. How this process occurs and more importantly, why, has recently become the focus of several research groups, prompting this review in which we discuss two related phenomena that accompany the reversible polyploidy of tumor cells: the induction of meiosis genes such as MOS and the decrease in genomic instability observed during the reversion from polyploidy to para-diploidy. The reversible polyploidy likely provides the means through which the balance between increased chromosome instability (CIN), driving genetic variation and decreased CIN, necessary for perpetuating these malignant clones, is maintained. These concepts are integrated with recent findings that many meiotic and self-renewal genes become activated during reversible polyploidy and lead us to the hypothesis that tumor cell immortality may be achieved through germline-like transmission. Oncogene (2010) 29, 5447-5451; doi:10.1038/onc.2010.310; published online 2 August 2010	[Erenpreisa, J.] Latvian Biomed Res & Study Ctr, LV-1067 Riga, Latvia; [Cragg, M. S.] Univ Southampton, Sch Med, Gen Hosp, Tenovus Lab,Canc Sci Div, Southampton SO16 6YD, Hants, England	Latvian Biomedical Research & Study Centre; University of Southampton	Erenpreisa, J (corresponding author), Latvian Biomed Res & Study Ctr, LV-1067 Riga, Latvia.	katrina@biomed.lu.lv; msc@soton.ac.uk	Cragg, Mark S/E-5965-2010	Cragg, Mark S/0000-0003-2077-089X				Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chandhok NS, 2009, CURR OPIN GENET DEV, V19, P74, DOI 10.1016/j.gde.2008.12.004; Choi T, 1996, P NATL ACAD SCI USA, V93, P4730, DOI 10.1073/pnas.93.10.4730; Chu K, 2004, RADIAT RES, V162, P270, DOI 10.1667/RR3221; CLEVELAND LR, 1947, SCIENCE, V105, P287, DOI 10.1126/science.105.2724.287; DELAHOZ C, 1993, J CELL SCI, V104, P31; Duesberg P, 2006, CONTRIB MICROBIOL, V13, P16, DOI 10.1159/000092963; Erenpreisa J, 2005, CELL BIOL INT, V29, P1012, DOI 10.1016/j.cellbi.2005.10.005; Erenpreisa J, 2005, CELL BIOL INT, V29, P981, DOI 10.1016/j.cellbi.2005.10.002; Erenpreisa JA, 2000, CELL BIOL INT, V24, P635, DOI 10.1006/cbir.2000.0558; Erenpreisa J, 2008, CELL BIOL INT, V32, P1044, DOI 10.1016/j.cellbi.2008.06.003; Erenpreisa J, 2007, CELL BIOL INT, V31, P1507, DOI 10.1016/j.cellbi.2007.08.013; Erenpreisa J, 2009, EXP CELL RES, V315, P2593, DOI 10.1016/j.yexcr.2009.05.011; Extavour C, 2009, CURR BIOL, V19, pR489, DOI 10.1016/j.cub.2009.05.015; Forer A, 2009, CELL BIOL INT, V33, P253, DOI 10.1016/j.cellbi.2008.11.004; FUKASAWA K, 1994, CELL GROWTH DIFFER, V5, P1093; Ganem NJ, 2007, CELL, V131, P437, DOI 10.1016/j.cell.2007.10.024; Gergely F, 2008, GENE DEV, V22, P2291, DOI 10.1101/gad.1715208; Gisselsson D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001871; Gorgoulis VG, 2001, CANCER RES, V61, P538; Goshima G, 2005, J CELL BIOL, V171, P229, DOI 10.1083/jcb.200505107; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haroske G, 2001, ANAL CELL PATHOL, V23, P89, DOI 10.1155/2001/657642; Hoglund M, 2002, CANCER GENET CYTOGEN, V135, P103, DOI 10.1016/S0165-4608(01)00645-8; HURST LD, 1991, J THEOR BIOL, V150, P561, DOI 10.1016/S0022-5193(05)80447-3; Ianzini F, 2002, RADIAT PROT DOSIM, V99, P289, DOI 10.1093/oxfordjournals.rpd.a006787; Ianzini F, 2009, CANCER RES, V69, P2296, DOI 10.1158/0008-5472.CAN-08-3364; Illidge TM, 2000, CELL BIOL INT, V24, P621, DOI 10.1006/cbir.2000.0557; Ivanov A, 2003, J CELL SCI, V116, P4095, DOI 10.1242/jcs.00740; Kalejs M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-6; KONDRASHOV AS, 1994, NATURE, V370, P213, DOI 10.1038/370213a0; Kondrashov AS, 1997, ANNU REV ECOL SYST, V28, P391, DOI 10.1146/annurev.ecolsys.28.1.391; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Lee HO, 2009, GENE DEV, V23, P2461, DOI 10.1101/gad.1829209; Ling YH, 1998, CANCER RES, V58, P3633; Martin F, 2009, CELL BIOL INT, V33, P702, DOI 10.1016/j.cellbi.2009.02.016; NAGL W, 1978, ENDOPOLYPLOIDY POLYT; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; Page AW, 1997, CURR OPIN GENET DEV, V7, P23, DOI 10.1016/S0959-437X(97)80105-0; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; Prieur-Carrillo G, 2003, RADIAT RES, V159, P705, DOI 10.1667/RR3009; Puig PE, 2008, CELL BIOL INT, V32, P1031, DOI 10.1016/j.cellbi.2008.04.021; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Raikov I.B., 1982, PROTOZOAN NUCL MORPH; Rajaraman R., 2007, International Journal of Human Genetics, V7, P29; Rajaraman R, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-25; Salmina K, 2010, EXP CELL RES, V316, P2099, DOI 10.1016/j.yexcr.2010.04.030; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Storchova Z, 2006, NATURE, V443, P541, DOI 10.1038/nature05178; Sundaram M, 2004, CANCER BIOL THER, V3, P207, DOI 10.4161/cbt.3.2.663; Therman Eeva, 1989, Critical Reviews in Oncogenesis, V1, P293; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Verlhac MH, 1996, DEVELOPMENT, V122, P815; Vitale I, 2010, EMBO J, V29, P1272, DOI 10.1038/emboj.2010.11; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266; Wheatley D, 2008, CELL BIOL INT, V32, P1029, DOI 10.1016/j.cellbi.2008.06.001; Wilkins AS, 2009, GENETICS, V181, P3, DOI 10.1534/genetics.108.099762; Wu JQ, 2008, J CELL SCI, V121, P3509, DOI 10.1242/jcs.036855; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	66	52	53	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5447	5451		10.1038/onc.2010.310	http://dx.doi.org/10.1038/onc.2010.310			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20676137				2022-12-17	WOS:000282945800002
J	Chen, J; Miller, EM; Gallo, KA				Chen, J.; Miller, E. M.; Gallo, K. A.			MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells	ONCOGENE			English	Article						MLK3; JNK; migration; invasion; Bim; AP-1; breast cancer	MIXED-LINEAGE KINASE; BASEMENT-MEMBRANE CULTURES; GENE-EXPRESSION PROFILES; P38 MAPK PATHWAYS; N-TERMINAL KINASE; PROTEIN-KINASE; C-JUN; SRC-HOMOLOGY-3 DOMAIN; SIGNALING PATHWAYS; DEPENDENT PATHWAY	The malignant phenotype in breast cancer is driven by aberrant signal transduction pathways. Mixed-lineage kinase-3 (MLK3) is a mammalian mitogen-activated protein kinase kinase kinase (MAP3K) that activates multiple MAPK pathways. Depending on the cellular context, MLK3 has been implicated in apoptosis, proliferation, migration and differentiation. Here we investigated the effect of MLK3 and its signaling to MAPKs in the acquisition of malignancy in breast cancer. We show that MLK3 is highly expressed in breast cancer cells. We provide evidence that MLK3's catalytic activity and signaling to c-jun N-terminal kinase (JNK) is required for migration of highly invasive breast cancer cells and for MLK3-induced migration of mammary epithelial cells. Expression of active MLK3 is sufficient to induce the invasion of mammary epithelial cells, which requires AP-1 activity and is accompanied by the expression of several proteins corresponding to AP-1-regulated invasion genes. To assess MLK3's contribution to the breast cancer malignant phenotype in a more physiological setting, we implemented a strategy to inducibly express active MLK3 in the preformed acini of MCF10A cells grown in 3D Matrigel. Induction of MLK3 expression dramatically increases acinar size and modestly perturbs apicobasal polarity. Remarkably, MLK3 expression induces luminal repopulation and suppresses the expression of the pro-apoptotic protein BimEL, as has been observed in Her2/Neu-expressing acini. Taken together, our data show that MLK3-JNK-AP-1 signaling is critical for breast cancer cell migration and invasion. Our current study uncovers both a proliferative and novel antiapoptotic role for MLK3 in the acquisition of a malignant phenotype in mammary epithelial cells. Thus, MLK3 may be an important therapeutic target for the treatment of invasive breast cancer. Oncogene (2010) 29, 4399-4411; doi: 10.1038/onc.2010.198; published online 31 May 2010	[Miller, E. M.; Gallo, K. A.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Chen, J.] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; [Gallo, K. A.] Michigan State Univ, Cell & Mol Biol Program, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Gallo, KA (corresponding author), Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.	gallok@msu.edu	Wang, Limin/O-3724-2015		MSU-Health and Biomedical Research Institute [HBRI-729]; DoD [BC085020]	MSU-Health and Biomedical Research Institute; DoD(United States Department of Defense)	This work was supported by an MSU-Health and Biomedical Research Institute seed grant (KAG HBRI-729) and a DoD Breast Cancer Idea Award (KAG BC085020). Confocal microscopes were provided through the MSU Center for Advanced Microscopy. We are grateful to Cephalon Inc. for CEP-11004; Ariad Pharmaceuticals for AP21967 and for parental inducible expression vectors; Richard Mulligan (Harvard Medical School) for the 293GPG packaging cell line and Daniel DiMaio (Yale Cancer Center) for the pBabe-Tam67 construct. We thank Mauricio Reginato (Drexel University) for advice on Bim immunoblotting and Bradley Smith (Department of Physiology, MSU) for help with the morphometric analysis of the MCF10A cells grown in 3D culture. We appreciate the constructive input from the members of the MSU-Breast Cancer Signaling Networks Consortium.	BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; BROWN PH, 1993, ONCOGENE, V8, P877; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Ching YP, 2007, CANCER RES, V67, P3601, DOI 10.1158/0008-5472.CAN-06-3994; Cui XJ, 2006, CANCER RES, V66, P5304, DOI 10.1158/0008-5472.CAN-05-2858; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Du Y, 2005, J BIOL CHEM, V280, P42984, DOI 10.1074/jbc.M502671200; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Goicoechea SM, 2009, ONCOGENE, V28, P587, DOI 10.1038/onc.2008.408; Hall JP, 2002, J CELL BIOCHEM, V86, P1, DOI 10.1002/jcb.10187; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jacinto A, 2002, DEV CELL, V3, P9, DOI 10.1016/S1534-5807(02)00208-3; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Johung K, 2007, J VIROL, V81, P2102, DOI 10.1128/JVI.02348-06; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Khatlani TS, 2007, ONCOGENE, V26, P2658, DOI 10.1038/sj.onc.1210050; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lester RD, 2005, J BIOL CHEM, V280, P39273, DOI 10.1074/jbc.M509446200; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Minet E, 2001, EXP CELL RES, V265, P114, DOI 10.1006/excr.2001.5180; Murakata C, 2002, BIOORG MED CHEM LETT, V12, P147, DOI 10.1016/S0960-894X(01)00690-4; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nielsen DL, 2009, CANCER TREAT REV, V35, P121, DOI 10.1016/j.ctrv.2008.09.003; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; Rizki A, 2007, CANCER RES, V67, P11106, DOI 10.1158/0008-5472.CAN-07-2348; Schachter KA, 2006, J BIOL CHEM, V281, P19134, DOI 10.1074/jbc.M603324200; Shacka JJ, 2006, CELL DEATH DIFFER, V13, P1506, DOI 10.1038/sj.cdd.4401831; Shaw KRM, 2004, J MAMMARY GLAND BIOL, V9, P297, DOI 10.1007/s10911-004-1402-z; Simpson KJ, 2008, NAT CELL BIOL, V10, P1027, DOI 10.1038/ncb1762; SOMMERS CL, 1994, CELL GROWTH DIFFER, V5, P839; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Stronach B, 2002, GENE DEV, V16, P377, DOI 10.1101/gad.953002; Su S, 2009, ONCOGENE, V28, P3047, DOI 10.1038/onc.2009.163; Swenson-Fields KI, 2008, MOL CELL, V32, P43, DOI 10.1016/j.molcel.2008.09.007; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Timoshenko AV, 2007, BRIT J CANCER, V97, P1090, DOI 10.1038/sj.bjc.6603993; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Vivanco I, 2007, CANCER CELL, V11, P555, DOI 10.1016/j.ccr.2007.04.021; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wilsbacher Julie L, 2006, Cell Commun Signal, V4, P5, DOI 10.1186/1478-811X-4-5; Yeh YT, 2006, INT J CANCER, V118, P2678, DOI 10.1002/ijc.21707; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhang H, 2001, J BIOL CHEM, V276, P45598, DOI 10.1074/jbc.M107176200; Zhang H, 2004, J BIOL CHEM, V279, P19457, DOI 10.1074/jbc.M311377200; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559	59	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	2010	29	31					4399	4411		10.1038/onc.2010.198	http://dx.doi.org/10.1038/onc.2010.198			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20514022				2022-12-17	WOS:000280559100004
J	Luo, W; Gangwal, K; Sankar, S; Boucher, KM; Thomas, D; Lessnick, SL				Luo, W.; Gangwal, K.; Sankar, S.; Boucher, K. M.; Thomas, D.; Lessnick, S. L.			GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance	ONCOGENE			English	Article						Ewing's sarcoma; EWS/FLI; GSTM4; transformation	GLUTATHIONE-S-TRANSFERASE; CELL-DEATH; GENE; GROWTH; TRANSLOCATION; REPRESSION; PHENOTYPE; FUSION; FAMILY; NKX2.2	Ewing's sarcoma is a malignant bone-associated tumor of children and young adults. Most cases of Ewing's sarcoma express the EWS/FLI fusion protein. EWS/FLI functions as an aberrant ETS-type transcription factor and serves as the master regulator of Ewing's sarcoma-transformed phenotype. We recently showed that EWS/FLI regulates one of its key targets, NR0B1, through a GGAA-microsatellite in its promoter. Whether other critical EWS/FLI targets are also regulated by GGAA-microsatellites was unknown. In this study, we combined transcriptional analysis, whole genome localization data, and RNA interference knockdown to identify glutathione S-transferase M4 (GSTM4) as a critical EWS/FLI target gene in Ewing's sarcoma. We found that EWS/FLI directly binds the GSTM4 promoter, and regulates GSTM4 expression through a GGAA-microsatellite in its promoter. Reduction of GSTM4 levels caused a loss of oncogenic transformation. Furthermore, reduction of GSTM4 resulted in an increased sensitivity of Ewing's sarcoma cells to chemotherapeutic agents, suggesting a role for this protein in drug resistance. Consistent with this hypothesis, patients with Ewing's sarcoma whose tumors had higher levels of GSTM4 expression had worse outcomes than those with lower expression levels. These data show that GSTM4 contributes to the cancerous behavior of Ewing's sarcoma and define a wider role for GGAA-microsatellites in EWS/FLI function than previously appreciated. These data also suggest a novel therapeutic resistance mechanism, in which the central oncogenic abnormality directly regulates a resistance gene. Oncogene (2009) 28, 4126-4132; doi:10.1038/onc.2009.262; published online 31 August 2009	[Luo, W.; Gangwal, K.; Sankar, S.; Lessnick, S. L.] Univ Utah, Ctr Childrens Canc Res, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Luo, W.; Gangwal, K.; Sankar, S.; Boucher, K. M.; Lessnick, S. L.] Univ Utah, Sch Med, Dept Oncol Sci, Salt Lake City, UT 84112 USA; [Thomas, D.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Lessnick, S. L.] Univ Utah, Sch Med, Div Pediat Hematol Oncol, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Michigan System; University of Michigan; Utah System of Higher Education; University of Utah	Lessnick, SL (corresponding author), Univ Utah, Ctr Childrens Canc Res, Huntsman Canc Inst, 2000 Circle Hope,Room 4242, Salt Lake City, UT 84112 USA.	stephen.lessnick@hci.utah.edu	SANKAR, SAVITA/R-6821-2017	Boucher, Kenneth/0000-0003-2833-0127	Shriver Sarcoma Initiative; Sunbeam Foundation; Huntsman Cancer Institute/Huntsman Cancer Foundation; Alex's Lemonade Stand Foundation; NIH [P30 CA042014]; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER	Shriver Sarcoma Initiative; Sunbeam Foundation; Huntsman Cancer Institute/Huntsman Cancer Foundation; Alex's Lemonade Stand Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Andrea Bild and Matt Topham for critical reading of the manuscript; Nikko Ronquillo, Mohan Kaadige and Kym Zumbrennen for technical assistance; and Elizabeth Leibold and members of the Lessnick laboratory for helpful discussions. This work was supported by funds awarded to SLL from the Terri Anna Perine Sarcoma Fund, the Liddy Shriver Sarcoma Initiative, the Sunbeam Foundation and Huntsman Cancer Institute/Huntsman Cancer Foundation, and by a grant to WL from the Alex's Lemonade Stand Foundation. We also acknowledge the NIH support to the Huntsman Cancer Institute (P30 CA042014).	ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Camp RL, 2008, J CLIN ONCOL, V26, P5630, DOI 10.1200/JCO.2008.17.3567; COMSTOCK KE, 1993, J BIOL CHEM, V268, P16958; COMSTOCK KE, 1994, ARCH BIOCHEM BIOPHYS, V311, P487, DOI 10.1006/abbi.1994.1266; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DuBois SG, 2009, PEDIATR BLOOD CANCER, V52, P324, DOI 10.1002/pbc.21822; Gangwal K, 2008, CELL CYCLE, V7, P3127, DOI 10.4161/cc.7.20.6892; Gangwal K, 2008, P NATL ACAD SCI USA, V105, P10149, DOI 10.1073/pnas.0801073105; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396; Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565; Kinsey M, 2006, MOL CANCER RES, V4, P851, DOI 10.1158/1541-7786.MCR-06-0090; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Liloglou T, 2002, LUNG CANCER-J IASLC, V37, P143, DOI 10.1016/S0169-5002(02)00078-8; Magwere T, 2008, EUR J CANCER, V44, P2276, DOI 10.1016/j.ejca.2008.06.008; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Myatt SS, 2008, ONCOGENE, V27, P985, DOI 10.1038/sj.onc.1210705; Owen LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001965; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Stegmaier K, 2007, PLOS MED, V4, P702, DOI 10.1371/journal.pmed.0040122; Tirado OM, 2006, CANCER RES, V66, P9937, DOI 10.1158/0008-5472.CAN-06-0927	24	52	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2009	28	46					4126	4132		10.1038/onc.2009.262	http://dx.doi.org/10.1038/onc.2009.262			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19718047				2022-12-17	WOS:000272560500008
J	Deng, Z; Wan, M; Cao, P; Rao, A; Cramer, SD; Sui, G				Deng, Z.; Wan, M.; Cao, P.; Rao, A.; Cramer, S. D.; Sui, G.			Yin Yang 1 regulates the transcriptional activity of androgen receptor	ONCOGENE			English	Article						androgen receptor; Yin Yang 1; prostate cancer; PSA promoter; transcription	PROSTATE-SPECIFIC ANTIGEN; GENE-EXPRESSION; CANCER CELLS; FACTOR YY1; FACTOR YIN-YANG-1; RESPONSE ELEMENT; RNAI TECHNOLOGY; IN-VIVO; P53; REPRESSION	The multifunctional protein Yin Yang 1 (YY1) has an important role in epigenetic regulation of gene expression. YY1 is highly expressed in various types of cancers, including prostate cancer. Currently, the mechanism underlying the functional role of YY1 in prostate tumorigenesis remains unclear. In this report, we investigated the functional interplay between YY1 and androgen receptor (AR), and the effect of YY1 on AR-mediated transcription. We found that YY1 physically interacts with AR both in a cell-free system and in cultured cells. YY1 is required for the optimal transcriptional activity of AR in promoting the transcription of the prostate-specific antigen (PSA) promoter. However, ectopic YY1 expression in LNCaP cells did not further enhance the reporter driven by the PSA promoter, suggesting that an optimal level of YY1 is already established in prostate tumor cells. Consistently, YY1 depletion in LNCaP cells reduced endogenous PSA levels, but overexpressed YY1 did not significantly increase PSA expression. We also observed that YY1-AR interaction is essential to YY1-mediated transcription activity of AR and YY1 is a necessary component in the complex binding to the androgen response element. Thus, our study demonstrates that YY1 interacts with AR and regulates its transcriptional activity. Oncogene (2009) 28, 3746-3757; doi: 10.1038/onc.2009.231; published online 10 August 2009	[Sui, G.] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Comprehens Canc, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Sui, G (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 1 Med Ctr Blvd,Hanes 4052, Winston Salem, NC 27157 USA.	gsui@wfubmc.edu	Deng, Zhiyong/D-4656-2012	Sui, Guangchao/0000-0002-8164-5585	Department of Cancer Biology and Comprehensive Cancer Center of Wake Forest University; NCI training [5T32CA079448-09]; NATIONAL CANCER INSTITUTE [T32CA079448] Funding Source: NIH RePORTER	Department of Cancer Biology and Comprehensive Cancer Center of Wake Forest University; NCI training(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Purnima Dubey and Ms Karen Klein for critical reading of the article. We also thank Dr Suzy Torti and Dr Wei Wang for providing the access to some equipment, and Dr Kazushi Inoue for the EMSA protocol. The support for the work came from the grant of American Cancer Society (RSG09-082-01-MGO) and the startup fund from the Department of Cancer Biology and Comprehensive Cancer Center of Wake Forest University to GS. PC is supported by NCI training Grant 5T32CA079448-09.	Bain M, 2005, EUR J CELL BIOL, V84, P543, DOI 10.1016/j.ejcb.2004.12.024; Baritaki S, 2007, INT J ONCOL, V31, P69; Begon DY, 2005, J BIOL CHEM, V280, P24428, DOI 10.1074/jbc.M503790200; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Craft N, 1999, CANCER RES, V59, P5030; de Nigris F, 2006, EUR J CANCER, V42, P2420, DOI 10.1016/j.ejca.2006.06.008; Dehm SM, 2005, EXPERT REV ANTICANC, V5, P63, DOI 10.1586/14737140.5.1.63; Deng ZY, 2007, MOL CELL BIOL, V27, P3780, DOI 10.1128/MCB.01761-06; Erkeland SJ, 2003, BLOOD, V101, P1111, DOI 10.1182/blood-2002-04-1207; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gregory CW, 2001, CANCER RES, V61, P2892; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Gross M, 2004, ONCOGENE, V23, P3059, DOI 10.1038/sj.onc.1207443; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hirawat S, 2003, CANCER INVEST, V21, P400, DOI 10.1081/CNV-120018232; Joshi B, 2007, BIOCHEM J, V401, P155, DOI 10.1042/BJ20060364; Koivisto P, 1997, CANCER RES, V57, P314; Lapouge G, 2007, INT J CANCER, V121, P1238, DOI 10.1002/ijc.22830; Rao A, 2003, UROLOGY, V61, P864, DOI 10.1016/S0090-4295(02)02414-7; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Rylski M, 2008, J BIOL CHEM, V283, P35140, DOI 10.1074/jbc.M804540200; Santiago FS, 2007, CIRC RES, V101, P146, DOI 10.1161/CIRCRESAHA.106.145235; Seligson D, 2005, INT J ONCOL, V27, P131; Sharifi Nima, 2006, Am J Ther, V13, P166, DOI 10.1097/00045391-200603000-00013; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sui G, 2005, METH MOL B, V309, P205; Tannous BA, 2005, MOL THER, V11, P435, DOI 10.1016/j.ymthe.2004.10.016; Taplin ME, 1999, CANCER RES, V59, P2511; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; Wang HT, 2007, MOL CELL BIOL, V27, P4374, DOI 10.1128/MCB.02020-06; Wilkinson FH, 2006, P NATL ACAD SCI USA, V103, P19296, DOI 10.1073/pnas.0603564103; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001	43	52	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3746	3757		10.1038/onc.2009.231	http://dx.doi.org/10.1038/onc.2009.231			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19668226	Green Accepted			2022-12-17	WOS:000271023200007
J	Hernando, E; Sarmentero-Estrada, J; Koppie, T; Belda-Iniesta, C; de Molina, VR; Cejas, P; Ozu, C; Le, C; Sanchez, JJ; Gonzalez-Baron, M; Koutcher, J; Cordon-Cardo, C; Bochner, BH; Lacal, JC; de Molina, AR				Hernando, E.; Sarmentero-Estrada, J.; Koppie, T.; Belda-Iniesta, C.; de Molina, V. Ramirez; Cejas, P.; Ozu, C.; Le, C.; Sanchez, J. J.; Gonzalez-Baron, M.; Koutcher, J.; Cordon-Cardo, C.; Bochner, B. H.; Lacal, J. C.; de Molina, A. Ramirez			A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas	ONCOGENE			English	Article						bladder cancer; choline kinase; therapeutic target; tumor promoter	TRANSITIONAL-CELL CARCINOMA; ONCOGENE ADDICTION; RADICAL CYSTECTOMY; HUMAN CANCER; INHIBITION; CARCINOGENESIS; PROLIFERATION; MECHANISM; STRATEGY; THERAPY	Bladder cancer is one of the most common causes of death in industrialized countries. New tumor markers and therapeutic approaches are still needed to improve the management of bladder cancer patients. Choline kinase-alpha (ChoK alpha) is a metabolic enzyme that has a role in cell proliferation and transformation. Inhibitors of ChoK alpha show antitumoral activity and are expected to be introduced soon in clinical trials. This study aims to assess whether ChoK alpha plays a role in the aggressiveness of bladder tumors and constitutes a new approach for bladder cancer treatment. We show here that ChoK alpha is constitutively altered in human bladder tumor cells. Furthermore, in vivo murine models, including an orthotopic model to mimic as much as possible the physiological conditions, revealed that increased levels of ChoK alpha potentiate both tumor formation (P <= 0.0001) and aggressiveness of the disease on different end points (P = 0.011). Accordingly, increased levels of ChoK alpha significantly reduce survival of mice with bladder cancer (P = 0.05). Finally, treatment with a ChoK alpha-specific inhibitor resulted in a significant inhibition of tumor growth (P = 0.02) and in a relevant increase in survival (P = 0.03). Oncogene (2009) 28, 2425-2435; doi:10.1038/onc.2009.91; published online 18 May 2009	[Sarmentero-Estrada, J.; Lacal, J. C.; de Molina, A. Ramirez] Natl Biotechnol Ctr, TCD Pharma, Madrid 28049, Spain; [Bochner, B. H.] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA; [Belda-Iniesta, C.; Cejas, P.; Gonzalez-Baron, M.] CSIC UAM La Paz, Hosp Univ La Paz, Div Med Oncol, Translat Oncol Unit, Madrid, Spain; [de Molina, V. Ramirez] Hosp Clin San Carlos, Madrid, Spain; [Sanchez, J. J.] Univ Autonoma Madrid, Dept Stat, E-28049 Madrid, Spain; [Lacal, J. C.; de Molina, A. Ramirez] CSIC UAM La Paz, Translat Oncol Unit, Inst Invest Biomed, Madrid, Spain	Memorial Sloan Kettering Cancer Center; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital Universitario La Paz; Hospital Clinico San Carlos; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	de Molina, AR (corresponding author), Natl Biotechnol Ctr, TCD Pharma, Darwin 3, Madrid 28049, Spain.	aramirez@cnb.csic.es	estrada, jacinto sarmentero/C-6777-2019; Le, Hongbiao/H-4735-2011; Lacal, Juan Carlos/AAL-2235-2020; de Molina, Ana Ramirez/AAA-3848-2019; Lacal, Juan Carlos/N-9064-2015	estrada, jacinto sarmentero/0000-0002-0118-4919; Hernando, Eva/0000-0003-1023-0312; Belda Iniesta, Cristobal/0000-0003-3254-7492; Lacal, Juan Carlos/0000-0002-1908-2777; Bochner, Bernard/0000-0003-0846-0848	NATIONAL CANCER INSTITUTE [R24CA083084] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA083084, 1R24CA83084, R24 CA083084-08] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Saffar NMS, 2006, CANCER RES, V66, P427, DOI 10.1158/0008-5472.CAN-05-1338; Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; Banez-Coronel M, 2008, CURR CANCER DRUG TAR, V8, P709, DOI 10.2174/156800908786733432; CHIN J, 1991, J UROLOGY, V145, P1297, DOI 10.1016/S0022-5347(17)38618-4; CordonCardo C, 1997, CANCER RES, V57, P1217; Gallego-Ortega D, 2006, INT J ONCOL, V29, P335; GALLEGOORTEGA D, DIFFERENTIAL R UNPUB; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Glunde K, 2005, CANCER RES, V65, P11034, DOI 10.1158/0008-5472.CAN-05-1807; Glunde K, 2007, LANCET ONCOL, V8, P855, DOI 10.1016/S1470-2045(07)70289-9; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jonkers J, 2004, CANCER CELL, V6, P535, DOI 10.1016/j.ccr.2004.12.002; Kikuchi E, 2004, CLIN CANCER RES, V10, P1835, DOI 10.1158/1078-0432.CCR-03-0099; Kikuchi E, 2003, J UROLOGY, V170, P1375, DOI 10.1097/01.ju.0000075504.13456.41; Lacal J C, 2001, IDrugs, V4, P419; Lu ML, 2002, CLIN CANCER RES, V8, P171; Mullerad M, 2005, J UROLOGY, V174, P741, DOI 10.1097/01.ju.0000164730.38431.5c; Nakagami K, 1999, JPN J CANCER RES, V90, P419, DOI 10.1111/j.1349-7006.1999.tb00764.x; Oliveira P. A., 2006, Experimental Oncology, V28, P2; Quek ML, 2005, J UROLOGY, V174, P103, DOI 10.1097/01.ju.0000163267.93769.d8; Ramirez de Molina A, 2005, CANCER RES, V65, P5647, DOI 10.1158/0008-5472.CAN-04-4416; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Ramirez de Molina A, 2004, CANCER RES, V64, P6732, DOI 10.1158/0008-5472.CAN-04-0489; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; Ramirez de Molina A, 2007, LANCET ONCOL, V8, P889, DOI 10.1016/S1470-2045(07)70279-6; Rodriguez-Gonzalez A, 2005, INT J ONCOL, V26, P999; Rodriguez-Gonzalez A, 2003, ONCOGENE, V22, P8803, DOI 10.1038/sj.onc.1207062; Rodriguez-Gonzalez A, 2004, ONCOGENE, V23, P8247, DOI 10.1038/sj.onc.1208045; Sanderson KM, 2007, J UROLOGY, V177, P2088, DOI 10.1016/j.juro.2007.01.133; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697	34	52	56	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2425	2435		10.1038/onc.2009.91	http://dx.doi.org/10.1038/onc.2009.91			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448670	Green Accepted			2022-12-17	WOS:000267601400001
J	Ngan, S; Stronach, EA; Photiou, A; Waxman, J; Ali, S; Buluwela, L				Ngan, S.; Stronach, E. A.; Photiou, A.; Waxman, J.; Ali, S.; Buluwela, L.			Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells	ONCOGENE			English	Article						prostate cancer; LNCaP cells; androgens; anti-androgens; real-time RT-PCR; microarrays	LIGAND-BINDING DOMAIN; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; RECEPTOR ACTIVATION; RESPONSIVE GENES; TUMOR-SUPPRESSOR; NUCLEAR RECEPTOR; HORMONE-RECEPTOR; GROWTH; EXPRESSION; BETA	The androgen receptor (AR) mediates the growth-stimulatory effects of androgens in prostate cancer cells. Identification of androgen-regulated genes in prostate cancer cells is therefore of considerable importance for de. ning the mechanisms of prostate-cancer development and progression. Although several studies have used microarrays to identify AR-regulated genes in prostate cancer cell lines and in prostate tumours, we present here the results of gene expression microarray profiling of the androgen-responsive LNCaP prostate-cancer cell line treated with R1881 for the identification of androgen-regulated genes. We show that the expression of 319 genes is stimulated by 24h after R1881 addition, with a similar number (300) of genes being significantly repressed. Expression of the upregulated genes, as well as of 60 of the most robustly downregulated genes, was carried out using quantitative RT-PCR (Q-RT-PCR) over a time-course of R1881 treatment from 0 to 72 h. Q-RT-PCR was also carried out following treatment with other AR agonists (dihydrotestosterone, estradiol and medroxyprogesterone) and antagonists (cyproterone acetate, hydroxyflutamide and bicalutamide). This study provides a comprehensive analysis of androgen-regulated gene expression in the LNCaP prostate cancer cell line, and identifies a number of androgen-regulated genes, not described previously, as candidates for mediating androgen responses in prostate cancer cells. Oncogene (2009) 28, 2051-2063; doi:10.1038/onc.2009.68; published online 13 April 2009	[Ngan, S.; Stronach, E. A.; Photiou, A.; Waxman, J.; Ali, S.; Buluwela, L.] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London W1 0NN, England	Imperial College London	Ali, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Oncol, Du Cane Rd, London W1 0NN, England.	simak.ali@imperial.ac.uk; l.buluwela@imperial.ac.uk	Ali, Simak/M-6912-2018	Ali, Simak/0000-0002-1320-0816; Coombes, Raoul Charles/0000-0002-4811-1100	Joron trust; Hammersmith Hospital trustees; Prostate Cancer Charity; Cancer Research UK	Joron trust; Hammersmith Hospital trustees; Prostate Cancer Charity; Cancer Research UK(Cancer Research UK)	We are grateful to the members of the group for advice and support. Our particular thanks go to Drs Greg Brooke and Charlotte Bevan for discussions, and to Dr Lev Soinov for aiding the analysis of the microarray data. This work was carried out through the support of the Joron trust, Hammersmith Hospital trustees, Prostate Cancer Charity and Cancer Research UK.	Abdulkadir SA, 2002, MOL CELL BIOL, V22, P1495, DOI 10.1128/MCB.22.5.1495-1503.2002; Agoulnik IU, 2006, J CELL BIOCHEM, V99, P362, DOI 10.1002/jcb.20811; Akashi T, 2006, ONCOL REP, V16, P831; Arnold JT, 2007, PROSTATE, V67, P1152, DOI 10.1002/pros.20585; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Brooke GN, 2008, ONCOGENE, V27, P2941, DOI 10.1038/sj.onc.1210955; Burmester JK, 2004, HUM HERED, V57, P172, DOI 10.1159/000081443; Busillo JM, 2007, BBA-BIOMEMBRANES, V1768, P952, DOI 10.1016/j.bbamem.2006.11.002; CARTER HB, 1990, PROSTATE, V16, P39; Chen H, 2002, CANCER RES, V62, P338; Cheng I, 2006, JNCI-J NATL CANCER I, V98, P123, DOI 10.1093/jnci/djj013; Chintharlapalli S, 2005, J BIOL CHEM, V280, P24903, DOI 10.1074/jbc.M500107200; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; DAVIES P, 1991, J ENDOCRINOL, V131, P5, DOI 10.1677/joe.0.1310005; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Furr BJA, 1996, UROLOGY, V47, P13, DOI 10.1016/S0090-4295(96)80003-3; Gottlieb B, 2004, HUM MUTAT, V23, P527, DOI 10.1002/humu.20044; Guo YP, 1999, CANCER RES, V59, P1366; Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.3.CO;2-1; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Heemers HV, 2006, MOL ENDOCRINOL, V20, P2265, DOI 10.1210/me.2005-0479; Hodgson MC, 2007, CANCER RES, V67, P8388, DOI 10.1158/0008-5472.CAN-07-0617; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Kim MJ, 2002, CANCER RES, V62, P2999; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Lau KM, 2000, CANCER RES, V60, P3175; Lee MY, 2009, BIOCHEM J, V417, P313, DOI 10.1042/BJ20080762; Lu NZ, 2006, PHARMACOL REV, V58, P782, DOI 10.1124/pr.58.4.9; Malkowicz SB, 1996, UROLOGY, V47, P29, DOI 10.1016/S0090-4295(96)80005-7; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; MCCONNELL JD, 1991, UROL CLIN N AM, V18, P1; Myung SJ, 2006, P NATL ACAD SCI USA, V103, P12098, DOI 10.1073/pnas.0603235103; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Ono T, 2003, CELL, V115, P109, DOI 10.1016/S0092-8674(03)00724-4; Qi W, 2008, BIOCHEM J, V416, P453, DOI 10.1042/BJ20080651; Rae JM, 2006, PROSTATE, V66, P886, DOI 10.1002/pros.20403; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shanmugam I, 2007, CELL DEATH DIFFER, V14, P2085, DOI 10.1038/sj.cdd.4402227; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Simone F, 2003, BLOOD, V101, P2355, DOI 10.1182/blood-2002-06-1664; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Sobel RE, 2005, J UROLOGY, V173, P342, DOI 10.1097/01.ju.0000141580.30910.57; Steketee K, 2002, INT J CANCER, V100, P309, DOI 10.1002/ijc.10495; Storlazzi CT, 2003, HUM MOL GENET, V12, P2349, DOI 10.1093/hmg/ddg237; Takahashi Y, 2007, MOL CARCINOGEN, V46, P117, DOI 10.1002/mc.20254; Tamura K, 2007, CANCER RES, V67, P5117, DOI 10.1158/0008-5472.CAN-06-4040; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368; Xiao WH, 2003, CANCER RES, V63, P4698; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yoon HG, 2006, MOL ENDOCRINOL, V20, P1048, DOI 10.1210/me.2005-0324; Yuen HF, 2006, MODERN PATHOL, V19, P931, DOI 10.1038/modpathol.3800602; Zha S, 2005, PROSTATE, V63, P316, DOI 10.1002/pros.20177; Zha S, 2003, CANCER RES, V63, P7365	63	52	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2009	28	19					2051	2063		10.1038/onc.2009.68	http://dx.doi.org/10.1038/onc.2009.68			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445BF	19363526				2022-12-17	WOS:000266023900006
J	Yang, J; Song, K; Krebs, TL; Jackson, MW; Danielpour, D				Yang, J.; Song, K.; Krebs, T. L.; Jackson, M. W.; Danielpour, D.			Rb/E2F4 and Smad2/3 link survivin to TGF-beta-induced apoptosis and tumor progression	ONCOGENE			English	Article						prostate cancer; promoter regulation; apoptosis; CDE; CHR; E2F	GROWTH-FACTOR-BETA; EPITHELIAL-CELL LINES; PROSTATE-CANCER CELLS; TRANSCRIPTIONAL REPRESSION; MALIGNANT-TRANSFORMATION; C-MYC; RECEPTOR; EXPRESSION; ACTIVATION; MECHANISMS	Survivin is a prosurvival protein overexpressed in many cancers through mechanisms that remain poorly explored, and is implicated in control of tumor progression and resistance to cancer chemotherapeutics. Here, we report a critical role for survivin in the induction of apoptosis by transforming growth factor-beta (TGF-beta). We show that TGF-beta rapidly downregulates survivin expression in prostate epithelial cells, through a unique mechanism of transcriptional suppression involving Smads 2 and 3, Rb/E2F4, and the cell-cycle repressor elements CDE and CHR. This TGF-beta response is triggered through a Smad2/3-dependent hypophosphorylation of Rb and the subsequent association of the Rb/E2F4 repressive complex to CDE/CHR elements in the proximal region of the survivin promoter. Viral-mediated gene delivery experiments, involving overexpressing or silencing survivin, reveal critical roles of survivin in apoptosis induced by TGF-b alone or in cooperation with cancer therapeutic agents. We propose a novel TGF-beta/Rb/survivin axis with a putative role in the functional switch of TGF-beta from tumor suppressor to tumor promoter.	[Yang, J.; Song, K.; Krebs, T. L.; Danielpour, D.] Case Western Reserve Univ, Div Gen Med Sci Oncol, Case Sch Med, Cleveland, OH 44106 USA; [Yang, J.] Case Western Reserve Univ, Case Sch Med, Dept Biochem, Cleveland, OH 44106 USA; [Jackson, M. W.] Case Western Reserve Univ, Case Sch Med, Dept Pathol, Cleveland, OH 44106 USA; [Danielpour, D.] Case Western Reserve Univ, Case Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Danielpour, D (corresponding author), Case Western Reserve Univ, Div Gen Med Sci Oncol, Case Sch Med, Wolstein Res Bldg,2103 Cornell Rd,Room 3532, Cleveland, OH 44106 USA.	dxd49@case.edu			Gene Expression and Genotyping Facility; Case Comprehensive Cancer Center [P30 CA43703]; NCI [R01CA092102, R01CA102074]; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA102074, R01CA092102] Funding Source: NIH RePORTER	Gene Expression and Genotyping Facility; Case Comprehensive Cancer Center; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Gene Expression and Genotyping Facility, the Flow Cytometry Core Facility of the Case Comprehensive Cancer Center (P30 CA43703). Grant support: NCI grants R01CA092102 and R01CA102074 (to D Danielpour).	Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; DANIELPOUR D, 1994, CANCER RES, V54, P3413; Danielpour D, 2006, CYTOKINE GROWTH F R, V17, P59, DOI 10.1016/j.cytogfr.2005.09.007; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Hsing AY, 1996, CANCER RES, V56, P5146; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Jarrard DF, 2002, CANCER LETT, V185, P191, DOI 10.1016/S0304-3835(02)00282-3; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; Kishi H, 2004, J UROLOGY, V171, P1855, DOI 10.1097/01.ju.0000120317.88372.03; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Lucibello FC, 1997, NUCLEIC ACIDS RES, V25, P4921, DOI 10.1093/nar/25.24.4921; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Pennati M, 2004, ONCOGENE, V23, P386, DOI 10.1038/sj.onc.1207071; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shariat SF, 2004, CANCER, V100, P751, DOI 10.1002/cncr.20039; Sharma A, 2007, CANCER RES, V67, P6192, DOI 10.1158/0008-5472.CAN-06-4424; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Song K, 2003, J BIOL CHEM, V278, P38342, DOI 10.1074/jbc.M304583200; Song K, 2003, CANCER RES, V63, P4358; Song KY, 2006, EMBO J, V25, P58, DOI 10.1038/sj.emboj.7600917; Tang BW, 1999, CANCER RES, V59, P4834; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Wajapeyee N, 2006, J BIOL CHEM, V281, P16207, DOI 10.1074/jbc.M600539200; Wang H, 2005, J BIOL CHEM, V280, P5154, DOI 10.1074/jbc.M411575200; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang M, 2005, ONCOGENE, V24, P2474, DOI 10.1038/sj.onc.1208490	44	52	55	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2008	27	40					5326	5338		10.1038/onc.2008.165	http://dx.doi.org/10.1038/onc.2008.165			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18504435	Green Accepted			2022-12-17	WOS:000259096100005
J	Cornforth, AN; Davis, JS; Khanifar, E; Nastiuk, KL; Krolewski, JJ				Cornforth, A. N.; Davis, J. S.; Khanifar, E.; Nastiuk, K. L.; Krolewski, J. J.			FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells	ONCOGENE			English	Article						FLIP; androgen; Forkhead; TRAIL; prostate cancer; apoptosis	PROSTATE-CANCER CELLS; FORKHEAD TRANSCRIPTION FACTOR; INHIBITORY PROTEIN GENE; RAT VENTRAL PROSTATE; FACTOR FKHR; DEATH; RECEPTOR; AKT; EXPRESSION; PTEN	Androgen-withdrawal-induced apoptosis (AWIA) is deregulated in androgen refractory prostate cancer. Androgens have been shown to positively regulate expression of the antiapoptotic FADD-like interleukin-1 beta-converting enzyme (FLICE)-like inhibitory protein (FLIP), and reduced FLIP expression precedes apoptosis after androgen withdrawal. Here, we show that FLIP protein expression is downregulated in castrated rats, while in LNCaP cells, androgens regulate FLIP in a manner that is dependent on phosphoinositol-3-kinase (PI3K) and Akt signaling. Specifically, treatment of LNCaP cells with LY294002, or expression of either PTEN or a non-phosphorylatable form of FOXO3a (FOXO3aTM), downregulates FLIP protein and mRNA. Conversely, treatment with androgens in the absence of PI3/Akt signaling, or following expression of FOXO3aTM, leads to increased FLIP expression. A FOXO3a binding site was identified in the FLIP promoter and shown necessary for the combined effects of androgens and FOXO3a on FLIP transcription. FOXO3a binds the androgen receptor, suggesting that the transcriptional synergy depends on an interaction between these proteins. Finally, LNCaP cells are sensitized to TRAIL-induced apoptosis by PTEN or LY294002, and rescued by androgens. FOX-O3aTMalso sensitizes cells to androgen-inhibited TRAIL apoptosis. Androgen rescue was diminished when either FOXO3a or FLIP was reduced by siRNA. These data support a role for FOXO3a in AWIA.	[Cornforth, A. N.; Davis, J. S.; Khanifar, E.; Nastiuk, K. L.; Krolewski, J. J.] Univ Calif Irvine, Dept Pathol & Lab Med, Sch Med, Irvine, CA 92697 USA; [Krolewski, J. J.] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Sch Med, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Krolewski, JJ (corresponding author), Univ Calif Irvine, Dept Pathol & Lab Med, Sch Med, Med Sci 1 D450, Irvine, CA 92697 USA.	jkrolews@uci.edu		Davis, Jennifer/0000-0001-9456-1682	NATIONAL CANCER INSTITUTE [T32CA009054] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA009054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ayala G, 2004, CLIN CANCER RES, V10, P6572, DOI 10.1158/1078-0432.CCR-04-0477; Bertram J, 2006, PROSTATE, V66, P895, DOI 10.1002/pros.20411; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Daskivich TJ, 2006, CURR OPIN UROL, V16, P173, DOI 10.1097/01.mou.0000193392.77469.e2; de la Taille A, 1999, PROSTATE, V40, P89, DOI 10.1002/(SICI)1097-0045(19990701)40:2<89::AID-PROS4>3.0.CO;2-E; Furutani T, 2002, BIOCHEM BIOPH RES CO, V294, P779, DOI 10.1016/S0006-291X(02)00564-8; Gao S, 2005, MOL ENDOCRINOL, V19, P1792, DOI 10.1210/me.2004-0445; Gao S, 2006, J MOL ENDOCRINOL, V36, P463, DOI 10.1677/jme.1.01991; Hermans KG, 2004, GENE CHROMOSOME CANC, V39, P171, DOI 10.1002/gcc.10311; Huang HJ, 2004, J BIOL CHEM, V279, P13866, DOI 10.1074/jbc.M314143200; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kimura K, 2001, CANCER RES, V61, P5611; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Liao YD, 2003, INT J CANCER, V107, P676, DOI 10.1002/ijc.11471; Longley DB, 2006, ONCOGENE, V25, P838, DOI 10.1038/sj.onc.1209122; Lynch RL, 2005, MOL CANCER RES, V3, P163, DOI 10.1158/1541-7786.MCR-04-0163; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Marti A, 1999, CELL DEATH DIFFER, V6, P1190, DOI 10.1038/sj.cdd.4400610; MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P2963, DOI 10.1210/endo-127-6-2963; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Nastiuk KL, 2003, J CELL PHYSIOL, V196, P386, DOI 10.1002/jcp.10283; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Roth W, 2004, VITAM HORM, V67, P189; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Srikanth S, 1998, CANCER RES, V58, P834; Sugihara A, 2001, IN VIVO, V15, P385; Suzuki A, 1996, ONCOGENE, V13, P31; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Yuan XJ, 2002, ONCOGENE, V21, P319, DOI 10.1038/sj/onc/1205054; Zhang XP, 2004, CANCER RES, V64, P7086, DOI 10.1158/0008-5472.CAN-04-1498	38	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4422	4433		10.1038/onc.2008.80	http://dx.doi.org/10.1038/onc.2008.80			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18391984				2022-12-17	WOS:000257881700005
J	Huang, J; Chen, J				Huang, J.; Chen, J.			VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation	ONCOGENE			English	Article						VprBP; Merlin; E3 ligase; degradation	CUL4-DDB1 UBIQUITIN LIGASE; NF2 TUMOR-SUPPRESSOR; CELL-CYCLE; NEUROFIBROMATOSIS TYPE-2; PLASMA-MEMBRANE; PROTEIN VPR; ARREST; GROWTH; DDB1; RAC	Inactivation of the neurofibromatosis type 2 ( NF2) tumor suppressor gene function has been observed not only in familial schwannomas and other central nervous system tumors, but also in malignant tumors unrelated to the NF2 syndrome, indicating a broader role of NF2 in human tumorigenesis. The NF2-encoded protein Merlin is closely related to the Ezrin-Radixin-Moesin family of membrane/cytoskeleton linker proteins, and has been demonstrated to suppress tumor growth by inhibiting extracellular signal-regulated kinase ( ERK) and Rac1 activation. Interestingly, serum deprivation has been shown to regulate Merlin at the protein level, however, exactly how such condition affects Merlin remains elusive. In this study, we provide evidence to show that Merlin is regulated in a Roc1-Cullin4A-DDB1-dependent manner. Following serum stimulation, Merlin is recruited to the E3 ligase complex through a direct interaction with the WD40-containing adaptor protein VprBP. Loading of Merlin to the E3 ubiquitin ligase complex resulted in its polyubiquitination, and consequently its proteasome-mediated degradation. Consistently, VprBP depletion abolished the in vivo interaction of Merlin and Roc1-Cullin4A-DDB1, which resulted in Merlin stabilization and inhibited ERK and Rac activation. Together, our data revealed a novel regulatory mechanism for the tumor suppressor function of Merlin.	[Huang, J.; Chen, J.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA	Yale University	Chen, J (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, Hunter Bldg 213C,333 Cedar St,POB 208040, New Haven, CT 06520 USA.	Junjie.chen@yale.edu	CHEN, JUNJIE/HHM-8428-2022					Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Angers S, 2006, NATURE, V443, P590, DOI 10.1038/nature05175; Belzile JP, 2007, PLOS PATHOG, V3, P882, DOI 10.1371/journal.ppat.0030085; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; den Bakker MA, 2000, J NEUROSCI RES, V62, P764, DOI 10.1002/1097-4547(20001215)62:6<764::AID-JNR2>3.0.CO;2-V; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Gutmann DH, 1997, NEUROBIOL DIS, V3, P247, DOI 10.1006/nbdi.1997.0128; He YZJ, 2006, GENE DEV, V20, P2949, DOI 10.1101/gad.1483206; Higa LA, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-5; Higa LA, 2006, NAT CELL BIOL, V8, P1277, DOI 10.1038/ncb1490; HOFER B, 1994, GENE, V144, P9, DOI 10.1016/0378-1119(94)90196-1; Hrecka K, 2007, P NATL ACAD SCI USA, V104, P11778, DOI 10.1073/pnas.0702102104; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Le Rouzic E, 2007, CELL CYCLE, V6, P182, DOI 10.4161/cc.6.2.3732; Lee J, 2007, MOL CELL, V26, P775, DOI 10.1016/j.molcel.2007.06.001; Lee JY, 2006, ONCOGENE, V25, P1143, DOI 10.1038/sj.onc.1209150; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Tan L, 2007, J VIROL, V81, P10822, DOI 10.1128/JVI.01380-07; Trofatter J A, 1993, Cell, V75, P826; Wen XY, 2007, J BIOL CHEM, V282, P27046, DOI 10.1074/jbc.M703955200; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; Zhang SG, 2001, GENE, V263, P131, DOI 10.1016/S0378-1119(00)00583-7	29	52	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2008	27	29					4056	4064		10.1038/onc.2008.44	http://dx.doi.org/10.1038/onc.2008.44			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18332868				2022-12-17	WOS:000257325100005
J	Alsheich-Bartok, O; Haupt, S; Alkalay-Snir, I; Saito, S; Appella, E; Haupt, Y				Alsheich-Bartok, O.; Haupt, S.; Alkalay-Snir, I.; Saito, S.; Appella, E.; Haupt, Y.			PML enhances the regulation of p53 by CK1 in response to DNA damage	ONCOGENE			English	Article						PML; CK1; p53; Mdm2; threonine 18 phosphorylation	ACUTE PROMYELOCYTIC LEUKEMIA; NUCLEAR-BODIES; PROTEIN-KINASE; HUMAN CANCERS; PHOSPHORYLATION; MDM2; BINDING; UBIQUITINATION; DEGRADATION; INHIBITOR	In response to stress, p53 is accumulated and activated to induce appropriate growth inhibitory responses. This requires the release of p53 from the constraints of its negative regulators Mdm2 and Mdm4. A key event in this dissociation is the phosphorylation of p53 at threonine residue (Thr18) within the Mdm2/4-binding domain. Casein kinase 1 (CK1) plays a major role in this phosphorylation. The promyelocytic leukemia protein (PML) regulates certain modi. cations of p53 in response to DNA damage. Here, we investigated the role of PML in the regulation of Thr18 phosphorylation. We found that PML enhances Thr18 phosphorylation of endogenous p53 in response to stress. On DNA damage, CK1 accumulates in the cell, with a proportion concentrated in the nucleus together with p53 and PML. Furthermore, CK1 interacts with endogenous p53 and PML, and this interaction is enhanced by genotoxic stress. Inhibition of CK1 impairs the protection of p53 by PML from Mdm2-mediated degradation. Our findings support a role for PML in the regulation of p53 by CK1. We propose that following DNA damage, PML facilitates Thr18 phosphorylation by recruiting p53 and CK1 into PML nuclear bodies, thereby protecting p53 from inhibition by Mdm2, leading to p53 activation.	[Alsheich-Bartok, O.; Haupt, S.; Alkalay-Snir, I.; Haupt, Y.] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, Dept Immunol, IL-91120 Jerusalem, Israel; [Saito, S.; Appella, E.] NCI, Cell Biol Lab, Ctr Canc Res, Natl Inst Hlth, Bethesda, MD 20892 USA	Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Haupt, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, Dept Immunol, IL-91120 Jerusalem, Israel.	haupt@md.huji.ac.il		Haupt, Ygal/0000-0001-5925-0096	NATIONAL CANCER INSTITUTE [ZIABC005599, Z01BC005599] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; HOEKSTRA MF, 1994, MOL BIOL CELL, V5, P877, DOI 10.1091/mbc.5.8.877; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Lai ZH, 2000, ARCH BIOCHEM BIOPHYS, V381, P278, DOI 10.1006/abbi.2000.1998; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Maritzen T, 2003, EUR J CELL BIOL, V82, P369, DOI 10.1078/0171-9335-00323; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Muller S, 1998, BLOOD, V92, P4308, DOI 10.1182/blood.V92.11.4308.423k36_4308_4316; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Salomoni P, 2002, NAT CELL BIOL, V4, pE152, DOI 10.1038/ncb0602-e152; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; Soubeyrand S, 2004, EUR J BIOCHEM, V271, P3776, DOI 10.1111/j.1432-1033.2004.04319.x; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Wang ZG, 1998, SCIENCE, V279, P1547; Wolff S, 2006, FEBS LETT, V580, P6477, DOI 10.1016/j.febslet.2006.10.068; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zimber A, 2004, CELL SIGNAL, V16, P1085, DOI 10.1016/j.cellsig.2004.03.020	30	52	54	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3653	3661		10.1038/sj.onc.1211036	http://dx.doi.org/10.1038/sj.onc.1211036			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18246126				2022-12-17	WOS:000256659300002
J	Tsuruma, R; Ohbayashi, N; Kamitani, S; Ikeda, O; Sato, N; Muromoto, R; Sekine, Y; Oritani, K; Matsuda, T				Tsuruma, R.; Ohbayashi, N.; Kamitani, S.; Ikeda, O.; Sato, N.; Muromoto, R.; Sekine, Y.; Oritani, K.; Matsuda, T.			Physical and functional interactions between STAT3 and KAP1	ONCOGENE			English	Article						IL-6; STAT3; KAP1; transcriptional regulation; phosphorylation	ZINC-FINGER PROTEINS; TRANSCRIPTIONAL ACTIVATION; COREPRESSOR COMPLEX; SIGNAL TRANSDUCERS; PHOSPHORYLATION; ACETYLATION; PATHWAYS; TYROSINE; DOMAIN; FAMILY	Signal transducers and activators of transcription (STATs) mediate cell proliferation, differentiation and survival in immune responses, hematopoiesis, neurogenesis and other biological processes. For example, STAT3 has been reported to be constitutively activated in numerous cancer cells. To clarify the molecular mechanisms underlying the STAT activation, we performed yeast two-hybrid screening and identified KAP1/TIF1b as a novel STAT-binding partner. KAP1 is a universal corepressor protein for the Kruppel-associated box zinc-finger protein superfamily of transcriptional repressors. We found endogenous KAP1 associated with endogenous STAT3 in vivo. Importantly, small-interfering RNA-mediated reduction of KAP1 expression enhanced interleukin (IL)-6-induced STAT3-dependent transcription and gene expression. Furthermore, reduction of KAP1 expression resulted in the marked accumulation of STAT3 phosphorylated on Ser727 in the nucleus, a modi. cation that regulates its transcriptional activation. These results indicate that KAP1 may serve as a transcriptional regulator of the IL-6/STAT3 signaling pathway.	[Tsuruma, R.; Ohbayashi, N.; Kamitani, S.; Ikeda, O.; Sato, N.; Muromoto, R.; Sekine, Y.; Matsuda, T.] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; [Oritani, K.] Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Osaka, Japan	Hokkaido University; Osaka University	Matsuda, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Muromoto, Ryuta/E-4203-2012; Sekine, Yuichi/S-8813-2019; Matsuda, Tadashi/A-3835-2012	Muromoto, Ryuta/0000-0002-7474-493X; Sekine, Yuichi/0000-0002-2861-603X; Matsuda, Tadashi/0000-0002-3089-3757				Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Herrmann A, 2004, J CELL SCI, V117, P339, DOI 10.1242/jcs.00833; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Ohbayashi N, 2007, BIOL PHARM BULL, V30, P1860, DOI 10.1248/bpb.30.1860; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Satou A, 2001, J BIOL CHEM, V276, P46562, DOI 10.1074/jbc.M104937200; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Schuringa JJ, 2001, FEBS LETT, V495, P71, DOI 10.1016/S0014-5793(01)02354-7; Sekine Y, 2007, ONCOGENE, V26, P6038, DOI 10.1038/sj.onc.1210426; Sekine Y, 2006, ONCOGENE, V25, P5801, DOI 10.1038/sj.onc.1209578; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	22	52	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					3054	3059		10.1038/sj.onc.1210952	http://dx.doi.org/10.1038/sj.onc.1210952			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18037959	Green Submitted			2022-12-17	WOS:000255681700012
J	Dobbyn, HC; Hill, K; Hamilton, TL; Spriggs, KA; Pickering, BM; Coldwell, MJ; de Moor, CH; Bushell, M; Willis, AE				Dobbyn, H. C.; Hill, K.; Hamilton, T. L.; Spriggs, K. A.; Pickering, B. M.; Coldwell, M. J.; de Moor, C. H.; Bushell, M.; Willis, A. E.			Regulation of BAG-1 IRES-mediated translation following chemotoxic stress	ONCOGENE			English	Article						BAG-1; translation; IRES; internal ribosome entry; polypyrimidine tract binding protein	INTERNAL RIBOSOME ENTRY; TRACT-BINDING-PROTEIN; CELL-DEATH; HEAT-SHOCK; BREAST-CANCER; MESSENGER-RNA; EXPRESSION; INITIATION; GROWTH; APOPTOSIS	There are three major isoforms of BAG-1 in mammalian cells, termed BAG-1L ( p50), BAG-1M ( p46) and BAG-1S ( p36) that function as pro-survival proteins and are associated with tumorigenesis and chemoresistance. Initiation of BAG-1 protein synthesis can occur by both cap-dependent and cap-independent mechanisms and it has been shown that synthesis of BAG-1S is dependent upon the presence of an internal ribosome entry segment ( IRES) in the 5'-UTR of BAG-1 mRNA. We have shown previously that BAG-1 IRES-meditated initiation of translation requires two trans-acting factors poly ( rC) binding protein 1 ( PCBP1) and polypyrimidine tract binding protein ( PTB) for function. The former protein allows BAG-1 IRES RNA to attain a structure that permits binding of the ribosome, while the latter protein appears to be involved in ribosome recruitment. Here, we show that the BAG-1 IRES maintains synthesis of BAG-1 protein following exposure of cells to the chemotoxic drug vincristine but not to cisplatin and that this is brought about, in part, by the relocalization of PTB and PCBP1 from the nucleus to the cytoplasm.	[Dobbyn, H. C.; Hill, K.; Hamilton, T. L.; Spriggs, K. A.; Pickering, B. M.; Coldwell, M. J.; de Moor, C. H.; Bushell, M.; Willis, A. E.] Univ Nottingham, Sch Pharm, Chair Canc Cell Biol, Nottingham NG7 2RD, England	University of Nottingham	Willis, AE (corresponding author), Univ Nottingham, Sch Pharm, Chair Canc Cell Biol, Univ Pk, Nottingham NG7 2RD, England.	anne.willis@nottingham.ac.uk	de Moor, Cornelia/AAE-8043-2020	de Moor, Cornelia/0000-0001-8776-0085; Willis, Anne/0000-0002-1470-8531	Biotechnology and Biological Sciences Research Council [C14959, BBS/B/03556] Funding Source: Medline; Wellcome Trust [075802] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Back SH, 2002, J VIROL, V76, P2529, DOI 10.1128/JVI.76.5.2529-2542.2002; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Bushell M, 2006, MOL CELL, V23, P401, DOI 10.1016/j.molcel.2006.06.012; Cato ACB, 2001, J STEROID BIOCHEM, V78, P379, DOI 10.1016/S0960-0760(01)00114-5; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Fraser CS, 1999, BIOCHEM J, V342, P519, DOI 10.1042/0264-6021:3420519; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Hague A, 2002, J PATHOL, V197, P60, DOI 10.1002/path.1076; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kamath RV, 2001, MOL BIOL CELL, V12, P3808, DOI 10.1091/mbc.12.12.3808; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Pickering BM, 2004, MOL CELL BIOL, V24, P5595, DOI 10.1128/MCB.24.12.5595-5605.2004; Pickering BM, 2003, NUCLEIC ACIDS RES, V31, P639, DOI 10.1093/nar/gkg146; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Qin XL, 2004, J BIOL CHEM, V279, P13721, DOI 10.1074/jbc.M312854200; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Takahashi A, 1997, BRAIN RES PROTOC, V1, P70, DOI 10.1016/S1385-299X(96)00013-X; Tang SC, 1999, J CLIN ONCOL, V17, P1710, DOI 10.1200/JCO.1999.17.6.1710; Townsend PA, 2003, CANCER RES, V63, P4150; Townsend PA, 2003, BBA-REV CANCER, V1603, P83, DOI 10.1016/S0304-419X(03)00002-7; Townsend PA, 2002, J PATHOL, V197, P51, DOI 10.1002/path.1081; Wang C, 2003, MOL BIOL CELL, V14, P2425, DOI 10.1091/mbc.E02-12-0818; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Xie JY, 2003, P NATL ACAD SCI USA, V100, P8776, DOI 10.1073/pnas.1432696100; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	34	52	61	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1167	1174		10.1038/sj.onc.1210723	http://dx.doi.org/10.1038/sj.onc.1210723			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700523	Green Accepted			2022-12-17	WOS:000253136700016
